11.06.2014 Views

B O O K - American College of Rheumatology

B O O K - American College of Rheumatology

B O O K - American College of Rheumatology

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

program<br />

B O O K<br />

Pre-Conference Courses: Saturday, November 6 - Sunday, November 7, 2010<br />

Annual Scientific Sessions: Monday, November 8 - Thursday, November 11, 2010<br />

Exhibits: Monday, November 8 - Wednesday, November 10, 2010


Maximize Your Annual Meeting Experience with SessionSelect!<br />

Stay current with the latest information presented at<br />

this year’s ACR/ARHP Annual Scientific Meeting. Within<br />

24 hours <strong>of</strong> virtually every live session, video recordings<br />

<strong>of</strong> the presentations, including oral abstract sessions,<br />

will be available online to view as webcasts during the<br />

meeting. This special <strong>of</strong>fer is only extended to 2010<br />

scientific attendees.<br />

To learn more about SessionSelect<br />

visit the ACR Resource Center<br />

located in the International Boulevard<br />

Lobby or the ACR website at<br />

www.rheumatology.org/education.<br />

As scientific attendee, you<br />

get FREE ACCESS to over<br />

200 hours <strong>of</strong> online annual<br />

meeting content –<br />

Over $500 <strong>of</strong><br />

added value!<br />

ACR SessionSelect


program<br />

B O O K<br />

ABOUT ACR/ARHP EDUCATION<br />

The <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> and the Association <strong>of</strong> <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals, a<br />

division <strong>of</strong> the ACR, are organizations <strong>of</strong> physicians, health pr<strong>of</strong>essionals and scientists serving members<br />

through programs, including education and research. Through these programs, the ACR and the ARHP foster<br />

excellence in the care <strong>of</strong> people with rheumatic and musculoskeletal diseases. The 2010 ACR/ARHP Annual<br />

Scientific Meeting programs have been independently planned by the ACR Committee on Education, the ACR<br />

Annual Meeting Planning Committee, the ARHP Annual Meeting Program Committee, and the ARHP Clinical<br />

Focus Course Task Force.<br />

This program is sponsored by the <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> for educational purposes only. The<br />

material presented is not intended to represent the only or the best methods appropriate for the medical<br />

conditions being discussed, but rather are intended to present the opinions <strong>of</strong> the authors/ presenters, which<br />

may be helpful to other healthcare pr<strong>of</strong>essionals. Attendees participating in this medical education program<br />

do so with the full knowledge that they waive any claim they may have against the ACR for reliance on any<br />

information presented during these educational activities. The ACR does not guarantee, warrant or endorse<br />

any commercial products or services.<br />

PROGRAM OBJECTIVES<br />

At the conclusion <strong>of</strong> the 2010 ACR/ARHP annual meeting, participants should be able to:<br />

• identify recent developments in the diagnosis and management <strong>of</strong> patients with rheumatic diseases<br />

• outline new technologies for the treatment <strong>of</strong> rheumatologic problems<br />

• describe potential challenges in the delivery <strong>of</strong> care to patients with rheumatic diseases and to specify<br />

possible solutions<br />

• utilize new research data to improve the quality <strong>of</strong> care <strong>of</strong> patients with rheumatic diseases<br />

Printing <strong>of</strong> this publication is supported by Amgen, Inc. and Pfizer Inc.<br />

This publication was printed by an FSC validated printer on eco-friendly paper.


ACR/ARHP 2010 ANNUAL SCIENTIFIC MEETING<br />

OVERALL NEEDS ASSESSMENT/PRACTICE GAPS<br />

The <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> and the<br />

Association <strong>of</strong> <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals are<br />

committed to providing comprehensive education to<br />

improve the knowledge and performance <strong>of</strong> physicians,<br />

health pr<strong>of</strong>essionals and scientists. Through evidencebased<br />

educational programs, the organization strives to<br />

enhance practice performance and improve the quality<br />

<strong>of</strong> care in those with or at risk for arthritis, rheumatic and<br />

musculoskeletal diseases. The 2010 annual meeting program<br />

has been developed independent <strong>of</strong> commercial influence.<br />

The following groups were involved in the planning process:<br />

the ACR Committee on Education; the ACR Annual Meeting<br />

Planning Committee; the ARHP Education Committee and the<br />

ARHP Annual Meeting Program Planning Committee.<br />

The program is the result <strong>of</strong> a planning process that identified<br />

educational needs to change or enhance the knowledge,<br />

competence or performance <strong>of</strong> rheumatology pr<strong>of</strong>essionals.<br />

The program’s content was derived from both needs<br />

assessment and practice gap analysis based on pr<strong>of</strong>essional<br />

activities, practice setting, ABIM recertification requirements<br />

and physician attributes.<br />

PROGRAM HIGHLIGHTS<br />

• Educational tracks to help attendees identify content<br />

targeted to them. Tracks include: business <strong>of</strong> rheumatology,<br />

clinical, clinical and research, clinical practice, educators,<br />

fellow-in-training, pediatrics, pediatrics and clinical, and<br />

research<br />

• Latest science and best-practices presented through peerreviewed<br />

and selected clinical and scientific abstracts, and<br />

invited speakers providing clinical, evidence-based and<br />

quality focused content<br />

• Diverse formats <strong>of</strong> education delivery, including: didactic<br />

lectures, debates, and interactive sessions, such as poster<br />

tours, Meet the Pr<strong>of</strong>essors and Workshop sessions<br />

• A larger forum for discussion <strong>of</strong> practical management<br />

issues such as the Curbside Consults – Ask the Pr<strong>of</strong>essors<br />

session and Medical Aspects lectures<br />

• Extensive learning opportunities in the basic science <strong>of</strong><br />

rheumatology, an area <strong>of</strong> the program developed by a<br />

subcommittee <strong>of</strong> US and internationally prominent basic<br />

scientists. Offerings include: Basic Science Symposia, State<strong>of</strong>-the-Art<br />

Lectures, a series <strong>of</strong> Immunology Updates for the<br />

Clinicians, and a Basic Science pre-meeting course<br />

• Clinical management sessions, including the Thieves’<br />

Market and basic management <strong>of</strong> difficult issues<br />

• A specific pediatric rheumatology track plus content<br />

integrated throughout the program designed to<br />

provide a high-level educational program to pediatric<br />

rheumatologists; and relevant updates to adult<br />

rheumatologists<br />

• Formal presentations <strong>of</strong> new practice guidelines provided<br />

to alert the membership and explain, in an open forum, the<br />

data supporting the guidelines and propose approaches for<br />

implementation<br />

• Over 40 workshops designed to provide hands-on skills<br />

training


TABLE OF CONTENTS<br />

ACCREDITATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8<br />

Meeting Evaluations, CME Credit, ARHP Certificates <strong>of</strong> Participation and<br />

Certificates <strong>of</strong> Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8<br />

Conflict <strong>of</strong> Interest/Disclosure Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8<br />

Copyright Materials Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8<br />

ACR/ARHP Abstract Embargo Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />

Important Locations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />

MEETING INFORMATION . . . . . . . . . . . . . . . . . . . . . . . .10<br />

Ask Me Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Cell Phone, Pages, PDAs & Other Electronic Devices . . . . . . . . . . . . . . . . . . . 10<br />

Attire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Food Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Meeting Room Capacity/Important Fire Safety Information . . . . . . . . . . . . 10<br />

Photography and Videotaping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Special Needs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Name Badges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Emergency Contact Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

No Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Opening Event at the Georgia Aquarium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />

Shuttle Bus Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11<br />

Session Descriptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11<br />

Guide to Help Navigate the Meeting . . . . . . . . . . . . . . . . . . . . . . . . . .11<br />

MEETING SERVICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12<br />

ACR Resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12<br />

ACR Practice Advocacy Coding Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12<br />

ACR/ARHP Membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Announcements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

REF Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

REF Donor’s Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Electronic Syllabus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

Wireless Access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

2010 REF 5K Run/Walk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />

In-Room Encore Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14<br />

Replay Café (Exhibit Hall) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14<br />

ACR/ARHP Meeting Hotels + Map . . . . . . . . . . . . . . . . . . . . . . . . . . . .15<br />

Special Offers at the Annual Scientific Meeting . . . . . . . . . . . . . . . .16<br />

POSTER SESSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16<br />

Poster Presenter Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />

Poster Session Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />

Guided Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />

PRE-CONFERENCE PROGRAM . . . . . . . . . . . . . . . . . . .17<br />

Saturday, November 6, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17<br />

ACR Musculoskeletal Ultrasound Course for Rheumatologists -<br />

Day One . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />

ACR Clinical Research Conference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />

ACR Certified <strong>Rheumatology</strong> Coder Course – Day One . . . . . . . . . . . . . . . . . 20<br />

ACR Basic Research Conference - Day One . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />

ACR/ABIM Maintenance <strong>of</strong> Certification Learning Session -<br />

2010 Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />

Sunday, November 7, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22<br />

ACR/ARHP Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />

ACR Musculoskeletal Ultrasound Course for Rheumatologists -<br />

Day Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />

ACR Basic Research Conference – Day Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23<br />

ACR Review Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23<br />

ARHP Clinical Focus Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />

ACR Certified <strong>Rheumatology</strong> Coder Exam – Day Two . . . . . . . . . . . . . . . . . . . 26<br />

ACR/ARHP Opening Lecture and Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />

ACR/ARHP Opening Event . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />

ACR/ARHP ANNUAL SCIENTIFIC MEETING . . . . .27<br />

Monday, November 8, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27<br />

ARHP Special Session: ARHP First-Time Attendee Orientation . . . . . . . . . . 27<br />

ARHP Special Session: Moderator Orientation . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />

ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />

ACR REF Special Session: REF Oscar S. Gluck, MD, Memorial<br />

Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />

ARHP Special Session: ARHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . 30<br />

ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />

ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />

ACR Medical Aspects <strong>of</strong> Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />

ACR Poster Session A and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />

Exhibits and Replay Cafe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />

Morning Snack Breaks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />

ARHP General Session I - Keynote Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />

2010 Program Book 3


TABLE OF CONTENTS<br />

ACR Plenary Session I: Discovery 2010. . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />

ARHP Special Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />

ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />

ACR REF Special Session - REF Memorial Lectureship: <strong>Rheumatology</strong><br />

Education 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />

ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Exhibit Hall Afternoon Snack Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />

ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />

ACR REF Special Session - ACR REF “Within Our Reach” Lecture:<br />

Finding a Cure for Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />

ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />

REF 25th Anniversary Celebration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />

ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />

ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />

ACR Special Session: Legislative Update from Capitol Hill . . . . . . . . . . . . . . 52<br />

ACR REF Special Session: ACR REF Clinician Scholar Educator<br />

Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />

ACR Special Session: REF Edmond L. Dubois, MD, Memorial<br />

Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />

REF Industry Roundtable-Supported Symposia . . . . . . . . . . . . . . . . . . . . . . . . 54<br />

Tuesday, November 9, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .55<br />

REF 5K Run /Walk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />

ACR/ARHP Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />

ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />

ACR Special Session - News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />

ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58<br />

ACR Medical Aspects <strong>of</strong> Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />

ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />

ACR/ARHP Poster Session B and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />

Exhibits and Replay Café . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60<br />

Morning Snack Breaks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />

ARHP General Session II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />

ACR Plenary Session II: Discovery 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />

ARHP Special Session: Networking at Noon . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />

ACR Special Session: Contract Negotiations for Physicians . . . . . . . . . . . . . 65<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />

ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />

ACR Special Session: Clinical Teaching Strategies in the Outpatient Clinic<br />

Setting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67<br />

Exhibit Hall Afternoon Snack Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />

ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />

ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />

ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75<br />

ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />

ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />

ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />

ACR Special Session: ILAR Global Health Project . . . . . . . . . . . . . . . . . . . . . . . 84<br />

ACR REF Special Session: REF Marshall J. Schiff, MD, Memorial<br />

Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />

ACR Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />

ARHP Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />

Wine and Cheese Reception (Exhibit Hall). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />

ACR Study Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />

Wednesday, November 10, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .94<br />

ACR Medical Aspects <strong>of</strong> Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />

ACR Special Session: The Changing Faces <strong>of</strong> the <strong>Rheumatology</strong><br />

Workforce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />

ACR Special Session: Insurance Roundtable Discussion . . . . . . . . . . . . . . . . 94<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />

ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />

ACR REF Special Session: REF Paul Klemperer, MD, Memorial<br />

Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />

4<br />

2010 Program Book


TABLE OF CONTENTS<br />

ACR/ARHP Poster Session C and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />

Exhibits and Replay Café . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />

Morning Snack Breaks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100<br />

ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />

ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />

ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />

ACR Plenary Session III: Discovery 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />

ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />

ARHP Special Sessions: ARHP Occupational and Physical Therapy<br />

Networking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />

ARHP Special Sessions: ARHP Office Nurse Networking . . . . . . . . . . . . . . . 105<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />

ACR Special Session: ACR Leadership Town Hall Meeting . . . . . . . . . . . . . . 106<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />

ACR Study Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107<br />

ACR Special Session: Career Opportunities in <strong>Rheumatology</strong>: Making a<br />

Choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />

ACR Basic Science Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />

ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114<br />

ACR Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115<br />

ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />

ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />

ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120<br />

ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120<br />

ACR Basic Science Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />

ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />

ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />

REF Industry Roundtable-Supported Symposia . . . . . . . . . . . . . . . . . . . . . . . 132<br />

Thursday, November 11, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .133<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />

ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />

ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />

ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134<br />

ACR Basic Science Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135<br />

ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />

ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />

ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146<br />

ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147<br />

Industry-Supported Post Conference Symposia . . . . . . . . . . . . . . . . . . . . . . . 147<br />

ACR POSTER SESSION<br />

(ABSTRACTS # 1-619) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148<br />

Antiphospholipid Syndrome I<br />

(Abstracts #1 - 14) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148<br />

Cytokines, Mediators, Gene Regulation I<br />

(Abstracts #15 - 39) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149<br />

Education<br />

(Abstracts #40 - 48) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150<br />

Epidemiology and Health Services Research: Inflammatory Arthritis<br />

(Abstracts #49 - 91) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders I<br />

(Abstracts #92 - 117) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />

Imaging <strong>of</strong> Rheumatic Disease I: X-ray, CT and MRI<br />

(Abstracts #118 - 143) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154<br />

Metabolic and Crystal Arthropathies - Therapeutics and Outcomes<br />

(Abstracts #144 - 166) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157<br />

Orthopedics, Low Back Pain, and Rehabilitation<br />

(Abstracts #167 - 178) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158<br />

Osteoarthritis - Clinical Aspects: Biomechanics, Function, and Imaging I<br />

(Abstracts #179 - 205) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />

Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Juvenile<br />

Idiopathic Arthritis I<br />

(Abstracts #206 - 241) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161<br />

Pediatric <strong>Rheumatology</strong> - Pathogenesis and Genetics: Bench to Bedside-<br />

The Science <strong>of</strong> Pediatric <strong>Rheumatology</strong> (Abstracts #242- 268) . . . . . . . . . 163<br />

Rheumatoid Arthritis - Animal Models: Cytokines, Novel Therapeutics and<br />

Mechanisms <strong>of</strong> Action<br />

(Abstracts #269 - 293) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165<br />

Rheumatoid Arthritis - Clinical Aspects: Drug Studies, Drug Safety, Disease<br />

Activity and Remission, Infections I<br />

(Abstracts #294 - 347) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />

Rheumatoid Arthritis - Human Etiology and Pathogenesis I<br />

(Abstracts #348 - 372) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170<br />

Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene<br />

Therapy: Safety, Non-Biologic DMARDs, Switching Biologics I<br />

(Abstracts #373 - 421) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172<br />

Systemic Lupus Erythematosus - Animal Models<br />

(Abstracts #422 - 443) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I<br />

(Abstracts #444 - 485) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177<br />

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />

Genetics and Mechanisms<br />

(Abstracts #486 - 511) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and<br />

Treatment I<br />

(Abstracts #512 - 559) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182<br />

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects<br />

and Therapeutics I<br />

(Abstracts #560 - 599) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186<br />

2010 Program Book 5


TABLE OF CONTENTS<br />

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis and<br />

Animal Models I<br />

(Abstracts #600 - 619) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189<br />

ACR/ARHP POSTER SESSION B<br />

(ABSTRACTS #733-1345) . . . . . . . . . . . . . . . . . . . . . . .191<br />

B-Cell Biology and Targets in Autoimmune Disease<br />

(Abstracts #733 - 753) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191<br />

Epidemiology and Health Services Research: MSK, CTD and SLE<br />

(Abstracts #754 - 796) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders II<br />

(Abstracts #797 - 821) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />

Genetics, Genomics and Proteomics in the Rheumatic Diseases<br />

(Abstracts #822 - 843) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196<br />

Innate Immunity and Rheumatic Disease<br />

(Abstracts #844- 868) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198<br />

Metabolic and Crystal Arthropathies - Pathogenesis, Epidemiology, and<br />

Clinical Manifestations II<br />

(Abstracts #869 - 889) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200<br />

Miscellaneous Rheumatic and Inflammatory Diseases I<br />

(Abstracts #890- 912) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />

Muscle Biology, Myositis and Myopathies: New Developments in the<br />

Diagnosis, Pathogenesis and Treatment <strong>of</strong> Myositis<br />

(Abstracts #913- 935) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />

Osteoarthritis - Clinical Aspects: Pain and Treatment II<br />

(Abstracts #936 - 955) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205<br />

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and<br />

Pathogenesis<br />

(Abstracts #956 - 983) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206<br />

Quality Measures and Innovation in Practice Management and Care<br />

Delivery<br />

(Abstracts #984 - 1014) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208<br />

Rheumatoid Arthritis - Clinical Aspects: Clinical Features, Disease Risk<br />

Factors, Bone in RA, CVD II<br />

(Abstracts #1015 - 1068) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209<br />

Rheumatoid Arthritis - Human Etiology and Pathogenesis II<br />

(Abstracts #1069 - 1094) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />

Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene<br />

Therapy: Predicting and Measuring Outcomes, Novel Compounds II<br />

(Abstracts #1095 - 1138) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />

Systemic Lupus Erythematosus - Clinical Aspects and Treatment II<br />

(Abstracts #1139 - 1180) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219<br />

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />

Cardiovascular Disease and Clinical<br />

(Abstracts #1181- 1200) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221<br />

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects<br />

and Therapeutics II<br />

(Abstracts #1201- 1239) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223<br />

T-Cell Biology and Targets in Autoimmune Disease<br />

(Abstracts #1240 - 1274) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225<br />

Large-Vessel Vasculitis and Behçet’s Disease I<br />

(Abstracts #1275 - 1315) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227<br />

ARHP Poster Session B: Osteoporosis<br />

(Abstracts #1316 - 1319) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />

ARHP Poster Session B: Behavioral Science<br />

(Abstracts #1320 - 1326) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />

ARHP Poster Session B: Foot<br />

(Abstracts #1327 - 1331) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />

ARHP Poster Session B: Patient Education/Support<br />

(Abstracts #1332 - 1338) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />

ARHP Poster Session B: Pediatrics<br />

(Abstracts #1339- 1345) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232<br />

ACR/ARHP POSTER SESSION C<br />

(ABSTRACTS #1466-2079) . . . . . . . . . . . . . . . . . . . . . .233<br />

Biology and Pathology <strong>of</strong> Bone and Joint: Osteoarthritis-Cartilage<br />

Degradation and Skeletal Turnover<br />

(Abstracts #1466 - 1503) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233<br />

Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />

(Abstracts #1504- 1509) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />

Cytokines, Mediators, Gene Regulation II<br />

(Abstracts #1510 - 1536) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236<br />

Epidemiology and Health Services Research: OP/OA<br />

(Abstracts #1537 - 1576) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237<br />

Genetics, Genomics and Proteomics: Rheumatoid Arthritis and SLE<br />

(Abstracts #1577 - 1612) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 240<br />

Imaging <strong>of</strong> Rheumatic Disease II: Ultrasound, PET, Capillary Microscopy<br />

and Molecular Imaging<br />

(Abstracts #1613 - 1637) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244<br />

Infection-Related Rheumatic Disease<br />

(Abstracts #1638 - 1649) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246<br />

Miscellaneous Rheumatic and Inflammatory Diseases II<br />

(Abstracts #1650- 1671) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247<br />

Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Pediatric<br />

Rheumatic Diseases II<br />

(Abstracts #1672 - 1706) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248<br />

Rheumatoid Arthritis - Animal Models: Pathogenesis, Novel Targets and<br />

Technology<br />

(Abstracts #1707 - 1733) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252<br />

Rheumatoid Arthritis - Clinical Aspects: Classification, Biomarkers,<br />

Predictors <strong>of</strong> Response, Disease Activity, Severity III<br />

(Abstracts #1734 -1787) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254<br />

Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene<br />

Therapy: Biologic DMARDs III<br />

(Abstracts #1788 - 1841) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257<br />

Systemic Lupus Erythematosus - Clinical Aspects and Treatment-<br />

Epidemiology and Health Services III<br />

(Abstracts #1842 - 1882) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />

Sjögren’s Syndrome<br />

(Abstracts #1883- 1918) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and<br />

Treatment II<br />

(Abstracts #1919 - 1964) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />

Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology, and<br />

Animal Models<br />

(Abstracts #1965- 1986) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />

6<br />

2010 Program Book


TABLE OF CONTENTS<br />

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis and<br />

Genetics II<br />

(Abstracts #1987 - 2008) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />

Vasculitis<br />

(Abstracts #2009 - 2049) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274<br />

Epidemiology and Health Services Research<br />

(Abstract #2089) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />

ARHP Poster Session C: Physical Exercise<br />

(Abstracts #2050-2061) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />

ARHP Poster Session C: Research Methods<br />

(Abstracts #2062-2068) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />

ARHP Poster Session C: Quality <strong>of</strong> Life<br />

(Abstracts #2069-2079) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />

REF Industry Roundtable-Supported Symposia . . . . . . . . . . . . . . .280<br />

Industry-Supported Post-Conference Symposia . . . . . . . . . . . . . . .284<br />

RECOGNITION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .286<br />

2010 ACR Annual Meeting Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287<br />

2010 ARHP Annual Meeting Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />

Floor Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .290<br />

Exhibitor Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .292<br />

Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297<br />

ACR/ARHP and REF Staff Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299<br />

INDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .301<br />

Invited Speaker/Moderator Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301<br />

ACR/ARHP Abstract Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />

ACR/ARHP Abstract Keyword Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357<br />

ACR/ARHP Abstract Moderator Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />

The most comprehensive<br />

online collection <strong>of</strong><br />

rheumatology-related images.<br />

Serving as a centralized resource for clinicians, researchers<br />

and health care pr<strong>of</strong>essionals, the <strong>Rheumatology</strong> Image Bank<br />

provides invaluable assistance in self-study or the education<br />

<strong>of</strong> others.<br />

Start your visual exploration <strong>of</strong> rheumatology today!<br />

To learn more about the <strong>Rheumatology</strong> Image Bank,<br />

visit the Resource Center located in the International<br />

Boulevard Lobby or http://images.rheumatology.org.<br />

2010 Program Book 7


CERTIFICATES OF CME CREDIT<br />

OR PARTICIPATION<br />

Accreditation Statement: The <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong> is accredited by the Accreditation Council for<br />

Continuing Medical Education (ACCME) to provide continuing<br />

medical education for physicians.<br />

Statement <strong>of</strong> Designation: The ACR designates this educational<br />

activity for a maximum <strong>of</strong> 48.5 AMA PRA Category 1 credits.<br />

Physicians should only claim credit commensurate with the<br />

extent <strong>of</strong> their participation in the activity.<br />

International Physicians: International physicians who register<br />

as part <strong>of</strong> a group and require AMA PRA Category 1 Credit(s),<br />

must provide the following information to your tour leader: full<br />

name, mailing address, telephone and fax numbers, and e-mail<br />

address. The information will be used to verify your meeting<br />

attendance.<br />

Health Pr<strong>of</strong>essional participants may claim hours to receive a<br />

Certificate <strong>of</strong> Participation for an activity designated for AMA<br />

PRA Category 1 Credit(s) credit.<br />

For non-CME sessions, attendees may also request a certificate<br />

<strong>of</strong> participation.<br />

MEETING EVALUATIONS, CME CREDIT/<br />

CERTIFICATES OF PARTICIPATION<br />

Computers are available for you to complete your CME/<br />

Certificate <strong>of</strong> Participation application and meeting evaluation<br />

form online during the meeting. In addition, you can complete<br />

the evaluation and print your certificate after you return home.<br />

If you are an international physician and require a Certificate<br />

<strong>of</strong> Attendance, this is enclosed in your meeting bag. If your<br />

country recognizes AMA PRA Category 1 Credit(s) TM in<br />

accordance with AMA PRA requirements, please complete a<br />

meeting evaluation and CME application.<br />

Your evaluation <strong>of</strong> the meeting is very important. The ACR/<br />

ARHP annual meeting planning committees use feedback from<br />

attendees to assist in the development <strong>of</strong> future educational<br />

activities; therefore, we encourage you to complete your<br />

evaluation and CME/Certificate application online.<br />

Conflict <strong>of</strong> Interest/Disclosure Statements<br />

As an educational provider accredited by the Accreditation<br />

Council for Continuing Medical Education (ACCME), the<br />

<strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> must ensure balance,<br />

independence, objectivity and scientific rigor in all its<br />

educational activities. Therefore, all speakers and moderators<br />

participating in an ACR-sponsored activity are required to<br />

disclose to the planning committee and audience any financial<br />

or other relationships including, but not limited to:<br />

None: Nothing to disclose<br />

1. Stock, stock options or bond holdings in a for-pr<strong>of</strong>it<br />

corporation or self-directed pension plan<br />

2. Research grants<br />

3. Employment (full or part-time)<br />

4. Ownership or partnership<br />

5. Consulting fees or other remuneration (payment)<br />

6. Non-remunerative positions <strong>of</strong> influence such as <strong>of</strong>ficer,<br />

board member, trustee or public spokesperson<br />

7. Receipt <strong>of</strong> royalties<br />

8. Speakers’ bureau<br />

9. Other<br />

Speakers, moderators and abstract authors submitted their<br />

disclosure online prior to publication. Disclosures for invited<br />

speakers are listed in the indices by presenters’ last name.<br />

Abstract author disclosures are published online and in a<br />

supplement to the October issue <strong>of</strong> Arthritis & Rheumatism.<br />

Disclosures for the Late-Breaking abstracts are published<br />

online and in the December issue <strong>of</strong> Arthritis & Rheumatism.<br />

Any individual who refuses to disclose relevant financial<br />

relationships will be disqualified from being a planning<br />

committee member, a presenter, an author <strong>of</strong> a CME<br />

activity, and cannot have control <strong>of</strong>, or responsibility for, the<br />

development, management, presentation or evaluation <strong>of</strong> the<br />

CME activity.<br />

ACR Disclosure Policy<br />

It is the policy <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> to<br />

ensure that its CME activities are independent and free <strong>of</strong><br />

commercial bias.<br />

To ensure content objectivity and balance, and guarantee that<br />

the content presented is in the best interest <strong>of</strong> its learners<br />

and the public, the ACR requires that everyone in a position<br />

to control content disclose all relevant financial relationships<br />

with any commercial interest if the relationship is financial and<br />

occurred within the past 12 months. If there are relationships<br />

that create a conflict <strong>of</strong> interest, these must be resolved in<br />

accordance with the ACR’s CME Resolution <strong>of</strong> Conflict policy<br />

prior to the participation <strong>of</strong> the individual in the development<br />

or presentation <strong>of</strong> CME content.<br />

COPYRIGHT MATERIALS POLICY<br />

The annual meeting is not a public event. Programs presented<br />

at the meeting are for the education <strong>of</strong> attendees and<br />

purchasers <strong>of</strong> recorded presentations as authorized by the<br />

ACR. The information and materials displayed and presented<br />

during this meeting are the property <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong> and the presenter and cannot be photographed,<br />

copied, photocopied, transformed to electronic format,<br />

reproduced, or distributed without written permission <strong>of</strong> the<br />

<strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> and the presenter. Any<br />

use <strong>of</strong> the program content for commercial purposes, which<br />

includes, but is not limited to oral presentations, audiovisual<br />

materials used by speakers, and program handouts without<br />

8<br />

2010 Program Book


the written consent <strong>of</strong> the ACR is prohibited. This policy applies<br />

before, during and after the meeting. The ACR will enforce its<br />

intellectual property rights and penalize those who infringe upon it.<br />

The names, insignias, logos and acronyms <strong>of</strong> the ACR, the ARHP<br />

and the REF are proprietary marks. Use <strong>of</strong> the names in any<br />

fashion, by any entity, for any purpose, is prohibited without<br />

the express written permission <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong>.<br />

MEDIA<br />

Credentialed media attend the annual meeting to cover stories for<br />

consumer, trade and other media outlets, and are easily identified<br />

by their black press ribbons. Media has access to all general<br />

sessions and limited access (at the discretion <strong>of</strong> speakers) to Meet<br />

the Pr<strong>of</strong>essor and Workshop sessions.<br />

Media may use hand-held audio recorders and still cameras;<br />

moving video recording is also permitted with the permission <strong>of</strong><br />

the presenter(s). The exception to this policy is that an exhibit<br />

may not be photographed or videotaped without the permission<br />

<strong>of</strong> the authorized exhibitor. Annual meeting attendees who have<br />

questions about the ACR’s media policies should contact Erin<br />

Latimer at elatimer@rheumatology.org.<br />

EMBARGO POLICY<br />

Accepted abstracts are made available to the public online in<br />

advance <strong>of</strong> the meeting and are published in a special supplement<br />

<strong>of</strong> Arthritis & Rheumatism. Information contained in those<br />

abstracts may not be released until the abstracts appear online.<br />

Academic institutions, private organizations and companies<br />

with products whose value may be influenced by information<br />

contained in an abstract may issue a press release to coincide<br />

with the availability <strong>of</strong> an ACR abstract online.<br />

However, the ACR continues to require that information that<br />

goes beyond that contained in the abstract, e.g., discussion <strong>of</strong><br />

the abstract done as part a scientific presentation or presentation<br />

<strong>of</strong> additional new information that will be available at the time<br />

<strong>of</strong> the meeting, is under embargo until 5:00 pm Eastern Time on<br />

Sunday, November 7th. Violation <strong>of</strong> this policy may result in the<br />

abstract being withdrawn from the meeting and other measures<br />

deemed appropriate.<br />

Authors are responsible for notifying financial and other sponsors<br />

about this policy.<br />

IMPORTANT LOCATIONS<br />

ACR Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A308<br />

telephone: 404-222-5800<br />

ACR Resource Center . . . . . . . . . . . International Blvd. Foyer<br />

Announcements . . . . . . . . . . . . . . . . .Hall A and B Connector<br />

Business Center . . . . . . . . . . . . . . . International Blvd. Foyer<br />

CME Center . . .International Blvd. Foyer (Registration Hall)<br />

Coat /Baggage . . . . International Blvd. Foyer (Concourse B)<br />

Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Halls A1-A2<br />

First Aid . . . . . . . . . . . . . . . . . . Entrance to Hall A1 (Sat. & Sun.)<br />

B410 (Mon. thru Thur.)<br />

Health Information Technology<br />

Demo Station . . . . . . . . . . . . . . . . . . . . . . Hall A-B Connector<br />

Health Information Technology Theater . . . . . . . . . . . . B402<br />

Hotel Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . . . International Blvd. Foyer (Registration Hall)<br />

Industry-Supported Symposia Information . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . Hallway opposite Sydney Marcus Auditorium<br />

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . . . . . . . .Halls A1 – A2 (Exhibit Hall Booth 555)<br />

Job Opportunities . . . . . . . . . . . . . . . . Opposite Room A312<br />

Lost and Found . . . . . . . . . . . . . . . . . . . . . . A308 (ACR Office)<br />

Membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . . . International Blvd. Foyer (Registration Hall)<br />

Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B212<br />

telephone: 404-222-5804<br />

Nursing Mothers’ Lounge . . . . . . . . . . . . . . . . . . . . . . . . B411<br />

Philanthropy Showcase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . . . . Halls A1 and A2 (Exhibit Hall Booth 1331)<br />

Prayer Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A408<br />

Recharge Stations . . . . . . . . . . . . . . . . . . . . . Halls A1 and A2<br />

REF 5K Run/Walk Registration . . . International Blvd. Foyer<br />

REF Booth . . . . . . . . . . . . . . . . . . . . International Blvd. Foyer<br />

REF Donors’ Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . . . . . . Executive Board Room (near Starbucks)<br />

Registration . . .Registration Hall (International Blvd. Foyer)<br />

Replay Café . . . . . . . Halls A1-A2 (Exhibit Hall – Booth 123)<br />

Restaurant Reservations . . . . . . . . International Blvd. Foyer<br />

Ribbon Distribution . . . . . . . . . . . . . . . . .Membership Booth<br />

. . . . . . . . . . . . . . International Blvd. Foyer (Registration Hall)<br />

Shuttle Bus and Taxi Lobby . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

. . . . . . . . . . . . International Blvd. Driver (near Concourse B)<br />

Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . A302<br />

Trainee Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A305<br />

Visitor Information . . . . . . . . . . . . . International Blvd. Foyer<br />

2010 Program Book 9


10<br />

MEETING INFORMATION<br />

Ask Me Staff<br />

If you have a question about the meeting or need directions to<br />

a room, look for one <strong>of</strong> the Ask Me staff who will be available<br />

throughout the convention center.<br />

Cell Phones, Pages, PDAs & Other Electronic Devices<br />

As a courtesy to meeting attendees, electronic devices must be<br />

operated in silent/vibrate mode within educational sessions;<br />

devices that beep, ring, etc. are prohibited. Cell phone<br />

conversations are not permitted in meeting rooms.<br />

Attire<br />

Attire is business casual. Suits and ties are not required.<br />

However, we suggest you bring a jacket or sweater as the<br />

temperatures in the meeting rooms vary.<br />

Children<br />

Children are not permitted in the educational sessions. To be<br />

admitted in the Exhibit Hall and social events, individuals 18<br />

years <strong>of</strong> age and over are required to pay the guest fee. An<br />

adult must accompany children at all times. Strollers, roller<br />

blades and children’s scooters are not permitted in the Exhibit<br />

Hall. You may arrange for child care through your hotel’s guest<br />

services department.<br />

Exhibit Hall<br />

Exhibitors provide the latest information on products and<br />

services available to rheumatologists, researchers and other<br />

health pr<strong>of</strong>essionals. The 2010 Exhibit Hall is located in Halls A1<br />

and A2 <strong>of</strong> the Georgia World Congress Center.<br />

New this year in the Exhibit Hall is the Replay Café. Visit the<br />

Replay Café to see missed sessions and grab a snack or lunch. In<br />

addition, visit one <strong>of</strong> the networking lounges in the Exhibit Hall<br />

to meet and catch up with your colleagues.<br />

NEW HOURS! We have revised Exhibit Hall hours based on your<br />

feedback:<br />

Monday, November 8: 9:00 am – 5:00 pm<br />

Tuesday, November 9: 9:00 am – 7:00 pm<br />

Wine and Cheese Reception from 5:15 – 6:45 pm<br />

Wednesday, November 10: 9:00 am – 2:00 pm<br />

The Innovation Theater is back by popular demand. Join<br />

participating exhibitors as they present a variety <strong>of</strong> topics in<br />

45-minute sessions.<br />

Food Service<br />

Pre-conference courses include a continental breakfast<br />

and a box lunch. Beverages are provided for Meet the<br />

Pr<strong>of</strong>essor and Workshop sessions. Morning snack will be<br />

available in the poster hall from 9:00 – 10:30 am, Monday –<br />

Wednesday. Afternoon refreshment breaks will be available<br />

in the Exhibit Hall on Monday and Tuesday from 2:00 – 3:00<br />

pm. Complimentary c<strong>of</strong>fee and light refreshments will be<br />

available in the exhibit hall from 9:00 – 10:00 am, Monday –<br />

Wednesday. On Thursday, complimentary c<strong>of</strong>fee will be served<br />

from 7:30–9:00 am in the International Boulevard Foyer <strong>of</strong><br />

the convention center. Food outlets will be open in several<br />

locations throughout the Georgia World Congress Center,<br />

including the Exhibit Hall. On Monday through Thursday, the<br />

Terrace Restaurant (Building B) will be open for breakfast from<br />

2010 Program Book<br />

6:30 – 10:30 am and will <strong>of</strong>fer a continental breakfast for $9.95<br />

and a hot buffet breakfast for $14.95. A luncheon buffet will be<br />

served from 11:30 am – 3:00 pm for $14.95.<br />

Meeting Room Capacity/Important Fire Safety Information<br />

Attendance at scientific sessions is on a first-come, first-served<br />

basis. Rooms which have reached the maximum capacity<br />

may be closed according to local fire and safety regulations.<br />

Standing in the aisle or against the walls is not permitted. If<br />

overcrowding occurs, staff/security personnel will close the<br />

session. If space does not permit you to attend a session, the<br />

session may be available on SessionSelect or replayed in the Inroom<br />

Encore Theater or the Replay Café in the Exhibit Hall.<br />

Photography and Videotaping<br />

Photographers will be present at the meeting. Registration<br />

and attendance at, or participation in, ACR meetings and other<br />

activities constitutes an agreement by the registrant for the<br />

ACR’s use and distribution (both now and in the future) <strong>of</strong><br />

the registrant or attendee’s image or voice in photographs,<br />

videotapes, electronic reproductions, and audio tapes <strong>of</strong><br />

such events and activities. Visual reproduction <strong>of</strong> sessions is<br />

prohibited without prior written permission <strong>of</strong> the ACR. The<br />

ACR reserves the rights to audio and video reproduction at the<br />

2010 ACR/ARHP Annual Scientific Meeting. See copyrighted<br />

materials policy for more information on page 8.<br />

Special Needs<br />

If you require special arrangements, please contact Ron Olejko<br />

in the ACR Office (Room A304) at (404) 222-5800.<br />

Wheelchair & Scooter Rentals<br />

If you did not make advance arrangements for an electric<br />

wheelchair or scooter, you can do so by calling ScootAround<br />

at (888) 441-7575 or by visiting the FedEx/Kinkos Business<br />

Center in the International Boulevard Lobby entrance <strong>of</strong> the<br />

Georgia World Congress Center.<br />

Name Badges<br />

For security reasons, your badge will be required for<br />

admittance to all sessions, exhibits, social events and shuttle<br />

buses. Please wear your badge so it can be easily seen at all<br />

times. Lost badges should be reported to the registration staff<br />

immediately.<br />

Emergency Contact Information<br />

Space is provided on the back <strong>of</strong> your badge to list name<br />

and telephone numbers <strong>of</strong> your emergency contacts. Please<br />

complete this information before inserting your badge in your<br />

badge holder.<br />

No Smoking<br />

All meeting facilities at the convention center, hotel meeting<br />

rooms and other venues have been designated as non-smoking<br />

areas.<br />

Opening Event at the Georgia Aquarium<br />

Sunday, November 7 at 7:00 pm<br />

Mingle with friends and colleagues as your walk alongside<br />

spectacular aquatic wonders in the largest indoor aquarium in<br />

the world. The Georgia Aquarium will be open to an exclusive<br />

audience - you! Tickets are $40 and are available on a firstcome,-first-served<br />

basis. To pick up or purchase ticket(s), please<br />

visit the registration hall in the International Boulevard foyer.


Shuttle Bus Service<br />

See shuttle signs in ACR hotel lobbies or at the International<br />

Boulevard Lobby entrance.<br />

SESSION DESCRIPTIONS<br />

ACR Clinical Symposia provide instruction to improve patient<br />

care. Developments from other specialties and practical patient<br />

management skills will be emphasized. Included are the<br />

following: Clinicopathologic Conference, Curbside Consults –<br />

Ask the Pr<strong>of</strong>essors, Great Debate, Clinical Reviews and Thieves’<br />

Market.<br />

ACR and ARHP Concurrent Abstract Sessions are the main<br />

forum for didactic presentation <strong>of</strong> original research related to<br />

rheumatic diseases.<br />

ACR and ARHP Poster Sessions feature poster presentation<br />

<strong>of</strong> abstracts, facilitating one-on-one interaction between the<br />

presenter and the audience.<br />

ACR and ARHP Pre-Conference Courses are designed to<br />

<strong>of</strong>fer attendees, with a specific interest, a unique learning<br />

opportunity. A separate registration is required.<br />

ACR Basic Science Symposia provide an update <strong>of</strong> the most<br />

recent scientific developments in the field <strong>of</strong> rheumatology.<br />

ACR Immunology Updates for Clinicians is a series <strong>of</strong> three one<br />

hour lectures designed to provide clinicians with an update <strong>of</strong><br />

the new developments in immunology.<br />

ACR Medical Aspects <strong>of</strong> Rheumatic Diseases Sessions cover<br />

topics in other subspecialty areas in internal medicine that are<br />

<strong>of</strong> importance to the practice <strong>of</strong> rheumatology, presented by<br />

experts from other medical subspecialties.<br />

ACR Meet the Pr<strong>of</strong>essor Sessions provide an opportunity for<br />

interaction and consultation with highly respected pr<strong>of</strong>essionals<br />

who have expertise in a particular area. Several sessions are<br />

designated for trainees only. A separate registration is required.<br />

ACR Plenary Sessions: Discovery 2010 – three plenary sessions<br />

will be <strong>of</strong>fered and each session will have a separate focus and<br />

will highlight abstracts <strong>of</strong> significant novelty and importance.<br />

ACR Practice Issues are sessions that address the major<br />

changes in the practice <strong>of</strong> rheumatology with the introduction<br />

<strong>of</strong> new medications, devices, and diagnostic and ancillary<br />

services for patients.<br />

ACR State-<strong>of</strong>-the-Art Lectures present current information<br />

about topics related to rheumatology and are presented by<br />

leading experts in their respective fields.<br />

ACR Study Groups are designed to bring together attendees<br />

with a common interest in one disease, a group <strong>of</strong> related<br />

disorders, or a specialized field <strong>of</strong> study for discussion and<br />

dissemination <strong>of</strong> information.<br />

ACR/ARHP Workshops are designed to bring attendees<br />

together to foster hands-on learning, and provide an<br />

opportunity for interaction and consultation with highly<br />

respected pr<strong>of</strong>essionals who have expertise in a particular area.<br />

Several sessions are designated for trainees only. A separate<br />

registration is required.<br />

ACR Year in Review highlights publications <strong>of</strong> major interest<br />

to the membership that have appeared in rheumatology<br />

literature since the last meeting. Both basic science and clinical<br />

perspectives are represented.<br />

ARHP Concurrent Sessions <strong>of</strong>fer educational programs <strong>of</strong><br />

interest to various health pr<strong>of</strong>essionals. Concurrent sessions<br />

include invited speakers; peer-reviewed programs and lectures;<br />

and research and special interest abstract sessions.<br />

ARHP General Sessions are interdisciplinary sessions scheduled<br />

without competing programs. The topics are <strong>of</strong> expansive<br />

interest or the speaker is <strong>of</strong> such status as to appeal to the<br />

membership at large.<br />

2010 SPECIAL SESSIONS<br />

ACR<br />

• ACR Leadership Town Hall Meeting . . . . . . . . . . . . . . . . . . .106<br />

• Career Opportunities in <strong>Rheumatology</strong>: Making a Choice . . 112<br />

• Clinical Teaching Strategies in the Outpatient Clinic Setting . .66<br />

• Contract Negotiations for Physicians . . . . . . . . . . . . . . . . . . .65<br />

• ILAR Global Health Project . . . . . . . . . . . . . . . . . . . . . . . . . . .84<br />

• Insurance Roundtable Discussion . . . . . . . . . . . . . . . . . . . . . .94<br />

• Legislative Update from Capitol Hill . . . . . . . . . . . . . . . . . . . .52<br />

• News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />

• The Changing Face <strong>of</strong> the <strong>Rheumatology</strong> Workforce:<br />

Gender Issues in the Workplace . . . . . . . . . . . . . . . . . . . . . .94<br />

ACR REF<br />

• ACR REF Clinician Scholar Educators Lecture . . . . . . . . . . . .53<br />

• ACR REF Memorial Lecture: <strong>Rheumatology</strong> Education 2010 . .37<br />

• REF Edmond L. Dubois, MD, Memorial Lectureship . . . . . . .53<br />

• REF Marshall J. Schiff, MD, Memorial Lectureship: Everything<br />

a Rheumatologist Should Know About Spine Surgery but Was<br />

Afraid to Ask . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .84<br />

• REF Oscar S. Gluck, MD, Memorial Lectureship -<br />

Osteoimmunology: Crosstalk Between the Immune<br />

and Bone Systems: Biologic and Clinical Implications . . . . .28<br />

• REF Paul Klemperer, MD, Memorial Lectureship: Systemic<br />

Sclerosis: Genetic? Autoimmune? One Disease? . . . . . . . . .98<br />

• REF “Within Our Reach” Lecture: Finding a Cure for<br />

Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .45<br />

ARHP<br />

• ARHP First-time Attendees Orientation . . . . . . . . . . . . . . . . .27<br />

• ARHP Moderators Orientation . . . . . . . . . . . . . . . . . . . . . . . .27<br />

• ARHP Networking at Noon . . . . . . . . . . . . . . . . . . . . . . . . . . .63<br />

• ARHP Networking for Georgia Health Pr<strong>of</strong>essionals and<br />

Physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35<br />

• ARHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . .30<br />

• ARHP Occupational and Physical Therapy Networking . . 105<br />

• ARHP Office Nurse Networking . . . . . . . . . . . . . . . . . . . . . 105<br />

• ARHP Pediatrics Networking . . . . . . . . . . . . . . . . . . . . . . . . .35<br />

• ARHP Research Coordinators Networking . . . . . . . . . . . . . .35<br />

2010 Program Book 11


GUIDE TO HELP NAVIGATE<br />

THE MEETING<br />

To navigate the meeting by track, look for these icons.<br />

BR Business <strong>of</strong> <strong>Rheumatology</strong><br />

C Clinical<br />

c/r Clinical and Research<br />

cP Clinical Practice<br />

Ed. Educators<br />

f Fellow-In-Training<br />

P Pediatrics<br />

P/C Pediatrics and Clinical<br />

R Research<br />

ARS<br />

AUDIENCE RESPONSE SYSTEM<br />

Audience Response System will be used in selected<br />

sessions to allow attendees to actively participate.<br />

PM PAIN MANAGEMENT<br />

The ACR designates certain sessions for pain<br />

management credit as required by the Medical Board <strong>of</strong><br />

California (AB487). This designation is identified by the<br />

icon shown and will be placed next to the session title.<br />

PS PATIENT SAFETY<br />

The ACR designates certain sessions that will satisfy<br />

patient safety/risk management requirements <strong>of</strong> the<br />

Medical Board <strong>of</strong> Pennsylvania. This designation is<br />

identified by the icon shown and will be placed next to<br />

the session title.<br />

In-ROOM ENCORE THEATER – no need to miss a<br />

session!<br />

Select ACR sessions will be recorded and replayed<br />

during the meeting in designated hotels. Therefore,<br />

if you missed one <strong>of</strong> the designated sessions you can<br />

watch the session later that day or the next day in the<br />

In-room Encore Theater. The sessions that have been<br />

scheduled to be replayed in the In-room Encore Theater<br />

are indicated with the icon above. Additional sessions<br />

may be added on site. Check the ACR/ARHP Daily News<br />

for new sessions. Please see page 14 for a tentative list<br />

<strong>of</strong> sessions.<br />

MEETING SERVICES<br />

ACR Resource Center – The Spot for All Things ACR!<br />

Located in the International Boulevard Foyer. Need information<br />

on upcoming educational activities in 2011? Would you like<br />

to view demos <strong>of</strong> popular ACR and ARHP online resources<br />

including CARE, the Advanced <strong>Rheumatology</strong> Course,<br />

SessionSelect or the <strong>Rheumatology</strong> Image Bank? Or do you just<br />

need directions to your next session? You’re in luck… the ACR<br />

Resource Center has it all.<br />

• Advocacy<br />

Stop by the Advocacy kiosk to get the most up-to-date<br />

information on the legislative and regulatory issues affecting<br />

your pr<strong>of</strong>ession. We have talking points on all ACR legislative<br />

priorities, instructions on how to contact your Members<br />

<strong>of</strong> Congress and tips on how to get more involved with the<br />

ACR’s advocacy efforts. You can also receive information on<br />

RheumPAC – the ACR’s political action committee.<br />

• Lupus Initiative<br />

New to the ACR Resource Center this year is the Lupus<br />

Initiative. This educational initiative, designed to reduce<br />

health disparities in lupus based on gender, race and<br />

ethnicity, will <strong>of</strong>fer demonstrations <strong>of</strong> its various educational<br />

resources for medical and health pr<strong>of</strong>essionals in training and<br />

in practice. Resources include: complimentary CME activities,<br />

physician-patient dialogue cards, suggested reading lists and<br />

much more. Lupus experts are encouraged to drop by to<br />

participate in our weekly online discussion.<br />

• Practice Management & Coding<br />

Visit with ACR certified coders and practice management<br />

experts for any coding, billing, insurance or practice<br />

management questions. We have all the resources you need<br />

for an efficient rheumatology practice. You can also pick up<br />

the latest copy <strong>of</strong> the ACR’s monthly RheumWATCH.<br />

• Publications<br />

The editorial <strong>of</strong>fice staff <strong>of</strong> the Arthritis & Rheumatism and<br />

Arthritis Care & Research journals will be available to answer<br />

questions concerning online article submission and article<br />

review processes for the journals.<br />

• Quality & Informatics<br />

Learn how enrollment in the RCR can benefit you. The<br />

RCR provides hands-on measurement tools and reports<br />

that enable you to comparatively assess the quality and<br />

outcome <strong>of</strong> rheumatologic care you provide. Find out how<br />

to incorporate this tool with the ACR’s practice improvement<br />

module.<br />

• Recertification<br />

Need help navigating Maintenance <strong>of</strong> Certification? Let<br />

the ACR guide you. We have answers to help steer your<br />

route to success with the <strong>American</strong> Board <strong>of</strong> Internal<br />

Medicine’s Maintenance <strong>of</strong> Certification program. An ABIM<br />

representative will be on-site for the entire meeting to help<br />

answer your questions.<br />

12<br />

2010 Program Book


ACR Resource Center Hours:<br />

Sunday, November 7<br />

Monday, November 8<br />

Tuesday, November 9<br />

Wednesday, November 10<br />

Thursday, November 11<br />

Noon – 6:00 pm<br />

7:00 am to 6:00 pm<br />

7:00 am to 6:00 pm<br />

7:00 am to 6:00 pm<br />

7:00 am to 1:30 pm<br />

Membership Booth<br />

Located in the registration hall (International Boulevard<br />

entrance). This is the place to go if you want to become a<br />

member, pay dues, reinstate your membership, learn more<br />

about member benefits and awards, or volunteer to serve on a<br />

committee.<br />

Lost and Found<br />

Found items should be returned to the ACR Office, room A308.<br />

If you are looking for a lost item, go to the ACR Office or call<br />

(404) 222-5800.<br />

Newsroom<br />

Located in room B212, use <strong>of</strong> the Newsroom is limited to media<br />

representatives with press passes.<br />

Announcements<br />

Located in the Hall A-B Connector, display boards will be<br />

available for posting announcements and events <strong>of</strong> interest.<br />

Posted materials are limited to 8.5” x 11” in size.<br />

Registration<br />

Registration counters are located in the registration hall<br />

(International Boulevard Foyer).<br />

Hours <strong>of</strong> operation are:<br />

Saturday, November 6 6:30 am – 6:00 pm<br />

Sunday, November 7 6:30 am – 7:45 pm<br />

Monday, November 8 6:30 am – 5:00 pm<br />

Tuesday, November 9 6:30 am – 5:00 pm<br />

Wednesday, November 10 6:30 am – 5:00 pm<br />

Thursday, November 11 7:00 am – 1:00 pm<br />

REF Booth<br />

Visit the REF Booth in the International Boulevard Foyer to find<br />

out more about what the REF is doing to ensure the future <strong>of</strong><br />

rheumatology. View and order the latest poster in the Rodnan<br />

Commemorative Gout Print poster series, learn more about<br />

REF programs and initiatives, and even receive a gift just for<br />

stopping by!<br />

REF Booth Hours:<br />

Sunday, November 7 Noon to 5:00 pm<br />

Monday, November 8 7:00 am to 5:00 pm<br />

Tuesday, November 9 7:00 am to 5:00 pm<br />

Wednesday, November 10 7:00 am to 5:00 pm<br />

Thursday, November 11 7:00 am to 1:00 pm<br />

REF Donors’ Lounge<br />

REF donors should plan to spend time in the Donors’ Lounge,<br />

located in the Executive Board Room (between Starbucks<br />

and Concourse A), and take advantage <strong>of</strong> special perks! Enjoy<br />

breakfast each morning and gourmet c<strong>of</strong>fee throughout<br />

the day; catch up on work and check e-mail at one <strong>of</strong> our<br />

private computer stations; grab refreshments or enjoy a<br />

complimentary chair massage. Donors must have <strong>of</strong>ficial donor<br />

access pass to gain entry and these passes can be claimed at<br />

the Donors’ Counter just outside the entrance to the Lounge.<br />

Donors who contributed a minimum cumulative amount <strong>of</strong><br />

$500 during fiscal year 2010 (July 1, 2009 through June 30,<br />

2010) are eligible to enjoy the Donors’ Lounge.<br />

Donors’ Lounge hours are:<br />

Sunday, November 7 Noon - 5:00 pm<br />

Monday, November 8 7:00 am - 6:00 pm<br />

Tuesday, November 9 7:00 am - 6:00 pm<br />

Wednesday, November 10 7:00 am - 6:00 pm<br />

Thursday, November 11 7:00 am - Noon<br />

Speaker Ready Room<br />

Located in room A302. Check-in is expected <strong>of</strong> all speakers.<br />

Plan to check-in 24 hours prior to your presentation time. In<br />

the Speaker Ready Room, you can review your presentation<br />

and approve the file to be uploaded to the central server.<br />

Pr<strong>of</strong>essional audiovisual technicians will be available to<br />

assist you. Computers in the Speaker Ready Room will be<br />

configured with hardware and s<strong>of</strong>tware exactly like the ones<br />

in the meetings rooms and will allow you to preview your<br />

presentation, identify problems and make corrections as<br />

necessary before your presentation.<br />

Hours <strong>of</strong> operation are:<br />

Saturday, November 6 6:30 am – 5:30 pm<br />

Sunday, November 7 6:30 am – 6:30 pm<br />

Monday, November 8 6:30 am – 6:00 pm<br />

Tuesday, November 9 6:30 am – 8:00 pm<br />

Wednesday, November 10 6:30 am – 6:00 pm<br />

Thursday, November 11 7:00 am – 12:30 pm<br />

Electronic Syllabus<br />

View, download and print speaker syllabi during and after the<br />

annual meeting.<br />

Wireless Access<br />

Free wireless access is available in the public hallways <strong>of</strong> the<br />

Georgia World Congress Center. Search for “ACR/ARHP 10” –<br />

no password required.<br />

2010 REF 5K RUN/WALK<br />

Tuesday, November 9, 2010<br />

6:00 – 8:00 am<br />

Your annual meeting experience will be just “peachy” when<br />

you decide to participate in the 2010 REF 5K Run/Walk.<br />

Discover Atlanta while helping the ACR Research and Education<br />

Foundation raise money to ensure the future <strong>of</strong> rheumatology.<br />

Complimentary shuttle service to and from the run event will<br />

be provided and all participants will receive an <strong>of</strong>ficial REF 5K<br />

Run/Walk T-shirt. Participants may register at the REF 5K Run/<br />

Walk Booth located in the registration area until 5:00 PM,<br />

Monday, November 8, or until the event sells out. A minimum<br />

donation <strong>of</strong> $50 is required and the event is limited to 350<br />

participants. Proceeds raised from this event will support<br />

grants, awards and activities provided by the REF.<br />

2010 Program Book 13


IN-ROOM ENCORE THEATER<br />

The following ACR/ARHP sessions will be recorded and replayed in<br />

select hotels. See page 15, for the list <strong>of</strong> hotels that <strong>of</strong>fer the In-room<br />

Encore Theater.<br />

Monday, November 8<br />

9:00 pm – Tuesday, November 9 • 9:00 pm<br />

ACR/ARHP Opening Lecture and Awards: An Infectious Etiology<br />

<strong>of</strong> Rheumatoid Arthritis<br />

From Sunday, November 7 • 5:45 – 6:30 pm<br />

ACR Clinical Symposium: Year in Review<br />

From Monday, November 8 • 7:15 - 8:30 am<br />

ACR Immunology Updates for the Clinicians: Innate Immunity<br />

and Inflammation<br />

From Monday, November 8 • 9:00 - 10:00 am<br />

ACR Medical Aspects <strong>of</strong> Rheumatic Diseases: Heparin and<br />

Antiphospholipid Syndrome-induced Thrombocytopenia<br />

From Monday, November 8 • 9:00 - 10:00 am<br />

ACR State-<strong>of</strong>-the-Art Lecture: Genetic Disorders <strong>of</strong> Connective<br />

Tissue and Joint Hypermobility<br />

From Monday, November 8 • 1:00 - 2:00 pm<br />

TOTAL HOURS: 5.0<br />

Wednesday, November 10 • 9:00 pm<br />

Thursday, November 11 • 9:00 pm<br />

ACR Clinical Symposium: The Brain and Systemic Lupus Erythematosus:<br />

2010 Update<br />

From Tuesday, November 9 • 1:00 - 2:00 pm<br />

ACR Clinical Symposium: Inflammatory Myopathy Update<br />

From Tuesday, November 9 • 4:30 - 6:00 pm<br />

ACR State-<strong>of</strong>-the-Art Lecture: From Fat to Joints – The Vicious Side <strong>of</strong><br />

Adipokines<br />

From Wednesday, November 10 • 8:45 - 9:45 am<br />

ACR Clinical Symposium: Controversies in Osteoporosis and Low Bone<br />

Mass: Who Do We Treat, For How Long, and at What Risks?<br />

From Wednesday, November 10 • 11:00 am - 12:30 pm<br />

ACR Clinical Symposium: Perioperative Management <strong>of</strong> Selected<br />

Problems in Patients with Rheumatic Disease<br />

From Wednesday, November 10 • 4:30 - 6:00 pm<br />

TOTAL HOURS: 6.5<br />

Tuesday, November 9 • 9:00 pm<br />

Wednesday, November 10 • 9:00 pm<br />

ACR Clinical Symposium: The Great Debate: Is it Time to Use Biologics<br />

as First-line Therapy in Rheumatoid Arthritis?<br />

From Monday, November 8 • 2:30 - 4:00 pm<br />

ACR State-<strong>of</strong>-the-Art Lecture: Methotrexate 2010<br />

From Tuesday, November 9 • 7:15 - 8:15 am<br />

ARHP Concurrent Session: Daltroy Memorial Lectureship: Adherence<br />

to Medical Regimens for Rheumatic Diseases and the Importance <strong>of</strong><br />

Patient-Clinician Communication<br />

From Tuesday, November 9 • 9:15 - 10:15 am<br />

ACR Clinical Symposium: Curbside Consults - Ask the Pr<strong>of</strong>essors<br />

From Tuesday, November 9 • 11:00 am - 12:30 pm<br />

TOTAL HOURS: 5.0<br />

14<br />

2010 Program Book


ACR Hotels + Map<br />

Complimentary shuttle service will be provided from designated<br />

hotels and the Georgia World Congress Center during peak times in<br />

the early morning and late afternoon. Service will also be provided<br />

for the opening event at the Georgia Aquarium. During those times<br />

the complimentary shuttle does not operate, transportation options<br />

include:<br />

Taxi: The flat fare with the Downtown, Midtown or Buckhead zones<br />

is $8 plus $2 for each additional person. Travel from one zone to<br />

another zone is metered. Approx. fare between Downtown and<br />

Midtown is $12; approx. fare from downtown to Buckhead is $27.<br />

MARTA: Most ACR hotels are with a short walk <strong>of</strong> the following<br />

MARTA (rail) stations: Peachtree Center, Civic Center, North Avenue,<br />

Midtown, Buckhead and Lenox Square. Fare is $2 plus .50 cents for a<br />

reusable Breeze card.<br />

Shuttle: Check the posted schedule in the lobbies <strong>of</strong> participating<br />

hotels and the Georgia World Congress Center for detailed shuttle<br />

times and information.<br />

If you require accessible transportation assistance, please call<br />

the ACR Shuttle bus desk (404) 903-0007 or stop at the ACR Shuttle<br />

Counter in the International Boulevard Foyer (near Concourse B).<br />

1. Atlanta Marriott Downtown<br />

160 Spring Street NW (404) 688-8600<br />

2. Atlanta Marriott Marquis (co-headquarters)*<br />

265 Peachtree Center Avenue (404) 521-0000<br />

3. Cancelled<br />

4. Days Inn Atlanta Downtown<br />

300 Spring Street (404) 523-1144<br />

5. Embassy Suites at Centennial Olympic Park*<br />

267 Marietta Street (404) 223-2300<br />

6. Georgian Terrace<br />

659 Peachtree Street (800) 651-2316<br />

7. Glenn<br />

110 Marietta Street (404) 521-2250<br />

8. Hampton Inn & Suites Atlanta Downtown<br />

161 Spring Street (404) 589-1111<br />

9. Hilton Atlanta*<br />

255 Courtland Street (404) 659-0000<br />

10. Hilton Garden Inn Atlanta Downtown*<br />

275 Baker Street (404) 577-2001<br />

11. Holiday Inn Atlanta Downtown<br />

101 Andrew Young Intl Boulevard (404) 524-5555<br />

12. Hotel Midtown<br />

125 10th Street (404) 873-4800<br />

13. Hyatt Regency Atlanta*<br />

265 Peachtree Street (404) 577-1234<br />

14. Loews Atlanta<br />

1065 Peachtree Street (404) 745-5000<br />

15. Omni Hotel at CNN Center (headquarters)*<br />

100 CNN Center (404) 659-0000<br />

16. Residence Inn Atlanta Downtown<br />

134 Peachtree Street (404)522-0950<br />

17. Ritz Carlton Atlanta*<br />

181 Peachtree Street (404) 659-0400<br />

18. Sheraton Atlanta*<br />

165 Courtland Street (404) 659-6500<br />

19. W Atlanta Downtown*<br />

45 Ivan Allen Jr. Boulevard (404) 582-5789<br />

20. Westin Peachtree Plaza Hotel<br />

210 Peachtree Street (404) 659-1400<br />

21. Cancelled<br />

*Hotels that <strong>of</strong>fer the in-room encore theater.<br />

Additional ACR/ARHP Housing:<br />

Courtyard by Marriott – Buckhead<br />

3332 Peachtree Road (404) 869-0818<br />

Embassy Suites - Buckhead<br />

3285 Peachtree Road (404) 261-7733<br />

Four Season Hotel Midtown<br />

75 14th Street (404) 881-9898<br />

Grand Hyatt Atlanta - Buckhead<br />

3300 Peachtree Road (404) 237-1234<br />

Mansion on Peachtree – Buckhead<br />

3376 Peachtree Road (404) 995-7500<br />

Marriott Buckhead Hotel & Conference Center<br />

3405 Lenox Road (404) 261-9250<br />

Regency Suites Hotel - Midtown<br />

975 West Peachtree Street (404) 876-5003<br />

Ritz-Carlton Buckhead<br />

3434 Peachtree Road (404) 237-2700<br />

W Atlanta – Buckhead<br />

3377 Peachtree Road (404) 500-3100<br />

Westin Buckhead<br />

3391 Peachtree Road (404) 365-0065<br />

2010 Program Book 15


SPECIAL OFFERS AT THE<br />

ANNUAL SCIENTIFIC MEETING<br />

Enhanced SessionSelect – no need to miss a session!<br />

Within 24 hours <strong>of</strong> virtually every live session at the annual<br />

meeting, recordings <strong>of</strong> the sessions will be made available<br />

through SessionSelect, your source for ACR education, online.<br />

For the 3rd year running, as a scientific attendee, you get FREE<br />

ACCESS to over 200 hours <strong>of</strong> online annual meeting content –<br />

over $500 <strong>of</strong> added value.<br />

Select sessions will be recorded and available to view as webcasts<br />

during and after the meeting. Therefore, if you missed one <strong>of</strong><br />

the designated sessions, you can watch it the next day through<br />

SessionSelect. The sessions that will be available through<br />

SessionSelect are indicated with the webcast icon above.<br />

Recordings <strong>of</strong> individual sessions are subject to change.<br />

<strong>College</strong> Showcase – NEW<br />

During intermissions <strong>of</strong> the scientific sessions, ACR staff and<br />

representatives will present live demonstrations <strong>of</strong> educational<br />

resources and tools at the ACR Resource Center, located in the<br />

International Boulevard Foyer. Presentations <strong>of</strong> educational<br />

resources and tools include the <strong>Rheumatology</strong> Image Bank<br />

SessionSelect; the Lupus Initiative; CARE (ACR’s self-assessment<br />

module); AIM (ACR’s practice improvement module);<br />

<strong>Rheumatology</strong> Clinical Registry and many more. Plan to stop<br />

by the ACR Resource Center for a brief demo on the way to<br />

your next session.<br />

Complimentary Information<br />

Attendees can stop by the ACR Resource Center for<br />

complimentary product brochures and patient education<br />

materials – to come discover all the <strong>College</strong> <strong>of</strong>fers you, your<br />

patients and your practice.<br />

Abstracts on ACR Web site<br />

Abstracts are available online at www.rheumatology.org.<br />

Medical Bag<br />

Don’t forget to pick up a Medical Bag prior to visiting the<br />

exhibits. Each bag contains special <strong>of</strong>fers and invitations from our<br />

exhibitors and will be distributed from the exhibition entrance<br />

while supplies last.<br />

Recharge Areas<br />

Recharge areas will include workstations with power outlets<br />

designed for you to connect your laptop, recharge your mobile or<br />

check e-mail via the complimentary Wi-fi-enabled Internet access.<br />

Free Give-a-Ways<br />

Looking for a souvenir to take home? Visit the ACR Resource Center<br />

to learn more about ACR and ARHP programs, resources and<br />

initiatives—and while there, pick up a free gift just for stopping by!<br />

POSTER SESSIONS<br />

Poster presentations facilitate one-on-one interaction between<br />

the presenter and the attendee. There will be one poster session<br />

per day on Monday, Tuesday and Wednesday. Posters will remain<br />

in the Georgia World Congress Center Halls B1 & B2 from 9:00<br />

am–6:00 pm, with presenters in attendance to answer questions<br />

about their abstracts from 9:00–11:00 am each day. There is no<br />

poster session on Thursday. The number on the poster boards<br />

refers to the abstract presentation number, and this number will<br />

change for each poster session.<br />

Poster Session Presenter Instructions<br />

If you are presenting a poster, please set up and remove your<br />

poster during the times listed below.<br />

Poster presenter ribbons will be available in the Speaker Ready<br />

Room – Room# A302.<br />

Posters must be removed by 6:30 pm. Posters not removed by<br />

6:30 pm will be removed and discarded. ACR is not responsible for<br />

lost, damaged or discarded posters.<br />

Poster Sessions - Monday, November 8 – Wednesday, November 10<br />

from 9:00 am–6:00 pm<br />

Set Up: 7:00–9:00 am<br />

Presentation: 9:00–11:00 am<br />

Poster Tours: 9:00–9:45 am; 10:15 – 11:00 am and 4:30 – 5:30 pm<br />

Posters to remain up until 6:00 pm<br />

Removal: 6:00–6:30 pm<br />

Guided Poster Tours<br />

Guided poster tours provide an opportunity for scientific<br />

attendees to ask questions and gain insights from leaders in the<br />

field while earning CME credits. Morning tours will <strong>of</strong>fer insights<br />

from both poster presenters and tour guides, while afternoon<br />

tours will exclusively feature the tour guide’s expert opinion.<br />

Although there is no fee to participate, pre-registration is required<br />

and each tour is limited to 20 registered scientific attendees. If<br />

you would like to participate and have not registered you can<br />

check tour availability and request a ticket in the registration area,<br />

located in the International Boulevard Foyer. If you registered<br />

in advance <strong>of</strong> the meeting your ticket was included with your<br />

meeting materials. Once you have your ticket, plan to collect<br />

your headset and meet your group 10 minutes before your tour<br />

departs from the entrance <strong>of</strong> the poster hall, located in Halls B1<br />

& B2.<br />

16<br />

2010 Program Book


to the premier meeting in rheumatology<br />

2011 ACR/ARHP Annual Scientific Meeting Call for Proposals<br />

Don’t miss the opportunity to propose a session concept,<br />

topic idea or speaker suggestion for the ACR/ARHP 2011<br />

Annual Scientific Meeting. Your ideas will assist the ACR/<br />

ARHP annual meeting planning committees in selecting<br />

quality topics and speakers for the 2011 annual meeting;<br />

therefore, we encourage you to submit<br />

your ideas/suggestions online.<br />

To view instructions and submit a proposal, visit<br />

www.rheumatology.org/education.<br />

2011 Study Groups Application<br />

Coordinate a study group and create a unique opportunity<br />

to network with peers that share your interest in a disease,<br />

disorder or specialized field <strong>of</strong> study.<br />

To view the guidelines and submit an application, visit<br />

www.rheumatology.org/education.<br />

ACR/ARHP proposals and study group applications must be<br />

submitted online by Monday, November 15, 2010.<br />

GO<br />

ACR/ARHP Scientific Sessions<br />

SATURDAY, NOVEMBER 6, 2010<br />

ACR/ARHP Registration<br />

6:30 am - 6:00 pm<br />

International Blvd. Foyer<br />

ACR Musculoskeletal Ultrasound<br />

Course for Rheumatologists –<br />

dAy One C<br />

7:30 am - 4:30 pm<br />

A412<br />

Admission to the ACR Musculoskeletal Ultrasound Course<br />

requires a separate registration.<br />

Moderator: Ralf G. Thiele, MD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Faculty: Rany Al Haj, MD; Shore Arthritis and Rheumatism<br />

Associates; Ocean, NJ<br />

Marina Backhaus, MD; University Medicine Berlin: Campus<br />

Charité Mitte; Berlin, Germany<br />

P. Scott Pollock, MD; Seattle, WA<br />

David A. Bong, MD; Instituto Poal de Reumatologia; Bruce, WI<br />

Jurgen Craig-Muller, MD; CentraCare Clinic; St. Cloud, MN<br />

Paul J. DeMarco, MD; Arthritis & Rheumatism Associates PC;<br />

Wheaton, MD<br />

Amy M. Evangelisto, MD; Arthritis Rheumatic and Back Disease<br />

Association; Philadelphia, PA<br />

David E. Feinstein, DO; Cooper Health System, Robert Wood<br />

Johnson Medical School; Camden, NJ<br />

Emilio Filippucci, MD, PhD; Università Politecnica delle Marche -<br />

Ancona; Jesi, Ancona, Italy<br />

Janak R. Goyal, MD; University <strong>of</strong> Medicine and Dentistry <strong>of</strong> New<br />

Jersey, Robert Wood Johnson Medical School; Perth Amboy, NJ<br />

Jay B. Higgs, MD; Wilford Hall Medical Center, Department <strong>of</strong> Air<br />

Force; San Antonio, TX<br />

Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />

Jacksonville; Ponte Vedra Beach, FL<br />

Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />

Madrid, Spain<br />

Midori Jane Nishio, MD; John Muir Medical Center; Walnut<br />

Creek, CA<br />

Anthony M. Reginato, PhD, MD; University Medicine Foundation,<br />

Rhode Island Hospital; Providence, RI<br />

2010 Program Book 17


saturday<br />

Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />

ON, Canada<br />

Jonathan Samuels, MD; New York University Hospital for Joint<br />

Disease; New York, NY<br />

Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch; Berlin, Germany<br />

Darren Tabechian, MD; University <strong>of</strong> Rochester School <strong>of</strong><br />

Medicine; Rochester, NY<br />

Mihaela Taylor, MD; University <strong>of</strong> California Los Angeles; Los<br />

Angeles, CA<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

Session Overview:<br />

Musculoskeletal ultrasound has been an imaging modality <strong>of</strong><br />

continuously growing importance over the last 15 years. Of<br />

all imaging modalities in rheumatology, ultrasound receives<br />

the greatest attention by rheumatologist researchers. More<br />

papers on musculoskeletal ultrasound are being published<br />

by rheumatologist than by any other specialty. Trained<br />

rheumatologists can agree more readily on ultrasound findings<br />

than musculoskeletal radiologists can on MRI findings, based<br />

on available literature. This suggests that operator dependency<br />

is less <strong>of</strong> a concern for rheumatologists, if they are adequately<br />

trained. However, such training opportunities continue to be<br />

scarce in the United States. This course is designed to help<br />

address the need for additional education.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• demonstrate the proper probe position and ultrasound<br />

machine settings to reliably obtain images<br />

• identify and describe normal sonographic anatomy for each<br />

joint area applying standardized protocols<br />

• explain how fundamental sonographic pathology <strong>of</strong> rheumatic<br />

diseases is distinguished from normal findings<br />

• assess standardized sonographic scanning protocols for each<br />

anatomical region, according to published guidelines<br />

• apply appropriate indications for the use <strong>of</strong> ultrasound in<br />

rheumatology<br />

• explain the requirements for billing, report generation and<br />

record keeping as they relate to musculoskeletal ultrasound<br />

• demonstrate evidence-based technique for ultrasound-guided<br />

procedures<br />

• cite the possibilities and limitations <strong>of</strong> implementation <strong>of</strong><br />

musculoskeletal ultrasound into clinical practice and patient<br />

care<br />

7:00 - 7:30 AM<br />

Continental Breakfast<br />

8:35 AM<br />

The Scope <strong>of</strong> Ultrasound in <strong>Rheumatology</strong><br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

9:05 AM<br />

The Shoulder - Lecture: Standard Scans, Sonographic Anatomy<br />

and Basic Sonographic Pathology<br />

Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />

Madrid, Spain<br />

9:35 - 9:50 AM<br />

Break<br />

9:50 AM<br />

Practice <strong>of</strong> Scanning: How to Position the Probe and Optimize<br />

the Image<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

10:05 AM<br />

Live Demonstration: Scanning <strong>of</strong> the Shoulder<br />

Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />

Madrid, Spain<br />

10:20 AM<br />

Hands on Scanning: The Shoulder<br />

Faculty<br />

11:45 AM - 12:30 PM<br />

Boxed Lunch<br />

12:30 pm<br />

The Elbow - Lecture: Standard Scans, Sonographic Anatomy<br />

and Basic Sonographic Pathology<br />

Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />

Jacksonville; Ponte Vedra Beach, FL<br />

1:00 pm<br />

Live Demonstration: Scanning <strong>of</strong> the Elbow<br />

Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />

Jacksonville; Ponte Vedra Beach, FL<br />

1:15 PM<br />

Hands on Scanning: The Elbow<br />

Faculty<br />

2:25 - 2:40 PM<br />

Break<br />

2:40 PM<br />

Hand and Wrist - Lecture: Standard Scans, Sonographic<br />

Anatomy and Basic Sonographic Pathology<br />

Emilio Filippucci, MD, PhD; Università Politecnica delle Marche -<br />

Ancona; Jesi, Ancona, Italy<br />

7:30 AM<br />

Introduction<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

7:35 AM<br />

Principles <strong>of</strong> Musculoskeletal Ultrasound for Rheumatologists<br />

Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch; Berlin, Germany<br />

8:05 AM<br />

Ultrasound in Pediatric <strong>Rheumatology</strong><br />

Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />

ON, Canada<br />

3:10 PM<br />

Live Demonstration: Hand and Wrist<br />

Emilio Filippucci, MD, PhD; Università Politecnica delle Marche -<br />

Ancona; Jesi, Ancona, Italy<br />

3:25 PM<br />

Hands on Scanning: Hand and Wrist<br />

Faculty<br />

18<br />

2010 Program Book


ACR Clinical Research Conference<br />

c/r PS<br />

8:00 am - 5:00 pm<br />

B406<br />

Admission to the ACR Clinical Research Conference requires a<br />

separate registration.<br />

Quality Improvement and Evidence Implementation<br />

Research<br />

Session Overview:<br />

Few topics in modern medicine evoke as much heated<br />

discussion and debate among both clinicians and researchers<br />

as quality measurement and quality improvement. While<br />

international efforts to tie reimbursement to health care quality<br />

are accelerating, there is also a growing body <strong>of</strong> research<br />

supporting methodology to implement evidence into practice. In<br />

the era <strong>of</strong> comparative effectiveness research, even the National<br />

Institutes <strong>of</strong> Health is expressing interest in type II translational<br />

research that utilizes methods <strong>of</strong> epidemiology, health services<br />

research and behavioral medicine. A growing number <strong>of</strong><br />

rheumatologists throughout the world have been engaged<br />

in such investigations and this conference will have special<br />

appeal to this expanding cadre, along with epidemiologists and<br />

outcomes researchers. Given the direct relevance <strong>of</strong> this topic to<br />

clinical care, it is anticipated that it will be <strong>of</strong> special interest to<br />

practicing clinicians as well.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe current research on quality improvement in<br />

rheumatic diseases<br />

• examine the research methods appropriate to assessment <strong>of</strong><br />

quality improvement and identify strengths and weaknesses<br />

<strong>of</strong> various study designs<br />

• describe the evidence for successful quality improvement<br />

interventions including cluster randomized trials, academic<br />

detailing, registries in persons with rheumatic diseases<br />

• assess the ACR approaches to fostering the documentation <strong>of</strong><br />

quality indicators<br />

7:00 - 8:00 AM<br />

Continental Breakfast<br />

8:00 AM<br />

Introduction<br />

Kenneth G. Saag, MD, MSc; University <strong>of</strong> Alabama-Birmingham;<br />

Birmingham, AL<br />

Session I: The Essentials<br />

Moderator: Maria E. Suarez-Almazor, MD, PhD; University <strong>of</strong><br />

Texas, MD Anderson Cancer Center; Houston, TX<br />

8:15 AM<br />

Overview <strong>of</strong> Translating Evidence Into Practice<br />

Jeroan Allison, MD, MS; University <strong>of</strong> Massachusetts Medical<br />

School; Worchester, MA<br />

8:45 AM<br />

Measuring Performance and Care Gaps in Musculoskeletal<br />

Medicine<br />

Catherine H. MacLean, MD, PhD; WellPoint, Inc.; Westlake<br />

Village, CA<br />

9:30 AM<br />

Group Randomized Trial Designs to Improve Quality<br />

David M. Murray, PhD; Ohio State University, <strong>College</strong> <strong>of</strong> Public<br />

Health; Columbus, OH<br />

10:00 - 10:15 AM<br />

Break<br />

10:15 AM<br />

Popular Methods to Improve Care: Benefit or Boondoggle?<br />

Stephen Soumerai, ScD; Harvard Medical School; Boston, MA<br />

11:00 AM<br />

Implementation Research and Functional Status<br />

John Ware, PhD; University <strong>of</strong> Massachusetts Medical School;<br />

Worchester, MA<br />

11:45 AM - 12:30 PM<br />

Boxed Lunch<br />

12:30 PM<br />

Quality Improvement vs. Evidence Implementation: Point-<br />

Counterpoint<br />

Richard S. Gitomer, MD, MBA; Emory University Hospital<br />

Midtown; Atlanta, GA<br />

Catarina Kiefe, MD, PhD; University <strong>of</strong> Massachusetts Medical<br />

School; Worchester, MA<br />

1:30 PM<br />

Persuading National Healthcare Providers to Improve Use<br />

<strong>of</strong> Drugs <strong>of</strong> and Devices in Musculoskeletal Disorders in the<br />

United Kingdom<br />

Alastair R. McLellan, MD; University <strong>of</strong> Glasgow, Western<br />

Infirmary; Glasgow, United Kingdom<br />

Session II: Applications to Musculoskeletal Medicine<br />

Moderator: J. Timothy Harrington, MD; University <strong>of</strong> Wisconsin,<br />

Madison, WI<br />

2:00 pm<br />

Adherence to Musculoskeletal Therapy and Methods to<br />

Improve It<br />

Jeffrey R. Curtis, MD, MPH; University <strong>of</strong> Alabama – Birmingham,<br />

Birmingham, AL<br />

2:30 PM<br />

Approaches to Improve Osteoporosis Quality <strong>of</strong> Care<br />

Daniel Solomon, MD, MPH; Brigham and Women’s Hospital;<br />

Boston, MA<br />

3:00 - 3:15 PM<br />

Break<br />

3:15 PM<br />

Rapid Cycle Quality Improvement in Arthritis and Osteoporosis<br />

Eric Newman, ScD; Harvard Medical School; Boston, MA<br />

4:00 PM<br />

Using Registries to Improve Quality: The Example <strong>of</strong> Building a<br />

Pediatric Network<br />

Esi Morgan DeWitt, MD; Geisinger Medical Center, Danville, PA<br />

4:30 PM<br />

ACR Efforts to Document and Improve Quality: RCR and Beyond<br />

Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center;<br />

Dallas, TX<br />

5:00 - 6:00 PM<br />

Networking Reception<br />

2010 Program Book 19<br />

saturday


saturday<br />

ACR Certified <strong>Rheumatology</strong> Coder<br />

Course – Day One cP<br />

9:00 am - 5:00 pm<br />

B313<br />

Admission to the ACR Certified <strong>Rheumatology</strong> Coder Course<br />

requires a separate registration. Registration includes CRHC<br />

review materials, examination and a boxed lunch. This course is<br />

not eligible for CME credit.<br />

Speakers: Antanya Chung; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>;<br />

Atlanta, GA<br />

Melesia Tillman; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>; Atlanta, GA<br />

Session Overview:<br />

The US Department <strong>of</strong> Labor anticipates the demand for<br />

individuals with a solid background in medical coding will<br />

increase as physician practices and hospitals continue to require<br />

accurate coding for appropriate reimbursement and to reduce<br />

audit risk. To help address this need, the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong>, in collaboration with the <strong>American</strong> Academy<br />

<strong>of</strong> Pr<strong>of</strong>essional Coders, has developed a rheumatology coding<br />

specialty credential to help coders demonstrate a superior<br />

level <strong>of</strong> expertise in the field <strong>of</strong> rheumatology. To receive the<br />

credential, coders must participate in the two-day rheumatology<br />

coding course and pass the examination. The course is designed<br />

to increase coding knowledge and help participaants prepare for<br />

the examination.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• exhibit pr<strong>of</strong>iciency in adjudicating claims for accurate medical<br />

coding for diagnoses, procedures, and services<br />

• demonstrate knowledge <strong>of</strong> medical coding rules and<br />

regulations along with keeping current on issues regarding<br />

medical coding, compliance, and reimbursement for<br />

rheumatology services<br />

• discuss human anatomy, physiology, and medical terminology<br />

commensurate with ability to correctly code provider services<br />

and diagnoses<br />

extends beyond their capacity to produce immunoglobulin.<br />

Their involvement in the initiation and regulation <strong>of</strong> the<br />

adaptive immune response comprises a burgeoning topic <strong>of</strong><br />

research. There has been intense interest in recent years in the<br />

participation <strong>of</strong> B-cells in autoimmune disease. In addition, it is<br />

increasingly recognized that regulatory B-cells may participate<br />

in numerous settings to down-regulate the immune response.<br />

These disparate aspects <strong>of</strong> B-cell biology are <strong>of</strong> high interest<br />

for potential application to the treatment <strong>of</strong> inflammation and<br />

autoimmunity.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify key concepts and major advances in B cell biology,<br />

including B cell development and regulation<br />

• explain approaches used to identify and quantify B cell<br />

subpopulations<br />

• describe examples <strong>of</strong> rheumatic diseases where B cells play<br />

important roles in pathogenesis<br />

• list the major pathways involved in B cell signaling<br />

• recite the concepts and rationale underlying the use <strong>of</strong> B celldirected<br />

therapies in autoimmune disease<br />

• state the major findings from clinical trials using B celldirected<br />

therapies in rheumatic disease<br />

• describe the challenges faced in therapeutic targeting <strong>of</strong> B<br />

cells, including potential toxicities<br />

1:00 PM<br />

Introduction<br />

B cells: An Evolutionary and Historic Perspective<br />

Max D. Cooper, MD; Emory University School <strong>of</strong> Medicine;<br />

Atlanta, GA<br />

Session I: B cell Development<br />

Moderator: Shiv Pillai, MD, PhD; Massachusetts General<br />

Hospital; Boston, MA<br />

1:45 PM<br />

Early B cell Development<br />

Paul Kincade, PhD; Oklahoma Medical Research Foundation;<br />

Oklahoma City, OK<br />

ACR Basic Research Conference –<br />

dAy One R<br />

1:00 - 5:30 pm<br />

B402<br />

Admission to the ACR Basic Research Conference requires a<br />

separate registration.<br />

The Immunobiology <strong>of</strong> B Cells: From Antibodies to<br />

Immunoregulation<br />

Moderators: Ann Marshak-Rothstein, PhD; University <strong>of</strong><br />

Massachusetts Medical School; Worcester, MA<br />

E. William St.Clair, MD; Duke University Medical Center; Durham,<br />

NC<br />

Session Overview:<br />

B cells are a heterogeneous subset <strong>of</strong> lymphocytes that are<br />

classically studied for their participation in humoral immunity.<br />

However, it is becoming increasingly apparent that B-cell<br />

participation in immune responses and in autoimmunity<br />

2:20 PM<br />

Molecular Regulation <strong>of</strong> B cell Subsets and Their Development<br />

Richard Hardy, PhD; Fox Chase Cancer Center; Philadelphia, PA<br />

2:55 PM<br />

B cell Receptor Stimulation and Lineage Decisions<br />

Shiv Pillai, MD, PhD; Massachusetts General Hospital; Boston,<br />

MA<br />

3:30 - 3:45 PM<br />

Break<br />

Session II: B cell Activation and Trafficking<br />

Moderator: David Rawlings, MD; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

3:45 PM<br />

B cell Receptor and Signaling Pathways<br />

David Rawlings, MD; University <strong>of</strong> Washington; Seattle, WA<br />

20<br />

2010 Program Book


4:20 PM<br />

Germinal Center Reactions<br />

Ann Haberrman, PhD; Yale School <strong>of</strong> Medicine; New Haven, CT<br />

4:55 PM<br />

Memory Plasma Cells and Protective and Pathogenic Immune<br />

Responses<br />

Andreas Radbruch, PhD; Forschungszentrum; Berlin, Germany<br />

5:30 - 6:30 PM<br />

Networking Reception<br />

ACR/ABIM Maintenance <strong>of</strong><br />

CertifiCAtion Learning Session - 2010<br />

Update in rheumatology c/r ARS<br />

1:00 - 5:30 PM<br />

A311<br />

Admission to the ACR/ABIM Maintenance <strong>of</strong> Certification<br />

Learning Session - 2010 Update requires a separate registration.<br />

Moderator: Carol A. Langford, MD, MHS; Cleveland Clinic;<br />

Cleveland, OH<br />

Session Overview:<br />

The <strong>American</strong> Board <strong>of</strong> Internal Medicine’s Maintenance <strong>of</strong><br />

Certification program requires rheumatologists certified after<br />

1990 to renew their certificates every ten years. Because <strong>of</strong> this,<br />

the ACR is dedicated to providing tools to rheumatologists to<br />

help fulfill their Maintenance <strong>of</strong> Certification requirements. The<br />

ACR/ABIM Maintenance <strong>of</strong> Certification Learning Session will<br />

review the ABIM 2010 Update Module worth 10 MOC points<br />

in the medical knowledge category. This live activity will help<br />

promote physicians lifelong learning efforts with while assisting<br />

them in preparing for the <strong>Rheumatology</strong> Maintenance <strong>of</strong><br />

Certification exam.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• assess strengths and weaknesses in rheumatology medical<br />

base knowledge<br />

• state the major developments in rheumatology over the past<br />

10 years<br />

• satisfy a self-evaluation requirement for the ABIM MOC<br />

program<br />

1:00 PM<br />

Introduction<br />

Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH<br />

1:15 PM<br />

Session I<br />

Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH<br />

3:00 PM<br />

Session II<br />

Mary Chester Wasko, MD, MSc; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

4:15 PM<br />

Session III<br />

Robert A. Kalish, MD; Tufts Medical Center; Boston, MA<br />

5:30 PM<br />

Conclusion<br />

Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH<br />

saturday<br />

2010 Program Book 21


sunday<br />

SUNDAY, NOVEMBER 7, 2010<br />

ACR/ARHP Registration<br />

6:30 am - 7:00 pm<br />

International Blvd. Foyer<br />

ACR Musculoskeletal Ultrasound<br />

Course for Rheumatologists –<br />

dAy Two C<br />

7:30 am - 4:30 pm<br />

A412<br />

Admission to the ACR Musculoskeletal Ultrasound Course<br />

requires a separate registration. See Day One for session<br />

overview and learning objectives.<br />

Moderator: Ralf G. Thiele, MD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Faculty: Rany Al Haj, MD; Shore Arthritis and Rheumatism<br />

Associates; Ocean, NJ<br />

Marina Backhaus, MD; University Medicine Berlin: Campus<br />

Charité Mitte; Berlin, Germany<br />

P. Scott Pollock, MD; Seattle, WA<br />

David A. Bong, MD; Instituto Poal de Reumatologia; Bruce, WI<br />

Jurgen Craig-Muller, MD; CentraCare Clinic; St. Cloud, MN<br />

Paul J. DeMarco, MD; Arthritis & Rheumatism Associates PC;<br />

Wheaton, MD<br />

Amy M. Evangelisto, MD; Arthritis Rheumatic and Back Disease<br />

Associates; Philadelphia, PA<br />

David E. Feinstein, DO; Cooper Health System, Robert Wood<br />

Johnson Medical School; Camden, NJ<br />

Emilio Filippucci, MD; Università Politecnica delle Marche -<br />

Ancona; Jesi, Ancona, Italy<br />

Janak R. Goyal, MD; University <strong>of</strong> Medicine and Dentistry <strong>of</strong> New<br />

Jersey, Robert Wood Johnson Medical School; Perth Amboy, NJ<br />

Jay B. Higgs, MD; Wilford Hall Medical Center, Department <strong>of</strong> Air<br />

Force; San Antonio, TX<br />

Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />

Jacksonville; Ponte Vedra Beach, FL<br />

Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />

Madrid, Spain<br />

Midori Jane Nishio, MD; John Muir Medical Center; Walnut<br />

Creek, CA<br />

Anthony M. Reginato, PhD, MD; University Medicine Foundation,<br />

Rhode Island Hospital; Providence, RI<br />

Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />

ON, Canada<br />

Jonathan Samuels, MD; New York University Hospital for Joint<br />

Disease; New York, NY<br />

Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch; Berlin, Germany<br />

Darren Tabechian, MD; University <strong>of</strong> Rochester School <strong>of</strong><br />

Medicine; Rochester, NY<br />

Mihaela Taylor, MD; University <strong>of</strong> California Los Angeles; Los<br />

Angeles, CA<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

7:00 - 7:30 AM<br />

Continental Breakfast<br />

7:30 AM<br />

Introduction<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

7:35 AM<br />

Billing, Coding and Report Generation<br />

Jay B. Higgs, MD; Wilford Hall Medical Center, Department <strong>of</strong> Air<br />

Force; San Antonio, TX<br />

8:00 AM<br />

The Hip - Lecture: Standard Scans, Sonographic Anatomy and<br />

Basic Sonographic Pathology<br />

Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch; Berlin, Germany<br />

8:30 AM<br />

Live Demonstration: Scanning <strong>of</strong> the Hip<br />

Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch; Berlin, Germany<br />

8:45 AM<br />

Hands on Scanning: The Hip<br />

Faculty<br />

9:45 - 10:00 AM<br />

Break<br />

10:00 AM<br />

The Knee - Lecture: Standard Scans, Sonographic Anatomy and<br />

Basic Sonographic Pathology<br />

Marina Backhaus, MD; University Medicine Berlin: Campus<br />

Charité Mitte;Berlin, Germany<br />

10:30 AM<br />

Live Demonstration: Scanning <strong>of</strong> the Knee<br />

Marina Backhaus, MD; University Medicine Berlin: Campus<br />

Charité Mitte; Berlin, Germany<br />

10:45 AM<br />

Hands on Scanning: The Knee<br />

Faculty<br />

Noon - 12:45 PM<br />

Boxed Lunch<br />

12:45 PM<br />

Foot and Ankle - Lecture: Standard Scans, Sonographic<br />

Anatomy and Basic Sonographic Pathology<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

1:15 PM<br />

Live Demonstration: Scanning <strong>of</strong> Foot and Ankle<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

1:30 PM<br />

Hands on Scanning: Foot and Ankle<br />

Faculty<br />

2:45 - 3:00 PM<br />

Break<br />

3:00 PM<br />

Ultrasound Needle Guidance - Lecture: Ultrasound Guidance <strong>of</strong><br />

Procedures<br />

Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

22<br />

2010 Program Book


3:30 PM<br />

Live Demonstration: Ultrasound Needle Guidance<br />

Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

3:45 PM<br />

Hands on Scanning: Ultrasound Needle Guidance<br />

Faculty<br />

ACR Basic Research Conference –<br />

dAy Two R<br />

8:00 am - 4:30 pm<br />

B402<br />

Admission to the ACR Basic Research Conference requires a<br />

separate registration. See Day One for session overview and<br />

learning objectives.<br />

Session III: Factors Promoting B Cell Autoreactivity<br />

and Protective Immunity<br />

Moderator: Ann Marshak-Rothstein, PhD; University <strong>of</strong><br />

Massachusetts Medical School; Worcester, MA<br />

7:00 - 8:00 AM<br />

Continental Breakfast<br />

8:00 AM<br />

Toll Like Receptor Signaling in B cells and Autoimmune Disease<br />

Ann Marshak-Rothstein, PhD; University <strong>of</strong> Massachusetts<br />

Medical School; Worcester, MA<br />

8:35 AM<br />

Ectopic Lymphoid Tissue<br />

Troy Randall, PhD; University <strong>of</strong> Rochester; Rochester, NY<br />

9:10 AM<br />

Memory B cells<br />

Inaki Sanz, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

9:45 - 10:00 AM<br />

Break<br />

Session IV: B Cell Regulation and B Cell Regulators<br />

Moderator: Garnett Kelsoe, PhD; Duke Univeristy Medical<br />

Center; Durham, NC<br />

12:30 PM<br />

B cell Lymphocyte Survival Factors<br />

Michael P. Cancro, PhD; University <strong>of</strong> Pennsylvania; Philadelphia,<br />

PA<br />

1:05 PM<br />

CD20-focused Therapies - Mechanisms <strong>of</strong> Action<br />

Martin J. Glennie, PhD; Univesity <strong>of</strong> Southampton - UK;<br />

Southampton, United Kingdom<br />

1:40 PM<br />

Innate B cells and Natural Antibodies<br />

Gregg J. Silverman, MD; University <strong>of</strong> California - San Diego; La<br />

Jolla, CA<br />

Session VI: Role <strong>of</strong> B cells in Autoimmunity: Lessons<br />

from Clinical Trials<br />

Moderator: E. William St.Clair, MD; Duke University Medical<br />

Center; Durham, NC<br />

2:15 PM<br />

Rheumatoid Arthritis<br />

Jonathan C.W. Edwards, MD; University <strong>College</strong> London; London,<br />

United Kingdom<br />

2:45 PM<br />

Lupus<br />

Jennifer H. Anolik, MD, PhD; University <strong>of</strong> Rochester; Rochester,<br />

NY<br />

3:15 PM<br />

Sjögren’s Syndrome<br />

E. William St.Clair, MD; Duke University Medical Center; Durham,<br />

NC<br />

3:45 PM<br />

ANCA-associated Vasculitis<br />

John H. Stone, MD, MPH; Massachusetts General Hospital;<br />

Boston, MA<br />

4:15 PM<br />

Wrap-up: Take Home Messages and Future Directions<br />

Betty Diamond, MD; Feinstein Institute for Medical Research;<br />

Manhasset, NY<br />

sunday<br />

10:00 AM<br />

Insights from Immunodeficiencies<br />

Eric Meffre, PhD; Yale University School <strong>of</strong> Medicine; New<br />

Haven, CT<br />

10:35 AM<br />

Role <strong>of</strong> Activation-induced Cytidine Deaminase in Tolerance<br />

Garnett Kelsoe, PhD; Duke Univeristy Medical Center; Durham,<br />

NC<br />

ACR Review Course C<br />

8:00 am - 4:00 pm<br />

Hall A3<br />

Admission to the Review Course requires a separate registration.<br />

Moderators: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />

Milwaukee, WI<br />

Gregory C. Gardner, MD; University <strong>of</strong> Washington; Seattle, WA<br />

11:10 AM<br />

Regulatory B cells<br />

Thomas F. Tedder, PhD; Duke University Medical Center;<br />

Durham, NC<br />

11:45 AM - 12:30 PM<br />

Boxed Lunch<br />

Session V: Emerging Concepts in B cell Directed<br />

Therapies<br />

Moderator: Michael P. Cancro, PhD; University <strong>of</strong> Pennsylvania;<br />

Philadelphia, PA<br />

7:00 - 8:00 AM<br />

Continental Breakfast<br />

8:00 AM<br />

Mixed Connective Tissue Disease is Not Really that Mixed<br />

Virginia D. Steen, MD; Georgetown University Medical Center;<br />

Washington, DC<br />

Talk Overview:<br />

Mixed connective tissue disease was first described in 1972. The<br />

concept has evolved over the years and the current approach to<br />

the diagnosis and treatment in adults and children has changed<br />

as well.<br />

2010 Program Book 23


sunday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the classification criteria and clinical manifestations <strong>of</strong><br />

mixed connective tissue disease<br />

• discuss diagnostic and treatment plans for patients with mixed<br />

connective tissue disease<br />

• determine if classification to mixed connective tissue disease<br />

vs. undifferentiated vs. overlap categories affects treatment<br />

and outcome<br />

8:45 AM<br />

Bowel Associated Rheumatologic Diseases<br />

Filip E. Van den Bosch, MD, PhD; University Hospital; Gent,<br />

Belgium<br />

Talk Overview:<br />

Inflammatory arthritis is associated with bowel disease and the<br />

gut inflammation is <strong>of</strong>ten subclinical. Rheumatologists must<br />

know the bowel disorders associated with arthritis in order to<br />

develop a treatment plan that will improve the arthritis and not<br />

worsen the gut disease. Disorders such as Celiac disease involve<br />

the gastrointestinal tract as well as joints and is present in up<br />

to one percent <strong>of</strong> the population. Rheumatologists should be<br />

aware <strong>of</strong> the possible associations with arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the role <strong>of</strong> gut inflammation in the pathogenesis <strong>of</strong><br />

inflammatory arthritis<br />

• explain the therapeutic options for patients with arthritis and<br />

bowel disease<br />

• discuss the relationship <strong>of</strong> celiac disease to arthritis and<br />

current diagnostic assessment<br />

9:30 AM<br />

Rheumatoid Arthritis: From Bench to Bed side in 40 Minutes<br />

Daniel E. Furst, MD; University <strong>of</strong> California-Los Angeles Medical<br />

School; Los Angeles, CA<br />

Talk Overview:<br />

Rheumatoid arthritis is a common condition seen in<br />

rheumatology practice. There are new diagnostic and treatment<br />

guidelines, diagnostic tests, genetic information, medications,<br />

currently available. In addition, new medications are about to<br />

be released and a whole new family <strong>of</strong> drugs are under study<br />

for therapy. The purpose <strong>of</strong> this talk is to review how far we<br />

have come in the last 10 years, review current best practice<br />

for diagnosis and treatment, and look into the near future <strong>of</strong><br />

rheumatoid arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review recent additions to understanding <strong>of</strong> the<br />

pathophysiology <strong>of</strong> rheumatoid arthritis<br />

• discuss current evidence-based treatment paradigms<br />

• discuss new or soon to be new medications and where they<br />

might be utilized<br />

10:15 - 10:45 AM<br />

Break<br />

10:45 AM<br />

Hepatitis C for the Rheumatologist<br />

Amy M. Joseph, MD; Veterans Affair Medical Center, Washington<br />

University; St. Louis, MO<br />

Talk Overview:<br />

Hepatitis C infection can cause and/or mimic a variety <strong>of</strong><br />

rheumatologic diseases. It is important that the clinical<br />

rheumatologist be familiar with the spectrum <strong>of</strong> illness caused<br />

by hepatitis C and understand current diagnostic and treatment<br />

approaches.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the pathophysiology and natural history <strong>of</strong> hepatitis<br />

C infection<br />

• review rheumatologic manifestations <strong>of</strong> hepatitis C<br />

• apply the current therapeutic approaches to hepatitis C<br />

associated rheumatologic illnesses<br />

11:30 AM<br />

Autoinflammatory Diseases for the Adult Rheumatologist<br />

Daniel L. Kastner, MD, PhD; NIAMS/NIH; Bethesda, MD<br />

Talk Overview:<br />

Autoinflammatory diseases are becoming more widely<br />

recognized in clinical medicine. Rheumatologists are <strong>of</strong>ten asked<br />

to see patients with unusual inflammatory syndromes. The<br />

purpose <strong>of</strong> this session is to review the pathophysiology, clinical<br />

manifestations, diagnostic options, and treatment <strong>of</strong> the more<br />

common autoinflammatory syndromes.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the pathophysiology <strong>of</strong> the autoinflammatory diseases<br />

• identify clinical manifestations and diagnostic evaluation for<br />

the autoinflammatory diseases<br />

• assess treatment options currently available or soon to be<br />

available<br />

12:15 - 1:15 PM<br />

Boxed Lunch<br />

1:15 PM<br />

<strong>Rheumatology</strong> Laboratory Testing: How it is Done and Why We<br />

Need to Know<br />

Mark H. Wener, MD; University <strong>of</strong> Washington; Seattle, WA<br />

Talk Overview:<br />

Newer diagnostic tests and new methods are being employed<br />

in the immunology laboratory; however, the limitations<br />

and benefits <strong>of</strong> such testing are important to understand in<br />

interpreting and utilizing immunology laboratory testing.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review recent advances/changes in immunology laboratory<br />

testing<br />

• discuss the probabilistic nature <strong>of</strong> laboratory testing<br />

• describe the pearls and pitfalls <strong>of</strong> testing in 2010<br />

2:00 PM<br />

Rheumatic Manifestations <strong>of</strong> Neoplastic Diseases<br />

Joanne Valeriano-Marcet, MD; University <strong>of</strong> South Florida;<br />

Tampa, FL<br />

Talk Overview:<br />

Rheumatologists are frequently asked to consult on patients<br />

with cancer and arthritis or autoimmune phenomenon. Adult<br />

and pediatric patients with cancer also frequently present first<br />

with a rheumatic complaint.<br />

24<br />

2010 Program Book


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe possible clinical presentations <strong>of</strong> patients with<br />

undiagnosed cancer<br />

• describe the common paraneoplastic syndromes<br />

• discuss rheumatologic complications <strong>of</strong> neoplastic diseases<br />

and their therapies<br />

2:45 - 3:15 PM<br />

Break<br />

3:15 PM<br />

Evidence-based Snacks for Rheumatologists<br />

George V. Lawry, MD; University <strong>of</strong> California-Irvine; Mission<br />

Viejo, CA<br />

Talk Overview:<br />

Many everyday processes that occur in a clinic are a result <strong>of</strong><br />

fellowship training. The purpose <strong>of</strong> this presentation is to cover<br />

three mini-topics and present evidence <strong>of</strong> best practice data for<br />

processes/issues clinicians take for granted.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss factors influencing efficacy <strong>of</strong> methotrexate therapy<br />

and review evidence for splitting high-dose oral methotrexate<br />

• establish side effect pr<strong>of</strong>ile <strong>of</strong> azathioprine and review<br />

evidence for thiopurine S-methyltransferase testing prior to<br />

azathioprine therapy<br />

• determine evidence for risk <strong>of</strong> pneumocystis pneumonia<br />

in immunosuppressed patients with rheumatic diseases<br />

and review practical strategy for pneumocystis pneumonia<br />

prophylaxis<br />

<strong>of</strong> new classes <strong>of</strong> treatment options, clinical practice has<br />

changed dramatically. Health care pr<strong>of</strong>essionals must have a<br />

fundamental knowledge <strong>of</strong> immunology and the mechanisms<br />

<strong>of</strong> action <strong>of</strong> these biologic agents. Familiarity with the pre-drug<br />

screening recommended for these agents and the appropriate<br />

safety and disease monitoring necessary when a person uses<br />

theses products is essential for the best patient outcomes. In<br />

addition, knowing how to obtain drug plan authorization for the<br />

use <strong>of</strong> biologics and educating patients and their support team<br />

members about the financial considerations <strong>of</strong> these treatments<br />

helps to ensure best rheumatology practice.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• explain immunologic principles and identify biologic targets<br />

for treatment <strong>of</strong> rheumatic diseases<br />

• discuss the safety and adverse effects <strong>of</strong> biotherapies<br />

• develop and apply patient education strategies to clinical<br />

practice<br />

• analyze complex cases and formulate patient care plans<br />

7:00 - 8:00 AM<br />

Continental Breakfast<br />

8:00 AM<br />

Introduction<br />

Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />

Angeles, CA<br />

8:15 AM<br />

Immunology Background for Biotherapies<br />

Troy R. Torgerson, MD, PhD; Children’s Hospital; Seattle, WA<br />

sunday<br />

ARHP Clinical Focus Course<br />

8:00 am - 4:30 pm<br />

c/r PS ARS<br />

A411<br />

Admission to the ARHP Clinical Focus Course requires a separate<br />

registration.<br />

Integrating Immunology and Biologics into Clinical<br />

Practice<br />

Moderator: Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los<br />

Angeles; Los Angeles, CA<br />

Session Overview:<br />

The National Arthritis Data Workgroup recently reviewed<br />

data from national and regional surveys to estimate national<br />

prevalence rates <strong>of</strong> various rheumatic diseases based on 2005<br />

U.S. Census data. The results were published in an article<br />

titled, “Estimates <strong>of</strong> the Prevalence <strong>of</strong> Arthritis and Other<br />

Rheumatic Conditions in the United States” in the January<br />

2008 issue <strong>of</strong> Arthritis & Rheumatism. Estimates include 1.3<br />

million adults with rheumatoid arthritis, 0.6 to 2.4 million with<br />

spondylarthritides, 161 to 322,000 with systemic lupus, and<br />

294,000 children with juvenile arthritis. Treatments for these<br />

rheumatic conditions include tumor necrosis factor inhibitors,<br />

which were first available clinically in the late 1990s, and other<br />

pharmacologic options including B cell targeted therapies, costimulatory<br />

molecules and cytokine antagonists that have more<br />

recently been approved. Other specific molecules are currently<br />

in various stages <strong>of</strong> study. With this rapid expansion<br />

9:15 AM<br />

Targeted Therapies: How Do They Work?<br />

Anne M. Stevens, MD, PhD; University <strong>of</strong> Washington; Seattle,<br />

WA<br />

10:15 - 10:30 AM<br />

Break<br />

10:30 AM<br />

Screening Patients for Safe Practice<br />

Josephine C. Garnoc, BSN; Beaumont Grosse Pointe Hospital;<br />

Grosse Pointe, MI<br />

11:15 AM<br />

Side Effects and Adverse Reactions<br />

Susan P. Bruce, PharmD; Northeastern Ohio Universities;<br />

Rootstown, OH<br />

Noon - 1:00 PM<br />

Lunch<br />

1:00 PM<br />

Cutting Through the Red Tape to Obtain Treatment<br />

Karen M. Ferguson, MS; Arthritis Northwest <strong>Rheumatology</strong>,<br />

PLLC; Spokane, WA<br />

1:45 PM<br />

Patient Education Applying What You’ve Learned<br />

Jane M. Denay, BSN, MSN, CFNP; Harbor Arthritis Center;<br />

Petoskey, MI<br />

Elizabeth L. Roth-Wojcicki, RN, MS, CPNP; Medical <strong>College</strong> <strong>of</strong><br />

Wisconsin; Wauwatosa, WI<br />

2010 Program Book 25


sunday<br />

2:45 - 3:00 PM<br />

Break<br />

3:00 PM<br />

Managing Complex Cases: Answering the Hard Questions<br />

Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center;<br />

Dallas, TX<br />

Andreas O. Reiff, MD; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />

Angeles, CA<br />

4:15 PM<br />

Summary<br />

Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />

Angeles, CA<br />

ACR Certified <strong>Rheumatology</strong> Coder<br />

Course Examination – Day Two cP<br />

11:00 am - 5:00 pm<br />

A311<br />

Admission to the ACR Certified <strong>Rheumatology</strong> Coder Course<br />

requires a separate registration. Registration includes CRHC<br />

review materials, examination and a boxed lunch. This course is<br />

not eligible for CME credit. See Day One for session overview and<br />

learning objectives.<br />

Speaker: Antanya Chung; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>;<br />

Atlanta, GA<br />

ACR/ARHP Opening Lecture and<br />

Awards<br />

5:00 - 6:30 pm<br />

Hall A3<br />

Moderators: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />

Dallas, TX<br />

Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute <strong>of</strong><br />

Chicago; Chicago, IL<br />

Session Overview:<br />

Auto-immunity is the consequence <strong>of</strong> anti-bacterial defenses<br />

gone awry. We combat bacteria in two ways: innate and<br />

acquired immunity. These are mediated, respectively, by<br />

phagocytosis (via Fc receptors and/or toll-like receptors) and<br />

by anaphylaxis (via C5a and/or C3a). Rheumatoid arthritis<br />

results when these defenses, genetically regulated, incite acute<br />

inflammation that is perpetuated by cytokines. Rheumatologists<br />

should be aware <strong>of</strong> the evidence that oral bacteria, such as<br />

Porphyromonas gingivalis, may play an early role in this process.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• cite the historical basis <strong>of</strong> phagocytosis and anaphylaxis<br />

• discuss the signal transduction mechanisms whereby immune<br />

complexes and anaphylatoxins found in rheumatoid arthritis<br />

joints lead to release <strong>of</strong> mediators such as prostaglandins and<br />

cytokines<br />

• state how steroidal and non-steroidal agents act to blunt<br />

these signal transduction pathways<br />

• relate the microbiology <strong>of</strong> oral bacteria such as<br />

Porphyromonas gingivalis to the chronic inflammation <strong>of</strong><br />

rheumatoid arthritis<br />

ACR/ARHP Opening Event<br />

7:00 - 10:00 pm<br />

Georgia Aquarium<br />

Admission to the ACR/ARHP Opening Event at the Georgia<br />

Aquarium is ticketed and requires a separate registration.<br />

Purchase your tickets in the ACR/ARHP registration area before<br />

7:45 PM to ensure you have access to this VIP event. Tickets will<br />

not be available for purchase at the Georgia Aquarium. For more<br />

information see pages 10 & 15.<br />

5:00 PM<br />

Presidential Address<br />

Stanley Cohen, MD; <strong>Rheumatology</strong> Associates; Dallas, TX<br />

Recognition <strong>of</strong> 2010 ACR Masters<br />

Recognition <strong>of</strong> 2010 Distinction Recipients<br />

Recognition <strong>of</strong> ARHP Merit Awards, Lifetime Achievement<br />

Award and President’s Award<br />

Recognition <strong>of</strong> Fellows Award<br />

5:45 PM<br />

An Infectious Etiology <strong>of</strong> Rheumatoid Arthritis<br />

Gerald Weissmann, MD; New York University Medical<br />

Center; New York, NY<br />

26<br />

2010 Program Book


MONDAY, NOVEMBER 8, 2010<br />

ACR/ARHP Registration<br />

6:30 am - 5:00 pm<br />

International Blvd. Foyer<br />

ARHP Special Sessions<br />

7:00 - 8:00 am<br />

B309<br />

First-Time Attendees Orientation<br />

First time ARHP annual meeting attendees are invited to an<br />

orientation to learn the ‘ins and outs’ <strong>of</strong> the annual meeting. The<br />

ARHP Membership and Nominations Committee will be on hand<br />

to provide advice to assist you in planning how to get the most<br />

out <strong>of</strong> your first annual meeting.<br />

This session is not eligible for CME credit. C<strong>of</strong>fee and tea will be<br />

provided.<br />

Moderator: Pamela J. Degotardi, PhD; Queens <strong>College</strong> City<br />

University <strong>of</strong> New York Honors; Flushing, NY<br />

B308<br />

Moderators Orientation<br />

This session is not eligible for CME credit. C<strong>of</strong>fee and tea will be<br />

provided.<br />

Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />

Albuquerque, NM<br />

ACR Basic Science Symposium<br />

7:15 - 8:45 am<br />

B402<br />

Molecular Mechanisms <strong>of</strong> Inflammatory Signaling in<br />

Cartilage Destruction R<br />

Moderators: Richard F. Loeser, MD; Wake Forest University;<br />

Winston-Salem, NC<br />

Anna H. Plaas, PhD; Rush University; Chicago, IL<br />

7:15 AM<br />

ESE:1: Transcriptional and Epigenetic Regulation <strong>of</strong> Cartilage<br />

Remodeling<br />

Mary B. Goldring, PhD; Hospital for Special Surgery; Weill Cornell<br />

Medical <strong>College</strong>; New York, NY<br />

7:45 AM<br />

Chemokines, Cytokines, and their Modulation During Joint<br />

Degeneration<br />

Qian Chen, PhD; Brown University, Rhode Island Hospital;<br />

Providence, RI<br />

8:15 AM<br />

Stimulation <strong>of</strong> Cartilage Destruction by S100 Proteins in<br />

Experimental Arthritis<br />

Peter Van Lent, MD; Radbound University Medical Centre;<br />

Nijmegen, Netherlands<br />

Session Overview:<br />

Cartilage destruction is a central feature <strong>of</strong> many types <strong>of</strong><br />

arthritis. Currently there are no therapies proven to slow or<br />

prevent cartilage destruction. An improved understanding <strong>of</strong><br />

the mechanisms <strong>of</strong> inflammatory signaling in cartilage will<br />

potentially lead to new therapeutic targets for diseases affecting<br />

cartilage, including osteoarthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the role <strong>of</strong> transcription factors activated by<br />

inflammatory mediators in mediating cartilage destruction<br />

• assess the roles <strong>of</strong> chemokines and cytokines in cartilage<br />

matrix destruction<br />

• analyze the role <strong>of</strong> the S100 proteins, which include the<br />

alarmins, in mediating cartilage destruction<br />

ACR Clinical Symposium<br />

7:15 - 8:30 am<br />

Hall A3<br />

Year in Review c/r<br />

Moderator: Joel A. Block, MD; Rush University Medical Center;<br />

Chicago, IL<br />

7:15 AM<br />

Image Competition Presentation<br />

Alan N. Baer, MD, Audiovisual Aids Subcommittee Chair; Johns<br />

Hopkins University; Baltimore, MD<br />

7:30 AM<br />

Clinical Perspective<br />

Michael H. Weisman, MD; Cedars-Sinai Medical Center; Los<br />

Angeles, CA<br />

8:00 AM<br />

Basic Science Perspective<br />

John P. Atkinson, MD; Washington University School <strong>of</strong><br />

Medicine; St. Louis, MO<br />

Session Overview:<br />

<strong>Rheumatology</strong> is a rapidly advancing field, with substantive<br />

scientific breakthroughs being translated into clinical use<br />

constantly. Therefore, it is important for rheumatologist to<br />

maintain knowledge <strong>of</strong> the most important advances. During<br />

this session, leaders in the field will review and summarize the<br />

most important publications from the previous year in the basic<br />

science and the clinical practice <strong>of</strong> rheumatology.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss selected recent publications on the pathophysiological<br />

basis <strong>of</strong> rheumatic diseases by literature review <strong>of</strong> important<br />

publications<br />

• identify selected treatment modalities for rheumatic diseases<br />

from the recent published literature<br />

• enumerate how these new advances may impact the practice<br />

<strong>of</strong> rheumatology<br />

monday<br />

2010 Program Book 27


monday<br />

ACR REF Special Session<br />

7:15 - 8:15 am<br />

B406<br />

REF Oscar S. Gluck, MD, Memorial Lectureship -<br />

Osteoimmunology: Crosstalk Between the Immune<br />

and Bone Systems: Biologic and Clinical Implications<br />

c/r<br />

Moderator: Michael J. Maricic, MD; Catalina Pointe<br />

<strong>Rheumatology</strong>; Tucson, AZ<br />

Speaker: Hiroshi Takayanagi, MD, PhD; Tokyo Medical and<br />

Dental University; Tokyo, Japan<br />

Session Overview:<br />

Many <strong>of</strong> the molecules and signal pathways controlling the<br />

differentiation and activity <strong>of</strong> osteoclasts also are involved in<br />

regulating immune cell function and activity. The integration <strong>of</strong><br />

knowledge from the fields <strong>of</strong> immunology and bone cell biology<br />

has reshaped our understanding <strong>of</strong> the mechanisms involved<br />

in osteoclast-mediated bone resorption and identified new<br />

approaches for treating clinical conditions associated with bone<br />

loss.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the signal pathways involved in osteoclast<br />

differentiation and activation<br />

• discuss the common mechanism by which cytokines and<br />

signal pathways regulate immune and bone cells<br />

• describe the potential applications <strong>of</strong> discoveries in the field<br />

<strong>of</strong> osteoimmunology for treating clinical disorders associated<br />

with bone loss<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

7:30 - 8:30 am<br />

B313<br />

Toll-like Receptors Activation <strong>of</strong> B cells in<br />

Autoimmune Disease R<br />

Moderator: Jennifer H. Anolik, MD, PhD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Speaker: Ann Marshak-Rothstein, PhD; University <strong>of</strong><br />

Massachusetts Medical School; Worcester, MA<br />

Session Overview:<br />

In recent years it has become clear that toll-like receptors play<br />

a key role in the initiation and perpetuation <strong>of</strong> autoimmune<br />

responses. Thus, immune complexes such as those found in<br />

autoimmune disease contain ligands for toll-like receptors,<br />

including ribonucleic acid or deoxyribonucleic acid, which can<br />

provide costimulatory signals for autoreactive B cells, promoting<br />

their inappropriate activation and survival. Moreover, toll-like<br />

receptors represent important therapeutic targets. Thus, a state<strong>of</strong>-the-art<br />

review <strong>of</strong> interactions between B cells and toll-like<br />

receptors is timely.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the role <strong>of</strong> toll-like receptors pathways in B cell<br />

activation and contributions to autoimmune disease<br />

• identify how the balance <strong>of</strong> stimulatory and inhibitory signals<br />

on B cells may define the outcome <strong>of</strong> toll-like receptors<br />

activation<br />

• provide the rationale for toll-like receptors targeted therapies<br />

in autoimmunity and the potential limitations <strong>of</strong> such<br />

approaches<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

7:45 - 9:15 am<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Ankylosing Spondylitis: Disease Modification (001)<br />

Speaker: Walter P. Maksymowych, MD; University <strong>of</strong> Alberta;<br />

Edmonton, AB, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• outline what is known about the pathophysiology <strong>of</strong> disease<br />

modification in spondylarthritis<br />

• review outcomes relevant to the concept <strong>of</strong> disease<br />

modification in spondylarthritis and assess their relevance to<br />

clinical practice<br />

• review therapeutic issues relevant to the concept <strong>of</strong> disease<br />

modification<br />

• discuss assessment <strong>of</strong> disease modification clinical trial<br />

B208<br />

Behçet’s Disease (002)<br />

Speaker: Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul,<br />

Turkey<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the epidemiology and diagnostic evaluation <strong>of</strong><br />

Behçet’s syndrome<br />

• describe current approaches to the management <strong>of</strong> patients<br />

with Behçet’s syndrome<br />

B209<br />

Central Nervous System Vasculitis (003)<br />

Speaker: Rula Hajj-Ali, MD; Cleveland Clinic; Cleveland, OH<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss an approach to the evaluation <strong>of</strong> a patient referred<br />

with possible central nervous system vasculitis<br />

• review the major entities in the differential diagnosis <strong>of</strong><br />

primary angiitis <strong>of</strong> the central nervous system<br />

• create a consistent therapeutic approach to the treatment <strong>of</strong><br />

vasculitis involving the brain and/or spinal cord<br />

B210<br />

Controversies in Sjögren’s Syndrome (004)<br />

Speaker: Frederick B. Vivino, MD; Pennsylvania Presbyterian<br />

Medical Center; Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify major morbidities in Sjögren’s syndrome patients<br />

• discuss current treatment algorithms for dry eyes, dry mouth<br />

and systemic manifestations<br />

• determine strategies to prevent Sjögren’s related<br />

complications<br />

28<br />

2010 Program Book


B301<br />

Dermatological Manifestations <strong>of</strong> Rheumatic Diseases<br />

(005) f<br />

Speaker: Nicole Fett, MD; Perelman Center for Advanced<br />

Medicine; Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• cite the diagnostic criteria for skin diseases with<br />

rheumatologic implications<br />

• construct a differential diagnosis for these conditions<br />

• design a strategy for management <strong>of</strong> skin disease seen in<br />

patients with rheumatologic diseases<br />

B302<br />

Pain: Difficult Patient Interactions (006) PM<br />

Speaker: Dennis J. Boyle, MD; Denver Health Medical Center;<br />

Denver, CO<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine what constitutes a difficult patient interaction<br />

• describe how to diagnosis relationship issues<br />

• discuss opioid use and the legal issues that surround them<br />

B303<br />

Pediatrics: Difficult to Treat Juvenile Idiopathic<br />

Arthritis (007) P<br />

Speaker: Murray H. Passo, MD; Medical University <strong>of</strong> South<br />

Carolina; Charleston, SC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• utilize laboratory testing in the management <strong>of</strong> patients with<br />

systemic lupus erythematosus<br />

• determine the most relevant and beneficial therapeutic<br />

approach<br />

• identify appropriate assessment tools for use in management<br />

and prognosis<br />

B304<br />

Pulmonary Hypertension in the Rheumatic Diseases<br />

(008)<br />

Speaker: Dinesh Khanna, MD, MSc; University <strong>of</strong> California-Los<br />

Angeles; Los Angeles, CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine the epidemiology <strong>of</strong> pulmonary arterial<br />

hypertension in rheumatic diseases<br />

• discuss the algorithm for diagnosis <strong>of</strong> pulmonary arterial<br />

hypertension in rheumatic diseases<br />

• describe the available treatments for pulmonary arterial<br />

hypertension in rheumatic diseases<br />

B305<br />

Rheumatoid Arthritis: Challenging Cases (009)<br />

Speaker: Edward C. Keystone, MD; University <strong>of</strong> Toronto;<br />

Toronto, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss management <strong>of</strong> patients with refractory rheumatoid<br />

arthritis<br />

• identify novel treatment options for those failing conventional<br />

therapies<br />

B306<br />

Rheumatoid Arthritis: Difficult Rheumatoid Arthritis<br />

(010)<br />

Speaker: Nancy A. Shadick, MD, MPH; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define difficult to treat rheumatoid arthritis<br />

• create effective management plans for complicated<br />

rheumatoid arthritis patients<br />

ACR Workshops<br />

7:45 - 9:45 am<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B201<br />

Creating Presentations Using PowerPoint: Basic (201)<br />

Speaker: Steve W. Blevins, MBA; <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong>; Atlanta, GA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• demonstrate advanced slide transition techniques<br />

• integrate audio, video and narration into slides<br />

• create presentations that can be published on a local Web site<br />

and be viewed in a browser<br />

B204<br />

Joint Injection Techniques (202) cP PS<br />

Speakers: Atul A. Deodhar, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Kenneth S. O’Rourke, MD; Wake Forest University School <strong>of</strong><br />

Medicine; Winston-Salem, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss indications and contraindications for joint aspirations<br />

and injections<br />

• identify and avoid common mistakes in joint injection<br />

procedures<br />

• perform common joint and s<strong>of</strong>t tissue injections on upper and<br />

lower extremities<br />

B203<br />

Musculoskeletal Ultrasonography: Basic (203) f<br />

Speakers: Janak R. Goyal, MD; University <strong>of</strong> Medicine and<br />

Dentistry <strong>of</strong> New Jersey, Robert Wood Johnson Medical School;<br />

Perth Amboy, NJ<br />

Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine;<br />

Ponte Vedra Beach, FL<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the indications for ultrasound in rheumatic diseases<br />

• discuss the techniques <strong>of</strong> ultrasonography<br />

• identify normal and abnormal anatomical structures by<br />

ultrasound imaging<br />

monday<br />

2010 Program Book 29


monday<br />

30<br />

B202<br />

Synovial Fluid Analysis and Crystal Identification<br />

(204) f<br />

Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />

Center; Blue Bell, PA<br />

Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;<br />

Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• prepare synovial fluid samples for microscopic examination<br />

• identify various components <strong>of</strong> synovial fluid<br />

• identify crystals in synovial fluid<br />

ARHP Special Session<br />

8:00 - 9:45 am<br />

A411<br />

All ARHP attendees are invited to this kick-<strong>of</strong>f forum for the<br />

annual meeting. A continental breakfast will be served.You will<br />

have an opportunity to meet and network with other health<br />

pr<strong>of</strong>essionals and the ARHP leadership. This session is not<br />

eligible for CME credit. The ARHP thanks Amgen, Inc. and Pfizer<br />

Inc for supporting the Networking Forum.<br />

ARHP Networking Forum<br />

8:00 AM<br />

Breakfast<br />

8:35 AM<br />

Membership Recruitment Award Presentation<br />

The ARHP Membership Recruitment Award is presented to<br />

one ARHP and one ACR member who have recruited the most<br />

members in the current year.<br />

Jeanne F. Boyle, BSN, University <strong>of</strong> New Mexico Medical Center,<br />

Albuquerque, New Mexico<br />

Arthur D. Bankhurst, MD, University <strong>of</strong> New Mexico Medical<br />

Center, Albuquerque, New Mexico<br />

ARHP Graduate Student Recognition Award Presentation<br />

The ARHP Graduate Student Recognition Award recognizes<br />

creative research or clinical project efforts that merge theory<br />

and clinical practice in assessing and/or improving the lives<br />

<strong>of</strong> patients with theumatic disease, broadly defined and<br />

encourages the interest <strong>of</strong> non-medical graduate student in the<br />

field <strong>of</strong> rheumatology.<br />

Shilpa Bhupathiraju, MS, Tufts University, Malden, MA<br />

Lisa R. Jewett, BA, McGill University & Jewish General Hospital,<br />

Montreal, QC, Canada<br />

8:45 am<br />

Presidental Welcome<br />

Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute <strong>of</strong><br />

Chicago; Chicago, IL<br />

8:50 am<br />

Program Overview<br />

Benjamin J. Smith, PA-C; McIntosh Clinic PC; Thomasville, GA<br />

2010 Program Book<br />

ACR Practice Issues<br />

8:30 - 10:00 am<br />

A311<br />

Transforming Rheumatologic Care with the Electronic<br />

Health Record BR C PS<br />

Moderator: Charles M. King, MD; Internal Medicine Associates;<br />

Belden, MS<br />

8:30 AM<br />

State <strong>of</strong> the Current HIT Landscape<br />

Stacey Empson, JD, MHA; Courtyard Group; Evanston, IL<br />

9:05 AM<br />

EHR 1.0: EHR in Your Office-Let’s Get Started (Breakout Session<br />

A)<br />

Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center;<br />

Dallas, TX<br />

Matthew W. Morgan, MD; Courtyard Group; Toronto, ON,<br />

Canada<br />

9:05 AM<br />

EHR 2.0: Making Health Technology Work for You - EHR Users<br />

Group (Breakout Session B)<br />

Christi J. Inman, MD; University<strong>of</strong> Utah; Salt Lake City, UT<br />

Session Overview:<br />

The successful adoption <strong>of</strong> health information technology/<br />

electronic health record systems will serve rheumatology<br />

practices by supporting efforts to reduce risk, improve<br />

coordination for care, improve adherence to recommended<br />

guidelines, and improve health outcomes for patients. But for<br />

many practices, successfully selecting and implementing an<br />

electronic health record system can be difficult. Often in small<br />

groups or solo practices the clinician or administrator has little<br />

technical knowledge and access to limited resources. They don’t<br />

have a proven process, the tools, or the experience for selecting<br />

an electronic health record system and for fully integrating the<br />

system into practice workflows. As a result, many practices<br />

struggle to realize the financial and operational benefits <strong>of</strong> an<br />

electronic health record. The cost <strong>of</strong> failure will be high in terms<br />

<strong>of</strong> dollars and morale.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the business cases for electronic health record systems<br />

that are relevant to rheumatology<br />

• describe the technology components that support improved<br />

quality and efficiency <strong>of</strong> care delivery in the rheumatology<br />

practice<br />

• articulate the effect <strong>of</strong> these technologies on improving<br />

patient care processes, enhancing clinical outcomes and<br />

promoting patient and practice safety<br />

ACR Immunology Updates for<br />

Clinicians<br />

9:00 - 10:00 am<br />

B406<br />

Innate Immunity and Inflammation c/r<br />

Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Speaker: Harris R. Perlman, PhD; Northwestern University;<br />

Chicago, IL


Session Overview:<br />

The innate immune system can sense “danger” and induce<br />

inflammation and initiate tissue repair. Sensing danger in the<br />

setting <strong>of</strong> infection or tissue damage is important for normal<br />

host defenses and homeostasis. Moreover, in vaccine adjuvants<br />

can be used to boost immune responses by activating cells <strong>of</strong><br />

the innate immune system. However, there are clinical settings<br />

in which innate immunity goes awry triggering unnecessary<br />

inflammation, injury, and disease. Thus, the molecular<br />

mechanism leading from uric acid or calcium pyrophosphate<br />

crystals to gout or pseudogout are similar to those triggered by<br />

infection or tissue necrosis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the inflammasome, how it is activated and how it<br />

induces inflammation<br />

• discuss how crystals, such as urate, calcium pyrophosphate or<br />

even aluminum hydroxide, trigger activation <strong>of</strong> inflammation<br />

and why IL-1ra works for gout<br />

• explain the importance <strong>of</strong> innate immunity in resolution <strong>of</strong><br />

inflammation<br />

ACR Medical Aspects <strong>of</strong> Rheumatic<br />

Diseases<br />

9:00 - 10:00 am<br />

Hall A3<br />

Heparin and Antiphospholipid Syndrome-induced<br />

Thrombocytopenia cP ARS<br />

Moderator: Alexandra Villa-Forte, MD, MPH; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Speaker: John R. Bartholomew, MD; Cleveland Clinic; Cleveland,<br />

OH<br />

Session Overview:<br />

Heparin-induced thrombocytopenia and the antiphospholipid<br />

syndrome are disorders with distinct pathogenesis; however<br />

they share several clinical features, including thrombocytopenia<br />

and thrombotic events. Evaluation <strong>of</strong> patients with<br />

thrombocytopenia and thrombosis and distinguishing these two<br />

disorders require careful clinical assessment, as well as focused<br />

laboratory evaluation. An algorithmic approach to the evaluation<br />

and the differential diagnosis <strong>of</strong> patients with thrombocytopenia<br />

and thrombosis can be helpful to the rheumatologist.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the important elements <strong>of</strong> the clinical features and<br />

appropriate laboratory testing in the diagnosis <strong>of</strong> heparininduced<br />

thrombocytopenia and antiphospholipid syndrome<br />

• describe the clinical utility and limitations <strong>of</strong> auto-antibodies<br />

testing in the diagnosis <strong>of</strong> thrombocytopenia<br />

• discuss treatment options in heparin-induced<br />

thrombocytopenia<br />

Moderator: Kathleen M. O’Neil, MD; Oklahoma University<br />

Health Science Center; Oklahoma City, OK<br />

Speaker: Ann M. Reed, MD; Mayo Clinic; Rochester, MN<br />

Session Overview:<br />

Childhood-onset dermatomyositis shares many features with<br />

adult dermatomyositis, but there are also important differences.<br />

New insights into the pathophysiology <strong>of</strong> this disease include<br />

the roles played by matern<strong>of</strong>etal microchimerism, Treg and<br />

B lymphocytes in the inflammatory infiltrates, and new data<br />

from gene expression arrays, giving insights into this perplexing<br />

disease. Data from clinical trials including B cell depletion in<br />

juvenile dermatomyositis will be available in 2010; therefore,<br />

an update on current understanding <strong>of</strong> relevant pathogenic<br />

pathways in this disease is important.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the clinical spectrum <strong>of</strong> juvenile dermatomyositis and<br />

its multi-organ involvement<br />

• discuss the current knowledge <strong>of</strong> the pathophysiology <strong>of</strong><br />

juvenile dermatomyositis<br />

• assess the efficacy and safety <strong>of</strong> aggressive treatment<br />

modalities in juvenile dermatomyositis, and the role these<br />

therapies may play in treatment <strong>of</strong> patients with this disease<br />

Sidney J. Marcus Auditorium<br />

T cell Memory R<br />

Moderators: Keith B. Elkon, MD; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

Michael Ehrenstein, PhD; University <strong>College</strong> London School <strong>of</strong><br />

Medicine; London, United Kingdom<br />

Speaker: Rafi Ahmed, PhD; Emory University School <strong>of</strong> Medicine;<br />

Atlanta, GA<br />

Session Overview:<br />

Most autoimmune disorders are driven by T cells. Memory<br />

T cells are expanded and presumably provide a reservoir for<br />

autoreactivity that persists even when biologic therapy is<br />

used to block acute inflammation. It is therefore necessary<br />

to understand how memory T cells are generated and what<br />

strategies may prove effective in selectively impairing their<br />

function in autoimmune diseases.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify differences between naive and memory T cells<br />

phenotype and function<br />

• determine how T memory cells are generated in virus<br />

infections<br />

• describe which cytokines and ligands influence the function <strong>of</strong><br />

memory T cells<br />

ACR Poster Session A and Poster<br />

Tours<br />

9:00 am - 6:00 pm<br />

monday<br />

ACR State-<strong>of</strong>-the-Art Lectures<br />

9:00 - 10:00 am<br />

Thomas J. Murphy Ballroom<br />

Juvenile Dermatomyositis in 2010 - From Bench to<br />

Bedside P PS<br />

Halls B1 & B2<br />

Poster presenters will be available from 9:00 - 11:00 AM. Poster<br />

tours will be held 9:00 - 9:45 AM, 10:15 - 11:00 AM and 4:30 -<br />

5:30 PM.<br />

2010 Program Book 31


monday<br />

9:00 - 11:00 AM – Poster Presentations (Abstracts # 1 – 619)<br />

Guided Poster Tours<br />

Guided poster tours provide an opportunity for scientific<br />

attendees to ask questions and gain insights from leaders in<br />

the field while earning CME credits. Morning tours will <strong>of</strong>fer<br />

insights from both poster presenters and tour guides, while<br />

afternoon tours will exclusively feature the tour guide’s expert<br />

opinion. Although there is no fee to participate, pre-registration<br />

is required and each tour is limited to 20 registered scientific<br />

attendees. If you would like to participate and have not<br />

registered you can check tour availability and request a ticket<br />

in the registration area, located in the International Boulevard<br />

Foyer. If you registered in advance <strong>of</strong> the meeting your ticket was<br />

included with your meeting materials. Once you have your ticket,<br />

plan to collect your headset and meet your group 10 minutes<br />

before your tour departs from the entrance <strong>of</strong> the poster hall,<br />

located in Halls B1 & B2.<br />

Headsets: Each tour participant will receive a wireless headset.<br />

Participants who do not return their headsets within 10 minutes<br />

after the tour has ended will incur a fee.<br />

9:00 - 9:45 AM<br />

Antiphospholipid Syndrome<br />

Projen Chen, PhD; University <strong>of</strong> California - Los Angeles School <strong>of</strong><br />

Medicine; Los Angeles, CA<br />

Osteoarthritis: Clinical Aspects<br />

Roy D. Altman, MD; University <strong>of</strong> California – Los Angeles, Los<br />

Angeles, CA<br />

Pediatric P<br />

(Attendance limited to Pediatric Resident Program recipients.)<br />

Rayfel Schneider, MBBCh; Hospital for Sick Children; Toronto,<br />

ON, Canada<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Ernest Choy, MD; Kings <strong>College</strong> Hospital; London, United<br />

Kingdom<br />

Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />

and Treatment<br />

Christopher Ritchlin, MD; University <strong>of</strong> Rochester Medical<br />

Center; Rochester, NY<br />

Systemic Lupus Erthymatosus: Clinical Aspects<br />

Elena Massarotti, MD; Brigham and Women’s Hospital; Boston,<br />

MA<br />

10:15 - 11:00 AM<br />

Fellows Only: How to Navigate the Poster Hall f<br />

Calvin R. Brown, MD; Northwestern University, Chicago, IL<br />

Osteoarthritis - Clinical Aspects<br />

Joanne M. Jordan, MD, MPH; University <strong>of</strong> North Carolina<br />

Thurston ARC, Chapel Hill, NC<br />

Rheumatoid Arthritis Human Etiology and Pathogenesis<br />

Gary S. Firestein, MD; University California-San Diego School <strong>of</strong><br />

Medicine; La Jolla, CA<br />

Rheumatoid Arthritis Treatment: Small Molecules, Biologics<br />

and Gene Therapy<br />

S. Louis Bridges, Jr., MD; University <strong>of</strong> Alabama-Birmingham;<br />

Birmingham, AL<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Neal S. Birnbaum, MD; Pacific <strong>Rheumatology</strong> Association; San<br />

Francisco, CA<br />

Systemic Lupus Erythematosus: Clinical Aspects<br />

Rosalind Ramsey-Goldman, MD; Northwestern University<br />

Medical School; Chicago, IL<br />

4:30 - 5:30 PM<br />

Metabolic and Crystal Arthropathies<br />

N. Lawrence Edwards, MD; University <strong>of</strong> Florida; Gainesville, FL<br />

Orthopedics, Low Back Pain and Rehabilitation<br />

Jeffrey N. Katz, MD; Brigham and Women’s Hospital; Boston, MA<br />

Rheumatoid Arthritis: Clinical Aspects<br />

John J. Cush, MD; Baylor Research Institute; Dallas, TX<br />

Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />

and Treatment<br />

Desiree M. Van Der Heijde, MD, PhD; Leiden University Medical<br />

Center; Meerssen, Netherlands<br />

Exhibits and Replay Café<br />

9:00 am - 5:00 pm<br />

Halls A1 & A2<br />

Exhibits<br />

Halls A1 & A2 (Booth #123)<br />

Replay Café<br />

Exhibit Hall Morning SnACk Break<br />

9:00 - 10:00 am<br />

Halls A1 & A2<br />

Poster Hall Morning SnACk Break<br />

9:00 - 10:30 am<br />

Halls B1 & B2<br />

ARHP General Session I – Keynote<br />

Address<br />

10:00 - 11:00 am<br />

B313<br />

The Real Doc Hollywood Presents...Laughter is Good<br />

Medicine c/r PS<br />

Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />

Albuquerque, NM<br />

Speaker: Neil Shulman, MD; Emory University School <strong>of</strong><br />

Medicine; Atlanta, GA<br />

Session Overview:<br />

Diverse literature suggests that humor has been reported to<br />

have positive effects on various outcomes such as stress, health<br />

and immune function. Use <strong>of</strong> humor can be easily implemented.<br />

This session will provide participants with how to use humor<br />

effectively in their practices to improve patient outcomes and<br />

communication.<br />

32<br />

2010 Program Book


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• promote awareness about the importance <strong>of</strong> humor in<br />

maintaining good health and combating stress<br />

• identify tools and practices which can provide humor in one’s<br />

life<br />

• demonstrate an attitude <strong>of</strong> creativity and fun in healthcare<br />

and in everyday settings<br />

InnoVAtion Theater<br />

10:00 - 10:45 am<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Forest Pharmaceuticals.<br />

Please visit the Forest Pharmaceuticals exhibit booth for more<br />

information or see page 292. Seating and light refreshments are<br />

subject to availability.<br />

A Treatment Option for the Management <strong>of</strong><br />

Fibromyalgia<br />

ACR Workshops<br />

10:30 - 12:30 pm<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B201<br />

Designing a Web Site for Your Practice (205)<br />

Speaker: Peter J. Embi, MD, MS; University <strong>of</strong> Cincinnati;<br />

Cincinnati, OH<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the basics <strong>of</strong> creating Web sites on the internet<br />

• describe how to secure a Web address or domain name for a<br />

practice Web site<br />

• design a basic Web site using online or PC-based tools<br />

B204<br />

Osteoporosis: Interpreting Dual Energy X-ray<br />

Absorptiometry and Clinical Risk Factors: The New<br />

Fracture Risk Assessment Algorithm (206) PS<br />

Speaker: Stuart L. Silverman, MD; Cedars-Sinai Medical Center,<br />

University <strong>of</strong> California-Los Angeles; Beverly Hills, CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine how to combine bone mineral density and clinical<br />

risk factors in determination <strong>of</strong> absolute risk<br />

• discuss the concept <strong>of</strong> intervention threshold used in National<br />

Osteoporosis Foundation guidelines<br />

• review International Society for Clinical Densitometry<br />

guidelines for DXA interpretation<br />

• create a report for bone densitometry results<br />

B206<br />

Peripheral Magnetic Resonance Imaging in<br />

<strong>Rheumatology</strong> Practice (207)<br />

Speakers: Philip G. Conaghan, MD, PhD; Chapel Allerton<br />

Hospital; Leeds, United Kingdom<br />

Mikkel Østergaard, MD, PhD, DMSc; Hvidovre University<br />

Hospital; Hvidovre, Denmark<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />

the outpatient setting<br />

• review the merits and pitfalls <strong>of</strong> this technology<br />

B202<br />

Renal Histopathology in Systemic Lupus<br />

Erythematosus and Vasculitis (208)<br />

Speaker: Megan Troxell, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the pathologic changes that occur in lupus nephritis<br />

• discuss the pathologic basis for the classification <strong>of</strong> lupus<br />

nephritis and how it relates to clinical management<br />

• describe the histological changes in the kidneys <strong>of</strong> patients<br />

with vasculitis<br />

ACR Plenary Session I: Discovery 2010<br />

c/r<br />

11:00 am - 12:30 pm<br />

Hall A3<br />

Moderators: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />

Dallas, TX<br />

E. William St.Clair, MD; Duke University Medical Center; Durham,<br />

NC<br />

11:00 AM<br />

ACR REF Industry Roundtable Awards<br />

11:10 AM<br />

ACR Abstract Presentations Introduction<br />

11:15 AM<br />

620. Platelet C4d Is Associated with All-Cause Mortality in<br />

Patients with Systemic Lupus Erythematosus.<br />

Christine A. McBurney 5 , Amy H. Kao 2 , Abdus Sattar 3 , Apinya<br />

Lertratanakul 6 , Nicole L. Wilson 4 , Rutman Sarah 6 , Barbara Paul 6 ,<br />

Jeannine S. Navratil 6 , Joseph M. Ahearn 1 and Susan Manzi 7 ,<br />

1<br />

Wexford, PA, 2 Allegheny Singer Research Institute, Pittsburgh,<br />

PA, 3 Case Western University, 4 Magee Womens Hospital <strong>of</strong><br />

UPMC, Pittsburgh, PA, 5 University <strong>of</strong> Pittsburgh Medical Center,<br />

Pittsburgh, PA, 6 University <strong>of</strong> Pittsburgh School <strong>of</strong> the Health<br />

Sciences, 7 West Penn Allegheny Health System, Pittsburgh, PA<br />

11:30 AM<br />

621. β2-Glycoprotein Exists in a Distinct Molecular Post-<br />

Translational Oxidative State in the Antiphospholipid<br />

Syndrome: Novel Prognostic Assays and Insights into<br />

Antigenicity.<br />

Yiannis Ioannou 10 , Jing-Yun Zhang 8 , Miao Qi 11 , Gao Lu 12 , Jian<br />

Cheng Qi 11 , De-min Yu 7 , Herman Lau 6 , Allan D. Sturgess 5 ,<br />

Panayiotis Vlachoyiannopoulos 4 , Haralampos M. Moutsopoulos 3 ,<br />

monday<br />

2010 Program Book 33


monday<br />

Anisur Rahman 9 , Pericleous Charis 9 , Tatsuya Atsumi 1 , Takao<br />

Koike 2 , Bill Giannakopoulos 11 and Krilis A. Steven 11 , 1 Hokkaido<br />

University, Sapporo, Japan, 2 Hokkaido University, Japan, 3 Natl<br />

Univ <strong>of</strong> Athens Med Schl, Athens, Greece, 4 Natl Univ <strong>of</strong> Athens<br />

Med Schl, 5 St. George Hospital, Sydney, NSW, Australia, 6 St.<br />

George Hospital, 7 Tianjin Medical University, 8 Tianjin Medical<br />

University, University <strong>of</strong> New South Wales, 9 University <strong>College</strong><br />

London, 10 University <strong>College</strong> London, University <strong>of</strong> New South<br />

Wales, 11 University <strong>of</strong> New South Wales, 12University <strong>of</strong> New<br />

South Wales, Tianjin Medical University<br />

11:45 AM<br />

622. Normal Monocyte and Fibrocyte Behavior in Scleroderma<br />

Is Restored by Caveolin-1 Scaffolding Domain (CSD) Peptide:<br />

Implications for Treating Scleroderma Lung Disease.<br />

Elena Tourkina, James Oates, Ann H<strong>of</strong>bauer, Michael Bonner,<br />

Richard P. Visconti, Jing Zhang, Richard M. Silver and Stanley<br />

H<strong>of</strong>fman, Medical University <strong>of</strong> SC<br />

12:00 PM<br />

623. Clinical, Radiographic and Biomolecular Features <strong>of</strong> B Cell<br />

Synovitis in Rheumatoid Arthritis.<br />

Serena Bugatti 2 , Antonio Manzo 2 , Barbara Vitolo 2 , Chiara Fusetti 2 ,<br />

Roberto Caporali 2 , Costantino Pitzalis 1 and Carlomaurizio<br />

Montecucco 2 , 1 Centre for Experimental Medicine and<br />

<strong>Rheumatology</strong>, John Vane Science Centre, William Harvey<br />

Research Institute, St. Bartholomew’s and Royal London School<br />

<strong>of</strong> Medicine, London, 2 Chair and Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Laboratory <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Pavia, Fondazione<br />

IRCCS Policlinico San Matteo, Pavia, Italy<br />

12:15 PM<br />

624. Association <strong>of</strong> FRZB Variants with Hip Shape and<br />

Radiographic Hip Osteoarthritis: Preliminary Results.<br />

Julie Baker-LePain 4 , Kali Luker 2 , John A. Lynch 4 , Neeta Parimi 1 ,<br />

Michael C. Nevitt 3 , Mary Corr 6 and Nancy E. Lane 5 , 1 California<br />

Pacific Medical Center, 2 Stanford, 3 UCSF, San Francisco, CA,<br />

4<br />

UCSF, 5 Univ <strong>of</strong> California at Davis, Hillsborough, CA, 6 Univ <strong>of</strong><br />

California-San Diego, La Jolla, CA<br />

ARHP Concurrent Abstract Session<br />

11:15 am - 12:15 pm<br />

B311<br />

Issues in Lupus<br />

Moderator: Patricia J. Cornell, BSc; Poole Hospital; Poole Dorset,<br />

United Kingdom<br />

11:15 AM<br />

625. The Assessment <strong>of</strong> Health-Related Family Functioning in<br />

Systemic Lupus Erythematosus: Preliminary Validation <strong>of</strong> the<br />

SLE-FAMILY.<br />

Afton L. Hassett 6 , Tracy Li 1 , Diane C. Radvanski 3 , Steven Buyske 2 ,<br />

Samuel A. Schiff 4 and Patricia P. Katz 5 , 1Bristol-Myers Squibb,<br />

Princeton, NJ, 2 Rutgers University, 3 UMDNJ-Robert Wood<br />

Johnson Medical School, Union City, NJ, 4 UMDNJ-Robert<br />

Wood Johnson Medical School, 5 Univ <strong>of</strong> CA San Francisco, San<br />

Francisco, CA, 6 University <strong>of</strong> Michigan Medical School, Ann<br />

Arbor, MI<br />

11:30 AM<br />

626. Heart-Rate Recovery Immediately after Graded Exercise in<br />

Woman with Systemic Lupus Erythematosus.<br />

Danilo M. L. Prado 1 , Fabio Baptista 1 , Renata Miossi 1 , Fernanda R.<br />

Lima 1 , Ana Lucia S. Pinto 1 , Eduardo F. Borba 3 and Eloisa Bonfa2,<br />

1<br />

USP, Sao Paulo, SP, Brazil, 2 USP, Sao Paulo, Brazil, 3 USP<br />

11:45 AM<br />

627. Body Composition, Lower Extremity Strength, and Fatigue<br />

in SLE.<br />

Patricia Katz, Laura Julian, Jinoos Yazdany, Holly Wing, Sandi<br />

Kaplan, Laura Trupin and Ed Yelin, UCSF<br />

12:00 PM<br />

628. Physical Exercise Improves Endothelial Function in<br />

Patients with Systemic Lupus Erythematosus.<br />

Edgard T. Reis Neto, Aline E. Silva, Carlos M. C. Monteiro, Luciano<br />

M. Camargo, Neusa P. Silva, Marcelo M. Pinheiro and Emilia I.<br />

Sato, Universidade Federal de São Paulo, Brazil<br />

ARHP Concurrent Sessions<br />

11:15 am - 12:15 pm<br />

B309<br />

Evidence-based Non-pharmacological Treatment for<br />

Hip, Knee, and Hand Osteoarthritis: The New ACR<br />

Guidelines c/r PS PM<br />

Moderator: Marc C. Hochberg, MD, MPH; University <strong>of</strong><br />

Maryland; Baltimore, MD<br />

Speakers: Catherine L. Backman, PhD, OT(C); University <strong>of</strong> British<br />

Columbia; Vancouver, BC, Canada<br />

G. Kelley Fitzgerald, PhD, PT; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />

PA<br />

Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />

Marc C. Hochberg, MD, MPH; University <strong>of</strong> Maryland; Baltimore,<br />

MD<br />

Session Overview:<br />

Osteoarthritis is the primary cause <strong>of</strong> physical disability in<br />

adults and is a diagnosis commonly seen by physical therapists.<br />

It is critical that physical and occupational therapists use the<br />

best available evidence when choosing treatment strategies<br />

for osteoarthritis <strong>of</strong> the hip, knee and hand. The new ACR<br />

treatment guidelines, Recommendations for Non-pharmacologic<br />

and Pharmacologic Therapies in Hand, Hip and Knee<br />

Osteoarthritis,derived from a critical review <strong>of</strong> available research<br />

and consensus <strong>of</strong> a panel <strong>of</strong> experts from medicine, surgery<br />

and rehabilitation, provide a powerful framework within which<br />

therapists can choose an appropriate treatment regimen.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the review process used to evaluate the research<br />

evidence for non-pharmacological management <strong>of</strong><br />

osteoarthritis <strong>of</strong> the hip, knee and hand<br />

• identify which treatments have sufficient evidence <strong>of</strong> efficacy<br />

in osteoarthritis treatment to recommend their use in<br />

rehabilitation; which require additional research to determine<br />

their efficacy in treating osteoarthritis; and which have<br />

evidence <strong>of</strong> limited or no efficacy in treating osteoarthritis <strong>of</strong><br />

the hip, knee and hand<br />

34<br />

2010 Program Book


B308<br />

Inflammatory Eye Disease P/C<br />

Moderator: Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los<br />

Angeles; Los Angeles, CA<br />

Speakers: Andreas O. Reiff, MD; Children’s Hospital <strong>of</strong> Los<br />

Angeles; Los Angeles, CA<br />

Sukesh Sukumaran, MBBS, MD, DPMR; Children’s Hospital <strong>of</strong> Los<br />

Angeles; Los Angeles, CA<br />

Session Overview:<br />

Uveitis is the third leading cause <strong>of</strong> preventable, irreversible<br />

blindness in the developed world. Frequently, localized therapy<br />

is not sufficient to treat these complicated inflammatory<br />

processes. With the availability <strong>of</strong> chemotherapy and biologic<br />

treatments for these conditions, ophthalmologists are<br />

increasingly consulting with rheumatologists for input on<br />

systemic therapy and management. Therefore the rheumatology<br />

community must become familiar with the etiology and effects<br />

<strong>of</strong> treatment in inflammatory eye diseases.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• use a case study model to analyze and apply uveitis principles<br />

in the clinical context<br />

• review the etiology and common subtypes <strong>of</strong> uveitis<br />

• define the role <strong>of</strong> the rheumatologist in the uveitis treatment<br />

team<br />

• review the traditional pharmacologic treatment<br />

recommendations for uveitis and compare them to advanced<br />

treatments with biologics<br />

B310<br />

Physical Activity: The Arthritis Pain Reliever – The<br />

Revised Centers for Disease Control and Prevention<br />

Health Communications Campaign c/r PM PS<br />

Moderator: Gail C. Davis, RN, EdD; Texas Woman’s University;<br />

Denton, TX<br />

Speaker: Teresa J. Brady, PhD; Center for Disease Control;<br />

Atlanta, GA<br />

Session Overview:<br />

Enticing people with arthritis to increase their physical activity<br />

is a priority for both clinicians and public health practitioners.<br />

However, our collective efforts have been marginally effective<br />

as 44 percent <strong>of</strong> people with arthritis report no leisure time<br />

activity. Describing the required activity levels in concrete<br />

understandable terms, addressing the unique concerns <strong>of</strong><br />

people with arthritis, and highlighting the most desired potential<br />

benefits <strong>of</strong> physical activity can all help address this gap. In 2010<br />

the Centers for Disease Control and Prevention Arthritis Program<br />

released a revised version <strong>of</strong> the health communications<br />

campaign Physical Activity, The Arthritis Pain Reliever. The<br />

campaign was based on research findings related to physical<br />

activity attitudes, perceptions, and preferences among people<br />

with arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe key learnings derived from qualitative audience<br />

research about physical activity conducted among people with<br />

arthritis<br />

• discuss how these key learnings can be utilized in clinical<br />

practice<br />

• identify key elements <strong>of</strong> the revised Physical Activity: The<br />

Arthritis Pain Reliever health communications campaign<br />

• develop individual physical activity-related counseling and<br />

instruction plans<br />

InnoVAtion Theater<br />

12:15 - 1:00 pm<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Centocor Ortho Biotech Inc.<br />

Please visit the Centocor Ortho Biotech Inc. exhibit booth for<br />

more information or see page 292. Seating and boxed lunches<br />

are subject to availability.<br />

Choices and Challenges in Managing Psoriatic<br />

Arthritis<br />

ARHP Special Sessions<br />

12:30 - 1:30 pm<br />

The ARHP is <strong>of</strong>fering informal networking opportunities for<br />

rheumatology health pr<strong>of</strong>essional disciplines and students. These<br />

networking opportunities, led by facilitators, will allow open<br />

discussion and interaction with fellow attendees. Bring your<br />

lunch and join a group.<br />

These sessions are not eligible for CME credit.<br />

B310<br />

ARHP Networking for Georgia Health Pr<strong>of</strong>essionals<br />

and Physicians<br />

Facilitator: Joyce P. Carlone, MN, RN, FNP-BC; Emory University;<br />

Atlanta, GA<br />

B309<br />

ARHP Pediatrics Networking<br />

Facilitator: Karla B. Jones, MS, RN, CPNP; Nationwide Children’s<br />

Hospital; Columbus, OH<br />

B311<br />

ARHP Research Coordinators Networking<br />

Facilitators: Donah Z. Crawford, BS, MA; The Arthritis Group;<br />

Philadelphia, PA<br />

Lisa M. Kastanek, RN, CCRC; Physician Research Collaboration;<br />

Lincoln, NE<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

12:45 - 2:15 pm<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Adult Inflammatory Myopathy (011)<br />

Speaker: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />

Milwaukee, WI<br />

2010 Program Book 35<br />

monday


monday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the clinical manifestations <strong>of</strong> inflammatory myopathies<br />

including important extra-muscle manifestations<br />

• discuss diagnostic pearls for the evaluation <strong>of</strong> someone<br />

suspected <strong>of</strong> having an inflammatory myopathy<br />

• discuss the treatment paradigm for inflammatory myopathies<br />

B208<br />

Ankylosing Spondylitis: 2010 Update (012) PS<br />

Speaker: Desiree M. Van Der Heijde, MD, PhD; Leiden University<br />

Medical Center; Meerssen, Netherlands<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the natural history <strong>of</strong> ankylosing spondylitis and its<br />

early diagnosis<br />

• describe clinical and radiographic outcome measures used in<br />

ankylosing spondylitis trials<br />

• summarize available guidelines in the management <strong>of</strong><br />

ankylosing spondylitis<br />

• review the scientific data on biologic agents as possible<br />

disease modifying agents in the treatment <strong>of</strong> ankylosing<br />

spondylitis<br />

B209<br />

Cutaneous Vasculitis (013)<br />

Speaker: Nicole Fett, MD; Perelman Center for Advanced<br />

Medicine; Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• distinguish the clinical features <strong>of</strong> small and medium-sized<br />

vasculitides that involve the skin<br />

• gain insight into the pathological features <strong>of</strong> cutaneous<br />

vasculitis, which lead directly to clinical disease observable on<br />

the skin<br />

• identify vasculitis mimickers with cutaneous involvement<br />

• develop a rational approach to the evaluation and<br />

management <strong>of</strong> cutaneous vasculitis<br />

B301<br />

Osteoporosis: Novel Treatments (014) PS<br />

Speaker: Michael J. Maricic, MD; Catalina Pointe <strong>Rheumatology</strong>;<br />

Tucson, AZ<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review bone physiology and immunology emphasizing<br />

potential areas amenable to intervention<br />

• discuss current therapies for osteoporosis and their limitations<br />

• identify newer treatments available and therapies just over<br />

the horizon for osteoporosis<br />

B302<br />

Pain: Evaluation and Treatment <strong>of</strong> Back Pain (015) PM<br />

Speaker: David G. Borenstein, MD; Arthritis & Rheumatism<br />

Association; Washington, DC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine the appropriate use <strong>of</strong> diagnostic tests in the<br />

evaluation <strong>of</strong> low back pain<br />

• review effective therapies for low back pain<br />

• identify the types <strong>of</strong> exercises that prevent and treat low back<br />

pain<br />

B303<br />

Pediatrics: Juvenile Idiopathic Arthritis for Adult<br />

Rheumatologists (016) P<br />

Speaker: AnneMarie C. Brescia, MD; DuPont Hospital for<br />

Children; Wilmington, DE<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the International League <strong>of</strong> Associations for<br />

<strong>Rheumatology</strong> classification for juvenile rheumatoid arthritis/<br />

juvenile idiopathic arthritis<br />

• discuss current therapeutic strategies for juvenile rheumatoid<br />

arthritis/juvenile idiopathic arthritis<br />

• describe the role <strong>of</strong> interleukin-1 in the pathogenesis<br />

<strong>of</strong> systemic onset juvenile rheumatoid arthritis/juvenile<br />

idiopathic arthritis<br />

B304<br />

Pregnancy in Rheumatic Diseases (017)<br />

Speaker: Megan E.B. Clowse, MD, MPH; Duke University Medical<br />

Center; Durham, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the effects <strong>of</strong> pregnancy on the activity <strong>of</strong> rheumatic<br />

diseases<br />

• describe the challenging management issues unique to<br />

pregnancy<br />

B305<br />

Rheumatoid Arthritis: Early Rheumatoid Arthritis<br />

(018) PS<br />

Speaker: Johanna Hazes, MD, PhD; Erasmus Medical Centre<br />

Rotterdam; Rotterdam, Netherlands<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the clinical syndrome <strong>of</strong> rheumatoid arthritis early in<br />

its course<br />

• determine which modalities are <strong>of</strong> use in diagnosis and<br />

determining prognosis<br />

• evaluate which therapeutic regimens yield the best long-term<br />

outcomes<br />

B210<br />

Systemic Lupus Erythematosus: Difficult to Treat<br />

Systemic Lupus Erythematosus (019) P<br />

Speaker: Elena M. Massarotti, MD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• utilize laboratory testing in the management <strong>of</strong> patients with<br />

systemic lupus erythematosus<br />

• determine the most relevant and beneficial therapeutic<br />

approach<br />

• identify appropriate assessment tools for use in management<br />

and prognosis<br />

B306<br />

Vitamin D and Bone Health (020)<br />

Speaker: Karen E. Hansen, MD; University <strong>of</strong> Wisconsin;<br />

Madison, WI<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the metabolic consequences <strong>of</strong> vitamin D deficiency<br />

36<br />

2010 Program Book


and insufficiency<br />

• recall sources <strong>of</strong> controversy regarding the optimal vitamin D<br />

level for bone health<br />

• recall vitamin D assay variability and the challenges this<br />

provides in diagnosing deficiency<br />

• prescribe standard and alternative treatments for vitamin D<br />

deficiency<br />

ACR Clinical Symposium<br />

1:00 - 2:00 pm<br />

Thomas J. Murphy Ballroom<br />

Clinical Review: Immunizations and Rheumatic<br />

Diseases - An Update c/r cP PS<br />

Moderators: Zsuzsanna H. McMahan, MD; Johns Hopkins<br />

University; Baltimore, MD<br />

Arthur Kavanaugh, MD; University <strong>of</strong> California-San Diego; La<br />

Jolla, CA<br />

Speaker: Clifton O. Bingham, MD; Johns Hopkins University;<br />

Baltimore, MD<br />

Session Overview:<br />

This review is designed to provide an update on safety and<br />

efficacy issues as they relate to the immunization <strong>of</strong> patients<br />

with rheumatic disease. The diversity <strong>of</strong> the available<br />

treatments for rheumatic disease, as well as the increase in<br />

the recommended immunizations for adults, makes it critical<br />

to provide regular updates for clinicians. Rheumatologists are<br />

frequently required to render an opinion about the safety and<br />

efficacy <strong>of</strong> immunizations for their patients. The goals <strong>of</strong> this<br />

clinical review are to provide clinicians with updates on the<br />

effects <strong>of</strong> rheumatic drugs/biologics on vaccinations; evidence<br />

for efficacy <strong>of</strong> immunizations in rheumatic diseases; and safety<br />

<strong>of</strong> immunizations for patients with rheumatic diseases.<br />

in the physiological regulation <strong>of</strong> endogenous glucocorticoids<br />

and in understanding the cellular and molecular mechanisms <strong>of</strong><br />

glucocorticoid action.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the physiological mechanisms <strong>of</strong> glucocorticoid<br />

regulation<br />

• explain cellular and molecular mechanisms <strong>of</strong> glucocorticoid<br />

action<br />

• identify pharmacological approaches for optimizing the clinical<br />

efficacy <strong>of</strong> glucocorticoids in reducing potential adverse side<br />

effects in inflammatory and musculoskeletal conditions<br />

B406<br />

Genetic Disorders <strong>of</strong> Connective Tissue and Joint<br />

Hypermobility R<br />

Moderator: Rodney Grahame, MD; University <strong>College</strong> Hospital;<br />

London, United Kingdom<br />

Speaker: Peter H. Byers, MD; University <strong>of</strong> Washington; Seattle,<br />

WA<br />

Session Overview:<br />

Genetic alterations in connective tissue matrix proteins result<br />

in a number <strong>of</strong> conditions seen by both pediatric and adult<br />

rheumatologists. These conditions include Marfan’s and<br />

various types <strong>of</strong> Ehler-Danlo’s syndrome that result in joint<br />

hypermobility and contribute to the development <strong>of</strong> arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the common genetic disorders in connective tissue<br />

proteins<br />

• describe the contribution <strong>of</strong> genetic disorders in connective<br />

tissue proteins to joint disorders<br />

• analyze how mutations in connective tissue proteins can result<br />

in joint hypermobility<br />

monday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the efficacy and safety issues related to immunizations<br />

in adults with rheumatic diseases<br />

• examine the impact <strong>of</strong> specific rheumatic treatments on the<br />

efficacy <strong>of</strong> vaccinations<br />

• review the latest recommendations and guidelines for the<br />

immunization <strong>of</strong> adults<br />

ACR State-<strong>of</strong>-the-Art Lectures<br />

1:00 - 2:00 pm<br />

B313<br />

2010 Hench Lecture: Glucocorticoids-Physiologic<br />

Regulation, Mechanisms <strong>of</strong> Action and Optimizing<br />

Therapeutic Applications c/r<br />

Moderator: Steven R. Goldring, MD; Hospital for Special Surgery;<br />

New York, NY<br />

Speaker: George P. Chrousos, MD; Athens University<br />

Medical School; Patras, Greece<br />

Session Overview:<br />

Glucocorticoids have diverse and complex effects on the<br />

function and activity <strong>of</strong> multiple cells types and tissues. There<br />

have been major advances in dissecting mechanisms involved<br />

ACR REF Special Session<br />

1:00 - 2:00 pm<br />

A311<br />

ACR REF Memorial Lectureship: <strong>Rheumatology</strong><br />

Education 2010 Ed.<br />

The 2010 REF Memorial Lectureship is in honor <strong>of</strong> Walter Barr,<br />

MD.<br />

Moderator: David I. Daikh, MD, PhD; University <strong>of</strong> California, San<br />

Francisco, Veterans Affairs Medical Center; San Francisco, CA<br />

Speaker: Dennis W. Boulware, MD; Kaiser Permanente<br />

Medical Center; Honolulu, HI<br />

Session Overview:<br />

Many rheumatologists are currently unaware <strong>of</strong> the impact <strong>of</strong><br />

the Residency Review Committee on the field <strong>of</strong> rheumatology<br />

and how recent changes in the program requirements<br />

for rheumatology are impacting the new generation <strong>of</strong><br />

rheumatologists. This session will increase the awareness <strong>of</strong><br />

the issues relevant to rheumatology currently being addressed<br />

by the Residency Review Committee, the importance <strong>of</strong><br />

competency-based education and issues that the Accreditation<br />

Council for Graduate Medical Education is addressing for all<br />

graduate medical education.<br />

2010 Program Book 37


monday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the crucial issues that are being addressed by the<br />

Accreditation Council for Graduate Medical Education in 2010<br />

• discuss the recent changes in the program requirements by<br />

the Residency Review Committee for rheumatology<br />

• explain the important issues related to competency based<br />

education in rheumatology<br />

ACR/ARHP Workshops<br />

1:15 - 3:15 pm<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B203<br />

Adult Musculoskeletal Upper/Lower Examinations<br />

(209)<br />

Speaker: Arthur M. Mandelin, MD, PhD; Northwestern<br />

University; Chicago, IL<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss principles <strong>of</strong> adult musculoskeletal physical<br />

examination<br />

• detect and describe normal and abnormal adult<br />

musculoskeletal physical examination findings<br />

• demonstrate rheumatologic upper and lower musculoskeletal<br />

examinations for adult patients using patient volunteers<br />

B201<br />

Histopathology <strong>of</strong> Vasculitis (210)<br />

Speakers: Allen Burke, MD; University <strong>of</strong> Maryland Medical<br />

Center; Baltimore, MD<br />

Fabio Tavora, MD; <strong>American</strong> International Pathology<br />

Laboratories; Silver Spring, MD<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe histological features <strong>of</strong> normal blood vessels<br />

• distinguish pathologic reactions to vascular injury<br />

• identify histological features <strong>of</strong> major vasculitis syndromes<br />

B206<br />

Peripheral Magnetic Resonance Imaging in Clinical<br />

<strong>Rheumatology</strong> (211)<br />

Speakers: Ewa Olech, MD; Oklahoma Medical Research<br />

Foundation; Oklahoma City, OK<br />

Orrin M. Troum, MD; University <strong>of</strong> Southern California; Santa<br />

Monica, CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />

the outpatient setting<br />

• review the merits and pitfalls <strong>of</strong> this technology<br />

B204<br />

<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Lower<br />

Extremity and Lumbosacral Spine: Anatomical<br />

Correlates (212) f<br />

Speakers: Robert A. Kalish, MD; Tufts Medical Center; Boston,<br />

MA<br />

Pablo Villasenor Ovies, MD; Instituto Nacional de Ciencias<br />

Medicas y Nutricion; Tlalpan, Mexico<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review clinical and surface anatomy important to the<br />

rheumatologist<br />

• describe human anatomy to clinical syndromes seen in the<br />

practice <strong>of</strong> rheumatology<br />

• integrate these physical examination skills into a<br />

rheumatology practice<br />

Exhibit Hall Afternoon SnACk<br />

Break<br />

2:00 - 3:00 pm<br />

Halls A1 & A2<br />

InnoVAtion Theater<br />

2:00 - 2:45 pm<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Centocor Ortho Biotech Inc.<br />

Please visit the Centocor Ortho Biotech Inc. exhibit booth<br />

for more information or see page 292. Seating and light<br />

refreshments are subject to availability.<br />

New Way RA – Empowering Your Patients to Live<br />

Well with RA<br />

ACR Basic Science Symposium<br />

2:30 - 4:00 pm<br />

B406<br />

Toll-like Receptors and Inflammation: Towards<br />

Innovative Treatment <strong>of</strong> Rheumatoid Arthritis R<br />

Moderators: Paul P. Tak, MD, PhD; Academic Medical Center,<br />

University <strong>of</strong> Amsterdam; Amsterdam, Netherlands<br />

Timothy R.D.J. Radstake, MD, PhD; Radboud University Nijmegen<br />

Medical Centre; Nijmegen, Netherlands<br />

2:30 pm<br />

The Role <strong>of</strong> Toll-like Receptors in Rheumatoid Arthritis:<br />

Macrophages<br />

Richard M. Pope, MD; Northwestern University Medical School;<br />

Chicago, IL<br />

3:00 pm<br />

The Role <strong>of</strong> Toll-like Receptors in Rheumatoid Arthritis:<br />

Fibroblast-like Synoviocyte<br />

Diego Kyburz, MD; Center <strong>of</strong> Experimental <strong>Rheumatology</strong>;<br />

Zurich, Switzerland<br />

3:30 pm<br />

Therapeutic Targeting <strong>of</strong> Toll-like Receptors for Inflammatory<br />

Diseases<br />

Luke A. O’Neill, PhD; Trinity <strong>College</strong> Dublin; Dublin, Ireland<br />

38<br />

2010 Program Book


Session Overview:<br />

The advent <strong>of</strong> biological therapies has dramatically improved the<br />

treatment <strong>of</strong> rheumatoid arthritis, providing pro<strong>of</strong> <strong>of</strong> principle<br />

that targeted interventions may be effective. Still, not all<br />

patients respond and there is a need to develop new therapies.<br />

This symposium will address the role <strong>of</strong> toll-like receptors in the<br />

pathogenesis <strong>of</strong> rheumatoid arthritis as well as their potential<br />

as a new therapeutic target for the treatment <strong>of</strong> inflammatory<br />

disease.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• appraise the role <strong>of</strong> toll-like receptors in two key effector<br />

cells involved in the pathogenesis <strong>of</strong> rheumatoid arthritis -<br />

macrophages and fibroblast-like synoviocytes<br />

• identify the toll-like receptors as a new therapeutic target in a<br />

variety <strong>of</strong> immune-mediated inflammatory disorders<br />

ACR Clinical Symposia<br />

2:30 - 4:00 pm<br />

Thomas J. Murphy Ballroom<br />

Mouse to House: Lessons Learned About Lupus<br />

Therapeutics P PS<br />

Moderator: Richard A. Furie, MD; North Shore Long Island<br />

Jewish Health System; Lake Success, NY<br />

2:30 pm<br />

Protective and Pathogenic Functions for B Cells During Systemic<br />

Autoimmunity in Mice<br />

Thomas Tedder, PhD; Duke University Medical Center; Durham,<br />

NC<br />

2:55 pm<br />

Do Biologic Responses to Therapeutic Interventions in Mice<br />

Predict Results in Human Lupus?<br />

Anne Davidson, MB, BS; Feinstein Institute for Medical Research;<br />

Manhasset, NY<br />

Hall A3<br />

The Great Debate: Is it Time to Use Biologics as Firstline<br />

Therapy in Rheumatoid Arthritis? cP PS ARS<br />

Moderator: Eric M. Ruderman, MD; Northwestern University<br />

School; Chicago, IL<br />

2:30 pm<br />

Resolved: Aggressive Use <strong>of</strong> Non-biologic DMARDs is as<br />

Effective as Biologics in the Management <strong>of</strong> Rheumatoid<br />

Arthritis (Con)<br />

Daniel E. Furst, MD; University <strong>of</strong> California-Los Angeles School<br />

<strong>of</strong> Medicine; Los Angeles, CA<br />

3:15 pm<br />

Resolved: Aggressive Use <strong>of</strong> Non-biologic DMARDs is as<br />

Effective as Biologics in the Management <strong>of</strong> Rheumatoid<br />

Arthritis (Pro)<br />

Marc D. Cohen, MD; National Jewish Medical and Research<br />

Center; Denver, CO<br />

Session Overview:<br />

Biologic therapy has unquestionably altered the landscape <strong>of</strong><br />

treatment for rheumatoid arthritis, and some have even begun<br />

to suggest that it is time for these agents to supplant nonbiologic<br />

therapy as first-line therapy. Addressing this question<br />

involves complicated and intertwining issues <strong>of</strong> efficacy,<br />

toxicity and cost. The presenters <strong>of</strong> this session will debate<br />

whether biologic therapy should be the initial therapy for the<br />

management <strong>of</strong> rheumatoid arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the data supporting first-line use <strong>of</strong> biologic therapy<br />

in rheumatoid arthritis<br />

• identify the limitations <strong>of</strong> biologic therapies that make their<br />

use as first-line therapy inadvisable<br />

• identify gaps in data that will need to be filled in order to<br />

resolve question <strong>of</strong> biologic use as first-line therapy<br />

monday<br />

3:30 pm<br />

Lessons Learned from Clinical Trials in Human Systemic Lupus<br />

Erythematosus<br />

Bevra H. Hahn, MD; University <strong>of</strong> California-Los Angeles School<br />

<strong>of</strong> Medicine; Los Angeles, CA<br />

Session Overview:<br />

Significant advances in our knowledge <strong>of</strong> immune system<br />

disturbances in lupus have been made over the last several<br />

decades. However, understanding the science has not yet<br />

translated into a new drug for this potentially devastating illness.<br />

Addressing mouse models and human studies, this symposium<br />

will relate pathogenetic concepts to strategies for therapeutic<br />

interventions.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss animal models <strong>of</strong> lupus and how they have advanced<br />

the development <strong>of</strong> therapeutics for human disease<br />

• describe humoral and cellular effects <strong>of</strong> therapeutic<br />

interventions in patients with lupus<br />

• summarize clinical trial data and reconcile the variability <strong>of</strong><br />

observed responses<br />

ACR Concurrent Abstract Sessions<br />

2:30 - 4:00 pm<br />

A402<br />

Biology and Pathology <strong>of</strong> Bone and Joint: Molecular<br />

Basis <strong>of</strong> Osteoarthritis<br />

Moderators: Tariq M. Haqqi, MPH, PhD; Metro Health Medical<br />

Center; Richmond Heights, OH<br />

Hiroshi Asahara, MD, PhD; The Scripps Research Institute; La<br />

Jolla, CA<br />

2:30 pm<br />

629. TNF and IL-6 Differentially Regulate the Production <strong>of</strong><br />

DKK-1, a Master Regulator <strong>of</strong> Bone Remodelling, by Fibroblast-<br />

Like Synoviocytes.<br />

Nataliya Yeremenko 2 , Karin Polzer 3 , Gemma Righter 2 , Radjesh<br />

Bisoendial 2 , Jochen Zwerina 3 , Georg Schett 3 , Paul P. Tak 1 and<br />

Dominique Baeten 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />

Amsterdam, The Netherlands, 2 Division <strong>of</strong> Clinical Immunology<br />

and <strong>Rheumatology</strong>, Academic Medical Centre/University <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 3 Internal Medicine 3 ,<br />

Erlangen, Germany<br />

2010 Program Book 39


monday<br />

2:45 pm<br />

630. Adipogenic and Osteogenic Switch in Differentiation<br />

<strong>of</strong> Human Mesenchymal Stem Cells (hMSCs) Is Triggered by<br />

Hypoxia in a HIF-1 Dependent Manner.<br />

Markus Wagegg 3 , Timo Gaber 1 , Ferenz Lohanatha 1 , Manuela<br />

Jakstadt 1 , Grit Kasper 2 , Georg Duda 2 , Paula Kolar 3 , Gerd R.<br />

Burmester 4 and Frank Buttgereit 5 , 1Berlin-Brandenburg Center<br />

for Regenerative Therapies (BCRT), 2 Charité University Hospital,<br />

Center for Musculoskeletal Surgery, Berlin, Germany, 3 Charité<br />

University Hospital, Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, Berlin, Germany, 4 Charité University Hospital,<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Berlin,<br />

Germany, 5 Charite University Med-Berlin, Berlin, Germany<br />

3:00 pm<br />

631. Mitochondrial 8-Oxoguanine DNA Glycosylase (Ogg1)<br />

Regulates the Cellular Function and Survival <strong>of</strong> Osteoarthritic<br />

Chondrocytes in Response to Catabolic Stresses in<br />

Osteoarthritis.<br />

Kazuo Yudoh 2 and Rie Karasawa 1 , 1 Kawasaki, Japan, 2 St.<br />

Marianna University School Medicine, Kawasaki City, Japan<br />

3:15 pm<br />

632. Advanced Glycation End Products (AGEs)-Induced<br />

Expression <strong>of</strong> IL-6 and IL-8 in Human Osteoarthritis<br />

Chondrocytes Correlates with the Induction <strong>of</strong> Endoplasmic<br />

Reticulum Stress.<br />

Zafar Rasheed, Nahid Akhtar and Tariq M. Haqqi, Department <strong>of</strong><br />

Medicine, Metrohealth/CWRU, Cleveland, OH<br />

3:30 pm<br />

633. MicroRNA-199a-*Mediated Regulation <strong>of</strong><br />

Cyclooxygenase-2 Expression in Human OA Chondrocytes.<br />

Nahid Akhtar 1 , Zafar Rasheed 2 and Tariq M. Haqqi 1 , 1 Metrohealth<br />

Medical Center/CWRU, Cleveland, OH, 2 Metrohealth Medical<br />

Center/CWRU<br />

3:45 pm<br />

634. The Unfolded Protein Response (UPR) Is Impaired in Aging<br />

and Osteoarthritic Cartilage Chondrocytes.<br />

Matthew Husa 1 , Ru Liu-Bryan 2 , Shawn Grogan 3 , Haitao Yang 2 ,<br />

Bing Yang 2 , Martin Lotz 3 and Robert Terkeltaub 2 , 1 San Diego<br />

VA/UCSD, La Jolla, CA, 2 San Diego VA/UCSD, 3 Scripps Research<br />

Institute<br />

A315<br />

Cytokines, Mediators, Gene Regulation I<br />

Moderators: Alison Finnegan, PhD; Rush University Medical<br />

Center; Chicago, IL<br />

Oliver Distler, MD; University Hospital Zurich; Zurich, Switzerland<br />

2:30 pm<br />

Introductory Talk<br />

John J. O’Shea, MD; NIAMS/NIH; Bethesda, MD<br />

2:45 pm<br />

635. Decreased Collagen Induced Arthritis (CIA) Severity in<br />

MAPK Kinase 6 Deficient Mice: Pivotal Role <strong>of</strong> Th1 and Th17<br />

Cytokines.<br />

Deepa Hammaker 1 , Katharyn Topolewski 2 , Meghan Edgar 2 , David<br />

L. Boyle 1 and Gary S. Firestein 1 , 1UCSD School <strong>of</strong> Medicine, La<br />

Jolla, CA, 2 UCSD School <strong>of</strong> Medicine<br />

3:00 pm<br />

636. IL-7-Related TSLP: A Novel Potent Proinflammatory<br />

Mediator in Rheumatoid Arthritis That Activates Myeloid<br />

Dendritic Cells To Stimulate Th1 and Th17 Activity.<br />

F. M. Moret, C. E. Hack, K. M. G. van der Wurff-Jacobs,<br />

F. P. J. G. Lafeber and J. A. G. van Roon, <strong>Rheumatology</strong> &<br />

Clinical Immunology, University Medical Center Utrecht, The<br />

Netherlands<br />

3:15 pm<br />

637. Interleukin-12, Not the ITGAM Polymorphism (rs1143679),<br />

Correlates with Atherosclerosis Independent <strong>of</strong> Disease Activity<br />

in SLE.<br />

Manish Jain, Erin McDonnell, Jill P. Buyon and Robert M. Clancy,<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, New York University School <strong>of</strong><br />

Medicine<br />

3:30 pm<br />

638. Pro-Inflammatory Properties <strong>of</strong> IL-35 and Its Association<br />

with Disease Activity in Patients with Rheumatoid Arthritis.<br />

Maria Filkova 2 , Hana Hulejova 3 , Marketa Polanska 3 , Lucie Andres<br />

Cerezo 3 , Jiri Vencovsky 2 , Karel Pavelka 4 , Steffen Gay 1 and Ladislav<br />

Senolt 3 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>, University<br />

Hospital and Zurich Center <strong>of</strong> Integrative Human Physiology<br />

(ZIHP), Zurich, Switzerland, 2 Institute <strong>of</strong> <strong>Rheumatology</strong> and<br />

Connective Tissue Research Laboratory, Department <strong>of</strong><br />

<strong>Rheumatology</strong> <strong>of</strong> the 1st Faculty <strong>of</strong> Medicine, Charles University<br />

in Prague, Prague, Czech Republic, 3 Institute <strong>of</strong> <strong>Rheumatology</strong><br />

and Connective Tissue Research Laboratory, Department <strong>of</strong><br />

<strong>Rheumatology</strong> <strong>of</strong> the 1st Faculty <strong>of</strong> Medicine, Charles University<br />

in Prague, Czech Republic, Czech Republic, 4 Institute <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the 1st Faculty<br />

<strong>of</strong> Medicine, Charles University in Prague, Czech Republic, Czech<br />

Republic<br />

3:45 pm<br />

639. MAPK Kinase 3 (MKK3) Regulates Osteoclast<br />

Differentiation and Activation.<br />

David L. Boyle 3 , Meghan Edgar 4 , Mario M. Zaiss 1 , Georg Schett 2<br />

and Gary S. Firestein 3 , 1 Department <strong>of</strong> Internal Medicine 3 ,<br />

University <strong>of</strong> Erlangen-Nuremberg, 2 Friedrich Alexander Univ,<br />

Erlangen, Germany, 3 UCSD School <strong>of</strong> Medicine, La Jolla, CA,<br />

4<br />

UCSD School <strong>of</strong> Medicine<br />

A411<br />

Epidemiology and Health Services Research:<br />

Rheumatoid Arthritis<br />

Moderators: Kaleb D. Michaud, PhD; University <strong>of</strong> Nebraska<br />

Medical Center; Omaha, NE<br />

Ted R. Mikuls, MD; University <strong>of</strong> Nebraska Medical Center;<br />

Omaha, NE<br />

2:30 pm<br />

640. Tumor Necrosis Factor Inhibition Reduces the Incidence <strong>of</strong><br />

Alzheimer’s Disease in Rheumatoid Arthritis Patients.<br />

Richard C. Chou 2 , Michael A. Kane 3 , Shiva Gautam 1 and Sanjay<br />

Ghirmire 4 , 1Beth Israel Deaconess Medical Center, 2 Dartmouth-<br />

Hitchcock Medical Center, Milton, MA, 3 Massachusetts<br />

General Hospital and Massachusetts Institute <strong>of</strong> Technology,<br />

Georgetown, MA, 4 Verisk Health<br />

40<br />

2010 Program Book


2:45 pm<br />

641. Major Improvements in Outcomes <strong>of</strong> Rheumatoid Arthritis<br />

Since the Biologic Era and beyond: An Historical Overview from<br />

1989 until 2008 in a Large Inception Cohort <strong>of</strong> RA Patients.<br />

Wietske Kievit 1 , Jaap Fransen 2 , Maarten De Waal Malefijt 2 ,<br />

Alfons Den Broeder 3 and Piet van Riel 2 , 1 Radboud University<br />

Nijmegen Medical Centre, Nijmegen, The Netherlands, 2 Radboud<br />

University Nijmegen Medical Centre, 3 Sint Maartenskliniek<br />

3:00 pm<br />

642. Propensity-Adjusted Medication Effects on Survival in<br />

Rheumatoid Arthritis: 22-Year Follow-Up <strong>of</strong> 5629 Patients.<br />

Mary Chester Wasko 3 , Abhijit Dasgupta 1 , Helen Hubert 2 ,<br />

Bharathi Lingala 2 , James Fries 2 and Michael Ward 1 , 1 NIAMS/NIH,<br />

Bethesda, MD, 2 Stanford University, Palo Alto, CA, 3 University <strong>of</strong><br />

Pittsburgh, Pittsburgh PA<br />

3:15 pm<br />

643. Renal Dysfunction in Rheumatoid Arthritis Is Associated<br />

with Incident Cardiovascular Disease, Independently <strong>of</strong><br />

Traditional Risk Factors: The CARRE Study.<br />

Alper M. van Sijl 3 , Ingrid M. Visman 1 , Inge A. M. van den Oever 1 ,<br />

Mike J. L. Peters 5 , Alexandre E. Voskuyl 5 , Ben A. C. Dijkmans 4<br />

and Michael T. Nurmohamed 2 , 1 Jan van Breemen Institute, 2 Jan<br />

van Breemen Institute and VU Medical Centre, Amsterdam, The<br />

Netherlands, 3 Jan van Breemen Institute and VU Medical Centre,<br />

4<br />

VU Medical Centre, Amsterdam, The Netherlands, 5 VU Medical<br />

Centre<br />

3:30 pm<br />

644. Do Structural Damage and Inflammation Impact Physical<br />

Functioning Differently Based on Duration <strong>of</strong> Rheumatoid<br />

Arthritis?<br />

Martin J. Bergman 2 , Sanjoy Roy 1 , Naijun Chen 1 and Mary A.<br />

Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Arthritis and<br />

<strong>Rheumatology</strong>, Ridley Park, PA<br />

3:45 pm<br />

645. Common Vaccinations among Adults and the Risk <strong>of</strong><br />

Developing Rheumatoid Arthritis; Results from the Swedish<br />

EIRA Study.<br />

Camilla Bengtsson 2 , Meliha Kapetanovic 1 , Henrik Källberg 2 ,<br />

Berit Sverdrup 2 , Birgitta Nordmark 3 , Lars Klareskog 3 and Lars<br />

Alfredsson 2 , 1 Institute for Clinical Sciences, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Lund University, Lund, Sweden, 2 Institute <strong>of</strong><br />

Environmental Medicine, Karolinska Institutet, Stockholm,<br />

Sweden, 3 <strong>Rheumatology</strong> Unit, Department <strong>of</strong> Medicine,<br />

Karolinska Institutet, Karolinska University Hospital, Stockholm,<br />

Sweden<br />

A412<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />

Moderators: Daniel J. Clauw, MD; University <strong>of</strong> Michigan Chronic<br />

Pain & Fatigue Research; Ann Arbor, MI<br />

Don L. Goldenberg, MD; Newton-Wellesley Hospital; Newton,<br />

MA<br />

2:30 pm<br />

646. Individually Tailored Exercise and Telephone-Delivered<br />

Cognitive Behaviour Therapy in the Management <strong>of</strong> Chronic<br />

Widespread Pain (CWP): Results from a Primary Care Based<br />

Randomised Controlled Trial.<br />

Gary J. Macfarlane 1 , Chrysa Gkazinou 2 , Marcus Beasley 2 ,<br />

Elizabeth A. Jones 2 , Gordon J. Prescott 2 , Phil Hannaford 2 ,<br />

Phil Keeley 3 , Karina Lovell 3 , Paul McNamee 2 , Deborah P. M.<br />

Symmons 3 , Steve Woby 3 , John McBeth 3 and the MUSICIAN Study<br />

Team, 1 University <strong>of</strong> Aberdeen, Aberdeen, Scotland, United<br />

Kingdom, 2 University <strong>of</strong> Aberdeen, 3 University <strong>of</strong> Manchester<br />

2:45 pm<br />

647. Non-Invasive Cortical Electrostimulation in the Treatment<br />

<strong>of</strong> Fibromyalgia.<br />

Jeffrey B. Hargrove 2 , Robert M. Bennett5, David G. Simons 1 ,<br />

Susan J. Smith 3 , Sunil Nagpal 3 and Donald E. Deering 4 , 1 Emory<br />

University, 2 Kettering University, Flint, MI, 3 Michigan State<br />

University, 4 NeuroHealth Associates, 5 Oregon Health & Science<br />

Univ, Portland, OR<br />

3:00 pm<br />

648. Effect <strong>of</strong> Adding Milnacipran to Pregabalin for Managing<br />

Fibromyalgia: A Randomized, Open-Label, Controlled Study.<br />

Mildred V. Farmer 3 , Joel M. Trugman 2 , Yong Wang 2 and R.<br />

Michael Gendreau 1 , 1 Cypress Bioscience, Inc., San Diego, CA,<br />

2<br />

Forest Research Institute, 3 Meridien Research, St. Petersburg, FL<br />

3:15 pm<br />

649. Hypothalamic-Pituitary-Adrenal Axis Response to Mental<br />

Stress Predicts Chronic Widespread Pain Onset – Results from<br />

the SPICE Study.<br />

Gareth T. Jones, Gordon D. Waiter, Marcus Beasley, Chrysa<br />

Gkazinou and Gary J. Macfarlane, University <strong>of</strong> Aberdeen,<br />

Aberdeen, United Kingdom<br />

3:30 pm<br />

650. Altered Resting Connectivity between Individuals with<br />

Fibromyalgia and Healthy Controls.<br />

Tobias Schmidt-Wilcke 2 , Rupal Bhavsar 2 , Daniel J. Clauw 1 and<br />

David A. Williams 1 , 1 University <strong>of</strong> Michigan, Ann Arbor, MI,<br />

2<br />

University <strong>of</strong> Michigan<br />

3:45 pm<br />

651. Mortality in Fibromyalgia: An 8,186 Patient Study over 35<br />

Years.<br />

Frederick Wolfe 1 , Afton L. Hassett 3 , Brian T. Walitt 4 and Kaleb D.<br />

Michaud 2 , 1 National Data Bank for Rheumatic Diseases, Wichita,<br />

KS, 2 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE, 3 University <strong>of</strong><br />

Michigan Medical School, Ann Arbor, MI, 4 Washington Hospital<br />

Center, Washington, DC<br />

A410<br />

Pediatric <strong>Rheumatology</strong> - Pathogenesis and Genetics:<br />

Biological Basis for Pediatric Rheumatic Disease<br />

Moderators: Barbara S. Adams, MD; University <strong>of</strong> Michigan<br />

Health System; Ann Arbor, MI<br />

Nora G. Singer, MD; MetroHealth Medical Center; Cleveland, OH<br />

2:30 pm<br />

652. Detection <strong>of</strong> Specific Markers Using Proteomics: Our<br />

Research on the Marker in Patients with Kawasaki Disease<br />

(KD).<br />

Rie Karasawa 3 , Mikiya Fujieda 1 , Kazuhide Ohta 2 and Kazuo<br />

Yudoh 3 , 1 Department <strong>of</strong> Pediatrics, Kochi Medical School, Kochi<br />

University, Japan, 2 Department <strong>of</strong> Pediatrics, National Hospital<br />

Organization Kanazawa Medical Center, 3 Institute <strong>of</strong> Medical<br />

Science, St. Marianna University School <strong>of</strong> Medicine, Kawasaki,<br />

Japan<br />

2010 Program Book 41<br />

monday


monday<br />

2:45 pm<br />

653. Specific Subgroup <strong>of</strong> New-Onset Systemic Juvenile<br />

Idiopathic Arthritis without Overt Macrophage Activation<br />

Syndrome Shares Similar Gene Expression Signature<br />

with a Distinct Subset <strong>of</strong> Familial Hemophagocytic<br />

Lymphohistiocytosis.<br />

Keith A. Sikora, Ndate Fall, Michael G. Barnes, Janos Sumegi,<br />

Alexandra H. Filipovich and Alexei A. Grom, Cincinnati Children’s<br />

Hospital Medical Center, Cincinnati, OH<br />

3:00 pm<br />

654. A Genome-Wide Association Study for Juvenile Idiopathic<br />

Arthritis Identifies Chromosome Region 3q13 near the T Cell<br />

Receptor Co-Stimulatory Molecule CD80.<br />

Susan D. Thompson 1 , Miranda Marion 10 , Marc Sudman 2 , Paula<br />

S. Ramos 10 , Wendy Thomson 8 , Anne Hinks 8 , J. Peter Haas 7 ,<br />

Sampath Prahalad 4 , John F. Bohnsack 9 , Carol Wise 6 , Marilynn G.<br />

Punaro 5 , Carlos D. Rose 3 , Mary Ryan 2 , Monica Tsoras 2 , Michael<br />

Wagner 2 , Mehdi Keddache 2 , Timothy Howard 10 , Carl Langefeld 10<br />

and David N. Glass 1 , 1 Childrens Hospital Med Ctr, Cincinnati, OH,<br />

2<br />

Cincinnati Children’s Hospital Medical Center, 3 duPont Hospital<br />

for Children, Wilmington, DE, 4 Emory Children’s Center, Atlanta,<br />

GA, 5 Texas Scottish Rite Hospital for Children, Dallas, TX, 6 Texas<br />

Scottish Rite Hospital for Children, 7 University <strong>of</strong> Greifswald,<br />

8<br />

University <strong>of</strong> Manchester, 9 University <strong>of</strong> Utah, Salt Lake City, UT,<br />

10<br />

Wake Forest University<br />

3:15 PM<br />

655. Gene Expression Pr<strong>of</strong>iling in Peripheral Blood<br />

Mononuclear Cells Predicts Disease Flares in Children with<br />

Polyarticular Juvenile Idiopathic Arthritis Who Have Achieved<br />

Clinical Remission on Medication.<br />

Nicholas Knowlton 2 , Mark Barton Frank 2 , Nicholas E. Armstrong 1 ,<br />

Kaiyu Jiang 1 , Yanmin Chen 1 , Jeanette Osban 2 and James N.<br />

Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong> <strong>of</strong> Medicine,<br />

2<br />

Oklahoma Medical Research Foundation<br />

3:30 PM<br />

656. Levels <strong>of</strong> beta2-Glycoprotein-I May Reflect a Protective<br />

Effect on the Development <strong>of</strong> Heart Block in Fetuses Exposed<br />

to Maternal Anti-Ro Antibodies.<br />

Joanne H. Reed, Tom P. Gordon, Robert M. Clancy and Jill P.<br />

Buyon, New York University School <strong>of</strong> Medicine<br />

3:45 PM<br />

657. Pathogenic Consequences <strong>of</strong> Mutations <strong>of</strong> NLRP12 Gene.<br />

A New Cold-Induced Autoinflammatory Disease.<br />

Silvia Borghini 2 , Sara Tassi 1 , Sabrina Chiesa 3 , Francesco Caroli 2 ,<br />

Sonia Carta 1 , Roberta Caorsi 3 , Marco Di Duca 2 , Denise Lasigliè 3 ,<br />

Alberto Martini 3 , Isabella Ceccherini 2 , Anna Rubartelli 1 and<br />

Marco Gattorno 3 , 1 Institute for Cancer Research, Genoa, Italy,<br />

2<br />

Lab <strong>of</strong> Molecular Genetics, G. Gaslini Institute, Genoa, Italy,<br />

3<br />

<strong>Rheumatology</strong> Unit, G. Gaslini Institute, Genoa, Italy<br />

Sidney J. Marcus Auditorium<br />

Rheumatoid Arthritis - Clinical Aspects: Preclinical<br />

RA and Early RA I<br />

Moderators: Neal S. Birnbaum, MD; Pacific <strong>Rheumatology</strong><br />

Association; San Francisco, CA<br />

Jonathan Kay, MD; UMass Memorial Medical Center; Worcester,<br />

MA<br />

2:30 PM<br />

658. Application <strong>of</strong> the New ACR/EULAR Classification Criteria<br />

for Rheumatoid Arthritis to At-Risk Populations May Identify<br />

RA Prior to Clinical Presentation.<br />

Jason R. Kolfenbach 5 , Lezlie Derber 5 , Kevin D. Deane 9 , Jan<br />

Hughes-Austin 4 , Michael H. Weisman 3 , Jane Buckner 2 , Ted<br />

R. Mikuls 11 , James R. O’Dell 8 , Peter K. Gregersen 6 , Richard<br />

M. Keating 1 , Jill Norris 10 and V. Michael Holers 7 , 1O ak Park, IL,<br />

2<br />

Benaroya Research Institute at Virginia Mason, 3 Cedars-Sinai<br />

Medical Center, Los Angeles, CA, 4 Department <strong>of</strong> Epidemiology,<br />

Colorado School <strong>of</strong> Public Health, University <strong>of</strong> Colorado Denver,<br />

5<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Colorado at Denver,<br />

Aurora, CO, 6 N Shore Univ Hosp Rsch Ctr, Manhasset, NY, 7 Univ<br />

<strong>of</strong> Colorado School <strong>of</strong> Med, Aurora, CO, 8 University <strong>of</strong> Nebraska<br />

Medical Center, Omaha, NE, 9 University <strong>of</strong> Colorado at Denver,<br />

Aurora, CO, 10 University <strong>of</strong> Colorado Denver, Aurora, CO,<br />

11<br />

University <strong>of</strong> Nebraska Medical Center, Omaha, NE<br />

2:45 PM<br />

659. The Revised 2010 ACR/EULAR Diagnostic Criteria for<br />

Rheumatoid Arthritis Identify Many More Patients Who Are<br />

Eligible for Treatment and for Clinical Trials.<br />

Vivian P. Bykerk 5 , Gilles Boire 2 , Boulos Haraoui 4 , Carol A.<br />

Hitchon 8 , Ed C. Keystone 9 , J. Carter Thorne 6 , Diane S. Ferland 3 ,<br />

Janet E. Pope 7 and CATCH Investogators 1 , 1 Canada, Canada,<br />

2<br />

CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 3 Hopital<br />

Maisonneuve Rosement, Montreal, LaSalle, QC, Canada, 4 Institut<br />

de Rhumatologie, Montreal, QC, Canada, 5 Mt Sinai Hospital,<br />

University <strong>of</strong> Toronto, Toronto, ON, Canada, 6 Southlake Regional<br />

Health Care, Newmarket, ON, Canada, 7 St Joseph Health<br />

Care London, London, ON, Canada, 8 University <strong>of</strong> Manitoba,<br />

Winnipeg, MB, Canada, 9 University <strong>of</strong> Toronto, Toronto, ON,<br />

Canada<br />

3:00 PM<br />

660. A Novel Diagnostic Marker for RA, Anti-MCV.<br />

Rong W. Zablocki 1 , Annette Van der Helm – van Mil 3 , Tom<br />

Huizinga 3 and Srinivas Rao 2 , 1 Cypress Bioscience Inc, San Diego,<br />

CA, 2 Cypress Bioscience Inc, 3 Leiden University Medical Center,<br />

The Netherlands<br />

3:15 PM<br />

661. Smoking Is a Predictor <strong>of</strong> Very Early Presentation with<br />

Rheumatoid Arthritis.<br />

David W. Sharpley 1 , Sarang Chitale 2 , Cristina Estrach 2 , Robert N.<br />

Thompson 2 , Robert J. Moots 2 and Nicola J. Goodson 2 , 1Academic<br />

<strong>Rheumatology</strong> Department, Aintree University Hospitals,<br />

University <strong>of</strong> Liverpool, Liverpool, Merseyside, United Kingdom,<br />

2<br />

Academic <strong>Rheumatology</strong> Department, Aintree University<br />

Hospitals, University <strong>of</strong> Liverpool<br />

3:30 PM<br />

662. Long-Term Remission in Daily Clinical Practice: Excellent 2<br />

Year Results with Treatment To Target in Very Early Rheumatoid<br />

Arthritis, Results <strong>of</strong> the DREAM Remission Induction Cohort.<br />

Marloes Vermeer 5 , Ina H. Kuper 5 , Monique Hoekstra 1 , Hein<br />

J. Bernelot Moens 6 , Marcel D. Posthumus 4 , Herman L. M.<br />

Brus 3 , Piet L. C. M. van Riel 2 and Mart A. F. J. van de Laar 5 ,<br />

1<br />

Isala Klinieken, Zwolle, The Netherlands, 2 Radboud University<br />

Nijmegen Medical Centre, Nijmegen, The Netherlands,<br />

3<br />

TweeSteden Ziekenhuis, Tilburg, The Netherlands, 4 University<br />

Medical Center Groningen, Groningen, The Netherlands,<br />

42<br />

2010 Program Book


5<br />

University <strong>of</strong> Twente and Medisch Spectrum Twente, Enschede,<br />

The Netherlands, 6 Ziekenhuisgroep Twente, Almelo/Hengelo,<br />

The Netherlands<br />

3:45 PM<br />

663. The Association <strong>of</strong> Joint Damage and Treatment Response<br />

with ACPA Status in Recent Onset RA.<br />

M. van den Broek 3 , N. B. Klarenbeek 4 , M. L. Westedt 1 , H.<br />

D. Boom 5 , P. J. S. M Kerstens 2 , T. W. J. Huizinga 4 , B. A. C.<br />

Dijkmans 6 and C. F. Allaart 4 , 1 Bronovo Hospital, The Hague, The<br />

Netherlands, 2 JBI, Amsterdam, The Netherlands, 3 LUMC, Leiden,<br />

The Netherlands, 4 LUMC, Leiden, The Netherlands, 5 Spaarne<br />

Hospital, Ho<strong>of</strong>ddorp, The Netherlands, 6 VU Medical Centre,<br />

Amsterdam, The Netherlands<br />

B402<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical<br />

Aspects and Treatment - Imaging I<br />

Moderators: Desiree M. Van Der Heijde, MD, PhD; Leiden<br />

University Medical Center; Meerssen, The Netherlands<br />

Juergen Braun, MD; Rheumazentrum Ruhrgebiet; Herne,<br />

Germany<br />

2:30 PM<br />

664. Methotrexate Is Not Disease Modifying in Psoriatic<br />

Arthritis: The MIPA Trial.<br />

Gabrielle H. Kingsley 3 , Anna Kowalczyk 4 , Helen Taylor 4 , Fowzia<br />

Ibrahim 4 , Jonathan C. Packham 2 , Neil J. McHugh 7 , Diarmuid M.<br />

Mulherin 1 , George D. Kitas8, Kuntal Chakravarty 6 , Brian D. M.<br />

Tom 5 , Peter J. Maddison 9 and David L. Scott 4 , 1 Cannock Chase<br />

Hospital, Cannock, United Kingdom, 2 Haywood Hospital, Stoke<br />

on Trent, UK, 3 Kings <strong>College</strong> London, London, United Kingdom,<br />

4<br />

Kings <strong>College</strong> London, UK, 5 MRC Biostatistics Unit, University<br />

<strong>of</strong> Cambridge, UK, 6 Queens Hospital, Romford, UK, 7 Royal<br />

National Hospital for Rheumatic Diseases, Bath, UK, 8 Russells<br />

Hall Hospital, Dudley, UK, 9 Sport, Health and Exercise Science,<br />

University <strong>of</strong> Bangor, UK<br />

2:45 PM<br />

665. Rates and Predictors <strong>of</strong> Radiographic Sacroiliitis<br />

Progression over Two Years in Patients with Axial<br />

Spondyloarthritis.<br />

Denis Poddubnyy 1 , Martin Rudwaleit 1 , Hildrun Haibel 1 , Anja<br />

Weiss 3 , Elisabeth Märker-Hermann 4 , Henning Zeidler 5 , Jürgen<br />

Braun 6 and Joachim Sieper 2 , 1 Charité - Campus Benjamin<br />

Franklin, Berlin, Germany, 2 Charite Campus Benjamin Frankl,<br />

Berlin, Germany, 3 Deutsches Rheumaforschungszentrum,<br />

Berlin, Germany, 4 Dr. Horst Schmidt Kliniken, Wiesbaden,<br />

Germany, 5 Medizinische Hochschule, Hannover, Germany,<br />

6Rheumazentrum Ruhrgebiet, Herne, Germany<br />

3:00 PM<br />

666. High Prevalence <strong>of</strong> Axial Spondyloarthritis in Patients with<br />

Familial Mediteranean Fever, and a Greater Allelic Frequency<br />

<strong>of</strong> M694V in Familial Mediteranean Fever Patients with<br />

Radiograpic Sacroiliitis.<br />

Servet Akar 2 , Ozgul Soysal 2 , Feride Yuksel 1 , Dilek Solmaz 2 , Gercek<br />

Can 2 , Merih Birlik 2 , Mehmet Tunca 1 , Fatos Onen 2 and Nurullah<br />

Akkoc 2 , 1 Internal Medicine, Dokuz Eylul University Faculty <strong>of</strong><br />

Medicine, Izmir, Turkey, 2 <strong>Rheumatology</strong>, Dokuz Eylul University<br />

Faculty <strong>of</strong> Medicine, Izmir, Turkey<br />

3:15 PM<br />

667. Evidence That New Focal Fat Lesions Follow Resolution <strong>of</strong><br />

Spinal Inflammation in AS but Existing Lesions Are More Likely<br />

To Resolve with TNF Blocking Agents.<br />

Praveena Chiowchanwisawakit 1 , Robert G. W. Lambert 2 and<br />

Walter P. Maksymowych 2 , 1 Mahidol University, Bangkok,<br />

Thailand, 2 University <strong>of</strong> Alberta, Edmonton, AB, Canada<br />

3:30 PM<br />

668. New Bone Formation in the Spine <strong>of</strong> Patients with<br />

Diffuse Idiopathic Skeletal Hyperostosis (DISH) and Ankylosing<br />

Spondylitis (AS) – A Detailed Comparative Analysis <strong>of</strong> the Rates<br />

<strong>of</strong> Radiographic Progression over 6 Years.<br />

Xen<strong>of</strong>on Baraliakos 3 , Joachim Listing 1 , Jana Buschmann 3 , Anna<br />

von der Recke 3 and Juergen Braun 2 , 1 German Rheumatism<br />

Research Center, 2 Rheumazentrum Ruhrgebiet, Herne, Germany,<br />

3<br />

Rheumazentrum Ruhrgebiet Herne<br />

3:45 PM<br />

669. Relationship between Active Inflammatory Lesions<br />

in the Spine and Sacroiliac Joints and New Development<br />

<strong>of</strong> Fatty Infiltration on Whole-Body MRI in Early Axial<br />

Spondyloarthritis– Results <strong>of</strong> the ESTHER Trial at Week 48.<br />

In-Ho Song 1 , Kay-Geert Hermann 2 , Hildrun Haibel 1 , Christian<br />

Alth<strong>of</strong>f 2 , Joachim Listing 3 , Bruce Freundlich 4 , Martin<br />

Rudwaleit 1 and Joachim Sieper 1 , 1 Charite Campus Benjamin-<br />

Franklin, Medical Clinic I, <strong>Rheumatology</strong>, Berlin, Germany,<br />

2<br />

Charite Campus Mitte, Radiology, Berlin, Germany, 3 German<br />

Rheumatism Research Center, Berlin, Germany, 4 Wyeth/ Pfizer<br />

Inc., <strong>College</strong>ville, PA<br />

A311<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Pathogenesis, Animal Models and Genetics<br />

Moderators: David Abraham, PhD, BSc; University <strong>College</strong><br />

London; London, United Kingdom<br />

Robert A. Lafyatis, MD; Boston University School <strong>of</strong> Medicine;<br />

Arlington, MA<br />

2:30 PM<br />

670. Growth Differentiation Factor-9 Induced by Insulin-Like<br />

Growth Factor Binding Protein-5 May Contribute to Fibrosis in<br />

Systemic Sclerosis.<br />

Yukie Yamaguchi 2 and Carol A. Feghali-Bostwick 1 , 1 University <strong>of</strong><br />

Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh, Yokohama<br />

City University, Yokohama, Kanagawa, Japan<br />

2:45 PM<br />

671. Epithelial Cells Undergoing Epithelial Mesenchymal<br />

Transition (EMT) in Systemic Sclerosis Lack Caveolin-1 and<br />

Modulate WNT Signaling in the Dermis by Secreting SFRP4.<br />

Ilaria Tinazzi, Justin Gillespie, Giuseppina Abignano, Chiara<br />

Colato, Domenico Biasi, Paul Emery and Francesco Del Galdo,<br />

University <strong>of</strong> Leeds<br />

3:00 PM<br />

672. The Notch Pathway Controls Fibroblast Activation and<br />

Tissue Fibrosis in Systemic Sclerosis.<br />

Clara Dees 2 , Pawel Zerr 2 , Michal Tomcik 2 , Christian Beyer 2 ,<br />

Angelika Horn 2 , Alfiya Akhmetshina 2 , Katrin Palumbo 2 , Nicole<br />

Reich 2 , Jochen Zwerina 2 , Mark P. Mattson 3 , Oliver Distler 1 ,<br />

Georg Schett 2 and Joerg H. W. Distler 2 , 1 Center <strong>of</strong> Experimental<br />

<strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative Human<br />

monday<br />

2010 Program Book 43


monday<br />

Physiology, University Hospital Zurich, Switzerland, 2 Department<br />

<strong>of</strong> Internal Medicine 3 , University Erlangen-Nuremberg,<br />

Germany, 3 Laboratory <strong>of</strong> Neurosciences, National Institute on<br />

Aging Intramural Research Program, Baltimore, MD<br />

3:15 PM<br />

673. My<strong>of</strong>ibroblast Specific Gene Expression Signature in<br />

Systemic Sclerosis, More Than TGF-beta Induced Activation.<br />

Giuseppina Abignano 2 , Heidi Hermes, Justin Gillespie, Sergio<br />

A. Jimenez, Paul Emery and Francesco Del Galdo 1 , 1 Leeds,<br />

2<br />

University <strong>of</strong> Leeds<br />

3:30 PM<br />

674. Perturbed VEGF Signalling within the Pulmonary<br />

Vasculature <strong>of</strong> a TGFβ Dependent Mouse Model <strong>of</strong> Systemic<br />

Sclerosis.<br />

Emma C. Derrett-Smith 2 , Audrey Dooley 2 , Reshma Baliga 1 ,<br />

Adrian Hobbs 1 , Raymond MacAllister 1 , David Abraham 4 and<br />

Christopher P. Denton 3 , 1 Centre for Clinical Pharmacology, Rayne<br />

Institute, UCL, London, Canada, 2 Centre for <strong>Rheumatology</strong> and<br />

Connective Tissue Diseases, Royal Free Campus, UCL Medical<br />

School, London, 3 Royal Free Hospital, London, United Kingdom,<br />

4University <strong>College</strong> London, London, United Kingdom<br />

3:45 PM<br />

675. The IL13/IL4RA/CCL2 Pathway Drives Sclerodermatous<br />

Graft Versus Host Disease in Mice and Correlates with Disease<br />

Activity in Scleroderma Patients.<br />

Antonios O. Aliprantis 4 , Matthew Greenblatt 3 , Jennifer Sargent 2 ,<br />

Giuseppina Farina 6 , Kelly Tsang 3 , Robert A. Lafyatis 1 , Michael<br />

Whitfield 2 and Laurie Glimcher 5 , 1 Boston University School <strong>of</strong><br />

Medicine, Arlington, MA, 2 Department <strong>of</strong> Genetics, Dartmouth<br />

Medical School, 3 Department <strong>of</strong> Immunology and Infectious<br />

Diseases, Harvard School <strong>of</strong> Public Health, 4 Department <strong>of</strong><br />

Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Allergy and Immunology,<br />

Brigham and Women’s Hospital and Harvard Medical School and<br />

Department <strong>of</strong> Immunology and Infectious Diseases, Harvard<br />

School <strong>of</strong> Public Health, Boston, MA, 5 Department <strong>of</strong> Medicine,<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Allergy and Immunology, Brigham and<br />

Women’s Hospital and Harvard Medical School and Department<br />

<strong>of</strong> Immunology and Infectious Diseases, Harvard School <strong>of</strong> Public<br />

Health, 6 <strong>Rheumatology</strong> Section, Boston University School <strong>of</strong><br />

Medicine<br />

United Kingdom, 2 Addenbrooke’s Hospital, 3 Charles University,<br />

4<br />

Immunologie-Zentrum Zürich, Zurich, Switzerland, 5 Maastricht<br />

University Medical Center, Maastricht, The Netherlands,<br />

6<br />

Maastricht University Medical Center, 7 Nuffield Orthopaedic<br />

Centre, Oxford, United Kingdom, 8 Royal Adelaide Hospital,<br />

Adelaide, Australia, 9 University Hospital <strong>of</strong> Skane and Lund<br />

University, Lund, 10 University Hospital <strong>of</strong> Skane and Lund<br />

University, 11 University <strong>of</strong> Birmingham, Birmingham, United<br />

Kingdom<br />

2:45 PM<br />

677. Increased Circulating Osteoclast Precursors and Lesional<br />

Osteoclast-Like Multinucleated Giant Cells in the Lung <strong>of</strong><br />

Patients with Wegener’s Granulomatosis.<br />

Jin Kyun Park 1 , Frederic Askin 2 , Antony Rosen 3 and Stuart M.<br />

Levine 1 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns<br />

Hopkins University, 3 The Johns Hopkins University, Baltimore,<br />

MD<br />

3:00 PM<br />

678. Protocolised Versus Non-Protocolised Rituximab<br />

Treatment for Refractory ANCA-Associated Vasculitis.<br />

Rachel B. Jones 1 , Rona Smith 2 , Mary-Jane Guerry 2 , Simona<br />

Laurino 2 , Fausta Catapano 2 , Afzal Chaudhry 2 and David R. W.<br />

Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge, United Kingdom,<br />

2<br />

Addenbrooke’s Hospital<br />

3:15 PM<br />

679. Xenografted Nasal Mucosa from Wegener’s<br />

Granulomatosis Patients Induces Destruction <strong>of</strong> Human<br />

Cartilage in Immunodeficient Mice.<br />

Nina Kesel 2 , Dorothee Köhler 2 , Martin Laudien 5 , Konstanze Holl-<br />

Ulrich 3 , Astrid Jüngel 1 , Michel Neidhart 1 , Steffen Gay 1 , Renate<br />

E. Gay 1 , Elena Csernok 6 , Wolfgang L. Gross 6 , Udo Schumacher 4<br />

and Sebastian Ullrich 4 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>,<br />

University Hospital Zurich, Switzerland, 2 Dept. <strong>of</strong> Anatomy II:<br />

Experimental Morphology, University Medical Center Hamburg,<br />

Hamburg, Germany, 3 Dept. <strong>of</strong> Pathology, University Hospital<br />

<strong>of</strong> Schleswig-Holstein, Campus Lübeck, Lübeck, Germany,<br />

4<br />

University Medical Center Hamburg, 5University <strong>of</strong> Kiel, Dept.<br />

<strong>of</strong> Otorhinolaryngology, Head and Neck Surgery, Kiel, Germany,<br />

6<br />

University <strong>of</strong> Lübeck, Dept. For <strong>Rheumatology</strong>, Vasculitis Center<br />

UKSH & Clinical Center Bad Bramstedt, Lübeck, Germany<br />

A314<br />

ANCA-associated Vasculitis I<br />

Moderators: Simon Carette, MD; Toronto Western Hospital;<br />

Toronto, ON, Canada<br />

Loic P. Guillevin, MD; Hôpital Cochin-Paris Université; Paris,<br />

France<br />

2:30 PM<br />

676. Two Year Follow-Up Results from a Randomised Trial <strong>of</strong><br />

Rituximab Versus Cyclophosphamide for ‘Generalized’ ANCA-<br />

Associated Vasculitis: RITUXVAS.<br />

Rachel B. Jones 1 , Jan Willem Cohen Tervaert 5 , Thomas Hauser 4 ,<br />

Raashid Luqmani 7 , Matthew D. Morgan 11 , Chen Au Peh 8 , Caroline<br />

O. Savage 11 , Mårten Segelmark 9 , Vladimir Tesar 3 , Pieter van<br />

Paassen 6 , Dorothy Walsh2, Michael Walsh 2 , Kerstin Westman 10<br />

and David R. W. Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge,<br />

3:30 PM<br />

680. Rituximab for Remission Induction and Maintenance<br />

in ANCA-Associated Vasculitis: A Single-Center Ten-Year<br />

Experience in 108 Patients.<br />

Rodrigo Cartin-Ceba 3 , Jason Golbin 1 , Karina A. Keogh 3 , Tobias<br />

Peikert 3 , Fernando C. Fervenza 3 , Steven R. Ytterberg 2 and Ulrich<br />

Specks 3 , 1 Long Island Lung Center, 2 Mayo Clinic, Rochester, MN,<br />

3<br />

Mayo Clinic<br />

3:45 PM<br />

681. Hsp60 Proteolysis by Proteinase 3 Induces Neutrophil<br />

Degranulation: Implications for Amplification <strong>of</strong> Injury in<br />

Wegener’s Granulomatosis.<br />

Shinji Sato 4 , Jin Kyun Park 1 , Frederic Askin 3 , Antony Rosen 2<br />

and Stuart M. Levine 1 , 1 Johns Hopkins University, Baltimore,<br />

MD, 2 The Johns Hopkins University, Baltimore, MD, 3 The Johns<br />

Hopkins University, 4 Tokai University, Kamakura, Japan<br />

44<br />

2010 Program Book


ACR/ARHP Combined Abstract<br />

Session<br />

2:30 - 4:00 PM<br />

B310<br />

ACR/ARHP Combined Epidemiology and Health<br />

Services Research: Impact on Osteoarthritis<br />

Moderators: Joanne M. Jordan, MD, MPH; University <strong>of</strong> North<br />

Carolina Thurston ARC; Chapel Hill, NC<br />

Robert R. McLean, DSc, MPH; Hebrew Senior Life; Boston, MA<br />

2:30 PM<br />

682. Unpredictability <strong>of</strong> Intermittent Knee OA Pain – Impact on<br />

Pain, Function and Mood.<br />

Gillian A. Hawker 2 , Melissa R. French 3 , Joy G. Elkayam 3 and<br />

Aileen M. Davis 1 , 1 Toronto Western Research Insti, Toronto,<br />

ON, Canada, 2 Women’s <strong>College</strong> Hospital, Toronto, ON, Canada,<br />

3<br />

Women’s <strong>College</strong> Hospital, Toronto, Canada<br />

2:45 PM<br />

683. Low Positive Affect Predicts the Development <strong>of</strong> Disability<br />

over 30-Months: The MOST Study.<br />

Julie J. Keysor 1 , Lisa Fredman 4 , Bin Zhang 2 , Daniel K. White 3 ,<br />

James C. Torner 8 , Cora E. Lewis 6 , Irina Tolstykh 7 and David T.<br />

Felson 5 , 1 Boston Univ Sargent <strong>College</strong>, Boston, MA, 2 Boston Univ<br />

Schl <strong>of</strong> Medicine, Boston, MA, 3 Boston Univ School <strong>of</strong> Med,<br />

Boston, MA, 4 Boston University, 5 Boston University School <strong>of</strong><br />

Medicine, Boston, MA, 6 University <strong>of</strong> Alabama-Birmingham,<br />

Birmingham, AL, 7 University <strong>of</strong> California and San Francisco, San<br />

Francisco, CA, 8 University <strong>of</strong> Iowa, Iowa City, IA<br />

3:00 PM<br />

684. Potential Gender Effect on the Association between Knee<br />

Osteoarthritis and Risk <strong>of</strong> Indoor and Outdoor Falls in Elderly<br />

Men and Women.<br />

Uyen-Sa D. T. Nguyen 4 , Marian T. Hannan 5 , Robert H. Shmerling 2 ,<br />

Douglas P. Kiel 7 , Suzanne G. Leveille 8 , Carol A. Oatis 1 , Lien Quach 6<br />

and Yuqing Zhang 3 , 1 Arcadia University, Glenside, PA, 2 Beth<br />

Israel Deaconess Med Ctr., Boston, MA, 3 Boston Univ School <strong>of</strong><br />

Medicine, Boston, MA, 4 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA, 5 Hebrew SL & Harvard Med Sch, Boston, MA,<br />

6<br />

Institute for Aging Research, Hebrew SeniorLife, 7 Institute for<br />

Aging Research, Hebrew SeniorLife and Harvard Medical School,<br />

Boston, MA, 8 University <strong>of</strong> Massachusetts-Boston<br />

3:15 PM<br />

685. Increasing Prevalence <strong>of</strong> Knee Pain and Symptomatic Knee<br />

Osteoarthritis.<br />

Uyen-Sa D. T. Nguyen 5 , Yuqing Zhang 2 , Jingbo Niu 3 , Bin Zhang 1<br />

and David T. Felson 4 , 1 Boston Univ Schl <strong>of</strong> Medicine, Boston, MA,<br />

2<br />

Boston Univ School <strong>of</strong> Medicine, Boston, MA, 3 Boston University<br />

Schol <strong>of</strong> Medicine, Boston, MA, 4 Boston University School <strong>of</strong><br />

Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA<br />

Alabama-Birmingham, Birmingham, AL, 5 University <strong>of</strong> California<br />

at San Francisco, San Francisco, CA, 6 University <strong>of</strong> Iowa, Iowa<br />

City, IA<br />

3:45 PM<br />

687. When 1st Is Worst: Musculoskeletal Conditions Maintain<br />

15 Year Reign as the Most Common Cause <strong>of</strong> Disability in US<br />

Adults.<br />

Kristina Theis 4 , Jennifer M. Hootman 3 , Charles G. Helmick 2 and<br />

Matthew Brault 1 , 1Bureau <strong>of</strong> the Census, 2 CDC, Atlanta, GA,<br />

3<br />

Centers for Disease Control, Kennesaw, GA, 4 Centers for Disease<br />

Control and Prevention<br />

ACR REF Special Session<br />

2:30 - 4:00 PM<br />

A404<br />

ACR REF “Within Our Reach”: Finding a Cure for<br />

Rheumatoid Arthritis c/r<br />

Moderator: David R. Karp, MD, PhD; University <strong>of</strong> Texas<br />

Southwestern Medical Center; Dallas, TX<br />

2:30 PM<br />

CD154 CA Repeat Polymorphisms and Rheumatoid Arthritis<br />

Pathogenesis<br />

William F. C. Rigby, MD; Dartmouth-Hitchcock Medical Center;<br />

Lebanon, NH<br />

3:00 PM<br />

Periodontal Disease as an Initiation or Propagation Factor for<br />

Rheumatoid Arthritis<br />

Clifton O. Bingham, MD; Johns Hopkins University; Baltimore,<br />

MD<br />

3:30 PM<br />

Regulatory Antibody Treatment <strong>of</strong> Inflammatory Arthritis<br />

Gregg J. Silverman, MD; University <strong>of</strong> California - San Diego; La<br />

Jolla, CA<br />

Session Overview:<br />

This session includes results from cutting-edge research funded<br />

by the Within Our Reach campaign providing insight into the<br />

pathogenesis, diagnosis and treatment <strong>of</strong> rheumatoid arthritis.<br />

As this research has yielded dramatic results that will impact<br />

patient care, early exposure is vital to quickly move these<br />

discoveries from laboratory to the bedside.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• distinguish the role <strong>of</strong> repeat polymorphisms in the<br />

pathogenesis <strong>of</strong> rheumatoid arthritis<br />

• identify the role <strong>of</strong> periodontal disease as a factor in the<br />

pathogenesis <strong>of</strong> rheumatoid arthritis<br />

• describe how naturally occurring antibodies may prevent the<br />

development <strong>of</strong> inflammatory conditions<br />

monday<br />

3:30 PM<br />

686. Community Mobility Barriers Predict the Development <strong>of</strong><br />

30-Month Disability: The MOST Study.<br />

Julie J. Keysor 1 , Bin Zhang 2 , James C. Torner 6 , Cora E. Lewis 4 , Irina<br />

Tolstykh 5 and David T. Felson 3 , 1Boston Univ Sargent <strong>College</strong>,<br />

Boston, MA, 2 Boston Univ Schl <strong>of</strong> Medicine, Boston, MA, 3 Boston<br />

University School <strong>of</strong> Medicine, Boston, MA, 4 University <strong>of</strong><br />

ARHP Concurrent Abstract Session<br />

2:30 - 4:00 PM<br />

B311<br />

Physical Activity: Just “Move It”<br />

Moderator: Nadine M. Fisher, EdD; SUNY at Buffalo; Buffalo, NY<br />

2010 Program Book 45


monday<br />

2:30 PM<br />

688. Does Physical Activity Dose Predict Physical and Mental<br />

Health-Related Quality <strong>of</strong> Life in People with Arthritis?<br />

Dina L. Jones, Ruoxin Zhang, Melissa Himes and Jennifer L.<br />

Eicher, Morgantown, WV<br />

2:45 PM<br />

689. Ready and Waiting: Adults with Arthritis Are Interested in<br />

Population-Based Physical Activity Programs.<br />

Louise Murphy 2 , Teresa J. Brady 2 , Kristina A. Theis 2 , Julie Bolen 2<br />

and Patience White 1 , 1Arthritis Foundation, 2 Centers for Disease<br />

Control and Prevention<br />

3:00 PM<br />

690. Evaluation <strong>of</strong> Tai Chi Course Effectiveness for People with<br />

Arthritis.<br />

Leigh F. Callahan 1 , Jack H. Shreffler 3 , Betsy S. Hackney 3 , Kathryn<br />

Remmes Martin 2 and Brian Charnock 3 , 1 Univ <strong>of</strong> North Carolina,<br />

Chapel Hill, NC, 2 University <strong>of</strong> North Carolina, Chapel Hill, Chapel<br />

Hill, NC, 3 University <strong>of</strong> North Carolina, Chapel Hill<br />

3:15 PM<br />

691. Walk with Ease Program: One-Year Follow-Up.<br />

Leigh F. Callahan 2 , Jack H. Shreffler 4 , Mary Altpeter 4 , Laura<br />

O. Houenou 4 , Britta Schoster 4 , Kathryn Remmes Martin 3 ,<br />

Jennifer M. Hootman 1 and Todd Schwartz 4 , 1 Centers for Disease<br />

Control, Kennesaw, GA, 2 Univ <strong>of</strong> North Carolina, Chapel Hill,<br />

NC, 3 University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />

4<br />

University <strong>of</strong> North Carolina, Chapel Hill<br />

3:30 PM<br />

692. Fit and Strong!: Bolstering Maintenance <strong>of</strong> Physical<br />

Activity among Older Adults with Lower-Extremity<br />

Osteoarthritis.<br />

Susan L. Hughes 4 , Rachel B. Seymour 4 , Richard T. Campbell 3 ,<br />

Pankaja Desai 3 , Gail Huber 2 and Justina Chang 1 , 1 JAMA,<br />

2<br />

Northwestern University, 3 University <strong>of</strong> Illinois Chicago,<br />

4<br />

University <strong>of</strong> Illinois Chicago, Chicago, IL<br />

3:45 PM<br />

693. Characteristics <strong>of</strong> Persons with or at High Risk <strong>of</strong> Knee OA<br />

Achieving Recommended Physical Activity Levels: The MOST<br />

Study.<br />

Daniel K. White 1 , Tuhina Neogi 2 , Jingbo Niu 2 , Michael Nevitt 3 ,<br />

C. Elizabeth Lewis 4 , James Torner 5 and Doug Gross 2 , 1 Boston<br />

University, Boston, MA, 2 Boston University, 3 University California<br />

San Francisco, 4 University <strong>of</strong> Alabama, 5 University <strong>of</strong> Iowa<br />

ARHP Concurrent Sessions<br />

2:30 - 4:00 PM<br />

B313<br />

CAM is a SCAM! Complementary and Alternative<br />

“Medicince” Has No Place in <strong>Rheumatology</strong> c/r PM<br />

Moderator: Atul A. Deodhar, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Pro<br />

Donald M. Marcus, MD; Baylor <strong>College</strong> <strong>of</strong> Medicine; Houston, TX<br />

Con<br />

Steven S. Overman, MD, MPH; The Seattle Arthritis Clinic;<br />

Seattle, WA<br />

Session Overview:<br />

The prevailing attitudes and practices <strong>of</strong> rheumatologists<br />

in the US toward complementary and alternative medicine<br />

treatments vary. In a recently published national survey <strong>of</strong> 345<br />

rheumatologists practicing in the US, a widespread favorable<br />

opinion toward many types <strong>of</strong> complementary and alternative<br />

medicines was found, but not to all. Most rheumatology<br />

pr<strong>of</strong>essionals were unsure <strong>of</strong> the scientific underpinning <strong>of</strong><br />

the complementary and alternative medicines treatments and<br />

worried that most, if not all, therapies had no background <strong>of</strong><br />

rigorous testing. Despite these reservations, complementary and<br />

alternative medicines have become a multi-billion dollar industry<br />

within musculoskeletal medicine therapeutics. The speakers will<br />

debate whether complementary and alternative medicines are<br />

viable treatment options for people with rheumatic disease.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• state the prevalent use <strong>of</strong> complementary and alternative<br />

medicines by patients seen in a typical rheumatology practice<br />

• explain the scientific basis <strong>of</strong> commonly used complementary<br />

and alternative medicines therapies in musculoskeletal<br />

medicine<br />

• discuss the side effect pr<strong>of</strong>ile <strong>of</strong> complementary and<br />

alternative medicines therapies used by patients with<br />

rheumatologic problems<br />

B308<br />

Money Talks: How to Incentivize Staff cP<br />

Moderator: Debra Bancr<strong>of</strong>t Rizzo, MSN, FNP-C; Rheumatic<br />

Disease Center; Glendale, WI<br />

Speaker: Nancy A. Ho, MHA; Northwest Regional Ambulatory<br />

Service Center; Westminster, CO<br />

Session Overview:<br />

To provide more information about the management <strong>of</strong> a<br />

practice/clinic and the tools and resources available, this session<br />

is designed to inform attendees on how to create, implement<br />

and administer a gain sharing and/or incentive program into<br />

a rheumatology practice. Gain sharing/incentive programs<br />

are growing in popularity because they allow organizations to<br />

reward employees for goals that are critical to the success <strong>of</strong><br />

a practice. The goal is to improve the efficiency and quality <strong>of</strong><br />

the staff. Information will be provided about different types <strong>of</strong><br />

incentive goals that may be considered. Objectives suited to a<br />

physician practice and specific examples from one practice and<br />

their success story will be shared.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• develop an effective employee incentive plan<br />

• explain how staff incentive programs can be used across all<br />

tiers <strong>of</strong> employees<br />

• define the different parameters <strong>of</strong> measurable goals that<br />

might be used to determine performance<br />

• illustrate how the various elements <strong>of</strong> the program’s<br />

effectiveness that may enhance an employee’s individual and<br />

team performance<br />

• discuss specific ideas for enhancing teamwork and efficiency<br />

in a rheumatology practice<br />

46<br />

2010 Program Book


REF 25th Anniversary Celebration<br />

2:45 - 3:30 PM<br />

Halls A1 & A2<br />

REF Philanthropy Showcase (Booth#1325)<br />

ACR/ARHP Workshops<br />

4:00 - 6:00 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B203<br />

Musculoskeletal Ultrasound (213)<br />

Speaker: Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the indications for ultrasound in rheumatic diseases<br />

• discuss the techniques <strong>of</strong> ultrasonography<br />

• identify normal and abnormal anatomical structures by<br />

ultrasound imaging<br />

B204<br />

Pediatric Musculoskeletal Upper/Lower Examinations<br />

(214)<br />

Speaker: Christine W. Kennedy, MSN, RN, CPNP; Emory<br />

Children’s Center; Decatur, GA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss principles <strong>of</strong> pediatric musculoskeletal physical<br />

examination<br />

• detect and describe normal and abnormal pediatric<br />

musculoskeletal physical examination findings<br />

• demonstrate rheumatologic upper and lower musculoskeletal<br />

examinations for pediatric patients using patient volunteers<br />

B202<br />

Renal Histopathology in Systemic Lupus<br />

Erythematosus and Vasculitis (215)<br />

Speaker: Megan Troxell, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the pathologic changes that occur in lupus nephritis<br />

• discuss the pathologic basis for the classification <strong>of</strong> lupus<br />

nephritis and how it relates to clinical management<br />

• describe the histological changes in the kidneys <strong>of</strong> patients<br />

with vasculitis<br />

ARHP Concurrent Session<br />

4:00 - 6:00 PM<br />

B201<br />

You’ve Got the Power: How to Use and Teach<br />

Statistical Power for Studies and Grants R<br />

Moderator: Annette M. Oeser, BS, CCRP; Vanderbilt University<br />

Medical Center; Nashville, TN<br />

Speakers: Alyssa B. Dufour, MA; Hebrew Senior Life; Boston, MA<br />

Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard<br />

Medical School; Boston, MA<br />

Robert R. McLean, DSc, MPH; Hebrew Senior Life; Boston, MA<br />

Session Overview:<br />

Understanding the concept <strong>of</strong> statistical power is critical not only<br />

when designing a research study, but also when interpreting<br />

the results <strong>of</strong> a study. Often researchers have only rudimentary<br />

knowledge <strong>of</strong> calculating and interpreting power, and rely solely<br />

on statisticians to contend with power issues. The web-based<br />

activities covered in this session will allow participants to<br />

practice conducting power calculations with freely available<br />

power calculators.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the underlying concepts <strong>of</strong> statistical power and why<br />

it is important for research studies<br />

• utilize the methods <strong>of</strong> calculating statistical power, sample<br />

size, and minimal detectable difference when appropriate<br />

• effectively interpret and communicate results <strong>of</strong> statistical<br />

power calculations as both a rheumatology researcher and a<br />

consumer <strong>of</strong> the research literature in study design, grantwriting,<br />

IRB applications<br />

• utilize methods for teaching statistical power to students,<br />

including an interactive experience <strong>of</strong> conducting power<br />

analyses for case studies using web-based calculators<br />

ACR Basic Science Symposium<br />

4:30 - 6:00 PM<br />

A411<br />

The Revolution <strong>of</strong> Epigenetics in Autoimmunity R<br />

Moderator: Jennifer H. Anolik, MD, PhD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

4:30 PM<br />

The Relevance <strong>of</strong> Epigenetics for <strong>Rheumatology</strong><br />

Bruce C. Richardson, MD, PhD; University <strong>of</strong> Michigan; Ann<br />

Arbor, MI<br />

5:00 PM<br />

Epigenetic Influences in Systemic Lupus Erythematosus<br />

Revealed by Twin Studies<br />

Esteban Ballestar, PhD; Bellvitge Biomedical Research Institute;<br />

L’Hospitalet de Llobregat, Barcelona, Spain<br />

5:30 PM<br />

Epigenetic Influences in Rheumatoid Arthritis<br />

Steffen Gay, MD; University Hospital Zurich Switzerland; Zurich,<br />

Switzerland<br />

Session Overview:<br />

The term epigenetics refers to changes in gene expression<br />

caused by mechanisms other than changes in the underlying<br />

DNA sequence, examples include chromatin structure, histone<br />

modifications, DNA methylation, and microRNA regulation.<br />

It has become increasingly clear that epigenetics provides a<br />

critical alternative mechanism for modulating gene function<br />

to those arising from genetic changes and may explain the<br />

variable penetrance <strong>of</strong> autoimmune phenotypes. Epigenetic<br />

mechanisms are essential for normal development and function<br />

<strong>of</strong> the immune system. Similarly, a failure to maintain epigenetic<br />

monday<br />

2010 Program Book 47


monday<br />

homeostasis in the immune response due to factors including<br />

environmental influences, leads to aberrant gene expression,<br />

contributing to immune dysfunction and in some cases the<br />

development <strong>of</strong> autoimmunity in genetically predisposed<br />

individuals.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the variety <strong>of</strong> epigenetic mechanisms controlling gene<br />

expression<br />

• describe examples <strong>of</strong> dysregulation <strong>of</strong> epigenetic pathways in<br />

systemic lupus erythematosus and rheumatoid arthritis<br />

• define the relevance <strong>of</strong> DNA methylation epigenetic changes<br />

to the clinical expression <strong>of</strong> autoimmune disease such as<br />

systemic lupus erythematosus<br />

ACR Clinical Symposium<br />

4:30 - 6:00 PM<br />

Hall A3<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/Microscopic<br />

Polyangiitis: Understanding and Applying the Data<br />

from Recent Clinical Trials cP P/C PS ARS<br />

Moderators: Robert Spiera, MD; Hospital for Special Surgery;<br />

New York, NY<br />

Carol A. Langford, MD, MHS; Cleveland Clinic Foundation;<br />

Cleveland, OH<br />

• describe the data with the use <strong>of</strong> biologic agents in Wegener’s<br />

granulomatosis /microscopic polyangiitis<br />

• apply the results from clinical trials in Wegener’s<br />

granulomatosis /microscopic polyangiitis to the treatment <strong>of</strong><br />

patients with severe, non-severe, and relapsing disease<br />

ACR Concurrent Abstract Sessions<br />

4:30 - 6:00 PM<br />

A402<br />

Infection-related Rheumatic Disease<br />

Moderators: Daniel H. Solomon, MD, MPH; Brigham and<br />

Women’s Hospital; Boston, MA<br />

Cem Gabay, MD; University Hospital <strong>of</strong> Geneva; Geneva,<br />

Switzerland<br />

4:30 PM<br />

694. Parvovirus B19 Non-Structural Protein NS1 Forms<br />

Adducts with Cellular DNA, Induces Apoptosis, and Is<br />

Condensed in Apoptotic Bodies: A Model for Viral Induction <strong>of</strong><br />

Autoantibodies and Systemic Lupus Erythematosus.<br />

Leona Gilbert 3 , Pavan K. Dhanyamraju 3 , Eoin Wallace 3 , Elina<br />

Dadu 3 , Liping Wang 3 , Harry J. Whitlow 3 , Violetta Kivovich 1 and<br />

Stanley J. Naides 2 , 1 Pennsylvania State University, Milton S.<br />

Hershey Medical Center, 2 Quest Diagnostics Nichols Institute,<br />

San Juan Capistrano, CA, 3 University <strong>of</strong> Jyväskylä, Finland.<br />

48<br />

4:30 PM<br />

Data for the Use <strong>of</strong> Conventional Immunosuppressive Agents<br />

in the Treatment <strong>of</strong> Wegener’s Granulomatosis/Microscopic<br />

Polyangiitis<br />

Philip Seo, MD; Johns Hopkins Bayview Medical Center;<br />

Baltimore, MD<br />

4:55 PM<br />

Data for the Use <strong>of</strong> Biologic Agents in the Treatment <strong>of</strong><br />

Wegener’s Granulomatosis/Microscopic Polyangiitis<br />

Ulrich Specks, MD; Mayo Clinic; Rochester, MN<br />

5:20 PM<br />

So How do I Apply the Findings <strong>of</strong> these Trials to My Patient?:<br />

Opinions from a Case-based Panel Discussion<br />

John H. Stone, MD, MPH; Massachusetts General Hospital;<br />

Boston, MA<br />

David Jayne, MD; Addenbrookes Hospital University <strong>of</strong><br />

Cambridge; Cambridge, United Kingdom<br />

Session Overview:<br />

Wegener’s granulomatosis and microscopic polyangiitis are<br />

complex systemic vasculitides for which treatment is commonly<br />

directed by the rheumatologist. In recent years, a number <strong>of</strong><br />

important clinical trials have been conducted to investigate<br />

conventional and biologic immunosuppressive therapies. It is<br />

important for the rheumatologist to understand the efficacy<br />

and toxicity <strong>of</strong> different treatment options and to be able to<br />

apply the findings from recent trials to the care <strong>of</strong> patients with<br />

Wegener’s granulomatosis or microscopic polyangiitis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• explain the data for the efficacy and toxicity <strong>of</strong> conventional<br />

immunosuppressive agents in the treatment <strong>of</strong> Wegener’s<br />

granulomatosis /microscopic polyangiitis<br />

2010 Program Book<br />

4:45 PM<br />

695. Occurrence <strong>of</strong> Rheumatoid Arthritis-Associated<br />

Autoantibodies in Leishmania Donovani Infection.<br />

Erik Åhlin 1 , Amir Elshafie 2 , Musa A. M. Nur 4 , Sayda Hassan El<br />

Safi 3 and Johan Rönnelid 1 , 1 Clinical Immunology Unit, Uppsala<br />

University, Uppsala, Sweden, 2 Clinical Immunology Unit,<br />

Uppsala University, Uppsala, Sweden. Department <strong>of</strong> Pathology<br />

and Microbiology, Alribat University Hospital, Khartoum,<br />

Sudan, 3 Department <strong>of</strong> Microbiology and Parasitology,<br />

Faculty <strong>of</strong> Medicine, University <strong>of</strong> Khartoum, Sudan, 4 Unit <strong>of</strong><br />

<strong>Rheumatology</strong>, Alribat University Hospital, Khartoum, Sudan<br />

5:00 PM<br />

696. IL-12p70 Alteration in Antibiotic Treatment <strong>of</strong> Chlamydia-<br />

Induced Reactive Arthritis (ReA).<br />

Robert D. Inman 1 , Basil Chiu, Alan P. Hudson 3 and John D.<br />

Carter 2 , 1 Toronto Western Hospital, Toronto, ON, Canada, 2 Univ<br />

<strong>of</strong> South Florida, Tampa, FL, 3 Wayne State Univ Schl <strong>of</strong> Med,<br />

Detroit, MI<br />

5:15 PM<br />

697. The Efficacy and Safety <strong>of</strong> Vaccination Against H1N1<br />

in Patients with Rheumatoid Arthritis, Systemic Lupus<br />

Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis.<br />

Ori Elkayam 2 , Sharon Amir 2 , Michal Mandelboim 1 , Ella<br />

Mendelson 1 , Jonathan Wollman 2 , Uri Arad 2 , Daphna Paran 2 ,<br />

David Levartovsky 2 , Irena Wigler 2 and Dan Caspi 2 , 1 Center <strong>of</strong><br />

Virology, Sheba Medical Center, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Tel Aviv Medical Center<br />

5:30 PM<br />

698. Serious Infection in Rheumatoid Arthritis Patients<br />

Switching Anti-Tumor Necrosis Factor Drugs.<br />

Bao-Anh Nguyen-Khoa 2 , Earl L. Goehring, Jr 2 , Kimberly<br />

Alexander 1 , Wei Dong 1 , Pavel Napalkov 1 and Judith K. Jones 2 ,<br />

1<br />

Genentech, South San Francisco, CA, 2 The Degge Group Ltd,<br />

Arlington, VA


5:45 PM<br />

699. Defining Latent and/or Disseminated Active Tuberculous<br />

Infection with TST, Quantiferon Gold and Multisite Cultures in<br />

TNFi Exposed Individuals.<br />

Dilrukshie Cooray 2 , James S. Louie 4 , Rosalinda C. Moran 1 and<br />

George A. Karpouzas 3 , 1 Harbor- UCLA Medical Center, Carson,<br />

CA, 2 Harbor-UCLA Medical Center, Torrance, CA, 3 Harbor-UCLA<br />

Medical Center, Long Beach, CA, 4 University <strong>of</strong> California Los<br />

Angeles, Los Angeles, CA<br />

A404<br />

Miscellaneous Rheumatic and Inflammatory Diseases<br />

Moderators: W. Winn Chatham, MD; University <strong>of</strong> Alabama-<br />

Birmingham; Birmingham, AL<br />

Kristine M. Lohr, MD, MS; Kentucky Clinic; Lexington, KY<br />

4:30 PM<br />

700. Progressive Multifocal Leukoencephalopathy Associated<br />

with Biologic and Synthetic DMARD Therapy in Rheumatic<br />

Diseases: An Analysis <strong>of</strong> the FDA Adverse Event Reporting<br />

System Database.<br />

Eamonn S. Molloy 2 and Leonard H. Calabrese 1 , 1 Cleveland Clinic<br />

Foundation, Cleveland, OH, 2 St Vincent’s University Hospital,<br />

Dublin, Ireland<br />

4:45 PM<br />

701. Tocilizumab in Refractory Adult Still’s Disease: A Cohort<br />

Study.<br />

Xavier Puéchal, Michel de Bandt, Jean-Marie Berthelot, Maxime<br />

Breban, Jean-Jacques Dubost, Olivier Fain, Jean-Emmanuel Kahn,<br />

Laurence Lequen, Maïté Longy-Boursier, Aleth Perdriger, Thierry<br />

Schaeverbeke, Eric Toussirot, Jean Sibilia and The CRI, Center<br />

for Rare Systemic and Auto-immune Diseases, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Le Mans, France<br />

5:00 PM<br />

702. Clinical Implications <strong>of</strong> the NMO-IgG Antibody and<br />

Overlapping Neuromyelitis Optica Spectrum Disorder in<br />

Patients with Connective Tissue Disease and Myelitis.<br />

Jason R. Kolfenbach 1 , Brian J. Horner 3 and Sterling G. West 2 ,<br />

1<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Colorado at Denver,<br />

Aurora, CO, 2 University <strong>of</strong> Colorado at Denver, Aurora, CO,<br />

3<br />

University <strong>of</strong> Colorado Denver School <strong>of</strong> Medicine<br />

5:15 PM<br />

703. Diagnostic Significance <strong>of</strong> Serum Interleukin-18 Level in<br />

Adult-Onset Still’s Disease.<br />

Junko Maruyama 3 , Shigeko Inokuma 1 and Noboru Hagino 2 ,<br />

1<br />

Japanese Red Cross Medical Center, 2 The University <strong>of</strong> Tokyo<br />

Hospital, 3 Tokyo Metropolitan Komagome Hospital, Tokyo, Japan<br />

5:30 PM<br />

704. Extrapulmonary Course <strong>of</strong> Connective Tissue Disease and<br />

Survival after Lung Transplant.<br />

Troy K. Takagishi, Iffat Ahmed and Rodney Tehrani, Loyola<br />

University Medical Center<br />

5:45 PM<br />

705. Idiopathic Retroperitoneal Fibrosis: Treatment-Related<br />

Outcomes and Predictors <strong>of</strong> Clinical Response.<br />

Tanaz A. Kermani 1 , Cynthia S. Crowson 2 , Sara Achenbach 2 and<br />

Harvinder S. Luthra 1 , 1 Mayo Clinic, Rochester, MN, 2 Mayo Clinic<br />

A314<br />

Osteoarthritis - Clinical Aspects: Genetics, Novel<br />

Approaches, and Therapy<br />

Moderators: Timothy E. McAlindon, MD, MPH; Tufts Medical<br />

Center; Boston, MA<br />

Tuhina Neogi, MD, PhD; Boston University School <strong>of</strong> Medicine;<br />

Boston, MA<br />

4:30 PM<br />

706. Clinical Trial <strong>of</strong> Vitamin D To Reduce Pain and Structural<br />

Progression <strong>of</strong> Knee Osteoarthritis (OA).<br />

Timothy E. McAlindon 3 , Bess Dawson-Hughes 5, Jeffrey Driban 4 ,<br />

Michael LaValley 2 , Ji Yeon Lee 4 , Grace H. Lo 1 , Melynn Nuite 4 and<br />

Lori Lyn Price 4 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, 2 Boston University<br />

School <strong>of</strong> Public Health, 3 Tufts Medical Center, Boston, MA,<br />

4<br />

Tufts Medical Center, 5 USDA HNRC; Tufts University<br />

4:45 PM<br />

707. Interleukin-1 Receptor Antagonist (IL-1RN) Gene<br />

Variations Predict the Severity and Progression <strong>of</strong> Knee<br />

Osteoarthritis.<br />

Mukundan Attur 8 , Cheongun Oh 7 , Svetlana Krasnokutsky 6 ,<br />

Jonathan Samuels 5 , Leon Rybak 9 , Jenny Bencardino 9 , Jeffrey<br />

D. Greenberg 1 , Virginia Kraus 2 , Kenneth Kornman 4 and Steven<br />

B. Abramson 3 , 1 Millburn, NJ, 2 Duke University Medical Center,<br />

Durham, NC, 3 Hospital for Joint Dis/NYU, New York, NY,<br />

4<br />

Interleukin Genetics, 5 New York University Hospital for Joint<br />

Disease, New York, NY, 6 NYU Hospital for Joint Disease, New<br />

York, NY, 7 NYU-Hospital for Joint Diseases, 8 NYU-Hospital for<br />

Joint Diseases, New York, NY, 9 NYU-Hospital for Joint Diseases<br />

Radiology Dept.<br />

5:00 PM<br />

708. Hand Osteoarthritis (OA) a Predictor <strong>of</strong> Accelerated<br />

Progression in Knee OA?<br />

Jonathan Samuels 3 , Catherine Petchprapa 6 , Elizabeth L.<br />

Carpenter 6 , Svetlana Krasnokutsky 4 , Mukundan Attur 2 , Leon<br />

Rybak 5 , Jenny Bencardino 5 , Cheongeun Oh 6 and Steven B.<br />

Abramson 1 , 1 Hospital for Joint Dis/NYU, New York, NY, 2 Hospital<br />

for Joint Dis/NYU Langone Medical Center, 3 New York University<br />

Hospital for Joint Disease, New York, NY, 4 NYU Hospital for Joint<br />

Disease, New York, NY, 5 NYU Hospital for Joint Diseases, 6 NYU<br />

Langone Medical Center<br />

5:15 PM<br />

709. Bone Marrow Lesions (BMLs) Are Strongly Associated with<br />

Increased Bone Volume Fraction; “Virtual Bone Biopsy” Using<br />

MRI.<br />

Anna M. Tassinari 3 , Grace H. Lo 1 , Jeffrey Driban 3 , Lori Lyn Price 3 ,<br />

Erika Schneider 2 and Timothy E. McAlindon 3 , 1 Baylor <strong>College</strong> <strong>of</strong><br />

Medicine, Houston, TX, 2 The Cleveland Clinic, Cleveland, OH,<br />

3<br />

Tufts Medical Center, Boston, MA<br />

5:30 PM<br />

710. REGN475/SAR164877, a Nerve Growth Factor Inhibitor,<br />

in Osteoarthritis Patients with Moderate to Severe Knee Pain:<br />

Results <strong>of</strong> a Phase 2, Randomized, Double-Blind, Placebo-<br />

Controlled Study.<br />

Paul Tiseo 4 , Alan J. Kivitz 1 , John E. Ervin 2 , Scott J. Mellis 3 ,<br />

Haobo Ren 4 , Damir Skific 4 , Richard Wu 4 and Peter Powchik 4 ,<br />

1<br />

Altoona Arthritis & Osteo Ctr, Duncansville, PA, 2 Center<br />

for Pharmaceutical Res, Kansas City, MO, 3 Regeneron<br />

Pharmaceuticals, Inc., Tarrytown, NY, 4 Regeneron<br />

Pharmaceuticals, Inc.<br />

2010 Program Book 49<br />

monday


5:45 PM<br />

711. Novel Biomarkers <strong>of</strong> Knee Osteoarthritis Identified Using a<br />

Non-Targeted Metabolomic Approach.<br />

Guangju Zhai, Karsten Suhre, Deborah Hart, Christian Gieger,<br />

Nicole Soranzo and Tim D. Spector, King’s <strong>College</strong> London,<br />

London, United Kingdom<br />

A410<br />

Rheumatoid Arthritis - Animal Models: Insight in<br />

Pathogenesis and Novel Therapeutic Targets I<br />

Moderators: Wim B. Van Den Berg, PhD; Radboud University<br />

Nijmegen Medical Center; Nijmegen, The Netherlands<br />

Pierre Miossec, MD, PhD; Hopital E Herriot; Lyon, France<br />

Sidney J. Marcus Auditorium<br />

Rheumatoid Arthritis Treatment - Small Molecules,<br />

Biologics and Gene Therapy: Safety and Efficacy I<br />

Moderators: Maya H. Buch, MD, PhD; University <strong>of</strong> Leeds; Leeds,<br />

United Kingdom<br />

Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany<br />

4:30 PM<br />

718. Certolizumab Pegol Use in Pregnancy: Low Levels Detected<br />

in Cord Blood.<br />

Douglas Wolf 1 and Uma Mahadevan 2 , 1 Atlanta Gastroenterology<br />

Associates, Atlanta, GA, 2 UCSF Center for Colitis and Crohn’s<br />

Disease, San Francisco, CA<br />

monday<br />

50<br />

4:30 PM<br />

712. Anti-CD20 Therapy Inhibits the Progression <strong>of</strong> Synovitis<br />

and Focal Erosion in the Knee Joints but Not in the Ankle Joints<br />

<strong>of</strong> TNF-Tg Mice.<br />

Jie Li, Igor Kuzin, Christopher Ritchlin, Ignacio Sanz, Andrea<br />

Bottaro, Lianping Xing and Edward Schwarz, University <strong>of</strong><br />

Rochester, Rochester, NY<br />

4:45 PM<br />

713. Identifying the TLR4 Bearing Target Cell in Experimental<br />

Arthritis.<br />

Ben T. van den Brand, Shahla Abdollahi-Roodsaz, Miranda B.<br />

Bennink, Onno J. Arntz, Wim B. van den Berg and Fons A. J. van<br />

de Loo, Radboud University Nijmegen Medical Centre<br />

5:00 PM<br />

714. Local Expression <strong>of</strong> IL-27 Reduces Collagen Induced<br />

Arthritis through Reduction <strong>of</strong> Monocyte Migration and<br />

Vascularization.<br />

Sarah R. Pickens 4 , Michael V. Volin 1 , Arthur M. Mandelin 2<br />

and Shiva Shahrara 3 , 1 Midwestern University, 2 Northwester<br />

University, Chicago, IL, 3 Northwestern Univ Feinberg, Chicago, IL,<br />

4<br />

Northwestern University<br />

5:15 PM<br />

715. Impaired B Cell Immunity in IL-22 Knock-Out Mice in<br />

Collagen Induced Arthritis.<br />

Odilia Corneth 1 , Anne-Marie Mus 2 , Patrick Asmawidjaja 2 ,<br />

Laurens Kil 2 , Wenjun Ouyang 3 , Rudi Hendriks 2 and Erik Lubberts 2 ,<br />

1<br />

Erasmus MC, University Medical Center, Rotterdam, ZH,<br />

The Netherlands, 2 Erasmus MC, University Medical Center,<br />

3<br />

Genentech<br />

5:30 PM<br />

716. Repair <strong>of</strong> Bone Erosions in Inflammatory Arthritis Occurs<br />

as Inflammation Resolves, Accompanied by Alterations in the<br />

Wnt Signaling Pathway.<br />

M. M. Matzelle 4 , M. A. Gallant 3 , K. W. Condon 2 , N. C. Walsh 5 ,<br />

C. A. Manning 1 , J. B. Lian 1 , D. B. Burr 2 and Ellen M. Gravallese 1 ,<br />

1<br />

Worcester, MA, 2 Indianapolis, IN, 3 Department <strong>of</strong> Anatomy and<br />

Cell Biology, Indiana University School <strong>of</strong> Medicine, Indianapolis,<br />

IN, 4 Department <strong>of</strong> Medicine and Department <strong>of</strong> Cell Biology,<br />

University <strong>of</strong> Massachusetts Medical School, Worcester, MA, 5 St.<br />

Vincent’s Institute, Fitzroy, VIC, Australia<br />

5:45 PM<br />

717. SB1578, a Novel Selective JAK2 Inhibitor, Is Highly<br />

Efficacious in Rodent Models <strong>of</strong> Rheumatoid Arthritis.<br />

Kee Chuan Goh, Stefan Hart, Yung Kiang Loh, Yong Cheng Tan,<br />

Chithra Amalini, Ramesh Jayaraman, Kantharaj Ethirajulu and<br />

Jeanette Wood, S*BIO Pte Ltd.<br />

2010 Program Book<br />

4:45 PM<br />

719. Anti-TNF Therapy Reduces Adipocytokine Levels and<br />

Improves the Lipid Pr<strong>of</strong>ile in Patients with Rheumatoid<br />

Arthritis: A Possible Mechanism Contributing to Lowered<br />

Cardiovascular Risk.<br />

Marieke Herenius 2 , Ruth Klaasen 2 , Wilco de Jager 4 , Berent<br />

Prakken4, Daniëlle Gerlag 3 and Paul P. Tak 1 , 1 Academic Med Ctr/<br />

Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Department<br />

<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical<br />

Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

3Department <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>,<br />

Academic Medical Center, University <strong>of</strong> Amsterdam, The<br />

Netherlands, 4 Department <strong>of</strong> Pediatric Immunology, University<br />

Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht,<br />

The Netherlands<br />

5:00 PM<br />

720. Biologics and Risk <strong>of</strong> Lymphoma in Patients with<br />

Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.<br />

Lindsay C. Burns 1 , Mary De Vera 1 , Vidula Bhole 1 , Yanyan Zhu 3 ,<br />

Peter Grayson 2 , Devyani Misra 3 and Hyon K. Choi 4 , 1 Arthritis<br />

Research Centre <strong>of</strong> Canada, 2 Boston University, 3 Boston<br />

University School <strong>of</strong> Medicine, 4 Univ <strong>of</strong> British Columbia,<br />

Vancouver, BC, Canada<br />

5:15 PM<br />

721. The Comparative Incidence <strong>of</strong> Serious Infections among<br />

Rheumatoid Arthritis Patients Who Switch Biologic Agents.<br />

Jeffrey R. Curtis 3 , Fenglong Xie 2 , Lang Chen 2 , John Baddley 2 ,<br />

Timothy Beukelman 4 , Kenneth G. Saag 5 , Kevin Winthrop 1 and<br />

Elizabeth Delzell 2 , 1 OHSU, 2 Univ <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, 3 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />

AL, 4 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

5<br />

University <strong>of</strong> Alabama-Birmingham, Birmingham, AL<br />

5:30 PM<br />

722. Characteristics <strong>of</strong> Cases <strong>of</strong> PML among Patients with<br />

Selected Rheumatic and Autoimmune Diseases.<br />

Timothy Beukelman 5 , Fenglong Xie 3 , Lang Chen 3 , John Baddley 3 ,<br />

Elizabeth Delzell 3 , Carlos G. Grijalva 7 , Nivedita M. Patkar 2 ,<br />

Kenneth G. Saag 6 , Kevin Winthrop 1 and Jeffrey R. Curtis 4 , 1 OHSU,<br />

2<br />

Univ <strong>of</strong> AL at Birmingham, Birmingham, AL, 3 Univ <strong>of</strong> AL at<br />

Birmingham, 4 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />

AL, 5 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

6<br />

University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

7<br />

Vanderbilt<br />

5:45 PM<br />

723. Consequence <strong>of</strong> Remission Misclassification Due to<br />

Reduced Joint Counts Omitting the Forefeet.


Lilian H. D. van Tuyl 8 , Karin Britsemmer 3 , David T. Felson 2 , George<br />

A. Wells 6 , Josef S. Smolen 4 , Bin Zhang 1 , Julia Funovits 5 , Dirkjan<br />

van Schaardenburg 3 and Maarten Boers 7 , 1 Boston Univ Schl <strong>of</strong><br />

Medicine, Boston, MA, 2 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA, 3 Jan van Breemen Institute, 4 Krankenhaus Lainz,<br />

Vienna, Austria, 5 Medical University <strong>of</strong> Vienna, 6 Univ <strong>of</strong> Ottawa<br />

Faculty <strong>of</strong> Med, Ottawa, ON, Canada, 7 VU University Medical<br />

Center, Amsterdam, The Netherlands, 8 VU University Medical<br />

Center, Amsterdam<br />

A311<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Clinical Aspects and Therapeutics I<br />

Moderators: Laura K. Hummers, MD; Johns Hopkins University;<br />

Baltimore, MD<br />

Maureen D. Mayes, MD, MPH; University <strong>of</strong> Texas-Houston;<br />

Houston, TX<br />

4:30 PM<br />

724. Use <strong>of</strong> Serum Clara Cell 16-kDa (CC16) Levels as a Potential<br />

Indicator <strong>of</strong> Active Pulmonary Fibrosis in Systemic Sclerosis.<br />

Minoru Hasegawa, Manabu Fujimoto and Kazuhiko Takehara,<br />

Kanazawa University<br />

4:45 PM<br />

725. HLA DRB1*0407 and *1304 Are Predictive Biomarkers for<br />

Scleroderma Renal Crisis.<br />

Binh Y. Nguyen 1 , Maureen D. Mayes 6 , Frank C. Arnett 7 , Deborah<br />

J. del Junco 2 , Emilio B. Gonzalez 4 , Hilda T. Draeger 3 , Marilyn<br />

Perry 2 , Amir Hendiani 2 , John D. Reveille 5 and Shervin Assassi 1 ,<br />

1<br />

Univ <strong>of</strong> Texas Health Science Center Houston, Houston, TX,<br />

2<br />

Univ <strong>of</strong> Texas Health Science Center Houston, 3 Univ <strong>of</strong> Texas<br />

Health Science Center San Antonio, San Antonio, TX, 4 Univ <strong>of</strong><br />

Texas Medical Branch, Galveston, TX, 5 Univ Texas Health Sci Ctr,<br />

Houston, TX, 6 University <strong>of</strong> Texas-Houston, Houston, TX, 7 UT<br />

Medical School, Houston, TX<br />

5:00 PM<br />

726. GAVE (Gastric Antral Vascular Ectasia) in Early<br />

Diffuse SSc: Updated Report from the SCOT (Scleroderma<br />

Cyclophosphamide or Transplant) Trial.<br />

Emily W. Hung 9 , Maureen D. Mayes 10 , Lynette Keyes-Elstein 5 ,<br />

Leslie J. Cr<strong>of</strong>ford 6 , Mary Ellen Csuka 3 , Daniel E. Furst 8 , Ellen<br />

Goldmuntz 4 , Peter McSweeney 11 , Richard Nash 2 , Victor<br />

Machicao 7 and Keith Sullivan 1 , 1 Duke University Medical Center,<br />

for the SCOT Trial Investigators, Durham, NC, 2 Fred Hutchinson<br />

Cancer Research Center, 3 Medical <strong>College</strong> <strong>of</strong> Wisconsin,<br />

Milwaukee, WI, 4 NIAID, 5 Rho Federal Systems Inc., 6 Univ <strong>of</strong><br />

KY, Lexington, KY, 7 Univ <strong>of</strong> Texas Health Science Center at<br />

Houston, 8 University <strong>of</strong> California Los Angeles Medical School,<br />

Los Angeles, CA, 9 University <strong>of</strong> Texas at Houston, Houston, TX,<br />

10<br />

University <strong>of</strong> Texas-Houston, Houston, TX, 11 US Oncology<br />

5:15 PM<br />

727. A Formula To Predict Mean Pulmonary Artery Pressures<br />

in Patients with Connective Tissue Disease Based on<br />

Echocardiography, NTproBNP and O2 Saturation.<br />

Benjamin E. Schreiber 3 , Christopher J. Valerio 3 , Clive Handler 3 ,<br />

Greg Keir 1 , Athol U. Wells 1 , Christopher P. Denton 2 and J. Gerry<br />

Coghlan 3 , 1 Royal Brompton Hospital, London, 2 Royal Free<br />

Hospital, London, United Kingdom, 3 Royal Free Hospital, London,<br />

London, United Kingdom<br />

5:30 PM<br />

728. Predictive Factors <strong>of</strong> Hand Radiographic Lesions in<br />

Systemic Sclerosis: A Prospective Study.<br />

Jerome Avouac 4 , Giulia Mogavero 1 , Henri Guérini 2 , Jean-Luc<br />

Drapé 2 , Alessandro Mathieu 1 , Andre Kahan 3 and Yannick<br />

Allanore 3 , 1 2nd Chair <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Cagliari,<br />

Cagliari, Italy, 2 Paris Descartes University, Radiology B<br />

Department, Cochin Hospital, APHP, Paris, France, 3 Paris<br />

Descartes University, <strong>Rheumatology</strong> A Department, Cochin<br />

Hospital, APHP, Paris, France, 4 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP, Paris,<br />

France<br />

5:45 PM<br />

729. Predictive Value <strong>of</strong> Non-Invasive Tests for the Diagnosis<br />

<strong>of</strong> Scleroderma-Associated Pulmonary Hypertension: PHAROS<br />

Registry.<br />

Dinesh Khanna 4 , Rajeev Saggar 4 , Daniel E. Furst 4 , Yannick<br />

Allanore 3 , James R. Seibold 5 , Philip J. Clements 4 , Rajan Saggar 4 ,<br />

Chi-hong Tseng 4 , Paul Maranian 4 , Monique Hinchcliff 2 , Virginia<br />

Steen 1 and PHAROS Investigators, 1 Georgetown University,<br />

2<br />

Northwestern Univ, 3 Paris Descartes University, 4 UCLA, 5 Univ <strong>of</strong><br />

Connecticut<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

4:30 - 6:00 PM<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Antiphospholipid Syndrome (021) f PS<br />

Speaker: Doruk Erkan, MD; Hospital for Special Surgery; New<br />

York, NY<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the spectrum <strong>of</strong> antiphospholipid syndrome<br />

• determine the diagnostic utility <strong>of</strong> antiphospholipid antibody<br />

tests<br />

• describe the controversial aspects <strong>of</strong> primary and secondary<br />

thrombosis prevention in antiphospholipid syndrome<br />

• discuss the management <strong>of</strong> catastrophic antiphospholipid<br />

syndrome patients<br />

B208<br />

Crystal: Management <strong>of</strong> Gout (022) PS<br />

Speaker: Hyon K. Choi, MD, DrPH; University <strong>of</strong> British Columbia;<br />

Vancouver, BC, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the management <strong>of</strong> gout in patients with renal<br />

insufficiency or organ transplants<br />

• identify strategies to treat patients who are intolerant <strong>of</strong><br />

approved therapies<br />

• cite agents in development for the treatment <strong>of</strong><br />

hyperuricemia and gout<br />

B209<br />

Fibromyalgia (023) PM<br />

Speaker: Manuel Martinez-Lavin, MD; National Cardiology<br />

Institute; Mexico City, Mexico<br />

2010 Program Book 51<br />

monday


monday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the most recent thoughts regarding the<br />

pathophysiology <strong>of</strong> fibromyalgia and related disorders<br />

• prescribe a treatment program for the typical fibromyalgia<br />

patient and serve as a consultant to that patient and the<br />

primary care provider<br />

• describe the principles <strong>of</strong> a comprehensive treatment<br />

program for the more challenging fibromyalgia patient<br />

B210<br />

Immunodeficiency Syndromes (024)<br />

Speaker: Alton Melton, MD; Cleveland Clinic; Cleveland, OH<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the immunology and clinical manifestations <strong>of</strong> the<br />

major immune deficiency syndromes that both adult and<br />

pediatric rheumatologist might encounter<br />

• discuss the diagnostic evaluation for someone suspected <strong>of</strong><br />

having an immune deficiency syndrome<br />

• illustrate therapeutic options with cases<br />

B301<br />

Myopathy: Issues in Diagnosis and Treatment (025)<br />

f<br />

Speaker: Mark F. Gourley, MD; NIAMS; Bethesda, MD<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• distinguish inflammatory myopathies from other muscles<br />

diseases<br />

• plan a diagnostic work-up for a patient with signs and<br />

symptoms <strong>of</strong> muscle disease<br />

• design a treatment program for a patient with myositis<br />

B304<br />

Rheumatoid Arthritis: Outcome Measures in Clinical<br />

Practice (028) PS<br />

Speaker: Martin J. Bergman, MD; Arthritis and <strong>Rheumatology</strong>;<br />

Ridley Park, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss outcome measures used in rheumatoid arthritis<br />

• integrate outcome measures into an <strong>of</strong>fice-based practice<br />

B305<br />

Systemic Lupus Erythematosus: Central Nervous<br />

System (029)<br />

Speaker: F. Jorge Sanchez-Guerrero, MD; Instituto Nacional<br />

Nutricion; Mexico City, Mexico<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify manifestations <strong>of</strong> central nervous system lupus<br />

• select appropriate diagnostic tests in patients with central<br />

nervous system lupus<br />

• formulate a treatment plan<br />

B306<br />

Temporal Arteritis (030)<br />

Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the most current concepts in diagnosis <strong>of</strong> temporal<br />

arteritis, including the use <strong>of</strong> imaging modalities<br />

• identify evolving concepts in treatment <strong>of</strong> temporal arteritis,<br />

including appropriate use <strong>of</strong> corticosteroids, as well as the<br />

data regarding the efficacy <strong>of</strong> other “steroid sparing” agents<br />

• describe controversial areas in diagnosis and management <strong>of</strong><br />

temporal arteritis<br />

52<br />

B302<br />

Pediatric Systemic Lupus (026) P<br />

Speaker: Ilona S. Szer, MD; Rady Children’s Hospital; San Diego,<br />

CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss differences in presentation, disease course and<br />

treatment options between childhood-onset and adult-onset<br />

systemic lupus erythematosus<br />

• cite recent and ongoing research efforts in childhood-onset<br />

systemic lupus erythematosus<br />

• describe important developmental issues in the care <strong>of</strong><br />

children and adolescents with a chronic disease<br />

B303<br />

Psoriatic Arthritis (027)<br />

Speaker: Dafna D. Gladman, MD; Toronto Western Hospital;<br />

Toronto, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss advances in diagnosis and classification <strong>of</strong> psoriatic<br />

arthritis<br />

• determine if patients with psoriatic arthritis should be treated<br />

aggressively<br />

• determine treatment options for patients with psoriatic<br />

arthritis<br />

2010 Program Book<br />

ACR Special Session<br />

4:30 - 6:00 PM<br />

B313<br />

Legislative Update from Capitol Hill<br />

Moderator: Sharad Lakhanpal, MB, MD; University <strong>of</strong> Texas<br />

Southwestern; Dallas, TX<br />

This session is not eligible for CME credit.<br />

4:30 PM<br />

Health Policy Discussion<br />

Speaker to be announced<br />

Session Overview:<br />

Advocacy is a top priority <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong>. Legislative and regulatory actions include<br />

Medicare physician reimbursement, increased research funding<br />

for arthritis or lupus, health care reform, incentives for health<br />

information technology, and directly patients with rheumatic<br />

affect diseases. This session has been designed to provide<br />

rheumatologists and health pr<strong>of</strong>essionals a forum to discuss<br />

what is on the congressional agenda that could affect them and<br />

their patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss legislative actions that Congress has taken in the past<br />

year<br />

• explain Congress and the Administration’s role in creating<br />

health policy<br />

• assess health care legislation and its effects on the<br />

rheumatology pr<strong>of</strong>ession


ACR REF Special Sessions<br />

4:30 - 6:00 PM<br />

A315<br />

ACR REF Clinician Scholar Educator Lecture Ed.<br />

Moderators: Abby Goulder Abelson, MD; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Terry M. Wolpaw, MD, MHPE; Case Western School <strong>of</strong> Medicine;<br />

Cleveland, OH<br />

4:30 PM<br />

Introduction<br />

William T. Branch, Jr., MD; Emory School <strong>of</strong> Medicine; Atlanta,<br />

GA<br />

5:00 PM<br />

Rethinking <strong>Rheumatology</strong> Education: Focusing the Options for<br />

Medical Students<br />

Sharon L. Kolasinski, MD; Hospital <strong>of</strong> University Pennsylvania;<br />

Philadelphia, PA<br />

5:30 PM<br />

A Web-based Educational Tool to Teach a Standardized<br />

Musculoskeletal Examination in Children<br />

Yukiko Kimura, MD; Hackensack University Medical Center;<br />

Hackensack, NJ<br />

Session Overview:<br />

This session includes an overview on current issues in medical<br />

education, as well as an opportunity for clinician scholar<br />

educators to share their final project results with the broader<br />

audience. The purpose <strong>of</strong> this session is for rheumatologists<br />

to expand their repertoire <strong>of</strong> scholarship methods through<br />

interactive skill-based learning <strong>of</strong> principles and specific<br />

approaches, for collecting and analyzing qualitative data. This<br />

session will also serve to inform rheumatology educators, most<br />

importantly Training Program Directors, about new educational<br />

methods and curricula, including those developed via the ACR<br />

REF Clinician Scholar Educator Award recipients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss novel approaches to curriculum development for<br />

medical students and residents in the musculoskeletal and<br />

rheumatic diseases<br />

• implement new approaches to teaching in the rheumatic and<br />

musculoskeletal diseases<br />

• discuss important areas <strong>of</strong> overlap in medical education<br />

between geriatric medicine and rheumatology and the impact<br />

<strong>of</strong> this education on quality <strong>of</strong> care<br />

• describe the unique and important roles <strong>of</strong> the clinician<br />

scholar educator in medical education and training<br />

B402<br />

REF Edmond L. Dubois, MD, Memorial Lectureship:<br />

The Path from Gene to Function: Analysis <strong>of</strong> a Lupus<br />

Susceptibility Gene c/r<br />

Moderator: E. William St.Clair, MD; Duke University Medical<br />

Center; Durham, NC<br />

4:30 PM<br />

Single-Nucleotide Polymorphisms Associated with Systemic<br />

Lupus Erythematosus (SLE) Skew Alternative Splicing <strong>of</strong> Human<br />

Complement Receptor 2 (CR2/CD21) towards an Is<strong>of</strong>orm with<br />

Increased Ligand Binding Ability (Abstract #730).<br />

Susan A. Boackle, MD; University <strong>of</strong> Colorado Denver<br />

School <strong>of</strong> Medicine; Denver, CO<br />

Kara M. Lough 3 , Katherine B. Douglas 3 , Carissa L. Homme 3 ,<br />

Daniela Ulgiati 1 and Betty P. Tsao 2 , 1 School <strong>of</strong> Biomedical,<br />

Biomolecular and Chemical Sciences, University <strong>of</strong> Western<br />

Australia, 2 University <strong>of</strong> California, Los Angeles, 3 University <strong>of</strong><br />

Colorado Denver School <strong>of</strong> Medicine<br />

5:30 PM<br />

731. Further Defining Cancer Risk in Systemic Lupus: Updated<br />

Results in an Expanded International Multi-Centre Cohort.<br />

Sasha R. Bernatsky 4 , Ann E. Clarke 7 , Michelle A. Petri 1 , Murray B.<br />

Urowitz 14 , Paul R. Fortin 16 , Dafna D. Gladman 16 , Søren Jacobsen 12,<br />

Susan Manzi 20 , Graciela S. Alarcon 2 , Ellen M. Ginzler 13 , Christine<br />

A. Peschken 18 , Mary Anne Dooley 3 , John G. Hanly 10 , Ola Nived 19 ,<br />

Gunnar K. Sturfelt 17 , Jean-Luc Senecal 9 , Jeremy Labrecque 5 ,<br />

Elizabeth M. Turnbull 6 , Jennifer L. F. Lee 11 and Rosalind Ramsey-<br />

Goldman 8 , 1Timonium, MD, 2 Oakland, CA, 3 Capital Health<br />

and Dalhousie University, Chapel Hill, NC, 4 McGill UHC/RVH,<br />

Montreal, QC, Canada, 5 McGill University, Montreal, Canada,<br />

6<br />

McGill University Health Ctr, Montreal, QC, Canada, 7 Montreal<br />

General Hospital, Montreal, QC, Canada, 8 Northwestern<br />

University, Chicago, IL, 9 Notre-Dame Hospital, M-4243, Montreal,<br />

QC, Canada, 10 Queen Elizabeth II Health Services Center,<br />

Halifax, NS, Canada, 11 RI McGill Univ Health Ctr, Montreal, QC,<br />

Canada, 12 Rigshospitalet - 4242, Copenhagen, Denmark, 13 SUNY-<br />

Downstate Medical Center, Brooklyn, NY, 14 The Toronto Western<br />

Hospital, Toronto, ON, Canada, 15 Toronto Western Hospital,<br />

Toronto, ON, Canada, 16 Toronto Western Hospital, Toronto,<br />

ON, Canada, 17 UCL Div <strong>of</strong> Medicine, Room 331, 3rd Floor, Lund,<br />

Sweden, 18 Univ <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 19 University<br />

Hospital, Lund, Sweden, 20 West Penn Allegheny Health System,<br />

Pittsburgh, PA<br />

5:45 PM<br />

732. Hydroxychloroquine and Prevention <strong>of</strong> Anti-SSA/Ro<br />

Associated Cardiac Disease in Mothers with a Previous Child<br />

with Neonatal Lupus.<br />

Peter M. Izmirly 4 , Cecilia Pisoni 2 , Mimi Y. Kim 1 , Deborah Friedman 3 ,<br />

Carolina Llanos 5 , Nathalie Costedoat-Chalumeau 7 , Munther A.<br />

Khamashta 6 and Jill P. Buyon 4 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine,<br />

2<br />

King’s <strong>College</strong> <strong>of</strong> London, 3 New York Medical <strong>College</strong>, 4 NYU School<br />

<strong>of</strong> Medicine, New York, NY, 5 Pontificia Universidad Catolica de<br />

Chile, 6 The Rayne Institute, London, United Kingdom, 7 Universite<br />

Paris VI Pierre et Marie Curie<br />

ARHP Concurrent Sessions<br />

4:30 - 6:00 PM<br />

B309<br />

Juvenile Fibromyalgia P/C PM<br />

Moderator: Elizabeth G. Salt, PhD ARNP; University <strong>of</strong> Kentucky;<br />

Lexington, KY<br />

Speakers: Susmita Kashikar-Zuck, PhD; Cincinnati Children’s<br />

Hospital Medical Center; Cincinnati, OH<br />

Tracy V. Ting, MD; Cincinnati Children’s Hospital; Cincinnati, OH<br />

Session Overview:<br />

Juvenile fibromyalgia, a prevalent chronic pain syndrome,<br />

is characterized by widespread pain, fatigue, and sleep<br />

disturbance. A physical and emotional impact has been<br />

attributed to this health condition that results in altered peer<br />

relationships, irregular school attendance, and emotional issues.<br />

The diagnosis and evidence-based management <strong>of</strong> this health<br />

condition is important to improving patient outcomes.<br />

2010 Program Book 53<br />

monday


monday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the diagnostics criteria for juvenile fibromyalgia<br />

• state the prevalence and rates <strong>of</strong> disability due to this health<br />

condition<br />

• describe the suspected etiology <strong>of</strong> this health condition<br />

• define the role <strong>of</strong> family members in the management <strong>of</strong><br />

juvenile fibromyalgia<br />

• explain interventions used to treat juvenile fibromyalgia<br />

B310<br />

Osteoporosis Treatment Update C PS<br />

Moderator: Kori A. Dewing, MN, ARNP; VA Mason Medical<br />

Center; Everett, WA<br />

Speaker: Julie L. Carkin, MD; The Seattle Arthritis Clinic; Seattle,<br />

WA<br />

Session Overview:<br />

<strong>Rheumatology</strong> nurse practitioners, physician assistants and<br />

other health care team members serve a critical role in<br />

diagnosing and managing patients with osteoporosis. There is<br />

much debate about who should be treated and for how long.<br />

Therefore, it is important for rheumatology health care providers<br />

to be knowledgeable <strong>of</strong> the evidence-based data to ensure that<br />

treatment decisions are implemented to best meet the goal <strong>of</strong><br />

fracture prevention.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the clinical risk factors with bone mineral density to<br />

more accurately identify fracture risk<br />

• describe the scientific data supporting length <strong>of</strong> osteoprorsis<br />

treatment<br />

• define the rationale for continuing or discontinuing<br />

osteoporosis therapy<br />

B308<br />

Rehabilitation in the Age <strong>of</strong> Biologics C PS<br />

Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo,<br />

OH<br />

Speakers: Kamala M. Nola, PharmD, MS; Lipscomb <strong>College</strong> <strong>of</strong><br />

Pharmacy; Nashville, TN<br />

Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;<br />

Boston, MA<br />

Session Overview:<br />

There has been a national decline in referrals to occupational<br />

and physical therapy since the introduction <strong>of</strong> biologic therapies<br />

for the treatment <strong>of</strong> rheumatic diseases. As a result, patients<br />

are missing access to information to help with the management<br />

<strong>of</strong> their disease. Exercise, joint protection and activities <strong>of</strong><br />

daily living ideas are examples <strong>of</strong> what are missing from the<br />

management <strong>of</strong> their disease.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• cite the development and progression <strong>of</strong> the biologic<br />

medications<br />

• distinguish the different classes <strong>of</strong> biologics and how they<br />

treat the rheumatic diseases<br />

• describe the different methods <strong>of</strong> how these medications are<br />

administered<br />

• identify appropriate therapy treatments for patients on<br />

biologic medications<br />

• describe to physicians how therapy can complement the<br />

medical treatment for maximum positive outcomes <strong>of</strong> the<br />

patient<br />

• explain to patients how therapy can help minimize problems<br />

associated with the diseases these medications treat<br />

B311<br />

Reproductive and Sexual Health Issues for Women<br />

with Rheumatic Disease c/r<br />

Moderator: Susan M. Oliver, RN MSc; Pennine Musculoskeletal<br />

Partnership; Oldham, United Kingdom<br />

Speakers: Wendy Marder, MD; University <strong>of</strong> Michigan; Ann<br />

Arbor, MI<br />

W. Tracy Talmadge, PhD; Atlanta, GA<br />

Senait Fisseha, MD, JD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />

Session Overview:<br />

Among wom en with autoimmune disease, issues relating to<br />

premature ovarian failure, reproductive viability and general<br />

sexual health <strong>of</strong>ten get overlooked due to underlying severe<br />

disease activity or lack <strong>of</strong> awareness on the part <strong>of</strong> the health<br />

care provider. Autoimmune disease <strong>of</strong>ten affects women during<br />

their reproductive years, and the consequences <strong>of</strong> therapies<br />

administered during this time have larger implications that will<br />

impact them throughout their lives. It is important for health<br />

care providers to be aware <strong>of</strong> methods to preserve fertility<br />

among these patients and the burden <strong>of</strong> disease associated<br />

with premature ovarian failure and be prepared to discuss the<br />

options with patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the epidemiology, comorbidities, and public<br />

health burden <strong>of</strong> premature ovarian failure in patients<br />

with systemic disease exposed to gonadotoxic agents (e.g.,<br />

cyclophosphamide)<br />

• identify sexual health implications and management strategies<br />

for patients with early menopause and/or infertility<br />

• explain the emerging options for ovarian protection and<br />

fertility preservation and assess the pros and cons<br />

REF Industry Roundtable-<br />

Supported Symposia<br />

6:30 - 9:30 PM<br />

The REF would like to thank the industry leaders that have made<br />

a significant multi-year commitment to the REF for participation<br />

in the Industry Roundtable.<br />

In appreciation for their commitment, these industry leaders<br />

have been invited to host a symposium during the annual<br />

meeting. In 2010, there are two types <strong>of</strong> symposia <strong>of</strong>fered to<br />

attendees: CME-accredited and non-CME accredited. For CMEaccredited<br />

symposia, the sponsoring organization is responsible<br />

for planning and providing CME credit. The non-CME accredited<br />

symposia have been planned and will be implemented in<br />

accordance with the requirements <strong>of</strong> the FDA and applicable<br />

standards <strong>of</strong> the PhRMA Code on Interactions with Healthcare<br />

Pr<strong>of</strong>essionals. Please visit the organization’s exhibit booth, the<br />

industry-supported symposia booth or see page 280 for more<br />

information.<br />

54<br />

2010 Program Book


REF 5K Run/Walk<br />

6:00 - 8:00 am<br />

See page 13 for more information.<br />

TUESDAY, NOVEMBER 9, 2010<br />

ACR/ARHP Registration<br />

6:30 am - 5:00 PM<br />

International Blvd. Foyer<br />

ACR Clinical Symposium<br />

7:15 - 8:15 am<br />

Hall A3<br />

Clinicopathologic Conference: A 62-year-old Male with<br />

Ulcerative Rash and Joint Pain cP PM PS ARS<br />

Moderator: S. Sam Lim, MD, MPH; Emory University; Atlanta, GA<br />

7:15 am<br />

Case Presentation<br />

Karen Law, MD; Emory University School <strong>of</strong> Medicine; Atlanta,<br />

GA<br />

7:30 am<br />

Case Presentation<br />

Abeer Moanna, MD; Emory University School <strong>of</strong> Medicine;<br />

Atlanta, GA<br />

7:45 am<br />

Case Presentation<br />

Brian P. Pollack, MD, PhD; Emory University School <strong>of</strong> Medicine;<br />

Atlanta, GA<br />

8:00 am<br />

Case Presentation<br />

Karen Atkinson, MD; Emory University School <strong>of</strong> Medicine;<br />

Atlanta, GA<br />

Ulrich Specks, MD; Mayo Clinic; Rochester, MN<br />

Session Overview:<br />

Clinical problem-solving is fundamental to the practice <strong>of</strong><br />

rheumatology. Rheumatologists need to be able to develop<br />

a differential diagnosis and initiate a targeted diagnostic<br />

plan based on clinical presentation alone. The myriad<br />

<strong>of</strong> rheumatologic diseases with primary dermatologic<br />

manifestations require a coordinated approach combining<br />

input from consulting specialties with thoughtful laboratory<br />

and pathology interpretation. This session will provide the<br />

framework for diagnosing such a process in an efficient,<br />

conscientious, and cost-effective manner.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss clinical clues in a rheumatologic presentation that<br />

might lead a practitioner towards a more unusual diagnosis<br />

than that which is originally recognized<br />

• recognize the limitations and specificity <strong>of</strong> both common and<br />

newer laboratory testing in making a clinical diagnosis<br />

• integrate the anatomic and pathologic diagnosis with the<br />

preceding evaluation and discuss clinical follow-up<br />

ACR Immunology Updates for<br />

Clinicians<br />

7:15 - 8:15 am<br />

Sidney J. Marcus Auditorium<br />

Macrophage Differentiation c/r<br />

Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Speaker: John A. Hamilton, PhD, DSc; The University <strong>of</strong><br />

Melbourne; Parkville, VIC, Australia<br />

Session Overview:<br />

Macrophages are extraordinarily versatile playing beneficial<br />

roles in normal homeostasis, wound repair, and host defenses,<br />

but also playing important roles in tissue damage, fibrosis,<br />

chronic infection, atherosclerosis, and Alzheimer’s disease.<br />

In rheumatoid arthritis, macrophages are a major source <strong>of</strong><br />

tumor necrosis factor and other pro-inflammatory cytokines,<br />

but they are also capable <strong>of</strong> down-regulating and controlling<br />

inflammation. In systemic lupus erythematosus, defects in<br />

macrophage-mediated clearance <strong>of</strong> apoptotic debris allows<br />

activation <strong>of</strong> the α-interferon pathway and the deposition <strong>of</strong><br />

immune complexes in tissue. On the other hand, overly activated<br />

macrophages can be very destructive as seen in macrophage<br />

activation syndrome. Thus, if we are to follow the advice <strong>of</strong> Elie<br />

Metchnik<strong>of</strong>f, winner <strong>of</strong> the 1906 Nobel Prize and “stimulate the<br />

phagocyte”, we need to be very careful. Fortunately, there has<br />

been rapid progress in the study <strong>of</strong> macrophage differentiation<br />

and activation so that the factors responsible for different type<br />

<strong>of</strong> macrophages are beginning to become clear.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the characteristics and functions <strong>of</strong> classically<br />

activated macrophages, wound-healing macrophages,<br />

regulatory macrophages, and osteoclasts<br />

• describe the origin <strong>of</strong> macrophages and the factors that<br />

regulate activation/differentiation into the major macrophage<br />

populations<br />

• identify how different macrophage populations are important<br />

in host defenses and how infecting organisms try to use<br />

macrophages to subvert immunity<br />

• identify the beneficial and detrimental role <strong>of</strong> macrophages in<br />

rheumatologic disease<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

7:15 - 8:15 am<br />

Thomas J. Murphy Ballroom<br />

Methotrexate 2010 cP P/C PS<br />

Moderator: Eric M. Ruderman, MD; Northwestern University<br />

School; Chicago, IL<br />

7:15 AM<br />

Methotrexate: The Clear Standard <strong>of</strong> Care for Rheumatoid<br />

Arthritis<br />

Michael E. Weinblatt, MD; Brigham and Women’s Hospital;<br />

Boston, MA<br />

tuesday<br />

2010 Program Book 55


tuesday<br />

7:25 AM<br />

New Insights into Mechanisms <strong>of</strong> Action and Method <strong>of</strong><br />

Administration<br />

Joel M. Kremer, MD; The Center for <strong>Rheumatology</strong>; Albany, NY<br />

7:55 am<br />

Re-evaluating Methotrexate Toxicity and Monitoring in the<br />

Changing Landscape <strong>of</strong> Rheumatoid Arthritis Therapy<br />

Michael E. Weinblatt, MD; Brigham and Women’s Hospital;<br />

Boston, MA<br />

Session Overview:<br />

Methotrexate has become the mainstay <strong>of</strong> therapy in<br />

rheumatoid arthritis and psoriatic arthritis, both as monotherapy<br />

and as the anchor drug for additional biologic agents, and<br />

is frequently used as primary or adjunctive therapy in other<br />

rheumatologic diseases. Since the development <strong>of</strong> the ACR<br />

guidelines for monitoring hepatoxicity with methotrexate over<br />

10 years ago, new information has become available on the<br />

mechanism, toxicities, and the value <strong>of</strong> monitoring strategies<br />

for this drug. The current and future use <strong>of</strong> other agents in<br />

combination with methotrexate, which may share some <strong>of</strong><br />

the same organ toxicities, creates a challenge for practitioners<br />

trying to safely prescribe and monitor methotrexate therapy.<br />

This presentation will review the history <strong>of</strong> methotrexate use,<br />

update the data on its mechanism(s) <strong>of</strong> action and toxicity, and<br />

explore the challenges inherent in the use <strong>of</strong> methotrexate in<br />

combination with other agents.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify potential mechanisms for the effect <strong>of</strong> methotrexate<br />

in rheumatic diseases<br />

• describe the rationale for modifying the dose and method <strong>of</strong><br />

administration <strong>of</strong> methotrexate<br />

• identify potential toxicities associated with methotrexate,<br />

along with the rationale for, and details <strong>of</strong>, the existing<br />

guidelines for monitoring methotrexate therapy<br />

ACR Special Session<br />

7:30 - 8:30 am<br />

A411<br />

News from the National Institutes <strong>of</strong> Health: Updates<br />

and Opportunities R<br />

Moderators: Mariana J. Kaplan, MD; University <strong>of</strong> Michigan<br />

Medical Center; Ann Arbor, MI<br />

Raymond L. Yung, MD; University <strong>of</strong> Michigan Medical Center;<br />

Ann Arbor, MI<br />

7:30 am<br />

Cartilage Research at the National Institute on Aging<br />

John Williams, PhD; National Institute on Aging; Bethesda, MD<br />

7:50 am<br />

Enhancements to Peer Review and You<br />

Laura K. Moen, PhD; National Institute <strong>of</strong> Arthritis and<br />

Musculoskeletal and Skin; Bethesda, MD<br />

8:10 am<br />

Current and Future Needs and Opportunities for <strong>Rheumatology</strong><br />

Clinical Trials<br />

Robert H. Carter, MD; National Institute <strong>of</strong> Arthritis and<br />

Musculoskeletal and Skin/Nationl Institutes <strong>of</strong> Health; Bethesda,<br />

MD<br />

Session Overview:<br />

The National Institutes <strong>of</strong> Health represents the premier agency<br />

funding arthritis research. However, there is a gap in the ACR<br />

members’ knowledge <strong>of</strong> National Institutes <strong>of</strong> Health funding<br />

opportunities outside <strong>of</strong> National Institute <strong>of</strong> Arthritis and<br />

Musculoskeletal and Skin and National Institute <strong>of</strong> Allergy and<br />

Infectious Diseases. Additionally, recent major changes in the<br />

National Institutes <strong>of</strong> Health grant application process have<br />

significant impact on rheumatology researchers.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review funding opportunities and resources for basic arthritis<br />

research at the National Institute on Aging<br />

• describe the impact <strong>of</strong> recent changes in the National<br />

Institutes <strong>of</strong> Health grant application system<br />

• define the priorities for clinical research in rheumatic diseases<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

7:45 - 9:15 am<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Antiphospholipid Syndrome (031) PS<br />

Speaker: Robert A. S. Roubey, MD; University <strong>of</strong> North Carolina;<br />

Chapel Hill, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the diverse clinical subsets within the spectrum <strong>of</strong><br />

antiphospholipid syndrome<br />

• discuss the laboratory tests used to confirm antiphospholipid<br />

syndrome<br />

• analyze the therapeutic alternatives for the different<br />

manifestations <strong>of</strong> antiphospholipid syndrome, including the<br />

benefit/risk, adverse effects and limitations<br />

B208<br />

Crystal: Management <strong>of</strong> Gout (032) PS<br />

Speaker: Peter A. Simkin, MD; University <strong>of</strong> Washington; Seattle,<br />

WA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• critique recent changes in the epidemiology and complexity <strong>of</strong><br />

gout relevant to clinical practice<br />

• determine the basis and status <strong>of</strong> novel drugs for lowering<br />

serum urate in refractory patients<br />

• determine new developments in gout inflammation<br />

pathophysiology and how they point to novel treatment<br />

strategies<br />

B209<br />

Infections in Patients on Tumor Necrosis Factor<br />

Therapy (033) PS<br />

Speaker: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the risks <strong>of</strong> infections, including opportunistic<br />

infections, with biological response modifier therapies for<br />

rheumatoid arthritis<br />

56<br />

2010 Program Book


• discuss the principles <strong>of</strong> early detection and management <strong>of</strong><br />

infections in patients who develop infections<br />

• determine ways to reduce the risk <strong>of</strong> occurrence <strong>of</strong> infections<br />

in patients with rheumatoid arthritis<br />

B210<br />

Osteoarthritis: Update 2010 (034)<br />

Speaker: Richard F. Loeser, MD; Wake Forest University;<br />

Winston-Salem, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the potential causes and exacerbating factors <strong>of</strong> the<br />

disease<br />

• discuss the appropriate use <strong>of</strong> laboratory testing and imaging<br />

modalities<br />

• design an efficacious, safe and cost-effective therapeutic<br />

strategy<br />

B302<br />

Pediatric <strong>Rheumatology</strong> for Adult Rheumatologists<br />

(035) P f<br />

Speaker: Peter A. Nigrovic, MD; Harvard Medical School; Boston,<br />

MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• diagnose the various forms <strong>of</strong> arthritis that are unique to<br />

children<br />

• identify how the evaluation <strong>of</strong> children with rheumatic<br />

diseases may be different from that <strong>of</strong> adults<br />

• describe current treatments <strong>of</strong> arthritis in children<br />

B301<br />

Pediatrics: Dermatomyositis (036) P<br />

Speaker: Adam Huber, MD; IWK Health Centre; Halifax, NS,<br />

Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss recent research developments regarding juvenile<br />

dermatomyositis<br />

• describe the clinical assessment and management <strong>of</strong> juvenile<br />

dermatomyositis<br />

B303<br />

Reactive Arthritis: An Update (037)<br />

Speaker: Atul A. Deodhar, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify various causes <strong>of</strong> reactive arthritis<br />

• discuss mechanisms <strong>of</strong> disease pathogenesis<br />

• describe current treatment options for reactive arthritis<br />

B304<br />

Rheumatoid Arthritis: Biological Agents (038) PS<br />

Speaker: Larry W. Moreland, MD; University <strong>of</strong> Pittsburgh<br />

Medical Center; Pittsburgh, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify biologic agents in use for the treatment <strong>of</strong> rheumatoid<br />

arthritis<br />

• describe the risk/benefit pr<strong>of</strong>iles <strong>of</strong> biologic agents<br />

• discuss the emerging biologics and their advantages for the<br />

therapeutic algorithm<br />

B305<br />

Scleroderma: Systemic Sclerosis (039) PM<br />

Speaker: Christopher P. Denton, MD, PhD; Royal Free Hospital;<br />

London, United Kingdom<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the classification <strong>of</strong> systemic sclerosis and its impact<br />

on treatment and prognosis<br />

• apply cardiopulmonary testing to determine the relative<br />

contributions <strong>of</strong> alveolitis, fibrosis and vasculopathy<br />

• formulate a therapeutic regimen to improve quality <strong>of</strong> life and<br />

organ-specific symptomatology<br />

B306<br />

Vasculitis Mimics (040)<br />

Speaker: Alexandra Villa-Forte, MD, MPH; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify clinical settings in which vasculitis should be<br />

suspected<br />

• describe the different medical conditions that could mimic<br />

clinical presentations <strong>of</strong> vasculitis<br />

• identify the challenges in the diagnostic process and how<br />

ancillary test results could be misleading<br />

• discuss the process to distinguish between a vasculitic<br />

syndrome and a “vasculitis mimic”<br />

ACR/ARHP Workshops<br />

7:45 - 9:45 am<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check<br />

tomake sure the registration code on your ticket matches the<br />

code listed below in parentheses.<br />

B202<br />

Dermatopathology <strong>of</strong> Rheumatic Diseases (216)<br />

Speaker: Lynne Goldberg, MD; Boston University Medical<br />

Center; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review dermatopathology in rheumatic diseases<br />

• describe the importance <strong>of</strong> dermatopathology in clinical<br />

decision-making in patients with rheumatic diseases<br />

• apply the knowledge gained to clinical practice<br />

B201<br />

Excel Spreadsheets: Basic Concepts to Elevate Your<br />

Skills Beyond Those <strong>of</strong> Your Children (217)<br />

Speaker: Richard A. Furie, MD; North Shore Long Island Jewish<br />

Health System; Lake Success, NY<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• create a spreadsheet despite having no prior knowledge <strong>of</strong><br />

spreadsheet function or design<br />

• design a graph using spreadsheet date<br />

• distinguish between a database and a spreadsheet<br />

2010 Program Book 57<br />

tuesday


tuesday<br />

B206<br />

Joint Injections (Shoulder and Wrist Prosthetics) (218)<br />

Speaker: Gregory C. Gardner, MD; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe indications for upper extremity joint injection and<br />

aspiration<br />

• identify anatomic landmarks for injection <strong>of</strong> the shoulder and<br />

wrist using joint prosthetics<br />

• apply principles <strong>of</strong> joint aspiration and injection using<br />

shoulder and wrist joint prosthetics<br />

ARHP Concurrent Sessions<br />

7:45 - 8:45 am<br />

B310<br />

Clinical Trial Essentials: Budgets, Contracts and<br />

Regulations c/r<br />

Moderator: Lisa M. Kastanek, RN, CCRC; Physician Research<br />

Collaboration; Lincoln, NE<br />

Speaker: Donah Z. Crawford, BS, MA; The Arthritis Group;<br />

Philadelphia, PA<br />

Session Overview:<br />

For all members <strong>of</strong> the clinical trials team to be effective it<br />

is necessary for each member to understand the essentials<br />

required for successfully managing clinical trial sites and to be<br />

aware <strong>of</strong> the contract and budgetary considerations.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the elements required to legally and ethically<br />

conduct a clinical trial in the US<br />

• define the basic elements <strong>of</strong> a clinical trial contract, and<br />

budget<br />

• explain the roles <strong>of</strong> the members <strong>of</strong> a clinical trials team<br />

B308<br />

Hand X-ray Review and Interpretation cP<br />

Moderator: Aimee Wiener, ARNP C, MSN; Arthritis Autoimmune<br />

& Asthma; Daytona Beach, FL<br />

Speaker: Andrew J. Sulich, MD; Shores <strong>Rheumatology</strong>; St. Clair<br />

Shores, MI<br />

Session Overview:<br />

The ability to read and interpret hand X-rays is fundamental<br />

in understanding, diagnosing and managing rheumatologic<br />

conditions. For most health care pr<strong>of</strong>essionals in a rheumatology<br />

practice these skills are obtained on the job. This session will<br />

assist health care pr<strong>of</strong>essionals in developing their knowledge<br />

to better treat their patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe changes commonly seen in hand osteoarthritis<br />

including joints commonly affected, joint space narrowing,<br />

osteophytes, and mucous cysts<br />

• describe changes commonly seen in inflammatory arthritis<br />

conditions including juxtaarticular osteoporosis, generalized<br />

osteopenia, erosions, angulation, ankylosis, pencil-in-cup<br />

deformity, lysis <strong>of</strong> terminal phalanges, fluffy periostitis, new<br />

bone formation at enthesitis, and effusions<br />

• identify changes seen in hemachromatosis and pseudogout<br />

including chondrocalcinosis, squared <strong>of</strong>f bone ends and hooklike<br />

osteophytes in the 2nd and 3rd metacarpophalangeal<br />

joints<br />

• distinguish between erosive and classic osteoarthritis and<br />

rheumatoid arthritis and other inflammatory conditions,<br />

utilizing a systematic method for reading hand X-ray images<br />

B313<br />

Rheumatic Disease Update: Sjögren’s Syndrome c/r<br />

Moderator: Benjamin J. Smith, PA-C; McIntosh Clinic PC;<br />

Thomasville, GA<br />

Steven E. Carsons, MD; Winthrop University Hospital; Mineola,<br />

NY<br />

Session Overview:<br />

Sjögren’s syndrome is a common autoimmune disease seen<br />

in rheumatology practice. This potentially debilitating disease<br />

is <strong>of</strong>ten missed and/or treated inappropriately because <strong>of</strong><br />

confusion regarding diagnostic criteria and treatment strategies.<br />

This timely review will address these deficiencies.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the immunologic basis for primary Sjögren’s syndrome<br />

• describe the classification criteria for primary Sjögren’s<br />

syndrome<br />

• develop a management plan for a patient with Sjögren’s<br />

syndrome<br />

B309<br />

The Multidisciplinary Approach to Hereditary<br />

Periodic Fever Syndromes P/C<br />

Moderator: Bernadette McNally, MS, PAC; University <strong>of</strong> Utah;<br />

Salt Lake City, UT<br />

Speakers: Beverly K. Barham, RN MSN CCRC; NIAMS; Bethesda,<br />

MD<br />

Nicole D. Plass, BSN, MPA; National Institutes <strong>of</strong> Health;<br />

Bethesda, MD<br />

Session Overview:<br />

Hereditary periodic fever syndromes are rare diseases caused by<br />

genetic mutations that cause episodic inflammation. This lecture<br />

will provide health care providers with a basic overview <strong>of</strong> the<br />

phenotypic and genotypic presentations, health care needs, and<br />

treatment options for patients with familial Mediterranean fever,<br />

tumor necrosis factor-receptor associated periodic syndrome,<br />

hyper-immunoglobulinemia D with periodic fever syndrome and<br />

others.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the genotypic and phenotypic presentation <strong>of</strong><br />

familial Mediterranean fever, hyper-immunoglobulinemia D<br />

with periodic fever syndrome, tumor necrosis factor-receptor<br />

associated periodic syndrome and other periodic fever<br />

syndromes<br />

• develop a management plan for the health care needs <strong>of</strong><br />

families experiencing a member with a rare hereditary<br />

periodic fever syndrome<br />

• define treatment options and other resources for patients<br />

with hereditary periodic fever syndromes<br />

58<br />

2010 Program Book


ACR Medical Aspects <strong>of</strong> Rheumatic<br />

Diseases<br />

8:45 - 9:45 am<br />

Hall A3<br />

Update on Multiple Sclerosis<br />

cP P/C PS ARS<br />

Moderator: Nancy Y. Liu, MD; University <strong>of</strong> Massachusetts;<br />

Worcester, MA<br />

Speaker: Peter Riskind, MD, PhD; University <strong>of</strong> Massechussetts<br />

Memorial Health Center; Worcester, MA<br />

Session Overview:<br />

Multiple sclerosis is a primary inflammatory, autoimmune<br />

disease <strong>of</strong> the central nervous system. The manifestations <strong>of</strong><br />

multiple sclerosis may have clinical overlap with our patients<br />

with connective tissue disorders who have central nervous<br />

system involvement. As practicing rheumatologists, it is<br />

important to be familiar with new advances in pathogenesis,<br />

genetics, diagnosis, and therapeutics <strong>of</strong> multiple sclerosis. This<br />

knowledge should assist the clinician to differentiate patients<br />

with multiple sclerosis from the rheumatic patient with central<br />

nervous system manifestations.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• apply the recent advances in diagnosis <strong>of</strong> multiple sclerosis in<br />

evaluating patients with neurologic complaints<br />

• differentiate the clinical manifestations <strong>of</strong> multiple sclerosis<br />

from other central nervous system manifestations <strong>of</strong><br />

connective tissue disorders<br />

• review the recent advances in therapy for multiple sclerosis<br />

ACR State-<strong>of</strong>-the-Art Lectures<br />

8:45 - 9:45 am<br />

Sidney J. Marcus Auditorium<br />

Autophagy and Immune Function R<br />

Moderators: Roberto Caricchio, MD; Temple University;<br />

Philadelphia, PA<br />

Keith B. Elkon, MD; University <strong>of</strong> Washington; Seattle, WA<br />

Speaker: Vojo Deretic, PhD; University <strong>of</strong> New Mexico Health<br />

Sciences Center; Albuquerque, NM<br />

Session Overview:<br />

It has only been realized recently that, in addition to apoptosis<br />

and necrosis, a third form <strong>of</strong> cell death, autophagy occurs in<br />

specific physiological and pathophysiological circumstances.<br />

These circumstances include cancer, autoimmunity and<br />

infectious diseases. It is important for rheumatologists to<br />

understand what stimuli induce autophagy, how to identify cells<br />

dying by autophagy the interactions between toll-like receptor<br />

stimulation and autophagy that impacts inflammation.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine how the morphology <strong>of</strong> autophagy differs from<br />

apoptosis and necrosis<br />

• describe under what circumstances cells die by autophagy<br />

• discuss the pathophysiological implications <strong>of</strong> autophagy<br />

are and how this form <strong>of</strong> death may impact rheumatologic<br />

diseases<br />

B402<br />

Kinases as Therapeutic Targets R<br />

Moderator: Gary S. Firestein, MD; University California - San<br />

Diego School <strong>of</strong> Medicine; La Jolla, CA<br />

Speaker: John J. O’Shea, MD; NIAMS/NIH; Bethesda, MD<br />

Session Overview:<br />

Targeting kinases may be a new approach to treat various<br />

immune-mediated inflammatory diseases. Several targeted small<br />

molecules interfering with intracellular signaling pathways are<br />

under clinical development.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the therapeutic potential <strong>of</strong> targeted small molecules<br />

interfering with intracellular signaling pathway for the<br />

treatment <strong>of</strong> inflammatory disorders<br />

• define the mechanism <strong>of</strong> action <strong>of</strong> novel targeted small<br />

molecules interfering with kinases<br />

ACR/ARHP Poster Session B and<br />

Poster Tours<br />

9:00 am - 6:00 PM<br />

Halls B1 & B2<br />

Poster presenters will be available from 9:00 - 11:00 am. Poster<br />

tours will be held 9:00 - 9:45 am, 10:15 - 11:00 am and 4:30 -<br />

5:30 PM.<br />

9:00 – 11:00 am – Poster Presentations (Abstracts # 733 – 1345)<br />

Guided Poster Tours<br />

Guided poster tours provide an opportunity for scientific<br />

attendees to ask questions and gain insights from leaders in<br />

the field while earning CME credits. Morning tours will <strong>of</strong>fer<br />

insights from both poster presenters and tour guides, while<br />

afternoon tours will exclusively feature the tour guide’s expert<br />

opinion. Although there is no fee to participate, pre-registration<br />

is required and each tour is limited to 20 registered scientific<br />

attendees. If you would like to participate and have not<br />

registered you can check tour availability and request a ticket<br />

in the registration area, located in the International Boulevard<br />

Foyer. If you registered in advance <strong>of</strong> the meeting your ticket was<br />

included with your meeting materials. Once you have your ticket,<br />

plan to collect your headset and meet your group 10 minutes<br />

before your tour departs from the entrance <strong>of</strong> the poster hall,<br />

located in Halls B1 & B2.<br />

Headsets: Each tour participant will receive a wireless headset.<br />

Participants who do not return their headsets within 10 minutes<br />

after the tour has ended will incur a fee.<br />

9:00 - 9:45 am<br />

Quality <strong>of</strong> Life<br />

Jennifer M. Hootman, PhD, Centers for Disease Control,<br />

Kennesaw, GA<br />

Physical Activity/Exercise<br />

Mary E. Christenson, Pt, PhD, Regis University, Westminster, CO<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorder<br />

Don L. Goldenberg, MD; Newton-Wellesley Hospital; Newton,<br />

MA<br />

tuesday<br />

2010 Program Book 59


Rheumatoid Arthritis: Clinical Aspects<br />

Deborah P. Symmons, MD; Arthritis Research UK Epidemiology<br />

Unit; Manchester, United Kingdom<br />

Rheumatoid Arthritis Treatment: Small Molecules, Biologic and<br />

Gene Therapy<br />

Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany<br />

Systemic Lupus Erythematosus: Clinical Aspects<br />

Eliza Chakravarty, MD; Stanford University; Mountain View, CA<br />

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s:<br />

Clinical Aspects and Therapeutics<br />

Maureen D. Mayes, MD, MPH; University <strong>of</strong> Texas-Houston;<br />

Houston, TX<br />

Exhibits and Replay Café<br />

9:00 am - 7:00 pm<br />

Halls A1 & A2<br />

Exhibits<br />

Halls A1 & A2 (Booth #123)<br />

Replay Café<br />

Exhibit Hall Morning SnACk Break<br />

9:00 - 10:00 AM<br />

Halls A1 & A2<br />

tuesday<br />

10:15 - 11:00 am<br />

Behavioral Science<br />

Susan J. Bartlett, PhD, McGill University, Montreal, Canada<br />

Pain<br />

Carol L. Baird, DNS, ARPN, BC, Indiana University, Indianapolis,<br />

IN<br />

Muscle Biology, Myositis and Myophathies<br />

Frederick W. Miller, MD, PhD; National Institute <strong>of</strong><br />

Environmental Health Sciences, NIH, Kennsington, MD<br />

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and<br />

Pathogenesis<br />

Nancy E. Lane, MD; University <strong>of</strong> California-Davis, Hillsborough,<br />

CA<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Larry W. Moreland, MD; University <strong>of</strong> Pittsburgh Medical Center;<br />

Pittsburgh, PA<br />

Rheumatoid Arthritis Treatment: Small Molecules, Biologic and<br />

Gene Therapy<br />

Eric M. Ruderman, MD; Northwestern University School;<br />

Chicago, IL<br />

Systemic Lupus Erythematosus: Human Etiology and<br />

Pathogenesis<br />

Mary K. Crow, MD; Hospital for Special Surgery; New York, NY<br />

4:30 - 5:30 PM<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorder<br />

Daniel J. Clauw, MD; University <strong>of</strong> Michigan Chronic Pain &<br />

Fatigue Research; Ann Arbor, MI<br />

Osteoarthritis - Clinical Aspects<br />

Timothy E. McAlindon, MD, MPH; Tufts Medical Center, Boston,<br />

MA<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Jonathan Kay, MD; UMass Memorial Medical Center; Worcester,<br />

MA<br />

Vasculitis<br />

Alexandra Villa-Forte, MD, MPH; Cleveland Clinic Foundation;<br />

Cleveland, OH<br />

Poster Hall Morning SnACk Break<br />

9:00 - 10:30 am<br />

Halls B1 & B2<br />

ARHP Concurrent Abstract Session<br />

9:15 - 10:15 am<br />

B311<br />

Physical and Psychosocial Challenges in Scleroderma<br />

Moderator: Jane S. Brandenstein, BS, PT; Freedom, PA<br />

9:15 am<br />

1346. Frequency and Impact <strong>of</strong> Symptoms Experienced by<br />

Patients with Systemic Sclerosis: Results from a Canadian<br />

National Survey.<br />

Marielle Bassel 1 , Marie Hudson 3 , Suzanne S. Taillefer 4 , Orit<br />

Schieir 1 , Murray Baron 1 and Brett D. Thombs 2 , 1 Jewish General<br />

Hospital, Montreal, QC, Canada, 2 McGill University, Montreal,<br />

QC, Canada, 3 McGill University and Jewish General Hospital,<br />

4<br />

SMBD Jewish General Hospital, Montreal, QC, Canada<br />

9:30 am<br />

1347. Sociodemographic and Disease Correlates <strong>of</strong> Body Image<br />

in Systemic Sclerosis (SSc).<br />

Lisa R. Jewett 2 , Marie Hudson 3 , Murray Baron 1 , Brett D. Thombs 2<br />

and Canadian Scleroderma Research Group (CSRG), 1 Jewish<br />

General Hospital, Montreal, QC, Canada, 2 McGill University,<br />

Montreal, QC, Canada, 3 McGill University and Jewish General<br />

Hospital<br />

9:45 am<br />

1348. Development and Validation <strong>of</strong> the Brief-Satisfaction<br />

with Appearance Scale (Brief-SWAP) for Measuring Body Image<br />

in Systemic Sclerosis (SSc).<br />

Lisa R. Jewett 4 , Marie Hudson 5 , Jennifer A. Haythornthwaite 3 ,<br />

Leslie Heinberg 1 , Fredrick M. Wigley 3 , Murray Baron 2 , Brett D.<br />

Thombs 4 and Canadian Scleroderma Research Group (CSRG),<br />

1<br />

Cleveland Clinic Lerner <strong>College</strong> <strong>of</strong> Medicine <strong>of</strong> Case Western<br />

Reserve University, 2 Jewish General Hospital, Montreal, QC,<br />

Canada, 3 Johns Hopkins University School <strong>of</strong> Medicine, 4 McGill<br />

University, Montreal, QC, Canada, 5 McGill University and Jewish<br />

General Hospital<br />

60<br />

2010 Program Book


10:00 am<br />

1349. Work as a Daily Challenge: Working with Scleroderma.<br />

Cindy F. Mendelson 2 , Janet L. Poole 3 and Saralynn H. Allaire 1 ,<br />

1<br />

Boston Univ School <strong>of</strong> Medicine, Boston, MA, 2 Univ <strong>of</strong><br />

New Mexico, Albuquerque, NM, 3 University <strong>of</strong> New Mexico,<br />

Albuquerque, NM<br />

ARHP Concurrent Sessions<br />

9:15 - 10:15 am<br />

B309<br />

Daltroy Memorial Lecture: Adherence to Medical<br />

Regimens for Rheumatic Diseases and the Importance<br />

<strong>of</strong> Patient-Clinician Communication P/C PS<br />

Moderator: Maura D. Iversen, PT, DPT, SD, MPH; Northeastern<br />

University; Boston, MA<br />

Speaker: Michael A. Rap<strong>of</strong>f, PhD; University <strong>of</strong> Kansas<br />

Medical Center; Kansas City, KS<br />

Session Overview:<br />

Good patient-clinician communication is critical for optimal<br />

medical management and treatment outcomes for patients<br />

with rheumatic diseases. However, a clinician must be prepared<br />

to try various communication methods or techniques in order<br />

to attain good mutual understanding <strong>of</strong> the patient’s condition<br />

and treatment. This puts the patient at ease and allows for a<br />

better dialogue between the clinician and patient about the<br />

patient’s medical management. Clinicians who are successful<br />

communicators will enhance their patients’ adherence to the<br />

prescribed medical regimen.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the types and prevalence <strong>of</strong> adherence problems to<br />

medical regimens for rheumatic diseases<br />

• contrast the strengths and weaknesses <strong>of</strong> different methods<br />

for assessing adherence<br />

• document the importance <strong>of</strong> patient-clinician communication<br />

in enhancing adherence to medical regimens for rheumatic<br />

diseases<br />

B308<br />

Living with Osteoporosis cP PM<br />

Moderator: Janet S. Austin, PhD; NIAMS/NIH/DHHS; Bethesda,<br />

MD<br />

Speaker: Judith R. Gale, MPH, DPT, PT; Creighton University;<br />

Omaha, NE<br />

Session Overview:<br />

According to the National Osteoporosis Foundation,<br />

osteoporosis is the most common bone disease. There are an<br />

estimated 10 million people in the US with osteoporosis and an<br />

additional 34 million with osteopenia. Fifty percent <strong>of</strong> Caucasian<br />

women and 20 percent <strong>of</strong> men will experience a fracture related<br />

to osteoporosis, possibly leading to chronic pain, disability or<br />

death. The health care cost <strong>of</strong> these fractures was estimated at<br />

$17 billion in 2005.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the risk factors associated with osteoporosis<br />

• identify the clinical presentation <strong>of</strong> osteoporosis<br />

• describe the functional limitations related to this disease<br />

• discuss the management <strong>of</strong> osteoporosis<br />

B313<br />

Rheumatic Disease Update: Viral Arthritis c/r<br />

Moderator: Karen Huisinga, MN, ARNP, FNP; VA Puget Sound<br />

HCS; Bainbridge Island, WA<br />

Speaker: Leonard H. Calabrese, DO; Cleveland Clinic Foundation;<br />

Cleveland, OH<br />

Session Overview:<br />

Arthritis and arthralgias are well recognized and relatively<br />

common symptoms <strong>of</strong> viral infections. The most common viruses<br />

causing arthritis/arthralgias are parvovirus B-19, hepatitis B,<br />

hepatitis C, rubella, and the human immunodeficiency virus.<br />

Health care providers need a reappraisal <strong>of</strong> the diagnosis and<br />

advances in treatment <strong>of</strong> these diseases<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the common presentations <strong>of</strong> the human<br />

immunodeficiency virus related musculoskeletal syndrome<br />

• discuss the treatment options <strong>of</strong> hepatitis C arthritis<br />

• define the pathophysiology <strong>of</strong> hepatitis B and C related<br />

arthritis<br />

InnoVAtion Theater<br />

10:00 - 10:45 am<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Genentech and Biogen Idec.<br />

Please visit the Genentechand Biogen Idec exhibit booth for more<br />

information or see page 292. Seating and light refreshments are<br />

subject to availability.<br />

Bridging the Gap: A Peer-led Discussion on Effective<br />

Physician/Patient Dialogue<br />

ACR Workshops<br />

10:30 - 12:30 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B201<br />

Creating Presentations Using PowerPoint: Advanced<br />

(219)<br />

Speaker: Steve W. Blevins, MBA; <strong>American</strong> <strong>College</strong> <strong>of</strong><br />

<strong>Rheumatology</strong>; Atlanta, GA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• demonstrate advanced slide transition techniques<br />

• integrate audio, video and narration into slides<br />

• create presentations that can be published on a local Web site<br />

and be viewed in a browser<br />

B203<br />

Musculoskeletal Ultrasound (220) f<br />

Speaker: Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

2010 Program Book 61<br />

tuesday


tuesday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the indications for ultrasound in rheumatic diseases<br />

• discuss the techniques <strong>of</strong> ultrasonography<br />

• identify normal and abnormal anatomical structures by<br />

ultrasound imaging<br />

B204<br />

Osteoporosis: Interpreting Dual Energy X-ray<br />

Absorptiometry and Clinical Risk Factors: The New<br />

Fracture Risk Assessment Algorithm (221) PS<br />

Speaker: Stuart L. Silverman, MD; Cedars-Sinai Medical Center,<br />

University <strong>of</strong> California-Los Angeles; Beverly Hills, CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine how to combine bone mineral density and clinical<br />

risk factors in determination <strong>of</strong> absolute risk<br />

• discuss the concept <strong>of</strong> intervention threshold used in National<br />

Osteoporosis Foundation guidelines<br />

• review International Society for Clinical Densitometry<br />

guidelines for DXA interpretation<br />

• create a report for bone densitometry results<br />

B206<br />

Peripheral Magnetic Resonance Imaging in Clinical<br />

<strong>Rheumatology</strong> (222)<br />

Speakers: Ewa Olech, MD; Oklahoma Medical Research<br />

Foundation; Oklahoma City, OK<br />

Orrin M. Troum, MD; University <strong>of</strong> Southern California, Keck<br />

School <strong>of</strong> Medicine; Santa Monica, CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />

the outpatient setting<br />

• review the merits and pitfalls <strong>of</strong> this technology<br />

findings, clinicians and public health practitioners have been<br />

recommending participation in exercise programs for people<br />

with arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the health-related benefits <strong>of</strong> physical activity<br />

programs for people with arthritis<br />

• describe the evidence that supports the value <strong>of</strong> physical<br />

activity programs for people with arthritis<br />

• identify challenges and rewards in working with communities<br />

to conduct physical activity intervention trials<br />

• define the need for ongoing physical activity opportunities<br />

and choices for people with arthritis<br />

• discuss recommendations for forming and using community<br />

partnerships to disseminate physical activity interventions<br />

ACR Clinical Symposium<br />

11:00 am - 12:30 PM<br />

Hall A3<br />

Curbside Consults - Ask the Pr<strong>of</strong>essors<br />

cP PM PS ARS<br />

Moderator: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

11:00 am<br />

Vasculitis<br />

John H. Stone, MD, MPH; Massachusetts General Hospital;<br />

Sudbury, MA<br />

11:30 am<br />

Osteoporosis<br />

Kenneth G. Saag, MD, MSc; University <strong>of</strong> Alabama-Birmingham;<br />

Birmingham, AL<br />

ARHP General Session II<br />

10:45 - 11:45 am<br />

B313<br />

ARHP Distinguished Lecturer c/r PS<br />

Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />

Albuquerque, NM<br />

Speaker: Leigh F. Callahan, PhD; University <strong>of</strong> North<br />

Carolina; Chapel Hill, NC<br />

Session Overview:<br />

Numerous studies have shown that engaging in physical<br />

activity is beneficial for people with arthritis and physical<br />

activity programs have been developed specifically for people<br />

with arthritis. However, less than 1 percent <strong>of</strong> <strong>American</strong>s with<br />

arthritis have enrolled in or participated in these programs.<br />

Although persons with arthritis tend to be less fit than their<br />

peers without this condition, studies have demonstrated that<br />

persons with arthritis can safely participate in appropriate<br />

exercise programs to improve their cardiovascular fitness,<br />

muscular strength, psychosocial status, and functional status.<br />

The surgeon general’s report on physical activity and health<br />

indicated that exercise programs <strong>of</strong> moderate intensity<br />

are effective in individuals with rheumatoid arthritis or<br />

osteoarthritis. On the basis <strong>of</strong> this report and other research<br />

12:00 PM<br />

Rheumatic Therapeutics<br />

Iain B. McInnes, PhD; University <strong>of</strong> Glasgow; Glasgow, United<br />

Kingdom<br />

Session Overview:<br />

This session focuses on discussing difficult management<br />

decisions that must be made in the absence <strong>of</strong> strong data.<br />

Approaches are discussed that employ the synthesis <strong>of</strong><br />

published evidence and clinical experience. The topics were<br />

chosen following discussion with clinicians practicing in different<br />

environments, and input was solicited from the Annual Meeting<br />

Planning Committee members and the ACR membership, asking<br />

for suggestion <strong>of</strong> specific topics or case vignettes that pose<br />

particularly difficult treatment decision. Attendees will compare<br />

their personal management approaches regarding selected<br />

clinical problems with those <strong>of</strong> academic expert consultants and<br />

other clinicians in the audience.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• compare their personal management approaches to selected<br />

clinical problems with those <strong>of</strong> the presenters<br />

• develop an approach to treating patients experiencing<br />

relapses in giant cell arteritis or Wegener’s granulomatosis<br />

• describe therapeutic choices in patients with persistent pain<br />

following vertebral compression fractures<br />

• discuss alternative options in patients with anti-TNF therapy<br />

exacerbated psoriasis<br />

62<br />

2010 Program Book


ACR Plenary Session II: Discovery<br />

2010 c/r<br />

11:00 am - 12:30 PM<br />

Thomas J. Murphy Ballroom<br />

Moderators: Joel A. Block, MD; Rush University Medical Center;<br />

Chicago, IL<br />

Richard A. Furie, MD; North Shore Long Island Jewish Health<br />

System; Lake Success, NY<br />

11:00 am<br />

1350. Suppression <strong>of</strong> Collagen-Induced Arthritis in Mice by<br />

Anti-CD19 Antibody That Co-Engages BCR and Inhibitory<br />

Receptor FcγRIIb: Efficacy Does Not Require B Cell Depletion.<br />

Saso Cemerski 1 , Seung Y. Chu 2 , Erik Pong 2 , Holly M. Horton 2 , John<br />

R. Desjarlais 2 and David E. Szymkowski 1 , 1 Xencor, Inc., Monrovia,<br />

CA, 2 Xencor, Inc.<br />

11:15 am<br />

1351. Micro RNA 155 Deficiency Protects from the<br />

Development <strong>of</strong> Inflammatory Arthritis.<br />

Stephan Blüml 1 , Michael Bonelli 2 , Birgit Niederreiter 1 , Antonia<br />

Puchner 1 , Georg Mayr 1 , Marije Koenders 3 , Smolen Josef 1 and<br />

Redlich Kurt 1 , 1 Medical University Vienna, Austria, 2 Medical<br />

University Vienna, Austria 3 Radboud University Nijmegen<br />

Medical Center, Nijmegen, The Netherlands<br />

11:30 am<br />

1352. Down-Regulated MicroRNA-152 Induces Aberrant DNA<br />

Methylation in Scleroderma Endothelial Cells by Targeting DNA<br />

Methyltransferase 1.<br />

Yongqing Wang, Omar R. Kahaly and Bashar Kahaleh, University<br />

<strong>of</strong> Toledo, Toledo, OH<br />

11:45 am<br />

1353. SNAPIN: A Novel Endogenous TLR Ligand in Rheumatoid<br />

Arthritis.<br />

Bo Shi 3 , Qiquan Huang 3 , Margriet J. Vervoordeldonk 1 , Paul P. Tak 2<br />

and Richard M. Pope 4 , 1 Academic Medical Center, University <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />

Center, University <strong>of</strong> Amsterdam, 3 Northwestern University,<br />

Chicago, IL, 4 Northwestern University<br />

12:00 PM<br />

1354. TLR9 Induced Macrophage Activation Syndrome Is Driven<br />

by IFNγ Produced by Lymphocytes and Natural Killer Cells but Is<br />

Dampened by Lymphocyte Produced IL-10.<br />

Edward M. Behrens 2 , Katharine Slade 3 , Sheila Rao 3 , Portia A.<br />

Kreiger 1 , Michele Paessler 3 , Taku Kambayashi 5 and Gary A.<br />

Koretzky 4 , 1 A.I. DuPont Hospital for Children, 2 Childrens Hospital<br />

<strong>of</strong> Phil, Philadelphia, PA, 3 The Children’s Hospital <strong>of</strong> Philadelphia,<br />

4<br />

University <strong>of</strong> Pennsylvania, Philadelphia, PA, 5 University <strong>of</strong><br />

Pennsylvania<br />

12:15 PM<br />

1355. Genome-Wide Association Study <strong>of</strong> Ankylosing<br />

Spondylitis Identifies New Loci, a Tag SNP for HLA-B27, and an<br />

Interaction between HLA-B27 and Variants in ERAP1.<br />

Matthew A. Brown, on Behalf <strong>of</strong> the Wellcome Trust<br />

Case-Control Consortium 2 and Australo-Anglo-<strong>American</strong><br />

Spondyloarthritis Consortium, The University <strong>of</strong> Queensland<br />

Diamantina Institute, Brisbane, Queensland, Australia<br />

ARHP Special Session<br />

12:15 - 2:00 PM<br />

Omni Hotel – International Ballroom DEF<br />

Sit down with your colleagues, enjoy a light lunch and participate<br />

in an open discussion on various pre-selected research, practice<br />

and clinical topics. Each roundtable discussion will be facilitated<br />

by a rheumatology expert. All ARHP attendees are welcome.<br />

ARHP Networking at Noon<br />

The ARHP thanks Genentech, A Member <strong>of</strong> the Roche Group, for<br />

supporting Networking at Noon.<br />

ARHP Business Meeting<br />

Speaker: Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute<br />

<strong>of</strong> Chicago; Chicago, IL<br />

Inaguration <strong>of</strong> 41 st ARHP President<br />

Nadine T. James, RN, MSN, PhD; William Carey University;<br />

Hattiesburg, MS<br />

Table Topics: This is a tentative listing <strong>of</strong> topics and facilitators<br />

are subject to change.<br />

Adult Form Sharing<br />

Jane M. Denay, BSN, MSN, CFNP; Harbor Arthritis Center;<br />

Petoskey, MI<br />

Advanced Practice Roles in Physical Therapy<br />

Karen Huisinga, MN, ARNP, FNP; VA Puget Sound HCS;<br />

Bainbridge Island, WA<br />

Leslie J. Soever, BSc, PT, MSc; Mount Sinai Hospital; Toronto, ON,<br />

Canada<br />

Advocacy and Access to Care<br />

Deborah A. McCloskey, RN, BSN; University <strong>of</strong> Medicine and<br />

Dentistry <strong>of</strong> New Jersey, Robert Wood Johnson Medical School;<br />

New Brunswick, NJ<br />

Ankylosing Spondylitis<br />

Lori C. Guthrie, RN-C, BSN; DHHS/NIH/NIAMS; Bethesda, MD<br />

ARHP Grant/Award Opportunities<br />

Mary E. Christenson, PT, PhD; Regis University; Westminster, CO<br />

Arthritis and Employment<br />

Kristina A. Theis, MPH; Centers for Disease Control and<br />

Prevention; Atlanta, GA<br />

Clinical Research Coordinators<br />

Donah Z. Crawford, BS, MA; The Arthritis Group; Philadelphia, PA<br />

Lisa M. Kastanek, RN, CCRC; Physician Research Collaboration;<br />

Lincoln, NE<br />

Community-based Physical Activity Programs: What Data to<br />

Collect and Why<br />

Dina L. Jones, PhD, PT; West Virginia University; Morgantown,<br />

WV<br />

Diversity/Cultural Issues<br />

Jillian A. Rose; Hospital for Special Surgery; New York, NY<br />

Enhancing Patient Adherence<br />

Michael A. Rap<strong>of</strong>f, PhD; University <strong>of</strong> Kansas Medical Center;<br />

Kansas City, KS<br />

Epidemiology/Public Health<br />

Jennifer M. Hootman, PhD; Centers for Disease Control;<br />

Kennesaw, GA<br />

tuesday<br />

2010 Program Book 63


tuesday<br />

Forms Exchange for Those New to <strong>Rheumatology</strong><br />

Annelle B. Reed, MSN, CRNP; Children’s Hospital <strong>of</strong> Alabama;<br />

Birmingham, AL<br />

Georgia Health Pr<strong>of</strong>essionals<br />

Joyce P. Carlone, MN, RN, FNP-BC, Emory University, Atlanta, GA<br />

Hip and Knee Arthroplasty: Patient Discharge Instructions<br />

Victoria Gall, PT, MEd; Partners Healthcare; Hyde Park, MA<br />

Infusion and Injectable Therapies<br />

Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />

Angeles, CA<br />

International Nursing Developments<br />

Susan M. Oliver, RN MSc; Pennine Musculoskeletal Partnership;<br />

Oldham, United Kingdom<br />

Patricia J. Cornell, BSc; Poole Hospital; Poole Dorset, United<br />

Kingdom<br />

Measurements <strong>of</strong> Physical Activity<br />

Elizabeth A. Schlenk, PhD, RN; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

Susan L. Murphy, ScD, OTR; University <strong>of</strong> Michigan; Ann Arbor,<br />

MI<br />

Medications for Rheumatic Diseases<br />

Kamala M. Nola, PharmD, MS; Lipscomb <strong>College</strong> <strong>of</strong> Pharmacy;<br />

Nashville, TN<br />

Nurse Practioner Issues<br />

Christine A. Stamatos;Private Practice; Babylon, NY<br />

Nurse Practioner Issues - Pediatrics<br />

Karen L. Kerr, MSN NP CPNP PNP; Children’s Hospital <strong>of</strong><br />

Michigan; Detroit, MI<br />

Office Manager/Practice Administrator<br />

Stacey Busch, RN, BSN, MA; Family Arthritis Center; Jupiter, FL<br />

Office Nurse<br />

Lee A. Anderson, BSN; University <strong>of</strong> Minnesota Physicians;<br />

Champlin, MN<br />

Physician Assistant Issues<br />

Barbara A. Slusher, PA-C, MSW; League City, TX<br />

Pain Management<br />

Gail C. Davis, RN, EdD; Texas Woman’s University; Denton, TX<br />

Pediatrics<br />

Bernadette McNally, MS, PAC; University <strong>of</strong> Utah; Salt Lake City,<br />

UT<br />

Qualitative Research<br />

Laura Robbins; Hospital for Special Surgery; New York, NY<br />

Regional <strong>Rheumatology</strong> Network for NPs and PAs<br />

Susan L. Williams Judge; Seattle <strong>Rheumatology</strong> Associate;<br />

Seattle, WA<br />

Research Mentoring<br />

Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard<br />

Medical School; Boston, MA<br />

Technology/Internet/Web Applications<br />

Laura E. Ray, MA, MLS; Cleveland State University; Cleveland, OH<br />

Volunteering/Mentoring ARHP<br />

Pamela J. Degotardi, PhD; Queens <strong>College</strong> City University <strong>of</strong> New<br />

York Honors; Flushing, NY<br />

InnoVAtion Theater<br />

12:15 - 1:00 PM<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Lilly USA, LLC. Please visit the<br />

Lilly USA, LLC exhibit booth for more information or see page<br />

292. Seating and boxed lunches are subject to availability.<br />

Pathophysiology <strong>of</strong> Pain: Mechanisms and<br />

Manifestations<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

12:45 - 2:15 PM<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Basic Immunology for Clinical Rheumatologists (041)<br />

f<br />

Speaker: David M. Lee, MD, PhD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe how the immune system functions in normal<br />

individuals<br />

• identify abnormalities <strong>of</strong> immune regulation that lead to<br />

autoimmunity<br />

B208<br />

Crystal: Pseudogout (042)<br />

Speaker: Geraldine M. McCarthy, MD; Mater Misericordiae<br />

University Hospital; Dublin, Ireland<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the pathophysiology <strong>of</strong> calcium pyrophosphate disease<br />

• describe disease associations with calcium pyrophosphate<br />

dihydrate<br />

• identify agents used for the treatment <strong>of</strong> pseudogout<br />

B209<br />

Osteoporosis: Applying FRAX Methodology (043)<br />

Speaker: Thomas P. Olenginski, MD; Geisinger Medical Center;<br />

Danville, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• appreciate the fracture risk assessment tool model <strong>of</strong><br />

estimating absolute 10 year fracture probabilities<br />

• apply fracture risk assessment tool relative to new National<br />

Osteoporosis Foundation clinician guidelines for osteoporosis<br />

care<br />

• realize the ‘limitations’ <strong>of</strong> the fracture risk assessment tool<br />

model<br />

• integrate fracture risk assessment tool into dual energy X-ray<br />

absorptiometry reporting and clinical care<br />

64<br />

2010 Program Book


B210<br />

B301<br />

Pediatrics: Periodic Fevers in Children (044) P<br />

Speaker: Polly J. Ferguson, MD; University <strong>of</strong> Iowa Carver <strong>College</strong><br />

<strong>of</strong> Medicine; Iowa City, IA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the differential diagnosis and expanding spectrum <strong>of</strong><br />

these syndromes<br />

• relate the pathogenesis <strong>of</strong> these syndromes to knowledge <strong>of</strong><br />

the various gene functions<br />

• discuss the treatment rationale based on the pathogenesis<br />

and to expand on practical issues in the management <strong>of</strong> these<br />

patients<br />

Psoriatic Arthritis (045)<br />

Speaker: John D. Reveille, MD; University Texas Health Science<br />

Center; Houston, TX<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the molecular basis for the pathogenesis <strong>of</strong> psoriatic<br />

arthritis<br />

• discuss the recent advances in the treatment <strong>of</strong> patients with<br />

psoriatic arthritis<br />

B302<br />

Pulmonary Manifestations <strong>of</strong> Rheumatic Disease (046)<br />

Speaker: Paul F. Dellaripa, MD; Brigham and Women’s Hospital;<br />

Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify emerging concepts regarding the pathophysiology <strong>of</strong><br />

inflammation and fibrosis in autoimmune lung disease<br />

• determine the appropriate use <strong>of</strong> diagnostic tests in<br />

the evaluation <strong>of</strong> patients with rheumatic disorders and<br />

autoimmune lung disease<br />

• discuss the limits <strong>of</strong> traditional therapeutic options and<br />

possible emerging therapies in managing autoimmune lung<br />

disease<br />

B303<br />

Raynaud’s and Digital Ischemia (047)<br />

Speaker: Janet E. Pope, MD, MPH; St. Joseph Health Care<br />

London; London, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the pathogenesis<br />

• describe the appropriate diagnostic evaluation for this<br />

condition<br />

• review treatment options and means <strong>of</strong> evaluating treatment<br />

B304<br />

Rheumatoid Arthritis: Safety <strong>of</strong> Novel Therapies (048)<br />

PS<br />

Speaker: Daniel H. Solomon, MD, MPH; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the management <strong>of</strong> patients with refractory<br />

rheumatoid arthritis<br />

• identify novel treatment options for those failing conventional<br />

therapies<br />

B305<br />

Scleroderma Mimics (049)<br />

Speaker: Alan G. Tyndall, MD; University <strong>of</strong> Basel; Basel,<br />

Switzerland<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• create a differential diagnosis for conditions simulating<br />

scleroderma<br />

• formulate strategies to distinguish these various conditions<br />

• discuss why these various conditions may have similar<br />

manifestations<br />

B306<br />

Vasculitis: Update (050)<br />

Speaker: Peter A. Merkel, MD, MPH; Boston University School <strong>of</strong><br />

Medicine; West Newton, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the classification <strong>of</strong> vasculitis according to affected<br />

vessel size<br />

• utilize the various available laboratory tests, with emphasis on<br />

anti-neutrophilic cytoplasmic antibodies testing<br />

• identify current and novel therapeutic modalities<br />

ACR Special Session<br />

12:45 - 2:15 PM<br />

A410<br />

Contract Negotiations for Physicians BR f PS<br />

Moderator: Seth M. Berney, MD; Louisana State University;<br />

Shreveport, LA<br />

12:45 PM<br />

Contract Negotiations for Academics: How to Optimize Your<br />

Industrial Letter <strong>of</strong> Offer/Contract<br />

Robert Ortmann, MD, University <strong>of</strong> Arkansas; Fayetteville, AK<br />

1:05 PM<br />

Contract Negotiations for Industry: How to Optimize Your<br />

Industrial Letter <strong>of</strong> Offer/Contract<br />

Gregory J. Dennis, MD; Potomac, MD<br />

1:25 PM<br />

Contract Negotiations for Private Practice: How to Identify a<br />

Fair Private Practice or Hospital Practice Contract and How<br />

to Successfully Modify It to Correspond with Their Individual<br />

Needs<br />

Herbert Baraf, MD; Arthritis & Rheumatism Association;<br />

Wheaton, MD<br />

1:50 PM<br />

Contract Negotiations and the Legal Ramifications <strong>of</strong> the<br />

Contract: How to Optimize the Contract and Protect Yourself<br />

Joan M. Roediger, JD, LLM; Obermayer, Rebmann, Maxwell &<br />

Hippel LLP; Philadelphia, PA<br />

Session Overview:<br />

It is widely believed that physicians are not the ideal<br />

businesspeople for several years after the completion <strong>of</strong> their<br />

training because most internal medicine and rheumatology<br />

postgraduate programs do not prepare their fellows for the<br />

business <strong>of</strong> medicine. As physicians, we are expected to behave<br />

tuesday<br />

2010 Program Book 65


tuesday<br />

honorably and pr<strong>of</strong>essionally and frequently assume that all<br />

contracts and letters <strong>of</strong> employment will contain everything<br />

that we want and need. As a result, we do not realize that the<br />

responsibilities and expectations <strong>of</strong> the employee and employer<br />

are different. The employer’s priority is the financial stability <strong>of</strong><br />

the institution (practice, hospital, medical school or company). In<br />

order to create the best working relationship, the expectations<br />

and needs <strong>of</strong> both parties must be clearly and legally stated<br />

resulting in the final contract. However, because physicians are<br />

relatively untrained in contract negotiation, they frequently<br />

do not anticipate the implications <strong>of</strong> their actions or inactions,<br />

resulting in a suboptimal agreement. This session, is designed<br />

to educate fellows and post-fellowship rheumatologists on the<br />

practical and legal aspects <strong>of</strong> negotiating contacts and letters <strong>of</strong><br />

<strong>of</strong>fer with private practices, academic institutions and industry.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• explain the value <strong>of</strong> legal advice prior to signing a contract and<br />

the legal ramifications <strong>of</strong> the contract<br />

• identify a fair private practice or hospital practice contract<br />

and how to successfully modify it to correspond with their<br />

individual needs<br />

• negotiate a fair academic or industrial letter <strong>of</strong> <strong>of</strong>fer/contract<br />

ACR Clinical Symposium<br />

1:00 - 2:00 PM<br />

Thomas J. Murphy Ballroom<br />

The Brain and Systemic Lupus Erythematosus: 2010<br />

Update cP P/C PM PS<br />

Moderator: F. Jorge Sanchez-Guerrero, MD; Instituto Nacional<br />

Nutricion; Mexico City, DF, Mexico<br />

Speaker: John G. Hanly, MD; Queen Elizabeth II Health Services<br />

Center; Halifax, NS, Canada<br />

Session Overview:<br />

Patients with neuropsychiatric lupus are a diagnostic and<br />

therapeutic challenge for the practicing rheumatologist. The<br />

major challenges include: identifying the range <strong>of</strong> manifestations<br />

that are seen in neuropsychiatric lupus; making the accurate<br />

attribution (e.g., related to lupus, medications, comorbid<br />

conditions; and choosing the most appropriate therapeutic<br />

options. This review will focus on all aspects <strong>of</strong> neuropsychiatric<br />

lupus from diagnosis, to management.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• explain the clinical diversity <strong>of</strong> neuropsychiatric events in<br />

systemic lupus erythematosus<br />

• identify attribution <strong>of</strong> neuropsychiatric events and their<br />

impact on quality <strong>of</strong> life<br />

• describe the immunopathogenesis <strong>of</strong> primary<br />

neuropsychiatric lupus<br />

• explain therapeutic options for patients with neuropsychiatric<br />

lupus<br />

ACR Practice Issues<br />

1:00 - 2:00 PM<br />

A402<br />

Recovery Audit Contractor vs. Comprehensive Error<br />

Rate Testing Audits – Do You Know the Difference?<br />

BR C PS<br />

Moderator: Cynthia A. Weaver, MD; Rapid City Medical Center;<br />

Rapid City, SD<br />

1:00 PM<br />

Recovery Audit Contractor<br />

To be announced<br />

1:30 PM<br />

Comprehensive Error Rate Testing Audits<br />

James Cope, MD; AdvanceMed; Richmond, VA<br />

Session Overview:<br />

In an era <strong>of</strong> uncertainty for health care, rheumatologists are<br />

faced with working harder to increase compliance with complex<br />

Medicare rules. Most physician practices will need to process<br />

re-design to understand and prevent significant recoupment<br />

<strong>of</strong> payments deemed incorrect by Medicare. The Centers for<br />

Medicare and Medicaid Services increased scrutiny over all types<br />

<strong>of</strong> claims in an effort to reduce the payment error rate submitted<br />

for reimbursement. Their action plan delegated responsibility<br />

to several contractors, mainly through the Recovery Audit<br />

Contractors and Comprehensive Error Rate Testing, to identify<br />

and return improper payments to the Medicare Beneficiary<br />

Trust Fund. Since 2005, Centers for Medicare and Medicaid<br />

Services has collected nearly $440 million in improper<br />

Medicare payments through the Recovery Audit Contractors<br />

demonstration program.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify how and why the Recovery Audit Contractor or<br />

Comprehensive Error Rate Testing target sample claims for<br />

review<br />

• discuss how to effectively track medical necessity and coding<br />

errors<br />

• develop a system for appropriate corrective action as<br />

warranted to lower the error rate and improve the accuracy in<br />

billing, processing, and payment <strong>of</strong> Medicare claims<br />

ACR Special Session<br />

1:00 - 2:00 PM<br />

A406<br />

Clinical Teaching Strategies in the Outpatient Clinic<br />

Setting Ed.<br />

Moderator: Abby Goulder Abelson, MD; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Speaker: Terry M. Wolpaw, MD, MHPE; Case Western School <strong>of</strong><br />

Medicine; Cleveland, OH<br />

66<br />

2010 Program Book


Session Overview:<br />

As a clinical educator, it is important to consider the<br />

development <strong>of</strong> time efficient teaching methods in the<br />

clinical setting that provide insights into the students’ clinical<br />

reasoning strategies and uncertainties while remaining fully<br />

engaged in the priorities <strong>of</strong> patient care. This need spans both<br />

the outpatient and inpatient settings. It also spans the range<br />

<strong>of</strong> learners from first through fourth year medical students.<br />

This session will highlight the learner-centered model for<br />

case presentations, which depends mostly on students for its<br />

successful implementation, and follows a six step mnemonic<br />

called SNAPPS.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• demonstrate the SNAPPS case presentation technique to<br />

learners<br />

• implement learner-driven educational techniques in a clinical<br />

setting<br />

• realize the importance <strong>of</strong> expressing diagnostic reasoning<br />

and case-related uncertainties as part <strong>of</strong> developing clinical<br />

expertise<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

1:00 - 2:00 PM<br />

Sidney J. Marcus Auditorium<br />

Scleroderma: The Promise <strong>of</strong> Anti-fibrotic Therapies -<br />

A Translational Approach C PS<br />

Moderator: John R.P. Tesser, MD; Arizona Arthritis <strong>Rheumatology</strong><br />

Association; Paradise Valley, AZ<br />

Speaker: John Varga, MD; Northwestern University Feinberg<br />

School; Chicago, IL<br />

Session Overview:<br />

New advances in our understanding <strong>of</strong> scleroderma have<br />

elucidated underlying processes <strong>of</strong> vascular injury and aberrant<br />

wound healing. Immune activation and endothelial injury<br />

leading to overly abundant fibrosis <strong>of</strong> various tissues and organs<br />

result in the clinical manifestations <strong>of</strong> the disease. Treatment<br />

<strong>of</strong> already present fibrosis has proved to be a most difficult and<br />

<strong>of</strong>ten ineffective approach other than to control symptoms.<br />

Newer insights into the pathophysiologic mechanisms, both<br />

extracellular and intracellular, that lead to the fibrotic process<br />

<strong>of</strong>fer a new translational approach that identifies key target<br />

molecules. Therapeutic strategies that employ novel agents<br />

which affect these targets may allow for treatment intervention<br />

earlier in the disease process. Utilizing these new strategies in<br />

turn may improve our chances <strong>of</strong> clinical success.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• depict the transcriptional pr<strong>of</strong>iling that has identified potential<br />

key pathways involved in the fibrotic process<br />

• delineate the multiple extra-cellular cytokines, membrane<br />

receptors and intracellular enzyme cascades that drive fibrosis<br />

• identify available medications <strong>of</strong> different drug classes that<br />

have potential therapeutic activity to intervene in the fibrotic<br />

process, and review what evidence may be available as to<br />

their clinical therapeutic outcomes<br />

• characterize potential agents on the horizon and their<br />

mechanisms <strong>of</strong> action<br />

ACR Workshops<br />

1:15 - 3:15 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B204<br />

Diagnostic Errors in <strong>Rheumatology</strong>: Why They<br />

Happen and How We Can Avoid Them (223) PS<br />

Speakers: Joan Marie Von Feldt, MD, MS Ed; University <strong>of</strong><br />

Pennsylvania-Philadelphia, Veterans Affairs Medical Center;<br />

Philadelphia, PA<br />

Jennifer S. Myers, MD; University <strong>of</strong> Pennsylvania Hospital;<br />

Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the difference between systems errors and cognitive<br />

errors<br />

• illustrate the clinical decision making patterns <strong>of</strong> physicians<br />

• cite the most common biases that can lead to diagnostic error<br />

• develop skills in cognitive error recognition and self-reflection<br />

to reduce diagnostic errors in your practice<br />

B206<br />

Joint Simulator (224) f<br />

Speakers: Joanne Valeriano-Marcet, MD; University <strong>of</strong> South<br />

Florida; Tampa, FL<br />

Helen E. Bateman, MD; James A. Haley Veterans Affairs Hospital,<br />

University <strong>of</strong> Southern Florida; Tampa, FL<br />

Ashley G. Sterrett, MD; James A. Haley Veterans Affairs Hospital;<br />

Tampa, FL<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the anatomy relative to various joint, bursa, and<br />

tendon injections<br />

• perform and instruct others on the techniques<br />

• design a successful joint injection workshop using simulators<br />

B203<br />

Musculoskeletal Exam Skills I: General<br />

Musculoskeletal Examination Skills for Educators<br />

(225)<br />

Speakers: George V. Lawry, MD; University <strong>of</strong> California-Irvine;<br />

Mission Viejo, CA<br />

Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists;<br />

Appleton, WI<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• participate in a hands-on, skill building workshop where<br />

participants are paired together for one-on-one practice<br />

• practice the “General MS Exam”, a systematic, efficient,<br />

clinically effective examination taking 6-8 minutes<br />

• review strategies for increasing exposure <strong>of</strong> medical students,<br />

resident and fellow trainees to basic musculoskeletal physical<br />

examination skills<br />

tuesday<br />

2010 Program Book 67


B202<br />

Synovial Fluid Analysis and Crystal Identification<br />

(226)<br />

Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />

Center; Blue Bell, PA<br />

Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;<br />

Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• prepare synovial fluid samples for microscopic examination<br />

• identify various components <strong>of</strong> synovial fluid<br />

• identify crystals in synovial fluid<br />

Session Overview:<br />

Citrullination is an important post-translational protein<br />

modification, but citrullinated peptides may be the target <strong>of</strong><br />

autoantibodies in many individuals with rheumatoid arthritis.<br />

The presence <strong>of</strong> anti-cyclic citrullinated peptide antibodies in the<br />

serum is a harbinger <strong>of</strong> likely future development <strong>of</strong> rheumatoid<br />

arthritis, and <strong>of</strong>ten precedes disease onset by years.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe protein citrullination<br />

• explain the genetic susceptibility loci which may influence<br />

citrullination in rheumatoid arthritis, including the PADI4 locus<br />

• explain how abnormalities in citrullination may trigger an<br />

aberrant immune response in rheumatoid arthritis<br />

tuesday<br />

68<br />

Exhibit Hall Afternoon SnACk<br />

Break<br />

2:00 - 3:00 PM<br />

InnoVAtion Theater<br />

2:00 - 2:45 PM<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Actelion Pharmaceuticals US,<br />

Inc. Please visit the Actelion Pharmaceuticals US, Inc. exhibit<br />

booth for more information or see page 292. Seating and light<br />

refreshments are subject to availability.<br />

Clinical Perils in <strong>Rheumatology</strong>: Uncovering<br />

Pulmonary Arterial Hypertension in Your High-Risk<br />

Patient Populations—The Importance <strong>of</strong> Aggressive<br />

Screening and Early Diagnosis<br />

ACR Basic Science Symposium<br />

2:30 - 4:00 PM<br />

B313<br />

The Biology <strong>of</strong> Citrullination R<br />

Moderators: Alisa E. Koch, MD; Unversity <strong>of</strong> Michigan; Ann<br />

Arbor, MI<br />

Thomas W.J. Huizinga, MD; Leiden University Medical Centre;<br />

Leiden, Netherlands<br />

2:30 PM<br />

Biology <strong>of</strong> Protein Citrullination<br />

Ger Pruijn, PhD; Radboud University Nijmegen; Nijmegen,<br />

Netherlands<br />

3:00 PM<br />

Experimental Arthritis and Anti-CCP<br />

V. Michael Holers, MD; University <strong>of</strong> Colorado School <strong>of</strong><br />

Medicine; Aurora, CO<br />

3:30 PM<br />

Peptidylarginine Deiminases and the Relationship to<br />

Citrullination in Rheumatoid Arthritis<br />

Guy B. Serre, MD, PhD; University <strong>of</strong> Toulouse; Toulouse, France<br />

2010 Program Book<br />

ACR Clinical Symposia<br />

2:30 - 4:00 PM<br />

A404<br />

Autologous Stem Cell Transplantation in Pediatric<br />

<strong>Rheumatology</strong>: Indications and Associated Morbidity<br />

P PS<br />

Moderators: Alexei A. Grom, MD; Children’s Hospital Medical<br />

Center; Cincinnati, OH<br />

B. Anne Eberhard, MB; Schneider Children’s Hospital; New Hyde<br />

Park, NY<br />

2:30 PM<br />

Rationale for the Use <strong>of</strong> Autologous Stem Cell Transplantation<br />

in Childhood Rheumatic Diseases<br />

Lucy R. Wedderburn, MD, PhD; University <strong>College</strong> London;<br />

London, United Kingdom<br />

3:00 PM<br />

Review <strong>of</strong> Existing Protocols and Safety Data in Pediatric Stem<br />

Cell Transplantation<br />

Lisa Filipovich, MD; Cincinnati Children’s Medical Center;<br />

Cinncinatti, OH<br />

3:30 PM<br />

Update on the Autologous Stem Cell Transplantation<br />

Experience in Pediatric Rheumatic Diseases<br />

Nico M. Wulffraat, MD; University Medical Center Utrecht;<br />

Utrecht, Netherlands<br />

Session Overview:<br />

In pediatric rheumatology, autologous stem cell transplantation<br />

has been used in patients with systemic rheumatologic<br />

conditions refractory to more conventional treatments. The<br />

outcome studies show variable results that depend on the<br />

conditioning regimens and the specific underlying rheumatic<br />

disease. The identification <strong>of</strong> patients who might benefit from<br />

autologous stem cell transplantation is difficult, in part due<br />

to the fact that many pediatric rheumatologists have limited<br />

understanding <strong>of</strong> the risk/benefit ratio for the procedure.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the clinical rationale for the use <strong>of</strong> autologous stem<br />

cell transplantation in pediatric rheumatic diseases<br />

• identify patients for whom autologous stem cell<br />

transplantation might be an appropriate therapy<br />

• describe potential morbidity and mortality <strong>of</strong> autologous stem<br />

cell transplantation


Thomas J. Murphy Ballroom<br />

Giant Cell Arteritis - Diagnosis and Therapy C PS<br />

Moderator: Robert Spiera, MD; Hospital for Special Surgery; New<br />

York, NY<br />

2:30 PM<br />

Imaging in the Diagnosis <strong>of</strong> Giant Cell Arteritis: State <strong>of</strong> the Art<br />

Thornsten Alexander Bley, MD, PhD; University Hospital<br />

Freiburg; Freiburg, Germany<br />

3:00 PM<br />

Giant Cell Arteritis: Just Temporal Arteries, or So Much More?<br />

Gary S. H<strong>of</strong>fman, MD; Cleveland Clinic Foundation; Cleveland,<br />

OH<br />

3:30 PM<br />

Therapy <strong>of</strong> Giant Cell Arteritis: Beyond Steroids, or Using<br />

Steroids Better?<br />

Stephen A. Paget, MD; Hospital for Special Surgery; New York,<br />

NY<br />

Session Overview:<br />

Giant cell arteritis is the most frequently encountered vasculitis<br />

in persons over 50 years <strong>of</strong> age, and is among the more common<br />

vasculitides encountered by practicing rheumatologists. The<br />

disease is associated with significant disease and treatment<br />

related morbidities. The spectrum <strong>of</strong> disease and recognition<br />

<strong>of</strong> late vascular complications is expanding. Newer diagnostic<br />

modalities have been utilized that may facilitate early diagnosis.<br />

A number <strong>of</strong> therapies have been examined in well-done<br />

randomized trials hoping to demonstrate disease controlling/<br />

steroid sparing benefit, at times with conflicting results. This<br />

session will review the information regarding examined and<br />

emerging steroid sparing approaches, as well as update the<br />

“state <strong>of</strong> the art” with regard to diagnostic modalities, which has<br />

relevance to our evolving understanding <strong>of</strong> the spectrum <strong>of</strong> this<br />

disease and the potential for late vascular complications.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review data regarding the potential merits and pitfalls <strong>of</strong><br />

imaging modalities utilized in diagnosis and management,<br />

including positron emission tomography, Doppler ultrasound,<br />

and magnetic resonance imaging<br />

• discuss the role <strong>of</strong> these imaging modalities in diagnosis<br />

and management, and how this may impact diagnostic<br />

confirmation by biopsy<br />

• review understanding <strong>of</strong> spectrum <strong>of</strong> large vessel vasculitis, in<br />

particular recognition <strong>of</strong> late vascular complications, as well as<br />

early large vessel involvement<br />

• review the concepts <strong>of</strong> disease and treatment related damage<br />

• review recent trials <strong>of</strong> “steroid sparing” modalities<br />

(methotrexate, infliximab, “pulse” steroids)<br />

B402<br />

Psoriatic Disease: Clinical Spectrum and<br />

Comprehensive Treatment Strategies C PS<br />

Moderators: Christopher T. Ritchlin, MD; University <strong>of</strong> Rochester<br />

Medical Center; Rochester, NY<br />

Philip J. Mease, MD; Seattle <strong>Rheumatology</strong> Associate; Seattle,<br />

WA<br />

Hall A3<br />

2:30 PM<br />

Psoriasis: The Skin and Beyond<br />

Wolf-Henning Boehncke, MD; Johann Wolfgang Goethe<br />

University; Frankfurt, Germany<br />

3:00 PM<br />

Psoriatic Arthritis: Insights from the iPART Registry<br />

Dafna D. Gladman, MD; Toronto Western Hospital; Toronto, ON,<br />

Canada<br />

3:30 PM<br />

A Comprehensive Approach to the Treatment <strong>of</strong> Psoriatic<br />

Disease<br />

Arthur Kavanaugh, MD; University <strong>of</strong> California-San Diego; La<br />

Jolla, CA<br />

Session Overview:<br />

Psoriasis affects 3 to 5 percent <strong>of</strong> the US population and<br />

recent data indicate that this inflammatory skin disease is<br />

associated with an array <strong>of</strong> comorbidities that include not only<br />

arthritis but also obesity, cardiovascular disease, diabetes and<br />

anxiety/depression. In addition, psoriatic arthritis patients<br />

develop diverse musculoskeletal manifestations and in some<br />

cases, inflammatory bowel and eye disease. It is essential to<br />

accurately identify relevant extra-cutaneous manifestations<br />

and comorbidities and to implement comprehensive treatment<br />

strategies to maximize efficacy and compliance.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the association <strong>of</strong> psoriasis with obesity, metabolic<br />

syndrome and cardiovascular disease from an epidemiologic<br />

and pathophysiologic perspective<br />

• describe the risk factors for arthritis in psoriasis patients<br />

• summarize the data regarding the prevalence <strong>of</strong> the cardinal<br />

musculoskeletal manifestations, extra-articular features and<br />

comorbidities in psoriatic arthritis<br />

• demonstrate knowledge <strong>of</strong> comprehensive evidence-based<br />

treatment strategies that address the entire spectrum <strong>of</strong><br />

psoriatic disease<br />

Thieves’ Market: Show Me Your Best Cases<br />

ARS<br />

cP P/C<br />

Moderators: Richard A. Furie, MD; North Shore Long Island<br />

Jewish Health System; Lake Success, NY<br />

Zsuzsanna H. McMahan, MD; Johns Hopkins; Baltimore, MD<br />

Speakers: Korey R. Ullrich, MD; University <strong>of</strong> Colorado-Denver;<br />

Aurora, CO<br />

Elena Bagachuk, DO; North Shore University Hospital, Lake<br />

Success, NY<br />

Shawn M. Rose, MD, PhD; Northwestern University, Chicago, IL<br />

Hirenkumar Patel, MD, MBBS; Stonybrook University Hospital;<br />

Stonybrook, NY<br />

Benjamin Scheiber, MB, BS; Royal Free Hospital, London;<br />

London, United Kingdom<br />

Session Overview:<br />

During this session, five unique cases solicited from the<br />

ACR membership will be concisely presented. Cases chosen<br />

for presentation will be <strong>of</strong> the highest educational value to<br />

attendees. The presenter will provide a brief description <strong>of</strong> the<br />

case. This will be followed by a pictorial-laden discussion. This<br />

session will be <strong>of</strong> most interest to those who engage in patient<br />

care.<br />

tuesday<br />

2010 Program Book 69


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe unique and challenging diagnostic dilemmas<br />

• discuss the differential diagnosis<br />

• review methods used to identify the underlying diagnosis<br />

ACR Concurrent Abstract Sessions<br />

2:30 – 4:00 PM<br />

3:30 PM<br />

1360. Apolipoprotein E Receptor (apoER2) Is Involved<br />

for Thrombotic Complications in a Murine Model <strong>of</strong><br />

Antiphospholipid Syndrome.<br />

Z. Romay Penabad 1 , T. Shilagard 1 , G. Vargas 1 , R. Aguilar<br />

-Valenzuela 1 , P. de Groot 2 and S. Pierangeli 1 , 1 Univ <strong>of</strong> TX Med<br />

Branch, Galveston, TX, 2 University Hospital Utrecht, Utretch, The<br />

Netherlands<br />

tuesday<br />

A402<br />

Antiphospholipid Syndrome I<br />

Moderators: Pojen P. Chen, PhD; University <strong>of</strong> California-Los<br />

Angeles School <strong>of</strong> Medicine; Los Angeles, CA<br />

Robert A.S. Roubey, MD; University <strong>of</strong> North Carolina; Chapel<br />

Hill, NC<br />

2:30 PM<br />

1356. TLR-4 and Annexin A2 Involvement in Endothelial Cell<br />

Activation by Anti-Phospholipid Antibodies: Specific Silencing<br />

by Small Interfering RNAs.<br />

Elena Raschi 2 , Valentina Broggini 3 , Maria Orietta Borghi 4 , Claudia<br />

Grossi 2 and Pierluigi Meroni 1 , 1Instituto G. Pini University,<br />

Milano, Italy, 2 IRCCS Istituto Auxologico Italiano, Milan, Italy,<br />

3<br />

University <strong>of</strong> Milan, Italy, 4 University <strong>of</strong> Milan; IRCCS Istituto<br />

Auxologico Italiano, Milan, Italy<br />

2:45 PM<br />

1357. Role <strong>of</strong> Reactive Oxigen Species and ROS-Dependent<br />

Downstream Signalling in the Prothrombotic State Elicited by<br />

Antiphospholipid Antibodies from Primary Antiphospholipid<br />

Syndrome Patients.<br />

Chary Lopez-Pedrera 1 , Patricia Ruiz-Limon 1 , Maria Angeles<br />

Aguirre 1 , Nuria Barbarroja 1 , Antonio Rodriguez-Ariza 1 , Carlos<br />

Perez-Sanchez 1 , Eduardo Collantes-Estevez 1 , Jose Manuel<br />

Villalba 4 , Francisco Velasco 1 , Munther A. Khamashta 2 and Maria<br />

Jose Cuadrado 3 , 1Reina S<strong>of</strong>ia Hospital-IMIBIC, Cordoba, Spain,<br />

2<br />

The Rayne Institute, London, United Kingdom, 3 The Rayne<br />

Institute, London, United Kingdom, 4 University <strong>of</strong> Cordoba,<br />

Cordoba, Spain<br />

3:00 PM<br />

1358. Peptide & NMR Spectroscopy Studies <strong>of</strong> Recombinant<br />

Domain I Confirm Conformationally Correct Domain I and<br />

Non-Linear Epitope Binding to Anti-Domain I Antiphospholipid<br />

Antibodies.<br />

Charis Pericleous 2 , Toluwape Disu 4 , Jennifer Miles 1 , Diego<br />

Esposito 1 , Acely Garza-Garcia 1 , Paul C. Driscoll 1 , David S.<br />

Latchman 4 , David A. Isenberg 3 , Ian Giles 4 , Anisur Rahman 4<br />

and Yiannis Ioannou 4 , 1 National Institute <strong>of</strong> Medical Research,<br />

London, UK, 2 University <strong>College</strong> London, London, United<br />

Kingdom, 3 University <strong>College</strong> London, London, United Kingdom,<br />

4<br />

University <strong>College</strong> London, London, UK<br />

3:45 PM<br />

1361. C6-Deficient Mice Are Protected from the Pathogenic<br />

Effects <strong>of</strong> Antiphospholipid Antibodies.<br />

A. L. Carrera-Marin, R. Aguilar-Valenzuela, Z. Romay Penabad, E.<br />

Papalardo and S. Pierangeli, Univ <strong>of</strong> TX Med Branch, Galveston,<br />

TX<br />

A410<br />

Epidemiology and Health Services Research: Gout<br />

Moderators: Lisa G. Suter, MD; Yale University; New Haven, CT<br />

Jeffrey R. Curtis, MD, MPH; University <strong>of</strong> Alabama - Birmingham;<br />

Birmingham, AL<br />

2:30 PM<br />

1362. Short-Term Effects <strong>of</strong> Caffeinated Beverage Intake on Risk<br />

<strong>of</strong> Recurrent Gout Attacks.<br />

Tuhina Neogi 1 , Clara Chen 3 , Christine Chaisson 3 , David J. Hunter 4<br />

and Yuqing Zhang 2 , 1 Boston Univ Schl <strong>of</strong> Med, Boston, MA,<br />

2<br />

Boston Univ School <strong>of</strong> Medicine, Boston, MA, 3 Boston Univ<br />

School <strong>of</strong> Medicine, 4 University <strong>of</strong> Sydney, Boston, MA<br />

2:45 PM<br />

1363. Prevalence <strong>of</strong> Hyperuricemia in the US General<br />

Population: The National Health and Nutrition Examination<br />

Survey (NHANES) 1999-2008.<br />

Yanyan Zhu 1 , Bhavik Pandya 2 and Hyon Choi 1 , 1 Boston University<br />

<strong>of</strong> School <strong>of</strong> Medicine, Boston, MA, 2 Takeda Pharmaceuticals<br />

International, Inc, Deerfield, IL<br />

3:00 PM<br />

1364. Obesity Is Associated with a Younger Age at Gout<br />

Incidence.<br />

Mara A. McAdams 4 , Janet W. Maynard 2 , Judith A. Bolton<br />

H<strong>of</strong>fman 4 , Alan N. Baer 3 , Allan C. Gelber 1 and Josef Coresh 4 ,<br />

1<br />

Baltimore, MD, 2 Johns Hopkins Univ, Baltimore, MD, 3 Johns<br />

Hopkins University, Baltimore, MD, 4 Johns Hopkins, Bloomberg<br />

School <strong>of</strong> Public Health<br />

3:15 PM<br />

1365. Health Related Quality <strong>of</strong> Life (HRQOL) in Tophaceous vs.<br />

Non-Tophaceous Gout.<br />

Puja Khanna 2 , Jay Persselin 3 , Ron Hays 1 , Daniel Furst 1 , Harold<br />

Paulus 1 , Paul Maranian 1 and Dinesh Khanna 1 , 1UCLA, 2 UCLA and<br />

West LA VA, 3 West LA VA<br />

3:15 PM<br />

1359. A Novel, Simple Fluid Phase Binding Assay for the<br />

Detection <strong>of</strong> Serum Anti-Domain I Antibodies in Patients with<br />

the Antiphospholipid Syndrome.<br />

Charis Pericleous 2 , Acely Garza-Garcia 1 , Paul C. Driscoll 1 , David<br />

S. Latchman 4 , David A. Isenberg 3 , Ian P. Giles 4 , Anisur Rahman 4<br />

and Yiannis Ioannou 4 , 1National Institute <strong>of</strong> Medical Research,<br />

London, UK, 2 University <strong>College</strong> London, London, United<br />

Kingdom, 3 University <strong>College</strong> London, London, United Kingdom,<br />

4<br />

University <strong>College</strong> London, London, UK<br />

3:30 PM<br />

1366. Cherry Consumption and Risk <strong>of</strong> Recurrent Gout Attacks.<br />

Yuqing Zhang 3 , Clara Chen 1 , David J. Hunter 4 , Christine E.<br />

Chaisson 1 , Hyon K. Choi 5 and Tuhina Neogi 2 , 1Boston Univ<br />

Medical Ctr, Boston, MA, 2 Boston Univ Schl <strong>of</strong> Med, Boston,<br />

MA, 3 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 4 Sydney<br />

University, Sydney, Australia, 5 Univ <strong>of</strong> British Columbia,<br />

Vancouver, BC, Canada<br />

70<br />

2010 Program Book


3:45 PM<br />

1367. Serum Urate Levels in Young Adults Are Associated with<br />

the Risk <strong>of</strong> Incident Hypertension: Findings from the Coronary<br />

Artery Risk Development in Young Adults (CARDIA) Cohort.<br />

Angelo L. Gaffo 1 , David R. Jacobs 6 , Femke Sijtsma 5 , Cora E. Lewis 3 ,<br />

Ted R. Mikuls 2 and Kenneth G. Saag 4 , 1 Birmingham VAMC and<br />

University <strong>of</strong> Alabama at Birmingham, Birmingham, AL, 2 Univ<br />

<strong>of</strong> Nebraska Med Ctr, Omaha, NE, 3 University <strong>of</strong> Alabama at<br />

Birmingham, 4 University <strong>of</strong> Alabama-Birmingham, Birmingham,<br />

AL, 5 University <strong>of</strong> Minnesota, 6 University <strong>of</strong> Minnesota and<br />

University <strong>of</strong> Oslo<br />

A412<br />

Imaging <strong>of</strong> Rheumatic Disease: X-ray and MRI<br />

Moderators: Mikkel Ostergaard, DMSc, MD, PhD; Copenhagen<br />

University Hospital<br />

Barbara N. Weissman, MD; Brigham and Women’s Hospital;<br />

Boston, MA<br />

2:30 PM<br />

1368. Two-Year Radiographic Results from the TEAR Trial.<br />

Larry W. Moreland 7 , James R. O’Dell 9 , Harold E. Paulus 1 , Jeffrey<br />

R. Curtis 8 , Joan M. Bathon 3 , E. William St Clair 2 , S. Louis Bridges 6 ,<br />

Xiao Zhang 5 , George Howard 5 , Desiree M. Van Der Heijde 4 ,<br />

Stacey S. C<strong>of</strong>ield 5 and for the TEAR Trial Investigators, 1 Encino,<br />

CA, 2 Duke University, Durham, NC, 3 Johns Hopkins Univ Ste,<br />

Baltimore, MD, 4 Leiden University Medical Center, Meerssen,<br />

The Netherlands, 5 The University <strong>of</strong> Alabama at Birmingham,<br />

6<br />

Univ <strong>of</strong> Alabama-Birmingham, Birmingham, AL, 7 Univ <strong>of</strong><br />

Pittsburgh Med Ctr, Pittsburgh, PA, 8 University <strong>of</strong> Alabama -<br />

Brimingham, Birmingham, AL, 9 University <strong>of</strong> Nebraska Medical<br />

Center, Omaha, NE<br />

2:45 PM<br />

1369. Development and Validation <strong>of</strong> an MRI Joint Space<br />

Narrowing Score for Use in Rheumatoid Arthritis: A Potential<br />

Adjunct to the OMERACT RA MRI Scoring System.<br />

Mikkel Østergaard 4 , Pernille Bøyesen 5 , Iris Eshed 10 , Frédérique<br />

Gandjbakhch 7 , Siri Lillegraven 5 , Paul Bird 6 , Violaine Foltz 8 ,<br />

Annelies Boonen 9 , Marissa N. Lassere 12 , Kay-Geert Hermann 2 ,<br />

Allen Anandarajah 16 , Uffe Møller Døhn 3 , Jane Freeston 15 ,<br />

Charles G. Peterfy 11 , Harry K. Genant 14 , Espen Haavardsholm 5 ,<br />

Fiona M. McQueen 13 and Philip G. Conaghan 1 , 1 Chapel Allerton<br />

Hospital, Leeds, United Kingdom, 2 Charité University Hospital,<br />

Berlin, Germany, 3 Copenhagen University Hospitals at Hvidovre<br />

and Glostrup, Denmark, 4 Copenhagen University Hospitals at<br />

Hvidovre and Glostrup, Hvidovre, Denmark, 5 Diakonhjemmet<br />

Hospital, University <strong>of</strong> Oslo, Oslo, Norway, 6 Division <strong>of</strong> Medicine,<br />

St. George Hospital, University <strong>of</strong> NSW, Sydney, Australia,<br />

7<br />

Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC, Paris,<br />

France, 8 Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC,<br />

Paris, France, 9 Maastricht University Hospital, Maastricht,<br />

10<br />

Sheba Medical Centre, Tel Aviv University, Tel Aviv, Israel,<br />

11<br />

Spire Sciences LLC, Kentfield, CA, 12 St. George Hospital,<br />

University <strong>of</strong> NSW, Sydney, Kogarah, Australia, 13 University<br />

<strong>of</strong> Auckland School <strong>of</strong> Medicine, Auckland, New Zealand,<br />

14<br />

University <strong>of</strong> California San Francisco, Tiburon, CA, 15 University<br />

<strong>of</strong> Leeds, Leeds, UK, 16 University <strong>of</strong> Rochester, Rochester<br />

3:00 PM<br />

1370. Patterns <strong>of</strong> MRI Bone Erosion in Rheumatoid Arthritis<br />

– Which Bones Are Most Frequently Involved and Show Most<br />

Change?<br />

Mikkel Østergaard 3 , Uffe Møller Døhn 4 , Anne Duer-Jensen 3 ,<br />

Merete L. Hetland 3 , Kim Hørslev-Petersen 5 , Kristian Stengaard-<br />

Pedersen 1 , Peter Junker 6 , Jan Pødenphant 2 and Bo Ejbjerg 7 ,<br />

1<br />

Århus University Hospital, Åarhus, Denmark, 2 Copenhagen<br />

University Hospitals at Gent<strong>of</strong>te, Copenhagen, Denmark,<br />

3<br />

Copenhagen University Hospitals at Hvidovre and Glostrup,<br />

Copenhagen, Denmark, 4 Copenhagen University Hospitals at<br />

Hvidovre and Glostrup, Copenhagen, Denmark, 5 KIng Christian<br />

X’s Rheumatism Hospital, University <strong>of</strong> Southern Denmark,<br />

Gråsten, Denmark, 6 Odense University Hospital, Odense C,<br />

Denmark, 7 Slagelse Hospital, Denmark<br />

3:15 PM<br />

1371. MRI-Proven Bone Edema <strong>of</strong> Wrist and Finger Joints at<br />

Entry Is the Strongest Predictor toward Further Radiografic<br />

Progression in Patients with Undifferentiated Arthritis: Results<br />

from the Prospective Cohort at Nagasaki University.<br />

Junko Kita 7 , Atsushi Kawakami 7 , Mami Tamai 1 , Naoki Iwamoto 7 ,<br />

Shin-ya Kawashiri 8 , Kazuhiko Arima 2 , Akitomo Okada 7 , Tomohiro<br />

Koga 7 , Satoshi Yamasaki 7 , Hideki Nakamura 7 , Tomoki Origuchi 5 ,<br />

Kiyoshi Aoyagi 3 , Masataka Uetani 4 and Katsumi Eguchi 6 , 1 Center<br />

for Health Community Medicine, Nagasaki University, Nagasaki,<br />

Japan, 2 Department <strong>of</strong> Medical Gene Technology, Atomic Bomb<br />

Disease Institute, Nagasaki University Graduate School <strong>of</strong><br />

BIomedical Sciences, 3 Department <strong>of</strong> Public Health, Graduate<br />

School <strong>of</strong> Biomedical Sciences, Nagasaki University, Nagasaki,<br />

Japan, 4 Department <strong>of</strong> Radiology and Radiation Research,<br />

Graduate School <strong>of</strong> Biomedical Sciences, Nagasaki University,<br />

Nagasaki, Japan, 5 Nagasaki University School <strong>of</strong> Health Sciences,<br />

Nagasaki University, Nagasaki, Japan, 6 Sasebo City General<br />

Hospital, Sasebo, Nagasaki, 7 Unit <strong>of</strong> Translational Medicine,<br />

Department <strong>of</strong> Immunology and <strong>Rheumatology</strong>, Graduate School<br />

<strong>of</strong> Biomedical Sciences, Nagasaki University, Nagasaki, Japan,<br />

8<br />

Unit <strong>of</strong> Translational Medicine, Department <strong>of</strong> Immunology<br />

and <strong>Rheumatology</strong>, Graduate School <strong>of</strong> Biomedical Sciences,<br />

Nagasaki University, Nagasaki, Japan<br />

3:30 PM<br />

1372. Zoledronic Acid Does Not Reduce Erosive Progression in<br />

PsA but May Suppress MRI Bone Oedema.<br />

Richard Lloyd 3 , Anthony Doyle 3 , Nicola Dalbeth 3 , Maria Lobo 1 ,<br />

Elizabeth Robinson 5 , William Taylor 6 , Peter Jones 2 and Fiona M.<br />

McQueen 4 , 1 Auckland District Health Board, 2 QEHealth, 3 Univ<br />

<strong>of</strong> Auckland, 4 Univ <strong>of</strong> Auckland Sch <strong>of</strong> Med, Auckland, New<br />

Zealand, 5 University <strong>of</strong> Auckland, 6 University <strong>of</strong> Otago<br />

3:45 PM<br />

1373. Cartilage Damage and Osteophytes: MRI-Defined<br />

Atrophic and Hypertrophic Phenotypes <strong>of</strong> Knee Osteoarthritis<br />

in the Framingham Cohort.<br />

Frank Roemer, Ali Guermazi, Jingbo Niu, Yuqing Zhang and David<br />

Felson, Boston University<br />

A314<br />

Muscle Biology, Myositis and Myopathies: Insights into<br />

the Pathogenesis and Outcomes <strong>of</strong> Myositis<br />

Moderators: Ann M. Reed, MD; Mayo Clinic; Rochester, MN<br />

Robert G. Cooper, MD; Hope Hospital; Salford, United Kingdom<br />

tuesday<br />

2010 Program Book 71


tuesday<br />

2:30 PM<br />

1374. The Influence <strong>of</strong> Regulatory T-Cell Deficiency and<br />

Endogenous Muscle Tissue Antigens on the Development <strong>of</strong><br />

Inflammatory Myopathy in Mice.<br />

N. A. Young, R. Sharma, B. Kaffenberger, A. Friedman and W. N.<br />

Jarjour, The Ohio State University Medical Center, Columbus, OH<br />

2:45 PM<br />

1375. Blockade <strong>of</strong> TNFα or IL-1 Ameliorates Established<br />

C-Protein Induced Myositis <strong>of</strong> Mice.<br />

Takahiko Sugihara 2 , Naoko Okiyama 2 , Naoto Watanabe 2 ,<br />

Nobuyuki Miyasaka 1 and Hitoshi Kohsaka 1 , 1Department <strong>of</strong><br />

Medicine and <strong>Rheumatology</strong>, Graduate School <strong>of</strong> Medical and<br />

Dental Sciences, Tokyo Medical and Dental University, Tokyo,<br />

Japan, 2 Department <strong>of</strong> Medicine and <strong>Rheumatology</strong>, Graduate<br />

School <strong>of</strong> Medical and Dental Sciences, Tokyo Medical and<br />

Dental University, Japan<br />

3:00 PM<br />

1376. UPR Activation and IFNb Production in Myocytes in Adult<br />

and Juvenile Myositis.<br />

Ann M. Reed 1 , Molly S. Hein 1 and Robert A. Colbert 2 , 1Mayo<br />

Clinic, 2 NIH, NIAMS<br />

3:15 PM<br />

1377. A New ELISA System for Detecting Autoantibodies to<br />

aminoacyl-tRNA Synthetases: Usefulness in Myositis and<br />

Interstitial Pneumonia.<br />

Ran Nakashima 2 , Nakashima 2 , Yoshitaka Imura 4 , Shio Kobayashi 3 ,<br />

Yuji Hosono 4 , Naoichiro Yukawa 4 , Daisuke Kawabata 4 , Takaki<br />

Nojima 4 , Koichiro Ohmura 2 , Takashi Usui 4 , Takao Fujii 1 , Minae<br />

Seto 6 , Akihiro Murakami 5 and Tsuneyo Mimori 2 , 1 Department<br />

<strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Kyoto University<br />

Graduate School <strong>of</strong> Medicine, Sakyo-ku Kyoto, Japan,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />

Kyoto University Graduate School <strong>of</strong> Medicine, Kyoto, Japan,<br />

3<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />

Kyoto University Graduate School <strong>of</strong> Medicine, Kyoto, Japan,<br />

4<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Kyoto<br />

University Graduate School <strong>of</strong> Medicine, 5 Medical and Biological<br />

Laboratories CO., LTD, 6 Medical and Biological Laboratories Co.,<br />

Ltd., Nagano, Japan<br />

3:30 PM<br />

1378. Atherosclerotic Cardiovascular Disease among<br />

Hospitalized Dermatomyositis Patients in the US.<br />

Eleni Linos 3 , David Fiorentino3, Bharathi Lingala 3 , Eswar<br />

Krishnan 2 and Lorinda Chung 1 , 1 Stanford Univ Medical Center,<br />

Palo Alto, CA, 2 Stanford University, Palo Alto, CA, 3 Stanford<br />

University School <strong>of</strong> Medicine<br />

3:45 PM<br />

1379. Predictors <strong>of</strong> Response to B Cell Depleting Therapy in<br />

Adult and Juvenile Myositis.<br />

Ann M. Reed 1 , Kelly T. McNallan 1 , Cindy S. Crowson 1 and Chester<br />

V. Oddis 2 , 1 Mayo Clinic, 2 University <strong>of</strong> Pittsburgh<br />

A315<br />

Orthopedics, Low Back Pain and Rehabilitation<br />

Moderators: Beth L. Jonas, MD; University <strong>of</strong> North Carolina-<br />

Chapel Hill; Chapel Hill, NC<br />

Jeffrey N. Katz, MD; Brigham and Women’s Hospital; Boston, MA<br />

2:30 PM<br />

1380. Clinical Improvement and Structural Tissue Repair<br />

by Joint Distraction, in Treatment <strong>of</strong> End-Stage Knee<br />

Osteoarthritis.<br />

F. Intema 2 , K. Wiegant 3 , P. M. van Roermund 3 , A. C. A.<br />

Marijnissen 3 , S. Cot<strong>of</strong>ana 1 , F. Eckstein 1 , S. C. Mastbergen 3 and<br />

F. P. J. G. Lafeber 3 , 1 Institute <strong>of</strong> Anatomy and Muscoskeletal<br />

Research, Paracelsus Medical University, Salzburg, Austria,<br />

2<br />

<strong>Rheumatology</strong> & Clinical Immunology, University Medical<br />

Center Utrecht, Utrecht, The Netherlands, 3 <strong>Rheumatology</strong> &<br />

Clinical Immunology, University Medical Center Utrecht, The<br />

Netherlands<br />

2:45 PM<br />

1381. TNF Blockade during Elective Orthopaedic and Hand<br />

Surgery in Arthritis Patients: Friend or Foe?<br />

Elisabet Pettersson, Pierre Geborek and Anders Gülfe,<br />

Lund University, Dept <strong>of</strong> Clinical Sciences, Lund, Section for<br />

<strong>Rheumatology</strong>, Lund, Sweden<br />

3:00 PM<br />

1382. Guided Mesenchymal Stem Cell Layering Technique for<br />

Treatment <strong>of</strong> Osteoarthritis <strong>of</strong> the Knee.<br />

Nathan Wei 1 , Sheila Beard 1 , Sheila K. Delauter 1 , Carla Bitner 1 ,<br />

Rebecca Gillis 1 , Laura Rau 1 , Colleen Miller 1 and Thomas B. Clark 2 ,<br />

1<br />

Arthritis Treatment Center, Frederick, MD, 2 Musculoskeletal<br />

Ultrasound, Vista, CA<br />

3:15 PM<br />

1383. Increased Fat Mass Is Associated with High Levels <strong>of</strong> Low<br />

Back Pain Intensity and Disability.<br />

Donna Urquhart 4 , Patricia Berry 4 , Anita Wluka 4 , Boyd Strauss 3 ,<br />

Yuanyuan Wang 4 , Joseph Proietto 5 , Graeme Jones 2 , John Dixon 1<br />

and Flavia Cicuttini 4 , 1 Baker IDI Heart and Diabetes Institute,<br />

2<br />

Menzies Research Institute, 3 Monash Medical Centre, 4 Monash<br />

University, 5 University <strong>of</strong> Melbourne<br />

3:30 PM<br />

1384. Creatine Supplementation Associated to Resistance<br />

Training in Post-Menopausal Women with Knee Osteoarthritis<br />

Improves Physical Function: A Randomized, Double-Blinded,<br />

Placebo-Controlled Clinical Trial.<br />

Manoel Tavares Neves Junior 1 , Bruno Gualano 2 , Hamilton<br />

Roschel 2 , Marcelo Tatit Sapienza 2 , Fernanda Rodrigues Lima 2 ,<br />

Ana Lucia de Sa Pinto 2 , Ricardo Fuller 2 , Rosa Maria Rodrigues<br />

Pereira 2 , Antonio Herbert Lancha Junior 2 and Eloisa Silva Dutra<br />

de Oliveira Bonfa 2 , 1 Universidade de Sao Paulo, Sao Paulo, SP,<br />

Brazil, 2 Universidade de Sao Paulo<br />

3:45 PM<br />

1385. Role <strong>of</strong> Central Sensitization in Persistent Pain Post-Knee<br />

Replacement: The MOST Study.<br />

Tuhina Neogi 3 , Jingbo Niu 4 , Laura Frey-Law 9 , Lars Arendt-<br />

Nielsen 1 , Jasvinder Singh 8 , Joachim Scholz 2 , Clifford Woolf 2 , Irina<br />

Tolstykh 7 , Jessica L. Maxwell 4 , Barton Wise 6 and David T. Felson 5 ,<br />

1<br />

Aalborg University, Denmark, 2 Boston Childrens Hospital,<br />

3<br />

Boston Univ Schl <strong>of</strong> Med, Boston, MA, 4 Boston Univ School <strong>of</strong><br />

Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA, 6 UCDavis, Sacramento, CA, 7 UCSF, 8 University <strong>of</strong><br />

Alabama at Birmingham, Minneapolis, MN, 9 University <strong>of</strong> Iowa<br />

72<br />

2010 Program Book


A411<br />

Rheumatoid Arthritis - Human Etiology and<br />

Pathogenesis: RA Human Etiology and Pathogenesis I<br />

Moderators: Gary S. Firestein, MD; University <strong>of</strong> California – San<br />

Diego School <strong>of</strong> Medicine; La Jolla, CA<br />

Ellen M. Gravallese, MD; University <strong>of</strong> Massachusetts Medical<br />

School, Worchester, MA<br />

2:30 PM<br />

1386. Thrombin-Activatable Carboxypeptidase B (CPB) Plays a<br />

Central Role in Down-Regulating Inflammatory Responses in<br />

Rheumatoid Arthritis by Cleaving C5a.<br />

Jason J. Song 3 , Inyong Hwang 3 , Tiffany Wang 4 , Annette T.<br />

Lee 1 , S. Louis Bridges 5 , Peter K. Gregersen 1 , Lawrence Leung 4<br />

and William Robinson 2 , 1North Shore-LIJ Research Institute,<br />

Manhasset, NY, 2 Stanford Univ School <strong>of</strong> Med, Stanford, CA,<br />

3<br />

Stanford University, Palo Alto, CA, 4 Stanford University, 5 Univ <strong>of</strong><br />

Alabama-Birmingham, Birmingham, AL<br />

2:45 PM<br />

1387. The Liver X Receptor (LXR) Regulates Arthritis Fibroblast-<br />

Like Synoviocyte NFB Activity, IL-6 Production and Cell Invasion.<br />

Carl Petrus Linge 2 , Teresina Laragione 3 and Percio S. Gulko 1 ,<br />

1<br />

Feinstein Institutue Med Rsch, Manhasset, NY, 2 The Feinstein<br />

Institute for Medical Research, Manhasset, NY, 3 The Feinstein<br />

Institute for Medical Research<br />

3:00 PM<br />

1388. Cadherin-11 Engagement Increases Matrix<br />

Metalloproteinase Production by Rheumatoid Arthritis<br />

Fibroblast-Like Synoviocytes.<br />

Erika H. Noss, Sook-Kyung Chang and Michael B. Brenner,<br />

Brigham and Women’s Hospital, Boston, MA<br />

3:15 PM<br />

1389. Rheumatoid Synovial Fibroblasts Support Aid Expression<br />

and IG Class-Switching in B Cells Via a BAFF-Dependent TLR3-<br />

Stimulated Pathway.<br />

Michele Bombardieri 1 , Yvone N. W. Kam 1 , Fabia Brentano 1 ,<br />

Ken Choi 1 , Diego Kyburz 3 , Steffen Gay 3 , Iain B. McInnes 2 and<br />

Costantino Pitzalis 1 , 1 Queen Mary University London, London,<br />

United Kingdom, 2 University <strong>of</strong> Glasgow, Glasgow, United<br />

Kingdom, 3 University <strong>of</strong> Zurich, Zurich, Switzerland<br />

3:30 PM<br />

1390. Characteristic Oral and Intestinal Microbiota in<br />

Rheumatoid Arthritis (RA): A Trigger for Autoimmunity?<br />

Jose U. Scher 7 , Carles Ubeda 3 , Michael H. Pillinger 2 , Walter<br />

Bretz 6 , Yvonne Buischi 6 , Pamela B. Rosenthal 7 , Soumya M.<br />

Reddy 7 , Jonathan Samuels 4 , Peter M. Izmirly 7 , Rennie N. G.<br />

Howard 7 , Gary Solomon 8 , Yusuf Yazici 8 , Mukundan Attur 8 ,<br />

Michele Equinda 3 , Nicholas Socci 3 , Agnes Viale 3 , Eric Pamer 1 ,<br />

Dan R. Littman 9 , Gerald Weissmann 5 and Steven B. Abramson 10 ,<br />

1<br />

Lucille Castori Center for Microbes, Inflammation, and Cancer/<br />

MSKCC, 2 Manhattan VA Med Hospital, New York, NY, 3 Memorial<br />

Sloan-Kettering Cancer Center (MSKCC), 4 New York University<br />

Hospital for Joint Disease, New York, NY, 5 New York University<br />

Medical Center, New York, NY, 6 NYU <strong>College</strong> <strong>of</strong> Dentistry, 7 NYU<br />

Hospital for Joint Diseases, New York, NY, 8 NYU Hospital for Joint<br />

Diseases, 9 NYU School <strong>of</strong> Medicine, 10 NYU School <strong>of</strong> Medicine,<br />

NYU Hospital for Joint Diseases, New York, NY<br />

3:45 PM<br />

1391. Toll-Like Receptor 2 Activation Induces Angiogenesis,<br />

ICAM-1 Expression and EC Invasion in Rheumatoid Arthritis.<br />

Tajvur P. Saber 2 , Sinead NicUltaigh 3 , Jennifer McCormick 2 ,<br />

Douglas J. Veale 4 , Mary Connolly 2 and Ursula Fearon 1 , 1 Dublin,<br />

Ireland, 2 Dublin Academic Medical Centre, Dublin, Ireland,<br />

3<br />

Dublin Academic Medical Centre, Dublin, Ireland, 4 St Vincents<br />

Univ Hospital, Dublin, Ireland<br />

Sidney J. Marcus Auditorium<br />

Rheumatoid Arthritis Treatment - Small Molecules,<br />

Biologics and Gene Therapy: Existing Non-Biologic<br />

DMARDs II<br />

Moderators: Eric M. Ruderman, MD; North Western University<br />

<strong>of</strong> School <strong>of</strong> Medicine; Chicago, IL<br />

Alvin F. Wells, MD, PhD; <strong>Rheumatology</strong> and Immunotherapy<br />

Center; Oak Creek, WI<br />

2:30 PM<br />

1392. Radiological Progression in Patients with Early RA and a<br />

Good Clinical Response to MTX Monotherapy: Predictors and<br />

Clinical Implications.<br />

Hamed Rezaei 3 , Ronald Van Vollenhoven 2 , Kristina Forslind 1 ,<br />

Kristina Albertsson 3 , Helena Wallin 3 , Pierre Geborek 4 , S<strong>of</strong>ia<br />

Ernestam 3 , Ingemar Petersson 5 and Johan Bratt 3 , 1 Helsingborgs<br />

Hospital, 2 Karolinska University Hospital, Stockholm, Sweden,<br />

3<br />

Karolinska University Hospital, 4 Lund University Hospital,<br />

5<br />

Spenshult Hospital<br />

2:45 PM<br />

1393. In Early RA, Patients with a Good Initial Response to MTX<br />

Monotherapy Have Excellent Clinical Outcomes over Two Years<br />

<strong>of</strong> Therapy, but Radiological Progression Is Not Completely<br />

Prevented.<br />

Helena Wallin 4 , Ronald Van Vollenhoven 2 , Kristina Albertsson,<br />

Kristina Forslind, S<strong>of</strong>ia Ernestam, Ingemar F. Petersson 3 , Pierre<br />

Geborek, Hamed Rezaei, Johan Bratt 1 and The SWEFOT Study<br />

Group, 1 Karolinska Univ Hosp Huddinge, Stockholm, Sweden,<br />

2<br />

Karolinska University Hospital, Stockholm, Sweden, 3 Lund<br />

University Hosp, Lund, Sweden, 4 The Karolinska Institute,<br />

Stockholm, Sweden<br />

3:00 PM<br />

1394. Genetic Polymorphisms in Key Methotrexate (MTX)<br />

Pathway Genes Associated with Response to MTX Treatment in<br />

Rheumatoid Arthritis.<br />

Sally-Anne Owen 2 , Stephen Eyre 2 , Paul Martin 2 , Samantha<br />

Hider 1 , Ian N. Bruce 2 , Anne Barton 2 and Wendy Thomson 2 , 1 ARC<br />

National Primary Care Centre, Keele University, Staffordshire,<br />

United Kingdom, 2 Arthritis Research UK Epidemiology Unit, The<br />

University <strong>of</strong> Manchester, Manchester, United Kingdom<br />

3:15 PM<br />

1395. Observational Study To Evaluate the Relationship <strong>of</strong><br />

Methotrexate to Interstitial Lung Disease in Rheumatoid<br />

Arthritis.<br />

Liron Caplan 7 , Anne E. Hines 15 , Jay R. McDonald 10 , Angelique L.<br />

Zeringue 10 , Alyse Mann 6 , Paul H. Sufka 13 , Kevin G. Osgood 2 , Ted<br />

R. Mikuls 14 , Jasvinder Singh 3 , Itziar Quinzanos 5 , Lela Mansoori 11 ,<br />

Chrysoula Pappa 12 , Leah M. Haverhals 6 , Andre Barkhuizen 8 ,<br />

Douglas Phelps 1 , Roderick S. Hooker 4 , Hong Xian 10 , Prabha<br />

Ranganathan 9 , Fran Cunningham 17 and Seth Eisen 16 , 1 Albancy<br />

tuesday<br />

2010 Program Book 73


tuesday<br />

74<br />

VAMC, 2 Austin Diagnostic Clinic, Austin, TX, 3 Birmingham VAMC,<br />

Minneapolis, MN, 4 Dallas VAMC, Dallas, TX, 5 Denver Health,<br />

6<br />

Denver VAMC, 7 Denver VAMC, Aurora, CO, 8 Portland Rheum<br />

Clinic LLC, Lake Oswego, OR, 9 St. Louis VAMC, St. Louis, MO, 10 St.<br />

Louis VAMC, 11 Univ <strong>of</strong> Colorado, 12 Univ <strong>of</strong> Florida Jacksonville,<br />

Saint Augustine, FL, 13 Univ <strong>of</strong> Minneapolis, Minneapolis,<br />

MN, 14 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE, 15 University <strong>of</strong><br />

Colorado, 16 VA HSR&D, 17 VA PBM<br />

3:30 PM<br />

1396. Induction Therapy with Methotrexate and Prednisone in<br />

Rheumatoid or Very Early Arthritic Disease: IMPROVED Study.<br />

K. V. C. de Boer 5 , K. Visser 6 , H. K. Ronday 4 , A. A. Schouffoer 3 , J.<br />

H. L. M. Groenendael 2 , A. J. Peeters 9 , I. Speyer 1 , G. Collée 7 , P.<br />

B. J . Sonnaville 8 , B. A. M. Grillet 10 , T. W. J. Huizinga 6 and C. F.<br />

Allaart 5 , 1 Bronovo Hospital, The Hague, 2 Franciscus Hospital,<br />

Roosendaal, 3 Groene Hart Hospital, Gouda, 4 Haga Hospital, The<br />

Hague, 5 LUMC, Leiden, The Netherlands, 6 LUMC, Leiden, 7 MCH,<br />

the Hague, 8 Oosterschelde Hospital, Goes, 9 Reinier de Graaf<br />

Gasthuis, Delft, 10 Zorgsaam, Terneuzen<br />

3:45 PM<br />

1397. The Role <strong>of</strong> Low-Dose Oral Prednisone Treatment in Early<br />

Rheumatoid Arthritis: Effects on Clinical and Ultrasonographic<br />

Remission and Functional Outcome.<br />

Garifallia Sakellariou 1 , Monica Todoerti 2 , Carlo A. Scirè 2 , Serena<br />

Bugatti 2 , Carlomaurizio Montecucco 2 and Roberto Caporali 2 ,<br />

1<br />

Chair and Division <strong>of</strong> <strong>Rheumatology</strong>, Università degli Studi<br />

di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia,<br />

Lombardia, Italy, 2 Chair and Division <strong>of</strong> <strong>Rheumatology</strong>, Università<br />

degli Studi di Pavia, Fondazione IRCCS Policlinico San Matteo,<br />

Pavia, Italy<br />

A311<br />

Systemic Lupus Erythematosus - Clinical Aspects and<br />

Treatment: Renal<br />

Moderators: Frederic A. Houssiau, MD, PhD; Universite<br />

Catholique Louvain; Brussels, Belgium<br />

Eliza F. Chakravarty, MD; Stanford University; Mountain View, CA<br />

2:30 PM<br />

1398. Repeat Kidney Biopsies Fail To Detect Differences<br />

between Azathioprine and Mycophenolate M<strong>of</strong>etil<br />

Maintenance Therapy for Lupus Nephritis: Data from the<br />

MAINTAIN Nephritis Trial.<br />

Maria Stoenoiu 1 , Selda Aydin 1 , Carlos Vasconcelos 4 , Maria<br />

Tektonidou 5 , Isabelle Ravelingien 6 , Véronique le Guern 2 ,<br />

Geneviève Depresseux 1 , Ricard Cervera 3 , Jean-Pierre Cosyns 1<br />

and Frédéric A. Houssiau 1 , 1 Cliniques Universitaires Saint-Luc,<br />

Université Catholique de Louvain, Bruxelles, Belgium, 2 Hôpital<br />

Cochin, Paris, France, 3 Hospital Clinic, Barcelona, Spain, 4 Hospital<br />

Santo Antonio, Porto, Portugal, 5 National University <strong>of</strong> Athens,<br />

Athens, Greece, 6O.L. Vrouwziekenhuis, Aalst, Belgium<br />

2:45 PM<br />

1399. C4d on Circulating Cells and Renal Tissues in Lupus<br />

Nephritis as Novel Biomarkers.<br />

Kelly V. Liang 4 , Ibrahim Batal 2 , Sheldon Bastacky 4 , Lawrence<br />

Kiss, Theresa McHale, Nicole Wilson, Barbara Paul, Apinya<br />

Lertratanakul, Joseph M. Ahearn 1 , Susan Manzi 5 and Amy H.<br />

Kao 3 , 1 Wexford, PA, 2 Pittsburgh, PA, 3 Allegheny Singer Research<br />

Institute, Pittsburgh, PA, 4 University <strong>of</strong> Pittsburgh, Pittsburgh, PA,<br />

2010 Program Book<br />

5<br />

West Penn Allegheny Health System, Pittsburgh, PA<br />

3:00 PM<br />

1400. Are the Current Thresholds for SLE Proteinuric Flare<br />

Set Too High? Determining the 99% Confidence Intervals for<br />

Spontaneous Variation in Urine Protein/Creatinine Ration in<br />

SLE GN Patients Who Are Clinically Stable (Not Flaring).<br />

Stacy P. Ardoin 1 , Dan J. Birmingham 2 , Brad H. Rovin 2 , P. Hebert 3 ,<br />

C.-Y. Yu 2 and Lee A. Hebert 2 , 1 Ohio State University, Columbus,<br />

OH, 2 Ohio State University, 3 University <strong>of</strong> Washington<br />

3:15 PM<br />

1401. Systematic Review and Meta-Analysis <strong>of</strong><br />

Immunosuppressant Therapy Clinical Trials in Membranous<br />

Lupus Nephritis.<br />

Vikas Majithia 2 , Josh T. Swan 1 and Daniel Riche 3 , 1 Methodist<br />

Hospital, Houston, 2 University <strong>of</strong> Mississippi Medical Center,<br />

Jackson, MS, 3 University <strong>of</strong> Mississippi Medical Center<br />

3:30 PM<br />

1402. Treatment <strong>of</strong> Lupus Nephritis with Enteric-Coated<br />

Mycophenolate Sodium (EC-MPS) – MyLupus Exploratory<br />

Study.<br />

Andrea Doria, For the MyLupus Study Group, Padova, Italy<br />

3:45 PM<br />

1403. Machine Learning Models Using Multiple Low<br />

Abundance Protein Biomarker Levels Are Superior to Those<br />

Using Clinical Laboratory Values in Diagnosing ISN/RPS Class <strong>of</strong><br />

Lupus Nephritis.<br />

Jim C. Oates 2 , Michelle A. Petri 1 , Jonas S. Almeida 4 , Thomas W.<br />

Fleury 3 , Janech G. Michael 3 and John M. Arthur 3 , 1 Timonium,<br />

MD, 2 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />

3<br />

Medical University <strong>of</strong> South Carolina, 4 The University <strong>of</strong> Texas<br />

M. D. Anderson Cancer Center<br />

ACR/ARHP Combined Concurrent<br />

Abstract Session<br />

2:30 - 4:00 PM<br />

B311<br />

ACR/ARHP Combined Pediatric <strong>Rheumatology</strong> -<br />

Clinical and Therapeutic Aspects Abstracts: Quality <strong>of</strong><br />

Life in Children and Adolescents with Arthritis<br />

Moderators: Karen L. Kerr, MSN, NP, CPNP, PNP; Children’s<br />

Hospital <strong>of</strong> Michigan; Detroit, MI<br />

Hermine Brunner, MD, MSc.; Cincinnati Children’s Hospital<br />

Medical Center; Cincinnati, OH<br />

2:30 PM<br />

1404. Investigating Medication Adherence in Pediatric<br />

<strong>Rheumatology</strong> Using a Medical Claims Database.<br />

Caitlin M. Sgarlat 3 , Jorge M. Lopez-Benitez 2 , Emily Cox 1 and Ira<br />

B. Wilson 4 , 1 Express Scripts Inc. Research and Analysis, St. Louis,<br />

MO, 2 Tufts Medical Center and Floating Hospital for Children:<br />

Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Boston, MA, 3 Tufts Medical<br />

Center and Floating Hospital for Children: Division <strong>of</strong> Pediatric<br />

<strong>Rheumatology</strong>; Tufts University Sackler School <strong>of</strong> Graduate<br />

Biomedical Sciences, Boston, MA, 4Tufts Medical Center and<br />

Floating Hospital for Children; Tufts University Sackler School <strong>of</strong><br />

Graduate Biomedical Sciences


2:45 PM<br />

1405. Development <strong>of</strong> a Vision Related Quality <strong>of</strong> Life<br />

Instrument for Children with Juvenile Idiopathic Arthritis-<br />

Associated Uveitis.<br />

Sheila Angeles-Han 4 , Kenneth Griffin 7 , Melanie J. Harrison 5 ,<br />

Kerrie Fields 2 , Lori Ponder 2 , Rachel Reeves-Robb 3 , Marla<br />

Shainberg 3 , Phoebe Lenhart 3 , Amy Hutchinson 3 , Sunil Srivastava 3 ,<br />

Sampath Prahalad1, Scott Lambert 3 and Carolyn Drews-Botsch 6 ,<br />

1<br />

Emory Children’s Center, Atlanta, GA, 2 Emory Children’s Center,<br />

3<br />

Emory Eye Center, 4 Emory University, Atlanta, GA, 5 Pfizer, Blue<br />

Bell, PA, 6 Rollins School <strong>of</strong> Public Health, 7 Weill Cornell Medical<br />

<strong>College</strong><br />

3:00 PM<br />

1406. Sleep in Polyarticular Juvenile Idiopathic Arthritis: An<br />

Electronic Daily Diary Study.<br />

Maggie H. Bromberg 5 , Cecelia R. Valrie 4 , Mark Connelly 1 ,<br />

Kelly K. Anthony 3 , Lindsey Franks 3 , Karen M. Gil 6 and Laura<br />

E. Schanberg 2 , 1 Children’s Mercy Hospital and Clinics, 2 Duke<br />

Univ Medical Center, Durham, NC, 3 Duke University Medical<br />

Center, Durham, NC, 4 East Carolina University, 5 University <strong>of</strong><br />

North Carolina at Chapel Hill, Carrboro, NC, 6 University <strong>of</strong> North<br />

Carolina at Chapel Hill<br />

3:15 PM<br />

1407. Clinically Meaningful Improvements in Health-<br />

Related Quality <strong>of</strong> Life, Pain and Sleep Quality in Children<br />

with Polyarticular Juvenile Idiopathic Arthritis Treated with<br />

Abatacept over the Long Term.<br />

Daniel J. Lovell 3 , Nicolino Ruperto 15 , Pierre Quartier 19 , Eliana<br />

Paz 13 , Nadina Rubio-Perez 10 , Clovis A. Silva 5 , Carlos Abud-<br />

Mendoza 6 , Ruben Burgos Vargas 7 , Valeria Gerloni 16 , José A.<br />

Melo-Gomes (Andre Dos Santos) 14 , Claudia S. Magalhães 18 ,<br />

Flavio Sztajnbok 12 , Claudia Goldenstein-Schainberg 17 , Morton<br />

Scheinberg 8 , Inmaculada Calvo Penadés 11 , Michel Fischbach 4 ,<br />

Javier Orozco 9 , Lisa Rosenblatt 1 , Monica Mody 1 , Marleen Nys 2 ,<br />

Edward H. Giannini 3 and Alberto Martini 15 , 1Bristol-Myers<br />

Squibb, NJ, 2 Bristol-Myers Squibb, Braine-l’Alleud, Belgium,<br />

3<br />

Cincinnati Children’s Hospital Medical Center, Cincinnati, OH,<br />

4<br />

Hôpital Universitaire Hautepierre, Strasbourg, France, 5 Hospital<br />

Das Clinicas, Sao Paulo, Brazil, 6 Hospital General “Dr Ignacio<br />

Morones Prieto”, San Luis Potosì, Mexico, 7 Hospital General<br />

de México and Universidad Nacional Autónoma de México,<br />

Mexico City, Mexico, 8 Hospital Israelita Albert Einstein, Research<br />

Institute, São Paulo, Brazil, 9 Hospital San Javier, <strong>Rheumatology</strong>,<br />

Guadalajara, Jalisco, Mexico, 10 Hospital Universitario “Dr. J. E.<br />

Gonzalez”, Monterrey, Mexico, 11 Hospital Universitario La Fe,<br />

Valencia, Spain, 12 Hospital Universitario Pedro Ernesto, Rio<br />

de Janeiro, Brazil, 13 Instituto de Salud del Nino, Lima, Peru,<br />

14<br />

Instituto Portugues de Reumatologia, Lisbon, Portugal, 15 IRCCS<br />

G Gaslini, Pediatria II-PRINTO, Università di Genova, Genova,<br />

Italy, 16 Istituto Gaetano Pini, Milan, Italy, 17 Universidade de<br />

São Paulo, São Paulo, Brazil, 18 Universidade Estadual Paulista,<br />

Botucatu, Brazil, 19 Universite Paris-Descartes and Centre de<br />

Reference National Pour les Arthrites, Paris, France<br />

3:30 PM<br />

1408. Jointly Managing Arthritis: Information Needs <strong>of</strong> Children<br />

with Juvenile Idiopathic Arthritis (JIA) and Their Parents.<br />

Jennifer Stinson 4 , Brian M. Feldman 5 , Ciaran Duffy 3 , Adam<br />

Huber 2 , Lori Tucker 1 , Patrick McGrath 2 , Shirley M. Tse 5 , Ross<br />

Hetherington 5 , Lynn Spiegel 5 , Sarah Campillo 3 , Susanne<br />

Benseler 5 , Navreet Gill 5 , Meghan E. White 5 and Abi Vijenthira 5 ,<br />

1<br />

BC Children’s Hospital, 2 IWK Health Centre, 3 Montreal Children’s<br />

Hospital, 4 The Hospital for Sick Children, Toronto, ON, Canada,<br />

5<br />

The Hospital for Sick Children<br />

3:45 PM<br />

1409. Follow-Up Survey on Adolescent <strong>Rheumatology</strong> Patients’<br />

Online Activities and Social Support Systems: Opportunities for<br />

Transition Program Development.<br />

Peter Chira, Stanford University, Palo Alto, CA<br />

ARHP Concurrent Sessions<br />

2:30 - 4:00 PM<br />

B309<br />

From Managed Care to Medicare: Understanding<br />

Reimbursement cP<br />

Moderator: Barbara A. Slusher, PA-C, MSW; League City, TX<br />

Speaker: Kamala M. Nola, PharmD, MS; Lipscomb <strong>College</strong> <strong>of</strong><br />

Pharmacy; Nashville, TN<br />

Session Overview:<br />

The role <strong>of</strong> managed care and Medicare are an ever<br />

increasing component <strong>of</strong> rheumatology practice. Patient care<br />

considerations based on coverage decisions by managed care<br />

and Medicare occur daily. While there are regional variations in<br />

managed care and Medicare plans, both use similar population<br />

management tools to control cost while managing access to<br />

needed medical services and pharmaceuticals. Understanding<br />

the coverage and reimbursement process for medical and<br />

pharmaceutical products and services is critical to rheumatology<br />

health care providers.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the structure and function <strong>of</strong> commercial managed<br />

care companies and Medicare<br />

• differentiate between managed care and Medicare in<br />

coverage <strong>of</strong> medical and pharmaceutical benefits<br />

• describe the impact rheumatology pr<strong>of</strong>essionals can have on<br />

the process<br />

B308<br />

Musculoskeletal Pain and Cognitive Issues Related to<br />

Returning Military Personnel C PM<br />

Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo,<br />

OH<br />

Speakers: Daniel J. Clauw, MD; University <strong>of</strong> Michigan Chronic<br />

Pain & Fatigue Research; Ann Arbor, MI<br />

Mary W. Erickson, OTR, MAOL; Office <strong>of</strong> the Surgeon General<br />

Health Policy and Services; Falls Church, VA<br />

Session Overview:<br />

Pain, joint stiffness, fatigue, lethargy, headaches, and cognitive<br />

problems are common symptoms experienced by those having<br />

served in the US military during the Gulf War. Similar postdeployment<br />

musculoskeletal and somatic symptoms have<br />

been noted in veterans <strong>of</strong> nearly every war. The Veteran’s<br />

Administration has developed the Musculoskeletal Action Plan<br />

with the purpose <strong>of</strong> reducing injury rates, improving medical<br />

readiness, preventing injuries, optimizing performance, and<br />

providing program recommendations.<br />

tuesday<br />

2010 Program Book 75


tuesday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the symptoms commonly experienced by those<br />

serving the US and UK military during the Gulf War and other<br />

wars<br />

• explain the therapies that have been found to be effective for<br />

the treatment <strong>of</strong> these symptoms<br />

• describe the Veteran’s Administration’s Musculoskeletal<br />

Action Plan and how this plan can be utilized<br />

B310<br />

What’s New and Noteworthy in 2010: A Review <strong>of</strong><br />

<strong>Rheumatology</strong> Research for Health Pr<strong>of</strong>essionals C<br />

Moderator: Beverly K. Barham, RN, MSN, CCRC; NIAMS;<br />

Bethesda, MD<br />

2:30 PM<br />

Nursing<br />

Speaker: Elizabeth A. Schlenk, PhD, RN; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

3:00 PM<br />

Physical Therapy<br />

Speaker: Susan E. Klepper, PhD, PT; Columbia University; New<br />

York, NY<br />

3:30 PM<br />

Europe<br />

Speaker: Christina H. Opava, PhD; Karolinska Institutet;<br />

Huddinge, Sweden<br />

Session Overview:<br />

Based on the volume <strong>of</strong> information available, there is a need to<br />

summarize the most important and innovative research findings<br />

for health care providers to assist them in applying the research<br />

finding into practice.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify important research advances published in the<br />

rheumatology nursing, rehabilitation and European<br />

rheumatology arenas within the past 12 months<br />

• describe the significance <strong>of</strong> these advances for the individual<br />

practitioner<br />

• describe the significance <strong>of</strong> these advances for rheumatology<br />

research<br />

ACR/ARHP Workshops<br />

4:00 - 6:00 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B206<br />

Joint Injections (Knee and Ankle Prosthetics) (227)<br />

Speaker: Gregory C. Gardner, MD; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe indications for lower extremity joint injection and<br />

aspiration<br />

• identify anatomic landmarks for injection <strong>of</strong> the knee and<br />

ankle using joint prosthetics<br />

• apply principles <strong>of</strong> joint aspiration and injection using ankle<br />

and knee joint prosthetics<br />

B204<br />

Knee Braces and Foot Orthosis for Knee Osteoarthritis<br />

(228)<br />

Speakers: Howard J. Hillstrom, PhD; Hospital for Special Surgery;<br />

New York, NY<br />

Kelly D. Krohn, MD; Lilly USA, LLC; Indianapolis, IN<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the biomechanical rationale for the use <strong>of</strong> knee braces<br />

and foot orthoses for knee osteoarthritis<br />

• discuss the clinical data to support these modalities<br />

• apply these modalities to their patients<br />

B202<br />

Synovial Fluid Analysis and Crystal Identification<br />

(229)<br />

Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />

Center; Blue Bell, PA<br />

Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;<br />

Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• prepare synovial fluid samples for microscopic examination<br />

• identify various components <strong>of</strong> synovial fluid<br />

• identify crystals in synovial fluid<br />

B203<br />

Systemic Sclerosis: How to Perform Skin Scores (230)<br />

f<br />

Speakers: Daniel E. Furst, MD; University <strong>of</strong> California-Los<br />

Angeles Medical School; Los Angeles, CA<br />

Philip J. Clements, MD, MPH; University <strong>of</strong> California-Los Angeles<br />

School <strong>of</strong> Medicine; Los Angeles, CA<br />

Dinesh Khanna, MD, MSc; University <strong>of</strong> California-Los Angeles;<br />

Los Angeles, CA<br />

Maureen D. Mayes, MD, MPH; University <strong>of</strong> Texas-Houston;<br />

Houston, TX<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the usefulness and reasons to do a modified Rodman<br />

skin score<br />

• explain how to do a modified Rodman skin score<br />

• perform a modified Rodman skin score under the supervision<br />

<strong>of</strong> experts<br />

ACR Basic Science Symposium<br />

4:30 - 6:00 PM<br />

B313<br />

The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />

Towards Prevention <strong>of</strong> Disease? R<br />

Moderators: Paul P. Tak, MD, PhD; Academic Medical Center,<br />

University <strong>of</strong> Amsterdam; Amsterdam, Netherlands<br />

Karim Raza, BA, PhD; University <strong>of</strong> Birmingham; Edgbaston,<br />

Birmingham, United Kingdom<br />

76<br />

2010 Program Book


4:30 PM<br />

Anti-citrullinated Protein Antibodies in the Earliest Stages <strong>of</strong><br />

Rheumatoid Arthritis: Pathology and Promise<br />

Lars Klareskog, MD, PhD; Karolinska University Hospital;<br />

Stockholm, Sweden<br />

5:00 PM<br />

The Earliest Stage <strong>of</strong> Rheumatoid Arthritis in a North <strong>American</strong><br />

Native Population<br />

Hani S. El-Gabalawy, MD; University <strong>of</strong> Manitoba; Winnipeg, MB,<br />

Canada<br />

5:30 PM<br />

Preclinical Rheumatoid Arthritis: Where Does the Disease Start<br />

and Could the Disease be Prevented?<br />

Danielle M. Gerlag, MD, PhD; Academic Medical Center;<br />

Amsterdam, Noord-Holland, Netherlands<br />

Session Overview:<br />

It has recently become possible to study the earliest phases <strong>of</strong><br />

rheumatoid arthritis, including preclinical rheumatoid arthritis.<br />

Studies on early rheumatoid arthritis may provide crucial<br />

insights into its pathogenesis and may <strong>of</strong>fer the perspective<br />

<strong>of</strong> preventive strategies in the future. In this session, recent<br />

data on the pathogenesis <strong>of</strong> early and preclinical rheumatoid<br />

arthritis will be discussed and the outline <strong>of</strong> a recently started<br />

exploratory study aimed at prevention <strong>of</strong> rheumatoid arthritis<br />

will be presented.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the role <strong>of</strong> specific anti-citrullined protein antibodies<br />

in the earliest phase <strong>of</strong> rheumatoid arthritis<br />

• describe the immunogenetic risk in relationship to<br />

autoantibody positivity in a North <strong>American</strong> Native population<br />

with rheumatoid arthritis and their first-degree relatives<br />

• explain the changes in different compartments, including the<br />

synovial tissue, in the preclinical phase <strong>of</strong> rheumatoid arthritis<br />

ACR Clinical Symposia<br />

4:30 - 6:00 PM<br />

Thomas J. Murphy Ballroom<br />

Inflammatory Myopathy Update C PM PS<br />

Moderator: Chester V. Oddis, MD; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

4:30 PM<br />

Diagnostic Modalities in the Inflammatory Myopathies:<br />

Emerging Concepts<br />

Lisa Christopher-Stine, MD; Johns Hopkins University; Baltimore,<br />

MD<br />

4:55 PM<br />

Autoantibodies in Myositis: Clinical Relevance and Pathogenic<br />

Considerations<br />

Harsha Gunawardena, MD; University <strong>of</strong> Bath; Bath, United<br />

Kingdom<br />

5:50 PM<br />

Exercise Intervention in the Management <strong>of</strong> Myositis<br />

Ingrid E. Lundberg, MD, PhD; Karolinska Institutet; Stockholm,<br />

Sweden<br />

Session Overview:<br />

Patients with myositis continue to present challenges from a<br />

diagnostic and management standpoint. The topics covered in<br />

this symposium will aid the practicing rheumatologist in their<br />

assessment <strong>of</strong> patients with polymyositis and dermatomyositis.<br />

In addition to the routine diagnostic tools, there are important<br />

imaging options to consider in the assessment <strong>of</strong> myositis.<br />

Autoantibodies in myositis are important in the classification<br />

and prognosis <strong>of</strong> patients and many rheumatologists struggle<br />

with the clinical relevance <strong>of</strong> autoantibody assessment. Newer<br />

specificities may be more clinically useful. The management<br />

<strong>of</strong> myositis rarely included an exercise program, but recent<br />

data has shifted the paradigm and this symposium will review<br />

the importance <strong>of</strong> exercise in the treatment <strong>of</strong> inflammatory<br />

myopathy.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify and interpret newer diagnostic modalities in the<br />

assessment and management <strong>of</strong> patients with inflammatory<br />

myopathy<br />

• utilize autoantibodies in the clinical assessment <strong>of</strong> myositis<br />

and recognize their importance in the pathogenesis <strong>of</strong> disease<br />

• distinguish the beneficial effects <strong>of</strong> an exercise program in the<br />

treatment <strong>of</strong> patients with both active and inactive myositis<br />

Hall A3<br />

Update on Safety Issues in the Treatment <strong>of</strong><br />

Rheumatic Diseases – From the Food and Drug<br />

Administration and Beyond cP PS<br />

Moderators: Daniel J. Lovell, MD, MPH; Children’s Hospital<br />

Medical Center; Cincinnati, OH<br />

Eric M. Ruderman, MD; Northwestern University School;<br />

Chicago, IL<br />

4:30 PM<br />

Introduction - Update on Newly Identified Drug Safety Issues<br />

and Initiatives from the ACR Drug Safety Subcommittee<br />

Daniel J. Lovell, MD, MPH; Children’s Hospital Medical Center;<br />

Cincinnati, OH<br />

4:50 PM<br />

Update on Safety Issues and Food and Drug Administration<br />

Initiatives, Including Risk Evaluation and Mitigation Strategies<br />

Larissa Y. Lapteva, MD, MHS; Food and Drug Administration;<br />

Rockville, MD<br />

5:40 PM<br />

Question and Answer<br />

Session Overview:<br />

Timely communication <strong>of</strong> evolving safety information is a<br />

critical element in the ability <strong>of</strong> practitioners to provide the best<br />

care for their patients with rheumatic diseases. This session<br />

will provide an update to rheumatologists on late-breaking or<br />

evolving topics in patient safety, including any relevant Food and<br />

Drug Administration analysis or response to these issues.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify important safety issues in the drug treatment <strong>of</strong><br />

rheumatic diseases<br />

• integrate knowledge <strong>of</strong> new safety issues into their treatment<br />

strategies<br />

tuesday<br />

2010 Program Book 77


tuesday<br />

78<br />

• advise patients about the safety issues related to treatments<br />

for rheumatic diseases<br />

• describe the evolutions at the Food and Drug Administration<br />

that will affect drug safety monitoring and reporting<br />

ACR Concurrent Abstract Sessions<br />

4:30 - 6:00 PM<br />

A402<br />

B-Cell Biology and Targets in Autoimmune Disease<br />

Moderators: Chaim Putterman, MD; Albert Einstein <strong>College</strong> <strong>of</strong><br />

Medicine; Bronx, NY<br />

Yehuda Shoenfeld, MD; Sheba Medical Center; Ramat Gan, Israel<br />

4:30 PM<br />

1410. TLR7 and IFNα Influence B Cell Selection in the Germinal<br />

Center.<br />

Ioana Moisini 1 , Weiqing Huang 1 , Tony Marion 3 and Anne<br />

Davidson 2 , 1 Feinstein Institute, 2 Feinstein Institute for Medical<br />

Research, Manhasset, NY, 3 University <strong>of</strong> Tennessee<br />

4:45 PM<br />

1411. Impaired Somatic Hypermutation in Pre-Switch Memory<br />

B Cells and Modulation <strong>of</strong> Mutational Targeting in Memory B<br />

Cells during Tocilizumab Treatment in RA Patients.<br />

Khalid Muhammad 1 , Petra Roll 1 , Stefan Kleinert 2 , Thomas<br />

Seibold 2 , Martin Feuchtenberger 2 , Thomas Dörner 3 and Hans-<br />

Peter Tony 2 , 1 Department <strong>of</strong> Medicine II, <strong>Rheumatology</strong>/Clinical<br />

Immunology, University <strong>of</strong> Würzburg, Würzburg, Bayern,<br />

Germany, 2 Department <strong>of</strong> Medicine II, <strong>Rheumatology</strong>/Clinical<br />

Immunology, University <strong>of</strong> Würzburg, Würzburg, Germany,<br />

3<br />

Dept. <strong>of</strong> Medicine/<strong>Rheumatology</strong> and Clinical Immunology<br />

Charite Universitätsmedizin Berlin and DRFZ Berlin, Berlin,<br />

Germany<br />

5:00 PM<br />

1412. IL-17 Downregulates NF-КкB1/p50 and Upregulates<br />

BCL6 To Promote Germinal Center B Cell Differentiation in<br />

Autoimmune BXD2 Mice.<br />

Shutao Xie 2 , Hui-Chen Hsu 2 , Jun Li 2 , Qi Wu 2 , PingAr Yang 2 and<br />

John D. Mountz 1 , 1 Univ Alabama at Birmingham, Birmingham,<br />

AL, 2 Univ Alabama at Birmingham<br />

5:15 PM<br />

1413. Targeting the Splicing <strong>of</strong> mRNA in Autoimmune Diseases:<br />

BAFF Inhibition in Sjögren’s Syndrome as a Pro<strong>of</strong> <strong>of</strong> Concept.<br />

Nienke Roescher 5 , Jelle L. Vosters 2 , Ghada Al Saleh 6 , Patrick<br />

Dreyfus 7 , Sebastien Jacques 4 , Luis Garcia 7 , Gilles Chiocchia 4 ,<br />

Antoine Francois 6 , Jean Sibilia 6 , Paul P. Tak 1 , Jay A. Chiorini 5 ,<br />

Xavier Mariette 3 and Jacques-Eric Gottenberg 6 , 1 Academic<br />

Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

2<br />

Academic Medical Center/University <strong>of</strong> Amsterdam, 3 Bicetre<br />

Hospital, 4 Cochin Hospital, 5 National Institutes <strong>of</strong> Health,<br />

National Institute <strong>of</strong> Dental and Crani<strong>of</strong>acial Research,<br />

6<br />

Strasbourg Hospital, EA 4438, 7 UMR 7215 CNRS, Institut de<br />

Myologie<br />

5:30 PM<br />

1414. Adoptive Transfer <strong>of</strong> Long-Lived Plasma Cells from<br />

NZB/W Mice Causes Immune Complex Nephritis in Recipient<br />

Rag1-/- Mice.<br />

IImtiaz M. Mumtaz 1 , Bimba F. Hoyer 1 , Andreas Radbruch 4 and<br />

Falk Hiepe 2 , 1 Charité - Universitätsmedizin, Berlin, Germany,<br />

2010 Program Book<br />

2<br />

Charité - Universitätsmedizin, Berlin, Berlin, Germany,<br />

3<br />

Charité - Universitätsmedizin Berlin, Berlin, Germany, 4 German<br />

Rheumatism Research Center, Berlin, Germany<br />

5:45 PM<br />

1415. B Cells Induced Proteinuria and Glomerulopathy in<br />

Absence <strong>of</strong> Immune Complexes Similar to Minimal Change<br />

Disease.<br />

Alfred H. Kim 1 and Andrey S. Shaw 2 , 1 Washington Univ School <strong>of</strong><br />

Med, St. Louis, MO, 2 Washington Univ School <strong>of</strong> Med<br />

A411<br />

Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />

Moderators: Bruce N. Cronstein, MD; New York University<br />

Medical Center; New York, NY<br />

Zoltan Szekanecz, MD, PhD, DSC; University <strong>of</strong> Debrecen Medical<br />

Center; Debrecen, Hungary<br />

4:30 PM<br />

1416. Nuclear Factor-кB Inducing Kinase Is Preferentially<br />

Expressed in Rheumatoid Arthritis Synovial Tissue Containing<br />

Ectopic Lymphoid Neogenesis.<br />

Ae-Ri Noort 2 , Katinka P. M. van Zoest 3 , Mariagrazia Modesti 4 ,<br />

Sander W. Tas 2 and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />

Center/University <strong>of</strong> Amsterdam, The Netherlands, 3 Academic<br />

Medical Center/University <strong>of</strong> Amsterdam, 4 University <strong>of</strong> Rome<br />

4:45 PM<br />

1417. CXCL16 as an Early Response Chemokine in Rat Adjuvant<br />

and K/BxN Serum Induced Arthritis Models.<br />

Jeffrey H. Ruth 2 , Chrisitian S. Haas 1 , M. Asif Amin 2 , G.<br />

Kenneth Haines III 4 and Alisa E. Koch 3 , 1 University <strong>of</strong> Luebeck<br />

- Department <strong>of</strong> Medicine I, Luebeck, Germany, 2 University <strong>of</strong><br />

Michigan Medical School, Ann Arbor, MI, 3 Unversity <strong>of</strong> Michigan,<br />

Ann Arbor, MI, 4 Yale University Medical School<br />

5:00 PM<br />

1418. Angiogenic Potential <strong>of</strong> HMECs Is Driven by HIF-2α<br />

Overcoming the Effects <strong>of</strong> HIF-1α.<br />

Martin Hahne 2 , Steffi Luetkecosmann 1 , Cam Loan Tran 1 , Ferenz<br />

Lohanatha 1 , Manuela Jakstadt 6 , Grit Kasper 4 , Georg Duda 4 , Paula<br />

Kolar 4 , Timo Gaber 1 , Gerd R. Burmester 3 and Frank Buttgereit 5 ,<br />

1<br />

Berlin-Brandenburg Center for Regenerative Medicine, 2 Berlin-<br />

Brandenburg School for Regenerative Medicine, Germany,<br />

3<br />

Charite - University Medicine, Berlin, Germany, 4 Charite -<br />

University Medicine, 5 Charite University Med-Berlin, Berlin,<br />

Germany, 6 German Rheumatism Research Center<br />

5:15 PM<br />

1419. Soluble Junctional Adhesion Molecule-A Promotes<br />

Angiogenesis in Rheumatoid Arthritis.<br />

Bradley J. Rabquer 1 , George Boychev 2 , Jeffrey H. Ruth 2 , Thilo<br />

Stehle 3 and Alisa E. Koch 4 , 1University <strong>of</strong> Michigan, Ann Arbor,<br />

MI, 2 University <strong>of</strong> Michigan, 3 University <strong>of</strong> Tubingen, 4 Unversity<br />

<strong>of</strong> Michigan, Ann Arbor, MI.<br />

5:30 PM<br />

1420. Invasiveness <strong>of</strong> Rheumatoid Arthritis Synovial Fibroblasts<br />

Is Affected by Extracellular RNA and DNA.<br />

Birgit Zimmermann 3 , Silvia Fischer 1 , Stephanie Lefèvre 4 , Angela<br />

Lehr 6 , Jürgen Steinmeyer 5 , Henning Stürz 2 , Thomas Umscheid 7 ,<br />

Ulf Müller-Ladner 3 , Klaus T. Preissner 1 and Elena Neumann 3 ,<br />

1<br />

Dept <strong>of</strong> Biochemistry, Justus-Liebig-University Giessen, 2 Dept


<strong>of</strong> Experimental Orthopedics, University Hospital Giessen<br />

and Marburg, 3 Dept <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>,<br />

Justus-Liebig-University Giessen, Kerckh<strong>of</strong>f-Klinik, Bad Nauheim,<br />

Germany, 4 Dept <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, Justus-<br />

Liebig-University Giessen, Kerckh<strong>of</strong>f-Klinik, Bad Nauheim, 5 Dept<br />

<strong>of</strong> Orthopedics and Orthopedic Surgery, University Hospital<br />

Giessen and Marburg, 6 Dept <strong>of</strong> Orthopedics and Trauma Surgery,<br />

Markuskrankenhaus Frankfurt, Germany, 7 Dept <strong>of</strong> Vascular<br />

Surgery, Helios William Harvey Klinik<br />

5:45 PM<br />

1421. Citrullination <strong>of</strong> Extracellular Matrix Proteins Inhibits<br />

Synovial Fibroblast Invasion and Migration.<br />

Miriam A. Shelef 1 , David A. Bennin 3 and Anna Huttenlocher 2 ,<br />

1<br />

Department <strong>of</strong> Medicine, University <strong>of</strong> Wisconsin, Madison,<br />

WI, 2 Medical Microbiology & Immunology and Pediatrics,<br />

University <strong>of</strong> Wisconsin, Madison, WI, 3 Medical Microbiology &<br />

Immunology and Pediatrics, University <strong>of</strong> Wisconsin, Madison,<br />

WI<br />

A410<br />

Cytokines, Mediators, Gene Regulation II<br />

Moderators: Erik Lubberts, PhD; Erasmus MC; Rotterdam, ZH,<br />

The Netherlands<br />

Carla R. Scanzello, MD, PhD; Rush University Medical Center;<br />

Chicago, IL<br />

4:30 PM<br />

1422. The Role <strong>of</strong> miR-155 in the Activation <strong>of</strong> RA and PsA<br />

Synovial Fluid Monocytes.<br />

Mariola S. Kurowska-Stolarska 3 , Lucy Ballantine 3 , Bartosz E.<br />

Stolarski3, John Hunter 1 , Foo Y. Liew 4 , J. Alastair Gracie 4 and<br />

Iain B. McInnes 2 , 1 Gartnavel General Hospital, United Kingdom,<br />

2<br />

University <strong>of</strong> Glasgow, Glasgow, United Kingdom, 3 University<br />

<strong>of</strong> Glasgow, Glasgow, United Kingdom, 4 University <strong>of</strong> Glasgow,<br />

United Kingdom<br />

I. Kone-Paut 4 , H. J. Lachmann 12 , J. B. Kuemmerle-Deschner 6 ,<br />

E. Hachulla 3 , R. Cartwright 1 , J. Hoyer 2 , P. Quartier 11 , J. Smith 13 ,<br />

M. Gattorno 5 , K. Leslie 10 , J. Braun 9 , A. Widmer 7 , A. Ferreira 7 ,<br />

N. Patel 8 , R. Preiss 8 and P. N. Hawkins 12 , 1 Allergy Center at<br />

Brookstone, Columbus, GA, 2 Department <strong>of</strong> Internal Medicine<br />

and Nephrology, Universitaetsklinikum Giessen und Marburg<br />

GmbH, Marburg, Germany, 3 Hôpital Claude Huriez CHRU, Lille<br />

Cedex, France, 4 Hôpital Kremlin Bicetre, CEREMAI, Le Kremlin<br />

Bicetre, France, 5 Istituto Giannina Gaslini, Genova, Italy,<br />

6<br />

Klinik fuer Kinder-und Jugendmedizin, Universitaetsklinikum,<br />

Tuebingen, Germany, 7 Novartis Pharma AG, Basel, Switzerland,<br />

8<br />

Novartis Pharmaceuticals Corporation, East Hanover, NJ,<br />

9<br />

Rheumazentrum Ruhrgebiet, Herne, Germany, 10 UCSF School<br />

<strong>of</strong> Medicine, San Francisco, CA, 11 Unit’e d’Immunologie,<br />

Hematologie et Rhumatologie Pediatrique, Hopital Necker-<br />

Enfants Malades, Paris, France, 12 University <strong>College</strong> London<br />

Medical School, London, United Kingdom, 13 University <strong>of</strong><br />

Wisconsin Hospital and Clinics, Madison, WI<br />

5:30 PM<br />

1426. Osteoarthritis-Associated Basic Calcium Phosphate<br />

Crystals Activate the NLRP3 Inflammasome in a Syk Kinase<br />

Dependent Manner.<br />

Aisling Dunne 2 , Lisa Mielke 2 , Jurg Tschopp 3 , Kingston H. G. Mills 2<br />

and Geraldine M. McCarthy 1 , 1 Royal <strong>College</strong> <strong>of</strong> Surgeons, Ireland<br />

& Mater Hospital, Ireland, 2 Trinity <strong>College</strong> Dublin, Ireland,<br />

3<br />

University <strong>of</strong> Luasanne, Switzerland<br />

5:45 PM<br />

1427. Lipid-Cytokine-Chemokine Cascade Drives Neutrophil<br />

Recruitment in a Murine Model <strong>of</strong> Inflammatory Arthritis.<br />

Nancy D. Kim 3 , Richard C. Chou 1 , Christian Sadik 2 , Edward Seung 2 ,<br />

Yinan Lan 2 , Yoichiro Iwakura 4 and Andrew Luster 2 , 1 Dartmouth-<br />

Hitchcock Medical Center, Lebanon, NH, 2 Massachusetts<br />

General Hospital, 3 Massachusetts General Hospital, Boston, MA,<br />

4<br />

University <strong>of</strong> Tokyo<br />

tuesday<br />

4:45 PM<br />

1423. Rapid Improvement in Health-Related Quality <strong>of</strong> Life<br />

(HRQoL) in Gouty Arthritis Patients Treated with Canakinumab<br />

(ACZ885) Compared to Triamcinolone Acetonide.<br />

A. So 6 , M. De Meulemeester 4 , A. Pikhlak 2 , A. E. Yücel 1 , U.<br />

Arulmani 3 , D. Richard 3 , K. Stricker 3 , A. Ferreira3, V. Murphy 3 , P.<br />

Sallstig 3 and N. Schlesinger 5 , 1 Baskent University, Ankara, Turkey,<br />

2<br />

Moscow State University <strong>of</strong> Medicine and Dentistry, Moscow,<br />

Russian Federation, 3 Novartis Pharma AG, Basel, Switzerland,<br />

4<br />

Private PracticeGozée, Gozée, Belgium, 5 UMDNJ-Robert Wood<br />

Johnson Medical School, New Brunswick, NJ, 6 University <strong>of</strong><br />

Lausanne, Lausanne, Switzerland<br />

5:00 PM<br />

1424. Toll-Like Receptor Signals Modify the ER Stress Response.<br />

Jane C. Goodall 1 , Louise McNeill 2 , Lou Ellis 2 and J. Hill Gaston 2 ,<br />

1<br />

Cambridge University, Cambridge, Cambs, United Kingdom,<br />

2<br />

Cambridge University<br />

5:15 PM<br />

1425. Canakinumab (ILARIS®) Improves Health-Related Quality<br />

<strong>of</strong> Life (HRQoL) in Patients with Cryopyrin-Associated Periodic<br />

Fever Syndrome (CAPS): Results <strong>of</strong> a Phase III, Open-Label<br />

Study in a Large Cohort <strong>of</strong> CAPS Patients.<br />

A315<br />

Education<br />

Moderators: Abby Goulder Abelson, MD; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Joan Marie Von Feldt, MD, MS Ed; University <strong>of</strong> Pennsylvania-<br />

Philadelphia, Veterans Affairs Medical Center; Philadelphia, PA<br />

4:30 PM<br />

1428. The Impact <strong>of</strong> Patient-Physician Relationship<br />

Components on Physician Trust and Treatment Adherence in<br />

Patients with Rheumatic Disease.<br />

S<strong>of</strong>ia de Achaval 1 , Michael A. Kallen 1 , Vanessa L. Cox 1 , Marsha<br />

N. Richardson 1 and Maria E. Suarez-Almazor 2 , 1 The University <strong>of</strong><br />

Texas M. D. Anderson Cancer Center, Houston, TX, 2 University <strong>of</strong><br />

Texas, MD Anderson Cancer Center, Houston, TX<br />

4:45 PM<br />

1429. Development <strong>of</strong> an ACMGE Core Competency-Based<br />

Electronic Portfolio at the USC-LAC <strong>Rheumatology</strong> Fellowship<br />

Program.<br />

Karina Marianne D. Torralba 2 , Francisco P. Quismorio 3 , Beatrice<br />

A. Boateng 1 and Shylaja Rachabattula 4 , 1 Arkansas Children’s<br />

Hospital-University <strong>of</strong> Arkansas for Medical Sciences, 2 University<br />

<strong>of</strong> Southern California-Los Angeles County Medical Center,<br />

Pasadena, CA, 3 University <strong>of</strong> Southern California-Los Angeles<br />

2010 Program Book 79


tuesday<br />

County Medical Center, Los Angeles, CA, 4 University <strong>of</strong> Southern<br />

California-Los Angeles County Medical Center<br />

5:00 PM<br />

1430. An Updated Immunology Curriculum for <strong>Rheumatology</strong><br />

Fellows.<br />

Rahul K. Patel 1 , Lisa Hodge 1 , Jerry Simecka 1 and Bernard R.<br />

Rubin 2 , 1 UNT Health Science Center, Fort Worth, TX, 2 UNT Health<br />

Science Center, Birmingham, MI<br />

5:15 PM<br />

1431. A Case-Controlled Study <strong>of</strong> a Multimodal <strong>Rheumatology</strong><br />

Elective for Medical Residents.<br />

Deana M. Lazaro 4 , Sheen Yee Lim 2 , David R. Blumenthal 3 , Joshua<br />

Scheers-Masters 1 , Jeanne Macrae 1 and Matthew Avitable 1 ,<br />

1<br />

SUNY Downstate Medical Center, 2 SUNY Downstate-Brooklyn,<br />

Brooklyn, NY, 3 VA New York Harbor Healthcare System, Short<br />

Hills, NJ, 4 VA New York Harbor Healthcare System and SUNY<br />

Downstate Medical Center, Brooklyn, NY<br />

5:30 PM<br />

1432. Effect <strong>of</strong> Internal Medicine Resident Participation<br />

in Team-Based Learning on In-Training Exam Scores in<br />

<strong>Rheumatology</strong>.<br />

Karina Marianne D. Torralba 2 , Beatrice A. Boateng 1 , Ron Ben-Ari 3<br />

and Francisco P. Quismorio 2 , 1 Arkansas Children’s Hospital-<br />

University <strong>of</strong> Arkansas for Medical Sciences, 2 University <strong>of</strong><br />

Southern California-Los Angeles County Medical Center, Los<br />

Angeles, CA, 3 University <strong>of</strong> Southern California-Los Angeles<br />

County Medical Center<br />

5:45 PM<br />

1433. “Rheumapalooza”: An Intensive <strong>Rheumatology</strong><br />

Curriculum for Second Year Medical Students.<br />

Helen Emery 1 and Gregory Gardner 2 , 1 Seattle Children’s Hospital,<br />

2<br />

University <strong>of</strong> Washington<br />

A404<br />

Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic<br />

Aspects-Therapeutics<br />

Moderators: Egla C. Rabinovich, MD, MPH; Duke University<br />

Medical Center; Durham, NC<br />

Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,<br />

NY<br />

4:30 PM<br />

1434. Tocilizumab in Patients with Systemic Juvenile Idiopathic<br />

Arthritis: Efficacy Data from the Placebo-Controlled 12-Week<br />

Part <strong>of</strong> the Phase 3 TENDER Trial.<br />

Fabrizio De Benedetti 1 , Hermine Brunner 4 , Nicola Ruperto 9 ,<br />

Inmaculada Calvo 5 , Ruben Cuttica 10 , Clara Malattia 11 , Rayfel<br />

Schneider 2 , Patricia Woo 7 , Carine H. Wouters 8 , Ricardo Xavier 6 ,<br />

Lawrence S. Zemel 3 , Stephen Wright 12 , Andrew Kenwright 12 ,<br />

Alberto Martini 9 and Daniel J. Lovell 4 , 1 IRCCS Ospedale Pediatrico<br />

Bambino Gesu, Rome, Italy, 2 PRCSG, Toronto, ON, Canada,<br />

3<br />

PRCSG, Hartford, CT, 4 PRCSG, Cincinnati, OH, 5 PRINTO, Valencia,<br />

Spain, 6 PRINTO, Porto Alegre, Brazil, 7 PRINTO, London, United<br />

Kingdom, 8 PRINTO, Leuven, Belgium, 9 PRINTO, Genova, Italy,<br />

10<br />

PRINTO, Buenos Aires, Argentina, 11 PRINTO, 12 Roche, Welwyn,<br />

UK, Welwyn, United Kingdom<br />

4:45 PM<br />

1435. Canakinumab (ILARIS ® ) Provides Rapid Response and<br />

Sustained Remission in Children across Different Disease<br />

Severity Phenotypes <strong>of</strong> Cryopyrin Associated Periodic<br />

Syndrome (CAPS).<br />

P. Quartier 13 , E. Hachulla 2 , M. Gattorno 5 , R. Cartwright 1 , I. Kone-<br />

Paut 4 , F. Zulian 15 , E. Weisbarth-Riedel 6 , L. Lepore 10 , J. Hoyer 12 , I.<br />

Foeldvari 16 , E. Ramos 3 , P. N. Hawkins 14 , K. Leslie 11 , G. Krammer 8 ,<br />

R. Preiss 9 , A. Widmer 8 and J. B. Kuemmerle-Deschner 7 , 1Allergy<br />

Center at Brookstone, Columbus, GA, 2 Department <strong>of</strong> Internal<br />

Medicine, Hôpital Claude Huriez CHRU, Lille Cedex, France,<br />

3<br />

Department <strong>of</strong> Pediatrics, Hospital Central de Asturias, Oviedo,<br />

Spain, 4 Hôpital Kremlin Bicetre, CEREMAI, Le Kremlin Bicetre,<br />

France, 5 Istituto Giannina Gaslini, Genova, Italy, 6 Kinderklinik,<br />

Rheum. Ambulanz, Universitätsklinikum Hamburg-Eppendorf,<br />

Hamburg, Germany, 7 Klinik fuer Kinder-und Jugendmedizin,<br />

Universitaetsklinikum, Tuebingen, Germany, 8 Novartis Pharma<br />

AG, Basel, Switzerland, 9 Novartis Pharmaceuticals Corporation,<br />

East Hanover, NJ, 10 S.C.U. Clinica Pediatrica, IRCCS Burlo<br />

Gar<strong>of</strong>olo, Trieste, Italy, 11 UCSF School <strong>of</strong> Medicine, San Francisco,<br />

CA, 12 Universitaetsklinikum Giessen und Marburg GmbH,<br />

Marburg, Germany, 13 Universite Paris-Descartes and Unite<br />

d’Immuno-Hematologie et Rhumatologie Pediatrique, Necker-<br />

Enfants Malades, Assistance Publique Hopitaux de Paris, Paris,<br />

France, 14 University <strong>College</strong> London Medical School, London,<br />

UK, 15 University <strong>of</strong> Padova School <strong>of</strong> Medicine, Padova, Italy,<br />

16<br />

Zentrum für Reumatologie, Hamburger Zentrum fuer Kinderund<br />

Jugendrheumatologie, Hamburg, Germany<br />

5:00 PM<br />

1436. Prevention <strong>of</strong> Flare Recurrences in Childhood Refractory<br />

Chronic Uveitis: An Open-Label Comparative Study <strong>of</strong><br />

Adalimumab Versus Infliximab.<br />

Gabriele Simonini 5 , Andrea Taddio 1 , Marco Cattalini 4 , Roberto<br />

Caputo 3 , Cinzia De Libero 2 , Cecilia Bresci 5 , Monica Lorusso 5 ,<br />

Samuele Naviglio 1 , Loredana Lepore1 and Rolando Cimaz 5 ,<br />

1<br />

Department <strong>of</strong> Sciences <strong>of</strong> Reproduction and Development,<br />

Institute <strong>of</strong> Child Health, IRCCS Burlo Gar<strong>of</strong>olo, University <strong>of</strong><br />

Trieste, Trieste, Italy, 2 Opthalmology Unit, A.Meyer’s Children’s<br />

Hospital, Firenze, Italy, 3 Opthalmology Unit, A.Meyer’s Childrens<br />

Hospital, Firenze, Italy, 4 Pediatric Clinic, University <strong>of</strong> Brescia,<br />

Brescia, Italy, 5 <strong>Rheumatology</strong> Unit, Dpt <strong>of</strong> Pediatrics, University<br />

<strong>of</strong> Florence, A.Meyer’s Childrens Hospital, Firenze, Italy<br />

5:15 PM<br />

1437. Safety and Low Seroprotection/Seroconversion Rates <strong>of</strong><br />

Pandemic Influenza A Vaccine (Anti-H1N1/2009) in Juvenile<br />

Systemic Lupus Erythematosus.<br />

Lucia M. Campos 3 , Clovis A. A. Silva 3 , Nadia Aikawa 3 , Eloisa<br />

Bonfa 5 , Guilherme Trudes 3 , Ana Cristina M. Ribeiro 5 , Carla<br />

Gonçalves Saad 5 , Vilma Trindade Viana 5 , Maria do Carmo<br />

Timenetsky 1 , Alexander R. Precioso 2 and Rosa M. R. Pereira 4 ,<br />

1<br />

Instituto Adolpho Lutz, 2 Instituto Butantã, 3 Paediatric<br />

<strong>Rheumatology</strong> Unit, Faculdade de Medicina da Universidade de<br />

São Paulo, 4 <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />

Universidade de São Paulo, São Paulo, SP, Brazil, 5 <strong>Rheumatology</strong><br />

Division, Faculdade de Medicina da Universidade de São Paulo<br />

80<br />

2010 Program Book


5:30 PM<br />

1438. Mortality/Morbidity in Cardiac Neonatal Lupus and<br />

Associated Maternal/Fetal Risk Factors.<br />

Peter M. Izmirly 1 , Amit Saxena 1 , Zoey Smith 2 and Jill P. Buyon 1 ,<br />

1<br />

NYU School <strong>of</strong> Medicine, New York, NY, 2 NYU School <strong>of</strong><br />

Medicine<br />

5:45 PM<br />

1439. Methotrexate in Children with Juvenile Localized<br />

Scleroderma: A Randomized, Double-Blind, Placebo-Controlled<br />

Trial.<br />

Francesco Zulian 7 , Cristina Vallongo 8 , Giorgia Martini 8 , Fernanda<br />

Falcini 5 , Annalisa Patrizi 4 , Maria Alessio 3 , Francesco La Torre 6 ,<br />

Mario Cutrone 1 , Anna Belloni-Fortina 8 , Mauro Paradisi 2 , Silvana<br />

Martino 9 , Fabio Vittadello 8 and Giorgio Perilongo 8 , 1 Children’s<br />

Hospital <strong>of</strong> Mestre, 2 Dermatology, IDI IRCCS, Rome, 3 University<br />

Federico II Naples, 4 University <strong>of</strong> Bologna, 5 University <strong>of</strong><br />

Florence, Florence, Italy, 6 University <strong>of</strong> Messina, 7 University <strong>of</strong><br />

Padua, Padua, Italy, 8 University <strong>of</strong> Padua, 9 University <strong>of</strong> Turin<br />

Sidney J. Marcus Auditorium<br />

Rheumatoid Arthritis - Clinical Aspects: Outcomes<br />

Associated with Biologic Therapy for RA II<br />

Moderators: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

Joseph A. Markenson, MD, MPH; Hospital for Special Surgery;<br />

New York, NY<br />

4:30 PM<br />

1440. Methotrexate but Not TNF-Blockers Reduces Immune<br />

Response Following Pneumococcal Vaccination Using 7-Valent<br />

Conjugate Pneumococcal Vaccine (Prevenar®) in Adult Patients<br />

with Established Arthritis.<br />

Meliha C. Kapetanovic 5 , Carmen Roseman 5 , Göran Jönsson 1 ,<br />

Lennart Truedsson 4 , Tore Saxne 3 and Pierre Geborek 2 , 1 Dept<br />

<strong>of</strong> Clinical Sciences Lund, Section <strong>of</strong> Infectious Diseases, Lund<br />

University, Lund, Sweden, 2 Dept <strong>of</strong> Clinical Sciences Lund,<br />

Section <strong>of</strong> <strong>Rheumatology</strong>, Lund University, Lund, Sweden,<br />

3<br />

Dept <strong>of</strong> Clinical Sciences Lund, Section <strong>of</strong> <strong>Rheumatology</strong>, Lund<br />

University, Sweden, 4 Dept <strong>of</strong> Laboratory Medicine, Section <strong>of</strong><br />

Microbiology, Immunology and Glycobiology, Lund University,<br />

Lund, Sweden, 5 Section <strong>of</strong> <strong>Rheumatology</strong>, Lund University, Lund,<br />

Sweden<br />

4:45 PM<br />

1441. Lipid and Inflammation Parameters: A Translational,<br />

Randomized Placebo-Controlled Study To Evaluate Effects <strong>of</strong><br />

Tocilizumab: The MEASURE Study.<br />

Iain B. McInnes 7 , Janet S. Lee 6 , Wen Wu 6 , Jon T. Giles 5 , Joan<br />

M. Bathon 5 , Jane E. Salmon 4 , Andre D. Beaulieu 2 , Christine E.<br />

Codding 3 , Christian Delles 1 and Naveed Sattar 1 , 1 British Heart<br />

Foundation, Glasgow, United Kingdom, 2 Centre de Rhumatologie<br />

St-Louis, Montreal, QC, Canada, 3 Health Research <strong>of</strong> Oklahoma,<br />

Oklahoma City, OK, 4 Hospital for Special Surgery, New York, New<br />

York, NY, 5 Johns Hopkins University, Baltimore, MD, 6 Roche,<br />

Nutley, NJ, 7 University <strong>of</strong> Glasgow, Glasgow, United Kingdom<br />

5:00 PM<br />

1442. Tumor Necrosis Factor-α Inhibitors and Reduced Risk <strong>of</strong><br />

Developing Diabetes in Patients with Rheumatoid Arthritis.<br />

Jana Antohe 1 , Androniki Bili 1 , Jennifer A. Sartorius 2 , H. Lester<br />

Kirchner 2 , Stephanie J. Morris 1 , Sorina Dancea 1 and Mary Chester<br />

Wasko 3 , 1 Geisinger Health System, Danville, PA, 2 Geisinger Health<br />

System, 3 Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA<br />

5:15 PM<br />

1443. Superior Protection Against “Vulnerable” Coronary<br />

Plaque in Asymptomatic TNFi-Responders vs. DMARD<br />

Responders with Rheumatoid Arthritis (RA).<br />

George A. Karpouzas 1 , Naser Ahmadi2, Tae-Young Choi 2 ,<br />

Fereshteh Hajsadeghi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 ,<br />

1<br />

Harbor-UCLA, Long Beach, CA, 2Harbor-UCLA<br />

5:30 PM<br />

1444. Discontinuation <strong>of</strong> TNF-Inhibitor Treatment in Clinical<br />

Practice Has a Negative Impact on Radiographic Progression 2<br />

Years after Initiation <strong>of</strong> Therapy. Results from the Nationwide<br />

Danish DANBIO Registry.<br />

Lykke M. Ørnbjerg 1 , Mikkel Østergaard 1 , Pernille Bøyesen 13 ,<br />

Anja Thormann 1 , Ulrik Tarp 6 , Wolfgang Böhme 14 , Ditte<br />

Dencker 14 , Hanne Lindegaard 16 , Uta Poulsen 15 , Anette Hansen 2 ,<br />

Vibeke Ringsdal 5 , Anette Schlemmer 5 , Niels Graudal 10 , Anne<br />

R. Andersen 12 , Jakob Espesen 4 , Gina Kollerup 7 , Torben G.<br />

Christensen 11 , Randi Pelck 3 , Bente Glintborg 3 , Ole R. Madsen 2 ,<br />

Dorte V. Jensen 8 , Ole Majgaard 9 and Merete L. Hetland 1 ,<br />

1<br />

DANBIO Registry and Depts. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen<br />

University Hospitals at Hvidovre and Glostrup, Denmark,<br />

2<br />

Dept. <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, Gent<strong>of</strong>te<br />

University Hospital, Denmark, 3 Dept. <strong>of</strong> Internal Medicine,<br />

Copenhagen University Hospital at Holbæk, Denmark, 4 Dept.<br />

<strong>of</strong> Internal Medicine, Hospital Lillebaelt at Vejle, Denmark,<br />

5<br />

Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital at ålborg,<br />

Denmark, 6 Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital,<br />

Denmark, 7 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />

Hospital at Frederiksberg, Denmark, 8 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Copenhagen University Hospital at Hørsholm, Denmark, 9 Dept.<br />

<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at Næstved,<br />

Denmark, 10 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />

Hospital at Rigshospitalet, Denmark, 11 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Copenhagen University Hospital at Slagelse, Denmark, 12 Dept. <strong>of</strong><br />

<strong>Rheumatology</strong>, Copenhagen University Hospitals at Hvidovre and<br />

Glostrup, Denmark, 13 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet<br />

Hospital, Oslo, Norway, 14 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />

<strong>of</strong> South West Jutland at Esbjerg, Denmark, 15 Dept. <strong>of</strong><br />

<strong>Rheumatology</strong>, King Christian Xth Hospital, Gråsten, Denmark,<br />

16<br />

Dept. <strong>of</strong> <strong>Rheumatology</strong>, Odense University Hospital, Denmark<br />

5:45 PM<br />

1445. Immunogenicity in a 3-Year Follow-Up Cohort <strong>of</strong><br />

Adalimumab Treated Rheumatoid Arthritis Patients.<br />

Geertje M. Bartelds 1 , Charlotte L. Krieckaert 1 , Michael T.<br />

Nurmohamed 1 , Pauline van Schouwenburg 2 , Ben A. Dijkmans 3<br />

and Gerrit J. Wolbink 1 , 1 Jan van Breemen Institute, 2 Sanquin<br />

Research, 3 VU Medical Center<br />

A314<br />

Spondylarthritis and Psoriatic Arthritis: Pathogenesis,<br />

Etiology, and Animal Models<br />

Moderators: Walter P. Maksymowych, MD; University <strong>of</strong> Alberta;<br />

Edmonton, AB, Canada<br />

Maxime A. Breban, MD, PhD; Hôpital Ambroise Pare;<br />

Courbevoie, France<br />

4:30 PM<br />

1446. Fungal beta-Glucan Triggers Spondyloarthropathy and<br />

Crohn’s Disease in SKG Mice.<br />

2010 Program Book 81<br />

tuesday


tuesday<br />

Merja Ruutu 4 , Bijesh Yadav 4 , Gethin Thomas 4 , Roland Steck 2 ,<br />

Ge<strong>of</strong>frey Strutton 3 , Ai Tran 4 , Jared Velasco 4 , Mariapia Degli<br />

Esposti 1 , Martin Zinkernagel 1 , Matthew A. Brown 4 and Ranjeny<br />

Thomas 4 , 1 Lions Eye Institute, 2 Queensland University <strong>of</strong><br />

Technology, 3 Queenslande Health Pathology, 4 University <strong>of</strong><br />

Queensland Diamantina Institute<br />

4:45 PM<br />

1447. Deficiency in IFNγHas Markedly Different Effects on<br />

Uveitis Versus Arthritis in the Aggrecan-Induced Mouse Model<br />

<strong>of</strong> Spondyloarthropathy.<br />

Holly L. Rosenzweig 3 , Jelena M. Kezic 2 , Tibor T. Glant 5 , Stephen<br />

R. Planck 2 , Tammy M. Martin 1 , Michael P. Davey 6 and James T.<br />

Rosenbaum 4 , 1 Oregon Health & Science University, Portland,<br />

OR, 2 Oregon Health & Science University, 3 Oregon Health &<br />

Science University/VA Medical Ctr, Portland, OR, 4 Oregon Health<br />

Science Univ, Portland, OR, 5 Rush Med Ctr Cohn Bldg Rm 708,<br />

Chicago, IL, 6 VA Medical Ctr/Oregon Health & Science University,<br />

Portland, OR<br />

5:00 PM<br />

1448. Autoimmunity to Sperm and Testicular Antigens Precedes<br />

Onset <strong>of</strong> Spondyloarthritis in HLA-B27/Hu-β2-Microglobulin<br />

Transgenic Rats.<br />

Joel D. Taurog 1 , Claudia Rival 3 , Martha Dorris 2 , Nimman<br />

Satumtira 2 , Margaret Sun 3 and Kenneth S. K. Tung 3 , 1 U-Texas SW<br />

Med Ctr, Dallas, TX, 2 U-Texas SW Med Ctr, 3U-Virginia HSC<br />

5:15 PM<br />

1449. Mast Cells Contribute to Synovial Inflammation in Non-<br />

Psoriatic and Psoriatic Spondyloarthritis.<br />

Troy Noordenbos 1 , Nataliya Yeremenko 1 , Tineke Cantaert 1 ,<br />

Christine Teitsma 1 , Marleen van de Sande 1 , Paul P. Tak 1 , Juan<br />

Canete 2 and Dominique Baeten 1 , 1 Academic Medical Center/<br />

University <strong>of</strong> Amsterdam, 2 University Hospital Barcelona<br />

5:30 PM<br />

1450. Gene Silencing <strong>of</strong> ERAP1 and ERAP2 Displays Differential<br />

Effects on Intracellular Free Heavy Chain Accumulation and<br />

Peptide Presentation in B*27 Subtypes Associated with<br />

Ankylosing Spondylitis (AS).<br />

Nigil Haroon, Florence W. Tsui and Robert D. Inman, Toronto<br />

Western Hospital and Research Institute, University <strong>of</strong> Toronto,<br />

Toronto, Canada<br />

5:45 PM<br />

1451. Multiplex Assay <strong>of</strong> a Panel <strong>of</strong> 58 Biomarkers in<br />

Ankylosing Spondylitis: Identification <strong>of</strong> High Priority<br />

Candidates for Prediction <strong>of</strong> Structural Damage.<br />

Walter P. Maksymowych 4 , Nathalie Morency 4 , Stephanie<br />

Wichuk 4 , Proton Rahman 1 , Dafna D. Gladman 2 and Robert D.<br />

Inman 3 , 1 Memorial University Newfoundland, St. Johns, NL,<br />

Canada, 2 Toronto Western Hospital, Toronto, ON, Canada,<br />

3<br />

Toronto Western Hospital, Toronto, ON, Canada, 4 University <strong>of</strong><br />

Alberta, Edmonton, AB, Canada<br />

A311<br />

Systemic Lupus Erythematosus - Clinical Aspects and<br />

Treatment: New Therapies<br />

Moderators: Elena M. Massarotti, MD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Maria DallEra, MD; University California San Francisco; San<br />

Francisco, CA<br />

4:30 PM<br />

1452. Epratuzumab Demonstrates Clinically Meaningful<br />

Improvements in Patients with Moderate to Severe Systemic<br />

Lupus Erythematosus (SLE): Results from EMBLEM, a Phase<br />

IIb Study.<br />

Daniel J. Wallace 1 , Kenneth C. Kalunian 5 , Michelle A. Petri 2 ,<br />

Vibeke Strand 3 , Brian Kilgallen 4 , Lexy Kelley 4 and Caroline P.<br />

Gordon 6 , 1 West Hollywood, CA, 2 Timonium, MD, 3 Division <strong>of</strong><br />

Immunology and <strong>Rheumatology</strong>, Stanford University School <strong>of</strong><br />

Medicine, Palo Alto, CA, 4 UCB, Smyrna, GA, 5 UCSD School <strong>of</strong><br />

Medicine, La Jolla, CA, 6 University <strong>of</strong> Birmingham, Birmingham,<br />

United Kingdom<br />

4:45 PM<br />

1453. Aspreva Lupus Management Study (ALMS): Extra-Renal<br />

Activity Results from the Maintenance Phase.<br />

David A. Isenberg 4 , Gerald B. Appel 1 , Mary Anne Dooley 6 , Ellen<br />

M. Ginzler 3 , David Jayne 2 , David W<strong>of</strong>sy 5 , Neil Solomons 7 and<br />

Laura Lisk 8 , 1Columbia University, 2 Renal Unit, Addenbrooke’s<br />

Hospital, 3 SUNY-Downstate Medical Center, Brooklyn, NY,<br />

4<br />

University <strong>College</strong> London, London, United Kingdom, 5 University<br />

<strong>of</strong> California, San Francisco, San Francisco, CA, 6 University <strong>of</strong><br />

North Carolina at Chapel Hill, Chapel Hill, NC, 7 Vifor Pharma<br />

(formerly Aspreva Pharmaceuticals), Canada, 8 Vifor Pharma, UK<br />

5:00 PM<br />

1454. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease<br />

Activity and Severe Flares in Seropositive SLE Patients: BLISS-76<br />

Study Results through Wk 76.<br />

R. A. Furie 6 , O. Zamani 8 , D. J. Wallace 1 , D. Tegzova 4 , M. Petri 5 , J. T.<br />

Merrill 7 , W. W. Chatham 10 , W. Stohl 12 , A. Schwarting 11 , S. Cooper 2 ,<br />

Z. J. Zhong 3 , W. Freimuth 2 , D. R. Hough 2 , R. van Vollenhoven 9 and<br />

for the BLISS-76 Study Group, 1 Cedars-Sinai/UCLA, Los Angeles,<br />

CA, 2 Human Genome Sciences, Rockville, Rockville, MD, 3 Human<br />

Genome Sciences, Rockville, MD, Rockville, MD, 4 Institute <strong>of</strong><br />

<strong>Rheumatology</strong> and Rheumatological Clinic, Prague, Prague,<br />

Czech Republic, 5 Johns Hopkins University School <strong>of</strong> Medicine,<br />

Timonium, MD, 6 North Shore LIJ Health System, Lake Success,<br />

NY, 7 Oklahoma Medical Research Foundation, Oklahoma City,<br />

OK, 8 Rheumazentrum Favoriten, Wien, Wien, Austria, 9 The<br />

Karolinska Institute, Stockholm, Sweden, 10 UAB Arthritis Clinical<br />

Intervention Program, Birmingham, AL, 11 Universitätsmedizin der<br />

Johannes-Gutenberg-Universität Mainz, Sana Rheumazentrum<br />

Rheinland-Pfalz, Bad Kreuznach, Germany, Germany, 12 USC Keck<br />

School <strong>of</strong> Medicine, Los Angeles, CA<br />

5:15 PM<br />

1455. Efficacy and Safety <strong>of</strong> Ocrelizumab, a Humanized<br />

antiCD20 Antibody, in Patients with Active Proliferative Lupus<br />

Nephritis (LN): Results from the Randomized, Double-Blind<br />

Phase III BELONG Study.<br />

Eduardo F. Mysler 6 , Alberto J. Spindler 9 , Renato Guzman 2 ,<br />

Marc Bijl 8 , David Jayne 1 , Richard A. Furie 5 , Romeo Maciuca 3 ,<br />

Saba Shahdad 7 , David Close 4 , Paul Brunetta 3 and Jorn Drappa 3 ,<br />

1<br />

Addenbrookes Hospital, 2 Dept <strong>Rheumatology</strong>, 3 Genentech,<br />

4<br />

MedImmune Limited, 5 North Shore Long Island Jewish Health<br />

System, Lake Success, NY, 6 OMI, Buenos Aires, Argentina, 7 Roche,<br />

8<br />

Univ <strong>of</strong> Groningen, 9 Universidad Nacional Tucumán, Yerba<br />

Buena Tucuman, Argentina<br />

82<br />

2010 Program Book


5:30 PM<br />

1456. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease<br />

Activity across Multiple Organ Domains: Combined Efficacy<br />

Results from the Phase 3 BLISS-52 and -76 Studies.<br />

S. Manzi 10 , J. Sanchez-Guerrero 2 , J. T. Merrill 5 , R. A. Furie 4 , D.<br />

Gladman 8 , S. Navarra 11 , E. M. Ginzler 7 , D. D’Cruz 6 , A. Doria 9 , S.<br />

Cooper 1 , Z. J. Zhong 1 , D. Hough 1 , W. Freimuth 1 , M. Petri 3 and on<br />

Behalf <strong>of</strong> the BLISS-52 and -76 Study Groups, 1 Human Genome<br />

Sciences, Inc, Rockville, MD, 2 Instituto Nacional de Ciencias<br />

Médicas y Nutricíon Salvador Zubirán, Tlalpan, Mexico City, DF,<br />

Mexico, 3 Johns Hopkins School <strong>of</strong> Medicine, Baltimore, MD,<br />

4<br />

North Shore LIJ Health System, Lake Success, NY, 5 Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK, 6 St. Thomas’<br />

Hospital, London, London, United Kingdom, 7 SUNY Downstate<br />

Medical Center, Brooklyn, NY, 8 Toronto Western Hospital,<br />

Toronto, ON, Canada, 9 Universita’ di Padova, Padova, Italy,<br />

10<br />

University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine, PA, 11 University <strong>of</strong><br />

Santo Tomas Hospital, Manila, Philippines<br />

5:45 PM<br />

1457. Five-Year Experience with Belimumab, a BLyS-Specific<br />

Inhibitor, in Patients with Systemic Lupus Erythematosus (SLE).<br />

J. T. Merrill 6 , D. J. Wallace 1 , R. A. Furie 4 , M. A. Petri 3 , W. Stohl 10 ,<br />

W. W. Chatham 8 , J. McCune 9 , A. Weinstein 11 , J. McKay 5 , Z. J.<br />

Zhong 2 , L. Pineda 2 , J. Klein 2 , W. Freimuth 2 , E. M. Ginzler 7 and for<br />

the LBSL02/99 Study Group, 1 Cedars-Sinai/UCLA, Los Angeles,<br />

CA, 2 Human Genome Sciences, Inc, Rockville, Rockville, MD,<br />

3<br />

Johns Hopkins University School <strong>of</strong> Medicine, Timonium, MD,<br />

4<br />

North Shore LIJ Health System, Lake Success, NY, 5 Oklahoma<br />

Center for Arthritis Therapy & Research, Tulsa, OK, 6 Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK, 7 SUNY<br />

Downstate Medical Center, Brooklyn, NY, 8 UAB Arthritis Clinical<br />

Intervention Program, Birmingham, AL, 9 University <strong>of</strong> Michigan<br />

Health System, Ann Arbor, MI, 10 USC Keck School <strong>of</strong> Medicine,<br />

Los Angeles, CA, 11 Washington Hospital Center, Washington, DC<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

4:30 - 6:00 PM<br />

B207<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

Controversies in Sjögren’s Syndrome (051)<br />

Speaker: Frederick B. Vivino, MD; Pennsylvania Presbyterian<br />

Medical Center; Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify major morbidities in Sjögren’s syndrome patients<br />

• discuss current treatment algorithms for dry eyes, dry mouth<br />

and systemic manifestations<br />

• determine strategies to prevent Sjögren’s related<br />

complications<br />

B208<br />

Fibromyalgia (052) PM<br />

Speaker: Manuel Martinez-Lavin, MD; National Cardiology<br />

Institute; Mexico City, Mexico<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the most recent thoughts regarding the<br />

pathophysiology <strong>of</strong> fibromyalgia and related disorders<br />

• prescribe a treatment program for the typical fibromyalgia<br />

patient and serve as a consultant to that patient and the<br />

primary care provider<br />

• describe the principles <strong>of</strong> a comprehensive treatment<br />

program for the more challenging fibromyalgia patient<br />

B209<br />

Inflammatory Eye Disease/Uveitis (053)<br />

Sunil Kumar Srivastava, MD; Emory University; Atlanta, GA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the clinical manifestations <strong>of</strong> inflammatory eye disease<br />

encountered by rheumatologists<br />

• discuss diagnostic pearls for the evaluation <strong>of</strong> someone with<br />

inflammatory eye disease<br />

• discuss the treatment paradigms used for the inflammatory<br />

eye diseases<br />

B210<br />

Rheumatoid Arthritis: Difficult Cases (054) f<br />

Speaker: John J. Cush, MD; Baylor Research Institute; Dallas, TX<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the management <strong>of</strong> patients with refractory<br />

rheumatoid arthritis<br />

• identify novel treatment options for those failing conventional<br />

therapies<br />

• create effective management plans for complicated<br />

rheumatoid arthritis patients<br />

B301<br />

Rheumatoid Arthritis: Early Rheumatoid Arthritis<br />

(055) PS<br />

Speaker: Johanna Hazes, MD, PhD; Erasmus Medical Centre<br />

Rotterdam; Rotterdam, Netherlands<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the clinical syndrome <strong>of</strong> rheumatoid arthritis early in<br />

its course<br />

• determine which modalities are <strong>of</strong> use in diagnosis and<br />

determining prognosis<br />

• evaluate which therapeutic regimens yield the best long-term<br />

outcomes<br />

B302<br />

Spondylarthropathy: An Update (056)<br />

Speaker: Juergen Braun, MD; Rheumazentrum Ruhrgebiet;<br />

Herne, Germany<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the challenge in the early diagnosis <strong>of</strong><br />

spondylarthropathy<br />

• discuss mechanisms <strong>of</strong> disease pathogenesis<br />

• describe current treatment options for spondylarthropathy<br />

B303<br />

Still’s Disease, Febrile Illnesses (057)<br />

Speaker: Rayfel Schneider, MBBCh; Hospital for Sick Children;<br />

Toronto, ON, Canada<br />

tuesday<br />

2010 Program Book 83


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the clinical features <strong>of</strong> Still’s disease and other febrile<br />

syndromes<br />

• describe the immunogenetic mechanisms and treatment for<br />

adult Still’s disease and related syndromes<br />

5:00 PM<br />

Training in Pediatric <strong>Rheumatology</strong>: A Proposal for Latin<br />

America<br />

Carlos D. Rose, MD; duPont Hospital for Children; Wilmington,<br />

DE<br />

tuesday<br />

B304<br />

Systemic Lupus Erythematosus: Lupus Nephritis (058)<br />

Speaker: Frederic A. Houssiau, MD, PhD; Universite Catholique<br />

Louvain; Brussels, Belgium<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify lupus nephritis in early stages<br />

• describe poor prognostic factors<br />

• evaluate lupus nephritis therapy<br />

B305<br />

Systemic Lupus Erythematosus: Novel Treatments<br />

(059) PS<br />

Speaker: Robert G. Lahita, MD, PhD; Newark Beth Israel Hospital;<br />

Newark, NJ<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine the <strong>of</strong>f-label use <strong>of</strong> commercially available agents<br />

for features <strong>of</strong> systemic lupus erythematosus<br />

• discuss investigational therapies for systemic lupus<br />

erythematosus<br />

• identify potential risks <strong>of</strong> new therapies for systemic lupus<br />

erythematosus<br />

• identify host factors which may influence response to new<br />

therapies<br />

B306<br />

Vasculitis: An Update (060) f<br />

Speaker: Stuart M. Levine, MD; Johns Hopkins University;<br />

Baltimore, MD<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• understand the strengths and limitations <strong>of</strong> the current blood<br />

vessel size-based vasculitis classification system<br />

• utilize various imaging and laboratory tests in the diagnosis<br />

<strong>of</strong> vasculitis, with emphasis on antineutrophilic cytoplasmic<br />

antibodies<br />

• identify standard and novel therapeutic modalities in the<br />

treatment <strong>of</strong> the systemic vasculitides<br />

ACR Special Session<br />

4:30 - 6:00 PM<br />

A412<br />

ILAR Global Health Project P/C<br />

Moderators: Luis R. Espinoza, MD; Louisianna State University<br />

Medical Center; New Orleans, LA<br />

Antonio C. Ximenes, PhD; Hospital Geral Goiânia; Goiania, Brazil<br />

4:30 PM<br />

ILAR: Past, Present and Future<br />

David A. Fox, MD; University <strong>of</strong> Michigan Medical Center; Ann<br />

Arbor, MI<br />

Mark Andrejeski; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>; Atlanta,<br />

GA<br />

5:30 PM<br />

ILAR-East Africa <strong>Rheumatology</strong> Initiative<br />

Fotios Koumpouras, MD; Univeristy <strong>of</strong> Pittsburgh Medical<br />

Center; Pittsburgh, PA<br />

Omondi G. Oyoo, MD, MMed; University <strong>of</strong> Nairobi; Nairobi,<br />

Kenya<br />

Session Overview:<br />

The International League <strong>of</strong> Associations for <strong>Rheumatology</strong> has<br />

incurred a significant reorganization on its function, role, goals<br />

and mission in the past few years. Its member’s base (ACR,<br />

EULAR, PANLAR, APLAR); however, lacks a basic knowledge<br />

and understanding <strong>of</strong> these changes. ILAR, in order to fulfill<br />

its objectives need full support <strong>of</strong> its base and this session will<br />

assist a great deal to accomplish them.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the rationale for the reorganization<br />

• discuss the changes made<br />

• gain a better understanding <strong>of</strong> ILARS’s mission and goals<br />

• learn <strong>of</strong> funding opportunities for clinical research and<br />

education<br />

ACR REF Special Session<br />

4:30 - 6:00 PM<br />

B402<br />

REF Marshall J. Schiff, MD, Memorial Lectureship:<br />

Everything a Rheumatologist Should Know About<br />

Spine Surgery but Was Afraid to Ask c/r<br />

Moderator: Stephen A. Paget, MD; Hospital for Special Surgery;<br />

New York, NY<br />

Speaker: Scott D. Boden, MD; Emory Orthopaedics &<br />

Spine Center; Atlanta, GA<br />

Session Overview:<br />

Back pain represents one <strong>of</strong> the leading causes <strong>of</strong> loss <strong>of</strong> work<br />

days in the US, and is a common complaint in the outpatient<br />

setting. Rheumatologists need to be familiar with the latest<br />

evidence regarding diagnosis, prognosis, and indications for<br />

surgical intervention. This session will review current and<br />

emerging practices regarding spine surgery.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• distinguish the different etiologies <strong>of</strong> back pain, and their<br />

common presentations<br />

• identify the indications for surgical intervention<br />

• describe the role <strong>of</strong> recent findings concerning bone<br />

morphogenetic proteins in spine fusion<br />

5:30 PM<br />

1458. Effectiveness <strong>of</strong> the Global Posture Reeducation Method<br />

(GPR) and Segmental Stretching in the Treatment <strong>of</strong> Chronic<br />

Back Pain: A Randomized Controlled Trial.<br />

Marilene M. dos Santos 3 , Larissa S. Guimarães 5 , Lorena O.<br />

Souza 5 , Mariana M. Vasconcelos 5 , Taís M. Camargo 1 , Priscylla C.<br />

84<br />

2010 Program Book


Develly 5 , Bernardo L. F. Fernandes 4 and Virgínia F. M. Trevisani 2 ,<br />

1<br />

Brazil, 2 Federal University <strong>of</strong> São Paulo - UNIFESP/EPM, São<br />

Paulo, SP, Brazil, 3 Federal University <strong>of</strong> São Paulo - UNIFESP/<br />

EPM, Poços de Caldas, MG, Brazil, 4 Pontifical Catholic University<br />

<strong>of</strong> Minas Gerais - PUC Minas, Poços de Caldas, MG, Brazil,<br />

5<br />

Pontifical Catholic University <strong>of</strong> Minas Gerais - PUC Minas, Brazil<br />

5:45 PM<br />

1459. Epidemiology <strong>of</strong> Restricting Back Pain in Older Persons<br />

and Associations with Age, Sex, Obesity, and Depressive<br />

Symptoms.<br />

Una E. Makris 3 , Liana Fraenkel 1 , Ling Han 2 and Thomas M. Gill 3 ,<br />

1<br />

Department <strong>of</strong> Veterans Affairs, West Haven, CT, 2 Program on<br />

Aging, New Haven, CT, 3 Yale University School <strong>of</strong> Medicine<br />

ARHP Concurrent Abstract Session<br />

4:30 – 6:00 PM<br />

5:30 PM<br />

1464. Radiographic Knee Osteoarthritis and Knee Pain: Findings<br />

from 5 Racial/Ethnic Populations.<br />

Ke Wang 2 , Noriko Yoshimura 7 , Ling Xu 5 , Jianhao Lin 6 , Inje Kim 4 ,<br />

Michael Nevitt 8 , Hiroshi Kawaguchi 7 , David Felson 1 , Xiaozheng<br />

Kang 6 , Yuqing Zhang 1 and Hyun Ah Kim 3 , 1 BU. Sch. <strong>of</strong> Med.,<br />

Boston, 2 BU. Sch. <strong>of</strong> Med., 3 Hallym Univ., Sacred Heart Hosp.,<br />

Anyang, Korea, Republic <strong>of</strong>, 4 Hallym Univ., Sacred Heart Hosp.,<br />

Korea, Republic <strong>of</strong>, 5 Peking Union Medical <strong>College</strong>, Beijing, China,<br />

6<br />

Peking University, Beijing, China, 7 The University <strong>of</strong> Tokyo,<br />

Tokyo, Japan, 8 Univ. <strong>of</strong> California at San Francisco, San Francisco,<br />

CA<br />

5:45 PM<br />

1465. Impact <strong>of</strong> Buenos Dias, Artritis, a Spanish Health<br />

Communications Campaign Promoting Physical Activity among<br />

Spanish-Speaking People with Arthritis.<br />

Teresa J. Brady 2 and Jed Lam 1 , 1 Aeffect Inc., 2 Center for Disease<br />

Control, Atlanta, GA<br />

B311<br />

Don’t Despair Over Health Disparities<br />

Moderator: David A. Williams, PhD; University <strong>of</strong> Michigan<br />

Health System; Ann Arbor, MI<br />

4:30 PM<br />

1460. Life Course Socioeconomic Position and Health Outcomes<br />

in People with Self-Reported Arthritis.<br />

Jack H. Shreffler 3 , Britta Schoster 3 , Kathryn Remmes Martin 2<br />

and Leigh F. Callahan 1 , 1 Univ <strong>of</strong> North Carolina, Chapel Hill, NC,<br />

2<br />

University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />

3<br />

University <strong>of</strong> North Carolina, Chapel Hill<br />

4:45 PM<br />

1461. Perceived Helplessness as a Mediator between<br />

Household Income and Health Status in People with Self-<br />

Report Arthritis.<br />

Kathryn Remmes Martin 2 , Britta Schoster 3 and Leigh F. Callahan 1 ,<br />

1<br />

Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 2 University <strong>of</strong> North<br />

Carolina at Chapel Hill, Chapel Hill, NC, 3 University <strong>of</strong> North<br />

Carolina at Chapel Hill<br />

5:00 PM<br />

1462. An Examination <strong>of</strong> How Coping with Prescription<br />

Medication Costs and Medication Underuse Influences Physical<br />

and Mental Health <strong>of</strong> Individuals with Arthritis.<br />

Kathryn Remmes Martin 2 , Britta Schoster 2 , Jack Shreffler 3 and<br />

Leigh F. Callahan 1 , 1 Univ <strong>of</strong> North Carolina, Chapel Hill, NC,<br />

2<br />

University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />

3<br />

University <strong>of</strong> North Carolina at Chapel Hill<br />

5:15 PM<br />

1463. Disability and Knee Osteoarthritis: Associations with<br />

Individual and Community Socioeconomic Status.<br />

Leigh F. Callahan 2 , Joshua B. Knight 3 , Jack H. Shreffler 3 , Britta<br />

Schoster 3 , Jordan B. Renner 3 and Joanne M. Jordan 1 , 1 Chapel Hill,<br />

NC, 2 Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 3 University <strong>of</strong> North<br />

Carolina, Chapel Hill<br />

ARHP Concurrent Sessions<br />

4:30 - 6:00 PM<br />

B308<br />

Iatrogenic Misadventures: Complex Cases C PS<br />

Moderator: Atul A. Deodhar, MD; Oregon Health & Science<br />

University; Portland, OR<br />

4:30 PM<br />

Osteonecrosis<br />

Kenneth J. Scalapino, MD; Portland VA Medical Center; Portland,<br />

OR<br />

5:00 PM<br />

Transplant-related Musculoskeletal Syndromes<br />

Pascale Schwab, MD; Oregon Health & Science University;<br />

Portland, OR<br />

5:30 PM<br />

Biologics and Serious Infections<br />

Kevin L. Winthrop, MD, MPH; Oregon Health & Science<br />

University; Portland, OR<br />

Session Overview:<br />

Iatrogenic diseases occur in the treatment <strong>of</strong> patients with<br />

rheumatologic conditions and other diseases. Iatrogenic disease<br />

can vary but are the result <strong>of</strong> the treatments rheumatology<br />

pr<strong>of</strong>essionals use to care for their patients. <strong>Rheumatology</strong><br />

providers need to be aware <strong>of</strong> all potential complications related<br />

to the diagnosis and treatment <strong>of</strong> the disease, regardless <strong>of</strong><br />

whether the condition occurs as a known risk or side effect <strong>of</strong><br />

treatment.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the late side effects <strong>of</strong> using systemic corticosteroid<br />

treatment<br />

• describe various musculoskeletal symptoms as they relate to<br />

post transplant complications<br />

• describe the various infections associated with use <strong>of</strong> biologics<br />

and to identify and implement appropriate screening tests<br />

tuesday<br />

2010 Program Book 85


tuesday<br />

B309<br />

Practice Potpourri<br />

cP PS<br />

Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />

Albuquerque, NM<br />

4:30 PM<br />

Should I Be Doing QuantiFERON ® -TB Gold Test Instead <strong>of</strong> the<br />

PPD Skin Testing on All My Patients Before Starting Biologics?<br />

Kevin L. Winthrop, MD, MPH; Oregon Health & Science<br />

University; Portland, OR<br />

4:45 PM<br />

What is the Final Word on Non-steroidal Anti-inflammatory<br />

Drugs Causing Heart Attacks and Should I Avoid Using<br />

Altogether in my Arthritis Patients?<br />

Elaine Husni, MD, MPH; Cleveland Clinic Foundation; Cleveland,<br />

OH<br />

5:00 PM<br />

Should I Worry That My Patient Will Develop an Infusion<br />

Reaction, Having Stopped Infliximab For 3 Months For a Hip<br />

Replacement?<br />

Joyce M. Kortan, RN; Arthritis & Rheum Consultants; Edina, MN<br />

5:15 PM<br />

Is Splinting Appropriate for the Scleroderma Hand?<br />

Carole V. Dodge, OT CHT; University <strong>of</strong> Michigan Medical Center;<br />

Ann Arbor, MI<br />

5:30 PM<br />

What Should I Tell My Patient With Polymyositis Who Wants to<br />

Exercise and Lift Weights?<br />

Lisa G. Rider, MD; National Institute <strong>of</strong> Environmental Health<br />

Sciences; Garrett Park, MD<br />

5:45 PM<br />

Questions and Answers<br />

Session Overview:<br />

Health pr<strong>of</strong>essionals rely on the evidence-based literature and<br />

their own experiences to determine best treatment options for<br />

patient care. However, consulting with colleagues is an option<br />

that provides clinically relevant information and is convenient<br />

and readily available. The ARHP annual scientific meeting allows<br />

colleagues to network and share information with each other.<br />

The format <strong>of</strong> this session will allow for a formal sharing <strong>of</strong><br />

information about current practice problems.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify current strategies for practice management for<br />

selected clinical problems<br />

• discuss evidence for best practice solutions for current clinical<br />

problems<br />

Terence W. Starz, MD; Arthritis & Internal Medical Associates;<br />

Pittsburgh, PA<br />

Session Overview:<br />

Rheumatoid arthritis can severely limit functional activities,<br />

through various articular and extra-articular pathophysiologic<br />

mechanisms. A comprehensive approach to understanding the<br />

effects <strong>of</strong> impairments on functional activity and best methods<br />

for measuring and treating limitations in function is challenging.<br />

The purpose <strong>of</strong> this session is to review current knowledge <strong>of</strong><br />

how rheumatoid arthritis affects functional activity and the<br />

best evidence-based methods available to measure and treat<br />

patients with rheumatoid arthritis. This session will provide<br />

an overview <strong>of</strong> the definition <strong>of</strong> functional activities and will<br />

relate pathophysiologic mechanisms involved in rheumatoid<br />

arthritis with activities <strong>of</strong> daily living, vocation, avocation, and<br />

approaches and tools available for assessing function.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss pathophysiologic mechanisms <strong>of</strong> rheumatoid arthritis<br />

and their effect on functional activity<br />

• define and discuss the elements involved in various selfcare,<br />

work, and community activities that are measured by<br />

common patient-report instruments including an analysis <strong>of</strong><br />

their physical, mental and social components and potential<br />

adaptations<br />

• review the tools for assessing functional activity including the<br />

significance and grouping <strong>of</strong> the different elements<br />

• discuss strategies for treatment interventions that focus on<br />

activities <strong>of</strong> self-care, vocational and community activities<br />

Exhibit Hall Wine and Cheese<br />

Reception<br />

5:15 - 6:45 PM<br />

Halls A1 & A2<br />

ACR Study Groups<br />

6:45 - 8:00 PM<br />

B408<br />

Study Group sessions are planned by ACR members in an effort<br />

to network with those who share a common interest in an area<br />

<strong>of</strong> rheumatology. Study Groups are non-CME activites.<br />

ACR/EULAR Academic Exchange Program<br />

Moderators: Mariana J. Kaplan, MD; University <strong>of</strong> Michigan<br />

Medical Center; Ann Arbor, MI<br />

Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany<br />

B310<br />

Understanding Functional Activity in Rheumatoid<br />

Arthritis: What We Know and What We Don’t Know<br />

c/r<br />

Moderator: Patricia P. Katz, PhD; University <strong>of</strong> California - San<br />

Francisco; San Francisco, CA<br />

Speakers: Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

Joan C. Rogers, PhD, OTR/ L; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />

PA<br />

6:45 PM<br />

Aspects <strong>of</strong> IL-1 Signaling Pathways in Inflammatory Diseases<br />

Cem Gabay, MD; University Hospital <strong>of</strong> Geneva; Geneva,<br />

Switzerland<br />

7:10 PM<br />

What is New and in the Horizon in the Treatment <strong>of</strong><br />

Autoinflammatory Diseases<br />

Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul, Turkey<br />

86<br />

2010 Program Book


7:30 PM<br />

Role <strong>of</strong> IL-1 in Human Articular Cartilage: Lessons from<br />

Osteoarthritis<br />

Dirk Elewaut, MD, PhD; Universitair Ziekenhuis Gent; Ghent,<br />

Belgium<br />

7:45 PM<br />

Anakinra for the Treatment <strong>of</strong> Macrophage Activation<br />

Syndrome<br />

Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong> Alabama;<br />

Birmingham, AL<br />

Session Overview:<br />

The ACR/EULAR Academic Exchange Program seeks to bring<br />

together young academic rheumatologists from Europe and<br />

the United States to discuss basic and translational research<br />

programs in order to foster exchange <strong>of</strong> ideas and collaboration.<br />

The annual meeting <strong>of</strong> the ACR is an ideal forum in which to<br />

promote and encourage this kind <strong>of</strong> interaction. This particular<br />

session aims to highlight the new developments on the role<br />

<strong>of</strong> inflammatory diseases. This will be the 11th year <strong>of</strong> the<br />

study group meeting at the ACR Annual Scientific Meeting. Last<br />

year was highly successful with invited speakers, Drs. Thomas<br />

Huizinga and Robert Winchester, as well as two speakers from<br />

within the exchange group. The attendance was high and it was<br />

a great opportunity for interactions and exchanges between<br />

researchers from both sides <strong>of</strong> the Atlantic. This year’s session<br />

promises to be equally stimulating and productive.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify new developments in the treatment <strong>of</strong><br />

autoinflammatory diseases<br />

• identify novel molecular mechanisms <strong>of</strong> IL-1 signaling<br />

pathways in inflammatory diseases<br />

Session Overview:<br />

The antiphospholipid syndrome is a rapid evolving field <strong>of</strong> high<br />

interest to rheumatologists. The disease affects a significant<br />

proportion <strong>of</strong> SLE patients. APS is associated with thrombosis,<br />

pregnancy losses and aPL antibody positivity. A significant<br />

number <strong>of</strong> questions particularly with respect to treatment and<br />

diagnostic tests remain unanswered that will be discussed in<br />

this study group by internationally and well-recognized scientists<br />

in the field. Importantly new findings on pathogenesis <strong>of</strong> the<br />

disease may lead to the development <strong>of</strong> novel therapies to treat<br />

clinical manifestations <strong>of</strong> APS.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss new pathogenic mechanisms <strong>of</strong> thrombosis in APS<br />

• describe new targeted therapies to be used in treatment <strong>of</strong><br />

APS<br />

• discuss updates on antiphospholipid testing used in diagnosis<br />

<strong>of</strong> APS<br />

• describe clinical trials and studies in APS<br />

A411<br />

Autoantibodies in Diagnosis and Follow Up <strong>of</strong><br />

Rheumatic Diseases<br />

Moderator: Pierluigi Meroni, MD; Instituto G. Pini University;<br />

Milano, Italy<br />

6:45 PM<br />

Opening Comments<br />

Pierluigi Meroni, MD; Instituto G. Pini University; Milano, Italy<br />

6:50 PM<br />

Clinical Use <strong>of</strong> Anti-Citrullinated Peptide Antibodies for Setting<br />

a Phenotypic Diagnosis <strong>of</strong> RA<br />

Solbritt M. Rantapaa-Dahlqvist, MD, PhD; Umea, Sweden<br />

tuesday<br />

A314<br />

Antiphospholipid Syndrome<br />

Moderator: Silvia S. Pierangeli, PhD; University <strong>of</strong> Texas Medical<br />

Branch; Galveston, TX<br />

6:45 PM<br />

Pathogenic Mechanisms in APS - Can They Lead us to New<br />

Therapies?<br />

Anisur Rahman, MD; University <strong>College</strong> London; London, United<br />

Kingdom<br />

7:00 PM<br />

A New Mechanism in the Pathogenesis <strong>of</strong> the Antiphospholipid<br />

Syndrome: Implications for Thrombotic Risks Ratification<br />

Steven Krillis, MD; The University <strong>of</strong> New South Wales; Syndey,<br />

Kogarah, NSW, Australia<br />

7:15 PM<br />

Antiphospholipid Antibodies: Diagnostic Strategies for the<br />

Clinical Laboratory<br />

Tom Ortel, MD; Duke University Health System; Durham, NC<br />

7:30 PM<br />

The PROMISSE Study<br />

Jane E. Salmon, MD; Hospital for Special Surgery; New York, NY<br />

7:45 PM<br />

The APLA 2010 Congress: Update on Wet Workshop and APL<br />

Testing Task Force Recommendations<br />

E. Nigel Harris, MD; The University <strong>of</strong> the West Ind; Kingston,<br />

Jamaica<br />

7:15 PM<br />

Autoantibodies as Diagnostic and Prognostic Markers in Early<br />

Arthritis<br />

Gunter Steiner, PhD; Medical University <strong>of</strong> Vienna; Vienna,<br />

Austria<br />

7:35 PM<br />

Update on Inaccurate ANA in Southeast<br />

Merlin R. Wilson, MD; Wilson & Sanders Inc. Group Lab; New<br />

Orleans, LA<br />

7:45 PM<br />

FDA Update on ANA Testing<br />

Marilyn Lightfoote, PhD; Food and Drug Administration; Silver<br />

Spring, MD<br />

Session Overview:<br />

This is the fifth year that the Autoantibody Standardization<br />

Committee has organized this study group. For the 2007<br />

meeting we had 250 participants; for 2008 and 2009, we had<br />

400 participants. The goal <strong>of</strong> our committee is to promote<br />

the accurate use <strong>of</strong> autoantibodies with a clear focus on the<br />

relevance to practicing clinicians and clinical laboratories. There<br />

is a continuing need for rheumatologists to keep up-to-date with<br />

the rapidly progressing field <strong>of</strong> autoantibody diagnostics and<br />

their relevance to the diagnosis and management <strong>of</strong> rheumatic<br />

diseases.<br />

2010 Program Book 87


tuesday<br />

88<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe appropriate autoantibody testing requests and<br />

interpretation <strong>of</strong> results relevant to an early diagnosis and<br />

management <strong>of</strong> RA<br />

• identify the clinical value <strong>of</strong> measuring IgA RF in RA<br />

• describe the predictive value <strong>of</strong> RA marker antibodies<br />

• review the current status <strong>of</strong> “inaccurate ANA results”<br />

A412<br />

Behçet’s Disease<br />

Moderators: Yoshiaki Ishigatsubo, MD; Yokohama City Graduate<br />

School <strong>of</strong> Medicine; Yokohama, Japan<br />

Ahmet Gul, MD; Istanbul University; Istanbul, Turkey<br />

6:45 PM<br />

Genomewide Association Studies in Behçet’s Disease<br />

Daniel L. Kastner, MD, PhD; NIAMS, NIH; Bethesda, MD<br />

7:00 PM<br />

HLA-B51 and Behçet’s Disease<br />

Yeong W. Song, MD; Seoul National University Hospital; Seoul,<br />

Republic <strong>of</strong> Korea<br />

7:15 PM<br />

Immunological Features <strong>of</strong> Behçet’s Disease<br />

Mitsuhiro Takeno, MD, PhD; Yokohama City University, Japan<br />

7:30 PM<br />

Vascular Involvement in Behçet’s Disease<br />

Dorian O. Haskard, DM; Imperial <strong>College</strong>; London, United<br />

Kingdom<br />

7:45 PM<br />

Unmet Needs and Clinical Trials in Behçet’s Disease<br />

Ahmet Gul, MD; Istanbul University; Istanbul, Turkey<br />

Session Overview:<br />

Since the cause <strong>of</strong> Behçet’s Disease is still unknown, current<br />

treatment is aimed at easing the symptoms, reducing<br />

inflammation, and controlling the immune system. Recently,<br />

new idea such as auto inflammatory disease has been induced<br />

as the pathogenesis the disease. To understand current findings<br />

is helpful to find new treatment for Behçet’s Disease. Although<br />

Behçet’s Disease is common in the Middle East and Asia and<br />

rare in the United State and other regions, new insights need to<br />

be shared with the attendees so that everyone is aware <strong>of</strong> the<br />

latest developments.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the genetic aspect <strong>of</strong> Behçet’s Disease<br />

• discuss the immunological features <strong>of</strong> Behçet’s Disease<br />

• analyze <strong>of</strong> the endothelial cells and vascular involvement in<br />

Behçet’s Disease<br />

• discuss unmet need and clinical trials in Behçet’s Disease<br />

A406<br />

Economic Evaluations<br />

Moderators: Annemarie Braakman-Jansen, PhD; University <strong>of</strong><br />

Twente; Enschede, Netherlands<br />

Mart A. van de Laar, MD; University Twente and Medisch<br />

Sprectrum Twente; Enschede, Netherlands<br />

6:45 PM<br />

QALYs: Why use Them?<br />

Nick Bansback, PhD; St. Paul’s Hospital; Vancouver, Canada<br />

2010 Program Book<br />

7:00 PM<br />

QALYs: To Use or Not to Use<br />

Deborah P. Symmons, MD; University <strong>of</strong> Manchester;<br />

Manchester, United Kingdom<br />

7:15 PM<br />

The Patient’s Perspective<br />

Laurien Buitinga, MSc; University <strong>of</strong> Twente, Enschede,<br />

Netherlands; Enschede, Netherlands<br />

7:30 PM<br />

Much Ado About QALYs<br />

Annelies Boonen, MD, PhD; Maastricht University Medical<br />

Centre, Maastricht; Maastricht, Netherlands<br />

7:45 PM<br />

Discussion<br />

Session Overview:<br />

Economic evaluations are increasingly being used for decision<br />

making regarding treatment for patients. There are different<br />

methods for valuing health states in order to calculate “QALYs”<br />

for use in cost utility analysis. These methods can lead to<br />

very different results and might influence decision making.<br />

Another key issue is that <strong>of</strong> whose preferences should be used<br />

as the source <strong>of</strong> values: patients, doctors, decision-makers<br />

or those <strong>of</strong> the general public? Which method and values a<br />

researcher should use is dependent on the context <strong>of</strong> the<br />

research question. Should the research guide a clinical or policy<br />

decision? In this workshop the state <strong>of</strong> the art <strong>of</strong> health state<br />

valuations and implications for future research within the field <strong>of</strong><br />

rheumatology will be interactively discussed with the audience.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe how to value health states<br />

• analyze different perspectives used in economic evaluations<br />

• determine the proper valuation technique for use, based on<br />

the context <strong>of</strong> the research question<br />

• evaluate the use <strong>of</strong> tariffs<br />

B313<br />

Epidemiology <strong>of</strong> Axial Spondyloarthritis<br />

Moderators: John D. Reveille, MD; University Texas Health<br />

Science Center; Houston, TX<br />

Michael H. Weisman, MD; Cedars-Sinai Medical Center; Los<br />

Angeles, CA<br />

6:45 PM<br />

The GESPIC Experience<br />

Martin Rudawaleit, MD; University Hospital Charité – Campus<br />

Benjamin Franklin; Steglitz, Berlin, Germany<br />

7:10 PM<br />

Axial SpA in the US: The NHANES Survey<br />

Rosemarie Hirsch, MD, MPH; CDC - National Center for Health<br />

Statistics; Silver Spring, MD<br />

7:35 PM<br />

A Population Based Survey <strong>of</strong> Axial SpA in Mexico<br />

R. Burgos Vargas, MD; Hospital General de Mexico; Mexico City,<br />

Mexico<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• develop a better understanding <strong>of</strong> the presentation<br />

epidemiology <strong>of</strong> axial spondyloarthritis in a prospectively<br />

followed longitudinal cohort <strong>of</strong> patients from Germany<br />

• review the new data from NHANES 2009 on the prevalence <strong>of</strong><br />

axial spondyloarthritis in the United States


• compare the prevalence and epidemiology <strong>of</strong> SpA in a<br />

population-based questionnaire study from Mexico<br />

A402<br />

Genetics <strong>of</strong> Autoimmune Rheumatic Diseases in Latin<br />

America<br />

Moderator: Juan-Manuel Anaya, MD; CIB-Rosario University;<br />

Medellin, Colombia<br />

6:45 PM<br />

Admixture and Diversity in Latin America<br />

Maurico Arcos-Burgos, MD, PhD; University <strong>of</strong> Miami; Miami, FL<br />

7:10 PM<br />

Genetics <strong>of</strong> Rheumatoid Arthritis in Latin <strong>American</strong>s<br />

Angelica M. Delgado-Vega, MD; Uppsala University, Sweden<br />

7:30 PM<br />

Genetics <strong>of</strong> Systemic Lupus Erythematosus in Latin <strong>American</strong>s:<br />

Its Impact on ITGAM Association and Implications for<br />

Admixture Mapping in SLE<br />

Swapan K. Nath, PhD; Oklahoma Medical Research Foundation;<br />

Oklahoma City, OK<br />

7:50 PM<br />

The Common Autoimmunity Genes in Latin <strong>American</strong>s<br />

Juan-Manuel Anaya, MD; CIB-Rosario University; Medellin,<br />

Colombia<br />

Session Overview:<br />

Autoimmune rheumatic diseases are complex traits in which<br />

both genetic and environmental factors are incriminated<br />

in their etiopathogenesis. The expression <strong>of</strong> these diseases<br />

varies depending upon ethnicity and geography. The large and<br />

diverse population <strong>of</strong> Latin America is a powerful resource for<br />

elucidating the genetic basis <strong>of</strong> these complex traits.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• learn about the genetic landscape <strong>of</strong> Latin America and the<br />

genetic susceptibility <strong>of</strong> autoimmune rheumatic diseases in<br />

this population.<br />

A316<br />

Geriatric <strong>Rheumatology</strong><br />

Moderators: Yuri R. Nakasato, MD, MBA; University <strong>of</strong> North<br />

Dakota; Fargo, ND<br />

Raymond L. Yung, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />

6:45 PM<br />

Does Frailty in Old Age Amplify Glucocorticoid Toxicity?<br />

Eswar Krishnan, MD; Stanford University; Palo Alto, CA<br />

7:10 PM<br />

Use <strong>of</strong> DMARDs and Biological Therapy in the Older Population<br />

Richard Brasington, MD; Washington University School <strong>of</strong><br />

Medicine; St. Louis, MO<br />

7:35 PM<br />

Ideal <strong>Rheumatology</strong> Practice for the Older Patient<br />

Yuri R. Nakasato, MD, MBA; MeritCare/University <strong>of</strong> North<br />

Dakota; Fargo, ND<br />

Session Overview:<br />

<strong>Rheumatology</strong> faces an increasingly older, frail and complex<br />

population. The current structure is not prepared to sustain this<br />

challenge. Older patients have atypical presentations <strong>of</strong> common<br />

rheumatic conditions and diseases that may be the result <strong>of</strong><br />

the process <strong>of</strong> aging or associated with it. There is a higher life<br />

expectancy, but a higher morbidity and disability, most <strong>of</strong> them<br />

related to arthritis. <strong>Rheumatology</strong> struggles between improving<br />

quality <strong>of</strong> life versus not causing harmful side effects due to<br />

medications. Innovation <strong>of</strong> care, research, education and health<br />

policy <strong>of</strong> the older adult is critical to the future <strong>of</strong> rheumatology.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the phenomenon <strong>of</strong> frailty, how it differs from<br />

disability and increases propensity to drug toxicity in the<br />

elderly<br />

• distinguish important considerations in the management <strong>of</strong><br />

older patients with Disease Modifying Antirheumatic Drugs<br />

and biological therapy<br />

• analyze features <strong>of</strong> an ideal rheumatology practice for the<br />

older patient<br />

B409<br />

Global Musculoskeletal Health Initiatives<br />

Moderators: Lyn March, MD; University <strong>of</strong> Sydney Medical<br />

School; Sydney, Australia<br />

Anthony Woolf, MBBS; Royal Cornwall Hospital; Truro Cornwall,<br />

United Kingdom<br />

Richard H. Osborne, PhD; Deakin University; Melbourne,<br />

Australia<br />

Sherine E. Gabriel, MD, MSc; Mayo Clinic; Rochester, MN<br />

Peter Tugwe, MD; Institute <strong>of</strong> Population Health; Ottawa, ON,<br />

Canada<br />

6:45 PM<br />

Global Prevalence and Treatment <strong>of</strong> RA - Identifying Knowledge<br />

Gaps<br />

Marita Cross, MPH, PhD; Institute <strong>of</strong> Bone and Joint Research,<br />

University <strong>of</strong> Sydney; St. Leonards, NSW, Australia<br />

7:00 PM<br />

Global Bone Density and Osteoporotic Fracture Risk -<br />

Identifying Regional Variations for Priority Setting<br />

Lidia Sanchez-Riera, MD; Institute <strong>of</strong> Bone and Joint Research,<br />

University <strong>of</strong> Sydney; St. Leonards, NSW, Australia<br />

7:15 PM<br />

Other MSK Disorders - Towards Better Definitions and<br />

Representations<br />

Emma Smith, MSc(Phty), PhD; Institute <strong>of</strong> Bone and Joint<br />

Research, University <strong>of</strong> Sydney; St. Leonards, Australia<br />

7:30 PM<br />

Bridging the Knowledge Gaps - Strategies for Developing<br />

Consensus for Standardised Population-based Measurment <strong>of</strong><br />

MSK Conditions<br />

Anthony D. Woolf, MBBS; Royal Cornwall Hospital; Truro<br />

Cornwall, United Kingdom<br />

7:45 PM<br />

Beyond the Burden - Strategies for Identifying Global Inequity<br />

in Access to Evidence-Based MSK Health Care<br />

To be announced<br />

Session Overview:<br />

Much data are being collated across many countries in support<br />

<strong>of</strong> the Global Burden <strong>of</strong> Disease, Injuries and Risk Factors study.<br />

tuesday<br />

2010 Program Book 89


tuesday<br />

These collated data will provide the most comprehensive map<br />

<strong>of</strong> the presence and relative importance <strong>of</strong> MSK disease ever<br />

developed. There is a great need to allow international groups<br />

access to the findings and support individuals and organizations<br />

to use these data to guide local and global policymakers. This<br />

study group will provide an update <strong>of</strong> the GBD Study progress<br />

through presentations on systematic reviews <strong>of</strong> the global<br />

prevalence <strong>of</strong>, and DALYs associated MSK conditions. Global<br />

strategies for bridging gaps in the availability <strong>of</strong> MSK populationbased<br />

data and the inequity <strong>of</strong> access to evidence-based MSK<br />

health care and education will be discussed.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the key data required for the calculation <strong>of</strong> DALYs for<br />

MSK conditions<br />

• identify the regions <strong>of</strong> the world where population-based MSK<br />

data are deficient<br />

• explain the importance <strong>of</strong> collecting standardized MSK data<br />

from population-based health surveys<br />

• explain the principles involved in measuring equity and access<br />

to minimum standards <strong>of</strong> care for MSK conditions<br />

A315<br />

Joint Hypermobility Syndrome<br />

Moderators: Jaime F. Bravo, MD; Nuestra Sra de Los Angeles;<br />

Santiago, Chile<br />

Rodney Grahame, MD; University <strong>College</strong> Hospital; London,<br />

United Kingdom<br />

6:45 PM<br />

Are Some Joint Hypermobility Criteria More Closely Associated<br />

with Anxiety than Others?<br />

Antonio Bulbena, MD; Hospital del Mar and University; Bilbao,<br />

Spain<br />

7:00 PM<br />

Why is Joint Hypermobility Syndrome so Frequently Missed?<br />

Rodney Grahame, MD; University <strong>College</strong> Hospital; London,<br />

United Kingdom<br />

7:15 PM<br />

Treatment <strong>of</strong> Dysautonomia (Chronic Fatigue, Dizziness and<br />

Syncope)<br />

Jaime F. Bravo, MD; Nuestra Sra de Los Angeles; Santiago, Chile<br />

7:45 PM<br />

An Integrated Approach to the Physiotherapy Assessment and<br />

Management <strong>of</strong> Joint Hypermobility Syndrome<br />

Jane Simmonds, MCSP, MMACP; University <strong>of</strong> Herfordshire;<br />

Hatfield, Herfordshire, United Kingdom<br />

Session Overview:<br />

The interest about Joint Hypermobility Syndrome among<br />

rheumatologists has increased, but still in most cases the<br />

diagnosis <strong>of</strong> these patients is not made. There is a need not only<br />

to increase awareness about the condition, but also to learn<br />

how to treat these patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• appreciate that anxiety is very frequently associated to JHS<br />

and explains many symptoms<br />

• explain that JHS is frequent also in children and that the<br />

diagnosis is seldom made<br />

• treat effectively patients with Dysautonomia, improving<br />

significantly the quality <strong>of</strong> life <strong>of</strong> these patients<br />

• appreciate the role <strong>of</strong> physiotherapy and other allied health<br />

pr<strong>of</strong>essionals in the management <strong>of</strong> hypermobility syndrome<br />

B310<br />

Kawasaki Disease in the 21st Century - Genes,<br />

Pathogenesis, and Biologics<br />

Moderators: Anne M. Stevens, MD, PhD; Pediatrics, University <strong>of</strong><br />

Washington; Seattle, WA<br />

Polly J. Ferguson, MD; University <strong>of</strong> Iowa Carver <strong>College</strong> <strong>of</strong><br />

Medicine; Iowa City, IA<br />

6:45 PM<br />

The Pathogenesis <strong>of</strong> Kawasaki Disease: Novel Insights from<br />

Genetics and Immunology<br />

Rae S.M. Yeung, MD, PhD; Hospital for Sick Children; Toronto,<br />

ON, Canada<br />

7:15 PM<br />

Novel Strategies for Treatment and Monitoring for Kawasaki<br />

Disease<br />

Robert P. Sundel, MD; Children’s Hospital Medical Center;<br />

Boston, MA<br />

7:35 PM<br />

ACR Pediatrics Section Business Meeting<br />

Marisa S. Klein-Gitelman, MD, MPH; Children’s Memorial<br />

Hospital/North Western University; Chicago, IL<br />

Session Overview:<br />

Kawasaki disease is one <strong>of</strong> the most common forms <strong>of</strong> vasculitis<br />

affecting children, with coronary artery sequelae leading into<br />

adult years. Over the past decade progress has been made<br />

in identifying patients with atypical Kawasaki disease and<br />

in managing patients resistant to standard therapy. Biologic<br />

immunosuppressive and anticoagulation treatments provide<br />

novel options for treatment. Further, genetic and immunologic<br />

studies provide new insights into the pathogenesis <strong>of</strong> Kawasaki<br />

disease. A better understanding <strong>of</strong> the evidence for treatment<br />

and the recent basic science advances will aid adult and<br />

pediatric rheumatologists in the care <strong>of</strong> patients with Kawasaki<br />

Disease.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• recognize the signs and symptoms <strong>of</strong> typical and atypical KD<br />

and the risk factors for coronary aneurysms in children with<br />

fevers<br />

• describe the genes associated with Kawasaki disease risk, and<br />

hypotheses for pathogenesis<br />

• identify the indications for and recommendations for secondline<br />

immunosuppressive therapy for Kawasaki Disease<br />

patients who do not respond to IVIG, including corticosteroids,<br />

cyclophosphamide, and anti-TNF agents<br />

• know the evidence for recommendations for acute and<br />

chronic anticoagulation for KD<br />

A311<br />

Macrophage Activation Syndrome<br />

Moderators: Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong><br />

Alabama; Birmingham, AL<br />

Edward M. Behrens, MD; Children’s Hospital <strong>of</strong> Philadelphia;<br />

Philadelphia, PA<br />

90<br />

2010 Program Book


6:45 PM<br />

Macrophage Activation Syndrome in the Adult ICU<br />

Bita Shakoory, MD; University <strong>of</strong> Alabama-Birmingham;<br />

Birmingham, AL<br />

7:10 PM<br />

Distinguishing Sepsis from MAS<br />

Joseph Carcillo, MD; Children’s Hospital <strong>of</strong> Pittsburgh; Pittsburgh,<br />

PA<br />

7:35 PM<br />

Infectious Models <strong>of</strong> MAS<br />

Michael Jordan, MD, PhD; Children’s Hospital Medical Center,<br />

Cincinnati; Cincinnati, OH<br />

Session Overview:<br />

Macrophage activation syndrome is an <strong>of</strong>ten lethal entity<br />

associated with a variety <strong>of</strong> pediatric and adult infectious,<br />

oncologic, rheumatic (lupus, Still disease, vasculitis, etc.),<br />

and primary genetic disorders. Early recognition <strong>of</strong> MAS and<br />

institution <strong>of</strong> aggressive immunosuppressive therapy are keys to<br />

optimizing survival. Experts from different medical subspecialties<br />

have different perspectives <strong>of</strong> this end common pathway <strong>of</strong><br />

MAS. Genetic propensities for developing MAS, and animal<br />

models <strong>of</strong> MAS pathophysiology are being explored. What we<br />

learn about MAS from clinical and scientific experts in nonrheumatic<br />

fields will benefit adult and pediatric rheumatologists<br />

in diagnosing and treating patients who develop MAS.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the various infectious triggers <strong>of</strong> macrophage<br />

activation syndrome<br />

• discuss the diagnostic criteria for macrophage activation<br />

syndrome in the setting <strong>of</strong> infection<br />

• distinguish sepsis from macrophage activation syndrome<br />

• articulate the proposed pathophysiologic events leading to<br />

macrophage activation syndrome<br />

B311<br />

MRI<br />

Moderator: Mikkel Østergaard, MD, PhD, DMSc; Hvidovre<br />

University Hospital; Hvidovre, Denmark<br />

6:45 PM<br />

MRI <strong>of</strong> Cartilage in Osteoarthritis and Rheumatoid Arthritis -<br />

Introduction<br />

Mikkel Østergaard, MD, PhD, DMSc; Hvidovre University<br />

Hospital; Hvidovre, Denmark<br />

7:00 PM<br />

Function and Structure <strong>of</strong> Cartilage in Health and Disease: A<br />

MRI Perspective<br />

Deborah Burstein, PhD; Beth Israel Deaconess Medical Center;<br />

Boston, MA<br />

7:20 PM<br />

What Have We Learned about Cartilage from MRI Studies <strong>of</strong><br />

Osteoarthritis and How Can We Get?<br />

To be announced<br />

7:40 PM<br />

Challenges in MRI Assessment <strong>of</strong> Cartilage in RA and What<br />

Lessons to Learn from Studies in Osteoarthritis<br />

Philip G. Conaghan, MD, PhD; Chapel Allerton Hospital; Leeds,<br />

United Kingdom<br />

Session Overview:<br />

Increasing amounts <strong>of</strong> data on MRI in arthritides are emerging,<br />

and the technique is increasingly used in clinical trials and<br />

practice, making a forum for update on and discussion <strong>of</strong> this<br />

topic at ACR very relevant. An ACR study group addressing<br />

different aspects <strong>of</strong> MRI has existed since 2006, with varying<br />

focus and content. This year it is proposed to focus on “MRI <strong>of</strong><br />

cartilage in OA and RA”, and is expected to provide novel insights<br />

on MRI assessment <strong>of</strong> cartilage involvement in osteoarthritis and<br />

rheumatoid arthritis, and provide an option for crossfertilizatioin<br />

between the OA and RA research areas.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the current concepts MRI assessment <strong>of</strong> function and<br />

structure <strong>of</strong> cartilage in health and disease<br />

• discuss what has been learnt from MRI studies about cartilage<br />

and non-cartilage structures in osteoarthritis<br />

• describe the challenges <strong>of</strong> MRI assessment <strong>of</strong> cartilage in<br />

rheumatoid arthritis and which lessons can be learnt from<br />

MRI studies in osteoarthritis<br />

B308<br />

Neuro Endocrine Immunology<br />

Moderator: Frank Buttgereit, MD; Charite University Med-Berlin;<br />

Berlin, Germany<br />

6:45 PM<br />

The Immunomodulatory Properties <strong>of</strong> Adipokines and<br />

Adiponectin<br />

Ulf Muller-Ladner, MD; University Giessen/Kerckh<strong>of</strong>f-Clinic; Bad<br />

Nauheim, Germany<br />

7:05 PM<br />

Knowing the Fat for Fighting Diseases - Leptin: At the Crossroad<br />

<strong>of</strong> Energy Homeostasis, Immune Response and Systemic<br />

Inflammation<br />

Oreste Gualillo, PharmD, PhD; Santiago University Clinical<br />

Hospital; Santiago de Compostela, Spain<br />

7:25 PM<br />

The Impact <strong>of</strong> Abnormal Body Composition on Disease Activity<br />

in Rheumatoid Arthritis<br />

Jon T. Giles, MD; Johns Hopkins University; Baltimore, MD<br />

7:45 PM<br />

Panel Discussion<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe how adipokines modulate inflammation in adipose<br />

and mesenchymal tissue<br />

• identify the pathophysiology <strong>of</strong> white adipose tissue<br />

• explain useful concepts in counseling patients about<br />

behavioral changes to fight diseases<br />

• discuss how adiposity and adipokines affect inflammation and<br />

articular damage in rheumatoid arthritis<br />

A404<br />

Polymyalgia Rheumatica<br />

Moderators: Bhaskar Dasgupta, MD; Southend University<br />

Hospital; Essex, United Kingdom<br />

Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

tuesday<br />

2010 Program Book 91


tuesday<br />

6:45 PM<br />

Results from the PMR Classification Criteria Study<br />

Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

7:05 PM<br />

Update on Trials <strong>of</strong> Biologic Agents and Leflunomide in PMR<br />

and GCA<br />

Bhaskar Dasgupta, MD; Southend University Hospital; Essex,<br />

United Kingdom<br />

7:25 PM<br />

A Study <strong>of</strong> Educational Needs <strong>of</strong> Patients with PMR and GCA<br />

Richard Watts, DM; Ipswich Hospital; Ipswich, United Kingdom<br />

7:45 PM<br />

Update on Study <strong>of</strong> Temporal Artery Ultrasound Versus Biopsy<br />

in GCA<br />

Raashid Luqmani, DM; Nuffield Department <strong>of</strong> Orthopaedics,<br />

<strong>Rheumatology</strong> and Musculoskeletal Sciences; Oxford, United<br />

Kingdom<br />

Session Overview:<br />

The study group will be the forum for presenting results from<br />

the Prospective PMR Classification Criteria Study. It will also<br />

feature updates on therapeutic trials in PMR and GCA with<br />

leflunomide and biologic agents. A study <strong>of</strong> educational needs <strong>of</strong><br />

patients with PMR and GCA will be presented. Attendees will be<br />

updated on study <strong>of</strong> temporal artery ultrasound versus biopsy<br />

in GCA.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe results from the PMR classification criteria study<br />

• update on trials <strong>of</strong> leflunomide and biologic agents in PMR<br />

and GCA<br />

• explain a study <strong>of</strong> educational needs <strong>of</strong> patients with PMR and<br />

GCA<br />

• explain the study <strong>of</strong> temporal artery ultrasound versus biopsy<br />

in GCA<br />

B314<br />

Psoriatic Arthritis and Periarticular Imaging: Focus on<br />

Enthesitis, Dactylitis, and Nail Disease<br />

Moderators: Elaine Husni, MD, MPH; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Philip Helliwell, MD, PhD; University <strong>of</strong> Leeds; Leeds, United<br />

Kingdom<br />

6:45 PM<br />

The Role <strong>of</strong> Enthesitis in the Pathogenesis <strong>of</strong> Psoriatic Arthritis<br />

Dennis McGonagle, PhD; University <strong>of</strong> Leeds; Leeds, United<br />

Kingdom<br />

7:10 PM<br />

Clinical Assessment <strong>of</strong> Enthesitis: How Should This Be Done?<br />

Philip Helliwell, MD, PhD; University <strong>of</strong> Leeds; Leeds, United<br />

Kingdom<br />

7:35 PM<br />

Use <strong>of</strong> Ultrasound and Magnetic Resonance Imaging: Focus on<br />

Periarticular Disease in Patients with Psoriatic Arthritis<br />

Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />

Session Overview:<br />

Psoriatic arthritis is a unique inflammatory arthritis that<br />

encompasses both skin and joint involvement with common<br />

periarticular manifestations such as enthesitis and dactylitis. In<br />

fact, the initial insult may be enthesitis rather than the synovium<br />

and current area <strong>of</strong> research interest is in the early evaluation<br />

and detection <strong>of</strong> these clinical parameters. Therapeutic decisions<br />

may be influenced by the presence <strong>of</strong> active enthesis/dactylitis<br />

and current techniques <strong>of</strong> clinical examination and standard<br />

radiographs may underestimate the overall inflammatory<br />

burden. With the advances <strong>of</strong> imaging modalities, we will<br />

explore the utility <strong>of</strong> ultrasound and MRI for psoriatic diseases.<br />

We hope to bring together multidisciplinary disciplines in<br />

musculoskeletal radiologist and rheumatologist to help advance<br />

the field <strong>of</strong> psoriatic arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the overview <strong>of</strong> advances in imaging such as<br />

ultrasound in the utility <strong>of</strong> periarticular tissues in psoriatic<br />

arthritis<br />

• explore the relationship <strong>of</strong> immunohistology and imaging <strong>of</strong><br />

skin and joints for psoriatic diseases<br />

• identify the pathobiology and immuno-pathology underlying<br />

enthesitis in psoriatic disorders<br />

• appreciate the several clinical scoring methods for enthesitis,<br />

their reliability, sensitivity and specificity<br />

B309<br />

Sjögren’s Syndrome<br />

Moderators: Gabor G. Illei, MD; NIDCR/NIH; Bethesda, MD<br />

Nikolay P. Nikolov, MD; FDA/CDER/OND; Silver Spring, MD<br />

6:45 PM<br />

Animal Models in Sjögren’s Syndrome: Are They Any Good?<br />

Umesh Desmukh, PhD; University <strong>of</strong> Virginia; Charlottesville, VA<br />

7:10 pm<br />

From Bench to Bedside: Biological Markers <strong>of</strong> Disease Activity<br />

and Prognosis in Primary Sjögren’s Syndrome<br />

Jacques-Eric Gottenberg, MD, PhD; University <strong>of</strong> Strasbourg,<br />

France<br />

7:35 pm<br />

Autonomic Dysfunction: An Often Overlooked Feature <strong>of</strong><br />

Primary Sjogren’s Syndrome<br />

Thomas Mandl, MD, PhD: Malmo University Hospital; Malmo,<br />

Sweden<br />

Session Overview:<br />

The study group will address three topics ranging from animal<br />

models to clinical aspects <strong>of</strong> Sjögren’s syndrome providing inside<br />

in both the pathogenesis and clinical management <strong>of</strong> Sjögren’s<br />

syndrome. Speakers will discuss the role <strong>of</strong> B lymphocyte<br />

subsets and inflammatory mediators in the pathogenesis <strong>of</strong><br />

Sjögren’s and their potential as biomarkers, the advantages<br />

and limitations <strong>of</strong> various animal models and their relevance<br />

to human disease and the pathogenesis and treatment<br />

<strong>of</strong> autonomic dysfunction, one <strong>of</strong> the most challenging<br />

manifestation <strong>of</strong> Sjögren’s Syndrome. All three speakers will<br />

cover the basic aspects and the clinical implications <strong>of</strong> their<br />

topics.<br />

92<br />

2010 Program Book


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the advantages and limitations <strong>of</strong> animal models <strong>of</strong><br />

Sjögren’s syndrome and their relevance to human disease<br />

• identify the role <strong>of</strong> B cells, B cell directed cytokines and<br />

inflammatory mediators in the pathogenesis <strong>of</strong> Sjögren’s<br />

syndrome and their potential as biomarkers <strong>of</strong> disease activity<br />

and/or prognosis<br />

• develop a better understanding <strong>of</strong> the relationship between<br />

autonomic dysfunction and Sjögren’s syndrome and its clinical<br />

implications<br />

A410<br />

Skin Diseases<br />

Moderator: Jan P. Dutz, MD; University <strong>of</strong> Bristish Columbia;<br />

Vancouver, BC, Canada<br />

6:45 PM<br />

Cutaneous Side Effects <strong>of</strong> Anti-TNF Therapy<br />

David Wetter, MD; Mayo Clinic; Rochester, MN<br />

7:00 PM<br />

Multicentric Reticulocytosi a Dermatomyositis Mimic?<br />

Nicole Fett, MD; Perelman Center for Advanced Medicine;<br />

Philadelphia, PA<br />

7:15 PM<br />

Diagnosing and Treating Morphea<br />

Heidi Jacobe, MD; UT Southwestern Medical Center at Dallas;<br />

Dallas, TX<br />

7:30 PM<br />

Dematomyositis and Malignancy<br />

Jeffrey P. Callen, MD; University Louisville School Medicine;<br />

Louisville, KY<br />

7:40 PM<br />

Treatment <strong>of</strong> Raynaud’s in Patients with Low-Normal Blood<br />

Pressure<br />

Andrew G. Franks, MD; New York University; New York, NY<br />

tuesday<br />

7:50 PM<br />

Acquired Cutis Laxa<br />

Christan Vera Kellet, MD; Pontificia Universidad Catolica de<br />

Chile; Santigo, Chile<br />

Session Overview:<br />

Skin manifestations <strong>of</strong> rheumatic disease are common. This<br />

session will present six clinical cases involving the cutaneous<br />

manifestations <strong>of</strong> rheumatic diseases and their treatment.<br />

The range <strong>of</strong> diseases covered will include vascular disorders,<br />

dermatomyositis, sclerotic conditions, and skin drug reactions.<br />

Clinical features, importance <strong>of</strong> histopathology and treatment<br />

approaches will be covered and presented for discussion<br />

amongst attendees.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify common and unusual cutaneous manifestations <strong>of</strong><br />

rheumatic disease<br />

• describe the possible role <strong>of</strong> the dermatologist in comanagement<br />

<strong>of</strong> these conditions<br />

• identify the value and limitations <strong>of</strong> skin biopsy<br />

2010 Program Book 93


wednesday<br />

WEDNESDAY, NOVEMBER 10, 2010<br />

ACR/ARHP Registration<br />

6:30 am - 5:00 PM<br />

International Blvd. Foyer<br />

ACR Medical Aspects <strong>of</strong> Rheumatic<br />

Diseases<br />

7:15 - 8:15 am<br />

Hall A3<br />

Diabetes 2010: More than Autoimmunity and<br />

Adipocytes C PS<br />

Moderator: Gregory C. Gardner, MD; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

Speaker: Irl B. Hirsch, MD; University <strong>of</strong> Washington School <strong>of</strong><br />

Medicine; Seattle, WA<br />

Session Overview:<br />

Rheumatologists <strong>of</strong>ten care for patients with co-existing<br />

diabetes. A better understanding <strong>of</strong> the autoimmune nature<br />

<strong>of</strong> certain forms <strong>of</strong> diabetes may give us insight to our own<br />

diseases. Greater knowledge <strong>of</strong> this field in general will allow us<br />

to better care for our patients with diabetes spectrum illnesses.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the classification and pathophysiology <strong>of</strong> the various<br />

forms <strong>of</strong> diabetes<br />

• develop current and future treatment strategies for diabetes<br />

in its various forms including steroid associated diabetes<br />

• explain how medications used by rheumatologists might<br />

impact patients with diabetes<br />

ACR Special Session<br />

7:15 - 8:45 am<br />

A404<br />

The Changing Face <strong>of</strong> the <strong>Rheumatology</strong> Workforce:<br />

Gender Issues in the Workplace BR Ed.<br />

Moderator: Giovanni Franchin, MD, PhD; Feinstein Institute;<br />

Manhasset, NY<br />

7:15 am<br />

The New Face <strong>of</strong> <strong>Rheumatology</strong><br />

Abby Goulder Abelson, MD; Cleveland Clinic Foundation;<br />

Cleveland, OH<br />

7:30 am<br />

Gender Inequality and Barriers to a Successful Career: What<br />

Can We Learn from the Private Sector Initiative?<br />

Anne Camille Talley, MBA; Healthcare Businesswomen’s<br />

Association; Pittsgrove, NJ<br />

8:00 am<br />

Retention <strong>of</strong> Women in the <strong>Rheumatology</strong> Workplace<br />

Christy I. Sandborg, MD; Stanford Medical Center; Stanford, CA<br />

Robin K. Dore, MD; Robin K. Dore Incorporated; Tustin, CA<br />

8:30 am<br />

Panel Discussion<br />

Session Overview:<br />

The number <strong>of</strong> female physicians in the US has increased<br />

dramatically over the past thirty years. This trend is particularly<br />

pronounced in rheumatology as in 2009, 60 percent <strong>of</strong> all<br />

fellowship applicants were women. However, women still<br />

remain a minority in academic medicine <strong>of</strong> any kind as well as<br />

rheumatology, especially in more senior positions. According<br />

to the 2007-2008 Academic Workforce Study, although women<br />

represent 28.8 percent <strong>of</strong> academic appointments, only 15<br />

percent <strong>of</strong> full pr<strong>of</strong>essors are women, and only 7 percent <strong>of</strong><br />

adult rheumatology division chiefs are women. Additionally<br />

a recent study by The Center for Work-Life Policy, The Athena<br />

Project found that 52 percent <strong>of</strong> women ages 30-40 are leaving<br />

not only academic medicine, but also jobs in the private sector.<br />

Assuming that women will comprise a significant number,<br />

if not the majority <strong>of</strong> the workforce in rheumatology in the<br />

near future, the field needs to understand what factors are<br />

influencing women to choose rheumatology as a career,<br />

and more importantly, why women may not remain and/<br />

or advance in rheumatology in either academic or private<br />

practice settings. Identifying gender-related career barriers<br />

will guide the formulation <strong>of</strong> strategies to increase retention<br />

and promote the advancement <strong>of</strong> women in rheumatology,<br />

helping to ensure that the rheumatology workforce remains<br />

sufficient to meet anticipated future needs. This session<br />

intends to bring awareness to division chiefs, program<br />

directors and rheumatologists on the issue <strong>of</strong> gender in the<br />

rheumatology workforce, and its potential effect on the future <strong>of</strong><br />

rheumatology.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify workforce issues regarding women in academic<br />

medicine and in the private sector<br />

• describe the challenges to women in obtaining leadership<br />

positions<br />

• propose possible solutions to increase the recruitment<br />

and retention <strong>of</strong> women in academic medicine and their<br />

advancement in both the academic and private sector<br />

ACR Special Session<br />

7:15 - 9:15 am<br />

A412<br />

Insurance Roundtable Discussion BR<br />

This session is not eligible for CME credit.<br />

Moderators: Alex Limanni, MD; Arthritis Centers <strong>of</strong> Texas; Dallas,<br />

TX<br />

Gary R. Feldman, MD; Pacific Arthritis Care Center; Los Angeles,<br />

CA<br />

Speakers: Randall S. Krakauer, MD; Aetna; Princeton, NJ<br />

Alexander P. Ruggieri, MD; Anthem Care Management; Simi<br />

Valley, CA<br />

Erin McKenna PharmD; Anthem Care Management; Pittsburgh,<br />

PA<br />

Eileen M. Moynihan, MD; Highmark Medicare Services;<br />

Woodbury, MD<br />

94<br />

2010 Program Book


Session Overview:<br />

This roundtable discussion has been organized as part <strong>of</strong> the<br />

ACR’s initiative to encourage transparency and collaboration<br />

with insurance company respresentatives to ensure the needs<br />

<strong>of</strong> the patient are best addressed. Topics <strong>of</strong> discussion will<br />

include quality, transparency, tier 4 drug policies and priorauthorizations.<br />

The discussion is designed to generate candid<br />

dialogue regarding the needs and operational systems <strong>of</strong><br />

insurance companies and physicians, in an attempt to develop<br />

solutions that will streamline administrative processes, reduce<br />

costs and ensure effective deliverly <strong>of</strong> the appropriate care to<br />

patients. This session will be an open forum with questions and<br />

answers to follow.<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

7:15 - 8:15 am<br />

Sidney J. Marcus Auditorium<br />

Walk this Way: Biomechanics and Osteoarthritis R<br />

Moderator: Richard F. Loeser, MD; Wake Forest University;<br />

Winston-Salem, NC<br />

Speaker: Thomas Andriacchi, PhD; Stanford University; Stanford,<br />

CA<br />

Session Overview:<br />

Osteoarthritis is the result <strong>of</strong> biomechanical factors that cause<br />

abnormal or excessive joint loading. A better understanding<br />

<strong>of</strong> these factors has been gained over the past few years using<br />

advanced imaging and gait analysis. This lecture will present<br />

data based on these advances and review the latest findings as<br />

they relate to the pathogenesis <strong>of</strong> osteoarthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• analyze the biomechanical factors that predispose to knee<br />

and/or hip osteoarthritis<br />

• identify advances in technologies that utilize joint imaging<br />

with gait analysis<br />

• describe advances in understanding <strong>of</strong> biomechanical factors<br />

that will influence the management <strong>of</strong> osteoarthritis<br />

ARHP Concurrent Sessions<br />

7:45 - 8:45 am<br />

B309<br />

Disparities and Pain: Examining Research, Practice<br />

and Policy cP PM<br />

Moderator: Kristine Phillips, MD, PhD; University <strong>of</strong> Michigan;<br />

Ann Arbor, MI<br />

Speakers: Carmen R. Green, MD; University <strong>of</strong> Michigan; Ann<br />

Arbor, MI<br />

David A. Williams, PhD; University <strong>of</strong> Michigan Health System;<br />

Ann Arbor, MI<br />

Session Overview:<br />

Pain affects 100 million <strong>American</strong>s and is the most common<br />

cause <strong>of</strong> health care utilization. However, disparities exist in pain<br />

assessment and treatment, related to social determinants such<br />

as age, gender, class, and place <strong>of</strong> residence. Moreover, nonpharmacological<br />

interventions, such as aerobic exercise<br />

and cognitive-behavioral therapy, are underutilized in the<br />

management <strong>of</strong> chronic pain conditions, though response rates<br />

rival those <strong>of</strong> pharmacologic agents. Novel therapeutic delivery<br />

methods are overcoming barriers, and increasing accessibility <strong>of</strong><br />

therapeutic options in non-urban communities.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• outline disparities in pain care in the US and the role <strong>of</strong> social<br />

determinants on pain assessment, treatment and outcomes<br />

• summarize the current status <strong>of</strong> US health care reform related<br />

to pain and disparities, including relevant federal and state<br />

initiatives<br />

• describe why the combination <strong>of</strong> pharmacological and nonpharmacological<br />

interventions represents optimal care in<br />

chronic pain, and become familiar with intervention delivery<br />

methods suitable for both urban and rural environments<br />

B310<br />

Patient Education on the Run cP PS<br />

Moderator: Lee A. Anderson, BSN; University <strong>of</strong> Minnesota<br />

Physicians; Champlin, MN<br />

Speaker: Victoria L. Ruffing, RN; Johns Hopkins University;<br />

Baltimore, MD<br />

Session Overview:<br />

The need for health care pr<strong>of</strong>essionals to be aware <strong>of</strong> the<br />

alternative methods for educating adult patients in busy<br />

practices is ongoing and the available resources are constantly<br />

changing. Therefore, a summary <strong>of</strong> resources and methods to<br />

indentify the best management plans will be discussed.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss need for varied formats in patient education for adults<br />

• review patient learning styles<br />

• prioritize educational needs <strong>of</strong> adult patients with rheumatic<br />

diseases<br />

• identify available educational resources<br />

• discuss strategies for implementing educational programs<br />

B311<br />

Physical Activity and Osteoarthritis: Learning with the<br />

Community cP PS<br />

Moderator: Nadine M. Fisher, EdD; SUNY at Buffalo; Buffalo, NY<br />

Speakers: Mary E. Christenson, PT, PhD; Regis University;<br />

Westminster, CO<br />

Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;<br />

Boston, MA<br />

Session Overview:<br />

Incorporating appropriate physical activity into an individual’s<br />

routine for those living with osteoarthritis plays a key role<br />

in promoting health, enhancing functional activities, and<br />

improving the quality <strong>of</strong> life. Living in rural communities may<br />

<strong>of</strong>fer distinct challenges for people with arthritis to participate<br />

in physical activity, so involving the community to investigate<br />

factors associated with physical activity in this subpopulation is<br />

unique. Speakers will present the state <strong>of</strong> the evidence regarding<br />

physical activity in rural US communities in persons with arthritis<br />

and the results from a cross-sectional study informed by a rural<br />

advisory committee that investigated physical activity in adults<br />

with arthritis living in rural communities.<br />

wednesday<br />

2010 Program Book 95


wednesday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the state <strong>of</strong> the evidence regarding physical activity in<br />

adults with arthritis living in rural communities<br />

• describe the development <strong>of</strong> a community-based approach<br />

to learn about the levels <strong>of</strong> physical activity in a rural<br />

environment in persons with arthritis<br />

• examine perceived barriers/facilitators <strong>of</strong> physical activity in<br />

persons with arthritis in rural communities<br />

• identify benefits <strong>of</strong> physical activity in this subpopulation<br />

B308<br />

Using Pharmacogenomics to Improve Therapy for<br />

Pediatric Patients P/C PS<br />

Moderator: Bernadette McNally, MS, PAC; University <strong>of</strong> Utah;<br />

Salt Lake City, UT<br />

Speaker: Mara L. Becker, MD; Children’s Mercy Hospital; Kansas<br />

City, MO<br />

Session Overview:<br />

In the emerging field <strong>of</strong> personalized medicine, it is important to<br />

recognize that there is significant variability in drug response and<br />

toxicity between adults and children. Targeted therapy-based on<br />

age, genetics and development <strong>of</strong> the child may be the future<br />

<strong>of</strong> prescribing medications for rheumatic disease for children,<br />

specifically methotrexate. Ontogeny, the normal developmental<br />

process may affect aspects <strong>of</strong> pharmacological response in<br />

children including drug absorption, distribution, metabolism and<br />

excretion. Developmental expression <strong>of</strong> different pathways at<br />

different times may lead to variability in medication response.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe differences in disease expression and drug response<br />

in pediatric patients<br />

• define what makes children different, including developmental<br />

pharmacokinetics, pharmacogenetics in children and the role<br />

<strong>of</strong> ontogeny<br />

• summarize new pharmacogenomic data in commonly<br />

used medications in pediatrics and identify gaps in current<br />

knowledge<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

7:45 - 9:15 am<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Adult Inflammatory Myopathy (061)<br />

Speaker: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />

Milwaukee, WI<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss diagnostic pearls for the evaluation <strong>of</strong> someone<br />

suspected <strong>of</strong> having an inflammatory myopathy<br />

• discuss the treatment paradigm for inflammatory myopathies<br />

B208<br />

Crystal: Management <strong>of</strong> Gout (062) PS<br />

Speaker: Hyon K. Choi, MD, DrPH; University <strong>of</strong> British Columbia;<br />

Vancouver, BC, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the management <strong>of</strong> gout in patients with renal<br />

insufficiency or organ transplants<br />

• identify strategies to treat patients who are intolerant <strong>of</strong><br />

approved therapies<br />

• cite agents in development for the treatment <strong>of</strong><br />

hyperuricemia and gout<br />

B209<br />

Pediatrics: Spondyloarthritis in Children (063) P<br />

Speaker: Shirley Tse, MD; Hospital for Sick Children; Toronto, ON,<br />

Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe differences between spondylarthritis in children and<br />

adults<br />

• discuss the approach to diagnosis and treatment <strong>of</strong> children<br />

with spondylarthritis<br />

B210<br />

Pregnancy in Rheumatic Diseases (064)<br />

Speaker: Megan E.B. Clowse, MD, MPH; Duke University Medical<br />

Center; Durham, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the effects <strong>of</strong> pregnancy on the activity <strong>of</strong> rheumatic<br />

diseases<br />

• describe the challenging management issues unique to<br />

pregnancy<br />

B301<br />

Pulmonary Manifestations <strong>of</strong> Rheumatic Disease (065)<br />

Speaker: Paul F. Dellaripa, MD; Brigham and Women’s Hospital;<br />

Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify emerging concepts regarding the pathophysiology <strong>of</strong><br />

inflammation and fibrosis in autoimmune lung disease<br />

• determine the appropriate use <strong>of</strong> diagnostic tests in<br />

the evaluation <strong>of</strong> patients with rheumatic disorders and<br />

autoimmune lung disease<br />

• discuss the limits <strong>of</strong> traditional therapeutic options and<br />

possible emerging therapies in managing autoimmune lung<br />

disease<br />

B302<br />

Rheumatoid Arthritis: Biological Agents (066) PS<br />

Speaker: Larry W. Moreland, MD; University <strong>of</strong> Pittsburgh<br />

Medical Center; Pittsburgh, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify biologic agents in use for the treatment <strong>of</strong> rheumatoid<br />

arthritis<br />

• describe the risk/benefit pr<strong>of</strong>iles <strong>of</strong> biologic agents<br />

• discuss the emerging biologics and their advantages for the<br />

therapeutic algorithm<br />

96<br />

2010 Program Book


B303<br />

Scleroderma: Systemic Sclerosis (067) PM<br />

Speaker: Christopher P. Denton, MD, PhD; Royal Free Hospital;<br />

London, United Kingdom<br />

B202<br />

Dermatopathology <strong>of</strong> Rheumatic Diseases (231)<br />

Speaker: Lynne Goldberg, MD; Boston University Medical<br />

Center; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the classification <strong>of</strong> systemic sclerosis and its impact<br />

on treatment and prognosis<br />

• apply cardiopulmonary testing to determine the relative<br />

contributions <strong>of</strong> alveolitis, fibrosis and vasculopathy<br />

• formulate a therapeutic regimen to improve quality <strong>of</strong> life and<br />

organ-specific symptomatology<br />

B304<br />

Systemic Lupus Erythematosus: Difficult to Treat<br />

Systemic Lupus Erythematosus (068) P f<br />

Speaker: Elena M. Massarotti, MD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• utilize laboratory testing in the management <strong>of</strong> patients with<br />

systemic lupus erythematosus<br />

• determine the most relevant and beneficial therapeutic<br />

approach<br />

• identify appropriate assessment tools for use in management<br />

and prognosis<br />

B305<br />

Temporal Arteritis (069)<br />

Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the most current concepts in diagnosis <strong>of</strong> temporal<br />

arteritis, including the use <strong>of</strong> imaging modalities<br />

• identify evolving concepts in treatment <strong>of</strong> temporal arteritis,<br />

including appropriate use <strong>of</strong> corticosteroids, as well as the<br />

data regarding the efficacy <strong>of</strong> other “steroid sparing” agents<br />

• describe controversial areas in diagnosis and management <strong>of</strong><br />

temporal arteritis<br />

B306<br />

Vasculitis: Update (070) f<br />

Speaker: Peter A. Merkel, MD, MPH; Boston University School <strong>of</strong><br />

Medicine; West Newton, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the classification <strong>of</strong> vasculitis according to affected<br />

vessel size<br />

• utilize the various available laboratory tests, with emphasis on<br />

anti-neutrophilic cytoplasmic antibodies testing<br />

• identify current and novel therapeutic modalities<br />

ACR Workshops<br />

7:45 - 9:45 am<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review dermatopathology in rheumatic diseases<br />

• describe the importance <strong>of</strong> dermatopathology in clinical<br />

decision making in patients with rheumatic diseases<br />

• apply the knowledge gained to clinical practice<br />

B206<br />

Joint Simulator (232) f<br />

Speakers: Joanne Valeriano-Marcet, MD; University <strong>of</strong> South<br />

Florida; Tampa, FL<br />

Helen E. Bateman, MD; James A. Haley Veterans Affairs Hospital,<br />

University <strong>of</strong> Southern Florida; Tampa, FL<br />

Ashley G. Sterrett, MD; James A. Haley Veterans Affairs Hospital;<br />

Tampa, FL<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the anatomy relative to various joint, bursa, and<br />

tendon injections<br />

• perform and instruct others on the techniques<br />

• design a successful joint injection workshop using simulators<br />

B203<br />

Musculoskeletal Exam Skills II: Regional Examinations<br />

<strong>of</strong> the Shoulder and Low Back (233)<br />

Speakers: George V. Lawry, MD; University <strong>of</strong> California-Irvine;<br />

Mission Viejo, CA<br />

Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists;<br />

Appleton, WI<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• participate in a hands-on, skill building workshop where<br />

participants are paired together for one-on-one practice<br />

• apply a systematic, efficient, clinically effective examination <strong>of</strong><br />

the shoulder and low back taking 3-4 minutes each<br />

• practice techniques for assessing SC and AC joints, bursitis,<br />

rotator cuff tendinitis, impingement signs and glenohumeral<br />

rotation<br />

• practice techniques for inspection, palpation, ROM, hip<br />

examination, suspected nerve root irritation and Waddell’s<br />

categories<br />

B204<br />

<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Upper<br />

Extremity and Cervical Spine: Anatomical Correlates<br />

(234) f<br />

Speakers: Robert A. Kalish, MD; Tufts Medical Center; Boston,<br />

MA<br />

Pablo Villasenor Ovies, MD; Instituto Nacional de Ciencias<br />

Medicas y Nutricion; Tlalpan, Mexico<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review clinical and surface anatomy important to the<br />

rheumatologist<br />

• describe human anatomy to clinical syndromes seen in the<br />

practice <strong>of</strong> rheumatology<br />

• integrate these physical examination skills into a<br />

rheumatology practice<br />

2010 Program Book 97<br />

wednesday


ACR Clinical Symposium<br />

8:45 - 9:45 am<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

8:45 - 9:45 am<br />

wednesday<br />

98<br />

Hall A3<br />

Myositis 2010: A to Z c/r cP P/C PS<br />

Moderator: Chester V. Oddis, MD; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

Speaker: Frederick W. Miller, MD, PhD; National Institute <strong>of</strong><br />

Environmental Health Sciences, NIH; Kennsington, MD<br />

Session Overview:<br />

Patients with myositis are a diagnostic and therapeutic challenge<br />

for the practicing rheumatologist. ACR members frequently<br />

request updates on the inflammatory myopathies and the<br />

different subsets such as polymyositis, dermatomyositis, overlap<br />

syndromes and inclusion body myositis. This review will focus on<br />

all aspects <strong>of</strong> myositis including diagnosis, ongoing assessment<br />

and management considerations. The mimics <strong>of</strong> myositis will<br />

be considered along with the assessment and treatment <strong>of</strong> the<br />

refractory myositis patient.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify patients with the various clinical syndromes<br />

associated with the inflammatory myopathies<br />

• outline a diagnostic and therapeutic plan in patients<br />

diagnosed with idiopathic inflammatory myopathy<br />

• identify the mimics <strong>of</strong> myositis and assess and treat the<br />

patient with refractory disease<br />

ACR Immunology Updates for<br />

Clinicians<br />

8:45 - 9:45 am<br />

Thomas J. Murphy Ballroom<br />

Epigenetics 101 c/r<br />

Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Speaker: Robert A. Colbert, MD, PhD; NIAMS/NIH; Bethesda, MD<br />

Session Overview:<br />

Epigenetics is the regulation <strong>of</strong> gene expression without<br />

altering the nucleotide sequence <strong>of</strong> the genome. Epigenetics<br />

determines gene expression in cellular differentiation, e.g.,<br />

differential cytokine production in T cell subsets, and is involved<br />

in gene silencing including X chromosome inactivation in<br />

females. Epigenetics also explains the pathogenesis <strong>of</strong> druginduced<br />

lupus. Inhibitors <strong>of</strong> histone deacetylases target one<br />

mechanism <strong>of</strong> epigenetic regulation <strong>of</strong> gene expression. Histone<br />

deacetylases inhibition is being tested in a wide variety <strong>of</strong><br />

human malignancies and has shown promise in animal models<br />

<strong>of</strong> lupus.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe how different epigenetic mechanisms regulate gene<br />

expression<br />

• describe the important <strong>of</strong> epigenetics in the<br />

immunopathogenesis <strong>of</strong> human disease<br />

• discuss potential therapeutic applications <strong>of</strong> epigenetics<br />

2010 Program Book<br />

B406<br />

From Fat to Joints - The Vicious Side <strong>of</strong> Adipokines<br />

R<br />

Moderator: David S. Pisetsky, MD, PhD; Duke University Medical<br />

Center; Durham, NC<br />

Speaker: Ulf Muller-Ladner, MD; University Giessen/Kerckh<strong>of</strong>f-<br />

Clinic; Bad Nauheim, Germany<br />

Session Overview:<br />

Recent studies revealed several links between adipose tissue,<br />

adipocytokines, and arthritis. This presentation will review<br />

the evidence indicating that adipose tissue is not an innocent<br />

bystander tissue and may influence the inflammatory process.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• illustrate the variety <strong>of</strong> adipokines operative in non-metabolic<br />

inflammatory rheumatic diseases<br />

• describe the role <strong>of</strong> adipokines in inflammatory processes<br />

• visualize the potential <strong>of</strong> anti-adipokine targeted therapies in<br />

inflammatory conditions<br />

ACR REF Special Session<br />

8:45 - 9:45 am<br />

Sidney J. Marcus Auditorium<br />

REF Paul Klemperer, MD, Memorial Lectureship:<br />

Systemic Sclerosis: Genetic? Autoimmune? One<br />

Disease? c/r<br />

Moderator: E. William St.Clair, MD; Duke University Medical<br />

Center; Durham, NC<br />

Speakers: Frank C. Arnett, MD; University <strong>of</strong> Texas Medical<br />

School; Houston, TX<br />

Session Overview:<br />

Progressive systemic sclerosis is a devastating disease that<br />

all rheumatologists see regularly. It is essential that clinicians<br />

be familiar with the latest data concerning etiopathogenesis<br />

and disease classification in order to educate their patients<br />

and to manage the disease optimally. This lecture will update<br />

the attendees on current thinking about the genetic basis <strong>of</strong><br />

progressive systemic sclerosis and how that relates to diagnosis<br />

and management.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the aspects <strong>of</strong> systemic sclerosis that suggest a<br />

genetic etiology<br />

• review the autoimmune aspects <strong>of</strong> the disease<br />

• discuss which aspects <strong>of</strong> the clinical presentation suggest that<br />

there are several underlying disease processes and which<br />

suggest a single unifying etiology<br />

ACR/ARHP Poster Session C and<br />

Poster Tours<br />

9:00 am - 6:00 PM<br />

Halls B1 & B2<br />

Poster presenters will be available from 9:00 - 11:00 am.<br />

Poster tours will be held 9:00 - 9:45 am, 10:15 - 11:00 am<br />

and 4:30 - 5:30 PM.


9:00 - 10:30 am - Poster Hall Morning Snack Break<br />

9:00 - 11:00 am (Abstracts #1466 – 2079)<br />

Guided Poster Tours<br />

Guided poster tours provide an opportunity for scientific<br />

attendees to ask questions and gain insights from leaders in<br />

the field while earning CME credits. Morning tours will <strong>of</strong>fer<br />

insights from both poster presenters and tour guides, while<br />

afternoon tours will exclusively feature the tour guide’s expert<br />

opinion. Although there is no fee to participate, pre-registration<br />

is required and each tour is limited to 20 registered scientific<br />

attendees. If you would like to participate and have not<br />

registered you can check tour availability and request a ticket<br />

in the registration area, located in the International Boulevard<br />

Foyer. If you registered in advance <strong>of</strong> the meeting your ticket was<br />

included with your meeting materials. Once you have your ticket,<br />

plan to collect your headset and meet your group 10 minutes<br />

before your tour departs from the entrance <strong>of</strong> the poster hall,<br />

located in Halls B1 & B2.<br />

Headsets: Each tour participant will receive a wireless headset.<br />

Participants who do not return their headsets within 10 minutes<br />

after the tour has ended will incur a fee.<br />

9:00 - 9:45 am<br />

Pediatric P<br />

(Attendance limited to Pediatric Resident Program recipients.)<br />

Egla C. Rabinovich, MD, MPH; Duke University Medical Center;<br />

Durham, NC<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />

and Treatment<br />

Atul A. Deodhar, MD; Oregon Health & Science University;<br />

Portland, OR<br />

Systemic Lupus Erythematosus: Clinical Aspects<br />

Barri J. Fessler, MD; Univeristy <strong>of</strong> Alabama – Birmingham<br />

<strong>Rheumatology</strong>; Birmingham, AL<br />

Vasculitis<br />

Simon Carette, MD; Toronto Western Hospital; Toronto, ON,<br />

Canada<br />

Quality <strong>of</strong> Life<br />

Edward H. Yelin, PhD, University <strong>of</strong> California, San Francisco, CA<br />

Physical Activity/Exercise<br />

Mary E. Christenson, PT, PhD; Regis University; Westminster, CO<br />

10:15 - 11:00 am<br />

Epidemiology and Health Services Research<br />

Liana Fraenkel, MD, MPH; Yale University, Newtown, CT<br />

Miscellaneous Rheumatic and Inflammatory Diseases<br />

W. Winn Chatham, MD; University <strong>of</strong> Alabama at Birmingham;<br />

Birmingham, AL<br />

Pediatric <strong>Rheumatology</strong>: Clinical Aspects<br />

Balu H. Athreya, MD; DuPont Hospital for Children; Wilmington,<br />

DE<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Inmaculada Del Rincon, MD, MS; University <strong>of</strong> Texas Health<br />

Science Center - San Antonio; San Antonio, TX<br />

Systemic Lupus Erythematosus: Clinical Aspects<br />

Bevra H. Hahn, MD; University <strong>of</strong> California Los Angeles School<br />

<strong>of</strong> Medicine; Los Angeles, CA<br />

Pain<br />

Carol L. Baird, DNS, ARPN, BC; Indiana University; Indianapolis,<br />

IN<br />

Behavioral Science<br />

Susan J. Bartlett, PhD; McGill University; Montreal, QC, Canada<br />

4:30 - 5:30 PM<br />

Rheumatoid Arthritis: Clinical Aspects<br />

Iain B. McInnes, PhD; University <strong>of</strong> Glasgow; Glasgow, United<br />

Kingdom<br />

Sjögren’s Syndrome<br />

Jacques-Eric Gottenberg, MD, PhD; Strasbourg Hospitals;<br />

Strasbourg, France<br />

Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />

and Treatment<br />

Luis Espinoza, MD; Louisiana State University; New Orleans, LA<br />

Systemic Lupus Erythematosus: Clinical Aspects<br />

David A. Isenberg, MD; University <strong>College</strong> <strong>of</strong> London; London,<br />

United Kingdom<br />

Exhibits and Replay Café<br />

9:00 am - 2:00 pm<br />

Halls A1 & A2<br />

Exhibits<br />

Halls A1 & A2 (Booth #123)<br />

Replay Café<br />

Exhibit Hall Morning SnACk Break<br />

9:00 - 10:00 am<br />

Halls A1 & A2<br />

Poster Hall Morning SnACk Break<br />

9:00 - 10:30 am<br />

Halls B1 & B2<br />

ARHP Concurrent Abstract Session<br />

9:15 – 10:15 am<br />

B311<br />

Be Creative with Rheumatic Education: Where and<br />

How to Get It<br />

Moderator: Elizabeth Schlenk, PhD, RN; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

9:15 am<br />

2080. Where Do Adults with Arthritis Get Information about<br />

Arthritis?<br />

Louise Murphy 3 , Kristina A. Theis 3 , Teresa J. Brady 2 , Julie Bolen 3<br />

and Patience White 1 , 1 Arthritis Foundation, 2 Center for Disease<br />

Control, Atlanta, GA, 3 Centers for Disease Control and Prevention<br />

wednesday<br />

2010 Program Book 99


wednesday<br />

100<br />

9:30 am<br />

2081. Rheuma on the Road – The Rheuma Truck Mass<br />

Communication, Educational Advertising and Creative<br />

Community Care.<br />

Matthias K. Schneider 2 and Martina Blumenroth 1 , 1 Cooperative<br />

<strong>Rheumatology</strong> Association Rhine-Ruhr MNR-Klinik, Duesseldorf,<br />

Germany, 2 MNR-Klinik, Duesseldorf, Germany<br />

9:45 am<br />

2082. A Study <strong>of</strong> Pictorial Representation (Mind Map) To<br />

Convey Health Education on Osteomalacia to People with Low<br />

Language Literacy Skills.<br />

Adewale O. Adebajo 5 , David Walker 3 , Sandra Robinson 4 ,<br />

Yogenjagat Singh 3 , Philip Helliwell 2 and Anisur Rahman 1 ,<br />

1<br />

University <strong>College</strong> London, London, United Kingdome,<br />

2<br />

University <strong>of</strong> Leeds, Leeds, United Kingdom, 3 University<br />

<strong>of</strong> Newcastle, Newcastle, United Kingdom, 4 University <strong>of</strong><br />

Newcastler, Newcastle, United Kingdom, 5 University <strong>of</strong> Sheffield<br />

Medical School Sheffield United Kingdom, Sheffield, United<br />

Kingdom<br />

10:00 am<br />

2083. Using Social Media To Recruit for a Translational Lupus<br />

Research Study for the Millennial Generation – The SisSLE<br />

Experience.<br />

Marlene H. Kern 2 , Sally Kaplan 2 , Bonnie Gonzales 2 , Betty<br />

Diamond 1 and Peter K. Gregersen 2 , 1 Feinstein Institute for<br />

Medical Research, Manhasset, NY, 2 The Feinstein Institute for<br />

Medical Research, Manhasset, NY<br />

ARHP Concurrent Sessions<br />

9:15 - 10:15 am<br />

B309<br />

Building Effective Teams: Recommended Leadership<br />

Strategies cP PS<br />

Moderator: Michael J. Jennings, RT, CBDT; Arthritis Care; Troy, NY<br />

Speakers: Basia Belza, PhD, RN; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard<br />

Medical School; Boston, MA<br />

Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;<br />

Boston, MA<br />

Session Overview:<br />

Regardless <strong>of</strong> work setting or discipline, working collaboratively<br />

as a team enhances productivity, increases satisfaction, and<br />

leads to improved outcomes.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• compose clear objectives for team work and measurable<br />

outcomes<br />

• define the attributes <strong>of</strong> a successful team<br />

• build and/or transform team culture and define the context <strong>of</strong><br />

group interaction<br />

B308<br />

Pain Management In the Age <strong>of</strong> Abuse and Litigation<br />

c/r PS PM<br />

Moderator: Kori A. Dewing, MN, ARNP; VA Mason Medical<br />

Center; Everett, WA<br />

Speaker: Allan Gib<strong>of</strong>sky, MD, JD; Hospital for Special Surgery;<br />

New York, NY<br />

2010 Program Book<br />

Session Overview:<br />

Efforts to identify pain management barriers and attempts to<br />

modify those barriers through quality improvement programs<br />

have increased dramatically within health care organizations<br />

in recent years. National clinical practice guidelines for the<br />

management <strong>of</strong> acute pain and cancer pain have been published<br />

by numerous pr<strong>of</strong>essional societies including the <strong>American</strong> Pain<br />

Society and by the Agency for Health Care Policy and Research.<br />

There is general agreement, however, that the implementation<br />

<strong>of</strong> pain management strategies has proven problematic.<br />

Research on barriers to effectively manage pain indicates that<br />

problems fall into three main categories: those related to health<br />

care pr<strong>of</strong>essionals; those related to patients and families;<br />

and, those related to health care systems. Thus, health care<br />

pr<strong>of</strong>essionals may under treat pain for several reasons, including<br />

inadequate knowledge <strong>of</strong> pain management, inadequate<br />

knowledge <strong>of</strong> the side effects <strong>of</strong> analgesics, poor assessment <strong>of</strong><br />

pain, and concern about regulation <strong>of</strong> controlled substances.<br />

Despite efforts by organizations like Joint Commission on<br />

Accreditation <strong>of</strong> Healthcare Organizations to identify pain as<br />

“the fifth vital sign”, the health care system gives low priority<br />

to (and low reimbursement for) effective pain management<br />

strategies. This session will address strategies to effectively<br />

manage musculoskeletal and inflammatory pain in the clinical<br />

rheumatology setting and identify strategies to reduce the<br />

likelihood <strong>of</strong> litigation and administrative sanction related to use<br />

<strong>of</strong> controlled substances.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the incidence <strong>of</strong> prescription drug abuse in<br />

rheumatology<br />

• design strategies to reduce prescription drug abuse in a<br />

rheumatology practice<br />

• describe best practice strategies to protect against litigation<br />

related to prescription medication abuse<br />

B402<br />

Rheumatic Disease Update: Juvenile Idiopathic<br />

Arthritis P/C<br />

Moderator: Karen L. Kerr, MSN, NP, CPNP, PNP; Children’s<br />

Hospital <strong>of</strong> Michigan; Detroit, MI<br />

Speaker: Helen M. Emery, MD; Children’s Hospital & Regional<br />

Medicine; Seattle, WA<br />

Session Overview:<br />

Juvenile idiopathic arthritis remains the most common<br />

musculoskeletal problem in children below the age <strong>of</strong> 16 years.<br />

Many patients show frequent flares or persistent disease activity<br />

with significant morbidity and serious complications. Recent<br />

investigations in the pathophysiology <strong>of</strong> juvenile idiopathic<br />

arthritis have focused on mediators <strong>of</strong> the innate immune<br />

system and IL-1beta, IL-6 and IL-18 as well as phagocyte-specific<br />

S100-proteins are correlated with disease activity and secondary<br />

complications. These insights have lead to new promising<br />

treatment approaches, like application <strong>of</strong> recombinant anti-IL-1<br />

receptor antagonist or anti-IL-6 receptor antibodies in patients<br />

resistant to conventional anti-inflammatory treatment. With<br />

these new discoveries, rheumatology pr<strong>of</strong>essionals need to keep<br />

up with the pathophysiology and novel treatment options <strong>of</strong><br />

juvenile idiopathic arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the pathophysiology <strong>of</strong> systemic onset juvenile<br />

idiopathic arthritis


• describe the role <strong>of</strong> IL-1 and IL-6 in the development <strong>of</strong><br />

juvenile idiopathic arthritis and its therapeutic implications<br />

• develop a plan for management <strong>of</strong> ‘resistant cases’ <strong>of</strong> juvenile<br />

idiopathic arthritis<br />

ACR Practice Issues<br />

9:30 - 11:00 am<br />

A411<br />

CORC Forum: Health Care Reform – Where Are We<br />

Heading? BR cP PS<br />

Moderators: Matthew P. Bunyard, MD; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Raymond Hong, MD, MBA; Ohio Permanente Medical Group;<br />

Richfield, OH<br />

9:30 am<br />

Where Are We Heading? Health Care Reform – A Workable<br />

Approach<br />

J. B. Silvers, PhD; Case Western Reserve University; Cleveland,<br />

OH<br />

Nan Shen, MD; Shanghai Ren Ji Hospital; Shanghai, China<br />

Speaker: Angus W. Thomson, PhD; Univesity <strong>of</strong> Pittsburgh<br />

Medical School; Pittsburgh, PA<br />

Session Overview:<br />

Dendritic cells are pivotal regulators <strong>of</strong> the immune response.<br />

Dendritic cells sense pathogens and danger signals in the<br />

environment and trigger antigen specific immune responses.<br />

They also present antigens from self-tissues to induce immune<br />

tolerance. Recent studies have unveiled the mechanisms<br />

by which dendritic cells promote and maintain tolerance. In<br />

addition, tolerogenic dendritic cells can promote or restore<br />

antigen-specific tolerance in animal models and these cells hold<br />

promise for the treatment <strong>of</strong> human autoimmune diseases.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss how dendritic cells establish and maintain immune<br />

tolerance<br />

• explain how manipulation <strong>of</strong> dendritic cells can generate<br />

tolerogenic dendritic cells<br />

• describe how tolerogenic dendritic cells can be effective for<br />

the treatment <strong>of</strong> human autoimmune disease<br />

10:15 am<br />

The Need for Strategic Planning in a Time <strong>of</strong> Change<br />

John Freedman, MD, MBA; Freedman Healthcare, LLC; Newton,<br />

MA<br />

Session Overview:<br />

Health care reform is at the forefront <strong>of</strong> health care discussion<br />

today. The business case for quality and efficiency in health care<br />

has never been clearer. It has been postulated that the new<br />

system will encourage payers to reimburse only for consistent<br />

and efficient care. Increasing transparency will stimulate more<br />

patient ownership <strong>of</strong> their health concerns and finances.<br />

Patients will in turn demand care that meets their needs.<br />

Preparing for the future <strong>of</strong> health care is therefore critical to<br />

the survival <strong>of</strong> many organizations. This changing health care<br />

landscape will have implications for medical providers. Many<br />

agree that the current system is not working and something<br />

will need to be done in order to protect the physician-patient<br />

relationship. So where are we heading?<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the role <strong>of</strong> performance measurement in payment<br />

health care reform<br />

• identify opportunities for providers in the changing medical<br />

landscape<br />

• describe the risks for clinicians, medical equipment and<br />

pharmaceutical suppliers, and others as a result <strong>of</strong> health care<br />

reform<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

9:30 - 10:30 am<br />

B313<br />

Tolerogenic Dendritic Cells: Regulators <strong>of</strong> Immune<br />

Reactivity and Therapeutic Agents in Autoimmune<br />

Disease R<br />

Moderators: Christopher T. Ritchlin, MD; University <strong>of</strong> Rochester<br />

Medical Center; Rochester, NY<br />

InnoVAtion Theater<br />

10:00 - 10:45 am<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Covidien. Please visit the<br />

Covidien exhibit booth for more information or see page 292.<br />

Seating and light refreshments are subject to availability.<br />

An Alternative for Patients with Signs and Symptoms<br />

<strong>of</strong> Osteoarthritis <strong>of</strong> the Knee(s)<br />

ACR Workshops<br />

10:30 am - 12:30 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B201<br />

Electronic Health Record (235) PS<br />

Speaker: Salahuddin Kazi, MD; Dallas Veterans Affairs Medical<br />

Center; Dallas, TX<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the key elements in current clinical processes and<br />

workflow to help select the features <strong>of</strong> an electronic health<br />

record that will be most useful for the clinical practice<br />

• define “meaningful use” <strong>of</strong> EHR<br />

• establish the principles <strong>of</strong> medical informatics and how to<br />

apply them to a clinical setting<br />

B202<br />

Muscle Involvement in Rheumatic Diseases (236)<br />

Speaker: Sakir Humayun Gultekin, MD; Oregon Health & Science<br />

University; Portland, OR<br />

2010 Program Book 101<br />

wednesday


wednesday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the histological appearance <strong>of</strong> muscle in different<br />

rheumatic diseases<br />

• identify the histologic abnormalities <strong>of</strong> steroidmyopathy,<br />

polymyositis, dermatomyositis, and inclusion body myositis<br />

B203<br />

Musculoskeletal Exam Skills III: Regional<br />

Examinations <strong>of</strong> the Knee (237)<br />

Speakers: Paul C. Utrie, MD; Orthopedic and Sports Medicine<br />

Specialists; Appleton, WI<br />

George V. Lawry, MD; University <strong>of</strong> California-Irvine; Mission<br />

Viejo, CA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• participate in a hands-on, skill building workshop where<br />

participants are paired together for one-on-one practice<br />

• apply a systematic, efficient, clinically effective examination <strong>of</strong><br />

the knee (2 parts) taking 3-4 minutes each<br />

• practice techniques for assessing synovial swelling,<br />

patell<strong>of</strong>ermoral and ligamentous problems, Lachman and<br />

McMurray maneuvers<br />

B204<br />

Patient Questionnaires to Monitor Status and<br />

Document Improvement in Standard Care: Practical<br />

Considerations (238) PS<br />

Speaker: Theodore Pincus, MD; New York University Hospital for<br />

Joint Disease; Hastings-on-Hudson, NY<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• utilize patient questionnaires to monitor and document<br />

patient status in everyday rheumatology practice<br />

• describe how questionnaires can identify incomplete<br />

responses to therapies, and a need for changes in tight control<br />

<strong>of</strong> inflammation<br />

• increase awareness <strong>of</strong> the significance <strong>of</strong> patient<br />

questionnaire data in the prognosis <strong>of</strong> long-term<br />

ACR State-<strong>of</strong>-the-Art Lecture<br />

10:45 - 11:45 am<br />

B406<br />

Stem Cell Reprogramming: Molecular Mechanisms<br />

and Clinical Applications and Implications R<br />

Moderator: Lionel B. Ivashkiv, MD; Hospital for Special Surgery;<br />

New York, NY<br />

Speaker: Rocky S. Tuan, PhD; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />

PA<br />

Session Overview:<br />

Stem cell technologies are rapidly evolving and have potential<br />

clinical applications in treating autoimmune disorders and in<br />

repairing and regenerating connective tissues. An understanding<br />

<strong>of</strong> these molecular and cellular processes will be important for<br />

clinicians and scientists working in the field <strong>of</strong> rheumatology.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the stem cell niche and its role in maintaining stem<br />

cell survival<br />

• discuss the cellular and molecular events associated with stem<br />

cell reprogramming<br />

• identify potential clinical applications <strong>of</strong> cellular<br />

reprogramming<br />

ARHP Concurrent Sessions<br />

10:45 - 11:45 am<br />

B308<br />

Adaptations and Solutions to Help People with<br />

Scleroderma Continue to Work c/r PM<br />

Moderator: Patricia A. MacDonald, BSN, NP; Takeda Global R&D<br />

Inc.; Lake Forest, IL<br />

Speakers: Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />

Albuquerque, NM<br />

Session Overview:<br />

Work is a major part <strong>of</strong> life for most adults and the role <strong>of</strong><br />

worker is highly valued not only as a means to provide income,<br />

but also as a major source <strong>of</strong> social interaction, structure and<br />

identity. The impact <strong>of</strong> rheumatic conditions such as rheumatoid<br />

arthritis, osteoarthritis, and lupus, on working ability and work<br />

cessation has been studied extensively. However, systemic<br />

sclerosis or scleroderma, another rheumatic disease which<br />

starts during the years <strong>of</strong> peak earning power, has only limited<br />

research. A few recent studies have examined factors related<br />

to work disability, such as disease severity and duration,<br />

symptoms, such as pain and fatigue, and physical function<br />

in scleroderma, but little is known about how workers with<br />

scleroderma cope. Studies on other rheumatic disorders suggest<br />

that adaptations made in the work environment and outside the<br />

work environment were key factors in preventing work disability<br />

in persons. Thus, it is important to understand the challenges<br />

individuals with scleroderma encounter in a work environment<br />

and what accommodations and adaptations can be made, so<br />

that they can continue to work.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the symptoms <strong>of</strong> scleroderma and the challenges to<br />

remaining in the workforce such as environmental constraints,<br />

fatigue and pain, commuting, and lifestyle issues<br />

• identify and evaluate the available computer and ergonomic<br />

adaptations accommodations that may be appropriate<br />

recommendations for people with scleroderma<br />

• recognize the barriers and solutions from the perspective <strong>of</strong><br />

the person with scleroderma<br />

B309<br />

Evidence-based Practice: Creating and Using<br />

<strong>Rheumatology</strong> Critically Appraised Topics<br />

(RheumCAts) R<br />

Moderator: Jennifer M. Hootman, PhD; Centers for Disease<br />

Control; Kennesaw, GA<br />

Speakers: Laura D. Bilek, PhD, PT; University Nebraska Medical<br />

Center; Omaha, NE<br />

Mary E. Christenson, PT, PhD; Regis University; Westminster, CO<br />

Jennifer M. Hootman, PhD; Centers for Disease Control;<br />

Kennesaw, GA<br />

102<br />

2010 Program Book


Session Overview:<br />

For the clinician, it is virtually impossible to keep up-to-date on<br />

all the published research in rheumatology. The sheer volume<br />

<strong>of</strong> information available to us due to technological advances can<br />

be overwhelming to busy clinicians. Critically appraised topics<br />

are concise syntheses <strong>of</strong> the literature on a topic based on a<br />

clinically relevant question. This session will provide an overview<br />

<strong>of</strong> rheumatology critically appraised topics.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the purpose <strong>of</strong> rheumatology critically appraised topics<br />

• describe the process for proposing and creating rheumatology<br />

critically appraised topics<br />

• define how rheumatology critically appraised topics can be<br />

used to promote evidence-based clinical practice<br />

aware <strong>of</strong> the advances in the imaging and management options<br />

for this common condition taking into consideration the nature<br />

and location <strong>of</strong> the patient’s individual pathology.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the prevalence <strong>of</strong> osteoarthritis <strong>of</strong> spine in a typical<br />

rheumatology clinic<br />

• describe the role <strong>of</strong> imaging and its appropriate use in<br />

investigating osteoarthritis <strong>of</strong> the spine<br />

• list the indications for a surgical referral in a patient with<br />

osteoarthritis <strong>of</strong> spine<br />

ACR Clinical Symposium<br />

11:00 am - 12:30 PM<br />

B310<br />

Finding and Using Secondary Data Resources for<br />

Research: Beyond the National Health and Nutrition<br />

Examination Survey and the Usual Suspects c/r<br />

Moderator: Robert R. McLean, DSc, MPH; Hebrew Senior Life;<br />

Boston, MA<br />

Speakers: Michael M. Ward, MD; NIH/NIAMS/IRP; Bethesda, MD<br />

Grant H. Louie, MD, MHS; Johns Hopkins University; Baltimore,<br />

MD<br />

Session Overview:<br />

Secondary data are data collected by someone else, <strong>of</strong>ten used<br />

by researchers to address research questions different from<br />

their own. A wide range <strong>of</strong> secondary data is available from<br />

governmental and non-governmental sources that can be used<br />

to address health, social, and economic concerns relevant to<br />

rheumatology researchers.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• list secondary data resources<br />

• describe the types <strong>of</strong> research questions for which secondary<br />

data analysis is well suited<br />

• identify strengths and limitations <strong>of</strong> using secondary data<br />

B402<br />

Rheumatic Disease Update: Osteoarthritis <strong>of</strong> the Spine<br />

c/r PM<br />

Moderator: Kimberly F. Kimpton, PT; Centennial, CO<br />

Speaker: Rajiv K. Dixit, MD; Northern California Arthritis Center;<br />

Walnut Creek, CA<br />

Session Overview:<br />

Degenerative disorders in the spine are normal, age-related<br />

phenomena and largely asymptomatic in most cases, yet they<br />

are a major source <strong>of</strong> work disability and cause billions <strong>of</strong> dollars<br />

in lost productivity annually. Lumbar and cervical spondylosis<br />

also forms one <strong>of</strong> the most common consults in clinical practice<br />

for rheumatology pr<strong>of</strong>essionals. Conservative management <strong>of</strong><br />

lumbar and cervical spondylosis is the mainstay <strong>of</strong> treatment,<br />

and surgical intervention can be considered an appropriate and<br />

viable option only when conservative measures have failed.<br />

Although current standards in the surgical management <strong>of</strong><br />

lumbar and cervical degenerative disorders include discectomy,<br />

neural decompression, and instrumented spinal arthrodesis,<br />

new approaches that address this <strong>of</strong>ten-challenging clinical<br />

entity are on the horizon. <strong>Rheumatology</strong> pr<strong>of</strong>essionals should be<br />

Thomas J. Murphy Ballroom<br />

Controversies in Osteoporosis and Low Bone Mass:<br />

Who Do We Treat, For How Long, and at What Risks?<br />

C PS<br />

Moderators: Thomas P. Olenginski, MD; Geisinger Medical<br />

Center; Danville, PA<br />

John R.P. Tesser, MD; Arizona Arthritis <strong>Rheumatology</strong><br />

Association; Paradise Valley, AZ<br />

11:00 am<br />

Who Should We Currently Target for Treatment and<br />

Prevention?<br />

Chad L. Deal, MD; Cleveland Clinic Foundation; Cleveland, OH<br />

11:30 am<br />

Osteoporosis Prescription Treatment: Monitoring Strategies<br />

and Treatment Duration<br />

Nelson B. Watts, MD; University <strong>of</strong> Cincinatti; Cincinatti, OH<br />

12:00 PM<br />

Potential Risks <strong>of</strong> Osteoporosis Therapies: Focus on Atypical<br />

Femoral Fractures and Osteonecrosis <strong>of</strong> the Jaw<br />

Stuart L. Silverman, MD; Cedars-Sinai Medical Center, University<br />

<strong>of</strong> California-Los Angeles; Beverly Hills, CA<br />

Session Overview:<br />

Currently, there are seven FDA-approved medications to reduce<br />

osteoporosis fracture risks. In February 2008, the National<br />

Osteoporosis Foundation published an Updated Clinician’s Guide<br />

to the Prevention and Treatment <strong>of</strong> Osteoporosis. Along with<br />

this, the World Health Organization formulated an absolute<br />

fracture risk predictive methodology, which each country<br />

individually applies. Despite this new consensus on treatment<br />

intervention, important unanswered questions remain<br />

concerning duration <strong>of</strong> osteoporosis therapy, whether primarily<br />

as treatment or prevention. Similarly, our patients continue to<br />

have questions and concerns regarding medication side effects<br />

and long term risks. While osteonecrosis <strong>of</strong> the jaw continues<br />

to be a concern, more recently, atypical femoral fractures have<br />

appeared in the literature and have become a topic <strong>of</strong> clinical<br />

interest.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• summarize 2008 National Osteoporosis Foundation guidelines<br />

for treatment intervention and appraise prevention strategies<br />

• apply fracture risk predictive methodology <strong>of</strong> absolute<br />

fracture risk assessment<br />

wednesday<br />

2010 Program Book 103


wednesday<br />

• appraise strategies to monitor drug treatment response<br />

• develop potential strategies where one would limit duration<br />

<strong>of</strong> prescription treatment and other strategies where one<br />

would endorse indefinite therapy, whether for treatment and/<br />

or prevention <strong>of</strong> osteoporosis<br />

• discuss concerns and possible long-term risks associated with<br />

bisphosphonate, selective estrogen receptor modulators, and<br />

anabolic therapies<br />

ACR Plenary Session III: Discovery<br />

2010 c/r<br />

11:00 am - 12:30 PM<br />

Hall A3<br />

Moderators: Carol A. Langford, MD, MHS; Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

Alisa E. Koch, MD; Unversity <strong>of</strong> Michigan; Ann Arbor, MI<br />

11:00 am<br />

Introductory Talk<br />

Daniel E. Furst, MD; University <strong>of</strong> California-Los Angeles Medical<br />

School; Los Angeles, CA<br />

11:15 am<br />

2084. Rates <strong>of</strong> Malignancy Associated with Juvenile Idiopathic<br />

Arthritis and Its Treatment: An Observational Study <strong>of</strong> National<br />

U.S. Medicaid Administrative Claims Data.<br />

Timothy Beukelman 4 , Kevin Haynes 2 , Jeffrey R. Curtis 3 , Fenglong<br />

Xie 1 , Lang Chen 1 , Elizabeth Delzell 1 , Hopiy Kim 2 , Kenneth G. Saag 5<br />

and James D. Lewis 2 , 1 Univ <strong>of</strong> Alabama at Birmingham, 2 Univ <strong>of</strong><br />

Pennsylvania, 3 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />

AL, 4 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

5<br />

University <strong>of</strong> Alabama-Birmingham, Birmingham, AL<br />

11:30 am<br />

2085. Aspreva Lupus Management Study (ALMS): Maintenance<br />

Results.<br />

Ellen M. Ginzler 4 , Gerald B. Appel 1 , Mary Anne Dooley 7 , David<br />

A. Isenberg 5 , David Jayne 3 , David W<strong>of</strong>sy 6 , Neil Solomons 8 ,<br />

Laura Lisk 9 and David R. Close 2 , 1 Columbia University, New<br />

York, 2 MedImmune Ltd, 3 Renal Unit, Addenbrooke’s Hospital,<br />

Cambridge, United Kingdom, 4 SUNY-Downstate Medical Center,<br />

Brooklyn, NY, 5 University <strong>College</strong> London, London, United<br />

Kingdom, 6 University <strong>of</strong> California, San Francisco, San Francisco,<br />

CA, 7 University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />

8<br />

Vifor Pharma (formerly Aspreva Pharmaceuticals), BC, Canada,<br />

9<br />

Vifor Pharma, UK, Bagshot, Surrey, United Kingdom<br />

11:45 am<br />

2086. Efficacy <strong>of</strong> Tadalafil in Raynaud’s Phenomenon Secondary<br />

to Systemic Sclerosis: A Double Blind Randomized Placebo<br />

Controlled Parallel Group Multicentric Study.<br />

Vikas Agarwal 8 , Parasar Ghosh 6 , Aman Sharma 7 , Darshan Singh<br />

Bhakuni 5 , Sudeep Kumar 1 , Upendra Narayan Singh 1 , Rajesh<br />

Vijayvergiya 3 , Mukesh Kumar Yadav 4 , Geetabali Devi Laishram 2 ,<br />

Alakendu Ghosh 2 , Bhuban Majhi 2 , Dipankar Mukherjee, S.<br />

S. Islam and Aditya Kapoor, 1 Lucknow, India, 2 Kolkata, India,<br />

3<br />

Chandigarh, India, 4 Chandigarh, India, 5 Army Hospital Research<br />

& Refferal, New Delhi, India, 6 IPGMER, Kolkata, 7 PGIMER,<br />

Chandigarh, India, 8 SGPGIMS, Lucknow, UP, India<br />

12:00 pm<br />

2087. Efficacy <strong>of</strong> Canakinumab (ACZ885), a Fully Human Anti-<br />

Interleukin (IL)-1beta Monoclonal Antibody, in the Prevention<br />

<strong>of</strong> Flares in Gout Patients Initiating Allopurinol Therapy.<br />

Naomi Schlesinger 8 , Hsiao-Yi Lin 7 , Marc De Meulemeester 6 ,<br />

Evgeny L. Nasonov 2 , Jozef Rovensky 4 , Eduardo F. Mysler 5 ,<br />

Udayasankar Arulmani 3 , Gerhard Krammer 3 , Alison Balfour 3 ,<br />

Dominik Richard 3 , Peter Sallstig 3 and Alexander K. So 1 , 1 CHUV<br />

Vaudois, Lausanne, Switzerland, 2 Institue <strong>of</strong> <strong>Rheumatology</strong><br />

RAMS, Moscow, Russian Federation, 3 Novartis Pharma AG, Basel,<br />

Switzerland, 4 NURCH, Piestany, Slovakia, 5 OMI Organizacion<br />

Medica de Investigacion, Buenos Aires, Argentina, 6 Private<br />

Practice, Gozée, Belgium, 7 Taipei Veterans General Hospital,<br />

Taipei, 8 UMDNJ-Robert Wood Johnson Medical School, New<br />

Brunswick, NJ<br />

12:15 PM<br />

2088. Effects <strong>of</strong> Urate Lowering Therapy on Cardiovascular<br />

Mortality: A Taiwanese Cohort Study.<br />

Jiunn-Horng Chen 1 and Wen-Harn Pan 2 , 1 China Medical<br />

University, Taichung City, Taichung, Taiwan, 2 Institute <strong>of</strong><br />

Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Province<br />

<strong>of</strong> China<br />

ACR Practice Issues<br />

Noon - 1:00 PM<br />

B313<br />

The Ideal <strong>Rheumatology</strong> Practice BR C PS<br />

Moderator: Michael J. Maricic, MD; Catalina Pointe<br />

<strong>Rheumatology</strong>; Tucson, AZ<br />

12:00 PM<br />

Small, Single Specialty <strong>Rheumatology</strong> Practice<br />

David J. Ridley, MD; St. Paul Rheumatoloy PA; Eagan, MN<br />

12:20 PM<br />

Large, Single-Specialty <strong>Rheumatology</strong> Practice<br />

Herbert Baraf, MD; Arthritis & Rheumatism Association;<br />

Wheaton, MD<br />

12:40 PM<br />

Multi-Specialty <strong>Rheumatology</strong> Practice<br />

Carmen Perez-Masuelli, MD; Northwest Diagnostic; Houston, TX<br />

Session Overview:<br />

During the past 50 years, private practitioners have witnessed<br />

many substantial changes to the US health care system<br />

and have been pressured to change the way they practice<br />

medicine. What can be done to return the locus <strong>of</strong> control to<br />

rheumatology practices and ensure adequate compensation<br />

for work? Rheumatologists will have to redesign their practices<br />

to optimize efficiency and show that they can not only deliver<br />

superb care but also lower the total cost <strong>of</strong> health care. The<br />

“ideal medical practice” model can move us closer to this goal.<br />

Rheumatologists need to know what it takes to manage a<br />

practice in today’s financially challenged economy. To reach the<br />

ideal practice, physicians can learn from each other better than<br />

any text book.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify practical strategies that can be incorporated into a<br />

rheumatology practice for efficiency<br />

104<br />

2010 Program Book


• identify the aspects for day-to-day management <strong>of</strong> a practice<br />

• describe the process and benefits for establishing a<br />

compliance program<br />

ARHP Special Sessions<br />

Noon - 1:00 PM<br />

The ARHP is <strong>of</strong>fering informal networking opportunities for<br />

rheumatology health pr<strong>of</strong>essional disciplines and students. These<br />

networking opportunities, led by facilitators, will allow open<br />

discussion and interaction with fellow attendees. Bring your<br />

lunch and join a group.<br />

B311<br />

ARHP Occupational and Physical Therapy<br />

Networking<br />

Facilitators: Linda C. Li, BSc (PT) MSc PhD; University <strong>of</strong> British<br />

Columbia; Vancouver, BC, Canada<br />

Jan K. Richardson; PT, PhD, Duke University Medical<br />

Center,Durham, NC<br />

B310<br />

ARHP Office Nurse Networking<br />

Facilitator: Marilee K. Phillips, RN; Louisville, KY<br />

B208<br />

Antiphospholipid Syndrome (072) f PS<br />

Speaker: Doruk Erkan, MD; Hospital for Special Surgery; New<br />

York, NY<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the spectrum <strong>of</strong> antiphospholipid syndrome<br />

• determine the diagnostic utility <strong>of</strong> antiphospholipid antibody<br />

tests<br />

• describe the controversial aspects <strong>of</strong> primary and secondary<br />

thrombosis prevention in antiphospholipid syndrome<br />

• discuss the management <strong>of</strong> catastrophic antiphospholipid<br />

syndrome patients<br />

B209<br />

Basic Immunology for Clinical Rheumatologists (073)<br />

f<br />

Speaker: David M. Lee, MD, PhD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe how the immune system functions in normal<br />

individuals<br />

• identify abnormalities <strong>of</strong> immune regulation that lead to<br />

autoimmunity<br />

InnoVAtion Theater<br />

12:15 - 1:00 PM<br />

Halls A1 & A2 (Booth #555)<br />

The following non-CME activity has been planned and will be<br />

implemented in accordance with the requirements <strong>of</strong> the FDA<br />

and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals by Pfizer Inc. Please visit the Pfizer<br />

Inc. exhibit booth for more information or see page 292. Seating<br />

and boxed lunches are subject to availability.<br />

New Insights into the Role <strong>of</strong> the JAK Pathways in<br />

Rheumatoid Arthritis<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

12:45 - 2:15 PM<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Ankylosing Spondylitis: 2010 Update (071) PS<br />

Speaker: Desiree M. Van Der Heijde, MD, PhD; Leiden University<br />

Medical Center; Meerssen, The Netherlands<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the natural history <strong>of</strong> ankylosing spondylitis and its<br />

early diagnosis<br />

• describe clinical and radiographic outcome measures used in<br />

ankylosing spondylitis trials<br />

• summarize available guidelines in the management <strong>of</strong><br />

ankylosing spondylitis<br />

• review the scientific data on biologic agents as possible<br />

disease modifying agents in the treatment <strong>of</strong> ankylosing<br />

spondylitis<br />

B210<br />

Myopathy: Issues in Diagnosis and Treatment (074)<br />

Speaker: Mark F. Gourley, MD; NIAMS; Bethesda, MD<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• distinguish inflammatory myopathies from other muscles<br />

diseases<br />

• plan a diagnostic work-up for a patient with signs and<br />

symptoms <strong>of</strong> muscle disease<br />

• design a treatment program for a patient with myositis<br />

B301<br />

Osteoarthritis: Update 2010 (075)<br />

Speaker: Richard F. Loeser, MD; Wake Forest University;<br />

Winston-Salem, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the potential causes and exacerbating factors <strong>of</strong> the<br />

disease<br />

• discuss the appropriate use <strong>of</strong> laboratory testing and imaging<br />

modalities<br />

• design an efficacious, safe and cost-effective therapeutic<br />

strategy<br />

B302<br />

Raynaud’s and Digital Ischemia (076)<br />

Speaker: Janet E. Pope, MD, MPH; St. Joseph Health Care<br />

London; London, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the pathogenesis<br />

• describe the appropriate diagnostic evaluation for this<br />

condition<br />

• review treatment options and means <strong>of</strong> evaluating treatment<br />

2010 Program Book 105<br />

wednesday


B303<br />

Rheumatoid Arthritis: Challenging Cases (077)<br />

Speaker: Edward C. Keystone, MD; University <strong>of</strong> Toronto;<br />

Toronto, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss management <strong>of</strong> patients with refractory rheumatoid<br />

arthritis<br />

• identify novel treatment options for those failing conventional<br />

therapies<br />

B304<br />

Scleroderma: Systemic Sclerosis (078) f PM<br />

Speaker: Michael R. York, MD; Boston University Medical Center;<br />

Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the classification <strong>of</strong> systemic sclerosis and its impact<br />

on treatment and prognosis<br />

• apply cardiopulmonary testing to determine the relative<br />

contributions <strong>of</strong> alveolitis, fibrosis and vasculopathy<br />

• formulate a therapeutic regimen to improve quality <strong>of</strong> life and<br />

organ-specific symptomatology<br />

Speakers: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />

Dallas, TX<br />

David G. Borenstein, MD; Arthritis & Rheumatism Association;<br />

Washington, DC<br />

James R. O’Dell, MD; University <strong>of</strong> Nebraska Medical Center;<br />

Omaha, NE<br />

Audrey B. Uknis, MD; Temple University School <strong>of</strong> Medicine;<br />

Philadelphia, PA<br />

E. William St.Clair, MD; Duke University Medical Center; Durham,<br />

NC<br />

David I. Daikh, MD, PhD; University <strong>of</strong> California, San Francisco,<br />

Veterans Affairs Medical Center; San Francisco, CA<br />

Session Overview:<br />

The leadership town hall meeting will provide an open forum for<br />

members to discuss issues <strong>of</strong> importance to them directly with<br />

ACR leadership.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• have direct contact with ACR leadership to ask questions and<br />

voice concerns<br />

• have a better understanding about ACR initiatives and what<br />

the ACR is doing to address various practice and other issues<br />

wednesday<br />

106<br />

B305<br />

Systemic Lupus Erythematosus: Central Nervous<br />

System (079)<br />

Speaker: F. Jorge Sanchez-Guerrero, MD; Instituto Nacional<br />

Nutricion; Mexico City, DF, Mexico<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify manifestations <strong>of</strong> central nervous system lupus<br />

• select appropriate diagnostic tests in patients with central<br />

nervous system lupus<br />

• formulate a treatment plan<br />

B306<br />

Systemic Lupus Erythematosus: Novel Treatments<br />

(080) f PS<br />

Speaker: Ellen M. Ginzler, MD, MPH; SUNY-Downstate Medical<br />

Center; Brooklyn, NY<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine the <strong>of</strong>f-label use <strong>of</strong> commercially available agents<br />

for features <strong>of</strong> systemic lupus erythematosus<br />

• discuss investigational therapies for systemic lupus<br />

erythematosus<br />

• identify potential risks <strong>of</strong> new therapies for systemic lupus<br />

erythematosus<br />

• identify host factors which may influence response to new<br />

therapies<br />

ACR Special SessionS<br />

12:45 - 4:00 PM<br />

Thomas J. Murphy Ballroom<br />

This session is not eligible for CME credit.<br />

12:45 PM<br />

ACR Leadership Town Hall Meeting<br />

Moderator: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />

Dallas, TX<br />

2010 Program Book<br />

2:00 PM<br />

Business Meeting<br />

2:30 pm<br />

ACR Late-breaking Abstract Presentation<br />

Moderator: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

ACR Clinical Symposium<br />

1:00 - 2:00 PM<br />

Sidney J. Marcus Auditorium<br />

Clinical Review: Osteoporosis Therapeutics:<br />

ACR Glucocorticorticoid-induced Osteoporosis<br />

Recommendations and Therapy Update cP P/C PS<br />

Moderator: Thomas P. Olenginski, MD; Geisinger Medical<br />

Center; Danville, PA<br />

1:00 PM<br />

Treatment <strong>of</strong> Glucocorticoid-induced Osteoporosis: The New<br />

Guidelines<br />

Jennifer M. Grossman, MD; University <strong>of</strong> California Los Angeles;<br />

Sherman Oaks, CA<br />

Session Overview:<br />

Glucocorticoid-induced osteoporosis represents the most<br />

common cause <strong>of</strong> drug-induced osteoporosis. Glucocorticoidinduced<br />

osteoporosis is extremely relevant and pertinent to our<br />

daily practices. In 2010, updated ACR GIOP Recommendations<br />

were published and our FDA-approved glucocorticoid-induced<br />

osteoporosis treatment arsenal has expanded. This session<br />

will highlight the ACR GIOP Recommendations, <strong>of</strong>fer a concise<br />

treatment update, and introduce potential new agents in<br />

development.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• summarize new ACR Glucocorticoid-induced Osteoporosis<br />

Recommendations<br />

• appraise currently available osteoporosis treatments<br />

• discuss emerging therapeutic agents in development


ACR Study Groups<br />

1:00 - 2:00 PM<br />

B309<br />

Capillaroscopy in Rheumatic Diseases<br />

Moderators: Maurizio E. Cutolo, MD; University <strong>of</strong> Genova;<br />

Genova, Italy<br />

Ariane L. Herrick, MD; Rheumatic Diseases Centre; Trust Salford,<br />

United Kingdom<br />

1:00 PM<br />

Introduction with Brief History <strong>of</strong> Capillaroscopy<br />

Maurizio E. Cutolo, MD; University <strong>of</strong> Genova; Genova, Italy<br />

1:05 PM<br />

The Technique <strong>of</strong> Videocapillaroscopy<br />

Alberto Sulli, MD; University <strong>of</strong> Genoa, Italy<br />

1:20 PM<br />

Quantification <strong>of</strong> Microcirculatory Abnormalities using<br />

Capillaroscopy<br />

Ariane L. Herrick, MD; Rheumatic Diseases Centre; Trust Salford,<br />

United Kingdom<br />

1:30 PM<br />

Capillaroscopic Patterns: From Normal to Pathologic<br />

Maurizio E. Cutolo, MD; University <strong>of</strong> Genova; Genova, Italy<br />

1:40 PM<br />

Discussion<br />

1:45 PM<br />

Practical ‘Live’ Demonstration <strong>of</strong> Videocapillaroscopy<br />

Ariane L. Herrick, MD; Rheumatic Diseases Centre; Trust Salford,<br />

United Kingdom<br />

Maurizio E. Cutolo, MD; University <strong>of</strong> Genova; Genova, Italy<br />

Session Overview:<br />

Nailfold capillaroscopy provides a unique and noninvasive/<br />

safe window into the microcirculation, and abnormal nailfold<br />

capillaries are highly predictive <strong>of</strong> an underlying connective<br />

tissue disorder. Typical changes include widened capillaries<br />

and areas <strong>of</strong> avascularity. Recent advances in capillaroscopy,<br />

including videocapillaroscopy (which allows high magnification)<br />

and computerised s<strong>of</strong>tware, are revitalizing interest in<br />

capillaroscopy amongst rheumatologists. The ability to<br />

quantify abnormality means that capillaroscopy has the<br />

potential <strong>of</strong> becoming an early diagnostic tool and biomarker<br />

in scleroderma-spectrum disorders. A study group will inform<br />

attendees <strong>of</strong> these advances and stimulate the international<br />

dialogue necessary to standardize techniques and further<br />

broaden their clinical application.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss advantages and disadvantages <strong>of</strong> different<br />

capillaroscopy methods (dermoscopy, widefield<br />

capillaroscopy, videocapillaroscopy)<br />

• describe major capillaroscopic abnormalities suggestive <strong>of</strong> a<br />

scleroderma-spectrum disorder and score them<br />

• identify current and future clinical and research applications<br />

B308<br />

Childhood Vasculitis<br />

Moderators: Susanne M. Benseler, MD, PhD; The Hospital for<br />

Sick Children; Toronto, ON, Canada<br />

David A. Cabral, MBBS; British Columbia Children’s Hospital;<br />

Vancouver, BC, Canada<br />

1:00 PM<br />

Novel Approaches to Classifying Systemic Childhood Vasculitis<br />

David A. Cabral, MBBS; BC Children’s Hospital; Vancouver, BC,<br />

Canada<br />

1:15 PM<br />

Novel Biomarkers <strong>of</strong> Childhood Vasculitis<br />

Paul Brogan, BSc, MBCHB, PhD; <strong>Rheumatology</strong> Unit, Institute <strong>of</strong><br />

Child Health; London<br />

1:30 PM<br />

Disease Activity in Childhood Vasculitis<br />

Pavla Dolezalova, MD; 1st Faculty <strong>of</strong> Medicine and General<br />

Faculty Hospital; Praha, Czech Republic<br />

1:45 PM<br />

Measurement and Study Conduct in Childhood Vasculitis<br />

Raashid Luqmani, DM; Nuffield Department <strong>of</strong> Orthopaedics,<br />

<strong>Rheumatology</strong> and Musculoskeletal Sciences; Oxford, United<br />

Kingdom<br />

Session Overview:<br />

Successful international collaboration and the development<br />

<strong>of</strong> innovative, web-based data collection tools have recently<br />

advanced the field <strong>of</strong> childhood vasculitis. The international<br />

pediatric vasculitis investigator network was established,<br />

which is currently conducting important studies aiming to<br />

enhance disease recognition, validate classification proposals,<br />

develop and validate measures <strong>of</strong> disease activity and damage,<br />

standardize treatment protocols and ultimately improve the<br />

outcome <strong>of</strong> children with vasculitis worldwide. The study group<br />

application aims to formalize the strong association <strong>of</strong> the<br />

investigators with the ACR. The focus <strong>of</strong> the first study group<br />

session is classification and diagnostic challenges <strong>of</strong> childhood<br />

vasculitis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• recognize distinct entities in the spectrum <strong>of</strong> childhood<br />

vasculitis<br />

• classify pediatric vasculitis patients based on the newly<br />

validated classification system<br />

• identify novel biomarkers <strong>of</strong> childhood vasculitis<br />

• assess disease activity <strong>of</strong> pediatric vasculitis patients using the<br />

novel PVAS tool<br />

B311<br />

Clinical Research Methodology<br />

Moderator: Theodore Pincus, MD; New York University Hospital<br />

for Joint Disease; Hastings-on-Hudson, NY<br />

1:00 PM<br />

Improved Outcome Criteria for Rheumatic Diseases: The Role<br />

<strong>of</strong> IRT and CAT<br />

James F. Fries, MD; Stanford University Medical Center; Palo<br />

Alto, CA<br />

1:20 PM<br />

Diagnostic Criteria for Rheumatoid Arthritis - The New and The<br />

Old<br />

Yusuf Yazici, MD; Hospital for Joint Diseases; Hastings on<br />

Hudson, NY<br />

2010 Program Book 107<br />

wednesday


wednesday<br />

108<br />

1:40 PM<br />

Diagnosis is Classification <strong>of</strong> the Individual Patient - The Behçet<br />

Experience<br />

Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul, Turkey<br />

Session Overview:<br />

Recent changes to diagnostic criteria for rheumatoid arthritis will<br />

have an impact on how RCT and clinical research is conducted.<br />

We believe a forum where the impact <strong>of</strong> these changes and<br />

their every day rheumatology care applicability can be discussed<br />

would be <strong>of</strong> interest to the ACR membership.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss and compare new and old diagnostic criteria for RA<br />

• differentiate between diagnostic and classification criteria for<br />

rheumatologic conditions<br />

• explain real world application <strong>of</strong> the new criteria<br />

A412<br />

Crystalline Arthropathy<br />

Moderators: N. Lawrence Edwards, MD; University <strong>of</strong> Florida;<br />

Gainesville, FL<br />

Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />

Center; Blue Bell, PA<br />

1:00 PM<br />

Update on Renal Handling <strong>of</strong> Uric Acid and Mechanisms <strong>of</strong><br />

Hyperuricemia<br />

David Mount, MD, PhD; Brigham and Women’s Hospital; Boston,<br />

MA<br />

1:30 PM<br />

The Genetics <strong>of</strong> Hyperuricemia<br />

Anthony M. Reginato, PhD, MD; University Medicine Foundation,<br />

Rhode Island Hospital; Providence, RI<br />

Session Overview:<br />

The intense recent interest in gout and other medical conditions<br />

associated with hyperuricemia is evident by the marked increase<br />

in abstract submissions on these topics and the number <strong>of</strong> goutrelated<br />

symposia at ACR Annual meetings. The explosion <strong>of</strong> new<br />

science in these areas requires venues like the study group to<br />

foster discussion.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe new developments in the mechanisms <strong>of</strong> renal<br />

handling <strong>of</strong> uric acid<br />

• identify how these newly recognized transporters participate<br />

in disease states and their role pharmacologic interventions<br />

• recognize newly discovered genetic mechanisms <strong>of</strong><br />

hyperuricemia<br />

• discuss how genetics may help dictate individualized therapy<br />

in gout<br />

A411<br />

Hypermobility<br />

Moderators: Rodney Grahame, MD; University <strong>College</strong> Hospital;<br />

London, United Kingdom<br />

Jaime F. Bravo, MD; Nuestra Sra de Los Angeles; Santiago, Chile<br />

1:00 PM<br />

Genetic Approaches to the Dissection <strong>of</strong> Hypermobility<br />

Syndromes<br />

Peter H. Byers, MD; University <strong>of</strong> Washington; Seattle, WA<br />

2010 Program Book<br />

1:15 PM<br />

Why is Joint Hypermobility Syndrome So Frequently Missed?<br />

Rodney Grahame, MD; University <strong>College</strong> Hospital; London,<br />

United Kingdom<br />

1:30 PM<br />

Medical Treatment <strong>of</strong> Joint Hypermobility Syndrome<br />

Alan Hakim, MD; Whipps Cross University Hospital; London,<br />

United Kingdom<br />

1:45 PM<br />

Key Points in the Physical Therapy <strong>of</strong> Patients with Joint<br />

Hypermobility Syndrome<br />

Jane Simmonds, MCSP, MMACP; University <strong>of</strong> Herfordshire;<br />

Herfordshire, United Kingdom<br />

Session Overview:<br />

As rheumatologists become more aware <strong>of</strong> the high prevalence<br />

<strong>of</strong> hypermobility syndromes and as patients have higher<br />

expectations for diagnosis and treatment <strong>of</strong> these conditions,<br />

there is a greater need for rheumatologists and other health<br />

pr<strong>of</strong>essionals in rheumatology to equip themselves with<br />

knowledge about the scientific basis, the clinical presentation,<br />

treatment and natural history <strong>of</strong> these conditions, subject<br />

matter that in not widely available in training programs.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the genetic basis for the heritable disorders <strong>of</strong><br />

connective tissue<br />

• appreciate the pitfalls in the diagnosis <strong>of</strong> hypermobility<br />

syndromes and how a sound knowledge <strong>of</strong> the clinical<br />

classification and diagnostic criteria, combined with an<br />

understanding <strong>of</strong> the value <strong>of</strong> genetic testing can lead to<br />

precise diagnosis<br />

• cite the principles on which rational medical therapies are<br />

based<br />

• identify the role <strong>of</strong> physical therapy in the management <strong>of</strong><br />

hypermobility syndromes<br />

B310<br />

Imaging<br />

Moderators: Nikolay Tzaribachev, MD; Center for Rheumatic<br />

Diseases; Bad Bramstedt, Germany<br />

Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />

ON, Canada<br />

1:00 PM<br />

Advantages <strong>of</strong> Ultrasonography in Patients with RA and<br />

Implications in JIA<br />

Marina Backhaus, MD; University Medicine Berlin: Campus<br />

Charité Mitte; Berlin, Germany<br />

1:15 PM<br />

Clinical vs. Ultrasound Synovitis in Patients with JIA<br />

Silvia Magni-Manzoni, MD; Clinica Pediatrica; Pavia, Italy<br />

1:30 PM<br />

MRI Characteristics in Patients with JIA<br />

Marion A.J. van Rossum, MD, PhD; Emma Children’s Hospital;<br />

Amstrerdam, Netherlands<br />

1:45 PM<br />

The Silent Arthritis Concept - MRI Monitoring for Subclinical<br />

Arthritis<br />

Nikolay Tzaribachev, MD; Center for Rheumatic Diseases; Bad<br />

Bramstedt, Germany


Session Overview:<br />

Ultrasound and magnetic resonance imaging are sensitive<br />

imaging tools to define the degree <strong>of</strong> arthritis in patients with<br />

juvenile idiopathic arthritis. Data from adult patients with<br />

rheumatoid arthritis point to the importance <strong>of</strong> ultrasound and<br />

MRI for early diagnosis and therapeutic monitoring. In JIA both<br />

ultrasound and MRI criteria for arthritis urgently need to be<br />

defined and implemented in the remission criteria <strong>of</strong> JIA since<br />

the disease tends to progress silently in a group <strong>of</strong> patients<br />

leading to joint destruction and early arthrotic changes.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the advantages/disadvantages <strong>of</strong> ultrasound and MRI<br />

for the detection <strong>of</strong> arthritis in adults with RA and possible<br />

application in children with JIA<br />

• identify the risk <strong>of</strong> developing silent arthritis in patients with<br />

RA and children with JIA<br />

• articulate the benefits <strong>of</strong> monitoring the treatment by<br />

ultrasound/MRI in patients with RA and possible application in<br />

children with JIA<br />

• discuss the possible application <strong>of</strong> ultrasound/MRI for early<br />

diagnosis <strong>of</strong> JIA and treatment monitoring<br />

A314<br />

Interstitial Lung Diseases in the Rheumatic Diseases<br />

Moderators: Paul F. Dellaripa, MD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Kristin B. Highland, MD; Medical University <strong>of</strong> South Carolina;<br />

Charleston, SC<br />

1:00 PM<br />

Update on OMERACT in the Rheumatic Diseases<br />

Kristine Phillips, MD, PhD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />

Shikha Mittoo, MD, MHS; Univeristy <strong>of</strong> Manitoba; Winnipeg, MB,<br />

Canada<br />

Lesley Ann Saketkoo, MD, MPH; LSU Health Science Center;<br />

Highland Beach, FL<br />

1:20 PM<br />

RA and ILD: Results <strong>of</strong> Open Label Trials<br />

Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

1:40 PM<br />

Antisynthetase Syndrome and ILD: Environmental Factors<br />

Kristin B. Highland, MD; Medical University <strong>of</strong> South Carolina;<br />

Charleston, SC<br />

Session Overview:<br />

Interstitial lung disease is a feared manifestation <strong>of</strong> a variety<br />

<strong>of</strong> rheumatic diseases. While studies and a consortium exist<br />

for ILD/scleroderma, our understanding <strong>of</strong> the natural history,<br />

pathophysiology and treatment <strong>of</strong> ILD in other rheumatic<br />

disorders such as RA and dermatomyositis is poorly understood<br />

and no such consortium exists. A study group provides a<br />

forum for collaboration for clinical investigators to enhance<br />

our knowledge <strong>of</strong> and treatment <strong>of</strong> these life threatening<br />

manifestations <strong>of</strong> rheumatic diseases. This will be our third year<br />

and already our collaboration has netted the development <strong>of</strong> an<br />

OMERACT project and one prospective study in ILD. The group<br />

has become truly multidisciplinary and growing in size and scope<br />

and we would like to maintain that momentum.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify emerging epidemiologic and genetic mechanisms in<br />

ILD associated with myositis and antisynthetase syndrome<br />

• describe progress in the area <strong>of</strong> outcomes research regarding<br />

OMERACT in ILD and the rheumatic diseases<br />

B314<br />

JAW (Juvenile Arthritis Workgroup)<br />

Moderators: Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong><br />

Alabama; Birmingham, AL<br />

Marinka Twilt, MD, PhD; Erasmus MC Sophia Children’s Hospital/<br />

Leiden University Medical Center; Rotterdam, Netherlands<br />

1:00 PM<br />

Prevalence and Outcome <strong>of</strong> TMJ Arthritis in JIA Subtypes<br />

Rotraud K. Saurenmann, MD; University Children’s Hospital;<br />

Zurich, Switzerland<br />

1:15 PM<br />

Imaging Modalities for Detecting TMJ Arthritis<br />

Tore Larheim, DDS, PhD; University <strong>of</strong> Oslo; Oslo, Norway<br />

1:30 PM<br />

TMJ Arthritis and Intraarticular Corticosteroid Injections<br />

Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong> Alabama;<br />

Birmingham, AL<br />

1:45 PM<br />

Early Orthodontic Treatment <strong>of</strong> TMJ Arthritis<br />

Volkan Ozkan, MD; University <strong>of</strong> Frankfurt; Kronberg, Germany<br />

Session Overview:<br />

Temporomandibular joint arthritis occurs in up to 87 percent <strong>of</strong><br />

the children with juvenile idiopathic arthritis, many cases are<br />

asymptomatic. Late recognition leads to condylar destruction<br />

resulting in micro-/retrognathia, facial asymmetry and early<br />

arthritic changes. Several studies have tried to define the<br />

most sensitive clinical and imaging screening tool for early<br />

detection <strong>of</strong> TMJA, but the optimal screening tool and timing<br />

remain unclear. Recently intraarticular corticosteroids and early<br />

application <strong>of</strong> orthodontic devices have shown promising results.<br />

However, optimal therapy for prevention <strong>of</strong> short and long term<br />

consequences <strong>of</strong> TMJA in JIA remains unanswered.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the risk <strong>of</strong> developing TMJ arthritis in patients with JIA<br />

• discuss the advantages/disadvantages <strong>of</strong> clinical examination<br />

and imaging modalities to detect TMJ arthritis in children with<br />

JIA<br />

• articulate the benefits <strong>of</strong> intraarticular corticosteroid injection<br />

for the treatment <strong>of</strong> TMJ arthritis in patients with JIA<br />

• articulate the benefits <strong>of</strong> early orthodontic treatment<br />

A311<br />

Musculoskeletal Ultrasound<br />

Moderator: Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong><br />

<strong>of</strong> Medicine; Ponte Vedra Beach, FL<br />

1:00 PM<br />

Use <strong>of</strong> Ultrasound in Fibrosing Diseases<br />

Eugene Y. Kissin, MD; Boston University; Boston, MA<br />

wednesday<br />

2010 Program Book 109


1:15 PM<br />

<strong>American</strong> <strong>Rheumatology</strong> Focus Group for Ultrasound<br />

Presentation<br />

Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine;<br />

Ponte Vedra Beach, FL<br />

1:30 PM<br />

Use <strong>of</strong> Sonography for the Evaluation <strong>of</strong> Osteoarthritis<br />

Ingrid Moller, MD; Instituto Poal de Reumatologia; Barcelona,<br />

Spain<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• cite current research regarding gene therapies for inclusion<br />

body myositis and muscular dystrophies<br />

• describe the possible future application <strong>of</strong> gene therapy to<br />

patients with myositis<br />

• describe new developments in the cutaneous pathophysiology<br />

<strong>of</strong> dermatomyositis<br />

• review new approaches to evaluation and treatment <strong>of</strong> skin<br />

findings in dermatomyositis<br />

wednesday<br />

1:45 PM<br />

Comparison <strong>of</strong> Sonographic Scoring Systems in Rheumatoid<br />

Arthritis<br />

Marina Backhaus, MD; University Medicine Berlin: Campus<br />

Charité Mitte; Berlin, Germany<br />

Session Overview:<br />

Musculoskeletal sonography is an established imaging<br />

technique in rheumatology. It allows the assessment <strong>of</strong> s<strong>of</strong>t<br />

tissue pathology, and can detect destructive joint lesions earlier<br />

than conventional radiography. It is helpful in guidance <strong>of</strong><br />

therapy and needle biopsy. It adds an invaluable diagnostic and<br />

pathologic insight into daily rheumatologic practice. The interest<br />

in musculoskeletal sonography is growing in North America.<br />

We have identified a need to present a technological update<br />

in sonography as applied to rheumatology as well as novel<br />

sonographic concepts in the evaluation <strong>of</strong> some rheumatologic<br />

disease processes.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe how sonography can be used to asses disease activity<br />

in systemic sclerosis<br />

• recount the different ultrasound scoring systems for synovitis<br />

and erosions in rheumatoid arthritis<br />

• describe the uses and limitations <strong>of</strong> sonography in the<br />

evaluation <strong>of</strong> osteoarthritis<br />

• discuss issues facing rheumatologists performing sonography<br />

such as billing, certification, and credentialing<br />

B409<br />

Myositis<br />

Moderators: Frederick W. Miller, MD, PhD; National Institute <strong>of</strong><br />

Environmental Health Sciences, NIH; Kennsington, MD<br />

Lisa G. Rider, MD; National Institute <strong>of</strong> Environmental Health<br />

Sciences; Garrett Park, MD<br />

1:00 PM<br />

Prospects for Gene Therapies in Myositis and Other<br />

Myopathies<br />

Jerry R. Mendell, MD; The Research Institute at Nationwide<br />

Children’s Hospital; Columbus, OH<br />

1:30 PM<br />

New Understandings in the Pathogenesis, Clinical Findings, and<br />

Therapy <strong>of</strong> Cutaneous Dermatomyositis<br />

Victoria P. Werth, MD; University <strong>of</strong> Pennsylvania; Philadelphia,<br />

PA<br />

Session Overview:<br />

The goal <strong>of</strong> this session is to increase attendee awareness <strong>of</strong> new<br />

advances in the pathogenesis and treatment <strong>of</strong> myositis and<br />

related myopathies. This will be a combined adult and pediatric<br />

rheumatology study group that will also be <strong>of</strong> interest to allied<br />

health pr<strong>of</strong>essionals.<br />

A402<br />

Osteoarthritis<br />

Moderator: Anna H. Plaas, PhD; Rush University; Chicago, IL<br />

1:00 PM<br />

Post-Traumatic Joint Tissue Responses Correlated with Clinical<br />

Findings <strong>of</strong> Human OA Progression<br />

Carla R. Scanzello, MD, PhD; Rush University Medical Center;<br />

Chicago, IL<br />

1:20 PM<br />

Effects <strong>of</strong> Dynamic Loading on Injured Articular Cartilage In<br />

Vitro and In Vivo<br />

Rachel M. Miller Travis, BS; Longview, TX<br />

1:40 PM<br />

Glucocorticoid Receptor Pathways as Targets for Enhancing S<strong>of</strong>t<br />

Tissue Repair in Osteoarthritic Joints<br />

Christian Stehlik, PhD; Northwestern University; Chicago, IL<br />

B408<br />

Patient Involvement - Six Years Experience - The<br />

Practical Aspects and Impact on Service<br />

Moderators: Taher Mahmud, MD, MSc; Pembury Hospital;<br />

Tunbridge Wells, United Kingdom<br />

David P. D’Cruz, MD; St. Thomas Hospital; London, United<br />

Kingdom<br />

1:00 PM<br />

Patient Feedback Experience in the UK<br />

Taher Mahmud, MD, MSc; Pembury Hospital; Tunbridge Wells,<br />

United Kingdom<br />

1:10 PM<br />

Impact on the Service<br />

Taher Mahmud, MD, MSc; Pembury Hospital; Tunbridge Wells,<br />

United Kingdom<br />

1:30 PM<br />

Patient Feedback Experience London<br />

David P. D’Cruz, MD; St. Thomas Hospital; London, United<br />

Kingdom<br />

1:40 PM<br />

Patient Feedback from Other Clinical Settings and Discussion <strong>of</strong><br />

the Patient Feedback Approaches and Experiences <strong>of</strong> Others<br />

To be announced<br />

1:50 PM<br />

Future for Patient Feedback<br />

Taher Mahmud, MD, MSc; Pembury Hospital; Tunbridge Wells,<br />

United Kingdom<br />

110<br />

2010 Program Book


Session Overview:<br />

Fifty percent <strong>of</strong> patients with long term conditions do not take<br />

their medications. Furthermore patients can have variable clinic<br />

experience. Patient feedback is valuable but is it possible to<br />

survey every patient on every health care pr<strong>of</strong>essional contact/<br />

clinic visit? This session will discuss the impact on systems<br />

improvement and effects on team productivity and well as<br />

improving patient experience.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• explain approaches to acquiring systematic patient feedback<br />

• identify issues and develop solutions<br />

• identify practical approaches to measuring patient feedback in<br />

your practice settings<br />

B313<br />

Patient Perspective on Outcomes: Patients as Partners<br />

in the Research Process<br />

Moderators: John R. Kirwan, MD; Bristol Royal Infirmary; Bristol,<br />

United Kingdom<br />

Ingemar F. Petersson, MD; Lund University Hosp; Lund, Sweden<br />

Robert Marshall, MD; University Hospitals Bristol NHS<br />

Foundation Trust; Bristol, United Kingdom<br />

Christina H. Opava, PhD; Karolinska Institutet; Huddinge, Sweden<br />

1:00 PM<br />

Introduction: Including the Patient Perspective in Outcomes by<br />

Including Patients in the Research Process<br />

Ingemar F. Petersson, MD; Lund University Hosp; Lund, Sweden<br />

1:05 PM<br />

Working With Patients at a Local Level<br />

John R. Kirwan, MD; Bristol Royal Infirmary; Bristol, United<br />

Kingdom<br />

1:15 PM<br />

Personal Experience <strong>of</strong> Patient Involvement in Priority Setting<br />

in a National Research Granting Agency<br />

Robert Marshall, MD; University Hospitals Bristol NHS<br />

Foundation Trust; Bristol, United Kingdom<br />

1:25 PM<br />

A Nationwide Program <strong>of</strong> Patient Involvement<br />

Christina H. Opava, PhD; Karolinska Institutet; Huddinge, Sweden<br />

1:35 PM<br />

Panel Discussion/Summary<br />

Ingemar F. Petersson, MD; Lund University Hosp; Lund, Sweden<br />

Session Overview:<br />

The Patient Perspective in Outcomes Research Study Group has<br />

had good support at previous meetings. Over 60 participants<br />

attended in 2009. It has contributed to furthering research in<br />

the field through dissemination <strong>of</strong> findings and discussions that<br />

led to new research initiatives. The measurement <strong>of</strong> the broader<br />

impact <strong>of</strong> arthritis has become an important issue, particularly in<br />

relation to clinical trial outcomes. There is increasing recognition<br />

that including patients directly in the process <strong>of</strong> formulating,<br />

funding, conducting and interpreting research aids in the<br />

inclusion and consideration <strong>of</strong> outcomes directly relevant to<br />

patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the challenges faced by patients who become<br />

partners in the research process<br />

• describe the challenges faced by researchers when they work<br />

with patient partners<br />

• identify ways in which patients have enhanced research<br />

in:research groups, research funding allocation in<br />

<strong>Rheumatology</strong> and research promotion and development in a<br />

national movement<br />

• incorporate the patient perspective through the use <strong>of</strong> patient<br />

research partners<br />

A315<br />

Rehabilitative <strong>Rheumatology</strong><br />

Moderators: Helen M. Emery, MD; Children’s Hospital & Regional<br />

Medicine; Seattle, WA<br />

J. Carter Thorne, MD; Southlake Regional Health Care;<br />

Newmarket, ON, Canada<br />

Speaker: Helen M. Emery, MD; Children’s Hospital & Regional<br />

Medicine; Seattle, WA<br />

Session Overview:<br />

This Study Group session allows attendees interested in<br />

rehabilitative rheumatology to share their ideas on how<br />

to include rehabilitation in multiple facets <strong>of</strong> the specialty<br />

including discussion on proposed educational curriculum for<br />

rheumatology trainees in rehabilitation.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• <strong>of</strong>fer input into the proposed educational curriculum for<br />

rheumatology trainees in rehabilitation<br />

• participate in the multidisciplinary mangement <strong>of</strong> rheumatic<br />

diseases<br />

A316<br />

Scleroderma-Biomarkers<br />

Moderator: Robert A. Lafyatis, MD; Boston University School <strong>of</strong><br />

Medicine; Arlington, MA<br />

1:00 PM<br />

Chemokines as Scleroderma Biomarkers<br />

Timothy R.D.J. Radstake, MD, PhD; Radboud University Nijmegen<br />

Medical Centre; Nijmegen, Netherlands<br />

1:20 PM<br />

Biomarkers <strong>of</strong> Pulmonary Hypertension<br />

Harrison Farber, MD; Boston University Medical Center; Boston,<br />

MA<br />

1:40 PM<br />

Proteomic Approaches in Scleroderma Biomarkers<br />

Sergio A. Jimenez, MD; Thomas Jefferson University;<br />

Philadelphia, PA<br />

Session Overview:<br />

Biomarkers <strong>of</strong> disease activity and progression are needed to<br />

stratify patients for treatment<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify emerging biomarkers for pulmonary hypertension<br />

• understand challenges for biomarker discovery<br />

• discuss biomarkers that predict future disease complications<br />

wednesday<br />

2010 Program Book 111


wednesday<br />

A410<br />

Takayasu’s Arteritis<br />

Moderators: Peter A. Merkel, MD, MPH; Boston University<br />

School <strong>of</strong> Medicine; West Newton, MA<br />

Rafi Haner Direskeneli, MD; Marmara Medical University School<br />

<strong>of</strong> Medicine; Istanbul, Turkey<br />

1:00 PM<br />

Takayasu’s Arteritis and Giant-Cell Arteritis - Two Diseases or<br />

Part <strong>of</strong> the Same Spectrum?<br />

Cornelia M. Weyand, MD, PhD; Stanford University School <strong>of</strong><br />

Medicine; Stanford, CA<br />

1:10 PM<br />

Disease Assessment in Takayasu’s Arteritis<br />

Rafi Haner Direskeneli, MD; Marmara Medical University School<br />

<strong>of</strong> Medicine; Istanbul, Turkey<br />

1:20 PM<br />

Treatment <strong>of</strong> Takayasu’s Arteritis<br />

Peter A. Merkel, MD, MPH; Boston University School <strong>of</strong><br />

Medicine; West Newton, MA<br />

1:30 PM<br />

Clinical Trials in Takayasu’s Arteritis<br />

Carol A. Langford, MD, MHS; Cleveland Clinic Foundation;<br />

Cleveland, OH<br />

1:40 PM<br />

Panel Discussion<br />

Session Overview:<br />

Diagnosis, disease assessment, and management <strong>of</strong> Takayasu’s<br />

Arteritis is currently dependant on limited evidence and<br />

there are no sufficiently-validated disease assessment tools<br />

or controlled drug trials. Recent data suggests that giant-cell<br />

arteritis and Takayasu’s Arteritis might both be in a spectrum<br />

<strong>of</strong> vasculitis with overlapping clinical and pathophysiologic<br />

features. There is increased world-wide interest in research<br />

into Takayasu’s Arteritis as evidenced by recent publications<br />

<strong>of</strong> large patient series, adoption <strong>of</strong> new imaging modalities,<br />

development <strong>of</strong> new disease assessment tools, and initiation<br />

<strong>of</strong> international multicenter clinical trials. Past ACR Vasculitis<br />

Study Groups have attracted large audiences <strong>of</strong> both clinical<br />

investigators and clinicians.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• recognize the similarities and differences <strong>of</strong> giant cell<br />

arteritis and Takayasu’s arteritis both clinically and<br />

pathophysiologically; discuss the impact <strong>of</strong> these data on<br />

treatment and research<br />

• review current criteria for activity/remission and damage in<br />

Takayasu’s arteritis and the challenges to disease assessment<br />

• review the clinical data on treatment <strong>of</strong> Takayasu’s arteritis<br />

and discuss the unmet medical needs in the treatment <strong>of</strong><br />

Takayasu’s arteritis<br />

• outline current clinical trials in Takayasu’s arteritis and the<br />

challenges for conducting such trials<br />

A404<br />

Teaching and Assessing Arthrocentesis<br />

Moderators: Joanne Valeriano-Marcet, MD; University <strong>of</strong> South<br />

Florida; Tampa, FL<br />

Helen E. Bateman, MD; James A. Haley Veterans Affairs Hospital,<br />

University <strong>of</strong> Southern Florida; Tampa, FL<br />

Ashley G. Sterrett, MD; James A. Haley Veterans Affairs Hospital;<br />

Tampa, FL<br />

1:00 PM<br />

Achievement and Maintenance <strong>of</strong> Procedural Competency<br />

Through a Cadaver-based Mini-procedural Evaluation Exercise<br />

(mini-PEX)<br />

Kenneth S. O’Rourke, MD; Wake Forest University School <strong>of</strong><br />

Medicine; Winston-Salem, NC<br />

1:20 PM<br />

Do or Do Not, There is No Try: Teaching Arthrocentesis and<br />

Injection Skills Using Competency<br />

Gregory C. Gardner, MD; University <strong>of</strong> Washington; Seattle, WA<br />

1:40 PM<br />

Validating Simulators - or How Hard Can it Be?<br />

Maren L. Mahowald, MD; University <strong>of</strong> Minnesota Medical<br />

School; Minneapolis, MN<br />

Session Overview:<br />

Joint injection training is a necessary part <strong>of</strong> the skills required<br />

for internal medicine residents and advanced subspecialty<br />

rheumatology fellows. Additionally the decreasing numbers <strong>of</strong><br />

rheumatology specialists will require primary care providers to<br />

perform these procedures. Prior studies in the literature support<br />

the use <strong>of</strong> joint injection training to increase comfort levels for<br />

internal medicine residents, primary care providers, and medical<br />

students in performing these procedures.The importance <strong>of</strong><br />

this study group is to increase interest and awareness in using<br />

simulation as a safe way to practice and assess competency in<br />

the necessary skills prior to injection on real patients. Further<br />

research is necessary to define the exact role and limitation <strong>of</strong><br />

simulation to teach and assess competency <strong>of</strong> arthrocentesis<br />

skillsand are hoping to raise enthusiasm for further research<br />

efforts in this area.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the importance <strong>of</strong> validating a simulator<br />

• discuss whether all <strong>of</strong> the key elements in a joint injection<br />

procedure can be measured with a simulator<br />

• learn how to assess competency in joint injection training<br />

• describe the incorporation <strong>of</strong> rubric scoring <strong>of</strong> competency<br />

into a formative assessment <strong>of</strong> procedural skills <strong>of</strong><br />

rheumatology fellows<br />

ACR Special Session<br />

1:00 - 2:30 PM<br />

A406<br />

Career Opportunities in <strong>Rheumatology</strong>: Making a<br />

Choice BR Ed. f<br />

Moderator: David D. Sherry, MD; The Children’s Hospital <strong>of</strong><br />

Philadelphia; Philadelphia, PA<br />

1:00 PM<br />

Basic Research <strong>Rheumatology</strong><br />

James N. Jarvis, MD; Oklahoma University Health Sciences;<br />

Oklahoma City, OK<br />

112<br />

2010 Program Book


1:20 PM<br />

Academic <strong>Rheumatology</strong><br />

Seth M. Berney, MD; Louisana State University; Shreveport, LA<br />

1:40 PM<br />

Private Practice<br />

Joseph Flood, MD; Musculoskeletal Medical Specialists;<br />

Columbus, OH<br />

2:00 PM<br />

Government – Food and Drug Administration<br />

To be announced<br />

Session Overview:<br />

<strong>Rheumatology</strong> fellows who are completing their fellowship<br />

training <strong>of</strong>ten need direction in making career choices.<br />

Information regarding career choices may not be available to<br />

fellows within the Division <strong>of</strong> <strong>Rheumatology</strong> in which they are<br />

training. This special session presents several speakers from<br />

different career paths in rheumatology including private practice<br />

rheumatology, academic rheumatology, basic research, and<br />

government.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• provide examples <strong>of</strong> different career choices available to<br />

young rheumatologists<br />

• discuss the pros and cons <strong>of</strong> the various career choices in<br />

rheumatology<br />

ACR Workshops<br />

1:15 - 3:15 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B201<br />

Histopathology <strong>of</strong> Vasculitis (239)<br />

Speakers: Allen Burke, MD; University <strong>of</strong> Maryland Medical<br />

Center; Baltimore, MD<br />

Fabio Tavora, MD; <strong>American</strong> International Pathology<br />

Laboratories; Silver Spring, MD<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe histological features <strong>of</strong> normal blood vessels<br />

• distinguish pathologic reactions to vascular injury<br />

• identify histological features <strong>of</strong> major vasculitis syndromes<br />

B204<br />

Joint Injection Techniques (240) cP f PS<br />

Speakers: Atul A. Deodhar, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Kenneth S. O’Rourke, MD; Wake Forest University School <strong>of</strong><br />

Medicine; Winston-Salem, NC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss indications and contraindications for joint aspirations<br />

and injections<br />

• identify and avoid common mistakes in joint injection<br />

procedures<br />

• perform common joint and s<strong>of</strong>t tissue injections on upper and<br />

lower extremities<br />

B202<br />

Musculoskeletal Imaging (241) f<br />

Speaker: William Morrison, MD; Thomas Jefferson University<br />

Hospital; Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the potential causes and exacerbating factors <strong>of</strong> the<br />

disease<br />

• discuss the appropriate use <strong>of</strong> laboratory testing and imaging<br />

modalities<br />

• design an efficacious, safe and cost-effective therapeutic<br />

strategy<br />

ACR Basic Science Symposia<br />

2:30 - 4:00 PM<br />

B402<br />

B cell Effectors and Regulators R<br />

Moderator: Nan Shen, MD; Shanghai Ren Ji Hospital; Shanghai,<br />

China<br />

2:30 PM<br />

New Insights into B cell Tolerance<br />

Eric Meffre, PhD; Yale University School <strong>of</strong> Medicine; New<br />

Haven, CT<br />

3:00 PM<br />

Ectopic Lymphoneogenesis and Effector B cells in Target Tissue<br />

in Lupus Nephritis<br />

Marcus R. Clark, MD; University <strong>of</strong> Chicago; Chicago, IL<br />

3:30 PM<br />

Regulatory B cells in Health and Disease<br />

Claudia Mauri, PhD; University <strong>College</strong> London; London,<br />

England, United Kingdom<br />

Session Overview:<br />

B cells play a critical role in the pathogenesis <strong>of</strong> many<br />

autoimmune diseases by multiple mechanisms and are also<br />

targets <strong>of</strong> emerging therapies. In addition to pathogenic<br />

effector functions, recent data has suggested anti-inflammatory<br />

regulatory roles for B cells as well. These functions can be<br />

mediated by antibodies and multiple antibody independent<br />

mechanisms including B cell cytokine secretion and direct<br />

interaction with other immune cells. This symposium will focus<br />

on new advances in our understanding <strong>of</strong> B cell regulation and<br />

effector functions with direct application to the rheumatic<br />

diseases and emerging therapies.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the mechanisms by which autoreactive B cells are<br />

normally censored and how this may go awry in autoimmune<br />

disease<br />

• describe examples <strong>of</strong> B cell dysregulation in target tissue<br />

in lupus nephritis and other autoimmune diseases and the<br />

concept <strong>of</strong> ectopic lymphoneogenesis<br />

• identify the diversity <strong>of</strong> B cell subsets and function, including<br />

the ability to act in an anti-inflammatory regulatory role<br />

wednesday<br />

2010 Program Book 113


A412<br />

Cell Death: Receptors, Sensors and Inflammatory<br />

Pathways R<br />

Moderators: Keith B. Elkon, MD; University <strong>of</strong> Washington;<br />

Seattle, WA<br />

Dror Mevorach, MD; Hadassah University Hospital; Jerusalem,<br />

Israel<br />

2:30 PM<br />

TAM Receptors and Innate Immune Function<br />

Greg E. Lemke, PhD; Salk Institute; La Jolla, CA<br />

3:00 PM<br />

Intracellular Sensors <strong>of</strong> Nucleic Acids and the Regulation <strong>of</strong><br />

Innate Immunity by microRNAs<br />

Luke A. O’Neill, PhD; Trinity <strong>College</strong> Dublin; Dublin, Ireland<br />

3:30 PM<br />

Necrosis and Inflammation - Pathways Uncovered<br />

Kenneth L. Rock, MD; University <strong>of</strong> Massachusetts; Worcester,<br />

MA<br />

Session Overview:<br />

Autoimmune responses in systemic and, perhaps, some<br />

organ-specific diseases are thought to arise from stimulation<br />

by self antigen derived from dead or dying cells. Recent<br />

studies have elucidated specific cellular receptors as well as<br />

intracellular sensors that recognize distinct products <strong>of</strong> dying<br />

cells. Depending on which receptors and sensors are triggered,<br />

different patterns <strong>of</strong> cytokine are produced resulting in<br />

suppression or enhancement <strong>of</strong> immune response to self.<br />

3:30 PM<br />

New Treatments and Beyond for Acute and Chronic Gout<br />

Robert Terkeltaub, MD; VA Medical Center; San Diego, CA<br />

Session Overview:<br />

Gout is a common disease. Treatment protocols have been<br />

unchanged for many years. However, there remain patients who<br />

are difficult to treat due to co-morbidities. Further, advances in<br />

diagnosis, and new and potential therapeutic agents justify an<br />

examination <strong>of</strong> how these options can be applied currently and<br />

in the future.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• develop treatment strategies for patients with co-morbidities<br />

• explain novel diagnostic modalities in gout<br />

• assess new treatment options for gout<br />

Hall A3<br />

Rheumatoid Arthritis Treatment 2010: Traditional<br />

DMARDs, Biologic DMARDs and Newer Treatment<br />

Strategies C PM PS<br />

Moderators: Thomas P. Olenginski, MD; Geisinger Medical<br />

Center; Danville, PA<br />

John M. Davis, MD; Mayo Clinic; Rochester, MN<br />

2:30 PM<br />

Non-biologic Rheumatoid Arthritis Therapy: Traditional<br />

DMARDs<br />

James R. O’Dell, MD; University <strong>of</strong> Nebraska Medical Center;<br />

Omaha, NE<br />

wednesday<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the different effects <strong>of</strong> apoptotic and necrotic cells<br />

on immune cell function<br />

• identify which molecules are critically involved in engaging<br />

cellular responses<br />

• explain how different receptors and intracellular sensors cells<br />

trigger anti- or pro-inflammatory responses in macrophages<br />

and dendritic cells<br />

• discuss how aberrations in these pathways lead to systemic<br />

autoimmune responses<br />

ACR Clinical Symposia<br />

2:30 - 4:00 PM<br />

Sidney J. Marcus Auditorium<br />

Crystallizing Your Assessment and Treatment <strong>of</strong><br />

Difficult to Treat Gout C PM PS<br />

Moderators: Bruce I. H<strong>of</strong>fman, MD; Philadelphia, PA<br />

Naomi Schlesinger, MD; University <strong>of</strong> Medicine and Dentistry<br />

<strong>of</strong> New Jersey/Robert Wood Johnson Medical School; New<br />

Brunswick, NJ<br />

2:30 PM<br />

Treatment <strong>of</strong> Gout in the Difficult Patient-Transplant, and other<br />

Co-morbidities<br />

N. Lawrence Edwards, MD; University <strong>of</strong> Florida; Gainesville, FL<br />

3:00 PM<br />

New and Old Modalities Used to Diagnose Gout<br />

Naomi Schlesinger, MD; University <strong>of</strong> Medicine and Dentristry<br />

<strong>of</strong> New Jersery/Robert Wood Johnson Medical School; New<br />

Brunswick, NJ<br />

3:00 PM<br />

Biologic DMARD Therapy in Rheumatoid Arthritis: Applying an<br />

Expanded Arsenal<br />

Josef S. Smolen, MD; Krankenhaus Lainz; Vienna, Austria<br />

3:30 PM<br />

Newer Rheumatoid Arthritis Treatment Strategies<br />

Duncan Porter, MD; Gartnavel General Hospital; Glasgow, United<br />

Kingdom<br />

Session Overview:<br />

Since 1998, the use <strong>of</strong> new, targeted biologic therapies has<br />

revolutionized the treatment <strong>of</strong> rheumatoid arthritis. Currently,<br />

agents that inhibit the action <strong>of</strong> tumor necrosis factor alpha,<br />

IL-1, IL-6, as well as selective co-stimulatory blockade and B-cell<br />

depleting therapies are available. However, early diagnosis and<br />

use <strong>of</strong> methotrexate, sulfasalazine, or hydroxychloroquine still<br />

constitute many initial treatment strategies. In 2008, the ACR<br />

published recommendations for the use <strong>of</strong> non-biologic and<br />

biologic disease-modifying antirheumatic drugs in rheumatoid<br />

arthritis. Rheumatologists have an expanded treatment arsenal<br />

and seek to apply the best evidence to treat their patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the role and supportive evidence for non-biologic<br />

DMARD treatment in rheumatoid arthritis<br />

• appraise rheumatoid arthritis treatment goals and the current<br />

ACR treatment recommendations<br />

• assess the evidence supporting biologic DMARD therapy<br />

• review data from combination DMARD therapy<br />

• determine situations where DMARD may be tapered and/or<br />

withdrawn<br />

114<br />

2010 Program Book


ACR Concurrent Abstract Sessions<br />

2:30 - 4:00 PM<br />

A402<br />

Epidemiology and Health Services Research:<br />

Osteoarthritis<br />

Moderators: John D. FitzGerald, MD, PhD; University <strong>of</strong><br />

California-Los Angeles School <strong>of</strong> Medicine Rehabilitation; Los<br />

Angeles, CA<br />

Elena Losina, PhD; Brigham and Women’s Hospital; Boston, MA<br />

2:30 PM<br />

2090. Quality-Adjusted Life Expectancy Losses Due to<br />

Disparities in Total Knee Replacement (TKR) Offer and<br />

Acceptance Rates in African <strong>American</strong> (AA) Men and Women.<br />

Elena Losina 4 , Lisa G. Suter 6 , Alexander M. Weinstein 2 , Ilya<br />

Golovaty 2 , William M. Reichmann 3 , Sara A. Burbine 2 , Edward H.<br />

Yelin 5 and Jeffrey N. Katz 1 , 1Brigham & Womens Hosp, Boston,<br />

MA, 2 Brigham and Women’s Hospital, 3 Brigham and Women’s<br />

Hospital, Boston University, Boston, MA, 4 Brigham and Women’s<br />

Hospital, Boston University, Harvard Medical School, 5 University<br />

<strong>of</strong> California, San Francisco, CA, 6 Yale University, New Haven, CT<br />

2:45 PM<br />

2091. Age <strong>of</strong> Symptomatic Knee OA Onset: Impact on Costs and<br />

Quality <strong>of</strong> Life.<br />

Elena Losina 5 , William M. Reichmann 3 , Ilya Golovaty 2 , Edward H.<br />

Yelin6, Hanna Gerlovin 2 , Elizabeth A. Wright 2 , David J. Hunter 7 ,<br />

Daniel H. Solomon 4 and Jeffrey N. Katz 1 , 1 Brigham & Womens<br />

Hosp, Boston, MA, 2 Brigham and Women’s Hospital, 3 Brigham<br />

and Women’s Hospital, Boston University, Boston, MA, 4 Brigham<br />

and Women’s Hospital, Harvard Medical School, 5 Brigham and<br />

Womens Hospital, Boston, MA, 6 University <strong>of</strong> California, San<br />

Francisco, CA, 7 University <strong>of</strong> Sydney<br />

3:00 PM<br />

2092. Projecting Lifetime Risk <strong>of</strong> Symptomatic Knee OA<br />

and Total Knee Replacement (TKR) in Persons Sustaining<br />

a Complete Anterior Cruciate Ligament (ACL) Tear in Early<br />

Adulthood.<br />

Elena Losina 4 , Hanna Gerlovin 2 , Lisa G. Suter 7 , David J. Hunter 6 ,<br />

Sara A. Burbine 2 , William M. Reichmann 5 , Laurel Donnell-Fink 2 ,<br />

Daniel Hal Solomon 3 and Jeffrey N. Katz 1 , 1 Brigham & Womens<br />

Hosp, Boston, MA, 2 Brigham and Women’s Hospital, 3 Brigham<br />

and Womens Hospital, Boston, MA, 4 Brigham and Womens<br />

Hospital, Boston, MA, 5 Brigham and Womens Hospital, Boston<br />

University, Boston, MA, 6 University <strong>of</strong> Sydney, 7 Yale University,<br />

New Haven, CT<br />

3:15 PM<br />

2093. Validation <strong>of</strong> an Internet-Based Questionnaire for<br />

Ascertaining Cases <strong>of</strong> Hip and Knee Osteoarthritis.<br />

Charles R. Ratzlaff 2 , Jacek Kopec 2 and Mieke Koehoorn 1 ,<br />

1<br />

University <strong>of</strong> British Columbia, 2 University <strong>of</strong> British Columbia /<br />

Arthritis Research Centre <strong>of</strong> Canada<br />

3:30 PM<br />

2094. Prevalence <strong>of</strong> Symptomatic Knee and Hip OA: A<br />

Population-Based Survey in France.<br />

Francis Guillemin 4 , Anne-Christine Rat 5 , Bernard Mazières 10 ,<br />

Jacques Pouchot 6 , Liana Euller Ziegler 8 , Bruno Fautrel 11 , Patrice<br />

Fardellone 3 , Johanne Morvan 9 , Christian H. Roux 8 , Evelyne<br />

Verrouil 2 , Alain Saraux 1 , Joel Coste 7 and (the KHOALA Group),<br />

1<br />

Brest University, Brest, France, 2 C.H.U Toulouse, Toulouse,<br />

France, 3 INSERM ERI 12, C.H.U Amiens, Amiens, France,<br />

4<br />

INSERM, CIC-EC CIE6, Nancy-Université, Paul Verlaine Metz,<br />

Paris Descartes, EA 4360 Apemac, Vandoeuvre les Nancy,<br />

France, 5 INSERM, CIC-EC CIE6, Nancy-Université, Paul Verlaine<br />

Metz, Paris Descartes, EA 4360 Apemac, Nancy, France,<br />

6<br />

Nancy-Université, Paul Verlaine Metz, Paris Descartes, EA 4360<br />

Apemac, Toulouse, France, 7 Nancy-Université, Paul Verlaine<br />

Metz, Paris Descartes, EA 4360 Apemac, Paris, France, 8 Nice-<br />

University, Nice, France, 9 Quimper Hospital, Quimper, France,<br />

10<br />

Toulouse-University, Toulouse, France, 11 UPMC, C.H.U Pitie<br />

Salpetriere, Paris, France<br />

3:45 PM<br />

2095. Modifiable Predictors <strong>of</strong> Racial Differences in Gait<br />

Velocity in an Elderly Urban Cohort.<br />

Irene Blanco 2 , Joe Verghese 2 , Richard B. Lipton 2 , Chaim<br />

Putterman 1 and Carol A. Derby 2 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med,<br />

Bronx, NY, 2 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, Bronx, NY<br />

A311<br />

Osteoarthritis - Clinical Aspects: Pain and<br />

Biomechanics<br />

Moderators: Joel A. Block, MD; Rush University Medical Center;<br />

Chicago, IL<br />

Gillian A. Hawker, MD, MSc; Women’s <strong>College</strong> Hospital; Toronto,<br />

ON, Canada<br />

2:30 PM<br />

2096. Physical Activity Assessed by Accelerometry in Persons<br />

with Knee OA Compared to National Guidelines: The<br />

Osteoarthritis Initiative (OAI).<br />

Dorothy D. Dunlop 6 , Jing Song 5 , Pamela Semanik 8 , Leena<br />

Sharma5, Rowland W. Chang 4 , Joan M. Bathon 3 , Charles Eaton 1 ,<br />

Marc C. Hochberg 11 , W. Jerry Mysiw 7 , Rebecca Jackson 7 , C.<br />

Kent Kwoh 10 , Michael C. Nevitt 9 and Jennifer M. Hootman 2 ,<br />

1<br />

Brown University, 2 Centers for Disease Control, Kennesaw, GA,<br />

3<br />

Johns Hopkins Univ Ste, Baltimore, MD, 4 Northwestern Univ,<br />

Chicago, IL, 5 Northwestern University, Chicago, IL, 6 Northwestern<br />

University Medical School, Chicago, IL, 7 Ohio State University,<br />

8<br />

Rehabilitation Institute <strong>of</strong> Chicago, Chicago, IL, 9 UCSF, San<br />

Francisco, CA, 10 Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA, 11 University <strong>of</strong><br />

Maryland, Baltimore, MD<br />

2:45 PM<br />

2097. Brain Activity in Patients with Chronic Knee Pain Due to<br />

Osteoarthritis: Dissociating Evoked from Spontaneous Pain.<br />

Elle L. Parks 2 , Marwan N. Baliki 2 , Paul Y. Geha 3 , Thomas J.<br />

Schnitzer 1 and Apkar V. Apkarian 2 , 1 Northwestern University,<br />

Chicago, IL, 2 Northwestern University, 3 Yale University<br />

3:00 PM<br />

2098. Central Sensitization and Knee Pain in Osteoarthritis:<br />

Preliminary Results from the MOST Study.<br />

Tuhina Neogi 3 , Jingbo Niu 4 , Lars Arendt-Nielsen 1 , Joachim<br />

Scholz 2 , Laura Frey-Law 9 , Clifford Woolf 2 , Yuqing Zhang 4 , Larry<br />

Bradley 8 , Irina Tolstykh 7 , Michael C. Nevitt 6 and David T. Felson 5 ,<br />

1<br />

Aalborg University, Denmark, 2 Boston Childrens Hospital,<br />

3<br />

Boston Univ Schl <strong>of</strong> Med, Boston, MA, 4 Boston Univ School <strong>of</strong><br />

Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA, 6 UCSF, San Francisco, CA, 7 UCSF, 8 University <strong>of</strong><br />

Alabama at Birmingham, 9 University <strong>of</strong> Iowa<br />

2010 Program Book 115<br />

wednesday


wednesday<br />

3:15 PM<br />

2099. Gait Adaptation after 6 Months <strong>of</strong> Specialized Shoes in<br />

Knee Osteoarthritis.<br />

Najia Shakoor 3 , Roy H. Lidtke 4 , Markus A. Wimmer 2 , Kharma C.<br />

Foucher 2 , Rachel A. Mikolaitis 2 , Louis F. Fogg 2 , Alan J. Shoelson 2<br />

and Joel A. Block 1 , 1 Rush University Medical Center, Chicago,<br />

IL, 2 Rush University Medical Center, 3 Rush-University Medical<br />

Center, Chicago, IL, 4 University <strong>of</strong> Iowa<br />

3:30 PM<br />

2100. The Role <strong>of</strong> Varus and Valgus Alignment in the Initial<br />

Development <strong>of</strong> Cartilage Damage at the Knee: The MOST<br />

Study.<br />

Leena Sharma 3 , Orit Almagor 4 , Joan S. Chmiel 4 , David T. Felson 1 ,<br />

Ali Guermazi 2 , Frank Roemer 2 , James Torner 9 , Cora E. Lewis 6 , Neil<br />

Segal 9 , John A. Lynch 8 , Derek Cooke5, Jean Hietpas 8 and Michael<br />

C. Nevitt 7 , 1 Boston University, Boston, MA, 2 Boston University,<br />

3<br />

Northwestern University, Chicago, IL, 4 Northwestern University,<br />

5<br />

Queens University, 6 UAB, 7 UCSF, San Francisco, CA, 8 UCSF,<br />

9<br />

University <strong>of</strong> Iowa<br />

3:45 PM<br />

2101. Varus Thrust Is Associated with Worse Physical Function.<br />

William F. Harvey 3 , Grace H. Lo 1 , Erica McAdams 4 , Melanie<br />

A. Ripley 4 , Melynn Nuite 3 and Timothy E. McAlindon 2 , 1 Tufts<br />

Medical Center, Houston, TX, 2 Tufts Medical Center Box 406,<br />

Boston, MA, 3 Tufts Medical Ctr, Boston, MA, 4 Tufts Medical Ctr.<br />

A314<br />

Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic<br />

Aspects-Outcomes<br />

Moderators: Daniel J. Lovell, MD, MPH; Children’s Hospital<br />

Medical Center; Cincinnati, OH<br />

Carol A. Wallace, MD; University <strong>of</strong> Washington and Seattle<br />

Childrens’s Hospital; Seattle, WA<br />

2:30 PM<br />

2102. Pediatric Rheumatic Disease in the Intensive Care Unit:<br />

Lessons Learned from 15 Years Experience in a Tertiary Care<br />

Pediatric Hospital.<br />

Suhas M. Radhakrishna 2 , Bracha Shaham 2 , Katherine A. B.<br />

Marzan 2 , Diane E. Brown 3 and Andreas O. Reiff 1 , 1 Childrens Hosp<br />

LA MS60, Los Angeles, CA, 2 Childrens Hospital <strong>of</strong> Los Angeles,<br />

Los Angeles, CA, 3 Childrens Hospital <strong>of</strong> Los Angeles<br />

2:45 PM<br />

2103. Rates <strong>of</strong> Hospitalized Bacterial Infection in Juvenile<br />

Idiopathic Arthritis and Its Treatment: An Observational Study<br />

<strong>of</strong> National U.S. Medicaid Administrative Claims Data.<br />

Timothy Beukelman 5 , Fenglong Xie 2 , Lang Chen 2 , John W.<br />

Baddley 2 , Elizabeth Delzell 2 , Carlos G. Grijalva 3 , Nivedita M.<br />

Patkar 2 , Kenneth G. Saag 2 , Kevin L. Winthrop 1 and Jeffrey R.<br />

Curtis 2 , 1 Oregon Health & Science University, 2 Univ <strong>of</strong> Alabama at<br />

Birmingham, Birmingham, AL, 3 Vanderbilt University<br />

Hospital, Foxboro, MA, 4 Brigham and Women’s Hospital,<br />

5<br />

Brigham and Womens Hospital, Boston, MA, 6 Harvard School<br />

<strong>of</strong> Public Health, Boston, MA, 7 Stanford University School <strong>of</strong><br />

Medicine, 8 University <strong>of</strong> North Carolina, Chapel Hill<br />

3:15 PM<br />

2105. The Clinical Significance <strong>of</strong> a Single MVK Mutation in<br />

HIDS.<br />

Karyl S. Barron 2 , Amanda K. Ombrello 4 , Donald P. Goldsmith 1 ,<br />

Ivona Aksentijevich 4 , Anne Jones 5 , Beverly K. Barham 6 and Daniel<br />

L. Kastner 3 , 1 Drexel Univ <strong>College</strong> Med, Philadelphia, PA, 2 NIAID/<br />

NIH, Bethesda, MD, 3 NIAMS, NIH, Bethesda, MD, 4 NIAMS/NIH,<br />

5<br />

NIH, NIAMS, Damascus, MD, 6 Ntl Inst <strong>of</strong> Arthritis & MSK SD,<br />

Bethesda, MD<br />

3:30 PM<br />

2106. Biomarkers for Global and Renal Disease Activity in<br />

Juvenile Systemic Lupus Erythematosus (jSLE).<br />

Rina Mina 4 , Michael Bennett 3 , Joseph M. Ahearn 1 , Joshua<br />

Pendl 3 , Jamie Eaton 3 , Nicole Wilson 5 , Prasad Devarajan 3 and<br />

Hermine Brunner 2 , 1 Wexford, PA, 2 Cincinnati Child Hosp Med Ctr,<br />

Cincinnati, OH, 3 Cincinnati Children’s Hospital Medical Center,<br />

4<br />

Cincinnati Children’s Med Ctr, Cincinnati, OH, 5 Univerisity <strong>of</strong><br />

Pittsburgh<br />

3:45 PM<br />

2107. Childhood Primary Angiitis <strong>of</strong> the CNS: Identifying<br />

Disease Trajectories and Early Risk Factors for Persistently<br />

Higher Disease Activity.<br />

Tania Cellucci, Pascal N. Tyrrell, Suzanne Laughlin, Derek<br />

Armstrong, William Halliday, Shehla Sheikh and Susanne M.<br />

Benseler, The Hospital for Sick Children, University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada<br />

A315<br />

Quality Measures and Innovation in Practice<br />

Management and Care Delivery<br />

Moderators: J. Timothy Harrington, MD; University <strong>of</strong> Wisconsin;<br />

Madison, WI<br />

Matthew P. Bunyard, MD; Cleveland Clinic Foundation; Moreland<br />

Hills, OH<br />

2:30 PM<br />

2108. Predictive Validity <strong>of</strong> the New Preliminary ACR/EULAR<br />

Definitions for Remission in Rheumatoid Arthritis.<br />

David T. Felson 2 , Josef S. Smolen 3 , George A. Wells 5 , Bin Zhang 1 ,<br />

Lilian H. D. van Tuyl 7 , Julia Funovits 4 , Maarten Boers 6 and for the<br />

ACR/EULAR Commission To Redefine Remission in Rheumatoid<br />

Arthritis, 1 Boston Univ Schl <strong>of</strong> Medicine, Boston, MA, 2 Boston<br />

University School <strong>of</strong> Medicine, Boston, MA, 3 Krankenhaus Lainz,<br />

Vienna, Austria, 4 Medical University <strong>of</strong> Vienna, 5 Univ <strong>of</strong> Ottawa<br />

Faculty <strong>of</strong> Med, Ottawa, ON, Canada, 6 VU University Medical<br />

Center, Amsterdam, The Netherlands, 7 VU University Medical<br />

Center, Amsterdam<br />

3:00 PM<br />

2104. Outcomes <strong>of</strong> End-Stage Renal Disease Due to Lupus<br />

Nephritis among Children in the U.S., 1995-2006.<br />

Linda T. Hiraki 6 , Bing Lu 3 , M. Alan Brookhart 8 , Tamara<br />

Shaykevich 4 , Graciela S. Alarcon 1 , Daniel Hal Solomon 5 , Wolfgang<br />

Winkelmayer 7 and Karen H. Costenbader 2 , 1 Oakland, CA,<br />

2<br />

Brigham & Women, Boston, MA, 3 Brigham and Women’s<br />

2:45 PM<br />

2109. Three Physician-Assigned Global Estimates for<br />

Inflammation, Damage and Non-Inflammatory Symptoms/<br />

Fibromyalgia Help To Clarify Overall Physician Global Estimates<br />

<strong>of</strong> Status in Patients with Different Rheumatic Diseases.<br />

Martin J. Bergman 1 and Theodore Pincus 2 , 1 Arthritis and<br />

<strong>Rheumatology</strong>, Ridley Park, PA, 2 New York University Hospital for<br />

Joint Disease, Hastings-on-Hudson, NY<br />

116<br />

2010 Program Book


3:00 PM<br />

2110. Rheumatologists on the Road: A Subspecialist’s Role in<br />

Caring for the Homebound.<br />

Ruchi Jain 1 , Suma Dasari 2 , Theresa Soriano 2 , Linda DeCherrie 2<br />

and Leslie Dubin Kerr 2 , 1 Mount Sinai Medical Center, New York,<br />

NY, 2 Mount Sinai Medical Center<br />

3:15 PM<br />

2111. Validation <strong>of</strong> Electronic Audiovisual Media Assessments<br />

<strong>of</strong> Patients with Rheumatic Diseases.<br />

Sarah McNamara 1 , Lorraine O’ Neill 3 , John J. Carey 2 and Robert<br />

J. Coughlan 1 , 1 N.U.I Galway University Hospitals, Galway, Ireland,<br />

2<br />

N.U.I Galway University Hospitals, Galway, Ireland, 3 N.U.I.<br />

Galway University Hospitals, Galway, Ireland<br />

3:30 PM<br />

2112. See online itinerary builder for more information<br />

3:45 PM<br />

2113. Quality <strong>of</strong> Care in Patients with Systemic Lupus<br />

Erythematosus.<br />

Jinoos Yazdany 4 , Laura Trupin 5 , Chris Tonner 5 , Gabriela<br />

Schmajuk 3 , Joann Z. Gillis 2 , Pantelis Panopalis 1 , Laura J. Julian 5 ,<br />

Lindsey A. Criswell 5 , Patricia Katz5 and Edward Yelin 5 , 1 McGill<br />

University, 2 National Jewish Medical Center, 3 Stanford University,<br />

4<br />

UCSF, San Francisco, CA, 5 UCSF<br />

B406<br />

Rheumatoid Arthritis - Human Etiology and<br />

Pathogenesis: Anti-CCP in RA Etiology and<br />

Pathogenesis II<br />

Moderators: Andrew P. Cope, MD, PhD; Surrey, United Kingdom<br />

Ulf Müller-Ladner, MD; University Giessen/Kerckh<strong>of</strong>f-Clinic; Bad<br />

Nauheim, Germany<br />

2:30 PM<br />

2114. The Gene-Environment Interaction between HLA-SE and<br />

Smoking Plays an Important Role in Shaping the Reactivity <strong>of</strong><br />

the ACPA Response to Several Citrullinated Antigens.<br />

Annemiek Willemze 2 , Diane van der Woude 3 , Wendim Ghidey<br />

Alemayehu 1 , René R. P de Vries 4 , Tom W. J. Huizinga 3 , Leendert<br />

A. Trouw 3 and René E. M Toes 3 , 1 Leiden University Medical<br />

Center, Department <strong>of</strong> Medical Statistics, 2 Leiden University<br />

Medical Center, Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden, The<br />

Netherlands, 3 Leiden University Medical Center, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, 4 Leiden University Medical Center. Department<br />

<strong>of</strong> Immunohematology and Blood Transfusion<br />

2:45 PM<br />

2115. Antibodies <strong>of</strong> IgG, IgA and IgM Isotypes Against Cyclic<br />

Citrullinated Peptide Precede the Development <strong>of</strong> Rheumatoid<br />

Arthritis.<br />

Heidi Kokkonen 2 , Mohammed Mullazehi 4 , Ewa Berglin 2 ,<br />

Göran Hallmans 1 , Göran Wadell 3 , Johan Rönnelid 4 and Solbritt<br />

Rantapää-Dahlqvist 2 , 1 Department <strong>of</strong> Nutritional Research,<br />

Umeå University, Umeå, 2 Department <strong>of</strong> Public Health and<br />

Clinical Medicine/<strong>Rheumatology</strong>, Umeå University, Umeå,<br />

3<br />

Department <strong>of</strong> Virology, Umeå University, Umeå, 4 Division<br />

<strong>of</strong> Clinical Immunology, Uppsala University, Uppsala<br />

3:00 PM<br />

2116. Epitope Spreading <strong>of</strong> the Autoantibody Response in the<br />

Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis<br />

(RA).<br />

Jeremy Sokolove 2 , Reuven Bromberg 3 , Kevin D. Deane 5 , Piyanka<br />

Chandra 3 , Leslie Derber 6 , Jess D. Edison 7 , William R. Gilliland 8 , Jill<br />

Norris 5 , V. Michael Holers 4 and William Robinson 1 , 1 Stanford Univ<br />

School <strong>of</strong> Med, Stanford, CA, 2 Stanford University, Mountain<br />

View, CA, 3 Stanford University, 4 Univ <strong>of</strong> Colorado School <strong>of</strong><br />

Med, Aurora, CO, 5 University <strong>of</strong> Colorado Denver, Aurora, CO,<br />

6<br />

University <strong>of</strong> Colorado Denver, 7 Walter Reed Army Med Ctr,<br />

Washington, DC, 8 Walter Reed Army Med Ctr, Potomac, MD<br />

3:15 PM<br />

2117. Citrullinated Epitopes within the Atherosclerotic Plaque:<br />

A Target for Anti-Citrulline Protein Antibodies?<br />

Jeremy Sokolove 2 , Orr Sharpe 3 , Matthew Brennan 3 , Andrew J.<br />

Connolly 3 and William Robinson 1 , 1 Stanford Univ School <strong>of</strong> Med,<br />

Stanford, CA, 2 Stanford University, Mountain View, CA, 3 Stanford<br />

University<br />

3:30 PM<br />

2118. Risk Factors in Different Subsets <strong>of</strong> Rheumatoid Arthritis.<br />

Karin Lundberg 3 , Camilla Bengtsson 1 , Lena Israelsson 4 , Iskra<br />

Pollak-Dorocic 4 , Leonid Padyukov 4 , Lars Alfredsson 1 , Vivianne<br />

Malmström 4 and Lars Klareskog 2 , 1 Institute for Environmental<br />

Medicine, Karolinska Institutet, 2 Karolinska University Hospital,<br />

Stockholm, Sweden, 3 Reumatology Unit, Karolinska Institutet,<br />

Stockholm, Sweden, 4 Reumatology Unit, Karolinska Institutet<br />

3:45 PM<br />

2119. Anti-CCP Positivity in Patients with Lung Disease but No<br />

Apparent Articular RA: A Pre-RA State?<br />

Joshua J. Solomon 1 , Allen Stevens 1 , Mary Gill 1 , Jennifer<br />

Brandorff 1 , Jeffrey J. Swigris 1 , Kevin Deane 2 , Richard Martin 1 ,<br />

Roland M. du Bois 1 and Aryeh Fischer 1 , 1 National Jewish Health,<br />

2<br />

University <strong>of</strong> Colorado<br />

B313<br />

Systemic Lupus Erythematosus - Clinical Aspects and<br />

Treatment: SLE and Cardiovascular Disease<br />

Moderators: Christine Peschken, MD, MSc; University <strong>of</strong><br />

Manitoba; Winnipeg, MB, Canada<br />

Paola De Pablo, MD, MPH; University <strong>of</strong> Birmingham;<br />

Birmingham, United Kingdom<br />

2:30 PM<br />

2120. Prevalence <strong>of</strong> Flow Mediated Dilatation and Its<br />

Association with Framingham Risk Score in a Population <strong>of</strong><br />

Women with Systemic Lupus Erythematosus.<br />

Valentina Peeva 4 , Paula Harvey 3 , Jiandong Su 3 , Ellie Aghdassi 3 , Ali<br />

Al-Dhanhani 3 , Stacey Morrison 3 , Christian Pineau 2 , Janet Pope 1 ,<br />

Debbie Da Costa 2 and Paul R. Fortin 3 , 1 London, ON, Canada,<br />

2<br />

Montreal, QC, Canada, 3 Toronto, ON, Canada, 4 University Health<br />

Network, Toronto Western Hospital, Toronto, ON, Canada<br />

wednesday<br />

2010 Program Book 117


wednesday<br />

2:45 PM<br />

2121. Protection from Cardiovascular Events and Nephritis in<br />

SLE Correlates with Levels <strong>of</strong> IgM Natural Autoantibodies to<br />

Different Apoptosis-Associated Antigens.<br />

Caroline Gronwall 3 , Ehtisham Akhter 2 , Michelle A. Petri 1 and<br />

Gregg J. Silverman 3 , 1 Johns Hopkins University School <strong>of</strong><br />

Medicine, Timonium, MD, 2 Johns Hopkins University School <strong>of</strong><br />

Medicine, Baltimore, MD, 3 Univ <strong>of</strong> California San Diego, La Jolla,<br />

CA<br />

3:00 PM<br />

2122. Non-Calcified Coronary Plaque (NCP) in Systemic Lupus<br />

Erythematosus (SLE): Quantitative Analysis.<br />

Adnan N. Kiani 2 , Jens Vogel-Claussen 2 , Margaret Yew 2 , Laurence<br />

S. Magder 3 and Michelle A. Petri 1 , 1 Timonium, MD, 2 Johns<br />

Hopkins University, School <strong>of</strong> Medicine, Baltimore, MD,<br />

3<br />

University <strong>of</strong> Maryland, School <strong>of</strong> Medicine<br />

3:15 PM<br />

2123. Aspirin Response Is Impaired in Patients with Systemic<br />

Lupus Erythematosus.<br />

Vivian K. Kawai 1 , Ingrid B. Avalos 2 , Annette M. Oeser 5 , John<br />

Oates 4 , Ginger Milne 4 , Cecilia P. Chung 3 and C. Michael Stein 1 ,<br />

1<br />

Vanderbilt University, Nashville, TN, 2 Vanderbilt University,<br />

Brookline, MA, 3 Vanderbilt University, Baltimore, MD, 4 Vanderbilt<br />

University, 5 VUMC 23rd Ave South Pierce, Nashville, TN<br />

3:30 PM<br />

2124. Rates <strong>of</strong> Adverse Cardiovascular Events among SLE<br />

Patients Are Higher during Episodes <strong>of</strong> Disease Activity.<br />

Laurence S. Magder 2 and Michelle A. Petri 1 , 1 Timonium, MD,<br />

2<br />

Department <strong>of</strong> Epidemiology and Preventive Medicine,<br />

University <strong>of</strong> Maryland, School <strong>of</strong> Medicine, Baltimore, MD<br />

3:45 PM<br />

2125. Atherosclerosis Is Associated with Low 25(OH) Vitamin D<br />

Levels, Lack <strong>of</strong> Angiotensin Converting Enzyme Inhibitor Use,<br />

and Hyperlipidemia in African-<strong>American</strong> Lupus Patients.<br />

Roneka L. Ravenell 3 , Diane L. Kamen 4 , Spence David 5 , Hollis<br />

Bruce 2 , Almeida Jonas 1 and Jim C. Oates 3 , 1 Department <strong>of</strong><br />

Bioinformatics and Computational Biology, The University <strong>of</strong><br />

Texas M. D. Anderson Cancer Center, Houston, TX, 2 Department<br />

<strong>of</strong> Pediatrics, Medical University <strong>of</strong> South Carolina, Charleston,<br />

SC, 3 MUSC, Charleston, SC, 4 MUSC PO Box 250637, Charleston,<br />

SC, 5 Robarts Research Stroke Prevention and Atherosclerosis<br />

Research Centre, London, ON, Canada<br />

A410<br />

T Cell Biology and Targets in Autoimmune Disease<br />

Moderators: Jorg J. Goronzy, MD, PhD; Stanford University<br />

School <strong>of</strong> Medicine; Stanford, CA<br />

Joseph Holoshitz, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />

2:30 PM<br />

2126. Dipyridamole Inhibits SLE T Cell Activation and Alleviates<br />

Nephritis in Lupus-Prone Mice.<br />

Vasileios C. Kyttaris, Zheng Zhang, Ourania Kampagianni and<br />

George C. Tsokos, Beth Israel Deaconess Medical Center<br />

2:45 PM<br />

2127. Defective T Cell Tolerance in Rheumatoid Arthritis Due to<br />

Increased B-Raf and K-Ras Expression.<br />

Pratima Deshpande 2 , Karnail Singh 1 , Mingcan Yu 2 , Guangjin Li 2 ,<br />

Cornelia M. Weyand 3 and Jorg J. Goronzy 3 , 1 Emory University,<br />

Atlanta, GA, 2 Stanford University, Stanford, CA, 3 Stanford<br />

University School <strong>of</strong> Medicine, Stanford, CA<br />

3:00 PM<br />

2128. SLAP Deficiency Enhances Both Number and Function <strong>of</strong><br />

FoxP3+ Regulatory T Cells and Inhibits Chronic Arthritis in SKG<br />

Mice.<br />

Lisa K. Peterson 2 , Laura A. Shaw 2 , Anthony Joetham 3 , Shimon<br />

Sakaguchi 1 , Erwin W. Gelfand 5 and Leonard Dragone 4 , 1 Kyoto<br />

University; Osaka University, 2 National Jewish Health, Denver,<br />

CO, 3 National Jewish Health, 4 National Jewish Health; University<br />

<strong>of</strong> Colorado Denver; The Children’s Hospital, Denver, CO,<br />

5<br />

National Jewish Health; University <strong>of</strong> Colorado Denver; The<br />

Children’s Hospital<br />

3:15 PM<br />

2129. The Role <strong>of</strong> BAFF in Promoting the Development <strong>of</strong> IL-17-<br />

Producing Cells and Th17-Mediated Disease.<br />

Xiaohui Zhou 2 , Julie Wang 4 , Zhongmin Liu 1 , William Stohl 3 and<br />

Song Guo Zheng 4 , 1 Tongji University Medical School, 2 Univ S Calif<br />

Keek Schl <strong>of</strong> Med, Los Angeles, CA, 3 Univ Southern California, Los<br />

Angeles, CA, 4 USC Keck School <strong>of</strong> Medicine, Los Angeles, CA<br />

3:30 PM<br />

2130. Activated Th17 Cells Drive Rheumatoid Inflammation<br />

and Are Resistant to Inhibition by Natural Antagonists <strong>of</strong> Their<br />

Development.<br />

Jan Leipe 2 , Mathias Grunke 2 , Claudia Dechant 2 , Christiane<br />

Reindl 2 , Hendrik Schulze-Koops 1 and Alla Skapenko 2 , 1 University<br />

<strong>of</strong> Munich, Munich, Germany, 2 University <strong>of</strong> Munich, Germany<br />

3:45 PM<br />

2131. Regulatory T Cell Recovery in HCV-Related Autoimmunity<br />

through IL-2 Treatment.<br />

David Saadoun 2 , Michelle Rosenzwajg 1 , Lucile Musset 1 , Fabrice<br />

Carrat 1 , David Klatzmann 1 and Patrice Cacoub 1 , 1 Internal<br />

Medicine Department, 2 Internal Medicine Department and<br />

Immunology Laboratory Pitie Salpetriere Hospital<br />

ACR/ARHP Combined Abstract<br />

Session<br />

2:30 - 4:00 PM<br />

B310<br />

ACR/ARHP Combined Orthopedics, Low Back<br />

Pain and Rehabilitation: Hips and Knees: Focus on<br />

Function<br />

Moderator: Kimberly F. Kimpton, PT; Centennial, CO<br />

2:30 PM<br />

2132. Progressive Resistance Exercise in Women with Knee<br />

Osteoarthritis.<br />

Renata Jorge 1 , Marcelo Souza 2 , Aline Chiari 2 , Anamaria Jones 2 ,<br />

Império Lombardi, Jr 2 , Artur Fernandes2 and Jamil Natour 2 ,<br />

1<br />

UNIFESP, Sao Paulo, SP, Brazil, 2 UNIFESP<br />

118<br />

2010 Program Book


2:45 PM<br />

2133. Reasons for Decline in Walking Despite Improvements in<br />

Knee Pain: The MOST Study.<br />

Daniel K. White 2 , David T. Felson 4 , Jingbo Niu 3 , Michael C.<br />

Nevitt5, C. Elizabeth Lewis 6 , James Torner 7 and Tuhina Neogi 1 ,<br />

1<br />

Boston Univ Schl <strong>of</strong> Med, Boston, MA, 2 Boston Univ School<br />

<strong>of</strong> Med, Boston, MA, 3 Boston University, Boston, MA, 4 Boston<br />

University School <strong>of</strong> Medicine, Boston, MA, 5 UCSF, San Francisco,<br />

CA, 6 University <strong>of</strong> Alabama, 7 University <strong>of</strong> Iowa<br />

3:00 PM<br />

2134. Reduction <strong>of</strong> the Foot Plantar Maximum Vertical Force<br />

Using Medial-Wedge Insoles in Valgus Knee Osteoarthritis.<br />

Priscilla Teixeira Rodrigues 2 , Rosa M. R. Pereira 2 , Julia M. D.<br />

Greve 1 and Ricardo Fuller 2 , 1 Rheabilitation Division, Faculdade de<br />

Medicina da Universidade de São Paulo, 2 <strong>Rheumatology</strong> Division,<br />

Faculdade de Medicina da Universidade de São Paulo<br />

3:15 PM<br />

2135. Functional Benefits Following Dynamic Exercise in<br />

Patients with RA Taking Anti-TNFα Therapy Reflected in Lower<br />

Limb Function Tests but Not the HAQ.<br />

Angela Reid 1 , Audrey Brady 2 , Tara Cusack 5 , Catherine Blake 5 ,<br />

Anne Barbara Mongey 3 , Douglas J. Veale 4 and Oliver FitzGerald 3 ,<br />

1<br />

Our Lady’s Hospice, Dublin, Ireland, 2 Our Lady’s Hospice, 3 St.<br />

Vincent’s University Hospital, 4 St. Vincent’s University Hospital,<br />

5<br />

University <strong>College</strong> Dublin, Ireland<br />

3:30 PM<br />

2136. Co-Morbid Pain in Hips, Low Back, and Non-Operative<br />

Knee Associated with Physical Function before and after TKR.<br />

Patricia D. Franklin 2 , Wenjun Li 2 , David C. Ayers 2 and Carol A.<br />

Oatis 1 , 1 Arcadia University, Glenside, PA, 2 Univ <strong>of</strong> MA Med Schl,<br />

Worcester, MA<br />

3:45 PM<br />

2137. Predictors <strong>of</strong> 12 Year Revision Risk Following Primary<br />

THR for Osteoarthritis in the US Medicare Population.<br />

Jeffrey N. Katz 1 , Elizabeth A. Wright 1 , Akosua A. Nti 1 , John<br />

Wright 2 , Henrik Malchau 5 , John A. Baron 4 and Elena Losina 3 ,<br />

1<br />

Brigham and Women’s Hospital, Boston, MA, 2 Brigham and<br />

Women’s Hospital, 3 Brigham and Women’s Hospital, Boston, MA,<br />

4<br />

Dartmouth Medical School, 5 Massachusetts General Hospital<br />

ARHP Concurrent Abstract Session<br />

2:30 - 4:00 PM<br />

B311<br />

Keep Working with Arthritis<br />

Moderator: Catherine L. Backman, PhD, OT(C); University <strong>of</strong><br />

British Columbia; Vancouver, BC, Canada<br />

2:30 PM<br />

2138. Too Young? Arthritis Is “Main Cause” <strong>of</strong> Disability for<br />

Millions <strong>of</strong> Working-Age U.S. Adults.<br />

Kristina Theis 3 , Charles G. Helmick 1 , Jennifer M. Hootman 2 and<br />

Matthew Brault, 1 CDC, Atlanta, GA, 2 Centers for Disease Control,<br />

Kennesaw, GA, 3 Centers for Disease Control and Prevention<br />

2:45 PM<br />

2139. Arthritis and Labor Force Attachment among Working-<br />

Age Australians.<br />

Kristina A. Theis, Lucy Busija, Ross Wilkie, Gerald Elsworth and<br />

Richard H. Osborne, Deakin University<br />

3:00 PM<br />

2140. Association <strong>of</strong> Depressive Symptoms and Helplessness<br />

with Socioeconomic Status in People with Knee Osteoarthritis.<br />

Leigh F. Callahan 2 , Jack H. Shreffler 4 , Kathryn Remmes Martin 3 ,<br />

Britta Schoster 4 , Jordan Renner 4 and Joanne M. Jordan 1 , 1 Chapel<br />

Hill, NC, 2 Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 3 University<br />

<strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 4 University <strong>of</strong><br />

North Carolina, Chapel Hill<br />

3:15 PM<br />

2141. The Effect <strong>of</strong> a 6 Week Walking Program on Work Activity<br />

Limitations in Adults with Arthritis.<br />

Brian L. Charnock 3 , Kathryn Remmes Martin 2 , Jack Shreffler 3 ,<br />

Mary Altpeter 3 and Leigh F. Callahan 1 , 1 Univ <strong>of</strong> North Carolina,<br />

Chapel Hill, NC, 2 University <strong>of</strong> North Carolina at Chapel Hill,<br />

Chapel Hill, NC, 3 University <strong>of</strong> North Carolina at Chapel Hill<br />

3:30 PM<br />

2142. The Effect <strong>of</strong> Structural Deformities on Typing Styles <strong>of</strong><br />

Touch Typists with Rheumatoid Arthritis.<br />

Nancy A. Baker 2 , Norman P. Gustafson 2 , Hyekyoung Shin 3 and<br />

Joan C. Rogers 1 , 1Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh,<br />

Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh<br />

3:45 PM<br />

2143. Formation <strong>of</strong> Solutions for Rheumatic Condition-Related<br />

Work Barriers by Occupational and Physical Therapists (OTs/<br />

PTs).<br />

Saralynn H. Allaire 2 , Julie J. Keysor 1 , Nancy A. Baker 5 , Jingbo Niu 3<br />

and Michael P. LaValley 4 , 1 Boston Univ Sargent <strong>College</strong>, Boston,<br />

MA, 2 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 3 Boston<br />

University, Boston, MA, 4 BU School <strong>of</strong> Public Health, Boston, MA,<br />

5<br />

University <strong>of</strong> Pittsburgh, Pittsburgh, PA<br />

ARHP Concurrent Sessions<br />

2:30 - 4:00 PM<br />

B308<br />

Patient Participation in Research c/r<br />

Moderator: Mary E. Christenson, PT, PhD; Regis University;<br />

Westminster, CO<br />

Speakers: Christina H. Opava, PhD; Karolinska Institutet;<br />

Huddinge, Sweden<br />

Nadine T. James, RN, MSN, PhD; William Carey University;<br />

Hattiesburg, MS<br />

Session Overview:<br />

Participatory research is defined as a systematic inquiry<br />

with collaboration <strong>of</strong> those who are affected by the issue<br />

being studied. This session will provide an opportunity for<br />

international and North <strong>American</strong> members to collaborate and<br />

exchange ideas regarding research methods for people with<br />

arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss successful examples, from both past and present<br />

literature, <strong>of</strong> patient involvement in research teams<br />

• identify the potential issues surrounding patient participation<br />

in research<br />

• compare research studies with and without patient research<br />

team members by examining the results for application in<br />

practice<br />

• generate four research projects using people with arthritis as<br />

part <strong>of</strong> the research team<br />

2010 Program Book 119<br />

wednesday


wednesday<br />

B309<br />

When Pieces Don’t Fit C<br />

PM PS<br />

Moderator: Joyce P. Carlone, MN, RN, FNP-BC; Emory University;<br />

Atlanta, GA<br />

2:30 PM<br />

Undifferentiated Connective Tissue Disease<br />

Michael R. Liebling, MD; Los-Angeles Biomedical Research<br />

Institute; Torrance, CA<br />

3:00 PM<br />

Undifferentiated Spondylarthritis<br />

Luis R. Espinoza, MD; Louisianna State University Medical<br />

Center; New Orleans, LA<br />

3:30 PM<br />

Fibromyalgia Mimics<br />

Eduardo S. Paiva, MD; Universidade Federal do Parana; Curitiba<br />

Parana, Brazil<br />

Session Overview:<br />

Rheumatologic diseases are <strong>of</strong>ten difficult to diagnose and<br />

classify as there are various guidelines throughout the<br />

rheumatology pr<strong>of</strong>ession. Patients are referred to rheumatology<br />

pr<strong>of</strong>essionals because <strong>of</strong> their common symptoms and <strong>of</strong>ten<br />

times there is not one test alone which will confirm a diagnosis.<br />

Because <strong>of</strong> the many “grey” areas <strong>of</strong> rheumatology, it can be<br />

challenging to classify these patients and develop appropriate<br />

treatment for them. <strong>Rheumatology</strong> pr<strong>of</strong>essionals continually<br />

need to be apprised <strong>of</strong> diagnosis criteria and what to do when<br />

patients “don’t fit.”<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the classification for connective tissue diseases and<br />

recognize when patients do not meet full criteria<br />

• distinguish between ankylosing spondylitis and<br />

spondylarthropathies that fall outside the parameters <strong>of</strong> the<br />

disease<br />

• describe and identify other causes for diffuse musculoskeletal<br />

pain<br />

ACR Workshops<br />

4:00 - 6:00 PM<br />

Admission to each Workshop requires a separate registration<br />

and ticket. To verify which session you registered for, check to<br />

make sure the registration code on your ticket matches the code<br />

listed below in parentheses.<br />

B202<br />

Basic Statistical Concepts for the Medical Researcher<br />

(242)<br />

Speaker: Dorothy D. Dunlop, PhD; Northwestern University<br />

Medical School; Chicago, IL<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify factors influencing sample size and power<br />

• interpret confidence intervals, odds ratio and relative risk<br />

• describe factors that confound study results<br />

B204<br />

Osteoporosis: Focus on Dual Energy X-ray<br />

Absorptiometry Interpretation (243) f PS<br />

Speaker: Chad L. Deal, MD; Cleveland Clinic Foundation;<br />

Cleveland, OH<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine how to combine bone mineral density and clinical<br />

risk factors in determination <strong>of</strong> absolute risk<br />

• discuss the concept <strong>of</strong> intervention threshold used in National<br />

Osteoporosis Foundation guidelines<br />

• review International Society for Clinical Densitometry<br />

guidelines for DXA interpretation<br />

• create a report for bone densitometry results<br />

B206<br />

Peripheral Magnetic Resonance Imaging in<br />

<strong>Rheumatology</strong> Practice (244)<br />

Speakers: Philip G. Conaghan, MD, PhD; Chapel Allerton<br />

Hospital; Leeds, United Kingdom<br />

Mikkel Østergaard, MD, PhD, DMSc; Hvidovre University<br />

Hospital; Hvidovre, Denmark<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />

the outpatient setting<br />

• review the merits and pitfalls <strong>of</strong> this technology<br />

B203<br />

Physical Examination Skills for Improved Detection <strong>of</strong><br />

Synovitis and Cervical Thoracolumbar Disorders (245)<br />

Speaker: Edward C. Keystone, MD; University <strong>of</strong> Toronto;<br />

Toronto, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss sensitive techniques for the detection <strong>of</strong> synovitis in<br />

peripheral joints, especially elbows, wrists, hands, feet and<br />

knees<br />

• demonstrate techniques to determine the origin <strong>of</strong> referred<br />

pain from the neck and thoracolumbar spine<br />

• describe simple techniques to improve the symptoms <strong>of</strong><br />

mechanical neck and back pain at the bedside<br />

ARHP Concurrent Session<br />

4:00 - 6:00 PM<br />

B201<br />

Web-based Support <strong>of</strong> Clinical Practice and Teaching:<br />

Twittering, Blogging, and Doing the Wiki cP PS<br />

Moderator: Annette M. Oeser, BS, CCRP; Vanderbilt University<br />

Medical Center; Nashville, TN<br />

Speakers: Laura E. Ray, MA, MLS; Cleveland State University;<br />

Cleveland, OH<br />

Melanie Zibit, MEd, MBA; Brigham and Women’s Hospital;<br />

Lexington, MA<br />

120<br />

2010 Program Book


Session Overview:<br />

We are witnessing a rapid increase in the use <strong>of</strong> web-based tools<br />

by health care practitioners and educators to facilitate clinical<br />

activities and instructional sessions. The ease <strong>of</strong> use and speed<br />

<strong>of</strong> deployment makes Twitter, blogs, and wikis effective forums<br />

for communication. However, determining the most appropriate<br />

format for the specific needs <strong>of</strong> your practice, lecture, or class<br />

can be overwhelming. This interactive session will review key<br />

features for evaluating technological formats, demonstrate the<br />

use <strong>of</strong> Twitter, blogs, and wikis, and discuss how practitioners<br />

and educators have specifically used these technologies.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify features <strong>of</strong> web-based tools such as content<br />

integration and discussion forums for evaluating technological<br />

formats<br />

• describe how to create Twitter accounts, blogs, and wikis<br />

• discuss how Twitter, blogs, and wikis can enhance clinical<br />

practice and instructional sessions<br />

ACR Basic Science Symposia<br />

4:30 - 6:00 PM<br />

B402<br />

A Critical Role for Lipid Metabolism in the Interplay<br />

between Atherosclerosis and Autoimmune Disorders<br />

R<br />

Moderators: Radjesh Bisoendial, MD, PhD; Academic Medical<br />

Center University <strong>of</strong> Amsterdam; Amsterdam, Netherlands<br />

Zoltan Szekanecz, MD, PhD, DSC; University <strong>of</strong> Debrecen Medical<br />

Center; Debrecen, Hungary<br />

4:30 PM<br />

High-Density Lipoprotein Regulates Cellular Immune Responses<br />

via Adenosine Triphosphate-binding Cassette<br />

Alan Tall, MD; Columbia University; New York, NY<br />

5:00 PM<br />

The Dual Function <strong>of</strong> High Density Lipoproteins to Suppress<br />

Inflammatory Activity and Protect Against Heart Disease<br />

in Rheumatoid Arthrititis and Other Immune-mediated<br />

Inflammatory Diseases<br />

Kerry-Anne Rye, PhD; The Heart Research Institute; Newtown,<br />

Sydney, New South Wales, Australia<br />

5:30 PM<br />

Liver X Receptor Signaling at the Crossroads Between Immunity<br />

and Cholesterol Homeostasis<br />

Uwe JF. Tietge, MD; University Medical Center Groningen;<br />

Groningen, Netherlands<br />

Session Overview:<br />

Cardiovascular disease represents a major cause <strong>of</strong> increased<br />

morbidity and mortality in various immune-mediated<br />

inflammatory disorders. This symposium will provide insight into<br />

the factors involved in the increased cardiovascular risk and the<br />

underlying mechanisms.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the key players that integrate metabolic and<br />

inflammatory signaling in increased cardiovascular disease<br />

among individuals with immune-mediated inflammatory<br />

diseases<br />

• define the basics <strong>of</strong> the pathogenic mechanisms that drive<br />

atherosclerosis in immune-mediated inflammatory diseases<br />

B313<br />

Molecular Mechanisms <strong>of</strong> Ocular Inflammation R<br />

Moderators: James T. Rosenbaum, MD; Oregon Health & Science<br />

University; Portland, OR<br />

Holly L. Rosenzweig, PhD; Oregon Health & Science University;<br />

Portland, OR<br />

4:30 PM<br />

Is Macular Degeneration, the Leading Cause <strong>of</strong> Acquired<br />

Blindness, an Autoimmune Disease?<br />

Jayakrishna Ambati, MD; University <strong>of</strong> Kentucky; Lexington, KY<br />

5:00 PM<br />

The Role <strong>of</strong> IL-17 in Autoimmune Uveitis<br />

Rachel Caspi, PhD; National Eye Insitute; Bethesda, MD<br />

5:30 PM<br />

Are Biologic Therapies Indicated to Treat Inflammatory Eye<br />

Diseases?<br />

James T. Rosenbaum, MD; Oregon Health & Science University;<br />

Portland, OR<br />

Session Overview:<br />

The majority <strong>of</strong> rheumatologic diseases include a component <strong>of</strong><br />

ocular inflammation. A better understanding <strong>of</strong> the pathogenesis<br />

<strong>of</strong> ocular inflammation will lead to insights into inflammation in<br />

other organs involved in rheumatic diseases.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the relative contributions <strong>of</strong> TH1, TH2, and TH17 T cell<br />

subsets in an animal model <strong>of</strong> uveitis<br />

• describe the role <strong>of</strong> growth factors, toll receptors,<br />

chemokines, and monocytes in the pathogenesis <strong>of</strong> macular<br />

degeneration<br />

• define the role <strong>of</strong> biologic therapies in the treatment <strong>of</strong><br />

inflammatory eye diseases<br />

ACR Clinical Symposia<br />

4:30 - 6:00 PM<br />

Sidney J. Marcus Auditorium<br />

New Development in Systemic Juvenile Idiopathic<br />

Arthritis - From Bench to Effective Interventions P<br />

PS<br />

Moderators: Alexei A. Grom, MD; Children’s Hospital Medical<br />

Center; Cincinnati, OH<br />

Sampath Prahalad, MD, MSc; Emory Children’s Center; Atlanta,<br />

GA<br />

4:30 PM<br />

Introduction: Systemic Juvenile Idiopathic Arthritis as an<br />

Autoinflammatory Syndrom<br />

Sampath Prahalad, MD, MSc; Emory Children’s Center; Atlanta,<br />

GA<br />

4:40 PM<br />

IL-1 and Systemic Juvenile Idiopathic Arthritis<br />

Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,<br />

NY<br />

2010 Program Book 121<br />

wednesday


wednesday<br />

122<br />

5:10 PM<br />

IL-6 and Systemic Juvenile Idiopathic Arthritis<br />

Fabrizio De Benedetti, MD, PhD; IRCCS Ospedale Pediatrico<br />

Bambino Gesù; Rome, Italy<br />

5:40 PM<br />

Panel Discussion: Optimal Use and Timing <strong>of</strong> Biologic Therapies<br />

in Systemic Juvenile Idiopathic Arthritis<br />

Session Overview:<br />

The extraordinary progress in auto-inflammatory diseases has<br />

spilled over into systemic juvenile idiopathic arthritis, providing<br />

exciting new avenues for disease mechanisms. The extraordinary<br />

state <strong>of</strong> cytokine upregulation in systemic juvenile idiopathic<br />

arthritis and in its most severe complication, macrophage<br />

activation syndrome has been mirrored by the development<br />

<strong>of</strong> effective biological agents for the first time in history.<br />

Modulation <strong>of</strong> IL-1 and IL-6 became feasible and at the same<br />

time promising for the most severe form <strong>of</strong> juvenile arthritis.<br />

Soon, these treatments may be available to the pediatrician.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the main pathways involved in the pathogenesis <strong>of</strong><br />

systemic juvenile idiopathic arthritis<br />

• describe the distinct pattern <strong>of</strong> cytokine pr<strong>of</strong>iles in systemic<br />

juvenile idiopathic arthritis<br />

• explain the indications and the timing for intervention with<br />

biologic therapy<br />

A411<br />

Osteoarthritis - What is New in Old Joints C PM<br />

Moderators: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />

Milwaukee, WI<br />

Mariko L. Ishimori, MD; Cedars Sinai Medical Center; Los<br />

Angeles, CA<br />

4:30 PM<br />

Biomechanical Pathways in Osteoarthritis and Impact on<br />

Treatment<br />

Najia Shakoor, MD; Rush University Medical Center; Chicago, IL<br />

4:55 PM<br />

Current Pharmacologic Therapies in Osteoarthritis<br />

Marc C. Hochberg, MD, MPH; University <strong>of</strong> Maryland; Baltimore,<br />

MD<br />

5:20 PM<br />

Emerging Therapies for Osteoarthritis<br />

Thomas J. Schnitzer, MD, PhD; Northwestern University; Chicago,<br />

IL<br />

Session Overview:<br />

Osteoarthritis is the most common disability <strong>of</strong> aging. As the<br />

demographics shift to an older majority, osteoarthritis will<br />

continue to cause significant personal and societal burdens.<br />

Rheumatologists must remain current in the approach to care<br />

and potential future therapeutic options in order to advise<br />

referring physicians and patients.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the connection between biomechanical forces and the<br />

development <strong>of</strong> osteoarthritis<br />

• develop individualized treatment plans for patients with<br />

osteoarthritis<br />

• describe future therapies in osteoarthritis<br />

2010 Program Book<br />

Hall A3<br />

Perioperative Management <strong>of</strong> Selected Problems in<br />

Patients with Rheumatic Disease C PS<br />

Moderator: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />

Foundation; Cleveland, OH<br />

4:30 PM<br />

Recognizing and Managing Disease Associated Cardiovascular<br />

Risks and Postoperative Cardiac Complications in Patients with<br />

Rheumatic Disease<br />

Howard H. Weitz, MD; Thomas Jefferson University, Jefferson<br />

Medical <strong>College</strong>; Philadelphia, PA<br />

5:00 PM<br />

Anti-Inflammatory and Immunomodulatory Medications in the<br />

Perioperative Period<br />

Tim Bongartz, MD; Mayo Clinic; Rochester, MN<br />

5:30 PM<br />

Anticoagulation <strong>of</strong> Patients with Antiphospholipid Antibodies<br />

in the Perioperative Period<br />

Mark A. Crowther, MD, MSc; McMaster University; Hamilton,<br />

ON, Canada<br />

Session Overview:<br />

Patients with rheumatic diseases frequently require orthopedic<br />

and other surgical procedures. There are guidelines and<br />

published studies relating to the management <strong>of</strong> surgical<br />

patients, but they mainly deal with non-rheumatologic aspects<br />

<strong>of</strong> perioperative care. Despite the fact that rheumatologists may<br />

be providing chronic care for these patients and prescribing<br />

medications, which may impact perioperative outcome,<br />

perioperative management has not been an integral part <strong>of</strong> the<br />

training <strong>of</strong> rheumatology fellows in most programs, and has not<br />

been reviewed in-depth at the annual meeting in recent years.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• manage a patient’s anti-inflammatory and immunomodulatory<br />

medications in the perioperative period<br />

• provide appropriate anticoagulation therapy in the presence<br />

<strong>of</strong> antiphospholipid antibodies in the perioperative period<br />

• assess and minimize the effect <strong>of</strong> the perioperative cardiac<br />

risks in patients with rheumatic disease<br />

Thomas J. Murphy Ballroom<br />

Systemic Sclerosis: New Therapeutic Approaches P/C<br />

PS<br />

Moderator: Robert W. Simms, MD; Boston University School <strong>of</strong><br />

Medicine; Boston, MA<br />

4:30 PM<br />

Emerging Therapies in Interstitial Lung Disease Associated with<br />

Scleroderma<br />

Richard M. Silver, MD; Medical University <strong>of</strong> South Carolina;<br />

Charleston, SC<br />

5:00 PM<br />

Cardiovascular and Vascular Therapies in Scleroderma<br />

Fredrick M. Wigley, MD; Johns Hopkins University; Baltimore,<br />

MD<br />

5:30 PM<br />

Advances in Stem Cell Therapy in Systemic Sclerosis<br />

Alan G. Tyndall, MD; University <strong>of</strong> Basel; Basel, Switzerland


Session Overview:<br />

Systemic sclerosis remains a major therapeutic challenge for<br />

clinicians with significant potential morbidity and mortality.<br />

Emerging therapies provide significant potential opportunities<br />

for improved outcomes. Identifying which <strong>of</strong> these therapies<br />

<strong>of</strong>fers the greatest promise is <strong>of</strong> key importance.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• explain the pathogenesis <strong>of</strong> interstitial lung disease<br />

associated with scleroderma and outline the spectrum <strong>of</strong> new<br />

therapeutic options in interstitial lung disease associated with<br />

scleroderma<br />

• identify and synthesize the emerging data on cardiovascular<br />

complications including pulmonary hypertension to develop a<br />

therapeutic approach<br />

• describe the emerging role <strong>of</strong> stem cell therapy in scleroderma<br />

and synthesize new clinical trial data on stem cell therapy<br />

ACR Concurrent Abstract Sessions<br />

4:30 - 6:00 PM<br />

A402<br />

Genetics, Genomics and Proteomics: SLE<br />

Moderator: Betty P. Tsao, PhD; University <strong>of</strong> Californina-Los<br />

Angeles School <strong>of</strong> Medicine; Los Angeles, CA<br />

4:30 PM<br />

2144. Exome Resequencing in a Densely Affected<br />

Multigenerational SLE Pedigree.<br />

Graham Wiley 2 , Chee Paul Lin 2 , Indra Adrianto 3 , Jennifer A.<br />

Kelly 3 , Kathy L. Moser 2 , Kenneth M. Kaufman 3 , John B. Harley 4 ,<br />

Courtney Gray-McGuire 2 and Patrick M. Gaffney 1 , 1 Oklahoma<br />

Med Research Foundation, Oklahoma City, OK, 2 Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK, 3 Oklahoma<br />

Medical Research Foundation, 4 Univ <strong>of</strong> OK Hlth Sci Ctr,<br />

Oklahoma City, OK<br />

4:45 PM<br />

2145. Large-Scale Mapping <strong>of</strong> Systemic Lupus Erythematosus<br />

(SLE) Variants across Different Ethnicities Reveals That the IRF5-<br />

TNPO3 Region Is the Strongest Common Risk Factor.<br />

Timothy J. Vyse 8 , Paula S. Ramos 3 , Kenneth M. Kaufman 2 ,<br />

Jennifer A. Kelly 2 , Caroline Gallant 7 , Angelica Delgado 6 , Sharon<br />

A. Chung 10 , Lindsey A. Criswell 12 , Robert P. Kimberly 4 , Mary E.<br />

Comeau 3 , Adrienne H. Williams 3 , Laurie P. Russell 3 , Chaim O.<br />

Jacob 9 , Betty P. Tsao 11 , Marta E. Alarcon-Riquelme 5 , Kathy L.<br />

Moser 1 , Patrick M. Gaffney 1 , John B. Harley 13 , Carl D. Langefeld 3<br />

and SLEGEN Consortium, 1 Arthritis and Immunology Program,<br />

Oklahoma Medical Research Foundation, Oklahoma City,<br />

OK, 2 Arthritis and Immunology Program, Oklahoma Medical<br />

Research Foundation, 3 Dept Biostatistical Sciences, Wake<br />

Forest University Health Sciences, 4 Dept Medicine, University<br />

<strong>of</strong> Alabama at Birmingham, Birmingham, AL, 5 Dept <strong>of</strong> Genetics<br />

and Pathology, Uppsala University, Uppsala, Sweden, 6 Dept <strong>of</strong><br />

Genetics and Pathology, Uppsala University, 7 Dept <strong>of</strong> Genetics<br />

and Pathology, Uppsala University, Sweden, 8 Faculty <strong>of</strong> Medicine,<br />

Imperial <strong>College</strong>, London, UK, 9 Keck School <strong>of</strong> Medicine,<br />

University <strong>of</strong> Southern California, Los Angeles, CA, 10 Rosalind<br />

Russell Medical Research Center for Arthritis, University <strong>of</strong><br />

California, San Francisco, San Francisco, CA, 11 UCLA School <strong>of</strong><br />

Medicine, Los Angeles, CA, 12 UCSF-Box 0500, San Francisco, CA,<br />

13<br />

Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma City, OK<br />

5:00 PM<br />

2146. Targeted Resequencing in Systemic Lupus Erythematosus<br />

Genetic Risk Loci: Initial Results from the REVEAL<br />

(Resequencing Variants Enhancing Autoimmunity and Lupus)<br />

Resource.<br />

Patrick M. Gaffney 1 , Graham Wiley 2 , Jennifer A. Kelly 2 , Kenneth<br />

M. Kaufman 2 , John B. Harley 3 , Ekta Rai 4 and Edward K.<br />

Wakeland 4 , 1 Oklahoma Medical Research Foundation, Oklahoma<br />

City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma<br />

City, OK, 3 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma City, OK, 4 University<br />

<strong>of</strong> Texas Southwestern Medical Center, Dallas, TX<br />

5:15 PM<br />

2147. Identification <strong>of</strong> a Novel Systemic Lupus Erythematosus<br />

Susceptibility Locus at 11p13 near CD44 in a Multi-Ethnic Study.<br />

Christopher J. Lessard 3 , Indra Adrianto 1 , Jennifer A. Kelly 1 ,<br />

Kenneth M. Kaufman 1 , Marta E. Alarcon-Riquelme for the<br />

BIOLUPUS Network 2 , Juan-Manuel Anaya 4 , Sang-Cheol Bae 10 ,<br />

Elizabeth E. Brown for PROFILE 6 , Lindsey A. Criswell 14 , Jeffrey C.<br />

Edberg 8 , Barry I. Freedman 7 , Chaim O. Jacob 9 , Judith A. James 1 ,<br />

Robert P. Kimberly 8 , Javier Martin 13 , Joan T. Merrill 5 , Timothy<br />

B. Niewold 16 , Bernardo A. Pons-Estel 15 , Betty P. Tsao 12 , Timothy<br />

J. Vyse 11 , Courtney G. Montgomery 1 , John B. Harley 17 , R. Hal<br />

Sc<strong>of</strong>ield 1 , Patrick M. Gaffney 1 and Kathy L. Moser 1 , 1 Arthritis and<br />

Immunology Research Program, Oklahoma Medical Research<br />

Foundation, 2 Arthritis and Immunology Research Program,<br />

Oklahoma Medical Research Foundation and Center for<br />

Genomics and Oncological Research (GENyO), Granada, Spain,<br />

3<br />

Arthritis and Immunology Research Program, Oklahoma Medical<br />

Research Foundation and Department <strong>of</strong> Pathology, University<br />

<strong>of</strong> Oklahoma Health Sciences Center, Oklahoma City, OK, 4 Center<br />

for Autoimmune Diseases Research (CREA), Universidad del<br />

Rosario, Bogota, Columbia, 5 Clinical Pharmacology, Oklahoma<br />

Medical Research Foundation, 6 Department <strong>of</strong> Epidemiology,<br />

University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />

7<br />

Department <strong>of</strong> Internal Medicine, Wake Forest University<br />

Health Sciences, Winston-Salem, NC, 8 Department <strong>of</strong> Medicine,<br />

University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />

9<br />

Department <strong>of</strong> Medicine, University <strong>of</strong> Southern California, Los<br />

Angeles, CA, 10 Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University<br />

Hospital for Rheumatic Diseases, Seoul, Korea, 11 Division <strong>of</strong><br />

Medicine, Imperial <strong>College</strong> <strong>of</strong> London, London, UK, 12 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Medicine, University <strong>of</strong> California<br />

Los Angeles, Los Angeles, CA, 13 Instituto de Parasitologia y<br />

Biomedicina Lopez-Neyra, Consejo Superior de Investigaciones<br />

Cientificas (CSIC), Granada, Spain, 14 Rosalind Russell Medical<br />

Research Center for Arthritis, University <strong>of</strong> California San<br />

Francisco, 15 Sanatorio Parque, Rosario, Argentina, 16 Section<br />

<strong>of</strong> <strong>Rheumatology</strong> and Gwen Knapp Center for Lupus and<br />

Immunology Research, University <strong>of</strong> Chicago, 17 US Department<br />

<strong>of</strong> Veterans Affairs Medical Center, Department <strong>of</strong> Medicine,<br />

University <strong>of</strong> Oklahoma Health Sciences Center, and Cincinnati<br />

Children’s Hospital Medical Center<br />

5:30 PM<br />

2148. Study <strong>of</strong> Systemic Lupus Erythematosus Susceptibility<br />

Genes in a Hispanic Population: Identification <strong>of</strong> Six New<br />

Candidate Susceptibility Loci.<br />

Elena Sanchez-Rodriguez 1 , Kenneth M. Kaufman 3 , Jennifer<br />

A. Kelly 1 , Adrienne H. Williams 11 , Paula S. Ramos 11 , Astrid<br />

Rasmussen 1 , Chaim O. Jacob 9 , Patrick M. Gaffney 1 , Kathy<br />

2010 Program Book 123<br />

wednesday


wednesday<br />

L. Moser 1 , Betty P. Tsao 7 , Lindsey A. Criswell 8 , Robert P.<br />

Kimberly 6 , Timothy J. Vyse 4 , Carl D. Langefeld 11 , John B.<br />

Harley 10 , Bernardo Pons-Estel 5 , Marta E. Alarcon-Riquelme 2 and<br />

SLEGEN International Consortium, 1 Arthritis and Immunology<br />

Program, Oklahoma Medical Research Foundation, Oklahoma<br />

City, OK, 2 Arthritis and Immunology Program, Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK and Center<br />

for Genomics and Oncological Research (GENyO), Granada,<br />

Spain, 3 Arthritis and Immunology Program, Oklahoma Medical<br />

Research Foundation, Oklahoma City, OK and US Department <strong>of</strong><br />

Veterans Affairs Medical Center, Oklahoma City, OK, 4 Imperial<br />

<strong>College</strong> London, Hammersmith Hospital, London, UK, 5 Sanatorio<br />

Parque, Rosario, Argentina, 6 University <strong>of</strong> Alabama, Birmingham,<br />

AL, 7 University <strong>of</strong> California, Los Angeles, CA, 8 University <strong>of</strong><br />

California, San Francisco, CA, 9 University <strong>of</strong> Southern California,<br />

Los Angeles, CA, 10 US Department <strong>of</strong> Veterans Affairs Medical<br />

Center, Oklahoma City, OK and University <strong>of</strong> Oklahoma Health<br />

Sciences Center, Oklahoma City, OK, 11 Wake Forest University<br />

Health Sciences, NC<br />

5:45 PM<br />

2149. Peripheral Blood Expression Signatures Reflect Current<br />

Lupus Activity and Likelihood <strong>of</strong> Future Flare.<br />

Carolyn Meyer 4 , Jason W. Bauer 4 , Thearith Koeuth 4 , Joseph<br />

Wilson 4 , Michelle A. Petri 1 , Peter K. Gregersen 3 , Timothy W.<br />

Behrens 2 and Emily C. Baechler 4 , 1 Timonium, MD, 2 Genentech<br />

Inc, South San Francisco, CA, 3 The Feinstein Institute for Medical<br />

Research, Manhasset, Manhasset, NY, 4 University <strong>of</strong> Minnesota<br />

Department <strong>of</strong> Medicine, Minneapolis, MN<br />

A404<br />

Metabolic and Crystal Arthropathies - Pathogenesis,<br />

Prevalence, Imaging, and New Therapy<br />

Moderators: Frederic P. Liote, MD, PhD; Hopital Lariboisiere;<br />

Paris, France<br />

George Nuki, MB; Western General Hospital; Edinburgh, United<br />

Kingdom<br />

4:30 PM<br />

2150. The NALP3 Inflammasome Is Activated by Sodium<br />

Overload and Water Influx in Gouty Arthritis.<br />

Christine Schorn 1 , Benjamin Frey 2 , Christina Janko 1 , Georg<br />

Schett 3 and Martin Herrmann 1 , 1 Department <strong>of</strong> Internal<br />

Medicine III and Institute for Clinical Immunology, University<br />

<strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany, 2 Department <strong>of</strong><br />

Radiation Oncology, Friedrich-Alexander University <strong>of</strong> Erlangen-<br />

Nuremberg, Erlangen, Germany, 3 Friedrich Alexander Univ,<br />

Erlangen, Germany<br />

4:45 PM<br />

2151. Octacalcium Phosphate (OCP) Crystals Induce Synovial<br />

Inflammation and Cartilage.<br />

Nathalie Busso 1 , Véronique Chobaz 3 , Nathaliane Bagnoud 3 , Peter<br />

Van Lent 5 , Christelle Nguyen 4 , Frédéric Lioté 4 , Alexander So 2<br />

and Hang-Korng Ea 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, DAL CHUV,<br />

Lausanne, Switzerland, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, DAL,<br />

CHUV, Lausanne, Switzerland, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

DAL, CHUV, Lausanne, Switzerland, 4 INSERM U606, Hospital<br />

Lariboisière, University Paris VII, Paris, France, 5 Radboud<br />

University Nijmegen Medical Centre, Nijmegen, The Netherlands<br />

5:00 PM<br />

2152. Quantitative Documentation <strong>of</strong> Tophus Volume Change<br />

Using Dual Energy Computed Tomography Scans.<br />

Mohammed Abufayyah 3 , Savvas Nicolaou 3 , Arash Eftekhari 3 ,<br />

Graham Reid 3 , Kamran Shojania 2 , Steven Co 3 and Hyon K. Choi 1 ,<br />

1<br />

Boston University School <strong>of</strong> Medicine, Vancouver, BC, Canada,<br />

2<br />

Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada, 3 University <strong>of</strong><br />

British Columbia, Vancouver, BC, Canada<br />

5:15 PM<br />

2153. Lead and Gout – Going, Going…Not Gone!<br />

Eswar Krishnan 2 , Bharathi Lingala 3 , James F. Fries 1 and Vivek<br />

Bhalla 3 , 1 Stanford Univ Medical Ctr, Palo Alto, CA, 2 Stanford<br />

University, Palo Alto, CA, 3 Stanford University<br />

5:30 PM<br />

2154. Increasing Gout Prevalence in the US over the Last Two<br />

Decades: The National Health and Nutrition Examination<br />

Survey (NHANES).<br />

Yanyan Zhu 1 , Bhavik Pandya 2 and Hyon Choi 1 , 1 Boston University<br />

<strong>of</strong> School <strong>of</strong> Medicine, Boston, MA, 2 Takeda Pharmaceuticals<br />

International, Inc, Deerfield, IL<br />

5:45 PM<br />

2155. Independent Impact <strong>of</strong> Hyperuricemia on the Future Risk<br />

<strong>of</strong> Hypertension: A Systematic Review and Meta-Analysis.<br />

Peter C. Grayson 1 , Seo Young Kim 3 , Michael P. LaValley 2 and<br />

Hyon K. Choi 4 , 1 Boston University School <strong>of</strong> Medicine, 2 Boston<br />

University School <strong>of</strong> Public Health, Boston, MA, 3 Brigham &<br />

Women’s Hospital, Boston, MA, 4 Univ <strong>of</strong> British Columbia,<br />

Vancouver, BC, Canada<br />

A410<br />

Osteoporosis and Metabolic Bone Disease: Clinical<br />

Aspects and Pathogenesis<br />

Moderators: Berna Goker, MD; Gazi University Medical School;<br />

Ankara, Turkey<br />

Nancy E. Lane, MD; University <strong>of</strong> California at Davis;<br />

Hillsborough, CA<br />

4:30 PM<br />

2156. Effectiveness <strong>of</strong> Zoledronic Acid in the Prevention and<br />

Treatment <strong>of</strong> Glucocorticoid-Induced Osteoporosis in Men and<br />

Premenopausal Women.<br />

K. Saag 5 , C. Roux 2 , J.-P. Devogelaer 3 , C.-S. Lau 6 , J.-Y. Reginster 7 ,<br />

C. Bucci-Rechtweg 1 , G. Su 1 , P. N. Sambrook 8 and D. M. Reid 4 ,<br />

1<br />

Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2 Paris-<br />

Descartes University, Paris, France, 3 Universite Catholique de<br />

Louvain, Brussels, Belgium, 4 University <strong>of</strong> Aberdeen, Aberdeen,<br />

UK, 5 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />

6<br />

University <strong>of</strong> Dundee, Dundee, UK, 7 University <strong>of</strong> Liege, Liege,<br />

Belgium, 8 University <strong>of</strong> Sydney, Sydney, NSW, Australia<br />

4:45 PM<br />

2157. Long-Term Denosumab Treatment <strong>of</strong> Postmenopausal<br />

Women with Osteoporosis: Results from the First Year<br />

Extension Study <strong>of</strong> the FREEDOM Trial.<br />

Roland Chapurlat 6 , Socrates Papapoulos 11 , Henry G. Bone 12 ,<br />

Maria L. Brandi 16 , Jacques Brown 10 , Edward Czerwinski 9 , Nadia<br />

S. Daizadeh 1 , Andreas Grauer 1 , Christine Haller 2 , Marc-Antoine<br />

Krieg 4 , Cesar Libanati 3 , Zulema Man 5 , Dan Mellstrom 13 , Sebastiao<br />

Radominski 7 , Jean-Yves Reginster 17 , Heinrich Resch 15 , Jose A.<br />

Roman Ivorra 8 and Steven R. Cummings 14 , 1 Amgen Inc, Thousand<br />

124<br />

2010 Program Book


Oaks, CA, 2 Amgen Inc., San Francisco, CA, 3 Amgen Inc., Thousand<br />

Oaks, CA, 4 Centre Hospitalier Universitaire Vaudois, Lusanne,<br />

Switzerland, 5 Centro TIEMPO, Buenos Aires, Argentina, 6 Hopital<br />

E. Herriot, Lyon, France, 7 Hospital de Clinicas da Universidade<br />

Federal do Parana, Curitiba, Brazil, 8 Jefe Servicio Reumatologia,<br />

Valencia, Spain, 9 Krakowskie Centrum Medyczne, Krakow,<br />

Poland, 10 Laval University Department <strong>of</strong> Medicine, Quebec,<br />

QC, Canada, 11 Leiden University Medical Center, Leiden, The<br />

Netherlands, 12 Michigan Bone and Mineral Clinic, PC, Detroit,<br />

MI, 13 Osteoporosis Clinic, Center for Bone Research at the<br />

Sahlgrenska, Goteborg, Sweden, 14 SF Coordinating Center, San<br />

Francisco, CA, 15 St. Vincent Hospital Medical University, Vienna,<br />

Austria, 16 University <strong>of</strong> Florence, Florence, Italy, 17 University <strong>of</strong><br />

Leige, Leige, Belgium<br />

5:00 PM<br />

2158. IL-3 Inhibits Osteoclast Differentiation by Inducing <strong>of</strong> ID<br />

Expression.<br />

Chang Hoon Lee 5 , Myeung Su Lee 6 , Yun Kyung Hong 3 , Jin-<br />

Jeong Choi 2 , Min-Ho Whang 4 , Han-Bok Kwak 1 and Jae Min<br />

Oh 1 , 1 Anatomy, Wonkwang University, Iksan, Korea, Republic<br />

<strong>of</strong>, 2 <strong>Rheumatology</strong>, Cha University Hospital, Sungnam,<br />

3<br />

<strong>Rheumatology</strong>, Chonbuk University Hospital, 4 <strong>Rheumatology</strong>,<br />

Presbyterian Medical Center, Chonju, 5 <strong>Rheumatology</strong>,<br />

Wonkwang University Hospital, Iksan, Jeollabukdo, Republic <strong>of</strong><br />

Korea, 6 <strong>Rheumatology</strong>, Wonkwang University Hospital<br />

5:15 PM<br />

2159. Raloxifene for Prevention <strong>of</strong> Glucocorticoid-Induced<br />

Bone Loss: A 12-Month Randomized Double-Placebo-<br />

Controlled Trial.<br />

Chi Chiu Mok, Chi Hung To, Ling Yin Ho, Ka Lung Yu and Kwok<br />

Man Ma, Tuen Mun Hospital<br />

5:30 PM<br />

2160. Unsuppressed Parathyroid Hormone in Patients with<br />

Autoimmune Rheumatic Diseases: Implications for Vitamin D<br />

Supplementation.<br />

Pier Paolo Sainaghi 1 , Mattia Bellan 2 , Giuseppina Antonini 3 ,<br />

Giorgio Bellomo 3 and Mario Pirisi 1 , 1 Immuno-<strong>Rheumatology</strong><br />

Outpatient Unit, DMCS, “A. Avogadro” University and IRCAD<br />

(Interdisciplinary Reseach Center <strong>of</strong> Autoimmune Diseases),<br />

Novara, Novara, Italy, 2 Immuno-<strong>Rheumatology</strong> Outpatient Unit,<br />

DMCS, “A. Avogadro” University, Novara, Italy, 3 Laboratory <strong>of</strong><br />

Chemistry and Clinical Research, DSM, “A. Avogadro” University<br />

and “Maggiore della Carità” Hospital, Novara, Italy<br />

5:45 PM<br />

2161. Bone Remodeling in Postmenopausal Women Who<br />

Discontinued Denosumab Treatment.<br />

Rachel B. Wagman 1 , Jaques Brown 4 , David W. Dempster 2 , Beiying<br />

Ding 1 , Ricardo Dent 1 , Javier San Martin 1 , Andreas Grauer 1 and<br />

Jose R. Zanchetta 3 , 1 Amgen Inc., Thousand Oaks, CA, 2 Helen<br />

Hayes Hospital, West Haverstraw, NY, 3 Instituto de Ivestigaciones<br />

Metabolicas, Buenos Aires, Argentina, 4 Laval University<br />

Department <strong>of</strong> Medicine, Quebec, QC, Canada<br />

A314<br />

Rheumatoid Arthritis - Clinical Aspects: RA and<br />

Cardiovascular Disease III<br />

Moderators: Paul F. Dellaripa, MD; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Deborah P. Symmons, MD; University <strong>of</strong> Manchester;<br />

Manchester, United Kingdom<br />

4:30 PM<br />

2162. Longitudinal Predictors <strong>of</strong> Progression <strong>of</strong> Subclinical<br />

Carotid Atherosclerosis in Rheumatoid Arthritis.<br />

Jon T. Giles 3 , Wendy Post 5 , Roger S. Blumenthal 5 , Joseph Polak 6 ,<br />

Michelle A. Petri 1 , Allan C. Gelber 2 , Moyses Szklo 5 and Joan M.<br />

Bathon 4 , 1 Timonium, MD, 2 Baltimore, MD, 3 Johns Hopkins Univ,<br />

Baltimore, MD, 4 Johns Hopkins University, Baltimore, MD, 5 Johns<br />

Hopkins University, 6 Tufts-New England Medical Center<br />

4:45 PM<br />

2163. At What Age Is Carotid Ultrasound Most Effective in<br />

Predicting Cardiovascular Events and Mortality in Rheumatoid<br />

Arthritis?<br />

Inmaculada Del Rincon 3 , Mrisa Sahai 4 , Daniel H. O’Leary 2 , Daniel<br />

F. Battafarano 1 and Agustin Escalante 3 , 1 Brooke Army Medical<br />

Ctr, San Antonio, TX, 2 Tufts School <strong>of</strong> Medicine, 3 UTHSCSA, San<br />

Antonio, TX, 4 UTHSCSA<br />

5:00 PM<br />

2164. Higher Prevalence, Extent and Severity <strong>of</strong> “Vulnerable”<br />

Coronary Plaque in Asymptomatic Patients with Rheumatoid<br />

Arthritis (RA).<br />

George A. Karpouzas 1 , Naser Ahmadi 2 , Tae-Young Choi 2 ,<br />

Fereshteh Hajsadeghi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 ,<br />

1<br />

Harbor-UCLA, Long Beach, CA, 2 Harbor-UCLA<br />

5:15 PM<br />

2165. Anti-b2-Glycoprotein-1 (b2GP1) IgA Ab Are Highly<br />

Prevalent and Predict “Vulnerable” Coronary Plaque in<br />

Asymptomatic Patients with Rheumatoid Arthritis (RA).<br />

George A. Karpouzas 1 , Naser Ahmadi 2 , Tae-Young Choi 2 ,<br />

Fereshteh Hajsadeghi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 ,<br />

1<br />

Harbor-UCLA, Long Beach, CA, 2 Harbor-UCLA<br />

5:30 PM<br />

2166. Increased Epicardial and Thoracic Pre-Aortic Fat Depots<br />

Predict “Vulnerable” Coronary Plaque in Asymptomatic<br />

Patients with Rheumatoid Arthritis (RA).<br />

George A. Karpouzas 1 , Naser Ahmadi 2 , Fereshteh Hajsadeghi 2 ,<br />

Tae-Young Choi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 , 1 Harbor-<br />

UCLA, Long Beach, CA, 2 Harbor-UCLA<br />

5:45 PM<br />

2167. Citrullination Is Present in the Perivascular Interstitium<br />

<strong>of</strong> the Myocardium and Is Increased in Rheumatoid Arthritis<br />

Compared to Controls.<br />

Jon T. Giles 1 , Marc K. Halushka 4 , Fox-Talbot K. Mary 4 , Clifton<br />

O. Bingham 2 , Felipe Andrade 5 , Jin Kyun Park 3 , Antony Rosen 2 ,<br />

Justyna Fert-Bober 4 , Jennifer van Eyk 4 and Joan M. Bathon 2 ,<br />

1<br />

Johns Hopkins Univ, Baltimore, MD, 2 Johns Hopkins University,<br />

Baltimore, MD, 3 Johns Hopkins University, Baltimore, MD,<br />

4<br />

Johns Hopkins University, 5 Johns Hopkins University School <strong>of</strong><br />

Medicine, Baltimore, MD<br />

B406<br />

Rheumatoid Arthritis Treatment - Small Molecules,<br />

Biologics and Gene Therapy: Novel Compounds III<br />

Moderators: Jeffrey D. Greenberg, MD, MPH; New York<br />

University Hospital for Joint Disease; Millburn, NJ<br />

Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />

wednesday<br />

2010 Program Book 125


wednesday<br />

4:30 PM<br />

2168. ALD518 (BMS945429), a High Affinity Monoclonal<br />

Antibody Directed Against Interleukin-6, Reduces Disease<br />

Activity and Achieves Remission in Patients with Rheumatoid<br />

Arthritis and Inadequate Response to Methotrexate.<br />

Philip Mease 5 , Vibeke Strand 4 , Levan Shalamberidze 6 ,<br />

Aleksandar Dimic 3 , Richard Aranda 2 and Jeff Smith 1 , 1 Alder<br />

Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb,<br />

Princeton, NJ, 3 Institute <strong>of</strong> Rehabilitation and Treatment, Niska<br />

Banja, Serbia, 4 Stanford University, Palo Alto, CA, 5 Swedish<br />

Medical Center and University <strong>of</strong> Washington, Seattle, WA, 6 V.<br />

Tsitlanadze Scientific Practical Centre <strong>of</strong> <strong>Rheumatology</strong>, Tbilisi,<br />

Georgia<br />

4:45 PM<br />

2169. Efficacy and Safety <strong>of</strong> Ocrelizumab in Patients with Active<br />

Rheumatoid Arthritis Who Have an Inadequate Response to at<br />

Least One TNF Inhibitor: Results from the Phase III SCRIPT Trial.<br />

Paul P. Tak 1 , Philip J. Mease 7 , Mark C. Genovese 8 , Joel M.<br />

Kremer 9 , Boulos Haraoui 4 , Yoshiya Tanaka 10 , Clifton O. Bingham 5 ,<br />

Ali Ashrafzadeh 2 , Helen Travers 6 , Simon Safa-Leathers 6 , Sanjeev<br />

Kumar 6 and Wolfgang Dummer 3 , 1 Academic Med Ctr/Univ <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 2 Genentech, San<br />

Francisco, CA, 3 Genentech, 4 Institut de Rhumatologie, Montreal,<br />

QC, Canada, 5 Johns Hopkins University, Baltimore, MD, 6 Roche,<br />

7<br />

Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 8 Stanford Univ,<br />

Sunnyvale, CA, 9 The Center for <strong>Rheumatology</strong>, Albany, NY, 10 U<br />

Occupa & Environ Hlth, Kitakyushu, Japan<br />

5:00 PM<br />

2170. Safety, Tolerability, Pharmacokinetics,<br />

Pharmacodynamics and Efficacy <strong>of</strong> the Monoclonal Antibody<br />

ASK8007 Blocking Osteopontin in Patients with Rheumatoid<br />

Arthritis in a Randomized, Placebo-Controlled, Combined Firstin-Man<br />

and Pro<strong>of</strong>-<strong>of</strong>-Concept Study.<br />

M. Boumans 5 , J. Houbiers 1 , P. Verschueren 10 , A. Ishikura 2 , R.<br />

Westhovens 10 , E. Brouwer 4 , B. Rojkovich 8 , S. Kelly 3 , M. Den<br />

Adel 2 , J. Isaacs 7 , J. Gomez-Reino 9 , G. Holtkamp 2 , D. Gerlag 6 and<br />

P. Tak 6 , 1 Astellas Pharma Global Development, the Netherlands<br />

and Japan, Leiderdorp, The Netherlands, 2 Astellas Pharma<br />

Global Development, the Netherlands and Japan, 3 Centre for<br />

Experimental Medicine and <strong>Rheumatology</strong>, Queen Mary’s School<br />

<strong>of</strong> Medicine, London, 4 Department <strong>Rheumatology</strong>, University<br />

Medical Center Groningen, Groningen, The Netherlands,<br />

5<br />

Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />

Medical Center / University <strong>of</strong> Amsterdam, Amsterdam,<br />

Noord-Holland, The Netherlands, 6 Division <strong>of</strong> Clinical<br />

Immunology and <strong>Rheumatology</strong>, Academic Medical Center<br />

/ University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

7<br />

Musculoskeletal Research Group, Institute <strong>of</strong> Cellular Medicine,<br />

Newcastle University, Newcastle upon Tyne, United Kingdom,<br />

8<br />

<strong>Rheumatology</strong>, Buda Charity Hospital, Budapest, Hungary,<br />

9<br />

<strong>Rheumatology</strong>, Hospital Clinico Universitario, Santiago de<br />

Compostela, Spain, Santiago, Spain, 10 University Hospital Leuven,<br />

Leuven, Belgium<br />

5:15 PM<br />

2171. Tasocitinib (CP-690,550) Appears To Be Effective<br />

and Tolerated When Administered Either as Long-Term<br />

Monotherapy or on Background Methotrexate in Patients with<br />

Rheumatoid Arthritis.<br />

Carol A. Connell 1 , Richard Riese 2 , Susan Wood 2 , John Bradley 2<br />

and Samuel H. Zwillich 2 , 1Pfizer Inc, New London, CT, 2 Pfizer Inc.<br />

5:30 PM<br />

2172. A Randomized Dose-Ranging, Placebo-Controlled Study<br />

<strong>of</strong> INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects<br />

with Active Rheumatoid Arthritis.<br />

Maria W. Greenwald 1 , Rosanne Fidelus-Gort 4 , Rich Levy 4 , Jinjin<br />

Liang 4 , Kris Vaddi 4 , William V. Williams 3 , Robert Newton 4 ,<br />

Swamy Yeleswaram 4 , Robert Flores 4 , Edward McKeever 4 , James<br />

Rodgers 4 , Stacey Shepard 4 , Pierre-Yves Berclaz 2 , Chin Hyok Lee 2<br />

and Monica E. Luchi 3 , 1 Desert Medical, Palm Desert, CA, 2 Eli<br />

Lilly & Company, 3 Incyte Corporation, Wilmington, DE, 4 Incyte<br />

Corporation<br />

5:45 PM<br />

2173. A Large, Phase IIIb Non-Inferiority Trial <strong>of</strong> Subcutaneous<br />

(SC) Abatacept Compared with Intravenous (IV) Abatacept, in<br />

Patients with Rheumatoid Arthritis (RA).<br />

Mark C. Genovese 13 , Jose Arturo Covarrubias 3 , Gustavo Leon 5 ,<br />

Eduardo F. Mysler 8 , Mauro W. Keiserman 10 , Robert M. Valente 9 ,<br />

Peter Nash 15 , J. Abraham Simon 2 , Wieslawa Porawska 11 , Jane H.<br />

Box 14 , Clarence W. Leggerton 6 , Evgeny Nasonov 7 , Patrick Durez 4 ,<br />

Richard Aranda 1 , Ramesh Pappu 1 , Ingrid Delaet 1 , Julie Teng 1 and<br />

Rieke Alten 12 , 1 Bristol-Myers Squibb Co, Princeton, NJ, 2 Centro<br />

de Especialidades Médicas, Merida, Mexico, 3 Centro Medico de<br />

Las Americas, Merida, Yucatan, Mexico, 4 Cliniques Universitaires<br />

Saint-Luc, Université Catholique de Louvain, Brussels, Belgium,<br />

5<br />

De Ginecologia Y Reproduccion, Lima, Peru, 6 Department <strong>of</strong><br />

Medicine, Medical University <strong>of</strong> South Carolina, Charleston,<br />

SC, 7 Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow, Russia, 8 Organización<br />

Médica de Investigación, Buenos Aires, Argentina, 9 Physician<br />

Research Collaboration, Lincoln, Lincoln, NE, 10 Pontificial Catholic<br />

University, School <strong>of</strong> Medicine, Porto Alegre, Brazil, 11 Poznanski<br />

Osrodek Medyczny Novamed, Ponzan, Poland, 12 Schlosspark-<br />

Klinik, Charité, University Medicine Berlin, Department <strong>of</strong><br />

Internal Medicine II <strong>Rheumatology</strong>, Berlin, Germany, 13 Stanford<br />

University, Palo Alto, Sunnyvale, CA, 14 The Arthritis Clinic &<br />

Carolina Bone & Joint, Charlotte, NC, 15 University <strong>of</strong> Queensland,<br />

Brisbane, Australia<br />

A406<br />

Sjögren’s Syndrome<br />

Moderators: Alan N. Baer, MD; Johns Hopkins University;<br />

Baltimore, MD<br />

Athanasios G. Tzioufas, MD; Medical School-University <strong>of</strong><br />

Athens; Athens, Greece<br />

4:30 PM<br />

2174. Receptor-Mediated Small Interfering RNA Delivery in<br />

Sjögren’s Syndrome.<br />

Kaleb M. Pauley, Adrienne E. Gauna and Seunghee Cha,<br />

University <strong>of</strong> Florida, Gainesville, FL<br />

4:45 PM<br />

2175. Structure and Antigenicity <strong>of</strong> the Ro/La RNP Particle.<br />

hY1 RNA Differentiates the Recognition <strong>of</strong> Epitopes in Systemic<br />

Lupus Erythematosus and Sjögren’s Syndrome.<br />

John G. Routsias1, Nikos C. Kyriakidis 1 , Stathis Kotsakis 1 and<br />

Athanasios G. Tzioufas 2 , 1 Department <strong>of</strong> Pathophysiology,<br />

Medical School, University <strong>of</strong> Athens, Athens, Greece, 2 Medical<br />

School-Univ <strong>of</strong> Athens, Athens, Greece<br />

126<br />

2010 Program Book


5:00 PM<br />

2176. A Role <strong>of</strong> Autoimmune Response to M3 Muscarinic<br />

Acethylcholine Receptor in the Pathogenesis <strong>of</strong> Sjögren’s<br />

Syndrome Like Autoimmune Sialoadenitis.<br />

Mana Iizuka 2 , Hiroto Tsuboi 2 , Yumi Nakamura 2 , Naomi Matsuo 2 ,<br />

Isao Matsumoto 2 and Takayuki Sumida 1 , 1 Univ <strong>of</strong> Tsukuba/Inst<br />

Clin Med, Tsukuba City, Japan, 2 Univ <strong>of</strong> Tsukuba/Inst Clin Med<br />

5:15 PM<br />

2177. Δ4BAFF, an Alternate-Splice Is<strong>of</strong>orm That Acts as a<br />

Transcription Factor To Enhance BAFF Production in Primary<br />

Sjögren’s Syndrome.<br />

Jacques-Olivier Pers, Gabriel J. Tobon, Laëtitia Le Pottier and<br />

Pierre Youinou, Brest University, Brest, France<br />

5:30 PM<br />

2178. Local TACI-Ig Gene Therapy <strong>of</strong> the Salivary Gland <strong>of</strong> NOD<br />

Mice Reduces Auto-Immune Inflammation by Affecting the B<br />

Cell Compartment.<br />

Nienke Roescher 2 , Jelle L. Vosters 2 , Marco Guadagnoli 2 , Jan<br />

P. Medema 2 , Gabor G. Illei 4 , John A. Chiorini 3 and Paul P.<br />

Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />

The Netherlands, 2 Academic Medical Center-University <strong>of</strong><br />

Amsterdam, 3 National Insitutes <strong>of</strong> Health-National Institute<br />

<strong>of</strong> Dental and Crani<strong>of</strong>acial Research, 4 NIDCR, NIH #10 1N114,<br />

Bethesda, MD<br />

5:45 PM<br />

2179. EBV-mir-Bart13 Downregulates Stim1, a Protein Involved<br />

in Calcium Signaling, in Human Salivary Gland Cells and May<br />

Contribute to the Pathogenesis <strong>of</strong> Sjögren’s Syndrome.<br />

Alessia Gallo 1 , Mayank Tandon 1 , Gabor G. Illei 2 and Ilias Alevizos 1 ,<br />

1<br />

National Insitutes <strong>of</strong> Health-National Institute <strong>of</strong> Dental and<br />

Crani<strong>of</strong>acial Research, 2 NIDCR, NIH #10 1N114, Bethesda, MD<br />

A311<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical<br />

Aspects and Treatment - Biomarkers II<br />

Moderators: Daniel O. Clegg, MD; University <strong>of</strong> Utah Medical<br />

Center; Salt Lake City, UT<br />

Robert Landewe, MD; University Hospital Maastricht;<br />

Maastricht, The Netherlands<br />

4:30 PM<br />

2180. Striking Prevalence <strong>of</strong> Axial Spondyloarthritis in Primary<br />

Care Patients with Chronic Low Back Pain; a Cross-Sectional<br />

Study.<br />

Lonneke van Hoeven 3 , Jolanda Luime 1 , Huub Han 2 and Angelique<br />

Weel 4 , 1 Erasmus Medical Centre, 2 Maasstadziekenhuis,<br />

3<br />

Maasstadziekenhuis / Erasmus Medical Centre, Rotterdam, The<br />

Netherlands, 4 Maasstadziekenhuis Rotterdam, Rotterdam, The<br />

Netherlands<br />

4:45 PM<br />

2181. Screening for Axial Spondyloarthritis in a Primary Care:<br />

Comparison <strong>of</strong> Two Strategies in a Multicenter Prospective<br />

Study.<br />

Denis Poddubnyy 1 , Janis Vahldiek 1 , Inge Spiller 1 , Beate Buss 1 ,<br />

Martin Rudwaleit 1 and Joachim Sieper 2 , 1 Charité - Campus<br />

Benjamin Franklin, Berlin, Germany, 2 Charite Campus Benjamin<br />

Frankl, Berlin, Germany<br />

5:00 PM<br />

2182. Do the New EULAR/ACR Rheumatoid Arthritis<br />

Classification Criteria Identify Early Psoriatic Arthritis Patients?<br />

Laura C. Coates 2 , Philip G. Conaghan 2 , Paul Emery 2 , Michael J.<br />

Green 3 , Gamal Ibrahim 1 , Helen MakIver 1 and Philip S. Helliwell 2 ,<br />

1<br />

Bradford Hospitals NHS Trust, UK, Bradford, United Kingdom,<br />

2<br />

LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds,<br />

Leeds, UK, 3 York Hospitals NHS Trust, York, UK<br />

5:15 PM<br />

2183. The CASPAR Criteria Can Be Used To Identify Early<br />

Psoriatic Arthritis.<br />

Laura C. Coates 2 , Philip G. Conaghan 3 , Paul Emery 3 , Michael J.<br />

Green 4 , Gamal Ibrahim 1 , Helen MakIver 1 and Philip S. Helliwell 3 ,<br />

1<br />

Bradford Hospitals NHS Trust, UK, Bradford, United Kingdom,<br />

2<br />

LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds,<br />

Leeds, United Kingdom, 3 LIMM, Section <strong>of</strong> Musculoskeletal<br />

Disease, University <strong>of</strong> Leeds, UK, 4 York Hospital NHS Trust, York,<br />

UK<br />

5:30 PM<br />

2184. Supppression <strong>of</strong> Both DKK-1 and SOST in a Mouse<br />

Model <strong>of</strong> Ankylosing Spondylitis Implicates the WNT-Signalling<br />

Pathway in the Linkage <strong>of</strong> Inflammation and Bony Ankylosis in<br />

Spondyloarthritis.<br />

Gethin P. Thomas 2 , Ran Duan 3 , Allison Pettit 4 , Tibor Glant 1 and<br />

Matthew A. Brown 2 , 1 Rush University Medical Center, 2 The<br />

University <strong>of</strong> Queensland Diamantina Institute, 3 The University<br />

<strong>of</strong> Queensland Diamantina Institute, 4 University <strong>of</strong> Queensland<br />

Centre for Clinical Research<br />

5:45 PM<br />

2185. Genetic and Clinical Correlates in African <strong>American</strong>s with<br />

Ankylosing Spondylitis.<br />

Shervin Assassi 4 , Julie T. Dang 3 , Michael M. Ward 2 , Joel D.<br />

Taurog 6 , Michael H. Weisman 1 and John D. Reveille 5 , 1 Cedars-<br />

Sinai Medical Center, Los Angeles, CA, 2 NIH, NIAMS, IRP,<br />

Bethesda, MD, 3 Univ <strong>of</strong> Texas Health Science Center at Houston,<br />

4<br />

Univ <strong>of</strong> Texas Health Science Center at Houston, Houston, TX,<br />

5<br />

Univ Texas Health Sci Ctr, Houston, TX, 6 U-Texas SW Med Ctr,<br />

Dallas, TX<br />

A315<br />

Systemic Lupus Erythematosus - Animal Models<br />

Moderators: Philip L. Cohen, MD; Temple University;<br />

Philadelphia, PA<br />

Jane E. Salmon, MD; Hospital for Special Surgery; New York, NY<br />

4:30 PM<br />

2186. Neutrophil Gelatinase Associated Lipocalin (NGAL) and<br />

Its Role in the Pathogenesis <strong>of</strong> Nephritis Induced by Pathogenic<br />

Antibodies.<br />

Rahul Pawar 4 , Simona Gindea 4 , Arlene T. Tieng 3 , MIlena<br />

Pitashny 4 , Leal Herlitz 5 , Benjamin E. Levine 2 , Thorsten Berger 6 ,<br />

Tak W. Mak 6 and Chaim Putterman 1 , 1 Albert Einstein <strong>College</strong><br />

<strong>of</strong> Med, Bronx, NY, 2 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine,<br />

Woodmere, NY, 3 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, Bronx, NY,<br />

4<br />

Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, 5 Columbia-Presbyterian<br />

School <strong>of</strong> Medicine, 6 The Campbell Family Institute for Breast<br />

Cancer Research, Toronto, ON, Canada<br />

wednesday<br />

2010 Program Book 127


wednesday<br />

4:45 PM<br />

2187. Dependence <strong>of</strong> IFNα-Exaggerated Immunopathology and<br />

Clinical Disease on B Cells and BAFF in SLE-Prone NZM 2328<br />

Mice.<br />

Noam Jacob 6 , Shunhua Guo 6 , Alexis Mathian 3 , Michael N. Koss 6 ,<br />

Simona Gindea 2 , Chaim Putterman 1 , Chaim O. Jacob 5 and William<br />

Stohl 4 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx, NY, 2 Albert<br />

Einstein <strong>College</strong> <strong>of</strong> Medicine, 3 Hôpital de la Pitié-Salpêtrière,<br />

4<br />

Univ Southern California, Los Angeles, CA, 5 University <strong>of</strong><br />

Southern California Keck School <strong>of</strong> Medicine, Los Angeles, CA,<br />

6University <strong>of</strong> Southern California Keck School <strong>of</strong> Medicine<br />

5:00 PM<br />

2188. IFNα Induced SLE in NZB/W Mice Is T Cell Dependent but<br />

Blockade <strong>of</strong> TFH Does Not Prevent Disease.<br />

Zheng Liu 1 , Ramalingam Bethunaickan 1 , Weiqing Huang 1 and<br />

Anne Davidson 2 , 1 Feinstein Institute, 2 Feinstein Institute for<br />

Medical Research, Manhasset, NY<br />

5:15 PM<br />

2189. Type I IFN-Dependent CD86high Marginal Zone-Precursor<br />

B Cells Are Potent T Cell Costimulators in the BXD2 Mouse<br />

Model <strong>of</strong> Lupus.<br />

John S. Wang 3 , Qi Wu 3 , PingAr Yang 1 , Hao Li 1 , Jun Li 1 , John D.<br />

Mountz 2 and Hui-Chen Hsu 1 , 1 Univ Alabama at Birmingham,<br />

2<br />

Univ Alabama at Birmingham and VA Medical Center,<br />

Birmingham, AL, 3 Univ <strong>of</strong> Alabama at Birmingham<br />

5:30 PM<br />

2190. Identification <strong>of</strong> a Genetic Locus on New Zealand<br />

Black Chromosome 1 Congenic Mice That Leads to Increased<br />

Generation <strong>of</strong> T Follicular Helper and TH17 Cells.<br />

Nafiseh Talaei 4 , Yui-Ho Cheung 3 , Carolina Landolt-Marticorena 4 ,<br />

Babak Noamani 1 and Joan E. Wither 2 , 1 Toronto Western Research<br />

Institute, 2 University Health Network, Toronto, ON, Canada,<br />

3<br />

University <strong>of</strong> Toronto, 4 University <strong>of</strong> Toronto, Toronto, ON,<br />

Canada<br />

5:45 PM<br />

2191. Histone Deacetylase 9 Acts as an Epigenetic Switch<br />

in Aberrant CD4 T Cell Plasticity and PPAR-g Regulation in<br />

Systemic Lupus Erythematosus.<br />

Nilamadhab Mishra 3 , Kailin Yan 5 , Qiang Cao 6 , Christopher M.<br />

Reilly 2 , Jennifer Cann 4 and Benjamin A. Garcia 1 , 1 Princeton<br />

University, 2 Virginia Polytechnic Institute and State University<br />

and Edward Via <strong>College</strong> <strong>of</strong> Osteopathic Medicine, 3 Wake Forest<br />

Univ Health Scienc, Winston-Salem, NC, 4 Wake Forest University<br />

School <strong>of</strong> Medicine, 5 Wake Forest Unv Health Sciences, 6 Wake<br />

Forest UnvHealth Sciences<br />

A412<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Clinical Aspects and Therapeutics II<br />

Moderators: Murray Baron, MD; Jewish General Hospital; McGill,<br />

Canada<br />

Eric Hachulla, MD, PhD; National Scleroderma Centre; Lille<br />

Cedex, France<br />

4:30 PM<br />

2192. Long-Term Benefit <strong>of</strong> Mycophenolate M<strong>of</strong>etil for<br />

Treatment <strong>of</strong> Diffuse Cutaneous Systemic Sclerosis.<br />

Elizabeth Le 3 , Fredrick M. Wigley 1 , Ami A. Shah 2 , Francesco Boin 2<br />

and Laura K. Hummers 2 , 1 Johns Hopkins University, Baltimore,<br />

MD, 2 Johns Hopkins University, Baltimore, MD, 3 Johns Hopkins<br />

University<br />

4:45 PM<br />

2193. Imatinib Mesylate (Gleevec) in the Treatment <strong>of</strong> Diffuse<br />

Cutaneous Systemic Sclerosis: Results <strong>of</strong> a One Year, Phase IIa,<br />

Single Arm, Open Label Clinical Trial.<br />

Robert F. Spiera 1 , Jessica K. Gordon 2 , Jamie Mersten 2 , Cynthia<br />

Magro 3 , Mansi Mehta 2 , Horatio Wildman 3 , Stacey Kloiber 2 ,<br />

Kyriakos A. Kirou 2 , Stephen Lyman 2 and Mary K. Crow 2 , 1 Hospital<br />

for Special Surgery, New York, NY, 2 Hospital for Special Surgery,<br />

3<br />

Weill-Cornell Medical <strong>College</strong><br />

5:00 PM<br />

2194. Serious Complications and Mortality among 158 Patients<br />

with Systemic Sclerosis (SSc) in the Scleroderma Lung Study<br />

(SLS) Followed for up to 9 Years.<br />

Daniel E. Furst 4 , Dinesh Khanna 3 , Philip J. Clements 5 , Keith<br />

Sullivan 1 and Donald P. Tashkin 2 , 1 Duke, Durham, NC, 2 UCLA,<br />

3<br />

University <strong>of</strong> California Los Angeles, Los Angeles, CA, 4 University<br />

<strong>of</strong> California Los Angeles Medical School, Los Angeles, CA,<br />

5<br />

University <strong>of</strong> California Los Angeles School <strong>of</strong> Medicine, Los<br />

Angeles, CA<br />

5:15 PM<br />

2195. Productivity at Home and Work Place in Scleroderma –<br />

Analysis from the UCLA Scleroderma Quality <strong>of</strong> Life Study.<br />

Manjit K. Singh, Philip J. Clements, Daniel Furst, Paul Maranian<br />

and Dinesh Khanna, UCLA, Los Angeles, CA<br />

5:30 PM<br />

2196. Results <strong>of</strong> the Delphi for EULAR/ACR Classification<br />

Criteria Working Group in Systemic Sclerosis.<br />

Jaap Fransen 4 , Sindhu R. Johnson 5 , Alan Tyndall 6 , Murray<br />

Baron 1 , Marco Matucci-Cerinic 8 , Frank van den Hoogen 2 ,<br />

Janet E. Pope 3 and Dinesh Khanna 7 , 1 Jewish General Hospital,<br />

Montreal, QC, Canada, 2 Sint Maartenskliniek, 3 St Joseph Health<br />

Care London, London, ON, Canada, 4 The Radboud University<br />

Nijmegen Medical Centre, 5 Toronto Western Hospital, Toronto,<br />

ON, Canada, 6 University <strong>of</strong> Basel, 7 University <strong>of</strong> California Los<br />

Angeles, Los Angeles, CA, 8 University <strong>of</strong> Florence, Firenze, Italy<br />

5:45 PM<br />

2197. Antinuclear Antibody Screening in Systemic Sclerosis.<br />

Donna Rose Swistowski 2 , Nicole Saddic 3 , Victoria K. Shanmugam 1<br />

and Virginia D. Steen 4 , 1 Georgetown University Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Immunology, and Allergy, Great Falls, VA,<br />

2<br />

Georgetown University Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology,<br />

and Allergy, Bethesda, MD, 3 Georgetown University Hospital<br />

Department <strong>of</strong> Medicine, 4 Georgetown University Medical<br />

Center, Washington, DC<br />

B408<br />

Vasculitis II<br />

Moderators: Paul A. Monach, MD; Boston University; Boston,<br />

MA<br />

Cornelia M. Weyand, MD, PhD; Stanford University School <strong>of</strong><br />

Medicine; Stanford, CA<br />

128<br />

2010 Program Book


4:30 PM<br />

2198. Association between Vascular Physical Examination<br />

Findings and Angiographically-Detected Arterial Lesions in<br />

Subjects with Large Vessel Vasculitis.<br />

Peter C. Grayson 4 , Gunnar Tomasson 3 , David Cuthbertson 11 ,<br />

Simon Carette 9 , Gary S. H<strong>of</strong>fman 6 , Nader A. Khalidi 10 , Carol A.<br />

Langford 5 , Carol McAlear 4 , Paul A. Monach 1 , Philip Seo 7 , Kenneth<br />

J. Warrington 8 , Steven R. Ytterberg 8 and Peter A. Merkel 2 ,<br />

1<br />

Boston University, Boston, MA, 2 Boston University School <strong>of</strong><br />

Medicine, West Newton, MA, 3 Boston University School <strong>of</strong><br />

Medicine, Boston, MA, 4 Boston University School <strong>of</strong> Medicine,<br />

5<br />

Cleveland Clinic Foundation, Cleveland, OH, 6 Cleveland Clinic<br />

Foundation, Pepper Pike, OH, 7 Johns Hopkins Bayview Medical<br />

Center, Baltimore, MD, 8 Mayo Clinic, Rochester, MN, 9 Toronto<br />

Western Hospital, Toronto, ON, Canada, 10 University <strong>of</strong> Hamilton,<br />

Hamilton, ON, Canada, 11 University <strong>of</strong> South Florida<br />

4:45 PM<br />

2199. Sex, Age, and Birth Cohort Effects on Incidence <strong>of</strong> Giant<br />

Cell Arteritis.<br />

Maureen Dubreuil 1 , Hyon K. Choi 2 , Yuqing Zhang 2 and Yanyan<br />

Zhu 2 , 1 Boston Medical Center, Boston, MA, 2 Boston University<br />

School <strong>of</strong> Medicine, Boston, MA<br />

5:00 PM<br />

2200. Identification <strong>of</strong> JAK1 as a Candidate Inflammatory<br />

Signalling Pathway by Genome-Wide Expression Pr<strong>of</strong>iling in<br />

Monocytes from Patients with Behcet’s Disease.<br />

Haner Direskeneli 3 , Joseph J. Boyle 1 , Filiz T. Ozdemir 3 , Vuslat<br />

Yilmaz 2 , Emel Eksioglu-Demiralp 3 , Dorian Haskard 1 and Guher<br />

Saruhan-Direskeneli 2 , 1 Cardiovascular Sciences Centre, Imperial<br />

<strong>College</strong>, London, United Kingdom, 2 Istanbul University, Istanbul<br />

Faculty <strong>of</strong> Medicine, Istanbul, Turkey, 3 Marmara University,<br />

School <strong>of</strong> Medicine, Istanbul, Turkey<br />

5:15 PM<br />

2201. A Randomized, Controlled, Multicenter Phase III Study<br />

<strong>of</strong> the Efficacy and Safety <strong>of</strong> Rituximab (RTX) Monotherapy<br />

Versus the Best Available Treatment in Patients with Mixed<br />

Cryoglobulinemia Syndrome.<br />

Salvatore De Vita 15 , Luca Quartuccio 15 , Miriam Isola 8 , Paola<br />

Masolini 16 , Stefania Sacco 15 , Ginevra De Marchi 15 , Cesare<br />

Mazzaro 6 , Patrizia Scaini 13 , Marco Lenzi 4 , Mauro Campanini 1 ,<br />

Salvatore Scarpato 21 , Antonio Tavoni 20 , Maurizio Pietrogrande 9 ,<br />

Clodoveo Ferri 19 , Maria Teresa Mascia 18 , Dario Roccatello 3 , Anna<br />

Linda Zignego 2 , Paolo Pioltelli 11 , Armando Gabrielli 12 , Davide<br />

Filippini 14 , Oreste Perrella 5 , Sergio Migliaresi 17 , Massimo Galli 7 ,<br />

Giuseppe Monti 10 and Stefano Bombardieri 20 , 1 A.O. Maggiore-<br />

Medicina II, Novara, Italy, 2 Center for Systemic Manifestations<br />

<strong>of</strong> Hepatitis Viruses (MaSVE), Department <strong>of</strong> Internal Medicine,<br />

University <strong>of</strong> Florence, Florence, Italy, 3 Centro di Ricerche<br />

di Immunopatologia e Documentazione su Malattie Rare,<br />

Struttura Complessa a Direzione Universitaria di Immunologia<br />

Clinica, Ospedale S.G. Bosco, Torino, Italy, 4 Department <strong>of</strong><br />

Clinical Medicine, University <strong>of</strong> Bologna, S. Orsola-Malpighi<br />

Hospital, Bologna, Italy, 5 Department <strong>of</strong> Infectious Diseases and<br />

Immunology, Cotugno Hospital, Naples, Italy, 6 Department <strong>of</strong><br />

Internal Medicine, Pordenone General Hospital, Pordenone,<br />

Italy, 7 Dipartimento di Scienze Cliniche Luigi Sacco, Sezione di<br />

Malattie Infettive e Immunopatologia, Università degli Studi,<br />

Ospedale Luigi Sacco, Milano, Italy, 8 Institute <strong>of</strong> Statistics,<br />

University <strong>of</strong> Udine, Udine, Italy, Italy, 9 Internal Medicine Unit,<br />

Policlinico San Marco, Bergamo, Italy, Italy, 10 Internal Medicine<br />

Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio,<br />

Saronno, VA, Italy, Italy, 11 Internal Medicine, Donizetti Hospital,<br />

Monza, Italy, Italy, 12 Internal Medicine, Università Politecnica<br />

delle Marche, Ancona, Italy, Italy, 13 Nephrology Unit, Spedali<br />

Riuniti, Brescia, Italy, Italy, 14 <strong>Rheumatology</strong> Clinic, A.O. Niguarda<br />

Ca’ Granda Hospital, Milan, Italy, 15 <strong>Rheumatology</strong> Clinic, Azienda<br />

Ospedaliero-Universitaria “S. Maria della Misericordia”, Udine,<br />

Italy, 16 <strong>Rheumatology</strong> Clinic, Azienda Ospedaliero-Universitaria<br />

“S. Maria della Misericordia”, Udine, Italy, 17 <strong>Rheumatology</strong><br />

Clinic, University <strong>of</strong> Naples, Italy, Italy, 18 <strong>Rheumatology</strong> Unit,<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Modena e Reggio<br />

Emilia, Italy, Italy, 19 <strong>Rheumatology</strong> Unit, Department <strong>of</strong> Internal<br />

Medicine, University <strong>of</strong> Modena, Italy, Italy, 20 <strong>Rheumatology</strong><br />

Unit, Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Pisa, Pisa,<br />

Italy, Italy, 21 <strong>Rheumatology</strong> Unit, M. Scarlato Hospital, Scafati,<br />

Salerno, Italy, Italy<br />

5:30 PM<br />

2202. A New Polymorphism <strong>of</strong> the Fibroblast Growth Factor<br />

(FGF)23 Gene: A Promising Predictor <strong>of</strong> Coronary Damage in<br />

Kawasaki Disease (KD).<br />

Fernanda Falcini 1 , Laura Masi 3 , Francesco Franceschelli 3 , Gigliola<br />

Leoncini 3 , Serena Capannini 1 , Francesco La Torre 4 , Giuseppina<br />

Calcagno 4 , Marco Matucci Cerinic 2 and Maria Luisa Brandi 3 ,<br />

1<br />

Department <strong>of</strong> BioMedicine, Section <strong>of</strong> <strong>Rheumatology</strong>,<br />

Transition Clinic, University <strong>of</strong> Florence, Florence, Italy,<br />

2<br />

Department <strong>of</strong> BioMedicine, Section <strong>of</strong> <strong>Rheumatology</strong>,<br />

Transition Clinic, University <strong>of</strong> Florence, Florence, Italy,<br />

3<br />

Department <strong>of</strong> Internal Medicine, Metabolic Bone Diseases<br />

Unit, University <strong>of</strong> Florence, Italy, 4 Department <strong>of</strong> Paediatrics,<br />

<strong>Rheumatology</strong> Unit, University <strong>of</strong> Messina<br />

5:45 PM<br />

2203. Mepolizumab, a Humanized Anti-IL-5 Antibody, Has<br />

Steroid-Sparing Potential in Churg-Strauss Syndrome.<br />

Frank Moosig 1 , Kristina Butherus 1 , Bernhard Hellmich 2 and<br />

Wolfgang L. Gross 1 , 1 University Hospital Schleswig Holstein<br />

& Klinikum Bad Bramstedt, 2 University <strong>of</strong> Tübingen &<br />

Kreiskrankenhaus Plochingen<br />

ACR Meet the Pr<strong>of</strong>essor Sessions<br />

4:30 - 6:00 PM<br />

Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />

separate registration and ticket. To verify which session you<br />

registered for, check to make sure the registration code on your<br />

ticket matches the code listed below in parentheses.<br />

B207<br />

Dermatological Manifestations <strong>of</strong> Rheumatic Diseases<br />

(081) f<br />

Speaker: Nicole Fett, MD; Perelman Center for Advanced<br />

Medicine; Philadelphia, PA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• cite the diagnostic criteria for skin diseases with<br />

rheumatologic implications<br />

• construct a differential diagnosis for these conditions<br />

• design a strategy for management <strong>of</strong> skin disease seen in<br />

patients with rheumatologic diseases<br />

wednesday<br />

2010 Program Book 129


wednesday<br />

B208<br />

Infections in Patients on Tumor Necrosis Factor<br />

Therapy (082) PS<br />

Speaker: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the risks <strong>of</strong> infections, including opportunistic<br />

infections, with biological response modifier therapies for<br />

rheumatoid arthritis<br />

• discuss the principles <strong>of</strong> early detection and management <strong>of</strong><br />

infections in patients who develop infections<br />

• determine ways to reduce the risk <strong>of</strong> occurrence <strong>of</strong> infections<br />

in patients with rheumatoid arthritis<br />

B209<br />

Pain: Evaluation and Treatment <strong>of</strong> Back Pain (083) PM<br />

Speaker: David G. Borenstein, MD; Arthritis & Rheumatism<br />

Association; Washington, DC<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• determine the appropriate use <strong>of</strong> diagnostic tests in the<br />

evaluation <strong>of</strong> low back pain<br />

• review effective therapies for low back pain<br />

• identify the types <strong>of</strong> exercises that prevent and treat low back<br />

pain<br />

B210<br />

Psoriatic Arthritis (084)<br />

Speaker: Dafna D. Gladman, MD; Toronto Western Hospital;<br />

Toronto, ON, Canada<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss advances in diagnosis and classification <strong>of</strong> psoriatic<br />

arthritis<br />

• determine if patients with psoriatic arthritis should be treated<br />

aggressively<br />

• determine treatment options for patients with psoriatic<br />

arthritis<br />

B301<br />

Rheumatoid Arthritis: Difficult Cases (085) f<br />

Speaker: Nancy A. Shadick, MD, MPH; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the management <strong>of</strong> patients with refractory<br />

rheumatoid arthritis<br />

• identify novel treatment options for those failing conventional<br />

therapies<br />

• create effective management plans for complicated<br />

rheumatoid arthritis patients<br />

B302<br />

Rheumatoid Arthritis: Safety <strong>of</strong> Novel Therapies (086)<br />

PS<br />

Speaker: Daniel H. Solomon, MD, MPH; Brigham and Women’s<br />

Hospital; Boston, MA<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the management <strong>of</strong> patients with refractory<br />

rheumatoid arthritis<br />

• identify novel treatment options for those failing conventional<br />

therapies<br />

B303<br />

<strong>Rheumatology</strong> Practice 101: Starting Out in Practice<br />

for The Graduating Fellow (087) f<br />

Speaker: Michael J. Maricic, MD; Catalina Pointe <strong>Rheumatology</strong>;<br />

Tucson, AZ<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• appraise contracts with managed care companies and<br />

negotiating opportunities<br />

• evaluate how to buy in to an existing practice, hire a new<br />

associate, and meet the needs <strong>of</strong> a retiring partner<br />

• discuss the pros and cons <strong>of</strong> adding ancillary services (e.g.,<br />

infusion center, densitometry service, etc.), an <strong>of</strong>fice manager<br />

or practice administrator<br />

B304<br />

Spondylarthropathy: An Update (088)<br />

Speaker: Juergen Braun, MD; Rheumazentrum Ruhrgebiet;<br />

Herne, Germany<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the challenge in the early diagnosis <strong>of</strong><br />

spondylarthropathy<br />

• discuss mechanisms <strong>of</strong> disease pathogenesis<br />

• describe current treatment options for spondylarthropathy<br />

B305<br />

Systemic Lupus Erythematosus: Lupus Nephritis (089)<br />

Speaker: Frederic A. Houssiau, MD, PhD; Universite Catholique<br />

Louvain; Brussels, Belgium<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify lupus nephritis in early stages<br />

• describe poor prognostic factors<br />

• evaluate lupus nephritis therapy<br />

B306<br />

Vasculitis: An Update (090)<br />

Speaker: Stuart M. Levine, MD; Johns Hopkins University;<br />

Baltimore, MD<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• understand the strengths and limitations <strong>of</strong> the current blood<br />

vessel size-based vasculitis classification system<br />

• utilize various imaging and laboratory tests in the diagnosis<br />

<strong>of</strong> vasculitis, with emphasis on antineutrophilic cytoplasmic<br />

antibodies<br />

• identify standard and novel therapeutic modalities in the<br />

treatment <strong>of</strong> the systemic vasculitides<br />

130<br />

2010 Program Book


ARHP Concurrent Sessions<br />

4:30 - 6:00 PM<br />

B309<br />

A Foot Orthotic Is Not Just a Foot Orthotic c/r<br />

Moderator: Marian T. Hannan, DSc, MPH; Hebrew Senior Life,<br />

Harvard Medical School; Boston, MA<br />

Speaker: Dennis J. Janisse, C Ped; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />

Milwaukee, WI<br />

Session Overview:<br />

Pedorthics is an integral component for treatment/management<br />

<strong>of</strong> rheumatology patients. This session will provide education<br />

about how to lower friction and provide cushioning and support<br />

for the foot and new materials that are being used for foot<br />

orthoses, including ones that are antifungal and antibacterial,<br />

will be discussed.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe pedorthic care and modalities including footwear,<br />

shoe modifications, hosiery, and foot orthoses<br />

• identify new options in foot orthoses for arthritis patients and<br />

other related complications that occur<br />

• discuss ways to provide good care at a lower cost with<br />

innovative premade orthoses<br />

B311<br />

Labs and Treatment Options: What Do They Mean<br />

and How Do You Use? cP<br />

Moderator: Seetha U. Monrad, MD; University <strong>of</strong> Michigan<br />

Medical Center; Ann Arbor, MI<br />

Speakers: Robert W. Lightfoot, MD; University <strong>of</strong> Kentucky<br />

<strong>College</strong> <strong>of</strong> Medicine; Lexington, KY<br />

Mark H. Wener, MD; University <strong>of</strong> Washington; Seattle, WA<br />

Session Overview:<br />

Laboratory testing is an important evaluation tool used in<br />

rheumatology practices. Laboratory tests are frequently used<br />

to screen for, diagnose, and measure disease activity in those<br />

patients with suspected or diagnosed rheumatic disease. A<br />

patient’s history and physical exam along with the sensitivity,<br />

specificity, and the positive and negative predictive value <strong>of</strong> the<br />

specified test guides the interpretation <strong>of</strong> laboratory tests. It is<br />

important that members <strong>of</strong> the rheumatology health care team<br />

understand the principles, the interpretation, and the strengths<br />

and weaknesses <strong>of</strong> the laboratory tests used.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the laboratory tests used to screen for suspected<br />

rheumatic disease<br />

• explain how laboratory tests can assist to diagnose suspected<br />

rheumatic disease<br />

• define how laboratory tests are used to measure disease<br />

activity in those with diagnosed rheumatic disease<br />

B310<br />

Ready, Aim, Get Funded! R<br />

Participants will be limited to 20 and are asked to bring a onepage<br />

draft <strong>of</strong> specific aims for an actual grant proposal with<br />

them for review.<br />

Moderator: Laura D. Bilek, PhD, PT; University Nebraska Med<br />

Center; Omaha, NE<br />

Speakers: Jennifer M. Hootman, PhD; Centers for Disease<br />

Control; Kennesaw, GA<br />

Susan L. Murphy, ScD, OTR; University <strong>of</strong> Michigan; Ann Arbor,<br />

MI<br />

Session Overview:<br />

Successful grant applications start with specific aims that are<br />

clear, feasible and answer the proposed research question.<br />

Specific aims are one <strong>of</strong> the most important pieces <strong>of</strong> the grant<br />

application but <strong>of</strong>ten the most difficult to write. This session<br />

will be a hands-on approach to writing specific aims including<br />

examples <strong>of</strong> good and bad specific aims as well as small group<br />

peer and expert feedback for each participant.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• list characteristics <strong>of</strong> strong specific aims as part <strong>of</strong> the grant<br />

application<br />

• identify the components <strong>of</strong> good and bad specific aims<br />

• apply feedback from experienced grant writers and reviewers<br />

B308<br />

Work Assessments: A ‘How-To’ That Could Save Your<br />

Patient’s Life/Job c/r PS PM<br />

Moderator: Kristina A. Theis, MPH; Centers for Disease Control<br />

and Prevention; Atlanta, GA<br />

4:00 PM<br />

Work Experience Survey: Rheumatic Conditions<br />

Julie J. Keysor, PhD, PT; Boston University Sargent <strong>College</strong>;<br />

Boston, MA<br />

4:30 PM<br />

The Ergonomic Assessment Tool for Arthritis<br />

Catherine L. Backman, PhD, OT(C); University <strong>of</strong> British<br />

Columbia; Vancouver, BC, Canada<br />

5:00 PM<br />

Demonstration on Computer Ergonomics Assessment<br />

Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />

PA<br />

5:30 PM<br />

Questions and Answers<br />

Session Overview:<br />

People with rheumatic conditions are <strong>of</strong>ten at-risk for work<br />

disability, especially in jobs involving repetitive hand-intensive<br />

or manual work and this makes them a prime target for<br />

interventions designed to mediate against job loss. While health<br />

pr<strong>of</strong>essionals may be willing to help patients with their work<br />

challenges, they may not have had the training to do this.<br />

wednesday<br />

2010 Program Book 131


Despite advances in ergonomics and universal design, more<br />

<strong>of</strong>ten than not, people are expected to fit their jobs, rather<br />

than jobs being designed to fit people. Use <strong>of</strong> assessment tools<br />

and knowing the details <strong>of</strong> computer ergonomic assessments<br />

could aid health pr<strong>of</strong>essionals in helping patients to identify<br />

and overcome modifiable arthritis-related work challenges.<br />

This session will describe, from the macro to the micro, how to<br />

perform work assessments using existing tools and techniques<br />

that standardize the process and <strong>of</strong>fer support to health<br />

pr<strong>of</strong>essionals in these situations. Participants will learn what<br />

makes a good assessment tool, including why and how tools can<br />

be useful, when to use the tools and how to apply computer<br />

ergonomic assessment principles to be better able to assist<br />

patients/clients in making their job fit them and their arthritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify at least two currently available work challenge<br />

assessment tools and recognize the purpose and utility <strong>of</strong><br />

each tool<br />

• identify features that make an assessment tool relevant and<br />

useful to the arthritis population<br />

• define the key features <strong>of</strong> a computer ergonomic assessment<br />

• describe simple fixes that can be applied to improve work<br />

space without fear <strong>of</strong> disclosure<br />

wednesday<br />

REF Industry Roundtable-<br />

Supported Symposia<br />

6:30 - 9:30 PM<br />

The REF would like to thank the industry leaders that have made<br />

a significant multi-year commitment to the REF for participation<br />

in the Industry Roundtable.<br />

In appreciation for their commitment, these industry leaders<br />

have been invited to host a symposium during the annual<br />

meeting. In 2010, there are two types <strong>of</strong> symposia <strong>of</strong>fered to<br />

attendees: CME-accredited and non-CME accredited. For CMEaccredited<br />

symposia, the sponsoring organization is responsible<br />

for planning and providing CME credit. The non-CME accredited<br />

symposia have been planned and will be implemented in<br />

accordance with the requirements <strong>of</strong> the FDA and applicable<br />

standards <strong>of</strong> the PhRMA Code on Interactions with Healthcare<br />

Pr<strong>of</strong>essionals. Please visit the organization’s exhibit booth, the<br />

industry-supported symposia booth or see page 282 for more<br />

information.<br />

132<br />

2010 Program Book


THURSDAY, NOVEMBER 11, 2010<br />

ACR/ARHP Registration<br />

6:30 am - 5:00 PM<br />

International Blvd. Foyer<br />

ACR Clinical Symposium<br />

7:30 - 8:30 am<br />

Hall A3<br />

<strong>Rheumatology</strong> Roundup: Highlights from the 2010<br />

Annual Scientific Meeting c/r cP<br />

Speakers: John J. Cush, MD; Baylor Research Institute; Dallas, TX<br />

Arthur Kavanaugh, MD; University <strong>of</strong> California-San Diego; La<br />

Jolla, CA<br />

Session Overview:<br />

This session is intended to be an informative overview and<br />

will help attendees summarize the most interesting, novel,<br />

significant abstracts that were presented during the 2010 annual<br />

meeting. The session is presented by two rheumatologists,<br />

highlighting their respective subjective opinions.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• list research highlights from the scientific presentations<br />

• discuss the clinical impact <strong>of</strong> selected research reports<br />

presented at the meeting<br />

• evaluate the therapeutic potential <strong>of</strong> selected clinical trials<br />

presented at the meeting<br />

ACR Immunology Updates for<br />

Clinicians<br />

7:30 - 8:30 am<br />

B402<br />

Therapeutic Use <strong>of</strong> Mesenchymal Stem Cells in<br />

Rheumatologic Diseases c/r<br />

Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />

Rochester, NY<br />

Speaker: Christian Jorgensen, MD, PhD; Hospital Lapeyronie;<br />

Montpellier, France<br />

Session Overview:<br />

Mesenchymal stem cells have the capacity to differentiate<br />

into multiple cell types including chondrocytes, osteoblasts,<br />

adipocytes, myocytes, and fibroblasts. Surprisingly, in<br />

experimental models mesenchymal stem cells have also been<br />

found to ameliorate inflammation, improve angiogenesis, and<br />

prevent fibrosis. Mesenchymal stem cells can be isolated from<br />

bone marrow or fat and can be easily expanded in vitro. There<br />

are now approximately 100 clinical trials using mesenchymal<br />

stem cells including trials for Sjögren’s syndrome, systemic<br />

sclerosis, and lupus nephritis.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the phenotype, distribution, isolation, and in vitro<br />

culture <strong>of</strong> mesenchymal stem cells<br />

• discuss how mesenchymal stem cells have been used in<br />

animal models <strong>of</strong> human disease<br />

• explain how mesenchymal stem cells are being tested as<br />

therapy for human rheumatologic disease<br />

ACR Practice Issues<br />

7:30 - 8:30 am<br />

B406<br />

ICD -10 Preparation - Developing a Blueprint for<br />

Implementation BR cP<br />

Moderators: Christopher L. Colglazier, MD; Kunath, Burte and<br />

Temming MD; Cincinnati, OH<br />

Raymond Hong, MD, MBA; Ohio Permanente Medical Group;<br />

Richfield, OH<br />

Speaker: Gloryanne Bryant, BS, RHIA, RHIT, CCS; Kaiser<br />

Foundation Health Plan Inc. and Hospitals; Oakland, CA<br />

Session Overview:<br />

The Department <strong>of</strong> Health and Human Services announced the<br />

date <strong>of</strong> October 1, 2013 for ICD-10-CM implementation. ICD-10<br />

implementation will ripple across many departments in health<br />

care organizations including health information management,<br />

coding, revenue cycle, billing and patient financial services. ICD-<br />

10 will also stretch into the information technology department,<br />

where s<strong>of</strong>tware and hardware upgrades and solutions will be<br />

needed to manage the new codes. Medical staff leadership<br />

needs to be on board to help reinforce the physician and<br />

clinical documentation changes required to ensure accurate<br />

coding, billing and reimbursement. It is necessary to have an<br />

implementation plan established and begun well in advance to<br />

ensure a successful transition to ICD-10-CM and ICD-10-PCS. A<br />

key to successful planning is the timeliness <strong>of</strong> training and other<br />

activities. It is important for physicians to establish reasonable<br />

plan to prepare themselves and their staff.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• identify the basic variances between ICD-9-CM and ICD-10<br />

• discuss how to locate the necessary resources and information<br />

that is important for physician practices to transition to ICD-10<br />

• identify an appropriate impact assessment plan<br />

ACR State-<strong>of</strong>-the-Art Lectures<br />

7:30 - 8:30 am<br />

B313<br />

Clinical Review: New Insights into Primary Central<br />

Nervous System Vasculitis in Children P<br />

Moderator: Kathleen M. O’Neil, MD; Oklahoma University<br />

Health Science Center; Oklahoma City, OK<br />

Speaker: Susanne M. Benseler, MD, PhD; The Hospital for Sick<br />

Children; Toronto, ON, Canada<br />

Session Overview:<br />

Among the most perplexing and potentially devastating diseases<br />

faced by rheumatologists are the inflammatory diseases <strong>of</strong> the<br />

central nervous system. Collaborative work among neurologists<br />

and rheumatologists, radiology and pathology have helped<br />

identify subsets <strong>of</strong> children with primary central nervous system<br />

vasculitis with differing clinical presentation and diagnostic<br />

findings that impact how one approaches and treats these<br />

extremely ill children.<br />

2010 Program Book 133<br />

thursday


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the clinical spectrum <strong>of</strong> inflammatory central nervous<br />

system disease in children<br />

• discuss the current diagnostic evaluation <strong>of</strong> these children<br />

• review the data on treatment <strong>of</strong> children with different<br />

presentations <strong>of</strong> central nervous system vasculitis and how<br />

this affects outcome<br />

Sidney J. Marcus Auditorium<br />

Pain, the Brain, and the Immune System: Links to<br />

Understanding Pain Management R PM<br />

Moderator: James P. Witter, MD, PhD; NIH/NIAMS; Bethesda,<br />

MD<br />

Speaker: Joyce A. DeLeo, PhD; Dartmouth Medical School;<br />

Hanover, NH<br />

Session Overview:<br />

Treatment <strong>of</strong> pain remains a major clinical challenge due to the<br />

chronic nature <strong>of</strong> many <strong>of</strong> the diseases and conditions cared<br />

for by rheumatologists. Clinicians face a dilemma, due to the<br />

recognition that pain is <strong>of</strong>ten not adequately treated, but yet at<br />

the same time current treatments are under scrutiny due to a<br />

rise in complications. Better treatment approaches are needed.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• distinguish between acute pain and chronic pain<br />

• describe the mechanisms <strong>of</strong> chronic pain including peripheral,<br />

spinal and supraspinal sites <strong>of</strong> modulation<br />

• translate the knowledge <strong>of</strong> mechanisms <strong>of</strong> chronic pain into<br />

different therapeutic approaches with a focus on glia and the<br />

immune system<br />

8:00 am<br />

2205. Safety without Borders: Upper and Lower<br />

Gastrointestinal Safety <strong>of</strong> Celecoxib in a Pooled Analysis <strong>of</strong><br />

52 Prospective, Randomised, Double-Blinded, Parallel-Group<br />

Clinical Trials.<br />

Gurkirpal Singh 3 , George Triadafilopoulos 3 , Naurang Agrawal 1 ,<br />

Ge<strong>of</strong>f Makinson 2 , Chunming Li 2 and Ha Nguyen 2 , 1 KUMC, 2 Pfizer,<br />

3<br />

Stanford University<br />

8:15 am<br />

2206. Dose Matters: The Risk <strong>of</strong> Complicated Gastroduodenal<br />

Ulcers with Naproxen Is Dose-Dependent.<br />

Gurkirpal Singh 3 , Ajitha Mannalithara, Amrita Sehgal 4 , Alka<br />

Mithal 2 , Mark Sostek 1 and George Triadafilopoulos 3 , 1 Astra<br />

Zeneca, 2 ICORE, 3 Stanford University, 4 University <strong>of</strong> California<br />

Berkeley<br />

8:30 am<br />

2207. Disappointing Responsiveness <strong>of</strong> the SF-6D to<br />

Improvement in Patients Receiving a First TNF-Blocker: Results<br />

<strong>of</strong> the DREAM Registry.<br />

Laurien Buitinga 3 , Louise M. A. Braakman-Jansen 4 , Erik Taal 4 ,<br />

Wietske Kievit 1 , Henk Visser 2 , Piet L. C. M . Van Riel 1 and Mart A.<br />

F. J. van de Laar 5 , 1 Radboud University Nijmegen Medical Centre,<br />

2<br />

Rijnstate Hospital, Arnhem, 3 University <strong>of</strong> Twente, Enschede,<br />

Overijssel, The Netherlands, 4 University <strong>of</strong> Twente, Enschede,<br />

The Netherlands, 5 University <strong>of</strong> Twente; Medical Spectrum<br />

Twente, Enschede<br />

ARHP Concurrent Sessions<br />

7:45 - 8:45 am<br />

thursday<br />

ARHP Concurrent Abstract Session<br />

7:45 - 8:45 am<br />

B311<br />

Rheumatic Medications: More or Less?<br />

Moderator: Donald R. Miller, PharmD; North Dakota State<br />

University; Fargo, ND<br />

7:45 am<br />

2204. Periodontal Disease Hampers Anti-TNF Treatment<br />

Response in Rheumatoid Arthritis.<br />

Cynthia Savioli 1 , Gisele Maria Campos Fabri 2 , Ana Luisa Calich 5 ,<br />

Ana Cristina Medeiros Ribeiro 5 , Julio Cesar Moraes 5 , Carla<br />

Gonçalves Saad 5 , Jozélio Freire Carvalho 5 , Clovis Almeida Silva 4 ,<br />

Eloísa Bonfá 5 and José Tadeu Tesseroli Siqueira 3 , 1 Dentistry and<br />

<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />

Universidade de São Paulo, Osasco, São Paulo, Brazil, 2 Dentistry<br />

and <strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina<br />

da Universidade de São Paulo, 3 Dentistry Division, Faculdade<br />

de Medicina da Universidade de São Paulo, 4 Paediatric<br />

<strong>Rheumatology</strong> Unit, <strong>Rheumatology</strong> Division (CEDMAC),<br />

Faculdade de Medicina da Universidade de São Paulo,<br />

5<br />

<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />

Universidade de São Paulo<br />

B308<br />

How to Understand and Apply the Results <strong>of</strong> a Journal<br />

Article: What You Really Need to Know About<br />

Statistics c/r<br />

Moderator: Robert R. McLean, DSc, MPH; Hebrew Senior Life;<br />

Boston, MA<br />

Speaker: Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

Session Overview:<br />

As health care moves towards making evidence-based practice a<br />

standard <strong>of</strong> care, it is increasingly necessary for practitioners to<br />

have the tools for integrating evidence into practice. To achieve<br />

evidence-based practice health care practitioners must be able<br />

to read and understand the results <strong>of</strong> a research study so they<br />

can apply the results to clinical practice. Unfortunately, many<br />

health care practitioners are unable to interpret the statistics<br />

used in a typical journal article. Interpreting and communicating<br />

the evidence to patients, clinical associates and third party<br />

payers is difficult without the ability to understand statistics. This<br />

presentation will assist practitioner to link evidence to practice<br />

by providing practitioners with a concrete explanation <strong>of</strong> basic<br />

statistics and their interpretation. From this knowledge <strong>of</strong><br />

statistics, the results <strong>of</strong> a research article will be interpreted and<br />

then applied to a case study drawn from clinical practice.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the basic types <strong>of</strong> statistics and how to interpret<br />

them<br />

134<br />

2010 Program Book


• apply these basic statistics to interpret the results section <strong>of</strong> a<br />

journal article<br />

• apply the results <strong>of</strong> the journal article to a case study<br />

B309<br />

Measure by Measure: Assessing Psychological Health<br />

and Well-Being in Scleroderma c/r PM PS<br />

Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />

Albuquerque, NM<br />

Speakers: Ghassan El Baalbaki, PhD; Jewish General Hospital;<br />

Montreal, QC, Canada<br />

Katherine Milette, BSc; Jewish General Hospital; Montreal, QC,<br />

Canada<br />

Brett D. Thombs, BA, MA, PhD; McGill University; Montreal, QC,<br />

Canada<br />

Session Overview:<br />

Patient-reported outcomes relate to patient health, well-being,<br />

and response to treatment based on patient perspectives.<br />

Patient-reported outcomes may reflect broad constructs, such<br />

as quality <strong>of</strong> life or disability, or narrower constructs, such<br />

as individual symptoms including pain or fatigue. There is<br />

relatively little research on important patient-reported outcomes<br />

related to psychological health and well-being in scleroderma,<br />

including pain, pruritus (itching), sexual function, body image,<br />

depression, and fatigue. One factor that has hindered research<br />

on patient-reported outcomes related to psychological health<br />

and well-being in scleroderma is the lack <strong>of</strong> assessment tools<br />

validated for use with scleroderma patients. Since scleroderma is<br />

a uniquely complex, multi-system disease that impacts patients<br />

in many different ways, it is important to have measures that are<br />

validated specifically for use in scleroderma. There are validation<br />

data for broad measures <strong>of</strong> quality <strong>of</strong> life and disability, as well<br />

as data supporting the use <strong>of</strong> a visual analog scale to measure<br />

pain in scleroderma. Until recently, however, there were no<br />

validation data on any other patient-reported outcomes,<br />

including depression, fatigue, pruritus, sexual function, or body<br />

image. The low prevalence <strong>of</strong> scleroderma has historically made<br />

funding for research difficult. However, with startup funds<br />

from a Canadian Institutes <strong>of</strong> Health Research (CIHR) Team<br />

Development grant and ongoing funding from a CIHR Team grant<br />

(2007-2012), the Canadian Scleroderma Research Group (CSRG)<br />

established a pan-Canadian, multi-center Registry to recruit<br />

patients for annual assessments. There are currently 15 centers<br />

involved, and over 1,000 patients enrolled, with expected<br />

ongoing enrollment <strong>of</strong> 100-150 new patients per year. Data from<br />

this registry including the core concerns related to psychological<br />

health and well-being <strong>of</strong> patients with scleroderma and the<br />

validated assessment strategies will be discussed.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• define the characteristics <strong>of</strong> core psychosocial concerns <strong>of</strong><br />

patients with scleroderma<br />

• describe the validated tools to assess symptoms <strong>of</strong><br />

depression, fatigue, pain, pruritus, body image distress and<br />

body image avoidance, and sexual function among patients<br />

with scleroderma<br />

• describe strengths and limitations <strong>of</strong> validated assessment<br />

tools for use among patients with scleroderma<br />

• select publicly-available, validated measures for use in their<br />

own scleroderma studies<br />

B310<br />

Successful Coping with Rheumatic Disease c/r PS<br />

Moderator: Christina Bode, PhD; University <strong>of</strong> Twente;<br />

Enschede, Netherlands<br />

7:45 am<br />

Goal-Management Strategies in Rheumatic Diseases<br />

Christina Bode, PhD; University <strong>of</strong> Twente; Enschede,<br />

Netherlands<br />

8:05 am<br />

Adaptation and Self-Management<br />

Stanton P. Newman, PhD; University <strong>College</strong> London; London,<br />

United Kingdom<br />

8:15 am<br />

Successful Adaptation from the <strong>Rheumatology</strong> Health Care<br />

Provider Perspective<br />

Mart A. van de Laar, MD; University Twente and Medisch<br />

Sprectrum Twente; Enschede, Netherlands<br />

Session Overview:<br />

Unless significant improvements in medical treatment for<br />

inflammatory rheumatic diseases are made, living with arthritis<br />

means taking medication, making life style changes, coping<br />

with pain, fatigue, and decreases in physical functioning.<br />

Besides effects that are directly related to arthritis, patients<br />

have to cope with changes in social relationships, work abilities,<br />

possibilities for participation, the image <strong>of</strong> themselves and also<br />

with changes in their personal, future perspective. Patients <strong>of</strong>ten<br />

describe these demands as “a job on top <strong>of</strong> all other aspects<br />

<strong>of</strong> my life.” Criteria for successful adjustment can be defined in<br />

relation to coping with symptoms <strong>of</strong> arthritis or from a more<br />

comprehensive perspective that includes all aspects <strong>of</strong> life.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe different criteria for successful adaptation to a<br />

rheumatic disease<br />

• compare the contribution <strong>of</strong> self-management and goalmanagement<br />

strategies and interventions to successful<br />

adaptation<br />

• discuss how the application <strong>of</strong> self-management and goalmanagement<br />

strategies fit with clinical practice<br />

ACR Basic Science Symposia<br />

9:00 - 10:30 am<br />

B313<br />

Bisphosphonates: Mechanism <strong>of</strong> Action and<br />

Optimizing Clinical Use R<br />

Moderator: Steven R. Goldring, MD; Hospital for Special Surgery;<br />

New York, NY<br />

9:00 AM<br />

Structural and Functional Properties <strong>of</strong> Bisphosphonates<br />

R. Graham Russell, MD, PhD, FRS; The Botnar Research Centre,<br />

Univesity <strong>of</strong> Oxford; Headington, Oxford, United Kingdom<br />

9:30 AM<br />

Effects <strong>of</strong> Bisphosphonates on Bone Remodeling and Quality<br />

David B. Burr, PhD; Indiana University School <strong>of</strong> Medicine;<br />

Indianapolis, IN<br />

thursday<br />

2010 Program Book 135


thursday<br />

10:00 AM<br />

Optimal use <strong>of</strong> Bisphosphonates in Clinical Disorders<br />

Felicia Cosman, MD; Helen Hayes Hospital; West Haverstraw, NY<br />

Session Overview:<br />

The mechanism <strong>of</strong> action <strong>of</strong> bisphosphonates has been<br />

elucidated and has led to new insights and potential applications<br />

for treatment <strong>of</strong> skeletal disorders. Optimizing their clinical use<br />

and avoidance <strong>of</strong> potential complications is critically important<br />

in the treatment <strong>of</strong> patients with skeletal disorders.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the mechanism <strong>of</strong> action <strong>of</strong> bisphosphonates<br />

• discuss the optimal therapeutic use in treating skeletal<br />

disorders<br />

• describe potential novel bisphosphonates and their clinical<br />

application<br />

Thomas J. Murphy Ballroom<br />

Immunopathogenesis <strong>of</strong> Systemic Sclerosis R<br />

Moderator: Robert A. Lafyatis, MD; Boston University School <strong>of</strong><br />

Medicine; Arlington, MA<br />

9:00 AM<br />

Gene Expression Analyses - Insights into Immune Dysreguation<br />

in Systemic Sclerosis<br />

Filemon K. Tan, MD, PhD; University <strong>of</strong> Texas - Houston Medical<br />

School; Houston, TX<br />

9:30 AM<br />

Connecting Inflammation and Fibrosis - Innate Immunity in<br />

Systemic Sclerosis<br />

Robert A. Lafyatis, MD; Boston University School <strong>of</strong> Medicine;<br />

Arlington, MA<br />

10:00 AM<br />

The Basic Biology <strong>of</strong> IL-33 and Its Potential Role in<br />

Inflammation and Fibrosis<br />

Foo Y. Liew, BSc, PhD, DSc; University <strong>of</strong> Glasgow, Glasgow<br />

Biomedical Research Centre; Glasgow, Scotland, United Kingdom<br />

Session Overview:<br />

Our understanding <strong>of</strong> immunity and autoimmunity in systemic<br />

sclerosis pathogenesis has made rapid progress in both<br />

innate adaptive immune mechanisms contributing to fibrosis.<br />

Immune regulatory gene associations with scleroderma have<br />

re-emphasized the importance <strong>of</strong> immune pathogenesis in this<br />

disease.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe basic immune pathogenesis in systemic sclerosis<br />

• identify how innate immunity might lead to inflammation and<br />

fibrosis in target organs<br />

• interpret key pr<strong>of</strong>ibrotic cytokines, their sources and their<br />

roles in fibrosis<br />

• discuss key alterations in gene regulation seen in patients with<br />

systemic sclerosis<br />

ACR Clinical Symposia<br />

9:00 - 10:30 AM<br />

B406<br />

Pediatric Spondylarthropathies: From Genetics to the<br />

Clinic P<br />

Moderators: Larry B. Vogler, MD; Emory University School <strong>of</strong><br />

Medicine; Atlanta, GA<br />

Carlos D. Rose, MD; duPont Hospital for Children; Wilmington,<br />

DE<br />

9:00 AM<br />

Advances in the Genetics and Pathogenesis <strong>of</strong> the<br />

Spondylarthropathies<br />

Robert A. Colbert, MD, PhD; NIAMS/NIH; Bethesda, MD<br />

9:30 AM<br />

Enthesitis Related Arthritis in the Context <strong>of</strong> Juvenile Idiopathic<br />

Arthritis: Clinical Features<br />

Shirley Tse, MD; Hospital for Sick Children; Toronto, ON, Canada<br />

10:00 AM<br />

Using and Interpreting Imaging in the Diagnosis and Monitoring<br />

<strong>of</strong> the Spondylarthropathies<br />

Thomas J. Learch, MD; Cedar-Sinai Medical Center; Los Angeles,<br />

CA<br />

Session Overview:<br />

There have been new developments in disease mechanism for<br />

the spondylarthropathies resulting mainly form work on the<br />

transgenic rat model and the processing <strong>of</strong> the B27 molecule.<br />

The availability <strong>of</strong> new imaging techniques has certainly shed<br />

light on the nature <strong>of</strong> enthesitis and the new discoveries on<br />

the contribution <strong>of</strong> bone in the pathologic process. Finally, the<br />

pediatric spondylarthropathies have been reclassified and now<br />

constitute a new category <strong>of</strong> juvenile idiopathic arthritis; a<br />

critical review <strong>of</strong> the new classification is worthy <strong>of</strong> re-visiting.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• discuss the most widely accepted possible mechanisms <strong>of</strong><br />

disease associated with HLA-B27 moiety<br />

• discuss the clinical features <strong>of</strong> enthesitis related arthritis and<br />

the most characteristic radiologic findings that distinguishes<br />

this group from the other forms <strong>of</strong> chronic arthritis<br />

• discuss the pros and cons <strong>of</strong> classifying the<br />

spondylarthropathies with the rest <strong>of</strong> the subsets <strong>of</strong> juvenile<br />

idiopathic arthritis<br />

Hall A3<br />

Remission in Rheumatoid Arthritis c/r PS<br />

Moderators: David T. Felson, MD, MPH; Boston University School<br />

<strong>of</strong> Medicine; Boston, MA<br />

Maarten Boers, MD, PhD, MSc; VU University Medical Center;<br />

Amsterdam, The Netherlands<br />

9:00 AM<br />

Why Do We Need a New Definition <strong>of</strong> Remission in<br />

Rheumatoid Arthritis?<br />

Maarten Boers, MD, PhD, MSc; VU University Medical Center;<br />

Amsterdam, The Netherlands<br />

136<br />

2010 Program Book


9:15 AM<br />

The ACR/EULAR Definition <strong>of</strong> Rheumatoid Arthritis Remission:<br />

How was it Developed and How Will it Work?<br />

David T. Felson, MD, MPH; Boston University School <strong>of</strong> Medicine;<br />

Boston, MA<br />

9:50 AM<br />

Working Towards a Definition <strong>of</strong> Remission in Juvenile<br />

Idiopathic Arthritis<br />

Carol A. Wallace, MD; University <strong>of</strong> Washington and Seattle<br />

Childrens’s Hospital; Seattle, WA<br />

10:10 AM<br />

Applying Remission Criteria to Clinical Practice<br />

Josef S. Smolen, MD; Krankenhaus Lainz; Vienna, Austria<br />

Session Overview:<br />

As increasingly effective therapies are developed for rheumatoid<br />

arthritis and juvenile idiopathic arthritis, it is more important<br />

than ever to identify patients who achieve remission in<br />

response to these therapies, and to develop tools to measure<br />

and document this response. Recognizing the limitations <strong>of</strong><br />

the existing Pinal’s definition <strong>of</strong> rheumatoid arthritis remission<br />

and the definition based on the Disease Activity Score,<br />

representatives from ACR and EULAR have now developed<br />

a new definition <strong>of</strong> remission. This session will present the<br />

development <strong>of</strong> this definition and review the evidence that<br />

supports it. In addition, work that has been done to develop a<br />

definition <strong>of</strong> disease remission in juvenile idiopathic arthritis will<br />

also be discussed.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the need for a consistent definition <strong>of</strong> remission in<br />

rheumatoid arthritis<br />

• define rheumatoid arthritis remission using the new<br />

definition, in clinical trials and clinical practice<br />

• contrast the elements <strong>of</strong> remission in rheumatoid arthritis<br />

with those in juvenile idiopathic arthritis<br />

• explain the utility <strong>of</strong> defining remission in clinical practice<br />

ACR Concurrent Abstract Sessions<br />

9:00 - 10:30 AM<br />

A404<br />

Epidemiology and Health Services Research: General<br />

Interest<br />

Moderators: Jolanda Cibere, MD, PhD; Arthritis Research Center<br />

<strong>of</strong> Canada; Vancouver, BC, Canada<br />

Shikha Mittoo, MD, MHS; University <strong>of</strong> Manitoba; Winnipeg, MB,<br />

Canada<br />

9:00 AM<br />

2208. Multiple Medications Use in Adults with Chronic Disease,<br />

with and without a Musculoskeletal Condition.<br />

Gillian A. Hawker 3 , Ruth Croxford 1 and Elizabeth M. Badley 2 ,<br />

1<br />

Institute <strong>of</strong> Clinical and Evaluative Sciences, Toronto, Canada,<br />

2<br />

Toronto Western Research Institute, Toronto, ON, Canada,<br />

3<br />

Women’s <strong>College</strong> Hospital, Toronto, ON, Canada<br />

9:15 AM<br />

2209. Population-Based Estimates <strong>of</strong> Common Comorbidities<br />

and Cardiovascular Disease in Ankylosing Spondylitis.<br />

Ann B. I. Bremander 2 , Ingemar F. Petersson 1 , Stefan Bergman4<br />

and Martin Englund 3 , 1 Lund University Hosp, Lund, Sweden,<br />

2<br />

Musculoskeletal Sciences, Department <strong>of</strong> Orthopedics,<br />

Clinical Sciences Lund, Lund University, Oskarstrom, Sweden,<br />

3<br />

Musculoskeletal Sciences, Department <strong>of</strong> Orthopedics, Clinical<br />

Sciences Lund, Lund University, Lund, Sweden, 4 Research and<br />

Development Center, Spenshult Hospital for Rheumatic Diseases,<br />

Oskarstrom, Sweden<br />

9:30 AM<br />

2210. Elevated Maternal Serum Alpha Fetoprotein Predicts<br />

Reduction in RA Disease Symptoms during Pregnancy but Does<br />

Not Reduce Risk for Preterm Delivery.<br />

Don Nguyen 4 , Gretchen Bandoli 1 , Diana Johnson 3 and Christina<br />

D. Chambers 2 , 1 San Diego State University, 2 University <strong>of</strong><br />

California San Diego, San Diego, CA, 3 University <strong>of</strong> California San<br />

Diego, 4 University <strong>of</strong> California SanDiego<br />

9:45 AM<br />

2211. Cardiovascular Disease Prevalence in a Primary Care<br />

Cohort <strong>of</strong> Individuals with Inflammatory Arthritis, Diabetes,<br />

and Osteoarthritis: A Comparative Cross-Sectional Study.<br />

Mark M. J. Nielen 4 , Alper M. van Sijl 3 , Mike J. L. Peters 1 , Robert<br />

A. Verheij 4 , Francois G. Schellevis 4 and Michael T. Nurmohamed 2 ,<br />

1<br />

Department <strong>of</strong> Internal Medicine, VU Medical Centre,<br />

Amsterdam, The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Jan van Breemen Institute, Amsterdam, Netherlands,<br />

Amsterdam, The Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Jan van Breemen Institute, Amsterdam, Netherlands,<br />

4<br />

Netherlands Institute for Health Services Research (NIVEL),<br />

Utrecht, The Netherlands<br />

10:15 AM<br />

2212. Impact <strong>of</strong> Age, Gender, Obesity, and Steroid Use on<br />

Quinolone-Associated Tendon Disorders.<br />

Barton Wise 3 , Christine Peloquin 2 , Hyon K. Choi 4 , Nancy E. Lane 5<br />

and Yuqing Zhang 1 , 1 Boston Univ School <strong>of</strong> Medicine, Boston,<br />

MA, 2 Boston University School <strong>of</strong> Medicine, Boston, MA, 3 Ctr<br />

for Healthy Aging-UC Davis, Sacramento, CA, 4 Univ <strong>of</strong> British<br />

Columbia, Vancouver, BC, Canada, 5 Univ <strong>of</strong> California at Davis,<br />

Hillsborough, CA<br />

10:30 AM<br />

2213. Bisphosphonate (BisP) Use May Be a Risk Factor<br />

for Osteonecrosis (ON) in Those Who Have Not Used<br />

Glucocorticoids (GCs): Data from the Health Improvement<br />

Network (THIN).<br />

Steven C. Vlad 2 , Hyon K. Choi 3 , Christine Peloquin 2 and Yuqing<br />

Zhang 1 , 1 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 2 Boston<br />

University School <strong>of</strong> Medicine, Boston, MA, 3 Univ <strong>of</strong> British<br />

Columbia, Vancouver, BC, Canada<br />

A411<br />

Genetics, Genomics and Proteomics: RA and Other<br />

Rheumatic Diseases<br />

Moderators: Lindsey A. Criswell, MD, MPH; University <strong>of</strong><br />

California-San Francisco; San Francisco, CA<br />

John B. Harley, MD; University <strong>of</strong> Oklahoma Health Science<br />

Center; Oklahoma City, OK<br />

thursday<br />

2010 Program Book 137


thursday<br />

9:00 AM<br />

2214. Genome-Wide Association Study <strong>of</strong> Systemic Sclerosis<br />

Clinical Features Identifies New Disease Risk Variants.<br />

Olga Gorlova 16 , Jose-Ezequiel Martin 15 , Blanca Rueda 15 , Bobby P.<br />

C. Koeleman 19 , Maria Teruel 15 , Lina-Marcela Diaz-Gallo 15 , Jasper<br />

C. Broen 12 , Madelon C. Vonk 17 , Carmen P. Simeon 14 , Behrooz Z.<br />

Alizadeh 8 , Marieke J. H. Coenen 8 , Alexandre E. Voskuyl 9 , Annemie<br />

J. Schuerwegh 8 , Piet L. C. M . van Riel 8 , Ruben van ‘t Slot 8 , Annet<br />

Italiaander 8 , Roel A. Oph<strong>of</strong>f 8 , Nico Hunzelmann 3 , Norberto<br />

Ortego-Centeno 6 , Miguel A. González-Gay 6 , María F González-<br />

Escribano 6 , Paolo Airo 4 , Jaap van Laar 1 , Jane Worthington 1 ,<br />

Roger Hesselstrand 7 , Vanessa Smith 2 , Filip de Keyser 2 , Fredric<br />

Houssiau 2 , Meng May Chee 1 , Rajan Madhok 1 , Paul Shiels 1 , Rene<br />

Westhovens 2 , Alexander Kreuter 3 , Hans Kiener 10 , Elfride de<br />

Baere 2 , Torsten Witte 3 , Leonid Padykov 7 , Lars Klareskog 7 , Rafaella<br />

Scorza 4 , Benedicte A. Lie 5 , Anna-Maria H<strong>of</strong>fmann-Vold 3 , Patricia<br />

Carreira 6 , John Varga, Monique Hinchcliff, Annette T. Lee, Pravitt<br />

Gourh, Christopher I. Amos, Gabriella Riemekasten 11 , Ariane<br />

Herrick 20 , Lorenzo Beretta 21 , Peter K. Gregersen 13 , Sandeep<br />

Agarwal 18 , Shervin Assassi 18 , Filemon K. Tan 18 , Frank C. Arnett 18 ,<br />

Timothy R. D. J. Radstake 17 , Maureen D. Mayes 18 and Javier<br />

Martin 15 , 1 United Kingdom, 2 Belgium, 3 Germany, 4 Italy, 5 Norway,<br />

6<br />

Spain, 7 Sweden, 8 The Netherlands, 9 The The Netherlands,<br />

10<br />

Austria, 11 Charité University Hospital, Germany, 12 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Radboud University Nijmegen Medical Center,<br />

The Netherlands, 13 Feinstein Institute <strong>of</strong> Medical Research,<br />

14<br />

Hospital Valle de Hebron, Spain, 15 Instituto de Parasitologia<br />

y Biomedicina Lopez-Neyra, Spain, 16 MD Anderson, 17 Radboud<br />

University Nijmegen Medical Center, The Netherlands, 18 The<br />

University <strong>of</strong> Texas Health Science Center–Houston, 19 University<br />

Medical Center Utrecht, The Netherlands, 20 University <strong>of</strong><br />

Manchester, Manchester Academic Health Science Centre,<br />

United Kingdom, 21 University <strong>of</strong> Milan, Italy<br />

9:15 AM<br />

2215. Genetic Markers <strong>of</strong> Rheumatoid Arthritis Susceptibility<br />

in Anti-Citrullinated Peptide Antibody Negative and Shared<br />

Epitope Negative Patients.<br />

Sebastien Viatte 1 , Darren Plant 2 , John Bowes 2 , Anne Barton 2 and<br />

Jane Worthington 1 , 1 Arthritis Research UK Epidemiology Unit,<br />

The University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />

2<br />

Arthritis Research UK Epidemiology Unit, The University <strong>of</strong><br />

Manchester<br />

9:30 AM<br />

2216. A Signature <strong>of</strong> Aberrant Responsiveness <strong>of</strong> the Peripheral<br />

Immune System Predicts the 6-Month Risk <strong>of</strong> Infections in<br />

Rheumatoid Arthritis.<br />

Megan L. Krause, John M. Davis III, Michael A. Strausbauch,<br />

Cynthia S. Crowson, Terry M. Therneau, Eric L. Matteson, Keith L.<br />

Knutson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN<br />

9:45 AM<br />

2217. Homozygous 3.2kb Deletion in LEPREL1 (P3H2) Intron<br />

1 Reduces Cytokine Production and Protects from Multiple<br />

Inflammatory Diseases.<br />

Yohei Kirino 14 , Michael J. Ombrello 15 , Ahmet Gul 11 , Kai Wang 1 ,<br />

Akira Meguro 7 , Barbara Yang 14 , Massimo Gadina 14 , Fulya Cosan 11 ,<br />

Neslihan Abaci 3 , Katherine Siminovitch 9 , Peter K. Gregersen 12 ,<br />

Phaedon Kaklamanis 8 , Young-Hun Cho 10 , Dongsik Bang 2 , Hongwei<br />

Sun 14 , Christopher Amos 16 , Massa Hama 4 , Mitsuhiro Takeno 4 ,<br />

Nobuhisa Mizuki 7 , Hidetoshi Inoko 5 , Shigeaki Ohno6, Yoshiaki<br />

Ishigatsubo 17 , Hakon Hakonarson 1 , Daniel L. Kastner 13 and<br />

Elaine Remmers 14 , 1 Center for Applied Genomics, The Children’s<br />

Hospital <strong>of</strong> Philadelphia, 2 Department <strong>of</strong> Dermatology, Yonsei<br />

University <strong>College</strong> <strong>of</strong> Medicine, 3 Department <strong>of</strong> Genetics,<br />

Institute for Experimental Medicine, 4 Department <strong>of</strong> Internal<br />

Medicine and Clinical Immunology, Yokohama City University<br />

Graduate School <strong>of</strong> Medicine, 5 Department <strong>of</strong> Molecular Life<br />

Science, Division <strong>of</strong> Molecular Medical Science and Molecular<br />

Medicine, Tokai University School <strong>of</strong> Medicine, 6 Department<br />

<strong>of</strong> Ocular Inflammation and Immunology, Hokkaido University<br />

Graduate School <strong>of</strong> Medicine, 7 Department <strong>of</strong> Ophthalmology<br />

and Visual Science, Yokohama City University Graduate School<br />

<strong>of</strong> Medicine, 8 Department <strong>of</strong> <strong>Rheumatology</strong>, Athens Medical<br />

Center, Athens, Greece, 9 Departments <strong>of</strong> Medicine, Immunology<br />

and Molecular Genetics, Department <strong>of</strong> Medicine, University <strong>of</strong><br />

Toronto, Mount Sinai Hospital and University Health Network,<br />

10<br />

Graduate School <strong>of</strong> Medical Science and Engineering, KAIST,<br />

11<br />

Istanbul Faculty <strong>of</strong> Medicine, Department <strong>of</strong> Internal Medicine,<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Istanbul University, 12 N Shore Univ<br />

Hosp Rsch Ctr, Manhasset, NY, 13 NIAMS, NIH, Bethesda, MD,<br />

14<br />

NIAMS/National Institute <strong>of</strong> Health, 15 NIAMS/National Institute<br />

<strong>of</strong> Health, Bethesda, MD, 16 University <strong>of</strong> Texas M. D. Anderson<br />

Cancer Center, 17 Yokohama City Grad Sch <strong>of</strong> Med, Yokohama,<br />

Japan<br />

10:00 AM<br />

2218. Association <strong>of</strong> IL2RB Polymorphisms with Erosive Disease<br />

in ACPA Positive Early Rheumatoid Arthritis (RA): Results from<br />

the ESPOIR Cohort.<br />

Adeline Ruyssen-Witrand 3 , Delphine Nigon 4 , Alain G . Cantagrel 5 ,<br />

Cédric Lukas 7 , Jacques Morel 7 , Jean Sibilia 6 , Anne Cambon-<br />

Thomsen 1 and Arnaud L. Constantin 2 , 1 INSERM, U558,<br />

Toulouse, France, 2 Purpan University Hospital, Toulouse, France,<br />

3<br />

<strong>Rheumatology</strong> Center, Purpan Teaching Hospital, Toulouse,<br />

Toulouse, France, 4 <strong>Rheumatology</strong> Center, Purpan Teaching<br />

Hospital, Toulouse, France, 5 <strong>Rheumatology</strong> Center, Purpan<br />

Teaching Hospital, Toulouse, University Paul Sabatier, Toulouse,<br />

France, 6 <strong>Rheumatology</strong> Department, Hautepierre Teaching<br />

Hospital, Strasbourg, France, 7 <strong>Rheumatology</strong> Department,<br />

Lapeyronie Teaching Hospital, Montpellier, France<br />

10:15 AM<br />

2219. Discovery and Replication <strong>of</strong> JIA Predisposition Genes<br />

by Genome-Wide Association and Validation <strong>of</strong> Candidates in<br />

Fibroblast-Like Synoviocytes.<br />

Terri H. Finkel 9 , Haitao Zhang 1 , Benedicte A. Lie 10 , Edward M.<br />

Behrens 3 , Mara L. Becker 2 , Carol Wise 6 , Marilynn Punaro 7 ,<br />

Emma Reuschel 8 , Debra Shivers 8 , Berit Flatø 4 , Øystein Førre 4 ,<br />

Jane Munro 11 , Justine Ellis 11 and Hakon Hakonarson 5 , 1 Center<br />

for Applied Genomics, The Children’s Hospital <strong>of</strong> Philadelphia,<br />

2<br />

Children’s Mercy Hospital, Kansas City, MO, 3 Childrens Hospital<br />

<strong>of</strong> Phil, Philadelphia, PA, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Oslo University Hospital, Rikshospitalet, Norway, 5 Division <strong>of</strong><br />

Genetics, The Children’s Hospital <strong>of</strong> Philadelphia, University <strong>of</strong><br />

Pennsylvania, 6 Division <strong>of</strong> Medical Genetics, Texas Scottish Rite<br />

Hospital for Children, 7 Division <strong>of</strong> <strong>Rheumatology</strong>, Texas Scottish<br />

Rite Hospital for Children, 8 Division <strong>of</strong> <strong>Rheumatology</strong>, The<br />

Children’s Hospital <strong>of</strong> Philadelphia Research Institute, 9 Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, The Children’s Hospital <strong>of</strong> Philadelphia,<br />

University <strong>of</strong> Pennsylvania, Philadelphia, PA, 10 Institute <strong>of</strong><br />

138<br />

2010 Program Book


Immunology, Oslo University Hospital, Rikshospitalet, Norway,<br />

11<br />

Murdoch Childrens Research Institute, Royal Children’s<br />

Hospital, Melbourne, Australia<br />

A410<br />

Imaging <strong>of</strong> Rheumatic Disease: Ultrasound<br />

Moderators: Wolfgang A. Schmidt, MD; Medical Center for<br />

<strong>Rheumatology</strong> Berlin-Buch; Berlin, Germany<br />

Anna Maria Iagnocco, MD; Sapienza University <strong>of</strong> Rome, Rome,<br />

Italy<br />

9:00 AM<br />

2220. High Frequency <strong>of</strong> Subclinical Ultrasound-Detected<br />

Synovitis in Juvenile Idiopathic Arthritis Patients with Clinically-<br />

Defined Inactive Disease.<br />

Silvia Magni-Manzoni 1 , Carlo A. Scirè 3 , Angelo Ravelli 2 , Catherine<br />

Klersy 4 , Silvia Rossi 3 , Valentina Muratore 1 , Chiara Visconti 1 ,<br />

Stefano Lanni 1 , Pietro Merli 1 and Carlomaurizio Montecucco 3 ,<br />

1<br />

Dep.Pediatrics, Fondazione IRCCS Policlinico S. Matteo, Pavia,<br />

Italy, 2 II Pediatric Unit, IRCCS Gaslini, Genova, Italy, 3 Reumatology<br />

Unit, Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy,<br />

4<br />

Scientific Dep, Fondazione IRCCS Policlinico S.Matteo, Pavia,<br />

Italy<br />

9:15 AM<br />

2221. Ultrasonography at the Onset <strong>of</strong> Early Arthritis Predicts<br />

Joint Erosions at One Year: Results <strong>of</strong> the ESPOIR Cohort<br />

Ultrasound Study.<br />

Thomas Funck-Brentano 4 , Fréderique Gandjbakhch 4 , Fabien<br />

Etchepare 4 , Sandrine Jousse 2 , Cedric Lukas 3 , Violaine Foltz 4 , Alain<br />

Saraux 2 , Philippe Goupille 5 , Patrick Boumier 1 , Pierre Bourgeois 4<br />

and Bruno Fautrel 4 , 1 Amiens, 2 Brest Universitary Hospital,<br />

3<br />

Immuno-rhumatologie, Hopital Lapeyronie, Montpellier, France,<br />

4<br />

<strong>Rheumatology</strong> Department, Pitié-Salpetrière Hospital, Paris 6<br />

University, France, 5 Tours Universitary Hospital<br />

9:30 AM<br />

2222. CRP-Levels and Duration <strong>of</strong> Morning Stiffness as<br />

Predictors <strong>of</strong> Active Rheumatoid Arthritis as Verified by<br />

Ultrasound in Routine Clinical Practice.<br />

Christian Dejaco 5 , Christina Duftner 2 , Edith Wipfler-Freißmuth 3 ,<br />

Helmut Weiss 4 , Winfried B. Graninger 5 and Michael Schirmer 1 ,<br />

1<br />

Department <strong>of</strong> Internal Medicine I, Medical University<br />

Innsbruck, Innsbruck, Austria, 2 Department <strong>of</strong> Internal Medicine,<br />

General Hospital <strong>of</strong> the Elisabethinen Klagenfurt, Klagenfurt,<br />

Austria, 3 Department <strong>of</strong> Internal Medicine, Hospital <strong>of</strong> the<br />

Barmherzige Brüder Marschallgasse Graz, Graz, Austria,<br />

4<br />

Department <strong>of</strong> Radiology, General Hospital <strong>of</strong> the Elisabethinen<br />

Klagenfurt, Klagenfurt, Austria, 5 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Medical University Graz, Graz, Austria<br />

9:45 AM<br />

2223. Resistant Tennis Elbow (RTE) Due to Radial Tunnel<br />

Syndrome: Clinical Presentation, Sonographic Findings and<br />

Surgical Correlation.<br />

David A. Bong 3 , Jordi Palau 1 , Ingrid Möller 1 and Esperanza<br />

Naredo 2 , 1 Barcelona Sonoanatomy Group, 2 Hosptial Universitario<br />

Severo Ochoa, Madrid, Spain, 3 Instituto Poal de Reumatologia,<br />

Bruce, WI<br />

10:00 AM<br />

2224. Clinic Based MSK Ultrasound in the Diagnosis and<br />

Treatment <strong>of</strong> Shoulder Pain – A Randomized Prospective Study.<br />

Aamir Saeed 2 , Mumtaz Khan, Siobhan Morrissey and Alexander<br />

D. Fraser 1 , 1 Castleroberts, County Limerick, Ireland, 2 Mid<br />

Western Regional Hospital, Limerick, Ireland<br />

10:15 AM<br />

2225. Sonographic Needle Guidance and Cost-Effectiveness <strong>of</strong><br />

Intraarticular Injections for Osteoarthritis <strong>of</strong> the Knee.<br />

Natalia R. Chavez-Chiang 3 , Wilmer L. Sibbitt 4 , Suzanne Delea 2 ,<br />

Kye Park 6 , Arthur D. Bankhurst 5 , Philip A. Band 1 and Hillary<br />

Norton 3 , 1 New York University School <strong>of</strong> Medicine, 2 University<br />

<strong>of</strong> New Mexico, Albuquerque, NM, 3 University <strong>of</strong> New Mexico,<br />

4<br />

University <strong>of</strong> New Mexico HSC, Albuquerque, NM, 5 University<br />

<strong>of</strong> NM Med Ctr, Albuquerque, NM, 6 Univresity <strong>of</strong> New Mexico,<br />

Albuquerque, NM<br />

A311<br />

Innate Immunity and Rheumatic Disease<br />

Moderators: Robert M. Clancy, PhD ; New York University School<br />

<strong>of</strong> Medicine; New York, NY<br />

George C. Tsokos, MD; Harvard Medical School/Beth Israel<br />

Hospital; Boston, MA<br />

9:00 AM<br />

2226. Identification <strong>of</strong> NLRP1 as a Systemic Sclerosis<br />

Susceptibility Gene: A New Clue for the Contribution <strong>of</strong> Innate<br />

Immunity in SSc Pathogenesis.<br />

Philippe Dieudé 7 , Mickaël Guedj 4 , Julien Wipff 6 , Gabriela<br />

Riemekasten 2 , Paolo Airo 8 , Inga Melchers 1 , Marco Matucci-<br />

Cerinic 10 , Eric Hachulla 5 , Catherine Boileau 9 , Yannick Allanore 3<br />

and and the GENESYS Consortium, 1 Clinical Research Unit for<br />

<strong>Rheumatology</strong>, University Medical Center, Freiburg, Germany,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />

University Hospital, Schumannstr. 20/21, D-10117, Berlin,<br />

Germany, 3 Hopitaux de Paris Cochin, Paris, France, 4 Laboratoire<br />

Statistique et Génome, UMR CNRS-8071 / INRA-1152 /<br />

Université d’Evry Val d’Essonne, France, 5 National Scleroderma<br />

Centre, Lille Cedex, France, 6 Paris Descartes University,<br />

Department <strong>of</strong> <strong>Rheumatology</strong> A, Cochin Hospital, Paris, France,<br />

7<br />

Paris Diderot University, Department <strong>of</strong> <strong>Rheumatology</strong>, Bichat<br />

Claude Bernard Hospital, APHP, Paris, France, 8 <strong>Rheumatology</strong><br />

and Clinical Immunology, Spedali Civili, Brescia, Italy, 9 Saint<br />

Quentin Yvelines University, Laboratoire de Biochimie<br />

Hormonale et Génétique, Ambroise Paré Hospital, AP-HP,<br />

Boulogne, France, 10 University <strong>of</strong> Florence, Firenze, Italy<br />

9:15 AM<br />

2227. MASP-1 and Pro-Factor D Proteins Are Present in<br />

Synoviocytes and May Locally Activate the Complement<br />

Alternative Pathway To Induce Inflammatory Arthritis in Mice.<br />

Nirmal K. Banda 4 , Minoru Takahashi 2 , Magdalena J. Glogowska 4 ,<br />

Kazue Takahashi 3 , Gregory L. Stahl 1 , Teizo Fujita 2 , William<br />

P. Arend 4 and V. Michael Holers 4 , 1 Center for Experimental<br />

Therapeutics and Reperfusion Injury, Brigham and Women’s<br />

Hospital, Boston, MA, 2 Department <strong>of</strong> Immunology, Fukushima<br />

Medical University School <strong>of</strong> Medicine, Fukushima, Japan,<br />

3<br />

Department <strong>of</strong> Immunology, Massachusetts General Hospital<br />

for Children, Boston, MA, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, University<br />

<strong>of</strong> Colorado at Denver, Aurora, CO<br />

thursday<br />

2010 Program Book 139


9:30 AM<br />

2228. Mutated NLRP3 in Cryopyrin-Associated Periodic<br />

Syndromes Is Released from Restriction by CARD8.<br />

Sayaka Ito 2 , Yukichi Hara 3 , Yukio Shima 1 and Tetsuo Kubota 3 ,<br />

1<br />

Kyorin University, 2 Tokyo Medical and Dental University, Tokyo,<br />

Japan, 3 Tokyo Medical and Dental University<br />

Jochen Zwerina 5 , Georg Schett 5 , Stefan Dübel 3 and Reinhard<br />

Voll5, 1 Georg-August-University <strong>of</strong> Göttingen, 2 Johann Wolfgang<br />

Goethe University Frankfurt am Main, 3 Technical University<br />

<strong>of</strong> Braunschweig, 4 University <strong>of</strong> Erlangen-Nürnberg, Erlangen,<br />

Germany, 5 University <strong>of</strong> Erlangen-Nürnberg, 6 University <strong>of</strong><br />

Münster<br />

thursday<br />

9:45 AM<br />

2229. Complement Component C5 Plays a Central Role in<br />

Osteoarthritis.<br />

William Robinson 3 , Andrew L. Rozelle 1 , Tamsin M. Lindstrom,<br />

Reuben Gobezie, V. Michael Holers 4 , David M. Lee 2 and Qian<br />

Wang, 1 Menlo Park, CA, 2 Brigham and Womens Hospital, Boston,<br />

MA, 3 Stanford Univ School <strong>of</strong> Med, Stanford, CA, 4 Univ <strong>of</strong><br />

Colorado School <strong>of</strong> Med, Aurora, CO<br />

10:00 AM<br />

2230. Toll-Like Receptor 2 Negatively Regulates FCg Receptor<br />

Response in Macrophages and Inhibits FCgR-Mediated<br />

Arthritis.<br />

Shahla Abdollahi-Roodsaz 3 , Marije I. Koenders 2 , Fons A. J. van de<br />

Loo 4 and Wim B. Van Den Berg 1 , 1 Radboud Univ Nijmegen Med<br />

Cntr, Nijmegen, The Netherlands, 2 <strong>Rheumatology</strong> Research and<br />

Advanced Therapeutics, Radboud University Nijmegen Medical<br />

Centre, Nijmegen, 3 <strong>Rheumatology</strong> Research and Advanced<br />

Therapeutics, Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands, Nijmegen, The Netherlands,<br />

4<br />

<strong>Rheumatology</strong> Research and Advanced Therapeutics, Radboud<br />

University Nijmegen Medical Centre, Nijmegen, The Netherlands<br />

10:15 AM<br />

2231. A Novel Role <strong>of</strong> Endothelin-1 in Linking Ro60-ssRNA<br />

Immune Complexes to Cardiac Fibrosis in Congenital Heart<br />

Block.<br />

David Alvarez-Carbonell 4 , Jiri Zavadil 5 , Rosanna Abellar 1 , Franck<br />

Barrat 2 , Robert Clancy 3 and Jill Buyon 5 , 1 Columbia University<br />

Medical Center, 2 Dynavax Technologies, 3 New York University<br />

School <strong>of</strong> Mediciine, 4 New York University School <strong>of</strong> Medicine,<br />

New York, NY, 5 New York University School <strong>of</strong> Medicine<br />

B402<br />

Rheumatoid Arthritis - Animal Models: T cell<br />

Pathogenesis and Novel Therapeutic Targets II<br />

Moderators: Linda K. Myers, MD; Univeristy <strong>of</strong> Tennessee<br />

Medical Group Inc.; Memphis, TN<br />

Paul H. Wooley, PhD; Christi Regional Medical Center,<br />

Orthopaedic Research Instititue; Wichita, KS<br />

9:00 AM<br />

2232. Mucosal Associated Invariant T Cells Contribute to the<br />

Pathogenesis <strong>of</strong> Arthritis.<br />

Asako Chiba, Ryohsuke Tajima, Yusei Miyazaki, Takashi<br />

Yamamura and Sachiko Miyake, Department <strong>of</strong> Immunology,<br />

National Institute <strong>of</strong> Neuroscience, NCNP<br />

9:15 AM<br />

2233. WITHDRAWN<br />

9:30 AM<br />

2234. An Endothelium-Specific NF-kappaB Inhibitor<br />

Ameliorates Inflammatory Joint Diseases.<br />

Bettina Sehnert 4 , Harald Burkhardt 2 , Falk Nimmerjahn 5 , Johannes<br />

Wessels 1 , Agnes Machnik 5 , Dietmar Vestweber 6 ,<br />

9:45 AM<br />

2235. Citrullination <strong>of</strong> Mouse Collagen Breaks Tolerance and<br />

Induces an Inflammatory Arthritis in the Absence <strong>of</strong> Adjuvant.<br />

Jordan P. Lacy, Michael J. Duryee, Carlos D. Hunter, James R.<br />

O’Dell, Ted R. Mikuls, Ge<strong>of</strong>frey M. Thiele and Lynell W. Klassen,<br />

University <strong>of</strong> Nebraska Medical Center<br />

10:00 AM<br />

2236. Differentiation and Activation <strong>of</strong> Regulatory<br />

T-Lymphocytes in a TNF-alpha Transgenic Model <strong>of</strong> Arthritis,<br />

and the Impact <strong>of</strong> Passive or Active Anti-TNF Therapies.<br />

Jerome Biton 2 , Luca Semerano 3 , Laure Delavallée 2 , Geraldine<br />

Grouard-Vogel 1 , Delphine Lemeiter 2 , Marie-Christophe Boissier 3<br />

and Natacha Bessis 2 , 1 Neovacs, Paris, France, 2 Paris 13 University,<br />

Bobigny, France, 3 Paris 13 University and APHP, Bobigny, France<br />

10:15 AM<br />

2237. The TRAF6 Binding Molecule p62/SQSTM1 Controls<br />

Inflammatory Bone Destruction in hTNFtg Mice.<br />

Adelheid Korb 7 , Marianne Niedermeier 3 , Anja Hillmann 7 ,<br />

Susanne Bürgis 1 , George Kollias 5 , Sven Herrmann 2 , Thomas Pap 4 ,<br />

Thomas Weide 7 , André Gessner 6 and Herrmann Pavenstädt 7 ,<br />

1<br />

Department <strong>of</strong> Immunology, University Erlangen, Erlangen,<br />

Germany, 2 European Institute <strong>of</strong> Molecular Imaging, University<br />

Muenster, Germany, 3 Institute for Experimental Musculoskeletal<br />

Medicine, University Hospital Muenster, Muenster, Germany,<br />

4<br />

Institute for Experimental Musuculoskeletal Medicine,<br />

University Hospital Muenster, Muenster, Germany, 5 Institute <strong>of</strong><br />

Immunology, Biomedical Science Research Center, Vari, Greece,<br />

6<br />

Institute <strong>of</strong> Microbiology - Clinical Microbiology, Immunology<br />

and Hygiene, University Hospital Erlangen, Erlangen,<br />

Germany, 7 Internal Medicine D, Department <strong>of</strong> Nephrology<br />

and <strong>Rheumatology</strong>, University Hospital Muenster, Muenster,<br />

Germany<br />

A412<br />

Systemic Lupus Erythematosus - Clinical Aspects and<br />

Treatment<br />

Moderators: Murat Inanc, MD; Istanbul University, Istanbul<br />

Faculty <strong>of</strong> Medicine; Istanbul, Turkey<br />

Diane L. Kamen, MD; Medical University <strong>of</strong> South Carolina;<br />

Charleston, SC<br />

9:00 AM<br />

2238. Low Blood Concentration <strong>of</strong> Hydroxychloroquine Is<br />

Associated with Failure <strong>of</strong> Hydroxychloroquine Treatment in<br />

Patients with Cutaneous Lupus: Results <strong>of</strong> a Prospective Study.<br />

Camille Francès 1 , Anne Cosnes 1 , Pierre Duhaut 2 , Noël Zahr 3 ,<br />

Boutros Soutou 1 , Saskia Oro 1 , Didier Bessis 1 , Jacqueline<br />

Chevrant-Breton 1 , Nadege Cordel 1 , Dan Lipsker 1 and Nathalie<br />

Costedoat-Chalumeau 3 , 1 Department <strong>of</strong> Dermatology, Hôpital<br />

Tenon, Paris, France, 2 Department <strong>of</strong> Dermatology, Hôpital<br />

Tenon, 3 Internal Medicine Department, French National<br />

Reference Center for SLE, Pitié-Salpêtrière Hospital (GHPS), Paris,<br />

France<br />

140<br />

2010 Program Book


9:15 AM<br />

2239. Factors Associated with Low Blood Concentration <strong>of</strong><br />

Hydroxychloroquine in 523 Patients with Systemic Lupus<br />

Erythematosus: Data from the PLUS Study.<br />

Nathalie Costedoat-Chalumeau 2 , Lionel Galicier 2 , Camille<br />

Francès 2 , Olivier Aumaître 2 , Frédéric Lioté 2 , Véronique Le Guern 2 ,<br />

Nicolas Limal 2 , Amar Smail 2 , J. Ninet 2 , Laurent Perard 2 , Du Le Thi<br />

Huong 2 , Bouchra Asli 2 , Catherine Grandpeix 2 , Laurent Sailler 2 ,<br />

F. Ackermann 2 , Thomas Papo 2 , Benoit Brihaye 2 , Olivier Fain 2 ,<br />

Jérome Stirnemann 2 , Moez Jallouli 2 , Gaelle Leroux 2 , Jean-<br />

Sébastien Hulot 2 , Philippe Lechat 2 , Lucile Musset 2 , Jean-Charles<br />

Piette 2 , Zahir Amoura 2 and The Investigators <strong>of</strong> the PLUS Study 1 ,<br />

1<br />

Internal Medicine Department, French National Reference<br />

Center for SLE, Pitié-Salpêtrière Hospital, Paris, France, 2 Internal<br />

Medicine Department, French National Reference Center for<br />

SLE, Pitié-Salpêtrière Hospital<br />

9:30 AM<br />

2240. Mortality in a Multinational Inception Cohort <strong>of</strong> SLE.<br />

Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique Ibanez 32 ,<br />

Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E. Clarke 15 , Sasha<br />

R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 , John G. Hanly 19 ,<br />

David A. Isenberg 24 , Anisur Rahman 25 , Paul R. Fortin 33 , Daniel<br />

J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 , Graciela S.<br />

Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar K. Sturfelt 27 ,<br />

Ola Nived 27 , Kristjan Steinsson 12 , Munther A. Khamashta 21 ,<br />

Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi34,<br />

Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 , Cynthia B.<br />

Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 ,<br />

Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 ,<br />

Diane L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 30 , 1 West<br />

Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta,<br />

GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital,<br />

East Kilbride, United Kingdom, 6 Hanyang University Medical<br />

Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial,<br />

8<br />

Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto<br />

Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantonsspital<br />

Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University<br />

Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal<br />

Infirmary, Manchester, United Kingdom, 14 Medical University<br />

South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />

Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn<br />

Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />

18<br />

Oklahoma Med Research Foundation, Oklahoma City, OK,<br />

19<br />

Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />

20<br />

SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />

Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />

Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />

24<br />

UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong><br />

Medicine, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 University<br />

Hospital Lund, Lund, Sweden, 28 University <strong>of</strong> Alabama, Oakland,<br />

CA, 29 University <strong>of</strong> Birmingham, Birmingham, United Kingdom,<br />

30<br />

University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 31 University<br />

<strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 32 University <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, 33 University <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />

Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA<br />

9:45 AM<br />

2241. Mycophenolate M<strong>of</strong>etil and Hydroxychloroquine but Not<br />

Azathioprine Improve HDL Function in Women with SLE.<br />

Maureen McMahon 3 , Jennifer M. Grossman 4 , Jessica Gomez 3 ,<br />

Lori Sahakian 3 , Weiling Chen 3 , John Fitzgerald 3 , Brian Skaggs 2 ,<br />

Joan T. Merrill 1 and Bevra H. Hahn 5 , 1 Oklahoma Med Research<br />

Foundation, Oklahoma City, OK, 2 UCLA, Los Angeles, CA, 3 UCLA<br />

School <strong>of</strong> Medicine, Los Angeles, CA, 4 University <strong>of</strong> California Los<br />

Angeles, Sherman Oaks, CA, 5 University <strong>of</strong> California Los Angeles<br />

School <strong>of</strong> Medicine, Los Angeles, CA<br />

10:00 AM<br />

2242. Screening for Cognitive Impairment in Systemic Lupus<br />

Erythematosus.<br />

John G. Hanly 2 , Li Su 3 , Vern Farewell 3 , Tina Linehan 1 and John D.<br />

Fisk 2 , 1 Capital Health, Halifax, NS, Canada, 2 Capital Health and<br />

Dalhousie University, Halifax, NS, Canada, 3 MRC Biostatistics<br />

Unit, Institute <strong>of</strong> Public Health, University Forvie Site,<br />

Cambridge, UK<br />

10:15 AM<br />

2243. Autoantibodies as Biomarkers for the Prediction <strong>of</strong><br />

Neuropsychiatric Events in Systemic Lupus Erythematosus.<br />

John G. Hanly 2 , Murray B. Urowitz 20 , Li Su 13 , Sang Cheol-Bae 6 ,<br />

Caroline Gordon 26 , Jorge Sanchez-Guerrero 7 , Ann Clarke 12 , Sasha<br />

Bernatsky 12 , Archana Vasudevan 17 , David Isenberg 23 , Anisur<br />

Rahman 23 , Daniel J. Wallace 3 , Paul Fortin 20 , Dafna Gladman 20 ,<br />

Mary Anne Dooley 28 , Ian Bruce 19 , Kristjan Steinsson 10 , Munther<br />

Khamashta 18 , Susan Manzi 29 , Rosalind Ramsey-Goldman 14 ,<br />

Gunnar Sturfelt 24 , Ola Nived 24 , Cynthia Aranow 4 , Ronald van<br />

Vollenhoven 9 , Manuel Ramos-Casals 16 , Ken Kalunian 21 , Graciela<br />

Alarcon 25 , Barri J. Fessler 25 , Guillermo Ruiz-Irastorza 22 , Michelle<br />

Petri 8 , Sam Lim 5 , Diane Kamen 11 , Christine Peschken 27 , Vern<br />

Farewell 13 , Kara Thompson 2 , Chris Theriault 1 and Joan Merrill 15 ,<br />

1<br />

Capital Health, Halifax, NS, Canada, 2 Capital Health and<br />

Dalhousie University, Halifax, NS, Canada, 3 Cedars-Sinai/David<br />

Geffen School <strong>of</strong> Medicine at UCLA, Los Angeles, CA, 4 Columbia<br />

University Medical Center, New York, NY, 5 Emory University,<br />

Atlanta, GA, 6 Hanyang University Hospital for Rheumatic<br />

DIseases, Seoul, Korea, 7 Instituto Nacional de Ciencias Medicas<br />

y Nutricion, Mexico City, Mexico, 8 John Hopkins University<br />

School <strong>of</strong> Medicine, Baltimore, MD, 9 Karolinska Institute,<br />

Stockholm, Sweden, 10 Landspitali University Hospital, Reykjavik,<br />

Iceland, 11 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />

12<br />

Montreal General Hospital, McGill University Health Centre,<br />

Montreal, QC, Canada, 13 MRC Biostatistics Unit, Institute<br />

<strong>of</strong> Public Health, University Forvie Site, Cambridge, United<br />

Kingdom, 14 Northwestern University and Feinberg School <strong>of</strong><br />

Medicine, Chicago, IL, 15 Oklahoma Medical Research Foundation,<br />

Oklahoma City, OK, 16 Servicio Enfermedades Autoinmunes<br />

Hospital Clínico y Provincial, Barcelona, Spain, 17 SUNY Downstate<br />

Medical Center, Brooklyn, NY, 18 The Rayne Institute, St. Thomas’<br />

Hospital, King’s <strong>College</strong> London School <strong>of</strong> Medicine, London,<br />

United Kingdom, 19 The University <strong>of</strong> Manchester, Manchester,<br />

United Kingdom, 20 Toronto Western Hospital and University<br />

<strong>of</strong> Toronto, ON, Canada, 21 UCSD School <strong>of</strong> Medicine, La Jolla,<br />

CA, 22 Universidad del Pais Vasco, Barcelona, Spain, 23 University<br />

<strong>College</strong>, London, United Kingdom, 24 University Hospital<br />

Lund, Lund, Sweden, 25 University <strong>of</strong> Alabama at Birmingham,<br />

thursday<br />

2010 Program Book 141


thursday<br />

Birmingham, AL, 26 University <strong>of</strong> Birmingham, Birmingham,<br />

United Kingdom, 27 University <strong>of</strong> Manitoba, Winnipeg, Canada,<br />

28<br />

University <strong>of</strong> North Carolina, Chapel Hill, NC, 29 University <strong>of</strong><br />

Pittsburgh School <strong>of</strong> Medicine, Pittsburgh, PA<br />

ARHP Concurrent Abstract Session<br />

9:15 - 10:45 AM<br />

B311<br />

What a Pain Rheumatic Diseases Can Be!<br />

Moderator: Brett D. Thombs, MA, PhD; McGill University;<br />

Montreal, QC, Canada<br />

9:15 AM<br />

2244. Patell<strong>of</strong>emoral Osteoarthritis in Middle-Aged Adults:<br />

What Are the Best Measures <strong>of</strong> Physical Performance and Pain<br />

for Use in the Clinic and in Research?<br />

Lisa T. Hoglund 3 , Margery A. Lockard 1 , Jinsup Song 2 and Mary<br />

F. Barbe 2 , 1 Drexel University, Dresher, PA, 2 Temple University,<br />

Philadelphia, PA, 3 University <strong>of</strong> the Sciences in Philadelphia,<br />

Morrisville, PA<br />

9:30 AM<br />

2245. Differences in Muscle Strength and Pain Thresholds<br />

between Postmenopausal Women with and without RA.<br />

Ulrika Thoors, Christina H. Opava, Birgitta Glenmark, Eva Kosek,<br />

Ingrid E. Lundberg and Cecilia Fridén, Karolinska Institutet,<br />

Stockholm, Sweden<br />

9:45 AM<br />

2246. Fibromyalgia Diagnosis Is Significantly Impacted by the<br />

Number <strong>of</strong> Tender Points Presented on Patient Physical Exam.<br />

Terence W. Starz 1 , Robert J. Sanchez 2 , Bruce Duncan 3 , Kaite Ka 3 ,<br />

Elizabeth Pinner 2 , Shera D. Gruen 2 and Dennis C. Turk 4 , 1 Arthritis<br />

& Internal Med Associates, Pittsburgh, PA, 2 Pfizer, 3 Roger Green<br />

and Associates, 4 University <strong>of</strong> Washington, Seattle, WA<br />

10:00 AM<br />

2247. Measuring Pain in Systemic Sclerosis: The Short-Form<br />

McGill Pain Questionnaire or a Single Item Measure <strong>of</strong> Pain? A<br />

Confirmatory Factor Analysis.<br />

Ghassan El Baalbaki 1 , Janie Lober 2 , Marie Hudson 4 , Murray<br />

Baron 1 , Brett D. Thombs 3 and Canadian Scleroderma Research<br />

Group (CSRG), 1 Jewish General Hospital, Montreal, QC, Canada,<br />

2<br />

McGill University, 3 McGill University, Montreal, QC, Canada,<br />

4<br />

McGill University and Jewish General Hospital<br />

10:15 AM<br />

2248. Daily Electronic Reports <strong>of</strong> Pain and Activity Difficulties<br />

in Children with JIA Versus Children with Other Rheumatic<br />

Diseases.<br />

Mark Connelly 1 , Maggie H. Bromberg 4 , Kelly K. Anthony 3 , Lindsey<br />

Franks 2 , Karen M. Gil 4 and Laura E. Schanberg 2 , 1 Children’s Mercy<br />

Hospital and Clinics, Kansas City, MO, 2 Duke University Medical<br />

Center, Durham, NC, 3 Duke Unviversity Medical Center, Durham,<br />

NC, 4 University <strong>of</strong> North Carolina at Chapel Hill<br />

10:30 AM<br />

2249. How Do Patients Approach Risk-Benefit Trade-Offs: A<br />

Qualitative Analysis Using a Think Aloud Protocol.<br />

Liana Fraenkel, Paul Falzer and Kristin Mattocks, Yale University,<br />

Newtown, CT<br />

ARHP Concurrent Sessions<br />

9:15 - 10:45 AM<br />

B310<br />

Putting ACR Osteoarthritis Guidelines into Practice:<br />

Clinical Applications for the Hip and Knee c/r PM<br />

PS<br />

Moderator: Donald R. Miller, PharmD; North Dakota State<br />

University; Fargo, ND<br />

Speakers: G. Kelley Fitzgerald, PhD, PT; University <strong>of</strong> Pittsburgh;<br />

Pittsburgh, PA<br />

Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />

Kyle Gibson; University <strong>of</strong> Missouri; Columbia, MO<br />

Session Overview:<br />

Osteoarthritis is the primary cause <strong>of</strong> physical disability in adults<br />

and is a diagnosis commonly seen by therapists. Evidencebased<br />

practice is a pr<strong>of</strong>essional expectation, and the soon to be<br />

released ACR Guidelines for the Management <strong>of</strong> Osteoarthritis<br />

<strong>of</strong> the Hip, Knee and Hand, <strong>of</strong>fer practitioners a rich resource<br />

for clinical decision-making. However, the appropriate use <strong>of</strong><br />

evidence in practice requires both knowledge <strong>of</strong> the evidence<br />

and skills to apply the evidence in a clinical setting. For a busy<br />

practitioner, evidence-based practice behaviors are influenced<br />

by a number <strong>of</strong> factors, including belief in the relevance <strong>of</strong><br />

the evidence and self-efficacy for evidence-based practice.<br />

The purpose <strong>of</strong> this session is to provide therapists with the<br />

knowledge and skills to effectively apply the ACR osteoarthritis<br />

guidelines to management <strong>of</strong> hip and knee osteoarthritis in<br />

clinical practice.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the clinical relevancy <strong>of</strong> the guidelines<br />

• select best tests/measures and interventions consistent with<br />

the guidelines<br />

• determine client characteristics that influence response to<br />

specific interventions<br />

• describe treatment plans consistent with guideline<br />

recommendations and specific patient characteristics<br />

B309<br />

Teaching Our Pediatric Patients: Making the Complex<br />

Simple P/C PS<br />

Moderator: Karla B. Jones, MS, RN, CPNP; Nationwide Children’s<br />

Hospital; Columbus, OH<br />

Speakers: Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los<br />

Angeles; Los Angeles, CA<br />

Session Overview:<br />

Treatment success in children with rheumatic conditions<br />

requires that both parents and the children have an<br />

understanding <strong>of</strong> these very complex diseases. Health care<br />

providers are faced with assessing and educating not only<br />

the parents but the child or adolescent. This requires an<br />

interdisciplinary team with specific skills to evaluate the child’s<br />

psychological development level to best meet their educational<br />

needs with those <strong>of</strong> their adult parents. In addition, determining<br />

age appropriate materials that meet the needs <strong>of</strong> both children<br />

and parents is essential.<br />

142<br />

2010 Program Book


Upon completion <strong>of</strong> this session, participants should be able to:<br />

• review the disease process <strong>of</strong> systemic lupus erythematosus<br />

and juvenile idiopathic arthritis and the most common<br />

medications utilized<br />

• discuss age appropriate methods to educate children and<br />

adolescents regarding SLE and JIA<br />

• discuss age appropriate methods to educate children and<br />

adolescents regarding common treatments used for SLE and<br />

JIA<br />

• identify available age appropriate materials and resources for<br />

patient, family, and educators use<br />

ACR Clinical Symposium<br />

11:00 AM - 12:30 PM<br />

B406<br />

2010 ACR Recommendations for the Treatment <strong>of</strong><br />

Juvenile Idiopathic Arthritis P PS<br />

Moderator: Liana Fraenkel, MD, MPH; Yale University; Newtown,<br />

CT<br />

11:00 AM<br />

ACR Recommendations for the Treatment <strong>of</strong> Juvenile Idiopathic<br />

Arthritis<br />

Timothy Beukelman, MD, MSCE; University <strong>of</strong> Alabama-<br />

Birmingham; Birmingham, AL<br />

12:00 PM<br />

Panel Discussion<br />

Timothy Beukelman, MD, MSCE; University <strong>of</strong> Alabama-<br />

Birmingham; Birmingham, AL<br />

Daniel J. Lovell, MD, MPH; Children’s Hospital Medical Center;<br />

Cincinnati, OH<br />

Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,<br />

NY<br />

Session Overview:<br />

Major advances in treatment over the last 15 years have<br />

greatly improved outcomes for children with juvenile idiopathic<br />

arthritis, yet there are no prior validated guidelines <strong>of</strong>fering<br />

recommendations for the safest and most effective treatment<br />

<strong>of</strong> juvenile idiopathic arthritis. Clinical practice guidelines are an<br />

important way to promote effective care and to improve patient<br />

outcomes. This symposium will present the methodology and<br />

results <strong>of</strong> the newly developed evidence and consensus-based<br />

ACR recommendations for the treatment <strong>of</strong> juvenile idiopathic<br />

arthritis and seek public feedback and discussion.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe the recommended treatment approach for different<br />

juvenile idiopathic arthritis phenotypes: 4 or fewer affected<br />

joints; 5 or more affected joints; presence <strong>of</strong> sacroiliitis;<br />

systemic arthritis<br />

• apply the recommended indications for biologic agents in the<br />

treatment <strong>of</strong> juvenile idiopathic arthritis<br />

• review the recommendations for monitoring <strong>of</strong> adverse<br />

effects <strong>of</strong> therapeutics in juvenile idiopathic arthritis<br />

ACR Concurrent Abstract Sessions<br />

11:00 AM – 12:30 PM<br />

A410<br />

Antiphospholipid Syndrome II<br />

Moderators: Silvia Pierangeli, MD; University <strong>of</strong> Texas Medical<br />

Branch, Galeston, TX<br />

Robert A.S. Roubey, MD; University <strong>of</strong> North Carolina; Chapel<br />

Hill, NC<br />

11:00 AM<br />

2250. Evaluation <strong>of</strong> ‘Non-Criteria” Antiphospholipid (aPL)<br />

Assays at a Wet Workshop during the 13th International<br />

Congress on Antiphospholipid Antibodies.<br />

Roger Albesa 1 , Victoria Nelson 1 , Zakera Shums 1 , Gary Norman 1 ,<br />

X.-X. Gu 2 , Jacob Rand 2 , Walter Binder 1 , Bas deLaat 4 and Silvia<br />

S. Pierangeli 3 , 1 INOVA Diagnostics, San Diego, CA, 2 Montefiore,<br />

Albert Einstein School <strong>of</strong> Medicine, New York, NY, 3 Univ <strong>of</strong> TX<br />

Med Branch, Galveston, Galveston, TX, 4 Utretch Medical Center,<br />

Utrecht, The Netherlands<br />

11:15 AM<br />

2251. Evaluation <strong>of</strong> the Performance <strong>of</strong> Monoclonal and<br />

Polyclonal Antibody Standards in Different Assays for the<br />

Detection <strong>of</strong> Antiphospholipid (aPL) Antibodies: Report<br />

<strong>of</strong> a Wet Workshop at the 13th International Congress on<br />

Antiphospholipid Antibodies.<br />

Ricardo Forastiero 8 , Elizabeth Papalardo 6 , Michael Watkins 1 ,<br />

Hoang Nguyen 1 , Maria Crisostomo 1 , Wendy Vandam 1 , JOel<br />

Hardy 1 , Roger Albesa 2 , Victoria Nelson 2 , Zakera Shums 2 , Gary<br />

Norman 2 , Walter Binder 2 , Kerrie Morin 3 , Catherine Kirbach 3 ,<br />

Karl Mattias 4 , Gabriella Lakos 5 and Sivia S. Pierangeli 7 , 1Bio-Rad<br />

Laboratories, Hercules, CA, 2 INOVA Diagnostics, San Diego, Ca,<br />

3<br />

Instrumentation Laboratories, Bedford, MA, 4 Phadia GMBH,<br />

Freiburg, Germany, 5 TherTest, Lombard, IL, 6 Univ <strong>of</strong> TX Med<br />

Branch, Galveston, Galveston, TX, 7 Univ <strong>of</strong> TX Med Branch,<br />

Galveston, TX, 8 Universidad Favaloro, Buenos Aires, Argentina<br />

11:30 AM<br />

2252. Comparative Evaluation <strong>of</strong> Different Immunoassays<br />

for the Detection <strong>of</strong> Antiphospholipid Antibodies: Report <strong>of</strong><br />

a Wet Workshop during the 13th International Congress on<br />

Antiphospholipid Antibodies.<br />

Ricardo Forastiero 9 , Elizabeth Papalardo 8 , Kerrie Morin 4 ,<br />

Catherine Quirbach 4 , Gabriella Lakos 6 , Karl Mattias 5 , Roger<br />

Albesa 3 , Victoria Nelson 3 , Zakera Shums 3 , Gary Norman 3 ,<br />

Walter Binder 3 , Bruno Larida 1 , Maria Crisostomo 2 , Michael<br />

Watkins 2 , Hoang Nguyen 2 , Wendy Vandam 2 , Joel Hardy 2 and<br />

Silvia S. Pierangeli 7 , 1 Bio-Rad Laboratories, Hercules, CA, 2 Bio-<br />

Rad Laboratories, Her, 3 INOVA Diagnostics, San Diego, CA,<br />

4<br />

Instrumentation Laboratories, Bedford, MA, 5 Phadia GMBH,<br />

Freiburg, Germany, 6 TheraTest Laboratories, Lombard, IL, 7 Univ<br />

<strong>of</strong> TX Med Branch, Galveston, Galveston, TX, 8 Univ <strong>of</strong> TX Med<br />

Branch, Galveston, TX, 9 Universidad Favaloro, Buenos Aires<br />

Argentina<br />

11:45 AM<br />

2253. Elevated Cytokines and Chemokine Levels in<br />

Antiphospholipid Antibody (aPL)-Positive Patients.<br />

Vijaya L. Murthy, Shraddha Jatwani, Renan A. Aguilar-Valenzuela,<br />

Ellis D. Doan, Elizabeth Papalardo, Emilio B. González and Silvia<br />

S. Pierangeli, University <strong>of</strong> Texas Medical Branch, Galveston, TX<br />

thursday<br />

2010 Program Book 143


12:00 PM<br />

2254. The Involvement <strong>of</strong> CD36 in the Monocyte Activation by<br />

Antiphospholipid Antibodies.<br />

Masaru Kato 1 , Tatsuya Atsumi 2 , Kenji Oku 3 , Olga Amengual 3 ,<br />

Yuichiro Fujieda 3 , Kotaro Otomo 3 , Tetsuya Horita 3 , Shinsuke<br />

Yasuda 3 and Takao Koike 3 , 1 Department <strong>of</strong> Medicine II, Hokkaido<br />

University Graduate School <strong>of</strong> Medicine, Sapporo, Hokkaido,<br />

Japan, 2 Department <strong>of</strong> Medicine II, Hokkaido University<br />

Graduate School <strong>of</strong> Medicine, Sapporo, Japan, 3 Department <strong>of</strong><br />

Medicine II, Hokkaido University Graduate School <strong>of</strong> Medicine<br />

12:15 PM<br />

2255. Potential Protein Targets for the Treatment<br />

<strong>of</strong> the Antiphospholipid Syndrome with Statins and<br />

Hydroxychloroquine.<br />

Anastasia Lambrianides 2 , Silvia S. Pierangeli 1 , Katie Bell 3 , Wendy<br />

Heywood 3 , David S. Latchman 3 , David A. Isenberg 3 , Anisur<br />

Rahman 3 and Ian Giles 3 , 1 Univ <strong>of</strong> TX Medical Branch, Galveston,<br />

TX, 2 University <strong>College</strong> London, London, United Kingdom,<br />

3<br />

University <strong>College</strong> London, London, UK<br />

B313<br />

Rheumatoid Arthritis - Clinical Aspects: Radiographic<br />

and Other Outcomes in RA IV<br />

Moderators: Earnest Choy, MD; Kings <strong>College</strong> Hospital; London,<br />

United Kingdom<br />

Piet L. Van Riel, MD, PhD; University Hospital Nijmegen;<br />

Nijmegen, The Netherlands<br />

12:00 PM<br />

2260. Interleukin-6 Levels Are Associated with Elevated Ankle<br />

Brachial Index in Rheumatoid Arthritis.<br />

Cecilia P. Chung 4 , Jon T. Giles 3 , Moyses Szklo 5 , Wendy Post 5 ,<br />

Michelle A. Petri 1 , Roger Blumenthal 5 , Allan C. Gelber 2 , Russell<br />

Tracy 6 and Joan M. Bathon 4 , 1 Timonium, MD, 2 Baltimore, MD,<br />

3<br />

Johns Hopkins Univ, Baltimore, MD, 4 Johns Hopkins University,<br />

Baltimore, MD, 5 Johns Hopkins University, 6 University <strong>of</strong><br />

Vermont<br />

12:15 PM<br />

2261. Diagnostic Accuracy <strong>of</strong> the 2010 ACR/EULAR Used at<br />

Baseline after a 10 Year Follow Up in a Cohort <strong>of</strong> Patients with<br />

Recent-Onset Arthritis.<br />

Divi Cornec 5 , Sophie Varache 6 , Johanne Morvan 5 , Valérie<br />

Devauchelle-pensec 5 , Jean-Marie Berthelot 7 , Sandrine Joussejoulin<br />

5 , Catherine Le Henaff 2 , Sylvie Hoang 4 , Jean-Baptiste<br />

Thorel 1 , Antoine Martin 3 , Gérard Chalès 8 , Pierre Youinou 5 and<br />

Alain Saraux 5 , 1 CH Lorient, 2 CH Morlaix, 3 CH St Brieuc, 4 CH<br />

Vannes, 5 CHU Brest, 6 CHU Brest, 7 CHU Nantes, 8 CHU Rennes<br />

B402<br />

Rheumatoid Arthritis Treatment - Small Molecules,<br />

Biologics and Gene Therapy: Existing Biologics IV<br />

Moderators: Daniel E. Furst, MD; University <strong>of</strong> California Los<br />

Angeles Medical School; Los Angeles, CA<br />

Veena K. Ranganath, MD; University <strong>of</strong> California Los Angeles<br />

Medical School; Los Angeles, CA<br />

thursday<br />

11:00 AM<br />

2256. Irreversible Physical Disability in Rheumatoid Arthritis<br />

(RA) Is Determined by Cartilage Damage Rather Than Bone<br />

Destruction.<br />

Josef S. Smolen 2 and Daniel Aletaha 1 , 1 Medical University <strong>of</strong><br />

Vienna, Austria, 2 Medical University <strong>of</strong> Vienna and Hietzing<br />

Hospital, Vienna, Austria<br />

11:15 AM<br />

2257. The Impact <strong>of</strong> Body Weight on the Progression <strong>of</strong><br />

Radiographic Joint Damage in Rheumatoid Arthritis Patients.<br />

Axel Finckh 4 , Almut Scherer 1 , Anne Lubbeke-Wolff 3 , Hans<br />

Schwarz 1 and Cem Gabay 2 , 1 SCQM Foundation, Switzerland,<br />

2<br />

Univ Hosp <strong>of</strong> Geneva, Geneva, Switzerland, 3 University <strong>of</strong><br />

Geneva, Switzerland, 4 University <strong>of</strong> Geneva, Geneva, Switzerland<br />

11:30 AM<br />

2258. Clinical Rather Than Serologic Measures <strong>of</strong> Inflammation<br />

Determine Radiographic Progression in Rheumatoid Arthritis<br />

(RA).<br />

Daniel Aletaha 1 and Josef S. Smolen 2 , 1 Medical University <strong>of</strong><br />

Vienna, Austria, 2 Medical University <strong>of</strong> Vienna and Hietzing<br />

Hospital, Vienna, Austria<br />

11:45 AM<br />

2259. Coronary Atherosclerosis in Patients with RA and Acute<br />

Coronary Events: No Different Than in the Rest <strong>of</strong> Us?<br />

Marie E. Holmqvist 1 , Lennart T. H. Jacobsson 3 , Lars Alfredsson 1 ,<br />

Stefan James 4 and Johan Askling 2 , 1 Karolinska Institutet,<br />

2<br />

Karolinska University Hospital, 3 Malmö University Hospital,<br />

4<br />

Uppsala University Hospital<br />

11:00 AM<br />

2262. Tocilizumab (TCZ) Plus Methotrexate (MTX) in<br />

Rheumatoid Arthritis (RA) Patients (pts) Who Increased TCZ<br />

Dose from 4 mg/kg to 8 mg/kg: LITHE Radiographic and Safety<br />

Data.<br />

Roy M. Fleischmann 4 , Ricardo Blanco 2 , Geraldo Castelar-<br />

Pinheiro 3 , Emma Vernon 5 , Christopher Mela 5 and Joel M.<br />

Kremer 1 , 1 Albany Medical <strong>College</strong>, Albany, NY, 2 Hospital Marqués<br />

de Valdecilla Cantabria, 3 Hospital Universitario Pedro Ernesto,<br />

Rio de Janeiro, Brazil, 4 Metroplex Clinical Research Center,<br />

Dallas, TX, 5 Roche, Welwyn, United Kingdom<br />

11:15 AM<br />

2263. Rituximab Treatment Induces the Expression <strong>of</strong> Genes<br />

Involved in Healing Processes in the Rheumatoid Arthritis<br />

Synovium.<br />

Ilse Gutierrez-Roelens 4 , Christine Galant 3 , Ivan Theate 3 , Rik J.<br />

Lories 2 , Patrick Durez 4 , Adrien Nzeusseu Toukap 4 , Benoît Van<br />

den Eynde 1 , Frédéric A. Houssiau 4 and Bernard R. Lauwerys 4 , 1 de<br />

Duve Institute & Ludwig Institute for Cancer Research, Brussels<br />

Branch, 2 Department <strong>of</strong> Musculoskeletal Sciences, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Laboratory for Skeletal Development and<br />

Joint Disorders, Katholieke Universiteit Leuven, 3 Department<br />

<strong>of</strong> Pathology, Cliniques Universitaires Saint-Luc, Université<br />

Catholique de Louvain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Cliniques<br />

Universitaires Saint-Luc, Université Catholique de Louvain<br />

11:30 AM<br />

2264. Golimumab and Methotrexate Combination Therapy<br />

Significantly Improves Synovitis, Osteitis and Bone Erosion<br />

Compared to Methotrexate Alone – A Magnetic Resonance<br />

Imaging Study <strong>of</strong> Methotrexate-Naïve Rheumatoid Arthritis<br />

Patients.<br />

144<br />

2010 Program Book


Mikkel Østergaard 6 , Paul Emery 4 , Philip G. Conaghan 5 , Roy M.<br />

Fleischmann 7 , Weichun Xu 2 , Elizabeth C. Hsia 3 , Anna Beutler 1 and<br />

Mahboob U. Rahman 3 , 1 Centocor Research and Development,<br />

Inc., <strong>College</strong>ville, PA, 2 Centocor Research and Development, Inc.,<br />

3<br />

Centocor Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania<br />

School <strong>of</strong> Medicine, Malvern, PA, 4 Chapel Allerton Hospital,<br />

Leeds, United Kingdom, 5 Chapel Allerton Hospital, Leeds, United<br />

Kingdom, 6 Copenhagen University Hospital at Glostrup and<br />

Hvidovre, Hvidovre, Denmark, 7 University <strong>of</strong> Texas SW Medical<br />

Center, Dallas, TX<br />

11:45 AM<br />

2265. Changes in CRP Levels Are Associated with Clinical<br />

Response Patterns during Treatment with Infliximab — A<br />

Potential Role for CRP in Guiding Dose Optimization.<br />

Cees Meeuwisse 5 , Josef S. Smolen 4 , Dimitrios Boumpas 7 , E.<br />

William St Clair 2 , Mahboob U. Rahman 1 , Nathan Vastesaeger 6 ,<br />

Wilbert van Duijnhoven 5 , Robert L. H. Nelissen 5 and Ronald Van<br />

Vollenhoven 3 , 1 Centocor, Malvern, PA, 2 Duke University Medical<br />

Center, Durham, NC, 3 Karolinska University Hospital, Stockholm,<br />

Sweden, 4 Krankenhaus Lainz, Vienna, Austria, 5 MSD, Oss, The<br />

Netherlands, 6 MSD, Brussels, Belgium, 7 University Hospital <strong>of</strong><br />

Heraklion, Crete, Greece<br />

Gilles Hayem 7 , Rim Ben M’Barek 8 , Eric Toussirot 4 , Christian<br />

Compaoré 6 , Thao Pham 9 , Eric Houvenagel 13 , Antoine Martin 3 ,<br />

Nathalie Balandraud 9 , Jean-Marie Berthelot 10 , Grégoire Cormier 2 ,<br />

Anne Dubois 1 , Rose-Marie Javier 11 , Sylvain Lanot 12 , Marie-<br />

José Wattiaux 7 , Olivier C. Meyer 8 and Daniel Wendling 5 , 1 CH<br />

Brive, France, 2 CH La Roche sur Yon, France, 3 CH Saint-Brieuc,<br />

France, 4 CHU Besançon, France, 5 CHU Besançon, for the “Club<br />

Rhumatismes et Inflammation”, Besancon, France, 6 CHU Bichat,<br />

Paris, France, 7 CHU Bichat, Paris, France, 8 CHU Bichat, Paris,<br />

Tunisia, 9 CHU Marseille, France, 10 CHU Nantes, France, 11 CHU<br />

Strasbourg, France, 12 Private Office, Paris, France, 13 UC Lille,<br />

France<br />

11:30 AM<br />

2270. Radiographic Findings after 5 Years <strong>of</strong> Infliximab<br />

Treatment in Patients with Ankylosing Spondylitis.<br />

Xen<strong>of</strong>on Baraliakos 6 , Frank Heldmann 6 , Desiree M. Van<br />

Der Heijde 4 , Joachim Listing 3 , Joachim Sieper 2 , Alessandra<br />

Oortwijn 1 , Rebecca Bolce 1 and Juergen Braun 5 , 1 Centocor Inc,<br />

2<br />

Charite Campus Benjamin Frankl, Berlin, Germany, 3 German<br />

Rheumatism Research Center, 4 Leiden University Medical Center,<br />

Meerssen, The Netherlands, 5 Rheumazentrum Ruhrgebiet,<br />

Herne, Germany, 6 Rheumazentrum Ruhrgebiet Herne<br />

12:00 PM<br />

2266. Comparative Effectiveness <strong>of</strong> Biologic Therapies for<br />

Treating Rheumatoid Arthritis (RA) in Patients Who Failed an<br />

Anti–Tumor Necrosis Factor Agent: A Meta-Regression Analysis.<br />

A. Benedict 2 , D. J. Vanness 3 , S. Roy 1 and M. A. Cifaldi 1 , 1 Abbott<br />

Laboratories, 2 United BioSource Corporation, 3 University <strong>of</strong><br />

Wisconsin<br />

12:15 PM<br />

2267. Clinical and Radiological Efficacy <strong>of</strong> Biologics in<br />

Rheumatoid Arthritis Patients Naive or Inadequate Responders<br />

to Methotrexate: A Metanalysis.<br />

Pierreisnard Audrey, Issa Nahema, Barnetche Thomas, Richez<br />

Christophe and Schaeverbeke Thierry, Bordeaux University<br />

Hospital, <strong>Rheumatology</strong> Department, France<br />

A404<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical<br />

Aspects and Treatment - Therapy III<br />

Moderators: Luis R. Espinoza, MD; Louisianna State University<br />

Medical Center; New Orleans, LA<br />

Maxime Dougados, MD; Hospital Cochin; Paris, France<br />

11:00 AM<br />

2268. Outcome <strong>of</strong> an Education and Home Exercise Program<br />

for Ankylosing Spondylitis Patients: A Nationwide Randomized<br />

Study.<br />

Carlos Rodríguez-Lozano 2 , Xavier Juanola 2 , Juan Cruz-<br />

Martínez 1 , Andrés Peña-Arrébola 4 , Juan Mulero 2 and Eduardo<br />

Collantes 3 , 1 for the Spondylarthropathies Study Group <strong>of</strong><br />

the Spanish Society <strong>of</strong> <strong>Rheumatology</strong> (GRESSER), 2 for the<br />

Spondylarthropathies Study Group <strong>of</strong> the Spanish Society <strong>of</strong><br />

<strong>Rheumatology</strong> (GRESSER), 3 for the Spondylarthropathies Study<br />

Group <strong>of</strong> the Spanish Society <strong>of</strong> <strong>Rheumatology</strong> (GRESSER);<br />

Hospital Ramón y Cajal. Madrid, 4 Hospital Ramón y Cajal. Madrid<br />

11:15 AM<br />

2269. SAPHO Syndrome Treated by TNF alpha-Blocking Agents.<br />

Report <strong>of</strong> 45 Cases.<br />

11:45 AM<br />

2271. Effects <strong>of</strong> Etanercept vs. Sulfasalazine on Acute<br />

Inflammatory Lesions as Detected by Whole Body MRI in Early<br />

Axial Spondyloarthritis – A 48 Week Randomized Controlled<br />

Trial.<br />

In-Ho Song 2 , Kay-Geert Hermann 4 , Hildrun Haibel 3 , Christian<br />

Alth<strong>of</strong>f 4 , Joachim Listing 7 , Gerd-Rüdiger Burmester 5 , Andreas<br />

Krause 6 , Martin Bohl-Bühler 9 , Bruce Freundlich 8 , Martin<br />

Rudwaleit 3 and Joachim Sieper 1 , 1 Charite Benjamin-Franklin,<br />

Med. Clinic I, <strong>Rheumatology</strong>, Berlin, Germany, 2 Charite Campus<br />

Benjamin, Med. Clinic I, <strong>Rheumatology</strong>, Berlin, Germany, 3 Charite<br />

Campus Benjamin-Franklin, Med. Clinic I, <strong>Rheumatology</strong>, Berlin,<br />

Germany, 4 Charite Campus Mitte, Radiology, Berlin, Germany,<br />

5<br />

Charite Campus Mitte, <strong>Rheumatology</strong>, Berlin, Germany, 6 Clinic<br />

Buch Rheumatologie, Berlin, Germany, 7 German Rheumatism<br />

Research Center, Berlin, Germany, 8 Pfizer- Wyeth, PA, 9 Private<br />

Practice, <strong>Rheumatology</strong>, Potsdam, Germany<br />

12:00 PM<br />

2272. A Prospective Inception Cohort Study <strong>of</strong> the Clinical<br />

Presentation and Response to Treatment <strong>of</strong> Undifferentiated<br />

Spondyloarthritis Versus Ankylosing Spondylitis and Psoriatic<br />

Arthritis.<br />

Jacqueline E. Paramarta 2 , Leen E. De Rycke 3 , Carmen A.<br />

Ambarus 3 , Paul P. Tak 1 and Dominique L. Baeten 2 , 1 Academic<br />

Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

2<br />

Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />

Medical Center/University <strong>of</strong> Amsterdam, Amsterdam,<br />

The Netherlands, 3 Division <strong>of</strong> Clinical Immunology and<br />

<strong>Rheumatology</strong>, Academic Medical Center/University <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands<br />

12:15 PM<br />

2273. Do Patients with Psoriatic Arthritis Who Present Early<br />

Fare Better Than Those Presenting Later in the Disease?<br />

Dafna D. Gladman 1 , Arane Thavaneswaran 2 and Vinod<br />

Chandran 2 , 1 Toronto Western Hospital, Toronto, ON, Canada,<br />

2<br />

University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto Western<br />

Hospital<br />

2010 Program Book 145<br />

thursday


thursday<br />

A311<br />

Systemic Lupus Erythematosus - Human Etiology and<br />

Pathogenesis: Etiology and Pathogenesis<br />

Moderators: Mariana J. Kaplan, MD; University <strong>of</strong> Michigan<br />

Medical Center; Ann Arbor, MI<br />

Andras Perl, MD, PhD; Upstate Medical University; Syracuse, NY<br />

11:00 AM<br />

Introductory Talk: IL-17 in Lupus Nephritis<br />

George C.Tsokos, MD; Harvard Medical School/Beth Israel<br />

Hospital; Boston, MA<br />

11:15 AM<br />

2274. Identification <strong>of</strong> cis-Regulatory Element Binding<br />

Differences in the C8orf13/BLK Promoter Region Linked with<br />

Risk <strong>of</strong> SLE.<br />

Rufei Lu 5 , Nicolas Dominguez 6 , Susan Macwana 5 , Celi Sun 5 ,<br />

Jennifer A. Kelly 5 , Kenneth M. Kaufman 5 , Carl D. Langefeld 11 ,<br />

Marta Alarcon-Riquielme for BIOLUPUS Network 5 , Sang-Cheol<br />

Bae 2 , Elizabeth E. Brown for PROFILE 9 , Gary S. Gilkeson 3 , Timothy<br />

B. Niewold 10 , Betty P. Tsao8, Nan Shen 7 , Kathy L. Moser 4 , John<br />

B. Harley 1 , Slegen, Carol Webb 5 , Judith A. James 5 , Swapan K.<br />

Nath 5 , Patrick M. Gaffney 5 and Joel M. Guthridge 5 , 1 Cincinnati<br />

Children’s Hospital Medical Center, 2 Hanyang University Hospital<br />

for Rheumatic Diseases, 3 Medical University <strong>of</strong> South Carolina,<br />

4<br />

Oklahoma Med Research Foundation, 5 Oklahoma Medical<br />

Research Foundation, 6 Oklahoma Medical Reserch Foundation,<br />

7<br />

Shanghai Ren Ji Hospital, 8 UCLA School <strong>of</strong> Medicine, 9 University<br />

<strong>of</strong> Alabama at Birmingham, 10 University <strong>of</strong> Chicago, 11 Wake<br />

Forest University Health Sciences<br />

11:30 AM<br />

2275. The HRES-1/RAB4 Lupus Susceptibility Gene Promotes<br />

Nitric Oxide Production in Human T Cells through Direct<br />

Interaction with Endothelial Nitric Oxide Synthase Interacting<br />

Protein.<br />

Tiffany N. Telarico 1 , Edward H. Doherty 1 , David R. Fernandez 1 ,<br />

Adam Bartos 1 , Stephanie Oess 2 , Werner Muller-Esterl 2 and<br />

Andras Perl 3 , 1 SUNY, 2 University <strong>of</strong> Frankfurt, 3 Upstate Medical<br />

Univ, Syracuse, NY<br />

11:45 AM<br />

2276. Transcriptional Inflammatory Mechanism in Murine<br />

Lupus Nephritis: An Insight into Human Disease.<br />

Tania C. Gonzalez Rivera 3 , Celine C. Berthier 3 , Viji Nair 3 ,<br />

Ramalingam Bethunaickan 1 , Matthias Kretzler 3 , Anne Davidson 2<br />

and ERCB Consortium, 1 Feinstein Institute, Manhasset, NY,<br />

2<br />

Feinstein Institute for Medical Research, Manhasset, NY,<br />

3<br />

University <strong>of</strong> Michigan, Ann Arbor, MI<br />

12:00 AM<br />

2277. SLE Serum Deposits C4d on Red Blood Cells, Decreases<br />

Red Blood Cell Membrane Deformability, and Promotes NO<br />

Production.<br />

Ionita C. Ghiran 1 , Ourania Kampagianni 1 , Mark L. Zeidel 1 , Sergey<br />

S. Shevkoplyas 2 , Jennie M. Burns 2 , George C. Tsokos 1 and<br />

Vasileios C. Kyttaris 1 , 1 Beth Israel Deaconess Medical Center,<br />

2<br />

Tulane University<br />

12:15 PM<br />

2278. What Are the Pathways by Which Interferon-alpha<br />

Decreases Vasculogenesis in Lupus?<br />

Seth G. Thacker 2 , Celine Berthier 2 , Deborah Mattinzoli 1 ,<br />

Maria-Pia Rastaldi 1 , Matthias Kretzler 2 and Mariana J. Kaplan 3 ,<br />

1<br />

Fondazione IRCCS Ospedale Maggiore Policlinico & Fondazione<br />

D’Amico per la Ricerca Sulle Malattie Renali, 2 University <strong>of</strong><br />

Michigan, 3 University <strong>of</strong> Michigan Medical Center, Ann Arbor, MI<br />

ARHP Concurrent Abstract Session<br />

11:00 AM - 12:30 PM<br />

B311<br />

Rheumatoid Arthritis: From Clinic to Home<br />

Moderator: Joyce P. Carlone, MN, RN, FNP-BC; Emory University;<br />

Atlanta, GA<br />

11:00 AM<br />

2279. The Nurse’s Role in Treatment and Management<br />

<strong>of</strong> Patients with Rheumatoid Arthritis: A Delphi-Based<br />

Recommendation on Patient Unmet Needs.<br />

Jane E. D. Cottrell 2 , Monique Jonas 1 and Leeanna M. Bulinckx 3 ,<br />

1<br />

Charité University Hospital, Berlin, Germany, 2 Mount Sinai<br />

Hospital, Toronto, ON, Canada, 3 PerCuro Clinical Research Ltd,<br />

Victoria, BC, Canada<br />

11:15 AM<br />

2280. Self-Efficacy and Follow-Up with Nursing, Medical or<br />

Shared Care for Outpatients with Rheumatoid Arthritis.<br />

Jette Primdahl 3 , Lis Wagner 2 and Kim Hørslev-Petersen 1 , 1 King<br />

Christian X’s Hospital for Rheumatic Diseases in Graasten and<br />

University <strong>of</strong> Southern Denmark, Graasten, Denmark, 2 Research<br />

Unit <strong>of</strong> Nursing, University <strong>of</strong> Southern Denmark, Odense,<br />

Denmark, 3 University <strong>of</strong> Southern Denmark, Sønderborg,<br />

Denmark<br />

11:30 AM<br />

2281. Future Expectations and Worst Case Scenarios <strong>of</strong> Patients<br />

with Rheumatoid Arthritis: A Focus Group Study in Patients.<br />

Laurien Buitinga 3 , Louise M. A. Braakman-Jansen 1 , Erik Taal 2 and<br />

Mart A. F. J. Van de Laar 4 , 1 University <strong>of</strong> Twente, Enschede, The<br />

Netherlands, 2 University <strong>of</strong> Twente, Enschede, The Netherlands,<br />

3<br />

University <strong>of</strong> Twente, 4 University <strong>of</strong> Twente; Medical Spectrum<br />

Twente, Enschede<br />

11:45 AM<br />

2282. Mapping Pathways through Care: Accounts <strong>of</strong> Help-<br />

Seeking in Early Rheumatoid Arthritis (RA).<br />

Anne Townsend 2 , Catherine L. Backman 3 , Paul Adam 1 , Susan<br />

M. Cox 4 , Linda C. Li 3 and Erahse Team, 1 Mary Pack Arthritis<br />

Centre, 2 Maurice Young Centre for Applied Ethics, University<br />

<strong>of</strong> British Columbia, Vancouver, BC, Canada, 3 University <strong>of</strong><br />

British Columbia, Vancouver, BC, Canada, 4 University <strong>of</strong> British<br />

Columbia<br />

12:00 PM<br />

2283. Home-Based Exercise Therapy in Patients with<br />

Rheumatoid Arthritis: A Systematic Review.<br />

Emalie J. Hurkmans 3 , Florus J. van der Giesen 2 , Thea P. M. Vliet<br />

Vlieland 1 , Jan W. Schoones 5 and Cornelia H. M. van den<br />

146<br />

2010 Program Book


Ende 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Orthopaedics,<br />

Leiden University Medical Center, Leiden, The Netherlands,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Groene Hart Ziekenhuis,<br />

Gouda, The Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Leiden University Medical Center, Leiden, The Netherlands,<br />

4<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Sint Maartenskliniek, Nijmegen,<br />

The Netherlands, 5 Walaeus Library, LUMC, Leiden, The<br />

Netherlands, The Netherlands<br />

12:15 PM<br />

2284. An Interactive Website Reduces the Information Need<br />

Regarding the Accessibility <strong>of</strong> Health Care Services in RA<br />

Patients.<br />

Jorit J. L. Meesters 1 , Ingeborg G. de Boer 2 , Marta Fiocco 2 and<br />

Thea P. M. Vliet Vlieland 1 , 1 Leiden University Medical Center,<br />

Leiden, The Netherlands, 2 Leiden University Medical Center<br />

ARHP Concurrent Sessions<br />

11:00 AM - 12:30 PM<br />

B310<br />

Top 10 in ‘10: Top 10 Public Health Advances in the<br />

First 10 Years <strong>of</strong> the Centers for Disease Control and<br />

Prevention Arthritis Program C<br />

Moderator: Emily C. Somers, PhD, ScM; University <strong>of</strong> Michigan<br />

Health System; Ann Arbor, MI<br />

Speakers: Teresa J. Brady, PhD; Centesr for Disease Control;<br />

Atlanta, GA<br />

Charles G. Helmick, MD; Centers for Disease Control; Atlanta, GA<br />

Session Overview:<br />

Both health care reform and the <strong>American</strong> Recovery and<br />

Re-investment Act are emphasizing the importance <strong>of</strong> public<br />

health and prevention. The Centers for Disease Control and<br />

Prevention Arthritis Program, created in 1999 by a congressional<br />

appropriation, has spearheaded activating the public health<br />

system to respond to the challenge <strong>of</strong> arthritis as a public<br />

health problem in addition to a clinical problem. This focus on<br />

addressing arthritis as a public health problem has resulted in<br />

numerous advances in the last 10 years. This session is designed<br />

to provide attendees with an in depth review <strong>of</strong> the arthritisrelated<br />

advances in public health that have occurred since the<br />

creation <strong>of</strong> the program.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• describe a public health approach, and key elements <strong>of</strong> the<br />

public health approach to arthritis<br />

• list recent advances in arthritis related public health science<br />

• discuss recent advances in arthritis-related public health<br />

practice<br />

B309<br />

Total Shoulder Arthroplasty and Reverse Total<br />

Shoulder Arthroplasty: Surgery and Rehabilitation<br />

C<br />

Moderator: Jennifer L. Trizuto, MPT; Mills Health Center; San<br />

Mateo, CA<br />

Speakers: Victoria Gall, PT, MEd; Partners Healthcare; Hyde Park,<br />

MA<br />

Scott D. Pennington, MD; Peachtree Orthopaedic Clinic; Atlanta,<br />

GA<br />

Session Overview:<br />

Shoulder arthroplasty surgery changed in 2004 with the Food<br />

and Drug Administration approval <strong>of</strong> the reverse total shoulder<br />

arthroplasty. The procedure and rehabilitation are very<br />

complex and differs significantly from the traditional shoulder<br />

arthroplasty. Both <strong>of</strong> these procedures are being preformed<br />

outside <strong>of</strong> academic teaching facilities, so it is essential that<br />

therapists in all clinic settings who treat orthopedic patients be<br />

familiar with the protocols.<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• list the indications for a total shoulder arthroplasty and for an<br />

reverse total shoulder arthroplasty<br />

• explain the precautions for a total shoulder arthroplasty and<br />

an reverse total shoulder arthroplasty<br />

• use the protocols as guidelines when following the surgeon’s<br />

specific instructions<br />

Industry-Supported Post-<br />

Conference Symposia<br />

1:00 - 4:00 PM<br />

In 2010, there are two types <strong>of</strong> symposia <strong>of</strong>fered to attendees:<br />

CME-accredited and non-CME accredited. For CME-accredited<br />

symposia, the sponsoring organization is responsible for<br />

planning and providing CME credit. The non-CME accredited<br />

symposia have been planned and will be implemented in<br />

accordance with the requirements <strong>of</strong> the FDA and applicable<br />

standards <strong>of</strong> the PhRMA Code on Interactions with Healthcare<br />

Pr<strong>of</strong>essionals. Please visit the organization’s exhibit booth, the<br />

industry-supported symposia booth or see page 283 for more<br />

information.<br />

thursday<br />

2010 Program Book 147


ACR Poster Session A<br />

148<br />

Halls B1 & B2<br />

2010 Program Book<br />

MONDAY, NOVEMBER 8, 2010<br />

Antiphospholipid Syndrome<br />

1. Acquired Resistance to Activated Protein C Is a Feature <strong>of</strong> Both<br />

Systemic Lupus Erythematosus (SLE) and Antiphospholipid<br />

Syndrome (APS) and Is More Marked in Patients with SLE<br />

and APS. Denis Wahl 3 , Stéphane Zuily 4 , Agnès Brunette 2 ,<br />

Marie Prestat-Tilly 4 , Véronique Regnault 2 , Jean Devignes 1 and<br />

Thomas Lecompte 1 , 1 Biological Haematology Department,<br />

Nancy University Hospital, Vandoeuvre les Nancy, France,<br />

2<br />

INSERM U961, Nancy Université, Vandoeuvre les Nancy,<br />

France, 3 Vascular Medicine Unit, Vandoeuvre les Nancy, France,<br />

4<br />

Vascular Medicine Unit, Nancy University Hospital, Vandoeuvre<br />

les Nancy, France.<br />

2. AGTRL1 and PRKCH Are Genetic Risk Factors for<br />

Antiphospholipid Syndrome. Hisako Nakagawa 1 , Tetsuya<br />

Horita 2 , Toshio Odani 2 , Yuichiro Fujieda 2 , Masaru Kato 2 , Kotaro<br />

Otomo 2 , Yasuko Nakagawa 2 , Shinsuke Yasuda 2 , Tatsuya Atumi 2<br />

and Takao Koike 2 , 1 Department <strong>of</strong> Medicine II, Hokkaido<br />

University Graduate School <strong>of</strong> Medicine, Sapporo, Hokkaido,<br />

Japan, 2 Department <strong>of</strong> Medicine II, Hokkaido University<br />

Graduate School <strong>of</strong> Medicine.<br />

3. Anti-β2 Glycoprotein I Antibodies from Leprosy Patients Do<br />

Not Show Thrombogenic Effects in an In Vivo Animal Model.<br />

Ricardo Forastiero 2 , Marta Martinuzzo 2 , Mariano Vega-<br />

Ostertag 2 , Gabriela de Larranaga 2 and Silvia S. Pierangeli 1 , 1 Univ<br />

<strong>of</strong> TX Medical Branch, Galveston, TX, 2 Universidad Favaloro,<br />

Buenos Aires, Argentina.<br />

4. Antiphospholipid Antibodies in Children with Systemic<br />

Lupus Erythematosus – 18 Years <strong>of</strong> Clinical Experience<br />

from North India. Surjit Singh 2 , Jasmina Ahluwalia 1 , Shano<br />

Naseem 3 , Deepti Suri 2 and Amit Rawat 2 , 1 Department <strong>of</strong><br />

Hematology, Post Graduate Institute <strong>of</strong> Medical Education<br />

and Research, Chandigarh, India, 2 Division <strong>of</strong> Pediatric Allergy<br />

and Immunology, Advanced Pediatrics Centre, Post Graduate<br />

Institute <strong>of</strong> Medical Education and Research, Chandigarh, India,<br />

3<br />

Division <strong>of</strong> Pediatric Hematology, Advanced Pediatrics Centre,<br />

Post Graduate Institute <strong>of</strong> Medical Education and Research,<br />

Chandigarh, India.<br />

5. Antiphospholipid Score (aPL-S): A Comprehensive Predictive<br />

Marker <strong>of</strong> Developing Thrombosis in Autoimmune Diseases.<br />

Kotaro Otomo 1 , Tatsuya Atsumi 2 , Yuichiro Fujieda 3 , Masaru<br />

Kato 3 , Olga Amengual 3 , Tetsuya Horita 3 , Shinsuke Yasuda 3<br />

and Takao Koike 3 , 1 Hokkaido Graduate School <strong>of</strong> Medicine,<br />

Department <strong>of</strong> Medicine II, Sapporo, Hokkaido, Japan,<br />

2<br />

Hokkaido Graduate School <strong>of</strong> Medicine, Department <strong>of</strong><br />

Medicine II, Sapporo, Japan, 3 Hokkaido Graduate School <strong>of</strong><br />

Medicine, Department <strong>of</strong> Medicine II.<br />

6. Antiphospholipid Syndrome (APS) Clinical Research Task Force<br />

(CRTF) Report. Doruk Erkan 2 , Ronald Derksen 6 , Roger A. Levy 3 ,<br />

Samuel Machin 5 , Thomas Ortel 1 , Silvia S. Pierangeli 4 , Robert A.<br />

S. Roubey 7 , Michael D. Lockshin 2 and on Behalf <strong>of</strong> APS Clinical<br />

Research Task Force, 1 Duke University Health System, Durham,<br />

NC, 2 Hospital for Special Surgery, New York, New York, NY,<br />

3<br />

Univ Estado Do Rio de Janeiro, Rio de Janeiro, Brazil, 4 Univ <strong>of</strong><br />

TX Medical Branch, Galveston, TX, 5 University <strong>College</strong> London<br />

Hospitals, London, UK, 6 University Medical Centre, Utrecht,<br />

Netherlands, 7 University <strong>of</strong> North Carolina, Chapel Hill, NC.<br />

7. Decreased Fibrin Clot Porosity in Patients with Antifosfolipid<br />

Syndrome. Anna Vikerfors 2 , Aleksandra Antovic 1 , Elisabet<br />

Svenungsson 2 , Katarina Bremme 3 and Margareta Holmström 4 ,<br />

1<br />

Department <strong>of</strong> Clinical Sciences, Karolinska Institutet/Danderyd<br />

Hospital, Stockholm, Sweden, 2 Department <strong>of</strong> Medicine,<br />

<strong>Rheumatology</strong> Unit, Karolinska Institutet/Karolinska University<br />

Hospital, Stockholm, Sweden, 3 Department <strong>of</strong> Woman and<br />

Child Health, Division <strong>of</strong> Obstetrics and Gynaecology, Karolinska<br />

Institutet/Karolinska University Hospital, Stockholm, Sweden,<br />

4<br />

Hematology Division, Department <strong>of</strong> Medicine, Karolinska<br />

Institutet/Karolinska University Hospital, Stockholm, Sweden.<br />

8. Global Analyses <strong>of</strong> Antiphospholipid Antibodies That Impair<br />

Antithrombin Inactivation <strong>of</strong> Procoagulant Factors. Meifang<br />

Wu 2 , Jennifer M. Grossman 3 , John FitzGerald 2 , Bevra H. Hahn 4<br />

and Pojen P. Chen 1 , 1 UCLA Schl <strong>of</strong> Medicine, Los Angeles, CA,<br />

2<br />

UCLA School <strong>of</strong> Medicine, 3 University <strong>of</strong> California Los Angeles,<br />

Sherman Oaks, CA, 4 University <strong>of</strong> California Los Angeles School<br />

<strong>of</strong> Medicine, Los Angeles, CA.<br />

9. Influenza Vaccination Can Induce New Onset Anticardiolipins<br />

but Not β2-Glycoprotein-I Antibodies among Patients with<br />

Systemic Lupus Erythematosusβ. Evan Glenn Vista 3 , Sherry<br />

R. Crowe 3 , Amy B. Dedeke 3 , Jourdan R. Anderson 2 , Linda F.<br />

Thompson 3 , Gillian Air 4 and Judith A. James 1 , 1 Oklahoma Med<br />

Research Foundation, Oklahoma City, OK, 2 Oklahoma Medical<br />

Research Foundation, 3 Oklahoma Medical Research Foundation,<br />

Oklahoma City, OK, 4 University <strong>of</strong> Oklahoma Health Science<br />

Center, Oklahoma City, OK.<br />

10. Platelet Activation and Paradoxical Inhibition <strong>of</strong> ADP<br />

Induced Aggregation by Antiphospholipid Antibodies. Kenji<br />

Oku 4 , Tatsuya Atsumi 2 , Olga Amengual 3 , Masahiro Ieko 1 , Shin<br />

Furukawa 6 , Hirohiko Kitakawa 6 , Yuji Hori 6 , Kazuyoshi Nihei 6 ,<br />

Yuuichiro Fujieda 3 , Kotaro Otomo 5 , Masaru Kato 3 , Tetsuya<br />

Horita 3 , Shinsuke Yasuda 3 and Takao Koike 3 , 1 Health Sciences<br />

University <strong>of</strong> Hokkaido, 2 Hokkaido University Graduate School<br />

<strong>of</strong> Medicine Internal Medicine II, Sapporo, Japan, 3 Hokkaido<br />

University Graduate School <strong>of</strong> Medicine Internal Medicine II,<br />

4<br />

Hokkaido University Graduate School <strong>of</strong> Medicine Internal<br />

Medicine II, Kushiro Red Cross Hospital, Japan, 5 Hokkaido<br />

UniversityGraduate School <strong>of</strong> Medicine Internal Medicine II,<br />

6<br />

Kushiro Red Cross Hospital.<br />

11. Prevalence and Prognostic Significance <strong>of</strong> Thrombotic<br />

Microangiopathy in Rheumatologic Patients: Clinical and<br />

Immunological Associations. Spyros Aslanidis, Athina<br />

Pyrpasopoulou, Stella Douma, Areti Triantafyllou, Michail<br />

Doumas and Chrysanthos Zamboulis, 2nd Propedeutic Dept <strong>of</strong><br />

Internal Medicine, Hippokration Hospital, Thessaloniki, Greece.<br />

12. Prevalence <strong>of</strong> Antibodies to Prothrombin (PT) and<br />

Prothrombin/Phosphatidylserine (PS) in a Cohort <strong>of</strong> Lupus<br />

Anticoagulant (LAC) Positive Samples. R. Aguilar-Valenzuela 2 , J.<br />

Dlott 1 , U. Khan 2 , M. Belter 1 , E. Doan 2 , N. Gould 1 , A. Schleh 2 and<br />

S. Pierangeli 2 , 1 Quest Diagnostics, Chantilly, VA, 2 Univ <strong>of</strong> TX Med<br />

Branch, Galveston, TX.<br />

13. The Influence <strong>of</strong> Thrombovascular Events on the Quality<br />

<strong>of</strong> Life in APS and SLE Patients. Amaris K. Balitsky, Valentina<br />

Peeva, Jiandong Su, Erik Yeo, Carol Landolt-Marticorena, Dafna<br />

D. Gladman, Murray B. Urowitz and Paul R. Fortin, University<br />

<strong>of</strong> Toronto Antiphospholipid Clinic, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Toronto Western Hospital.<br />

14. Utility <strong>of</strong> Anti-Phosphatidylserine/Prothrombin and IgA<br />

Antiphospholipid Assays in Antiphospholipid Syndrome.<br />

Ehtisham Akhter 3 , Walter L. Binder 2 , Zakera Shums 2 and<br />

Michelle A. Petri 1 , 1 Timonium, MD, 2 Inova Diagnostics Inc, San<br />

Diego, CA, 3 Johns Hopkins University, Baltimore, MD.


ACR Poster Session A<br />

Cytokines, Mediators, Gene Regulation I<br />

15. BAFF Expression Correlates with Idiopathic Inflammatory<br />

Myopathy Disease Activity Measures, Interferon Signature<br />

and Autoantibodies. Kelly T. McNallan 1 , Hatice Bilgic 3 , Cynthia<br />

S. Crowson 2 , Steven R. Ytterberg 2 , Shreyasee Amin 2 , Peterson<br />

J. Erik 3 , Emily C. Baechler 3 and Ann M. Reed 2 , 1 Mayo Clinic,<br />

Rochester, MN, 2 Mayo Clinic, 3 University <strong>of</strong> Minnesota.<br />

16. Blockade <strong>of</strong> TLR2 Prevents Spontaneous and Induced Cytokine<br />

Release from Rheumatoid Arthritis Ex Vivo Synovial Explant<br />

Cultures. Sinead Nic An Ultaigh 1 , Tajvur Saber 1 , Jerome<br />

Dellacasagrande 2 , Brian Keogh 2 , William McCormack 2 , Mary<br />

Reilly 2 , Luke O’ Neill 2 , Peter McGuirk 2 , Ursula Fearon 1 and<br />

Douglas J. Veale 1 , 1 Dublin Academic Medical Centre, Dublin,<br />

Ireland, 2 Opsona Therapeutics Ltd, Dublin, Ireland.<br />

17. CCL15/Leukotactin-1: A Novel Mediator <strong>of</strong> Rheumatoid<br />

Arthritis Fibroblast-Like Synoviocyte Migration Via CCR3 and<br />

MAP Kinases. Eric K. Owens 1 , Karolina Klosowska 2 , Michael<br />

V. Volin 2 , Brian Zanotti 2 and James M. Woods 2 , 1 Midwestern<br />

University, Downers Grove, IL, 2 Midwestern University.<br />

18. Chronic Exposure to IL-6 Amplifies Macrophage Response to<br />

Toll-Like Receptor (TLR) Ligands. Raffaele Strippoli 1 , Francesco<br />

Carvello 2 , Loredana De Pasquale 2 , Luisa Bracci-Laudiero 2 and<br />

Fabrizio de Benedetti 2 , 1 IRCCS Ospedale Pediatrico Bambino<br />

Gesu, Rome, Italy, 2 IRCCS Ospedale Pediatrico Bambino Gesu,<br />

Rome, Italy.<br />

19. CX3CR1 Deficient Mice Have Decreased Th17 and Antigen-<br />

Specific Humoral Responses in the Collagen Induced Arthritis<br />

(CIA) Model. Teresa K. Tarrant 2 , Peng Liu 3 , Rishi Rampersad 3 ,<br />

Denise Esserman 3 , Lisa Rothlein, Marcus W. McGinnis 3 , David J.<br />

Fitzhugh 3 , Dhavalkumar D. Patel 1 and Alan M. Fong 3 , 1 Novartis<br />

Pharma AG, Basel, Switzerland, 2 UNC School <strong>of</strong> Medicine,<br />

Chapel Hill, NC, 3 UNC School <strong>of</strong> Medicine.<br />

20. Cytokine Expression in Synovial Tissue <strong>of</strong> Psoriatic Arthritis<br />

and Its Relation to Lymphoid Neogenesis, Erosive Disease<br />

and Disease Activity: A Longitudinal Study. Raquel Celis 1 ,<br />

Julio Ramírez 1 , Raimon Sanmarti 1 , José L. Pablos 2 and Juan D.<br />

Cañete 1 , 1 Servicio Reumatología, Hospital Clinic and IDIBAPS,<br />

Barcelona, Spain, 2 Unidad de Investigación, Hospital 12 de<br />

Octubre, Madrid, Spain.<br />

21. DNA Hypomethylation Upregulates CXCL12 in Rheumatoid<br />

Arthritis Synovial Fibroblasts. Emmanuel Karouzakis 1 , Yvonne<br />

Rengel 1 , Astrid Jüngel 1 , Christoph Kolling 3 , Renate E. Gay 1 ,<br />

Beat A. Michel 1 , Paul P. Tak 2 , Steffen Gay 1 , Michel Neidhart 1<br />

and Caroline Ospelt 1 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong><br />

and Zurich Center <strong>of</strong> Integrative Human Physiology (ZIHP),<br />

University Hospital Zurich, 2 Department <strong>of</strong> Clinical Immunology<br />

and <strong>Rheumatology</strong>, University <strong>of</strong> Amsterdam, 3 Schulthess Clinic,<br />

Zürich.<br />

22. Downregulation <strong>of</strong> the Chemokine Receptor CX3CR1 in Active<br />

RA Associated with a Pro-Osteoclastognic Phenotype. Grainne<br />

Murphy 1 , John Ryan 1 , Harney Sinead 1 , Fergus Shanahan 1 ,<br />

Michael Molloy 1 and Noel Caplice 2 , 1 Cork University Hospital,<br />

Cork, Ireland, 2 University <strong>College</strong> Cork, Cork, Ireland.<br />

23. Downstream Targets <strong>of</strong> IL-17 in Rheumatoid Arthritis. Sarah<br />

R. Pickens 4 , Richard M. Pope 3 , Michael V. Volin 1 and Shiva<br />

Shahrara 2 , 1 Midwestern University, 2Northwestern Univ<br />

Feinberg, Chicago, IL, 3 Northwestern Univ Med School, Chicago,<br />

IL, 4 Northwestern University.<br />

24. Elevated BLyS Levels Are Associated with an Increase in<br />

Autoantibody Specificites and ANA Titer in Systemic Lupus<br />

Erythematosus. Lauren L. Ritterhouse 3 , Amanda R. Moyer 3 ,<br />

Virginia C. Roberts 2 , Amy B. Dedeke 2 , Sherry R. Crowe 3 , Gillian<br />

M. Air 4 , Linda F. Thompson 3 , Joel M. Guthridge 3 and Judith A.<br />

James 1 , 1 Oklahoma Med Research Foundation, Oklahoma City,<br />

OK, 2 Oklahoma Medical Research Foundation, Oklahoma City,<br />

OK, 3 Oklahoma Medical Research Foundation, 4 University <strong>of</strong><br />

Oklahoma Health Sciences Center.<br />

25. Elevated Levels <strong>of</strong> CXCL9 or CXCL10 in Sera <strong>of</strong> Patients with<br />

Early RA Predict Greater Difficulty in Achieving Remission<br />

during the First Year <strong>of</strong> Treatment. Gregory R. Emkey 5 ,<br />

Klemen Strle 6 , Christopher R. Antolini 3 , Deborah S. Collier 5 ,<br />

Margaret Seton 5 , Arezou Khosroshahi 5 , Mark Fisher 2 , Nancy D.<br />

Kim 4 , John H. Stone 1 , Andrew D. Luster 4 and Allen C. Steere 5 ,<br />

1<br />

Massachusetts General Hospital, Sudbury, MA, 2 Massachusetts<br />

General Hospital, Haddon Heights, NJ, 3 Massachusetts General<br />

Hospital, Denver, CO, 4 Massachusetts General Hospital,<br />

Charlestown, MA, 5 Massachusetts General Hospital, Boston,<br />

MA, 6Massachusetts General Hospital.<br />

26. Elevated Serum CX3CL1 Levels in Adult-Onset Still’s Disease:<br />

Potential Involvement in Hemophagocytic Syndrome. Tsuyoshi<br />

Kasama 1 , Kumiko Ohtsuka 2 , Michihito Sato 2 , Ryo Takahashi 2 ,<br />

Kuninobu Wakabayashi 2 and Takeo Isozaki 2 , 1 Showa University<br />

School <strong>of</strong> Med, Shinagawa-ku Tokyo, Japan, 2 Showa University<br />

School <strong>of</strong> Med.<br />

27. Gallic Acid Diminishes Cellular Proliferation and Pro-<br />

Inflammatory Gene Expressions in Fibroblast Like Synoviocytes<br />

from Patients with Rheumatoid Arthritis. Soo-Jin Chung 1 ,<br />

Tae-Yeon Kim 2 , Yong-Jin Kwon 2 , Yong-Beom Park 2 , Soo-Kon Lee 2<br />

and Min-Chan Park 3 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />

Republic <strong>of</strong> Korea, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />

South Korea, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Yonsei University<br />

<strong>College</strong> <strong>of</strong> Medicine, Seoul, Korea, Republic <strong>of</strong>.<br />

28. WITHDRAWN<br />

29. Interleukine 34 Is Expressed in the Synovial Tissue from OA<br />

and RA Patients. Celine Cozic 1 , Benoit Le G<strong>of</strong>f 1 , Anne Riet 1 ,<br />

Marie-Francoise Heymann 1 , Celine Charrier 1 , Regis Brion 1 ,<br />

Sophie Touchais 3 , Marguerite Chemel 4 , Dominique Heymann 1<br />

and Jean-Marie Berthelot 2 , 1 INSERM UMR S 957, 2 INSERM UMR<br />

S 957 and <strong>Rheumatology</strong> Unit, CHU Nantes, Nantes, France,<br />

3<br />

Orthopedic Surgery Unit, CHU Nantes, 4 <strong>Rheumatology</strong> Unit,<br />

CHU Nantes.<br />

30. Oncostatin M, Acting through Oncostatin M Receptor, Is a<br />

Potent Regulator <strong>of</strong> IL-6 and RANKL Expression in Mouse<br />

Synovial Fibroblasts. Benoit Le G<strong>of</strong>f 3 , Narelle M. McGregor 1 ,<br />

T. John Martin 2 , Evange Romas 1 , Natalie A. Sims 1 and Nicole<br />

C. Walsh 1 , 1 St Vincent’s Institute, Fitzroy, VIC, Australia, 2 St<br />

Vincent’s Institute, Fitzroy, Australia, 3 St Vincent’s Institute and<br />

INSERM, UMR-S 957, Fitzroy, VIC, Australia.<br />

31. Oral Bisphosphonates and Risk <strong>of</strong> Atypical Femur Fractures<br />

in a Population-Based Cohort: A Propensity Score-Matched<br />

Analysis. Seo Young Kim 2 , Sebastian Schneeweiss 3 , Jeffrey<br />

N. Katz 1 , Raisa Levin 4 and Daniel H. Solomon 2 , 1 Brigham and<br />

Women’s Hosp, Boston, MA, 2 Brigham and Women’s Hospital,<br />

Boston, MA, 3 Brigham and Women’s Hospital, Boston, 4 Brigham<br />

and Women’s Hospital.<br />

2010 Program Book 149


ACR Poster Session A<br />

150<br />

32. Selective Involvement <strong>of</strong> ERK and JNK MAP Kinases in the<br />

Synovial Tissue <strong>of</strong> Patients with Early Arthritis. Daphne<br />

de Launay, Marleen van de Sande, Gijs van de Sande,<br />

Carla Wijbrandts, Danielle Gerlag, Paul Peter Tak and Kris<br />

Reedquist, Academic Medical Center, University <strong>of</strong> Amsterdam,<br />

Amsterdam, The Netherlands.<br />

33. Serum Concentrations <strong>of</strong> Cytokines in the IL-23/IL-17A<br />

Pathway May Be Modulated by Polymorphisms in IL-23R. Lisa<br />

K. Stamp 1 , Jody Hazlett 2 , Tony Merriman 2 , John Highton 2 and<br />

Paul Hessian 2 , 1 University <strong>of</strong> Otago, Christchurch, New Zealand,<br />

2<br />

University <strong>of</strong> Otago.<br />

34. Synovitis in Rheumatoid Arthritis: Paradoxical Inverse<br />

Relationship between Kinase Phosphorylation Status and<br />

CXCL13, a Biomarker <strong>of</strong> Inflammation. Sanna Rosengren and<br />

David L. Boyle, UCSD School <strong>of</strong> Medicine, La Jolla, CA.<br />

35. The microRNA 18a Enhances IL-6 Signaling through Inhibition<br />

<strong>of</strong> PIAS3. Matthias Brock 2 , Michelle Trenkmann 1 , Renate E. Gay 3 ,<br />

Beat A. Michel 4 , Steffen Gay 5 , Rudolf Speich 6 and Lars C. Huber 6 ,<br />

1<br />

Center for Experimental <strong>Rheumatology</strong> and Zurich Center for<br />

Integrative Human Physiology (ZIHP), University Zurich, Zurich,<br />

Switzerland, 2 Center for Experimental <strong>Rheumatology</strong> and Zurich<br />

Center for Integrative Human Physiology (ZIHP), University<br />

Zurich, Zürich, Switzerland, 3 Rheum Clinic, Univ Hospital,<br />

Zurich, Switzerland, 4 University Hospital, Zurich, Switzerland,<br />

5<br />

University Hospital Zurich, Zurich, Switzerland, 6 Working Group<br />

for Pulmonary Hypertension, Department for Internal Medicine,<br />

University Hospital Zurich, Zurich, Switzerland.<br />

36. TL1A Expressed on the Rheumatoid Fibroblast-Like<br />

Synoviosytes Mediates Signalling Induced by DcR3. Masayasu<br />

Takahashi, Dept. <strong>of</strong> Orthopaedic Surgery, Kobe Univ. Graduate<br />

School <strong>of</strong> Medicine, Kobe, Japan.<br />

37. Visfatin/NAMPT-Mediated NGF Stimulation in Articular<br />

Chondrocytes: A Potential Link between Pain and Obesity-<br />

Induced Osteoarthritis. Sabrina Priam 2 , Emilie Pecchi 3 ,<br />

Marjolaine Gosset 3 , Xavier Houard 2 and Francis Berenbaum 1 ,<br />

1<br />

Faculty <strong>of</strong> Medicine P&M Curie, Paris, France, 2 UPMC, Paris,<br />

France, Metropolitan, 3 UPMC.<br />

38. Vitamin D Suppresses Th17 Cytokines Via Down Regulation<br />

<strong>of</strong> RORgammat and NFATC2 and by Differential Regulation<br />

<strong>of</strong> GATA3. Anne-Marie Mus 2 , Jan Piet van Hamburg 2 , Patrick<br />

Asmawidjaja 2 , Johanna M. W. Hazes 2 , Hans van Leeuwen 2 , Louis<br />

Boon 1 , Edgar Colin 2 and Erik Lubberts 2 , 1 Bioceros, 2 Erasmus MC,<br />

University Medical Center.<br />

39. XCL1/Lymphotactin Induces Rheumatoid Arthritis Fibroblast-<br />

Like Synoviocytes Migration through MAP Kinases. Karolina<br />

Klosowska and James M. Woods, Midwestern University,<br />

Downers Grove, IL.<br />

Education<br />

40. An Audit on Patients’ Knowledge <strong>of</strong> Methotrexate. Evin<br />

Sowden, Wajeed Hassan, Ann Gooden, Bridget Jepson,<br />

Tamsheela Kausor, Ifraz Shafait, John Brockbank, Robert Ley<br />

and Lee-Suan Teh, Royal Blackburn Hospital, Blackburn, United<br />

Kingdom.<br />

41. Educating Primary Care Providers on Rheumatoid Arthritis<br />

Translates to Changes in Practice and Referrals: Results from<br />

the RAPID Continuing Medical Education Program. Clifton<br />

Bingham 3 , Karen Costenbader 1 , Steven Bender 2 , Daniel Duch 2<br />

and Michael Weinblatt 1 , 1 Brigham and Women’s, 2 Curatio CME<br />

Institute, 3 Johns Hopkins, Baltimore, MD.<br />

2010 Program Book<br />

42. Information Sources for Rheumatoid Arthritis: More Than Just<br />

the Rheumatologist. Katie Garneau 1 , Maura Iversen 4 , Saira Jan 3 ,<br />

Hsun Tsao 1 , Daniel Hal Solomon 2 and Kavita Parmar 3 , 1 Brigham<br />

and Women’s Hospital, 2 Brigham and Womens Hospital, Boston,<br />

MA, 3 Horizon Blue Cross Blue Shield, 4 Northeastern University,<br />

Brigham and Women’s Hospital, Harvard Medical School,<br />

Boston, MA.<br />

43. Knee and Shoulder Cadaver Teaching Improves Internal<br />

Medicine Residents’ Self-Reported Anatomy, Exam and<br />

Injection Skills. Jessica Berman 2 , Michael H. Pillinger 3 , Bradley<br />

Jensen 2 , Jennifer Hammann 2 and Stephen A. Paget 1 , 1 Hospital<br />

for Special Surgery, New York, NY, 2 Hospital for Special Surgery,<br />

New York, NY, 3 NYU-Manhattan VA Med Hospital, New York, NY.<br />

44. Medical Student Education in the Electronic Age: A Web-Based<br />

Virtual Teaching Tool. Ernesto J. Rodriguez 1 , Abie Alias 1 , Aasim<br />

Rehman 1 , Vanessa Osting 1 , Tanisha Battle 2 , Lara Westphal 2 ,<br />

Ashley G. Sterrett 3 , Helen Bateman 3 , John D. Carter 1 and Joanne<br />

Valeriano-Marcet 3 , 1 University <strong>of</strong> South Florida, Tampa, FL,<br />

2<br />

University <strong>of</strong> South Florida, 3 USF/JAHVA, Tampa, FL.<br />

45. <strong>Rheumatology</strong> Fellowship Curricular Rotation in<br />

Musculoskeletal Ultrasound. Dimitrios A. Pappas 2 , Marzouq A.<br />

Qubti 2 , Clifton O. Bingham III 2 and Allan C. Gelber 1 , 1 Baltimore,<br />

MD, 2 Johns Hopkins University, Baltimore, MD.<br />

46. Team-Based Learning in <strong>Rheumatology</strong> Resident Education:<br />

Two-Year Results on Receptiveness and Attitudes <strong>of</strong> Residents<br />

towards Collaborative Learning and Teamwork. Karina<br />

Marianne D. Torralba 2 , Beatrice A. Boateng 1 , Ron Ben-Ari 4 and<br />

Francisco P. Quismorio 3 , 1 Arkansas Children’s Hospital-University<br />

<strong>of</strong> Arkansas for Medical Sciences, 2 University <strong>of</strong> Southern<br />

California-Los Angeles County Medical Center, Pasadena, CA,<br />

3<br />

University <strong>of</strong> Southern California-Los Angeles County Medical<br />

Center, Los Angeles, CA, 4 University <strong>of</strong> Southern California-Los<br />

Angeles County Medical Center.<br />

47. The First Pediatric <strong>Rheumatology</strong> Objective Structured Clinical<br />

Examination: Providing Clinical Skills Feedback for Fellows<br />

and Program Directors. Megan L. Curran 1 and David D. Sherry 2 ,<br />

1<br />

Children’s Memorial Hospital, Northwestern University’s<br />

Feinberg School <strong>of</strong> Medicine, Chicago, IL, 2 The Children’s<br />

Hospital <strong>of</strong> Philadelphia, Philadelphia, PA.<br />

48. Utilization <strong>of</strong> Ambulatory Medical Clinic for <strong>Rheumatology</strong><br />

Education. James M. Ross, Lehigh Valley Health Network,<br />

Macungie, PA.<br />

Epidemiology and Health Services Research: Inflammatory<br />

Arthritis<br />

49. A Novel Baseline Biomarker <strong>of</strong> Acute-Phase Serum Amyloid<br />

A (A-SAA) and Serum Interleukin–2 Receptor alpha (sIL-2Rα)<br />

Predicted Long-Term (18 to 35 Yrs) Mortality <strong>of</strong> Incident<br />

Rheumatoid Arthritis (RA) and Matched Non-RA Cohort<br />

Controls (CN). Alfonse T. Masi 2 , Jean C. Aldag 2 and Jean D. Sipe 1 ,<br />

1<br />

Center for Scientific Review, NIH, Bethesda, MD, 2 University <strong>of</strong><br />

Illinois <strong>College</strong> <strong>of</strong> Medicine at Peoria, Peoria, IL.<br />

50. A Prediction Score To Differentiate Rheumatoid Arthritis<br />

from Undifferentiated Arthritis in an Early Arthritis Cohort.<br />

Christian Waimann 2 , Fernando DalPra 2 , Jimena Hogrefe 2 ,<br />

Josefina Marcos 2 , Soledad Retamozo 2 , Francisco Caeiro 2 , Luciana<br />

Casalla 2 , Mariana Benegas 2 , Oscar Rillo 2 , Horacio Berman 2 ,<br />

Alberto Berman 2 , Rodrigo García Salinas 2 , Antonio Catalán<br />

Pellet 2 , Federico Ceccato 2 , Sergio Paira 2 , Juan Carlos Marcos 2 ,<br />

José Maldonado Cocco 2 , Luis Cattogio 2 , Enrique Soriano 2 and<br />

Gustavo Citera 1 , 1 CONAART, Buenos Aires, Argentina, 2 CONAART,<br />

Argentina.


ACR Poster Session A<br />

51. Association <strong>of</strong> Patient Cost-Cutting Behaviors with Clinical<br />

Outcomes, Health Status, and Lost Work Productivity in<br />

Individuals with Rheumatoid Arthritis. Susan C. Bolge 1 , Ahmad<br />

B. Naim 2 , Chureen Carter 2 , Marco DiBonaventura 3 and Mike<br />

Ingham 2 , 1 Centocor Ortho Biotech Services, LLC, Horsham, PA,<br />

2<br />

Centocor Ortho Biotech Services, LLC, 3 KantarHealth.<br />

52. Baseline Factors Related to Response to Conventional DMARD<br />

Treatments. Kimberly L. Sterling 1 , Gebra Cuyun Carter 1 , Susan<br />

Messing 6 , George Reed 5 , Rui Chen 6 , Kimberly Kaukeinen 6 , Xin<br />

Tu 6 , David R. Nelson 2 , Khaled Sarsour 3 , Ronald A. Cantrell 3 ,<br />

Carlos I. Alatorre 3 and Jeffrey Greenberg 4 , 1 Eli Lilly and Co,<br />

Indianapolis, IN, 2 Eli Lilly and Co, 3 Eli Lilly and Co, Indianapolis,<br />

IN, 4 New York University School <strong>of</strong> Medicine, New York, NY,<br />

5<br />

University <strong>of</strong> Massachusetts, Amherst, MA, 6 University <strong>of</strong><br />

Rochester, Rochester, NY.<br />

53. Cerebrovascular and Venous Thromboembolic Events Predict<br />

Mortality in Rheumatoid Arthritis. A. Kirstin Bacani 2 , Sherine E.<br />

Gabriel 2 , Cynthia S. Crowson 1 and Eric L. Matteson 2 , 1 Rochester,<br />

MN, 2 Mayo Clinic, Rochester, MN.<br />

54. Changes in Corticosteroid Use after DMARD Initiation in<br />

Patients with Rheumatoid Arthritis. Vivian K. Kawai 5 , Carlos<br />

Grijalva 6 , Patrick Arbogast 6 , Jeffrey R. Curtis 4 , Daniel Hal<br />

Solomon 1 , Elizabeth Delzell 3 , Rita Ouellet-Hellstrom 2 , Ed<br />

Mitchel 6 , C. Michael Stein 5 and Marie R. Griffin 6 , 1 Brigham and<br />

Womens Hospital, Boston, MA, 2 FDA, 3 University <strong>of</strong> Alabama,<br />

4<br />

University <strong>of</strong> Alabama - Brimingham, Birmingham, AL,<br />

5<br />

Vanderbilt University, Nashville, TN, 6 Vanderbilt University.<br />

55. Changes in EQ-5D and SF-6D during Rituximab Treatment<br />

– Results from the CERERRA Collaboration. Elisabeth Lie 5 ,<br />

Katerina Chatzidionysiou7, Evgeny Nasonov9, Galina Lukina9,<br />

Cem Gebay 12 , Karel Pavelka 2 , Dan Nordström 6 , Matija Tomsic 13 ,<br />

Merete L. Hetland 3 , Ulrik Tarp 1 , Piet L. C. M. van Riel 1 0, Juan J.<br />

Gomez-Reino 11 , Ronald Van Vollenhoven8 and Tore K. Kvien 5 ,<br />

1<br />

Aarhus University Hospital, Aarhus, Denmark, 2 Charles<br />

University, Prague, Czech Republic, 3 Copenhagen University<br />

Hospital at Glostrup/DANBIO Registry, Copenhagen, Denmark,<br />

4<br />

Diakonhjemmet Hospital, Oslo, Norway, 5 Diakonhjemmet<br />

Hospital, Oslo, Norway, 6 Helsinki University Central Hospital,<br />

Helsinki, Finland, 7 Karolinska University Hospital, Stockholm,<br />

Sweden, 8 Karolinska University Hospital, Stockholm, Sweden,<br />

9<br />

Moscow Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow, Russian<br />

Federation, 10 Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands, 11 University Hospital <strong>of</strong> Santiago,<br />

Santiago, Spain, 12 University Hospitals <strong>of</strong> Geneva/SCQM<br />

Registry, Geneva, Switzerland, 13 University Medical Center <strong>of</strong><br />

Ljubljana, Ljubljana, Slovenia.<br />

56. Comparison <strong>of</strong> the Efficacy <strong>of</strong> Tocilizumab and TNFα-Inhibitors<br />

on the DAS28 in “Real Life” Conditions in Rheumatoid Arthritis<br />

(RA) Patients after DMARD Failure. Jörg Kaufmann 2 , Eugen<br />

Feist 1 , Hagen Schmidt 3 , Anne-Eve Roske 4 and Adrian Kielhorn 4 ,<br />

1<br />

Campus Charité Mitte, Med. Klinik Abt. Rheumatologie u.<br />

Klin. Immunologie, Berlin, Germany, 2 Praxis für Innere Medizin<br />

und Rheumatologie, Ludwigsfelde, Germany, 3 Praxis für Innere<br />

Medizin und Rheumatologie, Berlin, Germany, 4 Roche Pharma<br />

AG, Grenzach-Whylen, Germany.<br />

57. Demyelinating Events in Seniors with Rheumatoid Arthritis<br />

(RA): A Population-Based Study. Jessica Widdifield 7 , Sasha R.<br />

Bernatsky 2 , J. Michael Paterson 1 , Nadia Gunraj 1 , Janet E. Pope 5 ,<br />

J. Carter Thorne 4 , Alfred A. Cividino 3 and Claire Bombardier 6 ,<br />

1<br />

Institute for Clinical Evaluative Science, 2 McGill UHC/RVH,<br />

Montreal, QC, Canada, 3 McMaster University, Hamilton, ON,<br />

Canada, 4 Southlake Regional Health Care, Newmarket, ON,<br />

Canada, 5 St Joseph Health Care London, London, ON, Canada,<br />

6<br />

University <strong>of</strong> Toronto, Toronto, ON, Canada, 7 University <strong>of</strong><br />

Toronto.<br />

58. Descriptive Epidemiology <strong>of</strong> Adult Rheumatoid Arthritis in<br />

an Insurance Claims Database. Martin M. Crane 1 , Maneesh<br />

Juneja 3 , Fayaz A. Aziz 3 , Regina H. Kurrasch 2 , Myron E. Chu 2 ,<br />

Emilia Quattrocchi 3 , Stephanie Manson 4 and David J. Chang 2 ,<br />

1<br />

GlaxoSmithKline R&D, Research Triangle, NC, 2 GlaxoSmithKline<br />

R&D, King <strong>of</strong> Prussia, PA, 3 GlaxoSmithKline R&D, 4 United<br />

Biosource.<br />

59. Different Factors Are Important for RA Patients and<br />

Rheumatologists Regarding DMARD Escalation. Laura van<br />

Hulst 2 , Wietske Kievit 1 , Piet van Riel 2 and Liana Fraenkel 3 ,<br />

1<br />

Radboud University Nijmegen Medical Centre, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Nijmegen, The Netherlands, 2 Radboud University<br />

Nijmegen Medical Centre, Department <strong>of</strong> <strong>Rheumatology</strong>, 3 Yale<br />

University School <strong>of</strong> Medicine, Department <strong>of</strong> Medicine, VA<br />

Connecticut Healthcare System, Section <strong>of</strong> <strong>Rheumatology</strong>.<br />

60. DMARD Use for Rheumatoid Arthritis as Reported in the<br />

National Ambulatory Medical Care Survey, 1996-2007. Daniel<br />

Hal Solomon 4 , John Ayanian 3 , M. Alan Brookhart 6 , Sebastian<br />

Schneeweiss 2 , Tamara Shaykevich 2 , Edward H. Yelin 5 and Jeffrey<br />

N. Katz 1 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham and<br />

Women’s Hospital, 3 Brigham and Women’s Hospital, Harvard<br />

Medical School, 4 Brigham and Womens Hospital, Boston, MA,<br />

5<br />

University <strong>of</strong> California, San Francisco, CA, 6 University <strong>of</strong> North<br />

Caroline.<br />

61. Early Life Socioeconomic Factors and Rheumatoid Arthritis<br />

(RA) in Adulthood. Christine G. Parks 2 , Aimee A. D’Aloisio 1 , Lisa<br />

A. DeRoo 1 , Huiber Kirstin 3 and Dale P. Sandler, 1 National Institute<br />

<strong>of</strong> Environmental Health Science, Research Triangle Park, NC,<br />

2<br />

National Institute <strong>of</strong> Environmental Health Science, Research<br />

Triangle Park, NC, 3 UNC, School <strong>of</strong> Public Health, Chapel Hil NC.<br />

62. Effect <strong>of</strong> Disease-Modifying Anti-Rheumatic Drug (DMARD)<br />

Exposure on Head and Neck Cancer in a National Cohort <strong>of</strong><br />

Veterans with Rheumatoid Arthritis. Christopher R. Phillips 2 ,<br />

Angelique L. Zeringue 3 , Jay R. McDonald 1 , Seth A. Eisen 3 , Liron<br />

Caplan 4 and Prabha Ranganathan 5 , 1 Division <strong>of</strong> Infectious<br />

Disease, St. Louis Veterans Affairs Medical Center, 2 Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Washington University School <strong>of</strong> Medicine,<br />

Paducah, KY, 3 St. Louis Veterans Affairs Medical Center, 4 Univ <strong>of</strong><br />

CO-Denver Med Sc, Aurora, CO, 5 Washington University School<br />

<strong>of</strong> Medicine, St. Louis, MO.<br />

63. Elaboration and Validation <strong>of</strong> a Questionnaire To Assess the<br />

Impact <strong>of</strong> Rheumatoid Arthritis (RA) on Sexuality, with Patient<br />

Involvement: QUALISEX. Laure Gossec 2 , Catherine Solano 4 ,<br />

Simon Paternotte 2 , Catherine Beauvais 3 , Christelle Sordet 6 ,<br />

Philippe Gaudin 1 and Aleth Perdriger 5 , 1 Grenoble University<br />

Hospital, France, 2 Paris Cochin University Hospital, France,<br />

3<br />

Paris Saint Antoine University Hospital, France, 4 Paris, France,<br />

5<br />

Rennes University Hospital, France, 6 Strasbourg University<br />

Hospital, France.<br />

64. Geographical Variation <strong>of</strong> Rheumatoid Arthritis in Stockholm<br />

County, Sweden. Henrik Källberg 4 , Veronica M. Vieira 2 , Jamie E.<br />

Hart 1 , Karen H. Costenbader 3 , Marie Holmqvist 5 , Lars Klareskog 6 ,<br />

Lars Alfredsson 5 and Elizabeth W. Karlson 3 , 1 Channing<br />

Laboratory, Department <strong>of</strong> Medicine, Brigham and Women’s<br />

Hospital and Harvard Medical School, Boston Massachusetts,<br />

Department <strong>of</strong> Epidemiology, Harvard School <strong>of</strong> Public Health,<br />

Boston Massachusetts, 2 Department <strong>of</strong> Environmental Health,<br />

Boston University School <strong>of</strong> Public Health, Boston, MA,<br />

3<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology and Allergy, Brigham<br />

and Women’s Hospital and Harvard Medical School, Boston<br />

Massachusetts, 4 Institute <strong>of</strong> Environmental Medicine, Karolinska<br />

Institutet, Stockholm, Sweden, 5 Institute <strong>of</strong> Environmental<br />

Medicine, Karolinska Institutet, Stockholm, Sweden,<br />

6<br />

<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Medicine, Karolinska<br />

Institutet/Karolinska Hospital, Stockholm, Sweden.<br />

2010 Program Book 151


ACR Poster Session A<br />

65. H2607 – Country <strong>of</strong> Residence Affects the Ability <strong>of</strong> Patients<br />

with Rheumatoid Arthritis (RA) To Achieve a Favorable<br />

Employment Status. Ronald van Vollenhoven 2 , Mary Cifaldi 1 ,<br />

Annelies Boonen 4 , Sanjoy Roy 1 , Naijun Chen 1 and Vibeke<br />

Strand 3 , 1 Abbott Laboratories, Abbott Park, IL, 2 Karolinska<br />

University Hospital and Karolinska Institute, Stockholm,<br />

Sweden, 3 Stanford University, Palo Alto, CA, 4 University Hospital<br />

Maastricht, Maastricht, The Netherlands.<br />

66. HLA Class II Associations Differ in Indian (Asian) Patients<br />

Suffering from RA: Regional Population (Urban and Rural)<br />

Surveys Using COPCORD Bhigwan Model. Anuradha<br />

Venugopalan 2 , Arvind Chopra 3 and Renu Bharadwaj 1 , 1 BJ<br />

Medical <strong>College</strong>, Pune, India, 2 Center for Rheumatic Diseases,<br />

Pune, India, 3 Center for Rheumatic Diseases.<br />

67. Hospitalizations Following Heart Failure Diagnosis in<br />

Rheumatoid Arthritis Patients. Cynthia S. Crowson, John<br />

M. Davis III, Veronique L. Roger, Eric L. Matteson, Terry M.<br />

Therneau and Sherine E. Gabriel, Mayo Clinic, Rochester, MN.<br />

68. WITHDRAWN<br />

69. Importance <strong>of</strong> Changes in People/Patient Reported<br />

Outcomes in Rheumatoid Arthritis Patients Treated with<br />

Anti-TNF Therapies. The Example <strong>of</strong> the RAID (Rheumatoid<br />

Arthritis Impact Disease) Score after Etanercept Therapy.<br />

Maxime Dougados 2 , Mahaut Ripert 4 , Pascal Hilliquin 1 , Patrice<br />

Fardellone 5 , Olivier Brocq 3 and Isabelle Logeart 4 , 1 CH sud<br />

Francilien, Corbeil-Essonnes, France, 2 Hôpital Cochin and<br />

University <strong>of</strong> Paris, Paris, France, 3 Hopital Princesse Grace de<br />

Monaco, Monaco, 4 Pfizer France, la Défense, France, 5 University<br />

Hospital Amiens, Amiens, France.<br />

70. Inadequate Treatment <strong>of</strong> Rheumatoid Arthritis (RA). K.<br />

Andrew Crighton 3 , Elliot D. Rosenstein 4 , Jared S. Young 5 , Yukiko<br />

Kimura 2 and Victor S. Sloan 1 , 1 Celgene Corporation, Summit,<br />

NJ, 2 Hackensack Univ Medical Ctr, Hackensack, NJ, 3 Prudential<br />

Financial, Newark, NJ, 4 Saint Barnabas Medical Center,<br />

Livingston, Far Hills, NJ, 5 Thomson Reuters, Ann Arbor, MI.<br />

71. Increased Risk <strong>of</strong> Total Mortality with Anti-Cyclic Citrullinated<br />

Peptide (Anti-CCP) Positivity among Postmenopausal Women<br />

Reporting RA. Rachel H. Mackey 5 , Lewis H. Kuller 5 , Michael<br />

Holers 4 , Kevin Deane 4 , Brian Walitt 2 , Bill Robinson 3 , Yuefang<br />

Chang 5 , Charles Eaton 1 , Iulia Grillo 1 , Monica Bertoia 1 and Larry<br />

W. Moreland 5 , 1 Brown University, 2 Georgetown University,<br />

3<br />

Stanford University, 4 University <strong>of</strong> Colorado, 5 University <strong>of</strong><br />

Pittsburgh.<br />

72. Independent Impact <strong>of</strong> Statin Discontinuation on Mortality<br />

in Patients with Rheumatoid Arthritis: A Population-Based<br />

Study. Mary A. De Vera 1 , Hyon K. Choi 3 , Michal Abrahamowicz 2 ,<br />

Jacek Kopec 1 and Diane V. Lacaille 1 , 1 Arthritis Research Centre<br />

<strong>of</strong> Canada, Vancouver, BC, Canada, 2 McGill University, Montreal,<br />

QC, Canada, 3 Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />

73. Joint Damage Progresses in DAS28 Remission and Is Driven<br />

by Residual Joint Swelling. Daniel Aletaha and Josef S. Smolen,<br />

Medical University <strong>of</strong> Vienna, Austria.<br />

74. Large Discrepancy between Expected and Observed Ratios <strong>of</strong><br />

Biologic Treated Rheumatoid Arthritis Patients Also Compliant<br />

on DMARDs. Denis Choquette 2 , Mark Arundine 1 and Oliver<br />

Thomas 1 , 1 Mississauga, ON, Canada, 2 Institut de Rhumatologie<br />

de Montréal, Montreal, QC, Canada.<br />

75. Leflunomide and the Risk <strong>of</strong> Hepatotoxicity: A Review <strong>of</strong> Post-<br />

Marketing Data. Jane L. Gilbert 1 , Kate Gelperin 2 , Joann Lee 2 ,<br />

Poonam Mishra 2 , Lauren Choi 2 , Allen Brinker 2 , David Graham 2 ,<br />

Robert Boucher 2 , Mark Avigan 2 and John Senior 2 , 1 FDA,<br />

Washington, DC, 2 FDA.<br />

76. Meta-Analysis and Biologics – Comparing Apples to Apples:<br />

An Example Using Radiographic Outcomes in Rheumatoid<br />

Arthritis. Mike Ingham 1 and Chureen Carter 2 , 1 Centocor Ortho<br />

Biotech Services, LLC, Horsham, PA, 2 Centocor Ortho Biotech<br />

Services, LLC.<br />

77. Multiple Serum Cytokines/Chemokines Are Associated<br />

with RA-Related Autoantibodies in First-Degree Relatives<br />

without Rheumatoid Arthritis (RA): Studies <strong>of</strong> the Etiology<br />

<strong>of</strong> Rheumatoid Arthritis (SERA). Jan M. Hughes-Austin 8 , Kevin<br />

D. Deane 9 , Lezlie Derber 8 , Jason R. Kolfenbach 10 , Michael<br />

Weisman 2 , Jane Buckner 12 , James R. O’Dell 6 , Ted R. Mikuls 11 ,<br />

Peter K. Gregersen 3 , Richard M. Keating 1 , William Robinson 4 ,<br />

V. Michael Holers 5 and Jill Norris 7 , 1 Oak Park, IL, 2 Cedars Sinai<br />

Medical Center, 3 N Shore Univ Hosp Rsch Ctr, Manhasset, NY,<br />

4<br />

Stanford Univ School <strong>of</strong> Med, Stanford, CA, 5 Univ <strong>of</strong> Colorado<br />

School <strong>of</strong> Med, Aurora, CO, 6 University <strong>of</strong> Nebraska Medical<br />

Center, Omaha, NE, 7 University <strong>of</strong> Colorado Denver, Aurora,<br />

CO, 8 University <strong>of</strong> Colorado Denver, 9 University <strong>of</strong> Colorado<br />

School <strong>of</strong> Med, Aurora, CO, 10 University <strong>of</strong> Colorado School <strong>of</strong><br />

Medicine, Aurora, CO, 11 University <strong>of</strong> Nebraska Medical Center,<br />

Omaha, NE, 12 Virginia Mason Research Center.<br />

78. Noncardiac Vascular Disease in Rheumatoid Arthritis (RA):<br />

Increase in Venous Thromboembolic Events? A. Kirstin Bacani,<br />

Sherine E. Gabriel, Cynthia S. Crowson and Eric L. Matteson,<br />

Mayo Clinic, Rochester, MN.<br />

79. Perception <strong>of</strong> RA Disease Activity by Patients and Physicians:<br />

Reasons for and Estimators <strong>of</strong> Discrepancies. Paul Studenic,<br />

Josef S. Smolen and Daniel Aletaha, Medical University <strong>of</strong><br />

Vienna, Austria.<br />

80. Permanent Working Disability Caused by Rheumatoid Arthritis<br />

Is Declining, Partly Due to Use <strong>of</strong> TNF-Inhibitors – Results<br />

from a Nationwide Finnish Register in 2000-2007. Vappu<br />

Rantalaiho 6 , Hannu Kautiainen 1 , Salme Järvenpää 3 , Lauri Virta 5 ,<br />

Timo Pohjolainen 4 , Markku Korpela 6 , Timo Möttönen 7 and Kari<br />

Puolakka 2 , 1 Jyväskylä Central Hospital, Finland, 2 Lappeenranta<br />

Central Hospital, Finland, 3 Medcare Foundation, Finland, 4 Orton<br />

Rehabilitation Unit, Finland, 5 Social Incurance Institution,<br />

Finland, 6 Tampere University Hospital, Finland, 7 Turku University<br />

Hospital, Finland.<br />

81. Prescription Patterns in Pregnant Women with Rheumatoid<br />

Arthritis. Bindee Kuriya 3 , Sonia Hernandez-Diaz 4 , Jun Liu 2 ,<br />

Gregory Daniel 5 and Daniel Hal Solomon 1 , 1 Brigham and<br />

Women’s Hospital, Boston, MA, 2 Brigham and Women’s<br />

Hospital, 3 Harvard School <strong>of</strong> Public Health, Brookline, MA,<br />

4<br />

Harvard School <strong>of</strong> Public Health, 5 HealthCore Inc., Wilmington,<br />

DE.<br />

82. Relative Importance <strong>of</strong> Patient’s Opinion and Physician’s<br />

Criteria <strong>of</strong> Disease Activity Versus Information <strong>of</strong> Disease<br />

Duration and Rheumatologist Type <strong>of</strong> Exercise for Treatment<br />

Decision in Rheumatoid Arthritis: DUO Study. Maxime<br />

Dougados 2 , Henri Nataf 1 , Ghislaine Steinberg 4 , Géraldine<br />

Martineau 4 , Stéphanie Rouanet 4 and Bruno Falissard 3 , 1 Centre<br />

Hospitalier François Quesnay, Mantes-La-Jolie, France, 2 Hospital<br />

Cochin, Paris, France, 3 INSERM U669, PSIGIAM, Paris, France,<br />

4<br />

Roche, Neuilly-sur-Seine, France.<br />

152<br />

2010 Program Book


ACR Poster Session A<br />

83. Respiratory Cause Mortality Was Greater in 54 Incident<br />

Rheumatoid Arthritis (RA) Patients Than 204 Community-<br />

Based, Non-RA Matched Cohort Controls (CN). Alfonse T. Masi<br />

and Jean C. Aldag, University <strong>of</strong> Illinois <strong>College</strong> <strong>of</strong> Medicine at<br />

Peoria, Peoria, IL.<br />

84. Rheumatoid Arthritis (RA) Is the Only One <strong>of</strong> 8 Diseases for<br />

Which a Patient History and Physical Examination (Versus<br />

Laboratory Tests and Ancillary Studies) Were Rated as Most<br />

Important for Clinical Decisions by >50% in a Physician Survey.<br />

Lauren McCollum 4 , Sangmo Park 4 , Tuulikki Sokka 2 , Hasan Yazici 1<br />

and Theodore Pincus 3 , 1 Cerrahpasa Medical Faculty, Istanbul,<br />

Turkey, 2 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 3 New York<br />

University Hospital for Joint Disease, Hastings-on-Hudson, NY,<br />

4<br />

NYU Hospital for Joint Diseases.<br />

85. Similar Performance <strong>of</strong> New and Old Criteria for Rheumatoid<br />

Arthritis in an Early Arthritis Cohort in Amsterdam. Karin<br />

Britsemmer, Jennie Ursum and Dirkjan van Schaardenburg, Jan<br />

van Breemen Institute Amsterdam.<br />

86. WITHDRAWN<br />

87. The Impact <strong>of</strong> Health Beliefs on Therapeutic Adherence in<br />

Patients with Rheumatoid Arthritis (RA). Tara J. Rizvi 1 , John<br />

Gomez 1 , S<strong>of</strong>ia de Achaval 2 , Michael A. Kallen 2 , Vanessa L. Cox 2 ,<br />

Marsha N. Richardson 2 , Bernard Ng 1 , John D. Reveille 3 and<br />

Maria E. Suarez-Almazor 4 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston,<br />

TX, 2 The University <strong>of</strong> Texas M. D. Anderson Cancer Center,<br />

Houston, TX, 3 Univ Texas Health Sci Ctr, Houston, TX, 4 University<br />

<strong>of</strong> Texas, MD Anderson Cancer Center, Houston, TX.<br />

88. TNF and Natural Atheroprotective Antibodies Against<br />

Phosphorylcholine: Implications for Biologics in RA. S<strong>of</strong>ia<br />

Ajeganova, Roland Fiskesund, Ingiäld Hafström and Johan<br />

Frostegård, Karolinska Institutet, Sweden.<br />

89. TNF Therapy Reduces the Odds <strong>of</strong> Worsening Disability<br />

Trajectories in Rheumatoid Arthritis over at Least 2 Years –<br />

Data from the NDB-Portugal Cohort. S<strong>of</strong>ia Pedro 1 , Elizabeth<br />

Benito-Garcia 1 , Joana Vasconcelos 1 , Irina Chaves 1 , Rita<br />

Marques 1 , Andreia Rodrigues 1 , Kaleb Michaud 3 and Fred Wolfe 2 ,<br />

1<br />

Bioepi Clinical and Translational Research Center, Oeiras,<br />

Portugal, 2 National Databank for Rheumatic Diseases, Kansas,<br />

3<br />

University <strong>of</strong> Nebraska Medical Center, NE.<br />

90. TNF-alpha Blocking Therapy Lowers Cardiovascular Risk in<br />

Rheumatoid Arthritis. Ingrid M. Visman 1 , Alper M. van Sijl 3 ,<br />

Mike J. L. Peters 5 , Carlo J. J. van Dongen 1 , Ben A. C. Dijkmans 4<br />

and Michael T. Nurmohamed 2 , 1 Jan van Breemen Institute, 2 Jan<br />

van Breemen Institute and VU Medical Centre, Amsterdam,<br />

The Netherlands, 3 Jan van Breemen Institute and VU Medical<br />

Centre, 4 VU Medical Centre, Amsterdam, The Netherlands, 5 VU<br />

Medical Centre.<br />

91. Validation <strong>of</strong> the Work Performance Visual Analog Scale:<br />

Measuring Work and Household Productivity <strong>of</strong> Patients with<br />

Early, Aggressive Rheumatoid Arthritis. Dennis Revicki 2 , Sanjoy<br />

Roy 1 , Miriam Kimel 2 , Chris Thompson 2 and Mary Cifaldi 1 , 1 Abbott<br />

Laboratories, Abbott Park, IL, 2 United Biosource Corporation,<br />

Bethesda, MD.<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders I<br />

92. Candidate Gene Studies <strong>of</strong> Fibromyalgia: A Systematic Review<br />

and Meta-Analysis. Young Ho Lee, Sung Jae Choi, Jong Dae Ji<br />

and Gwan Gyu Song, KUMC, Seoul, Korea, Republic <strong>of</strong>.<br />

93. Clinical Determinants <strong>of</strong> Physical Activity in Fibromyalgia<br />

Patients. Dennis Ang 1 , Anthony Kaleth 3 , Silvia Bigatti 2 , Steven<br />

Mazzuca 2 , Chandan Saha 2 and Robert Bandy 2 , 1 Indiana<br />

University, Indianapolis, IN, 2 Indiana University, 3 Indiana<br />

University-Purdue University Indianapolis.<br />

94. Development <strong>of</strong> Responder Definitions for Fibromyalgia<br />

Clinical Trials. Lesley M. Arnold 8 , Philip J. Mease 6 , David A.<br />

Williams 7 , Susan A. Martin 5 , Fujun Wang 2 , Birol Emir 4 , Chinglin<br />

Lai 3 and Rong Zablocki 1 , 1 Cypress Bioscience, Inc., 2 Eli Lilly<br />

and Company, 3 Jazz Pharmaceuticals, 4 Pfizer, Inc., 5 RTI-Health<br />

Solutions, 6 Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 7 Univ<br />

<strong>of</strong> MI Hlth System-Lobby M, Ann Arbor, MI, 8 University <strong>of</strong><br />

Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH.<br />

95. Does Obesity in Patients with Fibromyalgia Modify Response<br />

to Tai Chi Therapy: Analysis <strong>of</strong> a Randomized Controlled Trial.<br />

Chenchen Wang 1 , Christopher H. Schmid 2 , Yoojin Lee 2 and<br />

Timothy McAlindon 1 , 1 Tufts Medical Center, Boston, MA, 2 Tufts<br />

Medical Center.<br />

96. Dorsal Root Ganglia/Sympathetic Ganglia Sodium Channels<br />

Gene Polymorphisms in Fibromyalgia. Gilberto Vargas-Alarcon,<br />

Edith Alvarez-Leon, Jose-Manuel Fragoso, Angelica Vargas, Aline<br />

Martinez, Maite Vallejo and Manuel Martinez-Lavin, National<br />

Institute <strong>of</strong> Cardiology, Mexico.<br />

97. Durability <strong>of</strong> Response in a 38-Week Open-Label Study <strong>of</strong><br />

Sodium Oxybate in Patients with Fibromyalgia. Michael<br />

Spaeth 5 , I. Jon Russell 7 , Serge Perrot 6 , Sarah Alvarez-Horine 3 ,<br />

Diane R. Guinta 1 , Y. Grace Wang 2 and Robert M. Bennett 4 , 1 Jazz<br />

Pharmaceuticals Inc., Palo Alto, CA, 2 Jazz Pharmaceuticals Inc.,<br />

3<br />

Jazz Pharmaceuticals, Inc., 4 Oregon Health and Science Univ,<br />

Portland, OR, 5 Rheumatologische Schwerpunktpraxis, 6 Service<br />

de Medecine Interne et Centre de la Douleur, Hôtel-Dieu,<br />

7<br />

University <strong>of</strong> Texas Health Science Center, San Antonio, TX.<br />

98. Effects <strong>of</strong> Milnacipran Added to Pregabalin on Cognition and<br />

Mental Clarity in Fibromyalgia Patients. Robert S. Katz 4 , Robert<br />

H. Palmer 2 , Yong Wang 3 and R. Michael Gendreau 1 , 1 Cypress<br />

Bioscience, Inc, San Diego, CA, 2 Forest Research Institute, Jersey<br />

City, NJ, 3 Forest Research Institute, 4 Rush University Medical<br />

Center, Chicago, IL.<br />

99. Fatigue in Fibromyalgia Patients: A Qualitative Study Exploring<br />

a Conceptual Framework. Philip J. Mease 4 , Lisa D’Ambrosio 3 ,<br />

Asha Hareendran 6 , Maureen Mohyde 2 , Robin Pokrzywinski 6 ,<br />

Kristin Seymour 5 and Steven Blum 1 , 1 Forest Research Institute,<br />

2<br />

Outcome Sciences, 3 Outcome Sciences and MIT AgeLab,<br />

4<br />

Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 5 Seattle<br />

<strong>Rheumatology</strong> Associates, 6 United BioSource Corporation.<br />

100. Fibromyalgia Criteria and Severity Scales for Clinical and<br />

Epidemiological Studies: A Modification <strong>of</strong> the ACR Preliminary<br />

Diagnostic Criteria for Fibromyalgia. Frederick Wolfe 2 , Daniel<br />

J. Clauw 7 , Mary Ann Fitzcharles 1 , Don L. Goldenberg 3 , Winfried<br />

Häuser 6 , Robert S. Katz 4 , Philip J. Mease 5 , Anthony S. Russell 8 ,<br />

I. Jon Russell 10 and John B. Winfield 9 , 1 Montreal West, QC,<br />

Canada, 2 National Data Bank for Rheumatic Diseases, Wichita,<br />

KS, 3 Newton-Wellesley Hosp, Newton, MA, 4 <strong>Rheumatology</strong><br />

Associates, Chicago, IL, 5 Seattle <strong>Rheumatology</strong> Associate,<br />

Seattle, WA, 6 Technische Universität München, Munich,<br />

Germany, 7 UM/Chronic Pain & Fatigue Res, Ann Arbor, MI,<br />

8<br />

University <strong>of</strong> Alberta, Edmonton, AB, Canada, 9 University <strong>of</strong><br />

North Carolina, Chapel Hill, NC, 10 University <strong>of</strong> Texas HSC, San<br />

Antonio, TX.<br />

2010 Program Book 153


ACR Poster Session A<br />

154<br />

101. Fibromyalgia Is Associated with a Disruption <strong>of</strong> Emotional<br />

Modulation <strong>of</strong> Pain, but Not Emotional Modulation <strong>of</strong> Spinal<br />

Nociception. Jennifer L. DelVentura 1 , Ellen L. Terry 2 , Emily J.<br />

Bartley 2 , Ashley Vincent 2 , Ewa Olech 3 and Jamie L. Rhudy 2 ,<br />

1<br />

The University <strong>of</strong> Tulsa, Tulsa, OK, 2 The University <strong>of</strong> Tulsa,<br />

3<br />

University <strong>of</strong> Oklahoma, Health Sciences Center.<br />

102. Fibromyalgia with and without Comorbid Positional Cervical<br />

Cord Compression (PC3): An Iron-Clad Difference. Patrick B.<br />

Wood 2 , Tobias Schmidt-Wilcke 3 and Andrew J. Holman 1 , 1 Pacific<br />

<strong>Rheumatology</strong> Assoc, Renton, WA, 2 Pacific <strong>Rheumatology</strong><br />

Associates, Renton, WA, 3 University <strong>of</strong> Michigan.<br />

103. Flt3-L Is a Novel Biomarker Increased in Cerebrospinal Fluid<br />

<strong>of</strong> Patients with Primary Fibromyalgia and Sjogren Syndrome.<br />

Jan L. Bjersing, Mats Dehlin, Henrik Zetterberg, Anette Larsson,<br />

Malin Erlandsson, Kaisa Mannerkorpi and Maria Bokarewa, Dept<br />

<strong>Rheumatology</strong>, Gothenburg University, Sweden.<br />

104. Hysterectomy Status and Fibromyalgia Symptom Severity.<br />

Mary O. Whipple, Ann Vincent, Terry H. Oh, Connie A. Luedtke<br />

and Tanya L. Hoskin, Mayo Clinic, Rochester, MN.<br />

105. Improvement in Multiple Dimensions <strong>of</strong> Fatigue in<br />

Fibromyalgia Patients Treated with Duloxetine. Lesley M.<br />

Arnold 2 , Fujun Wang 1 , Jonna Ahl 1 , Paula Gaynor 1 and Madelaine<br />

Wohlreich 1 , 1 Lilly USA LLC, Indianapolis, IN, 2 Women’s Health<br />

Research Program, Department <strong>of</strong> Psychiatry, University <strong>of</strong><br />

Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH.<br />

106. Novel Treatment <strong>of</strong> Tendinopathies with a Sulfated<br />

Disaccharide <strong>of</strong> Hyaluronic Acid-Promising In Vitro Results.<br />

Anna Torrent 1 , Ramon Ruhí 1 , Carlos Aláez 1 , Constanze<br />

Buhrmann 2 and Mehdi Shakibaei 3 , 1 BIOIBERICA S.A., Palafolls,<br />

Barcelona, Spain, 2 Ludwig-Maximilians-University, Munich,<br />

Germany, 3 Ludwig-Maximilians-University Munich, Munich,<br />

Germany.<br />

107. Outcome for a Prospective Cohort <strong>of</strong> Fibromyalgia Patients<br />

Receiving Tailored Treatments in a Multidisciplinary Pain<br />

Center. Mary-Ann Fitzcharles, Pantelis Panopalis, Ann Gamsa,<br />

Mark Ware and Yoram Shir, McGill University.<br />

108. Predictors <strong>of</strong> Clinical Outcome in Fibromyalgia: Single Center<br />

Experience <strong>of</strong> a Brief Interdisciplinary Fibromyalgia Treatment<br />

Program. Terry H. Oh 1 , Tanya L. Hoskin 1 , Connie L. Luedtke 2 ,<br />

Toby N. Weingarten 2 , Ann Vincent 2 and Jeffrey M. Thompson 2 ,<br />

1<br />

Mayo Clinic, Rochester, MN, 2 Mayo Clinic.<br />

109. Should Rheumatologists Retain Ownership <strong>of</strong> Fibromyalgia?<br />

A Survey <strong>of</strong> Ontario Rheumatologists. Sassan Ghazan-Shahi,<br />

Tanveer E. Towheed and Wilma Hopman, Queen’s University,<br />

Kingston, ON, Canada.<br />

110. The Course <strong>of</strong> Fibromyalgia – A Long-Term Longitudinal Cohort<br />

Study. Brian Walitt 5 , Winfried Häuser 3 , Afton Hassett 4 , Robert S.<br />

Katz 2 and Frederick Wolfe 1 , 1 National Databank for Rheumatic<br />

Diseases, 2 Rush University, 3 Technische Universität München,<br />

4<br />

University <strong>of</strong> Michigan Medical School, 5 Washington Hospital<br />

Center, Washington, DC.<br />

111. The Development <strong>of</strong> Fibromyalgia: Examination <strong>of</strong> Rates<br />

and Predictors in Patients with Osteoarthritis (OA). Frederick<br />

Wolfe 1 and Winfried Häuser 2 , 1 National Data Bank for Rheumatic<br />

Diseases, Wichita, KS, 2 Technische Universität München,<br />

Munich, Germany.<br />

2010 Program Book<br />

112. The Development <strong>of</strong> Fibromyalgia: Examination <strong>of</strong> Rates<br />

and Predictors in Patients with Rheumatoid Arthritis (RA).<br />

Frederick Wolfe 1 , Winfried Häuser 3 , Afton L. Hassett 4 , Robert<br />

S. Katz 2 and Brian T. Walitt 5 , 1 National Data Bank for Rheumatic<br />

Diseases, Wichita, KS, 2 Rush University Medical Center, Chicago,<br />

IL, 3 Technische Universität München, 4 University <strong>of</strong> Michigan<br />

Medical School, 5 Washington Hospital Center, Washington, DC.<br />

113. The Effect <strong>of</strong> Duloxetine on Cognition in Patients with<br />

Fibromyalgia. Philip J. Mease 3 , Lesley Arnold 4 , Fujun Wang 1 ,<br />

Jonna Ahl 1 , Richard Mohs 1 , Paula Gaynor 1 and Madelaine<br />

Wohlreich 2 , 1 Eli Lilly and Company, 2 Lilly USA, LLC, 3 Seattle<br />

<strong>Rheumatology</strong> Associate, Seattle, WA, 4 Women’s Health<br />

Research Program, Department <strong>of</strong> Psychiatry, University <strong>of</strong><br />

Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH.<br />

114. The Effectiveness <strong>of</strong> Botulinum Toxin Type-A and Prilocaine<br />

Injections in My<strong>of</strong>ascial Pain Syndrome. Mehmet Zeki Kiralp,<br />

Baki Ozdemir, Engin Cakar, Oguz Durmus, Levent Tekin and Umit<br />

Dincer, Gülhane Military Medical Academy, Haydarpasa Training<br />

Hospital, Department <strong>of</strong> Physical Medicine and Rehabilitation,<br />

Istanbul, Turkey.<br />

115. The Patient Specific Functional Scale Outperforms the<br />

Fibromyalgia Impact Questionnaire Physical Function Scale.<br />

Chad S. Boomershine 1 , Kim A. Edwards 2 , Jennifer Y. Hong 2 and<br />

Kenneth A. Wallston 2 , 1 Vanderbilt University, Nashville, TN,<br />

2<br />

Vanderbilt University.<br />

116. The Revised Version <strong>of</strong> the Fibromyalgia Impact Questionnaire:<br />

Association with Physical Function and Quality <strong>of</strong> Life. Seong-<br />

Rye Seo 1 , Sung-Ji Lee 3 , Tae-Jong Kim 3 , Yong-Wook Park 3 and<br />

Shin-Seok Lee 2 , 1 Chonnam Natl Univ Med School, Gwangju,<br />

Republic <strong>of</strong> Korea, 2 Chonnam Natl Univ Med School, Gwangju,<br />

Korea, Republic <strong>of</strong>, 3 Chonnam Natl Univ Med School.<br />

117. Treatment with FDA Approved Therapies in Patients with<br />

Fibromyalgia. Brian T. Walitt 3 , Robert S. Katz 2 and Frederick<br />

Wolfe 1 , 1 National Data Bank for Rheumatic Diseases, Wichita,<br />

KS, 2 <strong>Rheumatology</strong> Associates, Chicago, IL, 3 Washington Hospital<br />

Center, Washington, DC.<br />

Imaging <strong>of</strong> Rheumatic Disease I: X-ray, CT and MRI<br />

118. A Novel Tool for Fully Automatic Quantification <strong>of</strong> MRI<br />

Synovitis in Rheumatoid Arthritis Is More Sensitive to Change<br />

Than the Current Standard Semi-Quantitative Assessment.<br />

Michael A. Bowes 1 , Jane E. Freeston 4 , Edward J. Vital 4 , Graham<br />

Vincent 2 , Gwenael Guillard 2 , Paul Bird 5 , Paul Emery and Philip<br />

G. Conaghan 4 , 1 Imorphics Ltd, Manchester, United Kingdom,<br />

2<br />

Imorphics Ltd, 4 Section <strong>of</strong> Musculoskeletal Disease, University<br />

<strong>of</strong> Leeds, UK, 5 University <strong>of</strong> NSW, Sydney, Australia.<br />

119. Application <strong>of</strong> High-Resolution Peripheral Quantitative<br />

Computed Tomography (HR-pQCT) To Quantify Bony Damage<br />

in Rheumatoid Arthritis. Cheryl C. M. Barnabe 1 , Liam Martin 1 ,<br />

Steven K. Boyd 2 and Susan G. Barr 1 , 1 University <strong>of</strong> Calgary,<br />

Calgary, AB, Canada, 2 University <strong>of</strong> Calgary.<br />

120. Baseline CRP Predicts Early Improvement in Synovitis, Osteitis,<br />

and Erosion on MRI in RA Patients Treated with Tocilizumab:<br />

Results from the ACT-RAY MRI Substudy. Orrin M. Troum 6 ,<br />

Charles G. Peterfy 4 , Jeffrey L. Kaine 3 , Carol Chung 1 , Andrew<br />

Anisfeld 1 , Ewa Olech 2 and Philip G. Conaghan 5 , 1 Genentech,<br />

a Member <strong>of</strong> the Roche Group, South San Francisco, CA,<br />

2<br />

Oklahoma University Health Sciences Center, Oklahoma City,<br />

OK, 3 Sarasota Arthritis Research Center, Sarasota, FL, 4 Spire<br />

Sciences and Synarc, San Francisco, Kentfield, CA, 5 University<br />

<strong>of</strong> Leeds, Leeds, United Kingdom, 6 University <strong>of</strong> Southern<br />

California, Santa Monica, CA, Santa Monica, CA.


ACR Poster Session A<br />

121. Bone Density Measurement in Osteoarthritis Using Digital<br />

Radiographic Procedures. M. B. Kinds 2 , L. W. Bartels 1 , A. C. A.<br />

Marijnissen 3 , K. L. Vincken 1 , H. W.A.M. de Jong 1 , M. A. Viergever 1<br />

and F. P. J. G. Lafeber 3 , 1 Image Sciences Institute, University<br />

Medical Center Utrecht, The Netherlands, 2 <strong>Rheumatology</strong><br />

& Clinical Immunology, Image Sciences Institute, University<br />

Medical Utrecht, The Netherlands, Utrecht, The Netherlands,<br />

3<br />

<strong>Rheumatology</strong> & Clinical Immunology, University Medical<br />

Center Utrecht, The Netherlands.<br />

122. Bone Marrow Lesion (BML) Size in Osteoarthritic Knees<br />

Correlates with Extent <strong>of</strong> Cartilage Damage and Predicts<br />

Longitudinal Cartilage Loss. Jeffrey B. Driban 3 , Grace H. Lo 1 ,<br />

Ji Yeon Lee 2 , Robert J. Ward 3 , Eric Miller 5 and Timothy E.<br />

McAlindon 4 , 1 Tufts Medical Center, Houston, TX, 2 Tufts Medical<br />

Center, Brookline, MA, 3 Tufts Medical Center, Boston, MA, 4 Tufts<br />

Medical Center Box 406 , Boston, MA, 5 Tufts University.<br />

123. Decreased Incidence <strong>of</strong> Synovitis, Osteitis, and Erosion in Early<br />

RA Patients Treated with Adalimumab Plus Methotrexate<br />

Compared to Those with Methotrexate Alone: High-Field<br />

MRI Analysis from OPTIMA. Charles Peterfy 4 , Boulos Haraoui 5 ,<br />

Patrick Durez 3 , Kaushik Patra 2 and Hartmut Kupper 1 , 1 Abbott<br />

GmbH & Co. KG, Ludwigshafen, Germany, 2 Abbott Laboratories,<br />

Abbott Park, IL, 3 Cliniques Universitaires Saint-Luc, Université<br />

Catholique de Louvain, Brussels, Belgium, 4 Spire Sciences, San<br />

Francisco, CA, 5 University <strong>of</strong> Montreal Hospital Centre, Hopital<br />

Notre Dame, Montreal, QC, Canada.<br />

124. Detection <strong>of</strong> Radiographic Progression in Early Knee<br />

Osteoarthritis (CHECK): Sensitivity to Change <strong>of</strong> Knee Images<br />

Digital Analysis Compared to Altman Grading. M. B. Kinds 3 , S.<br />

M. A. Bierma-Zeinstra 1 , A. C. A. Marijnissen 5 , M. A. Viergever 2 , J.<br />

W. J. Bijlsma 5 , P. M. J. Welsing 4 and F. P. J. G. Lafeber 5 , 1 General<br />

Practice, Erasmus University Rotterdam, the Netherlands,<br />

2<br />

Image Sciences Institute, University Medical Center Utrecht,<br />

The Netherlands, 3 <strong>Rheumatology</strong> & Clinical Immunology,<br />

Image Sciences Institute, University Medical Center Utrecht,<br />

The Netherlands, 4 <strong>Rheumatology</strong> &Clinical Immunology,<br />

Julius Center for Health Sciences & Primary Care, University<br />

Medical Center Utrecht, The Netherlands, 5 <strong>Rheumatology</strong> &<br />

Clinical Immunology, University Medical Center Utrecht, The<br />

Netherlands.<br />

125. Discriminative Power <strong>of</strong> Different Combinations <strong>of</strong> Bones and<br />

Joints for Assessing Change in Rheumatoid Arthritis with MRI:<br />

Results Based on Pooled Data from Four Multisite Clinical<br />

Trials. Charles G. Peterfy 8 , Peter Countryman 7 , Julie DiCarlo 7 ,<br />

Annarita Gabriele 4 , Tim M. Shaw 3 , Andrew Anisfeld 5 , Wayne<br />

H. Tsuji 1 , Ewa Olech 6 and Norman B. Gaylis 2 , 1 Amgen, Seattle,<br />

WA, 2 Arthritis & Rheumatic Disease, Aventura, FL, 3 F H<strong>of</strong>fmann<br />

La-Roche, Ltd, Welwyn Gladen City Herts, United Kingdom,<br />

4<br />

F H<strong>of</strong>fmann La-Roche, Ltd, Italy, 5 Genentech, a Member <strong>of</strong><br />

the Roche Group, 6 Oklahoma Medical Research Foundation,<br />

Oklahoma City, OK, 7 Spire Sciences, LLC, San Francisco, CA,<br />

8<br />

Spire Sciences, LLC, Kentfield, CA.<br />

126. Giant Cell Arteritis and MRI Evaluation <strong>of</strong> the Cranial Arteries.<br />

Marie I. Clements-Baker 1 , Samir Patel 4 , Ryan Rebello 2 , George<br />

Ionnadis 5 and Nader Khalidi 3 , 1 St Joseph’s Healthcare Hamilton<br />

Ontario, Canada McMaster University, Hamilton, ON, Canada,<br />

2<br />

St Joseph’s Healthcare Hamilton, Mcmaster University,<br />

Hamilton, ON, Canada, 3 St. Joseph’s Healthcare Hamilton,<br />

McMaster University, Hamilton, ON, Canada, 4 St. Joseph’s<br />

Healthcare Hamilton, Mcmaster University, 5 St. Joseph’s<br />

Healthcare Hamilton. McMaster University.<br />

127. High-Field MRI and Powerdoppler Sonography –<br />

Supplementary Imaging Techniques in Assesing Disease<br />

Activity in Patients with Psoriasis Arthritis (PsA) and<br />

Rheumatoid Arthritis (RA) in Sustained Clinical Remission.<br />

Maria Hoehle, Rheumatologic Practice, Hamburg, Germany.<br />

128. Inflammatory Osteophyte Formation Is Different from<br />

Degenerative Osteophyte Formation. Stephanie Finzel,<br />

Christian Ernet, Christian Stach, Klaus Engelke, Matthias<br />

Englbrecht and Georg Schett, University <strong>of</strong> Erlangen-<br />

Nuremberg.<br />

129. Magnetic Resonance Elastography for the Evaluation <strong>of</strong> Liver<br />

Fibrosis in Patients with Rheumatoid Arthritis Receiving<br />

Methotrexate. Deana D. Hoganson 1 , Jun Chen 2 , Richard L.<br />

Ehman 2 , Jayant A. Talwalkar 2 , Clement J. Michet 1 , Meng Yin and<br />

Eric L. Matteson 1 , 1 Mayo Clinic, Rochester, MN, 2 Mayo Clinic.<br />

130. Magnetic Resonance Imaging (MRI) <strong>of</strong> the Spine May Be Useful<br />

in Patients with Non-Radiographic Axial Spondyloarthritis<br />

(NRASpA) without Active Sacroiliitis on MRI. Guillaume<br />

Direz 1 , Manuel Couchot 2 , Philippe Cotty 1 , Denis Mulleman 3 and<br />

Philippe M. Goupille 1 , 1 University Hospital, Tours, Tours, France,<br />

2<br />

University Hospital, Tours, Tours, France, 3 University Hospital,<br />

Tours, Tours, France.<br />

131. Malalignment <strong>of</strong> the Knee Is Associated with an Increased Risk<br />

for Incident and Enlarging Subchondral Bone Marrow Lesions<br />

in the More Loaded Compartments: The MOST Study. Daichi<br />

Hayashi 3 , Martin Englund 5 , Frank Roemer 4 , Jingbo Niu 1 , Leena<br />

Sharma 6 , Neil Segal 9 , Cora Lewis 8 , David T. Felson 2 , Michael<br />

C. Nevitt 7 and Ali Guermazi 4 , 1 Boston University, Boston, MA,<br />

2<br />

Boston University School <strong>of</strong> Medicine, Boston, MA, 3 Boston<br />

University School <strong>of</strong> Medicine, Boston, MA, 4 Boston University<br />

School <strong>of</strong> Medicine, 5 Lund University, Sweden, 6 Northwestern<br />

University, Chicago, IL, 7 UCSF, San Francisco, CA, 8 University <strong>of</strong><br />

Alabama at Birmingham, 9 University <strong>of</strong> Iowa.<br />

132. MRI and X-Ray Measured Changes in Joint Space Narrowing<br />

Are Closely Associated in Early RA Patients: A Pilot Study.<br />

Siri Lillegraven 2 , Pernille Bøyesen 2 , Mikkel Østergaard 3 ,<br />

Sølve Sesseng 2 , Tore K. Kvien 1 and Espen A. Haavardsholm 2 ,<br />

1<br />

Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet<br />

Hospital, Oslo, Norway, 3 Hvidovre University Hospital, Hvidovre,<br />

Denmark.<br />

133. MRI Bone Edema Is an Independent Predictor <strong>of</strong> Development<br />

<strong>of</strong> Rheumatoid Arthritis in Patients with Early Undifferentiated<br />

Arthritis. Anne Duer-Jensen 7 , Kim Hørslev-Petersen 10 , Merete<br />

L. Hetland 1 , Lene Bak 5 , Bo J. Ejbjerg 9 , Michael S. Hansen 6 , Julia<br />

S. Johansen 3 , Hanne M. Lindegaard 8 , Henrik Vinterberg 11 , Jakob<br />

M. Møller 4 and Mikkel Ostergaard 2 , 1 Copenhagen Univ Hosp<br />

Hvidovre and Glostrup, Hvidovre, Denmark, 2 Copenhagen<br />

University Hospitals at Hvidovre and Glostrup, Hvidovre,<br />

Denmark, 3 Dept <strong>of</strong> Oncology, Copenhagen University Hospital<br />

at Herlev, 4 Dept <strong>of</strong> Radiology, Copenhagen University Hospital<br />

at Herlev, 5 Dept <strong>of</strong> Radiology, Sygehus Lillebælt, Kolding, 6 Dept<br />

<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at Gent<strong>of</strong>te,<br />

7<br />

Dept <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at<br />

Glostrup and Hvidovre, Denmark, 8 Dept <strong>of</strong> <strong>Rheumatology</strong>,<br />

Odense University Hospital, 9 Dept <strong>of</strong> <strong>Rheumatology</strong>, Slagelse<br />

Hospital, 10 King Christian Xth Hospital for Rheumatic Diseases,<br />

Gråsten, 11 <strong>Rheumatology</strong> Clinic, Amagerbrogade, Copenhagen.<br />

2010 Program Book 155


ACR Poster Session A<br />

156<br />

134. MRI Inflammation in the Sacroiliac Joints Is Associated with<br />

CTX-II and Changes in Systemic Inflammation during TNFα<br />

Inhibitor Therapy. Susanne Juhl Pedersen 8 , Inge Juul Sørensen 13 ,<br />

Robert Lambert 5 , Kay-Geert Hermann 17 , Patrick Garnero 18 ,<br />

Julia S. Johansen 1 , Ole Rintek Madsen 9 , Annette Hansen 15 ,<br />

Michael Sejer Hansen 10 , Gorm Thamsborg 9 , Lis Smedegaard<br />

Andersen 19 , Ole Majgaard 14 , Anne Gitte L<strong>of</strong>t 16 , Jon Erlendsson 11 ,<br />

Karsten Asmussen 7 , Anne Grethe Jurik 3 , Jakob Møller 4 , Maria<br />

Hasselquist 4 , Dorrit Mikkelsen 2 , Thomas Skjødt 6 and Mikkel<br />

Østergaard 12 , 1 Dep. <strong>of</strong> Internal Medicine, Herlev Hospital,<br />

Copenhagen, Denmark, 2 Dep. <strong>of</strong> Radiology, Aabenraa Hospital,<br />

Aabenraa, Denmark, 3 Dep. <strong>of</strong> Radiology, Aarhus University<br />

Hospitals, Aarhus, Denmark, 4 Dep. <strong>of</strong> Radiology, Herlev<br />

University Hospital, Copenhagen, Denmark, 5 Dep. <strong>of</strong> Radiology,<br />

University <strong>of</strong> Alberta, Canada, 6 Dep. <strong>of</strong> Radiology, Vejle<br />

Hospital, Vejle, Denmark, 7 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Bispebjerg<br />

Hospital, Copenhagen, Denmark, 8 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Gent<strong>of</strong>te and Herlev Hospitals, Copenhagen, Denmark, 9 Dep.<br />

<strong>of</strong> <strong>Rheumatology</strong>, Gent<strong>of</strong>te Hospital, Copenhagen, Denmark,<br />

10<br />

Dep. <strong>of</strong> <strong>Rheumatology</strong>, Herlev Hospital, Copenhagen,<br />

Denmark, 11 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Horsens Hospital, Denmark,<br />

12<br />

Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre and Glostrup Hospitals,<br />

Copenhagen, Denmark, 13 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre<br />

and Glostrup Hospitals and DANBIO, Copenhagen, Denmark,<br />

14<br />

Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre Hospital, Copenhagen,<br />

Denmark, 15 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Rigshospitalet, Copenhagen,<br />

Denmark, 16 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Vejle Hospital, Denmark,<br />

17<br />

Departments <strong>of</strong> Radiology, Charité University Hospital, Berlin,<br />

Germany, 18 INSERM Unit 664, Lyon, and Cisbio Bioassays<br />

Bagnols/Cèze, France, 19 Rheumatism Hospital, University <strong>of</strong><br />

Southern Denmark, Graasten, Denmark.<br />

135. Quantitative Characterization <strong>of</strong> Bone Marrow Edema in<br />

Patients with Rheumatoid Arthritis. Xiaojuan Li 1 , Daniel Kuo 2 ,<br />

Warapat Virayavanich 2 , Thomas M. Link 2 , Sarah B. Gratton 2 ,<br />

Jonathan Graf 2 and John Imboden 2 , 1 University <strong>of</strong> California,<br />

San Francisco, San Francisco, CA, 2 University <strong>of</strong> California, San<br />

Francisco.<br />

136. Quantitative In Vivo HR-pQCT Imaging <strong>of</strong> 3D Radiocarpal and<br />

Metacarpophalangeal Joint Space Distances in Rheumatoid<br />

Arthritis. Andrew J. Burghardt 2 , Christina Kurhanewicz 3 , John<br />

B. Imboden 1 , Sharmila Majumdar 3 , Thomas M. Link 3 and<br />

Xiaojuan Li 2 , 1 Department <strong>of</strong> Medicine, University <strong>of</strong> California,<br />

San Francisco and Division <strong>of</strong> <strong>Rheumatology</strong>, San Francisco<br />

General Hospital, 2 Musculoskeletal Quantitative Imaging<br />

Research Group, Department <strong>of</strong> Radiology and Biomedical<br />

Imaging, University <strong>of</strong> California, San Francisco, San Francisco,<br />

CA, 3 Musculoskeletal Quantitative Imaging Research Group,<br />

Department <strong>of</strong> Radiology and Biomedical Imaging, University <strong>of</strong><br />

California, San Francisco.<br />

137. Radiographic Severity <strong>of</strong> Knee Osteoarthritis Predicts<br />

Quantitative Bone Marrow Lesions on MRI. Svetlana<br />

Krasnokutsky 4 , Ravinder Regatte 2 , Jenny Bencardino 2 , Leon<br />

Rybak 2 , Ilana Belitskaya-Lévy 2 , Jonathan Samuels 1 , Mukundan<br />

Attur 3 and Steven B. Abramson 4 , 1 New York University Hospital<br />

for Joint Disease, New York, NY, 2 NYU Langone Medical Center,<br />

3<br />

NYU Langone Medical Center, NYU Hospital for Joint Diseases,<br />

4<br />

NYU Langone Medical Center, NYU Hospital for Joint Diseases,<br />

New York, NY.<br />

2010 Program Book<br />

138. REMISSION PLUS: Multicenter Evaluation <strong>of</strong> Low-Field MRI<br />

for Monitoring Treatment Response in Rheumatoid Arthritis<br />

Patients. Ben Ostendorf 8 , Sabine Kamp 8 , Birthe Koerbl 2 ,<br />

Dorothea Reichelt 1 , Klaus Strassburger 2 , Axel Scherer 1 , Sabine<br />

Blaschke 9 , Edmund Edelmann 6 , Ino Gao 7 , Gernot Keyßer 11 ,<br />

Hans-Martin Lorenz 5 , Ulf Müller-Ladner 10 , Hans-Georg Pott 3 ,<br />

Marisa Walther 4 and Matthias Schneider 8 , 1 Department <strong>of</strong><br />

Radiology, Heinrich-Heine-University Düsseldorf, Düsseldorf,<br />

NRW, Germany, 2 German Diabetes Center at the Heinrich-<br />

Heine-University Düsseldorf, Leibniz Center for Diabetes<br />

Research, Institute <strong>of</strong> Biometrics and Epidemiology, Düsseldorf,<br />

NRW, Germany, 3 <strong>Rheumatology</strong> Center, Hannover, Hannover,<br />

Germany, 4 <strong>Rheumatology</strong> Clinic, Berlin-Buch, Berlin, Germany,<br />

5<br />

<strong>Rheumatology</strong> Department, Heidelberg University Hospital,<br />

Heidelberg, Germany, 6 <strong>Rheumatology</strong> Office, Bad Aibling,<br />

Bad Aibling, Germany, 7 <strong>Rheumatology</strong> Office, Heidelberg,<br />

Heidelberg, Germany, 8 <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Endocrinology, Diabetology and <strong>Rheumatology</strong>, Rhine-Ruhr<br />

<strong>Rheumatology</strong> Center, Heinrich-Heine-University Düsseldorf,<br />

Düsseldorf, NRW, Germany, 9 <strong>Rheumatology</strong>, Göttingen<br />

University Hospital, Göttingen, Germany, 10 <strong>Rheumatology</strong>,<br />

Kerckh<strong>of</strong>f Clinic, Bad Nauheim, Germany, 11 <strong>Rheumatology</strong>,<br />

Martin Luther University, Halle-Wittenberg, Halle, Germany.<br />

139. Repair <strong>of</strong> Bone Erosions in Patients Treated with TNF<br />

Antagonists in the Real World. Kaoru Takase 2 , Kouji Kobayashi 3 ,<br />

Kayo Terauchi 3 , Toshiyuki Watanabe 3 , Reikou Watanabe 3 ,<br />

Maasa Hama 3 , Rhusuke Yoshimi 3 , Hiroshi Kobayashi 3 , Atsushi<br />

Ihata 3 , Atsuhisa Ueda 3 , Mitsuhiro Takeno 3 , Haruko Ideguchi 1 ,<br />

Shigeru Ohno 1 and Yoshiaki Ishigatsubo 2 , 1 Center for<br />

Rheumatic Diseases, Yokohama City University Medical Center,<br />

2<br />

Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />

Yokohama City University Graduate School <strong>of</strong> Medicine,<br />

Yokohama, Japan, 3 Department <strong>of</strong> Internal Medicine and Clinical<br />

Immunology, Yokohama City University Graduate School <strong>of</strong><br />

Medicine.<br />

140. Responsiveness to Change and Reliability <strong>of</strong> Radiographic<br />

Joint Space Width in Osteoarthritis <strong>of</strong> the Knee: A Systematic<br />

Review. William M. Reichmann 2 , Jean Francis Maillefert 4 , David<br />

J. Hunter 5 , Jeffrey N. Katz 1 , Philip G. Conaghan 3 and Elena<br />

Losina 2 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham and<br />

Womens Hospital, Boston, MA, 3 Chapel Allerton Hospital, Leeds,<br />

United Kingdom, 4 Dijon University Hospital, Dijon, France,<br />

5<br />

University <strong>of</strong> Sydney, Boston, MA.<br />

141. Synovitis and Osteitis Is Very Frequent in Rheumatoid Arthritis<br />

(RA) Patients in Clinical Remission: Results from a MRI Study<br />

<strong>of</strong> 300 RA Patients in Clinical Remission or Low Disease Activity<br />

State. Frederique Gandjbakhch 5 , Philip G. Conaghan 12 , Bo<br />

Ejbjerg 2 , Espen Haavardsholm 3 , Violaine Foltz 6 , Andrew Brown 12 ,<br />

Uffe Moller Dohn 11 , Marissa Lassere 9 , Jane Freeston 12 , Pernille<br />

Bøyesen 3 , Paul Bird 4 , Bruno Fautrel 6 , Merete Lund Hetland 2 ,<br />

Paul Emery 1 , Pierre Bourgeois 6 , Kim Hørslev-Petersen 8 , Tore<br />

Kvien 3 , Fiona M. McQueen 10 and Mikkel Østergaard 7 , 1 Chapel<br />

Allerton Hospital, Leeds, United Kingdom, 2 Copenhagen<br />

University Hospitals at Hvidovre and Glostrup, Denmark,<br />

3<br />

Diakonhjemmet Hospital, University <strong>of</strong> Oslo, Oslo, Norway,<br />

4<br />

Division <strong>of</strong> Medicine, University <strong>of</strong> NSW, Sydney Australia,<br />

5<br />

Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC, Paris,<br />

France, 6 Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC,<br />

Paris, France, 7 Hvidovre University Hospital, Hvidovre, Denmark,<br />

8<br />

King Christian X’s Hospital for Rheumatic Diseases, University<br />

<strong>of</strong> Southern Denmark, 9 St. George Hospital, University <strong>of</strong> NSW,<br />

Sydney, Australia, 10 Univ <strong>of</strong> Auckland Sch <strong>of</strong> Med, Auckland,<br />

New Zealand, 11 University Hospitals at Hvidovre and Glostrup,<br />

Denmark, 12 University <strong>of</strong> Leeds, Leeds, UK.


ACR Poster Session A<br />

142. The Intra- and Inter-Reader Reliability <strong>of</strong> the Oslo Hand<br />

Osteoarthritis (HOA) Magnetic Resonance Imaging (MRI)<br />

Score. Ida Kristin Haugen 2 , Siri Lillegraven 2 , Barbara Slatkowsky-<br />

Christensen 2 , Espen Haavardsholm 2 , Sølve Sesseng 2 , Tore K.<br />

Kvien 1 , Desiree M. Van Der Heijde 3 and Pernille Bøyesen 2 ,<br />

1<br />

Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet<br />

Hospital, 3 Leiden University Medical Center, Meerssen, The<br />

Netherlands.<br />

143. Validity and Responsiveness to Change <strong>of</strong> Radiograph-Based<br />

Joint Space Narrowing Metric Measurement: A Systematic<br />

Review. Delphine Chu Miow Lin 6 , William M. Reichmann 2 , Laure<br />

Gossec 4 , Elena Losina 1 , Philip G. Conaghan 5 and Jean-Francis<br />

Maillefert 3 , 1 Department <strong>of</strong> Orthopaedic Surgery, Brigham and<br />

Women’s Hospital, Boston, MA, 2 Department <strong>of</strong> Orthopaedic<br />

Surgery, Brigham and Women’s Hospital, Boston, MA and<br />

3<br />

. Department <strong>of</strong> Biostatistics, Boston University School <strong>of</strong><br />

Public Health, Boston, MA, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Dijon University Hospital, Dijon, F-21078, France, University<br />

<strong>of</strong> Burgundy, Dijon, F-21079, France, INSERM U887, Dijon,<br />

F-21079, France, 4 Paris Descartes University, Medicine Faculty;<br />

UPRES-EA 4058; APHP, <strong>Rheumatology</strong> B Department, Cochin<br />

Hospital, Paris France, 5 Section <strong>of</strong> Musculoskeletal Disease,<br />

University <strong>of</strong> Leeds & NIHR Leeds Musculoskeletal Biomedical<br />

Research Unit, Leeds, UK, 6 Tours Medicine Faculty; Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Tours University Hospital, Tours, France.<br />

Metabolic and Crystal Arthropathies - Therapeutics and Outcomes<br />

I<br />

144. A Single Cohort, Dose Escalation Phase 1 Study <strong>of</strong> Intravenous<br />

Infusion <strong>of</strong> Pegsiticase (Formerly Uricase-PEG 20), a Drug for<br />

Managing Hyperuricemia in Refractory Gout. Tony Fiorino 3 ,<br />

Alan J. Kivitz 1 , Patricia Pardo 5 , Rocelle Flores 2 , Zhihua Zhang 2 and<br />

John S. Bomalaski 4 , 1 Altoona Arthritis & Osteo Ctr, Duncansville,<br />

PA, 2 EnzymeRx, 3 EnzymeRx, Paramus, NJ, 4 EnzymeRx, Wayne,<br />

PA, 5 Miami Research Associates, Miami, FL.<br />

145. Canakinumab (ACZ885) Relieves Pain and Controls<br />

Inflammation Rapidly in Patients with Difficult-To-Treat Gouty<br />

Arthritis: Comparison with Triamcinolone Acetonide. A. So 6 ,<br />

M. De Meulemeester 4 , A. Pikhlak 2 , A. E. Yücel 1 , U. Arulmani 3 , D.<br />

Richard 3 , V. Murphy 3 , P. Sallstig 3 and N. Schlesinger 5 , 1 Baskent<br />

University, Ankara, Turkey, 2 Moscow State University <strong>of</strong><br />

Medicine and Dentistry, Moscow, Russian Federation, 3 Novartis<br />

Pharma AG, Basel, Switzerland, 4 Private Practice, Gozée,<br />

Belgium, 5 UMDNJ-Robert Wood Johnson Medical School, New<br />

Brunswick, NJ, 6 University <strong>of</strong> Lausanne, Lausanne, Switzerland.<br />

146. Change in Uric Acid Level Is Associated with Change in Patient<br />

Reported Outcomes in the Context <strong>of</strong> a Clinical Trial for<br />

Chronic Gout. Will Taylor 1 , Steve Hamburger 2 , Lisa K. Stamp 5 ,<br />

Zebulun D. Horowitz 3 and Nicola Dalbeth 4 , 1 Department <strong>of</strong><br />

Medicine, University <strong>of</strong> Otago Christchurch, New Zealand,<br />

2<br />

Savient Pharmaceuticals, Inc., E. Brunswick NJ, 3 Savient<br />

Pharmaceuticals, Inc., E. Brunswick NJ, Baskingridge, NJ,<br />

4<br />

Univ Auckland, Auckland, New Zealand, 5 University <strong>of</strong> Otago<br />

Christchurch, Christchurch, New Zealand.<br />

147. Chronologic Age, Renal Function, and Comorbid Conditions<br />

(Physiologic Age) <strong>of</strong> Patients with Gout Did Not Increase<br />

Likelihood <strong>of</strong> Adverse Events (AEs): AGREE Study Post Hoc<br />

Analyses. Daniel E. Furst 1 , Paul Maranian 1 , Matthew W. Davis 3 ,<br />

Suman Wason 3 , Dinesh Khanna 1 and Robert Terkeltaub 2 ,<br />

1<br />

University <strong>of</strong> California Los Angeles, Los Angeles, CA,<br />

2<br />

University <strong>of</strong> California San Diego, San Diego, CA, 3 URL Pharma,<br />

Inc, Philadelphia, PA.<br />

148. Colchicine Use Is Associated with Decreased Diagnosis <strong>of</strong><br />

Myocardial Infarction (MI) and Trend toward Reduction <strong>of</strong> All-<br />

Cause Mortality and C-Reactive Protein (CRP) Levels: Insights<br />

from the NY VA Gout Cohort. Aaron Lehmann 5 , Laura Schneck 5 ,<br />

Robert T. Keenan 2 , William O’Brien 6 , Daria B. Crittenden 6 , Kristen<br />

Lee 6 , Rekha Tadoori 6 , Jeffrey D. Greenberg 1 , Bruce N. Cronstein 3 ,<br />

Steven Sedlis 4 and Michael H. Pillinger 5 , 1 Millburn, NJ, 2 Duke<br />

University, Durham, NC, 3 New York Univ Med Ctr, New York, NY,<br />

4<br />

NYU Langone Medical Center, 5 NYU Langone Medical Center,<br />

NYU Hospital for Joint Diseases, New York, NY, 6 NYU Langone<br />

Medical Center, NYU Hospital for Joint Diseases.<br />

149. Effect <strong>of</strong> Multiple Doses <strong>of</strong> Febuxostat on the<br />

Pharmacokinetics <strong>of</strong> a Single Dose <strong>of</strong> Theophylline. Max Tsai,<br />

Jingtao Wu, Lhanoo Gunawardhana and Himanshu Naik, Takeda<br />

Global Research &Development Center, Inc., Deerfield, IL.<br />

150. Effects <strong>of</strong> a Purine Nucleoside Phosphorylase Inhibitor,<br />

BCX4208, on the Serum Uric Acid Concentrations in Patients<br />

with Gout. David Fitz-Patrick 2 , Waymon Drummond 4 , John<br />

Pappas 3 and Alan S. Hollister 1 , 1 BioCryst Pharmaceuticals,<br />

Inc., Durham, NC, 2 East-West Medical Research Institute,<br />

Honolulu, HI, 3 Kentucky Medical Research Center, Lexington, KY,<br />

4<br />

Renaissance Clinical Research, Dallas, TX.<br />

151. Efficacy and Tolerability <strong>of</strong> Celecoxib in the Treatment<br />

<strong>of</strong> Moderate to Extreme Pain Associated with Acute<br />

Gouty Arthritis: A Randomized Controlled Trial. H. Ralph<br />

Schumacher 4 , Manuela Berger 3 , Julie Li-Yu 5 , Fernando Perez-<br />

Ruiz 1 , Ruben Burgos Vargas 2 and Chunming (Mark) Li 3 , 1 Hospital<br />

de Cruces, Baracaldo, Spain, 2 Hospital General de México,<br />

México City, Mexico, 3 Pfizer Inc., New York, NY, 4 University <strong>of</strong><br />

Pennsylvania VA Medical Center, Philadelphia, PA, 5 University <strong>of</strong><br />

Santo Tomas Hospital, Manila, Philippines.<br />

152. Evaluation <strong>of</strong> Rilonacept for Prevention <strong>of</strong> Gout Flares during<br />

Initiation <strong>of</strong> Urate-Lowering Therapy: Results <strong>of</strong> a Phase 3,<br />

Randomized, Double-Blind, Placebo-Controlled Trial. Robert<br />

Terkeltaub 6 , H. Ralph Schumacher 5 , Kenneth G. Saag 4 , James<br />

Clower 7 , William Jennings 1 , Robert R. Evans 2 , Jian Wang 3 ,<br />

Shirletta King-Davis 3 and Steven P. Weinstein 2 , 1 Radiant<br />

Research, San Antonio, TX, 2 Regeneron Pharmaceuticals, Inc.,<br />

Tarrytown, NY, 3 Regeneron Pharmaceuticals, Inc., 4 University<br />

<strong>of</strong> Alabama-Birmingham, Birmingham, AL, 5 VA Medical Center<br />

and UPenn, Philadelphia, PA, 6 VA Medical Ctr, San Diego, CA,<br />

7<br />

Westside Center for Clinical Research, Jacksonville, FL.<br />

153. Evaluation <strong>of</strong> Rilonacept in Patients with Gouty Arthritis<br />

Experiencing an Acute Gout Attack. Robert Terkeltaub 6 , H.<br />

Ralph Schumacher 5 , Craig Curtis 1 , Neil Patterson 2 , Robert<br />

R. Evans 3 , Jian Wang 4 , Shirletta King-Davis 4 and Steven P.<br />

Weinstein 3 , 1 Compass Research, Orlando, FL, 2 Private Practice,<br />

Oviedo, FL, 3 Regeneron Pharmaceuticals, Inc., Tarrytown,<br />

NY, 4 Regeneron Pharmaceuticals, Inc., 5 VA Medical Center,<br />

Philadelphia, PA, 6 VA Medical Ctr, San Diego, CA.<br />

154. Febuxostat Versus Allopurinol in the Treatment <strong>of</strong> Gout<br />

in Subjects >65 Years <strong>of</strong> Age: A Subgroup Analysis <strong>of</strong> the<br />

CONFIRMS Trial. Eswar Krishnan 1 , Patricia A. MacDonald 2 ,<br />

Barbara Hunt 2 and Robert Jackson 2 , 1 Stanford University,<br />

Stanford, CA, 2 Takeda Global Research & Development Center,<br />

Inc., Lake Forest, IL.<br />

155. Healthcare Utilization and Productivity at Home and Work<br />

Place in Tophaceous vs. Non-Tophaceous Gout. Puja Khanna 3 ,<br />

Jay Persselin 1 , Ron Hays 2 , Daniel Furst 2 , Harold Paulus 2 , Paul<br />

Maranian 2 and Dinesh Khanna 2 , 1 Greater Los Angeles VA, 2 UCLA,<br />

3<br />

UCLA and Greater Los Angeles VA.<br />

2010 Program Book 157


ACR Poster Session A<br />

156. Patient Knowledge and Beliefs Concerning Gout and Its<br />

Treatment. Leslie R. Harrold 4 , Kathleen M. Mazor 2 , Daniel<br />

Peterson 3 , Cassandra Firneno 3 and Robert A. Yood 1 , 1 Fallon<br />

Clinic, Worcester, MA, 2 Meyers Primary Care Insitute/UMass<br />

Medical School, 3 Meyers Primary Care Institute, 4 UMass Medical<br />

Schl, Worcester, MA.<br />

157. Progressive Reduction in Tophus Burden with Pegloticase<br />

Therapy in Patients with Chronic Gout Refractory to<br />

Conventional Therapy. Herbert Baraf 1 , Sergio R. Gutierrez-<br />

Urena 4 , Janitzia Vazquez-Mellado 5 , Claudia Rehrig 6 , Faith<br />

Ottery 6 , John S. Sundy 2 and Robert A. Yood 3 , 1 Arthritis &<br />

Rheumatism Association, Wheaton, MD, 2 Duke University<br />

Medical Center, Durham, NC, 3 Fallon Clinic, Worcester, MA,<br />

4<br />

Hospital Civil de Guadelajara, Guadalajara, Mexico, 5 Hospital<br />

General de México, México City, 6 Savient Pharmaceuticals, Inc.<br />

158. Safety and Efficacy <strong>of</strong> Febuxostat (FEB) Treatment in Subjects<br />

with Gout and Severe Allopurinol (ALLO) Adverse Reactions.<br />

Saima Chohan and Michael A. Becker, University <strong>of</strong> Chicago,<br />

Chicago, IL.<br />

159. Serum Urate Levels Have an Impact on Renal Function in<br />

Patients with Gout Withdrawing Urate-Lowering Therapy<br />

(ULT). Fernando Perez-Ruiz 1 , Ana M. Herrero-Beites 2 and Miguel<br />

A. Gonzalez-Gay 3 , 1 Hospital de Cruces, Jopelana, Spain, 2 Hospital<br />

de Górliz, 3 Hospital Univesitario Marqués de Valdecilla.<br />

160. The Combination <strong>of</strong> Tranilast with Allopurinol Results in<br />

Enhanced Urate Lowering. John S. Sundy 4 , Michael M. Kitt 5 ,<br />

Sue G. Griffith 1 , Randall R. Stoltz 2 and Ronald Goldblum 3 ,<br />

1<br />

ClinPharma Resources, San Diego, CA, 2 Covance, Evansville,<br />

IN, 3 CPC Inc, Carlsbad, CA, 4 Duke University Medical Center,<br />

Durham, NC, 5 Nuon Therapeutics, Inc., San Mateo, CA.<br />

161. The Effect <strong>of</strong> Allopurinol on Renal Function in Patients with<br />

Hyperuricemia: A Case-Control Study. Aneesa Krishnamurthy 1 ,<br />

Deana M. Lazaro 5 , David R. Blumenthal 4 , Donald A. Gerber 2 and<br />

Peter L. Flom 3 , 1 SUNY Downstate Medical Center, Kew Garden<br />

Hills, NY, 2 SUNY Downstate Medical Center, Brooklyn, NY, 3 SUNY<br />

Downstate Medical Center, 4 VA New York Harbor Healthcare<br />

System, Short Hills, NJ, 5 VA New York Harbor Healthcare System<br />

and SUNY Downstate Medical Center, Brooklyn, NY.<br />

162. The Impact <strong>of</strong> Deficits in Gout Care on Hospitalizations.<br />

Prachaya Nitichaikulvatana 1 , Katherine Upchurch 2 and Leslie<br />

Harrold 2 , 1 University <strong>of</strong> Massachusetts Medical School,<br />

Worcester, 2 University <strong>of</strong> Massachusetts Medical School.<br />

163. The Safety and Efficacy <strong>of</strong> Anakinra in the Treatment <strong>of</strong><br />

Acute Gout in Hospitalized Patients. Michael Cho 1 , Pradipta<br />

Ghosh 3 , Gurpreet Hans 4 , Julia J. Rhiannon 2 , Gregory C. Gardner 1<br />

and Peter A. Simkin 1 , 1 University <strong>of</strong> Washington, Seattle,<br />

WA, 2 University <strong>of</strong> Washington, Seattle, WA, 3 University <strong>of</strong><br />

Washington, Lake Forest Park, WA, 4 University <strong>of</strong> Washington,<br />

Kirkland, WA.<br />

164. Tranilast Inhibits Urate Transport Mediated by URAT1 and<br />

GLUT9. Asim Mandal 3 , Daniel Emerling 1 , Tito Serafini 1 and David<br />

B. Mount 2 , 1 Nuon Therapeutics, Inc., San Mateo, CA 94403,<br />

2<br />

Renal Division, VA Boston Healthcare System and Brigham &<br />

Women’s Hospital, Harvard Medical School, Boston, MA, 3 Renal<br />

Division, VA Boston Healthcare System and Brigham & Women’s<br />

Hospital, Harvard Medical School, Boston, MA 02115.<br />

165. Urate-Lowering (UL) Efficacy and Safety <strong>of</strong> Febuxostat (FEB)<br />

and Allopurinol (ALLO) in Women with Gout, an Older Subset<br />

<strong>of</strong> Gout Subjects with Increased Comorbidity. Saima Chohan 3 ,<br />

Michael A. Becker 3 , Patricia A. MacDonald 1 , Solomon Chefo 2<br />

and Robert Jackson 2 , 1 Takeda Global R&D Inc, Lake Forest, IL,<br />

2<br />

Takeda Global Research & Development Center, Inc, Deerfield,<br />

IL, 3 University <strong>of</strong> Chicago, Chicago, IL.<br />

166. Use <strong>of</strong> Pegloticase in Chronic Gout Refractory to Conventional<br />

Therapy Is Associated with Significant Clinical Benefit: Tender<br />

Joint and Swollen Joint Counts and Patient Global Assessment<br />

(Health Assessment Questionnaire). David R. Mandel 3 , Herbert<br />

Baraf 1 , Claudia Rehrig 5 , Zebulun D. Horowitz 6 , Faith D. Ottery 4<br />

and Robert A. Yood 2 , 1 Arthritis & Rheumatism Association,<br />

Wheaton, MD, 2 Fallon Clinic, Worcester, MA, 3 Private<br />

Practive, Mayfield Village, OH, 4 Savient Pharmaceuticals, Inc,<br />

5<br />

Savient Pharmaceuticals, Inc., 6 Savient Pharmaceuticals, Inc.,<br />

Baskingridge, NJ.<br />

Orthopedics, Low Back Pain, and Rehabilitation<br />

167. A Specific Chemokine Expression Pattern Is Associated<br />

with Synovial Inflammation and Symptoms in Patients with<br />

Traumatic Knee Injury Undergoing Arthroscopic Meniscectomy.<br />

Carla R. Scanzello 7 , Brian McKeon 6 , Bryan H. Swaim 6 , Edward<br />

DiCarlo 5 , Eva Umoh 4 , Veero Kanda 8 , Anjali Nair 8 , David M. Lee 2 ,<br />

John C. Richmond 6 , Jeffrey N. Katz 1 , Mary K. Crow 3 and Steven<br />

R. Goldring 3 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham<br />

and Womens Hospital, Boston, MA, 3 Hospital for Special<br />

Surgery, New York, NY, 4 Hospital for Special Surgery, New York<br />

NY, 5 Hosptial for Special Surgery, New York NY, 6 New England<br />

Baptist Hospital, Boston MA, 7 Rush University Medical Center,<br />

Chicago, IL, 8 Rush University Medical Center, Chicago IL.<br />

168. A Systematic Review and Meta-Analysis <strong>of</strong> the Impact <strong>of</strong><br />

Total Shoulder Arthroplasty on Health-Related Quality <strong>of</strong><br />

Life. Michael J. Carter 1 , Ted R. Mikuls 1 , Smita Nayak 2 , Edward V.<br />

Fehringer 1 and Kaleb D. Michaud 1 , 1 Univ <strong>of</strong> Nebraska Med Ctr,<br />

Omaha, NE, 2 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

169. Cane Use in Hip Osteoarthritis. Karen L. Perell-Gerson 1 ,<br />

Constance Heiney 4 , Nancy D. Harada 4 , Jennifer M. Yentes 2 ,<br />

Sulabha Masih 4 and Meika A. Fang 3 , 1 Georgia Gwinnett <strong>College</strong>,<br />

Lawrenceville, GA, 2 University <strong>of</strong> Nebraska at Omaha, 3 VA<br />

Greater Los Angeles Healthcare System, Los Angeles, CA, 4 VA<br />

Greater Los Angeles Healthcare System, Los Angeles, CA.<br />

170. Comorbid Subjective Health Complaints in Patients with<br />

Sciatica, a Prospective Study Including Comparison with<br />

the General Population. Lars Grøvle 2 , Anne J. Haugen 2 ,<br />

Camilla Ihlebaek 5 , Anne Keller 1 , Bård Natvig 4 , Jens I. Brox 6<br />

and Margreth Grotle 3 , 1 Department <strong>of</strong> Physical Medicine and<br />

Rehabilitation, Oslo University Hospital, Ullevaal, 2 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Østfold Hospital Trust, Fredrikstad, Norway,<br />

3<br />

FORMI (Communication Unit for Musculoskeletal Disorders),<br />

Oslo University Hospital, Ullevaal, 4 National Resource Centre<br />

for Rehabilitation in <strong>Rheumatology</strong>, Diakonhjemmet Hospital<br />

& Department <strong>of</strong> General Practice and Community Medicine,<br />

ASAM, University <strong>of</strong> Oslo, 5 Research Group <strong>of</strong> Nature, Health<br />

and Quality <strong>of</strong> Life, Norwegian University <strong>of</strong> Life Sciences,<br />

Aas, 6 Section for Back Surgery and Physical Medicine and<br />

Rehabilitation, Orthopaedic Department, Oslo University<br />

Hospital, Rikshospitalet.<br />

158<br />

2010 Program Book


ACR Poster Session A<br />

171. Early Progressive Rehabilitation Following Total Knee<br />

Arthroplasty Improves Outcomes. Michael J. Bade 2 , Tami<br />

Struessel 2 and Jennifer E. Stevens-Lapsley 1 , 1 University <strong>of</strong><br />

Colorado Denver, Aurora, CO, 2 University <strong>of</strong> Colorado Denver.<br />

172. Facet Joint Injections for Low Back Pain Improve Quality<br />

<strong>of</strong> Life. Cecilia Mercieca 2 , Stefania Chetcuti Zammit 2 , Josef<br />

Lauri 1 and Andrew Albert Borg 2 , 1 Department <strong>of</strong> Mathematics,<br />

University <strong>of</strong> Malta, Malta, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Mater Dei Hospital, Msida, Malta.<br />

173. Fat Mass Is a Predictor <strong>of</strong> Disabling Foot Pain: A Cross-<br />

Sectional Study. Stephanie Tanamas 4 , Anita Wluka 4 , Patricia<br />

Berry 4 , Hylton Menz 2 , Boyd Strauss 4 , Miranda Davies-Tuck 4 ,<br />

Joseph Proietto 5 , John Dixon 1 , Graeme Jones 3 and Flavia<br />

Cicuttini 4 , 1 Baker IDI Heart and Diabetes Institute, 2 La Trobe<br />

University, 3 Menzies Research Institute, 4 Monash University,<br />

5<br />

University <strong>of</strong> Melbourne.<br />

174. Is There an Association between Living Situation and Pain<br />

Severity at the Time Patients Choose Total Hip Replacement?<br />

Yvonne C. Lee 1 , Huong T. Do 3 and Lisa A. Mandl 2 , 1 Brigham and<br />

Women’s Hospital, Boston, MA, 2 Hospital for Special Surgery,<br />

New York, NY, 3 Hospital for Special Surgery.<br />

175. OMERACT Responder Analysis <strong>of</strong> Patients Treated with<br />

Duloxetine for Chronic Low Back Pain. Vladimir Skljarevski 1 ,<br />

Matthew J. Bair 2 , Melissa J. Ossanna 1 , Eli Frakes 1 , Shuyu Zhang 1<br />

and Karla Alaka 1 , 1 Eli Lilly and Company, 2 Roudebush VA Medical<br />

Center.<br />

176. The Clinical Benefit <strong>of</strong> Joint Distraction in Treatment <strong>of</strong><br />

Advanced Ankle OA May Be Partly Explained by Subchondral<br />

Bone Changes. F. Intema 1 , T. P. Thomas 2 , D. D. Anderson 2 , J.<br />

Elkins 2 , S. C. Mastbergen 1 , F. P. J. G. Lafeber 1 , T. D. Brown 2 ,<br />

A. Amendola 2 and C. L. Saltzman 3 , 1 <strong>Rheumatology</strong> &Clinical<br />

Immunology, University Medical Center Utrecht, The<br />

Netherlands, 2 The University <strong>of</strong> Iowa, Iowa City, IA, 3 The<br />

University <strong>of</strong> Utah, Salt Lake City, UT.<br />

177. The Safety and Patient Acceptability <strong>of</strong> Suprascpular Nerve<br />

Block. E. Michael Shanahan 2 , Kieran Ross Shanahan 2 , Catherine<br />

Hill 1 , Malcolm Smith 2 and Michael John Ahern 2 , 1 Adelaide<br />

University, Adelaide, South Australia, Australia, 2 Flinders<br />

University, Adelaide, South Australia, Australia.<br />

178. Using the Patient Generated Index (PGI) To Measure<br />

Personalized Quality <strong>of</strong> Life (QoL) in Patients Undergoing Total<br />

Knee Arthroplasty (TKA). Maria A. Lopez-Olivo 2 , Michael A.<br />

Kallen 2 , Chong H. Pak 2 , Sherwin J. Siff 1 , Glenn C. Landon 1 , David<br />

Edelstein 1 , Kausha C. Robinson 2 and Maria E. Suarez-Almazor 3 ,<br />

1<br />

St. Luke’s Episcopal Health System, Houston, TX, 2 The University<br />

<strong>of</strong> Texas M.D. Anderson Cancer Center, Houston, TX, 3 University<br />

<strong>of</strong> Texas, MD Anderson Cancer Center, Houston, TX.<br />

Osteoarthritis - Clinical Aspects: Biomechanics, Function, and<br />

Imaging I<br />

179. Adiponectin but Not Leptin and Resistin, Is Associated with the<br />

Progression <strong>of</strong> Hand Osteoarthritis. Erlangga Yusuf 1 , Andreea<br />

Ioan-Facsinay 2 , Jessica Bijsterbosch 2 , Joanneke Kwekkeboom 2 ,<br />

P. Eline Slagboom 2 , Tom W. J. Huizinga 2 and Margreet<br />

Kloppenburg 2 , 1 LUMC, Leiden, The Netherlands, 2 LUMC, The<br />

Netherlands.<br />

180. Association <strong>of</strong> Knee, Ankle, and Midfoot Osteoarthritis and<br />

Physical Performance. Gary McDaniel 1 , Jordan B. Renner 2 ,<br />

Richard Sloane 1 and Virginia B. Kraus 1 , 1 Duke University Medical<br />

Center, Durham, NC, 2 University <strong>of</strong> North Carolina School <strong>of</strong><br />

Medicine.<br />

181. Associations between Composite Measures <strong>of</strong> Multi-<br />

Joint Osteoarthritis, Gait Speed, and Health Assessment<br />

Questionnaire Scores: The Johnston County Osteoarthritis<br />

Project. Amanda E. Nelson 6 , Robert F. DeVellis 5 , Jordan B.<br />

Renner 5 , Jama Purser 3 , Todd A. Schwartz 5 , Philip G. Conaghan 1 ,<br />

Virginia Byers Kraus 2 and Joanne M. Jordan 4 , 1 Chapel Allerton<br />

Hospital, Leeds, United Kingdom, 2 Duke Univ Med Ctr, Durham,<br />

Durham, NC, 3 Duke Univ Med Ctr, Durham, NC, 4 Thurston<br />

Arthritis Research Center, Univ <strong>of</strong> North Carolina, Chapel Hill,<br />

Chapel Hill, NC, 5 Thurston Arthritis Research Center, Univ <strong>of</strong><br />

North Carolina, Chapel Hill, NC, 6 UNC School <strong>of</strong> Medicine,<br />

Chapel Hill, NC.<br />

182. Associations between Radiographic Hand Osteoarthritis and<br />

Femorotibial Cartilage Thickness and Thinning in Subjects<br />

with Prevalent or at High Risk <strong>of</strong> Knee Osteoarthritis – Data<br />

from OAI. Ida Kristin Haugen 2 , Sebastian Cot<strong>of</strong>ana 5 , Martin<br />

Englund 3 , Tore K. Kvien 1 , Donatus Dreher 4 , Michael C. Nevitt 6 ,<br />

Nancy E. Lane 7 and Felix Eckstein 5 , 1 Diakonhjemmet Hospital,<br />

Oslo, Norway, 2 Diakonhjemmet Hospital, 3 Lund University,<br />

Boston University, Lund, Sweden, 4 Merck Serono SA, 5 Paracelsus<br />

Medical University, Chondrometrics GmbH, 6 UCSF, San<br />

Francisco, CA, 7 Univ <strong>of</strong> California at Davis, Hillsborough, CA.<br />

183. Change in Weight over 10 Years Is Associated with Bone<br />

Marrow Lesions in a Population-Based Cohort Study <strong>of</strong><br />

Adult Women. Sharon Brennan 1 , Flavia Cicuttini 1 , Julie Pasco 1 ,<br />

Margaret Henry 2 , Yuanyuan Wang 1 , Mark Kotowicz 2 , Ge<strong>of</strong>frey<br />

Nicholson 2 and Anita Wluka 1 , 1 Monash University, 2 University <strong>of</strong><br />

Melbourne.<br />

184. Comorbidity and Health Status in Early Osteoarthritis <strong>of</strong><br />

Hip and Knee; CHECK Cohort. J. Wesseling 2 , S. M. A. Bierma-<br />

Zeinstra 1 , J. Dekker 4 , K. J. Gorter 3 , J. W. J. Bijlsma 3 and on Behalf<br />

<strong>of</strong> the CHECK Group, 1 Erasmus University Medical Center<br />

Rotterdam, 2 <strong>Rheumatology</strong> & Clinical Immunology, University<br />

Medical Center Utrecht, Utrecht, The Netherlands, 3 University<br />

Medical Center Utrecht, 4 VU University Medical Center<br />

Amsterdam.<br />

185. Do Bony Enlargements Correlate with Radiological Findings<br />

in Hand Osteoarthritis (HOA)? Roshan Dhawale 3 , Niveditha<br />

Mohan 2 , Michael J. Hannon 4 and C. Kent Kwoh 1 , 1 Univ <strong>of</strong><br />

Pittsburgh, Pittsburgh, PA, 2 Univ <strong>of</strong> Pittsburgh Arth Inst,<br />

Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh, Pittsburgh, PA,<br />

4<br />

University <strong>of</strong> Pittsburgh.<br />

186. Frailty and 3-Year Mobility Outcome in Persons with or at<br />

Higher Risk for Knee Osteoarthritis. September Cahue 4 , Karen<br />

W. Hayes 2 , Jing Song 4 , Dorothy D. Dunlop 3 , Joan S. Chmiel 4 ,<br />

Marc C. Hochberg 5 , Carmelita J. Colbert 1 and Leena Sharma 3 ,<br />

1<br />

Northwestern University, LaGrange, IL, 2 Northwestern<br />

University, Downers Grove, IL, 3 Northwestern University,<br />

Chicago, IL, 4 Northwestern University, 5 University <strong>of</strong> Maryland,<br />

Baltimore, MD.<br />

187. Greater Burden <strong>of</strong> Disease in Erosive Hand Osteoarthritis.<br />

Mariko L. Ishimori 1 , Roy D. Altman 4 , Myles J. Cohen 2 , Jerome I.<br />

Rotter 2 and Michael H. Weisman 3 , 1 Cedars Sinai Medical Center,<br />

Los Angeles, CA, 2 Cedars-Sinai, 3 Cedars-Sinai Medical Center, Los<br />

Angeles, CA, 4 UCLA, Agua Dulce, CA.<br />

188. Image Processing and Machine Learning Methods Applied to<br />

MRI Trabecular Morphometry in Knee Osteoarthritis. Jason<br />

Nochlin 4 , Eric Miller 4 , Grace H. Lo 2 , Anna Tassinari 1 and Timothy<br />

E. McAlindon 3 , 1 Tufts Medical Center, Boston, MA, 2 Tufts<br />

Medical Center, Houston, TX, 3 Tufts Medical Center Box 406,<br />

Boston, MA, 4 Tufts University, Medford, MA.<br />

2010 Program Book 159


ACR Poster Session A<br />

189. Knee Confidence and Physical Function Outcome in Persons<br />

with Knee Osteoarthritis. Carmelita J. Colbert 1 , Jing Song 4 ,<br />

Dorothy D. Dunlop 3 , Joan S. Chmiel 4 , Karen W. Hayes 2 ,<br />

September Cahue 4 , Kirsten Moisio 4 , Alison H. Chang 3 and Leena<br />

Sharma 3 , 1 Northwestern University, LaGrange, IL, 2 Northwestern<br />

University, Downers Grove, IL, 3 Northwestern University,<br />

Chicago, IL, 4 Northwestern University.<br />

190. Lateral Compartment Unloading in People with Medial Knee<br />

Osteoarthritis. Deepak Kumar, Katherine S. Rudolph and Kurt<br />

Manal, University <strong>of</strong> Delaware, Newark, DE.<br />

191. Lower Extremity Muscle Function, Quality <strong>of</strong> Life and Physical<br />

Function Outcomes and Their Relation to Subsequent<br />

Knee Replacement in a 24 Month Period – Data from the<br />

Osteoarthritis Initiative (OAI). Bjoern Buehring 1 , Boris<br />

Bershadsky 2 and M. Elaine Husni 1 , 1 Cleveland Clinic, Cleveland,<br />

OH, 2 Cleveland Clinic.<br />

192. Morphological Changes in Articular Cartilage and Subchondral<br />

Bone in Tibi<strong>of</strong>emoral and Patell<strong>of</strong>emoral Joints Following<br />

Arthroscopic Partial Medial Meniscectomy. Yuanyuan Wang 2 ,<br />

Alasdair Dempsey 3 , David Lloyd 3 , Peter Mills 1 , Tim Wrigley 4 ,<br />

Kim Bennell 4 , Ben Metcalf 4 , Fahad Hanna 2 and Flavia Cicuttini 2 ,<br />

1<br />

Griffith University, 2 Monash University, 3 The University <strong>of</strong><br />

Western Australia, 4 University <strong>of</strong> Melbourne.<br />

193. MRI-Defined Risk Factors for Cartilage Loss over a 6 Months<br />

Period. Frank W. Roemer 1 , C. Kent Kwoh 2 , Michael J. Hannon 2 ,<br />

Stephanie M. Green 2 , John M. Jakicic 2 , Robert Boudreau 2 ,<br />

Michel D. Crema 1 and Ali Guermazi 1 , 1 Boston University,<br />

2<br />

University <strong>of</strong> Pittsburgh.<br />

194. Neuromuscular Responses to Perturbations during Walking<br />

in Knee Osteoarthritis: Influence <strong>of</strong> Instability, Strength,<br />

Proprioception and Stiffness. Deepak Kumar, Darcy Reisman,<br />

Charles B. Swanik and Katherine S. Rudolph, University <strong>of</strong><br />

Delaware, Newark, DE.<br />

195. Peri-Articular Bone Density Is Strongly Correlated with Static<br />

Alignment and Varus Thrust. Grace H. Lo 1 , William F. Harvey 2 ,<br />

Melanie Ripley 3 , Erica McAdams 3 , Melynn Nuite 2 and Timothy<br />

E. McAlindon 4 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 Tufts<br />

Medical Center, Boston, MA, 3 Tufts Medical Center, 4 Tufts<br />

Medical Center Box 406 , Boston, MA.<br />

196. Prediction <strong>of</strong> Total Knee Replacement in a Two-Year Multi-<br />

Centre Clinical Trial in Knee Osteoarthritis: Results from a 4-6<br />

Year Observation. Jean-Pierre Raynauld 3 , Johanne Martel-<br />

Pelletier 1 , Marc Dorais 5 , François Abram 4 , Boulos Haraoui 2 , Denis<br />

Choquette 2 and Jean-Pierre Pelletier 6 , 1 CR-CHUM, Notre-Dame<br />

Hospital, Montreal, QC, Canada, 2 Osteoarthritis Research Unit,<br />

University <strong>of</strong> Montreal Hospital Research Centre (CRCHUM),<br />

Notre-Dame Hospital, Montreal, QC, Canada, 3 Osteoarthritis<br />

Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />

(CRCHUM), Notre-Dame Hospital, 4 Research and Development,<br />

ArthroVision Inc., Montreal, 5 StatSciences Inc., Notre-Dame de<br />

l’Ile-Perrot, 6 University <strong>of</strong> Montreal Hospital Research Centre<br />

(CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada.<br />

197. Prevalence <strong>of</strong> MRI-Detected Joint Pathology <strong>of</strong> the Knee in a<br />

Population-Based Sample: Framingham Osteoarthritis Study.<br />

Jingbo Niu 3 , Yuqing Zhang 1 , Ali Guermazi 4 , Frank W. Roemer 4<br />

and David T. Felson 2 , 1 Boston Univ School <strong>of</strong> Medicine, Boston,<br />

MA, 2 Boston University School <strong>of</strong> Medicine, Boston, MA,<br />

3<br />

Boston University School <strong>of</strong> Medicine, Boston, MA, 4 Boston<br />

University School <strong>of</strong> Medicine.<br />

198. Relation <strong>of</strong> Hand Enthesophytes on Plain Radiographs with<br />

Findings <strong>of</strong> Knee Enthesopathy: Is Osteoarthritis a Generalized<br />

Enthesopathy? Nadia Gibson 1 , Mary M. Clancy 4 , Jingbo Niu 3 ,<br />

Peter Grayson 2 , Piran Aliabadi 6 , Ali Guermazi 2 and David T.<br />

Felson 5 , 1 Boston Medical Center, Boston, MA, 2 Boston Medical<br />

Center, 3 Boston University, Boston, MA, 4 Boston University<br />

Sch Med, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA, 6 Brigham’s and Women Hospital.<br />

199. Responsiveness and Reliability <strong>of</strong> MRI in Osteoarthritis:<br />

Analytic Literature Review. David J. Hunter 5 , Weiya Zhang 1 ,<br />

Philip G. Conaghan 4 , Kelly Hirko, Leo Menashe, William M.<br />

Reichmann 2 and Elena Losina 3 , 1 United Kingdom, 2 Brigham and<br />

Womens Hosp, Boston, MA, 3 Brigham and Womens Hospital,<br />

Boston, MA, 4 Chapel Allerton Hospital, Leeds, United Kingdom,<br />

5<br />

University <strong>of</strong> Sydney, Sydney, NSW, Australia.<br />

200. `The Effects <strong>of</strong> Hip Muscle Training on Knee Joint Loading<br />

in Medial Knee Osteoarthritis. Julia Daher 1 , Joel A. Block 2 ,<br />

Markus Wimmer 1 , Dale R. Sumner 1 and Laura E. Thorp 3 , 1 Rush<br />

University Medical Center, 2 Rush University Medical Center,<br />

Chicago, IL, 3 Rush University Medical Center, Chicago, IL.<br />

201. The Relationship between Symptoms <strong>of</strong> Medial Tibi<strong>of</strong>emoral<br />

Osteoarthritis and Toe-Out Angle during Walking: The<br />

MOST Study. K. Douglas Gross 4 , Jingbo Niu 3 , Yuqing Zhang 1 ,<br />

Michael C. Nevitt 6 , Cora E. Lewis 5 , James Torner 7 and David T.<br />

Felson 2 , 1 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 2 Boston<br />

University School <strong>of</strong> Medicine, Boston, MA, 3 Boston University<br />

School <strong>of</strong> Medicine, Boston, MA, 4 MGH Institute <strong>of</strong> Health<br />

Pr<strong>of</strong>essions, Boston, MA, 5 University <strong>of</strong> Alabama, Birmingham,<br />

Birmingham, AL, 6 University <strong>of</strong> California, San Francisco, San<br />

Francisco, CA, 7 University <strong>of</strong> Iowa, Iowa City.<br />

202. The Relationship between Varus and Valgus Thrust and<br />

Meniscal Damage in Persons with Knee Osteoarthritis. Alison<br />

H. Chang 4 , Ali Guermazi 1 , Frank Roemer 1 , Kirsten Moisio 5 , Jing<br />

Song 5 , Dorothy D. Dunlop 4 , Michael C. Nevitt 6 , Carmelita J.<br />

Colbert 2 , John A. Lynch 7 , Karen W. Hayes 3 and Leena Sharma 4 ,<br />

1<br />

Boston University, 2 Northwestern University, LaGrange, IL,<br />

3<br />

Northwestern University, Downers Grove, IL, 4 Northwestern<br />

University, Chicago, IL, 5 Northwestern University, 6 UCSF, San<br />

Francisco, CA, 7 UCSF.<br />

203. Thigh Muscle Quality Correlates with Function, Leg Strength,<br />

and Walking Speed, but Not with Alignment in Individuals with<br />

Obesity and Knee Osteoarthritis. Rachel W. Holt 3 , Richard F.<br />

Loeser 5 , Cralen Davis 4 , Claudine Legault 4 , Barb Nicklas 4 , Jeffrey<br />

Carr 4 , David J. Hunter 1 and Stephen P. Messier 2 , 1 New England<br />

Baptist Hospital, Boston, MA, 2 Wake Forest Univ, Winston-<br />

Salem, NC, 3 Wake Forest Univ., Winston Salem, NC, 4 Wake<br />

Forest Univ., 5 Wake Forest University, Winston-Salem, NC.<br />

204. Understanding the Individual Burden <strong>of</strong> Osteoarthritis:<br />

Development <strong>of</strong> a Conceptual Model. Lucy Busija 3 , Richard<br />

H. Osborne 2 and Rachelle Buchbinder 1 , 1 Cabrini Institute and<br />

Monash University, Malvern, Australia, 2 Deakin University,<br />

Melbourne, Australia, 3 University <strong>of</strong> Melbourne.<br />

205. Vibratory Sense Deficits in Radiographic Knee Osteoarthritis:<br />

The Multicenter Osteoarthritis Study (MOST). Najia Shakoor 4 ,<br />

Tuhina Neogi 1 , David T. Felson 3 , Jingbo Niu 2 , Laura Frey Law 7 ,<br />

Cora E. Lewis 6 and Michael C. Nevitt 5 , 1 Boston Univ Schl <strong>of</strong> Med,<br />

Boston, MA, 2 Boston University, Boston, MA, 3 Boston University<br />

School <strong>of</strong> Medicine, Boston, MA, 4 Rush-University Medical<br />

Center, Chicago, IL, 5 UCSF, San Francisco, CA, 6 University <strong>of</strong><br />

Alabama, 7 University <strong>of</strong> Iowa, Iowa City, IA.<br />

160<br />

2010 Program Book


ACR Poster Session A<br />

Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Juvenile<br />

Idiopathic Arthritis I<br />

206. A Critical Appraisal <strong>of</strong> Lumbar Spine DXA Bone Mineral<br />

Density in a Longitudinal Study <strong>of</strong> Children with JIA. Maureen<br />

G. Leffler 1 , Justine Shults 6 , Sogol Mostoufi-Moab 2 , Babette<br />

S. Zemel 7 , Sarah E. Dubner 5 , Mary B. Leonard 4 and Jon M.<br />

Burnham 3 , 1 AI duPont Hospital for Children, Thomas Jefferson<br />

University, 2 Children’s Hospital <strong>of</strong> Philadelphia, 3 Children’s<br />

Hospital <strong>of</strong> Philadelphia, University <strong>of</strong> Pennsylvania School <strong>of</strong><br />

Medicine, Center for Clinical Epidemiology and Biostatistics,<br />

Philadelphia, PA, 4 Children’s Hospital <strong>of</strong> Philadelphia, University<br />

<strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Center for Clinical<br />

Epidemiology and Biostatistics, 5 Seattle Children’s Hospital,<br />

University <strong>of</strong> Washington School <strong>of</strong> Medicine, 6 University<br />

<strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Center for Clinical<br />

Epidemiology and Biostatistics, 7 University <strong>of</strong> Pennsylvania<br />

School <strong>of</strong> Medicine, Children’s Hospital <strong>of</strong> Philadelphia.<br />

207. Adolescents with Juvenile Idiopathic Arthritis Currently<br />

Followed in a Tertiary Care Hospital Have a Better Psychosocial<br />

Well-Being Than Healthy Adolescents. Marta Bertamino 4 ,<br />

Giovanni Filocamo 5 , Sara Dalprà 4 , Elena Palmisani 4 , Nicoletta<br />

Solari 4 , Silvia Magni-Manzoni 1 , Benedetta Schiappapietra 4 ,<br />

Nicolino Ruperto 4 , Alberto Martini 3 and Angelo Ravelli 2 , 1 IRCCS<br />

Fondazione Policlinico San Matteo, Pavia, Italy, 2 IRCCS G. Gaslini<br />

and Università di Genova, Genova, Italy, 3 IRCCS G. Gaslini and<br />

Università di Genova, Genova, Italy, 4 IRCCS G. Gaslini, Genova,<br />

Italy, 5 Policlinico Sant’Orsola, Bologna, Italy.<br />

208. An International Consensus Survey <strong>of</strong> the Diagnostic Criteria<br />

for Macrophage Activation Syndrome in Systemic Juvenile<br />

Idiopathic Arthritis. Sergio Davì 4 , Alessandro Consolaro 4 ,<br />

Dinara Guseinova 4 , Angela Pistorio 4 , Alberto Martini 3 , Randy<br />

Q. Cron 1 and Angelo Ravelli 2 , 1 Children’s Hospital <strong>of</strong> Alabama<br />

and University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />

2<br />

IRCCS G. Gaslini and Università di Genova, Genova, Italy, 3 IRCCS<br />

G. Gaslini and Università di Genova, Genova, Italy, 4 IRCCS G.<br />

Gaslini, Genova, Italy.<br />

209. Anakinra as First-Line Disease Modifying Therapy in Systemic<br />

Juvenile Idiopathic Arthritis – Report <strong>of</strong> 46 Patients from an<br />

International Multicenter Series. Peter A. Nigrovic 4 , Melissa<br />

Mannion 14 , Andrew S. Zeft 15 , Egla C. Rabinovich 8 , Marion A.<br />

J. van Rossum 9 , Elisabetta Cortis 2 , Manuela Pardeo 2 , Paivi M.<br />

Miettunen 1 , Ginger L. Janow 5 , James D. Birmingham 10 , Aaron T.<br />

Eggebeen 10 , Erin M. Janssen 3 , Andrew I. Shulman 4 , Mary Beth<br />

F. Son 4 , Sandy D. Hong 13 , Karla B. Jones 11 , Norman T. Ilowite 7 ,<br />

Randy Q. Cron 6 and Gloria C. Higgins 12 , 1 Alberta Childrens<br />

Hospital, Calgary, AB, Canada, 2 Bambino Gesù Hospital, Rome,<br />

Italy, 3 Children’s Hospital Boston, Cambridge, MA, 4 Children’s<br />

Hospital Boston, Boston, MA, 5 Children’s Hospital Montefiore,<br />

New York, NY, 6 Children’s Hospital <strong>of</strong> Alabama, Birmingham,<br />

AL, 7 Children’s Hospital Montefiore, Bronx, NY, 8 Duke University<br />

Medical Center, Durham, NC, 9 Emma Children’s Hospital,<br />

Amsterdam, The Netherlands, 10 Michigan State Univ, Grand<br />

Rapids, MI, 11 Nationwide Children’s Hospital, Columbus, OH,<br />

12<br />

Nationwide Childrens Hosp, Columbus, OH, 13 U <strong>of</strong> Iowa<br />

Children’s Hosp, Iowa City, IA, 14 Univ <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL, 15 University <strong>of</strong> Utah, Salt Lake City, UT.<br />

210. Antinuclear Antibody Positive Patients Should Be Grouped as<br />

a Separate Category in the Classification <strong>of</strong> Juvenile Idiopathic<br />

Arthritis. Angelo Ravelli 2 , Giulia C. Varnier 4 , Sheila K. Oliveira 5 ,<br />

Esteban Castell 4 , Olga Arguedas 4 , Alessandra Magnani 4 , Angela<br />

Pistorio 4 , Nicolino Ruperto 4 , Silvia Magni-Manzoni 1 , Bianca<br />

Lattanzi 4 , Roberta Galasso 4 and Alberto Martini 3 , 1 IRCCS<br />

Fondazione Policlinico San Matteo, Pavia, Italy, 2 IRCCS G. Gaslini<br />

and Università di Genova, Genova, Italy, 3 IRCCS G. Gaslini and<br />

Università di Genova, Genova, Italy, 4 IRCCS G. Gaslini, Genova,<br />

Italy, 5 Universidade Federal do Rio de Janeiro, Rio de Janeiro,<br />

Brazil.<br />

211. Are They Ready for Adult Care? An Assessment <strong>of</strong> Variables<br />

Affecting Patient Autonomy When Transitioning from<br />

Pediatric to Adult <strong>Rheumatology</strong>. Sharon E. Banks 3 , Catherine<br />

A. Bingham 1 and Brandt P. Groh 2 , 1 Hershey Medical Center,<br />

Zionsville, PA, 2 Hershey Medical Center, Hershey, PA, 3 Hershey<br />

Medical Center.<br />

212. Assessment <strong>of</strong> Activity in Children with Enthesitis Related<br />

Arthritis Using Bath Ankylosing Spondylitis Disease Activity<br />

Index (BASDAI). Marìa M. Katsicas 2 and Ricardo A. G. Russo 1 ,<br />

1<br />

Hospital de Pediatrìa Pr<strong>of</strong> Dr JP Garrahan, Buenos Aires,<br />

Argentina, 2 Hospital de Pediatrìa Pr<strong>of</strong> Dr JP Garrahan.<br />

213. Benefit <strong>of</strong> Intra-Articular Corticosteroid Injections by Oral<br />

and Maxill<strong>of</strong>acial Surgery Treating Temporomandibular Joint<br />

Arthritis in Children with Juvenile Idiopathic Arthritis. Tyler<br />

Sharpe 2 , Jennifer Good 2 , Timothy Beukelman 3 , Peter Waite 2 and<br />

Randy Q. Cron 1 , 1 Children’s Hospital <strong>of</strong> Alabama, Birmingham,<br />

AL, 2 Univ <strong>of</strong> Alabama-Birmingham, 3 University <strong>of</strong> Alabama-<br />

Birmingham, Birmingham, AL.<br />

214. Cancer Risk in Juvenile Idiopathic Arthritis. Sasha R. Bernatsky 1 ,<br />

Ann E. Clarke 5 , Kiem G. Oen 9 , Ciaran M. Duffy 4 , Alan M.<br />

Rosenberg 8 , Jeremy Labrecque 2 , Elizabeth M. Turnbull 3 ,<br />

Jennifer L. F. Lee 7 and Rosalind Ramsey-Goldman 6 , 1 McGill<br />

UHC/RVH, Montreal, QC, Canada, 2 McGill University, Canada,<br />

3<br />

McGill University Health Ctr, Montreal, QC, Canada, 4 Montreal<br />

Childrens Hospital, Montreal, QC, Canada, 5 Montreal General<br />

Hospital, Montreal, QC, Canada, 6 Northwestern University,<br />

Chicago, IL, 7 RI McGill Univ Health Ctr, Montreal, QC, Canada,<br />

8<br />

Royal Univ Hosp, Saskatoon, SK, Canada, 9 University <strong>of</strong><br />

Manitoba, Winnipeg, MB, Canada.<br />

215. Childhood Idiopathic Chondrolysis: A Form <strong>of</strong> Monoarthritis?<br />

Rafka Chaiban 1 and Robert P. Sundel 2 , 1 Children’s Hospital<br />

Boston, Boston, MA, 2 Childrens Hosp Medical Center, Boston,<br />

MA.<br />

216. Clinical Outcomes after Withdrawal <strong>of</strong> Anti-Tumor Necrosis<br />

Factor-Alpha Therapy in Juvenile Idiopathic Arthritis: A<br />

Twelve-Year Experience. Kevin W. Baszis 2 , Dana Toib 2 , Richard<br />

Brasington 1 , Allison King 3 , Jingnan Mao 3 , Andrew J. White 2 , Jane<br />

Garbutt 3 and Anthony R. French 2 , 1 Washington Univ Schl <strong>of</strong><br />

Med, St Louis, MO, 2 Washington University School <strong>of</strong> Medicine,<br />

Department <strong>of</strong> Pediatrics, St Louis, MO, 3 Washington University<br />

School <strong>of</strong> Medicine, Department <strong>of</strong> Pediatrics.<br />

217. Contribution <strong>of</strong> TNFalpha–308 and T676G TNF-RII<br />

Polymorphism on Response to Etanercept and Posibility To<br />

Discontinue Treatment. Jelena Vojinovic 1 , Gordana Susic 3 ,<br />

Jelena Basic 2 , Dragana Lazarevic 1 and Nemanja Damjanov 3 ,<br />

1<br />

Dept Ped <strong>Rheumatology</strong>, University Clinic Center Nis, Nis,<br />

Serbia, 2 Institute <strong>of</strong> Biochemestry Faculty <strong>of</strong> Medicine Nis, Nis,<br />

Serbia, 3 Institute <strong>of</strong> <strong>Rheumatology</strong> Belgrade, Belgrade, Serbia.<br />

2010 Program Book 161


ACR Poster Session A<br />

162<br />

218. Effectiveness <strong>of</strong> Dexamethasone Iontophoresis in<br />

Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic<br />

Arthritis (JIA). Rina Mina 3 , Paula G. Melson 3 , Stephanie Powell 2 ,<br />

Claas H. Hinze 1 , Joshua Pendl 2 , Thomas B. Graham 5 and Hermine<br />

I. Brunner 4 , 1 Children’s National Medical Center, Rockville, MD,<br />

2<br />

Cincinnati Children’s Hosp Medical Ctr, 3 Cincinnati Children’s<br />

Hospital Medical Ctr, Cincinnati, OH, 4 Cincinnati Children’s Med<br />

Ctr, Cincinnati, OH, 5 Vanderbilt Children’s Hospital, Nashville,<br />

TN.<br />

219. Effectiveness <strong>of</strong> Etanercept in Juvenile Psoriatic Arthritis<br />

and in Children with Enthesitis Related Arthritis. Marieke H.<br />

Otten 3 , Femke H. M. Prince 4 , Marinka Twilt 7 , Nico M. Wulffraat 12 ,<br />

Rebecca ten Cate 7 , Esther P. A. H. Hoppenreijs 9 , Yvonne<br />

Koopman-Keemink 6 , Simone L. Gorter 10 , Wineke Armbrust 11 ,<br />

Koert M. Dolman 8 , Joost F. Swart 13 , Arnold P. Oranje 4 , Flora<br />

B. de Waard-van der Spek 2 , Marion A. J. van Rossum 1 and<br />

Lisette W. A. van Suijlekom-Smit 5 , 1 Academic Medical Centre<br />

Emma Children’s Hospital and Jan van Breemen Institute<br />

Amsterdam, 2 Erasmus MC Rotterdam, 3 Erasmus MC Sophia<br />

Children’s Hospital Rotterdam, Rotterdam, The Netherlands,<br />

4<br />

Erasmus MC Sophia Children’s Hospital Rotterdam, 5 Erasmus<br />

MC Sophia Children’s Hospital Rotterdam, The Netherlands,<br />

6<br />

Haga Ziekenhuis Juliana Children’s Hospital The Hague, 7 Leiden<br />

University Medical Centre, 8 St Lucas Andreas Hospital and<br />

Jan van Breemen Institute Amsterdam, 9 St Maartenskliniek<br />

Nijmegen, 10 University Hospital Maastricht, 11 University Medical<br />

Centre Groningen Beatrix Children’s Hospital, 12 Utrecht Medical<br />

Centre Wilhelmina Children’s Hospital, 13 VU Medical Centre and<br />

Jan van Breemen Institute Amsterdam.<br />

220. Efficacy and Safety <strong>of</strong> Oral and Parenteral Methotrexate<br />

Therapy in Children with Juvenile Idiopathic Arthritis. Gerd<br />

Horneff 2 , Gerd Ganser, Ivan Foeldvari 1 , Andreas Urban and<br />

Ariane Klein, 1 Hamburg, Germany, 2 Asklepios Clinic Sankt<br />

Augustin, Germany.<br />

221. Electronic Medical Record (EMR) Entries Can Provide a Source<br />

for Quality Improvement Projects for Juvenile Idiopathic<br />

Arthritis (JIA): Results <strong>of</strong> a Pilot Study. Michael L. Miller 2 , Jason<br />

Ruprecht 1 , George Lales, Sean McKenna and Frank Dupont,<br />

1<br />

Chicago, IL, 2 Childrens Memorial Hospital, Chicago, IL.<br />

222. Evaluation <strong>of</strong> the Role <strong>of</strong> Bone Mass Determinants in<br />

the Prediction <strong>of</strong> Bone Strength in Patients with Juvenile<br />

Idiopathic Arthritis (JIA): Bone Status Assessment Using<br />

pQCT, DXA and QUS. Fernanda Falcini 1 , Loredana Cavalli 2 ,<br />

Laura Masi 2 , Serena Capannini 1 , Giovanni D’Elia 4 , Valentina<br />

Denaro 1 , Marco Matucci Cerinic 1 , Stefano Stagi 3 and Maria Luisa<br />

Brandi 2 , 1 Department <strong>of</strong> BioMedicine, Section <strong>of</strong> <strong>Rheumatology</strong>,<br />

Transition Clinic, Florence, Italy, 2 Department <strong>of</strong> Internal<br />

Medicine, Endocrinology Unit, University <strong>of</strong> Florence, Florence,<br />

Italy, 3 Pediatric Unit, Villamarina Hospital, Piombino, Livorno,<br />

Italy, 4 Radiology Unit, AOC Careggi, Florence, Italy.<br />

223. Gut Inflammation in Pediatric Spondyloarthritis. Matthew<br />

Stoll 2 , Marilynn G. Punaro 3 and Molly Dempsey-Robertson 1 ,<br />

1<br />

Texas Scottish Rite Hospital for Children, 2 UT Southwestern<br />

Med Ctr, Dallas, TX, 3 UT Southwestern Medical Ctr, Dallas, TX.<br />

224. Immunogenicity and Short Term Safety <strong>of</strong> Pandemic Influenza<br />

Vaccine (Anti-H1n1) in Patients with Juvenile Idiopathic<br />

Arthritis. Nadia E. Aikawa 3 , Lucia M. A. Campos 5 , Clovis A. Silva 5 ,<br />

Vanessa R. Guissa 5 , Adriana M. Sallum 5 , Adriana A. Jesus 5 , Julio<br />

B. Moraes 4 , Cleonice Bueno 4 , Maria C. S. T. Timenetsky 1 , Alex R.<br />

Precioso 2 and Claudia Goldenstein-Schainberg 4 , 1 Adolpho Lutz<br />

Institute, University <strong>of</strong> Sao Paulo, 2 Butantan Institute, 3 Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Pediatric Reumatology Unit, Universidade<br />

de Sao Paulo, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Universidade de Sao<br />

Paulo, 5 Pediatric Reumatology Unit, Universidade de Sao Paulo.<br />

2010 Program Book<br />

225. Intra-rater Reliability <strong>of</strong> the Bath Ankylosing Spondylitis<br />

Disease Activity Index (BASDAI) and the Bath Ankylosing<br />

Spondylitis Functional Index (BASFI) in Children with<br />

Spondyloarthritis. Michelle Batthish 2 , Alisa Rachlis, Bertha<br />

Wong, Samantha Stevens, Michelle Anderson, Brian M.<br />

Feldman 1 , Ronald M. Laxer 1 , Joanne Marcuz, Margaret Reaume,<br />

Lynn Spiegel, Kristi Whitney-Mahoney and Shirley M. L. Tse 1 ,<br />

1<br />

Toronto, ON, Canada, 2 The Hospital for Sick Children, The<br />

University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

226. Juvenile Idiopathic Arthritis (JIA) Classification: An Audit <strong>of</strong><br />

a Tertiary Paediatric <strong>Rheumatology</strong> Service’s Adherence to<br />

ILAR (Edmonton 2001) Classification Criteria. Angela J. Cox 2 ,<br />

Sern Chin Lim 1 , Roger C. Allen 3 , Jonathan D. Akikusa 1 and<br />

Jane Munro 1 , 1 Royal Children’s Hospital, Melbourne, Victoria,<br />

Australia, 2 Royal Children’s Hospital, Melbourne, Australia,<br />

3<br />

Royal Childrens Hospital, Melbourne, Australia.<br />

227. Long-Term Outcome <strong>of</strong> Patients with Juvenile Idiopathic<br />

Arthritis Treated with Etanercept – Results <strong>of</strong> the Biologic<br />

Register JuMBO. Kirsten Minden 3 , Martina Niewerth 4 , Angela<br />

E. Zink 2 , Eva Seipelt 6 , Ivan Foeldvari 5 , Hermann Girschick 7 and<br />

Gerd Horneff 1 , 1 Asklepios Kinderklinik St. Augustin GmbH,<br />

2<br />

German Arthritis Res Centre, Berlin, Germany, 3 German<br />

Rheumatism Research Center Berlin, a Leibnitz Institute,<br />

Berlin, Germany, 4 German Rheumatism Research Center Berlin,<br />

a Leibnitz Institute, 5 Hamburger Zentrum für Kinder- und<br />

Jugendrheumatologie am Klinikum Eilbek, Hamburg, Germany,<br />

6<br />

Immanuel Krankenhaus Berlin-Buch, Germany, 7 Scientific<br />

Advisory Board.<br />

228. Magnetic Resonance Imaging Findings <strong>of</strong> Temporomandibular<br />

Joint in Patients with Active and Inactive Juvenile Idiopathic<br />

Arthritis. Liete Zwir, Soraia Souza, Maria Teresa Terreri, Antônio<br />

Sérgio Guimarães, Artur Fernandes and Maria Odete Hilário,<br />

UNIFESP.<br />

229. Methotrexate and Leflunomide Combination Therapy Is a Safe<br />

and Effective Alternative to Methotrexate and Etanercept in<br />

JIA. Arturo Borzutzky 1 , Tamy Lagunas 2 , David Zurakowski 2 and<br />

Robert P. Sundel 3 , 1 Children’s Hospital Boston, Boston, MA,<br />

2<br />

Children’s Hospital Boston, 3 Childrens Hosp Medical Center,<br />

Boston, MA.<br />

230. Methotrexate Gives Protection Against the New Onset <strong>of</strong><br />

Uveitis in Combination with Etanercept. Data from the<br />

German Etanercept Registry. Ivan Foeldvari 1 , Nina Thome 2<br />

and Gerd Horneff 2 , 1 Hamburger Zentrum Fuer Kinder- und<br />

Jugendrheumatologie, Hamburg, Germany, 2 Kinder- und<br />

Jugendrheumatologie Asklepios Clinics, Sankt Augustin, Sant<br />

Augustin, Germany.<br />

231. Obesity and Disease Activity in Juvenile Idiopathic Arthritis.<br />

Christina F. Pelajo 1 , Jorge M. Lopez-Benitez 2 and Laurie C.<br />

Miller 2 , 1 Floating Hospital for Children at Tufts Medical Center,<br />

Boston, MA, 2 Floating Hospital for Children at Tufts Medical<br />

Center.<br />

232. Preliminary Definition <strong>of</strong> Remission and Minimal Disease<br />

Activity Cut-Points for the Juvenile Arthritis Disease Activity<br />

Score (JADAS). Alessandro Consolaro 3 , Giovanni Filocamo 4 ,<br />

Bianca Lattanzi 3 , Giulia C. Varnier 3 , Angela Pistorio 3 , Nicolino<br />

Ruperto 3 , Alberto Martini 2 and Angelo Ravelli 1 , 1 IRCCS G. Gaslini<br />

and Università di Genova, Genova, Italy, 2 IRCCS G. Gaslini and<br />

Università di Genova, Genova, Italy, 3 IRCCS G. Gaslini, Genova,<br />

Italy, 4 Policlinico Sant’Orsola, Bologna, Italy.


ACR Poster Session A<br />

233. Prevalence <strong>of</strong> Enthesitis in Pediatric Patients with Enthesitis-<br />

Related Arthritis. Pamela Weiss 2 , Andrew J. Klink 4 , Edward<br />

M. Behrens 1 , David D. Sherry 5 , Terri H. Finkel 3 , Mark Ramos 4 ,<br />

Robert Grundmeier 4 , Ron Keren 4 and Chris Feudtner 4 ,<br />

1<br />

Childrens Hospital <strong>of</strong> Phil, Philadelphia, PA, 2 The Children’s<br />

Hosp <strong>of</strong> Philadelphia, Philadelphia, PA, 3 The Children’s Hospital<br />

<strong>of</strong> Philadelphia, Philadelphia, PA, 4 The Children’s Hospital<br />

<strong>of</strong> Philadelphia, 5 The Children’s Hospital <strong>of</strong> Philadelphia,<br />

Philadelphia, PA.<br />

234. Prospective Study <strong>of</strong> Infliximab for Treatment <strong>of</strong> Pediatric<br />

Uveitis. Egla C. Rabinovich 4 , Janet Wootton 4 , Lawrence S.<br />

Zemel 3 , Lisa F. Imundo 2 , Jennifer E. Weiss 5 , Leslie S. Abramson 7 ,<br />

Mark F. Hoeltzel 1 , Deborah M. Levy 6 and David Wallace 4 ,<br />

1<br />

Children’s Mercy Hospital, Kansas City, MO, 2 Childrens Hospital<br />

<strong>of</strong> NY, New York, NY, 3 Connecticut Childrens Med Ctr, Hartford,<br />

CT, 4 Duke University Medical Center, Durham, NC, 5 Hackensack<br />

Univ Med Ctr, Hackensack, NJ, 6 The Hospital for Sick Children,<br />

Toronto, ON, Canada, 7 University <strong>of</strong> Vermont, Morrisville, VT.<br />

235. Safety and Efficacy <strong>of</strong> H1N1 Influenza Vaccination in Children<br />

with Chronic Inflammatory Rheumatic Diseases. Catherine<br />

F. Cortot 1 and Robert P. Sundel 2 , 1 Children’s Hospital Boston,<br />

Brookline, MA, 2 Childrens Hosp Medical Center, Boston, MA.<br />

236. Status <strong>of</strong> Vaccination Coverage in Children with Juvenile<br />

Idiopathic Arthritis (JIA) Followed at a Pediatric Tertiary-Care<br />

Center. Marie-Paule Morin 1 , Élise Fortin 3 , Caroline Quach 3 and<br />

Gaëlle Chédeville 2 , 1 The Montreal Children’s Hospital, Montreal,<br />

QC, Canada, 2 The Montreal Children’s Hospital, Montréal, QC,<br />

Canada, 3 The Montreal Children’s Hospital.<br />

237. The Clinical Feature <strong>of</strong> 2009-2010 Influenza Virus Infection<br />

during Tocilizumab Treatment for Systemic Onset Juvenile<br />

Idiopathic Arthritis. Toru Uchimura 1 , Tomoyuki Imagawa 1 ,<br />

Takuma Hara 1 , Masako Kikuchi 1 , Ryoki Hara 2 , Takako Miyamae 1 ,<br />

Masaaki Mori 1 , Akiyoshi Nariai 3 , Toshihiro Mitsuda 1 and<br />

Shumpei Yokota 1 , 1 Department <strong>of</strong> Pediatrics Yokohama City<br />

University, Yokohama, Japan, 2 Department <strong>of</strong> Pediatrics<br />

Yokohama City University, 3 Department <strong>of</strong> Pediatrics Yokohama<br />

Minami Kyosai Hospital, Yokohama, Japan.<br />

238. The Financial Burden <strong>of</strong> Juvenile Idiopathic Arthritis. Andrea<br />

Ens 2 , Bianca A. Lang 1 , Suzanne E. Ramsey 1 , Elizabeth Stringer 2<br />

and Adam M. Huber 1 , 1 IWK Health Ctr, Halifax, NS, Canada, 2 IWK<br />

Health Ctr.<br />

239. Usage <strong>of</strong> TNFα Inhibitors for the Treatment <strong>of</strong> Juvenile<br />

Idiopathic Arthritis: Data from a National U.S. Administrative<br />

Claims Database. Timothy Beukelman 3 , Fenglong Xie 1 and<br />

Jeffrey R. Curtis 2 , 1 Univ <strong>of</strong> Alabama at Birmingham, 2 University<br />

<strong>of</strong> Alabama - Brimingham, Birmingham, AL, 3 University <strong>of</strong><br />

Alabama-Birmingham, Birmingham, AL.<br />

240. Use <strong>of</strong> Abatacept for Childhood Refractory Vision-Threatening<br />

Uveitis. Gabriele Simonini 2 , De Libero Cinzia 1 , Roberto Caputo 1 ,<br />

Teresa Giani 2 , Laura Pascoli 2 , Ilaria Pagnini 2 and Rolando Cimaz 2 ,<br />

1<br />

Opthalmology Unit, A Meyer Children’s Hospital, Florence,<br />

Italy, 2 <strong>Rheumatology</strong> Unit Dpt <strong>of</strong> Pediatrics, A.Meyer Children’s<br />

Hospital-University <strong>of</strong> Florence, Italy.<br />

241. Use <strong>of</strong> TNFα Antagonists in the Treatment <strong>of</strong> Chronic Non-<br />

Bacterial Osteomyelitis (CNO). Sara Stern 2 , Katherine Marzan 2 ,<br />

Arturo Borzutzky 1 , Evan Steinberg 3 and Andreas Reiff 2 , 1 Boston<br />

Children’s Hospital, Boston, MA, 2 Childrens Hospital Los<br />

Angeles, Los Angeles, CA, 3 Kaiser-Permanente Sunset Hospital,<br />

Los Angeles, CA.<br />

Pediatric <strong>Rheumatology</strong> - Pathogenesis and Genetics: Bench to<br />

Bedside - The Science <strong>of</strong> Pediatric <strong>Rheumatology</strong><br />

242. A Pilot Study <strong>of</strong> Gene Expression (GE) Pr<strong>of</strong>iles in Juvenile<br />

Dermatomyositis (JDM) Responders and Non-Responders:<br />

Diagnostic and Follow-Up Muscle Biopsy (MBx) Data. Lauren<br />

M. Pachman 1 , Yi-Wen Chen 2 , Peter Hendrickson 1 , Sheela<br />

Shrestha 1 , Gabrielle Morgan 1 and Simone Sredni 1 , 1 Children’s<br />

Memorial Research Center, Chicago, IL, 2 Children’s National<br />

Medical Center.<br />

243. A Whole Blood Gene Expression Pr<strong>of</strong>ile <strong>of</strong> Untreated Children<br />

with Polyarticular JIA Enrolled in the TREAT Trial. Mark Barton<br />

Frank 3 , Kaiyu Jiang 2 , Yanmin Chen 2 , Melissa Bebak 3 , Carol A.<br />

Wallace 4 , Susan Thompson 1 and James N. Jarvis 2 , 1 Cincinnati<br />

Children’s Hospital Medical Center, 2 Dept. <strong>of</strong> Pediatrics, U <strong>of</strong> OK<br />

<strong>College</strong> <strong>of</strong> Medicine, 3 Oklahoma Medical Research Foundation,<br />

4<br />

Seattle Children’s Medical Center.<br />

244. Angiopoietin-Like 4 Is Expressed in Human Synovial Fibroblasts<br />

and Expression Is Increased in Response to TGFβ. Ndate Fall 2 ,<br />

Malinda Frederick 2 , Alexei A. Grom 1 and Sherry Thornton 3 ,<br />

1<br />

Childrens Hospital Medical Center, Cincinnati, OH, 2 Childrens<br />

Hosp Med Ctr, 3 Childrens Hospital Medical Center, Cincinnati,<br />

OH.<br />

245. Anti-CCP Antibodies Identify a Subset <strong>of</strong> RF-Negative Juvenile<br />

Idiopathic Arthritis. Anne E. Tebo 2 , Troy D. Jaskowski 1 , K. Wayne<br />

Davis 1 , April Vigus 6 , Bronte Clifford 4 , Andrew S. Zeft 5 , Bernadette<br />

McNally 5 , Harry R. Hill 2 , John F. Bohnsack 5 and Sampath<br />

Prahalad 3 , 1 ARUP Laboratories, 2 ARUP Laboratories, Univ Utah,<br />

3<br />

Emory Children’s Center, Atlanta, GA, 4 Nationwide Children’s<br />

Hospital, 5 University <strong>of</strong> Utah, Salt Lake City, UT, 6 University <strong>of</strong><br />

Utah.<br />

246. CD4+CD161+ Cells with Th1 or Th17/Th1 Pr<strong>of</strong>ile Accumulate in<br />

the Synovial Fluid <strong>of</strong> Patients with Juvenile Diopathic Arthritis<br />

and Correlate with Inflammation Parameters. Rolando Cimaz 1 ,<br />

L. Cosmi 2 , L. Maggi 2 , V. Santarlasci 2 , M. Capone 2 , F. Borriello 3 ,<br />

F. Frosali 2 , V. Querci 2 , G. Simonini 2 , G. Barra 3 , F. Liotta 2 , R. De<br />

Palma 3 , E. Maggi 2 , S. Romagnani 2 and F. Annunziato 2 , 1 University<br />

<strong>of</strong> Florence, Firenze, Italy, 2 University <strong>of</strong> Florence, 3 University <strong>of</strong><br />

Naples.<br />

247. Characterization <strong>of</strong> Granulocyte Transcriptome in Polyarticular<br />

Juvenile Idiopathic Arthritis (JIA). Mark Barton Frank 3 ,<br />

Kaiyu Jiang 1 , Yanmin Chen 1 , Jeanette Osban 3 , Pascal Gellert 2<br />

and James N. Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong> <strong>of</strong><br />

Medicine, 2 Max Planck-Institute for Heart and Lung Research,<br />

3<br />

Oklahoma Medical Research Foundation.<br />

248. CLARITY: ChiLdhood Arthritis Risk Factor Identification sTudY.<br />

Justine Ellis 1 , Jane Munro 2 , Anne-Louise Ponsonby 1 , Angela<br />

Pezic 1 , Betty Lim 1 , Raul Chavez 1 , William Siero 1 , Jonathan<br />

Akikusa 2 and Roger Allen 2 , 1 Murdoch Childrens Research<br />

Institute, Melbourne, Parkville, Victoria, Australia, 2 Royal<br />

Children’s Hospital, Melbourne, Parkville, Victoria, Australia.<br />

249. Costimulation Mediated Rescue <strong>of</strong> Superantigen Stimulated T<br />

Cells in Kawasaki Disease. Aaron Wong 2 and Rae S. M. Yeung 1 ,<br />

1<br />

Hospital for Sick Children, Toronto, ON, Canada, 2 The Hospital<br />

for Sick Children, Toronto, ON, Canada.<br />

250. Detection <strong>of</strong> Potentially Disease Associated Copy Number<br />

Variants in Children with Rheumatoid Arthritis. Sampath<br />

Prahalad 1 , Jennifer Gladys Mulle 2 , Anne Dodd 3 , Jennifer<br />

Prozonic 3 , Milton Brown 3 , Andrew S. Zeft 4 , John F. Bohnsack 4 ,<br />

Stephen T. Warren 3 , M. Katharine Rudd 3 and Christa L. Martin 3 ,<br />

1<br />

Emory Children’s Center, Atlanta, GA, 2 Emory University,<br />

Atlanta, GA, 3 Emory University, 4 University <strong>of</strong> Utah, Salt Lake<br />

City, UT.<br />

2010 Program Book 163


ACR Poster Session A<br />

251. Differences in Transcription Pr<strong>of</strong>iles in Juvenile Idiopathic<br />

Arthritis (JIA) Patients Who Achieved Remission Using<br />

Different Therapies. Mark Barton Frank 2 , Kaiyu Jiang 1 , Yanmin<br />

Chen 1 and James N. Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong><br />

<strong>of</strong> Med, 2 Oklahoma Medical Research Foundation.<br />

252. Disease Activity, Proteinuria, and Vitamin D Status in<br />

Children with Systemic Lupus Erythematosus and Juvenile<br />

Dermatomyositis. Angela B. Robinson 1 , Myrtle Thierry-Palmer 2 ,<br />

Keisha L. Gibson 3 and Egla C. Rabinovich 1 , 1 Duke University<br />

Medical Center, Durham, NC, 2 Morehouse School <strong>of</strong> Medicine,<br />

3<br />

University <strong>of</strong> North Carolina at Chapel Hill.<br />

253. Effect <strong>of</strong> Methotrexate and Genotype on RBC Folate<br />

Concentrations and Polyglutamate Distribution in JIA. Mara L.<br />

Becker 1 , Leon van Haandel 5 , Roger Gaedigk 3 , Bradley Thomas 3 ,<br />

Mark F. Hoeltzel 2 , Andrew Lasky 4 , John Stobaugh 5 and J. Steven<br />

Leeder 3 , 1 Children’s Mercy Hospital, Kansas City, MO, 2 Children’s<br />

Mercy Hospitals and Clinics, Kansas City, MO, 3 Children’s Mercy<br />

Hospitals and Clinics, 4 Childrens Mercy Hospitals and Clinics,<br />

Kansas City, MO, 5 University <strong>of</strong> Kansas.<br />

254. Genetic Variation Associated with Methotrexate Response in<br />

Juvenile Idiopathic Arthritis: Role <strong>of</strong> the Mitochondrial and<br />

Purine Synthesis Pathways. Mara L. Becker 1 , Roger Gaedigk 3 ,<br />

Bradley Thomas 3 , Andrew Lasky 4 , Mark F. Hoeltzel 2 , Hongying<br />

Dai 3 and J. Steven Leeder 3 , 1 Children’s Mercy Hospital, Kansas<br />

City, MO, 2 Children’s Mercy Hospitals and Clinics, Kansas City,<br />

MO, 3 Children’s Mercy Hospitals and Clinics, 4 Childrens Mercy<br />

Hospitals and Clinics, Kansas City, MO.<br />

255. Hierarchy <strong>of</strong> Risk Conferred by the HLA-DR Shared Epitope in<br />

Childhood Onset Rheumatoid Arthritis. Sampath Prahalad 3 ,<br />

Susan D. Thompson 2 , Karen Conneely 6 , Yunxuan Jiang 6 , Jennifer<br />

Prozonic 6 , Milton Brown 6 , Sheila Angeles-Han 5 , Larry B. Vogler 7 ,<br />

Christine W. Kennedy 4 , Carol A. Wallace 14 , Carol Wise 12 ,<br />

Marilynn G. Punaro 11 , Ann M. Reed 8 , Jane L. Park 10 , Elizabeth<br />

D. Mellins 9 , Andrew S. Zeft 13 , John F. Bohnsack 13 and David N.<br />

Glass 1 , 1 Childrens Hospital Med Ctr, Cincinnati, OH, 2 Cincinnati<br />

Childrens Hospital Med Ctr, Cincinnati, OH, 3 Emory Children’s<br />

Center, Atlanta, GA, 4 Emory Children’s Center, Decatur, GA,<br />

5<br />

Emory University, Atlanta, GA, 6 Emory University, 7 Emory<br />

University School <strong>of</strong> Medicine, Atlanta, GA, 8 Mayo Clinic,<br />

Rochester, MN, 9 Stanford University Med Ctr, Stanford, CA,<br />

10<br />

Stanford University Med Ctr, San Jose, CA, 11 Texas Scottish Rite<br />

Hospital for Children, Dallas, TX, 12 Texas Scottish Rite Hospital<br />

for Children, 13 University <strong>of</strong> Utah, Salt Lake City, UT, 14 University<br />

<strong>of</strong> Washington and Seattle Childerns’s Hospital, Seattle, WA.<br />

256. HLA Associations in Oligo- and Polyarticular RF (-) Juvenile<br />

Idiopathic Arthritis-Associated Uveitis. Sheila Angeles-<br />

Han 5 , Andrew S. Zeft 8 , John F. Bohnsack 8 , Bronte Clifford 7 ,<br />

Lori Ponder 1 , Jennifer Prozonic 3 , Milton Brown 3 , Christine W.<br />

Kennedy 4 , Larry B. Vogler 6 and Sampath Prahalad 2 , 1 Children’s<br />

Healthcare <strong>of</strong> Atlanta, 2 Emory Children’s Center, Atlanta, GA,<br />

3<br />

Emory Children’s Center, 4 Emory Children’s Center, Decatur,<br />

GA, 5 Emory University, Atlanta, GA, 6 Emory University School <strong>of</strong><br />

Medicine, Atlanta, GA, 7 Nationwide Children’s Hospital Research<br />

Institute, 8 University <strong>of</strong> Utah, Salt Lake City, UT.<br />

257. Hyaluronidase Mutation (HYAL1) Presenting as JIA, a<br />

Description <strong>of</strong> an Extended Family Provides New Information<br />

and Characterizes This Genetic Disorder That Causes<br />

Widespread Synovitis. Lisa F. Imundo 2 and Wendy Chung 1 ,<br />

1<br />

Columbia University, NY, NY, 2 Columbia University, New York,<br />

NY.<br />

258. Leukocyte Expression <strong>of</strong> Transcription Factor HNF4a, a<br />

Regulator <strong>of</strong> Gene Expression in Polyarticular Juvenile<br />

Idiopathic Arthritis. Kaiyu Jiang 1 , Yanmin Chen 1 , Mark Barton<br />

Frank 2 and James N. Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong><br />

<strong>of</strong> Medicine, 2 Oklahoma Medical Research Foundation.<br />

259. Low Serum Levels <strong>of</strong> NT-proCNP in Children with Poly-Articular<br />

Onset Juvenile Rheumatoid Arthritis. Fozia Khan 1 , Ann<br />

Pokelsek 2 , Lori Galla 2 , Mary Toth 2 and Hulya Bukulmez 3 , 1 Akron<br />

Children’s Hospital, NEOUCOM, Akron, OH and MetroHealth<br />

Medical Center, CWRU, Cleveland, OH, 2 Akron Children’s<br />

Hospital, NEOUCOM, OH, 3 MetroHealth Medical Center, CWRU,<br />

Cleveland, OH.<br />

260. Novel Founder Mutation in IL1RN Accounts for Deficiency<br />

<strong>of</strong> the IL-1 Receptor (DIRA) in Brazil. Adriana Almeida Jesus 4 ,<br />

Clovis Artur Almeida Silva 4 , Peter W. Kim 2 , Tuyet H. Pham 2 ,<br />

Débora Romeo Bertola 4 , Magda Carneiro-Sampaio 4 , Barbara<br />

Yang 2 , Deborah Stone 2 , Dawn Chapelle 2 , Nicole Plass 2 , Massimo<br />

Gadina 2 , John Sims 1 , Hatem El-Shanti 3 and Raphaela Goldbach-<br />

Mansky 2 , 1 Amgen Inc, Thousand Oaks, CA, 2 NIAMS/NIH,<br />

Bethesda, MD, 3 Shafallah Medical Genetics Center, Doha, Qatar,<br />

4<br />

Universidade de São Paulo, Sao Paulo, Brazil.<br />

261. Novel Mutations <strong>of</strong> Camptodactyly Arthropathy Coxa Vara<br />

Pericarditis (CACP) Syndrome: A Study on Ten Cases. Sara<br />

Ciullini Mannurita 7 , Marina Vignoli 7 , Lucia Bianchi 7 , Chiara<br />

Azzari 7 , Maurizio de Martino 7 , Angelo Ravelli 4 , Anuela Kondi 6 ,<br />

Valeria Gerloni 5 , Rebecca ten Kate 2 , Luciana Breda 3 , Eleonora<br />

Gambineri 7 and Fernanda Falcini 1 , 1 Department <strong>of</strong> BioMedicine,<br />

Section <strong>of</strong> <strong>Rheumatology</strong>, Transition Clinic, University <strong>of</strong><br />

Florence, 2 Department <strong>of</strong> Pediatrics, Leiden University Medical<br />

Centre, The Netherlands, 3 Department <strong>of</strong> Pediatrics, University<br />

<strong>of</strong> Chieti, Chieti, Italy, 4 Istituto di Ricovero e Cura a Carattere<br />

Scientifico G. Gaslini and Università degli Studi di Genoa,<br />

5<br />

Istituto G. Pini, Milan, Italy, 6 Pediatric Department, University<br />

Hospital Centre, Tirana, Albania, 7 University <strong>of</strong> Florence,<br />

Department <strong>of</strong> Sciences for Woman and Child’s Health.<br />

262. Plasma Osteopontin as a Marker for Damage in Pediatric<br />

Systemic Lupus Erythematosus. Ornella J. Rullo 2 , Jennifer M.<br />

P. Woo 2 , Alice D. C. H<strong>of</strong>tman 1 , Timothy B. Niewold 5 , Angela<br />

Presson 4 , Deborah K. McCurdy 2 and Betty P. Tsao 3 , 1 CHOC-<br />

Children’s, Orange, CA, 2 Mattel Children’s UCLA, Los Angeles,<br />

CA, 3 UCLA School <strong>of</strong> Medicine, Los Angeles, CA, 4 UCLA School <strong>of</strong><br />

Public Health, 5 University <strong>of</strong> Chicago, Chicago, IL.<br />

263. Predominance <strong>of</strong> Complement Components C1q and C4 Bound<br />

to Circulating Immune Complexes (CICs) in Juvenile Idiopathic<br />

Arthritis (JIA): Support for Classical Pathway Activation.<br />

Brooke E. Gilliam 1 , Melinda R. Reed 2 , Anil K. Chauhan 1 , Amanda<br />

Dehlendorf 2 and Terry L. Moore 2 , 1 Saint Louis University, St.<br />

Louis, MO, 2 Saint Louis University, St Louis, MO.<br />

264. Rheumatoid Arthritis Susceptibility Loci; PTPRC, PTPN2,<br />

IKZF3, c5orf30, BLK and CD247 Are Also Associated with<br />

Juvenile Idiopathic Arthritis. Anne Hinks 1 , Steve Eyre 2 , Paul<br />

Martin 2 , Edward Flynn 2 , Jon Packham 3 , Anne Barton 2 , Jane<br />

Worthington 2 and Wendy Thomson 2 , 1 Arthritis Research UK<br />

Epidemiology Unit, University <strong>of</strong> Manchester, Manchester,<br />

United Kingdom, 2 Arthritis Research UK Epidemiology Unit,<br />

University <strong>of</strong> Manchester, 3 Haywood Hospital, University <strong>of</strong><br />

North Staffordshire.<br />

265. Role <strong>of</strong> IL-1b in the Development <strong>of</strong> Human TH17 Cells: Lesson<br />

from Patients Carrying NLPR3 Gene Mutations. Denise Lasigliè,<br />

Elisabetta Traggiai, Federica Penco, Silvia Federici, Andrea<br />

Accogli, Antonella Buoncompagni, Alberto Martini and Marco<br />

Gattorno, G. Gaslini Institute, Genoa, Italy.<br />

164<br />

2010 Program Book


ACR Poster Session A<br />

266. Subtype Specific Genetic Associations for Juvenile Idiopathic<br />

Arthritis (JIA): ERAP1 with the Enthesitis Related Arthritis<br />

Subtype and IL23R with Juvenile Psoriatic Arthritis. Anne<br />

Hinks 1 , Paul Martin 2 , Edward Flynn 2 , Steve Eyre 2 , Jon Packham 3 ,<br />

Anne Barton 2 , Jane Worthington 2 and Wendy Thomson 2 ,<br />

1<br />

Arthritis Research UK Epidemiology Unit, University <strong>of</strong><br />

Manchester, Manchester, United Kingdom, 2 Arthritis Research<br />

UK Epidemiology Unit, University <strong>of</strong> Manchester, 3 Haywood<br />

Hospital, University Hospital <strong>of</strong> North Staffordshire.<br />

267. The Role <strong>of</strong> Platelets and CD40L in the Pathogenesis <strong>of</strong><br />

Kawasaki Disease. Parnian Arjmand 2 and Rae S. M. Yeung 1 ,<br />

1<br />

Hospital for Sick Children, Toronto, ON, Canada, 2 University <strong>of</strong><br />

Toronto, The Hospital for Sick Children, Toronto, ON, Canada.<br />

268. Urinary Biomarkers To Distinguish Class IV vs Class V Lupus<br />

Nephritis. Hermine Brunner 1 , Michael Bennett 2 , Lindsey Romick-<br />

Rosendale 5 , Michiko Suzuki 3 , Shannen L. Nelson 2 , Joshua Pendl 3 ,<br />

Adnan Kiani 4 , Lena Das 3 , Michelle Petri 4 , Kenneth Greis 6 , Pavel<br />

Shiyanov 7 , Michael Kennedy 5 and Prasad Devarajan 3 , 1 Cincinnati<br />

Child Hosp Med Ctr, Cincinnati, OH, 2 Cincinnati Children’s Med<br />

Ctr, Cincinnati, OH, 3 Cincinnati Children’s Med Ctr, 4 John Hopkins<br />

Med Ctr, 5 Miami University, Oxford, 6 University <strong>of</strong> Cincinnati,<br />

7<br />

WPAFB, Dayton.<br />

Rheumatoid Arthritis - Animal Models: Cytokines, Novel Therapeutics<br />

and Mechanisms <strong>of</strong> Action<br />

269. AC430, a Potent JAK2 Inhibitor, Provides Protection in Multiple<br />

Inflammatory and Autoimmune Disease Models. Barbara<br />

Belli 1 , Daniel Brigham 2 , Alan Dao 2 , Ron Nepomuceno 2 , Eduardo<br />

Setti 2 , Gary Liu 2 , Michael Hadd 2 , Shripad Bhagwat 2 , Wendell<br />

Wierenga 2 , Mark W. Holladay 2 and Robert C. Armstrong 2 , 1 Ambit<br />

Biosciences, San Diego, CA, 2 Ambit Biosciences.<br />

270. Anti-CXCL5 Therapy Ameliorates IL-17 Induced Arthritis.<br />

Sarah R. Pickens 4 , Michael V. Volin 1 , Arthur M. Mandelin 2<br />

and Shiva Shahrara 3 , 1 Midwestern University, 2 Northwester<br />

University, Chicago, IL, 3 Northwestern Univ Feinberg, Chicago,<br />

IL, 4 Northwestern University.<br />

271. Beneficial Effects <strong>of</strong> Systemic IFNβ Are Mediated by IL-1Ra:<br />

Implications for Rheumatoid Arthritis. Mary Corr 4 , David L.<br />

Boyle 3 , Lisa Ronacher 4 , Brian R. Lew 4 , Lisa G. M. van Baarsen 2 ,<br />

Paul P. Tak 1 and Gary S. Firestein 4 , 1 Academic Med Ctr/Univ <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />

Center, Amsterdam, The Netherlands, 3 UCSD Schl <strong>of</strong> Medicine,<br />

La Jolla, CA, 4 UCSD School <strong>of</strong> Medicine, La Jolla, CA.<br />

272. Combined Depletion <strong>of</strong> Interleukin-1 and Interleukin-6 Does<br />

Not Exceed Single Depletion <strong>of</strong> Interleukin-1 in TNF-Mediated<br />

Arthritis. Silvia Hayer, Birgit Niederreiter, Josef Smolen and Kurt<br />

Redlich, Medical University <strong>of</strong> Vienna, Department <strong>of</strong> Internal<br />

Medicine III, Division <strong>of</strong> <strong>Rheumatology</strong>, Vienna, Austria.<br />

273. Efficacy <strong>of</strong> the Selective CSF1R (Fms) Inhibitor PLX5622 in<br />

Mouse Models <strong>of</strong> Rheumatoid Arthritis. Gaston Habets,<br />

Jiazhong Zhang, Betsy Burton, Chao Zhang, Prabha Ibrahim,<br />

Bernice Wong, Marika Nespi, Wayne Spevak, Ben Powell, Brian<br />

West, Paul Lin, Gideon Bollag and Peter Hirth, Plexxikon.<br />

274. HMPL-011, a Small Molecule Compound, Modulates Pro-<br />

Inflammatory Cytokine Production, in Part, Via Potentiating<br />

IL-10 Production. Weihua Gu 2 , Weigang He 2 , Yan Qiu 2 , Zhenhao<br />

Zhou 2 , Xiaomin Dai 2 , Wuzhong Shen 2 , Xiaoning Yang 2 , Linfang<br />

Wang 2 , Yuan Zhou 2 , Yu Cai 2 , Edwin Lee 2 , Wei Deng 2 , Weiguo<br />

Su 1 and Haoran Zhao 1 , 1 Hutchison MediPharma Ltd, Shanghai,<br />

China, 2 Hutchison MediPharma Ltd.<br />

275. IL-1 Driven IL-22 Expression by TH17 Cells Aggravates<br />

Experimental Arthritis. Renoud J. Marijnissen 3 , Marije I.<br />

Koenders 3 , Mark H. T. Stappers 4 , Leo A. B. Joosten 1 , Ruben<br />

L. Smeets 2 , Cheryl Nickerson-Nutter 5 , Annemieke M. H.<br />

Boots 2 and Wim B. van den Berg 3 , 1 Department <strong>of</strong> Internal<br />

Medicine, RUNMC, Nijmegen, The Netherlands, 2 Department<br />

<strong>of</strong> Pharmacology, MSD, Oss, The Netherlands, 3 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, RUNMC, Nijmegen, The Netherlands,<br />

4<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, RUNMC, The Netherlands,<br />

5<br />

Inflammation, Pfizer, Cambridge, MA.<br />

276. IL-27 Is Increased by IL-17 from Synovial Macrophage and<br />

Bone Marrow-Derived Dendritic Cells in Collagen-Induced<br />

Arthritis. Seunghoon Baek 5 , Juin Kim 4 , Huashu Jin 4 , Seonghu<br />

Park 5 , Youngeun Park 5 , Joungwook Lee 1 , MIRA Cho 6 , Geuntae<br />

Kim 3 , Junhee Lee 2 and Sungil Kim 5 , 1 Busan St Mary Hospital,<br />

Korea, Republic <strong>of</strong>, 2 Choonhae Hospital, Korea, Republic <strong>of</strong>,<br />

3<br />

Kosin University Medical School, Korea, Republic <strong>of</strong>, 4 Pusan<br />

National University Hospital Research Institutes, Korea, Republic<br />

<strong>of</strong>, 5 Pusan National University Medical School, Korea, Republic<br />

<strong>of</strong>, 6 Pusan National University Medical Shool, Korea, Republic <strong>of</strong>.<br />

277. IL-32 Aggravated Synovial Inflammation and Bone Destruction,<br />

and Increased Synovial NK Cells in Experimental Arthritis<br />

Models. Geun-Tae Kim 2 , Ju-In Kim 4 , Hua-Shu Jin 4 , Seong-Hu<br />

Park 3 , Young-Eun Park 3 , Seung-Hoon Baek 3 , Joung-Wook Lee 1<br />

and Sung-Il Kim 3 , 1 Department <strong>of</strong> Internal Medicine, Busan<br />

St. Mary’s Medical Center, 2 Department <strong>of</strong> Internal Medicine,<br />

Kosin University, <strong>College</strong> <strong>of</strong> Medicine, Busan, Korea, Republic <strong>of</strong>,<br />

3<br />

Department <strong>of</strong> Internal Medicine, Pusan National University,<br />

School <strong>of</strong> Medicine, 4 Research Institute, Pusan National<br />

University.<br />

278. IL-7 Correlates with Severity <strong>of</strong> Proteoglycan-Induced Arthritis,<br />

and Arthritis Severity Is Diminished by IL-7 Neutralization.<br />

Sarita A. Y. Hartgring 3 , Cynthia R. Willis 1 , Kim M. G. van der<br />

Wurff-Jacobs 3 , Femke Broere 2 , Johannes W. J. Bijlsma 3 , Floris<br />

P. J. G. Lafeber 3 and Joel A. G. van Roon 3 , 1 Inflammation<br />

Dept. Amgen Inc, Seattle WA, 2 Inst. Infectious Diseases &<br />

Immunology, UU, Utrecht, The Netherlands, 3 <strong>Rheumatology</strong> &<br />

Clinical Immunology, University Medical Center Utrecht, The<br />

Netherlands.<br />

279. Immunomodulatory Properties <strong>of</strong> Novel CRAC Channel<br />

Inhibitors Exhibit Promising Potential in Rheumatoid Arthritis.<br />

Kanthikiran V. S. Varanasi, Meyyappan Muthuppalaniappan,<br />

Gayatriswaroop Merikapudi, Sridhar Veeraraghavan, Kasi V.<br />

Routhu, Srikant Viswanadha and Swaroop Vakkalanka, Incozen<br />

Therapeutics Pvt. Ltd..<br />

280. Inhibition <strong>of</strong> c-Fos/AP-1 Suppresses Passive Anti-Collagen<br />

Antibody-Induced Arthritis in Mice. Masaaki Mikami 4 , Yukihiko<br />

Aikawa 5 , Akira Hashiramoto 3 , Mari Yamamoto 5 , Hidetoshi<br />

Murao 5 , Hisaaki Chaki 5 , Hirokazu Narita 5 , Shuichi Hirono 1<br />

and Shunichi Shiozawa 2 , 1 Department <strong>of</strong> Pharmaceutical<br />

Sciences, School <strong>of</strong> Pharmacy, Kitasato University, Tokyo, Japan,<br />

2<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Kobe University Graduate School<br />

<strong>of</strong> Health Sciences and Medicine/ The Center for Rheumatic<br />

Diseases, Kobe University Hospital, Kobe, Japan, 3 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Kobe University Graduate School <strong>of</strong> Health<br />

Sciences and Medicine/ The Center for Rheumatic Diseases,<br />

Kobe University Hospital, Kobe, Japan, 4 Research Laboratories,<br />

Toyama Chemical Co., Ltd., Toyama, Japan, 5 Research<br />

Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan.<br />

2010 Program Book 165


ACR Poster Session A<br />

281. Innovative Treatment <strong>of</strong> Experimental Arthritis and Inhibition<br />

<strong>of</strong> Human Osteoclasts Differentiation by Dendrimers. Myriam<br />

Hayder 2 , Mary Poupot 1 , Jean-Pierre Majoral 4 , Cédric Olivier<br />

Turrin 4 , Anne-Marie Caminade 4 , Alain Cantagrel 3 , Jean-Jacques<br />

Fournié 1 , Rémy Poupot 1 and Jean-Luc Davignon 3 , 1 INSERM U563,<br />

CPTP, IFR150, Toulouse, France, 2 JE2510, IFR150, Paul Sabatier<br />

University, Toulouse, France, 3 JE2510, IFR150, Paul Sabatier<br />

University, University Hospital Purpan, Toulouse, France,<br />

4<br />

Laboratoire de Chimie de Coordination, CNRS, Toulouse,<br />

France.<br />

282. IRF-1 Reduces TNFα-Induced-IL-18 Bioactivity in Rheumatoid<br />

Arthritis Synovial Fibroblasts by Induction <strong>of</strong> IL-18BPa.<br />

Hubert Marotte 1 , Adam J. Pinney 2 , Tatiana Fedorora 2 , Nalin<br />

Lalwani 2 , Pei-Suen Tsou 2 , Bradley J. Rabquer 2 and Alisa E.<br />

Koch 3 , 1 University <strong>of</strong> Michigan Medical School, Ann Arbor,<br />

MI, 2 University <strong>of</strong> Michigan Medical School, 3 Veteran’s<br />

Administration and University <strong>of</strong> Michigan.<br />

283. Liposomal Targeting <strong>of</strong> Glucocorticoids to the Synovial Lining<br />

during Experimental Arthritis Inhibits M1 Macrophage<br />

Activation in Favour <strong>of</strong> M2 Differentiation. Wouter H<strong>of</strong>kens 2 ,<br />

Gert Storm 3 , Wim B. Van Den Berg 1 and Peter van Lent 2 ,<br />

1<br />

Radboud Univ Nijmegen Med Cntr, Nijmegen, The Netherlands,<br />

2<br />

Radboud University Nijmegen Medical Center, 3 Utrecht<br />

University.<br />

284. Nanoparticles <strong>of</strong> LDE: A Potential Delivery Route for MTX<br />

in Sinovial Tissue <strong>of</strong> Antigen-Induced Arthritis. Suzana B.<br />

V. Mello 2 , Eloisa D. O. Bonfá 3 , Claudete J. Valduga 1 , Adriana<br />

Bugaralli 1 , Elaine R. Tavarez 1 and Raul Maranhão 1 , 1 Heart<br />

Institute (InCor), Faculdade de Medicina da Uiversidade de<br />

São Paulo, 2 Reumatology Division, Faculdade de Medicina da<br />

Unversidade de São Paulo, São Paulo, Brazil, 3 <strong>Rheumatology</strong><br />

Division, Faculdade de Medicina da Universidade de São Paulo.<br />

285. Novel Small Molecule Aminopyridizines Inhibit Rat<br />

Collagen-Induced Arthritis and Suppress Proinflammatory<br />

Cytokine Pathways. Soo-In Choi 2 , Lori D. Klaman 3 , Bruce<br />

Connop 3 , Aleksandra Pastrak 3 and Ernest Brahn 1 , 1 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine, Los Angeles, CA,<br />

2<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine and<br />

VA Greater Los Angeles Healthcare System, Los Angeles, CA,<br />

3<br />

Transition Therapeutics.<br />

286. PCI-45292, a Novel Btk Inhibitor with Optimized<br />

Pharmaceutical Properties, Demonstrates Potent Activities in<br />

Mouse Models <strong>of</strong> Arthritis. Betty Y. Chang 2 , Patricia Thiemann 1 ,<br />

Nadia Moore 3 , Michelle Francesco 3 , Min Mei Huang 3 , Chitra<br />

Mani 3 , Purvi Jejurkar 3 , Danielle Tonev 3 , Wei Chen 3 , Joseph J.<br />

Buggy 3 and David J. Loury 3 , 1 Pharmacyclics, 2 Pharmacyclics,<br />

Research, Sunnyvale, CA, 3 Pharmacylics.<br />

287. Recognition <strong>of</strong> IL-23 Dependent and Independent Stages<br />

during Autoimmune Collagen-Induced Arthritis. Ferry<br />

Cornelissen 2 , Patrick Asmawidjaja 2 , Anne-Marie Mus 2 , Odilia<br />

Corneth 2 , Kristine Kikly 1 and Erik Lubberts 2 , 1 Eli Lilly, 2 Erasmus<br />

MC, University Medical Center.<br />

288. RO2492, a Phosphoinositide-3-Kinase d Inhibitor, Shows<br />

Inhibitory Effects in a Variety <strong>of</strong> Human Cell Types and<br />

Suppresses Collagen-Induced Arthritis in Mice. Cheng Liao 4 ,<br />

Pei-Yuan Hsu 4 , Shu Jin 2 , Vaishali Patel 2 , Mattew C. Lucas 3 , Yong<br />

Nam Kim 3 , Joe Dalpoto 3 , Karim Dabbagh 3 , Emma Masteller 3 ,<br />

Brian R. Wong 1 , Satwant K. Narula 2 and Julie A. Demartino 3 ,<br />

1<br />

H<strong>of</strong>fma-La Roche Inc., San Francisco, CA, 2 H<strong>of</strong>fma-La Roche<br />

Inc., Nutley, NJ, 3 H<strong>of</strong>fma-La Roche Inc., 4 H<strong>of</strong>fmann-La Roche Inc.,<br />

Nutley, NJ.<br />

289. Selective Switch Pocket Kinase Inhibitors Suppress<br />

Autoimmune Inflammatory Models <strong>of</strong> Rheumatoid Arthritis.<br />

Soo-In Choi 3 , Scott C. Wise 1 , Daniel L. Flynn 1 , Zejin Zhu 3 and<br />

Ernest Brahn 2 , 1 Deciphera Pharmaceuticals, 2 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine, Los Angeles, CA,<br />

3<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine and VA<br />

Greater Los Angeles Healthcare System, Los Angeles, CA.<br />

290. The Effects <strong>of</strong> Low Dose Etanercept on Disease Control<br />

and Radiographic Progression in Moderate to Severe<br />

Rheumatoid Arthritis. Bernd Raffeiner 1 , Costantino Botsios 2 ,<br />

Paolo Sfriso 2 , Francesca Ometto 2 , Livio Bernardi 2 , Silvano<br />

Todesco 2 and Leonardo Punzi 2 , 1 University Hospital <strong>of</strong> Padova -<br />

<strong>Rheumatology</strong> Unit, Padova, Italy, 2 University Hospital <strong>of</strong> Padova<br />

- <strong>Rheumatology</strong> Unit (Italy).<br />

291. TNF Inhibitors Induce the Fibrosis in Deep Lining Layers <strong>of</strong> the<br />

Synovium with Degeneration <strong>of</strong> Synoviocytes in Rheumatoid<br />

Arthritis. Shunsei Hirohata 1 , Tetsuya Tomita 2 , Hideki Yoshikawa 3<br />

and Masahisa Kyogoku 4 , 1 Kitasato Univ School <strong>of</strong> Med,<br />

Kanagawa, Japan, 2 Osaka Univ Med School, Suita Osaka, Japan,<br />

3<br />

Osaka Univ Med School, 4 Tohoku Univ School <strong>of</strong> Med.<br />

292. TNFα-Induced Adipose-Related Protein (TIARP) Regulates<br />

Autoimmune Arthritis Via the Suppression <strong>of</strong> IL-6. Asuka<br />

Inoue 1 , Isao Matsumoto 2 , Yoko Tanaka-Watanabe 2 , Kayo<br />

Yamamoto 2 , Naoto Umeda 2 , Yuki Tanaka 2 and Takayuki Sumida 3 ,<br />

1<br />

Division <strong>of</strong> Clinical Immunology, Doctoral Program in Clinical<br />

Sciences, Graduate School <strong>of</strong> Comprehensive Human Sciences,<br />

University <strong>of</strong> Tsukuba/ JSPS Research Fellow, Tsukuba City,<br />

Ibaraki, Japan, 2 University <strong>of</strong> Tsukuba, 3 University <strong>of</strong> Tsukuba/<br />

Inst Clin Med, Tsukuba City, Japan.<br />

293. Tyrosin Kinases Are Essential Mediators in the Development<br />

<strong>of</strong> Antigen Induced Arthritis Regulating Formation <strong>of</strong><br />

Dendritic Cells and Antigen Presentation. Mats I. Dehlin 1 ,<br />

S<strong>of</strong>ia Andersson 2 , Malin Erlandsson 2 and Maria Bokarewa 2 ,<br />

1<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Inflammation Research,<br />

Sahlgrenska University Hospital, University <strong>of</strong> Göteborg,<br />

Gothenburg, Sweden, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and<br />

Inflammation Research, Sahlgrenska University Hospital,<br />

University <strong>of</strong> Göteborg, Sweden.<br />

Rheumatoid Arthritis - Clinical Aspects: Drug Studies, Drug<br />

Safety, Disease Activity and Remission, Infections I<br />

294. A Decrease in Neutrophil Counts Following a Single Infusion<br />

<strong>of</strong> Tocilizumab Is Predictive <strong>of</strong> Low Disease Activity and<br />

Remission after 24 Weeks. Jasemine Saech 2 , Kathrin Kuhr 1 ,<br />

Matthias Laudes 1 , Olaf Schultz 1 , Thomas Rath 1 , Tobias Roehrs 1<br />

and Andrea Rubbert-Roth 1 , 1 University Clinic Cologne,<br />

2<br />

University Clinic <strong>of</strong> Cologne, Cologne.<br />

295. A Simplified Disease Activity Score (DAS): Validation in the<br />

BeSt Trial. Rosanne Koevoets 6 , Yvonne Goekoop-Ruyterman 2 ,<br />

Desiree M. Van Der Heijde 5 , K. H. Han 7 , H. K. Ronday 1 , T. W. J.<br />

Huizinga 6 , P. J. S. M Kerstens 3 , B. A. C. Dijkmans 8 and Cornelia<br />

F. Allaart 4 , 1 Haga Hospital, Den Hague, 2 Haga Hospital, Den<br />

Hague, The Netherlands, 3 JBI, Amsterdam, 4 Leiden Univ Med<br />

Ctr, Leiden, The Netherlands, 5 Leiden University Medical Center,<br />

Meerssen, The Netherlands, 6 Leiden University Medical Centre,<br />

Leiden, The Netherlands, 7 Maasstad Hospital, Rotterdam, 8 VU<br />

Medical Centre, Amsterdam, The Netherlands.<br />

296. Aiming To Reach Remission – Is It Worthwhile? Helga Radner 3 ,<br />

Josef S. Smolen 1 and Daniel Aletaha 2 , 1 Krankenhaus Lainz,<br />

Vienna, Austria, 2 Medical University <strong>of</strong> Vienna, Vienna, Austria,<br />

3<br />

Medical University Vienna, Vienna, Austria.<br />

166<br />

2010 Program Book


ACR Poster Session A<br />

297. Body Weight and Response to Biologics in RA and<br />

Spondyloarthritides. Obesity Reduces the Rate <strong>of</strong> Remission-<br />

Response. The GISEA Registry. Gianfranco Ferraccioli 2 ,<br />

Francesco Trotta 5 , Leonardo Punzi 11 , Clodoveo Ferri 10 ,<br />

Piercarlo Sarzi-Puttini 6 , Lisa Maria Bambara 4 , Giovanni<br />

Triolo 3 , Roberto Giacomelli 1 , Roberto Gerli 12 , Roberto Gorla 7 ,<br />

Angelo Marchesoni 13 , Walter Grassi 9 and G. Lapadula 8 ,<br />

1<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> L’Aquila,<br />

L’Aquila, Italy, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, UCSC, Rome,<br />

Italy, 3 <strong>Rheumatology</strong> Department, University <strong>of</strong> Palermo,<br />

Palermo, Italy, 4 <strong>Rheumatology</strong> Department, University <strong>of</strong><br />

Verona, Verona, Italy, 5 <strong>Rheumatology</strong> Division, University <strong>of</strong><br />

Ferrara, Ferrara, Italy, 6 <strong>Rheumatology</strong> Unit, L Sacco University,<br />

Milano, Italy, 7 <strong>Rheumatology</strong> Unit, Spedali Civili <strong>of</strong> Brescia,<br />

Brescia, Italy, 8 <strong>Rheumatology</strong> Unit, University <strong>of</strong> Bari, Bari,<br />

Italy, 9 <strong>Rheumatology</strong> Unit, University <strong>of</strong> Marche, Jesi, Italy,<br />

10<br />

<strong>Rheumatology</strong> Unit, University <strong>of</strong> Modena, Modena, Italy,<br />

11<br />

<strong>Rheumatology</strong> Unit, University <strong>of</strong> Padova, Padova, Italy,<br />

12<br />

<strong>Rheumatology</strong> Unit, University <strong>of</strong> Perugia, Perugia, Italy, 13 UOC<br />

DH <strong>of</strong> <strong>Rheumatology</strong>, G. Pini Orthopaedic Institute, Milano, Italy.<br />

298. Celecoxib, a Selective COX-2 Inhibitor Improved Upper<br />

Gastrointestinal (GI) Adverse Lesions in Patients with<br />

Rheumatoid Arthritis on Long-Term NSAID Therapy with<br />

Endoscopic Evaluation. Shigeyoshi Tsuji 1 , Hir<strong>of</strong>umi Miyoshi 2 ,<br />

Tetsuya Tomita 3 , Takanobu Nakase 2 , Masayuki Hamada 2 ,<br />

Takahiro Oomae 2 , Chikako Tsumoto 2 , Yoshimasa Hirata 2 ,<br />

Munetaka Iguchi 2 , Shoko Edogawa 2 , Hideo Kawai 2 and Hideki<br />

Yoshikawa 4 , 1 Hoshigaoka Kosei-Nenkin Hospital, Hirakata City,<br />

Osaka, Japan, 2 Hoshigaoka Kosei-Nenkin Hospital, 3 Osaka Univ<br />

Med School, Suita Osaka, Japan, 4 Osaka Univ Med School.<br />

299. Changes in Lipoproteins Associated with MTX, MTX +<br />

Etanercept, and Triple DMARD Therapy among Early RA<br />

Patients in the TEAR Trial. Jeffrey R. Curtis 6 , Christina Charles-<br />

Schoeman 2 , Shuo Yang 4 , Lang Chen 4 , Stacey C<strong>of</strong>ield 4 , George<br />

Howard 4 , Theresa M. McVie 4 , Larry W. Moreland 5 , James R.<br />

O’Dell 7 , Harold E. Paulus 1 , Monika Safford 4 and S. Louis Bridges 3 ,<br />

1<br />

Encino, CA, 2 UCLA, Santa Monica, CA, 3 Univ <strong>of</strong> Alabama-<br />

Birmingham, Birmingham, AL, 4 Univ <strong>of</strong> Alabama-Birmingham,<br />

5<br />

Univ <strong>of</strong> Pittsburgh Med Ctr, Pittsburgh, PA, 6 University <strong>of</strong><br />

Alabama - Brimingham, Birmingham, AL, 7 University <strong>of</strong> Nebraska<br />

Medical Center, Omaha, NE.<br />

300. DAS28 Level at Baseline Best Predicts Which Patients with New<br />

Onset Inflammatory Arthritis Will Ultimately Require Biologic<br />

Therapy. Vivian P. Bykerk 9 , Gilles Boire 6 , Boulos Haraoui 3 , Carol<br />

Hitchon 7 , Diane Ferland 2 , Carter Thorne 4 , Ed C. Keystone 8 ,<br />

Janet E. Pope 5 and CATCH Investogators 1 , 1 Canada, 2 Hopital<br />

Maisonneuve Rosement, Montreal, PQ, Canada, 3 Institut de<br />

Rhumatologie de Montreal, Montreal, PQ, Canada, 4 South<br />

Lake Regional Health Center, Newmarket, Newmarket, ON,<br />

Canada, 5 St Joseph Health Care London, London, ON, Canada,<br />

6<br />

Universite de Sherbrooke, Sherbrooke, PQ, Canada, 7 University<br />

<strong>of</strong> Manitoba, Winnipeg, MB, Canada, 8 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada, 9 University <strong>of</strong> Toronto, Boston, MA.<br />

301. Decreased Rate <strong>of</strong> Remission at 1 Year in Menopaused Women<br />

with Early Inflammatory Arthritis: The ESPOIR Cohort Study.<br />

Cédric Lukas 2 , Ihsane Hmamouchi 2 , Xavier Le Loet 3 , Bruno<br />

Fautrel 1 and Bernard Combe 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

La Pitie Salpetriere Hospital, Paris, France, 2 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Lapeyronie Hospital, Montpellier, France,<br />

3<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Rouen Hospital, Rouen, France.<br />

302. Demographic, Disease and Treatment Characteristics <strong>of</strong> the<br />

Rheumatoid Arthritis Population Enrolled in the AMORA Study<br />

(Applications for Methotrexate Optimization in Rheumatoid<br />

Arthritis) in Evaluating the Avise PGSM Test. Prashanth R.<br />

Sunkureddi 1 , Judith F. Gendreau 2 , Rong Zablocki 3 and Dawn<br />

Navis 3 , 1 Clear Lake <strong>Rheumatology</strong>, Nassau Bay, TX, 2 Cypress<br />

Bioscience, Inc, San Diego, CA, 3 Cypress Bioscience, Inc.<br />

303. Demonstration <strong>of</strong> the Structural Efficacy <strong>of</strong> Very Early DMARD<br />

Initiation in Early Inflammatory Arthritis in Clinical Practice:<br />

Results <strong>of</strong> a Propensity Analysis in the ESPOIR. Cédric Lukas 3 ,<br />

Bernard G. Combe 4 , Philippe Ravaud 1 , Jean Sibilia 2 , Robert<br />

Landewe 6 and Desiree M. Van Der Heijde 5 , 1 Department<br />

<strong>of</strong> Epidemiology and Biostatistics, Bichat Hospital, Paris,<br />

France, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Hautepierre Hospital,<br />

Strasbourg, France, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Lapeyronie<br />

Hospital, Montpellier, France, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Lapeyronie Hospital, Montpellier, France, 5 Leiden University<br />

Medical Center, Meerssen, The Netherlands, 6 Univ Hosp<br />

Maastricht, Maastricht, The Netherlands.<br />

304. Derivation <strong>of</strong> a Preliminary Administrative Claims-Based<br />

Algorithm To Identify Lack <strong>of</strong> Effectiveness <strong>of</strong> Rheumatoid<br />

Arthritis Medications. Jeffrey R. Curtis 7 , Shuo Yang 4 , John<br />

Baddley 1 , Grant W. Cannon 9 , Lang Chen 5 , Elizabeth Delzell 5 ,<br />

Nivedita M. Patkar 2 , Kenneth G. Saag 8 , Monika Safford 3 ,<br />

Jasvinder Singh 1 and Ted R. Mikuls 6 , 1 Birmingham VAMC/UAB,<br />

2<br />

Univ <strong>of</strong> AL at Birmingham, Birmingham, AL, 3 Univ <strong>of</strong> AL at<br />

Birmingham, 4 Univ <strong>of</strong> Alabama at Birmingham, 5 Univ <strong>of</strong> Alabama<br />

at Birmingham, Birmingham, 6 Univ <strong>of</strong> Nebraska Med Ctr,<br />

Omaha, NE, 7 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />

AL, 8 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

9<br />

University <strong>of</strong> Utah, Salt Lake City, UT.<br />

305. Differences in Disease Severity and Response to Biologic<br />

Agents in a Racially Diverse US-Based Cohort <strong>of</strong> Patients with<br />

Rheumatoid Arthritis (RA). George A. Karpouzas 2 , Rosalinda<br />

Moran 2 , Soha Dolatabadi 1 and Michael Weisman 1 , 1 Cedars Sinai,<br />

2<br />

Harbor-UCLA.<br />

306. Disease Activity in Patients with Early Rheumatoid Arthritis<br />

Receiving Stable Conventional DMARDs Significantly Influences<br />

the Timing <strong>of</strong> Achieving a Low Disease State and Remission<br />

at 3 Versus 6 Months. Pooneh Akhavan 3 , Vivian P. Bykerk 3 ,<br />

Ye Sun 4 , J. Hochman 7 , Janet E. Pope 10 , Janet E. Pope 10 , Carol<br />

A. Hitchon 11 , Gilles Boire 8 , Boulos Haraoui 2 , Diane S. Ferland 6 ,<br />

J. Carter Thorne 9 , Deborah A. Weber 5 , Ed C. Keystone 12 and<br />

All CATCH Investigators 1 , 1 Canada, 2 Institut de Rhumatologie,<br />

Montreal, QC, Canada, 3 Mount Sinai Hospital, University <strong>of</strong><br />

Toronto, Toronto, ON, Canada, 4 Mount Sinai Hospital, University<br />

<strong>of</strong> Toronto, Toronto, ON, Canada, 5 Mt Sinai Hosp, Toronto, ON,<br />

Canada, 6 <strong>Rheumatology</strong>, Hopital Maisonneuve, LaSalle, QC,<br />

Canada, 7 <strong>Rheumatology</strong>, University <strong>of</strong> Toronto, 8 Sherbrooke<br />

University, Sherbrooke, QC, Canada, 9 Southlake Regional Health<br />

Care, Newmarket, ON, Canada, 10 St Joseph Health Care London,<br />

London, ON, Canada, 11 University <strong>of</strong> Manitoba, Winnipeg, MB,<br />

Canada, 12 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

307. Does Sequence Matter When Switching from One Anti–Tumor<br />

Necrosis Factor Agent to Another? O. Baser 3 , S. Roy 1 , C.<br />

Akin 2 and M. A. Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL,<br />

2<br />

Brigham and Women’s Hospital, Boston, MA, 3 University <strong>of</strong><br />

Michigan, Ann Arbor, MI.<br />

2010 Program Book 167


ACR Poster Session A<br />

168<br />

308. Durability <strong>of</strong> Clinical Remission in Rheumatoid Arthritis<br />

Based on Various Criteria. Femke H. M. Prince 2 , Vivian P.<br />

Bykerk 2 , Nancy A. Shadick 1 , Jing Cui 2 , Michele Frits 2 , Christine<br />

K. Iannaccone 2 , Michael E. Weinblatt 3 and Daniel Hal Solomon 3 ,<br />

1<br />

Brigham & Womens Hospital, Boston, MA, 2 Brigham and<br />

Women’s Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology and<br />

Allergy, BRASS, Boston, MA, 3 Brigham and Womens Hospital,<br />

Boston, MA.<br />

309. Effect <strong>of</strong> Anti-Tumor Necrosis Factor Alpha Therapy on<br />

Cardiovascular Events in Rheumatoid Arthritis: A Systematic<br />

Review and Meta-Analysis. Cheryl C. M. Barnabe 2 , Billie-Jean<br />

Martin 1 and William A. Ghali 2 , 1 Libin Cardiovascular Institute,<br />

2<br />

University <strong>of</strong> Calgary, Calgary, AB, Canada.<br />

310. Effect <strong>of</strong> Intensive Repletion and Maintenance Vitamin D<br />

Therapy in Rheumatoid Arthritis Patients. Uzma J. Haque 1 ,<br />

Kevin Fontaine 2 and Susan J. Bartlett 3 , 1 Johns Hopkins School <strong>of</strong><br />

Medicine, Lutherville, MD, 2 Johns Hopkins School <strong>of</strong> Medicine,<br />

3<br />

McGill University, Montreal, QC, Canada.<br />

311. Effectiveness <strong>of</strong> Initial Treatment Allocation Based on Expert<br />

Opinion for Prevention <strong>of</strong> Rapid Radiological Progression<br />

in a Daily Practice Early RA Cohort. Anne Durnez 2 , Geert<br />

Vanderschueren 1 , Luc Lateur 1 , Rene Westhovens 2 and Patrick<br />

Verschueren 2 , 1 University Hospital Leuven Radiology, Leuven,<br />

Belgium, 2 University Hospital Leuven <strong>Rheumatology</strong>, Leuven,<br />

Belgium.<br />

312. ESR, CRP, or RF Status at Presentation Is Only Marginally<br />

Predictive <strong>of</strong> Future Treatments with Methotrexate or Biologic<br />

Agents over 25 Years in Two Settings in the United States and<br />

in Finland. Tuulikki Sokka 1 , Hannu Kautiainen 2 and Theodore<br />

Pincus 3 , 1 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 2 Medcare<br />

Oy, Annekoski, Finland, 3 New York University Hospital for Joint<br />

Disease, Hastings-on-Hudson, NY.<br />

313. Invasive Fungal Infections in Seniors with Rheumatoid<br />

Arthritis: A Population-Based Study from the Ontario Biologics<br />

Research Initiative. Jessica Widdifield 7 , Sasha R. Bernatsky 3 ,<br />

J. Michael Paterson 1 , Nadia Gunraj 2 , Janet E. Pope 6 , J. Carter<br />

Thorne 5 , Alfred A. Cividino 4 and Claire Bombardier 7 , 1 Institute<br />

for Clinical Evaluative Science, Canada, 2 Institute for Clinical<br />

Evaluative Science, 3 McGill UHC/RVH, Montreal, QC, Canada,<br />

4<br />

McMaster University, Hamilton, ON, Canada, 5 Southlake<br />

Regional Health Care, Newmarket, ON, Canada, 6 St Joseph<br />

Health Care London, London, ON, Canada, 7 University <strong>of</strong><br />

Toronto.<br />

314. Is DAS28 Remission Good Enough? Disease Activity and<br />

Functionality in Rheumatoid Arthritis, Results <strong>of</strong> the DREAM<br />

Remission Induction Cohort. Marloes Vermeer 3 , Ina H. Kuper 3 ,<br />

Monique Hoekstra 1 , Hein J. Bernelot Moens 4 , Piet L. C. M. van<br />

Riel 2 and Mart A. F. J. van de Laar 3 , 1 Isala Klinieken, Zwolle,<br />

The Netherlands, 2 Radboud University Nijmegen Medical<br />

Centre, Nijmegen, The Netherlands, 3 University <strong>of</strong> Twente<br />

and Medisch Spectrum Twente, Enschede, The Netherlands,<br />

4<br />

Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands.<br />

315. Low Rate <strong>of</strong> Rheumatoid Arthritis Remission in Real Life: Might<br />

Predictive Factors Explain? Elodie Loppin 2 , Ronan Garlantezec 1<br />

and Elisabeth Solau-Gervais 2 , 1 Public Heatlh Department,<br />

University Hospital Brest, France, 2 <strong>Rheumatology</strong> Department<br />

University Hospital Poitiers, France.<br />

316. Lymphocytopenia and Infection Risk in Rheumatoid Arthritis:<br />

A Population Based Analysis. Deana D. Hoganson 2 , Eric L.<br />

Matteson 1 , Patrick D. Fitz-Gibbon 3 and Cynthia S. Crowson 3 ,<br />

1<br />

Mayo Clinic, Rochester, MN, 2 Mayo Clinic Rochester, Rochester,<br />

MN, 3 Mayo Clinic Rochester.<br />

2010 Program Book<br />

317. Measures <strong>of</strong> Disease Activity Provide Various Clinical Decisions<br />

in Individual Patients. P. H. P. de Jong 1 , J. M. W. Hazes 2 , J. J.<br />

Luime 2 and A. E. A. M. Weel 3 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

ErasmusMC, Rotterdam, The Netherlands, 2 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, ErasmusMC, Rotterdam, 3 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Maasstad Hospital, Rotterdam.<br />

318. Minocycline and Doxycycline Therapy in Community Patients<br />

with Rheumatoid Arthritis (RA): Incidence, Patient-Level<br />

Determinants <strong>of</strong> Use and Side Effects. Christopher J. Smith 2 ,<br />

Harlan R. Sayles 2 , Ted R. Mikuls 1 and Kaleb D. Michaud 1 , 1 Univ <strong>of</strong><br />

Nebraska Med Ctr, Omaha, NE, 2 University <strong>of</strong> Nebraska Med Ctr,<br />

Omaha, NE.<br />

319. Multi-Centre, Cross-Sectional, Observational Study <strong>of</strong> the<br />

Safety <strong>of</strong> Methotrexate and Leflunomide in Combination in<br />

the Treatment <strong>of</strong> Patients with Rheumatoid Arthritis The<br />

SMILE Study – Safety <strong>of</strong> Methotrexate In Combination with<br />

Leflunomide. Paul Bird 2 , Hedley Griffiths 1 and The Optimising<br />

Patient Outcomes in Australian RheumatoLogy [OPAL]<br />

Consortium, 1 Barwon <strong>Rheumatology</strong> Service, Victoria, Australia,<br />

2<br />

Combined <strong>Rheumatology</strong> Practice (CRP), University <strong>of</strong> NSW,<br />

Sydney, NSW, Australia.<br />

320. Multi-Centre, Observational Study Shows High Proportion <strong>of</strong><br />

Australian Rheumatoid Arthritis Patients Have Inadequate<br />

Disease Control. Ge<strong>of</strong>frey Littlejohn 2 and Kathleen E. Tymms 1 ,<br />

1<br />

Canberra <strong>Rheumatology</strong>, Canberra, ACT, Australia, 2 Monash<br />

Medical Centre, Clayton, Victoria, Australia.<br />

321. Multiple Courses <strong>of</strong> Rituximab Produce Sustained Efficacy<br />

in Patients with Rheumatoid Arthritis with an Inadequate<br />

Response to One or More TNF Inhibitors. Edward C. Keystone 6 ,<br />

Roy M. Fleischmann 5 , Paul Emery 2 , Maxime Dougados 3 , Sarah<br />

Williams 4 , Matthew D. Linnik 1 and Mark Reynard 4 , 1 Biogen<br />

Idec, San Diego, San Diego, CA, 2 Chapel Allerton Hospital,<br />

Leeds, United Kingdom, 3 Hospital Cochin, Paris, France, 4 Roche<br />

Products Ltd, Welwyn Garden City, UK, 5 University <strong>of</strong> Texas<br />

Southwestern Medical Center, Dallas, Dallas, TX, 6 University <strong>of</strong><br />

Toronto, Toronto, ON, Canada.<br />

322. National Trends in Drug Use, Health Status and Costs in Older<br />

<strong>American</strong>s with Rheumatoid Arthritis. Leslie R. Harrold 3 , Becky<br />

Briesacher 4 , Daniel Peterson 1 and Jerry H. Gurwitz 2 , 1 Meyers<br />

Primary Care Institute, 2 Meyers Primary Care Institute/UMass<br />

Medical School, 3 UMass Medical Schl, Worcester, MA, 4 UMass<br />

Medical School.<br />

323. Pandemic H1N1 Influenza Vaccination Responses in Rheumatid<br />

Arthritis and Systemic Lupus Erythematosus Patients: An<br />

Association with Serum IL17 and CXCL13 Level. Sung-Hoon<br />

Park 1 , Hwa-Jeong Lee 2 , Hyun-Hee Kwon 2 , Seong-Kyu Kim 2 and<br />

Jung-Yoon Choe 2 , 1 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />

Medicine, Arthritis and Autoimmunity Research Center, Daegu,<br />

Korea, Republic <strong>of</strong>, 2 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />

Medicine, Arthritis and Autoimmunity Research Center.<br />

324. Patient Preferences for Biologic Agents in Rheumatoid<br />

Arthritis: A Discrete Choice Experiment. David A. Navarta 2 ,<br />

Federico Augustovski 3 , Andrea Beratarrechea 3 , Vilma Irazola 3 ,<br />

Fernando Rubinstein 3 , Pablo Tesolin 3 , Juan M. Gonzalez 6 ,<br />

Veronica Lencina 4 , Marina Scolnik 2 , Christian Wainmann 5 ,<br />

Gustavo Citera 4 and Enrique R. Soriano 1 , 1 Hospital Italiano<br />

de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires,<br />

Capital Federal, Argentina, 2 Hospital Italiano de Buenos<br />

Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina,<br />

Argentina, 3 Institute for Clinical Effectiveness and Health Policy,<br />

Buenos Aires, Argentina, 4 Instituto Rehabilitacion Psic<strong>of</strong>isica,<br />

Buenos Aires, Argentina, 5 Instituto Rehabilitacion Psic<strong>of</strong>isica,<br />

Buenos Aires, Argentina, 6 RTI Health Solutions, NC.


ACR Poster Session A<br />

325. Patient Risk Perception <strong>of</strong> Teratogenicity <strong>of</strong> Disease Modifying<br />

Anti-Rheumatic Drugs. Eliza F. Chakravarty 3 , Megan E. Clowse 2 ,<br />

Karen H. Costenbader 1 , Christina Chambers 4 and Kaleb<br />

Michaud 5 , 1 Brigham and Womens Hospital, 2 Duke University,<br />

Durham, NC, 3 Stanford University, 4 University <strong>of</strong> California, San<br />

Diego, 5 University <strong>of</strong> Nebraska.<br />

326. Post-Treatment Changes in Serum C-Reactive Protein Levels<br />

and Clinical Response in Rheumatoid Arthritis. Paul Emery 8 ,<br />

Eric L. Matteson 6 , Mark C. Genovese 7 , Sarah Sague 1 , Elizabeth<br />

C. Hsia 3 , Mittie K. Doyle 4 , Hongtao Fan 2 , Michael Elash<strong>of</strong>f 5 and<br />

Mahboob U. Rahman 4 , 1 Centocor Research and Development,<br />

Inc., Malvern, PA, 2 Centocor Research and Development, Inc.,<br />

3<br />

Centocor Research and Development, Inc./Univ <strong>of</strong> Pennsylvania<br />

School <strong>of</strong> Medicine, Malvern, PA, 4 Centocor Research and<br />

Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />

Malvern, PA, 5 Elash<strong>of</strong>f Consulting, 6 Mayo Clinic, Rochester, MN,<br />

7<br />

Stanford Universit, Sunnyvale, CA, 8 University Leeds, Leeds,<br />

United Kingdom.<br />

327. Practice Patterns <strong>of</strong> US Rheumatologists Related to<br />

Diagnosis and Assessment <strong>of</strong> Disease Activity as Well as<br />

Switching Biologic Therapies in Rheumatoid Arthritis. Marco<br />

DiBonaventura 2 , Sanjoy Roy 1 , Jochen Ertl 2 and Mary A. Cifaldi 1 ,<br />

1<br />

Abbott Laboratories, Abbott Park, IL, 2 Kantar Health, New York,<br />

NY.<br />

328. Predictors <strong>of</strong> Successful Cessation <strong>of</strong> TNF Blockers in Patients<br />

with RA. M. van den Broek 4 , N. B. Klarenbeek 5 , L. Dirven 5 , A.<br />

A. Schouffoer 1 , H. M. J. Hulsmans 2 , P. J. S. M Kerstens 3 , T. W.<br />

J. Huizinga 5 , B. A. C. Dijkmans 6 and C. F. Allaart 5 , 1 Groene Hart<br />

Hospital, Gouda, The Netherlands, 2 Haga Hospital, The Hague,<br />

The Netherlands, 3 Jan van Breemen Instituut, Amsterdam,<br />

The Netherlands, 4 LUMC, Leiden, The Netherlands, 5 LUMC,<br />

Leiden, The Netherlands, 6 VU Medical Centre, Amsterdam, The<br />

Netherlands.<br />

329. Prevalence <strong>of</strong> Reactivation <strong>of</strong> Hepatitis B Virus Replication<br />

in Rheumatoid Arthritis Patients. Dai Tanaka 2 , Yukitomo<br />

Urata 4 , Ryoko Uesato 3 , Kenji Kowatari 3 , Yoshihide Nakamura 1<br />

and Taisuke Nitobe 3 , 1 Department <strong>of</strong> Orthopaedic Surgery,<br />

Hirosaki University Graduate School <strong>of</strong> Medicine, 2 Department<br />

<strong>of</strong> Orthopaedic Surgery, Seihoku Chuo Hospital, Gosyogawara,<br />

Aomori, Japan, 3 Department <strong>of</strong> Orthopaedic Surgery, Seihoku<br />

Chuo Hospital, 4 Departments <strong>of</strong> <strong>Rheumatology</strong>, Seihoku Chuo<br />

Hospital, Gosyogawara, Japan.<br />

330. Primary Anti-TNF Failures Experience Better Clinical Responses<br />

but Similar Health Care Utilization to a Second Anti-TNF Agent<br />

Than Secondary Failures: Analysis <strong>of</strong> the Alberta Rheumatoid<br />

Arthritis Biologics Registry. Walter P. Maksymowych 2 , Arto<br />

Ohinmaa 1 , Liam Martin 3 , Anthony S. Russell 2 , Susan G. Barr 3 ,<br />

Dale Sholter 2 , Chris J. Penney 3 , Charles Yan 1 and Philip Jacobs 1 ,<br />

1<br />

Institute <strong>of</strong> Health Economics, Edmonton, AB, Canada,<br />

2<br />

University <strong>of</strong> Alberta, Edmonton, AB, Canada, 3 University <strong>of</strong><br />

Calgary, Calgary, AB, Canada.<br />

331. Rate <strong>of</strong> Remission in Clinical RA Patients by ACR/EULAR<br />

Criteria. Shadi H. Shahouri 3 , James D. Anderson 5 , Ruth E. Busch 2 ,<br />

Timothy S. Shaver 4 , Shirley Y. Wang 3 , David N. Weidensaul 1 ,<br />

Martin J. Bergman 6 , Kaleb D. Michaud 8 and Frederick Wolfe 7 ,<br />

1<br />

ARCKArthritis & Rheum Clinics KS, Wichita, KS, 2 Arthritis &<br />

Rheum Clinic, Wichita, KS, 3 Arthritis & Rheum Clinic <strong>of</strong> KS,<br />

Wichita, KS, 4 Arthritis & Rheum Clinics KS, Wichita, KS, 5 Arthritis<br />

& Rheum Clinics KS, Leawood, KS, 6 Arthritis and <strong>Rheumatology</strong>,<br />

Ridley Park, PA, 7 Natil Data Bank for Rheumatic, Wichita, KS,<br />

8<br />

Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE.<br />

332. Rituximab Alters the HDL Particle from a Pro-Inflammatory<br />

into an Anti-Inflammatory Property in Good Responding<br />

Rheumatoid Arthritis Patients. Hennie G. Raterman 2 , Han H.<br />

M. Levels 1 , Alexandre E. Voskuyl 2 , Willem F. Lems 2 , Ben A. C.<br />

Dijkmans 2 and Michael T. Nurmohamed 2 , 1 Academical Medical<br />

Center, The Netherlands, 2 VU University Medical Center,<br />

Amsterdam, The Netherlands.<br />

333. Rituximab-Reduced Immunoglobulin Free Light Chains in<br />

RA Correlate with Disease Suppression: A Novel Mechanism<br />

<strong>of</strong> Action <strong>of</strong> Rituximab. J. Tekstra 3 , T. Groot Kormelink 2 , R.<br />

Thurlings 1 , M. Boumans 1 , K. Vos 1 , P. P. Tak 1 , J. W. J. Bijlsma 3 , F.<br />

P. J. G. Lafeber 3 , F. A. Redegeld 2 and J. A. G. van Roon 3 , 1 Clinical<br />

Immunology & <strong>Rheumatology</strong>, Academic Medical Center/<br />

University <strong>of</strong> Amsterdam, The Netherlands, 2 Pharmacology and<br />

Pathophysiology, Utrecht Institute for Pharmaceutical Sciences,<br />

Fac. Science, Utrecht, the Netherlands, 3 <strong>Rheumatology</strong> &<br />

Clinical Immunology, University Medical Center Utrecht, The<br />

Netherlands.<br />

334. Seven Year Results <strong>of</strong> DAS Steered Treatment in the BeSt<br />

Study: Clinical and Radiological Outcomes. L. Dirven 5 , M. van<br />

den Broek 5 , N. B. Klarenbeek 5 , M. V. van Krugten 1 , P. A. H. M.<br />

van der Lubbe 2 , P. J. S. M. Kerstens 3 , T. W. J. Huizinga 5 , B. A. C.<br />

Dijkmans 6 and C. F. Allaart 4 , 1 Admiraal de Ruyter Hospital, 2 Haga<br />

Hospital, 3 Jan van Breemen Institute, 4 Leiden Univ Med Ctr,<br />

Leiden, The Netherlands, 5 Leiden University Medical Center, 6 VU<br />

Medical Centre, Amsterdam, The Netherlands.<br />

335. Surveillance <strong>of</strong> Surgical Site Infection in Patients with<br />

Rheumatoid Arthritis. Kengo Harigane 1 , Yuichi Mochida 2 ,<br />

Katsushi Ishii 2 , Naoya Taki 2 , Naoto Mitsugi 2 and Tomoyuki<br />

Saito 3 , 1 Yokohama City University Medical Center, Yokohama,<br />

Kanagawa, Japan, 2 Yokohama City University Medical Center,<br />

3<br />

Yokohama City University School <strong>of</strong> Medicine.<br />

336. Sustained Remission in Early RA: Results from SONORA Study.<br />

Claire Bombardier 3 , Pooneh Akhavan 2 , Maggie Chen 1 and<br />

Xiuying Li 1 , 1 University Health Network, 2 University <strong>of</strong> Toronto,<br />

University Health Network, 3 University <strong>of</strong> Toronto, University<br />

Health Network, Mount Sinai Hospital, Toronto, ON, Canada.<br />

337. Sustained Remission, a Realistic Target in Early Rheumatoid<br />

Arthritis Patients Treated with Conventional DMARDs. Irazú<br />

Contreras-Yáñez, Marina Rull-Gabayet and Virginia Pascual-<br />

Ramos, Instituto Nacional de Ciencias Médicas y Nutrición<br />

Salvador Zubirán, Ciudad de México, DF, Mexico.<br />

338. Switching Patterns for Biologic Drugs among Patients with<br />

Rheumatoid Arthritis Who Have Previously Failed at Least<br />

One Biologic Agent. Stephen Johnston 2 , Sarika Ogale 1 , Nicole<br />

Princic 3 , Bong-Chul Chu 3 and Tripthi Kamath 1 , 1 Genentech USA,<br />

Inc., 2 Thomson Reuters, Washington, DC, 3 Thomson Reuters.<br />

339. Systemic Immunosuppressives and the Risk <strong>of</strong> Diabetes in<br />

Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). Daniel<br />

Hal Solomon 3 , Elena M. Massarotti 1 , Raj Garg 2 , Claire Canning 2 ,<br />

Jun Liu 2 and Sebastian Schneeweiss 2 , 1 Brigham & Women’s<br />

Hospital, Boston, MA, 2 Brigham and Women’s Hospital,<br />

3<br />

Brigham and Womens Hospital, Boston, MA.<br />

340. The Belgian MIRA (MabThera in Rheumatoid Arthritis)<br />

Registry: Clues for the Optimization <strong>of</strong> Rituximab Treatment<br />

Strategies. Bert Vander Cruyssen 2 , Patrick Durez 1 , Rene<br />

Westhovens 5 , Ilse H<strong>of</strong>fman 3 , M. J. Kaiser 4 and Filip De Keyser,<br />

1<br />

Cliniques Universitaires Saint-Luc, Brussels, 2 Ghent University<br />

Hosptial, 3 GZA St-Augustinus Hospital Antwerp, Belgium,<br />

4<br />

University Hospital Liege, Liege, Belgium, 5 University Hospitals<br />

KULeuven, Leuven, Belgium.<br />

2010 Program Book 169


ACR Poster Session A<br />

341. The Incidence <strong>of</strong> Herpes Zoster in Seniors with Rheumatoid<br />

Arthritis. Jessica Widdifield 7 , Sasha R. Bernatsky 2 , J. Michael<br />

Paterson 1 , Nadia Gunraj 1 , Janet E. Pope 5 , J. Carter Thorne 4 ,<br />

Alfred A. Cividino 3 and Claire Bombardier 6 , 1 Institute for Clinical<br />

Evaluative Science, 2 McGill UHC/RVH, Montreal, QC, Canada,<br />

3<br />

McMaster University, Hamilton, ON, Canada, 4 Southlake<br />

Regional Health Care, Newmarket, ON, Canada, 5 St Joseph<br />

Health Care London, London, ON, Canada, 6 University <strong>of</strong><br />

Toronto, Toronto, ON, Canada, 7 University <strong>of</strong> Toronto.<br />

342. The Influence <strong>of</strong> Systemic Glucocorticoid Therapy upon the<br />

Risk <strong>of</strong> Non-Serious Infection in Patients with Rheumatoid<br />

Arthritis. William G. Dixon 3 , Abbas Kezouh 2 , Sasha R. Bernatsky 1<br />

and Samy Suissa 2 , 1 McGill UHC/RVH, Montreal, QC, Canada,<br />

2<br />

McGill University, 3 The University <strong>of</strong> Manchester, Manchester,<br />

United Kingdom.<br />

343. Three Months <strong>of</strong> Therapy with DMARDs Is an Inadequate<br />

Period <strong>of</strong> Time To Alter the Treatment in Patients with Early<br />

Rheumatoid Arthritis When Treating to a Target <strong>of</strong> Low Disease<br />

State or Remission. Results from Canadian Early ArThritis<br />

CoHort (CATCH). Pooneh Akhavan 4 , Vivian P. Bykerk 5 , Ye Sun 6 ,<br />

J. Hochman 12 , Janet E. Pope 9 , Carol A. Hitchon 1 , Gilles Boire 10 ,<br />

Boulos Haraoui 2 , Diane S. Ferland 7 , J. Carter Thorne 8 , Deborah<br />

A. Weber 5 , Ed C. Keystone 11 and CATCH Investogators 3 , 1 Arthritis<br />

Center, University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 2 Institut<br />

de Rhumatologie, Montreal, QC, Canada, 3 M, Canada, 4 Mount<br />

Sinai Hospital, University <strong>of</strong> Toronto, Toronto, ON, Canada, 5 Mt<br />

Sinai Hospital, Toronto, ON, Canada, 6 Mt Sinai Hospital, Toronto,<br />

ON, Canada, 7 <strong>Rheumatology</strong>, Hopital Maisonneuve, Rosement,<br />

University <strong>of</strong> Montreal, LaSalle, QC, Canada, 8 Southlake Regional<br />

Health Care, Newmarket, ON, Canada, 9 St Joseph Health Care<br />

London, London, ON, Canada, 10 Universite de Sherbrooke,<br />

Sherbrooke, QC, Canada, 11 University <strong>of</strong> Toronto, Toronto, ON,<br />

Canada, 12 University <strong>of</strong> Toronto, Toronto, ON.<br />

344. Treating to Target with TNFi in Active Established Rheumatoid<br />

Arthritis Results in Longer Drug Survival Than Routine Care<br />

with TNFi: Results from the Optimization <strong>of</strong> Humira RCT. Janet<br />

E. Pope 4 , J. Carter Thorne 3 , Boulos Haraoui 2 and John Sampalis 1 ,<br />

1<br />

Montreal, ON, Canada, 2 Institut de Rhumatologie, Montreal,<br />

QC, Canada, 3 Southlake Regional Health Care, Newmarket, ON,<br />

Canada, 4 St. Joseph’s Health Care, London, ON, Canada.<br />

345. Tumor Necrosis Factor-α Inhibitor Use Does Not Affect Lipid<br />

Pr<strong>of</strong>iles in Patients with Rheumatoid Arthritis. Stephanie J.<br />

Morris 1 , Jana L. Antohe 1 , Jennifer Sartorius 2 , H. Les Kirchner 2 ,<br />

Sorina Dancea 1 , Mary Chester Wasko 3 and Androniki Bili 1 ,<br />

1<br />

Geisinger Health System, Danville, PA, 2 Geisinger Health<br />

System, 3 Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

346. Urinary Tract Infections in Rheumatoid Arthritis. Colin C.<br />

Edgerton 1 , Kaleb D. Michaud 3 and Frederick Wolfe 2 , 1 Eisenhower<br />

Army Medical Center, Evans, GA, 2 Natilonal Data Bank for<br />

Rheumatic Disease, Wichita, KS, 3 Univ <strong>of</strong> Nebraska Med Ctr,<br />

Omaha, NE.<br />

347. Women with RA Achieve Remission Less Frequently Than Men,<br />

Using the CORRONA Database among 6668 Patients. Daniel E.<br />

Furst 5 , Veena Ranganath 4 , Joel M. Kremer 1 , James Louie 4 , Dinesh<br />

Khanna 4 , Lawrence Rasouliyan 2 and Jeffrey D. Greenberg 3 ,<br />

1<br />

Albany Medical <strong>College</strong>, 2 ICON, 3 NYU, 4 UCLA, 5 University <strong>of</strong><br />

California Los Angeles Medical School, Los Angeles, CA.<br />

Rheumatoid Arthritis - Human Etiology and Pathogenesis I<br />

348. A Novel Splicing Regulatory Mechanism in Generating a<br />

Truncated Human Death Receptor 3 (DR3) Gene Product That<br />

Contributes to the Pathogenesis <strong>of</strong> Rheumatoid Arthritis.<br />

Masaru Mizuhara 2 , Akira Hashiramoto 3 , Kohsuke Yoshida 1 and<br />

Shunichi Shiozawa 4 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />

Graduate School <strong>of</strong> Health Science, Kobe, Hyogo, Japan,<br />

2<br />

Department <strong>of</strong> Biophysics, Kobe University Graduate School <strong>of</strong><br />

Health Science, Kobe, Japan, 3 Department <strong>of</strong> Biophysics, Kobe<br />

University Graduate School <strong>of</strong> Health Science/Department <strong>of</strong><br />

Medicine, Kobe University Graduate School <strong>of</strong> Medicine/The<br />

Center for Rheumatic Diseases, Kobe University Hospital, Kobe,<br />

Hyogo, Japan, 4 Department <strong>of</strong> Biophysics, Kobe University<br />

Graduate School <strong>of</strong> Health Science/Department <strong>of</strong> Medicine,<br />

Kobe University Graduate School <strong>of</strong> Medicine/The Center for<br />

Rheumatic Diseases, Kobe University Hospital, Kobe, Japan.<br />

349. BAFF Expression on the Surface <strong>of</strong> RA Synovial Fibroblasts<br />

(RASFib) Facilitates B Cell Responses to IL-15. Yolanda<br />

Garcia-Carmona, Marta Benito-Miguel, Alejandro Balsa, Emilio<br />

Martin-Mola and Maria Eugenia Miranda-Carus, Hospital La Paz,<br />

Madrid, Spain, Hospital La Paz, Madrid, Spain, Hospital La Paz,<br />

Madrid.<br />

350. Characterization <strong>of</strong> Fibrinogen-Specific CD4 T Cells Using<br />

Peptide-MHC Tetramers. Laura F. Su 1 and Mark M. Davis 2 ,<br />

1<br />

Stanford, Mountain View, CA, 2 Stanford.<br />

351. Defective ERK Signaling in Hematopoietic Progenitor Cells in<br />

Rheumatoid Arthritis. Ines Colmegna 2 , Sergei Pryschep 1 , Hisashi<br />

Oishi 3 , Jorg J. Goronzy 3 and Cornelia M. Weyand 3 , 1 Georgia<br />

Institute <strong>of</strong> Technology, 2 McGill University, Montreal, QC,<br />

Canada, 3 Stanford University.<br />

352. Human STEAP4 (Six-Transmembrane Epithelial Antigen<br />

<strong>of</strong> Prostate 4) Regulates Inflammatory Cytokines and the<br />

Proliferation <strong>of</strong> Fibroblast-Like Synoviocyte in Patients<br />

with RA. Yoko Tanaka, Isao Matsumoto, Naoto Umeda, Kayo<br />

Yamamoto, Yuki Tanaka, Asuka Inoue and Takayuki Sumida,<br />

University <strong>of</strong> Tsukuba.<br />

353. IL-15 Promotes Osteoclastogenesis Via Phospholipase D<br />

Signaling Pathway in Rheumatoid Arthritis. Ji-Min Kim 1 ,<br />

Mi-Kyung Park 2 , Mi-La Cho 2 , Yong-Geun Jung 1 , Su-Jin Moon 1 ,<br />

Seung-Ki Kwok 1 , Ji-Hyeon Ju 1 , Kyung-Su Park 1 , Ho-Youn Kim 1<br />

and Sung-Hwan Park 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />

<strong>of</strong> Internal Medicine, Seoul St. Mary’s Hospital, The Catholic<br />

University <strong>of</strong> Korea, Seoul, Korea, Republic <strong>of</strong>, 2 Rheumatism<br />

Research Center, Catholic Research Institute <strong>of</strong> Medical Science,<br />

The Catholic University <strong>of</strong> Korea, Seoul, Korea, Republic <strong>of</strong>.<br />

354. IL-17A and IL-17F Contribute to the Progression <strong>of</strong> Rheumatoid<br />

Arthritis by Inducing a CXCR4-Dependent Invasive Phenotype<br />

in Synoviocytes. Arnaud Hot 2 , Saloua Zrioual 1 , Vanina Lenief 1<br />

and Pierre Miossec 1 , 1 Hospital Edouard Herriot, Lyon, Lyon,<br />

France, 2 Immunogenomics and Inflammation Research Unit<br />

and Department <strong>of</strong> Immunology and <strong>Rheumatology</strong>, Hospital<br />

Edouard Herriot, Lyon, France.<br />

355. In Rheumatoid Arthritis, Naïve B Cells Prevail in the Peripheral<br />

Blood, Whereas Memory B Cells Accumulate in the Joint<br />

Compartment, Express ZAP-70 and Characterize the Aggregate<br />

Pattern. Alessandro Michelutti 2 , Elisa Gremese 2 , Barbara<br />

Tolusso 2 , Francesca Morassi 1 , Rosalia Privitera 2 , Silvia Canestri 2 ,<br />

Giusy Peluso 2 , Silvia L. Bosello 2 and Gianfranco Ferraccioli 2 ,<br />

1<br />

Division <strong>of</strong> Histopathology, Catholic University <strong>of</strong> Sacred Heart,<br />

Rome, Italy, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Catholic University <strong>of</strong><br />

Sacred Heart, Rome, Italy.<br />

170<br />

2010 Program Book


ACR Poster Session A<br />

356. Influence <strong>of</strong> TNF-α, MMP-3, TIMP-3 and HLA Class II Genes<br />

Polymorphisms in the Rheumatoid Arthritis Articular<br />

Damage. Renata T. Alarcon 5 , Artur R. C. Fernandes 5 , Geraldo<br />

R. C. Pinheiro 3 , Magali J. G. Usnayo 3 , Luis C. M. Porto 4 , Juliana<br />

Cardoso-Oliveira 3 , Gustavo M. Fabricio-Silva 3 , Ieda M. M.<br />

Laurindo 1 , Manoel B. Bertolo 2 , Mario Yazbek 2 , Mariana G.<br />

Soares 5 , Neusa P. Silva 5 , Kaline M. C. Pereira 5 and Luis E. C.<br />

Andrade 5 , 1 Universidade de Sao Paulo, Sao Paulo, SP, Brazil,<br />

2<br />

Universidade Estadual de Campinas, Campinas, SP, Brazil,<br />

3<br />

Universidade Estadual do Rio de Janeiro, Rio de Janeiro, RJ,<br />

Brazil, 4 Universidade Estadual do Rio de Janeiro, Rio de Janeiro,<br />

RF, Brazil, 5 Universidade Federal de Sao Paulo - UNIFESP, Sao<br />

Paulo, SP, Brazil.<br />

357. Inhibition <strong>of</strong> the Recycling <strong>of</strong> Polyamines Restores DNA<br />

Methylation in Rheumatoid Arthritis Synovial Fibroblasts.<br />

Emmanuel Karouzakis 1 , Christoph Kolling 2 , Renate E. Gay 1 ,<br />

Beat A. Michel 1 , Steffen Gay 1 and Michel Neidhart 1 , 1 Center <strong>of</strong><br />

Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative<br />

Human Physiology (ZIHP), University Hospital Zurich, 2 Schulthess<br />

Clinic, Zurich.<br />

358. Interleukin-6 Promotes Pathological Angiogenesis by<br />

Modulating Angiopoietin Expression in Rheumatoid Arthritis.<br />

Ken Kayakabe 1 , Takashi Kuroiwa 2 , Noriyuki Sakurai 2 , Hidekazu<br />

Ikeuchi 2 , Akito Maeshima 2 , Keiju Hiromura 2 and Yoshihisa<br />

Nojima 2 , 1 Department <strong>of</strong> Medicine and Clinical Science, Gunma<br />

University Graduate School <strong>of</strong> Medicine, Maebashi, Gunma,<br />

Japan, 2 Department <strong>of</strong> Medicine and Clinical Science, Gunma<br />

University Graduate School <strong>of</strong> Medicine.<br />

359. MicroRNA and mRNA Integrated Analysis in Rheumatoid<br />

Arthritis Synovial Macrophages. Jong Dae Ji 3 , Bit-Na-Ra Lee 5 ,<br />

Tae-Hwan Kim 5 , Jae-Bum Jun 5 , Dae-Hyun Yoo 5 , Kyung-Sun Na 2 ,<br />

Jin-Hyun Woo 4 , Sung Jae Choi 4 , Young Ho Lee 4 , Jeongwon Sohn 1<br />

and Gwan Gyu Song 4 , 1 Department <strong>of</strong> Biochemistry, <strong>College</strong> <strong>of</strong><br />

Medicine, Korea University, Seoul, Korea, 2 Kim’s Clinic, Seoul,<br />

Korea, 3 <strong>Rheumatology</strong>, <strong>College</strong> <strong>of</strong> Medicine, Korea University,<br />

Seoul, Korea, Republic <strong>of</strong>, 4 <strong>Rheumatology</strong>, <strong>College</strong> <strong>of</strong> Medicine,<br />

Korea University, Seoul, Korea, 5 The Hospital for Rheumatic<br />

Diseases, Hanyang University, Seoul, Korea.<br />

360. Mitochondrial Mutagenesis in Synovial Tissue Is Associated<br />

with In Vivo Hypoxia, Inflammation and Oxidative Damage.<br />

Monika Biniecka 2 , Edward Fox 1 , Chin T. Ng 2 , Len Harty 2 , Ursula<br />

Fearon 2 , Douglas J. Veale 2 and Jacintha O’Sullivan 2 , 1 Department<br />

<strong>of</strong> Pathology, University <strong>of</strong> Washington, Seattle, WA, 2 Translation<br />

Research Group, Dublin Academic Medical Centre, St. Vincent’s<br />

University Hospital, Dublin, Co. Dublin, Ireland.<br />

361. Nerve Fiber Repulsion by Semaphorins – More Redundancy<br />

Than Expected in the Rheumatoid Arthritis Joint. Susanne<br />

Klatt, Alexander Fassold and Rainer H. Straub, University<br />

Hospital Regensburg, Regensburg, Germany, University Hospital<br />

Regensburg, Regensburg, Germany.<br />

362. Phosphoinositide 3-Kinase Delta (PI3Kδ) Regulation and<br />

Function in RA. Beatrix Bartok 2 , David Boyle 2 , Christian Rommel 1<br />

and Gary S. Firestein 3 , 1 Intellikine, 2 UCSD, San Diego, 3 UCSD.<br />

363. Platelet Microparticle Proteome: Insight into Role <strong>of</strong><br />

Microparticles under Different Stimulatory Conditions. Roopa<br />

Shree Subbaiah 5 , K. C. Sekhar Rao 1 , Peter Nigrovic 2 , David Lee 4 ,<br />

Masaru Miyagi 1 , Eric Boilard 3 and Reuben Gobezie 6 , 1 Case<br />

Center for Proteomics and Bioinformatics, School <strong>of</strong> Medicine,<br />

Case Western Reserve University, Cleveland, OH, 2 Center for<br />

Adults with Pediatric Rheumatic Illness (CAPRI), Pediatric and<br />

Adult <strong>Rheumatology</strong>, Children’s Hospital Boston, Brigham and<br />

Women’s Hospital, Boston, MA, 3 Department <strong>of</strong> <strong>Rheumatology</strong><br />

and Immunology, CHUL, QC, Canada, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Immunology and Allergy, Brigham & Women’s Hospital, Boston,<br />

MA, 5 The Department <strong>of</strong> Orthopaedic Surgery, Case Western<br />

Reserve University, School <strong>of</strong> Medicine, University Hospitals<br />

<strong>of</strong> Cleveland, Cleveland, OH, 6 The Department <strong>of</strong> Orthopaedic<br />

Surgery, Case Western Reserve University, School <strong>of</strong> Medicine,<br />

University Hospitals <strong>of</strong> Cleveland, Cleveland, OH.<br />

364. Post-Transcriptional Regulation <strong>of</strong> IL-6 Production by Zc3h12a<br />

in Fibroblast-Like Synovial Cells. Tomohiro Koga, Satoshi<br />

Yamasaki, Akitomo Okada, Shin-ya Kawashiri, Hideki Nakamura,<br />

Atsushi Kawakami and Katsumi Eguchi, Nagasaki University,<br />

Nagasaki, Japan, Nagasaki University, Nagasaki, Japan.<br />

365. Role <strong>of</strong> IL-17 in Pannus Formation and Osteoclastogenesis in<br />

Rheumatoid Arthritis. Hiroshi Ito 2 , Hidehiro Yamada 3 , Toshiko<br />

Nozaki Shibata 2 , Hir<strong>of</strong>umi Mitomi 2 , Kiyomi Matsuo 2 , So Nomoto 1<br />

and Shoichi Ozaki 4 , 1 Department <strong>of</strong> Orthopaedic Surgery and<br />

<strong>Rheumatology</strong>, Saiseikai Yokohama Tobu Hospital, 2 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, St. Marianna<br />

University School <strong>of</strong> Medicine, Kawasaki, Japan, 3 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, St. Marianna<br />

University School <strong>of</strong> Medicine, Kawasaki, Japan, 4 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, St. Marianna University School <strong>of</strong> Medicine,<br />

Kawasaki, Japan.<br />

366. Role <strong>of</strong> Raf Kinase Inhibitor Protein in Cytokines, Matrix<br />

Metalloproteinases Regulation and Invasiveness <strong>of</strong><br />

Rheumatoid Fibroblast-Like Synobiocytes. Joong Kyong Ahn 1 ,<br />

You Sun Lee 2 , Eun-Jung Park 3 , Ji-Won Hwang 3 , Ji-Min Oh 3 ,<br />

Jaejoon Lee 3 , Chan-Hong Jeon 4 , Eun-Mi Koh 3 and Hoon-Suk<br />

Cha 3 , 1 Kangbuk Samsung Hospital, Sungkyunkwan University<br />

School <strong>of</strong> Medicine, 2 Masan Samsung Hospital, Sungkyunkwan<br />

University School <strong>of</strong> Medicine, 3 Samsung Medical Center,<br />

Sungkyunkwan University School <strong>of</strong> Medicine, 4 Soonchunhyang<br />

University <strong>College</strong> <strong>of</strong> Medicine.<br />

367. Sublining CD79a+ B Cell Correlates with Joint Destruction in<br />

Rheumatoid Arthritis. Ying-qian Mo 2 , Lie Dai 1 , Dong-hui Zheng 3 ,<br />

Lang-jing Zhu 2 , Xiu-ning Wei 4 and Bai-yu Zhang 2 , 1 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Sun Yat-sen Memorial Hospital, Sun Yat-sen<br />

University, Guangzhou, China, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Sun Yat-sen Memorial Hospital, Sun Yat-sen University,<br />

Guangzhou, China, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Sun Yat-sen<br />

Memorial Hospital, Sun Yat-sen University, Guangzhou, China,<br />

4<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Sun Yat-sen Memorial Hospital,<br />

Sun Yat-sen University, Guangzhou, China.<br />

368. SUMO-2/3 Regulates Apoptosis and MMP Expression in RA<br />

Fibroblast-Like Synoviocytes. Svetlana Frank 3 , Simon Strietholt 3 ,<br />

Christine Seyfert 2 , Thomas Pauly 1 , George Kollias 4 , Thomas<br />

Pap 5 and Marvin A. Peters 3 , 1 Department <strong>of</strong> Nephrology and<br />

<strong>Rheumatology</strong>, Heinrich-Heine University, 2 Department <strong>of</strong><br />

Orthopaedic Surgery, Zeisigwaldkliniken, Chemnitz, Germany,<br />

3<br />

Institute <strong>of</strong> Experimental Musculoskeletal Medicine, University<br />

<strong>of</strong> Muenster, Muenster, Germany, 4 Institute <strong>of</strong> Immunology,<br />

Biomedical Sciences Research Center, Vari, Greece, 5 University<br />

Hospital Münster, Münster, Germany.<br />

369. The 6-O Extracellular Endosulfatases as Novel Regulators <strong>of</strong><br />

Synovitis. Yoon Hoon Hong 1 , Shuhei Otsuki 1 , Shugeru Miyaki 1 ,<br />

Beatriz Caramez 2 , Noboru Taniguchi 1 and Martin Lotz 1 , 1 The<br />

Scripps Research Institute, La Jolla, CA, 2 The Scripps Research<br />

Institute, La Jolla, CA.<br />

2010 Program Book 171


ACR Poster Session A<br />

370. The Critical Role <strong>of</strong> STAT3 in the Th17 Differentiation <strong>of</strong> RA<br />

Synovial T Cells. Ji Hyeon Ju, Mi-La Cho, Ji Min Kim, Yong-Geun<br />

Jeong, Seung-Ki Kwok, Kyung Su Park, Sung-Hwan Park and Ho-<br />

Youn Kim, <strong>College</strong> <strong>of</strong> Medicine, The Catholic University <strong>of</strong> Korea.<br />

371. TNFα-Driven IL-32 Expression in Rheumatoid Arthritis Synovial<br />

Tissue Amplifies an Inflammatory Cascade. Bas Heinhuis 4 ,<br />

Marije I. Koenders 4 , Piet L. van Riel 2 , Charles A. Dinarello 3 ,<br />

Mihai G. Netea 1 , Wim B. van den Berg 4 and Leo A. B. Joosten 1 ,<br />

1<br />

Department <strong>of</strong> Medicine, Radboud University Nijmegen<br />

Medical Centre, Nijmegen the Netherlands, 2 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands, 3 Division <strong>of</strong> Infectious Diseases,<br />

University <strong>of</strong> Colorado Denver, Aurora, CO, 4 <strong>Rheumatology</strong><br />

Research & Advanced Therapeutics, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />

Nijmegen the Netherlands.<br />

372. Underexpression <strong>of</strong> TIM-3 and Blunted Galectin-9-Induced<br />

Apoptosis <strong>of</strong> CD4+ T Cells in Rheumatoid Arthritis. Jaejoon<br />

Lee 4 , Ji-Min Oh 6 , Ji Won Hwang 6 , Eun-Jung Park 6 , Eun-Kyung<br />

Bae 3 , Joong Kyong Ahn 1 , Yoo Sun Lee 2 , Eun-Mi Koh 5 and<br />

Hoon-Suk Cha 4 , 1 Kangbook Samsung Hospital, Sungkyunkwan<br />

University School <strong>of</strong> Medicine, 2 Masan Samsung Hospital,<br />

Sungkyunkwan University School <strong>of</strong> Medicine, 3 Samsung<br />

Biomedical Research Institute, 4 Samsung Medical Center,<br />

Sungkyunkwan University School <strong>of</strong> Medicine, Seoul, Korea,<br />

Republic <strong>of</strong>, 5 Samsung Medical Center, Sungkyunkwan University<br />

School <strong>of</strong> Medicine, Seoul, Korea, Republic <strong>of</strong>, 6 Samsung<br />

Medical Center, Sungkyunkwan University School <strong>of</strong> Medicine.<br />

Rheumatoid Arthritis Treatment - Small Molecules, Biologics<br />

and Gene Therapy: Safety, Non-Biologic DMARDs, Switching<br />

Biologics I<br />

373. Appearance <strong>of</strong> Non-Rheumatoid Arthralgia after Tocilizumab<br />

Treatment in RA Patients with High Disease Activity. Osamu<br />

Saiki 2 and Hiroshi Uda 1 , 1 Sakai Onshinkai Hospital, Sakai, Japan,<br />

2<br />

Shiraishi Hospital, Imabari, Japan.<br />

374. Are Venous Thrombotic Events (VTE) Increased in Patients with<br />

Rheumatoid Arthritis (RA) Treated with Anti-TNF Therapy?<br />

Results from the British Society for <strong>Rheumatology</strong> Biologics<br />

Register (BSRBR). Rebecca Davies, James Galloway, Kath D.<br />

Watson, Mark Lunt, BSRBR Control Centre Consortium, Deborah<br />

P. M. Symmons, Kimme L. Hyrich and on Behalf <strong>of</strong> the British<br />

Society for <strong>Rheumatology</strong> Biologics Register, University <strong>of</strong><br />

Manchester.<br />

375. Assessment <strong>of</strong> Cardiovascular Markers after 24 Weeks <strong>of</strong><br />

Abatacept or Rituximab Therapy in Patients with Rheumatoid<br />

Arthritis. Sylvain Mathieu 3 , Gauthier Szymanski 1 , Jean-Jacques<br />

Dubost 2 , Natacha Mrozek 4 , Ge<strong>of</strong>froy Marceau 1 , Jean-Michel<br />

Ristori 4 and Martin Soubrier 4 , 1 Biochimie, CHU Gabriel<br />

Montpied, Clermont-Ferrand, France, 2 Humatologie, CHU<br />

Gabriel Montpied, Clermont-Ferrand, France, 3 Rhumatologie,<br />

CHU Gabriel Montpied, Clermont-Ferrand, France,<br />

4<br />

Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand,<br />

France.<br />

376. Before Beginning Anti-TNF, a Better Targeted Screening and<br />

a Twice Decrease Frequency <strong>of</strong> Latent Tuberculosis (TB) with<br />

IFN gamma Release Assays (IGRA) Compared with Tuberculin<br />

Skin Test. Results in 396 Patients from the ETAT Study. Xavier<br />

Mariette 3 , Gabriel Baron 3 , Frédéric Lioté 3 , Philippe Goupille 4 ,<br />

René-Marc Flipo 1 , Bernard Combe 2 , Florence Tubach 3 ,<br />

Dominique Emilie 3 , Dominique Salmon 3 , Marc Leman 3 , Guislaine<br />

Carcelain 3 and Philippe Ravaud 3 , 1 Lille University, 2 Montpellier<br />

University, 3 Paris University, 4 Tours University.<br />

377. Better Results Are Achieved with Switching Directly to<br />

Biologics Than Switching Via DMARD Combinations in RA<br />

Patients Who Have Failed Methotrexate as Their Initial<br />

DMARD: Real Life Data from NOR-DMARD. Elisabeth Lie 2 , Till<br />

Uhlig 2 , Knut Mikkelsen 3 , Synøve Kalstad 5 , Erik Rødevand 4 , Cecilie<br />

Kaufmann 1 and Tore K. Kvien 2 , 1 Buskerud Central Hospital,<br />

Norway, 2 Diakonhjemmet Hospital, Norway, 3 Lillehammer<br />

Hospital for Rheumatic Diseases, Lillehammer, Norway, 4 St.<br />

Olavs Hospital, Norway, 5 University Hospital <strong>of</strong> Northern<br />

Norway, Norway.<br />

378. Characterization <strong>of</strong> Laboratory Parameters in Long-Term<br />

Extension Studies <strong>of</strong> Tocilizumab in Rheumatoid Arthritis.<br />

William Rigby 3 , Daniel E. Furst 8 , Warren Rizzo 1 , Alexandra<br />

Balbir-Gurman 5 , Moshe Zilberstein 6 , Emma Vernon 7 , Joel M.<br />

Kremer 2 , Andrea Rubbert-Roth 9 and Ronald F. van Vollenhoven 4 ,<br />

1<br />

Advanced Arthritis Care, Scottsdale, AZ, 2 Albany Medical<br />

<strong>College</strong>, Albany, NY, 3 Dartmouth Medical School, Lebanon, NH,<br />

4<br />

Karolinska University Hospital, Stockholm, Sweden, 5 Rambam<br />

Health Care Campus, Haifa, Israel, 6 Roche, Nutley, NJ, 7 Roche,<br />

Welwyn, UK, 8 UCLA Medical Center, Los Angeles, CA, 9 University<br />

<strong>of</strong> Cologne, Cologne, Germany.<br />

379. Disease Activity, Calendar Year, and Physician Preference Are<br />

Associated with Switching <strong>of</strong> Biologic Agents for Reasons<br />

<strong>of</strong> Inadequate Efficacy. Jeffrey R. Curtis 3 , Ying Shan 4 , Joel M.<br />

Kremer 2 , Jeffrey D. Greenberg 1 and George Reed 4 , 1 Millburn,<br />

NJ, 2 The Center for <strong>Rheumatology</strong>, Albany, NY, 3 University<br />

<strong>of</strong> Alabama - Brimingham, Birmingham, AL, 4 University <strong>of</strong><br />

Massachusetts.<br />

380. Early Clinical Response to Treatment Predicts Long-Term<br />

Outcome in RA Patients: 5 Year Follow-Up Results <strong>of</strong> a MTX-<br />

Based Tight Control Strategy (CAMERA). M. F. Bakker 1 , J. W. G.<br />

Jacobs 1 , P. M. J. Welsing 1 , S. A. Vreugdenhil 4 , C. van Booma-<br />

Frankfort 2 , S. P. Linn-Rasker 3 , E. Ton 1 , F. P. J. G. Lafeber 1 and J. W.<br />

J. Bijlsma 1 , 1 <strong>Rheumatology</strong> & Clinical Immunology, University<br />

Medical Center Utrecht, The Netherlands, 2 <strong>Rheumatology</strong>,<br />

Diakonessenhuis Utrecht, The Netherlands, 3 <strong>Rheumatology</strong>,<br />

Meander Medical Center Amersfoort, The Netherlands,<br />

4<br />

<strong>Rheumatology</strong>, St. Antonius Hospital Nieuwegein, The<br />

Netherlands.<br />

381. Early Development <strong>of</strong> Antibodies Against Infliximab Predicts<br />

Withdrawal Due to Adverse Drug Reactions in Patients with<br />

Rheumatoid Arthritis. Sophine B. Krintel 2 , Veit Peter Grunert 4 ,<br />

Merete L. Hetland 1 , Julia S. Johansen 3 , Matthias Rothfuss 4<br />

and Ursula Klause 4 , 1 DANBIO Registry and Department <strong>of</strong><br />

<strong>Rheumatology</strong> at Copenhagen University Hospital, Hvidovre<br />

and Glostrup, Hvidovre, Denmark, 2 DANBIO Registry and<br />

Department <strong>of</strong> <strong>Rheumatology</strong> at Copenhagen University<br />

Hospital, Hvidovre and Glostrup and Department <strong>of</strong> Medicine<br />

at Copenhagen University Hospital, Herlev, Valby, Denmark,<br />

3<br />

Medicine and Oncology at Copenhagen University Hospital,<br />

Herlev, Denmark, 4 Roche Diagnostics GmbH, Penzberg,<br />

Penzberg, Germany.<br />

382. Effect <strong>of</strong> Switching Anti–Tumor Necrosis Factor Agents on<br />

Clinical Outcomes for Patients with Rheumatoid Arthritis.<br />

Amir Goran 2 , Sanjoy Roy 1 , Marco DiBonaventura 2 , Jochen Ertl 2<br />

and Mary Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Kantar<br />

Health, New York, NY.<br />

172<br />

2010 Program Book


ACR Poster Session A<br />

383. Efficacy and Safety <strong>of</strong> Ocrelizumab in Patients with Active<br />

Rheumatoid Arthritis Who Had an Inadequate Response to<br />

Methotrexate: Results from the Phase III STAGE Trial. William<br />

F. C. Rigby 2 , Hans Peter T. Tony 7 , Kurt R. Oelke 5 , Bernard G.<br />

Combe 8 , Andrew J. Laster 1 , Helen Travers 6 , Carlos A. Von<br />

Muhlen 4 , Elena Fisheleva 6 , Carmen Martin 6 and Wolfgang<br />

Dummer 3 , 1 Arthritis & Osteoporosis Consultants <strong>of</strong> the<br />

Carolinas, Charlotte, NC, 2 Dartmouth Medical School, Lebanon,<br />

NH, 3 Genentech Inc, San Francisco, CA, 4 Pontifical Catholic<br />

University <strong>of</strong> Rio Grande do Sul, Porto Alegre, Brazil, 5 Rheumatic<br />

Disease Center, Glendale, WI, 6 Roche, Welwyn Garden City,<br />

UK, 7 Universitätsklinikum Würzburg, Wuerzburg, Germany,<br />

8<br />

Université Montpellier, Montpellier, France.<br />

384. First Experiences with Pregnancies in RA Patients (pts)<br />

Receiving Tocilizumab (TCZ) Therapy. Andrea Rubbert-Roth 4 ,<br />

Philippe M. Goupille 1 , Shahrzad Moosavi 3 and Antony Hou 2 ,<br />

1<br />

Hopital Trousseau, Tours, France, 2 Inland <strong>Rheumatology</strong> Clinical<br />

Trials, Upland, CA, 3 Roche, Nutley, NJ, 4 University <strong>of</strong> Cologne,<br />

Cologne, Germany.<br />

385. Golimumab and Cardiovascular Disease Markers in<br />

Inflammatory Arthritides. Bruce Kirkham 3 , Mary C. Wasko 8 ,<br />

Joan M. Bathon 4 , Elizabeth C. Hsia 2 , Roy M. Fleischmann 6 , Mark<br />

C. Genovese 7 , Eric L. Matteson 5 , Hongjuan Liu 1 and Mahboob U.<br />

Rahman 2 , 1 Centocor Research and Development, Inc., 2 Centocor<br />

Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania School<br />

<strong>of</strong> Medicine, Malvern, PA, 3 Guy’s and St. Thomas’ Hospital,<br />

London, United Kingdom, 4 Johns Hopkins Univ., School <strong>of</strong><br />

Medicine, Baltimore, MD, 5 Mayo Clinic, Rochester, MN,<br />

6<br />

<strong>Rheumatology</strong> Associates, Dallas, TX, 7 Stanford University,<br />

Sunnyvale, CA, 8 Univ. <strong>of</strong> Pittsburgh.<br />

386. Golimumab and Cardiovascular Disease: Carotid Artery<br />

Ultrasound Evaluation and Cardiovascular Adverse Events.<br />

Joan M. Bathon 5 , Mary Chester Wasko 7 , Bruce Kirkham 4 , Pierre-<br />

Jean Touboul 6 , Elizabeth C. Hsia 3 , Weichun Xu 2 , Jiandong Lu 1 and<br />

Mahboob U. Rahman 3 , 1 Centocor Research and Development,<br />

Inc., Malvern, PA, 2 Centocor Research and Development,<br />

Inc., 3 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />

Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 4 Guy’s & St.<br />

Thomas’ Hospital, London, United Kingdom, 5 Johns Hopkins<br />

University, Baltimore, MD, 6 Paris-Diderot University, London,<br />

United Kingdom, 7 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

387. Hepatitis B Virus Reactivation in Rheumatoid Arthritis and<br />

Ankylosing Spondylitis Patients Using Anti-TNFα Agents: A<br />

Retrospective Analysis <strong>of</strong> 52 Cases with or without Anti-Viral<br />

Prophylaxis. Han Hee Ryu 5 , Eun Young Lee 5 , Kichul Shin 4 , In<br />

Ah Choi 5 , Chul Kim 5 , Yoon Jong Lee 5 , Bin Yoo 7 , Min-Chan Park 6 ,<br />

Yong-Beom Park 6 , Sang-Cheol Bae 1 , Wan Hee Yoo 3 , Sung Il<br />

Kim 2 , Jun Wan Kim 5 , Eun Bong Lee 5 and Yeong Wook Song 5 ,<br />

1<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University Hospital for<br />

Rheumatic Diseases, Seoul, Korea, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Internal Medicine Pusan National University<br />

Hospital Institutes, Busan, Korea, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Internal Medicine, Chonbuk National University<br />

Medical School and Research Institute <strong>of</strong> Clinical Medicine,<br />

Jeonju, Korea, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Seoul National University Hospital, Seoul,<br />

Korea, Republic <strong>of</strong>, 5 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Seoul National University Hospital, Seoul,<br />

Korea, 6 Divsion <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul, Korea,<br />

7<br />

Divsion or <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />

University <strong>of</strong> Ulsan, Asan Medical Center, Seoul, Korea.<br />

388. Individual Dose Response Relation for MTX: Prediction <strong>of</strong> the<br />

Optimally Effective Dose in Patients with Early Rheumatoid<br />

Arthritis. Paco M. J. Welsing 1 , Marije F. Bakker 2 and Johannes<br />

W. G. Jacobs 2 , 1 <strong>Rheumatology</strong> & Clinical Immunology and<br />

Julius Center for Health Sciences and Primary Care, University<br />

Medical Center Utrecht, The Netherlands, 2 <strong>Rheumatology</strong> &<br />

Clinical Immunology, University Medical Center Utrecht, The<br />

Netherlands.<br />

389. Long-Term Effect <strong>of</strong> Anti TNF-Alpha Therapies on Insulin<br />

Resistance, Body Composition and Adipokines in Rheumatoid<br />

Arthritis Patients. Esmeralda Delgado-Frias 3 , Vanesa Hernández-<br />

Hernández 2 , Iván Ferraz-Amaro 1 , Juan Carlos Quevedo 1 , Jose R.<br />

Muñiz, Maria T. Arce-Franco, Judith Lopez-Fernandez, Andres<br />

Franco-Maside and Federico Diaz-Gonzalez, 1 La Laguna, S/C<br />

Tenerife, Spain, 2 La Laguna, S/C Tenerfe, Spain, 3 Hospital<br />

Universitario de Canarias, Tenerife, La Laguna, S/C Tenerife,<br />

Spain.<br />

390. Long-Term Safety <strong>of</strong> Abatacept: Integrated Analysis <strong>of</strong><br />

Clinical Program Data <strong>of</strong> up to 7 Years <strong>of</strong> Treatment. Marc<br />

C. Hochberg 7 , Rene Westhovens 4 , Richard Aranda 2 , Sheila M.<br />

Kelly 2 , Nadar Khan 2 , Keqin Qi 2 , Ramesh Pappu 2 , Ingrid Delaet 2 ,<br />

Allison Luo 2 , Anne Torbeyns 3 , Larry W. Moreland 6 , Roger B.<br />

Cohen 5 , Sheila Gujrathi 2 and Michael E. Weinblatt 1 , 1 Brigham<br />

& Womens Hospital, Boston, MA, 2 Bristol-Myers Squibb,<br />

Princeton, NJ, 3 Bristol-Myers Squibb, Braine-l’Alleud, Belgium,<br />

4<br />

Catholic University <strong>of</strong> Leuven, Leuven, Belgium, 5 Fox Chase<br />

Cancer Center, Philadelphia, PA, 6 Univ <strong>of</strong> Pittsburgh Med Ctr,<br />

Pittsburgh, PA, 7 University <strong>of</strong> Maryland, Baltimore, MD.<br />

391. Long-Term Safety <strong>of</strong> Rituximab: Follow-Up <strong>of</strong> the Rheumatoid<br />

Arthritis Clinical Trials and Retreatment Population. Ronald<br />

van Vollenhoven 5 , Paul Emery 2 , Clifton O. Bingham 4 , Edward<br />

C. Keystone 9 , Roy M. Fleischmann 8 , Daniel E. Furst 7 , Katherine<br />

Macey 6 , Marianne Sweetser 1 , Patricia Lehane 6 , Pam Farmer 3<br />

and Simon G. Long 6 , 1 Biogen Idec Inc, 2 Chapel Allerton Hospital,<br />

Leeds, United Kingdom, 3 Genentech Inc, 4 Johns Hopkins<br />

University, Baltimore, MD, 5 Karolinska Institute, Stockholm,<br />

Sweden, 6 Roche Products Ltd, 7 University <strong>of</strong> California Los<br />

Angeles Medical School, Los Angeles, CA, 8 University <strong>of</strong> Texas<br />

Southwestern Medical Center, Dallas, TX, 9 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada.<br />

392. Low-Dose Glucocorticoid Chronotherapy <strong>of</strong> Rheumatoid<br />

Arthritis: 12 Week Efficacy and Safety <strong>of</strong> Modified-Release<br />

(MR) Prednisone. Frank Buttgereit 2 , Daksha P. Mehta 3 , John R.<br />

Kirwan 1 , Jacek Szechinski 7 , Maarten Boers 12 , Rieke Alten 10 , Jerzy<br />

Supronik 8 , István Szombati 9 , Ulrike Römer 4 , Stephan Witte 5 ,<br />

Amy Grahn 6 and Kenneth G. Saag 11 , 1 Bristol Royal Infirmary,<br />

Bristol, United Kingdom, 2 Charite University Med-Berlin,<br />

Berlin, Germany, 3 Ctr Arthritis & Osteoporosis, Elizabethtown,<br />

KY, 4 Horizon Pharma GmbH, Mannheim, Germany, 5 Horizon<br />

Pharma GmbH, Mannheim, Germany, 6 Horizon Pharma, Inc.,<br />

Northbrook, IL, 7 Med. University Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Wroclaw, Poland, 8 NZOZ Centrum Medyczne, Bialystok, Poland,<br />

9<br />

OEC, Budapest, Hungary, 10 Schlosspark-Klinik, UnivMed, Berlin,<br />

Germany, 11 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

12<br />

VU University Medical Center, Amsterdam, The Netherlands.<br />

393. Metanalysis on the Effect <strong>of</strong> TNF-Inhibitors on Lipid Pr<strong>of</strong>ile.<br />

Claire Immediato Daien 1 , Yohan Duny 3 , Thomas Barnetche 2<br />

and Jacques Morel 1 , 1 Département de Rhumatologie,<br />

Hôpital Lapeyronie, Montpellier, France, 2 Département de<br />

Rhumatologie, Hôpital Pellegrin, Bordeaux, France, 3 Institut<br />

Universitaire de Recherche Clinique, Service de Biostatistiques,<br />

Epidémiologie et Santé Publique, Montpellier, France.<br />

2010 Program Book 173


ACR Poster Session A<br />

174<br />

394. Methothrexate Directly Inhibits RANKL Expression and<br />

Osteoclasts Formation in Very Early Arthritis. Shankar Revu,<br />

Petra Neregård, Erik Afklint and Anca Irinel Catrina, Department<br />

<strong>of</strong> Medicine, <strong>Rheumatology</strong> Unit, Karolinska University Hopsital<br />

and Karolinska Institute, Stockholm, Sweden.<br />

395. Non-Infectious Pulmonary Complications <strong>of</strong> Biologic Agents<br />

for Rheumatic Diseases – A Systematic Literature Review.<br />

Andreas Hadjinicolaou 2 , Shweta Bhagat 1 and Andrew Ostor 1 ,<br />

1<br />

<strong>Rheumatology</strong> Research Unit, Addenbrooke’s Hospital,<br />

Cambridge, Cambridge, United Kingdom, 2 University <strong>of</strong><br />

Cambridge, United Kingdom.<br />

396. Parenteral MTX as an Initial Treatment Strategy for Early<br />

Rheumatoid Arthritis: Results from a Nationwide Cohort.<br />

Vivian P. Bykerk 2 , David S. Rowe 3 , Janet E. Pope 5 , CATCH<br />

Scientific Advisory Committee 1 , Ashley Bonner 1 and J. Carter<br />

Thorne 4 , 1 Canada, 2 Mt Sinai Hospital, Toronto, ON, Canada,<br />

3<br />

Saba University School <strong>of</strong> Medicine, Stouffville, ON, Canada,<br />

4<br />

Southlake Regional Health Care, Newmarket, ON, Canada, 5 St<br />

Joseph Health Care London, London, ON, Canada.<br />

397. Polymorphisms in the Folate Metabolism Gene MTHFR<br />

(C677T and A1298C) Are Not Associated with Methotrexate<br />

Adherence: Findings from the Veteran’s Affairs Rheumatoid<br />

Arthritis (VARA) Registry. Lisa A. Davis 2 , Grant W. Cannon 5 ,<br />

Roger Wolff 6 , Leah Haverhals 3 , Ted R. Mikuls 7 , Andreas M.<br />

Reimold 1 , Gail S. Kerr 8 , John S. Richards 8 , Dannette S. Johnson 4<br />

and Liron Caplan 2 , 1 Dallas VAMC, Dallas, TX, 2 Denver VAMC,<br />

Aurora, CO, 3 Denver VAMC, 4 Jackson VAMC, Jackson, MS, 5 Salt<br />

Lake City VAMC, Salt Lake City, UT, 6 Salt Lake City VAMC, 7 Univ<br />

<strong>of</strong> Nebraska Med Ctr, Omaha, NE, 8 Washington, D.C. VAMC,<br />

Washington, DC.<br />

398. Pooled Analysis <strong>of</strong> Observational Studies on Lymphoma<br />

Incidence among Rheumatoid Arthritis (RA) Patients Initiating<br />

Etanercept Therapy. Peter McCroskery 2 , Virgil C. Dias 2 , Scott<br />

Stryker 3 , Bojena Bitman 3 , Sean Z. Zhao 2 and Debra J. Zack 1 ,<br />

1<br />

Amgen Inc, Thousand Oaks, CA, 2 Amgen Inc., Thousand Oaks,<br />

CA, 3 Amgen Inc.<br />

399. Post-Marketing Surveillance Program <strong>of</strong> Tocilizumab for<br />

RA in Japan – Interim Analyses <strong>of</strong> 3,881 Patients. Takao<br />

Koike 2 , Masayoshi Harigai 8 , Shigeko Inokuma 3 , Naoki<br />

Ishiguro 6 , Junnosuke Ryu 7 , Tsutomu Takeuchi 5 , Syuji Takei 4 ,<br />

Yoshiya Tanaka 10 , Hisashi Yamanaka 9 and Kyoko Ito 1 , 1 Chugai<br />

Pharmaceutical Co.Ltd, 2 Hokkaido University, Japan, 3 Japanese<br />

Red Cross Medical Center, 4 Kagoshima University, Kagoshima<br />

City, Japan, 5 Keio University, Toyko, Japan, 6 Nagoya University,<br />

7<br />

Nihon University, 8 Tokyo Medical and Dental University, Tokyo,<br />

Japan, 9 Tokyo Womens Med Univ, Shinjuku-ku, Tokyo, Japan, 10 U<br />

Occupa & Environ Hlth, Kitakyushu, Japan.<br />

400. Predictive Risk Factors <strong>of</strong> Severe Infections in RA Patients<br />

Treated with Abatacept in Real Life: Results from the<br />

Orencia and Rheumatoid Arthritis (ORA) Registry. Jacques-<br />

Eric Gottenberg 11 , Philippe Ravaud 5 , Thomas Bardin 7 , Patrice<br />

Cacoub 6 , Aain Cantagrel 12 , Bernard Combe 9 , Maxime Dougados 3 ,<br />

René-Marc Flipo 8 , Bertrand Godeau 4 , Loic Guillevin 3 , Eric<br />

Hachulla 8 , Xavier Le Loët 10 , Thierry Schaeverbeke 2 , Jean<br />

Sibilia 11 , Gabriel Baron 5 and Xavier Mariette 1 , 1 Bicetre Hospital,<br />

2<br />

Bordeaux Hospital, 3 Cochin Hospital, 4 Henri Mondor Hospital,<br />

5<br />

Hotel Dieu Hospital, 6 La Pitié Hospital, 7 Lariboisière Hospital,<br />

8<br />

LIlle Hospital, 9 Montpellier Hospital, 10 Rouen Hospital,<br />

11<br />

Strasbourg Hospital, 12 Toulouse Hospital.<br />

401. Pregnancy Outcomes in Patients with Autoimmune Diseases<br />

Treated with Rituximab. Eliza F. Chakravarty 1 , Elaine Murray 2 ,<br />

Ariella Kelman 2 and Pamela Farmer 3 , 1 Mountain View, CA,<br />

2<br />

Genentech, South San Francisco, CA, 3 Genentech.<br />

2010 Program Book<br />

402. Pulmonary Function in Patients with Rheumatoid Arthritis<br />

Treated with Anti-TNF Biologic Agents. Andrew J. Odden 1 , Ann<br />

J. Impens 2 , Elena Schiopu 2 , Kevin Flaherty 1 and Kristine Phillips 2 ,<br />

1<br />

University <strong>of</strong> Michigan, 2 University <strong>of</strong> Michigan, Ann Arbor, MI.<br />

403. Rate <strong>of</strong> Serious Infections in RA Patients Who Subsequently<br />

Receive Other Biologic Therapies after Discontinuing<br />

Rituximab Treatment. Mark C. Genovese 8 , Ferdinand<br />

Breedveld 4 , Paul Emery 2 , Stanley B. Cohen 6 , Ed C. Keystone 9 ,<br />

Eric L. Matteson 5 , Laura Burke 7 , Akiko Chai 3 , William Reiss 3 ,<br />

Marianne Sweetser 1 and Tim Shaw 7 , 1 Biogen Idec, 2 Chapel<br />

Allerton Hospital, Leeds, United Kingdom, 3 Genentech, 4 Leiden<br />

Univ, 5 Mayo Clinic, Rochester, MN, 6 <strong>Rheumatology</strong> Associates,<br />

Dallas, TX, 7 Roche, 8 Stanford Univ, Sunnyvale, CA, 9 University <strong>of</strong><br />

Toronto, Toronto, ON, Canada.<br />

404. Rates <strong>of</strong> Tuberculosis and Nontuberculous Mycobacterial<br />

Disease among Rheumatoid Arthritis Patients Who Use<br />

Anti-Tumor Necrosis Factor alpha Therapy; from the SAfety<br />

<strong>of</strong> Biologic ThERapy (SABER) Study. K. L. Winthrop 2 , John<br />

Baddley 4 , Lang Chen 4 , Liyan Liu 1 , Carlos G. Grijalva 8 , Nivedita M.<br />

Patkar 3 , Fenlong Xie 4 , Elizabeth Delzell 4 , Timothy Beukelman 6 ,<br />

Lisa J. Herrinton 1 , Kenneth G. Saag 7 and Jeffrey R. Curtis 5 ,<br />

1<br />

Kaiser-Permanente, 2 OSHU, 3 Univ <strong>of</strong> AL at Birmingham,<br />

Birmingham, AL, 4 Univ <strong>of</strong> AL at Birmingham, 5 University<br />

<strong>of</strong> Alabama-Brimingham, Birmingham, AL, 6 University <strong>of</strong><br />

Alabama-Birmingham, Birmingham, AL, 7 University <strong>of</strong> Alabama-<br />

Birmingham, Birmingham, AL, 8 Vanderbilt.<br />

405. Real Life Analysis <strong>of</strong> the Romanian Experience in Switching<br />

from Anti-TNF Based Therapy to Rituximab. Ioan Ancuta 1 ,<br />

Catalin Codreanu 2 , Ruxandra Maria Ionescu 4 , Horatiu Bolosiu 5 ,<br />

Magda Parvu 3 and Lia Georgescu 6 , 1 ”Dr. I. Cantacuzino” Hospital,<br />

Bucharest, Romania, 2 ”Dr. I. Stoia” Center for Rheumatic<br />

Diseases, Bucharest, Romania, 3 ”N. Gh. Lupu” Clinical Hospital,<br />

Bucharest, Romania, 4 ”Sfanta Maria” Clinical Hospital,<br />

Bucharest, Romania, 5 <strong>Rheumatology</strong> Clinic, Cluj - Napoca,<br />

Romania, 6 <strong>Rheumatology</strong> Clinic, Tirgu-Mures, Targu - Mures,<br />

Romania.<br />

406. Real Life Treatment with Rituximab in TNF Blocker Non-<br />

Responders Is Superior to Treatment with a Second TNF<br />

Blocker. Joern Kekow 4 , Ulf Müller-Ladner 2 , Hendrik Schulze-<br />

Koops 1 , Ralf Link 3 , Steffen Breuer 3 and Monika Kobialko 3 ,<br />

1<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Munich, Germany,<br />

2<br />

Justus-Liebig University Giessen, Kerckh<strong>of</strong>f Clinic, Bad Nauheim,<br />

Germany, 3 Roche Pharma AG, Grenzach-Wyhlen, Germany,<br />

4<br />

Specialized Hospital for <strong>Rheumatology</strong> & Orthopaedics,<br />

Vogelsang-Gommern, Vogelsang-Gommern, Germany.<br />

407. Risk <strong>of</strong> Malignancies in Patients with Rheumatoid Arthritis<br />

Treated with Biologic Therapy: Meta-Analysis <strong>of</strong> Controlled<br />

Trials. Maria A. Lopez-Olivo 4 , Juan A. Martinez-Lopez 2 , Jean H.<br />

Tayar 7 , Jose Polo Cueto 5 , Eduardo N. Pollono 3 , M. Rosa Gonzales-<br />

Crespo 1 , Stephanie Fulton 6 and Maria E. Suarez-Almazor 7 ,<br />

1<br />

Hospital 12 de Octubre, 2 Spanish Society <strong>of</strong> <strong>Rheumatology</strong>,<br />

Spain, 3 Texas Tech University Health Science Center - Paul Foster<br />

School <strong>of</strong> Medicine, 4 The University <strong>of</strong> Texas M.D. Anderson<br />

Cancer Center, Houston, TX, 5 The University <strong>of</strong> Texas MD<br />

Anderson Cancer Center, 6 University <strong>of</strong> Texas, MD Anderson<br />

Cancer Center, Houston, TX, 7 UT M D Anderson Cancer Ctr,<br />

Houston, TX.<br />

408. Risk <strong>of</strong> Malignancy during Anti-TNF alfa Therapy in Patients<br />

with Rheumatoid Arthritis: Systematic Review and Meta-<br />

Analysis <strong>of</strong> Registries, Long-Term Extension Studies and<br />

Randomized Controlled Trials. Pierre Le Blay 3 , Gael Mouterde 4 ,<br />

Thomas Barnetche 1 and Bernard G. Combe 2 , 1 Bordeaux<br />

University Hospital, 2 Hopital Lapeyronie, Montpellier, France,<br />

3<br />

Hopital Lapeyronie, France, 4 Hopital Lapeyronie.


ACR Poster Session A<br />

409. Rituximab vs TNF-Inhibitor Cycling in Patients Who Previously<br />

Failed to TNF-Inhibitors: The MIRAR Study. Juan-Jesús Gómez-<br />

Reino 1 , Raimon Sanmartí 2 , Ana-Belen Romero 3 and Laura<br />

Monclus 3 , 1 Hospital Clínico Universitario / Xeral de Galicia,<br />

Santiago de Compostela, 2 Hospital Clinic, Barcelona, 3 Roche.<br />

410. Rituximab vs. Anti-TNF after Failure <strong>of</strong> Anti-TNF: An<br />

Observational Study. Katerina Chatzidionysiou 2 and Ronald<br />

Van Vollenhoven 1 , 1 Karolinska University Hospital, Stockholm,<br />

Sweden, 2 Karolinska University Hospital, Stockholm.<br />

411. Safety and Tolerability <strong>of</strong> Tocilizumab in Long-Term Extension<br />

Studies <strong>of</strong> Rheumatoid Arthritis. Mark C. Genovese 5 , Anthony<br />

Sebba 7 , Andrea Rubbert-Roth 6 , Juan J. Scali 1 , Moshe Zilberstein 3 ,<br />

Emma Vernon 4 and Ronald F. van Vollenhoven 2 , 1 Durand<br />

University Hospital, Buenos Aires, Argentina, 2 Karolinska<br />

University Hospital, Stockholm, Sweden, 3 Roche, Nutley, NJ,<br />

4<br />

Roche, Welwyn, UK, 5 Stanford University Medical Center, Palo<br />

Alto, Palo Alto, CA, 6 University <strong>of</strong> Cologne, Cologne, Germany,<br />

7<br />

University <strong>of</strong> South Florida, Palm Harbor, FL.<br />

412. Safety <strong>of</strong> Combination Therapies in Early RA: A Systematic<br />

Comparison between Combination DMARDs and TNF<br />

Inihibitors with Methotrexate. Margaret H. Y. Ma 2 , Andrew P.<br />

Cope 1 and David L. Scott 2 , 1 Surrey, United Kingdom, 2 Academic<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, King’s <strong>College</strong> London.<br />

413. Scleritis: A New Paradoxical Effect <strong>of</strong> Etanercept? A Series <strong>of</strong><br />

3 Cases and a Systematic Literature Review <strong>of</strong> Etanercept-<br />

Associated Inflammatory Eye Disease. Cécile Gaujoux-Viala 1 ,<br />

Cecilia Giampietro 2 , Thomas Gaujoux 3 , Hang-Korng Ea 4 ,<br />

Philippe Orcel 4 and Frédéric Lioté 4 , 1 Paris 6 – Pierre et Marie<br />

Curie University; <strong>Rheumatology</strong>, Pitié-Salpêtrière Hospital,<br />

Paris, France, 2 Paris 6 – Pierre et Marie Curie University;<br />

<strong>Rheumatology</strong>, Pitié-Salpêtrière Hospital, Paris, France<br />

2<br />

University <strong>of</strong> L’Aquila, L’Aquila, Italy, 3 Paris 7 University,<br />

Medicine Faculty; AP-HP, Lariboisière Hospital, Ophtalmology<br />

Department, Paris, France, 4 Paris Diderot University, School<br />

<strong>of</strong> Medicine; Lariboisière Hospital, AP-HP, <strong>Rheumatology</strong><br />

Department, Paris, France.<br />

414. Serious Infections with Ocrelizumab in Rheumatoid Arthritis:<br />

Pooled Results from Double-Blind Periods <strong>of</strong> the Ocrelizumab<br />

Phase III RA Program. Paul Emery 3 , William F. C. Rigby 5 , Paul P.<br />

Tak 1 , T. Dörner 4 , Ewa Olech 9 , Mark C. Genovese 11 , G. Ferraccioli 2 ,<br />

Emilio Martin-Mola 8 , Maxime Dougados 7 , Helen Travers 10 , E.<br />

Fisheleva 10 and Wolfgang Dummer 6 , 1 Academic Med Ctr/Univ<br />

<strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Catholic Univ,<br />

3<br />

Chapel Allerton Hospital, Leeds, United Kingdom, 4 Charité<br />

Univ Hospital, 5 Dartmouth-Hitchcock Med Ctr, Lebanon,<br />

NH, 6 Genentech, 7 Hospital Cochin, Paris, France, 8 Hospital<br />

Universitario La Paz, Madrid, Spain, 9 Oklahoma Medical<br />

Research Foundation, Oklahoma City, OK, 10 Roche, 11 Stanford<br />

Univ, Sunnyvale, CA.<br />

415. Subsequent Therapy <strong>of</strong> Patients with Biologic Response<br />

Modifiers after a Diagnosis <strong>of</strong> Coccidiomycosis Infection. Sara<br />

Taroumian 3 , Jeffrey R. Lisse 5 , Eric P. Gall 5 , Rafael G. Grau 5 , Neil<br />

M. Ampel 2 , Susan E. Hoover 4 , James Yanes 4 and Berchman Vaz 1 ,<br />

1<br />

Tucson, AZ, 2 Southern Arizona VA Health Care System, Tucson,<br />

AZ, 3 The University <strong>of</strong> Arizona Department <strong>of</strong> Internal Medicine,<br />

Tucson, AZ, 4 The University <strong>of</strong> Arizona Section <strong>of</strong> Infectious<br />

Diseases, Tucson, AZ, 5 The University <strong>of</strong> Arizona Section <strong>of</strong><br />

<strong>Rheumatology</strong>, Arizona Arthritis Center, Tucson, AZ.<br />

416. Switching Patients (pts) with Rheumatoid Arthritis (RA) from<br />

Intravenous (IV) to Subcutaneous (SC) Abatacept Is Well<br />

Tolerated and Sustains Previously Established Efficacy. Edward<br />

C. Keystone 9 , Joel M. Kremer 6 , Anthony S. Russell 7 , Jane H.<br />

Box 1 , Carlos Abud-Mendoza 5 , Mario Alberto Garza Elizondo 4 ,<br />

Allison Luo 2 , Richard Aranda 2 , Ingrid Delaet 2 , Rene Swanink 3 ,<br />

Sheila Gujrathi 2 and Michael E. Luggen 8 , 1 Box Arthritis and<br />

<strong>Rheumatology</strong> <strong>of</strong> the Carolinas, Charlotte, NC, 2 Bristol-Myers<br />

Squibb, Princeton, NJ, 3 Bristol-Myers Squibb, Braine-l’Alleud,<br />

Belgium, 4 Faculty <strong>of</strong> Medicine, Universidad Autónoma de Nuevo<br />

León, Monterrey, NL, Mexico, 5 Regional Unit <strong>of</strong> <strong>Rheumatology</strong>,<br />

Faculty <strong>of</strong> Medicine and Central Hospital, University <strong>of</strong> San Luis<br />

Potosí, San Luis Potosi, Mexico, 6 The Center for <strong>Rheumatology</strong>,<br />

Albany, NY, 7 University <strong>of</strong> Alberta, Edmonton, AB, Canada,<br />

8<br />

University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH,<br />

9<br />

University <strong>of</strong> Toronto and Mount Sinai Hospital, Toronto, ON,<br />

Canada.<br />

417. The Effect on MTX Polyglutamate Concentration Pr<strong>of</strong>ile<br />

after Changing from Oral to Subcutaneous Methotrexate in<br />

Rheumatoid Arthritis. Lisa K. Stamp 4 , John L. O’Donnell 1 , Peter<br />

Chapman 3 , Mei Zhang 2 , Jill James 3 , Christopher Frampton 5 and<br />

Murray Barclay 5 , 1 Canterbury Health Laboratories, Christchurch,<br />

New Zealand, 2 Canterbury Health Laboratories, 3 Christchurch<br />

Hospital, 4 University <strong>of</strong> Otago, Christchurch, New Zealand,<br />

5<br />

University <strong>of</strong> Otago.<br />

418. TNF Switch after Failure <strong>of</strong> One or More TNF Inhibitors –<br />

Results <strong>of</strong> an Observational Study. Katerina Chatzidionysiou 2<br />

and Ronald Van Vollenhoven 1 , 1 Karolinska University Hospital,<br />

Stockholm, Sweden, 2 Karolinska University Hospital, Stockholm.<br />

419. TNF Therapy and the Risk <strong>of</strong> Serious Infection and Malignancy<br />

in Patients with Early Rheumatoid Arthritis: A Meta-Analysis<br />

<strong>of</strong> Randomized Controlled Trials. Andrew E. Thompson 2 , Janet<br />

E. Pope 1 and Scott W. Rieder 3 , 1 St Joseph Health Care London,<br />

London, ON, Canada, 2 University <strong>of</strong> Western Ontario, London,<br />

ON, Canada, 3 University <strong>of</strong> Western Ontario.<br />

420. Treatment with Infliximab Improves Clinical Response and<br />

Physical Function in Patients with Moderate or Severe<br />

Rheumatoid Arthritis Actively Switch from Etanercept or<br />

Adalimumab Therapy. Roy M. Fleischmann 8 , John A. Goldman 2 ,<br />

Marjatta Leirisalo-Repo 4 , Ellen I. Zanetakis 7 , Hisham S. El-Kadi 1 ,<br />

Herbert L. Kellner 6 , Rebecca Bolce 3 , Jim Wang 5 , Raphael<br />

Dehoratius 3 and Dennis Decktor 3 , 1 Arthritis and Osteoporosis<br />

Association, Freehold, NJ, 2 Atlanta Center for Clinical Research,<br />

3<br />

Centocor Ortho Biotech Services, LLC, 4 Helsinki University<br />

Central Hospital, Helsinki, Finland, 5 Johnson and Johnson<br />

Pharmaceutical Research and Development, LLC, 6 Medizinische<br />

Poliklinik/Munich University Hospital, Munchen, Germany,<br />

7<br />

Oklahoma Center for Arthritis Therapy, Tulsa, OK, 8 University <strong>of</strong><br />

Texas SW Medical Center, Dallas, TX.<br />

421. Varicella Zoster Virus (VZV) Infections Are Increased in<br />

Patients with Rheumatoid Arthritis (RA) Treated with Anti-TNF<br />

Therapy; Results from the British Society for <strong>Rheumatology</strong><br />

Biologics Register (BSRBR). James Galloway 1 , Alison Moseley 2 ,<br />

Lousie Mercer 2 , Will Dixon 2 , Bo Fu 2 , Andrew Ustianowski 2 ,<br />

Kath Watson 2 , Mark Lunt 2 , BSRBR Control Centre Consortium 2 ,<br />

Kimme Hyrich 2 , Deborah Symmons 2 and on Behalf <strong>of</strong> the British<br />

Society for <strong>Rheumatology</strong> Biologics Register 2 , 1 University <strong>of</strong><br />

Manchester, Manchester, United Kingdom, 2 University <strong>of</strong><br />

Manchester.<br />

2010 Program Book 175


ACR Poster Session A<br />

Systemic Lupus Erythematosus - Animal Models<br />

422. Altered microRNA Expression in the Murine Tri-Congenic<br />

B6.Sle123 Model. Barry Garchow 1 , Yiu Tak Leung 3 , Roberto<br />

Caricchio 2 and Marianthi Kiriakidou 1 , 1 Department <strong>of</strong> Medicine,<br />

University <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Philadelphia,<br />

PA, 2 Temple Univ Med Office Bldg, Philadelphia, PA, 3 Thomas<br />

Jefferson University Hospital, Philadelphia, PA.<br />

423. Amelioration <strong>of</strong> Lupus Nephritis by a Macromolecular Prodrug<br />

<strong>of</strong> Dexamethasone in NZB/W F1 Mice. Fang Yuan 2 , Richard K.<br />

Nelson 2 , Xin-ming Liu 2 , Karen A. Gould 2 and Dong Wang 1 , 1 Univ<br />

Nebraska Med Ctr, Omaha, NE, 2 University <strong>of</strong> Nebraska Medical<br />

Center.<br />

424. An Intrinsic B Cell Defect That Affects Toll-Like Receptor<br />

Signaling Supports Autoimmunity in New Zealand Black<br />

Chromosome 13 Congenic Mice. Christina Loh 2 , Evelyn Pau 3 ,<br />

Nan-Hua Chang 1 and Joan E. Wither 2 , 1 University Health<br />

Network, 2 University <strong>of</strong> Toronto, Toronto, ON, Canada,<br />

3<br />

University <strong>of</strong> Toronto.<br />

425. Breach <strong>of</strong> B Cell Tolerance in New Zealand Black Chromosome<br />

1 Congenic Mice. Nan-Hua Chang 1 , Evelyn Pau 3 , Christina Loh 3<br />

and Joan E. Wither 2 , 1 Toronto Western Research Institute,<br />

Toronto, ON, Canada, 2 University Health Network, Toronto, ON,<br />

Canada, 3 University <strong>of</strong> Toronto.<br />

426. Dysfunction <strong>of</strong> Hematopoietic Stem Cells in Lupus Mice. Haitao<br />

Niu 2 , Luokun Xie 3 , Laurence Marguerite Morel 4 , Betty Diamond 1<br />

and Yong-rui Zou 3 , 1 Feinstein Institute for Medical Research,<br />

Manhasset, NY, 2 The Feinstein Institute for Medical Research,<br />

Manhasset, NY, 3 The Feinstein Institute for Medical Research,<br />

4<br />

University <strong>of</strong> Florida.<br />

427. Engraftment <strong>of</strong> PBMC from SLEand ACL Donors into BALB-<br />

Rag2 -/- IL2Rgc - KO Mice: A Promising Model for Studying<br />

SLE. Danieli Andrade 1 , Milena Vukelic 2 , Patricia B. Redecha 1 ,<br />

Xiaoping Qing 1 , Giorgio Perino 3 , Jane E. Salmon 2 and Gloria C.<br />

Koo 4 , 1 Hospital for Special Surgery, NY, NY, 2 Hospital for Special<br />

Surgery, New York, NY, 3 Hospital for Special Surgery, NY, NY,<br />

4<br />

Hospital for Special Surgery, New York, NY.<br />

428. Enhancement <strong>of</strong> IL-17 and Interferon-gamma Inflammatory<br />

Pathways in IRF9-/- MRL/lpr Mice with Disrupted Type I<br />

Interferon Signaling. Alvina D. Chu 2 , Nicole H. Kattah 3 , Michael<br />

T. Wong 3 , Catherine Tadina 3 and Paul J. Utz 1 , 1 Stanford Univ Schl<br />

<strong>of</strong> Med, Stanford, CA, 2 Stanford University School <strong>of</strong> Medicine,<br />

Palo Alto, CA, 3 Stanford University School <strong>of</strong> Medicine.<br />

429. Epistatic Interactions between Lupus Susceptibility Loci on<br />

New Zealand Black Chromosomes 1 and 13 Lead to Marked<br />

Expansion <strong>of</strong> Dendritic Cell Populations but Have Little Effect<br />

on Autoimmunity. Yui Ho Cheung 2 , Evelyn Pau 2 and Joan E.<br />

Wither 1 , 1 University Health Network, Toronto, ON, Canada,<br />

2<br />

University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

430. Hypercholesterolaemia and Autoimmunity Interact in a<br />

Mouse Model <strong>of</strong> Systemic Lupus Erythematosus To Enhance<br />

Both Atherosclerosis and Renal Inflammation, but by Distinct<br />

Mechanisms. Myles J. Lewis 2 , Talat H. Malik 2 , Liliane M. Fossati-<br />

Jimack 2 , Daniele Carassiti 2 , Terence H. Cook 2 , Dorian O. Haskard 1<br />

and Marina Botto 1 , 1 Imperial <strong>College</strong>, London, United Kingdom,<br />

2<br />

Imperial <strong>College</strong>.<br />

431. IL-17 Promotes Autoimmunity in Pristane-Induced Lupus.<br />

Elaine V. Lourenco, Chunlin Cai, Bevra H. Hahn and Antonio La<br />

Cava, UCLA.<br />

432. IL-21 Promotes Autoimmune Features in Chronic Graft Versus<br />

Host Disease by Enhancing T Follicular Helper Development<br />

and B Cell Response. Vinh Nguyen 3 , Irina G. Luzina 1 , Qing Chen 1 ,<br />

Horea Rus 1 and Violeta Rus 2 , 1 Baltimore, MD, 2 Univ <strong>of</strong> Maryland<br />

Schl <strong>of</strong> Med, Baltimore, MD, 3 University <strong>of</strong> Maryland School <strong>of</strong><br />

Medicine, Baltimore, MD.<br />

433. Interferon Regulatory Factor-5 (IRF-5) Is Critical for the<br />

Development <strong>of</strong> Lupus in MRL/lpr Mice. Yoshifumi Tada 3 , Seiji<br />

Kondo 4 , Shigehisa Aoki 2 , Syuichi Koarada 3 , Hisako Inoue 3 , Rie<br />

Suematsu 3 , Akihide Ohta 1 and Kohei Nagasawa 3 , 1 Department<br />

<strong>of</strong> Clinical Nursing, Saga University, Saga, Japan, 2 Department<br />

<strong>of</strong> Pathology, Saga University, Saga, Japan, 3 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Saga University, Saga, Japan, 4 National Hospital<br />

Organization Kyushu Medical Center, Fukuoka, Japan.<br />

434. Interferonα Causes SLE by Expanding CD3+ CD4- CD8- Double<br />

Negative T Cell (DN T Cell). Chieri Akiyama 1 , Eriko Honda 1 ,<br />

Akira Hashiramoto 2 , Dean W. Felsher 3 and Shunichi Shiozawa 2 ,<br />

1<br />

Department <strong>of</strong> Biophysics, Graduate School <strong>of</strong> Health<br />

Science, Kobe University, Kobe, Hyogo, Japan, 2 Department <strong>of</strong><br />

Biophysics, Graduate School <strong>of</strong> Health Science, Kobe University/<br />

Department <strong>of</strong> Medicine, Graduate School <strong>of</strong> Medicine, Kobe<br />

University/The Center for Rheumatic Disease, Kobe University<br />

Hospital, Kobe, Japan, 3 Stanford University, School <strong>of</strong> Medicine,<br />

Division <strong>of</strong> Oncology, Department <strong>of</strong> Medicine and Pathology,<br />

Stanford, CA.<br />

435. IRF4-Deficient Lupus-Prone MRL/lpr Mice Lack Serum Ig/<br />

Auto-Abs and Th17 Cells but Develop Non-Immune Complex-<br />

Mediated Diffuse Proliferative Glomerulonephritis and<br />

Dermatitis/Ear Necrosis. Hideharu Sekine 4 , Takeshi Machida 1 ,<br />

Eiji Suzuki 3 , Efrain Martinez Avila 3 , Phil Ruiz 5 , Christopher M.<br />

Reilly 6 and Gary S. Gilkeson 2 , 1 Fukushima Medical University,<br />

Fukushima, Japan, 2 Med Univ <strong>of</strong> South Carolina, Charleston, SC,<br />

3<br />

Medical University <strong>of</strong> South Carolina, Charleston, SC, 4 Medical<br />

University <strong>of</strong> South Carolina/Fukushima Medical University,<br />

Charleston, SC, 5 University <strong>of</strong> Miami, Miami, FL, 6 Virginia Tech,<br />

VA.<br />

436. Long-Term Anti-CD20 Treatment Reduces Antibody-Secreting<br />

Ells in NZB/W Lupus Mouse. Wensheng Wang 2 , Terasa Owen 2 ,<br />

Travis Ichikawa 2 and Jennifer H. Anolik 1 , 1 University <strong>of</strong> Rochester,<br />

Rochester, NY, 2 University <strong>of</strong> Rochester Medical Center,<br />

Rochester, NY.<br />

437. Mitochondrial Dysfunction in T Cells Precede Disease<br />

Development in Lupus-Prone Mice. Tiffany Telarico 4 , David R.<br />

Fernandez 4 , Ann F. H<strong>of</strong>bauer 2 , Gary S. Gilkeson 1 , Jim C. Oates 3<br />

and Andras Perl 5 , 1 Med Univ <strong>of</strong> South Carolina, Charleston, SC,<br />

2<br />

Medical University <strong>of</strong> South Carolina, 3 MUSC, Charleston, SC,<br />

4<br />

SUNY, 5 Upstate Medical Univ, Syracuse, NY.<br />

438. Molecular Mechanisms <strong>of</strong> Lupus Dyslipidemia in Mice.<br />

Nilamadhab Mishra 1 , Kailin Yan 3 and Qiang Cao 2 , 1 Wake Forest<br />

Univ Health Scienc, Winston-Salem, NC, 2 Wake Forest University<br />

Health Sciences, 3 Wake Forest University Unv Health Sciences.<br />

439. Nuclear Modifications during Apoptosis Are Required To<br />

Maintain Tolerance to Nuclear Antigens. Neelakshi R. Jog 1 ,<br />

Eline Luning-Prak 2 and Roberto Caricchio 1 , 1 Temple University,<br />

2<br />

University <strong>of</strong> Pennsylvania.<br />

440. PARP-1 Deficiency Leads to More Severe Glomerulonephritis<br />

and Increased Mortality in an Inducible Mouse Model <strong>of</strong> SLE.<br />

Maximilian F. Koenig 1 , Serena M. Bagnasco 1 , Janelle Montagne 1 ,<br />

Antony Rosen 2 and Thomas Grader-Beck 2 , 1 Johns Hopkins School<br />

<strong>of</strong> Medicine, 2 Johns Hopkins School <strong>of</strong> Medicine, Baltimore, MD.<br />

176<br />

2010 Program Book


ACR Poster Session A<br />

441. Recombinant Chaperonin 10 Suppresses Cutaneous Lupus and<br />

Lupus Nephritis in MRL-(Fas)lpr Mice. Onkar P. Kulkarni 3 , Mi<br />

Ryu 3 , Claudia Kantner 3 , Miklos Sardy 2 , Dean Naylor 1 , Richard<br />

Brown 1 , Daina Vanags 1 and Hans-Joachim Anders 3 , 1 CBio Ltd,<br />

Eight Mile Plains, Queensland, Australia, 2 Department <strong>of</strong><br />

Dermatology and Allergology, University <strong>of</strong> Munich, Munich,<br />

Germany, 3 Medizinische Poliklinik-Innenstadt, University <strong>of</strong><br />

Munich, Munich, Germany.<br />

442. TGF-β-Induced CD4+Foxp3+ Cells Suppress Lupus-Like<br />

Syndrome through Induction <strong>of</strong> Formation <strong>of</strong> Tolerogenic<br />

DC. Xiaohui Zhou 4 , Julie Wang 4 , David A. Horwitz 2 , Huimin<br />

Fan 3 , Hejian Zou 1 , Zhongmin Liu 3 and Song Guo Zheng 4 , 1 Fudan<br />

University Medical School, 2 LAC/USC Medical Center, Los<br />

Angeles, CA, 3 Tongji University Medical School, 4 University <strong>of</strong><br />

Southern California.<br />

443. Widespread Upregulation <strong>of</strong> mEPCR in Kidney, Spleen<br />

and Liver <strong>of</strong> a Nephritic NZM B/W F1: Implications to<br />

Microvascular Disease. Sherry Xu 1 and Robert M. Clancy 2 , 1 NYU<br />

School <strong>of</strong> Medicine, 2 Tisch Hospital 4 - 407 , New York, NY.<br />

Systemic Lupus Erythematosus - Clinical Aspects and Treatment I<br />

444. Anti C1q Antibodies in Patients with Systemic Lupus<br />

Erythematosus and Cutaneous Vasculitis: A Controlled Study.<br />

Shirish R. Sangle 1 , Loh Yet Lin 2 , Esther Sanchez 2 , Davies Rachel 2<br />

and David P. D’Cruz 2 , 1 St Thomas’ Hospital, London, United<br />

Kingdom, 2 St Thomas’ Hospital, United Kingdom.<br />

445. Antimalarials May Attenuate the Risk <strong>of</strong> Metabolic Syndrome<br />

in SLE: Results from an International Imception Cohort<br />

Registry. M. H. X. Ting 2 , R. P. Donn 3 , M. Lunt 3 , M. B. Urowitz 4 ,<br />

D. D. Gladman 1 , D. Ibanez 1 , C. Gordon 1 , S. C. Bae 1 , A. Clarke 1 ,<br />

S. Bernatsky 1 , J. Hanly 1 , D. Isenberg 1 , A. Rahman 1 , J. Sanchez-<br />

Guerrero 1 , J. Romero-Diaz 1 , P. R. Fortin 1 , D. Wallace 1 , E. Ginzler 1 ,<br />

A. Vasudevan 1 , J. Merrill 1 , G. S. Alarcon 1 , B. Fessler 1 , G. Sturfelt 1 ,<br />

O. Nived 1 , K. Steinsson 1 , M. Khamashta 1 , M. Petri 1 , S. Manzi 1 , M.<br />

Dooley 1 , R. Ramsey-Goldman 1 , C. Aranow 1 , R. Van Vollenhoven 1 ,<br />

M. Ramos 1 , T. Stoll 1 , K. Kalunian 1 , A. Zoma 1 , P. Maddison 1 and I.<br />

N. Bruce 3 , 1 Systemic Lupus International Collaborating Clinics,<br />

Toronto, ON, Canada, 2 The University <strong>of</strong> Manchester, Salford,<br />

Manchester, United Kingdom, 3 The University <strong>of</strong> Manchester,<br />

4<br />

Toronto Western Hospital, Toronto, ON, Canada.<br />

446. Arthritis in an Ethnically Diverse Systemic Lupus<br />

Erythematosus Population. Guada Respicio 1 , Clare Cleveland 1 ,<br />

Kim Taylor 1 and Lindsey A. Criswell 2 , 1 Rosalind Russell Medical<br />

Research Center for Arthritis, University <strong>of</strong> California, San<br />

Francisco, San Francisco, CA, 2 UCSF-Box 0500, San Francisco, CA.<br />

447. Association <strong>of</strong> Low-Dose Pulsed Intravenous<br />

Cyclophosphamide Therapy and Amenorrhea in 62 Patients<br />

with Systemic Lupus Erythematosus: A Case-Control Study.<br />

Sayumi Baba 1 , Yasuhiro Katsumata 4 , Yasushi Kawaguchi 2 , Kae<br />

Takagi 1 , Takahisa Gono 1 , Yuko Okamoto 1 , Yuko Ota 1 , Masako<br />

Hara 1 and Hisashi Yamanaka 3 , 1 Tokyo Women’s Medical<br />

University, Tokyo, Japan, 2 Tokyo Women’s Medical University,<br />

Tokyo, Japan, 3 Tokyo Women’s Medical University, Shinjuku-ku,<br />

Tokyo, Japan, 4 Tokyo Women’s Medical University.<br />

448. Atherosclerotic Vascular Events in a Multinational Inception<br />

Cohort <strong>of</strong> SLE: Description and Attribution over an 8 Year<br />

Period. Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique<br />

Ibanez 32 , Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E.<br />

Clarke 15 , Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 ,<br />

John G. Hanly 19 , David A. Isenberg 24 , Anisur Rahman 25 , Paul R.<br />

Fortin 33 , Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 ,<br />

Graciela S. Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar<br />

K. Sturfelt 27 , Ola Nived 27 , Kristjan Steinsson 12 , Munther A.<br />

Khamashta 21 , Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 ,<br />

Susan Manzi 34 , Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 ,<br />

Cynthia B. Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth<br />

C. Kalunian 26 , Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter<br />

J. Maddison 16 , Diane L. Kamen 14 , S. Sam Lim 3 and Christine A.<br />

Peschken 30 , 1 West Hollywood, CA, 2 Timonium, MD, 3 Emory<br />

University, Atlanta, GA, 4 Feinstein Institute, Manhasset, NY,<br />

5<br />

Hairmyres Hospital, East Kilbride, United Kingdom, 6 Hanyang<br />

University Medical Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital<br />

Clinico I Provincial, Spain, 8 Hospital de Cruces, Universidad<br />

del Pais Vasco, Spain, 9 Instituto Nacional Nutricion, Mexico<br />

City, DF, Mexico, 10 Kantonsspital Schaffhausen, Schaffhausen,<br />

Switzerland, 11 Karolinska University Hospital, Sweden,<br />

12<br />

Landspitalinn University Hospital, Iceland, 13 Manchester Royal<br />

Infirmary, Manchester, United Kingdom, 14 Medical University<br />

<strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />

Montreal, QC, Canada, 16 North West Whales NHS Trust, Colwyn<br />

Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />

18<br />

Oklahoma Med Research Foundation, Oklahoma City, OK,<br />

19<br />

Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />

20<br />

SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />

Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />

Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />

24<br />

UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong><br />

Medicine, United Kingdom, 26 UCSD School <strong>of</strong> Medicine, La Jolla,<br />

CA, 27 University Hospital Lund, Lund, Sweden, 28 University <strong>of</strong><br />

Alabama, Oakland, CA, 29 University <strong>of</strong> Birmingham, Birmingham,<br />

United Kingdom, 30 University <strong>of</strong> Manitoba, Winnipeg, MB,<br />

Canada, 31 University <strong>of</strong> North Carolina, Chapel Hill, NC,<br />

32<br />

University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital,<br />

33<br />

University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital,<br />

Toronto, ON, Canada, 34 West Penn Allegheny Health System,<br />

Pittsburgh, PA.<br />

449. Attention Deficit and Hyperactivity Disorder Scores Are<br />

Elevated and Associated with Disease Activity and Fatigue in<br />

Patients with Systemic Lupus Erythematosus. Ricardo J. Garcia,<br />

Lisa Francis, Maha Dawood, Irene Ramos, Stephen Faraone and<br />

Andras Perl, SUNY.<br />

450. Autoantibody Response to Adjuvant and Non-Adjuvant H1N1<br />

Vaccination in SLE. Murray B. Urowitz, Anoja Anton, Domonique<br />

Ibañez and Dafna D. Gladman, Toronto Western Hospital,<br />

Toronto, ON, Canada, Toronto Western Hospital, Toronto, ON,<br />

Canada.<br />

451. Belimumab, a BLyS-Specific Inhibitor, Reduced Corticosteroid<br />

Use in Patients with Active SLE: Results from the Phase 3<br />

BLISS-52 and -76 Studies. R. F. van Vollenhoven 9 , A. Gallacher 3 ,<br />

S. Navarra 11 , E. M. Ginzler 8 , M. A. Dooley 10 , R. Cervera 4 , E. K. Li 2 ,<br />

R. A. Levy 5 , R. Gúzman 7 , Z. J. Zhong 6 , S. Cooper 6 , L. Pineda 6 , D.<br />

Hough 6 , D. J. Wallace 1 and for the BLISS- 52 and - 76 Study Groups,<br />

1<br />

Cedars-Sinai/UCLA, Los Angeles, CA, 2 Chinese University <strong>of</strong><br />

Hong Kong, Hong Kong, China, 3 Hospital Británico de Buenos<br />

Aires, Argentina, 4 Hospital Clinic, Barcelona, Spain, 5 Hospital<br />

Universitário Pedro Ernesto, Rio de Janeiro, Brazil, 6 Human<br />

Genome Sciences, Inc, Rockville, MD, 7 SaludCoop, Bogotá,<br />

Colombia, 8 SUNY Downstate Medical Center, Brooklyn, NY, 9 The<br />

Karolinska Institute, Stockholm, Sweden, 10 University <strong>of</strong> North<br />

Carolina at Chapel Hill, Chapel Hill, NC, 11 University <strong>of</strong> Santo<br />

Tomas Hospital, Manila, Philippines.<br />

2010 Program Book 177


ACR Poster Session A<br />

452. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease Activity,<br />

Flares, and Prednisone Use in Patients with Seropositive SLE:<br />

Combined Efficacy Results from the Phase 3 BLISS-52 and -76<br />

Studies. M. A. Petri 5 , R. A. Levy 3 , J. T. Merrill 7 , S. Navarra 10 , R.<br />

Cervera 2 , R. F. van Vollenhoven 8 , S. Manzi 11 , D. Gladman 9 , A.<br />

Gallacher 1 , L. Pineda 4 , Z. J. Zhong 4 , D. Hough 4 , W. Freimuth 4 ,<br />

R. A. Furie 6 and for the BLISS- 52 and - 76 Study Groups, 1 Hospital<br />

Británico de Buenos Aires, Argentina, 2 Hospital Clinic, Barcelona,<br />

Spain, 3 Hospital Universitário Pedro Ernesto, Rio de Janeiro,<br />

Brazil, 4 Human Genome Sciences, Inc, Rockville, MD, 5 Johns<br />

Hopkins University School <strong>of</strong> Medicine, Timonium, MD, 6 North<br />

Shore LIJ Health System, Lake Success, NY, 7 Oklahoma Medical<br />

Research Foundation, Oklahoma City, OK, 8 The Karolinska<br />

Institute, Stockholm, Sweden, 9 Toronto Western Hospital,<br />

Toronto, ON, Canada, 10 University <strong>of</strong> Santo Tomas Hospital,<br />

Manila, Philippines, 11 West Penn Allegheny Health System,<br />

Pittsburgh, PA.<br />

453. BILAG-Measured Improvement in Moderately and Severely<br />

Affected Body Systems in Patients with Systemic Lupus<br />

Erythematosus (SLE) by Epratuzumab: Results from EMBLEM,<br />

a Phase IIb Study. Kenneth C. Kalunian 5 , Daniel J. Wallace 1 ,<br />

Michelle A. Petri 2 , Frederic A. Houssiau 6 , Marilyn C. Pike 3 ,<br />

Brian Kilgallen 4 , Lexy Kelley 4 and Caroline P. Gordon 7 , 1 West<br />

Hollywood, CA, 2 Timonium, MD, 3 Massachusetts General<br />

Hospital, Harvard Medical School, Boston, MA, 4 UCB, Smyrna,<br />

GA, 5 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 6 Universite<br />

Catholique Louvain, Brussels, Belgium, 7 University <strong>of</strong><br />

Birmingham, Birmingham, United Kingdom.<br />

454. Biologics Use in SLE in 7 Centers – Data from the International<br />

Registry for Biologics in SLE (IRBIS). Ronald Van Vollenhoven 4 ,<br />

Søren Jacobsen 9 , Daniel J. Wallace 1 , John G. Hanly 8 , Michelle<br />

A. Petri 2 , David A. Isenberg 10 , Ann E. Clarke 7 , Julia F. Simard 3 ,<br />

Christian A. Pineau 6 , Sasha R. Bernatsky 5 and for the SLICC<br />

Group, 1 West Hollywood, CA, 2 Timonium, MD, 3 Clinical<br />

Epidemiology Unit, Stockholm, Sweden, 4 Karolinska University<br />

Hospital, Stockholm, Sweden, 5 McGill UHC/RVH, Montreal, QC,<br />

Canada, 6 McGill Univ Health Center, Montreal, QC, Canada,<br />

7<br />

Montreal General Hospital, Montreal, QC, Canada, 8 Queen<br />

Elizabeth II Health Services Center, Halifax, NS, Canada,<br />

9<br />

Rigshospitalet - 4242 , Copenhagen, Denmark, 10 UCL Div <strong>of</strong><br />

Medicine, London, United Kingdom.<br />

455. Carotid Plaque Area Correlates Better Than Intima Media<br />

Thickness with Cardiovascular Risk Factors and Clinical<br />

Ischemic Heart Disease in Lupus Patients. Lihi Eder, Murray<br />

B. Urowitz, Dominique Ibanez and Dafna D. Gladman, Toronto<br />

Western Hospital, Toronto, ON, Canada.<br />

456. Circulating Pro-Angiogenic Cells Are Reduced in Patients<br />

with SLE Independent <strong>of</strong> the Presence <strong>of</strong> Coronary<br />

Artery Calcification. Joshua Baker 1 , Lifeng Zhang 2 , Sotonye<br />

Imadojemu 2 , Alexis Sharpe 2 , Sarita Patil 2 , Jonni Moore 2 ,<br />

Emile R. Mohler III 2 and Joan Marie Von Feldt 3 , 1 University <strong>of</strong><br />

Pennsylvania, Philadelphia, PA, 2 University <strong>of</strong> Pennsylvania,<br />

3<br />

University <strong>of</strong> Pennsylvania-Philadelphia, Veterans Affairs<br />

Medical Center, Philadelphia, PA.<br />

457. Effect <strong>of</strong> Belimumab, a B-Lymphocyte Stimulator–Specific<br />

Inhibitor, on Functional Antibodies to Pneumococcal, Tetanus,<br />

and Influenza Vaccines. W. W. Chatham 6 , D. J. Wallace 1 , W.<br />

Stohl 11 , K. Latinis 8 , S. Manzi 10 , J. McCune 9 , D. Tegzová 3 , J.<br />

McKay 5 , H. E. Avila-Armengol 4 , T. O. Utset 7 , Z. J. Zhong 2 , D.<br />

Hough 2 , W. Freimuth 2 , T. S. Migone 2 and for the BLISS- 76 Study<br />

Group, 1 Cedars-Sinai/UCLA, Los Angeles, CA, 2 Human Genome<br />

Sciences, Inc, Rockville, MD, 3 Institute <strong>of</strong> <strong>Rheumatology</strong> and<br />

Rheumatological Clinic, Prague, Czech Republic, 4 Instituto<br />

Jalisciense de Investigacion Clinica, Guadalajara, Mexico,<br />

5<br />

Oklahoma Center for Arthritis Therapy & Research, Tulsa, OK,<br />

6<br />

UAB Arthritis Clinical Intervention Program, Birmingham, AL,<br />

7<br />

University <strong>of</strong> Chicago, IL, 8 University <strong>of</strong> Kansas Medical Center,<br />

Kansas City, KS, 9 University <strong>of</strong> Michigan Health System, Ann<br />

Arbor, MI, 10 University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine, PA,<br />

11<br />

USC Keck School <strong>of</strong> Medicine, Los Angeles, CA.<br />

458. Effect <strong>of</strong> Systemic Lupus Erythematosus (SLE) on Pregnancy<br />

Outcome: An Analysis <strong>of</strong> 268 Pregnancies. Chi Chiu Mok and<br />

Ling Yin Ho, Tuen Mun Hospital.<br />

459. Effects <strong>of</strong> Disease Activity and Use <strong>of</strong> Antimalarials on the<br />

Risk <strong>of</strong> Coronary-Artery Calcifications in SLE Patients. Juanita<br />

Romero-Díaz 3 , Florencia Vargas-Worackova 1 , Eric Kimura-<br />

Hayama 2 , Carlos Aguilar-Salinas 3 and Jorge Sanchez-Guerrero 4 ,<br />

1<br />

Instituto Nacional ce Ciencias Medicas y Nutricion Salvador<br />

Zubiran, 2 Instituto Nacional de Cardiologia Ignacio Chavez,<br />

3<br />

Instituto Nacional de Ciencias Medicas y Nutricion Salvador<br />

Zubiran, 4 Instituto Nacional de Ciencias Medicas y Nutricion<br />

Salvador Zubiran, Mexico.<br />

460. Elevated Levels <strong>of</strong> Plasma Micro-Particles (PMPs) in Systemic<br />

Lupus Erythematosus (SLE) Are Associated with Higher Risk<br />

<strong>of</strong> Thrombosis. Aisha Lateef 3 , Laurence S. Magder 4 , Jayesh<br />

Jani 2 , Thomas S. Kickler 2 and Michelle A. Petri 1 , 1 Timonium, MD,<br />

2<br />

Johns Hopkins University, 3 National University Health System,<br />

Singapore, Singapore, 4 University <strong>of</strong> Maryland Medical School.<br />

461. Evaluation <strong>of</strong> Cardiac Function and Myocardial Damage in<br />

Women with Systemic Lupus Erythematosus (SLE) by Cardiac<br />

MRI. Mala S. Kaul 2 , Han Kim 2 , E. William St Clair 2 and Megan<br />

E. B. Clowse 1 , 1 Duke Univ Med, Durham, NC, 2 Duke University,<br />

Durham, NC.<br />

462. Fulvestrant (Faslodex) an Estrogen Selective Receptor Down<br />

Regulator in the Therapy <strong>of</strong> Female SLE Patients, One to Two<br />

Year Following Faslodex Study Termination Revealed Mild<br />

Reactivation <strong>of</strong> the Serologic Parameters and Disease Activity.<br />

Nabih I. Abdou 1 , Virginia Rider 3 and Cindy A. Greenwell 2 , 1 Center<br />

for Rheumatic Disease Allergy & Immunology, Kansas City, MO,<br />

2<br />

Center for Rheumatic Disease Allery & Immunology, Kansas<br />

City, MO, 3 University <strong>of</strong> Pittsburg, Pittsburg, KS.<br />

463. Hydroxychloroquine Can Interfere with Flow Cytometric<br />

Analysis <strong>of</strong> Blood Cells from Patients Taking This Medication.<br />

Louise Fraser 1 , Graham H. Mitchell 1 , Shirish Sangle 2 , Lee Meng<br />

Choong 2 , Richard Ellis 1 , Jo Spencer 1 and David P. D’Cruz 3 ,<br />

1<br />

Department <strong>of</strong> Immunobiology, King’s <strong>College</strong> London, 2 Lupus<br />

Research Unit, St Thomas’ Hospital, 3 St Thomas Hospital,<br />

London, United Kingdom.<br />

464. Immunogenicity <strong>of</strong> the Quadrivalent Recombinant HPV<br />

Vaccine in Female Systemic Lupus Erythematosus Patients<br />

Aged 9 to 26 Years. Arzu Soybilgic 2 , Karen Onel 1 , Tammy O.<br />

Utset 1 , Kenneth A. Alexander 1 and Linda Wagner-Weiner 1 , 1 Univ<br />

<strong>of</strong> Chicago, Chicago, IL, 2 University <strong>of</strong> Illinois at Chicago, Chicago,<br />

IL.<br />

178<br />

2010 Program Book


ACR Poster Session A<br />

465. Immunoglobulin Levels as Potential Predictors <strong>of</strong> Response to<br />

B-Cell Depletion (BCD). Sara C. Croca 1 and David A. Isenberg 2 ,<br />

1<br />

Hospital de Santa Maria, Department <strong>of</strong> Medicine 1 , Lisbon,<br />

Portugal, 2 UCL Div <strong>of</strong> Medicine, Room 331 , 3 rd Floor, London,<br />

United Kingdom.<br />

466. Influenza Humoral Immune Responses in Patients with<br />

Systemic Lupus Erythematosus. Evan Glenn Vista 3 , Sherry<br />

Crowe 2 , Linda Thompson 2 , Gillian Air 4 and Judith A. James 1 ,<br />

1<br />

Oklahoma Med Research Foundation, Oklahoma City, OK,<br />

2<br />

Oklahoma Medical Research Foundation, 3 Oklahoma Medical<br />

Research Foundation, Oklahoma City, OK, 4 University <strong>of</strong><br />

Oklahoma Health Science Center.<br />

467. Low-Dose Combination <strong>of</strong> Mycophenolate M<strong>of</strong>etil and<br />

Tacrolimus for Refractory Lupus Nephritis: An Open-Labeled<br />

Trial. Chi Chiu Mok, Chi Hung To, Pak To Chan, Ka Lung Yu and<br />

Ling Yin Ho, Tuen Mun Hospital.<br />

468. Lupus Disease Severity Is Not a Risk for Cervical Intraepithelial<br />

Neoplasia in SLE. J. Patricia Dhar 3 , Lucie Gregoire 3 , Wayne<br />

Lancaster 3 , Azadeh Stark 1 , Ann Schwartz 3 , Daniel Schultz 2 ,<br />

Lynnette Essenmacher 3 , Joel Ager 3 , Lisa Chiodo 3 , Mujitaba<br />

Husain 3 and Robert J. Sokol 3 , 1 Geisinger Health Systems,<br />

Danville, PA, 2 Hernry Ford Health Systems, Detroit, MI, 3 Wayne<br />

State University, Detroit, MI.<br />

469. Lupus Nephritis: Decrease in Proteinuria and Sustained<br />

Stabilization <strong>of</strong> Disease Activity in Patients under Prolonged<br />

Immunoadsorption (IAS). Georg H. Stummvoll 2 , Peter<br />

Biesenbach 1 , Sabine Schmaldienst 1 , Josef Smolen 3 and Kurt<br />

Derfler 1 , 1 Dept. <strong>of</strong> Nephrology, Medical University <strong>of</strong> Vienna,<br />

Austria, 2 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Medical University <strong>of</strong> Vienna,<br />

Vienna, Austria, 3 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Medical University <strong>of</strong><br />

Vienna, Austria.<br />

470. Peripheral Vascular Disease in Systemic Lupus Patients.<br />

Rayford June 3 , Robert C. Gilkeson 1 , Shweta Bhatt 4 and Lisabeth<br />

Scalzi 2 , 1 Case Western Reserve University, 2 Penn State Univ<br />

Hershey Medical, Hershey, PA, 3 Penn State Univ Hershey<br />

Medical, 4 University <strong>of</strong> Rochester.<br />

471. PiHDL and High Plasma Leptin Levels Are Predictors <strong>of</strong><br />

Longitudinal Progression <strong>of</strong> Subclincal Atherosclerosis in SLE.<br />

Maureen A. McMahon 5 , Jennifer M. Grossman 7 , Lori Sahakian 5 ,<br />

Brian Skaggs 5 , John D. FitzGerald 6 , Christina Charles-Schoeman 3 ,<br />

Alan H. Gorn 4 , Michael H. Weisman 2 , Daniel J. Wallace 1 and<br />

Bevra H. Hahn 8 , 1 West Hollywood, CA, 2 Cedars-Sinai Medical<br />

Center, Los Angeles, CA, 3 UCLA, Santa Monica, CA, 4 UCLA<br />

Medical Center, Los Angeles, CA, 5 UCLA School <strong>of</strong> Medicine,<br />

Los Angeles, CA, 6 UCLA School <strong>of</strong> Medicine Rehabilitation, Los<br />

Angeles, CA, 7 University <strong>of</strong> California Los Angeles, Sherman<br />

Oaks, CA, 8 University <strong>of</strong> California Los Angeles School <strong>of</strong><br />

Medicine, Los Angeles, CA.<br />

472. Positivity for Anti-RNP Antibody Is a Risk Factor for Adverse<br />

Effects by Trimethoprim-Sulphamethoxazole, a Prophylaxis<br />

Agent <strong>of</strong> P. jiroveci Pneumonia, in Patients with Collagen-<br />

Vasular Diseases. Reika Maezawa 1 , Kazuhiro Kurasawa 2 ,<br />

Satoko Arai 2 , Takayoshi Owada 2 and Takeshi Fukuda 2 , 1 Clinical<br />

Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan,<br />

2<br />

Dokkyo Medical University, Mibu, Tochigi, Japan.<br />

473. Potential Risk Factors for Lupus Nephritis. Mehrnaz Hojjati 3 ,<br />

Semi Ayub 4 , Qi Wang 5 , Timothy W. Behrens 2 , Emily Gillespie 5<br />

and Michelle A. Petri 1 , 1 Timonium, MD, 2 Genentech Inc, South<br />

San Francisco, CA, 3 Univ <strong>of</strong> Minnesota, Minneapolis, MN, 4 Univ<br />

<strong>of</strong> Minnesota, Little Canada, MN, 5 Univ <strong>of</strong> Minnesota.<br />

474. Predictors <strong>of</strong> Rate <strong>of</strong> Progression in Organ Damage in SLE.<br />

Sneha Purvey 2 , Laurence S. Magder 3 , Hong Fang 2 and Michelle<br />

A. Petri 1 , 1 Timonium, MD, 2 Johns Hopkins University School <strong>of</strong><br />

Medicine, 3 University <strong>of</strong> Maryland School <strong>of</strong> Medicine.<br />

475. Pregnancy Outcomes among African <strong>American</strong> Patients with<br />

Systemic Lupus Erythematosus (SLE) Compared to Controls.<br />

April Barnado 1 , Lee Wheless 4 , Anna K. Meyer 4 , Gary S. Gilkeson 2<br />

and Diane L. Kamen 3 , 1 Duke University Medical Center, Durham,<br />

NC, 2 Med Univ <strong>of</strong> South Carolina, Charleston, SC, 3 Medical<br />

University <strong>of</strong> South Carolina, Charleston, SC, 4 Medical University<br />

<strong>of</strong> South Carolina.<br />

476. Prevalence and Persistence <strong>of</strong> Metabolic Syndrome in a<br />

Multicentre International Inception Cohort <strong>of</strong> Patients with<br />

SLE. Murray B. Urowitz 34 , Dafna D. Gladman 22 , Dominique<br />

Ibanez 33 , Ian N. Bruce 13 , Caroline P. Gordon 30 , Sang-Cheol Bae 6 ,<br />

Ann E. Clarke 15 , Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 ,<br />

John G. Hanly 19 , David A. Isenberg 25 , Anisur Rahman 24 , Paul R.<br />

Fortin 27 , Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 ,<br />

Graciela S. Alarcón 29 , Barri J. Fessler 23 , Gunnar K. Sturfelt 28 , Ola<br />

Nived 28 , Kristjan Steinsson 12 , Munther A. Khamashta 21 , Michelle<br />

A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi 35 , Mary<br />

Anne Dooley 32 , Ronald V. Vollenhoven 11 , Cynthia B. Aranow 4 ,<br />

Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 , Asad<br />

A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 , Diane<br />

L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 31 , 1 West<br />

Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta,<br />

GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital,<br />

East Kilbride, United Kingdom, 6 Hanyang University Medical<br />

Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial,<br />

8<br />

Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto<br />

Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantonsspital<br />

Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University<br />

Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal<br />

Infirmary, Manchester, United Kingdom, 14 Medical University<br />

<strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />

Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn<br />

Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />

18<br />

Oklahoma Med Research Foundation, Oklahoma City, OK,<br />

19<br />

Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />

20<br />

SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />

Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />

Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />

24<br />

UCL Div <strong>of</strong> Medicine, 25 UCL Div <strong>of</strong> Medicine, London, United<br />

Kingdom, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 Univerity <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />

Canada, 28 University Hospital Lund, Lund, Sweden, 29 University<br />

<strong>of</strong> Alabama, Oakland, CA, 30 University <strong>of</strong> Birmingham,<br />

Birmingham, United Kingdom, 31 University <strong>of</strong> Manitoba,<br />

Winnipeg, MB, Canada, 32 University <strong>of</strong> North Carolina at Chapel<br />

Hill, Chapel Hill, NC, 33 University <strong>of</strong> Toronto Lupus Clinic, Toronto<br />

Western Hospital, 34 University <strong>of</strong> Toronto Lupus Clinic, Toronto<br />

Western Hospital, Toronto, ON, Canada, 35 West Penn Allegheny<br />

Health System, Pittsburgh, PA.<br />

477. Risk <strong>of</strong> Renal Flares and Decline in Renal Function in Patients<br />

with Active Lupus Nephritis Treated with Mycophenolate<br />

M<strong>of</strong>etil (MMF). Chi Chiu Mok 2 , King Yee Ying 1 , Cheuk Wan Yim 3<br />

and Woon Leung Ng 3 , 1 Princess Margaret Hospital, 2 Tuen Mun<br />

Hospital, 3 United Christian Hospital.<br />

2010 Program Book 179


ACR Poster Session A<br />

180<br />

478. Safety and Efficacy <strong>of</strong> a Pandemic 2009 Influenza A (H1N1)<br />

Monovalent, Unadjuvanted Vaccine in Systemic Lupus<br />

Erythematosus Patients. Alexis Mathian 3 , Herve Devilliers 2 ,<br />

Anne Krivine 1 , Nathalie Costedoat-Chalumeau 3 , Julien Haroche 3 ,<br />

Du Boutin-Le Thi Huong 3 , Bertrand Wechsler 3 , Baptiste Hervier 3 ,<br />

Makoto Miyara 3 , Nathalie Morel 3 , Jean-Charles Piette 3 , Brigitte<br />

Autran 3 , Flore Rozenberg 1 and Zahir Amoura 3 , 1 Hôpital Cochin,<br />

2<br />

Hôpital Dijon, 3 Hôpital Pitié Salpêtrière.<br />

479. Serum Osteoprotegrin (OPG) in Systemic Lupus<br />

Erythematosus. Adnan N. Kiani 2 , Pal Aukrust 3 , Thor Ueland 3 ,<br />

Laurence S. Magder 4 , Hollan Ivana 3 and Michelle A. Petri 1 ,<br />

1<br />

Timonium, MD, 2 Johns Hopkins University School <strong>of</strong> Medicine,<br />

Baltimore, MD, 3 Oslo University Hospital, 4 University <strong>of</strong><br />

Maryland.<br />

480. Steroid Free Remission in Systemic Lupus Erythematosus.<br />

Akiko Suda 3 , Haruko Ideguchi 1 , Shigeru Ohno 1 , Mitsuhiro<br />

Takeno 2 , Shohei Nagaoka 4 and Yoshiaki Ishigatsubo 5 , 1 Center for<br />

Rheumatic Disease, Yokohama City University Medical Center,<br />

2<br />

Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />

Yokohama City University Graduate School <strong>of</strong> Medicine,<br />

3<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Yokohama Minami Kyosai<br />

Hospital, Yokohama, Japan, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Yokohama Minami Kyosai Hospital, 5 Yokohama City Grad Sch <strong>of</strong><br />

Med, Yokohama, Japan.<br />

481. The Novel Pandemic Influenza A (H1N1) 2009 Vaccine: Low<br />

Rate <strong>of</strong> Seroconversion after Vaccination in Systemic Lupus<br />

Erythematosus. Eduardo F. Borba 4 , Carla G. S. Saad 5 , Ana Luisa<br />

G. Calich 5 , Sandra G. Pasoto 5 , Vilma S. T. Viana 5 , Maria do Carmo<br />

S. T. Timenetsky 2 , Alexander R. Precioso 3 and Eloisa Bonfa 1 ,<br />

1<br />

Faculdade de Medicina da Universidade de São Paulo, Sao<br />

Paulo, Brazil, 2 Instituto Adolpho Lutz, Brazil, 3 Instituto Butantan,<br />

Brazil, 4 <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />

Universidade de São Paulo, Sao Paulo, Brazil, 5 <strong>Rheumatology</strong><br />

Division, Faculdade de Medicina da Universidade de São Paulo,<br />

Brazil.<br />

482. The Presence <strong>of</strong> Renal Platelet Microthrombosis in Patients<br />

with Lupus Nephritis Correlates with the Degree <strong>of</strong><br />

Macrophagic Infiltration. Elena Gonzalo 4 , María Paz Martinez-<br />

Vidal 2 , Begoña Santiago 4 , Natalia Redondo 4 , Estibaliz Loza 1 ,<br />

José Luis Pablos 3 and María Galindo 3 , 1 Fundación Española de<br />

Reumatología, Sociedad Española de Reumatología, Madrid,<br />

Spain, 2 Servicio de Reumatología, Hospital 12 de Octubre,<br />

Madrid, Madrid, Spain, 3 Unidad de Investigación y Servicio de<br />

Reumatología, Hospital 12 de Octubre, Madrid, Madrid, Spain,<br />

4<br />

Unidad de Investigación, Hospital 12 de Octubre, Madrid,<br />

Madrid, Spain.<br />

483. The Relationship between N Terminal Pro Brain Natriuretic<br />

Peptide (NT-proBNP) and Atherosclerosis in SLE Patients. Diana<br />

Goldenberg 2 , Emily Miller 2 , Naveed Sattar 3 , Paul Welsh 4 , Mary<br />

Roman 5 and Jane E. Salmon 1 , 1 Hospital for Special Surgery, New<br />

York, NY, 2 Hospital for Special Surgery, New York, NY, 3 University<br />

<strong>of</strong> Glasgow, Glasgow, United Kingdom, 4 University <strong>of</strong> Glasgow,<br />

5<br />

Weill Cornell Medical <strong>College</strong>, New York, NY.<br />

484. Underuse <strong>of</strong> Hydroxychloroquine among Patients with<br />

Systemic Lupus Erythematosus. Aimee O. Hersh 2 , Daniel J.<br />

Shapiro 3 , Edward H. Yelin 4 and Gabriela Schmajuk 1 , 1 Stanford<br />

University, Palo Alto, CA, 2 UCSF, San Francisco, CA, 3 UCSF,<br />

4<br />

University <strong>of</strong> California, San Francisco, CA.<br />

485. Vitamin D Deficiency in Systemic Lupus Erythematosus (SLE) Is<br />

Not Associated with Coronary Artery Calcium (CAC) or Carotid<br />

Plaque. Adnan N. Kiani 2 , Laurence S. Magder 3 and Michelle A.<br />

Petri 1 , 1 Timonium, MD, 2 Johns Hopkins University, School <strong>of</strong><br />

Medicine, Baltimore, 3 University <strong>of</strong> Maryland.<br />

2010 Program Book<br />

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />

Genetics and Mechanisms<br />

486. 9G4 Autoantibodies Dominate the Anti-Apoptotic Cell<br />

Autoimmune Response in SLE. Scott A. Jenks 1 , Elise Palmer 2 ,<br />

Elides Marin 2 and Ignacio Sanz 1 , 1 Univ <strong>of</strong> Rochester, Rochester,<br />

NY, 2 Univ <strong>of</strong> Rochester.<br />

487. ASF/SF2, a Protein Involved in Multiple RNA and microRNA<br />

Processing Pathways, Is a Novel Autoantigen in SLE. Amit<br />

Golding 6 , Ehtisham Akhter 4 , Tonie Hines 3 , Felipe Andrade 4 ,<br />

Ranjan Sen 5 , Livia Casciola-Rosen 2 , Antony Rosen 7 and Michelle<br />

A. Petri 1 , 1 Timonium, MD, 2 John Hopkins University, Baltimore,<br />

MD, 3 John Hopkins University, 4 Johns Hopkins University School<br />

<strong>of</strong> Medicine, Baltimore, MD, 5 NIA/National Institues <strong>of</strong> Health,<br />

6<br />

NIAID/National Institutes <strong>of</strong> Health, Bethesda, MD, 7 The Johns<br />

Hopkins University, Baltimore, MD.<br />

488. Association <strong>of</strong> adam33 Polymorphisms with Systemic Lupus<br />

Erythematosus. Seung-Cheol Shim, Mi-Kyoung Lim and Dong-<br />

Hyuk Sheen, Eulji University, Daejeon, Korea, Republic <strong>of</strong>.<br />

489. Binding <strong>of</strong> Apoptotic Fetal Cardiocytes by Anti-Ro/La<br />

Antibodies Stimulates uPA/uPAR-Dependent Activation<br />

<strong>of</strong> TGFbeta and Potentiates Fibrosis. Paraskevi Briassouli 2 ,<br />

Daniel Rifkin 1 , Jill P. Buyon 1 and Robert M. Clancy 1 , 1 New York<br />

University School <strong>of</strong> Medicine, 2 New York University Medical<br />

Center, New York, NY.<br />

490. Binding Target for C-Reactive Protein Is Released from<br />

Secondary Necrotic Cells. Christina Janko 1 , Christine Schorn 1 ,<br />

Luis Munoz 1 , Manfred Rauh 3 , Kirsten Lauber 2 , Georg Schett 1<br />

and Martin Herrmann 1 , 1 Department <strong>of</strong> Internal Medicine 3<br />

and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />

Nuremberg, Erlangen, Germany, 2 Department <strong>of</strong> Internal<br />

Medicine I, University <strong>of</strong> Tuebingen, Tuebingen, Germany,<br />

3<br />

Department <strong>of</strong> Paediatrics and Adolescent Medicine, University<br />

<strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany.<br />

491. C1q and Complement Proteins Induce a Non-Caspase-<br />

Dependent, Non –Necrotic, Cell Death, That Protects from<br />

Autoimmunity. Mizhir Atallah, Amir Grau and Dror Mevorach,<br />

Hadassah-Hebrew University.<br />

492. Characterisation <strong>of</strong> Ex Vivo Leukocyte Rolling and Adhesion<br />

Responses in SLE. Eric F. Morand 1 , Qiang Cheng 2 , Alberta<br />

Hoi 2 and Michael J. Hickey 2 , 1 Monash University, Melbourne,<br />

Australia, 2 Monash University.<br />

493. Inhibition <strong>of</strong> Cytosolic Nucleic Acid Receptor Pathways Using<br />

the Small Molecule IKKε/TBK1 Kinase Inhibitor MPI-0485520.<br />

Burt Richards, Ju-Fen Zhu, Nathan Seager, Monica Cronin, Harry<br />

Austin, Thomas Douce, Daniel Cimbora, Ryan Holcomb, Daniel<br />

Wettstein and Paul Bartel, Myrexis, Inc., Salt Lake City, UT.<br />

494. Inhibition <strong>of</strong> Interferon-Alpha by Sialylated IgG in Response<br />

to TLR7 and TLR9 Activation Is Mediated by a Soluble Factor<br />

Produced by Monocytes. Alice E. Wiedeman 2 , Deanna M.<br />

Santer 2 , Fabian Käsermann 1 , Sylvia Miescher 1 and Keith B.<br />

Elkon 2 , 1 CSL Behring, 2 University <strong>of</strong> Washington.<br />

495. IRF5 SLE-Risk Haplotype Is Strongly Enriched in Anti-Ro Positive<br />

Mothers <strong>of</strong> Neonatal Lupus Patients with Diverse Diagnoses.<br />

Timothy B. Niewold 2 , Silvia N. Kariuki 2 , Beverly S. Franek 2 , Jill P.<br />

Buyon 1 and Robert M. Clancy 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, New<br />

York University School <strong>of</strong> Medicine, 2 Section <strong>of</strong> <strong>Rheumatology</strong><br />

and Gwen Knapp Center for Lupus and Immunology Research,<br />

University <strong>of</strong> Chicago.


ACR Poster Session A<br />

496. IRF8 Allele Associated with Susceptibility to Multiple<br />

Sclerosis Is Associated with Serum Interferon Alpha and<br />

Serologic Pr<strong>of</strong>ile in Systemic Lupus Erythematosus. Beverly<br />

S. Franek 2 , Silvia N. Kariuki 2 , Jasmine Arrington 2 , Rachel A.<br />

Mikolaitis 3 , Meenakshi Jolly 3 , Tammy O. Utset 2 , Dimitrios T.<br />

Boumpas 1 , George Goulielmos 1 and Timothy B. Niewold 2 ,<br />

1<br />

Internal Medicine and <strong>Rheumatology</strong>, Clinical Immunology and<br />

Allergy, University <strong>of</strong> Crete Medical School, Heraklion, Greece,<br />

2<br />

Section <strong>of</strong> <strong>Rheumatology</strong> and Gwen Knapp Center for Lupus<br />

and Immunology Research, University <strong>of</strong> Chicago, 3 Section <strong>of</strong><br />

<strong>Rheumatology</strong>, Rush University Medical Center.<br />

497. Leptin Promotes T Cell Autoimmunity through Modulation <strong>of</strong><br />

the PKB/Akt/mTOR Pathway in Systemic Lupus Erythematosus<br />

(SLE) Patients. Elaine V. Lourenco, Bevra H. Hahn, Noriko Iikuni,<br />

Sarah J. Kim, Maida Wong, Ram P. Singh, Jennifer Grossman and<br />

Antonio La Cava, UCLA.<br />

498. Low C4A Gene Copy Number in Systemic Lupus<br />

Erythematosus. Kaline M. C. Pereira 4 , Atila G. A. Faria 4 , Eloisa<br />

S. Moreira 1 , Viviane C. Santos 3 , Marcelle Grecco 3 , Neusa P.<br />

Silva 3 and Luis Eduardo C. Andrade 2 , 1 Hospital Sirio Libanes,<br />

Brazil, 2 Universidade Federal de São Paulo, Sao Paulo,<br />

Brazil, 3 Universidade Federal de Sao Paulo - UNIFESP, Brazil,<br />

4<br />

Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo, SP,<br />

Brazil.<br />

499. Lupus Immune Complex Gene Expression Arrays Reveal<br />

Divergent Pro- and Anti-Inflammatory Pathways Induced<br />

Depending on the Presence <strong>of</strong> Plasmacytoid Dendritic Cells<br />

and C1q. Deanna M. Santer and Keith B. Elkon, University <strong>of</strong><br />

Washington, Seattle, WA.<br />

500. Meta-Analysis <strong>of</strong> Autoimmune Variants Shared between<br />

Systemic Lupus Erythematosus (SLE) and 16 Other Diseases<br />

Identifies Novel SLE Loci. Paula S. Ramos 3 , Patrick M. Gaffney 1 ,<br />

Lindsey A. Criswell 12 , Mary E. Comeau 3 , Adrienne H. Williams 3 ,<br />

Robert R. Graham 8 , Sharon A. Chung 10 , Raphael Zidovetzki 5 ,<br />

Jennifer A. Kelly 2 , Kenneth M. Kaufman 2 , Chaim O. Jacob 9 ,<br />

Robert P. Kimberly 4 , Betty P. Tsao 11 , Marta E. Alarcon-Riquelme 6 ,<br />

Timothy J. Vyse 7 , John B. Harley 13 , Kathy L. Moser 1 , Carl D.<br />

Langefeld 3 and SLEGEN Consortium, 1 Arthritis and Immunology<br />

Program, Oklahoma Medical Research Foundation, Oklahoma<br />

City, OK, 2 Arthritis and Immunology Program, Oklahoma Medical<br />

Research Foundation, 3 Dept Biostatistical Sciences, Wake<br />

Forest University Health Sciences, 4 Dept Medicine, University<br />

<strong>of</strong> Alabama at Birmingham, Birmingham, AL, 5 Dept <strong>of</strong> Cell<br />

Biology and Neuroscience, University <strong>of</strong> California, Riverside,<br />

6<br />

Dept <strong>of</strong> Genetics and Pathology, Uppsala University, Uppsala,<br />

Sweden, 7 Faculty <strong>of</strong> Medicine, Imperial <strong>College</strong>, London, UK,<br />

8<br />

Immunology Biomarkers Group, Genentech, 9 Keck School <strong>of</strong><br />

Medicine, University <strong>of</strong> Southern California, Los Angeles, Los<br />

Angeles, CA, 10 Rosalind Russell Medical Research Center for<br />

Arthritis, University <strong>of</strong> California, San Francisco, San Francisco,<br />

CA, 11 UCLA School <strong>of</strong> Medicine, Los Angeles, CA, 12 UCSF-Box<br />

0500, San Francisco, CA, 13 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma<br />

City, OK.<br />

501. MicroRNA miR-146a, Type I Interferon, and Race in Systemic<br />

Lupus Erythematosus. Paul R. Dominguez 1 , Minoru Satoh 2 ,<br />

Angela R. Ceribelli 1 , Eric S. Sobel 2 , Yi Li 2 , Westley H. Reeves 2 and<br />

Edward K. .L Chan 2 , 1 Department <strong>of</strong> Oral Biology, University <strong>of</strong><br />

Florida, Gainesville, FL, 2 University <strong>of</strong> Florida, Gainesville, FL.<br />

502. Multiple Independent Major Histocompatibility Complex<br />

Associations with Nephritis and Autoantibody Production in<br />

Systemic Lupus Erythematosus. Sharon A. Chung 7 , Kimberly<br />

E. Taylor 7 , Suzanne L. May 10 , Patricia P. Ramsay 9 , Hong L.<br />

Quach 9 , Julie A. Lane 2 , Joanne Nititham 8 , Janelle A. Noble 2 ,<br />

Diana L. Quach 9 , Jennifer A. Kelly 5 , Kathy L. Moser 4 , Timothy<br />

W. Behrens 3 , Michael F. Seldin 11 , John B. Harley 1 , Patrick M.<br />

Gaffney 4 , Lisa F. Barcellos 9 and Lindsey A. Criswell 6 , 1 Children’s<br />

Hospital Cincinnati Medical Center, Cincinnati, OH, 2 Children’s<br />

Hospital Oakland Research Institute, Oakland, CA, 3 Genentech,<br />

Inc., South San Francisco, CA, 4 Oklahoma Medical Research<br />

Foundation, Oklahoma City, OK, 5 Oklahoma Medical Research<br />

Foundation, Oklahoma City, OK, 6 Rosalind Russell Medical<br />

Research Center for Arthritis, University <strong>of</strong> California, San<br />

Francisco, San Francisco, CA, 7 Rosalind Russell Medical Research<br />

Center for Arthritis, University <strong>of</strong> California, San Francisco,<br />

8<br />

Rosalind Russell Medical Research Center for Arthritis,<br />

University <strong>of</strong> California, San Francisco, CA, 9 University <strong>of</strong><br />

California, Berkeley, CA, 10 University <strong>of</strong> California, Berkely, CA,<br />

11<br />

University <strong>of</strong> California, Davis, CA.<br />

503. NK Cells Regulate the IFN-α Production by Plasmacytoid<br />

Dendritic Cells Via Soluble Factors and Cell-Cell Contact. Niklas<br />

Hagberg 2 , Ol<strong>of</strong> Berggren 2 , Gunnar V. Alm 1 , Maija-Leena Eloranta 2<br />

and Lars Rönnblom 2 , 1 Department <strong>of</strong> Biomedical Sciences and<br />

Veterinary Public Health, Swedish University <strong>of</strong> Agricultural<br />

Sciences, Uppsala, Sweden, 2 Department <strong>of</strong> Medical Sciences,<br />

Uppsala University, Uppsala, Sweden.<br />

504. Novel Fc gamma Receptor 3B Gene (FCGR3B) Allele Variants<br />

and Polymorphism Distribution in Brazilian Systemic Lupus<br />

Erythematosus Patients and Blood Bank Donors. Viviane<br />

C. Santos 2 , Marcelle Grecco 2 , Kaline M. C. Pereira 2 , Luis E. C.<br />

Andrade 2 and Neusa P. Silva 1 , 1 Universidade Federal de São<br />

Paulo, São Paulo, Brazil, 2 Universidade Federal de São Paulo,<br />

Brazil.<br />

505. Numerical and Functional Deficiencies <strong>of</strong> Natural Killer T Cells<br />

in Systemic Lupus Erythematosus: Their Dysfunction Related<br />

to Up-Regulation <strong>of</strong> Cbl-b. Young-Nan Cho 2 , Sung-Ji Lee 3 ,<br />

Seong-Rye Seo 3 , Seung-Jung Kee 1 , Tae-Jong Kim 3 , Shin-Seok Lee 3<br />

and Yong-Wook Park 2 , 1 Department <strong>of</strong> Laboratory Medicine,<br />

Chonnam National University Medical School and Hospita,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Chonnam National University<br />

Medical School and Hospital, Gwangju, Republic <strong>of</strong> Korea,<br />

3<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Chonnam National University<br />

Medical School and Hospital.<br />

506. Paucity <strong>of</strong> PD-L1 Expression on Monocytes during Active<br />

Systemic Lupus Erythematosus Is Regulated by IL-10, TNF-α<br />

and TGF-β. Anne M. Stevens 3 , Jing-Ni Ou 1 and Alice Wiedeman 2 ,<br />

1<br />

Center for Immunity and Immunotherapies, Seattle Children’s<br />

Research Institute, Seattle, WA, 2 Department <strong>of</strong> Immunology,<br />

University <strong>of</strong> Washington, Seattle, WA, 3 Pediatrics, U. <strong>of</strong><br />

Washington, Seattle, WA.<br />

507. RFX1 Regulates CD70 and CD11a Expression by Recruiting<br />

the Histone Methyltransferase SUV39H1 in Lupus T Cells.<br />

Ming Zhao, Xiaoyan Wu, Fei Gao, Qing Zhang, Heng Yin and<br />

Qianjin Lu, Second Xiangya Hospital, Central South University,<br />

Changsha, China.<br />

2010 Program Book 181


ACR Poster Session A<br />

508. The HLA Haplotype DQA1+, DQB1+, DR4- Identifies Lupus<br />

Patients in Whom Anti-dsDNA Titers Correlate with<br />

Disease Activity. Mikhail Olferiev 1 , Kyriakos A. Kirou 1 , Dorthe<br />

Lundsgaard 4 , Klaus S. Frederiksen 3 , Jan Fleckner 2 and Mary<br />

K. Crow 1 , 1 Hospital for Special Surgery, New York, NY, 2 Novo<br />

Nordisk, 3 Novo Nordisk, Denmark, 4 Novo Nordisk, Copenghagen,<br />

Denmark.<br />

509. The Integrity <strong>of</strong> Double Strand Break Repair in Pediatric<br />

Systemic Lupus Erythematosus Cells. Robert C. Davies 2 , Kelly<br />

Pettijohn 2 , Francesca Fike 2 , Jiexi Wang 2 , Shareef A. Nahas 2 ,<br />

Richard A. Gatti 3 and Deborah K. McCurdy 1 , 1 Mattel Children’s<br />

UCLA-<strong>Rheumatology</strong>, Los Angeles, CA, 2 UCLA-Pathology<br />

and Laboratory Medicine, 3 UCLA-Pathology and Laboratory<br />

Medicine; Human Genetics.<br />

510. The Lupus Africa to US Gradient Revisited – Genetic Versus<br />

Environmental Factors in Lupus. Gary S. Gilkeson 1 , Diane L.<br />

Kamen 4 , Natasha M. Ruth 3 , Anna Meyer 2 and Darrius Maggi 5 ,<br />

1<br />

Med Univ <strong>of</strong> South Carolina, Charleston, SC, 2 MUSC, 3 MUSC,<br />

Charleston, SC, 4 MUSC PO Box 250637 , Charleston, SC, 5 West Africa<br />

Fistula Foundation.<br />

511. The Variant <strong>of</strong> MHC Class I Polypeptide-Related Sequence<br />

(MICA) Is a Genetic Risk Factor for SLE Independent <strong>of</strong> HLA-<br />

DRB1 and Modulates the Behavior <strong>of</strong> NK Cell Via NKG2D<br />

Receptor. Kohsuke Yoshida 1 , Koichiro Komai 2 , Kazuko Shiozawa 7 ,<br />

Aya Mashida 2 , Takahiko Horiuchi 6 , Yuki Tanaka 4 , Masato<br />

Nose 5 , Akira Hashiramoto 3 and Shunichi Shiozawa 3 , 1 Dept. <strong>of</strong><br />

Biophysics, Kobe Univ. Graduate School <strong>of</strong> Health Sciences,<br />

Kobe, Hyogo, Japan, 2 Dept. <strong>of</strong> Biophysics, Kobe Univ. Graduate<br />

School <strong>of</strong> Health Sciences, Kobe, Japan, 3 Dept. <strong>of</strong> Biophysics,<br />

Kobe Univ. Graduate School <strong>of</strong> Health Sciences/ Department<br />

<strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong> Medicine/<br />

The Center for Rheumatic Diseases, Kobe University Hosp.,<br />

Kobe, Japan, 4 Dept. <strong>of</strong> Clinical Immunology, <strong>Rheumatology</strong>,<br />

and Infectious Diseases, Kyushu Univ., Fukuoka, Japan, 5 Dept.<br />

<strong>of</strong> Pathogenomics, Ehime Univ. Graduate School <strong>of</strong> Medicine,<br />

Ehime, Japan, 6 Div. <strong>of</strong> Genome Analysis, Medicine Institute<br />

<strong>of</strong> Bioregulation, Kyushu Univ., Fukuoka, Japan, 7 Rheumatic<br />

Diseases Center, Konan-Kakogawa Hosp., Kakogawa, Japan.<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects<br />

and Treatment I<br />

512. Acute Anterior Uveitis in Ankylosing Spondylitis: Clinical<br />

Characteristics and Impact <strong>of</strong> Biologic Therapy. Nai Lee<br />

Lui 1 , Finbar (Barry) D. O’Shea 3 , Hua Shen 2 , Richard J. Cook 2<br />

and Robert D. Inman 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong><br />

and Immunology, Singapore General Hospital, Singapore,<br />

2<br />

Department <strong>of</strong> Statistics and Actuarial Science, University <strong>of</strong><br />

Waterloo, Canada, 3 St James’s Hospital, Dublin, Ireland, 4 Toronto<br />

Western Hospital, Toronto, ON, Canada.<br />

513. Ankylosing Spondylitis: High Frequency <strong>of</strong> Varicocele<br />

Associated with Teratozoospermia. Lucia A. Nukumizu 5 , Carla<br />

G. S. Saad 5 , Breno P. de Almeida 5 , Jozélio F. Carvalho 5 , Marcello<br />

Cocuzza 2 , Celio R. Goncalves 5 , Osmar Saito 1 , Eloisa Bonfa 3 and<br />

Clovis A. A. Silva 4 , 1 Department <strong>of</strong> Radiology - Faculdade de<br />

Medicina da Universidade de São Paulo, Brazil, 2 Department <strong>of</strong><br />

Urology - Faculdade de Medicina da Universidade de São Paulo,<br />

Brazil, 3 Faculdade de Medicina da Universidade de São Paulo,<br />

Sao Paulo, Brazil, 4 Pediatric Reumatology Unit, Faculdade de<br />

Medicina da Universidade de São Paulo, Brazil, 5 <strong>Rheumatology</strong><br />

Division - Faculdade de Medicina da Universidade de São Paulo,<br />

Brazil.<br />

514. Application <strong>of</strong> Composite Disease Activity Scores in Psoriatic<br />

Arthritis to the PRESTA Dataset. Oliver M. FitzGerald 3 , Philip<br />

Helliwell 5 , Aizad Mumtaz 4 , Laure Coates 5 , Ronald Pedersen 2 and<br />

Charles T. Molta 1 , 1 Pfizer, Inc., Paoli, PA, 2 Pfizer, Inc., <strong>College</strong>ville,<br />

PA, 3 University <strong>College</strong> Dublin, Ranelagh Dublin, Ireland,<br />

4<br />

University <strong>College</strong> Dublin, Dublin, Ireland, 5 University <strong>of</strong> Leeds,<br />

Leeds, United Kingdom.<br />

515. Association <strong>of</strong> BMI and Psoriatic Arthritis Disease Activity.<br />

Elena Eberle 2 , Eric Knight 2 , Donald A. Raddatz 2 , Susan<br />

Messing 5 , George Reed 4 , Jeffrey D. Greenberg 1 and Joel M.<br />

Kremer 3 , 1 Millburn, NJ, 2 Bassett Healthcare, Cooperstown,<br />

NY, 3 The Center for <strong>Rheumatology</strong>, Albany, NY, 4 University <strong>of</strong><br />

Massachusetts, Worchester, MA, 5 University <strong>of</strong> Rochester,<br />

Rochester, NY.<br />

516. Can We Discontinue Anti-TNF Therapy in Patients with<br />

Ankylosing Spondylitis and Remission? A Systematic Literature<br />

Review. Miguel A. Abad 3 , Ana M. Ortiz 2 , Estibaliz Loza 1 , Juan<br />

A. Martinez Lopez 1 , Maria P. Rosario 1 and Loreto Carmona 1 ,<br />

1<br />

Fundación Española de Reumatología, Madrid, Spain,<br />

2<br />

Hospital Universitario de la Princesa, Madrid, Spain, Spain,<br />

3<br />

<strong>Rheumatology</strong> Unit, Hospital Virgen del Puerto, Plasencia,<br />

Spain, Spain.<br />

517. Clinical and Demographic Characterization <strong>of</strong> a Colombian<br />

Cohort <strong>of</strong> Patients with Diagnosis <strong>of</strong> Spondylarthritis. Wilson<br />

A. Bautista 1 , John Londoño 3 , Marlon Porras 3 and Rafael R. Valle 2 ,<br />

1<br />

Military Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Bogota, Colombia,<br />

2<br />

Military Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Bogota, Colombia,<br />

3<br />

Military Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Bogota, Colombia.<br />

518. Comparison <strong>of</strong> ASAS Partial Remission and Low ASDAS as<br />

Indicators <strong>of</strong> Remission-Like States in Ankylosing Spondylitis.<br />

Desiree van der Heijde 4 , Joachim Sieper 3 , Steve Brown 2 ,<br />

Frederic Lavie 1 and Aileen Pangan 2 , 1 Abbott Laboratories,<br />

Rungis, France, 2 Abbott Laboratories, Abbott Park, IL, 3 Charité<br />

Universitätsmedizin Berlin, Berlin, Germany, 4 Leiden University<br />

Medical Center, Leiden, The Netherlands.<br />

519. Complex Assessment <strong>of</strong> Subclinical Vascular Disease<br />

Associated with Ankylosing Spondylitis. Nóra Bodnár 3 , György<br />

Kerekes 2 , Zoltan Szekanecz 1 , Ildiko Seres 4 , György Paragh 4 , Pál<br />

Soltész 2 , Gabriella Szücs 3 and Sándor Szántó 3 , 1 University <strong>of</strong><br />

Debrecen Med Ctr, Debrecen, Hungary, 2 University <strong>of</strong> Debrecen<br />

Medical and Health Sciences Center, Department <strong>of</strong> Medicine,<br />

3<br />

University <strong>of</strong> Debrecen Medical and Health Sciences Center,<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, 4 University <strong>of</strong> Debrecen Medical<br />

and Health Sciences Center, First Department <strong>of</strong> Medicine.<br />

520. Correlates <strong>of</strong> Physical Function in Axial Spondylarthropathy:<br />

Fear <strong>of</strong> Movement as an Independent Contributor. Thijs<br />

Swinnen 3 , Johan Vlaeyen 4 , Wim Dankaerts 1 , Rene Westhovens 5<br />

and Kurt de Vlam 2 , 1 Department <strong>of</strong> Rehabilitation Sciences,<br />

Catholic University <strong>of</strong> Leuven, Leuven, Belgium, 2 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, University Hospitals Leuven, Sint Martens<br />

Leerne, Belgium, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, University<br />

Hospitals Leuven, Department <strong>of</strong> Rehabilitation Sciences,<br />

Catholic University <strong>of</strong> Leuven, Leuven, Belgium, 4 Research<br />

Group on Health Psychology, Catholic University <strong>of</strong> Leuven,<br />

Department <strong>of</strong> Clinical Psychological Science, Maastricht<br />

University, Leuven, Belgium, 5 University Hospitals Leuven,<br />

Department <strong>of</strong> Rehabilitation Sciences, Catholic University <strong>of</strong><br />

Leuven, Leuven, Belgium.<br />

182<br />

2010 Program Book


ACR Poster Session A<br />

521. DC-STAMP (Dendritic Cell-Specific Transmembrane protein),<br />

a Potential Biomarker To Predict the Risk <strong>of</strong> Psoriasis Patients<br />

in Developing Psoriatic Arthritis. Yahui Grace Chiu 1 , Sutha<br />

Shanmugarajah 3 , Ben Panepento 1 , Lihi Eder 2 , Vinod Chandran 2 ,<br />

Dafna Gladman 2 , Sharon Moorehead 1 , Rick Barrett 1 and<br />

Christopher T. Ritchlin 1 , 1 AIR Unit, University <strong>of</strong> Rochester,<br />

Rochester, NY, 2 UHN-Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 UHN-Toronto Western Hospital, Toronoto, ON, Canada.<br />

522. Development and Validation <strong>of</strong> a Questionnaire for Evaluation<br />

<strong>of</strong> Spondyloarthritis Related Manifestations in the First Degree<br />

Relatives <strong>of</strong> Patients with Ankylosing Spondylitis. Roozbeh<br />

Sharif 4 , John D. Reveille 6 , Michael H. Weisman 1 , Michael M.<br />

Ward 2 , Laura A. Diekman 4 , Mamatha Hanumanthaiah 5 and<br />

Shervin Assassi 3 , 1 Cedars-Sinai Medical Center, Los Angeles, CA,<br />

2<br />

NIH, NIAMS, IRP, Bethesda, MD, 3 Univ <strong>of</strong> Texas Health Science,<br />

Houston, TX, 4 Univ <strong>of</strong> Texas Health Science Center Houston,<br />

Houston, TX, 5 Univ <strong>of</strong> Texas Health Science Center Houston,<br />

6<br />

Univ Texas Health Sci Ctr, Houston, TX.<br />

523. Differences in Body Mass Index among Individuals with<br />

Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and the<br />

General Population. Vidula M. Bhole 1 , Hyon K. Choi 5 , Lindsay<br />

C. Burns 1 , Cristián Vera Kellet 2 , Diane V. Lacaille 1 , Dafna D.<br />

Gladman 3 and Jan P. Dutz 4 , 1 Arthritis Research Centre <strong>of</strong> Canada,<br />

Vancouver, BC, Canada, 2 Department <strong>of</strong> Dermatology, Pontificia<br />

Universidad Católica de Chile, Santiago, 3 Toronto Western<br />

Hospital, Toronto, ON, Canada, 4 Univ <strong>of</strong> BC, Vancouver, BC,<br />

Canada, 5 Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />

524. Disease Activity Assessment by ASDAS Doesn’t Predict<br />

Sacroiliac Inflammation with MRI in Axial SpA. Sibel Z. Aydin 2 ,<br />

Alex Bennett 1 , Paul Emery 2 , Dennis McGonagle 2 and Helena<br />

Marzo-Ortega 2 , 1 Defence Medical Rehabilitation Centre, Headley<br />

Court, Epsom, Surrey, 2 Section <strong>of</strong> Musculoskeletal Diseases, The<br />

Leeds Institute <strong>of</strong> Molecular Medicine. University <strong>of</strong> Leeds, UK.<br />

525. Estimation <strong>of</strong> Optimal Cutt-Off Point <strong>of</strong> Ankylosing Spondylitis<br />

Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis<br />

Disease Activity Index (BASDAI) and Mini-BASDAI. Ruxandra<br />

Schiotis 7 , Eliza Muñoz Gomariz 3 , Juan Mulero 5 , Xavier Juanola 4 ,<br />

Janitzia Vazquez-Mellado 1 , Percival D. Sampaio-Barros 2 and<br />

Eduardo Collantes 6 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, General<br />

Hospital <strong>of</strong> México, México City, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

University <strong>of</strong> São Paulo, 3 Instituto Maimónides de Investigación<br />

Biomédica /Hospital Universitario Reina S<strong>of</strong>ia, Cordoba,<br />

Spain, 4 <strong>Rheumatology</strong> Department, H. U. Bellvitge, Barcelona,<br />

5<br />

<strong>Rheumatology</strong> Department, Hospital Puerta de Hierro<br />

Majadahonda. Madrid, Spain, 6 <strong>Rheumatology</strong> Department,<br />

Hospital Reina S<strong>of</strong>ía. Córdoba, Spain, 7 University <strong>of</strong> Medicine<br />

and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.<br />

526. Evaluation <strong>of</strong> the New ASAS Instrument To Assess Disease<br />

Activity, the ASDAS, in Patients with Ankylosing Spondylitis<br />

Treated with TNF Blockers over 8 Years. Xen<strong>of</strong>on Baraliakos 4 ,<br />

Claudia Fritz 2 , Joachim Listing 2 , Joachim Sieper 1 and Juergen<br />

Braun 3 , 1 Charite Campus Benjamin Frankl, Berlin, Germany,<br />

2<br />

German Rheumatism Research Center, 3 Rheumazentrum<br />

Ruhrgebiet, Herne, Germany, 4 Rheumazentrum Ruhrgebiet<br />

Herne.<br />

527. Evolution <strong>of</strong> Familial Spondyloarthritis (SPA) without<br />

Radiographic Sacroiliitis over Time: Results <strong>of</strong> a Prospective<br />

Follow Up Study. Nadine Zeboulon-Ktorza 3 , Roula Said-<br />

Nahal 1 , Maria-Antonietta D’Agostino 3 and Maxime Breban 2 ,<br />

1<br />

Hôpital Ambroise Paré, Assistance Publique Hôpitaux de<br />

Paris, Boulogne-Billancourt, France, 2 Hôpital Ambroise Paré,<br />

Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt,<br />

France; INSERM Unité 1016 ; Université Versailles Saint Quentin<br />

en Yvelines, F- 78000 , Versailles, France, 3 Hôpital Ambroise Paré,<br />

Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt,<br />

France; Université Versailles Saint Quentin en Yvelines, F- 78000 ,<br />

Versailles, France.<br />

528. Frequency <strong>of</strong> Iridocyclitis at Onset in a Large Series <strong>of</strong> Patients<br />

with Early Psoriatic Arthritis. Fabrizio Cantini 2 , Carlotta<br />

Nannini 2 , Emanuele Cassarà 2 , Olga Kaloudi 2 , Massimo Susini 1<br />

and Laura Niccoli 2 , 1 Ophthalmology Unit, Hospital <strong>of</strong> Prato,<br />

Prato, Tuscany, Italy, 2 <strong>Rheumatology</strong> Unit, Hospital <strong>of</strong> Prato,<br />

Prato, Tuscany, Italy.<br />

529. Hip Involvement Concerns 18% <strong>of</strong> Spondyloarthritis Patients,<br />

Is Often Bilateral and Total Joint Replacement Leads to Good<br />

Functional Results in These Patients. Vincent Burki, Simon<br />

Paternotte, Muriel Elhai, Isabelle Fabreguet, Eugenie Koumakis,<br />

Magali Meyer, Judith Payet, Fanny Roure, Laure Gossec and<br />

Maxime Dougados, Paris Descartes University, Cochin Hospital,<br />

Paris, France.<br />

530. HLA-Cw*06 Allele Increases the Duration <strong>of</strong> Time between<br />

the Onset <strong>of</strong> Psoriasis and Psoriatic Arthritis. Lihi Eder 2 ,<br />

Vinod Chandran 2 , Fawnda Pellett 2 , Sutha Shanmugarajah 2 ,<br />

Hua Shen 3 , Richard Cook 3 and Dafna D. Gladman 1 , 1 Toronto<br />

Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto<br />

Psoriatic Arthritis Clinic, Toronto Western Hospital, 3 University<br />

<strong>of</strong> Waterloo.<br />

531. Hypertension and Diabetes Significantly Enhance the Risk<br />

for Cardiovascular Disease in Patients with Psoriasic Arthritis<br />

(PsA). Maria Helena Sampaio Favarato 1 , Carla Gonçalves Saad 2 ,<br />

Célio Roberto Gonçalves 2 , Percival Degrava Sampaio-Barros 2 and<br />

Claudia Goldenstein-Schainberg 2 , 1 <strong>Rheumatology</strong>, HC-FMUSP,<br />

São Paulo, Brazil, 2 <strong>Rheumatology</strong>, HC-FMUSP.<br />

532. Identification <strong>of</strong> the Clinical Features That Can Distinguish<br />

between Psoriatic Polyenthesitis and Fibromyalgia. Antonio<br />

Marchesoni 6 , Valentina Varisco 6 , Fabiola Atzeni 7 , Antonio<br />

Spadaro 3 , Ennio Lubrano 5 , Salvatore D’Angelo 10 , Alberto Cauli 4 ,<br />

Carlo Salvarani 8 , Giuseppe Provenzano 2 , Raffaele Scarpa 9 ,<br />

Daniela Melchiorre 1 , Piercarlo Sarzi Puttini 7 , Ignazio Olivieri 10 ,<br />

Mariangela Atteno 9 , Monica Montepane 3 , Gabriele De Marco 6 ,<br />

Laura Rotunno 6 and Maria Manara 6 , 1 AOUC University <strong>of</strong><br />

Florence, Italy, 2 CTO Hospital, Palermo, Italy, 3 Department <strong>of</strong><br />

Clinical and Medical Therapy, Sapienza-University <strong>of</strong> Rome,<br />

Italy, 4 Department <strong>of</strong> Medical Sciences, University <strong>of</strong> Cagliari,<br />

Italy, 5 Fondazione Maugeri, IRCCS, Telese Terme, Italy, 6 G.Pini<br />

Orthopedic Institute, Milan, Italy, 7 L. Sacco University Hospital,<br />

Milan, Italy, 8 Reggio Emilia Hospital, Italy, 9 <strong>Rheumatology</strong><br />

Research Unit, University Federico II Naples, Italy, 10 San Carlo<br />

Hospital <strong>of</strong> Potenza, Italy.<br />

2010 Program Book 183


ACR Poster Session A<br />

184<br />

533. Impact <strong>of</strong> Environmental Factors on Disease Activity in<br />

Spondyloarthritis (SPA): Results <strong>of</strong> the Prospective Co-Env<br />

Cohort. Nadine Zeboulon-Ktorza 9 , Pierre-Yves Boelle 6 , Roula<br />

Said-Nahal 1 , Maria Antonietta D’Agostino 7 , Jean-Francois Vibert 6 ,<br />

Emmanuelle Durand 1 , Homa Madrakian 1 , Odile Launay 3 , Alfred<br />

Mahr 2 , Antoine Flahault 4 , Thomas Hanslik 8 and Maxime Breban 5 ,<br />

1<br />

Assistance Publique Hôpitaux de Paris, Hôpital Ambroise<br />

Paré, F-92100, Boulogne Billancourt, France, 2 Assistance<br />

Publique Hôpitaux de Paris, Hôpital Cochin, F-75014, Paris,<br />

France, 3 Assistance Publique Hôpitaux de Paris, Hôpital Cochin,<br />

F-75014, Paris, France; Universite Paris Descartes, Faculte<br />

de Médecine; INSERM (Institut National de la Santé et de la<br />

Recherche Medicale, 4 EHESP School <strong>of</strong> Public Health, F-35200,<br />

Rennes, France, 5 Hôpital Ambroise Paré, Assistance Publique<br />

Hôpitaux de Paris, Boulogne-Billancourt, France, INSERM Unité<br />

1016, Université Versailles Saint Quentin en Yvelines, F-78000,<br />

Versailles, France, 6 INSERM, UMR S 707, F-75012, Paris, France;<br />

UPMC Université Paris 06, UMR S707, F-75012, Paris, France;<br />

APHP Hopital Saint Antoine F-75 012 Paris France, 7 Université<br />

Versailles Saint Quentin en Yvelines, F-78000, Versailles, France;<br />

Assistance Publique Hôpitaux de Paris, Hôpital Ambroise<br />

Paré, F-92100, Boulogne Billancourt, France;, 8 Universite<br />

Versailles Saint Quentin en Yvelines, F-78000, Versailles, France;<br />

Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare,<br />

F-92100, Boulogne Billancourt, France; INSERM, UMR S707,<br />

F-75012, Paris, France; UPMC Universite Paris , 9 UNIVERSITY <strong>of</strong><br />

Versailles Saint Quentin en Yvelines, F-78000, Versailles, France;<br />

APHP Hopital Ambroise Paré F-92100 Boulogne Billancourt,<br />

France; Inserm UMR-S 707 F-75012, Paris, France.<br />

534. Increased Risk <strong>of</strong> Cardiovascular Disease in Patients with<br />

Active Ankylosing Spondylitis. Inger J. Berg, Anne G. Semb,<br />

Hanne Dagfinrud, Camilla Fongen, Sella A. Provan and Tore<br />

K. Kvien, Dep <strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital,<br />

Increased Risk <strong>of</strong> Gastrointestinal Complications among Persons<br />

with Ankylosing Spondylitis: A Population-Based Study from<br />

Québec, Canada. Adrian R. Levy 3 , Shelagh M. Szabo 3 , Walter<br />

P. Maksymowych 4 , Sumati Rao 1 , Diane V. Lacaille 2 and Mary<br />

Cifaldi 1 , 1 Abbott, 2 Arthritis Research Ctr Canada, Vancouver, BC,<br />

Canada, 3 Oxford Outcomes, 4 University <strong>of</strong> Alberta, Edmonton,<br />

AB, Canada.<br />

536. Inflammation in an Individual Joint Predicts Damage to That<br />

Joint in Psoriatic Arthritis. Vinod Chandran 3 , Lynne Creswell 1 ,<br />

Vernon T. Farewell 1 and Dafna D. Gladman 2 , 1 MRC Biostatistics<br />

Unit, Cambridge, UK, 2 Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />

Western Hospital.<br />

537. Inflammatory Bowel Disease Markers in the Stool <strong>of</strong> Patients<br />

with Ankylosing Spondylitis Compared to Healthy Controls.<br />

Franziska Matzkies 1 , Dermot McGovern 2 , Stephen Targan 2 and<br />

Michael H. Weisman 3 , 1 Cedars Sinai, San Bruno, CA, 2 Cedars<br />

Sinai, Los Angeles, CA, 3 Cedars-Sinai Medical Center, Los<br />

Angeles, CA.<br />

538. Influence <strong>of</strong> Fc-Gamma Receptor IIA (CD32) and IIIA (CD16)<br />

Polymorphisms on the EULAR Response to Anti-Tumor<br />

Necrosis Factor-alpha Therapy in Psoriatic Arthritis: A<br />

Longitudinal Study with 2 Years Follow-Up. Julio Ramirez 7 ,<br />

José Luis Fernández-Sueiro 6 , Raquel López-Mejías 1 , Carlos<br />

Montilla 5 , Belen Suarez 2 , Raimon Sanmartí 4 , Concepción Moll 3 ,<br />

Francisco Blanco 6 , Francisco Lozano 1 and Juan D. Cañete 3 ,<br />

1<br />

Servicio de Inmunología, Hospital Clínic y Universidad de<br />

Barcelona, Barcelona, Spain, 2 Servicio de Inmunología, Hospital<br />

Clínic y Universidad de Barcelona, Barcelona, Spain, 3 Servicio<br />

de Reumatología, Hospital Clínic e IDIBAPS, Barcelona, Spain,<br />

4<br />

Servicio de Reumatología, Hospital Clinic e IDIBAPS, Barcelona,<br />

2010 Program Book<br />

Spain, 5 Servicio de Reumatología, Hospital Clinico de Salamanca,<br />

Salamanca, Spain, 6 Servicio de Reumatología, Hospital Juan<br />

Canalejo, La Coruña, Spain, 7 Servicio Reumatología, Hospital<br />

Clinic e IDIBAPS, Barcelona, Spain.<br />

539. Intestinal Microsporidiosis: High Risk in Rheumatic<br />

Diseases Patients under Anti-TNF Therapy Combined with<br />

Methotrexate. Nadia E. Aikawa 3 , Aline O. Twardowsky 5 ,<br />

Jozelio Carvalho 5 , Clovis Silva 4 , Ivan Silva 2 , Ana Medeiros 5 ,<br />

Carla Gonçalves 5 , Julio Moraes 5 and Eloisa Bonfa 1 , 1 Faculdade<br />

Medicina, Sao Paulo, Brazil, 2 <strong>Rheumatology</strong> Division<br />

(CEDMAC) and Infectology Division, Faculdade de Medicina da<br />

Universidade de Sao Paulo, 3 <strong>Rheumatology</strong> Division (CEDMAC)<br />

and Pediatric <strong>Rheumatology</strong> Unit, Faculdade de Medicina da<br />

Universidade de Sao Paulo, Sao Paulo, Brazil, 4 <strong>Rheumatology</strong><br />

Division (CEDMAC) and Pediatric <strong>Rheumatology</strong> Unit, Faculdade<br />

de Medicina da Universidade de Sao Paulo, 5 <strong>Rheumatology</strong><br />

Division (CEDMAC), Faculdade de Medicina da Universidade de<br />

Sao Paulo.<br />

540. Involvement <strong>of</strong> the Anterior Chest Wall in Patients with<br />

Spondyloarthritis: Relationships between Clinical Symptoms<br />

and Imaging Features. Roberta Ramonda 2 , Alessandro Lo<br />

Nigro 2 , Mariagrazia Lorenzin 2 , Valentina Modesti 2 , Federico<br />

Angelini 1 , Carla Campana 2 , Paola Frallonardo 2 and Leonardo<br />

Punzi 2 , 1 Radiology Unit, University <strong>of</strong> Padova, 2 <strong>Rheumatology</strong><br />

Unit, University <strong>of</strong> Padova.<br />

541. Long Term Pr<strong>of</strong>ile <strong>of</strong> Cytokine, Metalloproteinase and Cartilage<br />

Biomarkers in Psoriatic Arthritis Patients Treated with Biologic<br />

Therapy. Jose Luis Fernandez-Sueiro, J. C. Fernández-Lopez, N.<br />

Oreiro-Villar, S. Pertega-Diaz, J. A. Pinto and FJ Blanco, Complejo<br />

Hospitalario Universitario La Coruña, La Coruña, Spain.<br />

542. Myocardial Infarction and Cardiovascular Risk Pr<strong>of</strong>ile in<br />

Ankylosing Spondylitis. A Systematic Review and Meta-<br />

Analysis. Sylvain Mathieu 3 , Laure Gossec 2 , Maxime Dougados 1<br />

and Martin Soubrier 3 , 1 Hospital Cochin, Paris, France,<br />

2<br />

Rhumatologie B, Hôpital Cochin, Paris, France, Paris, France,<br />

3<br />

Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand,<br />

France.<br />

543. National Survey <strong>of</strong> Patients with Psoriatic Arthritis in Spain:<br />

Disease Activity, Pharmacological Therapy and Impact on<br />

Quality <strong>of</strong> Life. Juan D. Cañete 1 , Julio Ramírez 2 and Rosario<br />

Rodríguez 3 , 1 Arthritis Unit, <strong>Rheumatology</strong> Dpt. Hospital Clinic<br />

and IDIBAPS, Barcelona, Spain, 2 IDIBAPS, Barcelona, Spain,<br />

3<br />

Medical Dept, San<strong>of</strong>i-Aventis Spain, Barcelona, Spain.<br />

544. Performance <strong>of</strong> Different Criteria Sets for Inflammatory Back<br />

Pain in Patients with Axial Spondyloarthritis with and without<br />

Radiographic Sacroiliitis. Dilek Solmaz 3 , Servet Akar 3 , Ozgul<br />

Gunduz 3 , Feride Yuksel 1 , Gercek Can 3 , Vedat Gerdan 3 , Yesim<br />

Akkoc 2 , Merih Birlik 3 , Fatos Onen 3 and Nurullah Akkoc 3 , 1 Internal<br />

Medicine, Dokuz Eylul University Faculty <strong>of</strong> Medicine, 2 Physical<br />

Therapy and Rehabilitation, Ege University Faculty <strong>of</strong> Medicine,<br />

3<br />

<strong>Rheumatology</strong>, Dokuz Eylul University Faculty <strong>of</strong> Medicine,<br />

Izmir, Turkey.<br />

545. Pregnancy in Ankylosing Spondylitis Is Associated with<br />

Fluctuation in Back Pain but Return to Baseline Postpartum:<br />

A Case Control Study. Nai Lee Lui 1 , Adele Carty 4 , Nigil Haroon 3 ,<br />

Sutha Shanmugarajah 4 , Hua Shen 2 , Richard J. Cook 2 , Dafna D.<br />

Gladman 5 and Robert D. Inman 6 , 1 Department <strong>of</strong> <strong>Rheumatology</strong><br />

and Immunology, Singapore General Hospital, Singapore,<br />

2<br />

Department <strong>of</strong> Statistics and Actuarial Science, University <strong>of</strong><br />

Waterloo, Canada, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Toronto Western<br />

Hospital, Toronto, ON, Canada, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Toronto Western Hospital, Toronto, Canada, 5 Toronto Western<br />

Hospital, Toronto, ON, Canada, 6 Toronto Western Hospital,<br />

Toronto, ON, Canada.


ACR Poster Session A<br />

546. Prevalence and Characteristics <strong>of</strong> Uveitis in US Veterans<br />

with Seroneagative Spondyloarthropathy. Hashem Monshie-<br />

Vahabzadeh 4 , Saloomeh Vahadat 4 , J. Steuart S. Richards 4 ,<br />

Andreas Reimold 1 , Jessica Walsh 2 and Gail S. Kerr 3 , 1 Dallas<br />

VA Medical Center, Dallas, TX, 2 Salt Lake City VA Medical<br />

Center, Salt Lake City, UT, 3 VA Medical Center Washington<br />

DC, Washington, DC, 4 VA Medical Center Washington, DC,<br />

Washington, DC.<br />

547. Prevalence <strong>of</strong> Metabolic Syndrome in Patients with<br />

Seronegative Spondyloarthritis. Marwin Gutierrez 1 , Andrea<br />

Becciolini 1 , Emilio Filippucci 1 , Fausto Salaffi 1 , Rossella De<br />

Angelis 1 , Bernd Raffeiner 4 , Marco Canzoni 2 , Viviana Ravagnani 3 ,<br />

Chiara Bertolazzi 1 , Maria L. Sorgi 2 , Domenico Biasi 3 , Leonardo<br />

Punzi 4 and Walter Grassi 1 , 1 Clinica Reumatologica, Università<br />

Politecnica delle Marche, Jesi, Ancona, Italy, 2 Dipartimento<br />

di Clinica e Terapia Medica, Sapienza Università di Roma,<br />

Italy, 3 Unità Semplice di Reumatologia, Università degli<br />

Studi di Verona, Italy, 4 UOC Reumatologia, Clinica Medica e<br />

Sperimentale, Politecnico Universitario, Padova, Italy.<br />

548. Prospective Serum Levels Assessment <strong>of</strong> DKK-1 and SOST in<br />

Patients with Ankylosing Spondylitis and Treated with Anti-<br />

TNFa Treatments. Corinne Miceli-Richard 1 , Stéphanie Malbos 1 ,<br />

Stephan Pavy 1 , Sami Kolta 3 , Karine Briot 3 , Jérémie Sellam 5 ,<br />

Xavier Mariette 2 , Christian Roux 3 and Maxime Dougados 4 ,<br />

1<br />

Bicêtre Hospital, Université Paris XI Sud, 2 Bicetre Hospital/Paris<br />

Univ, Le Kremlin Bicetre, France, 3 Cochin Hospital, Université<br />

Paris-Descartes, 4 Hospital Cochin, Paris, France, 5 Saint-Antoine<br />

Hospital, Paris.<br />

549. Radiographic Progression Is Influenced by ERAP1<br />

Polymorphisms with Gender and Age Being C<strong>of</strong>actors. Nigil<br />

Haroon 2 , Walter P. Maksymowych 4 , Proton Rahman 1 , Florence<br />

W. Tsui 3 and Robert D. Inman 2 , 1 St Claires Mercy Hospital, St<br />

Johns, NL, Canada, 2 Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 Toronto Western Research Institute and University <strong>of</strong><br />

Toornto, 4 University <strong>of</strong> Alberta, Edmonton, AB, Canada.<br />

550. Recently Diagnosed Ankylosing Spondylitis: Gender<br />

Differences and Factors Related to Delay in the Diagnosis.<br />

The North Israeli Study <strong>of</strong> ANkylosing Spondylitis (NISAN).<br />

Gleb Slobodin 1 , Iris Reychan 7 , Nina Avshovich 5 , Alexandra<br />

Balbir-Gurman 6 , Nina Boulman 2 , Mona Elias 3 , Joy Feld 3 , Reuven<br />

Mader 4 , Doron Markovitz 6 , Doron Rimar 2 , Itzhak Rosner 2 ,<br />

Michael Rozenbaum 2 , Devy Zisman 3 and Majed Odeh 2 , 1 Bnai<br />

Zion Medical Center, Haifa, Israel, 2 Bnai Zion Medical Center,<br />

3<br />

Carmel Medical Center, 4 Haemek Medical Center, Afula, Israel,<br />

5<br />

Hillel Yaffe Mecial Center, 6 Rambam Medical Center, 7 Technion.<br />

551. The ECHOSPA MRI Module for Diagnosis <strong>of</strong> Early<br />

Spondyloarthritis (SpA): Preliminary Validation and<br />

Assessment <strong>of</strong> Diagnostic Utility. Walter P. Maksymowych 4 ,<br />

Damien Loeuille 2 , Alexandra Desvignes-Engelbert 2 , Olivia Judet 3 ,<br />

Isabelle Chary-Valckenaere 2 , Robert Lambert 4 , Maxime A.<br />

Breban 1 and Maria-Antonietta D’Agostino 3 , 1 Courbevoie, France,<br />

2<br />

Faculté de Médecine de Nancy, Vandoeuvre les Nancy, France,<br />

3<br />

Université Versailles Saint Quentin en Yvelines, Boulogne-<br />

Billancourt, France, 4 University <strong>of</strong> Alberta, Edmonton, AB,<br />

Canada.<br />

552. The New ASAS Classification Criteria for Axial and Peripheral<br />

Spondylarthritis: Valid in the Latin <strong>American</strong> Patients,<br />

but…. John D. Londono 1 , Marlon B. Porras 2 , Enrique Calvo 4 ,<br />

Pedro Santos 3 , Wilson Bautista 3 , Consuelo Romero-Sánchez 3 ,<br />

Mabel Avila 3 , Ana María Santos 3 and Rafael Valle-Oñate 3 ,<br />

1<br />

Spondylarthropathies Group / <strong>Rheumatology</strong> Division, Hospital<br />

Militar Central / Universidad de La Sabana, Chía, Cundinamarca,<br />

Colombia, 2 Spondylarthropathies Group / <strong>Rheumatology</strong><br />

Division, Hospital Militar Central / Universidad de La Sabana,<br />

Bogotá, Cundinamarca, Colombia, 3 Spondylarthropathies Group<br />

/ <strong>Rheumatology</strong> Division, Hospital Militar Central / Universidad<br />

de La Sabana, Bogotá, Colombia, 4 Universidad Nacional de<br />

Colombia, Bogotá, Colombia.<br />

553. The New ASAS Criteria for Axial SpA Does Not Predict the<br />

Development <strong>of</strong> mNYC AS at 8 Years in a Cohort <strong>of</strong> Very Early<br />

IBP Patients. Sibel Z. Aydin 2 , Alex Bennett 1 , Paul Emery 2 , Dennis<br />

McGonagle 2 and Helena Marzo-Ortega 2 , 1 Defence Medical<br />

Rehabilitation Centre, Headley Court, Epsom, Surrey, United<br />

Kingdom, 2 Section <strong>of</strong> Musculoskeletal Diseases, The Leeds<br />

Institute <strong>of</strong> Molecular Medicine. University <strong>of</strong> Leeds, Leeds,<br />

United Kingdom.<br />

554. The Prevalence <strong>of</strong> Cardiovascular Risk Factors in Patients with<br />

Early Psoriatic Arthritis. Majed M. Khraishi 3 , Rana Aslanov 1<br />

and Don MacDonald 2 , 1 Memorial University <strong>of</strong> Newfoundland,<br />

2<br />

Newfoundland and Labrador Centre for Health Information,<br />

3<br />

Nexus Clinical Research, St Johns, NL, Canada.<br />

555. Time to Diagnosis <strong>of</strong> Ankylosing Spondylitis in an Irish Cohort<br />

and the Effect on Work Disability. Catherine Sullivan 2 and Oliver<br />

M. FitzGerald 1 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, St Vincents<br />

University Hospital, Ranelagh Dublin, Ireland, 2 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, St Vincents University Hospital, Elm Park, Dublin<br />

4<br />

, Ireland.<br />

556. Urolithiasis in Ankylosing Spondylitis – Are Stone Formers<br />

Also Bone Formers? Nai Lee Lui 1 , Adele Carty 5 , Nigil Haroon 3 ,<br />

Hua Shen 2 , Richard Cook 2 and Robert D. Inman 4 , 1 Department<br />

<strong>of</strong> <strong>Rheumatology</strong> and Immunology, Singapore General Hospital,<br />

Singapore, 2 Department <strong>of</strong> Statistics and Actuarial Science,<br />

University <strong>of</strong> Waterloo, Canada, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Toronto Western Hospital, Toronto, ON, Canada, 4 Toronto<br />

Western Hospital, Toronto, ON, Canada, 5 Toronto Western<br />

Hospital.<br />

557. Validation <strong>of</strong> the Patient Acceptable Work State (PAWS):<br />

Establishing Thresholds for Major Work Transition in<br />

Ankylosing Spondylitis. Walter P. Maksymowych 3 , Sumati Rao 1 ,<br />

Annelies Boonen 2 , Naijun Chen 1 and Mary Cifaldi 1 , 1 Abbott<br />

Laboratories, Abbott Park, IL, 2 University Hospital Maastricht,<br />

Maastricht, Netherlands, 3 University <strong>of</strong> Alberta, Edmonton, AB.<br />

558. Variation during Different Decades <strong>of</strong> Diagnostic and<br />

Therapeutic Delay in Patients <strong>of</strong> Ankylosing Spondylitis (AS).<br />

Giuliana Salvadorini 2 , Francesca Bandinelli 2 , Andrea Delle<br />

Sedie 1 , Lucrezia Riente 1 , Antonio Candelieri 3 , Sergio Generini 2 ,<br />

Nicola Possemato 1 , Stefano Bombardieri 1 and Marco Matucci<br />

Cerinic 2 , 1 Department <strong>Rheumatology</strong> <strong>of</strong> University <strong>of</strong> Pisa, Pisa,<br />

Italy, 2 Division <strong>of</strong> <strong>Rheumatology</strong> AOUC, University <strong>of</strong> Florence,<br />

Department <strong>of</strong> Biomedicine, DENOThe Centre, Florence, Italy,<br />

3<br />

Laboratory <strong>of</strong> Decision Engineering for Health Care Delivery,<br />

Department <strong>of</strong> Electronics, Informatics and Systems, University<br />

<strong>of</strong> Cosenza, Italy.<br />

2010 Program Book 185


ACR Poster Session A<br />

559. Week 12 Response Is a Better Predictor Than Baseline<br />

Disease Characteristics <strong>of</strong> Long-Term Remission in Ankylosing<br />

Spondylitis. Joachim Sieper 3 , Desiree van der Heijde 4 ,<br />

Steve Brown 2 , Frederic Lavie 1 and Aileen Pangan 2 , 1 Abbott<br />

Laboratories, Rungis, France, 2 Abbott Laboratories, Abbott Park,<br />

IL, 3 Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Leiden<br />

University Medical Center, Leiden, The Netherlands.<br />

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical<br />

Aspects and Therapeutics I<br />

560. A Multi-Center, Open-Label, Pro<strong>of</strong> <strong>of</strong> Concept Study <strong>of</strong><br />

Imatinib Mesylate Demonstrates No Benefit for the Treatment<br />

<strong>of</strong> Fibrosis in Patients with Early, Diffuse Systemic Sclerosis.<br />

Oliver Distler 8 , Jorg H. W. Distler 9 , John Varga 4 , Christopher<br />

P. Denton 7 , Robert A. Lafyatis 1 , Fredrick M. Wigley 3 , Georg<br />

Schett 2 , Marco Matucci-Cerinic 10 , Timothy M. Wright 5 , Arthur<br />

P. Bertolino 6 and Peter Gergely, Jr 6 , 1 Boston University School<br />

<strong>of</strong> Medicine, Arlington, MA, 2 Friedrich Alexander Univ,<br />

Erlangen, Germany, 3 Johns Hopkins University, Baltimore, MD,<br />

4<br />

Northwestern Univ Feinberg School, Chicago, IL, 5 Novartis<br />

Institutes for Biomedical Research, Cambridge, MA, 6 Novartis<br />

Institutes for Biomedical Research, 7 Royal Free Hospital,<br />

London, United Kingdom, 8 University Hospital Zurich, Zurich,<br />

Switzerland, 9 University <strong>of</strong> Erlangen, Erlangen, Germany,<br />

10<br />

University <strong>of</strong> Florence, Firenze, Italy.<br />

561. Baseline Differences in the “Borderline” Pulmonary<br />

Hypertension vs. “Normal” Hemodynamics: PHAROS Registry.<br />

Dinesh Khanna 4 , Rajeev Saggar 4 , Daniel Furst 4 , Lorinda Chung 3 ,<br />

James Seibold 5 , Tracy Frech 7 , ELENA Schiopu 6 , Rajan Saggar 4 ,<br />

Marcy Bolster 2 , Virginia Steen 1 and PHAROS Investigators,<br />

1<br />

Georgetown University, 2 MUSC, 3 Stanford, 4 UCLA, 5 Univ <strong>of</strong><br />

Connecticut, 6 Univ <strong>of</strong> Michigan, 7 Univ <strong>of</strong> Utah.<br />

562. Cigarette Smoking Is Not a Risk Factor for Systemic Sclerosis.<br />

Prateek Chaudhary 3 , Xing Chen 6 , Shervin Assassi 3 , Olga Gorlova 7 ,<br />

Hilda Draeger 5 , Emilio Gonzalez 8 , Terry McNearney 1 , Marilyn<br />

Perry 3 , Jason Anderson 4 and Maureen D. Mayes 2 , 1 Indianapolis,<br />

IN, 2 University <strong>of</strong> Texas Health Science Center at Houston,<br />

Houston, TX, 3 University <strong>of</strong> Texas Health Science Center<br />

Houston, Houston, TX, 4 University <strong>of</strong> Texas Health Science<br />

Center Houston, 5 University <strong>of</strong> Texas Health Science Center San<br />

Antonio, San Antonio, TX, 6 University <strong>of</strong> Texas MD Anderson<br />

Cancer Center, Houston, TX, 7 University <strong>of</strong> Texas MD Anderson<br />

Health Science Center, Houston, TX, 8 University <strong>of</strong> Texas Medical<br />

Branch at Galveston, Galveston, TX.<br />

563. Clinical Characteristics <strong>of</strong> Systemic Sclerosis Sine Scleroderma<br />

Associated Interstitial Lung Disease. Rohit Aggarwal 3 , Mary<br />

Lucas 2 , Noreen Fertig 2 and Thomas A. Medsger 1 , 1 Univ <strong>of</strong><br />

Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh, 3 University<br />

<strong>of</strong> Pittsburgh Medical Center, Pittsburgh, PA.<br />

564. Clinical Predictive Factors on Response to Oral Monotherapy in<br />

Patients with Systemic Sclerosis-Associated Pulmonary Arterial<br />

Hypertension. Yih Chang Lin, Soumya Chatterjee, Meng Xu,<br />

Raed Dweik and Joseph Parambil, Cleveland Clinic.<br />

565. Combined Analysis <strong>of</strong> Outcomes <strong>of</strong> Sitaxentan Treatment<br />

<strong>of</strong> Pulmonary Arterial Hypertension (PAH) Associated with<br />

Systemic Sclerosis (Scleroderma). James R. Seibold 5 , Marco<br />

Matucci-Cerinic 6 , Michael Louie 3 , Stephen Watt 3 , Simon A. Teal 4 ,<br />

Xuexuan Liu 1 , Lie-Ju Hwang 3 and David Langleben 2 , 1 Aerotek,<br />

Houston, TX, 2 Cardiology, Montreal Jewish Hospital, Montreal,<br />

Canada, 3 Pfizer Inc, New York, NY, 4 Pfizer Ltd, Tadworth, Surrey,<br />

UK, 5 <strong>Rheumatology</strong>, University <strong>of</strong> Connecticut, Farmington,<br />

Farmington, CT, 6 University <strong>of</strong> Florence, Firenze, Italy.<br />

566. Comparative Analysis <strong>of</strong> Change in Modified Rodnan Skin<br />

Score in Patients with Diffuse Systemic Sclerosis Receiving<br />

Imatinib Mesylate Suggests Similar Disease Course to Matched<br />

Patients Receiving Standard Therapy. Christopher P. Denton 9 ,<br />

Svetlana I. Nihtyanova 2 , John Varga 5 , Oliver Distler 10 , Fredrick M.<br />

Wigley 4 , Robert A. Lafyatis 1 , Jorg H. W. Distler 11 , Georg Schett 3 ,<br />

Marco Matucci-Cerinic 12 , Timothy M. Wright 6 , Monica Costa<br />

Antunes 8 , Amy Racine 8 , Arthur P. Bertolino 7 and Peter Gergely,<br />

Jr 7 , 1 Boston University School <strong>of</strong> Medicine, Arlington, MA,<br />

2<br />

Center for <strong>Rheumatology</strong> and Connective Tissue Diseases, UCL<br />

Medical School, London, United Kingdom, 3 Friedrich Alexander<br />

Univ, Erlangen, Germany, 4 Johns Hopkins University, Baltimore,<br />

MD, 5 Northwestern Univ Feinberg School, Chicago, IL, 6 Novartis<br />

Institutes for Biomedical Research, Cambridge, MA, 7 Novartis<br />

Institutes for Biomedical Research, 8 Novartis Pharma, 9 Royal<br />

Free Hospital, London, United Kingdom, 10 University Hospital<br />

Zurich, Zurich, Switzerland, 11 University <strong>of</strong> Erlangen, Erlangen,<br />

Germany, 12 University <strong>of</strong> Florence, Firenze, Italy.<br />

567. Comparison <strong>of</strong> Estimated Pulmonary Artery Systolic<br />

Pressure by Echocardiography (PASPECHO) and Right Heart<br />

Catheterization (PASPRHC) in Patients with Systemic Sclerosis<br />

(Scleroderma, SSc). Elena Schiopu 3 , Ann J. Impens 3 , Melvyn<br />

Rubenfire 2 , Fazleomar Mahmood 3 and Kristine Phillips 1 ,<br />

1<br />

University <strong>of</strong> Michigan, Ann Arbor, MI, 2 University <strong>of</strong> Michigan,<br />

Division <strong>of</strong> Cardiology, Ann Arbor, MI, 3 University <strong>of</strong> Michigan,<br />

Scleroderma Program, Ann Arbor, MI.<br />

568. Determination <strong>of</strong> the Accurate Incidence <strong>of</strong> Pulmonary Arterial<br />

Hypertension in Patients with Systemic Sclerosis, Mixed<br />

Connective Tissue Disease and Systemic Lupus Erythematosus<br />

by Prospective Study for 3-Years. Sumiaki Tanaka 1 , Kenta<br />

Hoshi 4 , Junichi Tanaka 4 , Tatsuhiko Wada 4 , Toshimichi Matsui 4 ,<br />

Tatsuo Nagai 4 , Jun Okada 2 and Shunsei Hirohata 3 , 1 Drexel<br />

University <strong>College</strong> <strong>of</strong> MedicineDepartment <strong>of</strong> <strong>Rheumatology</strong><br />

and Infectious Diseases, Kitasato University School <strong>of</strong> Medicine,<br />

Sagamihara, Kanagawa, Japan, 2 Drexel University <strong>College</strong><br />

<strong>of</strong> MedicineDepartment <strong>of</strong> <strong>Rheumatology</strong> and Infectious<br />

Diseases, Kitasato University School <strong>of</strong> Medicine, Sagamihara,<br />

Japan, 3 Drexel University <strong>College</strong> <strong>of</strong> MedicineDepartment <strong>of</strong><br />

<strong>Rheumatology</strong> and Infectious Diseases, Kitasato University<br />

School <strong>of</strong> Medicine, Kanagawa, Japan, 4 Drexel University <strong>College</strong><br />

<strong>of</strong> MedicineDepartment <strong>of</strong> <strong>Rheumatology</strong> and Infectious<br />

Diseases, Kitasato University School <strong>of</strong> Medicine.<br />

569. Difficulty Using World Health Organization Criteria To<br />

Categorize Pulmonary Hypertension in Patients with<br />

Systemic Sclerosis. Jessica K. Gordon 3 , Mardi Gomberg-<br />

Maitland 5 , Barbara M. Segal 2 , Robyn T. Domsic 6 , Ami A.<br />

Shah 4 , Laura K. Hummers 4 , Virginia D. Steen 1 , Evelyn Horn 7<br />

and PHAROS Investigators, 1 Georgetown University Medical<br />

Center, Washington, DC, 2 Hennepin County Medical Center,<br />

Minneapolis, MN, 3 Hospital for Special Surgery, New York,<br />

NY, 4 Johns Hopkins University, Baltimore, MD, 5 University <strong>of</strong><br />

Chicago, 6 University <strong>of</strong> Pittsburgh, Pittsburgh, PA, 7 Weill-Cornell<br />

Medical <strong>College</strong>.<br />

570. Dyspnea in Scleroderma Patients from the PHAROS Registry:<br />

A Major Contributor to Disability. Lorinda Chung 2 , Hubert<br />

Chen 3 , Dinesh Khanna 5 , Ann J. Impens 4 , Virginia D. Steen 1 and<br />

PHAROS Investigators, 1 Georgetown University Medical Center,<br />

Washington, DC, 2 Stanford Univ Medical Center, Palo Alto,<br />

CA, 3 UCSF, 4 Univ <strong>of</strong> Michigan Lobby M 2500, Ann Arbor, MI,<br />

5<br />

University <strong>of</strong> California Los Angeles, Los Angeles, CA.<br />

186<br />

2010 Program Book


ACR Poster Session A<br />

571. Epidemiology <strong>of</strong> Systemic Sclerosis in the Afro-Caribbean<br />

Population <strong>of</strong> Martinique, FWI: A Population-Based Study.<br />

Christophe Deligny, Vincent Goeb, Marie Elise Truchetet,<br />

Valentine Kahn, Veronique Dehlinger, Patrick Numéric, Christian<br />

Derancourt, Georges Jean Baptiste and Serge Arfi, CHU de Fort<br />

de France, Fort de France, Martinique.<br />

572. European Scleroderma Study Group (ESCSG) Activity Index<br />

Is Correlated to Quality <strong>of</strong> Life Measures Both at Admission<br />

and Overtime. Gabriele Valentini 2 , Michele Iudici 3 , Giuseppina<br />

Abignano 3 , Serena Vettori 1 and Giovanna Cuomo 3 , 1 Italy,<br />

2<br />

<strong>Rheumatology</strong> Unit - Second University <strong>of</strong> Naples, Napoli, Italy,<br />

3<br />

<strong>Rheumatology</strong> Unit- Second University <strong>of</strong> Naples, Italy.<br />

573. Evaluation <strong>of</strong> an Imatinib Response Gene Signature in Patients<br />

with Systemic Sclerosis. Lorinda Chung 3 , Pedro Ruiz 5 , Tammara<br />

Wood 1 , Stanford Shoor 2 , William Robinson 4 , Michael Whitfield 1 ,<br />

Howard Chang 5 and David Fiorentino 5 , 1 Dartmouth Medical<br />

School, 2 Kaiser Permanente <strong>of</strong> Northern California, 3 Stanford<br />

Univ Medical Center, Palo Alto, CA, 4 Stanford Univ School <strong>of</strong><br />

Med, Stanford, CA, 5 Stanford University School <strong>of</strong> Medicine.<br />

574. Evaluation <strong>of</strong> the Effect <strong>of</strong> Ambrisentan on Digital<br />

Microvascular Flow in Patients with Systemic Sclerosis Using<br />

Laser Doppler Perfusion Imaging. Nilanjana Bose 2 , James F.<br />

Bena 2 , Charles M. Trunick 3 , Debora J. Bork 2 , Geetha Krishnan 2 ,<br />

John Petrich 2 and Soumya Chatterjee 1 , 1 Cleveland Clinic,<br />

Richmond Heights, OH, 2 Cleveland Clinic, Cleveland, OH,<br />

3<br />

Cleveland Clinic.<br />

575. Identification <strong>of</strong> New Autoantibody Specificities in Different<br />

Subsets <strong>of</strong> Systemic Sclerosis Patients. Guillaume Bussone 3 ,<br />

Hanadi Dib 4 , Mathieu C. Tamby 1 , Cédric Broussard 5 , Loïc<br />

Guillevin 2 and Luc Mouthon 2 , 1 Université Paris Descartes,<br />

Institut Cochin, INSERM U1016, CNRS (UMR 8104), Paris,<br />

France, 2 Universite Paris Descartes, Faculte de Medecine,<br />

Pole de Medecine Interne et Centre de Reference Pour les<br />

Vascularites Necrosantes et la Sclerodermie Systemique, Hopital<br />

Cochin, Assistance Publique-Hopitaux de Paris, Paris, 3 Universite<br />

Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR<br />

8104), Paris, France, 4 Universite Paris Descartes, Institut Cochin,<br />

INSERM U1016, CNRS (UMR 8104), Paris, France, 5 Universite<br />

Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR<br />

8104), Plate-forme Proteomique Paris 5 , Paris.<br />

576. Intravenous Immunoglobulin (IVIg) in the Treatment <strong>of</strong><br />

Systemic Sclerosis (SSc) Associated Myopathy. Arnaud Dzeing-<br />

Ella 7 , Alice Bérezné 7 , Brigitte Ranque 4 , François-Jérôme Authier 1 ,<br />

Yannick Allanore 5 , Jean Cabane 3 , Eric Hachulla 2 , Loïc Guillevin 7<br />

and Luc Mouthon 6 , 1 Service d’Histologie, Hôpital Henri-<br />

Mondor, Creteil, France, 2 Service de Medecine Interne, Hôpital<br />

Claude-Huriez, Lille, 3 Service de Medecine Interne, Hôpital<br />

Saint-Antoine, Paris, France, 4 Service de Medecine Interne,<br />

HEGP, Paris, France, 5 Service de Rhumatologie A, Hôpital Cochin,<br />

Paris, France, 6 Universite Paris Descartes, Faculte de Medecine,<br />

Pole de Medecine Interne et Centre de Reference Pour les<br />

Vascularites Necrosantes et la Sclerodermie Systemique, Hopital<br />

Cochin, Assistance Publique-Hopitaux de Paris, Paris, France,<br />

7<br />

Universite Paris Descartes, Faculte de Medecine, Pole de<br />

Medecine Interne et Centre de Reference Pour les Vascularites<br />

Necrosantes et la Sclerodermie Systemique, Hopital Cochin,<br />

Assistance Publique-Hopitaux de Paris, Paris.<br />

577. Modeling Smoking in Systemic Sclerosis: A Comparison <strong>of</strong><br />

Different Statistical Approaches. Marie Hudson 3 , Ernest Lo 2 ,<br />

Russell Steele 3 and Murray Baron 1 , 1 Jewish General Hospital,<br />

Montreal, QC, Canada, 2 Lady Davis Institute, Jewish General<br />

Hospital, 3 McGill University.<br />

578. Nailfold Microangiopathy and Pheripheral Blood Perfusion<br />

Correlate with Internal Organ Involvement in Sistemic<br />

Sclerosis. Alberto Sulli 1 , Carmela Ferrone 2 , Carmen Pizzorni 2 ,<br />

Elisa Alessandri 2 , Francesca Ravera 2 , Giuseppe Zampogna 2 ,<br />

Bruno Seriolo 2 and Maurizio Cutolo 1 , 1 Research Laboratory and<br />

Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine, University <strong>of</strong> Genova, Genova, Italy, 2 Research<br />

Laboratory and Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Genova,<br />

Genova, Italy.<br />

579. Oral N-acetylcysteine in the Treatment <strong>of</strong> Raynaud’s<br />

Phenomenon Secondary to Systemic Sclerosis: A Randomized,<br />

Double-Blind, Placebo-Controlled Clinical Trial. Marcelo<br />

José Uchoa Correa 2 , Henrique A. Mariz 3 , Luis Eduardo Coelho<br />

Andrade 3 and Cristiane Kayser 1 , 1 Universidade Federal de São<br />

Palo, Brazil, 2 Universidade Federal de São Paulo, São Paulo,<br />

Brazil, 3 Universidade Federal de São Paulo, Brazil.<br />

580. Outcomes <strong>of</strong> Barrett’s Esophagus Related to Systemic Sclerosis:<br />

A 3-Year EULAR/EUSTAR Prospective Follow-Up Study.<br />

Julien Wipff 11 , Romain Coriat 9 , Michela Masciocchi 5 , Paola<br />

Caramaschi 2 , Chris T. Derk 7 , Eric Hachulla 8 , Valeria Riccieri 12 , Luc<br />

Mouthon 10 , Dorota Krasowska 1 , L. P. Ananyeva 6 , Andre Kahan 3 ,<br />

Marco Matucci-Cerinic 13 , Stanislas Chaussade 9 and Yannick<br />

Allanore 4 , 1 Department <strong>of</strong> Dermatology, Medical University <strong>of</strong><br />

Lublin, Lublin, 2 Department <strong>of</strong> Medicine, Verona University,<br />

Verona, 3 Hopital Cochin, Paris, France, 4 Hopitaux de Paris<br />

Cochin, Paris, France, 5 Immunological Clinic, Mangiagalli Regina<br />

Elena Fundation, Milan, 6 Institute <strong>of</strong> <strong>Rheumatology</strong>, Russian<br />

Academy <strong>of</strong> Medical Science, Moscow, 7 Jefferson Medical<br />

<strong>College</strong>, Philadelphia, PA, 8 National Scleroderma Centre, Lille<br />

Cedex, France, 9 Paris Descartes University, Gastroenterology<br />

Dpt, Cochin Hospital, 10 Paris Descartes University, Internal<br />

Medicine Dpt, Cochin Hospital, 11 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Dpt, Cochin Hospital, 12 Sapienza University<br />

<strong>of</strong> Rome, Medical Clinic and Therapy Department, Rome,<br />

13<br />

University <strong>of</strong> Florence, Firenze, Italy.<br />

581. WITHDRAWN<br />

582. Preclinical Evaluation <strong>of</strong> Cardiac Involvement in Systemic<br />

Sclerosis Patients by Speckle Tracking Strain Analysis. Anne<br />

A. Schouffoer 3 , Kai H. Yiu 1 , Maarten K. Ninaber 2 , Jan Stolk 2 ,<br />

Thea P. M. Vliet-Vlieland 3 , Eduard R. Holman 1 , Tom W. J.<br />

Huizinga 3 , Jeroen J. Bax 1 , Nina Ajmone Marsan 1 and Annemie<br />

J. M. Schuerwegh 4 , 1 Department <strong>of</strong> Cardiology, Leiden, The<br />

Netherlands, 2 Department <strong>of</strong> Pulmonology, Leiden, The<br />

Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden, The<br />

Netherlands, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University<br />

Medical Center, Leiden, The Netherlands.<br />

583. Preliminary Composite Response Index for Raynaud’s<br />

Phenomenon. Dinesh Khanna 2 , Paul Maranian 2 , Daniel Furst 2 ,<br />

James Seibold 3 , Marco Matucci Cerinic 4 , Jeff Gregory 1 and<br />

Harold Paulus 2 , 1 MediQuest, 2 UCLA, 3 Univ <strong>of</strong> Conneticut, 4 Univ<br />

<strong>of</strong> Florence.<br />

584. Prevalence <strong>of</strong> Coronary Heart Disease in a Cohort <strong>of</strong> Australian<br />

Scleroderma Patients. Gene-Siew Ngian 2 , Joanne Sahhar 7 , Jill<br />

Byron 14 , Susanna Proudman 9 , Catherine Hill 8 , Janet Roddy 11 ,<br />

Peter Youssef 12 , Kathleen Tymms 1 , Leslie Schrieber 10 , Wendy<br />

Stevens 14 , Jane Zochling 6 , Peter Nash 15 , Allan Sturgess 13 , Gabor<br />

Major 5 , Ian Wicks 3 and Sharon Van Doornum 4 , 1 Canberra<br />

<strong>Rheumatology</strong>, Australia, 2 Department <strong>of</strong> Medicine (RMH/<br />

WH), University <strong>of</strong> Melbourne, Melbourne, Victoria, Australia,<br />

3<br />

Department <strong>of</strong> Medicine (RMH/WH), University <strong>of</strong> Melbourne,<br />

Melbourne, Australia, 4 Department <strong>of</strong> Medicine (RMH/WH),<br />

2010 Program Book 187


ACR Poster Session A<br />

University <strong>of</strong> Melbourne, 5 John Hunter Hospital, Newcastle,<br />

Australia, 6 Menzies Research Institute, University <strong>of</strong> Tasmania,<br />

Hobart, Australia, 7 Monash Medical Centre, Melbourne,<br />

Australia, 8 Queen Elizabeth Hospital, Adelaide, Australia,<br />

9<br />

Royal Adelaide Hospital, Adelaide, Australia, 10 Royal North<br />

Shore Hospital, Sydney, Australia, 11 Royal Perth Hospital, Perth,<br />

Australia, 12 Royal Prince Alfred Hospital, Sydney, Australia, 13 St<br />

George Hospital, Sydney, Australia, 14 St Vincent’s Hospital,<br />

Melbourne, Australia, 15 Sunshine Coast <strong>Rheumatology</strong>,<br />

Australia.<br />

585. Pulmonary Artery Diameter Is Associated with Pulmonary<br />

Hypertension in Patients with Systemic Sclerosis (SSc).<br />

Elena Schiopu 4 , Ann J. Impens 4 , Barry H. Gross 3 , Fazleomar<br />

Mahmood 4 , James R. Seibold 1 and Kristine Phillips 2 , 1 University<br />

<strong>of</strong> Connecticut Health Center, Farmington, CT, 2 University <strong>of</strong><br />

Michigan, Ann Arbor, MI, 3 University <strong>of</strong> Michigan, Department<br />

<strong>of</strong> Radiology, Ann Arbor, MI, 4 University <strong>of</strong> Michigan,<br />

Scleroderma Program, Ann Arbor, MI.<br />

586. Pulmonary Hypertension Assessment and Recognition <strong>of</strong><br />

Outcomes in Scleroderma (PHAROS): Comparison <strong>of</strong> Outcomes<br />

in Subtypes <strong>of</strong> Pulmonary Hypertension. Robyn T. Domsic 6 ,<br />

Lorinda Chung 3 , Mardi Gomnberg-Maitland 4 , Jessica K. Gordon 2 ,<br />

Barbara M. Segal 5 , Virginia D. Steen 1 and PHAROS Investigators,<br />

1<br />

Gerogetown University Medical Center, Washington, DC,<br />

2<br />

Hospital for Special Surgery, New York, NY, 3 Stanford University<br />

Medical Center, Palo Alto, CA, 4 University <strong>of</strong> Chicago Medical<br />

Center, Chicago, IL, 5 University <strong>of</strong> Minnesota, Minneapolis, MN,<br />

6<br />

University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

587. Pulmonary Hypertension by Age <strong>of</strong> Scleroderma Onset and<br />

Subtype. Rebecca L. Manno 2 , Fredrick M. Wigley 1 and Laura K.<br />

Hummers 2 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns<br />

Hopkins University, Baltimore, MD.<br />

588. Reproducibility <strong>of</strong> Semi-Automated Quantitative Nailfold<br />

Capillaroscopy Measurements in Patients with Systemic<br />

Sclerosis. Andrea K. Murray 4 , Tonia L. Moore 4 , Andy Vail 1 ,<br />

Joanne Manning 2 and Ariane L. Herrick 3 , 1 <strong>Rheumatology</strong><br />

Directorate, HealthMethodology Research Group, Manchester<br />

Academic Health ScienceCentre, The University <strong>of</strong><br />

Manchester, Salford Royal Hospital, Salford, UK, 2 Salford Royal<br />

NHSFoundation Trust, Salford, 3 The University <strong>of</strong> Manchester,<br />

Manchester Academic Health Science Centre, Manchester,<br />

Salford Royal Hospital, Salford, Greater Manchester, United<br />

Kingdom, 4 The University <strong>of</strong> Manchester, Manchester Academic<br />

Health Science Centre, Manchester, Salford Royal Hospital, UK.<br />

589. Risk Associated with African <strong>American</strong> Race in Relation<br />

to Prevalence <strong>of</strong> Cardinal Organ System Manifestations in<br />

Scleroderma. Elizabeth N. Le 3 , Rebecca L. Manno 3 , Laura K.<br />

Hummers 3 , Fredrick M. Wigley 2 and Allan C. Gelber 1 , 1 Baltimore,<br />

MD, 2 Johns Hopkins University, Baltimore, MD, 3 Johns Hopkins<br />

University, Baltimore, MD.<br />

590. Role <strong>of</strong> N-Terminal Pro-BNP in Detecting Clinically-Significant<br />

Cardiac Involvement in Systemic Sclerosis Patients. Cecilia<br />

Chighizola 3 , Benjamin Schreiber 2 , Pier Luigi Meroni 3 , Gerry<br />

Coghlan 1 , Christopher P. Denton 4 and Voon Ong 1 , 1 Center for<br />

<strong>Rheumatology</strong> and Connective Tissue Diseases, UCL Medical<br />

School, Royal Free Hospital, London, United Kingdom, 2 Center<br />

for <strong>Rheumatology</strong> and Connective Tissue Diseases, UCL Medical<br />

School, Royal Free Hospital, London, 3 <strong>Rheumatology</strong> Division,<br />

Department <strong>of</strong> Internal Medicine, Istituto G. Pini, University<br />

<strong>of</strong> Milan, Milan, Italy, 4 Royal Free Hospital, London, United<br />

Kingdom.<br />

591. Scleroderma Autoantibodies and Disease Subtype Predict<br />

Pulmonary Hypertension Classification in the PHAROS<br />

Registry. Monique E. Hinchcliff 5 , Aryeh Fischer 4 , Nadera Sweiss 6 ,<br />

Maureen Mayes 7 , Marcy Bolster 3 , Virginia Steen 1 and PHAROS<br />

Investigators 2 , 1 Georgetown University, 2 Gerogetwon University,<br />

3<br />

Medical University <strong>of</strong> South Carolina, 4 National Jewish Health,<br />

5<br />

Northwestern University, 6 University <strong>of</strong> Chicago, 7 University <strong>of</strong><br />

Texas-Houston Medical School.<br />

592. Scleroderma Lung Disease: Effect <strong>of</strong> Co-Existent Pulmonary<br />

Hypertension on Progression <strong>of</strong> Interstitial Lung Disease.<br />

Anupama Shahane, Joseph Parambil, Meng Xu and Soumya<br />

Chatterjee, Cleveland Clinic.<br />

593. Sildenafil Increases Vasodilation in Systemic Sclerosis: An<br />

Interim Analysis from a Single Centre Pilot Study. Silvia<br />

Bellando-Randone, Irene Miniati, Serena Guiducci, Maria Letizia<br />

Conforti, Jelena Blagojevic, Ginevra Fiori, Francesca Bartoli,<br />

Francesca Nacci and Marco Matucci-Cerinic, Department <strong>of</strong><br />

Biomedicine Section <strong>of</strong> <strong>Rheumatology</strong> University <strong>of</strong> Florence,<br />

Italy.<br />

594. Subclinical Atherosclerosis Is Increased in Systemic Sclerosis<br />

— A Case-Control Study. Karen M. Au 1 , Maureen A. McMahon 1 ,<br />

Daniel E. Furst 3 , Bevra H. Hahn 4 , Nagesh Ragavendra 1 , Amber<br />

Bechtel 1 , Lori Sahakian 1 and Dinesh Khanna 2 , 1 UCLA School <strong>of</strong><br />

Medicine, Los Angeles, CA, 2 University <strong>of</strong> California Los Angeles,<br />

Los Angeles, CA, 3 University <strong>of</strong> California Los Angeles Medical<br />

School, Los Angeles, CA, 4 University <strong>of</strong> California Los Angeles<br />

School <strong>of</strong> Medicine, Los Angeles, CA.<br />

595. Symptom Burden, Quality <strong>of</strong> Life and Attitudes toward<br />

Palliative Care in Patients with Pulmonary Hypertension with<br />

and without Systemic Sclerosis. Nicole M. Orzechowski 1 , Keith<br />

M. Swetz 2 , Tait D. Shanafelt 3 , Jeff A. Sloan 3 , Paul J. Novotny 3 ,<br />

Robert P. Frantz 3 and Michael D. McGoon 3 , 1 Dartmouth<br />

Hitchcock Med Center, Lebanon, NH, 2 Mayo Clinic, Rochester,<br />

MN, 3 Mayo Clinic.<br />

596. The Degree <strong>of</strong> Skin Involvement Predicts Distinct Interstitial<br />

Lung Disease Outcomes in Systemic Sclerosis. Tricia R. Cottrell,<br />

Fredrick Wigley, Robert Wise and Francesco Boin, Johns Hopkins<br />

University, Baltimore, MD.<br />

597. The Effect <strong>of</strong> Gastric Acid Suppression with Esomeprazole<br />

on Treprostinil Diethanolamine Pharmacokinetics in Healthy<br />

Volunteers. Kristan Rollins 2 , Susan Walker 2 , Jennifer Kates 2 ,<br />

Kevin Laliberte 2 and Allison Lim 1 , 1 United Therapetutics,<br />

Research Triangle Park, NC, 2 United Therapeutics.<br />

598. The Pulmonary Arterial Hypertension Quality Enhancement<br />

Research Initiative (PAH-QuERI): Comparing Baseline<br />

Characteristics, Management and Survival in Patients with<br />

Idiopathic PAH (IPAH) to Patients with Systemic Sclerosis<br />

Related PAH (SSc-PAH). Philip J. Clements 2 , Amparo Casanova 1 ,<br />

Tan Mary 1 , Channick Richard 4 , Valerie McLaughlin 6 , Ron Oudiz 2 ,<br />

Lew Rubin 5 , Tapson Victor 3 and Langer Anatoly 1 , 1 Canadian<br />

Heart Research Center, 2 David Geffen School <strong>of</strong> Medicine<br />

at UCLA, 3 Duke University Medical Center, Durham, NC,<br />

4<br />

Massachusetts General Hospital, 5 University <strong>of</strong> California at San<br />

Diego, 6 University <strong>of</strong> Michigan Health System.<br />

188<br />

2010 Program Book


ACR Poster Session A<br />

599. Validation <strong>of</strong> 6 Minute Walking Distance in Patients with<br />

Pulmonary Arterial Hypertension Associated with Systemic<br />

Sclerosis. Dörte Huscher 11 , Nicholas Roubinis 17 , Jerome<br />

Avouac 18 , Frank Behrens 10 , Christopher P. Denton 1 , Daniel E.<br />

Furst 8 , Ivan Foeldvari 14 , Marc Humbert 19 , Otylia Kowal-Bielecka 4 ,<br />

Marco Matucci-Cerinic 3 , Peter Nash 6 , Christian F. Opitz 2 ,<br />

David Pittrow 13 , Lewis J. Rubin 7 , James R. Seibold 9 , Marius M.<br />

Hoeper 12 , Mark F. Morris 15 , Simon A. Teal 16 and Oliver Distler 5 ,<br />

1<br />

Centre for <strong>Rheumatology</strong>, Royal Free Campus, University<br />

<strong>College</strong> Medical School, London, United Kingdom, 2 Department<br />

<strong>of</strong> Internal Medicine, DRK-Kliniken Berlin Köpenick, Berlin,<br />

Germany, 3 Department <strong>of</strong> Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Denothe Center, University <strong>of</strong> Florence, Italy, 4 Department <strong>of</strong><br />

<strong>Rheumatology</strong> and Internal Medicine, Medical University <strong>of</strong><br />

Bialystok, Poland, 5 Department <strong>of</strong> <strong>Rheumatology</strong>, University<br />

Hospital Zurich, Zurich, Switzerland, 6 Dept. <strong>of</strong> Medicine,<br />

University <strong>of</strong> Queensland, Queensland, Australia, 7 Division<br />

<strong>of</strong> Pulmonary and Critical Care Medicine, University <strong>of</strong><br />

California, San Diego School <strong>of</strong> Medicine, La Jolla, 8 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Medicine, David Geffen School<br />

at UCLA, Los Angeles, CA, 9 Division <strong>of</strong> <strong>Rheumatology</strong>, University<br />

<strong>of</strong> Connecticut, Farmington, CT, 10 Division <strong>of</strong> <strong>Rheumatology</strong>/<br />

ZAFES, J.W. Goethe University, Frankfurt, Germany, 11 German<br />

Rheumatism Research Centre, Berlin, Germany, 12 Hannover<br />

Medical School, Department <strong>of</strong> Pneumology, Hannover,<br />

Germany, 13 Institute for Clinical Pharmacology, Medical<br />

Faculty, Technical University, Dresden, Germany, 14 Pediatric<br />

<strong>Rheumatology</strong> Clinic, General Hospital Eilbek, Germany, 15 Pfizer<br />

Ltd, Sandwich, UK, 16 Pfizer Ltd, Tadworth, UK, 17 Quanticate Ltd,<br />

Hitchin, UK, 18 <strong>Rheumatology</strong> A Department, RDU, Paris, France,<br />

19<br />

Service de Pneumologie et Reanimation Respiratoire, Centre<br />

des Maladies Vasculaires Pulmonaires, Hopital Antoine-Beclere,<br />

Université Paris-Sud, Clamart, France.<br />

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis<br />

and Animal Models I<br />

600. Adenosine A 2 A Receptor Occupancy Promotes Dermal Fibrosis<br />

by Modulating FLI 1 and CTGF Expression. Hailing Liu 3 , Edwin<br />

Chan 2 , Patricia Fernández 2 and Bruce N. Cronstein 1 , 1 New York<br />

Univ Med Ctr, New York, NY, 2 NYU School <strong>of</strong> Medicine, 3 NYU<br />

School <strong>of</strong> Medicine, New York, NY.<br />

601. Adipocyte-Targeted Wnt Activation Results in Spontaneous<br />

Dermal Fibrosis and Subcutaneous Lipoatrophy. Jun Wei 3 ,<br />

Denisa S. Melichian 2 , Kazuhiro Kumora 2 , Ormond Macdougald 4<br />

and John Varga 1 , 1 Northwestern Univ Feinberg School, Chicago,<br />

IL, 2 Northwestern University Feinberg School <strong>of</strong> Medicine,<br />

3<br />

Northwestern University Feinberg School <strong>of</strong> Medicine, Chicago,<br />

IL, 4 University <strong>of</strong> Michigan.<br />

602. Cadherin 11 Promotes Pulmonary Fibrosis through Production<br />

<strong>of</strong> TGF β and the Regulation <strong>of</strong> Epithelial to Mesenchymal<br />

Transition. Daniel J. Schneider 1 , Minghua Wu 4 , Thuy T. Le 2 ,<br />

Seo-Hee Cho 3 , Michael B. Brenner 5 , Michael R. Blackburn 2<br />

and Sandeep K. Agarwal 4 , 1 Department <strong>of</strong> Biochemistry and<br />

Molecular Biology, University <strong>of</strong> Texas Health Science Center,<br />

Houston, TX, 2 Department <strong>of</strong> Biochemistry and Molecular<br />

Biology, University <strong>of</strong> Texas Health Science Center, 3 Department<br />

<strong>of</strong> Pediatrics, Pediatric Research Center, University <strong>of</strong> Texas<br />

Health Science Center, 4 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunogenetics, The University <strong>of</strong> Texas-Houston Medical<br />

School, Houston, TX, 5 Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology<br />

and Allergy, Brigham and Women’s Hospital and Harvard<br />

Medical School.<br />

603. Cadherin-11 in Systemic Sclerosis and Its Role in Dermal<br />

Fibrosis. Minghua Wu 3 , Michael B. Brenner 1 , Maureen D.<br />

Mayes 4 , Frank C. Arnett 5 , Filemon K. Tan 6 and Sandeep K.<br />

Agarwal 2 , 1 Brigham & Womens Hospital, Boston, MA, 2 Division<br />

<strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics, University <strong>of</strong><br />

Texas Health Science Center at Houston, Houston, TX, 3 Division<br />

<strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics, University <strong>of</strong><br />

Texas Health Science Center at Houston (UTHSC-H), Houston,<br />

TX, 4 University <strong>of</strong> Texas-Houston, Houston, TX, 5 UT Medical<br />

School, Houston, TX, 6 UT-Houston Med School, Houston, TX.<br />

604. Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor,<br />

Represses Fibrotic Changes in a Murine Model <strong>of</strong> Pulmonary<br />

Fibrosis. Galina Bogatkevich 3 , Anna Ludwicka-Bradley 3 , Paul J.<br />

Nietert 4 , Joanne van Ryn 1 and Richard M. Silver 2 , 1 Boehringer<br />

Ingelheim, 2 Medical University <strong>of</strong> South Carolina, Charleston,<br />

SC, 3 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />

4<br />

Medical University <strong>of</strong> South Carolina.<br />

605. Endothelial Dysfunction and Abnormal Collagen V Deposition<br />

in Pulmonary Vasculature <strong>of</strong> Experimental Systemic Sclerosis<br />

Model. Roberta G. Marangoni 2 , Edwin R. Parra 1 , Ana Paula P.<br />

Velosa 3 , Walcy R. Teodoro 3 , Vera L. Capelozzi 1 and Natalino H.<br />

Yoshinari 3 , 1 Pathology Department, Faculdade de Medicina da<br />

Universidade de São Paulo, 2 <strong>Rheumatology</strong> Division, Faculdade<br />

de Medicina da Universidade de São Paulo, São Paulo, SP,<br />

Brazil, 3 <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />

Universidade de São Paulo.<br />

606. Genetic Deletion or Pharmacologic Antagonism <strong>of</strong> LPA1<br />

Ameliorates Dermal Fibrosis in a Mouse Model <strong>of</strong> Systemic<br />

Sclerosis. Flavia V. Castelino 3 , Jon Seiders 1 , Gretchen Bain 1 ,<br />

Chris King 1 , James Swaney 1 , Dan Lorrain 1 , Jerold Chun 5 , Andrew<br />

D. Luster 2 and Andrew M. Tager 4 , 1 Amira Pharmaceuticals,<br />

2<br />

Massachusetts General Hospital, Charlestown, MA,<br />

3<br />

Massachusetts General Hospital, Boston, MA, 4 Massuchusetts<br />

General Hospital, 5 Scripps Research Institute.<br />

607. Inactivation <strong>of</strong> the Transcription Factor STAT4 Prevents<br />

Inflammation-Driven Fibrosis in Systemic Sclerosis Animal<br />

Models. Jerome Avouac 3 , Barbara G. Fürnrohr 2 , Michal Tomcik 4 ,<br />

Katrin Palumbo 2 , Pawel Zerr 2 , Angelika Horn 2 , Clara Dees 2 ,<br />

Alfiya Akhmetshina 2 , Christian Beyer 2 , Oliver Distler 1 , Georg<br />

Schett 5 , Yannick Allanore 6 and Jorg H. W. Distler 7 , 1 Center <strong>of</strong><br />

Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative<br />

Human Physiology, University Hospital Zurich, Zurich,<br />

Switzerland, 2 Department <strong>of</strong> Internal Medicine III and Institute<br />

for Clinical Immunology, University <strong>of</strong> Erlangen-Nuremberg,<br />

Erlangen, Germany, 3 Department <strong>of</strong> Internal Medicine III<br />

and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />

Nuremberg, Erlangen, Germany, Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital, and INSERM<br />

U781, Necker Hospital, Paris, Fr, 4 Department <strong>of</strong> Internal<br />

Medicine III, University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />

Germany and Institute <strong>of</strong> <strong>Rheumatology</strong> and Connective<br />

Tissue Research Laboratory, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong><br />

the First Faculty <strong>of</strong> Medicine, Charles University i, 5 Friedrich<br />

Alexander Univ, Erlangen, Germany, 6 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital, and INSERM<br />

U781, Necker Hospital, Paris, France, 7 University <strong>of</strong> Erlangen,<br />

Erlangen, Germany.<br />

608. Induction <strong>of</strong> Peripheral Tissue Ischemia and Anti-Endothelial<br />

Antibodies after B Cell Adoptive Transfer from RNP-Immunized<br />

Mice. YunJuan Zang 3 , Irina Fernandez 3 , Maite Chavez 3 , Laisel<br />

Martinez 1 and Eric L. Greidinger 2 , 1 Miami VA Medical Center,<br />

2<br />

Miami VA Medical Center and University <strong>of</strong> Miami Miller School<br />

<strong>of</strong> Medicine, Miami, FL, 3 University <strong>of</strong> Miami Miller School <strong>of</strong><br />

Medicine.<br />

2010 Program Book 189


ACR Poster Session A<br />

609. Mice Lacking the Receptor-Like Protein Tyrosine Phosphatase<br />

CD148 Are Protected from Bleomycin-Induced Pulmonary<br />

Fibrosis. Tamiko R. Katsumoto 1 , Kevin K. Kim 2 , Alexis N.<br />

Brumwell 2 , John X. Nguyen 2 , Jing W. Zhu 2 , Mark R. Looney 2 ,<br />

Harold A. Chapman 2 and Arthur Weiss 2 , 1 UCSF, South San<br />

Francisco, CA, 2 UCSF.<br />

610. Noggin +/LacZ Heterozygous Mice Have Reduced Pulmonary<br />

Fibrosis in the Bleomycin Induced Model. Ellen de Langhe 2 ,<br />

Vanessa De Vooght 2 , Frank P. Luyten 1 and Rik Lories 1 , 1 KU<br />

Leuven, Leuven, Belgium, 2 KU Leuven.<br />

611. Nr4a1 Ameliorates the Pro-Fibrotic Effects <strong>of</strong> TGFβ in Systemic<br />

Sclerosis (SSc) and Might Be an Interesting Target for Anti-<br />

Fibrotic Therapies. Katrin Palumbo 1 , Alfiya Akhmetshina 1 ,<br />

Pawel Zerr 1 , Michal Tomcik 1 , Angelika Horn 1 , Clara Dees 1 , Oliver<br />

Distler 3 , Georg Schett 2 and Jorg H. W. Distler 4 , 1 Department<br />

<strong>of</strong> Internal Medicine III and Institute for Clinical Immunology,<br />

University <strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany,<br />

2<br />

Friedrich Alexander Univ, Erlangen, Germany, 3 University<br />

Hospital Zurich, Zurich, Switzerland, 4 University <strong>of</strong> Erlangen,<br />

Erlangen, Germany.<br />

612. Osteopontin in Systemic Sclerosis and Its Role in Dermal<br />

Fibrosis. Minghua Wu 2 , Daniel J. Schneider 1 , Maureen D.<br />

Mayes 3 , Shervin Assassi 2 , Frank C. Arnett 4 , Filemon K. Tan 5 ,<br />

Michael R. Blackburn 1 and Sandeep K. Agarwal 2 , 1 Department<br />

<strong>of</strong> Biochemistry and Molecular Biology, UTHSC-H, Houston,<br />

TX, 2 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics,<br />

University <strong>of</strong> Texas Health Science Center at Houston, Houston,<br />

TX, 3 University <strong>of</strong> Texas-Houston, Houston, TX, 4 UT Medical<br />

School, Houston, TX, 5 UT-Houston Med School, Houston, TX.<br />

613. Relevance <strong>of</strong> Epithelial Phenotypic Switching in the<br />

Pathogenesis <strong>of</strong> Systemic Sclerosis. Xu Shiwen 1 , S. Sonnylal 3 ,<br />

A. Tam 2 , R. Stratton 2 , A. Leask 2 , C. P. Denton 2 , J. Norman 2<br />

and D. Abraham 2 , 1 <strong>Rheumatology</strong>, London, United Kingdom,<br />

2<br />

<strong>Rheumatology</strong>,, United Kingdom, 3 UT M. D. Anderson Cancer,<br />

Houston, TX.<br />

614. S100A4 as a Novel Mediator <strong>of</strong> TGF-β Driven Dermal Fibrosis<br />

in Systemic Sclerosis. Michal Tomcik 4 , Pawel Zerr 2 , Katrin<br />

Palumbo 2 , Barbara G. Fürnrohr 2 , Jerome Avouac 3 , Angelika<br />

Horn 2 , Clara Dees 2 , Alfiya Akhmetshina 2 , Christian Beyer 2 ,<br />

Radim Becvar 7 , Oliver Distler 1 , Mariam Grigorian 6 , Ladislav<br />

Senolt 7 , Georg Schett 5 and Jorg H. W. Distler 8 , 1 Center <strong>of</strong><br />

Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative<br />

Human Physiology, University Hospital Zurich, Switzerland,<br />

2<br />

Department <strong>of</strong> Internal Medicine III and Institute for<br />

Clinical Immunology, University <strong>of</strong> Erlangen-Nuremberg,<br />

Erlangen, Germany, 3 Department <strong>of</strong> Internal Medicine III<br />

and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />

Nuremberg, Erlangen, Germany and Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department Cochin Hospital, Paris, France,<br />

4<br />

Department <strong>of</strong> Internal Medicine III, University <strong>of</strong> Erlangen-<br />

Nuremberg, Erlangen, Germany and Institute <strong>of</strong> <strong>Rheumatology</strong><br />

and Connective Tissue Research Laboratory, Department<br />

<strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the First Faculty <strong>of</strong> Medicine, Charles<br />

University i, 5 Friedrich Alexander Univ, Erlangen, Germany,<br />

6<br />

Institute <strong>of</strong> Cancer Biology, Danish Cancer Society, Copenhagen,<br />

Denmark, 7 Institute <strong>of</strong> <strong>Rheumatology</strong> and Connective Tissue<br />

Research Laboratory, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the<br />

First Faculty <strong>of</strong> Medicine, Charles University in Prague, Czech<br />

Republic, 8 University <strong>of</strong> Erlangen, Erlangen, Germany.<br />

615. The Synthetic Cannabinoid Ajulemic Acid Targets<br />

Scleroderma Fibrosis. Estrella Garcia Gonzalez 3 , Enrico Selvi 2 ,<br />

Balistreri Epifania 3 , Alfiya Akhmetshina 1 , Sauro Lorenzini 3 ,<br />

Kathrin Palumbo 1 , Mauro Galeazzi 3 and Jorg W. H. Distler 1 ,<br />

1<br />

Departement <strong>of</strong> Internal Medicine III and Institute for Clinical<br />

Immunology -Friedrich-Alexander University-Erlangen-Germany,<br />

2<br />

<strong>Rheumatology</strong> Unit - Departement <strong>of</strong> Clinical Medicine and<br />

Immunological Sciences-University <strong>of</strong> Siena, Siena, Italy,<br />

3<br />

<strong>Rheumatology</strong> Unit - Departement <strong>of</strong> Clinical Medicine and<br />

Immunological Sciences-University <strong>of</strong> Siena- Italy.<br />

616. The Transcription Factor AP-1 Mediates the Pro-Fibrotic Effects<br />

<strong>of</strong> TGFβ and Contributes to the Development <strong>of</strong> Experimental<br />

Dermal Fibrosis. Jerome Avouac 3 , Katrin Palumbo 2 , Michal<br />

Tomcik 4 , Pawel Zerr 2 , Clara Dees 2 , Angelika Horn 2 , Alfiya<br />

Akhmetshina 2 , Christian Beyer 2 , Shunichi Shiozawa 5 , Oliver<br />

Distler 1 , Georg Schett 6 , Yannick Allanore 7 and Jorg H. W. Distler 8 ,<br />

1<br />

Center <strong>of</strong> Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong><br />

Integrative Human Physiology, University Hospital Zurich, Zurich,<br />

Switzerland, 2 Department <strong>of</strong> Internal Medicine III and Institute<br />

for Clinical Immunology, University <strong>of</strong> Erlangen-Nuremberg,<br />

Erlangen, Germany, 3 Department <strong>of</strong> Internal Medicine III<br />

and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />

Nuremberg, Erlangen, Germany, Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital and INSERM U 781 ,<br />

Necker Hospital, Paris, Fra, 4 Department <strong>of</strong> Internal Medicine<br />

III, University <strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany and<br />

Institute <strong>of</strong> <strong>Rheumatology</strong> and Connective Tissue Research<br />

Laboratory, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the First Faculty<br />

<strong>of</strong> Medicine, Charles University i, 5 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />

Medicine, Kobe University Hospital, Kobe, Japan, 6 Friedrich<br />

Alexander Univ, Erlangen, Germany, 7 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital and INSERM<br />

U781, Necker Hospital, Paris, France, 8 University <strong>of</strong> Erlangen,<br />

Erlangen, Germany.<br />

617. The Triterpenoid CDDO Abrogates Canonical TGF-beta<br />

Signaling and Fibrotic Responses in Normal and Scleroderma<br />

Fibroblasts by Stabilizing the Anti-Oxidant Nuclear Factor-<br />

Like 2 (Nrf2). Kazuhiro Komura 2 , Jun Wei 2 , Gabriel Lord 2 and<br />

John Varga 1 , 1 Northwestern Univ Feinberg School, Chicago, IL,<br />

2<br />

Northwestern University Feinberg School <strong>of</strong> Medicine.<br />

618. Urantide Prevents and Alleviates Monocrotaline Induced<br />

Pulmonary Arterial Hypertension in Wistar Rats. Yifang<br />

Mei 1 , Hong Jin 3 , Hao Wang 2 , Wei Tian 2 , Yanping Zhao 2 and<br />

Zhiyi Zhang 2 , 1 The First Affiliated Hospital <strong>of</strong> Harbin Medical<br />

University, Harbin, Heilongjiang, China, 2 The First Affiliated<br />

Hospital <strong>of</strong> Harbin Medical University, Harbin, China, 3 The<br />

First Affiliated Hospital <strong>of</strong> Shantou University Medical <strong>College</strong>,<br />

Shantou, China.<br />

619. Visfatin/NAMPT in Interstitial Pneumonia <strong>of</strong> Patients with<br />

Systemic Sclerosis and Scleroderma Mice Model Induced<br />

by Bleomycin. Hirahito Endo 2 , Tatsuhiro Yamamoto 1 , Kaichi<br />

Kaneko 3 , Yoshie Kusunoki 3 , Natsuko Kusunoki 3 and Shinichi<br />

Kawai 3 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine, Toho University School <strong>of</strong> Medicine, Ohmori-nishi,<br />

Ohta-ku, Japan, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Toho University School <strong>of</strong> Medicine, Ohmorinishi,<br />

Oh-taku, Japan, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Toho University School <strong>of</strong> Medicine.<br />

190<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

Halls B1 & B2<br />

TUESDAY, NOVEMBER 9, 2010<br />

B-Cell Biology and Targets in Autoimmune Disease<br />

733. A Systems Biology Approach to Understanding SLE Complexity.<br />

John Jung 5 , Jennifer Hossler 5 , Youqun Huang 5 , Elise Palmer 5 ,<br />

Elides Marin 5 , Tracy Sanford 5 , Ehtisham Akhter 2 , Michelle A.<br />

Petri 1 , Alex Rosenberg 5 , Jennifer H. Anolik 3 , Chungwen Wei 5 and<br />

Ignacio Sanz 4 , 1 Timonium, MD, 2 John Hopkin University School<br />

<strong>of</strong> Medicine, Baltimore, MD, 3 University <strong>of</strong> Rochester, Rochester,<br />

NY, 4 University <strong>of</strong> Rochester Medical Center, Rochester, NY,<br />

5<br />

University <strong>of</strong> Rochester Medical Center, Rochester, NY.<br />

734. Antibodies from Antibody-Secreting Cells Following<br />

Vaccination in Patients with Systemic Lupus Erythematosus<br />

Are Autoreactive and Polyspecific. Kenneth A. Smith 2 , Lori<br />

Garman 3 , Jennifer Morris 3 , Linda Thompson 3 , Patrick C. Wilson 4<br />

and Judith A. James 1 , 1 Oklahoma Medical Research Foundation,<br />

Oklahoma City, OK, 2 Oklahoma Medical Research Foundation,<br />

Fort Wayne, IN, 3 Oklahoma Medical Research Foundation,<br />

4<br />

University <strong>of</strong> Chicago.<br />

735. Antibodies to CCP Versus the Unmodified Arginine-Containing<br />

Peptide (CAP) as a Serological Marker To Differentiate SLE<br />

from RA. Jason Chan 2 , Rufus Burlingame 1 , Angela Ceribelli 2 ,<br />

Eric S. Sobel 3 , Yi Li 3 , Westley H. Reeves 3 , Edward K. .L Chan 3 and<br />

Minoru Satoh 3 , 1 INOVA Diagnostics, Inc., 2 University <strong>of</strong> Florida,<br />

3<br />

University <strong>of</strong> Florida, Gainesville, FL.<br />

736. Apoptotic Cell Bodies and Blebs Stimulate Self Reactive B-Cells<br />

Via Engagement <strong>of</strong> the BCR and Endosomal Toll-Like Receptors.<br />

John McCahan 2 , Nathanial Green 1 and Ann Marshak-Rothstein 3 ,<br />

1<br />

Boston University, Boston, MA, 2 <strong>Rheumatology</strong> Section, Boston<br />

University, 3 The University <strong>of</strong> Massachusetts Medical School,<br />

Worcester MA.<br />

737. B Cell-Dependent Regulation (Breg) <strong>of</strong> T-Cell Proliferation Is<br />

Deficient in Systemic Lupus Erythematosus (SLE). Jacques-<br />

Olivier Pers, Sébastien Lemoine, Ahsen Morva, Christophe Jamin<br />

and Pierre Youinou, Brest University.<br />

738. B Cells Modify Regulatory T Cells in Healthy Individuals but<br />

Not in Patients with Systemic Lupus Erythematosus. Mark<br />

N. Lazarus, Hardeep S. Kalsi, David A. Isenberg and Michael R.<br />

Ehrenstein, UCL Div <strong>of</strong> Medicine, London, United Kingdom.<br />

739. BAFF Binding Receptors (BBR) Related To Relapse after<br />

Rituximab in Patients with Reumatoid Arthritis (RA).<br />

Inmaculada De la Torre 1 , Lara Valor 1 , Rita Moura 2 , Maria J.<br />

Leandro 3 , Jonathan C. W. Edwards 3 and Geraldine Cambridge 3 ,<br />

1<br />

Hospital Gregorio Maranon, Madrid, Spain, 2 Instituto de<br />

Biologia Molecular, Lisboa, Portugal, 3 University <strong>College</strong> London,<br />

London, UK.<br />

740. Cellular and Serological Changes Following B Cell Repopulation<br />

after Rituximab Therapy Suggest Antibody-Independent Roles<br />

for B Cells in Systemic Lupus Erythematosus. Mark N. Lazarus,<br />

Andrew Fester, Tabitha Turner-Stokes, David A. Isenberg and<br />

Michael R. Ehrenstein, UCL Div <strong>of</strong> Medicine, London, United<br />

Kingdom.<br />

741. Elevated Serum BAFF Correlates with Loss <strong>of</strong> Mature B Cells<br />

and Promotes B Cell Recovery in Mice after B Cell Depletion<br />

Treatment. Yue Wang 2 , Sandra Gallagher 1 , Isharat Yusuf 1 , Bahija<br />

Jallal 1 , Anthony Coyle 1 and Ronald Herbst 1 , 1 MedImmune LLC,<br />

2<br />

MedImmune LLC, Gaithersburg, MD.<br />

742. Elimination <strong>of</strong> Autoantibody Producing Plasma Cells Using<br />

CXCR4 Antagonist AMD3100. Jason Weinstein 4 , Yuan Xu 1 ,<br />

Matthew Delano 3 , Yi Li 2 , Lijun Yang 1 , Eric S. Sobel 2 , Lyle<br />

Moldawer 1 and Westley H. Reeves 2 , 1 University <strong>of</strong> Florida,<br />

2<br />

University <strong>of</strong> Florida, Gainesville, FL, 3 Universsity <strong>of</strong> Florida,<br />

4<br />

Yale University.<br />

743. Expression <strong>of</strong> the Idiotope 9G4 on Autoantibodies and B Cells<br />

from Patients with Rheumatoid Arthritis (RA): Description <strong>of</strong><br />

a New B Cell Phenotype. Inmaculada De la Torre 1 , Rita Moura 2 ,<br />

Maria J. Leandro 3 , Jonathan C. W. Edwards 3 and Geraldine<br />

Cambridge 3 , 1 Hospital Gregorio Maranon, Madrid, Spain,<br />

2<br />

Instituto de Biologia Molecular, Lisbon, Portugal, 3 University<br />

<strong>College</strong> London, London, UK.<br />

744. Expression <strong>of</strong> ZAP-70 in B-Cell Is a Feature <strong>of</strong> Peripheral<br />

Blood Repopulation after Rituximab Therapy in Rheumatoid<br />

Arthritis. Francesca Faustini, Barbara Tolusso, Giusy Peluso, Elisa<br />

Gremese, Silvia Canestri, Graziella D’Antona, Antonella Laria<br />

and Gianfranco Ferraccioli, Division <strong>of</strong> <strong>Rheumatology</strong>, Catholic<br />

University <strong>of</strong> the Sacred Heart, Rome, Italy.<br />

745. In Vivo Effects <strong>of</strong> Tocilizumab on Peripheral B Cells in Patients<br />

with Rheumatoid Arthritis. Petra Roll 2 , Khalid Muhammad 2 ,<br />

Mathias Schumann 2 , Stefan Kleinert 2 , Thomas Dörner 1 and<br />

Hans-Peter Tony 2 , 1 <strong>Rheumatology</strong> and Clinical Immunology<br />

Charite Universitätsmedizin Berlin and DRFZ Berlin, Berlin,<br />

Germany, 2 <strong>Rheumatology</strong>/Clinical Immunology, University <strong>of</strong><br />

Würzburg, Würzburg, Germany.<br />

746. Predominant Suppression <strong>of</strong> Plasmablasts by<br />

Cyclophosphamide in Patients with Systemic Lupus<br />

Erythematosus: A Possible Therapeutic Mechanism. Yuko<br />

Okamoto 1 , Yasuhiro Katsumata 5 , Yasushi Kawaguchi 2 , Manabu<br />

Kawamoto 5 , Sayumi Baba 5 , Kae Takagi 5 , Takahisa Gono 5 , Yuko<br />

Ota 5 , Masako Hara 4 and Hisashi Yamanaka 3 , 1 Tokyo Women’s<br />

Medical University, Tokyo, Japan, 2 Tokyo Women’s Medical<br />

University, Tokyo, Japan, 3 Tokyo Women’s Medical University,<br />

Shinjuku-ku, Tokyo, Japan, 4 Tokyo Women’s Medical University,<br />

Kamakura Kanagawa, Japan, 5 Tokyo Women’s Medical<br />

University.<br />

747. Progesterone Receptors Regulate Humoral Immunity. Alan<br />

Wong, Chang Li, Ed Clark and Grant Hughes, University <strong>of</strong><br />

Washington.<br />

748. SLAP Deficiency Alters Both Central and Peripheral B Cell<br />

Tolerance Leading to Decreased Autoantibody Production. Lisa<br />

K. Peterson 2 , Laura A. Shaw 2 , Luke F. Pennington 1 and Leonard L.<br />

Dragone 2 , 1 Denver, CO, 2 National Jewish Health, Denver, CO.<br />

749. SLE Anti-CD45/B220 9G4 Autoantibodies Induce Attenuated<br />

BCR Signaling: Implication for Disease Pathogenesis. Scott A.<br />

Jenks 2 , Anna E. Schroeder 1 and Ignacio Sanz 2 , 1 Duke University,<br />

Durham, NC, 2 Univ <strong>of</strong> Rochester, Rochester, NY.<br />

750. Specific Histone Deacetylase (HDAC2) Inhibition in B Cells May<br />

Protect Lupus. Nilamadhab Mishra 1 , Kristen Delany 3 and Issac<br />

Snowhite 2 , 1 Wake Forest Univ Health Scienc, Winston-Salem,<br />

NC, 2 Wake Forest Univ Health Science, 3 Wake Forest Univ Health<br />

Sciences.<br />

751. The Effects <strong>of</strong> the Anti-CD22 Monoclonal Antibody<br />

Epratuzumab on B-Cell Surface Proteins. Anthony Shock 1 , Derek<br />

Brown 2 , Kenneth Crook 2 and Timothy Bourne 2 , 1 UCB, Slough,<br />

Berkshire, Slough, United Kingdom, 2 UCB, Slough, Berkshire, UK.<br />

2010 Program Book 191


ACR Poster Session B<br />

752. The Effects <strong>of</strong> the Anti-CD22 Monoclonal Antibody<br />

Epratuzumab on Peripheral Blood B Cells and Immune<br />

Responses In Vivo, and Immunoglobulin Production In Vitro.<br />

Anthony Shock 1 , Derek Brown 2 , Kenneth Crook 2 , Stevan Shaw 2 ,<br />

Timothy Bourne 2 , Roland Foulkes 2 and Ge<strong>of</strong>frey Rose 2 , 1 UCB,<br />

Slough, Berkshire, Slough, United Kingdom, 2 UCB, Slough,<br />

Berkshire, UK.<br />

753. TNF Blockade Impairs the Induction <strong>of</strong> T-Cell Dependent<br />

Antibody Responses. Gabriela Franco Salinas 1 , Leen De Rycke 2 ,<br />

Sophie Brouard 4 , Vojislav Jovanovic 4 , Frederique Moizant 4 ,<br />

Tineke Cantaert 2 , Mirjam van der Burg 3 , Barbara Barendregt 3 ,<br />

Paul Peter Tak 2 , Jean-Paul Soulillou 4 and Dominique Baeten 2 ,<br />

1<br />

Academisch Medisch Centrum, University <strong>of</strong> Amsterdam,<br />

Amsterdam, Noord Holland, The Netherlands, 2 Academisch<br />

Medisch Centrum, University <strong>of</strong> Amsterdam, Amsterdam, The<br />

Netherlands, 3 Immunology, Erasmus Medical Center, Rotterdam,<br />

Netherlands, 4 Institut de Transplantation et Recherche en<br />

Transplantation, INSERM U 643 , Nantes, France.<br />

Epidemiology and Health Services Research: MSK, CTD and SLE<br />

754. A Systematic Literature Review <strong>of</strong> the Direct Costs <strong>of</strong><br />

Systemic Lupus Erythematosus (SLE) in the United States<br />

(US). Katherine A. Slawsky 1 , Ancilla Fernandes 2 , Susan Manzi 3 ,<br />

Lauren Fusfeld 1 and Thomas F. Goss 1 , 1 Boston Healthcare<br />

Associates, Inc., Boston MA and Washington DC, 2 MedImmune<br />

LLC, Gaithersburg, MD, 3 West Penn Allegheny Health System,<br />

Pittsburgh, PA.<br />

755. A Systematic Review To Appraise the Quality <strong>of</strong> Cost-<br />

Effectiveness Studies <strong>of</strong> Biologic Agents for the Treatment<br />

<strong>of</strong> Rheumatoid Arthritis. Maria A. Lopez-Olivo 1 , Yomei Shaw 2<br />

and Maria E. Suarez-Almazor 3 , 1 The University <strong>of</strong> Texas M.D.<br />

Anderson Cancer Center, Houston, TX, 2 The University <strong>of</strong><br />

Texas M.D. Anderson Cancer Center, 3 University <strong>of</strong> Texas, MD<br />

Anderson Cancer Center, Houston, TX.<br />

756. Agreement between Tuberculin Skin Test and Interferon-Assay<br />

in Korean Patients with Rheumatoid Arthritis and Ankylosing<br />

Spondylitis before Initiation <strong>of</strong> Anti-Tumor Necrosis Factor<br />

Therapy. Yong-Geun Jeong 1 , Ji-Min Kim 3 , Su-Jin Moon 3 , Seung-Ki<br />

Kwok 3 , Ji-Hyeon Ju 3 , Kyung-Su Park 3 , Sung-Hwan Park 2 and Ho-<br />

Youn Kim 1 , 1 Seoul St. Mary’s Hospital, The Catholic University <strong>of</strong><br />

Korea, Seoul, Republic <strong>of</strong> Korea, 2 Seoul St. Mary’s Hospital, The<br />

Catholic University <strong>of</strong> Korea, Seoul, Korea, Republic <strong>of</strong>, 3 Seoul St.<br />

Mary’s Hospital, The Catholic University <strong>of</strong> Korea, Seoul, South<br />

Korea.<br />

757. Assessing Systemic Lupus Erythematosus Disease Severity and<br />

Disease Flares: Development <strong>of</strong> a Claims-Based Algorithm.<br />

Cindy P. Garris 2 , Priti M. Jhingran 2 , Nicole M. Engel-Nitz 4 , Aylin<br />

A. Riedel 5 , George Goldberg 4 , Damon L. Bass 1 and Gregory J.<br />

Dennis 3 , 1 GlaxoSmithKline, King <strong>of</strong> Prussia, PA, 2 GlaxoSmithKline,<br />

Research Triangle Park, NC, 3 Human Genome Sciences,<br />

Rockville, MD, 4 i 3 Innovus, Eden Prarie, MN, 5 i 3 Innovus, Eden<br />

Prarie, NC.<br />

758. Colonization and Infection by Staphylococcus Aureus among<br />

Those Using Biologic Therapy. Cara Varley 1 , Atul A. Deodhar 1 ,<br />

Benjamin Ehst 1 , Antony Bakke 1 , Andrew Blauvelt 1 , Robert Vega 2<br />

and Kevin Winthrop 1 , 1 Oregon Health & Science University,<br />

Portland, OR, 2 Oregon State Public Health Laboratory, Hillsboro,<br />

OR.<br />

759. Comprehensive Health Economic Assessment <strong>of</strong> Sequenced<br />

Treatment with Biologics in Moderate-to-Severe Rheumatoid<br />

Arthritis: Analysis Based on ACR50 and ACR70 Responses.<br />

Erkki J. O. Soini 1 , Taru A. Hallinen 1 , Markku J. Kauppi 3 , Ville<br />

Vihervaara 4 and Kari Puolakka 2 , 1 ESiOR Oy, Kuopio, Finland,<br />

2<br />

Lappeenranta Central Hospital, Lappeenranta, Finland,<br />

3<br />

Päijät-Häme Central Hospital, Lahti, Finland, 4 Roche Oy, Espoo,<br />

Finland.<br />

760. Correlations between 3 Work-Related Patient-Reported<br />

Outcome Instruments for Patients with Ankylosing Spondylitis.<br />

Annelies Boonen 2 , Walter P. Maksymowych 3 , Sumati Rao 1 ,<br />

Naijun Chen 1 and Mary Cifaldi 1 , 1 Abbott Laboratories,<br />

Abbott Park, IL, 2 University Hospital Maastricht, Maastricht,<br />

Netherlands, 3 University <strong>of</strong> Alberta, Edmonton, AB.<br />

761. Costs for Health Care, Prescribed Drugs, and Sick Leave Differ<br />

for Patients with Different Types <strong>of</strong> Spondylarthropathy. Ann<br />

B. I. Bremander 1 , Aleksandra Turkiewicz 2 , Martin Englund 2 ,<br />

Emma Haglund 3 , Gisela Kobelt 2 , Ingemar F. Petersson 2 and<br />

Britta Strömbeck 2 , 1 Musculoskeletal Research Center, Dept. <strong>of</strong><br />

Orthopedics, Clinical Sciences, Lund University, Lund, Research<br />

and Development Cente at Spenshult Hospital for Rheumatic<br />

Diseases, Oskarstrom, Sweden, 2 Musculoskeletal Research<br />

Center, Dept. <strong>of</strong> Orthopedics, Clinical Sciences, Lund University,<br />

Lund, Sweden, 3 Musculoskeletal Research Center, Dept. <strong>of</strong><br />

Orthopedics, Clinical Sciences, Lund University, Lund, Sweden,<br />

Research and Development Cente at Spenshult Hospital for<br />

Rheumatic Diseases, Halmstad, Sweden.<br />

762. Dietary Intake <strong>of</strong> Vitamin D during Adolescence and Risk <strong>of</strong><br />

Adult Onset Systemic Lupus Erythematosus and Rheumatoid<br />

Arthritis. Linda T. Hiraki 3 , Karen H. Costenbader 1 , Kassandra<br />

Munger 4 and Elizabeth W. Karlson 2 , 1 Brigham & Women, Boston,<br />

MA, 2 Brigham and Womens Hospital, Boston, MA, 3 Harvard<br />

School <strong>of</strong> Public Health, Boston, MA, 4 Harvard School <strong>of</strong> Public<br />

Health.<br />

763. Direct and Indirect Costs <strong>of</strong> Spondlyoarthritis Patients Preand<br />

Post-Diagnosis. Noam Kirson 2 , Howard Birnbaum 2 , Sumati<br />

Rao 1 , Elyse Swallow 2 , Tracy Waldman 2 , Elias Dayoub 2 and Mary<br />

Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Analysis Group,<br />

Inc., Boston, MA.<br />

764. Distinguishing Levels <strong>of</strong> Disease Flare in Patients with Systemic<br />

Lupus Erythematosus Using Administrative Claims Data.<br />

Nicole Engel-Nitz 5 , James Burke 5 , Cindy P. Garris 3 , Priti Jhingran 1 ,<br />

Damon L. Bass 2 and Gregory J. Dennis 4 , 1 GlaxoSmithKline,<br />

2<br />

GlaxoSmithKline, King <strong>of</strong> Prussia, PA, 3 GlaxoSmithKline, RTP, NC,<br />

4<br />

Human Genome Sciences, 5 i 3 Innovus.<br />

765. Does Cigarette Smoking Affect Disease Phenotype in Systemic<br />

Lupus Erythematosus. Meenakshi Jolly 2 , Rachel A. Mikolaitis 4 ,<br />

Joel A. Block 4 and Michelle Petri 1 , 1 John Hopkins University,<br />

2<br />

Rush University Medical Center, Chicago, IL, 3 Rush University<br />

Medical Center, Chicago, IL, 4 Rush University Medical Center.<br />

766. Early and Persistent Clinical Remission Reduces Long-Term<br />

Disability in Inflammatory Polyarthritis: Results from the<br />

Norfolk Arthritis Register. Carlo Alberto Scirè 2 , Suzanne M.<br />

Verstappen 1 , Hoda Mjriafari 1 , Diane Bunn 3 , Mark Lunt 1 , Ian<br />

Bruce 1 , Carlomaurizio Montecucco 2 and Deborah P. Symmons 4 ,<br />

1<br />

Arthritis Research UK Epidemiology Unit, Stopford Building,<br />

The University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, IRCCS Policlinico San Matteo<br />

Foundation, University <strong>of</strong> Pavia, Pavia, Italy, 3 Norfolk Arthritis<br />

Register, Norfolk and Norwich University Hospital, Norwich,<br />

United Kingdom., 4 Univ <strong>of</strong> Manchester, Manchester, United<br />

Kingdom.<br />

192<br />

2010 Program Book


ACR Poster Session B<br />

767. Economic Evaluation <strong>of</strong> Rituximab Versus Alternative Anti-<br />

Tumor Necrosis Factor (TNF) Therapy after Failure <strong>of</strong> Anti-TNF<br />

for Treatment <strong>of</strong> Rheumatoid Arthritis in Mexico. Fernando<br />

Carlos 2 and Patricia Clark 1 , 1 Hospital Infantil Federico Gómez<br />

México, Mexico City, Mexico, 2 R A C Salud Consultores, S.A. de<br />

C.V..<br />

768. High Level <strong>of</strong> Disease Activity in Chronic Inflammatory<br />

Rheumatisms Increases the Rate <strong>of</strong> Indeterminate Interferon-<br />

Gamma-Release Assay Results for Latent Tuberculosis<br />

Infection Detection. Félicie Costantino 2 , Gilbert Faure 1 , Marcelo<br />

De Carvalho 1 , Anne-Christine Rat 2 , Hervé Dintinger 2 , Damien<br />

Loeuille 2 and Isabelle Chary-Valckenaere 2 , 1 Immunology<br />

(EA RHEM4369) Department, Nancy University Hospital,<br />

Vandoeuvre-lès-Nancy, France, 2 <strong>Rheumatology</strong> department,<br />

Nancy University Hospital, Vandoeuvre-lès-Nancy, France.<br />

769. Improving Health-Related Quality <strong>of</strong> Life in Patients with<br />

Systemic Lupus Erythematosus (SLE): The Role <strong>of</strong> Disease<br />

Control, Steroid Reduction and Smoking Cessation. Mark J.<br />

Harrison 5 , Nicola Dale 1 , Sahena Haque 2 , Joanna Shelmerdine 6 ,<br />

Lee-Suan Teh 4 , Yasmeen Ahmad 3 and Ian N. Bruce 1 , 1 Arthritis<br />

Research UK Epidemiology Unit, The University <strong>of</strong> Manchester,<br />

Manchester, United Kingdom, 2 Arthritis Research UK<br />

Epidemiology Unit, The University <strong>of</strong> Manchester, Manchester,<br />

United Kingdom, 3 Betsi Cadwaladr University Health Board-<br />

West, <strong>Rheumatology</strong>, Llandudno, United Kingdom, 4 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Royal Blackburn Hospital, Blackburn, United<br />

Kingdom, 5 Health Sciences Research Group, The University<br />

<strong>of</strong> Manchester, Manchester, UK, 6 The Kellgren Centre for<br />

<strong>Rheumatology</strong>, Central Manchester Foundation Trust,<br />

Manchester, UK.<br />

770. Increase in Direct and Decrease in Indirect Costs <strong>of</strong><br />

Rheumatoid Arthritis in Germany between 2002 and 2008.<br />

Dörte Huscher 2 , Katja Thiele 2 , Andrea Pfaefflin 2 , Sascha<br />

Bisch<strong>of</strong>f 2 , Rieke Alten 4 , Ulrich von Hinueber 3 , Matthias K.<br />

Schneider 5 and Angela Zink 1 , 1 German Rheumatism Research<br />

Centre and Charité University Hospital, Berlin, Germany,<br />

2<br />

German Rheumatism Research Centre, Berlin, Germany,<br />

3<br />

Hildesheim, Germany, 4 Schlosspark-Klinik KG, Department<br />

<strong>of</strong> Internal Medicine II, <strong>Rheumatology</strong>, Clinical Immunology<br />

Osteology, Berlin, Germany, 5 University Hospital Düsseldorf,<br />

Duesseldorf, Germany.<br />

771. Increased Risk <strong>of</strong> Valvular and Nonvalvular Cardiovascular<br />

Disease in Younger Individuals with Ankylosing Spondylitis: A<br />

Population-Based Study. Adrian R. Levy 3 , Shelagh M. Szabo 3 ,<br />

Sumati Rao 1 , Diane V. Lacaille 2 , Mary Cifaldi 1 and Walter P.<br />

Maksymowych 4 , 1 Abbott, 2 Arthritis Research Ctr Canada,<br />

Vancouver, BC, Canada, 3 Oxford Outcomes, 4 University <strong>of</strong><br />

Alberta, Edmonton, AB, Canada.<br />

772. Is There an Advantage for a Lupus Specific Quality <strong>of</strong> Life<br />

Measure over SF-36? Zahi Touma 2 , Dafna D. Gladman 3 ,<br />

Dominique Ibanez 2 and Murray B. Urowitz 1 , 1 The Toronto<br />

Western Hospital, Toronto, ON, Canada, 2 Toronto Western<br />

Hospital, Toronto, ON, Canada, 3 Toronto Western Hospital,<br />

Toronto, ON, Canada.<br />

773. Life Expectancy, Standardized Mortality Ratios and Causes <strong>of</strong><br />

Deaths <strong>of</strong> Six Rheumatic Diseases in Hong Kong, China. Chi<br />

Chiu Mok 1 , Raymond C. L. Kwok 2 , Ling Yin Ho 1 , Pak To Chan 1 and<br />

Paul S. F. Yip 2 , 1 Tuen Mun Hospital, 2 University <strong>of</strong> Hong Kong.<br />

774. Lower Body Mass Index Is Associated with an Increased Risk <strong>of</strong><br />

Giant Cell Arteritis. Karin Jakobsson 3 , Lennart T. H. Jacobsson 2 ,<br />

Kenneth J. Warrington 1 , Eric L. Matteson 1 , Kimberly P. Liang 5 ,<br />

Olle Melander 4 and Carl Turesson 3 , 1 Mayo Clinic, Rochester,<br />

MN, 2 Skåne University Hospital, Malmo, Sweden, 3 Skåne<br />

University Hospital, Malmö, Sweden, 4 Skåne University Hospital,<br />

5<br />

University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

775. Obstetrical and Neonatal Outcomes in Rheumatic Disease.<br />

Cheryl C. M. Barnabe, Peter Faris and Hude Quan, University <strong>of</strong><br />

Calgary, Calgary, AB, Canada.<br />

776. Patient Perceptions and Access to Resources Influence Patient<br />

Decisions To Attend <strong>Rheumatology</strong> Appointments. Valerie<br />

Milne 2 , Robin Kearns 1 and Andrew A. Harrison 3 , 1 University <strong>of</strong><br />

Auckland, New Zealand, New Zealand, 2 University <strong>of</strong> Otago,<br />

Wellington, Wellington, New Zealand, 3 University <strong>of</strong> Otago,<br />

Wellington, New Zealand, New Zealand.<br />

777. Patient-Reported Outcome Measures in Patients with<br />

Polymyalgia Rheumatica (PMR): Results from an International,<br />

Prospective, Multi-Centre Study. ACR – EULAR Study Group<br />

for Development <strong>of</strong> Classification Criteria for PMR. Bhaskar<br />

Dasgupta 16 , Marco A. Cimmino 10 , Hilal Maradit-Kremers 3 ,<br />

Wolfgang A. Schmidt 19 , Schirmer Michael 5 , Carlo Salvarani 11 ,<br />

Peter Mandl 20 , Artur Bachta 4 , Maria C. Cid 17 , Haner Direskeneli 13 ,<br />

Pierluigi Macchioni 11 , Peter V. Balint 1 , Christina Duftner 9 ,<br />

Christian Dejaco 14 , Hanna Slott-Jensen 18 , Zsuzsa Schmidt 20 ,<br />

Gyula Poór 20 , Annamaria Iagnocco 24 , Victor Martínez-Taboada 28 ,<br />

Elizabeth Nordborg 26 , Nicolò Pipitone 11 , Pierre Duhaut 27 , Carlotta<br />

Nannini 25 , Georgina Espígol-Frigolé 2 , Sibel Z. Aydin 13 , Khalid<br />

Ahmed 15 , Raashid Luqmani 21 , Brian Hazelman 12 , Colin Pease 22 ,<br />

Richard J. Wakefield 22 , Neil Gonter 23 , Ralph Marcus 23 , Clement<br />

J. Michet 7 , Mehrdad Mazlumzadeh 8 , Andy Abril 6 , Cynthia S.<br />

Crowson 3 and Eric L. Matteson 7 , 13 rd <strong>Rheumatology</strong> Department,<br />

National Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy,<br />

Budapest, 2 Center for Diagnosis Imaging, Hospital Clínic,<br />

Montserrat del Amo, Barcelona, Spain, 3 Department <strong>of</strong> Health<br />

Sciences Research, Mayo Clinic, Rochester, MN, 4 Department<br />

<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />

Warszawa, Poland, 5 Department <strong>of</strong> Internal Medicine I, Medical<br />

University Innsbruck, Innsbruck, Austria, 6 Department <strong>of</strong><br />

Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />

Jacksonville, FL, 7 Department <strong>of</strong> Internal Medicine, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN, 8 Department<br />

<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />

Scottsdale, AZ, 9 Department <strong>of</strong> Internal Medicine, General<br />

Hospital <strong>of</strong> the Elisabethinen, Klagenfurt, Austria, 10 Department<br />

<strong>of</strong> Internal Medicine, University <strong>of</strong> Genova, Genova, Italy,<br />

11<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Arcispedale S. Maria<br />

Nuova, Reggio Emilia, Italy, 12 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Cambridge University, Cambridge, UK, 13 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />

Turkey, 14 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />

Graz, Graz, Austria, 15 Department <strong>of</strong> <strong>Rheumatology</strong>, Princess<br />

Alexandra Hospital, Harlow, United Kingdom, 16 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Southend University Hospital, Essex, United<br />

Kingdom, 17 Department <strong>of</strong> Systemic Autoimmune Hospital<br />

Clinic Provincial, Barcelona, Spain, 18 Gent<strong>of</strong>te Hospital,<br />

<strong>Rheumatology</strong> Division, Hellerup, Denmark, 19 Immanuel<br />

Krankenhaus Berlin: Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch Berlin, Berlin, Germany, 20 National Institute<br />

<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />

21<br />

Nuffield Department <strong>of</strong> Orthopaedics, <strong>Rheumatology</strong> and<br />

Musculoskeletal Sciences, Oxford University, Oxford, UK,<br />

22<br />

<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />

Leeds, Leeds, UK, 23 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />

Teaneck, NJ, 24 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />

Department, Sapienza Università di Roma, Policlinico Umberto<br />

I, Rome, Italy, 25 <strong>Rheumatology</strong> Unit, Ospedale Misericordia e<br />

Dolce, Prato, Italy, 26 Sahlgren University Hospital, Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Göteborg, Sweden, 27 Service de Medecine<br />

Interne, Amiens, France, 28 Servicio de Reumatología, Hospital<br />

Universitario Marques de Valdecilla, Facultad de Medicina,<br />

Universidad de Cantabria, Santander, Spain.<br />

2010 Program Book 193


ACR/ARHP Poster Session B<br />

778. Psychometric Properties <strong>of</strong> a Self-Administered Early<br />

Inflammatory Arthritis Detection Tool. Mary J. Bell 3 , Joel P.<br />

Scarf 2 and Ruben Tavares 1 , 1 McMaster University, Hamilton, ON,<br />

Canada, 2 Sunnybrook Health Science Ctr, Toronto, ON, Canada,<br />

3<br />

Sunnybrook Health Sciences Ctr, Toronto, ON, Canada.<br />

779. Reproductive History and Functional Outcome in Women<br />

with Recent-Onset Inflammatory Polyarthritis. Elizabeth M.<br />

Camacho 1 , Mark Lunt 1 , Tracey M. Farragher 1 , Mark Harrison 1 ,<br />

Suzanne M. Verstappen 1 , Diane K. Bunn 2 and Deborah P.<br />

Symmons 3 , 1 Arthritis Research UK Epidemiology Unit, Stopford<br />

Building, The University <strong>of</strong> Manchester, Manchester, United<br />

Kingdom, 2 Norfolk Arthritis Register, School <strong>of</strong> Medicine Health<br />

Policiy & Practice, University <strong>of</strong> East Anglia, Norwich UK, 3 Univ<br />

<strong>of</strong> Manchester, Manchester, United Kingdom.<br />

780. Rheumatic Diseases among Oklahoma Tribal Populations.<br />

Jasmine R. Gaddy 8 , Amy B. Dedeke 4 , Wendy Klein 3 , Fabio<br />

Mota 2 , Tina Cooper 2 , M. Sohail Khan 1 , Virginia Roberts 5 , Jeremy<br />

Levin 5 , Scott Stewart 5 , Rebecca Stormont 6 and Judith A. James 7 ,<br />

1<br />

Cherokee Nation, 2 Chickasaw Nation, 3 Oklahom Research<br />

Foundation, OKC, OK, 4 Oklahoma Medical Research Foundation,<br />

OKC, OK, 5 Oklahoma Medical Research Foundation, 6 University<br />

<strong>of</strong> Oklahoma HSC, 7 University <strong>of</strong> Oklahoma HSC, Oklahoma<br />

Medical Research Foundation, OKC, OK, 8 University <strong>of</strong> Oklahoma<br />

HSC, Oklahoma Medical Research Foundation, Veteran’s Affairs<br />

Medical Center, OKC, OK.<br />

781. Rheumatoid Arthritis (RA) Impact on Work and RA-Related<br />

Indirect Costs during the First Three Years after RA Diagnosis.<br />

An Economic Analysis from the ESPOIR Cohort. Sabrina<br />

Dadoun 6 , Sandy Lucier 2 , Marie De Rosa 2 , Alain Saraux 3 , Francis<br />

Berenbaum 4 , Isabelle Durand-Zaleski 2 , Francis Guillemin 1 , Karine<br />

Chevreul 7 and Bruno Fautrel 5 , 1 Nancy, France, 2 Paris, France,<br />

3<br />

CHU de la Cavale Blanche, Brest Cedex, France, 4 Faculty <strong>of</strong><br />

Medicine P&M Curie, Paris, France, 5 Pitie Salpetriere Hospital,<br />

Paris, France, 6 Pitie Salpetriere Hospital, Paris, France, 7 URC Eco,<br />

Paris, France.<br />

782. Screening for Latent Tuberculosis Infection (LTBI) –<br />

Performance <strong>of</strong> Tuberculous Skin Test and Interferon-gamma<br />

Release Assays (IGRA) under Real Life Conditions. Stefan<br />

Kleinert 7 , Hans Peter T. Tony 7 , Klaus Krueger 6 , Jacqueline<br />

Detert 1 , Frank Mielke 4 , Gerd R. Burmester 2 , Roland Diel 3 ,<br />

Martin Feuchtenberger 8 and Christian Kneitz 5 , 1 Charité -<br />

Universitätsmedizin Berlin, Dep. <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, CC 12 , 2 Charité Berlin, 3 Department <strong>of</strong> Pneumology,<br />

Medical School (MHH) Hannover, 4 Gemeinschaftspraxis Innere<br />

Medizin, Dres. Mielke, Berlin, 5 Klinik für Innere Medizin II<br />

(Klinische Immunologie und Rheumatologie, Klinikum Südstadt<br />

Rostock), 6 Praxiszentrum St.Bonifatius München, 7 <strong>Rheumatology</strong><br />

/ Clinical Immunology, Med. Klinik 2 , University <strong>of</strong> Wuerzburg,<br />

Wuerzburg, Germany, 8 <strong>Rheumatology</strong> / Clinical Immunology,<br />

Med. Klinik 2 , University <strong>of</strong> Wuerzburg.<br />

783. Seasonal Variation in Vitamin D Levels in Patients with<br />

Psoriatic Arthritis from Northern and Southern Latitudes<br />

and Its Association with Clinical Outcomes. Zahi Touma 5 ,<br />

Lihi Eder 4 , Devy Zisman 1 , Joy Field 1 , Vinod Chandran 5 , Cheryl<br />

Rosen 5 , Hua Shen 2 , Richard Cook 2 and Dafna D. Gladman 3 , 1 ”Lin”<br />

Medical Centre, Clalit Health Service, Carmel Medical Centre,<br />

Haifa, Israel, 2 Division <strong>of</strong> Biostatistics, University <strong>of</strong> Waterloo,<br />

Waterloo, ON, Canada, 3 Toronto Western Hospital, Toronto, ON,<br />

Canada, 4 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />

Western Hospital, Torotn, ON, Canada, 5 University <strong>of</strong> Toronto<br />

Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, ON,<br />

Canada.<br />

784. Sedentarity Is an Independent Cardiovascular Risk Factor in<br />

Rheumatologic Patients. Marco Antivalle 1 , Cecilia Imperio 2 ,<br />

Michele Battellino 2 , Alessandra Mutti 2 , Maria Chiara Ditto 2 ,<br />

Alberto Batticciotto 2 , Fabiola Atzeni 2 and Piercarlo Sarzi-Puttini 2 ,<br />

1<br />

<strong>Rheumatology</strong> Unit, L. Sacco University Hospital Milano,<br />

MIlano, Italy, 2 <strong>Rheumatology</strong> Unit, L. Sacco University Hospital<br />

Milano, Italy.<br />

785. Sex Differences in Pain Level and Location in Inflammatory<br />

Arthritis: A Systematic Review and Meta-Analysis. Cheryl C.<br />

M. Barnabe 2 , Louis Bessette, Cathy Flanagan, Sharon LeClercq 3<br />

and Vivian P. Bykerk 1 , 1 Mt Sinai Hospital, Toronto, ON, Canada,<br />

2<br />

University <strong>of</strong> Calgary, Calgary, AB, Canada, 3 University <strong>of</strong><br />

Calgary.<br />

786. Sleep Disturbances in Adults with Arthritis: Prevalence,<br />

Mediators, and Subgroups at Greatest Risk. Grant H. Louie 2 ,<br />

Maria G. Tektonidou 1 , Alberto J. Caban-Martinez 4 and Michael<br />

M. Ward 3 , 1 National University Health System, Singapore,<br />

Athens, Greece, 2 NIH, Bethesda, MD, 3 NIH, NIAMS, IRP,<br />

Bethesda, MD, 4 University <strong>of</strong> Miami Miller School <strong>of</strong> Medicine,<br />

Miami, FL.<br />

787. The Comparative Responsiveness <strong>of</strong> the EQ-5D and SF-6D<br />

to Change in Patients with Early Arthritis: Results from the<br />

ESPOIR Cohort. Cécile Gaujoux-Viala 1 , Anne-Christine Rat 2 ,<br />

Francis Guillemin 2 , René-Marc Flipo 5 , Patrice Fardellone 4 , Pierre<br />

Bourgeois 3 and Bruno Fautrel 3 , 1 1INSERM, CIC-EC CIE6 2CHU<br />

Nancy, Epidemiologie et Evaluation Cliniques 3 Nancy-University,<br />

Metz University, Paris Descartes University, EA 4360 Apemac<br />

4<br />

Paris 6 – Pierre et Marie Curie University; <strong>Rheumatology</strong>, Pitie-<br />

Salpêtriere Hospital, 2 1INSERM, CIC-EC CIE 6 , Nancy, France 2 CHU<br />

Nancy, Epidemiologie et Evaluation Cliniques, Nancy, France<br />

3<br />

Nancy-University, Paul Verlaine Metz University, Paris Descartes<br />

University, EA 4360 Apemac, Nancy, France, 3 Paris 6 – Pierre<br />

et Marie Curie University; <strong>Rheumatology</strong>, Pitié-Salpêtrière<br />

Hospital, Paris, France, 4 <strong>Rheumatology</strong>, Amiens University,<br />

France, 5 <strong>Rheumatology</strong>, Lille University 2, France.<br />

788. The Economic Burden <strong>of</strong> Uveitis. S. E. Kirbach, O. A. Hayes and<br />

M. A. Cifaldi, Abbott Laboratories.<br />

789. The Effect <strong>of</strong> Health Insurance and Physician Specialty on<br />

Quality <strong>of</strong> Care for SLE. Edward H. Yelin 6 , Jinoos Yazdany 6 , Laura<br />

Trupin 6 , Chris Tonner 6 , Gabriela Schmajuk 3 , Patricia P. Katz 5 ,<br />

Lindsey A. Criswell 4 , Laura J. Julian 6 , Joann Z. Gillis 2 and Pantelis<br />

Panopalis 1 , 1 McGill University, Montreal, QC, Canada, 2 National<br />

Jewish Medical Center, Denver, CO, 3 Stanford University, Palo<br />

Alto, CA, 4 UCSF-Box 0500, San Francisco, CA, 5 Univ <strong>of</strong> CA San<br />

Francisco, San Francisco, CA, 6 University <strong>of</strong> California, San<br />

Francisco, San Francisco, CA.<br />

790. The Georgia Lupus Registry: Health Care Utilization Rises<br />

during the Transition from Pediatric to Adult Systemic Lupus<br />

Erythematosus (SLE) Care. S. Sam Lim 3 , Gaobin Bao 1 , Larry B.<br />

Vogler 4 and Cristina M. Drenkard 2 , 1 Emory University, 2 Emory<br />

University, Atlanta, GA, 3 Emory University, Atlanta, GA, 4 Emory<br />

University School <strong>of</strong> Medicine, Atlanta, GA.<br />

791. The Impact <strong>of</strong> RA Diagnoses on Cost Related Medication<br />

Nonadherence in Older Patients: 2004-2007. Leslie R. Harrold 3 ,<br />

Becky A. Briesacher 4 , Daniel Peterson 2 , Jeanne Madden 1 , Jerry<br />

H. Gurwitz 2 and Stephen B. Soumerai 1 , 1 Harvard Medical School,<br />

Boston, MA, 2 Meyers Primary Care Institute, Worcester, MA,<br />

3<br />

UMass Medical Schl, Worcester, MA, 4 UMass Medical School,<br />

Worcester, MA.<br />

194<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

792. The Influence <strong>of</strong> Immunosuppressive Therapy and Underlying<br />

Diseases on Vaccine Responses to Influenza A H1N1/09<br />

Vaccines in Inflammatory Rheumatic Diseases. Cem Gabay,<br />

Sara Meier, Danielle Gascon, Karin Posfay-Barbe, Christophe<br />

Combesure, M. Bel, Laurent Kaiser, Pierre-Andre Guerne and<br />

Claire-Anne Siegrist, Univ Hosp <strong>of</strong> Geneva, Geneva, Switzerland.<br />

793. The Risk <strong>of</strong> Myocardial Infarction among Patients with<br />

Psoriatic Arthritis. Thorvardur J. Love 1 , Daniel Hal Solomon 3 and<br />

Elizabeth W. Karlson 2 , 1 Brigham and Women’s Hospital, Boston,<br />

MA, 2 Brigham and Womens Hosp, Boston, MA, 3 Brigham and<br />

Womens Hospital, Boston, MA.<br />

794. Validation <strong>of</strong> a Self-Administered Inflammatory Arthritis<br />

Detection Tool for <strong>Rheumatology</strong> Triage. Mary J. Bell 6 , George<br />

A. Wells 7 , Vivian P. Bykerk 3 , Peter Tugwell 1 , Ruben Tavares 2 ,<br />

Francis Guillimen 4 and Joel Scarf 5 , 1 Institute <strong>of</strong> Population Hlth,<br />

Ottawa, ON, Canada, 2 MaMaster University, 3 Mt Sinai Hospital,<br />

Toronto, ON, Canada, 4 Nancy University, 5 Sunnybrook Health<br />

Sciences Ctr, 6 Sunnybrook Health Sciences Ctr, Toronto, ON,<br />

Canada, 7 Univ <strong>of</strong> Ottawa Faculty <strong>of</strong> Med, Ottawa, ON, Canada.<br />

795. Validation <strong>of</strong> the SF-6D Utility Measure in Patients with<br />

Systemic Lupus Erythematosus (SLE). Mark J. Harrison 5 , Nicola<br />

Dale 1 , Sahena Haque 2 , Joanna Shelmerdine 6 , Lee-Suan Teh 4 ,<br />

Yasmeen Ahmad 3 and Ian N. Bruce 1 , 1 Arthritis Research UK<br />

Epidemiology Unit, The University <strong>of</strong> Manchester, Manchester,<br />

United Kingdom, 2 Arthritis Research UK Epidemiology Unit,<br />

The University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />

3<br />

Betsi Cadwaladr University Health Board-West, <strong>Rheumatology</strong>,<br />

Llandudno, United Kingdom, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Royal Blackburn Hospital, Blackburn, United Kingdom, 5 Health<br />

Sciences Research Group, The University <strong>of</strong> Manchester,<br />

Manchester, UK, 6 The Kellgren Centre for <strong>Rheumatology</strong>, Central<br />

Manchester Foundation Trust, Manchester, UK.<br />

796. Working Status in Patients with Early Inflammatory<br />

Polyarthritis: Results from the Norfolk Arthritis Register<br />

(NOAR). S. M. M. Verstappen 1 , M. Lunt 1 , T. Marshall 2 , D.<br />

K. Bunn 2 , J. Chipping 2 and D. P. M. Symmons 1 , 1 Arthritis<br />

Research UK Epidemiology Unit, The University <strong>of</strong> Manchester,<br />

Manchester, United Kingdom, 2 Norfolk Arthritis Register, Norfolk<br />

and Norwich University Hospital, Norwich, United Kingdom,<br />

United Kingdom.<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders II<br />

797. A Randomized Attention-Controlled Study <strong>of</strong> Motivational<br />

Interviewing To Encourage Exercise in Fibromyalgia: Week<br />

12 Interim Analysis. Dennis C. Ang 3 , Anthony S. Kaleth 1 , Sylvia<br />

M. Bigatti 2 , Steven A. Mazzuca 3 , Chandan K. Saha 2 and Robert<br />

W. Bandy 2 , 1 Indiana Univ Purdue Univ Indianapolis, 2 Indiana<br />

University, 3 Indiana University, Indianapolis, IN.<br />

798. Correlation between Bone Mineral Density and Urine<br />

Carboxyl Terminal <strong>of</strong> Collagen Type (CTX) in Premenopausal<br />

Fibromyalgia Patients. Alaa Alsalawy 3 , Mohammed M. Kamel 2<br />

and Ibrahim Eweis 1 , 1 AlAzhar University, Cairo, Egypt, 2 ALAzhar<br />

University, Alkhobar, Saudi Arabia, 3 Tanta University, Tanta,<br />

Egypt.<br />

799. Cyclobenzaprine (CBP) Is a Potent Antagonist <strong>of</strong> Serotonin<br />

Receptor 2a (5-HT2a) and α-2 Adrenergic Receptors:<br />

Mechanistic Implications for Promoting Restorative Sleep in<br />

Fibromyalgia Syndrome (FMS). Herbert W. Harris 1 and Seth<br />

Lederman 2 , 1 Krele Pharmaceuticals, Saddle Brook, NJ, 2 Krele<br />

Pharmaceuticals, New York, NY.<br />

800. Developing an Improved PROMIS Fatigue Short-Form for<br />

Use in Patients with Fibromyalgia. Stephen Schilling 5 , Steven<br />

I. Blum 1 , Stavros Tourkodimitris 2 , Andy Stankus 3 and David A.<br />

Williams 4 , 1 Forest Research Institute, Jersey City, NJ, 2 Forest<br />

Research Institute, 3 KantarHealth, 4 Univ <strong>of</strong> MI Hlth System-<br />

Lobby M, Ann Arbor, MI, 5 University <strong>of</strong> Michigan.<br />

801. Evaluation <strong>of</strong> Drug-Drug Interactions <strong>of</strong> Sodium Oxybate:<br />

Results from Pharmacokinetic/Pharmacodynamic Studies with<br />

Duloxetine, Lorazepam, and Tramadol. Mark Eller, Whitney<br />

Halladay and Annette Madrid, Jazz Pharmaceuticals, Inc..<br />

802. Fibromyalgia Patients with High Global Disease Severity,<br />

Depression, Anxiety or Cognitive Dysfunction Are Likely<br />

To Benefit from Cognitive Behavioral Therapy. Chad S.<br />

Boomershine 1 , Cara L. Hammonds 1 , Jennifer Y. Hong 2 and<br />

Kenneth A. Wallston 2 , 1 Vanderbilt University, Nashville, TN,<br />

2<br />

Vanderbilt University.<br />

803. Identifying Fibromyalgia Subgroups Using Cluster Analysis:<br />

Relationships with Clinical Variables. Shin-Seok Lee 3 , Seong-Ho<br />

Kim 6 , Seong-Su Nah 11 , Ji Hyun Lee 8 , Seong-Kyu Kim 2 , Yeon-Ah<br />

Lee 10 , Seung-Jae Hong 10 , Hyun-Sook Kim 4 , Hye-Soon Lee 5 , Hyoun<br />

Ah Kim 1 , Chung-Il Joung 7 and Sang-Hyon Kim 9 , 1 Ajou University<br />

Hospital, Ajou University School <strong>of</strong> Medicine, 2 Catholic<br />

University <strong>of</strong> Daegu, School <strong>of</strong> Medicine, 3 Chonnam Natl Univ<br />

Med School, Gwangju, Korea, Republic <strong>of</strong>, 4 <strong>College</strong> <strong>of</strong> Medicine,<br />

Chosun University, 5 Hanyang University <strong>College</strong> <strong>of</strong> Medicine,<br />

6<br />

Inje University Haeundae Paik Hospital, 7 Konyang University<br />

Medical School, 8 Maryknoll Medical Center, 9 School <strong>of</strong><br />

Medicine, Keimyung University, 10 School <strong>of</strong> Medicine, Kyung Hee<br />

University, 11 Soonchunhyang University, <strong>College</strong> <strong>of</strong> Medicine.<br />

804. Lack <strong>of</strong> Detection <strong>of</strong> Xenotropic Murine Leukemia Virus-<br />

Related Virus (XMRV) in Patients with Fibromyalgia. Jorge<br />

J. Gonzalez Martin 1 , Gabriel Herrero-Beaumont 2 and Rafael<br />

Delgado 3 , 1 Reumatología, IIS-Fundación Jiménez Díaz, 28040,<br />

2<br />

Reumatología, IIS-Fundación Jimenez Díaz, 28040, 3 Servicio de<br />

Microbiología, Imas 12 , Hospital Universitario 12 de Octubre.<br />

805. Milnacipran Improves Pain and Global Status Independent<br />

<strong>of</strong> Changes in Depressive Symptoms in Patients with<br />

Fibromyalgia. Lesley M. Arnold 5 , R. Michael Gendreau 1 , Judy<br />

Gendreau 2 , Allan Spera 3 and Wei Chen 4 , 1 Cypress Bioscience,<br />

Inc., San Diego, CA, 2 Cypress Bioscience, Inc., 3 Forest Research<br />

Institute, Jersey City, NJ, 4 Forest Research Institute, 5 University<br />

<strong>of</strong> Cincinnati, Cincinnati, OH.<br />

806. Milnacipran Reduces the Overall Severity <strong>of</strong> Fibromyalgia<br />

Symptoms in Patients with Fibromyalgia. Robert H. Palmer 2 ,<br />

Robert M. Bennett 4 , Yong Wang 3 and R. Michael Gendreau 1 ,<br />

1<br />

Cypress Bioscience, Inc., San Diego, CA, 2 Forest Research<br />

Institute, Jersey City, NJ, 3 Forest Research Institute, 4 Oregon<br />

Health & Science Univ, Portland, OR.<br />

807. National Fibromyalgia Association Survey on Children with<br />

Fibromyalgia: Preliminary Results. Sanjida Ali 1 and Rae Marie<br />

Gleason 2 , 1 Forest Research Institute, Jersey City, NJ, 2 National<br />

Fibromyalgia Association.<br />

808. Nocturnal Heart Rate Variability Parameters. A Potential<br />

Fibromyalgia Biomarker. Claudia Lerma, Aline Martinez, Natllely<br />

Ruiz, Angelica Vargas, Oscar Infante and Manuel Martinez-Lavin,<br />

National Institute <strong>of</strong> Cardiology, Mexico.<br />

809. Orthostatic Stress Reverses Sympathetic but Not<br />

Parasympathetic Abnormalities <strong>of</strong> Fibromyalgia Patients.<br />

Florence Luong 2 , Donald D. Price 2 , Michael E. Robinson 2<br />

and Roland Staud 1 , 1 Univ <strong>of</strong> Florida JHMHC, Gainesville, FL,<br />

2<br />

University <strong>of</strong> Florida.<br />

2010 Program Book 195


ACR/ARHP Poster Session B<br />

810. Over-Reporting Is a Central Determinant <strong>of</strong> Pain and Symptom<br />

Reporting in Fibromyalgia. Frederick Wolfe, National Data Bank<br />

for Rheumatic Diseases, Wichita, KS.<br />

811. Proteomic Mass Spectra Classification in Fibromyalgic Patients.<br />

Camillo Giacomelli 3 , Laura Bazzichi 3 , Federica Ciregia 2 , Chiara<br />

Baldini 3 , Francesca Sernissi 2 , Pasquale Pepe 1 , Laura Giusti 2 ,<br />

Antonio Lucacchini 2 and Stefano Bombardieri 3 , 1 Department<br />

<strong>of</strong> Clinical Pharmacology, University <strong>of</strong> Pisa, Pisa, Italy,<br />

2<br />

Department <strong>of</strong> Psychiatry, Neurobiology, Pharmacology and<br />

Biotechnology. University <strong>of</strong> Pisa, Pisa, Italy, 3 <strong>Rheumatology</strong><br />

Unit. Department <strong>of</strong> Internal Medicine. University <strong>of</strong> Pisa, Pisa,<br />

Italy.<br />

812. Sexual Dysfunction in Female Fibromyalgia Patients. Jacob N.<br />

Ablin 4 , Inna Gurevitz 3 , Hagit Cohen 1 and Dan Buskila 2 , 1 Ben-<br />

Gurion University <strong>of</strong> the Negev, Beer Sheva, Israel, 2 Soroka<br />

Medical Center, Beer Sheva, Israel, 3 Soroka Medical Center, Beer<br />

- Sheva, Israel, 4 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.<br />

813. Simplifying Fibromyalgia Assessment: The VASFIQ Brief<br />

Symptom Scale. Chad S. Boomershine, Gergana Zlateva,<br />

Yi Wang, Ed Whalen and Birol Emir, Vanderbilt University,<br />

Nashville, TN.<br />

814. Sodium Oxybate Improves Pain, Function, and PGIC in Patients<br />

with Fibromyalgia: A Pooled Analysis <strong>of</strong> 2 Pivotal Clinical<br />

Trials. I. Jon Russell 5 , Robert M. Bennett 3 , Cayetano Alegre 1 ,<br />

John B. Winfield 4 , Chinglin Lai 2 , Y. Grace Wang 2 and Beverly<br />

Benson 2 , 1 Hospital de la Vall d’Hebron, Alella, Spain, 2 Jazz<br />

Pharmaceuticals, Inc., 3 Oregon Health & Science University,<br />

Portland, OR, 4 University <strong>of</strong> North Carolina, Chapel Hill, NC,<br />

5<br />

University <strong>of</strong> Texas Health Science Center, San Antonio, TX.<br />

815. Sodium Oxybate Improves Sleep and Fatigue in Patients with<br />

Fibromyalgia: Pooled Analysis from 2 Pivotal Clinical Trials.<br />

Stuart L. Silverman 3 , Andrew J. Holman 4 , Beverly Benson 1 , Sarah<br />

Alvarez-Horine 1 , Y. Grace Wang 1 and Piercarlo Sarzi-Puttini 2 ,<br />

1<br />

Jazz Pharmaceuticals, Inc., 2 L. Sacco University Hospital, Milano,<br />

Italy, 3 Osteoporosis Medical Center, Beverly Hills, CA, 4 Pacific<br />

<strong>Rheumatology</strong> Associates, Inc., Renton, WA.<br />

816. SPECT Imaging <strong>of</strong> the Brain: Regional Cerebral Blood<br />

Flow before and after Treatment <strong>of</strong> Patients with Primary<br />

Fibromyalgia. Manal Osman 3 , Osama Hajji 3 , Ola Abdul Nasser 3 ,<br />

Ahmad Khodair 2 and Nashwa Al Sarraf 1 , 1 Internal Medicine<br />

Department, Faculty <strong>of</strong> Medicine, Cairo University, Cairo,<br />

Egypt, 2 Radiology Department, Faculty <strong>of</strong> Medicine, Ain Shams<br />

University, Cairo, Egypt, 3 <strong>Rheumatology</strong> and Rehabilitation<br />

Department, Faculty <strong>of</strong> Medicine, Ain Shams University, Cairo,<br />

Egypt.<br />

817. The Prevalence <strong>of</strong> Fibromyalgia in Patients with Chronic<br />

Hepatitis C Infection. Ausaf Mohammad 1 , John J. Carey 4 , Eoin<br />

R. Storan 2 , Margaret Scarry 2 , Mary B. Keane 2 , Angela Moore 2 ,<br />

Ann Lyons 2 , Maureen O’ Grady 2 , Catriona Minihan 2 and John M.<br />

Lee 3 , 1 Department <strong>of</strong> Hepatology and <strong>Rheumatology</strong>, Galway<br />

University Hospital, Ireland, 2 Galway University Hospital,<br />

3<br />

Hepatology Galway University Hospital, 4 <strong>Rheumatology</strong> Merlin<br />

Park University Hospital.<br />

818. The Prevalence <strong>of</strong> Fibromyalgia in Patients with Hereditary<br />

Hemochromatosis. Ausaf Mohammad 1 , John J. Carey 4 , Eoin R.<br />

Storan 2 , Margaret Scarry 2 , Mary B. Keane 2 , Angela Moore 2 , Ann<br />

Lyons 2 , Maureen O’ Grady 2 , Catriona Minihan 2 and John M.<br />

Lee 3 , 1 Department <strong>of</strong> Hepatology and <strong>Rheumatology</strong> Galway<br />

University Hospital, Ireland, 2 Galway University Hospital,<br />

3<br />

Hepatology Galway University Hospital, 4 <strong>Rheumatology</strong> Merlin<br />

Park University Hospital.<br />

819. Use <strong>of</strong> Path Analysis To Evaluate the Effects <strong>of</strong> Sodium Oxybate<br />

on Pain Reduction in Patients with Fibromyalgia. Fowzia<br />

Ibrahim 2 , Chinglin Lai 1 and Ernest Choy 3 , 1 Jazz Pharmaceuticals,<br />

Inc., 2 King’s <strong>College</strong> London, 3 Kings <strong>College</strong> Hospital, London,<br />

United Kingdom.<br />

820. Very Low Dosage (VLD) Bedtime Cyclobenzaprine (CBP)<br />

Reduces Cyclic Alternating Pattern (CAP) Rate Indices <strong>of</strong><br />

EEG Sleep Instability and Improves Pre-Sleep Fatigue in<br />

Fibromyalgia Syndrome (FMS). Harvey Mold<strong>of</strong>sky 1 , Herbert W.<br />

Harris 2 , Tad Archambault 4 , Terence Kwong 1 and Seth Lederman 3 ,<br />

1<br />

Centre for Sleep & Chronobiology, Toronto, ON, Canada, 2 Krele<br />

Pharmaceuticals, Saddle Brook, NJ, 3 Krele Pharmaceuticals, New<br />

York, NY, 4 VirtuStat Ltd, North Wales, PA.<br />

821. Vibrotactile Analgesia Is Not Abnormal in Fibromyalgia<br />

Patients. Casey T. Goldman 2 , Donald D. Price 2 , Michael<br />

E. Robinson 2 and Roland Staud 1 , 1 Univ <strong>of</strong> Florida JHMHC,<br />

Gainesville, FL, 2 University <strong>of</strong> Florida.<br />

Genetics, Genomics and Proteomics in the Rheumatic Diseases<br />

822. A Putative Functional Variant within the Ubiquitin-Associated<br />

Domain-Containing Protein 2 Gene (UBAC2) Is Associated<br />

with Increased Risk <strong>of</strong> Behcet’s Disease. Amr H. Sawalha 7 ,<br />

Travis Hughes 6 , Ajay Nadig 6 , Vuslat Yilmaz 2 , Kenan Aksu 1 ,<br />

Gokhan Keser 1 , Ayse Cefle 3 , Ayten Yazici 3 , Andac Ergen 5 , Haner<br />

Direskeneli 4 and Güher Saruhan-Direskeneli 2 , 1 Ege University,<br />

2<br />

Istanbul University, 3 Kocaeli University, 4 Marmara University,<br />

Istanbul, Turkey, 5 Okmeydani Research and Education Hospital,<br />

6<br />

OMRF, 7 University <strong>of</strong> Oklahoma, OMRF, VAMC, Oklahoma City,<br />

OK.<br />

823. A Role for PACE4 in Pain in Mice and Humans: Pain Phenotype<br />

<strong>of</strong> a PACE4 Null Mutant and Genetic Association with<br />

Knee Osteoarthritis Pain. Anne-Marie M. Malfait 6 , Albert B.<br />

Seymour 5 , Ana M. Valdes 4 , Linda S. Wood 5 , Kathryn Durham 5 ,<br />

Micky Tortorella 3 , Nigel K. Arden 8 , Frances L. Vaughn 7 , Paul<br />

E. Leaverton 7 , Deborah J. Hart 4 , Robert E. Sorge 1 , Susana<br />

G. Sotocinal 2 , Ara Schorscher-Petcu 1 and Jeffrey S. Mogil 1 ,<br />

1<br />

Dept <strong>of</strong> Psychology and Alan Edwards Centre for Research<br />

on Pain, McGill University, Montreal, QC, Canada, 2 Dept <strong>of</strong><br />

Psychology and Alan Edwards Centre for Research on Pain,<br />

McGill University, 3 Guangzhou Institute <strong>of</strong> Biomedical Health,<br />

Guangzhou, China, 4 King’s <strong>College</strong> London, London, United<br />

Kingdom, 5 Pfizer Global Research and Development, Cambridge,<br />

MA, 6 Rush University Medical Center, Chicago, IL, 7 The Arthritis<br />

Research Institute <strong>of</strong> America, Clearwater, FL, 8 University <strong>of</strong><br />

Oxford, Oxford, United Kingdom.<br />

824. Analysis <strong>of</strong> the Influence <strong>of</strong> PTPN22 Gene Polymorphisms in<br />

Systemic Sclerosis. Lina Marcela Diaz-Gallo 7 , Pravitt Gourh 27 ,<br />

Jasper Broen 4 , Carmen Simeón 16 , Vicent Fonollosa 16 , Norberto<br />

Ortego-Centeno 13 , M. C. Vonk 4 , Marieke Coenen 5 , Gabriela<br />

Riemekasten 2 , Nicolas Hunzelmann 1 , Roger Hesselstrand 3 ,<br />

Filemon K. Tan 26 , Sandeep K. Agarwal 26 , John D. Reveille 26 ,<br />

Shervin Assassi 26 , Francisco J. García-Hernandez 17 , Patricia<br />

Carreira 18 , Maria Teresa Camps 12 , Antomio Fernandez-Nebro 19 ,<br />

Paloma Garcia de la Peña 23 , R. Rios 13 , T. Nearney 30 , D. Hilda 28 ,<br />

Miguel Angel González-Gay 22 , Paolo Airo 25 , Lorenzo Beretta 8 ,<br />

Raffaella Scorza 8 , Ariane Herrick 10 , Jane Worthington 9 , Ana<br />

Pros 21 , Inmaculada Gómez-Gracia 24 , Luis Trapiella 15 , Gerard<br />

Espinosa 14 , Ivan Castellvi 20 , Torsten Witte 6 , Filip De Keyser 29 ,<br />

Marie Vanthuyne 11 , Maureen D. Mayes 26 , Timothy R. D.J.<br />

Radstake 4 , Frank C. Arnett 26 , Javier Martin 7 and Blanca Rueda 7 ,<br />

1<br />

Department <strong>of</strong> Dermatology, University <strong>of</strong> Cologne, Germany,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />

196<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

University Hospital, Berlin, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Lund University Hospital, Lund, Sweden, 4 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands, 5 Department<strong>of</strong> Human Genetics,<br />

Radboud University Nijmegen Medical Centre, Nijmegen,<br />

The Netherlands, 6 Hannover Medical School, Hannover,<br />

Germany, 7 Instituto de Parasitología y Biomedicina Lopez-<br />

Neyra CSIC, Granada, Spain, 8 Referral Center for Systemic<br />

Autoimmune Diseases, University <strong>of</strong> Milan, Milan, Italy,<br />

9<br />

Rheumatic Diseases Centre, University <strong>of</strong> Manchester, Salford<br />

Royal NHS Foundatin Trust, UK, 10 Rheumatic Diseases Centre,<br />

University <strong>of</strong> Manchester, Salford Royal NHS Foundation Trust,<br />

UK, 11 <strong>Rheumatology</strong> Department, Universite Catholique de<br />

Louvain, 12 Servicio de Medicina Interna, Hospital Carlos Haya,<br />

Málaga, Spain, 13 Servicio de Medicina Interna, Hospital Clinico<br />

Universitario, Granada, Spain, 14 Servicio de Medicina Interna,<br />

Hospital Clinico, Barcelona, Spain, 15 Servicio de Medicina<br />

Interna, Hospital Universitario Central de Asturias, Oviedo,<br />

Spain, 16 Servicio de Medicina Interna, Hospital Valle de Hebron,<br />

Barcelona, Spain, 17 Servicio de Medicina Interna. Hospital Virgen<br />

del Rocio, Sevilla, Spain, 18 Servicio de Reumatología, Hospital 12<br />

de Octubre, Madrid, Spain, 19 Servicio de Reumatología, Hospital<br />

Carlos Haya, Málaga, Spain, 20 Servicio de Reumatología, Hospital<br />

de Sant Pau, Barcelona, Spain, 21 Servicio de Reumatología,<br />

Hospital del Mar, Barcelona, Spain, 22 Servicio de Reumatología,<br />

Hospital Marques de Valdecillas, Santander, Spain, 23 Servicio de<br />

Reumatología, Hospital Ramon y Cajal, Madrid, Spain, 24 Servicio<br />

de Reumatología. Hospital Reina S<strong>of</strong>ía, Córdoba, Spain,<br />

25<br />

Servizio di Reumatologia ed Immunologia Clinica Spedali Civili,<br />

Brescia, Italy, 26 The University <strong>of</strong> Texas Health Science Center<br />

at Houston Medical School, Department <strong>of</strong> Internal Medicine,<br />

Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics,<br />

27<br />

The University <strong>of</strong> Texas Health Science Center at Houston<br />

Medical School, Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />

<strong>Rheumatology</strong> and Clinical Immunogenetics., 28 The University<br />

<strong>of</strong> Texas Health Science Center at San Antonio, San Antonio, TX,<br />

29<br />

University <strong>of</strong> Ghent, Belgium, 30 University <strong>of</strong> Texas Medical<br />

Branch at Galveston, Galveston, TX.<br />

825. BLK Is Expressed in Human Peripheral T Cells and Thymocytes<br />

and Regulates CD4+ T Cell Numbers in Cord Blood. Kim R.<br />

Simpfendorfer 1 , Lina Olsson 2 , Nataly Manjarraz-Orduno 2 ,<br />

Houman Khalili 2 , Annette T. Lee 2 and Peter K. Gregersen 1 ,<br />

1<br />

Feinstein Institute for Medical Research, Manhasset, NY,<br />

2<br />

Feinstein Institute for Medical Research.<br />

826. Epigenetic Studies Characteristic <strong>of</strong> Muscle Biopsies (MBx)<br />

from Untreated Children with Juvenile Myositis (JM). Lauren<br />

M. Pachman, Min Wang, Hehuang Xie, Peter Hendrickson,<br />

Sheela Shrestha and Gabrielle Morgan, Children’s Memorial<br />

Research Center, Chicago, IL.<br />

827. Functional Change <strong>of</strong> 5-Aminoimidazole-4-Carboxamide<br />

Ribonucleotide Formyltransferase in Dermal Fibroblasts from<br />

Methotrexate-Sensitive and Resistant Mice. Xin You 2 , Bruce N.<br />

Cronstein 2 , Adrienne Williams 2 and Thierry Dervieux 1 , 1 Cypress<br />

Pharmaceuticals, 2 NYU.<br />

828. Functional Polymorphisms in the Inhibitory FCGR2B Associate<br />

with Efficacy <strong>of</strong> IVIG Treatment Response among Patients<br />

with Kawasaki Disease. Sadeep Shrestha 2 , Howard W. Wiener 1 ,<br />

Aditi Shendre 1 , Richard A. Kaslow 1 , Aaron K. Olson 3 , Mary Beth<br />

Lee 3 , Jeffrey C. Edberg 4 and Michael Portman 3 , 1 Department<br />

<strong>of</strong> Epidemiology, University <strong>of</strong> Alabama at Birmingham,<br />

2<br />

Department <strong>of</strong> Epidemiology, University <strong>of</strong> Alabama at<br />

Birmingham, Birmingham, AL, 3 Department <strong>of</strong> Pediatrics,<br />

University <strong>of</strong> Washington, Seattle Children’s Hospital, 4 Division<br />

<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Medicine, University <strong>of</strong> Alabama at Birmingham.<br />

829. Functional Variants in the Pre-B Cell Colony Enhancing Factor<br />

Gene Are Associated with Systemic Sclerosis Susceptibility<br />

and the Clinical Hallmark Pulmonary Arterial Hypertension.<br />

Jasper Broen 9 , Pravitt Gourh 7 , Madelon Vonk 9 , Lorenzo Beretta 10 ,<br />

Blanca Rueda 8 , Lenny Geurts-van Bon 9 , Christel Brouwer 9 ,<br />

Roger Hesselstrand 5 , Ariane Herrick 11 , Jane Worthington 11 ,<br />

Nico Hunzelmann 2 , Chris Denton 1 , Carmen Fonseca 1 , Gabriela<br />

Riemekasten 6 , Hans Kiener 4 , Raffaella Scorza 10 , C. Simeon 14 ,<br />

N. Ortego-Centeno 13 , M. Gonzalez-Gay 12 , Paolo Airo’ 15 ,<br />

Marieke Coenen 3 , Maureen Mayes 7 , Diego Kyburz 16 , Frank<br />

Arnett 7 , Javier Martin 8 and Timothy Radstake 9 , 1 Centre for<br />

<strong>Rheumatology</strong>, Royal Free and University <strong>College</strong> Medical<br />

School, London, United Kingdom, 2 Department <strong>of</strong> Dermatology,<br />

University <strong>of</strong> Cologne, Germany, 3 Department <strong>of</strong> Human<br />

Genetics, Radboud University Nijmegen Medical Center, The<br />

Netherlands, 4 Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />

<strong>Rheumatology</strong>, University <strong>of</strong> Vienna, Austria, 5 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Lund University Hospital, S- 221 85 Lund, Sweden,<br />

6<br />

Dept <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />

University Hospital and German Rheumatism Research Centre,<br />

a Leibniz Institute, 7 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunogenetics, Department <strong>of</strong> Internal Medicine, University<br />

<strong>of</strong> Texas Health Science Center at Houston (UTHSC-H), Houston,<br />

TX, 8 Instituto de Parasitología y Biomedicina, CSIC, Granada,<br />

Spain, 9 Radboud University Medical Center, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Nijmegen, The Netherlands, 10 Referral Center<br />

for Systemic Autoimmune Diseases, University <strong>of</strong> Milan, Italy,<br />

11<br />

Rheumatic Diseases Centre, University <strong>of</strong> Manchester, Salford<br />

Royal NHS Foundation Trust, UK, 12 Servicio de Medicina Interna,<br />

Hospital Clinico Universitario, Granada, Spain., 13 Servicio de<br />

Medicina Interna, Hospital Universitario Central de Asturias,<br />

Oviedo, Spain., 14 Servicio de Medinina Interna, Hospital Valle<br />

de Hebron, Barcelona, Spain, 15 Servizio di Reumatologia ed<br />

Immunologia Clinica, Spedali Civili, Brescia, Italia., 16 University<br />

Hospital Zurich Div. <strong>of</strong> <strong>Rheumatology</strong> Zurich, Switzerland..<br />

830. Gene Expression Pr<strong>of</strong>ile at the Initial Phase <strong>of</strong> Collagen-<br />

Induced Arthritis in the Synovium, Peripheral Blood and<br />

Thymus. Seung-Cheol Shim 2 , Mi-Kyung Lim 1 and Dong-Hyuk<br />

Sheen 1 , 1 Eulji University, Daejeon, Korea, Republic <strong>of</strong>, 2 Eulji<br />

University, Daeejon, Korea, Republic <strong>of</strong>.<br />

831. Genetic Variants Associated with Susceptibility to Knee<br />

Osteoarthritis: The Johnston County Osteoarthritis Project.<br />

Xiaodong Wu 3 , Venkateswarlu Kondragunta 4 , Jordan B. Renner 2 ,<br />

Gordon W. Duff 5 , Kenneth S. Kornman 4 and Joanne M. Jordan 1 ,<br />

1<br />

Chapel Hill, NC, 2 Department <strong>of</strong> Radiology and Thurston<br />

Arthritis Research Center, University <strong>of</strong> North Carolina at Chapel<br />

Hill, 3 Interleukin Genetics, Inc., Waltham, MA, 4 Interleukin<br />

Genetics, Inc., 5 School <strong>of</strong> Medicine, University <strong>of</strong> Sheffield.<br />

832. HLA-DRB1*04 Is a Novel Fetal Susceptibility Allele in<br />

Congenital Heart Block. Therese Östberg 2 , Stina Salomonsson 2 ,<br />

Bo Ding 4 , Håkan Eliasson 4 , Lars Alfredsson 4 , Lars Klareskog 5 ,<br />

Anders Hamsten 2 , Tomas Olsson 4 , Leonid Padyukov 2 , Tomas<br />

Axelsson 6 , Swedish Congenital Heart Block Study Group 7 , Fredrik<br />

Gadler 2 , Anders Jonzon 6 , Sven-Erik Sonesson 3 , Ingrid Kockum 4<br />

and Marie Wahren-Herlenius 1 , 1 Department <strong>of</strong> Medicine,<br />

Karolinska Institutet, Stockholm, 2 Department <strong>of</strong> Medicine,<br />

Karolinska Institutet, 3 Department <strong>of</strong> Women and Child Health,<br />

Karolinska Instituet, 4 Karolinska Institutet, 5 Karolinska University<br />

Hospital, Stockholm, Sweden, 6 Uppsala University, 7 www.<br />

combinesweden.se.<br />

2010 Program Book 197


ACR/ARHP Poster Session B<br />

833. IL13 Is a Risk Locus for Psoriatic Arthritis but Not Psoriasis<br />

Vulgaris. John Bowes 1 , Pauline Ho 2 , Salma Salah 1 , Richard<br />

B. Warren 5 , Eleanor Korendowych 7 , Neil McHugh 7 , Oliver<br />

FitzGerald 4 , Jonathon Packham 3 , Ann W. Morgan 6 , Christopher<br />

E. M. Griffiths 5 , Ian N. Bruce 2 , Jane Worthington 1 and<br />

Anne Barton 2 , 1 Arthritis Research UK Epidemiology Unit,<br />

The University <strong>of</strong> Manchester, UK, 2 Arthritis Research UK<br />

Epidemiology Unit, The University <strong>of</strong> Manchester, UK; The<br />

Kellgren Centre for <strong>Rheumatology</strong>, Manchester, UK, 3 Arthritis<br />

Research UK, National Primary Care Centre, Keele University<br />

UK, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, University <strong>College</strong> Dublin,<br />

Ireland, 5 Dermatological Sciences, The University <strong>of</strong> Manchester,<br />

UK., 6 NIHR-Leeds Musculoskeletal Biomedical Research Unit,<br />

University <strong>of</strong> Leeds, UK, 7 Royal National Hospital for Rheumatic<br />

Diseases.<br />

834. Major Differences among Proteomes <strong>of</strong> Macro-Vascular and<br />

Micro-Vascular Endothelial Cells: 2D-DIGE Approach. Hanadi<br />

Dib 1 , Philippe Chafey 3 , Guilhem Clary 3 , Morgane Le Gall 3 ,<br />

Cedric Broussard 4 , Luc Camoin 4 , Christian Federici 3 , Veronique<br />

Witko-Sarsat 3 , Mathieu C. Tamby 3 and Luc Mouthon 2 , 1 INSERM<br />

1016, Cochin Institute, Paris Descartes University, Paris, France,<br />

2<br />

INSERM 1016, Cochin Institute, Paris Descartes University,<br />

Paris, France, 3 INSERM 1016, Cochin Institute, Paris, France,<br />

4<br />

Proteomics Platform <strong>of</strong> Paris Descartes, Paris, France.<br />

835. mtDNA Haplogroups Define Two Phenotypes <strong>of</strong> Osteoarthritis<br />

(OA). Ignacio Rego-Pérez 4 , Mercedes Fernández-Moreno 5 , M.<br />

Deberg 1 , Sonia Pértega 3 , Carlos Fernández-López 5 , Natividad<br />

Oreiro 5 , Manuel Acasuso 2 , Victoria Bonome-González 2 , Y.<br />

Henrotin 1 and Francisco J. Blanco 5 , 1 Bone and Cartilage<br />

Res. Unit. Univ. <strong>of</strong> Liege, Liege, Belgium, 2 Centro de Salud<br />

Matogrande - SERGAS, A Coruña, Spain, 3 Epidemiology Unit.<br />

INIBIC-Complejo Hosp. Univ. A Coruna, A Coruna, Spain,<br />

4<br />

Osteoarticular and Aging Res. Lab. <strong>Rheumatology</strong> Div, INIBIC-<br />

Complejo Hosp, Univ. A Coruña, Coruña, Spain, 5 Osteoarticular<br />

and Aging Res. Lab. <strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp,<br />

Univ. A Coruña, A Coruña, Spain.<br />

836. Neurotransmitter Receptor Gene Polymorphisms Are<br />

Associated with Widespread Pain: Findings from the First<br />

Genome-Wide Association Study <strong>of</strong> Musculoskeletal Pain. Kate<br />

L. Holliday 3 , Tuhina Neogi 2 , David Felson 2 , Ke Wang 1 , Wendy<br />

Thomson 4 and John McBeth 4 , 1 Boston Univerity School <strong>of</strong> Public<br />

Health, 2 Boston University School <strong>of</strong> Medicine, 3 University<br />

<strong>of</strong> Manchester, Manchester, United Kingdom, 4 University <strong>of</strong><br />

Manchester.<br />

837. Pathogenesis <strong>of</strong> Idiopathic Recurrent Pericarditis and Role <strong>of</strong><br />

the TNFRSF1A Gene Mutations. Luca Cantarini, Orso Maria<br />

Lucherini, Maria Giuseppina Brizi and Mauro Galeazzi, Unit <strong>of</strong><br />

<strong>Rheumatology</strong>, University <strong>of</strong> Siena, Siena, Italy.<br />

838. Radiographic Kellgren-Lawrence (KL) Grade 1 Is Genetically<br />

Distinct from KL 0: Implications for Genetic Studies <strong>of</strong> Knee<br />

Osteoarthritis (OA). Venkateswarlu Kondragunta 3 , Xiaodong<br />

Wu 3 , Jordan B. Renner 2 , Gordon W. Duff 4 , Kenneth S. Kornman 3<br />

and Joanne M. Jordan 1 , 1 Chapel Hill, NC, 2 Department <strong>of</strong><br />

Radiology and Thurston Arthritis Research Center, University <strong>of</strong><br />

North Carolina at Chapel Hill, 3 Interleukin Genetics, Inc., 4 School<br />

<strong>of</strong> Medicine, University <strong>of</strong> Sheffield.<br />

839. Salivary Proteomic Pr<strong>of</strong>ile in Behçet’s Disease. Rosaria<br />

Talarico, Chiara Baldini, Laura Giusti, Ylenia Da Valle, Camillo<br />

Giacomelli, Elena Donadio, Francesca Sernissi, Anna d’Ascanio,<br />

Laura Bazzichi, Antonio Lucacchini and Stefano Bombardieri,<br />

<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Internal Medicine,<br />

University <strong>of</strong> Pisa, Pisa, Italy.<br />

840. Study <strong>of</strong> the Chondrogenic Differentiation Process by<br />

Metabolic Labeling <strong>of</strong> Mesenchymal Stem Cells. Beatriz Rocha 1 ,<br />

Valentina Calamia 2 , Patricia Fernández-Puente 2 , Jesús Mateos 2 ,<br />

Cristina Ruiz-Romero 2 and Francisco J. Blanco 2 , 1 Osteoarticular<br />

and Aging Research Lab, Proteomics Unit, Nodo Asociado<br />

de ProteoRed. INIBIC-Complejo Hospitalario Universitario A<br />

Coruña, A Coruña, Coruña, Spain, 2 Osteoarticular and Aging<br />

Research Lab, Proteomics Unit, Nodo Asociado de ProteoRed.<br />

INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruña,<br />

Spain.<br />

841. The FAAH Gene Is Involved in Risk <strong>of</strong> Symptomatic<br />

Osteoarthritis <strong>of</strong> the Knee and in Pain in Osteoarthritis. Ana<br />

M. Valdes 1 , Anne-Marie Malfait 3 , Sally Doherty 5 , Rosalina Das 4 ,<br />

Margaret Wheeler 5 , Deborah Hart 2 , Tim D. Spector 2 , Cyrus<br />

Cooper 6 , Michael Doherty 5 and Nigel K. Arden 6 , 1 King’s <strong>College</strong><br />

London, London, United Kingdom, 2 King’s <strong>College</strong> London, 3 Rush<br />

University Medical Center, Chicago, IL, 4 Rush University Medical<br />

Center, 5 University <strong>of</strong> Nottingham, United Kingdom, 6 University<br />

<strong>of</strong> Southampton - University <strong>of</strong> Oxford, United Kingdom.<br />

842. The Pr<strong>of</strong>ile <strong>of</strong> miRNA Expression during the Differentiation <strong>of</strong><br />

Murine Osteoclast. Inhye E. Ahn 1 , Ji Hyeon Ju 2 and Jin Sil Park 3 ,<br />

1<br />

Department <strong>of</strong> Internal Medicine, The Methodist Hospital,<br />

Houston, TX, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine, Catholic University <strong>of</strong> Korea, Seoul, Korea, Republic<br />

<strong>of</strong>, 3 <strong>Rheumatology</strong> Research Center, Catholic University <strong>of</strong><br />

Korea, Seoul, Korea, Republic <strong>of</strong>.<br />

843. Towards Allele-Specific Dynamic Proteomics: Measuring<br />

Protein Synthesis and Turnover Using Heavy Water Labelling<br />

and Peptide Mass Spectrometry. Michael J. Deery 1 , Alessandra<br />

De Riva 2 , Claudia Prevosto 2 , Sarah McDonald 2 and Robert<br />

Busch 2 , 1 Centre for Proteomics, University <strong>of</strong> Cambridge, 2 Dept<br />

<strong>of</strong> Medicine, University <strong>of</strong> Cambridge.<br />

Innate Immunity and Rheumatic Disease<br />

844. β2 Integrins Control the Pro-Inflammatory Phenotype <strong>of</strong> Type<br />

1 Macrophages and Dendritic Cells. Kim C. M. Santegoets 2 ,<br />

Mark H. Wenink 2 , Richard Huijbens 2 , Lenny van Bon 2 , Alessandra<br />

Cambi 2 , Piet L. Van Riel 3 , Wim B. Van Den Berg 1 and Timothy R.<br />

D. J. Radstake 2 , 1 Radboud Univ Nijmegen Med Cntr, Nijmegen,<br />

The Netherlands, 2 Radboud University Nijmegen Medical<br />

Center, 3 University Hosp Nijmegen, Nijmegen, The Netherlands.<br />

845. “Alarmins”S100A8 and A9 Are Expressed in Synovium <strong>of</strong><br />

Early OA Patients and Regulate Synovial Activation and<br />

Joint Destruction during Experimental Osteoarthritis. Peter<br />

van Lent 1 , Arjen Blom 1 , Rik Schelbergen 1 , Annet Sloetjes 1 ,<br />

Thomas Vogl 2 , Johannes Roth 2 and Wim van den Berg 1 , 1 Dep<br />

<strong>of</strong> <strong>Rheumatology</strong> University Hospital Nijmegen Medical<br />

Centre, Nijmegen, Gelderland, The Netherlands, 2 Institute <strong>of</strong><br />

Immunology Muenster, Muenster, Germany.<br />

846. Altered T Cell Signaling in Systemic Lupus Erythematosus (SLE):<br />

A Role for FcγRIII and Immune Complexes (ICs). Anil Chauhan 1 ,<br />

John P. Atkinson 3 and Terry L. Moore 2 , 1 Saint Louis University,<br />

Saint Louis, MO, 2 St Louis University, St Louis, MO, 3 Washington<br />

University School <strong>of</strong> Medicine, St Louis, MO.<br />

847. C5aR Is Expressed by Macrophages and Dendritic Cells in<br />

Close Proximity to T-Cells in Synovial Tissue from Patients<br />

with Rheumatoid Arthritis. Ditte Tornehave 1 and Lars<br />

Hornum 2 , 1 Histology, Biopharmaceuticals Research Unit,<br />

Novo Nordisk A/S, Måløv, Denmark, 2 Immunopharmacology,<br />

Biopharmaceuticals Research Unit, Novo Nordisk A/S, Måløv,<br />

Måløv, Denmark.<br />

198<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

848. Cellular Immunity in Rheumatoid Arthritis Patients Not<br />

Responding to Synthetic DMARDs. Andra Balanescu 3 , Ionela<br />

Victoria Neagoe 5 , Florian Berghea 3 , Carolina Negrei 2 , Magda<br />

Parvu 1 , Ruxandra Ionescu 4 , Denisa Predeteanu 4 , Violeta<br />

Bojinca 4 , Vasile Preoteasa 6 and Gina Manda 6 , 1 Colentina Clinical<br />

Hospital, Bucharest, Romaia, 2 Department <strong>of</strong> Toxicology,<br />

University <strong>of</strong> Medicine and Pharmacy Carol Davila, Bucharest,<br />

Romania, 3 Research Center <strong>of</strong> Rheumatic Diseases, Sf. Maria<br />

Hospital, University <strong>of</strong> Medicine and Pharmacy Carol Davila,<br />

Bucharest, Romania, 4 Research Center <strong>of</strong> Rheumatic Diseases,<br />

Sf. Maria Hospital, University <strong>of</strong> Medicine and Pharmacy Carol<br />

Davila, Bucharest, Romania, 5 Victor Babes National Institute <strong>of</strong><br />

Pathology, Bucharest, Romania, 6 Victor Babes National Institute<br />

<strong>of</strong> Pathology, Bucharest, Romania.<br />

849. Comprehensive Flow Cytometric Pr<strong>of</strong>iling <strong>of</strong> Peripheral<br />

Blood Dendritic Cells in Rheumatoid and Psoriatic Arthritis<br />

Patients. James Kobie 6 , Ben Panepento 6 , Jyh-Chiang E. Wang 6 ,<br />

Grace Chiu 6 , Darren Tabechian 8 , Allen P. Anandarajah 2 , Richard<br />

J. Looney 3 , Ralf G. Thiele 5 , Jennifer H. Anolik 1 , Ignacio Sanz 4 ,<br />

Sally Quataert 6 , Alex Rosenberg 6 and Christopher T. Ritchlin 7 ,<br />

1<br />

University <strong>of</strong> Rochester, Rochester, NY, 2 Univ <strong>of</strong> Rochester<br />

Med Ctr, Rochester, NY, 3 University <strong>of</strong> Rochester, Rochester, NY,<br />

4<br />

University <strong>of</strong> Rochester, Rochester, NY, 5 University <strong>of</strong> Rochester,<br />

Rochester, NY, 6 University <strong>of</strong> Rochester, 7 University <strong>of</strong> Rochester<br />

Medical Center, Rochester, NY, 8 University <strong>of</strong> Rochester School<br />

<strong>of</strong> Medicine, Rochester, NY.<br />

850. C-Reactive Protein Inhibition <strong>of</strong> the Response to Type I<br />

Interferon (IFN). Carolyn Mold 2 , Daniel Goldberg 1 , Carol Morris 1<br />

and Terry Du Clos 1 , 1 University <strong>of</strong> New Mexico, 2 University <strong>of</strong><br />

New Mexico, Albuquerque, NM.<br />

851. Endosomal Trafficking <strong>of</strong> Antigen in Antigen Cross-Presentation<br />

and the Cause <strong>of</strong> Lupus Tissue Injuries. Mai Takimoto 1 , Ken<br />

Tsumiyama 1 and Shunichi Shiozawa 2 , 1 Department <strong>of</strong> Biophysics,<br />

Kobe University Graduate School <strong>of</strong> Health Sciences, Kobe,<br />

Japan, 2 Department <strong>of</strong> Biophysics, Kobe University Graduate<br />

School <strong>of</strong> Health Sciences/Department <strong>of</strong> Medicine, Kobe<br />

University Graduate School <strong>of</strong> Medicine/The Center for<br />

Rheumatic Diseases, Kobe University Hospital, Kobe, Japan.<br />

852. Exposure to U1-RNP Components Induces Bone Marrow-<br />

Derived Dendritic Cell Trafficking to the Lung. Luis Sorell 4 ,<br />

YunJuan Zang 4 , Irina Fernandez 4 , Laisel Martinez 1 , Maria<br />

Carpintero 3 and Eric L. Greidinger 2 , 1 Miami VA Medical Center,<br />

2<br />

Miami VA Medical Center and University <strong>of</strong> Miami Miller School<br />

<strong>of</strong> Medicine, Miami, FL, 3 University <strong>of</strong> Miami Miller School<br />

<strong>of</strong> Medicine, Pembroke Pines, FL, 4 University <strong>of</strong> Miami Miller<br />

School <strong>of</strong> Medicine.<br />

853. Fas Expression in Myeloid Cells Is Required To Prevent<br />

Systemic Autoimmunity. Carla M. Cuda 1 , Hemant Agrawal 1 ,<br />

Evan Weber 2 , G. Kenneth Haines 3 and Harris R. Perlman 1 ,<br />

1<br />

Northwestern University, Chicago, IL, 2 Northwestern University,<br />

3<br />

Yale University.<br />

854. FLIP: The Novel Regulator <strong>of</strong> Macrophage Differentiation<br />

and Granulocyte Homeostasis. Qi Quan Huang 2 , Harris R.<br />

Perlman 2 , Zan Huang 3 , Robert Birkett 3 , John D. Crispino 3 and<br />

Richard M. Pope 1 , 1 Northwestern Univ Med School, Chicago, IL,<br />

2<br />

Northwestern University, Chicago, IL, 3 Northwestern University.<br />

855. IкB Kinase (IKK)ε: Bridging Innate and Adaptive Immunity in<br />

Collagen-Induced Arthritis (CIA). Deepa Hammaker 2 , Katharyn<br />

Topolewski 3 , David L. Boyle 1 and Gary S. Firestein 1 , 1 UCSD School<br />

<strong>of</strong> Medicine, La Jolla, CA, 2 Univ <strong>of</strong> California San Diego, La Jolla,<br />

CA, 3 University <strong>of</strong> California, San Diego.<br />

856. IMO-3100, a Toll-Like Receptor (TLR) Antagonist, Suppresses<br />

TLR7- and TLR9-Mediated Immune Responses in Non-<br />

Human Primates. Lakshmi Bhagat 2 , Jimmy X. Tang 2 , Tim<br />

Sullivan 2 , Ekambar R. Kandimalla 1 and Sudhir Agrawal 2 , 1 Idera<br />

Pharmaceuticals, Inc, Cambridge, MA, 2 Idera Pharmaceuticals,<br />

Inc.<br />

857. Involvement <strong>of</strong> Toll-Like Receptor 2 in Pristane-Induced Lupus.<br />

Vilma Urbonaviciute 3 , Silke Frey 2 , Carsten Kirschning 1 , Georg<br />

Schett 2 and Reinhard E. Voll 2 , 1 Essen, Germany, 2 Erlangen,<br />

Germany, 3 Department Internal Medicine 3 , University Hospital<br />

Erlangen, University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />

Germany.<br />

858. Mir-19b Regulates TLR2 Expression in Rheumatoid Arthritis<br />

Fibroblast-Like Synoviocytes. Lucas Philippe 3 , Guillaume<br />

Suffert 1 , Ghada Alsaleh 3 , Arnaud Theulin 3 , Jacques Eric<br />

Gottenberg 3 , Jean Sibilia 3 , Sebastien Pfeffer 2 and Dominique<br />

Wachsmann 3 , 1 Architecture et Réactivité de l’ARN, Université<br />

de Strasbourg, Institut de Biologie Moléculaire et Cellulaire<br />

du CNRS, Strasbourg, France, Metropolitan, 2 Architecture<br />

et Reactivite de l’ARN, Universite de Strasbourg, Institut de<br />

Biologie Moleculaire et Cellulaire du CNRS, Strasbourg, France,<br />

Metropolitan, 3 Laboratoire de Physiopathologie des Arthrites,<br />

EA4438, Faculté de Pharmacie, 74 Route du Rhin, Illkirch-<br />

Graffenstaden, France, Metropolitan.<br />

859. Myeloid but Not Lymphoid Bim Expression Is Required<br />

Suppress SLE-Like Disease. Hemant Agrawal 1 , Evan Weber 1 ,<br />

Alexander Misharin 1 , Carla M. Cuda 1 , G. Kenneth Haines 2 ,<br />

Rosalind Ramsey-Goldman 1 and Harris Perlman 1 , 1 Dept Med/Div<br />

<strong>Rheumatology</strong>, Northwestern University, 2 Yale University.<br />

860. Natural Killer (NK) Cells Resident in Normal Human Skin Are<br />

Distinct from Blood and Lung NK Cells. Ahmed Gehad 1 , Sandra<br />

King 1 and Robert Fuhlbrigge 2 , 1 Brigham and Women’s Hospital,<br />

2<br />

Children’s Hospital- Boston, Boston, MA.<br />

861. p21 Suppression <strong>of</strong> Inflammatory Arthritis Requires the PCNA<br />

Domain and Inhibition <strong>of</strong> p38. Angelica K. Gierut 1 , Melissa<br />

Mavers 3 , Carla M. Cuda 2 , Alexander Misharin 2 , Evan Weber 2<br />

and Harris R. Perlman 1 , 1 Northwestern University, Chicago, IL,<br />

2<br />

Northwestern University, 3 St. Louis University.<br />

862. Peripheral Blood Mononuclear Cells and Plasmacytoid<br />

Dendritic Cells from Healthy Human Females Exhibit Altered<br />

TLR7-Mediated Immune Responses Compared to Males.<br />

Melissa Precopio 1 , Dong Yu 2 , Ekambar R. Kandimalla 2 and<br />

Sudhir Agrawal 2 , 1 Idera Pharmaceuticals, Cambridge, MA, 2 Idera<br />

Pharmaceuticals.<br />

863. Post-Translational Control Mechanisms Regulate Dendritic Cell<br />

Activation <strong>of</strong> T Cell Responses. Dana Orange 1 , Jak Fak 2 , Nathalie<br />

Blachere 2 and Robert Darnell 2 , 1 The Hospital for Special Surgery,<br />

2<br />

The Rockefeller University.<br />

864. Reduced T-Cell-Dependent Humoral Immune Response in<br />

Microsomal Prostaglandin E Synthase-1 Null Mice. Rahul G.<br />

Matnani 2 , Fumiaki Kojima 2 , Jerold G. Woodward 2 and Leslie J.<br />

Cr<strong>of</strong>ford 1 , 1 Univ <strong>of</strong> KY, Lexington, KY, 2 Univ <strong>of</strong> KY.<br />

865. Regulation <strong>of</strong> VLA-4 in SLE Monocytes. Homaira Rahimi 1<br />

and Kathleen E. Sullivan 2 , 1 Children’s Hosp Philadelphia,<br />

Philadelphia, PA, 2 Childrens Hosp <strong>of</strong> Philadelphia, Philadelphia,<br />

PA.<br />

866. The Cholinergic Anti-Inflammatory Pathway as a Modulator<br />

<strong>of</strong> Immune Complex-Induced Acute Inflammation. Milena<br />

Vukelic 2 , Gloria Koo 2 and Jane E. Salmon 1 , 1 Hospital for Special<br />

Surgery, New York, NY, 2 Hospital for Special Surgery, New York,<br />

NY.<br />

2010 Program Book 199


ACR/ARHP Poster Session B<br />

200<br />

867. The Help <strong>of</strong> Autoantibody-Inducing CD4+ T Cell and Antigen<br />

Cross-Presentation Are Required for the Full-Maturation<br />

<strong>of</strong> Cytotoxic T Lymphocyte and Subsequent Lupus Kidney<br />

Disease. Yumi Miyazaki 1 , Ken Tsumiyama 1 and Shunichi<br />

Shiozawa 2 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />

Graduate School <strong>of</strong> Health Science, Kobe, Japan, 2 Department <strong>of</strong><br />

Biophysics, Kobe University Graduate School <strong>of</strong> Health Science/<br />

Department <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />

Medicine/The Center for Rheumatic Diseases, Kobe University<br />

Hospital, Kobe, Japan.<br />

868. Unique Role <strong>of</strong> the FcγRI (CD64) Cytoplasmic Domain in<br />

Mediating Phosphorylation Dependent Lipid Raft Localization.<br />

Andrew G. Gibson 3 , Xinrui Li 3 , Jeffrey C. Edberg 2 and Robert<br />

P. Kimberly 1 , 1 Univ Alabama at Birmingham, Birmingham,<br />

AL, 2 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />

3<br />

University <strong>of</strong> Alabama at Birmingham.<br />

Metabolic and Crystal Arthropathies - Pathogenesis, Epidemiology,<br />

and Clinical Manifestations II<br />

869. A Prospective Study <strong>of</strong> Correlates <strong>of</strong> Axial Gout. Rukmini<br />

M. Konatalapalli 4 , Elena Lumezanu 3 , James Jelinek 3 , Mark<br />

Murphey 1 , Elizabeth Carter 2 and Arthur Weinstein 3 , 1 Armed<br />

Force Institute, 2 Medstar Health Research Institute, 3 Washington<br />

Hospital Center, 4 Washington Hospital Center, DC.<br />

870. Acute Gout Results in Increased Plasma Myeloperoxidase: A<br />

Potential Mechanism for Increase Cardiovascular Risk? Lisa K.<br />

Stamp 1 , Irada Khalilova 2 and Tony Kettle 2 , 1 University <strong>of</strong> Otago,<br />

Christchurch, New Zealand, 2 University <strong>of</strong> Otago.<br />

871. A-SAA Induces Cytokine Production and Matrix<br />

Metalloproteinase Activity in Adipose and RA Synovial Tissue.<br />

Jennifer McCormick, Ronan M. Mullan, Mary Connolly, Chin<br />

Teck Ng, Ursula Fearon and Douglas J. Veale, Dublin Academic<br />

Medical Centre, Dublin, Ireland.<br />

872. Association <strong>of</strong> Vitamin K and Chondrocalcinosis <strong>of</strong> the Knee:<br />

The MOST and Framingham Osteoarthritis Studies. Devyani<br />

Misra 3 , Sarah L. Booth 8 , Micheal LaValley 3 , Irina Toltsykh 6 ,<br />

Micheal Nevitt 6 , C. Elizabeth Lewis 5 , James Torner 7 , Piran<br />

Aliabadi 4 , David T. Felson 2 and Tuhina Neogi 1 , 1 Boston Univ Schl<br />

<strong>of</strong> Med, Boston, MA, 2 Boston University School <strong>of</strong> Medicine,<br />

Boston, MA, 3 BUSM, Boston, MA, 4 BWH, Harvard University,<br />

Boston, MA, 5 UAB, Birmingham, AL, 6 UCSF, San Francisco, CA,<br />

7<br />

U-Iowa, Iowa City, IA, 8 USDA HNRCA, Tufts University, Boston,<br />

MA.<br />

873. Calcium Pyrophosphate Crystal Arthritis (CPPA) Is a Frequent<br />

Cause <strong>of</strong> “Refractory Gout”. Fernando Perez-Ruiz 1 , Ana M.<br />

Herrero-Beites 3 , Alberto Alonso-Ruiz 2 and Marcelo Calabozo 2 ,<br />

1<br />

Hospital de Cruces, Jopelana, Spain, 2 Hospital de Cruces,<br />

3<br />

Hospital de Górliz.<br />

874. Clinical and Genetic Subtypes <strong>of</strong> Hyperuricemia in a Renal<br />

Transplant Cohort. Gabriela Hernandez-Molina, Julio Granados,<br />

Adriana Torres, Antonio Cachafeiro-Vilar and Marina Rull-<br />

Gabayet, Instituto Nacional de Ciencias Medicas y Nutricion,<br />

Mexico City, Mexico.<br />

875. Diffuse Calcium-Containing Crystal Deposits in Human<br />

Osteoarthritic Articular Cartilage: Not Limited to the Medial<br />

Compartment. Christelle Nguyen 4 , Hang-Korng Ea 4 , Didier<br />

Hannouche 2 , Michel Daudon 3 , Dominique Bazin 1 and Frédéric<br />

Lioté 4 , 1 Laboratoire de Physique des Solides; Paris Sud<br />

University; Orsay; France, 2 Orthopaedic Surgery Department;<br />

Lariboisière Hospital; Paris Diderot University; Assistance<br />

Publique-Hôpitaux de Paris (AP-HP), Paris, 3 Service de Biochimie<br />

A; Necker Hospital; Paris Sud University; AP-HP; Paris, 4 UMR-S<br />

606, INSERM & Paris Diderot University; PRES Sorbonne Paris-<br />

Cite; Lariboisiere Hospital; Paris; France.<br />

2010 Program Book<br />

876. Factors Associated with an Acute Attack <strong>of</strong> Chronic Gout<br />

without Hyperuricemia. MinWook So 1 , SeungGeun Lee 3 ,<br />

YongGil Kim 3 , ChangKeun Lee 3 , HeeBom Moon 3 , Jiseon Oh 4 and<br />

Bin Yoo 2 , 1 ASAN Medical Ctr, Seoul, Korea, Republic <strong>of</strong>, 2 ASAN<br />

Medical Ctr, Seoul, Korea, Republic <strong>of</strong>, 3 ASAN Medical Ctr, 4 Ulsan<br />

University.<br />

877. Hyperuricemia and Gout: Nature Versus Nurture. Eswar<br />

Krishnan 3 , Christina N. Lessov-Schlaggar 4 , James F. Fries 2 , Ruth<br />

Krasnow 1 and Gary E. Swan 1 , 1 SRI International, 2 Stanford Univ<br />

Medical Ctr, Palo Alto, CA, 3 Stanford University, Palo Alto, CA,<br />

4<br />

WUSTL.<br />

878. Hyperuricemia as a Risk Factor for Hypertension among Young<br />

Adults without Metabolic Syndrome. Eswar Krishnan 1 , Bhavik<br />

Pandya 2 , Ali Hariri 3 and Omar Dabbous 2 , 1 Stanford University<br />

School <strong>of</strong> Medicine, Stanford, CA, 2 Takeda Pharmaceuticals<br />

International, Inc, Deerfield, IL, 3 Takeda Pharmaceuticals North<br />

America, Inc, Deerfield, IL.<br />

879. Individuals in the US General Population with Gout and<br />

Hyperuricemia Have Significantly Higher Comorbidities: The<br />

National Health and Nutrition Examination Survey (NHANES)<br />

2007-2008. Bhavik Pandya 2 , Yanyan Zhu 1 and Hyon Choi 1 ,<br />

1<br />

Boston University <strong>of</strong> School <strong>of</strong> Medicine, Boston, MA, 2 Takeda<br />

Pharmaceuticals International, Inc, Deerfield, IL.<br />

880. Low Prevalence <strong>of</strong> Coexistent Gout and Rheumatoid Arthritis<br />

in a Population <strong>of</strong> Veterans. Armine Tumyan 1 , Kara H. Prescott 2<br />

and Andreas M. Reimold 1 , 1 Dallas VA Medical Center and Univ <strong>of</strong><br />

TX Southwestern Med Ctr, Dallas, TX, 2 Dallas VA Medical Center<br />

and Univ <strong>of</strong> TX Southwestern Med Ctr, Cross Roads, TX.<br />

881. Monosodium Urate Monohydrate Crystals Inhibit Osteoblast<br />

Viability and Differentiation: Implications for Development <strong>of</strong><br />

Bone Erosion in Chronic Gout. Ashika Chhana 2 , Karen Callon 2 ,<br />

Bregina Pool 2 , Dorit Naot 2 , Fiona M. McQueen 2 , Jillian Cornish 2<br />

and Nicola Dalbeth 1 , 1 Univ Auckland, Auckland, New Zealand,<br />

2<br />

University <strong>of</strong> Auckland, Auckland, New Zealand.<br />

882. Number <strong>of</strong> Flares Are Associated with Both Gastrointestinal<br />

and Vascular Complications in Patients with Gout. Another<br />

Issue for Early Intervention. Fernando Perez-Ruiz 1 , Ana M.<br />

Herrero-Beites 2 and Miguel A. Gonzalez-Gay 3 , 1 Hospital de<br />

Cruces, Spain, 2 Hospital de Górliz, Spain, 3 Hospital Universitario<br />

Marqués de Valdecilla, Spain.<br />

883. Patients with Gout May Have a Decreased Risk <strong>of</strong> Colonic<br />

Polyps Relative to Patients with Osteoarthritis (OA): Insights<br />

from the NY VA Gout Database. Aaron Lehmann 3 , Laura<br />

Schneck 4 , Robert T. Keenan 1 , William O’Brien 2 , Daria Crittenden 2 ,<br />

Kristen Lee 2 , Rekha Tadoori, Fritz Francois 2 and Michael H.<br />

Pillinger 4 , 1 Duke University, Durham, NC, 2 NYU Langone Medical<br />

Center, 3 NYU Langone Medical Center, Flushing, NY, 4 NYU<br />

Langone Medical Center, New York, NY.<br />

884. P-Homocysteine Levels Are Independently Correlated to<br />

S-Urate but Not to Urate Lowering Treatment. Results <strong>of</strong> an<br />

Observational Study <strong>of</strong> 112 Patients with Gout. Ole Slot, Dept.<br />

<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital, Glostrup,<br />

Denmark.<br />

885. Rates <strong>of</strong> Meniscal Tearing Seen on Arthroscopy <strong>of</strong> Patients<br />

with Chondrocalcinosis. William Chun 1 , Humaira Hussain 3 ,<br />

Vincent J. Zarro 1 , Carolyn R. O’Connor 1 and Angel E. Checa 2 ,<br />

1<br />

Drexel University <strong>College</strong> <strong>of</strong> Medicine, Philadelphia, PA,<br />

2<br />

Drexel University <strong>College</strong> <strong>of</strong> Medicine, Cherry Hill, NJ, 3 Drexel<br />

University <strong>College</strong> <strong>of</strong> Medicine.


ACR/ARHP Poster Session B<br />

886. Screening for Hereditary Hemochromatosis in the<br />

<strong>Rheumatology</strong> Practice. Gunther Neeck 1 , Helge Wernitzsch 2 ,<br />

Andreas Klüter 2 , Martin Schulz 2 and Helmut Dotzlaw 2 , 1 Center<br />

for <strong>Rheumatology</strong> at Hospital Bad Doberan, Hohenfelde,<br />

Germany, 2 Center for <strong>Rheumatology</strong> at Hospital Bad Doberan,<br />

Germany.<br />

887. Synovial Extracellular Matrix Remodeling in Experimental<br />

Model <strong>of</strong> Diabetes. Sandra Aparecida Atayde 1 , Priscila Cristina<br />

Andrade 2 , Sérgio Catanozi 2 , Edna Regina Nakandakare 2 , Marisa<br />

Passarelli 2 , Ana Paula Pereira Velosa 2 , Vera Luiza Capelozzi 2 ,<br />

Edwin Roger Parra 2 , Natalino Hajime Yoshinari 2 and Walcy<br />

Rosolia Teodoro 2 , 1 University <strong>of</strong> São Paulo, São Paulo, Brazil,<br />

2<br />

University <strong>of</strong> São Paulo.<br />

888. The GOSPEL 1000 Study. Features <strong>of</strong> the Metabolic Syndrome<br />

in 1003 French Patients with Gout. Frédéric P. Lioté 7 , Hang-<br />

Korng Ea 2 , Pascal Guggenbuhl 1 , Alain Saraux 6 , Charles Lambert,<br />

Sabine Lanz 4 , Pierre Chiarelli 3 and Sylvie Lancrenon 5 , 1 Rennes,<br />

France, 2 Paris, France, 3 Courbevoie, France, 4 Chatou, France,<br />

5<br />

Bourg-la-Reine, France, 6 CHU de la Cavale Blanche, Brest Cedex,<br />

France, 7 Hopital Lariboisiere, Paris, France.<br />

889. Ultrasound Detects More Erosions in Gout Than Conventional<br />

Radiography. Ralf G. Thiele 2 and Naomi Schlesinger 1 , 1 UMDNJ/<br />

RWJMS, 2 University <strong>of</strong> Rochester, Rochester, NY.<br />

Miscellaneous Rheumatic and Inflammatory Diseases I<br />

890. A Comprehensive Tuberculosis Screening Program in Patients<br />

with Inflammatory Arthritis Treated with Golimumab, a<br />

Human Anti-TNF Antibody, in Phase 3 Clinical Trials. Elizabeth<br />

C. Hsia 4 , John J. Cush 1 , Eric L. Matteson 5 , Anna Beutler 2 ,<br />

Mittie K. Doyle 4 , Benjamin L. Hsu 3 and Mahboob U. Rahman 4 ,<br />

1<br />

Baylor Research Institute, Dallas, TX, 2 Centocor Research and<br />

Development, Inc., <strong>College</strong>ville, PA, 3 Centocor Research and<br />

Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />

Wynnewood, PA, 4 Centocor Research and Development, Inc./<br />

Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 5 Mayo<br />

Clinic, Rochester, MN.<br />

891. Anakinra in Adult Onset Stills Disease (AOSD). Clinically<br />

Beneficial Results in an Open, Randomized, Multicenter Study.<br />

Dan C. Nordström 3 , Ann Knight 11 , Reijo Luukkainen 8 , Ronald<br />

V. Vollenhoven 5 , Vappu Rantalaiho 9 , Anna Karjalainen 7 , Johan<br />

Brun 2 , Anne Proven 6 , Lotta Ljung 10 , Hannu Kautiainen 1 and<br />

Tom Pettersson 4 , 1 Central Finland Central Hospital, Finland,<br />

2<br />

Haukeland University Hospital, Norway, 3 Helsinki Univerity<br />

Central Hospital, Finland, 4 Helsinki University Central Hospital,<br />

Finland, 5 Karolinska Hospital, Sweden, 6 Martina Hansens<br />

Hospital, Norway, 7 Oulu University Hospital, Finland, 8 Rauma<br />

Hospital, Finland, 9 Tampere University Hospital, Finland, 10 Umeå<br />

University Hospital, Sweden, 11 Uppsala University Hospital,<br />

Sweden.<br />

892. Anti-Double Stranded DNA and Other Autoantibodies Are<br />

Common in Alaska Native Autoimmune Hepatitis Patients.<br />

Elizabeth D. Ferucci 1 , Kathy J. Hurlburt 1 , Stephen Livingston 1 ,<br />

Julia Plotnik 1 , James Gove 1 , Brian J. McMahon 1 and Judith A.<br />

James 2 , 1 Alaska Native Tribal Health Consortium, 2 Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK.<br />

893. Anti-U1C Autoantibody Specifically Interferes with the U1RNP-<br />

Mediated Splicing <strong>of</strong> Angiopoietin-1 (Ang1) Gene and Induces<br />

Functionally Defective Ang-1/ins Variant in the Patients with<br />

MCTD. Yuka Kosugi 1 , Koichiro Komai 1 , Shogo Funaki 1 , Aya<br />

Mashida 1 , Kazuko Shiozawa 3 , Akira Hashiramoto 2 and Shunichi<br />

Shiozawa 2 , 1 Dep. <strong>of</strong> Biophysics, Graduate School <strong>of</strong> Health<br />

Sciences, Kobe Univ., Kobe, Japan, 2 Dep. <strong>of</strong> Biophysics, Graduate<br />

School <strong>of</strong> Health Sciences, Kobe Univ./Dep. <strong>of</strong> Medicine,<br />

Graduate School <strong>of</strong> Medicine, Kobe Univ./The Center for<br />

Rheumatic Diseases, Kobe Univ., Hosp., Kobe, Japan, 3 Rheumatic<br />

Diseases Center, Konan Kakogawa Hosp., Kakogawa, Japan.<br />

894. Autoimmune Phenomena in Muckle-Wells Syndrome (MWS).<br />

Katharina Gramlich 1 , Reinhild Klein 4 , Sandra Hansmann 3 ,<br />

Susanne M. Benseler 5 and Jasmin B. Kuemmerle-Deschner 2 ,<br />

1<br />

Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics,<br />

University Hospital Tübingen, Tuebingen, Germany, 2 Division <strong>of</strong><br />

Pediatric <strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University<br />

Hospital Tübingen, Tuebingen, Germany, 3 Division <strong>of</strong> Pediatric<br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University Hospital<br />

Tübingen, Germany, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, University Hospital Tübingen, 5 The Hospital<br />

for Sick Children, Toronto, ON, Canada.<br />

895. Canakinumab (ILARIS®) Provides Rapid Response and<br />

Sustained Remission in Cryopyrin-Associated Periodic<br />

Syndrome (CAPS) Patients across All Severity Phenotypes.<br />

H. J. Lachmann 12 , J. B. Kuemmerle-Deschner 6 , E. Hachulla 3 , R.<br />

Cartwright 1 , I. Kone-Paut 4 , J. Hoyer 2 , P. Quartier 11 , J. Smith 14 ,<br />

M. Gattorno 5 , K. Leslie 10 , J. Braun 9 , A. Widmer 7 , N. Patel 8 , R.<br />

Preiss 8 and P. N. Hawkins 13 , 1 Allergy Center at Brookstone,<br />

Columbus, GA, 2 Department <strong>of</strong> Internal Medicine and<br />

Nephrology, Universitaetsklinikum Giessen und Marburg<br />

GmbH, Marburg, Germany, 3 Hôpital Claude Huriez CHRU, Lille<br />

Cedex, France, 4 Hôpital Kremlin Bicetre, CEREMAI, Le Kremlin<br />

Bicetre, France, 5 Istituto Giannina Gaslini, Genova, Italy,<br />

6<br />

Klinik fuer Kinder-und Jugendmedizin, Universitaetsklinikum,<br />

Tuebingen, Germany, 7 Novartis Pharma AG, Basel, Switzerland,<br />

8<br />

Novartis Pharmaceuticals Corporation, East Hanover, NJ,<br />

9<br />

Rheumazentrum Ruhrgebiet, Herne, Germany, 10 UCSF School<br />

<strong>of</strong> Medicine, San Francisco, CA, 11 Unit’e d’Immunologie,<br />

Hematologie et Rhumatologie Pediatrique, Hopital Necker-<br />

Enfants Malades, Paris, France, 12 University <strong>College</strong> London<br />

Medical School, London, United Kingdom, 13 University <strong>College</strong><br />

London Medical School, London, United Kingdom, 14 University<br />

<strong>of</strong> Wisconsin Hospital and Clinics, Madison, WI.<br />

896. Celecoxib Analogue Lacking COX-2-Inhibitory Activity Inhibits<br />

Arthritis by Supressing IL-23 and Inflammatory Cytokines.<br />

Asako Chiba 2 , Ryohsuke Tajima 2 , Miho Mizuno 2 , Chiharu Tomi 2 ,<br />

Iraide Alloza 3 , Takashi Yamamura 2 , Koen Vandenbroeck 3 and<br />

Sachiko Miyake 1 , 1 Department <strong>of</strong> Immunology, National Institute<br />

<strong>of</strong> Neuroscience, NCNP, Kodaira Tokyo, Japan, 2 Department<br />

<strong>of</strong> Immunology, National Institute <strong>of</strong> Neuroscience, NCNP,<br />

3<br />

Neurogenomiks Laboratory, Ikerbasque and Universidad Del<br />

País Vasco (UPV/EHU), Parque Tecnológico de Bizkaia.<br />

897. Comprehensive Analyses <strong>of</strong> MEFV, TNFRSF1A, MVK, and<br />

CIAS1 Mutations in 63 Patients with Clinically Periodic Fever<br />

Syndrome in Japan. Sayuri Kataoka 2 , Manabu Kawamoto 1 ,<br />

Yasushi Kawaguchi 3 , Takahisa Gono 1 , Masanori Hanaoka 1 , Hisae<br />

Ichida 1 , Yasuhiro Katsumata 1 , Yuko Okamoto 4 , Yuko Ota 2 , Ikuko<br />

Masuda 1 and Hisashi Yamanaka 1 , 1 Tokyo Women’s Medical<br />

University, 2 Tokyo Women’s Medical University, Japan, 3 Tokyo<br />

Women’s Medical University, 4 Tokyo Womens Med Univ.<br />

2010 Program Book 201


ACR/ARHP Poster Session B<br />

898. Defining the Aromatase Inhibitor Musculoskeletal Syndrome:<br />

A Prospective Trial. Ora Singer 1 , Alana B. Levine 1 , Tessa Cigler 3 ,<br />

Anne B. Moore 2 , Huong T. Do 1 and Lisa A. Mandl 1 , 1 Hospital for<br />

Special Surgery, New York, NY, 2 NY Presbyterian - Weill Cornell<br />

Medical Center, New York, NY, 3 NY Presbyterian-Weill Cornell<br />

Medical Center, New York, NY.<br />

899. Hearing Loss in Muckle-Wells-Syndrome. Assen Koitschev 1 ,<br />

Katharina Gramlich 3 , Sandra Hansmann 3 , Susanne M.<br />

Benseler 5 , Stefan Plontke 2 , Christiane Koitschev 2 , Ina<br />

Koetter 4 and Jasmin Kuemmerle-Deschner 3 , 1 Department <strong>of</strong><br />

Otorhinolaryngology, Klinikum Stuttgart, Germany, 2 Department<br />

<strong>of</strong> Otorhinolaryngology, University Hospital Tübingen,<br />

Germany, 3 Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Pediatrics, University Hospital Tübingen, Germany, 4 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, University<br />

Hospital Tübingen, Tuebingen, Germany, 5 The Hospital for Sick<br />

Children, Toronto, ON, Canada.<br />

900. Hearing Loss in Muckle-Wells-Syndrome – Effects <strong>of</strong> IL-1<br />

Inhibition. Assen Koitschev 1 , Katharina Gramlich 3 , Sandra<br />

Hansmann 3 , Susanne Benseler 4 , Stefan Plontke 2 , Christiane<br />

Koitschev 2 , Ina Koetter 6 , Ralph Preiss 5 and Jasmin Kuemmerle-<br />

Deschner 3 , 1 Department <strong>of</strong> Otorhinolaryngology, Klinikum<br />

Stuttgart, Germany, 2 Department <strong>of</strong> Otorhinolaryngology,<br />

University Hospital Tübingen, Germany, 3 Division <strong>of</strong> Pediatric<br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University Hospital<br />

Tübingen, Germany, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />

<strong>of</strong> Pediatrics, The Hospital for Sick Children, Toronto, Canada,<br />

5<br />

Novartis Pharmaceuticals Corporation, East Hanover, NJ,<br />

6<br />

University Hospital, Tuebingen, Germany.<br />

901. Inflammatory Arthritis Associated with Isolated Anti-CBir1<br />

Antibodies: Part <strong>of</strong> the Spectrum <strong>of</strong> “Seronegative” Arthritis?<br />

Melissa A. Peda 1 and Stanford L. Peng 2 , 1 Benaroya Research<br />

Institute, 2 Benaroya Research Institute and Virginia Mason<br />

Medical Center, Seattle, WA.<br />

902. Long Term Treatment with Anakinra in Patients with Adult-<br />

Onset Still Disease. Giampietro Cecilia 1 , Ridene Meriem 2 ,<br />

Fautrel Bruno 3 , Bourgeois Pierre 3 and CRI, 1 University <strong>of</strong> L’Aquila,<br />

L’Aquila, Italy, 2 University <strong>of</strong> Tunis, Tunis, Tunisia, 3 University<br />

Paris 6 – Pierre et Marie Curie University; <strong>Rheumatology</strong>, Pitie-<br />

Salpêtriere Hospital, Paris, France.<br />

903. Lymph Node and Bone Marrow Expression <strong>of</strong> Macrophage<br />

Migration Inhibitory Factor and IL18 in Adult-Onset Still’s<br />

Disease. Sung-Hoon Park 1 , Hwa-Jeong Lee 2 , Seong-Kyu Kim 2<br />

and Jung-Yoon Choe 2 , 1 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />

Medicine, Arthritis and Autoimmunity Research Center, Daegu,<br />

Korea, Republic <strong>of</strong>, 2 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />

Medicine, Arthritis and Autoimmunity Research Center.<br />

904. New Onset <strong>of</strong> Uveitis under Anti TNF Therapy. A Nationwide<br />

Series. Daniel Wendling, Julien Paccou, René-Marc Flipo,<br />

Emmanuelle Dernis, Guillaume Direz, Veronique Ferrazzi,<br />

Séverine Guillaume, Jean-Michel Ristori and Club Rhumatismes<br />

et Inflammation (CRI), <strong>Rheumatology</strong>, University Hospital,<br />

Besançon, Besançon, France.<br />

905. Preliminary Scores for the Evaluation <strong>of</strong> Disease Activity in<br />

Familial Mediterranean Fever, Mevalonate Kinase Deficiency,<br />

TNF-Receptor Associated Periodic Syndrome and Cryopyrin-<br />

Associated Diseases: Results from the AIDAI Consensus<br />

Conference. Maryam Piram 1 , Joost Frenkel 11 , Marco Gattorno 13 ,<br />

Seza Ozen 15 , Helen Lachmann 16 , Rafaela Goldbach-Mansky 17 ,<br />

Anna Simon 3 , Veronique Hentgen 10 , Benedicte Neven 7 , Katia<br />

Stankovic-stojanovic 18 , Jasmin Kuemmerle-Deschner 14 , Hal<br />

H<strong>of</strong>fman 8 , Sylvia Stojanov 4 , Agnes Duquesne 6 , Pascal Pillet 9 ,<br />

Alberto Martini 12 , Jacques Pouchot 5 and Isabelle Kone-Paut 2 ,<br />

1<br />

CEREMAI, Pediatric <strong>Rheumatology</strong>, Bicêtre Hospital, Paris<br />

University <strong>of</strong> Medicine, Le Kremlin Bicêtre, France, 2 CEREMAI,<br />

Pediatric <strong>Rheumatology</strong>, Bicêtre Hospital, Paris University <strong>of</strong><br />

Medicine, Le Krelmlin Bicêtre, France, 3 Department <strong>of</strong> General<br />

Internal Medicine, Radboud University Nijmegen Medical<br />

Centre, Nijmegen, The Netherlands, 4 Department <strong>of</strong> Infectious<br />

Diseases and Immunology, University Children’s Hospital,<br />

Munich, Germany, 5 Department <strong>of</strong> Internal Medicine, European<br />

Georges Pompidou Hospital, Paris-Descartes University,<br />

6<br />

Department <strong>of</strong> Nephrology and Pediatric <strong>Rheumatology</strong>,<br />

Hôpital Femme Mere Enfant, Hospices Civils de Lyon, Lyon,<br />

France, 7 Department <strong>of</strong> Pediatric Immuno-Hematology and<br />

Pediatric <strong>Rheumatology</strong>, Necker-Enfants Malades Hospital,<br />

Paris, 8 Department <strong>of</strong> Pediatrics and Medicine, University <strong>of</strong><br />

California at San Diego, Rady Children’s Hospital <strong>of</strong> San Diego,<br />

9<br />

Department <strong>of</strong> Pediatrics, Children’s Hospital <strong>of</strong> Bordeaux,<br />

France, 10 Department <strong>of</strong> Pediatrics, National Reference Center<br />

for Auto-inflammatory Disorders, Versailles-Le Chesnay<br />

Hospital, France, 11 Department <strong>of</strong> Pediatrics, University Medical<br />

Center Utrecht, Utrecht, The Netherlands, 12 Department <strong>of</strong><br />

Pediatrics, University Medical Center Utrecht, Utrtecht, The<br />

Netherlands; 3 UO Pediatria II and Department <strong>of</strong> Pediatrics, “G.<br />

Gaslini” Institute and University <strong>of</strong> Genoa, Italy, 13 Department<br />

<strong>of</strong> Pediatrics, University Medical Center Utrecht; 3 UO Pediatria<br />

II and Department <strong>of</strong> Pediatrics, “G. Gaslini” Institute and<br />

University <strong>of</strong> Genoa, Genoa, Italy, 14 Division <strong>of</strong> Pediatric<br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University Hospital<br />

Tübingen, Germany, 15 Hacettepe University Faculty <strong>of</strong> Medicine,<br />

Ankara, Turkey, 16 National Amyloidosis Centre, University<br />

<strong>College</strong> London Medical School, London, UK, 17 National Institute<br />

<strong>of</strong> Arthritis Musculoskeletal and Skin Disease, NIH, Bethesda,<br />

MD, 18 National Reference Center for Inflammatory Amyloidosis<br />

and Familial Mediterranean Fever, Department <strong>of</strong> Internal<br />

Medicine, Tenon University Hospital, Université Pierre et Marie<br />

Curie Paris 6 , Paris, France.<br />

906. Prevalence and Clinical Significance <strong>of</strong> Cry<strong>of</strong>ibrinogenemia<br />

in Patients with Renal Disorders. Benjamin Terrier, Hassan<br />

Izzedine, Lucile Musset, David Saadoun and Patrice Cacoub,<br />

Pitié-Salpétrière.<br />

907. Pseudo-Hypertrophic Osteoarthropathy in Lung Transplant<br />

Recipients on Long Term Voriconazole Therapy. Rajan Saggar 1 ,<br />

Tisha Wang 3 , Rajeev Saggar 3 and Roy D. Altman 2 , 1 UCLA, Los<br />

Angeles, CA, 2 UCLA, Agua Dulce, CA, 3 UCLA.<br />

908. QuantiFERON®-TB Gold In-Tube Test Versus Tuberculin Skin<br />

Test across RA, PsA, and AS Patients Prior to Treatment with<br />

Golimumab, a Human Anti-TNF Antibody. Elizabeth C. Hsia 5 ,<br />

Neil Schluger 6 , John J. Cush 1 , Richard E. Chaisson 7 , Eric L.<br />

Matteson 8 , Anna Beutler 3 , Mittie K. Doyle 2 , Benjamin L. Hsu 4<br />

and Mahboob U. Rahman 5 , 1 Baylor Research Institute, Dallas,<br />

TX, 2 Centocor Research and Development, Inc., Malvern,<br />

PA, 3 Centocor Research and Development, Inc., <strong>College</strong>ville,<br />

PA, 4 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />

Pennsylvania School <strong>of</strong> Medicine, Wynnewood, PA, 5 Centocor<br />

Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania School<br />

<strong>of</strong> Medicine, Malvern, PA, 6 Columbia University <strong>College</strong> <strong>of</strong><br />

Physicians & Surgeons, 7 Johns Hopkins University, 8 Mayo Clinic,<br />

Rochester, MN.<br />

202<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

909. Regulatory T-Cells in Familial Mediterranean Fever (FMF).<br />

Doron Rimar 2 , Itzhak Rosner 3 , Gleb Slobodin 3 , Nina Boulman 3 ,<br />

Aharon Kessel 1 , Elias Touby 1 and Michael Rozenbaum 3 ,<br />

1<br />

Immunology Unit, Bnai-Zion Medical Center, Haifa, Israel,<br />

2<br />

<strong>Rheumatology</strong> Unit, Bnai-Zion Medical Center, Haifa, Israel,<br />

3<br />

<strong>Rheumatology</strong> Unit, Bnai-Zion Medical Center, Haifa, Israel.<br />

910. Safety <strong>of</strong> Arthrocentesis in Patients on Chronic Warfarin<br />

Therapy with Therapeutic INR. Imdad Ahmed 2 and Elie<br />

Gertner 1 , 1 Regions Hospital, St Paul, MN, 2 Regions Hospital.<br />

911. Standardization <strong>of</strong> Antinuclear Antibody Assessment on<br />

HEp-2 Cells by Automated Interpretation. Karl Egerer 1 , Dirk<br />

Roggenbuck 4 , Rico Hiemann 6 , Max-Georg Weyer 5 , Barbara<br />

Lehmann 3 , Eugen Feist 3 and Gerd R. Burmester 2 , 1 Charite -<br />

University Medicine, Berlin, Germany, 2 Charite - University<br />

Medicine, Berlin, Germany, 3 Charite - University Medicine,<br />

4<br />

Medipan GmbH, Berlin Dahlewitz, Germany, 5 Medizinisches<br />

Versorgungszentrum für Laboratoriumsmedizin, Mikrobiologie,<br />

Virologie und Infektionsepidemiologie, Hygiene und<br />

Umweltmedizin, 6 University <strong>of</strong> Applied Science Lausitz.<br />

912. The CIRAS Study: A Case Control Study To Define the Clinical,<br />

Immunologic and Radiographic Features <strong>of</strong> the Aromatase<br />

Inhibitor Arthralgia Syndrome. Victoria K. Shanmugam 3 , James<br />

McCloskey 1 , Elizabeth Elston 4 , Sandra J. Allison 2 , Claudine<br />

Isaacs 5 and Jennifer Eng-Wong 5 , 1 Department <strong>of</strong> Internal<br />

Medicine, Georgetown University Medical Center, Washington,<br />

DC, 2 Department <strong>of</strong> Radiology, Georgetown University<br />

Medical Center, Washington, DC, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Immunology and Allergy, Georgetown University Medical<br />

Center, Washington, DC, 4 Georgetown University, 5 Lombardi<br />

Cancer Center, Georgetown University Medical Center,<br />

Washington, DC.<br />

Muscle Biology, Myositis and Myopathies: New Developments in<br />

the Diagnosis, Pathogenesis and Treatment <strong>of</strong> Myositis<br />

913. A Negative Anti-Nuclear Antibody Does Not Indicate<br />

Autoantibody Negativity. Rohit Aggarwal 2 , Noreen Fertig 2 ,<br />

Dana P. Ascherman 3 , Elaine A. Cassidy 1 and Chester V. Oddis 2 ,<br />

1<br />

Children’s Hospital Pittsburg, Pittsburgh, PA, 2 University <strong>of</strong><br />

Pittsburgh, Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh, Pittsburgh,<br />

PA.<br />

914. A Novel Form <strong>of</strong> an Autosomal Dominant Vacuolar Hereditary<br />

Myopathy. Christine Castro 5 , Ivona Aksentijevich 6 , Elaine<br />

Remmers 6 , Elisabeth Rushing 1 , Simona Bianconi 3 , Marjan<br />

Huizing 4 , Mildred Wilson 6 , Thomas Markello 2 , Daniel Kastner 6<br />

and Mark Gourley 6 , 1 Armed Forces Institute <strong>of</strong> Pathology,<br />

2<br />

National Institues <strong>of</strong> Health/National Human Genome Research<br />

Institute/Medical Genetics Branch, 3 National Institutes <strong>of</strong><br />

Health, 4 National Institutes <strong>of</strong> Health, National Human Genome<br />

Research Institute, Medical Genetics Branch, 5 National Institutes<br />

<strong>of</strong> Health, National Institute <strong>of</strong> Arthritis and Musculoskeletal<br />

and Skin Diseases, Bethesda, MD, 6 National Institutes <strong>of</strong> Health,<br />

National Institute <strong>of</strong> Arthritis and Musculoskeletal and Skin<br />

Diseases.<br />

915. Anti-SRP Auto-Antibody Titers Correlate with Serum Creatine<br />

Kinase in Necrotising Myopathy. Olivier Benveniste 1 , Laurent<br />

Drouot 3 , Fabienne Jouen 3 , Serge Herson 2 , Jean-Luc Charuel 2 ,<br />

Coralie Bloch 2 , Anthony Behin 2 , Zahir Amoura 2 , Isabelle Marie 4 ,<br />

Bruno Eymard 2 , Danièle Gilbert 3 , François Tron 3 , Lucile Musset 2<br />

and Olivier Boyer 3 , 1 Assistance Publique - Hôpitaux de Paris,<br />

Hôpital Pitié-Salpêtrière, Paris, France, 2 Assistance Publique -<br />

Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, France, 3 Inserm,<br />

U905, Rouen University, France, 4 Rouen University Hospital,<br />

Department <strong>of</strong> Internal Medicine, France.<br />

916. Clinical Manifestation and Prognostic Factor in Anti-Melanoma<br />

Differentiation-Associated Gene 5 Antibody-Associated<br />

Interstitial Lung Disease as a Complication <strong>of</strong> Dermatomyositis.<br />

Takahisa Gono 5 , Yasushi Kawaguchi 3 , Takashi Satoh 2 , Masataka<br />

Kuwana 1 , Yasuhiro Katsumata 5 , Kae Takagi 5 , Ikuko Masuda 3 ,<br />

Sayumi Baba 5 , Masanori Hanaoka 5 , Yuko Okamoto 5 , Yuko Ota 5 ,<br />

Sayuri Kataoka 5 and Hisashi Yamanaka 4 , 1 Keio University School,<br />

Tokyo, Japan, 2 Keio University School, 3 Tokyo Women’s Medical<br />

University, Tokyo, Japan, 4 Tokyo Women’s Medical University,<br />

Shinjuku-ku, Tokyo, Japan, 5 Tokyo Women’s Medical University.<br />

917. Efficacy and Tolerance <strong>of</strong> Rituximab in Refractory Idiopathic<br />

Inflammatory Myopathy. Data <strong>of</strong> the AIR Registry. Marion<br />

Couderc 3 , Jacques E. Gottenberg 12 , Xavier Mariette 2 , Eric<br />

Hachulla 9 , Jean Sibilia 11 , Olivier Fain 6 , Arnaud Hot 8 , Maxime<br />

Dougados 5 , Liana E. Euller-Ziegler 7 , Pierre Bourgeois 10 ,<br />

Claire Larroche 10 , Anne Tournadre 3 , Zahir Amoura 10 , Bernard<br />

Mazieres 14 , P. Arlet 13 , Michel De Bandt 1 , Thierry Schaeverbeke 4<br />

and Martin Soubrier 3 , 1 Aulnay Hospital, Carrieres Sur Seine,<br />

France, 2 Bicetre Hospital/Paris Univ, Le Kremlin Bicetre, France,<br />

3<br />

Clermont-Ferrand Hospital, 4 Groupe Hospitalier Pellegrin,<br />

Bordeaux, France, 5 Hospital Cochin, Paris, France, 6 Jean Verdier<br />

Hospital, Paris University, 7 L’Archet Hospital (University),<br />

Nice, France, 8 Lyon Hospital, 9 National Scleroderma Centre,<br />

Lille Cedex, France, 10 Paris Hospital, 11 Strasbourg Hospital,<br />

Strasbourg, France, 12 Strasbourg Hospitals, Strasbourg, France,<br />

13<br />

Toulouse Hopsital, 14 Toulouse Hospital.<br />

918. Efficacy <strong>of</strong> Allogeneic Mesenchymal Stem Cells Transplantation<br />

in Patients with Drug-Resistant Polymyositis and<br />

Dermatomyositis. Lingyun Sun 1 , Dandan Wang 2 , Huayong<br />

Zhang 2 , Jun Liang 2 and Xuebing Feng 2 , 1 Department <strong>of</strong><br />

<strong>Rheumatology</strong> and Immunology, The Affiliated Drum Tower<br />

Hospital <strong>of</strong> Nanjing University Medical School, Nanjing, Jiangsu,<br />

China, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and Immunology, The<br />

Affiliated Drum Tower Hospital <strong>of</strong> Nanjing University Medical<br />

School.<br />

919. ESR and CRP Do Not Correlate with Extent <strong>of</strong> Muscle Injury<br />

but Their Elevation Is Associated with Pulmonary Involvement<br />

in Idiopathic Inflammatory Myopathy. Jin Kyun Park 4 , Michael<br />

George 2 , Sonye K. Dan<strong>of</strong>f 3 , Marzouq A. Qubti 4 , Allan C. Gelber 1<br />

and Lisa Christopher-Stine 5 , 1 Baltimore, MD, 2 Department <strong>of</strong><br />

Medicine, University <strong>of</strong> Pennsylvania, 3 Division <strong>of</strong> Pulmonary<br />

and Critical Care Medicine, Johns Hopkins University School <strong>of</strong><br />

Medicine, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine,<br />

Johns Hopkins University School <strong>of</strong> Medicine, Baltimore, MD,<br />

5<br />

Johns Hopkins University, Baltimore, MD.<br />

920. Evaluation <strong>of</strong> Reliability, Validity, and Responsiveness <strong>of</strong> the<br />

CDASI and CAT-BM. Renato Goreshi 8 , Joyce Okawa 8 , Matt<br />

Rose 8 , Rui Feng 1 , Lela Lee 6 , Christopher Hansen 10 , Carolyn<br />

Bangert 9 , Kari Connolly 5 , Mark Davis 2 , Jeff Callen 7 , Nicole Fett 8 ,<br />

Steven Fakharzadeh 4 , Jennie Clarke 3 and Victoria Werth 8 ,<br />

1<br />

Center for Clinical Epidemiology and Biostatistics, University<br />

<strong>of</strong> Pennsylvania, 2 Mayo Clinic- Rochester, 3 Penn State Hershey,<br />

School <strong>of</strong> Medicine, 4 Philadelphia VA Medical Center, 5 University<br />

<strong>of</strong> California-San Francisco, School <strong>of</strong> Medicine, 6 University <strong>of</strong><br />

Colorado, School <strong>of</strong> Medicine, 7 University <strong>of</strong> Louisville, School<br />

<strong>of</strong> Medicine, 8 University <strong>of</strong> Pennsylvania, School <strong>of</strong> Medicine,<br />

9<br />

University <strong>of</strong> Texas, School <strong>of</strong> Medicine, 10 University <strong>of</strong> Utah,<br />

School <strong>of</strong> Medicine.<br />

2010 Program Book 203


ACR/ARHP Poster Session B<br />

921. Fasciitis Is a Common Lesion <strong>of</strong> Dermatomyositis<br />

Demonstrable Early after Disease Onset by En Bloc Biopsy<br />

Combined with Magnetic Resonance Imaging. Ken Yoshida 2 ,<br />

Daitaro Kurosaka 2 , Kensuke Joh 1 , Eigo Takahashi 2 , Kenichiro<br />

Hirai 2 , Kentaro Noda 2 , Taro Ukichi 2 , Kazuhiro Furuya 2 , Maimi<br />

Yanagimachi 2 , Isamu Kingetsu 2 and Akio Yamada 2 , 1 Division<br />

<strong>of</strong> Pathology, Sendai Shakai Hoken Hospital, 2 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, Jikei<br />

University School <strong>of</strong> Medicine, Tokyo, Japan.<br />

922. Immunosuppressive Treatments Do Not Alter Natural History<br />

<strong>of</strong> Sporadic Inclusion Body Myositis: The Paris/Oxford Study<br />

on 136 Patients. Benveniste Olivier 2 , Guiguet Marguerite 5 , Jane<br />

Freebody 4 , Serge Herson 2 , Odile Dubourg 3 , Waney Squier 4 ,<br />

Pascal Laforet 1 , Isabel Leite 4 , Bruno Eymard 1 and David Hilton-<br />

Jones 4 , 1 Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-<br />

Salpêtrière, Institut de Myologie, France, 2 Assistance Publique<br />

- Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Interne,<br />

France, 3 Assistance Publique - Hôpitaux de Paris, Hôpital<br />

Pitié-Salpêtrière, Neuropathologie, France, 4 Department <strong>of</strong><br />

Neurology, West Wing, John Radcliffe Hospital, Oxford, United<br />

Kingdom, 5 INSERM – UPMC UMR S 943, Biostatistique, Paris,<br />

France.<br />

923. Interleukin-18 Is a Key Mediator in Dermatomyositis:<br />

Contribution to Development <strong>of</strong> Interstitial Lung Disease.<br />

Takahisa Gono 2 , Yasushi Kawaguchi 1 , Tomoko Sugiura 2 , Kae<br />

Takagi 2 , Ikuko Masuda 1 , Hisae Ichida 2 , Yasuhiro Katsumata 2 ,<br />

Akiko Tochimoto 2 , Sayumi Baba 2 , Masanori Hanaoka 2 , Yuko<br />

Okamoto 2 , Yuko Ota 2 , Sayuri Kataoka 2 and Hisashi Yamanaka 3 ,<br />

1<br />

Tokyo Women’s Medical University, Tokyo, Japan, 2 Tokyo<br />

Women’s Medical University, 3 Tokyo Womens Med Univ,<br />

Shinjuku-ku, Tokyo, Japan.<br />

924. KL-6: A Serological Biomarker for Interstitial Lung Disease<br />

and Pulmonary Function in Patients with Polymyositis and<br />

Dermatomyositis. Sevim Barbasso Helmers 3 , Maryam Fathi 1 and<br />

Ingrid E. Lundberg 2 , 1 Department <strong>of</strong> Respiratory Medicine and<br />

Allergy, Karolinska Institutet, Stockholm, Sweden, 2 Karolinska<br />

Institutet, Stockholm, Sweden, 3 <strong>Rheumatology</strong> Unit, Dpt. <strong>of</strong><br />

Medicine, Karolinska University Hospital, Solna, Karolinska<br />

Institutet, Stockholm, Sweden.<br />

925. Longitudinal Assessment <strong>of</strong> Activity and Damage in a<br />

Synthetase Positive Cohort. Elaine A. Cassidy 1 , Rohit Aggarwal 3 ,<br />

Noreen Fertig 4 , Dana P. Ascherman 3 and Chester V. Oddis 2 ,<br />

1<br />

Children’s Hospital Pittsburgh Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh, Pittsburgh, PA,<br />

3<br />

University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine Division <strong>of</strong><br />

<strong>Rheumatology</strong> and Clinical Immunology, Pittsburgh, PA,<br />

4<br />

University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine Division <strong>of</strong><br />

<strong>Rheumatology</strong> and Clinical Immunology.<br />

926. Longitudinally Followed Serum Levels <strong>of</strong> B-Cell Activating<br />

Factor <strong>of</strong> the TNF Family Correlate with Disease Activity in<br />

Anti-Jo-1 Positive Patients with Myositis. Olga Krystufkova 1 ,<br />

Marta Mitterwald-Modra 2 , Herman Mann 2 , Louise Ekholm 5 ,<br />

Hana Hulejova 2 , Ingrid E. Lundberg 4 and Jiri Vencovsky 3 ,<br />

1<br />

Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 2 Institute<br />

<strong>of</strong> <strong>Rheumatology</strong>, 3 Institute <strong>of</strong> <strong>Rheumatology</strong> and Dept <strong>of</strong><br />

<strong>Rheumatology</strong> <strong>of</strong> the 1 st Faculty <strong>of</strong> Medicine, Charles University,<br />

Prague, Prague, Czech Republic, 4 Karolinska Institutet,<br />

Stockholm, Sweden, 5 Karolinska Institutet, Sweden.<br />

927. MHC Classes I and II Expressions in Membrane and<br />

Cytoplasm <strong>of</strong> Muscle Fibers in Untreated Juvenile and Adult<br />

Dermatomyositis. Adriana Maluf Elias Sallum, Samuel Katsuyuki<br />

Shinjo, Mary Souza Carvalho, Clóvis Artur Almeida da Silva,<br />

Maurício Levy-Neto and Suely Kazue Nagahashi Marie, Hospital<br />

das Clínicas da Faculdade de Medicina da Universidade de São<br />

Paulo, São Paulo, Brazil.<br />

928. MicroRNA Expression in Juvenile Dermatomyositis (JDM):<br />

Clues to Disease Pathogenesis and Chronicity. Simone Sredni,<br />

Peter Hendrickson, Sheela Shrestha and Lauren M. Pachman,<br />

Children’s Memorial Research Center, Chicago, IL.<br />

929. Non-Jo-1 Anti-Synthetase Autoantibodies Are Not Specific<br />

for Myositis and Are Associated with Poor Survival. Elaine A.<br />

Cassidy 1 , Rohit Aggarwal 3 , Noreen Fertig 3 , Mary Lucas 3 , Dana<br />

P. Ascherman 3 and Chester V. Oddis 2 , 1 Children’s Hospital <strong>of</strong><br />

Pittsburgh Division <strong>of</strong> <strong>Rheumatology</strong>, Pittsburgh, PA, 2 University<br />

<strong>of</strong> Pittsburgh, Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh School <strong>of</strong><br />

Medicine Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />

Pittsburgh, PA.<br />

930. Predictors <strong>of</strong> Survival in Patients with Anti-Synthetase<br />

Autoantibodies. Rohit Aggarwal 5 , Elaine A. Cassidy 1 , Noreen<br />

Fertig 4 , Mary Lucas 4 , Dana P. Ascherman 2 and Chester V. Oddis 3 ,<br />

1<br />

Children’s Hospital Pittsburg, Pittsburgh, PA, 2 University <strong>of</strong><br />

Pittsburgh, Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh, Pittsburgh,<br />

PA, 4 University <strong>of</strong> Pittsburgh, 5 University <strong>of</strong> Pittsburgh Medical<br />

Center, Pittsburgh, PA.<br />

931. Pulmonary Manifestations <strong>of</strong> Polymyositis and Long-Term<br />

Outcomes – A Retrospective Study. Catherine Bakewell 1 , James<br />

Hotaling 1 , Michael Huck 3 , Dale Wilson 3 , Jennifer Hayes 1 , Carolyn<br />

Spada 1 , Gurpreet Rawat 1 and Ganesh Raghu 2 , 1 University<br />

<strong>of</strong> Washington Medical Center, Seattle, WA, 2 University <strong>of</strong><br />

Washington Medical Center, Seattle, 3 University <strong>of</strong> Washington<br />

School <strong>of</strong> Medicine, Seattle, WA.<br />

932. Skin Ulcer Is a Prognostic Factor <strong>of</strong> Respiratory Failure in<br />

Interstitial Lung Disease in Patients with Polymyositis or<br />

Dermatomyositis. Kazuyoshi Ishigaki 3 , Yasunobu Takizawa 4 ,<br />

Junko Maruyama 4 , Ran Nakashima 1 , Tsuneyo Mimori 2 and<br />

Keigo Setoguchi 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, Kyoto University Graduate School <strong>of</strong> Medicine,<br />

Japan, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />

Kyoto University Graduate School <strong>of</strong> Medicine, Japan 3 Tokyo<br />

Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, Japan,<br />

4<br />

Tokyo Metropolitan Komagome Hospital.<br />

933. The Anti-Oxidant Function <strong>of</strong> High Density Lipoprotein<br />

and Paraoxanase-1 Are Abnormal in Patients with<br />

Dermatomyositis. Christina Charles-Schoeman 2 , Yuen Yin<br />

Lee 3 , John D. FitzGerald 4 , Veena K. Ranganath 1 and Srinivasa T.<br />

Reddy 3 , 1 UCLA School <strong>of</strong> Med Rehab 32-59, Los Angeles, CA,<br />

2<br />

UCLA School <strong>of</strong> Medicine, Los Angeles, CA, 3 UCLA School <strong>of</strong><br />

Medicine, 4 UCLA School <strong>of</strong> Medicine Rehabilitation, Los Angeles,<br />

CA.<br />

934. The Interferon Signature in Myositis Is Associated with RNA-<br />

Binding Protein Autoantibodies. Hatice Bilgic 4 , Joseph Wilson 4 ,<br />

Thearith Koeuth 4 , Kelly T. McNallan 2 , Steven R. Ytterberg 1 , Erik<br />

J. Peterson 3 , Ann M. Reed 1 and Emily C. Baechler 4 , 1 Mayo Clinic,<br />

Rochester, MN, 2 Mayo Clinic, <strong>Rheumatology</strong>, Rochester, MN,<br />

3<br />

University <strong>of</strong> Minnesota Department <strong>of</strong> Medicine, Minneapolis,<br />

MN, 4 University <strong>of</strong> Minnesota Department <strong>of</strong> Medicine,<br />

Minneapolis, MN.<br />

204<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

935. The Role <strong>of</strong> Innate Immunity in a Model <strong>of</strong> HRS-Induced<br />

Myositis. Makoto Soejima 4 , Eun Ha Kang 1 , Yasuhiro Katsumata 2 ,<br />

Xinyan Gu 3 , Paula Clemens 3 and Dana Ascherman 3 , 1 Seoul<br />

National University <strong>College</strong> <strong>of</strong> Medicine, 2 Tokyo Women’s<br />

Medical University, 3 University <strong>of</strong> Pittsburgh, 4 University <strong>of</strong><br />

Pittsburgh, Pittsburgh, PA.<br />

Osteoarthritis - Clinical Aspects: Pain and Treatment II<br />

936. 13-Week Efficacy and Safety Evaluation <strong>of</strong> Naproxcinod, a<br />

Cyclooxygenase Inhibiting Nitric Oxide Donator (CINOD), in<br />

Patients with Osteoarthritis <strong>of</strong> the Hip. Christoph Baerwald 3 ,<br />

Hayet Frayssinet 1 , Thierry Ferreira 1 , Brigitte Duquesroix 1 and<br />

Thomas Schnitzer 2 , 1 NicOx, SA, 2 Northwestern University,<br />

3<br />

Universitätsklinikum Leipzig.<br />

937. A Fixed-Dose Combination <strong>of</strong> Naproxen and Esomeprazole<br />

Magnesium (VIMOVO) Has Comparable Efficacy and<br />

Tolerability to Celecoxib in Patients with Osteoarthritis (OA)<br />

<strong>of</strong> the Knee: Results from Two Randomized, Controlled Trials.<br />

Marc C. Hochberg 4 , Byron Cryer 5 , John G. Fort 3 , Clara Hwang 1 ,<br />

Ola Svensson 2 and Mark B. Sostek 1 , 1 AstraZeneca, Wilmington,<br />

DE, 2 AstraZeneca, Sodertalje, Sweden, 3 POZEN, Inc, Chapel Hill,<br />

NC, 4 University <strong>of</strong> Maryland, Baltimore, MD, 5 University <strong>of</strong> Texas<br />

Southwestern Medical Center, Dallas, TX.<br />

938. Chondroitin Sulfate Treatment Is Effective at Reducing<br />

Cartilage Loss in the Tibi<strong>of</strong>emoral Compartment in Knee<br />

OA as Assessed by Magnetic Resonance Imaging (MRI).<br />

Jean-Pierre Pelletier 8 , Lukas M. Wildi 5 , Jean-Pierre Raynauld 5 ,<br />

André Beaulieu 3 , Louis Bessette 4 , Frédéric Morin 1 , François<br />

Abram 6 , Marc Dorais 7 and Johanne Martel-Pelletier 2 , 1 Centre<br />

de Recherche Musculo-squelettique, Trois-Rivières, 2 CR-CHUM,<br />

Notre-Dame Hospital, Montreal, QC, Canada, 3 Faculty <strong>of</strong><br />

Medicine, University <strong>of</strong> Laval, QC, 4 Groupe de Recherche en<br />

Rhumatologie et Maladies Osseuses, Sainte-Foy, 5 Osteoarthritis<br />

Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />

(CRCHUM), Notre-Dame Hospital, 6 Research and Development,<br />

ArthroVision Inc., Montreal, 7 StatSciences Inc., Notre-Dame de<br />

l’Ile-Perrot, 8 University <strong>of</strong> Montreal Hospital Research Centre<br />

(CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada.<br />

939. Chronic Pain Associated with Obesity in the Elderly Is in Part<br />

Explained by the Presence <strong>of</strong> Osteoarthritis. Irene Blanco 2 ,<br />

Richard B. Lipton 2 , Chaim Putterman 1 and Carol A. Derby 2 ,<br />

1<br />

Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx, NY, 2 Albert Einstein<br />

<strong>College</strong> <strong>of</strong> Medicine, Bronx, NY.<br />

940. Clinical Evaluation <strong>of</strong> Chondroitin 4&6 Sulfate (Condrosulf®) in<br />

the Treatment <strong>of</strong> Symptomatic Hand Osteoarthritis. A 6-Month<br />

Randomized Double-Blind, Placebo Controlled Study. Cem<br />

Gabay, Carole Medinger, Danielle Gascon and Axel Finckh, Univ<br />

Hosp <strong>of</strong> Geneva, Geneva, Switzerland.<br />

941. Controversies in the Use <strong>of</strong> Acupuncture for Osteoarthritis<br />

(OA). A Systematic Review <strong>of</strong> the Quality and Treatment<br />

Features <strong>of</strong> Randomized Clinical Trials (RCT). Maria F.<br />

Marengo 2 , Christian A. Waimann 2 , Maria A. Lopez-Olivo 2 , Carol<br />

Looney 1 and Maria E. Suarez-Almazor 3 , 1 The University <strong>of</strong> Texas<br />

M. D. Anderson Cancer Center, 2 The University <strong>of</strong> Texas M. D.<br />

Anderson Cancer Center, Houston, TX, 3 University <strong>of</strong> Texas, MD<br />

Anderson Cancer Center, Houston, TX.<br />

942. Disease Modifying Activity <strong>of</strong> Celecoxib on Articular Cartilage<br />

in Osteoarthritis? – A Randomized Clinical Trial. T. N. de Boer 2 ,<br />

S. C. Mastbergen 2 , A. M. Huisman 3 , A. A. Polak 1 , J. W. J. Bijlsma 2<br />

and F. P. J. G. Lafeber 2 , 1 Orthopedics, Sint Franciscus Gasthuis<br />

Rotterdam, Rotterdam, The Netherlands, 2 <strong>Rheumatology</strong><br />

& Clinical Immunology, University Medical Center Utrecht,<br />

Utrecht, The Netherlands, 3 <strong>Rheumatology</strong>, Sint Franciscus<br />

Gasthuis Rotterdam, Rotterdam, The Netherlands.<br />

943. Effects <strong>of</strong> Intraarticular (IA) Corticosteroid Injections on Bone<br />

Markers and Endogenous Cortisol in Patients with Knee<br />

Osteoarthritis (OA), a Pilot Study. Aruna Baratham 3 , Barbara<br />

P. Lukert 1 and Herbert B. Lindsley 2 , 1 Kansas City, KS, 2 Kansas<br />

University Med Ctr, Kansas City, KS, 3 KU Medical Ctr, Kansas City,<br />

KS.<br />

944. Efficacy and Safety <strong>of</strong> the Lidocaine Patch 5% (Lidoderm®)<br />

When Used as Adjunct Treatment in Patients with<br />

Osteoarthritis <strong>of</strong> the Knee. Alan Kivitz 1 , Ernest A. Kopecky 3 ,<br />

Yusong Chen 2 , Steve Xiang 2 , Matthew Wieman 2 and Errol M.<br />

Gould 2 , 1 Altoona Center for Clinical Research, Duncansville,<br />

PA, 2 Endo Pharmaceuticals Inc., Chadds Ford, PA, 3 Endo<br />

Pharmaceuticals Inc.<br />

945. Efficacy, Safety and Tolerability <strong>of</strong> HZT-501, Including<br />

Users <strong>of</strong> Low-Dose Aspirin, a Single-Tablet Combination <strong>of</strong><br />

Ibupr<strong>of</strong>en-Famotidine: Results <strong>of</strong> Two Phase 3 Trials. Michael<br />

E. Weinblatt 2 , Mark C. Genovese 5 , Alan J. Kivitz 1 , Alfonso E.<br />

Bello 4 , Amy Grahn 3 , Jeffrey W. Sherman 3 and Michael H. Schiff 6 ,<br />

1<br />

Altoona Arthritis & Osteo Ctr, Duncansville, PA, 2 Brigham<br />

& Womens Hospital, Boston, MA, 3 Horizon Pharma, Inc.,<br />

Northbrook, IL, 4 Illinois Bone & Joint Inst, Glenview, IL, 5 Stanford<br />

University, Stanford, Sunnyvale, CA, 6 University <strong>of</strong> Colorado,<br />

Denver, Greenwood Village, CO.<br />

946. Long Term Safety <strong>of</strong> an NSAID with Built-in Gastroprotection<br />

for Treatment <strong>of</strong> Pain and Inflammation Related to OA and<br />

RA: Results from a One Year Safety Trial <strong>of</strong> a Single-Tablet<br />

Combination <strong>of</strong> Ibupr<strong>of</strong>en-Famotidine vs. Ibupr<strong>of</strong>en Alone.<br />

Michael H. Schiff 6 , Mark C. Genovese 5 , Alan J. Kivitz 1 , Alfonso<br />

E. Bello 4 , Jeffrey W. Sherman 3 , Amy Grahn 3 and Michael E.<br />

Weinblatt 2 , 1 Altoona Arthritis & Osteo Ctr, Duncansville, PA,<br />

2<br />

Brigham & Womens Hospital, Boston, MA, 3 Horizon Pharma,<br />

Inc., Northbrook, IL, 4 Illinois Bone & Joint Inst, Glenview, IL,<br />

5<br />

Stanford University, Stanford, Sunnyvale, CA, 6 University <strong>of</strong><br />

Colorado, Denver, Greenwood Village, CO.<br />

947. Modified Bent Knee Approach for Highly Accurate Injection<br />

<strong>of</strong> the Knee. Suzanne Delea 1 , Wilmer L. Sibbitt 3 , Philip<br />

Band, Natalia Chavez-Chiang 2 , Hillary Norton 2 and Arthur D.<br />

Bankhurst 4 , 1 University <strong>of</strong> New Mexico, Albuquerque, NM,<br />

2<br />

University <strong>of</strong> New Mexico, 3 University <strong>of</strong> New Mexico HSC,<br />

Albuquerque, NM, 4 University <strong>of</strong> NM Med Ctr, Albuquerque,<br />

NM.<br />

948. OARSI-OMERACT Virtual Joint Replacement in Disease<br />

Modifying Osteoarthritis Drug (DMOAD) Randomized Clinical<br />

Trials (RCTs) for Knee and Hip Osteoarthritis (OA): Selection<br />

<strong>of</strong> Optimal Thresholds for Symptomatic Severity. Rebecca L.<br />

Manno 5 , Clifton O. Bingham 6 , Simon Paternotte 1 , Philippe Coste,<br />

Giampaolo Giacovelli 9 , Lucio C. Rovati 8 , Kenneth D. Brandt 7 ,<br />

Steven A. Mazzuca 4 , Daniel O. Clegg 10 , Helen Shi, Eleonora<br />

Tajana Messi 3 , Arturo Lanzarotti 3 and Maxime Dougados 2 , 1 AP-<br />

HP Cochin Hospital, René Descartes University, Paris, France,<br />

2<br />

Hospital Cochin, Paris, France, 3 IBSA Institut Biochimique SA,<br />

4<br />

Indiana Univ Schl <strong>of</strong> Medicine, Indianapolis, IN, 5 Johns Hopkins<br />

University, Baltimore, MD, 6 Johns Hopkins University, Baltimore,<br />

MD, 7 Kansas Univ Medical Center, Fairway, KS, 8 Rottapharm,<br />

Monza Milan, Italy, 9 Rottapharm, 10 University <strong>of</strong> Utah Med Ctr,<br />

Salt Lake City, UT.<br />

949. Pain Sensitivity and Biomarkers <strong>of</strong> Systemic Inflammation<br />

in Osteoarthritis. Yvonne C. Lee 2 , Bing Lu 1 , Joan M. Bathon 4 ,<br />

Jennifer A. Haythornwaite 5 , Michael T. Smith 5 , Gayle G. Page 5<br />

and Robert R. Edwards 3 , 1 Brigham and Women’s Hospital,<br />

Foxboro, MA, 2 Brigham and Women’s Hospital, Boston, MA,<br />

3<br />

Brigham and Womens Hospital, Chestnut Hill, MA, 4 Johns<br />

Hopkins University, Baltimore, MD, 5 Johns Hopkins University.<br />

2010 Program Book 205


ACR/ARHP Poster Session B<br />

950. Patient Global Impression <strong>of</strong> Change Results from a 1-Year<br />

Open-Label Extension Study <strong>of</strong> Tapentadol Extended<br />

Release in Patients with Chronic Osteoarthritis or Low Back<br />

Pain. Bettyanne McCann 2 , Robert Lange 1 , Bertil Wagner 2 ,<br />

Achim Steup 1 , Bernd Lange 1 and Mila Etrolpolski 2 , 1 Global<br />

Development, Grünenthal GmbH, Aachen, Germany, 2 Johnson<br />

& Johnson Pharmaceutical Research & Development, L.L.C.,<br />

Raritan, NJ.<br />

951. Racial/Ethnic Differences in Pain Sensation in Subjects with<br />

or at Risk <strong>of</strong> Knee Osteoarthritis: Analysis <strong>of</strong> the Multicenter<br />

Osteoarthritis (MOST) Study. Jasvinder Singh 1 , Tuhina Neogi 2 ,<br />

David T. Felson 3 , James Torner 7 , Kristin Baker 4 , Michael C.<br />

Nevitt 5 , Irina Tolstykh 5 and Cora E. Lewis 6 , 1 Birmigham VA<br />

Medical Center and University <strong>of</strong> Alabama, Minneapolis, MN,<br />

2<br />

Boston Univ Schl <strong>of</strong> Med, Boston, MA, 3 Boston University<br />

School <strong>of</strong> Medicine, Boston, MA, 4 Boston University School <strong>of</strong><br />

Medicine, 5 UCSF, San Francisco, CA, 6 University <strong>of</strong> Alabama,<br />

7<br />

University <strong>of</strong> Iowa.<br />

952. The Importance <strong>of</strong> Methodological Quality for the Association<br />

between Radiographic and Clinical Features <strong>of</strong> Hip and<br />

Knee Osteoarthritis: A Systematic Review. M. B. Kinds 2 , E. P.<br />

Vignon 5 , J. W. J. Bijlsma 4 , M. A. Viergever 1 , A. C. A. Marijnissen 4 ,<br />

F. P. J. G. Lafeber 4 and P. M. J. Welsing 3 , 1 Image Sciences<br />

Institute, University Medical Center Utrecht, The Netherlands,<br />

2<br />

<strong>Rheumatology</strong> & Clinical Immunology, Image Sciences<br />

Institute, University Medical Center Utrecht, The Netherlands,<br />

3<br />

<strong>Rheumatology</strong> & Clinical Immunology, Julius Center for Health<br />

Sciences & Primary Care, University Medical Center Utrecht, The<br />

Netherlands, 4 <strong>Rheumatology</strong> & Clinical Immunology, University<br />

Medical Center Utrecht, The Netherlands, 5 <strong>Rheumatology</strong>,<br />

University Hospital Lyon-Sud Pierre-Benite, France.<br />

953. Time to Onset <strong>of</strong> Gastrointestinal Adverse Events <strong>of</strong><br />

Naproxcinod vs. Naproxen and Placebo in Patients with<br />

Osteoarthritis. Byron Cryer 2 , Angel Lanas 1 , Rosanna Fleming 4 ,<br />

Fabrizio Dolphi 3 , Diana Aguirre 3 and Brigitte Duquesroix 3 ,<br />

1<br />

Aragon Health Sciences Institute, University <strong>of</strong> Zaragoza,<br />

2<br />

Department <strong>of</strong> Veterans Affairs Medical Center, 3 NicOx SA,<br />

4<br />

NicOx, Inc.<br />

954. Topical Dicl<strong>of</strong>enac Solution (PENNSAID®) Compared with Oral<br />

Dicl<strong>of</strong>enac in Osteoarthritis <strong>of</strong> the Knee: Pooled Analysis from<br />

2 Controlled Clinical Trials. Sanford H. Roth 1 and Philip Fuller 2 ,<br />

1<br />

Arizona Research and Education, Arthritis Research Laboratory,<br />

Arizona State University, Phoenix, AZ, 2 Covidien.<br />

955. Topical Dicl<strong>of</strong>enac Solution with the Absorption Enhancer<br />

Dimethyl Sulfoxide (PENNSAID®) for the Treatment <strong>of</strong><br />

Osteoarthritis <strong>of</strong> the Knee: Integrated Summary <strong>of</strong> Safety.<br />

Sanford H. Roth 1 and Philip Fuller 2 , 1 Arizona Research and<br />

Education, Arthritis Research Laboratory, Arizona State<br />

University, Phoenix, AZ, 2 Covidien.<br />

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and<br />

Pathogenesis<br />

956. Adenosine A2A Antagonist ZM241385 Increases Osteoblast<br />

Differentiation and Function In Vitro. Louisa Ziglar 2 and Bruce<br />

N. Cronstein 1 , 1 New York Univ Med Ctr, New York, NY, 2 NYU<br />

Medical Center, New York, NY.<br />

957. Algorithm for Using a Bone Formation Marker PINP To<br />

Monitor the Response to Teriparatide (TPTD) in Patients with<br />

Glucocorticoid-Induced Osteoporosis (GIO). Nancy E. Lane 2 ,<br />

Kyoungah See 1 , Margaret Warner 1 and John H. Krege 1 , 1 Eli Lilly,<br />

Indianapolis, IN, 2 Univ <strong>of</strong> California at Davis, Hillsborough, CA.<br />

958. Anti-Hypertensive Therapy and Bone Mineral Density: Analysis<br />

in a Population-Based U.S. Sample. Mitsuyo Kinjo 3 , Soko<br />

Setoguchi 1 and Daniel Hal Solomon 2 , 1 Brigham and Women’s<br />

Hospital, 2 Brigham and Womens Hospital, Boston, MA,<br />

3<br />

Okinawa Chubu Hospital, Japan.<br />

959. Bone Density Following Long-Duration Spaceflight and<br />

Recovery. Shreyasee Amin 1 , Sara Achenbach 1 , Elizabeth<br />

Atkinson 1 , L. Joseph Melton 1 , Sundeep Khosla 1 and Jean<br />

Sibonga 2 , 1 Mayo Clinic, 2 NASA-Johnson Space Center.<br />

960. Bone Geometry Parameters among Black and White Women<br />

with SLE. Jimmy D. Alele 2 , Diane L. Kamen 2 , Kelly J. Hunt 2 , Gary<br />

S. Gilkeson 1 and Rosalind Ramsey-Goldman 3 , 1 Med Univ <strong>of</strong><br />

South Carolina, Charleston, SC, 2 Medical University <strong>of</strong> South<br />

Carolina, Charleston, SC, 3 Northwestern University, Chicago, IL.<br />

961. Cardiovascular Disease Is Associated with Increased Bone Loss<br />

and Fracture Risk: A Systematic Review <strong>of</strong> the Association<br />

between Cardiovascular Disease and Osteoporosis. Debby den<br />

Uyl 2 , Mike T. Nurmohamed 1 , Lilian H. D. van Tuyl 2 , Hennie G.<br />

Raterman 2 and Willem F. Lems 2 , 1 Department <strong>Rheumatology</strong>/<br />

Jan van Breemen Institute, Amsterdam, The Netherlands,<br />

2<br />

Department <strong>Rheumatology</strong>/VU University Medical Centre,<br />

Amsterdam, The Netherlands.<br />

962. Cholecalciferol High Dose Supplementation Should Be<br />

Preferred in Rheumatic Patients Independently to the<br />

Presence <strong>of</strong> an Autoimmune Disease. Mattia Bellan 3 , Pier<br />

Paolo Sainaghi 1 and Mario Pirisi 2 , 1 Immuno-<strong>Rheumatology</strong><br />

Outpatient Unit, DMCS, “A. Avogadro” University and IRCAD<br />

(Interdisciplinary Reseach Center <strong>of</strong> Autoimmune Diseases),<br />

Novara, Novara, Italy, 2 Immuno-<strong>Rheumatology</strong> Outpatient Unit,<br />

DMCS, “A. Avogadro” University and IRCAD (Interdisciplinary<br />

Reseach Center <strong>of</strong> Autoimmune Diseases), Novara, Italy,<br />

3<br />

Immuno-<strong>Rheumatology</strong> Outpatient Unit, DMCS, “A. Avogadro”<br />

University, Novara, Italy.<br />

963. Differences in the Observed Rate <strong>of</strong> Hip Fracture in Male and<br />

Female Patients Diagnosed with Osteoarthritis or Ankylosing<br />

Spondylitis Compared with the Expected Based on the<br />

General Population Seeking Health Care. Martin Englund 2 ,<br />

Jonas Franklin 3 and Ingemar F. Petersson 1 , 1 Lund University<br />

Hosp, Lund, Sweden, 2 Musculoskeletal Sciences, Department<br />

<strong>of</strong> Orthopedics, Clinical Sciences Lund, Lund University, Lund,<br />

Sweden, 3 University Hospital, Akureyri, Iceland.<br />

964. Effect <strong>of</strong> Oral Ibandronate on Bone Microarchitecture in<br />

Women with Osteopenia – A Randomized Placebo-Controlled<br />

Trial. Roland Chapurlat 2 , Michel Laroche 4 , Thierry Thomas 1 ,<br />

Stéphanie Rouanet 5 , Pierre D. Delmas 2 and Marie-Christine de<br />

Vernejoul 3 , 1 CHU St Etienne, Saint Etienne, France, 2 INSERM<br />

U831, Université de Lyon, Hôpital E Herriot, Lyon, France,<br />

3<br />

Lariboisière Hospital, Paris, France, 4 Pôle Institut Locomoteur<br />

Hôpital Purpan, Toulouse, France, 5 Roche France, Neuilly,<br />

France.<br />

965. Effects <strong>of</strong> Glucocorticoid on Osteocyte Autophagy In Vivo. Wei<br />

Yao 1 , Junjing Jia 1 , Weiwei Dai 1 , Min Guan 1 , Lynda Bonewald 3 and<br />

Nancy E. Lane 2 , 1 UC Davis Medical Center, 2 Univ <strong>of</strong> California at<br />

Davis, Hillsborough, CA, 3 Univ. <strong>of</strong> Missouri at Kansas City, School<br />

<strong>of</strong> Dentistry, Dept. <strong>of</strong> Oral Biology, Kansas City, MO.<br />

966. Fracture Epidemiology among a Cohort <strong>of</strong> HIV-Infected Adults<br />

in the UK: An Epidemiologic Study. Karen Walker-Bone 1 ,<br />

Reshad Malik 2 , Martin Fisher 2 , Yvonne Gilleece 2 and Amanda<br />

Samarawickrama 2 , 1 Brighton& Sussex Medical School, Brighton,<br />

East Sussex, United Kingdom, 2 Brighton & Sussex University<br />

Hospitals NHS Trust.<br />

206<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

967. Fracture Incidence, Quality <strong>of</strong> Life and Back Pain in Women<br />

with Osteoporosis and Concomitant Glucocorticoid Use<br />

Treated with Teriparatide: 36 Month Results from the<br />

European Forsteo Observational Study (EFOS). Willem Lems 9 ,<br />

Bente Langdahl 6 , Osten Ljunggren 7 , Annabel Barrett 2 , Dimitrios<br />

Karras 8 , James Bernard Walsh 4 , Astrid Fahrleitner-Pammer 3 ,<br />

Gerald Rajzbaum 5 , Clare Barker 2 , Franz Jakob 1 and Fernando<br />

Marin 2 , 1 Julius-Maximilians-Univ, Würzburg, Germany, 2 Lilly<br />

Research Ctr., Windlesham, UK, 3 Med Univ, Graz, Austria, 4 St<br />

James’s Hosp Trinity <strong>College</strong>, Dublin, Ireland, 5 St Joseph Hosp,<br />

Paris, France, 6 Univ Hosp, århus, Denmark, 7 Univ Hosp, Uppsala,<br />

Sweden, 8 Veterans Admin Hosp, Athens, Greece, 9 VU Univ Hosp,<br />

Amsterdam, Netherlands.<br />

968. Fracture Risk Assessment and Osteoporosis Treatment<br />

Disparities in 4027 Japanese Patients with Rheumatoid<br />

Arthritis. Takefumi Furuya 2 , Takayuki Hosoi 1 , Eisuke Inoue 3 ,<br />

Atuo Taniguchi 3 , Shigeki Momohara 3 and Hisashi Yamanaka 4 ,<br />

1<br />

Department <strong>of</strong> Clinical Research and Development,<br />

National Center for Geriatrics and Gerontology, 2 Institute <strong>of</strong><br />

<strong>Rheumatology</strong>, Tokyo Women’s Medical University, Tokyo,<br />

Japan, 3 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s Medical<br />

University, 4 Tokyo Women’s Medical University, Shinjuku-ku,<br />

Tokyo, Japan.<br />

969. Health Care Utilization Following a Fracture: Global<br />

Longitudinal Study <strong>of</strong> Osteoporosis in Women (GLOW).<br />

George Ioannidis 3 , Jonathan D. Adachi 2 , Laura Pickard 3 , Roland<br />

Chapurlat 4 , Kenneth G. Saag 5 , Stuart L. Silverman 1 , Julie Flahive 6<br />

and Stephen Gehlbach 6 , 1 Cedars-Sinai Medical Center, University<br />

<strong>of</strong> California Los Angeles, Beverly Hills, CA, 2 McMaster<br />

University, Hamilton, ON, Canada, 3 McMaster University,<br />

4<br />

Universite de Lyon, 5 University <strong>of</strong> Alabama-Birmingham,<br />

Birmingham, AL, 6 University <strong>of</strong> Massachusetts.<br />

970. High Adherence with Bisphosphonate Therapy in US Veterans<br />

with Rheumatoid Arthritis. J. Steuart Richards 10 , Grant W.<br />

Cannon 9 , Candace L. Hayden 8 , Richard L. Amdur 11 , Ted R.<br />

Mikuls 6 , Andreas Reimold 2 , Liron Caplan 3 , Dannette S. Johnson 5 ,<br />

Pascale Schwab 7 , Deana Lazaro 1 , Bogdan N. Cherascu 4 and Gail<br />

S. Kerr 11 , 1 Brooklyn NY VA Medical Center, New York, NY, 2 Dallas<br />

TX VA Medical Center, Dallas, TX, 3 Denver CO VA Medical Center,<br />

Denver, CO, 4 Iowa City IA VA Medical Center, Iowa City, 5 Jackson<br />

MS VA Medical Center, Jackson, MS, 6 Omaha NE VA Medical<br />

Center, Omaha, NE, 7 Portland OR VA Medical Center, Portland,<br />

OR, 8 Salt Lake City UT VA Medical Center, Salt Lake City, UT, 9 Salt<br />

Lake City VA Medical Center, Salt Lake City, UT, 10 Washington<br />

DC VA Medical Cener, Washington, DC, 11 Washington DC VA<br />

Medical Center, Washington, DC.<br />

971. Impact <strong>of</strong> Incident Clinical Vertebral Fractures on Back Pain<br />

Outcomes in Postmenopausal Women Who Participated in the<br />

FREEDOM Trial. Michael C. Nevitt 11 , Stuart L. Silverman 3 , Hema<br />

Viswanathan 1 , Yu-Ching Yang 1 , Andrea Wang 1 , Steven Boonen 2 ,<br />

Sergio Ragi-Eis 4 , Patrice Fardellone 9 , Andreas Grauer 1 , Nigel<br />

Gilchrist 5 , Paul Lips 12 , Santiago Palacios 8 , Karel Pavelka 6 , Dennis<br />

Revicki 10 , James Simon 13 , David Macarios 1 and Ethel Siris 7 ,<br />

1<br />

Amgen Inc., Thousand Oaks, CA, 2 Bone Research Unit, Leuven<br />

University, Leuven, Belgium, 3 Cedars-Sinai Medical Center,<br />

University <strong>of</strong> California Los Angeles, Beverly Hills, CA, 4 CEDOES<br />

Diagnóstico e Pesquisa, Vitória (ES), Brazil, 5 CGM Research<br />

Trust and Canterbury District Health Board, Christchurch, New<br />

Zealand, 6 Charles University, Prague, Czech Republic, 7 Columbia<br />

University Medical Center, New York, NY, 8 Palacios Institute <strong>of</strong><br />

Woman’s Health, Madrid, Spain, 9 Service de Rhumatologie,<br />

Hôpital Nord, INSERM ERI 12, Amiens, France, 10 United<br />

BioSource Corporation, Bethesda, MD, 11 University <strong>of</strong> California<br />

San Francisco, San Francisco, CA, 12 VU University Medical<br />

Center, Amsterdam, The Netherlands, 13 Women’s Health &<br />

Research Consultants®, Washington, DC.<br />

972. Incidence <strong>of</strong> Low Energy Hip Fracture in Southern Norway<br />

Significantly Lower Than Reported from the Capital <strong>of</strong> Norway<br />

(Oslo). Andreas Diamantopoulos 1 , Gudrun Rohde 2 , Irene<br />

Johnsrud 1 , Inger Marie Skoie 1 , Villy Johnsen 1 , Marc C. Hochberg 3<br />

and Glenn Haugeberg 1 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Soerlandet Hospital SSHF, Kristiansand, Norway, 2 Faculty <strong>of</strong><br />

Health and Sport, University <strong>of</strong> Agder, Kristiansand, Norway,<br />

3<br />

University <strong>of</strong> Maryland, Baltimore, MD.<br />

973. Increases in Macrophage Inhibitory Factor Correlate with<br />

Increases in Bone Mineral Density in Glucocorticoid-Treated<br />

Patients with RA. Jos Nicolaas Hoes 1 , Marlies C. Van der Goes 2 ,<br />

Johannes W. G. Jacobs 2 , Johannes W. J. Bijlsma 2 and Joel A. G.<br />

Van Roon 2 , 1 University Medical Center Utrecht, Department<br />

<strong>of</strong> <strong>Rheumatology</strong> & Clinical Immunology, Utrecht, The<br />

Netherlands, 2 University Medical Center Utrecht, Department <strong>of</strong><br />

<strong>Rheumatology</strong> & Clinical Immunology.<br />

974. Low Bone Mineral Density in Depoprovera Users – An Under<br />

Recognised Health Issue. Mani Nallasivan 1 and Tim Gillott 2 ,<br />

1<br />

Diana Princess <strong>of</strong> Wales Hospital, Northern Lincolnshire and<br />

Goole Hospitals NHS Trust, Hull, Yorkshire, United Kingdom,<br />

2<br />

Diana Princess <strong>of</strong> Wales Hospital, Northern Lincolnshire and<br />

Goole Hospitals NHS Trust, Grimsby, Northeast Lincolnshire,<br />

United Kingdom.<br />

975. National Registry <strong>of</strong> Paget Disease <strong>of</strong> Bone. Estibaliz Loza, Nuria<br />

Guañabens, Maria Jesus Garcia de Yebenes, Antonio Morales,<br />

Javier Del Pino, Antonio Torrijos, Jesus Garrido, Jesus Tornero,<br />

Jorge Malouf, Jordi Carbonell and Manuel Rodriguez, Spanish<br />

Society <strong>of</strong> <strong>Rheumatology</strong>.<br />

976. Prevalence <strong>of</strong> Osteoporosis and Osteoporotic Fractures:<br />

A Population Based Survey Including Vertebral Fracture<br />

Assessment by Morphometry (VFA). Liana E. Euller-Ziegler 1 ,<br />

Christian H. Roux 1 , Veronique Breuil 1 , Virginie Dasilva 1 , Christine<br />

Albert-Sabonnadiere 1 , Christian Grisot 1 , Philippe Flory 1 , Yacine<br />

Allam 1 , Hasna Chami 1 , Gerard Ziegler 1 and Pascal Staccini 2 ,<br />

1<br />

L’Archet Hospital, University <strong>of</strong> Nice, Nice, France, 2 Labstic<br />

Santé, University <strong>of</strong> Nice, Nice, France.<br />

977. Proactively Contacting Men with Prostate Cancer Treated<br />

with Anti-Androgen Medications Improves the Evaluation and<br />

Treatment <strong>of</strong> Osteoporosis. Brian P. Oppermann 1 , Thomas M.<br />

Harrington 2 and William Ayoub 3 , 1 Geisinger Medical Center,<br />

Danville, PA, 2 Geisinger Medical Center, Danville PA, 3 Geisinger<br />

Medical Group, Scenary Park PA.<br />

978. Quality Assurance Study <strong>of</strong> the Use <strong>of</strong> Preventative Therapies<br />

in Glucocorticord Induced Osteoporosis (GIOP) in Early<br />

Inflammatory Arthritis (EIA): Results from the CATCH Cohort.<br />

Emily McKeown 10 , Vivian P. Bykerk 5 , Faye Deleon 4 , J. Carter<br />

Thorne 6 , Carol A. Hitchon 8 , Gilles Boire 2 , Boulos Haraoui 3 ,<br />

Diane S. Ferland 1 , Ed C. Keystone 9 and Janet E. Pope 7 , 1 LaSalle,<br />

QC, Canada, 2 CHUS - Sherbrooke University, Sherbrooke, QC,<br />

Canada, 3 Institut de Rhumatologie, Montreal, QC, Canada,<br />

4<br />

McMaster University, Hamilton, ON, Canada, 5 Mt Sinai<br />

Hospital, Toronto, ON, Canada, 6 Southlake Regional Health<br />

Care, Newmarket, ON, Canada, 7 St Joseph Health Care London,<br />

London, ON, Canada, 8 University <strong>of</strong> Manitoba, Winnipeg,<br />

MB, Canada, 9 University <strong>of</strong> Toronto, Toronto, ON, Canada,<br />

10<br />

University <strong>of</strong> Western Ontario, London, ON, Canada.<br />

979. Relationships between Changes in Bone Mineral Density or<br />

Bone Turnover Markers and Vertebral Fractures Incidence<br />

in Patients Treated with Bazedoxifene. Olivier Bruyere 2 ,<br />

Johann Detilleux 3 , Arkadi Chines 1 and Jean Y. Reginster 2 , 1 Pfizer,<br />

2<br />

University <strong>of</strong> Liege, Liege, Belgium, 3 University <strong>of</strong> Liege.<br />

2010 Program Book 207


ACR Poster Session B<br />

208<br />

980. The Direct Assessment <strong>of</strong> Nonvertebral Fractures in<br />

Community Experience (DANCE) Study: 2-Year Nonvertebral<br />

Fragility Fracture Results. Stuart L. Silverman 2 , Paul Miller 4 ,<br />

Anthony I. Sebba 1 , Michael Weitz 3 , Xiaohai Wan 5 , Kathleen<br />

Taylor 5 , Valerie Ruff 5 and Kelly D. Krohn 6 , 1 Arthritis Associates,<br />

Palm Harbor, FL, 2 Cedars-Sinai Medical Center, University <strong>of</strong><br />

California Los Angeles, Beverly Hills, CA, 3 Center Arthritis and<br />

<strong>Rheumatology</strong>, South Miami, FL, 4 Colorado Center for Bone<br />

Research, Lakewood, CO, 5 Eli Lilly and Company and/or One <strong>of</strong><br />

Its Subsidiaries, Indianapolis, IN, 6 Lilly USA, LLC, Indianapolis, IN.<br />

981. The Effects <strong>of</strong> Biologics on Bone Metabolism <strong>of</strong> Patients with<br />

Rheumatoid Arthritis. Tadashi Okano, Masahiro Tada, Shigeyuki<br />

Wakitani, Hiroaki Nakamura and Tatsuya Koike, Osaka City Univ<br />

Med School, Osaka, Japan.<br />

982. The Effects <strong>of</strong> Denosumab (DMAb) on Bone Mineral Density<br />

(BMD), Fracture and Safety Outcomes by Level <strong>of</strong> Renal<br />

Function. Sophie A. Jamal 8 , Peter R. Ebeling 7 , Osten Ljunggren 9 ,<br />

Catherine Stehman-Breen 1 , Steven R. Cummings 5 , Michael R.<br />

McClung 4 , Stefan Goemaere 3 , Edward Franek 2 , Yu-Ching Yang 1 ,<br />

Ogo I. Egbuna 1 and Paul Miller 6 , 1 Amgen Inc., Thousand Oaks,<br />

CA, 2 Central Clinical Hospital, Warsaw, Poland, 3 Ghent University<br />

Hospital, Belgium, 4 Oregon Osteoporosis Center, Portland, OR,<br />

5<br />

San Francisco Coordinating Center, CPMC Research Institute<br />

and University <strong>of</strong> California, San Francisco, San Francisco, CA,<br />

6<br />

University <strong>of</strong> Colorado Health Sciences Center, CO, 7 University<br />

<strong>of</strong> Melbourne, Melbourne, Australia, 8 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada, 9 Uppsala University Hospital, Sweden.<br />

983. The Serum Level <strong>of</strong> Undercarboxylated Osteocalcin (ucOC)<br />

in Patients with Rheumatoid Arthritis – A High Dose<br />

<strong>of</strong> Predonisolone Decrease the Serum Level <strong>of</strong> ucOC.<br />

Yoshitada Sakai 2 , Akira Hashiramoto 4 , Teppei Hashimoto 4 ,<br />

Yoshiko Kawasaki 4 , Chihiro Tanaka 4 , Shunichi Shiozawa 3 and<br />

Masahiro Kurosaka 1 , 1 Department <strong>of</strong> Orthopaedic Surgery,<br />

Kobe University Graduate School <strong>of</strong> Medicine, 2 The Center <strong>of</strong><br />

Rheumatic Diseases, Kobe University Hospital, Kobe, Hyogo,<br />

Japan, 3 The Center <strong>of</strong> Rheumatic Diseases, Kobe University<br />

Hospital, Kobe, Japan, 4 The Center <strong>of</strong> Rheumatic Diseases, Kobe<br />

University Hospital.<br />

Quality Measures and Innovation in Practice Management and<br />

Care Delivery<br />

984. “Early Arthritis: Early Act”. A Community-Based Knowledge<br />

Transfer Program To Improve Ability <strong>of</strong> General Practitionner<br />

to Rapidly Detect and Refer to the Rheumatologist Patients<br />

with Early Arthritis. Bruno Fautrel 3 , Patrick Froger 1 , Cecile<br />

Gaujoux-Viala 2 and Eric Leutenegger, 1 Lyon, France, 2 Paris,<br />

France, 3 Pitie Salpetriere Hospital, Paris, France.<br />

985. A Checklist <strong>of</strong> 10 Measures, 6 from a Patient Questionnaire<br />

& 4 Physician Global Scores, Requiring


ACR Poster Session B<br />

993. Early Experience with the <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

(ACR) <strong>Rheumatology</strong> Clinical Registry (RCR). Salahuddin<br />

Kazi 2 , Elizabeth A. Tindall 3 , Kristen McNiff 1 and Itara Barnes 1 ,<br />

1<br />

<strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>, Atlanta, GA, 2 Arthritis<br />

Consultation Center, Dallas, TX, 3 Oregon Health & Science<br />

University, West Linn, OR.<br />

994. Evaluating Adherence to Quality Indicators in Prevention<br />

<strong>of</strong> Glucocorticoid Induced Osteoporosis in Patients at the<br />

Veterans Affairs in Lexington. Magdalena Winiarska 1 , Joseph<br />

Conigliaro 2 , Heather Bush 2 , Lucia Hardi 1 , Elnaz N Tabrizi 1 and<br />

Leslie J. Cr<strong>of</strong>ford 3 , 1 Univ <strong>of</strong> Kentucky, Lexington, KY, 2 Univ <strong>of</strong><br />

Kentucky, 3 Univ <strong>of</strong> KY, Lexington, KY.<br />

995. Formal Joint Counts Are Performed at More Than 50% <strong>of</strong> Visits<br />

<strong>of</strong> Patients with Rheumatoid Arthritis in Usual Care outside<br />

<strong>of</strong> Clinical Research, by 64% <strong>of</strong> European Rheumatologists<br />

in 2010 Compared to 44% in 2003. Theodore Pincus 2 , Ed C.<br />

Keystone 4 , Marc de Longueville 3 and Sophie Costello 1 , 1 Costello<br />

Medical Consulting, 2 New York University Hospital for Joint<br />

Disease, Hastings-on-Hudson, NY, 3 UCB Pharma, 4 University <strong>of</strong><br />

Toronto, Toronto, ON, Canada.<br />

996. Frequency <strong>of</strong> PAP Smears among Lupus Patients – A Patient<br />

Report Survey. Eileen J. Lydon and H. Michael Belmont,<br />

NYUHJD, New York, NY.<br />

997. Impact <strong>of</strong> a Screening Protocol with Added Thoracic CT and<br />

Quantiferon on Prophylactic Treatment <strong>of</strong> Latent Tuberculosis<br />

in Anti-TNFa Candidate Patients. Nathalie Saidenberg-<br />

Kermanac’h 3 , Luca Semerano 4 , Jean-Marc Naccache 1 , Michel<br />

Brauner 2 , Géraldine Falgarone 4 , Dominique Dumont-Fischer 4 ,<br />

Xavier Guillot 4 and Marie-Christophe Boissier 4 , 1 Department<br />

<strong>of</strong> Pneumology, Avicenne Hospital (AP-HP), Bobigny, France,<br />

2<br />

Department <strong>of</strong> Radiology, Avicenne Hospital (AP-HP), Bobigny,<br />

France, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Avicenne Hospital (AP-<br />

HP), Bobigny, Bobigny, France, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Avicenne Hospital (AP-HP), Bobigny, France, EA 4222 , Paris- 13<br />

University, France.<br />

998. Implementation <strong>of</strong> an Electronic Interface for Medical Record<br />

Documentation in an Academic Pediatric <strong>Rheumatology</strong><br />

Outpatient Clinic. Jennifer M. P. Woo 2 , Miriam F. Parsa 2 , Gil<br />

Amarilyo 2 , Nasim Afsarmanesh 1 , Kerry T. Gallagher 2 , Ornella<br />

J. Rullo 2 and Deborah K. McCurdy 2 , 1 Division <strong>of</strong> Internal<br />

Medicine and Neurosurgery-Medicine; Hospital Medicine and<br />

Neurosurgical Clinical Quality Programs, UCLA, Los Angeles, CA,<br />

2<br />

Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, UCLA, Los Angeles, CA.<br />

999. Inpatient HiROC (High Risk Osteoporosis Clinic): Improving<br />

Osteoporosis Care Post Fracture. Gwynne L. Maloney-Saxon 2 ,<br />

Thomas P. Olenginski 3 , Cynthia K. Matzko 2 , Haiyan Sun 1 , Karen<br />

Mackiewicz 4 and Eric D. Newman 2 , 1 Center for Health Research,<br />

Danville, PA, 2 Geisinger Medical Center, Danville, PA, 3 Geisinger<br />

Medical Center, Danville, PA, 4 Geisinger Medical Center,<br />

Davnille, PA.<br />

1000. Lipid and C-Reactive Protein Screening Thresholds and CVD<br />

Risk in a Community Lupus Cohort. Christie M. Bartels 4 , Kevin<br />

Buhr 5 , Jerry Goldberg 2 , Carolyn Bell 3 and Robert Greenlee 1 ,<br />

1<br />

Marshfield Clinic Research Foundation, 2 Marshfield Clinic<br />

<strong>Rheumatology</strong>, 3 Univ <strong>of</strong> Wisconsin School <strong>of</strong> Medicine and<br />

Public Health, Dept <strong>of</strong> Medicine, <strong>Rheumatology</strong>, 4 Univ <strong>of</strong><br />

Wisconsin School <strong>of</strong> Medicine and Public Health, Dept <strong>of</strong><br />

Medicine, <strong>Rheumatology</strong>, Madison, WI, 5 University <strong>of</strong> Wisconsin<br />

Department <strong>of</strong> Biostatistics.<br />

1001. Measuring the Impact <strong>of</strong> Patient Educational Materials about<br />

Medications in Meeting Patient Needs: Development and<br />

Validation <strong>of</strong> the Medication Education Impact Questionnaire<br />

(MeiQ). Sabina Ciciriello 3 , Rachelle Buchbinder 1 , Ian Wicks 4<br />

and Richard H. Osborne 2 , 1 Cabrini Medical Center, Malvern,<br />

Australia, 2 Deakin University, Melbourne, Australia, 3 Royal<br />

Melbourne Hospital, Melbourne, Victoria, Australia, 4 Royal<br />

Melbourne Hospital, Melbourne, Australia.<br />

1002. Multispecialty Unit for Infusion Therapy: Patient, Nursing and<br />

Provider Satisfaction. Barbara E. Ostrov, Kristine Reynolds and<br />

Lisabeth V. Scalzi, Penn State Hershey, Hershey, PA.<br />

1003. Rheumatoid Arthritis (RA) Disease Activity Assessment and<br />

Treatment Decisions in <strong>Rheumatology</strong> Practice. J. Timothy<br />

Harrington 6 , Leslie R. Harrold 4 , George Reed 5 , Hong Chang 3 , Joel<br />

M. Kremer 2 and Jeffrey D. Greenberg 1 , 1 Millburn, NJ, 2 The Center<br />

for <strong>Rheumatology</strong>, Albany, NY, 3 Tufts Medical School, 4 UMass<br />

Medical Schl, Worcester, MA, 5 UMass Medical Schl, 6 University<br />

<strong>of</strong> Wisconsin, Madison, WI.<br />

1004. Scleroderma QuERI: Reduced Utility <strong>of</strong> Echocardiography in<br />

Pulmonary Hypertension Screening in the Community. James<br />

R. Seibold 6 , Amparo Casanova 1 , Mary Tan 1 , Daniel E. Furst 5 ,<br />

Nicholas Hill 4 , Vallerie V. McLaughlin 7 , Richard M. Silver 3 , Virginia<br />

D. Steen 2 and Anatoly Langer 1 , 1 Canadian Heart Research<br />

Centre, 2 Georgetown University Medical Center, Washington,<br />

DC, 3 Medical University <strong>of</strong> South Carolina, Charleston, SC, 4 Tufts<br />

Medical Center, 5 University <strong>of</strong> California Los Angeles Medical<br />

School, Los Angeles, CA, 6 University <strong>of</strong> Connecticut Health<br />

Center, Farmington, CT, 7 University <strong>of</strong> Michigan.<br />

1005. Secondary Fracture Prevention in Home Health Care: Initial<br />

Results from a Group Randomized Trial. Meredith L. Kilgore 2 ,<br />

Jeffrey R. Curtis 4 , Ryan C. Outman 5 , Julie Locher 1 , Jeroan Allison 3<br />

and Kenneth G. Saag 5 , 1 Univ <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL, 2 Univ <strong>of</strong> Alabama at Birmingham, 3 Univ<br />

<strong>of</strong> Massachusetts, Worcester, MA, 4 University <strong>of</strong> Alabama<br />

- Brimingham, Birmingham, AL, 5 University <strong>of</strong> Alabama-<br />

Birmingham, Birmingham, AL.<br />

1006. Self-Scheduling <strong>of</strong> DXA Scans To Improve Osteoporosis<br />

Screening in Women. Amy H. Warriner 2 , Ryan C. Outman 5 ,<br />

Kenneth G. Saag 5 , Sarah L. Morgan 1 , Elizabeth Kitchin 3 and<br />

Jeffrey R. Curtis 4 , 1 U <strong>of</strong> Alabama in Birm, Birmingham, AL, 2 Univ<br />

<strong>of</strong> Alabama at Birmingham, 3 Univ <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL, 4 University <strong>of</strong> Alabama - Brimingham,<br />

Birmingham, AL, 5 University <strong>of</strong> Alabama-Birmingham,<br />

Birmingham, AL.<br />

1007. Spanning Generations: Appointment Reminder Preferences<br />

among Outpatient <strong>Rheumatology</strong> Patients. Carl Gauthier 3 ,<br />

William E. Davis 2 and Robert J. Quinet 1 , 1 Ochsner Med Ctr-New<br />

Orleans, New Orleans, LA, 2 Ochsner Med-Ctr-New Orleans, New<br />

Orleans, LA, 3 Ochsner Med-Ctr-New Orleans, Hammond, LA.<br />

1008. Survey <strong>of</strong> Teen Transition Needs among Pediatric<br />

Rheumatologists in the United States and Canada: Barriers,<br />

Services and Opportunities. Tova Ronis 3 , Stacy P. Ardoin 2 ,<br />

Patience H. White 1 and Peter Chira 3 , 1 Arthritis Foundation,<br />

Bethesda, MD, 2 Ohio State University, Columbus, OH, 3 Stanford<br />

University, Palo Alto, CA.<br />

1009. Testing Patient Knowledge about Methotrexate: Development<br />

and Validation <strong>of</strong> the Methotrexate in Rheumatoid Arthritis<br />

Knowledge Test (MiRAK). Sabina Ciciriello 3 , Ian Wicks 4 , Richard<br />

H. Osborne 2 and Rachelle Buchbinder 1 , 1 Cabrini Medical Center,<br />

Malvern, Australia, 2 Deakin University, Melbourne, Australia,<br />

3<br />

Royal Melbourne Hospital, Melbourne, Victoria, Australia,<br />

4<br />

Royal Melbourne Hospital, Melbourne, Australia.<br />

2010 Program Book 209


ACR/ARHP Poster Session B<br />

210<br />

1010. The Impact <strong>of</strong> the ACR Treatment Recommendations on<br />

Physician Prescribing in a U.S. Cohort <strong>of</strong> Rheumatoid Arthritis<br />

Patients. Leslie R. Harrold 3 , Jeffrey D. Greenberg 1 , Jeffrey R.<br />

Curtis 5 , Daniel E. Furst 6 , Mary Jane Bentley 4 , Ying Shan 4 , George<br />

Reed and J. Timothy Harrington 7 , 1 Millburn, NJ, 3 UMass Medical<br />

Schl, Worcester, MA, 4 Umass Medical School, 5 University<br />

<strong>of</strong> Alabama - Brimingham, Birmingham, AL, 6 University <strong>of</strong><br />

California Los Angeles Medical School, Los Angeles, CA,<br />

7<br />

University <strong>of</strong> Wisconsin, Madison, WI.<br />

1011. The Preliminary Testing <strong>of</strong> a Core Set To Monitor SLE Patients<br />

in Routine Clinical Practice. Marta Mosca 6 , Chiara Tani 6 ,<br />

Federico Quaglierini 6 , Katia Goehner 5 , Joao Matos Costa 2 , Oskar<br />

Psenak 3 , Magdalena Szmyrka-Kaczmarek 7 , Jan Sznajd 4 , Nuntana<br />

Kasitanon 1 and Stefano Bombardieri 6 , 1 Chiang Mai, University,<br />

Thailand, 2 Hospital de Santarem, Portugal, 3 Saltzbugr University,<br />

Austria, 4 University Hospital, Krakow, Poland, 5 University<br />

Hospital, Zurich, Switzerland, 6 University <strong>of</strong> Pisa, Italy, 7 Wroclaw<br />

University, Poland.<br />

1012. The Use <strong>of</strong> Electronic Health Record To Improve Tuberculosis<br />

Screening in Pediatric <strong>Rheumatology</strong> Patients Receiving<br />

Biologic Response Modifiers. David W. Moser 4 , Elaine Haddix 5 ,<br />

Mary Beth Burns 5 , James Brown 3 , Anna Carmela P. Sagcal-<br />

Gironella 4 , Thomas A. Griffin 1 , Hermine Brunner 2 and Esi M.<br />

Morgan DeWitt 6 , 1 Childrens Hospital Med Ctr, Cincinnati, OH,<br />

2<br />

Cincinnati Child Hosp Med Ctr, Cincinnati, OH, 3 Cincinnati<br />

Children’s Hospital, 4 Cincinnati Children’s Hospital Medical<br />

Center, Cincinnati, OH, 5 Cincinnati Children’s Hospital Medical<br />

Center, 6 Cincinnati Children’s Hospital, Cincinnati, OH.<br />

1013. Treating Rheumatoid Arthritis to Target: Multinational<br />

Recommendations Assessment Questionnaire. Boulos<br />

Haraoui 13 , Josef S. Smolen 18 , Daniel Aletaha 21 , Ferdinand<br />

C. Breedveld 4 , Maarten de Wit 25 , Maxime Dougados 8 , Paul<br />

Emery 2 , Allan Gib<strong>of</strong>sky 9 , Desiree M. Van Der Heijde 19 , Gerd R.<br />

Burmester 3 , Mario Cardiel-Rios 7 , Catalin Codreanu 1 , Patrick<br />

Durez 23 , Joao Eurico Fonseca 11 , Winfried B. Graninger 20 , Verdat<br />

Hamuryudan 12 , Maria Jose Jannaut-Pena, Jochen Kalden 14 , Tore<br />

K. Kvien 5 , Ieda Laurindo 6 , Carlomaurizio Montecucco 16 , Jose A.<br />

Pereira Da Silva 24 , Guyla Poor 22 , Pedro Ivan Santos Moreno 10 ,<br />

Ewa Stanislawska-Biernat 15 , Tsutomu Takeuchi 17 and and the<br />

Treat to Target Taskforce, 1 Center <strong>of</strong> Rheumatic Diseases,<br />

Bucharest, Romania, 2 Chapel Allerton Hospital, Leeds, United<br />

Kingdom, 3 Charite - University Medicine, Berlin, Germany,<br />

4<br />

Dept. <strong>of</strong> <strong>Rheumatology</strong>, Leiden University, Medical Centre,<br />

Leiden, The Netherlands, 5 Diakonhjemmet Hospital, Oslo,<br />

Norway, 6 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Sao Paolo,<br />

Brazil, 7 Facultad de Ciencias Medicas y Bioplogicas Dr. Ignacio<br />

Chavez UMSNH, Morelia, Michoacan, Mexico, 8 Hospital Cochin,<br />

Paris, France, 9 Hospital for Special Surgery, New York, NY,<br />

10<br />

Hospital Militar Central, Bogota, Colombia, 11 Hospital Santa<br />

Maria, Lisboa, Portugal, 12 Instanbul University, Cerrahpasa<br />

Medical School, Istanbul, Turkey, 13 Institut de Rhumatologie,<br />

Montreal, QC, Canada, 14 Institute for Clinical Immunology,<br />

Erlangen, Germany, 15 Institute <strong>of</strong> <strong>Rheumatology</strong>, Warszawa,<br />

Poland, 16 IRCCS Policlinico S Matteo, Pavia, Italy, 17 Keio<br />

University, Toyko, Japan, 18 Krankenhaus Lainz, Vienna, Austria,<br />

19<br />

Leiden University Medical Center, Meerssen, The Netherlands,<br />

20<br />

Medical University <strong>of</strong> Graz, Graz, Austria, 21 Medical University<br />

<strong>of</strong> Vienna, Vienna, Austria, 22 National Institute <strong>of</strong> <strong>Rheumatology</strong><br />

and Physiotherapy, Budapest, Hungary, 23 Universite Catholique<br />

de Louvain, Brussels, Belgium, 24 University <strong>of</strong> Coimbra, Protuga,<br />

Algés, Portugal, 25 VU Medical Centre, Department <strong>of</strong> Medical<br />

Humanities, Amsterdam, The Netherlands.<br />

2010 Program Book<br />

1014. Using an Electronic Data Capture System To Measure<br />

Outcomes in Patients on Biologic DMARD Therapy: The<br />

<strong>Rheumatology</strong> Health Tracker (RHT). Sita A. Narayanan 1 , Jeffrey<br />

R. Lisse 2 , Alexis A. Alvarez 4 , Catherine Lo, Rafael G. Grau 3 , Eric P.<br />

Gall 2 and Oscar Furet 4 , 1 Univ <strong>of</strong> Arizona, Tucson, AZ, 2 Univ <strong>of</strong> AZ<br />

Arthritis Ctr, Tucson, AZ, 3 Univ <strong>of</strong> AZ Arthritis Ctr, Indianapolis,<br />

IN, 4 Univ <strong>of</strong> AZ Arthritis Ctr.<br />

Rheumatoid Arthritis - Clinical Aspects: Clinical Features, Disease<br />

Risk Factors, Bone in RA, CVD II<br />

1015. Anti-Cyclic Citrullinated Peptide Antibodies in Rheumatoid<br />

Arthritis Patients with Lymphoma. Eva Baecklund 10 , Karin<br />

Ekström Smedby 3 , Carin Backlin 5 , Johan Rönnelid 2 , Erik Åhlin 2 ,<br />

Rene Toes 6 , Johan Askling 4 , Ephraim Hochberg 1 , Mandakolathur<br />

Murali 7 , Lars Klareskog 8 , Tom Huizinga 9 , Fred Hochberg 1 and<br />

Jonathan Kay 11 , 1 Cancer Center, Massachusetts General Hospital,<br />

Boston, 2 Clinical Immunology, Uppsala University, 3 Epidemiology<br />

Unit, Karolinska Institutet at Karolinska University Hospital,<br />

Stockholm, 4 Epidemiology, <strong>Rheumatology</strong>, Karolinska Institutet<br />

at Karolinska University Hospital, Stockholm, 5 Genetics and<br />

Pathology, Uppsala University, 6 Immunology, Leiden University<br />

Medical Center, 7 Immunology, Massachusetts General<br />

Hospital, Boston, 8 Karolinska University Hospital, Stockholm,<br />

Sweden, 9 <strong>Rheumatology</strong>, Leiden University Medical Center,<br />

10<br />

<strong>Rheumatology</strong>, Medical Sciences, Uppsala University, Uppsala,<br />

Sweden, 11 UMass Memorial Medical Center, Worcester, MA.<br />

1016. Assessment <strong>of</strong> Cardiovascular Risk in Rheumatoid Arthritis.<br />

Impact <strong>of</strong> the New EULAR Recommendations. Montserrat<br />

Robustillo, Carmen Gomez-Vaquero, Javier Narváez, Jesus<br />

Rodriguez-Moreno, Paula Estrada, Laura López-Vives and<br />

Joan M. Nolla, <strong>Rheumatology</strong> Service. Hospital Universitari de<br />

Bellvitge.<br />

1017. Association between Serum Osteoprotegerin Levels and<br />

Carotid Atherosclerotic Plaque in Patients with Rheumatoid<br />

Arthritis. Yu Asanuma, Yuki Shimada and Toshihide Mimura,<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Applied Immunology, Faculty<br />

<strong>of</strong> Medicine, Saitama Medical University.<br />

1018. Body Composition Trends in Patients with Rheumatoid<br />

Arthritis: Associations with Disease Characteristics and<br />

Inflammatory Markers. Henry R. Kramer 1 , Joan M. Bathon 1<br />

and Jon T. Giles 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Johns Hopkins<br />

University, Baltimore, MD, 2 Johns Hopkins Univ, Baltimore, MD.<br />

1019. Cardiovascular Risk Estimates in Rheumatoid Arthritis in<br />

the Netherlands. Inger L. Meek 3 , Harald E. Vonkeman 2 and<br />

Mart A. F. J. van de Laar 1 , 1 Enschede, The The Netherlands,<br />

2<br />

Enschede, The Netherlands, 3 <strong>Rheumatology</strong> Centre Twente,<br />

University Twente & Medisch Spectrum Twente, Enschede, The<br />

Netherlands.<br />

1020. Circulating Immune Complexes in Patients with Severe<br />

Extra-Articular Rheumatoid Arthritis Induce Tumour Necrosis<br />

Factor Production by Peripheral Blood Mononuclear Cells.<br />

Carl Turesson 1 , Linda Mathsson 3 , Lennart Jacobsson 1 , Gunnar<br />

Sturfelt 2 and Johan Rönnelid 3 , 1 Skåne University Hospital,<br />

Malmö, Sweden, 2 Skåne University Hospital, Lund, Sweden,<br />

3<br />

Uppsala University Hospital, Uppsala, Sweden.<br />

1021. Clinical and Laboratory Risk Factors <strong>of</strong> Cardiovascular<br />

Disease (CVD) in a Cohort <strong>of</strong> Greek Patients with Early<br />

Rheumatoid Arthritis (RA). Nikolaos Papadopoulos 3 , Georgios<br />

Tsiaousis 2 , Marios Katsounaros 1 , Dimitrios Baltzis 3 and Vasiliki<br />

Galanopoulou 3 , 1 B’ Internal Medicine Clinic, Papanikolaou<br />

General Hospital, Thessaloniki, Greece, 2 Cardiologist, Kastoria,<br />

Greece, 3 <strong>Rheumatology</strong> Unit, Papageorgiou General Hospital,<br />

Thessaloniki, Thessaloniki, Greece.


ACR/ARHP Poster Session B<br />

1022. Computed Tomographic Densitometry (CTD) for the Evaluation<br />

<strong>of</strong> Interstitial Lung Fibrosis in Rheumatoid Arthritis (RA).<br />

Dimitrios A. Pappas 3 , Jon T. Giles 4 , Ge<strong>of</strong>frey Connors 2 , Noah<br />

Lechtzin 2 , Joan M. Bathon 3 and Sonye Dan<strong>of</strong>f 1 , 1 Division<br />

<strong>of</strong> Pulmonary and Critical Care, Johns Hopkins University,<br />

Baltimore, MD, 2 Division <strong>of</strong> Pulmonary and Critical Care, Johns<br />

Hopkins University, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Johns Hopkins<br />

University, Baltimore, MD, 4 Johns Hopkins Univ, Baltimore, MD.<br />

1023. Cystatin C, Renal Function and Atherosclerosis in Rheumatoid<br />

Arthritis. Ratchaya Lertnawapan 2 , Aihua Bian 2 , Yong Hee Rho 2 ,<br />

Vivian Kawai 2 , Paolo Raggi 1 , Annette Oeser 2 , Joseph Solus 2 ,<br />

Tebeb Gebretsadik 2 , Ayumi Shintani 2 and Charles Michael Stein 2 ,<br />

1<br />

Emory University, Atlanta, GA, 2 Vanderbilt University, Nashville,<br />

Nashville, TN.<br />

1024. Depressive Symptoms and Perceived Communication around<br />

Shared Decision Making among Patients with Rheumatoid<br />

Arthritis. Jennifer L. Barton 1 , Laura Trupin 2 , Mary E.<br />

Margaretten 1 , Laura J. Julian 5 , Jonathan D. Graf 1 , John Imboden 2 ,<br />

Edward H. Yelin 4 and Dean Schillinger 3 , 1 UCSF, San Francisco, CA,<br />

2<br />

UCSF, 3 UCSF, Center for Vulnerable Populations at San Francisco<br />

General Hospital, 4 University <strong>of</strong> California, San Francisco, CA,<br />

5<br />

University <strong>of</strong> California San Francisco, San Francisco, CA.<br />

1025. Differences in the Autonomic Reactivity Pattern upon<br />

Various Stressors in Patients with Rheumatoid Arthritis. Olga<br />

Malysheva 2 , Petra Baum 2 , Anke Voitzsch 1 and Christoph G. O.<br />

Baerwald 2 , 1 University Hopital, Leipzig, Germany, 2 University<br />

Hospital, Leipzig, Germany.<br />

1026. Disease Specific Cardiovascular Risk Factors in Patients with<br />

Rheumatic Diseases. Stefan Kleinert 2 , Margret Breunig 1 , Hans<br />

Peter T. Tony 3 , Martin Feuchtenberger 4 , Stefanie Bouma 1 ,<br />

Angermann E. Christiane 1 , Georg Ertl 1 and Stefan Stoerk 1 ,<br />

1<br />

Department <strong>of</strong> Cardiology, Med. Klinik 1 , University <strong>of</strong><br />

Wuerzburg, 2 <strong>Rheumatology</strong> / Clinical Immunology, Med. Klinik 2 ,<br />

University <strong>of</strong> Wuerzburg, Wuerzburg, Germany, 3 <strong>Rheumatology</strong><br />

/ Clinical Immunology, Med. Klinik 2 , University <strong>of</strong> Wuerzburg,<br />

Wuerzburg, Germany, 4 <strong>Rheumatology</strong> / Clinical Immunology,<br />

Med. Klinik 2 , University <strong>of</strong> Wuerzburg.<br />

1027. Do Men and Women Cope Differently with Disease Impact <strong>of</strong><br />

Rheumatoid Arthritis, and If So, Why? Matthias Englbrecht 2 ,<br />

Laure Gossec 1 , Anita DeLongis 3 , Tore K. Kvien 4 , Marieke<br />

Scholte-Voshaar 6 , Tuulikki Sokka 5 and Schett Georg 2 , 1 APHP,<br />

<strong>Rheumatology</strong> B Department, Paris Descartes University,<br />

Medicine Faculty, Paris, France, 2 Department <strong>of</strong> Internal<br />

Medicine 3 , University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />

Germany, 3 Department <strong>of</strong> Psychology, University <strong>of</strong> British<br />

Columbia, Vancouver, Canada, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Diakonhjemmet Hospital, Oslo, Norway, 5 Jyvaskyla Central<br />

Hospital, Jyvaskyla, Finland, 6 <strong>Rheumatology</strong>, VU University<br />

Medical Center and Jan van Breemen Institute, Amsterdam,<br />

Netherlands.<br />

1028. Effects <strong>of</strong> HMG-CoA Reductase Inhibitor on Progression <strong>of</strong><br />

Carotid Intima-Media Thickness and Arterial Stiffness in<br />

Rheumatoid Arthritis – A Randomized Controlled Trial. Lai-<br />

Shan Tam 3 , Edmund K. Li 2 , Qing Shang 3 , Brian Tomlinson 3 , Vivian<br />

W. Lee 3 , Kenneth K. Lee 3 , Martin Li 3 , Woon-Pang Kuan 1 , Tena K.<br />

Li 3 , Lorraine Tseung 3 , Gabriel Yip 3 , Ben Freedman 4 and Cheuk-<br />

Man Yu 3 , 1 Hospital Selayang, Malaysia, 2 The Chinese University<br />

<strong>of</strong> Hong Kong, Hong Kong, China, 3 The Chinese University <strong>of</strong><br />

Hong Kong, 4 University <strong>of</strong> Sydney.<br />

1029. Elevated Prevalence <strong>of</strong> Hypothyroidism in Female<br />

Inflammatory Arthritis Patients in Primary Care Amplifies<br />

the Prevalence <strong>of</strong> Cardiovascular Disease. Hennie G.<br />

Raterman 2 , Mark M. J. Nielen 1 , Mike J. L. Peters 2 , Robert A.<br />

Verheij 1 , Francois G. Schellevis 1 and Michael T. Nurmohamed 2 ,<br />

1<br />

Netherlands Institute for Health Services Research (NIVEL),<br />

Utrecht, The Netherlands, 2 VU University Medical Center,<br />

Amsterdam, The Netherlands.<br />

1030. Elevations in ApoC-III Containing Apolipoprotein Complexes<br />

Predict Coronary Atherosclerosis Progression in Rheumatoid<br />

Arthritis Patients. Joan M. Bathon 3 , Michael Centola 4 , Jon T.<br />

Giles 2 , Nicholas Knowlton 5 , Joshua Wages 5 , Adam J. Payne 5 , Guy<br />

Cavet 1 and Petar Alaupovic 5 , 1 Crescendo Biosciences, Inc., South<br />

San Francisco, CA, 2 Johns Hopkins Univ, Baltimore, MD, 3 Johns<br />

Hopkins Univ Ste, Baltimore, MD, 4 Oklahoma Med Research<br />

Foundation, Oklahoma City, OK, 5 Oklahoma Medical Research<br />

Foundation, Oklahoma City, OK.<br />

1031. Factors Associated with Upper and Lower Gastrointestinal<br />

Perforation in a Cohort <strong>of</strong> Patients with Rheumatoid Arthritis.<br />

Jeffrey R. Curtis 5 , Angel Lanas 4 , Winifred Werther 2 , Ani John 2 ,<br />

David A. Johnson 1 and Kathy L. Schulman 3 , 1 Eastern Virginia<br />

Medical School, Norfolk, VA, 2 Genentech, a Member <strong>of</strong> the<br />

Roche Group, South San Francisco, CA, 3 Outcomes Research<br />

Solutions, Inc. Bolton, MA, 4 Universidad de Zaragoza, Zaragoza,<br />

Spain, 5 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL.<br />

1032. Fatigue in Inflammatory Arthritis: Clinical Characteristics, and<br />

Contributory Factors Following 6-Months <strong>of</strong> Anti-TNF Therapy.<br />

Patricia Minnock 1 , Barry Bresnihan 3 , Gabrielle McKee 2 , Oliver<br />

FitzGerald 3 and Douglas Veale 3 , 1 <strong>Rheumatology</strong> Rehabilitation,<br />

Our Lady’s Hospice and Care Services, Dublin, Dublin, Ireland,<br />

2<br />

School <strong>of</strong> Nursing & Midwifery, Trinity <strong>College</strong> Dublin, Dublin,<br />

Ireland, 3 St Vincent’s University Hospital, Dublin, Dublin, Ireland.<br />

1033. Favorable Changes in the Lipid Pr<strong>of</strong>ile in the First Year <strong>of</strong> Early<br />

Arthritis. Karin Britsemmer 1 , Dirkjan van Schaardenburg 1 ,<br />

Willem F. Lems 2 and Michael T. Nurmohamed 1 , 1 Jan van<br />

Breemen Institute Amsterdam, 2 VU University Medical Center<br />

Amsterdam.<br />

1034. Free Fatty Acids Are Associated with Insulin Resistance but<br />

Not Coronary Artery Atherosclerosis in Rheumatoid Arthritis.<br />

Michelle J. Ormseth 2 , Larry Swift 4 , Sergio Fazio 4 , MacRae F.<br />

Linton 4 , Cecilia P. Chung 3 , Paolo Raggi 1 , Young-Hee Rho 2 , Joseph<br />

Solus 4 , Annette M. Oeser 5 , Aihua Bian 4 , Tebeb Gebretsadik 4 ,<br />

Ayumi Shintani 4 and C. Michael Stein 4 , 1 Emory University,<br />

2<br />

Vanderbilt University, Nashville, TN, 3 Vanderbilt University,<br />

Baltimore, MD, 4 Vanderbilt University, 5 VUMC 23rd Ave South<br />

Pierce, Nashville, TN.<br />

1035. Gene-Environment Interaction Determines Interstitial<br />

Lung Disease in Rheumatoid Arthritis. Jose Felix Restrepo 2 ,<br />

Inmaculada del Rincon 4 , Ricardo Zuniga 3 , Samvel Pogosian 4 and<br />

Agustin Escalante 1 , 1 Univ <strong>of</strong> Texas HSC San Antonio, San Antonio,<br />

TX, 2 Univ <strong>of</strong> Texas HSC, San Antonio, San Antonio, TX, 3 University<br />

<strong>of</strong> Texas HSC, San Antonio, TX, 4 UTHSCSA, San Antonio, TX.<br />

1036. Glucocorticoid Use Is Not Associated with an Increased Risk<br />

<strong>of</strong> Cerebrovascular Accidents in Patients with Rheumatoid<br />

Arthritis. A Population-Based Study. Antonio Avina-Zubieta 1 ,<br />

Michal Abrahamowicz 2 , Hyon K. Choi 4 , M. Mushfiqur Rahman 1 ,<br />

Marie-Pierre Sylvestre 3 , John Esdaile 1 and Diane V. Lacaille 1 ,<br />

1<br />

Arthritis Res Centre <strong>of</strong> Canada, Vancouver, BC, Canada,<br />

2<br />

Department <strong>of</strong> Epidemiology and Biostatistics, McGill<br />

University, Montreal, QC, Canada, 3 Samuel Lunenfeld Research<br />

Institute, 4 Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />

2010 Program Book 211


ACR/ARHP Poster Session B<br />

212<br />

1037. Heptavalent Conjugate Pneumococcal Vaccine (Prevenarâ)<br />

Elicits Similar Antibody Responses as 23-Valent Polysaccharide<br />

Vaccine (PPV) in Adult Patients with Established Arthritis.<br />

Meliha C. Kapetanovic 1 , Carmen Roseman 2 , Göran Jönsson 1 ,<br />

Lennart Truedsson 3 , Tore Saxne 1 and Pierre Geborek 1 , 1 Dept<br />

<strong>of</strong> Clinical Sciences Lund, Section <strong>of</strong> Infectious Diseases, Lund<br />

University, Lund, Sweden, 2 Dept <strong>of</strong> Clinical Sciences Lund,<br />

Section <strong>of</strong> <strong>Rheumatology</strong>, Lund University, Lund, Sweden, 3 Dept<br />

<strong>of</strong> Laboratory Medicine, Section <strong>of</strong> Microbiology, Immunology<br />

and Glycobiology, Lund University, Lund, Sweden.<br />

1038. Higher Prevalence <strong>of</strong> Coexisting Papillary Thyroid Cancer<br />

as Well as Autoimmune Thyroid Diseases in Patients with<br />

Rheumatoid Arthritis. Yeon-Ah Lee 3 , Sang-Hoon Lee 1 , Ran<br />

Song 2 , Kyoung Min Son, Hyung-In Yang and Seung-Jae Hong 4 ,<br />

1<br />

Seoul, Korea, Republic <strong>of</strong>, 2 Korea, Republic <strong>of</strong>, 3 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, School <strong>of</strong><br />

Medicine, KyungHee University, Seoul, Korea, Republic <strong>of</strong>,<br />

4<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />

School <strong>of</strong> Medicine, KyungHee University.<br />

1039. Hospital-Based Surgical Procedures and the Risk <strong>of</strong><br />

Perioperative Cardiovascular Events: A Comparison Study<br />

<strong>of</strong> Rheumatoid Arthritis and Diabetes Mellitus Using the<br />

National Inpatient Sample <strong>of</strong> the Healthcare Cost and<br />

Utilization Project. Ali Yazdanyar 2 , Mary C. Wasko 3 , Kevin L.<br />

Kraemer 3 and Michael M. Ward 1 , 1 National Institute <strong>of</strong> Arthritis<br />

and Musculoskeletal and Skin Diseases, 2 St Luke’s Hospital,<br />

Bethlehem, PA, 3 University <strong>of</strong> Pittsburgh.<br />

1040. Hypogonadism in Males with Rheumatoid Arthritis. Dannette<br />

S. Johnson and Robert W. McMurray, G.V. (Sonny) Montgomery<br />

VA and University <strong>of</strong> Mississippi Medical Center, Jackson, MS.<br />

1041. Il-17 as a Novel Predictor <strong>of</strong> Vascular Damage in Rheumatoid<br />

Arthritis. Wendy Marder 2 , Shokoufeh Khalatbari 3 , James D.<br />

Myles 3 , Rita P. Hench 2 , Susan Lustig 1 , Robert D. Brook 1 and<br />

Mariana J. Kaplan 2 , 1 Division <strong>of</strong> Cardiology, University <strong>of</strong><br />

Michigan, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Michigan,<br />

Ann Arbor, MI, 3 Michigan Institute for Clinical and Health<br />

Research, Ann Arbor, MI.<br />

1042. Incidence <strong>of</strong> Progressive Interstitial Pneumonia in Patients<br />

with Rheumatoid Arthritis. Yuko Takahashi, Hiroyuki Yamashita,<br />

Yo Ueda, Yuji Yoshida, Hiroshi Kaneko and Akio Mimori, Division<br />

<strong>of</strong> Rheumatic Diseases, National Center for Global Health and<br />

Medicine, Shinjyuku-ku, Tokyo, Japan.<br />

1043. Infertility in Women with RA and Pregnancy Loss in Women<br />

with SLE Contribute to Smaller Than Desired Family<br />

Size. Megan E. B. Clowse 3 , Eliza F. Chakravarty 1 , Karen H.<br />

Costenbader 2 , Christine D. Chambers 5 and Kaleb D. Michaud 4 ,<br />

1<br />

Mountain View, CA, 2 Brigham & Women, Boston, MA, 3 Duke<br />

Univ Med, Durham, NC, 4 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE,<br />

5<br />

University <strong>of</strong> California, San Diego.<br />

1044. Interstitial Lung Disease in Rheumatoid Arthritis: Effect on<br />

Physical Function, Disability, Mental Health and Survival over<br />

a 10-Year Period. Inmaculada Del Rincon 2 , Jose Felix Restrepo 3 ,<br />

Mrisa Sahai 2 , Daniel F. Battafarano 1 , L. Ricardo Zuniga-Montes 2<br />

and Agustin Escalante 2 , 1 Brooke Army Medical Ctr, San Antonio,<br />

TX, 2 UTHSCSA, San Antonio, TX, 3 UTHSCSA, Bogota, Colombia.<br />

1045. Lower Extremity Ulcers in Rheumatoid Arthritis. David M.<br />

DeMaria 2 , Christopher E. Attinger 1 and Victoria K. Shanmugam 2 ,<br />

1<br />

Center for Wound Healing, Georgetown University Medical<br />

Center, Washington, DC, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Immunology and Allergy, Georgetown University Medical<br />

Center, Washington, DC.<br />

2010 Program Book<br />

1046. Lower Prevalence and Severity <strong>of</strong> “Vulnerable” Coronary<br />

Plaque in a-TNF-Exposed Asymptomatic Patients with<br />

Rheumatoid Arthritis (RA). George A. Karpouzas 1 , Naser<br />

Ahmadi 2 , Tae-Young Choi 2 , Fereshteh Hajsadeghi 2 , Silvia Munoz 2<br />

and Mathew Bud<strong>of</strong>f 2 , 1 Harbor-UCLA, Long Beach, CA, 2 Harbor-<br />

UCLA.<br />

1047. Measuring Therapeutic Adherence in Rheumatoid Arthritis<br />

(RA) Using a Medication Event Monitoring System (MEMS®).<br />

Christian A. Waimann, Maria F. Marengo, S<strong>of</strong>ia de Achaval,<br />

Vanessa L. Cox, Araceli Garcia Gonzalez, Marsha N. Richardson<br />

and Maria E. Suarez-Almazor, The University <strong>of</strong> Texas MD<br />

Anderson Cancer Center, Houston, TX.<br />

1048. Polyautoimmunity and Autoimmune Aggregation in<br />

Rheumatoid Arthritis. Adriana Rojas-Villarraga 1 , Ricardo A.<br />

Cifuentes 3 , Diana Botello-Corzo 3 , Antonio Iglesias-Gamarra 4 ,<br />

Ruben D. Mantilla 5 and Juan-Manuel Anaya 2 , 1 Center for<br />

Autoimmune Diseases Research (CREA), Universidad del<br />

Rosario, 2 CREA, Universidad del Rosario, Bogota, Colombia,<br />

3<br />

CREA, Universidad del Rosario, 4 <strong>Rheumatology</strong> Unit,<br />

Universidad Nacional, 5 Riesgo de Fractura-CAYRE IPS.<br />

1049. Prediction <strong>of</strong> 10-Year Cardiovascular and All-Cause Mortality<br />

in Rheumatoid Arthritis Using the Ankle-Brachial Index.<br />

Carlos Ramirez 3 , Agustin Escalante 2 , Mrisa Sahai 3 , Daniel F.<br />

Battafarano 1 , Samvel Pogosian 3 and Inmaculada Del Rincon 2 ,<br />

1<br />

Brooke Army Medical Ctr, San Antonio, TX, 2 UTHSCSA, San<br />

Antonio, TX, 3 UTHSCSA.<br />

1050. Prevalence and Predictors <strong>of</strong> Pain in Rheumatoid Arthritis<br />

Patients in DAS28 Remission. Yvonne C. Lee 1 , Jing Cui 3 , Bing<br />

Lu 2 , Michelle Frits 3 , Christine K. Iannaccone 3 , Nancy A. Shadick 4 ,<br />

Michael E. Weinblatt 4 and Daniel Hal Solomon 4 , 1 Brigham &<br />

Womens Hospital, Boston, MA, 2 Brigham and Women’s Hospital,<br />

Foxboro, MA, 3 Brigham and Women’s Hospital, Boston, MA,<br />

4<br />

Brigham and Womens Hospital, Boston, MA.<br />

1051. Rheumatoid Arthritis Patients in Clinical Remission Manifest<br />

Persistent Joint Inflammation on Histology and Imaging. Allen<br />

P. Anandarajah 1 , Ralf G. Thiele 2 , Johnny Monu 4 , Gwy-Suk Seo 3 ,<br />

Aqiba Bokhari 3 and Christopher T. Ritchlin 5 , 1 Univ <strong>of</strong> Rochester<br />

Med Ctr, Rochester, NY, 2 University <strong>of</strong> Rochester, Rochester,<br />

NY, 3 University <strong>of</strong> Rochester, 4 University <strong>of</strong> Rochester Med Ctr,<br />

5<br />

University <strong>of</strong> Rochester Medical Center, Rochester, NY.<br />

1052. Rheumatoid Arthritis Patients Receive Less Frequent Acute<br />

Reperfusion and Secondary Prevention after Myocardial<br />

Infarction. Sharon Van Doornum 4 , Caroline Brand 3 , Vijaya<br />

Sundararajan 1 , Andrew Ajani 3 and Ian Wicks 2 , 1 Monash<br />

University, 2 Royal Melbourne Hospital, Melbourne, Australia,<br />

3<br />

Royal Melbourne Hospital, 4 University <strong>of</strong> Melbourne, Victoria,<br />

Australia.<br />

1053. Risk Factors for Coronary Heart Diseases in Japanese Patients<br />

with Rheumatoid Arthritis: From a Large Observational<br />

Study, IORRA. Eiichi Tanaka 1 , Eisuke Inoue 3 , Toru Yamada 3 ,<br />

Ayako Nakajima 3 , Atsuo Taniguchi 3 , Shigeki Momohara 3 and<br />

Hisashi Yamanaka 2 , 1 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s<br />

Medical University, Tokyo, Japan, 2 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />

Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan,<br />

3<br />

Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s Medical University.<br />

1054. Risk <strong>of</strong> Acute Coronary Syndromes in Relation to TNF-<br />

Inhibition in Early Rheumatoid Arthritis. Lotta Ljung 5 , Julia<br />

F. Simard 3 , Lennart T. H. Jacobsson 4 , Solbritt M. Rantapaa-<br />

Dahlqvist 1 and Johan Askling 2 , 1 Umea, Sweden, 2 Clinical<br />

Epidemiology Unit, 3 Clinical Epidemiology Unit, Stockholm,<br />

Sweden, 4 Malmo University Hospital, Malmo, Sweden, 5 Umea<br />

University Hospital.


ACR/ARHP Poster Session B<br />

1055. Sonographic Guidance and the Injection <strong>of</strong> the Rheumatoid<br />

Joint. Courtney R. Johnson 4 , Natalia Chavez Chiang 1 , Suzanne<br />

Delea 1 , Hilliary Norton, Wilmer L. Sibbitt 2 and Arthur D.<br />

Bankhurst 3 , 1 Albuquerque, NM, 2 University <strong>of</strong> New Mexico HSC,<br />

Albuquerque, NM, 3 University <strong>of</strong> NM Med Ctr, Albuquerque,<br />

NM, 4 UNM Carrie Tingley Hospital, Albuquerque, NM.<br />

1056. Statin Discontinuation and Risk <strong>of</strong> Acute Myocardial Infarction<br />

in Rheumatoid Arthritis: A Population-Based Study. Mary A.<br />

De Vera 1 , Hyon K. Choi 5 , Michal Abrahamowicz 3 , Jacek Kopec 1 ,<br />

Maria Victoria Goycochea-Robles 4 and Diane V. Lacaille 2 ,<br />

1<br />

Arthritis Research Centre <strong>of</strong> Canada, Vancouver, BC, Canada,<br />

2<br />

Arthritis Research Ctr Canada, Vancouver, BC, Canada, 3 McGill<br />

University, Montreal, QC, Canada, 4 Research Unit <strong>of</strong> Clinical<br />

Epidemiology, Hospital Regional 1 IMSS, Mexico City, Mexico,<br />

5<br />

Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />

1057. Stroke in Rheumatoid Arthritis: (When) Is There an Increased<br />

Risk? Marie E. Holmqvist 1 , Lennart T. H. Jacobsson 3 , Lars<br />

Alfredsson 1 and Johan Askling 2 , 1 Karolinska Institutet,<br />

2<br />

Karolinska University Hospital, 3 Malmö University Hospital.<br />

1058. Subclinical Atherosclerosis in Patients with Rheumatoid<br />

Arthritis Is Associated with Decreased Activity <strong>of</strong> Lecithin<br />

Cholesterol Acyl: Transferase, a High Density Lipoprotein<br />

(HDL)-Associated Protein Involved in Reverse Cholesterol<br />

Transport. Christina Charles-Schoeman 2 , Yuen Yin Lee 3 , Sogol<br />

Amjadi 3 , John D. FitzGerald 4 , Veena K. Ranganath 2 , Mihaela<br />

Taylor 3 , Maureen A. McMahon 2 , Harold E. Paulus 1 and Srinivasa<br />

T. Reddy 3 , 1 Encino, CA, 2 UCLA School <strong>of</strong> Medicine, Los Angeles,<br />

CA, 3 UCLA School <strong>of</strong> Medicine, 4 UCLA School <strong>of</strong> Medicine<br />

Rehabilitation, Los Angeles, CA.<br />

1059. Symptomatic Heart Failure, NT-proBNP Levels, and Diastolic<br />

Dysfunction in RA-Patients with and without Anti-TNFa<br />

Therapy. A Prospective Consecutive Cohort Study. Michael<br />

Gottwald 1 , Denio Ridjab 2 , Stephanie Glocke 1 , Kathrin Behring 1 ,<br />

Robert Lange 3 , Christian Butter 1 and Michael Zaenker 1 , 1 EFKH<br />

and Heart Center Brandenburg, Bernau, Germany, 2 EFKH and<br />

Heart Center Brandenburg, Bernau, Germany, 3 Hospitalverbund<br />

and Rheumazentrum Nord-Brandenburg.<br />

1060. The Clinical Features <strong>of</strong> 13 Women with Microchimerism<br />

in Rheumatoid Nodules. Christopher J. Atkins 4 , William F. N.<br />

Chan 1 , David Naismith 6 , Nicholas van der Westhuizen 6 , Janet<br />

Woo 3 , Valerie Cortez 5 and J. Lee Nelson 2 , 1 Fred Hutchinson<br />

Cancer Research Center, 2 Fred Hutchinson Cancer Research<br />

Center and University <strong>of</strong> Washington, 3 University <strong>of</strong> British<br />

Columbia, 4 University <strong>of</strong> Victoria, Victoria, BC, Canada,<br />

5<br />

University <strong>of</strong> Washington, 6 Vancouver Island Health Authority.<br />

1061. The Clinical Implication <strong>of</strong> Anti-Cyclic Citrullinated Peptide<br />

Antibody in Late Onset Rheumatoid Arthritis. Se Jin Jung 3 ,<br />

Yoon Kang 3 , You-Jung Ha 3 , Kwang-Hoon Lee 3 , Sang Won Lee 3 ,<br />

Min-Chan Park 1 , Soo Kon Lee 2 and Yong-Beom Park, 1 Gangnam<br />

Severance Hospital, Seoul, Korea, Republic <strong>of</strong>, 2 Yonsei Univ<br />

<strong>College</strong> <strong>of</strong> Med, Seoul, Korea, Republic <strong>of</strong>, 3 Yonsei Univ <strong>College</strong><br />

<strong>of</strong> Med.<br />

1062. The Effect <strong>of</strong> Calcium and Vitamin D Supplementation on the<br />

Incidence <strong>of</strong> Rheumatoid Arthritis in the Women’s Health<br />

Initiative Randomized Study. Marius Racovan 10 , Brian Walitt 10 ,<br />

Christopher Collins 10 , Mary Pettinger 2 , Christine Parks 4 , James<br />

Shikany 6 , Jean Wactawski-Wende 8 , JoAnn E. Manson 1 , Larry<br />

Moreland 9 , Nicole Wright 7 , Rebecca Jackson 5 and Barbara V.<br />

Howard 3 , 1 Brigham and Women’s Hospital, Harvard Medical<br />

School, 2 Fred Hutchinson Cancer Research Center, 3 MedStar<br />

Research Institute, 4 National Institute <strong>of</strong> Enviromental Health<br />

Sciences, 5 Ohio State University, 6 University <strong>of</strong> Alabama,<br />

7<br />

University <strong>of</strong> Arizona, 8 University <strong>of</strong> Buffalo, 9 University <strong>of</strong><br />

Pittsburgh, 10 Washington Hospital Center.<br />

1063. The Impact <strong>of</strong> Rheumatoid Arthritis (RA) on Women: Focus<br />

on Pain, Productivity and Relationships. Vibeke Strand 2 , Paul<br />

Emery 1 , Scott Fleming 4 and Catherine Griffin 3 , 1 Chapel Allerton<br />

Hospital, Leeds, United Kingdom, 2 Division <strong>of</strong> Immunology and<br />

<strong>Rheumatology</strong>, Stanford University School <strong>of</strong> Medicine, Palo<br />

Alto, CA, 3 Echo Research, London, UK, 4 UCB, Slough, UK.<br />

1064. There Are No Differences in Lipids between RA Patients and<br />

Their Siblings, Despite Higher Incidence <strong>of</strong> CHD in RA. Namita<br />

Kumar, Nicola J. Marshall, David J. Walker and Philip N. Platt,<br />

University Hospital <strong>of</strong> North Durham.<br />

1065. Thigh Fat and Muscle in Rheumatoid Arthritis: Associations<br />

with Disease Features and Physical Functioning. Henry R.<br />

Kramer 1 , Kevin R. Fontaine 1 , Joan M. Bathon 1 and Jon T. Giles 2 ,<br />

1<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Johns Hopkins University, Baltimore,<br />

MD, 2 Johns Hopkins Univ, Baltimore, MD.<br />

1066. TNF Inhibitors and the Risk <strong>of</strong> Fracture in Rheumatoid<br />

Arthritis. Daniel Hal Solomon 3 , Seo Young Kim 1 , Jun Liu 2 , Claire<br />

Canning 2 and Sebastian Schneeweiss 2 , 1 Brigham and Women’s<br />

Hospital, Boston, MA, 2 Brigham and Women’s Hospital,<br />

3<br />

Brigham and Womens Hospital, Boston, MA.<br />

1067. Traditional and Novel Risk Markers for Atherosclerosis but<br />

Not Clinical Measures <strong>of</strong> Inflammatory Disease Are Associated<br />

with Atheromatous Plaque Presence in Early Inflammatory<br />

Polyarthritis-Results from the Norfolk Arthritis Register<br />

(NOAR). Hoda Mirjafari 3 , Suzanne M. M. Verstappen 2 , Diane<br />

Bunn 6 , Helena Edlin 5 , Valentine Charlton-Menys 4 , Philip<br />

Pemberton 5 , Tarnya Marshall 6 , Paddy Wilson 6 , Mark Lunt 2 ,<br />

Deborah P. Symmons 7 and Ian N. Bruce 1 , 1 Arthritis Research<br />

UK Epidemiology Unit, Stopford Building, The University <strong>of</strong><br />

Manchester, Manchester, United Kingdom, 2 Arthritis Research<br />

UK Epidemiology Unit, Stopford Building, The University <strong>of</strong><br />

Manchester, 3 Arthritis Research UK Epidemiology Unit, The<br />

University <strong>of</strong> Manchester, 4 Cardiovascular Research Group,<br />

The University <strong>of</strong> Manchester, 5 Manchester Royal Infirmary,<br />

6<br />

Norfolk and Norwich University Hospital, 7 Univ <strong>of</strong> Manchester,<br />

Manchester, United Kingdom.<br />

1068. Unaffected First-Degree Relatives <strong>of</strong> RA Patients Exhibit a High<br />

Prevalence <strong>of</strong> Joint Symptoms That Is Not Explained by the<br />

Presence <strong>of</strong> RA Autoantibodies: Studies in a Predisposed North<br />

<strong>American</strong> Native Population. Irene Smolik 3 , Qier Tan 3 , Xikui<br />

Wang 3 , Donna Hart 3 , Marianna Newkirk 1 , Charles N. Bernstein 3 ,<br />

David B. Robinson 3 and Hani S. El-Gabalawy 2 , 1 McGill University,<br />

2<br />

University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 3 University <strong>of</strong><br />

Manitoba.<br />

Rheumatoid Arthritis - Human Etiology and Pathogenesis II<br />

1069. ‘Shared’ T-Cell Clones Identified in Lymph Nodes and Synovial<br />

Tissue <strong>of</strong> Early Rheumatoid Arthritis Patients Using a Novel<br />

High Throughput Sequencing Technology. Paul L. Klarenbeek 4 ,<br />

Marjolein J. de Hair 4 , Stefano Alivernini 4 , Marleen G. van de<br />

Sande 4 , Marieke E. Doorenspleet 4 , Barbera D. van Schaik 3 ,<br />

Ferco H. Berger 2 , Rebecca E. Esveldt 4 , Antoine H. van Kampen 3 ,<br />

Danielle M. Gerlag 4 , Frank Baas 5 , Paul P. Tak 1 and Niek de<br />

Vries 4 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />

The Netherlands, 2 Dept <strong>of</strong> Radiology, Academic Medical<br />

Center-University <strong>of</strong> Amsterdam, 3 Dept. <strong>of</strong> Clin. Epidemiology,<br />

Biostatistics and Bioinformatics, Academic Medical Center-<br />

University <strong>of</strong> Amsterdam, 4 Div <strong>of</strong> Clin Immunology &<br />

<strong>Rheumatology</strong>, Academic Medical Center-University <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 5 Lab. For Genome<br />

Analysis, Academic Medical Center-University <strong>of</strong> Amsterdam.<br />

2010 Program Book 213


ACR Poster Session B<br />

214<br />

1070. Anticitrullinated Peptide Antibodies (ACPAS) in the Sera<br />

<strong>of</strong> Heavy Smokers without Arthritis. A Differential Role <strong>of</strong><br />

Associated Pulmonary Disease? Virginia Ruiz-Esquide 3 , María<br />

José Gómara 4 , Víctor Peinado 1 , José Alfredo Gómez Puerta 3 ,<br />

María Victoria Hernández 2 , Joan A. Barberà 1 , Julio Ramírez 3 ,<br />

Juan de Dios Cañete 3 , Isabel Haro 4 and Raimon Sanmartí 3 ,<br />

1<br />

Pneumology Service, Hospital Clínic <strong>of</strong> Barcelona, Barcelona,<br />

Spain, 2 <strong>Rheumatology</strong> Service, Hospital Clínic <strong>of</strong> Barcelona,<br />

Barcelona, Spain, 3 <strong>Rheumatology</strong> Service. Hospital Clínic <strong>of</strong><br />

Barcelona, Barcelona, Spain, 4 Unit <strong>of</strong> Synthesis and Biomedical<br />

Applications <strong>of</strong> Peptides, IQAC-CSIC, Barcelona, Spain.<br />

1071. Anti-Citrullinated Protein Antibodies (ACPA) in Unaffected<br />

Siblings <strong>of</strong> ACPA-Positive Rheumatoid Arthritis Patients. Lillian<br />

Barra 1 , Elizabeth Wilson 1 , Matthias Scinocca 1 , Kelly Summers 1 ,<br />

Ewa Cairns 2 and David A. Bell 2 , 1 The University <strong>of</strong> Western<br />

Ontario, 2 The University <strong>of</strong> Western Ontario, London, ON,<br />

Canada.<br />

1072. Atherogenic Properties <strong>of</strong> Rheumatoid Arthritis Plasma:<br />

Effect on Cholesterol Transport Genes. Allison B. Reiss 1 ,<br />

Iryna Voloshyna 1 , Michael Littlefield 1 , Elise Belilos 1 , Kristina<br />

Belostocki 2 , Lois A. Bonetti 1 , Gary C. Rosenblum 1 and Steven E.<br />

Carsons 1 , 1 Winthrop University Hospital, Mineola, NY, 2 Winthrop<br />

University Hospital, Jamaica, NY.<br />

1073. Circulating Cytokines Influence the Fetal Growth in Pregnant<br />

Women with Rheumatoid Arthritis. Florentien D. O. de<br />

Steenwinkel 2 , Johanna M. W. Hazes 1 , Yaël A. de Man 1 , Anita C.<br />

S. Hokken 2 , Yolanda B. de Rijke 2 and Radboud J. E. M. Dolhain 1 ,<br />

1<br />

Erasmus Medical Center, Rotterdam, The Netherlands,<br />

2<br />

Erasmus Medical Center/Sophia Children’s Hospital, Rotterdam,<br />

The Netherlands.<br />

1074. Citrullination and Peptidylarginine Deiminase (PAD) Expression<br />

Is Detected in the Oral Mucosa and Periodontium in the<br />

Absence <strong>of</strong> Rheumatoid Arthritis. Clifton O. Bingham 1 , Mark A.<br />

Reynolds 3 , Jon Giles 2 , Felipe Andrade 2 , Joan M. Bathon 2 , Karen<br />

Fox-Talbot 2 and Marc K. Halushka 2 , 1 Johns Hopkins, Baltimore,<br />

MD, 2 Johns Hopkins, 3 University <strong>of</strong> Maryland Dental School.<br />

1075. Common Genetic Background for Rheumatoid Arthritis and<br />

Systemic Lupus Erythematosus. Gisela Orozco, Steve Eyre, Anne<br />

Hinks, Wendy Thomson, Jane Worthington and Anne Barton,<br />

Arthritis Research Campaign Epidemiology Unit, The University<br />

<strong>of</strong> Manchester.<br />

1076. Confirmation <strong>of</strong> the Especial Interaction <strong>of</strong> Autoimmunity<br />

Against Citrullinated α-Enolase with Genotypes Predisposing<br />

to Rheumatoid Arthritis. Antonio Gonzalez 1 , Ariana Montes 2 ,<br />

Rebeca Dieguez-Gonzalez 2 , Manuel Calaza 2 , Eva Perez-Pampin 2 ,<br />

Antonio Mera 2 and Juan J. Gomez-Reino 2 , 1 Hospital Clinico<br />

Universitario de Santiago, Santiago de Compostela, A Coruña,<br />

Spain, 2 Hospital Clinico Universitario de Santiago.<br />

1077. C-Reactive Protein (CRP) Single Nucleotide Polymorphisms<br />

(SNPs) Are Associated with Radiographic Damage and Plasma<br />

CRP Levels in African <strong>American</strong>s (AAs) with Early Rheumatoid<br />

Arthritis (RA). Maria I. Danila 6 , Lang Chen 5 , Desiree M. Van<br />

Der Heijde 2 , Doyt L. Conn 1 , Beth L. Jonas 7 , Leigh F. Callahan 8 ,<br />

Edwin A. Smith 3 , Richard Brasington 10 , Larry W. Moreland 9 , S.<br />

Louis Bridges 6 and Laura B. Hughes 4 , 1 Emory Univ Schl <strong>of</strong> Med,<br />

Atlanta, GA, 2 Leiden University Medical Center, Meerssen, The<br />

Netherlands, 3 Med Univ <strong>of</strong> South Carolina, Charleston, SC, 4 Univ<br />

<strong>of</strong> Alabama Birmingham, Birmingham, AL, 5 Univ <strong>of</strong> Alabama-<br />

Birmingham, 6 Univ <strong>of</strong> Alabama-Birmingham, Birmingham,<br />

AL, 7 Univ <strong>of</strong> N Carolina-Chapel Hill, Chapel Hill, NC, 8 Univ <strong>of</strong><br />

North Carolina, Chapel Hill, NC, 9 Univ <strong>of</strong> Pittsburgh Med Ctr,<br />

Pittsburgh, PA, 10 Washington Univ Schl <strong>of</strong> Med, St Louis, MO.<br />

2010 Program Book<br />

1078. Differential Association <strong>of</strong> IL23R Genetic Variants with Anti-<br />

CCP Positive and Negative Rheumatoid Arthritis Patients.<br />

Antonio Gonzalez 6 , Aida Ferreiro 5 , Eva Perez-Pampin 5 , Manuel<br />

Calaza 5 , Francisco J. Lopez-Longo 13 , Jose Luis Marenco 12 ,<br />

Francisco J. Blanco 9 , Rafael Caliz 14 , Javier Narvaez 10 , Federico<br />

Navarro 15 , Juan Cañete 3 , Arturo R. de la Serna 8 , Isidoro<br />

Gonzalez-Alvarez 11 , Gabriel Herrero-Beaumont 1 , Jose Luis<br />

Pablos 2 , Alejandro Balsa 7 , Benjamin Fernandez-Gutierrez 4<br />

and Juan J. Gomez-Reino 5 , 1 Fundacion Jimenez Diaz. Madrid,<br />

2<br />

Hospital 12 de Octubre, Madrid, 3 Hospital Clinic. Barcelona,<br />

4<br />

Hospital Clinico San Carlos, Madrid, 5 Hospital Clinico<br />

Universitario de Santiago, 6 Hospital Clinico Universitario de<br />

Santiago, Santiago de Compostela, Spain, 7 Hospital La Paz .<br />

Madrid, 8 Hospital Santa Creu e San Pau. Barcelona, 9 Hospital<br />

Universitario A Coruña, 10 Hospital Universitario de Bellvitge.<br />

Barcelona, 11 Hospital Universitario de la Princesa, 12 Hospital<br />

Universitario de Valme. Sevilla, 13 Hospital Universitario Gregorio<br />

Marañon, Madrid, 14 Hospital Universitario Virgen de las Nieves,<br />

Granada, 15 Hospital Universitario Virgen Macarena, Sevilla.<br />

1079. DNA Damage, T Cell Lymphopenia and Immunosenescence in<br />

Rheumatoid Arthritis. Lan Shao 1 , Hiroshi Fujii 2 , Jorg J. Goronzy 1<br />

and Cornelia M. Weyand 1 , 1 Stanford University School <strong>of</strong><br />

Medicine, Stanford, CA, 2 Tohoku University School <strong>of</strong> Medicine,<br />

Sendai, Japan.<br />

1080. Do Patients with Rheumatoid Arthritis Exhibit Differential<br />

Cellular Responses to Implant Wear Debris and Do the Implant<br />

Failure Mechanisms Differ from Non-RA Patients? Anant<br />

Vasudevan 5 , Edward F. DiCarlo 3 , Timothy Wright 2 , Dan Chen 2 ,<br />

Steven R. Goldring 1 and Lisa A. Mandl 4 , 1 Chief Scientific Officer,<br />

Hospital for Special Surgery, 2 Department <strong>of</strong> Biomechanics,<br />

Hospital for Special Surgery, 3 Department <strong>of</strong> Pathology and<br />

Laboratory Medicine, Hospital for Special Surgery, 4 Hospital for<br />

Special Surgery, New York, NY, 5 Yale School <strong>of</strong> Medicine, New<br />

York, NY.<br />

1081. Dual Roles <strong>of</strong> Heme Oxygenase-1 on Rheumatoid Arthritis:<br />

Anti-Inflammation Versus Angiogenesis. Kaoru Takase 2 , Shigeru<br />

Ohno 1 , Mitsuhiro Takeno 3 and Yoshiaki Ishigatsubo 4 , 1 Center for<br />

Rheumatic Diseases, Yokohama City University Medical Center,<br />

2<br />

Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />

Yokohama City University Graduate School <strong>of</strong> Medicine, Japan,<br />

3<br />

Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />

Yokohama City University Graduate School <strong>of</strong> Medicine, Japan<br />

4<br />

Yokohama City Grad Sch <strong>of</strong> Med, Yokohama, Japan.<br />

1082. Epstein Barr Virus Serologies and Future Risk <strong>of</strong> Rheumatoid<br />

Arthritis among Women. Barbara L. Goldstein 2 , Lori B. Chibnik 2 ,<br />

Elizabeth W. Karlson 2 and Karen H. Costenbader 1 , 1 Brigham &<br />

Women, Boston, MA, 2 Brigham and Women’s Hospital, Boston,<br />

MA.<br />

1083. Expanded Cytokine/Chemokine Testing Improves Prediction<br />

<strong>of</strong> Time to Future Diagnosis <strong>of</strong> Seropositive Rheumatoid<br />

Arthritis (RA) in an Age-Dependent Manner. Kevin D. Deane 8 ,<br />

Colin I. O’Donnell 2 , Lezlie A. Derber 3 , Jess D. Edison 10 , William<br />

R. Gilliland 1 , Wolfgang Hueber 4 , Jeremy Sokolove 6 , Piyanka E.<br />

Chandra 7 , Jill Norris 9 , William Robinson 5 and V. Michael Holers 8 ,<br />

1<br />

Department <strong>of</strong> Medicine, <strong>Rheumatology</strong> Section, Walter<br />

Reed Army Medical Center, Washington, DC, 2 Department <strong>of</strong><br />

Preventive Medicine and Biometrics, University <strong>of</strong> Colorado<br />

Denver, Denver, CO, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong><br />

Colorado School <strong>of</strong> Medicine, Aurora, CO, 4 Novartis Institutes<br />

for BioMedical Research, Basel, Switzerland, 5 Stanford Univ<br />

School <strong>of</strong> Med, Stanford, CA, 6 Stanford University School <strong>of</strong><br />

Medicine, Palo Alto, Mountain View, CA, 7 Stanford University<br />

School <strong>of</strong> Medicine, Palo Alto, CA, 8 Univ <strong>of</strong> Colorado School <strong>of</strong><br />

Med, Aurora, CO, 9 University <strong>of</strong> Colorado Denver, Aurora, CO,<br />

10<br />

Walter Reed Army Med Ctr, Washington, DC.


ACR Poster Session B<br />

1084. Gene Expression Pr<strong>of</strong>iling in Rheumatoid Arthritis Patients<br />

Following B Cell Depletion with Rituximab Reveals Changes in<br />

Type I IFN Activity Related to Clinical Responsiveness. Saskia<br />

Vosslamber 1 , Hennie G. Raterman 2 , Tineke C. T. M. van der<br />

PouwKraan 2 , Micheal T. Nurmohamed 2 , Willem F. Lems 2 , Ben A.<br />

C. Dijkmans 2 , Alexandre E. Voskuyl 2 and Cornelis L. Verweij 2 , 1 VU<br />

University Medical Center, Amsterdam, The Netherlands, 2 VU<br />

University Medical Center.<br />

1085. Heterogeneity in the Bone Marrow B Cell Compartment:<br />

Implications for Pathogenesis <strong>of</strong> Human RA. Arumugam<br />

Palanichamy, Chris Cistrone, Jennifer Hossler, Chungwen Wei,<br />

James Kobie, Inaki Sanz and Jennifer Anolik, University <strong>of</strong><br />

Rochester Medical Center.<br />

1086. High Level <strong>of</strong> Serum Matrix Metalloproteinase-3 Could Be<br />

Implicated in the Pathogenesis <strong>of</strong> Rheumatoid Interstitial<br />

Lung Disease. Yoshinobu Koyama 3 , Kosuke Tsuruno 1 , Toshiyuki<br />

Ota 2 and Kenji Fujii 1 , 1 Center for Rheumatic Diseases, Iizuka<br />

Hospital, 2 Department <strong>of</strong> Laboratory and Transfusion Medicine,<br />

University <strong>of</strong> Occupational and Environmental Health, 3 Iizuka<br />

Hospital, Iizuka, Japan.<br />

1087. Identification <strong>of</strong> Genes Associated with Erosion in Cohorts<br />

<strong>of</strong> Patients with Early Arthritis. Amir Kadi 5 , Brigitte Izac 5 ,<br />

Jean-Philippe Jais 3 , Thierry Lequerre 4 , Olivier Vittecoq 4 , Xavier<br />

Le Loet 4 , Philippe Dieude 1 , Corinne Miceli 3 , Maxime Breban 2<br />

and Gilles Chiocchia 5 , 1 AP-HP, Paris, France, 2 AP-HP, Boulogne-<br />

Billancourt, France, 3 AP-HP, 4 CHU Rouen, 5 Inserm U1016 / CNRS<br />

UMR8104, Paris, France.<br />

1088. In Early RA, Serum Increase <strong>of</strong> IL-21 Is Associated with<br />

Serum Level <strong>of</strong> IL-6, Autoantibody Secretion, Markers <strong>of</strong><br />

B-Cell Activation, and Radiographic Progression. Jacques-Eric<br />

Gottenberg 4 , Pascale Roux-Lombard 2 , Alain Cantagrel 5 , Alain<br />

Saraux 1 , Cedric Lukas 3 , Jean-Michel Dayer 2 and Xavier Mariette,<br />

1<br />

Brest Hospital, 2 Geneva Hospital, 3 Montpellier Hospital,<br />

4<br />

Strasbourg Hospital, 5 Toulouse Hospital.<br />

1089. Strong Activation <strong>of</strong> Dopamine Pathway in Synovial Tissue<br />

from Rheumatoid Arthritis Patients: New Target <strong>of</strong> Pathology?<br />

Silvia Capellino 1 , Christine Wolff 2 , Franca Marino 3 , Alessandra<br />

Luini 3 , Marco Cosentino 3 and Rainer H. Straub 1 , 1 University<br />

Hospital Regensburg, Dept. <strong>of</strong> Internal Medicine I, Regensburg,<br />

Germany, 2 University Hospital Regensburg, Dept. <strong>of</strong> Internal<br />

Medicine I, Regensburg, Germany, 3 University <strong>of</strong> Insubria,<br />

Varese, Italy.<br />

1090. T-Cell Subsets Dys-Regulation and Cytokines Are Predictive<br />

<strong>of</strong> RA Pathogenesis in an ACPA-Positive Background. Richard<br />

Cuthbert 2 , Rekha Parmar 2 , Jackie Nam 2 , Edith Villeneuve 2 , Diane<br />

Corscadden 2 , Karen Henshaw 2 , Paul Emery 1 and Frederique<br />

Ponchel 2 , 1 Chapel Allerton Hospital, Leeds, United Kingdom,<br />

2<br />

University <strong>of</strong> Leeds.<br />

1091. The Development <strong>of</strong> the ACPA Repertoire Prior to the Onset<br />

<strong>of</strong> Clinical RA. Lotte A. van de Stadt 4 , Margret de Koning 2 , Rob<br />

J. van de Stadt 1 , Gertjan Wolbink 2 , B. A. C. Dijkmans 5 , Dörte<br />

Hamann 3 and Dirkjan van Schaardenburg 2 , 1 Jan van Breemen<br />

Institiute, 2 Jan van Breemen Institute, 3 Sanquin Diagnostics,<br />

4<br />

Sanquin Research, 5 VU Medical Centre, Amsterdam, The<br />

Netherlands.<br />

1092. The Differential Effect <strong>of</strong> HLA-DRB1 *0901 Allele from Shared<br />

Epitope on the Development <strong>of</strong> Rheumatoid Arthritis. So-<br />

Young Bang 1 , Hye-Soon Lee 1 , Ji-Seon Lee 1 , Eun-Mi Kim 1 , Kyung<br />

Wha Lee 2 and Sang-Cheol Bae 1 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Hanyang University Hospital for Rheumatic Diseases, Korea,<br />

Republic <strong>of</strong>, 2 Hallym Institute for Genome Application, Hallym<br />

University Sacred Heart Hospital, Anyang, Korea, Republic <strong>of</strong>.<br />

1093. The Smoking-Induced Heat Shock Protein DNAjC6 Is<br />

Downregulated in Rheumatoid Arthritis. Caroline Ospelt 1 ,<br />

Joanna Stanczyk 2 , Christoph Kolling 3 , Renate E. Gay 1 and Steffen<br />

Gay 4 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong> and Center <strong>of</strong><br />

Integrative Human Physiology, Zurich, Switzerland, 2 Center <strong>of</strong><br />

Experimental <strong>Rheumatology</strong> and Center <strong>of</strong> Integrative Human<br />

Physiology, Zurich, Switzerland, 3 Schulthess Clinic Zurich,<br />

Switzerland, 4 University Hospital Zurich, Zurich, Switzerland.<br />

1094. Variability <strong>of</strong> Anti-CCP Kit Testing in Cohorts with and without<br />

RA. Kevin D. Deane 7 , Kristen Demoruelle 10 , Mark Parish 4 ,<br />

Whitney Hilton 4 , Lauren Harrington 4 , Lezlie Derber 4 , Jason R.<br />

Kolfenbach 6 , Jan M. Hughes-Austin 4 , Michael H. Weisman 3 ,<br />

Ted R. Mikuls 14 , James R. O’Dell 8 , Richard M. Keating 1 , Peter K.<br />

Gregersen 5 , Jane Buckner 2 , Irene Smolik 13 , Donna Hart 13 , Charles<br />

N. Bernstein 13 , David B. Robinson 12 , Jill Norris 9 , V. Michael<br />

Holers 7 and Hani S. El-Gabalawy 11 , 1 Oak Park, IL, 2 Benaroya<br />

Research Institute at Virginia Mason, Seattle, WA, 3 Cedars-Sinai<br />

Medical Center, Los Angeles, CA, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

University <strong>of</strong> Colorado School <strong>of</strong> Medicine, Aurora, CO, 5 N<br />

Shore Univ Hosp Rsch Ctr, Manhasset, NY, 6 Univ <strong>of</strong> CO Schl <strong>of</strong><br />

Med, Aurora, CO, 7 Univ <strong>of</strong> Colorado School <strong>of</strong> Med, Aurora, CO,<br />

8<br />

University <strong>of</strong> Nebraska Medical Center, Omaha, NE, 9 University<br />

<strong>of</strong> Colorado Denver, Aurora, CO, 10 University <strong>of</strong> Colorado School<br />

<strong>of</strong> Medicine, 11 University <strong>of</strong> Manitoba, Winnipeg, MB, Canada,<br />

12<br />

University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 13 University <strong>of</strong><br />

Manitoba, 14 University <strong>of</strong> Nebraska Medical Center, Omaha, NE.<br />

Rheumatoid Arthritis Treatment - Small Molecules, Biologics<br />

and Gene Therapy: Predicting and Measuring Outcomes, Novel<br />

Compounds II<br />

1095. A Phase IIa, Randomized, Double-Blind, Placebo-Controlled<br />

Clinical Study <strong>of</strong> Apilimod Mesylate, an Oral IL-12/IL-23<br />

Inhibitor, in Patients with Active Rheumatoid Arthritis. Sarah<br />

Krausz 3 , Maartje J. H. Boumans 3 , Daniëlle M. Gerlag 3 , Joelle<br />

Lufkin 4 , Arno W. R. van Kuijk 2 , Alian A. B. Bakker 3 , Maarten de<br />

Boer 3 , Beatrijs M. Lodde 3 , Kris A. Reedquist 3 , Eric W. Jacobson 4 ,<br />

Michael O’Meara 4 and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />

Center/University <strong>of</strong> Amsterdam, 3 Academic Medical Center-<br />

University <strong>of</strong> Amsterdam, 4 Synta Pharmaceuticals Corp.<br />

1096. ALD518 (BMS945429), a High-Affinity Anti-Interleukin-6<br />

Monoclonal Antibody, Provides Improvements in Health-<br />

Related Quality <strong>of</strong> Life (HRQoL) in Patients with Rheumatoid<br />

Arthritis (RA) and an Inadequate Response to Methotrexate.<br />

Vibeke Strand 3 , Levan Shalamberidze 6 , Aleksandar Dimic 4 ,<br />

Jeffrey Smith 1 , Robin Mukherjee 2 and Philip Mease 5 , 1 Alder<br />

Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb,<br />

Princeton, NJ, 3 Division <strong>of</strong> Immunology/<strong>Rheumatology</strong>, Stanford<br />

University, Palo Alto, CA, 4 Institute <strong>of</strong> Rehabilitation and<br />

Treatment, Niska Banja, Serbia, 5 Swedish Medical Center and<br />

University <strong>of</strong> Washington, Seattle, WA, 6 V. Tsitlanadze Scientific<br />

Practical Centre <strong>of</strong> <strong>Rheumatology</strong>, Tbilisi, Georgia.<br />

1097. Assessment <strong>of</strong> Inflammation and Damage by MRI in<br />

Established RA Patients with Methotrexate Inadequate<br />

Response Receiving Golimumab: Results <strong>of</strong> the GO-FORWARD<br />

Trial. Philip G. Conaghan 3 , Paul Emery 4 , Mikkel Østergaard 5 ,<br />

Ed C. Keystone 8 , Mark C. Genovese 7 , Lars Klareskog 6 , Weichun<br />

Xu 1 , Elizabeth C. Hsia 2 and Mahboob U. Rahman 2 , 1 Centocor<br />

Research and Development, Inc., 2 Centocor Research and<br />

Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />

Malvern, PA, 3 Chapel Allerton Hospital, Leeds, United Kingdom,<br />

4<br />

Chapel Allerton Hospital, Leeds, United Kingdom, 5 Copenhagen<br />

University Hospital at Glostrup and Hvidovre, 6 Karolinska<br />

University Hospital, Stockholm, Sweden, 7 Stanford University,<br />

Sunnyvale, CA, 8 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

2010 Program Book 215


ACR/ARHP Poster Session B<br />

1098. Biomarkers Predictors <strong>of</strong> Good EULAR Response to B Cell<br />

Depletion Therapy (BCDT) in Seropositive Rheumatoid Arthritis<br />

Patients. Gianfranco Ferraccioli 3 , Barbara Tolusso 3 , Francesca<br />

Bobbio Pallavicini 4 , Elisa Gremese 3 , Viviana Ravagnani 1 , Maurizio<br />

Benucci 5 , Edoardo Podesta’ 2 , Fabiola Atzeni 6 , Giusy Peluso 3 ,<br />

G. Biasi 1 , Mariangela Manfredi 5 , Piercarlo Sarzi Puttini 6 , Bruno<br />

Lagana’ 2 and Carlomaurizio Montecucco 4 , 1 Department <strong>of</strong><br />

Clinical and Experimental Medicine, Section <strong>of</strong> <strong>Rheumatology</strong> &<br />

Internal Medicine, University <strong>of</strong> Verona, Verona, Italy, 2 Division<br />

<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, S. Andrea University<br />

Hospital, “Sapienza” University <strong>of</strong> Rome, II School <strong>of</strong> Medicine,<br />

Rome, Italy, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Catholic University<br />

<strong>of</strong> the Sacred Heart, Rome, Italy, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

University <strong>of</strong> Pavia, IRCCS S. Matteo Foundation, Pavia, Italy,<br />

5<br />

<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Internal Medicine,<br />

Ospedale di S. Giovanni di Dio, Florence, Italy, 6 <strong>Rheumatology</strong><br />

Unit, University Hospital L. Sacco, Milan, Italy.<br />

1099. Candidate Gene Analysis in US Veteran Rheumatoid Arthritis<br />

Patients with Clinical Improvement during Treatment with<br />

Anti-Tumor Necrosis Factor Agents in the Veterans Affairs<br />

Rheumatoid Arthritis (VARA) Registry. Grant W. Cannon 5 ,<br />

Roger K. Wolff 5 , Jian Ying 8 , Candace L. Hayden 6 , Brian C. Sauer 6 ,<br />

Jeffrey R. Curtis 7 , Dannette S. Johnson 3 , Gail S. Kerr 9 , J. Steuart<br />

Richards 10 , Liron Caplan 2 , Andreas Reimold 1 and Ted R. Mikuls 4 ,<br />

1<br />

Dallas VA and University <strong>of</strong> Texas Southwestern, 2 Denver<br />

VA and University <strong>of</strong> Colorado, 3 Jackson VA and University <strong>of</strong><br />

Mississippi, 4 Omaha VA and University <strong>of</strong> Nebraska, 5 Salt Lake<br />

City VA and University <strong>of</strong> Utah, Salt Lake City, UT, 6 Salt Lake City<br />

VA and University <strong>of</strong> Utah, 7 University <strong>of</strong> Alabama, 8 University<br />

<strong>of</strong> Utah, 9 Washington DC VA and Georgetown and Howard<br />

Universities, 10 Washington DC VA and Georgetown University.<br />

1100. CCR1 Antagonist CCX354-C in Phase 2 Clinical Development<br />

for Rheumatoid Arthritis. Daniel J. Dairaghi, Vittorio Marchesin,<br />

Daniel A. Johnson, Shichang Miao, Lisa C. Seitz, Yu Wang,<br />

Penglie Zhang, Jay P. Powers, Bert Ho, Pirow J. Bekker, Juan C.<br />

Jaen and Thomas J. Schall, ChemoCentryx.<br />

1101. Change in CRP at 12 Weeks Predicts the Risk <strong>of</strong> Rapid<br />

Radiographic Progression at 2 Years in Methotrexate-Treated<br />

Patients with Early Rheumatoid Arthritis. Boulos Haraoui 4 ,<br />

Paul Emery 3 , Neelufar Mozaffarian 1 , Benoit Guerette 2 ,<br />

Hartmut Kupper 2 , Kaushik Patra 2 and Ed C. Keystone 5 , 1 Abbott<br />

Laboratories, Abbott Park, IL, 2 Abbott Laboratories, 3 Chapel<br />

Allerton Hospital, Leeds, United Kingdom, 4 Institut de<br />

Rhumatologie, Montreal, QC, Canada, 5 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada.<br />

1102. Clinical and Radiographic Implications <strong>of</strong> Time to Treatment<br />

Response in Patients with Early Rheumatoid Arthritis. Ed<br />

C. Keystone 7 , Michael E. Weinblatt 4 , Boulos Haraoui 5 , Benoit<br />

Guerette 2 , Neelufar Mozaffarian 1 , Kaushik Patra 3 and Arthur<br />

Kavanaugh 6 , 1 Abbott Laboratories, Abbott Park, IL, 2 Abbott<br />

Laboratories, France, 3 Abbott Laboratories, 4 Brigham &Womens<br />

Hospital, Boston, MA, 5 Institut de Rhumatologie, Montreal,<br />

QC, Canada, 6 University <strong>of</strong> California-San Diego, La Jolla, CA,<br />

7<br />

University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

1103. Composite Remission Using Clinical, Structural, and Functional<br />

Criteria in Patients with Rheumatoid Arthritis (RA) Treated<br />

with Etanercept. Mark C. Genovese 4 , Andrew S. Koenig 3 , Grace<br />

S. Park 1 and Scott W. Baumgartner 2 , 1 Amgen Inc., Thousand<br />

Oaks, CA, 2 Amgen, Inc., Thousand Oaks, CA, 3 Pfizer Inc., Blue<br />

Bell, PA, 4 Stanford University, Sunnyvale, CA.<br />

1104. DAS-Driven Therapy Versus Routine Care in Patients with<br />

Recent-Onset Active Rheumatoid Arthritis: Data from the<br />

GUEPAR Trial and ESPOIR Cohort. Martin Soubrier 1 , Cédric<br />

Lukas 2 , Jean Sibilia 3 , Bruno Fautrel 5 , Laure Gossec 4 , Simon<br />

Patternotte 4 and Maxime Dougados 4 , 1 CHU Clermont-Ferrand,<br />

Sevice de Rhumatologie, F-63003, Clermont-Ferrand, Puy-dedôme,<br />

France, 2 CHU Montpellier, Service de Rhumatologie,<br />

F-34295 Montpellier, France, 3 CHU Strasbourg, Service de<br />

Rhumatologie, Strasbourg, France, 4 Hôpital Cochin, Service de<br />

Rhumatologie, F-75014, Paris, France, 5 Hôpital Pitié-Salpétrière,<br />

Service de Rhumatologie, F-75013, Paris, France.<br />

1105. Differential Serum Glycosylation Changes in Rheumatoid and<br />

Psoriatic Arthritis – In Response to Anti-TNF Therapy. Azita<br />

Alavi 1 , Oliver M. FitzGerald 3 , Emily S. Collins 4 , Owen Fraser 2 ,<br />

Edward Tarelli 1 , Chin Teck Ng 4 , Barry Bresnihan 5 , Douglas J.<br />

Veale 4 and John S. Axford 1 , 1 St. Georges University <strong>of</strong> London,<br />

London, United Kingdom, 2 St. Georges University <strong>of</strong> London,<br />

London, United Kingdom, 3 St. Vincent’s University Hospital,<br />

Dublin, Ranelagh Dublin, Ireland, 4 St. Vincent’s University<br />

Hospital, Dublin, Dublin, Ireland, 5 St. Vincent’s University<br />

Hospital, Dublin, Co. Dublin, Ireland.<br />

1106. Double-Blind, Randomized, Controlled, Placebo-Included, Pilot<br />

Study Comparing Classical Ayurvedic Medicine, Methotrexate,<br />

and Their Combination in RA. Daniel E. Furst 3 , Manorama<br />

M. Venkatraman 4 , Mary McGann 1 , P. Ram Manohar 1 , Cathryn<br />

Booth-LaForce 4 , Dinesh Khanna 2 , K. G. Raveendran 1 , Reshmi<br />

Sarin 1 , Anita Mahapatra 1 , Jidesh Gopinath 1 and P. R. Krishna<br />

Kumar 1 , 1 The Ayurvedic Trust, 2 UCLA, 3 University <strong>of</strong> California<br />

Los Angeles Medical School, Los Angeles, CA, 4 University <strong>of</strong><br />

Washington.<br />

1107. HM-A42, a Novel Inhibitor <strong>of</strong> IKKβ Kinase Reverses Clinical<br />

and Histological Disease Parameters in Multiple Autoimmune<br />

Disease Models. Yu Cai 1 , Xinrong Wang 1 , Ping Ren 1 , Changwu<br />

Lu 1 , Jianlin He 1 , Xiaoming Dai 3 , Qianqian Dong 1 , Jun Yu 3 , Lei<br />

Fang 2 , Xiaoning Yang 1 , Lei Jiang 3 , Jia Li 1 , Weifang Xue 1 , Pingmin<br />

Tang 1 , Jian Wang 1 , Fang Yin 3 , Yongjuan Yu 3 , Jingshui Li 3 , Yang Sai 3 ,<br />

James Yan 3 , Jianguo Ji 3 , Weiguo Qing 3 , Weiguo Su 3 and Haoran<br />

Zhao 1 , 1 Hutchison MediPharma Ltd, Shanghai, China, 2 Hutchison<br />

MediPharma Ltd, Shanghai, China, 3 Hutchison MediPharma Ltd.<br />

1108. Impact <strong>of</strong> Genetic Interactions on Response to Adalimumab<br />

Plus Methotrexate Versus Methotrexate Alone: Six Month<br />

Results <strong>of</strong> the OPTIMA Trial. Alla Skapenko 3 , Kaushik Patra 2 ,<br />

Hartmut Kupper 1 and Hendrik Schulze-Koops 3 , 1 Abbott GmbH &<br />

Co. KG, Ludwigshafen, Germany, 2 Abbott Laboratories, Abbott<br />

Park, IL, 3 University <strong>of</strong> Munich, Munich, Germany.<br />

1109. Improved Disease Control in Response to Tocilizumab Therapy<br />

Is Accompanied by Decreased Platelet Reactivity in Patients<br />

with Rheumatoid Arthritis. Paul A. MacMullan 3 , Anne M.<br />

Madigan 1 , Paola Bagaglia 2 , Dermot Kenny 3 and Geraldine M.<br />

McCarthy 1 , 1 Mater Misericordiae Univ. Hosp, Dublin, Ireland,<br />

2<br />

Mater Misericordiae Univ. Hosp, Dublin, Ireland, 3 RCSI, Dublin,<br />

Ireland.<br />

1110. In Patients with Early Inflammatory Polyarthritis, ACPA<br />

Positivity and Inefficacy <strong>of</strong> the First DMARD Are Associated<br />

with the Need To Start a Biologic Later on: Results from the<br />

Norfolk Arthritis Register (NOAR). S. M. M. Verstappen 1 ,<br />

M. Lunt 1 , D. K. Bunn 2 , D. G. I. Scott 2 and D. P. M. Symmons 1 ,<br />

1<br />

Arthritis Research UK Epidemiology Unit, The University <strong>of</strong><br />

Manchester, Manchester, United Kingdom, 2 Norfolk Arthritis<br />

Register, Norfolk and Norwich University Hospital, Norwich,<br />

United Kingdom, United Kingdom.<br />

216<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

1111. Increasing Chance <strong>of</strong> Remission in Patients with Rheumatiod<br />

Arthritis. Anja Strangfeld 1 , Maria Eveslage 3 , Martin Aringer 4 ,<br />

Rainer Dockhorn 5 , Matthias Schneider 6 , Joachim Listing 3<br />

and Angela Zink 2 , 1 German Rheumatism Research Center,<br />

Berlin, Germany, 2 German Rheumatism Research Center and<br />

Charité University Medicine Berlin, 3 German Rheumatism<br />

Research Center, Berlin, 4 Rheumatologist, Dresden, Germany,<br />

5<br />

Rheumatologist, Weener, Weener, Germany, 6 Scientific<br />

Advisory Board, Düsseldorf.<br />

1112. Influence <strong>of</strong> ESR on EULAR Response Rates in Patients Treated<br />

with Tocilizumab. Results from the German Biologics Register<br />

RABBIT. Anja Strangfeld 1 , Maria Eveslage 1 , Joachim Listing 1 ,<br />

Peter Herzer 5 , Anke Liebhaber 4 , Brigitte Krummel-Lorenz 3<br />

and Angela Zink 2 , 1 German Rheumatism Research Center,<br />

Berlin, Germany, 2 German Rheumatism Research Center and<br />

Charité Berlin, Berlin, Germany, 3 Rheumatologist Frankfurt/M,<br />

Frankfurt, Germany, 4 Rheumatologist Halle/S, Halle/Saale,<br />

Germany, 5 Scientific Advisory Board, Munich, Munich, Germany.<br />

1113. Joint Space Narrowing Has a Stronger Impact on Physical<br />

Function Than Joint Erosion: Results from 8-Year Longitudinal<br />

Analyses. Desiree M. Van Der Heijde 2 , Robert Landewe 3 , Benoit<br />

Guerette 1 , Sanjoy Roy 1 , Kaushik Patra 1 and Ed C. Keystone 4 ,<br />

1<br />

Abbott Laboratories, 2 Leiden University Medical Center,<br />

Meerssen, The Netherlands, 3 Univ Hosp Maastricht, Maastricht,<br />

The Netherlands, 4 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

1114. Magnetic Resonance Imaging Assessments <strong>of</strong> Patients with<br />

RA and Their Association with Clinical and Radiographic<br />

Outcomes. Paul Emery 3 , Desiree M. Van Der Heijde 6 , Mikkel<br />

Østergaard 5 , Philip G. Conaghan 4 , Mark C. Genovese 7 , Ed<br />

C. Keystone 9 , Roy M. Fleischmann 8 , Weichun Xu 1 , Stephen<br />

Xu 1 , Elizabeth C. Hsia 2 and Mahboob U. Rahman 2 , 1 Centocor<br />

Research and Development, Inc., 2 Centocor Research and<br />

Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />

Malvern, PA, 3 Chapel Allerton Hospital, Leeds, United Kingdom,<br />

4<br />

Chapel Allerton Hospital, Leeds, United Kingdom, 5 Copenhagen<br />

University Hospital at Glostrup and Hvidovre, 6 Leiden University<br />

Medical Center, Meerssen, The Netherlands, 7 Stanford<br />

University, Sunnyvale, CA, 8 University <strong>of</strong> Texas SW Medical<br />

Center, Dallas, TX, 9 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

1115. Optimal Dose Prediction by Pharmacokinetic and Biomarker<br />

Response <strong>of</strong> Subcutaneous Tocilizumab Treatment – A<br />

Phase I/II Study Evaluating the Safety, Pharmacokinetics<br />

and Clinical Response in Patients with Rheumatoid Arthritis.<br />

Shuji Ohta 8 , Tomomi Tsuru 5 , Kimio Terao 2 , Seiji Mogi 7 , Midori<br />

Suzaki 4 , Hitoshi Nakashima 3 , Eisuke Shono 6 , Eriko Tarumi 1 and<br />

Masato Imai 6 , 1 Chugai Clinical Research Center Co., Ltd, 2 Chugai<br />

Pharmaceutical Co., Ltd., Tokyo, Japan, 3 Fukuoka University,<br />

4<br />

Med Co LTA PS Clinic, 5 Med Co LTA PS Clinic, Fukuoka, Japan,<br />

6<br />

Shono Rheumatism Clinic, 7 Taga General Hospital, Hitachi, Ltd,<br />

Japan 8 Taga General Hospital, Hitachi, Ltd, Japan.<br />

1116. Preclinical Development <strong>of</strong> Autologous, Autoantigen-Loaded<br />

Dendritic Cells Modified with Bay11-7082 for Tolerizing<br />

Immunotherapy in Anti-Citrullinated Peptide Antibody Positive<br />

Rheumatoid Arthritis Patients Bearing the HLA-DR Shared<br />

Epitope. Sakoontalla Ramnoruth 2 , Marion Brunck 2 , Claire Hyde 2 ,<br />

Shayna Street 2 , Ge<strong>of</strong>frey Strutton 1 , Christelle Capini 2 , Sebastien<br />

Bertin-Maghit 2 , Brendan O’Sullivan 2 and Ranjeny Thomas 2 ,<br />

1<br />

Queensland Health Pathology, 2 University <strong>of</strong> Queensland<br />

Diamantina Institute.<br />

1117. Prediction <strong>of</strong> One-Year Response to Etanercept and<br />

Methotrexate in Rheumatoid Arthritis Patients in TEMPO.<br />

Jeffrey R. Curtis 4 , Shuo Yang 7 , Lang Chen 6 , Grace S. Park 1 ,<br />

Bojena Bitman 2 , Brian C. Wang 3 , Iris Navarro-Millan 5 and<br />

Arthur Kavanaugh 8 , 1 Amgen Inc., Thousand Oaks, CA, 2 Amgen<br />

Inc., South San Francisco, CA, 3 KForce Clinical Research, South<br />

San Francisco, CA, 4 University <strong>of</strong> Alabama - Brimingham,<br />

Birmingham, AL, 5 University <strong>of</strong> Alabama at Birmingham,<br />

Vestavia, AL, 6 University <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL, 7 University <strong>of</strong> Alabama at Birmingham,<br />

8<br />

University <strong>of</strong> California-San Diego, La Jolla, CA.<br />

1118. Predictors <strong>of</strong> Response to Rituximab in Patients with Active<br />

Rheumatoid Arthritis and Inadequate Response to Anti-TNF<br />

Agents or Traditional DMARD. Javier Narvaez 4 , Cesar Díaz<br />

Torné 2 , Jose Miguel Ruiz 3 , Maria Victoria Hernández 1 , Vicens<br />

Torrente 2 , Sergio Ros 3 , Cesar Díaz López 2 , Arturo Rodriguez<br />

de la Serna 2 , Raimon Sanmartí 1 and Joan Miquel Nolla 4 ,<br />

1<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Clinic, Barcelona, Spain,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital de la Santa Creu i Sant<br />

Pau, Barcelona, Spain, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />

de Viladecans, Barcelona, Spain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Hospital Universitario de Bellvitge, Barcelona, Spain.<br />

1119. Pro<strong>of</strong> <strong>of</strong> Concept Study for a Potent p38 MAPK Dual Action<br />

Inhibitor BMS-582949 in Subjects with RA Receiving<br />

Concomitant Methotrexate. Mark C. Genovese 6 , Ling Gao 3 , Jie<br />

Yin 3 , Stefani Smith 3 , Michael E. Weinblatt 1 , Josef S. Smolen 5 ,<br />

Xiaoning Wang 3 , Gary Schieven 3 , Juan A. Garcia-Meijide 4 , Robert<br />

Latek 3 , Richard Pasternak 3 , Sanjeev Kaul 3 , Amit Roy 3 , Ralph<br />

Raymond 3 , Ulrich Thienel 3 and Jingsong Wang 2 , 1 Brigham &<br />

Womens Hospital, Boston, MA, 2 Bristol-Myers Squibb, Wayne,<br />

PA, 3 Bristol-Myers Squibb, 4 Hospital Clínico Universitario de<br />

Santiago, Santiago de Compostela, Spain, 5 Krankenhaus Lainz,<br />

Vienna, Austria, 6 Stanford University, Sunnyvale, CA.<br />

1120. Radiographic Progression Correlates Well with Patient-<br />

Reported RAPID3 Disease Activity Levels in Methotrexate<br />

(MTX)-Naive Patients with Early Rheumatoid Arthritis (RA):<br />

Insights from the AGREE Study. Edward C. Keystone 3 , Rene<br />

Westhovens 4 , Diane Moniz Reed 1 , Allison Covucci 1 and Alvin<br />

F. Wells 2 , 1 Bristol-Myers Squibb, Princeton, NJ, 2 Rheum &<br />

Immunotherapy Center, Oak Creek, WI, 3 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada, 4 UZ Gasthuisburg, Leuven, Leuven,<br />

Belgium.<br />

1121. REGN88/SAR153191, a Fully-Human Interleukin-6 Receptor<br />

Monoclonal Antibody, Reduces Acute Phase Reactants in<br />

Patients with Rheumatoid Arthritis: Preliminary Observations<br />

from Phase 1 Studies. Allen R. Radin 1 , Scott J. Mellis 1 , Martine<br />

Jasson 3 , Douglas Nadler 2 , Pavel Belomestnov 2 , Richard Wu 2 ,<br />

Stephanie Biedermann 2 , Damir Skific 2 and Jennifer Hamilton 2 ,<br />

1<br />

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2 Regeneron<br />

Pharmaceuticals, Inc., 3 San<strong>of</strong>i-aventis, SA.<br />

1122. Results from a Phase I Study <strong>of</strong> MLTA3698A, a Novel Anti-<br />

Lymphotoxin-a Monoclonal Antibody: Safety, Tolerability and<br />

Biologic Activity in Patients with Active Rheumatoid Arthritis.<br />

Brinda Emu 2 , Diana Luca 3 , Carolyn Offutt 3 , Jane Grogan 3 , John<br />

Davis 3 , Bernadette Rojkovich 1 , Marna Williams 3 , Meina Tang 3<br />

and June Lee 3 , 1 Budai Irgalmasrendi, 2 Genentech, Inc., South San<br />

Francisco, CA, 3 Genentech, Inc..<br />

2010 Program Book 217


ACR Poster Session B<br />

1123. Safety <strong>of</strong> a Novel Modified-Release (MR) Prednisone<br />

Formulation: Results <strong>of</strong> the “Circadian Administration <strong>of</strong><br />

Prednisone in Rheumatoid Arthritis” (CAPRA) Studies. Frank<br />

Buttgereit 1 , Jacek Szechinski 5 , Gisela Döring 6 , Stephan Witte 2 ,<br />

Christine Knauer 3 , Amy Grahn 4 , Kenneth G. Saag 8 and Rieke<br />

Alten 7 , 1 Charite University Med-Berlin, Berlin, Germany,<br />

2<br />

Horizon Pharma GmbH, Mannheim, Germany, 3 Horizon<br />

Pharma GmbH, Mannheim, Germany, 4 Horizon Pharma, Inc.,<br />

Northbrook, IL, 5 Med. Uni. Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Wroclaw, Poland, 6 Merck KGaA, 7 Schlosspark-Klinik, UnivMed,<br />

Berlin, Germany, 8 University <strong>of</strong> Alabama-Birmingham,<br />

Birmingham, AL.<br />

1124. Safety, Pharmacokinetics and Pharmacodynamics <strong>of</strong> ALD518<br />

(BMS-945429), a High-Affinity Monoclonal Antibody Directed<br />

Against Interleukin-6 (IL-6) Administered by Subcutaneous<br />

Injection: A Phase I Trial. Sepehr Shakib 2 , Barbara Francis 1 and<br />

Jeffrey Smith 1 , 1 Alder Biopharmaceuticals Inc., Bothell, WA,<br />

2<br />

Royal Adelaide Hospital, Adelaide, Australia.<br />

1125. Selective Activation <strong>of</strong> Naturally Occurring Regulatory T Cells<br />

(Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers<br />

<strong>of</strong> Clinical Activity and Early Phase II Results in Patients<br />

with Rheumatoid Arthritis (RA). Anatoliy Rudnev 1 , Sukanya<br />

Ragavan 6 , Christina Trollmo 6 , Vivianne Malmstroem 6 , Christian<br />

Becker 5 , Helmut Jonuleit 5 , Vibeke Strand 7 , Silke Aigner 1 , Niklas<br />

Czeloth 1 , Benjamin Daelken 1 , Andre Engling 1 , Helga Koch 1 ,<br />

Gabriele Niemann 1 , Frank Osterroth 1 , Christoph Uherek 1 ,<br />

Andrea Wartenberg-Demand 1 , Olga Ershova 4 , Tatiana Sotnikova 2<br />

and Alexander Orlov-Morozov 3 , 1 Biotest AG, Dreieich, Germany,<br />

2<br />

Botkin Clinical Hospital, Moscow, Russian Federation, 3 City<br />

Clinical Hospital Nr. 23 n.a. Medsantrud, Moscow, Russian<br />

Federation, 4 Clinical Hospital for Emergency Medical Care,<br />

Yaroslavl, Russian Federation, 5 Johannes-Gutenberg University,<br />

Mainz, Germany, 6 Karolinska Institute, Stockholm, Sweden,<br />

7<br />

Stanford University, Portola Valley, CA.<br />

1126. Serum Cytokine Pr<strong>of</strong>ile Predicts Response to Rituximab<br />

Therapy in Rheumatoid Arthritis. Edward M. Vital 4 , Richard J.<br />

Cuthbert 4 , Shouvik Dass 1 , Rekha Parmar 4 , Andrew C. Rawstron 3 ,<br />

Frederique C. Ponchel 1 and Paul Emery 2 , 1 Leeds, West Yorkshire,<br />

United Kingdom, 2 Chapel Allerton Hospital, Leeds, United<br />

Kingdom, 3 Leeds Teaching Hospitals NHS Trust, Leeds, West<br />

Yorkshire, United Kingdom, 4 University <strong>of</strong> Leeds, Leeds, West<br />

Yorkshire, United Kingdom.<br />

1127. Serum Markers Associated with Structural Damage in<br />

Methotrexate Naïve Rheumatoid Arthritis Patients Treated<br />

with MTX in Combination with Placebo or Golimumab, a<br />

Human Anti-TNFa Monoclonal Antibody. Carrie Wagner 2 ,<br />

Dion Chen 1 , Hongtao Fan 1 , Sudha Visvanathan 5 , Elizabeth C.<br />

Hsia 3 , Paul Emery 4 , Roy M. Fleischmann 6 , Michael Mack 1 and<br />

Mahboob U. Rahman 3 , 1 Centocor Research and Development,<br />

Inc., 2 Centocor Research and Development, Inc., Malvern,<br />

PA, 3 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />

Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 4 Chapel<br />

Allerton Hospital, Leeds, United Kingdom, 5 H<strong>of</strong>fmann La Roche,<br />

6<br />

University <strong>of</strong> Texas SW Medical Center, Dallas, TX.<br />

1128. Targeting Potassium Channels for the Treatment <strong>of</strong><br />

Rheumatoid Arthritis. Xueyou Hu 2 , Teresina Laragione 4 , Liang<br />

Sun 2 , Shyny Koshy 2 , Karlie R. Jones 2 , Frank T. Horrigan 2 , Percio<br />

S. Gulko 3 and Christine Beeton 1 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine,<br />

Houston, TX, 2 Baylor <strong>College</strong> <strong>of</strong> Medicine, 3 Feinstein Institute<br />

for Medical Research, Manhasset, NY, 4 Feinstein Institute for<br />

Medical Research.<br />

1129. Tasocitinib (CP-690,550), an Orally Available Selective Janus<br />

Kinase Inhibitor, Exhibits Sustained Safety and Efficacy in the<br />

Treatment <strong>of</strong> Rheumatoid Arthritis over 24 Months. Carol A.<br />

Connell, Richard Riese, Susan Wood, John Bradley and Samuel<br />

H. Zwillich, Pfizer Inc.<br />

1130. The Bacterial Effector Protein YopM Reduces Bone Destruction<br />

in Rheumatoid Arthritis (RA). Jessica Bertrand 1 , Christian<br />

Rüter 3 , Julia Scharnert 3 , Alexander Schmidt 3 and Thomas Pap 2 ,<br />

1<br />

Institute for Experimental Musculoskeletal Medicine, Münster,<br />

Germany, 2 Institute for Experimental Musculoskeletal Medicine,<br />

3<br />

Institute for Infectiology ZMBE.<br />

1131. The Effects <strong>of</strong> Manzamine A on Rheumatoid Arthritis<br />

Synoviocyte Cytokine Secretion. Kyle Chong 1 , Karolina<br />

Klosowska 1 and James M. Woods 2 , 1 Midwestern University,<br />

Downers Grove, IL, 2 Midwestern University.<br />

1132. The Hawthorne Effect, Sponsored Trials, and the<br />

Overestimation <strong>of</strong> Treatment Effectiveness. Frederick Wolfe 1<br />

and Kaleb D. Michaud 2 , 1 National Data Bank for Rheumatic<br />

Diseases, Wichita, KS, 2 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE.<br />

1133. The Relationship <strong>of</strong> Serum Cytokine Levels with Disease<br />

Activity Parameters and Ultrasonographic Findings in RA<br />

Patients before and after Treatment with TNF Antagonists.<br />

Nevsun Inanc 2 , Atilla Bulur 2 , Meryem Can 2 , Onder Ergonul 1 ,<br />

Pamir Atagunduz 2 , Sule Yavuz 2 and Haner Direskeneli 2 ,<br />

1<br />

Marmara University Medical School, Department <strong>of</strong> Infectious<br />

Diseases, 2 Marmara University Medical School, Division <strong>of</strong><br />

<strong>Rheumatology</strong>.<br />

1134. Therapeutic Potential <strong>of</strong> Human Umbilical Cord Mesenchymal<br />

Stem Cells in the Treatment <strong>of</strong> Rheumatoid Arthritis. Yanying<br />

Liu, Rong Mu, Shiyao Wang and Zhanguo Li, Peking University<br />

People’s Hospital.<br />

1135. TRA-8 (CS-1008), a Novel Anti-Arthritic Biologic Agent That<br />

Targets Macrophages with Low Toxicity. Jun Li 1 , Hui-Chen Hsu 2 ,<br />

PingAr Yang 2 , Qi Wu 2 and John D. Mountz 1 , 1 Division <strong>of</strong> Clinical<br />

Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine,<br />

University <strong>of</strong> Alabama at Birmingham, Birmingham, AL, 2 Division<br />

<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Medicine, University <strong>of</strong> Alabama at Birmingham, Birmingham,<br />

AL.<br />

1136. Treat-To-Target for the Management <strong>of</strong> Rheumatoid Arthritis:<br />

A Validation Using Patient Reported Outcomes Data from<br />

Two Phase III Clinical Trials <strong>of</strong> Golimumab. Ed C. Keystone 6 ,<br />

Roy M. Fleischmann 4 , Chenglong Han 3 , Paul Emery 2 , Mark C.<br />

Genovese 5 , Timothy Gathany 3 , Elizabeth C. Hsia 1 and Mahboob<br />

U. Rahman 1 , 1 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />

Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 2 Chapel Allerton<br />

Hospital, Leeds, United Kingdom, 3 Johnson and Johnson<br />

Pharmaceutical Services, LLC, 4 <strong>Rheumatology</strong> Associates, Dallas,<br />

TX, 5 Stanford University, Sunnyvale, CA, 6 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada.<br />

1137. WITHDRAWN<br />

1138. Validation <strong>of</strong> an Algorithm Using Genome-Wide SNP Analysis<br />

for Prediction <strong>of</strong> Responders, Non-Responders, and Adverse<br />

Events <strong>of</strong> Tocilizumab-Treated RA Patients Using Two<br />

Population Samples from Multiple Medical Cohorts. Tsukasa<br />

Matsubara 5 , Satoru Koyano 10 , Keiko Funahashi 10 , Takafumi<br />

Hagiwara 6 , Takako Miura 5 , Kosuke Okuda 5 , Akira Sagawa 11 ,<br />

Takeo Sakurai 2 , Hiroaki Matsuno 7 , Tomomaro Izumihara 3 , Eisuke<br />

Shono 12 , Kou Katayama 4 , Toyomitsu Tsuchida 13 , Mitsuhiro<br />

Iwahashi 1 , Tomomi Tsuru 9 and Motohiro Oribe 8 , 1 Higashi-<br />

218<br />

2010 Program Book


ACR Poster Session B<br />

hiroshima Memorial Hospital, Higashihiroshima, Japan, 2 Inoue<br />

Hospital, Takasaki, Japan, 3 Izumihara Rheumatic and Medical<br />

Clinic, Kagoshima, Japan, 4 Katayama Orthopedic Reumatology<br />

Clonic, Asahikawa, Japan, 5 Matsubara Mayflower Hospital,<br />

Kato, Japan, 6 Matsubara Mayflower Hospital, Kato, Japan,<br />

7<br />

Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 8 Oribe<br />

Rheumatism and Internal Medicine Clinic, Oita, Japan, 9 PS Clinic,<br />

Fukuoka, Japan, 10 Research Institute <strong>of</strong> Joint Diseases, Kobe,<br />

Japan, 11 Sagawa Akira <strong>Rheumatology</strong> Clinic, Sapporo, Japan,<br />

12<br />

Shono <strong>Rheumatology</strong> Clinic, Fukuoka, Japan, 13 Tsuchida Clinic,<br />

Chiba, Japan.<br />

Systemic Lupus Erythematosus - Clinical Aspects and Treatment II<br />

1139. 1α,25-Dihydroxyvitamin D3 Suppresses Differentiation,<br />

Maturation and Activation <strong>of</strong> Dendritic Cells from Patients<br />

with Systemic Lupus Erythematosus. Hai Jing Wu, Chak Sing<br />

Lau and Mo Yin Mok, The University <strong>of</strong> Hong Kong, Queen Mary<br />

Hospital, Hong Kong.<br />

1140. 30-Year Follow-Up <strong>of</strong> Lupus Nephritis in a Single Clinic –<br />

Outcome, Serology and Ethnicity. Sara C. Croca 2 , Teresa<br />

Rodrigues 1 and David A. Isenberg 3 , 1 Faculdade de Medicina<br />

de Lisboa, Laboratory <strong>of</strong> Biomathematics, Lisboa, Portugal,<br />

2<br />

Hospital de Santa Maria, Department <strong>of</strong> Medicine 1 , Lisboa,<br />

Portugal, 3 UCL Div <strong>of</strong> Medicine, London, United Kingdom.<br />

1141. A Flow Cytometric Receptor Occupancy Assay Demonstrates<br />

Dose-Dependent Blockade <strong>of</strong> B7RP-1 by AMG 557 on<br />

Circulating B Cells from SLE Subjects. Barbara A. Sullivan 1 ,<br />

Cherie L. Green 2 , Ming Zhang 1 , Christina Abbott 1 , Shelley<br />

Belouski 1 , John Thomas 1 , Kevin Gorski 1 , Gerald Siu 3 , James B.<br />

Chung 1 and John Ferbas 1 , 1 Amgen, Thousand Oaks, CA, United<br />

Kingdom, 2 Amgen, Thousand Oaks, CA, 3 GlaxoSmithKline,<br />

Stevenage, United Kingdom.<br />

1142. A Longitudinal Study <strong>of</strong> the Prolongation <strong>of</strong> the Corrected QT<br />

Interval in Anti-Ro/SSA Positive Adults with Systemic Lupus<br />

Erythematosus. Josiane Bourré-Tessier 3 , Thao Huynh 5 , Ann E.<br />

Clarke 4 , Sasha R. Bernatsky 1 , Lawrence Joseph 3 , Patrick Belisle 3<br />

and Christian A. Pineau 2 , 1 McGill UHC/RVH, Montreal, QC,<br />

Canada, 2 McGill Univ Health Center, Montreal, QC, Canada,<br />

3<br />

McGill University, 4 Montreal General Hospital, Montreal, QC,<br />

Canada, 5 Montreal General Hospital.<br />

1143. Allogeneic Mesenchymal Stem Cells Transplantation in Severe<br />

and Refractory Systemic Lupus Erythematosus. Lingyun Sun 1 ,<br />

Dandan Wang 1 , Huayong Zhang 1 , Jun Liang 1 , Xuebing Feng 1 and<br />

Yayi Hou 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Immunology, The<br />

Affiliated Drum Tower Hospital <strong>of</strong> Nanjing University Medical<br />

School, 2 Immunology Laboratory, Nanjing University Medical<br />

School.<br />

1144. Analysis <strong>of</strong> the Use <strong>of</strong> Rituximab in the Treatment <strong>of</strong> Lupus<br />

Nephritis. Sara C. Croca 1 and David A. Isenberg 2 , 1 Hospital de<br />

Santa Maria, Department <strong>of</strong> Medicine 1 , Lisbon, Portugal, 2 UCL<br />

Div <strong>of</strong> Medicine, London, United Kingdom.<br />

1145. Anti-Mullerian Hormone in Systemic Lupus Erythematodes<br />

– Is Fertility Affected? Joerg C. Henes 1 , Melanie Henes 4 ,<br />

Tanja Fehm 4 , Diethelm Wallwiener 4 , Lothar Kanz 2 , Ina<br />

Koetter 2 and Barbara Lawrenz 3 , 1 Department for Internal<br />

Medicine II; University Hospital Tuebingen, Tuebingen,<br />

Germany, 2 Department for Internal Medicine II; University<br />

Hospital Tuebingen, Germany, 3 Department <strong>of</strong> Gynecology<br />

and Obstetrics; University Hospital <strong>of</strong> Tuebingen, Germany,<br />

4<br />

Department <strong>of</strong> Gynecology and Obstetrics; University Hospital<br />

Tuebingen, Germany.<br />

1146. Belimumab, a BLyS-Specific Inhibitor, Significantly Reduced<br />

Autoantibodies, Normalized Low Complement, and Reduced<br />

Selected B-Cell Populations in Patients with Seropositive<br />

Systemic Lupus Erythematosus (SLE): The Phase 3 BLISS<br />

Studies. W. Stohl 12 , F. Hiepe 1 , M. Thomas 8 , M. A. Scheinberg 2 ,<br />

A. E. Clarke 9 , C. Aranow 10 , R. Jimenez 4 , F. Wellborne 5 , C. Abud-<br />

Mendoza 3 , D. Hough 6 , L. Pineda 7 , T. S. Migone 7 , W. Freimuth 7 , W.<br />

W. Chatham 11 and on Behalf <strong>of</strong> the BLISS- 52 and - 76 Study Groups,<br />

1<br />

Charité Universitätsmedizin, Berlin, Germany, 2 Hospital Abreu<br />

Sodré Pesquisa Clínica, Sao Paulo, SP, Brazil, 3 Hospital Central<br />

y Facultad de Medicina, San Luis Potosi, Mexico, 4 Hospital G.<br />

Fricke, Vina del Mar, Vina del Mar, Chile, 5 Houston Institute<br />

for Clinical Research, Houston, TX, 6 Human Genome Sciences,<br />

Inc, Rockville, MD, 7 Human Genome Sciences, Inc, Rockville,<br />

Rockville, MD, 8 Kerala Institute <strong>of</strong> Medical Sciences, Trivandrum,<br />

India, 9 McGill University Health Centre, The Montreal General<br />

Hospital, Montreal, QC, Canada, 10 The Feinstein Institute for<br />

Medical Research, Manhasset, Manhasset, NY, 11 UAB Arthritis<br />

Clinical Intervention Program, Birmingham, AL, 12 USC Keck<br />

School <strong>of</strong> Medicine, Los Angeles, CA.<br />

1147. Comparison <strong>of</strong> Serum Free Light Chains, Interferon and<br />

Interleukins as Biomarkers <strong>of</strong> Disease Activity in Systemic<br />

Lupus Erythematosus (SLE). Serene Francis 4 , Rohit Aggarwal 6 ,<br />

Rachel Mikolaitis 4 , Timothy B. Niewold 5 , Susanna Chubinskaya 4 ,<br />

Joel A. Block 1 , Winston Sequeira 2 and Meenakshi Jolly 3 , 1 Rush<br />

University Medical Center, Chicago, IL, 2 Rush University Medical<br />

Center, Chicago, IL, 3 Rush University Medical Center, Section<br />

<strong>of</strong> <strong>Rheumatology</strong>, Chicago, IL, 4 Rush University Medical Center,<br />

Section <strong>of</strong> <strong>Rheumatology</strong>, 5 University <strong>of</strong> Chicago, Section <strong>of</strong><br />

<strong>Rheumatology</strong>, Chicago, IL, 6 University <strong>of</strong> Pittsburgh Medical<br />

Center.<br />

1148. Coronary Calcification in SLE: Comparison with Multi-Ethnic<br />

Study <strong>of</strong> Atherosclerosis (MESA). Adnan N. Kiani 3 , Wendy Post 4 ,<br />

Moyses Szklo 2 , Joan M. Bathon 4 , Laurence S. Magder 6 , Russell<br />

Tracy 8 , Pamela Schreiner 7 , Daniel O’Leary 5 and Michelle A.<br />

Petri 1 , 1 Timonium, MD, 2 Johns Hopkins University, Department<br />

<strong>of</strong> Epidemiology, 3 Johns Hopkins University, School <strong>of</strong> Medicine,<br />

Baltimore, MD, 4 Johns Hopkins University, School <strong>of</strong> Medicine,<br />

5<br />

Tufts University, 6 University <strong>of</strong> Maryland, 7 University <strong>of</strong><br />

Minnesota, 8 University <strong>of</strong> Vermont.<br />

1149. Decrease in Complement (C3) Levels during Systemic Lupus<br />

Erythematosus Pregnancy Is Associated with Higher Rates <strong>of</strong><br />

Pre-Eclampsia. Aisha Lateef 2 , Laurence S. Magder 3 and Michelle<br />

A. Petri 1 , 1 Johns Hopkins Lupus Center, School <strong>of</strong> Medicine,<br />

Johns Hopkins University, Timonium, MD, 2 National University<br />

Health System, Singapore, Singapore, 3 University <strong>of</strong> Maryland<br />

Medical School, Baltimore, MD.<br />

1150. Dendritic Cells and Regulatory T CD4+CD25Bright in Pregnant<br />

Patients with Systemic Lupus Erythematosus. Luis J. Jara 1 ,<br />

Griselda Teresa Romero-Sánchez 1 , Laura A. Montiel-Cervantes 1 ,<br />

Gabriela Medina 1 , Polita Cruz-Cruz 2 , Jorge Vela-Ojeda 1 , Rafael<br />

Arias-Flores 1 , Olga Vera-Lastra 1 and Miguel A. Saavedra Salinas 1 ,<br />

1<br />

Hospital de Especialidades Centro Medico La Raza, IMSS,<br />

Mexico City, DF, Mexico, 2 Hospital de Gineco-Obstetricia No. 3 ,<br />

Centro Medico La Raza, IMSS, Mexico City, DF, Mexico.<br />

1151. Distinctions in the ISN/RPS 2003 Subclasses <strong>of</strong> Class IV Lupus<br />

Nephritis. Suhail Hameed 2 , Kun Chen 2 , Surya Seshan 3 and<br />

Michael D. Lockshin 1 , 1 Hosp for Spec Surgery, Cornell, New York,<br />

NY, 2 Hospital for Special Surgery, Cornell, New York, NY, 3 Weill<br />

Cornell Medical Center.<br />

2010 Program Book 219


ACR/ARHP Poster Session B<br />

220<br />

1152. Does Smoking Influence Disease Manifestations and Disease<br />

Severity in Systemic Lupus Erythematosus? Nayef Al Ghanim 2 ,<br />

Aqeel Ghanem 2 , Ebrahim Nahar 1 , John M. Esdaile 2 and Diane<br />

Lacaille 2 , 1 Mubarak Al Kabeer Hospital, Vancouver, BC, Canada,<br />

2<br />

University <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />

1153. Early Treatment with Rituximab (RTX) in Newly Diagnosed<br />

Systemic Lupus Erythematosus (SLE) Patients: A Steroid<br />

Sparing Regimen. Amara N. Ezeonyeji 2 and David A. Isenberg 1 ,<br />

1<br />

UCL Div <strong>of</strong> Medicine, Room 331, 3 rd Floor, London, United<br />

Kingdom, 2 University <strong>College</strong> London Hospital NHS Trust,<br />

London, United Kingdom.<br />

1154. Evidence <strong>of</strong> Peripheral B Cell Depletion in Subjects with<br />

Controlled Systemic Lupus Erythematosus (SLE) Following<br />

Subcutaneous Administration <strong>of</strong> SBI-087. Roy M. Fleischmann 3 ,<br />

Stanley B. Cohen 7 , Patricia Pardo 4 , Marianne L. Shaw 1 , Megan E.<br />

B. Clowse 2 , Kyri Dunussi-Joannopoulos 6 , Indranil Bhattacharya 6 ,<br />

Sudhakar T. Sridharan 5 , Annette Diehl 6 and Ian Gourley 6 ,<br />

1<br />

Altoona Center for Clinical Research, Duncansville, PA, 2 Duke<br />

University, Durham, NC, 3 Metroplex Clinical Research Center,<br />

Dallas, TX, 4 Miami Research Associates, 5 Pfizer Inc, <strong>College</strong>ville,<br />

PA, 6 Pfizer Inc, 7 <strong>Rheumatology</strong> Associates, Dallas, TX.<br />

1155. Fibroblast Growth Factor (FGF23) Serum Levels in Juvenile<br />

Onset Systemic Lupus Erythematosus (JSLE): A Potential<br />

Link with Renal Involvement. Fernanda Falcini 1 , Laura Masi 2 ,<br />

Serena Capannini 1 , Francesco Franceschelli 2 , Gigliola Leoncini 2 ,<br />

Valentina Denaro 1 , La Torre Francesco 3 , Giuseppina Calcagno 3 ,<br />

Marco Matucci Cerinic 1 and Maria Luisa Brandi 2 , 1 Dpt <strong>of</strong><br />

BioMedicine, <strong>Rheumatology</strong> Section, Transition Unit, University<br />

<strong>of</strong> Florence, 2 Dpt <strong>of</strong> Internal Medicine, Metabolic Bone Diseases<br />

Unit, University <strong>of</strong> Florence, Florence, 3 Dpt <strong>of</strong> Paediatrics,<br />

<strong>Rheumatology</strong> Unit, University <strong>of</strong> Messina, Messina, Italy.<br />

1156. Fracture Risk Assessment and Prevalence <strong>of</strong> Low Bone Mass in<br />

Canadian Females Living with Systemic Lupus Erythematosus<br />

(SLE). Jennifer J. Lee 6 , Angela M. Cheung 6 , Ellie Aghdassi 6 ,<br />

Stacey Morrison 6 , Valentina Peeva 6 , Carolyn Neville 1 , Sarah<br />

Hewitt 4 , Janet E. Pope 3 , Deborah DaCosta 2 and Paul R. Fortin 5 ,<br />

1<br />

McGill University, Montreal, QC, Canada, 2 McGill University, 3 St<br />

Joseph Health Care London, London, ON, Canada, 4 St. Joseph’s<br />

Health Care, 5 University Health Network, Toronto, ON, Canada,<br />

6<br />

University Health Network.<br />

1157. Immunosuppression in the Treatment <strong>of</strong> Systemic Lupus<br />

Erythematosus Associated Pulmonary Arterial Hypertension:<br />

Improvement in Functional and Exercise Capacity. Judith<br />

Ashouri 2 , Yon Sung 2 , Roham Zamanian 2 and Lorinda Chung 1 ,<br />

1<br />

Stanford Univ Medical Center, Palo Alto, CA, 2 Stanford<br />

University School <strong>of</strong> Medicine.<br />

1158. Immunosuppressive Drugs for Systemic Lupus in the Michigan<br />

Lupus Cohort: Increased Requirement for Cyclophosphamide<br />

and Mycophenolate M<strong>of</strong>etil in Men. Emily E. Lewis 3 , Emily<br />

Crooks 4 , Zhichao Sun 4 , Patricia C. Cagnoli 3 , Tania Gonzalez-<br />

Rivera 4 , Mariana J. Kaplan 3 , Wendy Marder 2 , Panduranga Rao 4 ,<br />

Emily C. Somers 1 and W. Joseph McCune 3 , 1 U <strong>of</strong> Michigan Health<br />

System, Ann Arbor, MI, 2 Univ <strong>of</strong> Michigan, Ann Arbor, MI,<br />

3<br />

University <strong>of</strong> Michigan, Ann Arbor, MI, 4 University <strong>of</strong> Michigan.<br />

1159. Increased Recruitment <strong>of</strong> Brain Activation within the<br />

Hippocampus in SLE Patients as Shown by Functional MRI<br />

May Be a Compensatory Mechanism To Cope with Memory<br />

Impairment. Daphna Paran 3 , Ifat Glikmann-Johnston 2 ,<br />

Talma Hendler 2 , Irena Litinsky 3 , Eli Vakil 1 , Dan Caspi 3 and<br />

Irit Shapira-Lichter 2 , 1 Department <strong>of</strong> Psychology and Gonda<br />

Multidisciplinary Brain Research Center, Bar-Ilan University,<br />

2<br />

Functional Brain Center, Wohl Institute for Advanced Imaging,<br />

Tel-Aviv Sourasky Medical Center, 3 <strong>Rheumatology</strong> Department,<br />

Tel-Aviv Soursky Medical Center.<br />

2010 Program Book<br />

1160. Inhibition <strong>of</strong> Complement Activation by Heparins but Not<br />

Fondaparinux on Alternative, Mannose/Mannan Binding<br />

Lectin (MBL) and Classical Pathways in Active SLE with Low C3/<br />

C4. Andrea A. Ramirez 1 , Ankur A. Kamdar 2 and Barry L. Myones 1 ,<br />

1<br />

Baylor <strong>College</strong> <strong>of</strong> Medicine/Texas Children’s Hospital, Houston,<br />

TX, 2 University <strong>of</strong> Texas Medical School at Houston, Houston, TX.<br />

1161. Long-Term Outcome <strong>of</strong> Autologous Hematopoietic Stem<br />

Cell Transplantation (AutoHSCT) Using Lymphoablative<br />

Conditioning in Treatment-Resistant Systemic Lupus<br />

Erythematosus. Gabor G. Illei 11 , Sarfaraz A. Hasni 7 , Nikolay P.<br />

Nikolov 1 , Francis Hakim 2 , Susan Leitman 2 , James Balow 9 , Howard<br />

Austin 4 , Juan Gea-Banacloche 2 , Unsong Oh 10 , Jeanie Odom 2 ,<br />

Donna Hardwick 8 , Claude Sportes 2 , Ronald Gress 2 , Steven<br />

Pavletic 2 , Cheryl Yarboro 6 , Paolo Muraro 5 and Peter Lipsky 3 ,<br />

1<br />

Bldg. 22 , Room 3335, HFD-570, Silver Spring, MD, 2 National<br />

Cancer Institute, 3 National Institue <strong>of</strong> Arthritis, Musculoskelatal<br />

and Skin Diseases, 4 National Institue <strong>of</strong> Dibetes, Digestive and<br />

Kidney DIseases, 5 National Institue <strong>of</strong> Neurological Diseases and<br />

Stroke, 6 National Institute <strong>of</strong> Arthritis, Musculoskelatal and Skin<br />

Diseases, 7 National Institute <strong>of</strong> Arthritis, Musculoskelatal and<br />

Skin Diseases, Bethesda, MD, 8 National Institute <strong>of</strong> Arthritis,<br />

Musculoskeletal and Skin Diseases, 9 National Institute <strong>of</strong><br />

Diabetes, Digestive and Kidney Diseases, 10 National Institute<br />

<strong>of</strong> Neurological Disroders and Stroke, 11 NIDCR, NIH #10 1N114,<br />

Bethesda, MD.<br />

1162. Microembolic Signals Detected by Transcranial Doppler<br />

Ultrasound Corresponds to Persistence <strong>of</strong> Foramen Ovale<br />

in Neuropsychiatric Lupus with Brain MRI Abnormalities.<br />

Melissa Padovan 2 , Alessandra Bortoluzzi 2 , Cristiano Azzini 1 ,<br />

Alessandro De Vito 1 , Maria Rosaria Tola 1 , Francesco Trotta 3<br />

and Marcello Govoni 3 , 1 Neurology Unit, Department <strong>of</strong><br />

Neurosciences, Azienda Ospedaliero-Universitaria Sant’Anna,<br />

Ferrara, Italy, 2 <strong>Rheumatology</strong> Unit, Department <strong>of</strong> Clinical and<br />

Experimental Medicine, University <strong>of</strong> Ferrara and Azienda<br />

Ospedaliero-Universitaria Sant’Anna - Ferrara, Ferrara, FE, Italy,<br />

3<br />

<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Clinical and Experimental<br />

Medicine, University <strong>of</strong> Ferrara and Azienda Ospedaliero-<br />

Universitaria Sant’Anna – Ferrara, Italy.<br />

1163. Multivariate Analysis <strong>of</strong> Vitamin D Insufficiency and Deficiency<br />

in SLE: The SOLD (Systemic Lupus Associates <strong>of</strong> Low Vitamin<br />

D) Project. Caroline D’Souza 2 , Kayode Jibril Bello 2 , Hong Fang 2 ,<br />

Laurence Magder 3 and Michelle A. Petri 1 , 1 Timonium, MD,<br />

2<br />

Johns Hopkins University, 3 University <strong>of</strong> Maryland.<br />

1164. Network Analysis <strong>of</strong> Associations between Serum Interferon<br />

Alpha, Serology, and Clinical Features in Systemic Lupus<br />

Erythematosus in a Large Multi-Ancestral Cohort. Corinna E.<br />

Weckerle 6 , Beverly S. Franek 7 , Jennifer Kelly 2 , Marissa Kumabe 7 ,<br />

Rachel Mikolaitis 5 , Stephanie Green 7 , Gail R. Bruner 3 , Tammy O.<br />

Utset 6 , Meenakshi Jolly 4 , Judith A. James 1 , John B. Harley 8 and<br />

Timothy B. Niewold 9 , 1 Oklahoma Med Research Foundation,<br />

Oklahoma City, OK, 2 Oklahoma Medical Research Foundation,<br />

3<br />

Oklahoma Medical Rsrch, Oklahoma City, OK, 4 Rush University<br />

Med Ctr, Chicago, IL, 5 Rush University Med Ctr, 6 Univ <strong>of</strong> Chicago<br />

Med Ctr, Chicago, IL, 7 Univ <strong>of</strong> Chicago Med Ctr, 8 Univ <strong>of</strong> OK Hlth<br />

Sci Ctr, Oklahoma City, OK, 9 University <strong>of</strong> Chicago, Chicago, IL.<br />

1165. Peripheral Neuropathy in Patients with Systemic Lupus<br />

Erythematosus. Brandusa Florica 2 , Jiandong Su 1 , Ellie Aghdassi 1 ,<br />

Dafna D. Gladman 1 , Murray B. Urowitz 1 and Paul R. Fortin 1 ,<br />

1<br />

University Health Network, 2 University <strong>of</strong> Toronto, Toronto, ON,<br />

Canada.


ACR/ARHP Poster Session B<br />

1166. Predictors <strong>of</strong> Mortality in Diffuse Alveolar Haemorrhage<br />

(DAH) Associated with Systemic Lupus Erythematosus. Marco<br />

U. Martínez-Martínez 2 , Eufrates Hernández-Núñez 3 , Enrique<br />

Cuevas-Orta 3 , Ricardo Moreno-Valdés 3 , Martin Saldaña-Barnad 3 ,<br />

Martin Magaña-Aquino 3 , Juan C. Rizo-Rodríguez 2 and Carlos<br />

Abud-Mendoza 1 , 1 <strong>Rheumatology</strong> Unit, Hospital Central and<br />

Faculty <strong>of</strong> Medicine, University <strong>of</strong> San Luis Potosí, San Luis<br />

Potosi, Mexico, 2 <strong>Rheumatology</strong> Unit, Hospital Central and<br />

Faculty <strong>of</strong> Medicine, University <strong>of</strong> San Luis Potosí, México,<br />

3<br />

<strong>Rheumatology</strong> Unit, Hospital Central and Faculty <strong>of</strong> Medicine,<br />

University <strong>of</strong> San Luis Potosí, Mexico.<br />

1167. Prefrontal Lobe Volume Could Reveal Working Memory<br />

Function in Patients with System Lupus Erythematosus. Yongfei<br />

Fang 2 , Haitao Lii 1 , Qinghua Zou 3 and Yun Lin 1 , 1 Department<br />

<strong>of</strong> Radiology, Southwest Hospital, Third Military Medical<br />

University, Chongqing, China, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Southwest Hospital, Third Military Medical University,<br />

Chongqing, China, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Southwest<br />

Hospital, Third Military Medical University, Chongqing, China.<br />

1168. Preliminary Results: Baseline Nutritional Vitamin D Level<br />

Does Not Predict Progression <strong>of</strong> Subclinical Atherosclerosis<br />

in Women with SLE. Apinya Lertratanakul 2 , Peggy Wu 2 , Alan<br />

R. Dyer 2 , Craig Langman 1 , William Pearce 2 , Kim Sutton-Tyrrell 4 ,<br />

George Kondos 3 , Daniel Edmundowicz 4 , James Carr 2 and<br />

Rosalind Ramsey-Goldman 2 , 1 Childrens Memorial Hospital,<br />

Chicago, IL, 2 Northwestern University, Chicago, IL, 3 University <strong>of</strong><br />

Illinois, Chicago, IL, 4 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

1169. Progression <strong>of</strong> Carotid Atherosclerosis and Its Determinants<br />

in Lupus Patients. Rosa Weiss Telles 3 , Cristina Costa Duarte<br />

Lanna 3 , Tulio Pinho Navarro 3 , Adriano Jose Souza 1 , Rodrigo<br />

Citton Padilha Reis 4 , Fabiana Lemos Sousa 2 , Luciana Andrade<br />

Rodrigues 3 and Antonio Luiz Ribeiro 3 , 1 Clinica Radiologica<br />

CONRAD, Brazil, 2 Hospital das Clinicas, Universidade Federal de<br />

Minas Gerais, Brazil, 3 School <strong>of</strong> Medicine, Universidade Federal<br />

de Minas Gerais , Brazil, 4 Statistics Department, Universidade<br />

Federal de Minas Gerais, Brazil.<br />

1170. Regional Brain Diffusion Abnormalities in Systemic Lupus<br />

Erythematosus. Simone Appenzeller 3 , Leticia Rittner 4 , Gabriel<br />

Leonard 1 , Martin Vielleux 2 , Bruce Pike 1 and Ann Clarke 1 , 1 McGill<br />

University, Canada, 2 McGill University, Canada 3 State University<br />

<strong>of</strong> Campinas, Brazil, 4 State University <strong>of</strong> Campinas, Brazil.<br />

1171. Renal Biopsy in Systemic Lupus Erithematosus Patients with<br />

Low Levels <strong>of</strong> Proteinuria. Esther Rodriguez, Julio Sánchez, Eva<br />

Salgado, Isabel Mateo, María Galindo and Patricia E. Carreira,<br />

<strong>Rheumatology</strong> Department, Hospital 12 de Octubre, Madrid,<br />

Spain.<br />

1172. Safety Pr<strong>of</strong>ile <strong>of</strong> Belimumab, a BLyS-Specific Inhibitor, in<br />

Patients with Active Systemic Lupus Erythematosus (SLE):<br />

Pooled Data from Phase 2 and 3 Studies. D. J. Wallace 1 , S.<br />

Navarra 12 , A. Gallacher 2 , R. Gúzman 10 , M. Thomas 7 , R. A. Furie 8 ,<br />

O. Zamani 9 , R. A. Levy 4 , R. van Vollenhoven 11 , S. Cooper 6 , Z.<br />

J. Zhong 5 , W. Freimuth 6 , L. Pineda 6 , R. Cervera 3 and for the<br />

BLISS-52 and -76 and LBSL02/99 Study Groups, 1 Cedars-Sinai/<br />

UCLA, Los Angeles, CA, 2 Hospital Británico de Buenos Aires,<br />

Buenos Aires, Argentina, 3 Hospital Clinic, Barcelona, Spain,<br />

4<br />

Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil,<br />

5<br />

Human Genome Sciences, Inc, Rockville, MD, 6 Human Genome<br />

Sciences, Inc, Rockville, Rockville, MD, 7 Kerala Institute <strong>of</strong><br />

Medical Sciences, Kerala, India, 8 North Shore LIJ Health System,<br />

Lake Success, NY, 9 Rheumazentrum Favoriten, Wien, Wien,<br />

Austria, 10 SaludCoop, Bogotá, Colombia, Bogotá, Colombia,<br />

11<br />

The Karolinska Institute, Stockholm, Sweden, 12 University <strong>of</strong><br />

Santo Tomas Hospital, Manila, Manila, Philippines.<br />

1173. Second Renal Biopsy in Proliferative Lupus Nephritis. Alberto<br />

Allievi 2 , Ana Malvar Perrin 2 , Bruno Lococo 2 , Mariac Cristina<br />

Basta 2 , Paola Pirruccio 2 , Sebastian Andres Muñoz 2 , Alejandra<br />

Quevedo 2 , Bernarda Fazzini 2 , Valeria Alberton 2 and Alejandro<br />

Iotti 1 , 1 Hospital Britanico, Ciudad Autonoma de Buenos Aires,<br />

Buenos Aires, Argentina, 2 Hospital Juan A Fernandez, Ciudad<br />

Autonoma de Buenos Aires, Buenos Aires, Argentina.<br />

1174. Seroprevalence <strong>of</strong> NMO-IgG (Anti-Aquaporin 4 Antibodies)<br />

in Patients with Neuropsychiatric Systemic Lupus<br />

Erythematosus. Jakub Zavada 4 , Petra Nytrova 1 , Klaus-Peter<br />

Wandinger 2 , Svobodova Radka 4 , Ivana Putova 4 , Dana Tegzova 4<br />

and Jiri Vencovsky 3 , 1 Department <strong>of</strong> Neurology, First Faculty<br />

<strong>of</strong> Medicine, Charles University in Prague and General<br />

University Hospital in Prague, Czech Republic, 2 Institute <strong>of</strong><br />

Experimental Immunology, Euroimmun, Lübeck, Germany,<br />

3<br />

Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 4 Institute <strong>of</strong><br />

<strong>Rheumatology</strong> and First Faculty <strong>of</strong> Medicine, Charles University<br />

in Prague, Czech Republic.<br />

1175. Serum Free Light Chains and Disease Activity in Systemic<br />

Lupus Erythematosus. Meenakshi Jolly 1 , Rohit Aggarwal 4 ,<br />

Rachel Mikolaitis 3 , Joel A. Block 2 and Winston Sequeira 1 , 1 Rush<br />

University Medical Center, Chicago, IL, 2 Rush University Medical<br />

Center, Chicago, IL, 3 Rush University Medical Center, 4 University<br />

<strong>of</strong> Pittsburgh Medical Center, Pittsburgh, PA.<br />

1176. Shrinking Lung Syndrome Is Associated with Pleuritis. David<br />

Allen 3 , Zoheir Bshouty 3 , Mellissa Moyen 3 , David B. Robinson 3 ,<br />

Christine A. Peschken 1 , Carol A. Hitchon 3 , Hani S. El-Gabalawy 2<br />

and Shikha Mittoo 1 , 1 Univ <strong>of</strong> Manitoba, Winnipeg, MB, Canada,<br />

2<br />

University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 3 University <strong>of</strong><br />

Manitoba, Winnipeg, MB, Canada.<br />

1177. The Metabolic Syndrome in Systemic Lupus Erythematosus:<br />

More Than the Sum <strong>of</strong> Its Parts? Ben Parker 3 , Yasmeen Ahmad 4 ,<br />

Joanna Shelmerdine 1 , Sahena Haque 2 and Ian N. Bruce 1 ,<br />

1<br />

Manchester, United Kingdom, 2 Manchester, United Kingdom,<br />

3<br />

Arthritis Research UK Epidemiology Unit, University <strong>of</strong><br />

Manchester, Manchester, United Kingdom, 4 Manchester Royal<br />

Infirmary, Manchester, United Kingdom.<br />

1178. The Prevalence <strong>of</strong> Liver Abnormalities in Patients with<br />

Systemic Lupus Erythematosus. Darryl Huang 2 , Ellie Aghdassi 2 ,<br />

Jiandong Su 2 and Paul R. Fortin 1 , 1 Toronto Western Hospital,<br />

Toronto, ON, Canada, 2 University Health Network, Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Toronto, ON, Canada.<br />

1179. Undertreatment <strong>of</strong> Active Disease May Increase Mortality in<br />

Lupus Patients with End Stage Renal Disease. Anna R. Broder 2<br />

and Chaim Putterman 1 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx,<br />

NY, 2 Montefiore Medical Ctr, Bronx, NY.<br />

1180. Vitamin D Levels Are Positively Associated with Complement<br />

among Patients with SLE. Michelle A. Petri 1 , Kayode Jibril Bello 2 ,<br />

Hong Fang 2 and Laurence Magder 3 , 1 Timonium, MD, 2 Johns<br />

Hopkins University School <strong>of</strong> Medicine, 3 University <strong>of</strong> Maryland<br />

School <strong>of</strong> Medicine.<br />

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />

Cardiovascular Disease and Clinical<br />

1181. Acute Flares <strong>of</strong> Neuropsychiatric Systemic Lupus<br />

Erythematosus (NPSLE) Are Sometimes Associated with Spikes<br />

<strong>of</strong> Interferon-alpha Activity in the CSF. Elisabet Svenungsson 2 ,<br />

Clio P. Mavragani 1 , Liisa Hopia 3 , Mohsen Khademi 3 , Anna<br />

Laveskog 2 , Mary K. Crow 1 and Magnus Andersson 2 , 1 Hospital for<br />

Special Surgery, New York, NY, 2 Karolinska Institutet, Stockholm,<br />

Sweden, 3 Karolinska Institutet, Sweden.<br />

2010 Program Book 221


ACR/ARHP Poster Session B<br />

1182. Allogeneic Mesenchymal Stem Cells Inhibited OAZ Expression<br />

in Patients with Systemic Lupus Erythematosus. Xuebing Feng 1 ,<br />

Rongliang Li 2 , Jing Huang 2 , Dandan Wang 2 , Xiaolei Ma 2 , Betty<br />

P. Tsao 3 and Lingyun Sun 2 , 1 Affiliated Drum Tower Hospital <strong>of</strong><br />

Nanjing University Medical School, Nanjing, China, 2 Affiliated<br />

Drum Tower Hospital <strong>of</strong> Nanjing University Medical School,<br />

3<br />

UCLA School <strong>of</strong> Medicine, Los Angeles, CA.<br />

1183. Analysis <strong>of</strong> Vascular Endothelium from Female Systemic Lupus<br />

Erythematosus (SLE) Patients Identifies an Interferon Signature<br />

That Correlates with Disease Activity. Diana Goldenberg 3 ,<br />

Mikhail Olferiev 3 , Duygu Onat 1 , Danieli Andrade 3 , Mary K. Crow 3 ,<br />

Paolo C. Colombo 1 and Jane E. Salmon 2 , 1 Columbia University<br />

<strong>College</strong> <strong>of</strong> Physicians and Surgeons, New York, NY, 2 Hospital for<br />

Special Surgery, New York, NY, 3 Hospital for Special Surgery, New<br />

York, NY.<br />

1184. Anti-C1q Antibodies Are Associated with Global Activity <strong>of</strong><br />

Systemic Lupus Erythematosus, but Not Specifically with<br />

Nephritis. Yuko Okamoto 1 , Yasuhiro Katsumata 5 , Yasushi<br />

Kawaguchi 2 , Kohei Miyake 5 , Manabu Kawamoto 5 , Kae Takagi 5 ,<br />

Takahisa Gono 5 , Sayumi Baba 5 , Yuko Ota 5 , Masako Hara 4 and<br />

Hisashi Yamanaka 3 , 1 Tokyo Women’s Medical University, Tokyo,<br />

Japan, 2 Tokyo Women’s Medical University, Tokyo, Japan, 3 Tokyo<br />

Women’s Medical University, Shinjuku-ku, Tokyo, Japan, 4 Tokyo<br />

Women’s Medical University, Kamakura Kanagawa, Japan,<br />

5<br />

Tokyo Women’s Medical University.<br />

1185. Biomarkers <strong>of</strong> Oxidative Stress, mTOR Activation, and Treg<br />

Depletion Correlate with Disease Activity in Patients with<br />

Systemic Lupus Erythematosus. Zhiwei Lai 1 , Adam Bartos 1 ,<br />

Tiffany Tekarico 1 , Robert Hanczko 1 , Gabriella Miklossy 1 , Brandon<br />

Clair 1 , John Jimah 1 , Lisa Francis 1 , Hajra Tily 1 , Ricardo Garcia 1 ,<br />

Maha Dawood 1 , David R. Fernandez 1 , Paul E. Phillips 2 , Ioana<br />

Coman 1 and Andras Perl 3 , 1 SUNY, 2 SUNY-Upstate Medical Univ,<br />

Syracuse, NY, 3 Upstate Medical Univ, Syracuse, NY.<br />

1186. CD138 RNA Can Be Detected in the Circulation <strong>of</strong> Patients with<br />

Systemic Lupus and Correlated to Other Factors Suggestive <strong>of</strong><br />

Plasma Cell Activation. Ming Chen 3 , Joy G. Hutcheson 2 , Stan<br />

Kamp 2 , Danny Walker 2 and Joan T. Merrill 1 , 1 Oklahoma Med<br />

Research Foundation, Oklahoma City, OK, 2 OMRF, Oklahoma<br />

City, OK, 3 OMRF, Allen, TX.<br />

1187. Characterisation <strong>of</strong> Lipid Order in Lymphocyte Subsets from<br />

Patients with Systemic Lupus Erythematosus (SLE). Laura<br />

Miguel 2 , Chrissie Lim 2 , David A. Isenberg 1 and Elizabeth C. Jury 2 ,<br />

1<br />

UCL Div <strong>of</strong> Medicine, London, United Kingdom, 2 University<br />

<strong>College</strong> London, London, United Kingdom.<br />

1188. Correlates <strong>of</strong> ANA Positivity in Healthy Individuals. David R.<br />

Karp 2 , Quan-Zhen Li 2 , Valerie K. Branch 2 , Jiexia Quan 3 and Nancy<br />

J. Olsen 1 , 1 Univ <strong>of</strong> TX Southwestern Med Ctr, Dallas, TX, 2 UT<br />

Southwestern Med Ctr, Dallas, TX, 3 UT Southwestern Med Ctr.,<br />

Dallas, TX.<br />

1189. Dysfunctional, Pro-Inflammatory High Density Lipoproteins<br />

Directly Influence Monocyte PDGFRβ Transcript Levels,<br />

TNFα Secretion, and Chemotaxis. Brian J. Skaggs 1 , Bevra H.<br />

Hahn 4 , Lori Sahakian 2 , Jennifer M. Grossman 3 and Maureen<br />

A. McMahon 1 , 1 UCLA School <strong>of</strong> Medicine, Los Angeles, CA,<br />

2<br />

UCLA School <strong>of</strong> Medicine, 3 University <strong>of</strong> California Los Angeles,<br />

Sherman Oaks, CA, 4 University <strong>of</strong> California Los Angeles School<br />

<strong>of</strong> Medicine, Los Angeles, CA.<br />

1190. Dysregulation <strong>of</strong> the Microvascular as Assessed by Expression<br />

<strong>of</strong> Protective and Injury Associated Markers Is Reflected in<br />

the Non-Lesional Non-Sunexposed Skin <strong>of</strong> Patients with Lupus<br />

Nephritis. Peter M. Izmirly 1 , Shane Meehan 2 , Sherry X. Xu 2 ,<br />

Anca D. Askanase 1 , Joan T. Merrill 3 , Jill P. Buyon 1 and Robert M.<br />

Clancy 4 , 1 NYU School <strong>of</strong> Medicine, New York, NY, 2 NYU School<br />

<strong>of</strong> Medicine, 3 Oklahoma Med Research Foundation, Oklahoma<br />

City, OK, 4 Tisch Hospital 4-407, New York, NY.<br />

1191. Evidence <strong>of</strong> N-methyl-D-aspartate Receptor (NMDAR)<br />

Expression on Primary Human Endothelial Cells. Cagri Yildirim-<br />

Toruner 3 , Paola Mina-Osario 2 and Betty Diamond 1 , 1 Feinstein<br />

Institute for Medical Research, Manhasset, NY, 2 Feinstein<br />

Institute for Medical Research, 3 Morgan Stanley Children’s<br />

Hospital <strong>of</strong> NewYork- Presbyterian Columbia University Medical<br />

Center, Feinstein Institute for Medical Research, New York, NY.<br />

1192. Expession <strong>of</strong> B Cell Subsets in SLE Pregnancy: Correlation<br />

with Preterm Birth. Megan E. B. Clowse 1 , Sara Sparks 2 , Sallie<br />

Allgood 2 , Mark Lanasa 2 and David S. Pisetsky 3 , 1 Duke Univ Med,<br />

Durham, NC, 2 Duke University, Durham, NC, 3 Duke University<br />

Medical Ctr, Durham, NC.<br />

1193. Increased Male Fetal Loss and Fewer Male Siblings in a Cohort<br />

<strong>of</strong> Systemic Lupus Erythematosus Families. Rachna Aggarwal 1<br />

and Robert H. Sc<strong>of</strong>ield 2 , 1 OUHSC, 2 OUHSC, OMRF, VA.<br />

1194. Low Levels <strong>of</strong> Atheroprotective Natural IgM Antibodies Against<br />

Phosphorylcholine and Increased Prevalence <strong>of</strong> Vulnerable<br />

Atherosclerotic Plaques in Patients with SLE. Cristina Anania 2 ,<br />

Thomas Gustafsson 2 , Xiang Hua 2 , Jun Su 2 , Mikael Heimbürger 1 ,<br />

Tomas Jogestrand 2 and Johan Frostegård 2 , 1 Abbot, 2 Karolinska<br />

Institutet.<br />

1195. Presence <strong>of</strong> HMGB1 (High Mobility Group Box 1) and<br />

Antibodies to HMGB1 in Systemic Lupus Erythematosus (SLE).<br />

Deena Abdulahad, Johanna Westra, Pieter Limburg, Cees<br />

Kallenberg and Marc Bijl, UMCG.<br />

1196. Reversal <strong>of</strong> CD3+/CD4+/CD25+/Foxp3+ Treg Depletion in<br />

Active SLE Patients with Rapamycin. Zhiwei Lai 1 , Tiffany N.<br />

Telarico 1 , Adam Bartos 1 , Gabriella Miklossy 1 , Robert Hanczko 1 ,<br />

John Jimah 1 , Brandon Clair 1 , Lisa Francis 1 , Hajra Tily 1 , Ricardo<br />

Garcia 1 , Paul E. Phillips 2 , Irene Ramos 1 and Andras Perl 3 , 1 SUNY,<br />

2<br />

SUNY-Upstate Medical Univ, Syracuse, NY, 3 Upstate Medical<br />

Univ, Syracuse, NY.<br />

1197. Strong Viral Associations among Filipinos with Systemic Lupus<br />

Erythematosus. Evan Glenn Vista 6 , Michael H. Weisman 3 ,<br />

Mariko L. Ishimori 1 , Jourdan Anderson 5 , Robelle Tanangunan 8 ,<br />

Noga Gal 2 , John B. Harley 7 , Guthridge Joel 5 , Sandra Navarra 8<br />

and Judith A. James 4 , 1 Cedars Sinai Medical Center, Los Angeles,<br />

CA, 2 Cedars-Sinai, 3 Cedars-Sinai Medical Center, Los Angeles,<br />

CA, 4 Oklahoma Med Research Foundation, Oklahoma City, OK,<br />

5<br />

Oklahoma Medical Research Foundation, 6 Oklahoma Medical<br />

Research Foundation, Oklahoma City, OK, 7 Univ <strong>of</strong> OK Hlth Sci<br />

Ctr, Oklahoma City, OK, 8 University <strong>of</strong> Santo Tomas Hospital.<br />

1198. TNFα Expression in Peripheral Blood Mononuclear Cells<br />

<strong>of</strong> Cutaneous Lupus & Dermatomyositis Patients. Adam S.<br />

Nabatian 2 , Maria Wysocka 4 , Muhammad M. Bashir 1 and Victoria<br />

P. Werth 3 , 1 Philadelphia VAMC, University <strong>of</strong> Pennsylvania,<br />

2<br />

UMDNJ-Robert Wood Johnson Medical School, Philadelphia<br />

VAMC, University <strong>of</strong> Pennsylvania, 3 University <strong>of</strong> Pennsylvania,<br />

Philadelphia, PA, 4 University <strong>of</strong> Pennsylvania.<br />

222<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

1199. Type I IFN Signature in Pregnant Patients with Lupus. Danieli<br />

Andrade 3 , Gloria C. Koo 3 , Patricia Redecha 3 , Kyriakos A. Kirou 3 ,<br />

Mimi Kim 1 , Mary K. Crow 3 and Jane E. Salmon 2 , 1 Albert Einstein<br />

<strong>College</strong> <strong>of</strong> Medicine, New York, NY, 2 Hospital for Special Surgery,<br />

New York, NY, 3 Hospital for Special Surgery, New York, NY.<br />

1200. Vitamin D and Vascular Stiffness in Patients with Systemic<br />

Lupus Erythematosus. John A. Reynolds 3 , Sahena Haque 4 ,<br />

Jacqueline L. Berry 4 , Lee-Suan Teh 2 , Pauline Ho 1 , Rachel<br />

Gorodkin 1 and Ian N. Bruce 4 , 1 Central Manchester University<br />

Hospitals NHS Foundation Trust, 2 East Lancashire Hospitals NHS<br />

Trust, 3 University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />

4<br />

University <strong>of</strong> Manchester.<br />

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical<br />

Aspects and Therapeutics II<br />

1201. A Pilot Study To Evaluate Digital Perfusion in Scleroderma<br />

Patients Treated with Oral Treprostinil. Ami A. Shah 2 , Laura<br />

K. Hummers 2 , Kristan D. Rollins 4 , Susan Walker 4 , Mike Wade 4 ,<br />

Cynthia Anderson 3 , Robert Wise 3 , Francesco Boin 2 and Fredrick<br />

M. Wigley 1 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns<br />

Hopkins University, Baltimore, MD, 3 Johns Hopkins University,<br />

4<br />

United Therapeutics.<br />

1202. An Analysis <strong>of</strong> Agreement <strong>of</strong> Guidelines for Management<br />

in SSc from a Large Database (CSRG: Canadian Scleroderma<br />

Research Group). Janet E. Pope 3 , Sarah Harding 4 , Sarit Khimdas 4 ,<br />

Ash Bonner 2 , Murray Baron 1 and The CSRG, 1 Jewish General<br />

Hospital, Montreal, QC, Canada, 2 McMaster University, 3 St<br />

Joseph Health Care London, London, ON, Canada, 4 University <strong>of</strong><br />

Western Ontario.<br />

1203. Are SSc Experts Doing What They Should Do? An Analysis <strong>of</strong><br />

Practice Variability in Large SSc Centers within the Canadian<br />

Scleroderma Research Group (CSRG) Shows Practice<br />

Differences. Sarah Harding 4 , Sarit Khimdas 4 , A. Bonner 2 , Murray<br />

Baron 1 and Janet E. Pope 3 , 1 Jewish General Hospital, Montreal,<br />

QC, Canada, 2 McMaster University, 3 St Joseph Health Care<br />

London, London, ON, Canada, 4 University <strong>of</strong> Western Ontario.<br />

1204. Assessing Health Status in Patients with Systemic Sclerosis:<br />

Construct Validity <strong>of</strong> the Karn<strong>of</strong>sky Performance Status Score.<br />

Christelle Nguyen 2 , Alice Bérezné 2 , François Rannou 3 , Caroline<br />

Mestre-Stanislas 2 , Sandrine Morell-Dubois 1 , Loïc Guillevin 2 ,<br />

Serge Poiraudeau 3 and Luc Mouthon 2 , 1 Universite Lille 2 ; Service<br />

de Medecine Interne; Centre de Reference Pour la Sclerodermie<br />

Systemique; Hopital Claude Huriez; Lille; France, 2 Universite<br />

Paris Descartes; Faculte de Medecine Paris Descartes; Pole de<br />

Medecine Interne, Centre de Reference Pour les Vascularites<br />

Necrosantes et la Sclerodermie Systemique; Hopital Cochin;<br />

Assistance Publique-Hopitaux de Paris (AP-HP); 3 Universite<br />

Paris Descartes; Faculte de Medecine Paris Descartes; Service<br />

de Medecine Physique et Readaptation; Hopital Cochin; AP-HP;<br />

Inserm, Institut Federatif de Recherche sur le Handicap, Paris.<br />

1205. Association <strong>of</strong> Gastrointestinal Involvement and Depressive<br />

Symptoms in Patients with Systemic Sclerosis. Vijay Bodukam 1 ,<br />

Ron D. Hays 2 , Paul Maranian 2 , Daniel E. Furst 2 , James R.<br />

Seibold 3 , Ann Impens 4 , Maureen D. Mayes 5 , Philip J. Clements 2<br />

and Dinesh Khanna 2 , 1 Interfaith Medical Center, Brooklyn,<br />

Los Angeles, CA, 2 UCLA, 3 Univ <strong>of</strong> Connecticut, 4 University <strong>of</strong><br />

MIchigan, 5 University <strong>of</strong> Texas Houston.<br />

1206. Bone Mineral Density and Body Composition in Systemic<br />

Sclerosis: A Case-Control Study. Chi Chiu Mok, Ling Yin Ho, Chi<br />

Hung To and Kwok Man Ma, Tuen Mun Hospital.<br />

1207. Clinical Significance <strong>of</strong> Defined ANCA Positivity in Systemic<br />

Sclerosis. Emma C. Derrett-Smith 2 , Svetlana Nihtyanova 2 ,<br />

Jennifer Parker 1 , Christopher Bunn 1 , Aine Burns 1 , Mark A.<br />

Little 1 and Christopher P. Denton 3 , 1 Centre for Immunology,<br />

Royal Free Campus, UCL Medical School, London, 2 Centre for<br />

<strong>Rheumatology</strong> and Connective Tissue Diseases, Royal Free<br />

Campus, UCL Medical School, London, 3 Royal Free Hospital,<br />

London, United Kingdom.<br />

1208. Cognitive Impairment in Systemic Sclerosis. Neslihan Yilmaz 2 ,<br />

Aynur Mollahasanoglu 1 , Meryem Can 2 , Müge Koçak 1 , Nese<br />

Tuncer 1 , Nevsun Inanç 2 and Sule Yavuz 2 , 1 Marmara University,<br />

Faculty <strong>of</strong> Medicine, Neurology Department, Istanbul, Turkey,<br />

2<br />

Marmara University, Faculty <strong>of</strong> Medicine, <strong>Rheumatology</strong><br />

Department, Istanbul, Turkey.<br />

1209. Coronary Artery Calcification in Systemic Sclerosis: There<br />

Was No Difference between SSc and Healthy Control Groups.<br />

Young-Eun Park 2 , Seong-Hu Park 2 , Seung-Hoon Baek 2 , Jun-<br />

Hee Lee 2 , Joung-Wook Lee 2 , Geun-Tae Kim 2 , Yeon-Ju Jeong 3 ,<br />

Su-Yeon Choi 4 , Wan-Hee Yoo 1 and Sung-Il Kim 2 , 1 Chonbuk<br />

National University Medical School, Jeonju, Jeonbuk, South<br />

Korea, 2 Department <strong>of</strong> Internal Medicine, School <strong>of</strong> Medicine,<br />

Pusan National University, Busan, South Korea, 3 Department<br />

<strong>of</strong> Radiology, School <strong>of</strong> Medicine, Pusan National University,<br />

Busan, South Korea, 4 Seoul National University Hospital<br />

Healthcare System Gangnam Center, Seoul, South Korea.<br />

1210. CXCL4, a Novel Marker for Systemic Sclerosis That Clearly<br />

Correlates with the Clinical Hallmarks and Pathological Events.<br />

Timothy Ruben Radstake 3 , Lenny van Bon 2 , Jasper Broen 2 ,<br />

Romy Beatriz-Christmann 1 , Alsya Affandi 1 , Madelon Vonk 2 ,<br />

Mike York 1 , Cindy Collins 1 , Mark Wenink 2 , Roger Hesselstrand 7 ,<br />

Dirk Wuttge 7 , Sandeep Agarwal 6 , John Reveille 6 , Joost Drenth 2 ,<br />

Jaqueline de Graaf 2 , Martin Den Heijer 2 , Cees Kallenberg 5 , Marc<br />

Bijl 4 , Wim van den Berg 2 , Joosten Leo 2 , Waander van Heerde 2 ,<br />

Piet van Riel 2 and Robert Lafyatis 1 , 1 Boston Medical Center,<br />

2<br />

Radboud University Nijmegen Medical Center, 3 Radboud<br />

University Nijmegen Medical Center / Boston Medical Center,<br />

Nijmegen, The Netherlands, 4 University Hospital Groninge,<br />

5<br />

University Hospital Groningen, 6 University Hospital Houston,<br />

TX, 7 University Hospital Lund, Sweden.<br />

1211. Determinants <strong>of</strong> Work Disability in Patients with Systemic<br />

Sclerosis: A Longitudinal Study <strong>of</strong> the GENISOS Cohort.<br />

Roozbeh Sharif 2 , Maureen D. Mayes 8 , Perry M. Nicassio 1 ,<br />

Emilio B. Gonzalez 6 , Hilda T. Draeger 5 , Terry A. McNearney 7 ,<br />

Deepthi K. Nair 3 , John D. Reveille 4 , Frank C. Arnett 9 and Shervin<br />

Assassi 2 , 1 Department <strong>of</strong> Psychiatry, University <strong>of</strong> California, Los<br />

Angeles, CA, 2 Division <strong>of</strong> <strong>Rheumatology</strong> and Immunogenetics,<br />

University <strong>of</strong> Texas Health Science Center at Houston, Houston,<br />

TX, 3 Division <strong>of</strong> <strong>Rheumatology</strong> and Immunogenetics, University<br />

<strong>of</strong> Texas Health Science Center at Houston, Houston, TX, 4 Univ<br />

Texas Health Sci Ctr, Houston, TX, 5 University <strong>of</strong> Texas Health<br />

Science Center at San Antonio, San Antonio, TX, 6 University <strong>of</strong><br />

Texas Medical Branch at Galveston, Galveston, TX, 7 University<br />

<strong>of</strong> Texas Medical Branch at Galveston, TX, 8 University <strong>of</strong> Texas-<br />

Houston, Houston, TX, 9 UT Medical School, Houston, TX.<br />

1212. Developing a Disease Activity and Therapeutic Response Index<br />

in Connective Tissue Disease Related Interstitial Lung Disease<br />

(CTD-ILD): Rationale, Aims, Design and Results from Tier 0,<br />

the Pre-Delphi Exercise. Lesley Ann Saketkoo 4 , Dörte Huscher 2 ,<br />

Dinesh Khanna 12 , Paul F. Dellaripa 1 , Kevin Flaherty 15 , Eric L.<br />

Matteson 5 , Chester V. Oddis 16 , Kristine Phillips 14 , David Pittrow 3 ,<br />

Athol Wells 8 , Christopher P. Denton 9 , Oliver Distler 11 , Otylia M.<br />

Kowal-Bielecka 6 , Vibeke Strand 10 , Kevin K. Brown 7 and James R.<br />

2010 Program Book 223


ACR/ARHP Poster Session B<br />

Seibold 13 , 1 Brigham & Womens Hospital, Boston, MA, 2 German<br />

Rheumatism Research Centre - Berlin, Berlin, Germany,<br />

3<br />

Institute <strong>of</strong> Clinical Pharmacology, Medical Faculty, University<br />

<strong>of</strong> Dresden, Dresden, Germany, 4 Louisiana State University<br />

Health Sciences Center - New Orleans, New Orleans, LA,<br />

5<br />

Mayo Clinic, Rochester, MN, 6 Medical University <strong>of</strong> Bialystok,<br />

Bialystok, Poland, 7 National Jewish Health, Denver, CO, 8 Royal<br />

Brompton Hospital and National Heart and Lung Institute,<br />

London, United Kingdom, 9 Royal Free Hospital, London, United<br />

Kingdom, 10 Stanford University; Palo Alto, Portola Valley, CA,<br />

11<br />

University Hospital Zurich, Zurich, Switzerland, 12 University<br />

<strong>of</strong> California Los Angeles, Los Angeles, CA, 13 University <strong>of</strong><br />

Connecticut Health Center, Farmington, CT, 14 University <strong>of</strong><br />

Michigan, Ann Arbor, MI, 15 University <strong>of</strong> Michigan, Ann Arbor,<br />

16<br />

University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

1213. Development <strong>of</strong> a Limited Scleroderma Cutaneous Activity and<br />

Damage Index. Lorinda Chung 1 , Daniel E. Furst 5 , Paul Maranian 3 ,<br />

Kait Arefiev 2 , Jeffrey Zwerner 2 , Dinesh Khanna 4 , Victoria P.<br />

Werth 6 and David Fiorentino 2 , 1 Stanford Univ Medical Center,<br />

Palo Alto, CA, 2 Stanford Univ Medical Center, 3 UCLA Medical<br />

School, 4 University <strong>of</strong> California Los Angeles, Los Angeles,<br />

CA, 5 University <strong>of</strong> California Los Angeles Medical School, Los<br />

Angeles, CA, 6 University <strong>of</strong> Pennsylvania, Philadelphia, PA.<br />

1214. Effect <strong>of</strong> Selective and Dual Endothelin Receptor Antagonists<br />

(ERAs) on SSc and Control Endothelial Cells Apoptosis.<br />

Yongqing Wang, Omar R. Kahaly and Bashar Kahaleh, University<br />

<strong>of</strong> Toledo, Toledo, OH.<br />

1215. Findings in Ocular Examination <strong>of</strong> Patients with Systemic<br />

Sclerosis. Niki Tsifetaki 3 , Charalampos Papagoras 3 , Contantinos<br />

A. Paschides 1 and Alexandros A. Drosos 2 , 1 Department <strong>of</strong><br />

Ophthalmology, Medical School, University <strong>of</strong> Ioannina,<br />

Ioannina, Greece, 2 Ioannina Medical School, Ioannina, Greece,<br />

3<br />

<strong>Rheumatology</strong> Clinic, Department <strong>of</strong> Internal Medicine,<br />

Medical School, University <strong>of</strong> Ioannina, Ioannina, Greece.<br />

1216. Genetic and Clinical Correlates <strong>of</strong> Anti-Fibrillarin (U3-RNP)<br />

Auto-Antibodies in African <strong>American</strong>s with Systemic Sclerosis.<br />

Roozbeh Sharif 2 , Marvin J. Fritzler 4 , John D. Reveille 3 , Shervin<br />

Assassi 1 , Maureen D. Mayes 5 and Frank C. Arnett 6 , 1 Univ <strong>of</strong><br />

Texas Health Science, Houston, TX, 2 Univ <strong>of</strong> Texas Health<br />

Science Center at Houston, Houston, TX, 3 Univ Texas Health Sci<br />

Ctr, Houston, TX, 4 University <strong>of</strong> Calgary, Calgary, AB, Canada,<br />

5<br />

University <strong>of</strong> Texas-Houston, Houston, TX, 6 UT Medical School,<br />

Houston, TX.<br />

1217. Impact <strong>of</strong> Systemic Sclerosis on Occupational and Pr<strong>of</strong>essional<br />

Activity with Attention to Patients with Digital Ulcers. Alice<br />

Berezne 3 , Raphaele Seror 2 , Sandrine Morell-Dubois 1 , Christelle<br />

Nguyen 4 , Eric Hachulla 1 , Loic Guillevin 4 and Luc Mouthon 4 ,<br />

1<br />

Service de Medecine Interne, Centre de Reference Pour la<br />

Sclerodermie Systemique, Hôpital Claude Huriez, Universite<br />

Lille 2 , Lille, France, Metropolitan, 2 Université Paris Descartes,<br />

Faculté de Médicine, Pôle de Médecine Interne, Centre de<br />

Reference Pour les Vascularites Necrosantes et la Sclerodermie<br />

Systemique, Hôpital Cochin, Assistance Publique-Hopitau,<br />

3<br />

Universite Paris Descartes, Faculte de Medicine, Pôle de<br />

Medecine Interne, Centre de Reference Pour les Vascularites<br />

Necrosantes et la Sclerodermie Systemique, Hôpital Cochin,<br />

Assistance Publique-Hôpitaux de Paris, Paris, Fra, 4 Universite<br />

Paris Descartes, Faculte de Medicine, Pole de Medecine Interne,<br />

Centre de Reference Pour les Vascularites Necrosantes et la<br />

Sclerodermie Systemique, Hopital Cochin, Assistance Publique-<br />

Hopitaux de Paris (AP-HP), Paris, France, Metro.<br />

1218. Is Surfactant D or CC-Chemokine Ligand 18 Biomarkers<br />

for Interstitial Lung Disease in Systemic Sclerosis? Shervin<br />

Assassi 2 , Julio Charles 3 , Frank C. Arnett 7 , Roozbeh Sharif 2 ,<br />

Robert E. Lasky 3 , Emilio B. Gonzalez 5 , Hilda T. Draeger 4 , Terry<br />

A. McNearney 1 , Sandeep K. Agarwal 2 , Ramana V. Gutala 3 , Rosa<br />

M. Estrada-Y-Martin 3 and Maureen D. Mayes 6 , 1 Eli Lilly and<br />

Co, Indianapolis, IN, 2 Univ <strong>of</strong> Texas Health Science Center at<br />

Houston, Houston, TX, 3 Univ <strong>of</strong> Texas Health Science Center at<br />

Houston, 4 Univ <strong>of</strong> Texas Health Science Center at San Antonio,<br />

San Antonio, TX, 5 Univ <strong>of</strong> Texas Medical Branch Galveston,<br />

Galveston, TX, 6 University <strong>of</strong> Texas-Houston, Houston, TX, 7 UT<br />

Medical School, Houston, TX.<br />

1219. Longitudinal Fatigue Severity Scale Scores Correlate with<br />

Modifiable Psychosocial Variables in Early Systemic Sclerosis.<br />

Astrud Lorraine Leyva 3 , Shervin Assassi 1 , Maureen D. Mayes 6 ,<br />

Deepthi K. Nair 1 , Michael Fischbach 2 , Roozbeh Sharif 1 , John D.<br />

Reveille 5 , Emilio B. Gonzalez 3 and Terry A. McNearney 4 , 1 Univ<br />

<strong>of</strong> Texas Health Science Center Houston, Houston, TX, 2 Univ <strong>of</strong><br />

Texas Health Science Center San Antonio, San Antonio, TX, 3 Univ<br />

<strong>of</strong> Texas Medical Branch, Galveston, TX, 4 Univ <strong>of</strong> Texas Medical<br />

Branch; Currently at Eli Lilly and Co, Indianapolis, IN, 5 Univ<br />

Texas Health Sci Ctr, Houston, TX, 6 University <strong>of</strong> Texas-Houston,<br />

Houston, TX.<br />

1220. Loss <strong>of</strong> Microvascular Response to Central Nervous Impulses<br />

to Finger Pulp in Systemic Sclerosis. Tone Kristin Bergersen 2 ,<br />

Anna-Maria H<strong>of</strong>fmann-Vold 1 , Oivind Midtvet 2 , Jan Tore Gran 2 ,<br />

Cato Mork 2 and Karin Toska 3 , 1 Oslo University Hospital, Oslo,<br />

PO Box 4950 Nydalen, Norway, 2 Oslo University Hospital, Oslo,<br />

Norway, 3 University <strong>of</strong> Oslo, PO Box 1103 Blindern, Norway.<br />

1221. Lower Education as a Proxy for Socioeconomic Status Is? Not<br />

Associated with Poor Outcomes in Systemic Sclerosis (SSc):<br />

Data from a Large SSc Cohort (Canadian Scleroderma Research<br />

Group). Samah Mansour 4 , Ashley Bonner 2 , Murray Baron 1 , Janet<br />

E. Pope 3 and The CSRG, 1 Jewish General Hospital, Montreal, QC,<br />

Canada, 2 McMaster University, 3 St Joseph Health Care London,<br />

London, ON, Canada, 4 University <strong>of</strong> Western Ontario.<br />

1222. Open Label Trial <strong>of</strong> Oral Treprostinil in Patients with Systemic<br />

Sclerosis and History <strong>of</strong> Digital Ulcers: Multiple Dose<br />

Pharmacokinetics and Tolerability. Elena Schiopu 6 , Laura K.<br />

Hummers 2 , Ami A. Shah 2 , Susan Walker 4 , Kristine Phillips 6 ,<br />

James R. Seibold 5 , Fredrick M. Wigley 1 and Kristan Rollins 3 ,<br />

1<br />

Johns Hopkins University, Baltimore, MD, 2 Johns Hopkins<br />

University, Baltimore, MD, 3 United Therapeutics, RTP, NC,<br />

4<br />

United Therapeutics, 5 University <strong>of</strong> Conneticut, Farmington, CT,<br />

6<br />

University <strong>of</strong> Michigan, Ann Arbor, MI.<br />

1223. Outcomes in a Newly Diagnosed Population <strong>of</strong> Connective<br />

Tissue Disease-Associated Pulmonary Arterial Hypertension<br />

Patients from the REVEAL Registry. Lorinda Chung 4 , Lori<br />

Parsons 1 , Paul M. Hassoun 2 , Michael McGoon 3 , David Badesch 6 ,<br />

Dave P. Miller 1 , Mark R. Nicolls 5 and Roham T. Zamanian 5 ,<br />

1<br />

ICON Clinical Research, 2 Johns Hopkins University, 3 Mayo<br />

Clinic, 4 Stanford Univ Medical Center, Palo Alto, CA, 5 Stanford<br />

University, 6 University <strong>of</strong> Colorado.<br />

1224. Patients with Systemic Sclerosis and Anti-Centromere<br />

Antibodies Are Affected with Accelerated Atherosclerosis.<br />

Annica Nordin 2 , Lena Björnådal 3 , Kerstin Jensen-Urstad 1<br />

and Elisabet Svenungsson 4 , 1 Dept. <strong>of</strong> Clinical Physiology,<br />

Södersjukhuset, Karolinska Institutet, Sweden, 2 Dept. <strong>of</strong><br />

Medicine, <strong>Rheumatology</strong> Unit, Karolinska Institutet, Stockholm,<br />

Sweden, 3 Dept. <strong>of</strong> Medicine, <strong>Rheumatology</strong> Unit, Karolinska<br />

Institutet, Sweden, Sweden, 4 Dept. <strong>of</strong> Medicine, <strong>Rheumatology</strong><br />

Unit, Karolinska Institutet, Sweden.<br />

224<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

1225. Physician Opinion <strong>of</strong> Variables That Differentiate Disease<br />

Activity and Damage in Systemic Sclerosis. Geneviève Gyger,<br />

Ernest Lo, Marie Hudson, Canadian Scleroderma Research<br />

Group and Murray Baron, McGill, Canada.<br />

1226. Plasma Endogenous Met- and Leu-Enkephalin Levels Are<br />

Decreased and Associated with Clinical and Laboratory<br />

Parameters in Early Systemic Sclerosis. Terry A. McNearney 4 ,<br />

Kathleen A. Sluka 2 , Chul W. Ahn 5 , John D. Reveille 6 , Michael<br />

Fischbach 1 and Maureen D. Mayes 3 , 1 Univ Texas Hlth Sci Ctr<br />

at San Antonio, San Antonio, TX, 2 University <strong>of</strong> Iowa Medical<br />

Center, Iowa City, IA, 3 University <strong>of</strong> Texas -Houston Health<br />

Sciences Center, Houston, TX, 4 University <strong>of</strong> Texas Medical<br />

Branch, Galveston, TX, 5 University <strong>of</strong> Texas Southwestern<br />

Medical Center, Dallas, TX, 6 University <strong>of</strong> Texas-Houston Health<br />

Sciences Center, Houston, TX.<br />

1227. Predictors <strong>of</strong> Interstitial Lung Disease in Early Systemic<br />

Sclerosis: A Prospective Longitudinal Study. Shervin Assassi 2 ,<br />

Roozbeh Sharif 2 , Robert E. Lasky 3 , Terry A. McNearney 1 , Rosa<br />

Estrada Y Martin 3 , Hilda T. Draeger 4 , Deepthi K. Nair 3 , Marvin<br />

J. Fritzler 6 , John D. Reveille 5 , Frank C. Arnett 8 and Maureen D.<br />

Mayes 7 , 1 Eli Lilly and Co, Indianapolis, IN, 2 Univ <strong>of</strong> Texas Health<br />

Science Houston, Houston, TX, 3 Univ <strong>of</strong> Texas Health Science<br />

Houston, 4 Univ <strong>of</strong> Texas Health Science San Antonio, San<br />

Antonio, TX, 5 Univ Texas Health Sci Ctr, Houston, TX, 6 University<br />

<strong>of</strong> Calgary, Calgary, AB, Canada, 7 University <strong>of</strong> Texas-Houston,<br />

Houston, TX, 8 UT Medical School, Houston, TX.<br />

1228. Prevalence and Correlates <strong>of</strong> Sleep Disturbance in Systemic<br />

Sclerosis — Results from the UCLA Scleroderma Quality <strong>of</strong> Life<br />

Study. Tracy M. Frech 1 , Ron D. Hays 2 , Paul Maranian 3 , Philip J.<br />

Clements 6 , Daniel E. Furst 5 and Dinesh Khanna 4 , 1 Department<br />

<strong>of</strong> Internal Medicine, University <strong>of</strong> Utah, Salt Lake City, UT,<br />

2<br />

Division <strong>of</strong> General Internal Medicine, David Geffen School <strong>of</strong><br />

Medicine, Los Angeles, CA, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, David<br />

Geffen School <strong>of</strong> Medicine, Los Angeles, CA, 4 University <strong>of</strong><br />

California Los Angeles, Los Angeles, CA, 5 University <strong>of</strong> California<br />

Los Angeles Medical School, Los Angeles, CA, 6 University <strong>of</strong><br />

California Los Angeles School <strong>of</strong> Medicine, Los Angeles, CA.<br />

1229. Prevalence <strong>of</strong> Associated Autoimmune Diseases in a Spanish<br />

Population with Systemic Sclerosis. Esther Francisca Vicente 2 ,<br />

María Jesús García-Arias 2 , Rosario García-Vicuña 2 , Alicia<br />

Humbría 2 , Juan Pedro López-Bote 2 and Santos Castañeda 1 ,<br />

1<br />

<strong>Rheumatology</strong> Department, Hospital Universitario de<br />

La Princesa, IIS Princesa, Madrid, Spain, 2 <strong>Rheumatology</strong><br />

Department, Hospital Universitario de La Princesa, IIS Princesa.<br />

1230. Serum Chemokine and Cytokine Levels as Indicators <strong>of</strong> Disease<br />

Activity in Patients with Systemic Sclerosis. Minoru Hasegawa,<br />

Manabu Fujimoto, Kazuhiko Takehara and Shinichi Sato,<br />

Kanazawa University.<br />

1231. Severe Pulmonary Fibrosis Is Uncommon in Scleroderma<br />

Patients with RNA Polymerase 3 Antibody. Virginia D. Steen 1 ,<br />

Robyn T. Domsic 2 and Thomas Medsger 2 , 1 Georgetown<br />

University, Washington, DC, 2 University <strong>of</strong> Pittsburgh.<br />

1232. Survival in Pulmonary Hypertension Associated with<br />

Scleroderma-Spectrum Disease: A Single Center Experience.<br />

Dinesh Khanna, Rajeev Saggar, Daniel Furst, Paul Maranian,<br />

Philip Clements and Rajan Saggar, UCLA.<br />

1233. Systemic Sclerosis Is an Independent Predictive Factor to<br />

Coronary Atherosclerosis. Mo Yin Mok, Chak Sing Lau, Sonny<br />

Chiu, Annette Tso, Ka Fung Mak, Woon Sing Wong, Pek Lan<br />

Khong and Karen S. L. Lam, The University <strong>of</strong> Hong Kong, Queen<br />

Mary Hospital, Hong Kong.<br />

1234. The Psychological Impact <strong>of</strong> Systemic Sclerosis-Related<br />

Telangiectases. Holly Ennis 3 , Helen L. Richards 1 , Claire Cassidy 3<br />

and Ariane L. Herrick 2 , 1 Mercy University Hospital, Cork, Co.<br />

Cork, Ireland, 2 Rheumatic Diseases Centre, Trust Salford, United<br />

Kingdom, 3 University <strong>of</strong> Manchester, Manchester, United<br />

Kingdom.<br />

1235. The Use <strong>of</strong> Calcium-Channel Blockers May Prevent the<br />

Development <strong>of</strong> Scleroderma Renal Crisis. Gaia Montanelli,<br />

Lorenzo Beretta, Alessandro Santaniello and Raffaella Scorza,<br />

Referral Center for Systemic Autoimmune Diseases.<br />

1236. Time <strong>of</strong> Transition through Different Patterns <strong>of</strong> Nailfold<br />

Microangiopathy in Systemic Sclerosis. Alberto Sulli 1 , Carmen<br />

Pizzorni 2 , Francesca Ravera 2 , Elisa Alessandri 2 , Giuseppe<br />

Zampogna 2 , Bruno Seriolo 2 and Maurizio Cutolo 1 , 1 Research<br />

Laboratory and Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Genova,<br />

Genova, Italy, 2 Research Laboratory and Academic Unit <strong>of</strong><br />

Clinical <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />

University <strong>of</strong> Genova, Genova, Italy.<br />

1237. Ultrasonographic Assessment <strong>of</strong> Hand Joint and Tendon<br />

Involvement in 30 Patients with Systemic Sclerosis. Emmanuel<br />

Chatelus, Hélène Chifflot, Viriginie Clavert, Christelle<br />

Sordet, Jacques-Eric Gottenberg and Jean Sibilia, Hospital <strong>of</strong><br />

Hautepierre, Strasbourg, France.<br />

1238. Vaccination Against Influenza in Patients with Scleroderma.<br />

Irena Litinsky 3 , Alexandra Balbir 2 , Devy Zisman 4 , Michal<br />

Mandelboim 1 , Ella Mendelson 1 , Marina Anouk 3 , Ilana Kaufman 3 ,<br />

Daphna Paran 3 and Ori Elkayam 3 , 1 Central Virology Laboratory,<br />

Sheba Medical Center, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Rambam Health Care Campus Background, 3 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Tel Aviv Medical Center, 4 <strong>Rheumatology</strong> Service,<br />

Carmel Medical Center.<br />

1239. Wound Fluid <strong>of</strong> Skin Ulcers in Systemic Sclerosis: Cellular and<br />

Cytokines’ Pr<strong>of</strong>ile Helps To Define Healers Versus Non Healers<br />

Characteristics. Stefano Alivernini 1 , Barbara Tolusso 2 , Mariarita<br />

Gigante 2 , Annunziata Capacci 2 , Francesca Faustini 2 , Silvia<br />

Laura Bosello 2 , Maria De Santis 2 and Gianfranco Ferraccioli 1 ,<br />

1<br />

<strong>Rheumatology</strong> Division, Catholic University <strong>of</strong> the Sacred Heart,<br />

Rome, Rome, Italy, 2 <strong>Rheumatology</strong> Division, Catholic University<br />

<strong>of</strong> the Sacred Heart, Rome, Italy, Italy.<br />

T Cell Biology and Targets in Autoimmune Disease<br />

1240. A Novel Role for the Jak-Stat Pathway in Rheumatoid Arthritis:<br />

Inhibition <strong>of</strong> TNF-Induced T Cell Attracting Chemokine<br />

Synthesis in Fibroblast-Like Synoviocytes (FLS) by Tasocitinib.<br />

Sanna Rosengren 2 , Gary S. Firestein 2 and David L. Boyle 1 , 1 UCSD<br />

Schl <strong>of</strong> Medicine, La Jolla, CA, 2 UCSD School <strong>of</strong> Medicine, La<br />

Jolla, CA.<br />

1241. A Th17 Immune Response Can Be Amplified by Human Th9<br />

Cells. Andreas Ramming 1 , Hendrik Schulze-Koops 2 and Alla<br />

Skapenko 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Munich,<br />

Munich, Bavaria, Germany, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

University <strong>of</strong> Munich, Munich, Germany.<br />

1242. Addition <strong>of</strong> Retinoic Acid and TGF-beta Accelerate the<br />

Maturation Naive CD8+ Cells into CD8+CD25+FOXP3+<br />

Regulatory Cells. J. Dixon Gray 1 , Stephanie Q. Pan 2 and David<br />

A. Horwitz 1 , 1 University <strong>of</strong> Southern California, Los Angeles, CA,<br />

2<br />

University <strong>of</strong> Southern California.<br />

2010 Program Book 225


ACR/ARHP Poster Session B<br />

1243 An Assessment <strong>of</strong> the Thromboembolic Potential <strong>of</strong> CDP7657,<br />

a Monovalent Fab’ PEG Anti-CD40L Antibody, in Rhesus<br />

Macaques. Ian Wakefield 2 , Olivier Harari 2 , David Hutto 1 , Linda<br />

Burkly 1 , Janine Ferrant 1 , Fred Taylor 1 , Martyn Robinson 2 ,<br />

Anthony Shock 2 , Timothy Bourne 2 and Christopher Peters 2 ,<br />

1<br />

Biogen Idec, 2 UCB.<br />

1244. Blockade <strong>of</strong> CD40L with a Monovalent Fab’ PEG Monoclonal<br />

Antibody Inhibits Disease in the Murine Collagen-Induced<br />

Arthritis Model. Alexander Vugler 2 , Daniel Sutton 2 , Diane<br />

Marshall 2 , Stevan Shaw 2 , Linda Burkly 1 , Janine Ferrant 1 , Ellen<br />

Garber 1 and Anthony Shock 2 , 1 Biogen Idec, 2 UCB.<br />

1245. CDP7657, a Monovalent Fab’ PEG Anti-CD40L Antibody,<br />

Inhibits Immune Responses in Both HuSCID Mice and Non-<br />

Human Primates. Ian Wakefield 2 , Christopher Peters 2 , Linda<br />

Burkly 1 , Ellen Garber 1 , Janine Ferrant 1 , Fred Taylor 1 , Lihe Su 1 ,<br />

Yen-Ming Hsu 1 , Martyn Robinson 2 , Timothy Bourne 2 , Roger<br />

Palframan 2 , Lisa Berry 2 , Olivier Harari 2 and Anthony Shock 2 ,<br />

1<br />

Biogen Idec, 2 UCB.<br />

1246. Characterization <strong>of</strong> Human Follicular Helper T Cells. Sang Taek<br />

Kim 3 , Jin-Young Choi 4 , Begona Lainez 4 , Leah DiPlacido 1 , Vivian E.<br />

Vlamakis 2 and Joseph E. Craft 4 , 1 Department <strong>of</strong> Immunobiology,<br />

Yale University School <strong>of</strong> Medicine, New Haven, CT, 2 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, University <strong>of</strong> Washington School <strong>of</strong> Medicine,<br />

Bothell, WA, 3 Section <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine, Yale University School <strong>of</strong> Medicine, Orange, CT,<br />

4<br />

Section <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />

Yale University School <strong>of</strong> Medicine, New Haven, CT.<br />

1247. Chronic Inflammatory Responses in Rheumatoid Arthritis:<br />

The Vicious Circle Might Be Related to Interaction <strong>of</strong> Th17<br />

Cells with FLS or Mesenchymal Stem Cells. Assia Eljaafari 1 ,<br />

Marie-Laure Tartelin 1 and Pierre Miossec 2 , 1 HCL and UCBL, Lyon,<br />

France, 2 HCL and UCBL, France.<br />

1248. Circulating FOXP3+ CTLA-4+ CD25+ Regulatory T Cells in<br />

Human Infants Counteract the Maturation and Homing<br />

Receptor Switch <strong>of</strong> CD4+ T Cells at 18 and 36 Months <strong>of</strong><br />

Age. Hardis Rabe 2 , Anna-Carin Lundell 2 , Kerstin Andersson 2 ,<br />

Ingegerd Adlerberth 1 , Agnes E. Wold 1 and Anna Rudin 3 , 1 Dept <strong>of</strong><br />

Clinical Bacteriology, 2 Dept <strong>of</strong> <strong>Rheumatology</strong> and Inflammation<br />

Research, 3 Dept <strong>of</strong> <strong>Rheumatology</strong> and Inflammation Research,<br />

The Sahlgrenska Academy at University <strong>of</strong> Gothenburg,<br />

Gothenburg, Sweden.<br />

1249. Critical Role <strong>of</strong> IL-21 in Modulating Th17 Responses and<br />

Regulatory T Cells in Behçet Disease. Guillaume Geri 1 , Benjamin<br />

Terrier 1 , Michelle Rosenzwajg 1 , Bertrand Wechsler 2 , Du Le<br />

Boutin 1 , Bahram Bodaghi 1 , Tu-Ahn Tran 1 , Nathalie Costedoat-<br />

Chalumeau 2 , Lucile Musset 1 , David Klatzman 1 , Patrice Cacoub 1<br />

and David Saadoun 1 , 1 Pitié-Salpetrière Hospital, Paris, France,<br />

2<br />

Pitie-Salpetriére Hospital, Paris, France.<br />

1250. CXCL13 Signals through CXCR5 To Upregulate Nuclear CXCR5<br />

and Bcl-6 and Promote the Development <strong>of</strong> Follicular T Helper<br />

Cells in Autoimmune BXD2 Mice. Yanna Ding 3 , Hui-Chen Hsu 1<br />

and John D. Mountz 2 , 1 Department <strong>of</strong> Medicine, The University<br />

<strong>of</strong> Alabama at Birmingham, 2 Department <strong>of</strong> Medicine, The<br />

University <strong>of</strong> Alabama at Birmingham; Birmingham VA Medical<br />

Center, 3 Department <strong>of</strong> Pathology, The Univerisity <strong>of</strong> Alabama at<br />

Birmingham.<br />

1251. Decreasing Fli1 Levels in Lupus T Cells Has Effects on Serum<br />

Immunoglobulin Levels and T Cell Infiltration in the Kidney.<br />

Erin Morris 1 , Maria I. Harrell 1 , John Svenson 1 , Laura Tonks 1 , John<br />

Zhang 3 and Tamara K. Nowling 2 , 1 MUSC, 2 Ralph Johnson VAMC/<br />

MUSC, Charleston, SC, 3 Ralph Johnson VAMC/MUSC.<br />

1252. Dendritic Cells and Continued Smoking in Rheumatoid<br />

Arthritis. Marina Kazantseva 3 , John Highton 1 , Lisa K. Stamp 4<br />

and Paul A. Hessian 2 , 1 Univ <strong>of</strong> Otago Med Sch, Dunedin,<br />

New Zealand, 2 University <strong>of</strong> Otago, Dunedin, New Zealand,<br />

3<br />

University <strong>of</strong> Otago, Dundein, New Zealand, 4 University <strong>of</strong><br />

Otago, Christchurch, New Zealand.<br />

1253. DNA Methylation Affects Gene Expression in CD4+CD28- T<br />

Cells through microRNAs. Dipak R. Patel, Anura Hewagama,<br />

Sushma Yarlagadda and Bruce C. Richardson, University <strong>of</strong><br />

Michigan, Ann Arbor, MI.<br />

1254. Dys-Regulation <strong>of</strong> T-Cell Subsets and Cytokines Is Associated<br />

with the Development <strong>of</strong> Inflammatory Symptoms in ACPA-<br />

Positive Asymptomatic Individual. Richard J. Cuthbert 2 , Rekha<br />

Parmar 2 , Jackie Nam 2 , Edith Villeneuve 2 , Diane Corscadden 2 ,<br />

Karen Henshaw 2 , Paul Emery 1 and Frederique Ponchel 2 , 1 Chapel<br />

Allerton Hospital, Leeds, United Kingdom, 2 University <strong>of</strong> Leeds,<br />

Leeds, UK.<br />

1255. Expression <strong>of</strong> K2P5.1 Potassium Channels on CD4+ T<br />

Lymphocytes Correlates with Disease Activity in Rheumatoid<br />

Arthritis Patients. Martin Feuchtenberger 2 , Stefan Bittner 3 ,<br />

Nicole Bobak 3 , Alexander M. Herrmann 3 , Kerstin Goebel 3 , Stefan<br />

Kleinert 3 , Heinz Wiendl 1 , Hans-Peter Tony 3 and Sven G. Meuth 3 ,<br />

1<br />

University <strong>of</strong> Muenster, 2 University <strong>of</strong> Wuerzburg, Wuerzburg,<br />

Germany, 3 University <strong>of</strong> Wuerzburg.<br />

1256. Foxp3+ CD4+ Tregs Prevent Arthritis by Promoting Clonal<br />

Anergy Induction in Self Ag-Specific CD4+ T Cells. Ryan<br />

Martinez 2 , Na Zhang 2 , Sara Nandiwada 2 , Stephanie Thomas 2 ,<br />

Bryce Binstadt 2 and Daniel L. Mueller 1 , 1 University <strong>of</strong> Minnesota<br />

Medical School, Minneapolis, MN, 2 University <strong>of</strong> Minnesota<br />

Medical School.<br />

1257. Gender and Sex Hormones Influence CD4+ Regulatory T Cells<br />

and Their Expression <strong>of</strong> FoxP3 in Healthy People and in SLE.<br />

Ravi K. Dinesh 1 , Bevra H. Hahn 2 and Ram P. Singh 1 , 1 David Geffen<br />

Schl <strong>of</strong> Med/UCLA, Los Angeles, CA, 2 University <strong>of</strong> California Los<br />

Angeles School <strong>of</strong> Medicine, Los Angeles, CA.<br />

1258. Identification <strong>of</strong> a Pathological TCR <strong>of</strong> Autoantibody-Inducing<br />

CD4+ T Cell That Induces Autoantibodies and Lupus-Like<br />

Immune Tissue Injury. Kohsuke Yoshida 1 , Ken Tsumiyama 2 and<br />

Shunichi Shiozawa 3 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />

Graduate School <strong>of</strong> Health Sciences, Kobe, Hyogo, Japan,<br />

2<br />

Department <strong>of</strong> Biophysics, Kobe University Graduate School <strong>of</strong><br />

Health Sciences, Kobe, Japan, 3 Department <strong>of</strong> Biophysics, Kobe<br />

University Graduate School <strong>of</strong> Health Sciences/Department <strong>of</strong><br />

Medicine, Kobe University Graduate School <strong>of</strong> Medicine/The<br />

Center for Rheumatic Diseases, Kobe University Hospital, Kobe,<br />

Japan.<br />

1259. IL-23 Suppresses IL-22 Levels and AHR Expression in Human<br />

CCR6+ Memory T Cells. Ferry Cornelissen, Jan Piet van<br />

Hamburg, Nadine Davelaar, Patrick Asmawidjaja, Anne-Marie<br />

Mus and Erik Lubberts, Erasmus MC, University Medical Center.<br />

1260. IL-23-Mediated RORγt Pathway Is Associated with Thymic<br />

Negative Selection <strong>of</strong> Autoreactive T Cells. Hao Li 2 , Hui-Chen<br />

Hsu 2 , Qi Wu 2 , PingAr Yang 2 , Jun Li 2 and John D. Mountz 1 , 1 Univ<br />

Alabama at Birmingham, Birmingham, AL, 2 Univ Alabama at<br />

Birmingham.<br />

1261. Immune Regulation by Peripheral Suppressor T Cells Induced<br />

upon Homotypic T Cell Interaction. Katja Thuemmler 1 , Leipe<br />

Jan 1 , Andreas Ramming 1 , Hendrik Schulze-Koops 2 and Alla<br />

Skapenko 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, LMU Munich, Munich,<br />

Germany, 2 LMU Munich, Munich, Germany.<br />

226<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

1262. Late Complement Complex in T Cell Function and Cell Death.<br />

Anil Chauhan 1 , John P. Atkinson 3 and Terry L. Moore 2 , 1 Saint<br />

Louis University, 2 St Louis University, St Louis, MO, 3 Washington<br />

University School <strong>of</strong> Medicine, St Louis, MO.<br />

1263. Linking Power Doppler Ultrasound with Th17 Cells in the RA<br />

Joint. Nicola J. Gullick 1 , Hayley G. Evans 2 , Leigh Church 3 , David<br />

Jayaraj 2 , Andrew Filer 3 , Bruce W. Kirkham 4 and Leonie S. Taams 2 ,<br />

1<br />

CMCBI, King’s <strong>College</strong> London, London, United Kingdom,<br />

2<br />

CMCBI, King’s <strong>College</strong> London, 3 <strong>Rheumatology</strong> Research Group,<br />

University <strong>of</strong> Birmingham, 4 <strong>Rheumatology</strong>, Guy’s& St Thomas’<br />

NHS Foundation Trust.<br />

1264. NKT Cell Is Required for the Break <strong>of</strong> T Cell Anergy, Inducing<br />

Autoantibody, and Generation <strong>of</strong> Autoantibody-Inducing CD4+<br />

T Cell That Causes Systemic Autoimmunity. Yuko Fujita 1 , Ken<br />

Tsumiyama 2 and Shunichi Shiozawa 3 , 1 Depertment <strong>of</strong> Biophysics,<br />

Kobe University Graduate School <strong>of</strong> Health Science, Kobe,<br />

Japan, 2 Depertment <strong>of</strong> Biophysics, Kobe University Graduate<br />

School <strong>of</strong> Health Science, Kobe, Japan, 3 Depertment <strong>of</strong><br />

Biophysics, Kobe University Graduate School <strong>of</strong> Health Science/<br />

Depertment <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />

Medicine/ The Center for Rheumatic Diseases, Kobe University<br />

Hospital, Kobe, Japan.<br />

1265. Peroxisome Proliferator-Activated Receptor α and γ Agonists<br />

Together with TGF-β Convert Human CD4+CD25- T Cells into<br />

Functional Foxp3+ Regulatory T Cells. Hitoshi Hasegawa 1 ,<br />

Jin Lei 2 , Takuya Matsumoto 2 and Masaki Yasukawa 2 , 1 Ehime<br />

University Graduate School <strong>of</strong> Medicine, Toon, Ehime, Japan,<br />

2<br />

Ehime University Graduate School <strong>of</strong> Medicine.<br />

1266. Phenotype and Functional Stability <strong>of</strong> TGF-β-Induced<br />

CD4+Foxp3+ Regulatory T Cells in Steady and Inflammatory<br />

States. NIng Kong 3 , Julie Wang 3 , David Brand 4 , Hejian Zou 1 ,<br />

Xuezhong Yu 2 and Song Guo Zheng 3 , 1 Fudan University Medical<br />

School, 2 H. Lee M<strong>of</strong>fitt Cancer Center and Research Institute,<br />

3<br />

USC Keck School <strong>of</strong> Medicine, 4 VA Medical Center, Memphis.<br />

1267. Plasmacytoid Dendritic Cells Control Peripheral Treg<br />

Conversion to the RNA-Binding Nuclear Self Antigen La/SS-B.<br />

A. Darise Farris 1 , Christina Lawrence 2 and Zi-jian Pan 2 , 1 Arthritis<br />

and Immunology Program, Oklahoma Medical Research<br />

Foundation, Oklahoma City, OK, 2 Oklahoma Medical Research<br />

Foundation, Oklahoma City, OK.<br />

1268. Protective Human CD4+CD25+FOXP3+ Regulatory T Cells<br />

Generated Ex-Vivo with IL-2, Retinoic Acid and TGF-bets Are<br />

Resistant to Pro-Inflammitory Cytokines. Xiaohui Zhou 1 , Chin<br />

Lan 1 , Juhua Wang 1 , Song-guo Zheng 1 and David A. Horwitz 2 ,<br />

1<br />

University <strong>of</strong> Southern California, 2 University <strong>of</strong> Southern<br />

California, Los Angeles, CA.<br />

1269. RANKL Expression in Human T-Lymphocytes Requires<br />

Cooperative Signaling through the T-Cell Receptor and<br />

Adhesion Molecule CD2. Bohdan P. Harvey and Zehra<br />

Kaymakcalan, Abbott Laboratories, Worcester, MA.<br />

1270. Regulation <strong>of</strong> Human T Cell Activation and Effector Functions<br />

by Kv1.3 and KCa3.1 Channels. Gang Chen 1 , Vaishali Patel 1 ,<br />

Rothschild Soto 2 , Chen Shiow-Ling 2 , Sandip Panicker 2 , Philip<br />

A. Nunn 2 and Julie A. DeMartino 2 , 1 Inflammation Discovery,<br />

H<strong>of</strong>fmann-La Roche, Inc., Nutley, NJ, 2 Inflammation Discovery,<br />

H<strong>of</strong>fmann-La Roche, Inc..<br />

1271. Role for IL-23 in Differentiation <strong>of</strong> Human Th17 Cells. Hiroshi<br />

Kato 1 , Laura Cooney 2 , Judith Endres 2 and David A. Fox 3 ,<br />

1<br />

University <strong>of</strong> Michigan, Northville, MI, 2 University <strong>of</strong> Michigan,<br />

Ann Arbor, MI, 3 University <strong>of</strong> Michigan Medical Center, Ann<br />

Arbor, MI.<br />

1272. Self-Organized Criticality Theory for the Cause <strong>of</strong><br />

Autoimmunity. Ken Tsumiyama 1 , Yumi Miyazaki 1 and Shunichi<br />

Shiozawa 2 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />

Graduate School <strong>of</strong> Health Science, Kobe, Japan, 2 Department <strong>of</strong><br />

Biophysics, Kobe University Graduate School <strong>of</strong> Health Science/<br />

Department <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />

Medicine/The Center for Rheumatic Diseases, Kobe University<br />

Hospital, Kobe, Japan.<br />

1273. SGN-70: Phase 1a Study <strong>of</strong> a Novel Humanized Antibody<br />

Targeting CD70 for the Treatment <strong>of</strong> Autoimmune Diseases.<br />

Jonathan G. Drachman 2 , Julie A. McEarchern 2 , Che-Leung Law 2 ,<br />

Luis Lopez-Lazaro 1 , Gabriele Fabian 1 and Michael Seiberling 1 ,<br />

1<br />

Covance Clinical Research Unit AG, Basel, Switzerland, 2 Seattle<br />

Genetics, Inc., Bothell, WA.<br />

1274. Vitamin D Suppresses the Pathogenic Behavior <strong>of</strong> Primary<br />

Th17 Cells from Patients with Early RA in Synovial Fibroblast<br />

Activation. Jan Piet van Hamburg 3 , Patrick Asmawidjaja 3 , Anne-<br />

Marie Mus 3 , Mieke Hazes 2 , Hans van Leeuwen 1 , Edgar Colin 2<br />

and Erik Lubberts 4 , 1 Department <strong>of</strong> Internal Medicine, Erasmus<br />

MC, University Medical Center Rotterdam, 2 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Erasmus MC, University Medical Center<br />

Rotterdam, 3 Departments <strong>of</strong> <strong>Rheumatology</strong> and Immunology,<br />

Erasmus MC, University Medical Center Rotterdam, 4 Erasmus<br />

MC, Rotterdam, ZH, The Netherlands.<br />

Large-Vessel Vasculitis and Behçet’s Disease I<br />

1275. 18F-Fluorodeoxyglucose Positron Emission Tomography<br />

Scanning (FDG-PET/CT) in Evaluation <strong>of</strong> Disease Activity<br />

in Takaysu Arteritis. Øyvind Palm 3 , Birgir Gudbrandsson 2 ,<br />

Torhild Garen 2 , Kjersti Johnsrud 1 and Jan Tore Gran 2 , 1 Section<br />

for Nuclear Medicine, OUS, Rikshospitalet, 2 Section for<br />

<strong>Rheumatology</strong>, OUS, Rikshospitalet, 3 Section for <strong>Rheumatology</strong>,<br />

OUS, Rikshospitalet, Oslo, Norway.<br />

1276. A Double-Blind Placebo Controlled Trial <strong>of</strong> Infliximab<br />

in Patients with Corticosteroid-Dependent Polymyalgia<br />

Rheumatica. Victor M. Martinez-Taboada 11 , Francisco Javier<br />

López-Longo 10 , Rosario García de Vicuña 8 , Jordi Gratacos 5 ,<br />

Georgina Espígol-Frigolé 2 , Julio Medina 6 , Javier Narváez 3 , Rosa<br />

Roselló 7 , Luis Carreño 9 , Iñigo Rua-Figueroa 4 and María Cintia<br />

Cid 1 , 1 Hospital Clinic, Barcelona, Spain, 2 Hospital Clinic, Spain,<br />

3<br />

Hospital de Bellvitge, Barcelona, Spain, 4 Hospital Doctor Negrín,<br />

Spain, 5 Hospital Parc Taulí, Barcelona, Spain, 6 Hospital Río<br />

Carrión, Palencia, Spain, 7 Hospital San Jorge de Huesca, Spain,<br />

8<br />

Hospital Universitario de la Princesa, Madrid, Spain, 9 Hospital<br />

Universitario Gregorio Maranón, Madrid, Spain, 10 Hospital<br />

Universitario Gregorio Maranón, Spain, 11 Hospital Universitario<br />

Marqués de Valdecilla, Santander, Spain.<br />

1277. Adverse Outcomes <strong>of</strong> Glucocorticoid Therapy among Patients<br />

with Giant Cell Arteritis. Laura López Vives, Javier Narvaez,<br />

Paula Estrada, Carmen Gómez Vaquero and Joan Miquel<br />

Nolla, Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario de<br />

Bellvitge, Barcelona, Spain.<br />

1278. Alemtuzumab (CAMPATH-1H) as Remission Induction Therapy<br />

in Behcet’s Disease. Rona M. Smith 1 , Yok W. Chow 2 and David<br />

R. W. Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge, United<br />

Kingdom, 2 Hospital Pantai Ayer Keroh Melaka, Malaysia.<br />

1279. Ankylosing Spondylitis Associated with Takayasu Arteritis.<br />

Süleyman Yildirim, Gülen Hatemi, Sebahattin Yurdakul, Izzet<br />

Fresko and Huri Ozdogan, Istanbul University, Cerrahpasa<br />

Medical School, <strong>Rheumatology</strong>.<br />

2010 Program Book 227


ACR/ARHP Poster Session B<br />

1280. Association <strong>of</strong> VEGF, NOS2, IL6, CCL2 and IL1RN<br />

Polymorphisms and Haplotypes with Susceptibility to Giant<br />

Cell Arteritis. A Simultaneous Study <strong>of</strong> 130 Potentially<br />

Functional SNPs in 14 Candiadte Genes. Anna Enjuanes 4 ,<br />

Yolanda Benavente 8 , Jose Hernandez-Rodriguez 6 , Carme<br />

Queralt 6 , Jordi Yagüe 1 , Pedro Jares 5 , Silvia de Sanjose 7 , Elias<br />

Campo 3 and Maria C. Cid 2 , 1 Department <strong>of</strong> Immunology,<br />

Barcelona, Spain, 2 Department<strong>of</strong> Systemic Autoimmune<br />

Diseases, Hospital Clinic, Barcelona, Spain, 3 Hematopathology<br />

Section, Department <strong>of</strong> Anatomic Pathology, Barcelona, Spain,<br />

4<br />

Hematopathology Section, Department <strong>of</strong> Anatomic Pathology,<br />

Hospital Clinic, Barcelona, Spain, 5 Hematopatholoy Section,<br />

Department <strong>of</strong> Anatomic Pathology, Barcelona, Spain, 6 Systemic<br />

Autoimmune Diseases, Barcelona, Spain, 7 Unit <strong>of</strong> Infection<br />

and Cancer, Cancer Epidemiology Research, Catalan Institute<br />

<strong>of</strong> Oncology, Barcelona, Spain, 8 Unit <strong>of</strong> Infection and Cancer.<br />

Cancer Epidemiology Research. Catalan Institute <strong>of</strong> Oncology.<br />

1281. Behcet’s Disease and the Major Histocompatibility Complex:<br />

Looking beyond HLA-B51. Michael J. Ombrello 2 , Yohei Kirino 2 ,<br />

Fulya Cosan 1 , Ahmet Gul 1 , Daniel L. Kastner 2 and Elaine<br />

F. Remmers 2 , 1 Istanbul Faculty <strong>of</strong> Medicine, Department<br />

<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Istanbul<br />

University, Istanbul, Turkey, 2 Laboratory <strong>of</strong> Clinical Investigation,<br />

NIAMS, NIH, Bethesda, MD.<br />

1282. Circulating Adipokine, Ghrelin and Acylated Ghrelin Levels<br />

in Patients with Takayasu’s Arteritis. Hatice Yilmaz 1 , Vedat<br />

Gerdan 3 , Didem Kozaci 4 , Servet Akar 3 , Gercek Can 3 , Aytac Gulcu 2 ,<br />

Volkan Cakir 2 , Yigit Goktay 2 , Merih Birlik 3 , Nurullah Akkoc 3 and<br />

Fatos Onen 3 , 1 Internal Medicine, Dokuz Eylul University Faculty<br />

<strong>of</strong> Medicine, Izmir, Turkey, 2 Radiology, Dokuz Eylul University<br />

Faculty <strong>of</strong> Medicine, Izmir, Turkey, 3 <strong>Rheumatology</strong>, Dokuz<br />

Eylul University Faculty <strong>of</strong> Medicine, Izmir, Turkey, 4 Science,<br />

Technology Research and Aplication Center, Aydin, Turkey.<br />

1283. Circulating Endothelial Cells and Endothelial Progenitor Cells in<br />

Takayasu Arteritis. Serkan Dogan 2 , Dilek Solmaz 4 , Ozden Piskin 1 ,<br />

Servet Akar 4 , Aytac Gulcu 3 , Faize Yuksel 1 , Volkan Cakir 3 , Gercek<br />

Can 4 , Yigit Goktay 3 , Merih Birlik 4 , Nurullah Akkoc 4 and Fatos<br />

Onen 4 , 1 Hematology, Dokuz Eylul University Faculty <strong>of</strong> Medicine,<br />

Izmir, Turkey, 2 Internal Medicine, Dokuz Eylul University Faculty<br />

<strong>of</strong> Medicine, Izmir, Turkey, 3 Radiology, Dokuz Eylul University<br />

Faculty <strong>of</strong> Medicine, Izmir, Turkey, 4 <strong>Rheumatology</strong>, Dokuz Eylul<br />

University Faculty <strong>of</strong> Medicine, Izmir, Turkey.<br />

1284. Clinical Characteristics, Treatment and Ethnic/Racial<br />

Differences in the Manifestations <strong>of</strong> 518 Behcet’s Syndrome<br />

Patients in the United States. Yusuf Yazici, Maria T. Filopoulos,<br />

Elizabeth Schimmel, Andy McCraken and Christopher<br />

Swearingen, NYU Hospital for Joint Diseases.<br />

1285. Clinical Features <strong>of</strong> Behçet’s Disease with Vascular<br />

Involvement. Hirotoshi Kikuchi 2 , Kurumi Asako 1 , Maki<br />

Takayama 1 , Hajime Kono 1 , Shunsei Hirohata 4 and Yasuo Ono 3 ,<br />

1<br />

Department <strong>of</strong> Internal Medicine, Teikyo University School<br />

<strong>of</strong> Medicine, 2 Department <strong>of</strong> Microbiology and Immunology,<br />

Teikyo University School <strong>of</strong> Medicine, Itabashi-ku, Tokyo,<br />

Japan, 3 Department <strong>of</strong> Microbiology and Immunology, Teikyo<br />

University School <strong>of</strong> Medicine, 4 Department <strong>of</strong> <strong>Rheumatology</strong><br />

and Infectious Disease, Kitasato University School <strong>of</strong> Medicine,<br />

Kanagawa, Japan.<br />

1286. Clinical Spectrum, Angiographic Findings and Outcome in<br />

Takayasu Arteritis, Using the Disease Extent Index for Takayasu<br />

Arteritis (DEI.TAK). Sivakumar M. Rajappa, Cerebrovascular and<br />

Vasculitis Research Foundation, Chennai, Tamilnadu, India.<br />

1287. Cluster Analysis <strong>of</strong> Vascular Involvement in Takayasu Arteritis:<br />

Extension <strong>of</strong> the Lesions Is Contiguous in the Aorta and<br />

Symmetric in Paired Arterial Beds. Laurent Arnaud 1 , Julien<br />

Haroche 1 , Dan Toledano 2 , Patrice Cacoub 1 , Nathalie Costedoat-<br />

Chalumeau 1 , Du Le Thi Huong-Boutin 1 , Philippe Cluzel 2 and<br />

Zahir Amoura 1 , 1 Department <strong>of</strong> Internal Medicine, Groupe<br />

Hospitalier Pitié-Salpêtriere, UPMC Univ Paris 6 , AP-HP, 47-83 bd<br />

de l’Hôpital, Paris, France, 2 Department <strong>of</strong> Radiology, Groupe<br />

Hospitalier Pitié-Salpêtrière, UPMC Univ Paris 6 , AP-HP, 47-83 bd<br />

de l’Hôpital, 75013, Paris, France..<br />

1288. Colchicine Does Not Decrease the Need for<br />

Immunosuppressive Use at Long Term in Behçet’s Syndrome.<br />

Vedat Hamuryudan 3 , Gülen Hatemi 3 , Sebahattin Yurdakul 3 , Cem<br />

Mat 1 , Koray Tascilar 3 , Yilmaz Ozyazgan 2 , Emire Seyahi 3 , Serdal<br />

Ugurlu 3 and Hasan Yazici 3 , 1 Istanbul University, Cerrahpasa<br />

Medical School, Dermatology, 2 Istanbul University, Cerrahpasa<br />

Medical School, Ophthalmology, 3 Istanbul University,<br />

Cerrahpasa Medical School, <strong>Rheumatology</strong>.<br />

1289. Diagnostic Value <strong>of</strong> Pathergy Phenomenon in Behcet’s Disease.<br />

Fereydoun Davatchi, Cheyda Chams-Davatchi, Farhad Shahram,<br />

Bahar Sadeghi Abdollahi, Abdolhadi Nadji, Massoomeh<br />

Akhlaghi, Tahereh Faezi and Roghieh Larimi, <strong>Rheumatology</strong><br />

Research Center, Tehran University <strong>of</strong> Medical Sciences, Tehran,<br />

Islamic Republic <strong>of</strong> Iran.<br />

1290. Disease Activity Assessment in Large Vessel Vasculitis. Luca<br />

Magnani 1 , Annibale Versari 1 , Diana Salvo 1 , Massimiliano Casali 1 ,<br />

Giuseppe Germanò 1 , Riccardo Meliconi 3 , Lia Pulsatelli 2 , Debora<br />

Formisano 1 , Gianluigi Bajocchi 1 , Nicolò Pipitone 1 , Luigi Boiardi 1<br />

and Carlo Salvarani 1 , 1 Arcispedale S Maria Nuova, Reggio<br />

Emilia, Italy, 2 Istituti Ortopedici Rizzoli, Bologna, Bologna, Italy,<br />

3<br />

University <strong>of</strong> Bologna, Bologna, Italy.<br />

1291. Disease Assessment in Takayasu’s Arteritis: Data from a<br />

Literature Search and a Survey <strong>of</strong> Expert Opinion. Haner<br />

Direskeneli 3 , Sibel Z. Aydin 3 , Peter A. Merkel 2 and Turkish<br />

Takayasu Study Group 1 , 1 Istanbul, Turkey, 2 Boston University<br />

School <strong>of</strong> Medicine, West Newton, MA, 3 Marmara University,<br />

School <strong>of</strong> Medicine, Istanbul, Turkey.<br />

1292. Effect <strong>of</strong> Glucocorticoids on Gelatinase (MMP-2 and MMP-<br />

9) Expression in Giant-Cell Arteritis (GCA) Using an Ex-Vivo<br />

Temporal Artery Culture Model. Marc Corbera-Bellalta, Ana<br />

García-Martínez, Ester Planas-Rigol, Ester Lozano, Marta<br />

Segarra, Georgina Espígol-Frigolé, José Hernández-Rodríguez,<br />

Itziar Tavera and Maria C. Cid, Department <strong>of</strong> Systemic<br />

Autoimmune Diseases. Hospital Clínic. University <strong>of</strong> Barcelona,<br />

IDIBAPS, Barcelona, Spain.<br />

1293. Efficacy <strong>of</strong> Cerebrospinal Fluid Testing and Magnetic<br />

Resonance Imaging for Diagnosis <strong>of</strong> Neuro-Behcet’s Disease:<br />

A Multicenter Retrospective Analysis. Shunsei Hirohata 3 ,<br />

Hirotoshi Kikuchi 5 , Tetsuji Sawada 6 , Hiroko Nagafuchi 4 , Masataka<br />

Kuwana 2 , Mitsuhiro Takeno 1 and Yoshiaki Ishigatsubo 7 ,<br />

1<br />

Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />

Yokohama City University Graduate School <strong>of</strong> Medicine, 2 Keio<br />

University School <strong>of</strong> Med, Tokyo, Japan, 3 Kitasato Univ School <strong>of</strong><br />

Med, Kanagawa, Japan, 4 St Marianna University School <strong>of</strong> Med,<br />

5<br />

Teikyo Univ School <strong>of</strong> Med, 6 Tokyo Medical University, Shinjuku<br />

Tokyo, Japan, 7 Yokohama City Grad Sch <strong>of</strong> Med, Yokohama,<br />

Japan.<br />

228<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

1294. Endothelin-1 (ET-1) Induces Collagen Type I and Type III<br />

Production by Temporal Artery-Derived Myointimal Cells.<br />

A Mechanism Potentially Leading to Intimal Hyperplasia in<br />

Giant-Cell Arteritis (GCA). Ester Planas-Rigol, Marc Corbera-<br />

Bellalta, Ester Lozano, Montserrat Butjosa, Sergio Prieto-<br />

González, José Hernández-Rodríguez, Marta Segarra and Maria<br />

C. Cid, Department <strong>of</strong> Systemic Autoimmune Diseases. Hospital<br />

Clínic. University <strong>of</strong> Barcelona, IDIBAPS, Barcelona, Spain.<br />

1295. Expansion <strong>of</strong> Peripheral Blood Plasma Blasts Reflects<br />

Disturbances <strong>of</strong> B Cell Homeostasis in Patients with Takayasu<br />

Arteritis and Success <strong>of</strong> B Cell Depletion Therapy. Bimba F.<br />

Hoyer 3 , Imtiaz M. Mumtaz 3 , Udo Schneider 2 , Rolf Keitzer 1 , Gerd-<br />

Rüdiger Burmester 2 , Andreas Radbruch 5 and Falk Hiepe 4 , 1 Dep.<br />

Pediatric <strong>Rheumatology</strong>, Charité Universityhospital Berlin, 2 Dep.<br />

<strong>Rheumatology</strong> and Clin. Immunology, Charité Universityhospital<br />

Berlin, 3 Dep. <strong>Rheumatology</strong> and Clin. Immunology, Charité<br />

Universityhospital Berlin and German Rheumatism Reserach<br />

Center Berlin, Berlin, Germany, 4 Dep. <strong>Rheumatology</strong> and Clin.<br />

Immunology, Charité Universityhospital Berlin and German<br />

Rheumatism Reserach Center Berlin, 5 German Rheumatism<br />

Reserach Center Berlin.<br />

1296. Expression and Function <strong>of</strong> Toll Like Receptors in Peripheral<br />

Blood Mononuclear Cells <strong>of</strong> Patients with Polymyalgia<br />

Rheumatica and Giant Cell Arteritis. Lorena Alvarez-Rodriguez 4 ,<br />

Marcos Lopez-Hoyos 4 , Cristina Mata 1 , Ana Fontalba 4 , Jaime<br />

Calvo-Alen 1 , Maria Jose Marin 4 , Jose Luis Fernandez-Luna 4 , Jesus<br />

Agüero-Balbin 4 , Maitane Aranzamendi-Zaldunbide 4 , Ricardo<br />

Blanco 4 , Ignacio Villa 2 , Orlando Pompei 4 , Marien Peiro 4 , Teresa<br />

Ruiz 1 and Victor M. Martinez-Taboada 3 , 1 Hospital de Sierrallana,<br />

Spain, 2 Hospital de Sierrallana, 3 Hospital Universitario Marques<br />

de Valdecilla, Santander, Spain, 4 Hospital Universitario Marques<br />

de Valdecilla.<br />

1297. Extracellular HMGB1 Is Increased in Patients with Behcet’s<br />

Disease with Intestinal Involvement. Joong Kyong Ahn 2 ,<br />

You Sun Lee 3 , Eun-Jung Park 4 , Ji-Won Hwang 4 , Ji-Min Oh 4 ,<br />

Jaejoon Lee 4 , Chan-Hong Jeon 1 , Eun-Mi Koh 4 and Hoon-Suk<br />

Cha 4 , 1 Bucheon Hospital, Soonchunhyang University <strong>College</strong><br />

<strong>of</strong> Medicine, 2 Kangbuk Samsung Hospital, Sungkyunkwan<br />

University School <strong>of</strong> Medicine, 3 Masan Samsung Hospital,<br />

Sungkyunkwan University School <strong>of</strong> Medicine, 4 Samsung<br />

Medical Center, Sungkyunkwan University School <strong>of</strong> Medicine.<br />

1298. Eye Involvement in Behcet’s Syndrome Patients in a North<br />

<strong>American</strong> Cohort. Johannes Nowatzky 3 , Maria T. Filopoulos 4 ,<br />

Christopher Swearingen 1 and Yusuf Yazici 2 , 1 Biostatistics UAMS<br />

Pediatrics, 2 Hospital for Joint Diseases, Hastings on Hudson, NY,<br />

3<br />

NYU Hospital for Joint Diseases, Brooklyn, NY, 4 NYU Hospital for<br />

Joint Diseases.<br />

1299. Glucocorticoid Therapy in Giant Cell Arteritis: Duration and<br />

Predictors for Long-Lasting Remission. Paula Estrada, Javier<br />

Narvaez, Laura Lopez Vives, Carmen Gomez Vaquero and<br />

Joan Miquel Nolla, Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />

Universitario de Bellvitge, Barcelona, Spain.<br />

1300. Infliximab Therapy Is Beneficial for Intestinal Behcet’s Disease<br />

in Japan. Reikou Watanabe, Mitsuhiro Takeno and Yoshiaki<br />

Ishigatsubo, Department <strong>of</strong> Internal Medicine and Clinical<br />

Immunology, Yokohama City Graduate School <strong>of</strong> Medicine.<br />

1301. Influence <strong>of</strong> CD40 rs1883832 Polymorphism in the<br />

Susceptibility to and Clinical Manifestations <strong>of</strong> Biopsy-<br />

Proven Giant Cell Arteritis. Luis Rodríguez-Rodríguez 8 , Santos<br />

Castañeda 4 , Tomás R. Vazquez-Rodriguez 7 , Inmaculada C.<br />

Morado 3 , Beatriz Marí-Alfonso 1 , Carmen Gómez-Vaquero 5 , Jose<br />

A. Miranda-Filloy 7 , Javier Narvaez 5 , Norberto Ortego-Centeno 2 ,<br />

Ricardo Blanco 6 , Benjamín Fernández-Gutiérrez 3 , Javier<br />

Martín 9 and Miguel A. Gonzalez-Gay 6 , 1 Department <strong>of</strong> Internal<br />

Medicine, Corporació Sanitaria Parc Taulí, Instituto Universitario<br />

Parc Taulí, UAB, Sabadell, Barcelona, Spain, 2 Department <strong>of</strong><br />

Internal Medicine, Hospital Clínico San Cecílio, Granada, Spain,<br />

3<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Clinico San Carlos,<br />

Madrid, Spain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital de<br />

la Princesa, Madrid, Spain, 5 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de<br />

Llobregat, Barcelona, Spain, 6 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Hospital Universitario Marqués de Valdecilla, IFIMAB, Santander,<br />

Spain, 7 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Xeral-Calde,<br />

Lugo, Spain, 8 Instituto de Parasitología y Biomedicina López-<br />

Neyra, C.S.I.C., Granada, and Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Hospital Clinico San Carlos, Madrid, Spain, 9 Instituto de<br />

Parasitología y Biomedicina López-Neyra, C.S.I.C., Granada,<br />

Spain.<br />

1302. Large-Vessel Involvement in Newly-Diagnosed Giant<br />

Cell Arteritis: A Case-Control Study Using Color-Doppler<br />

Sonography. Alessandra Ghinoi 1 , Luigi Boiardi 1 , Nicolò Pipitone 1 ,<br />

Giovanna Restuccia 1 , Alberto Nicolini 1 , Mauro Silingardi 1 ,<br />

Giuseppe Germanò 1 , Gianluigi Bajocchi 1 , Ilaria Chiarolanza 1 ,<br />

Luca Magnani 2 , Pierluigi Macchioni 1 , Andrea Caruso 1 and Carlo<br />

Salvarani 1 , 1 Arcispedale S Maria Nuova, Reggio Emilia, Italy,<br />

2<br />

Arcispedale S Maria Nuova, Reggia Emilia, Italy.<br />

1303. New Disease Activity Indices in the Management <strong>of</strong> Behcet’s<br />

Disease: A Comparative Study <strong>of</strong> Patients from Turkey and the<br />

USA. Gonca Mumcu, Yusuf Yazici, Nevsun Inanc, Tulin Ergun,<br />

Maria Filopoulos and Haner Direskeneli, Faculty <strong>of</strong> Health<br />

Sciences, Department <strong>of</strong> Health Informatics and Technologies,<br />

Marmara School <strong>of</strong> Medicine.<br />

1304. Normal Sedimentation Rate and C-Reactive Protein at<br />

Diagnosis in Biopsy-Proven Giant Cell Arteritis. Tanaz A.<br />

Kermani, Cynthia S. Crowson, Steven R. Ytterberg, Gene G.<br />

Hunder and Kenneth J. Warrington, Mayo Clinic, Rochester, MN.<br />

1305. Pediatric Behçet’s Disease, PED-BD: An International Cohort<br />

Study <strong>of</strong> 110 Patients. One-Year Follow-Up Data. Isabelle<br />

Koné-Paut 11 , Martha Darce Bello 11 , Farahd Shahram 15 , Marco<br />

Gattorno 7 , Rolando Cimaz 10 , Seza Ôzen 2 , Michael H<strong>of</strong>er 14 ,<br />

Ilknur Tugal-Tuktun 5 , Samir Assaad-Khalil 3 , Jasmin Kümmerle-<br />

Deschner 16 , Saida Benamour 4 , Soulaymane Al Mayouf 8 ,<br />

Christine Pajot 13 , Jordi Anton 9 , Albert Faye 12 , Susan Nielsen 6 ,<br />

Alexia Letierce 1 and Tu-Anh Tran 11 , 1 Bicêtre University Hospital,<br />

Clinical Research Unit, Le Kremlin-Bicêtre, France, 2 Hacettepe<br />

University, Department <strong>of</strong> Pediatrics, Ankara, Turkey, 3 Hospital<br />

Alexandria Hospital, Alexandria, Egypt, 4 IBN Rochid University<br />

Hospital, Casablanca, Morocco, 5 Istanbul University -<br />

Ophtalmology, Istambul, Turkey, 6 Pediatric Clinic, Blegdamsvej,<br />

Copenhagen, Denmark, 7 Pediatric <strong>Rheumatology</strong> G. Gaslini<br />

Scientific Institut, Genoa, Italy, 8 Pediatric <strong>Rheumatology</strong> King<br />

Fayçal Hospital, Riyadh, Saudi Arabia, 9 Pediatric <strong>Rheumatology</strong><br />

Unit, Sant Joan de Déu University Hospital, Esplugues de<br />

Llobregat, Spain, 10 Pediatric <strong>Rheumatology</strong>, A. Meyer Institut<br />

Florence, Florence, Italy, 11 Pediatric <strong>Rheumatology</strong>, Bicêtre<br />

University Hospital, Le Kremlin-Bicêtre, France, 12 Pediatric<br />

<strong>Rheumatology</strong>, Robert Debré University Hospital, Paris, France,<br />

13<br />

Pediatric <strong>Rheumatology</strong>, Toulouse University Hospital,<br />

Toulouse, France, 14 Pediatric <strong>Rheumatology</strong>, Vaudois University<br />

Hospital, Lausanne, Switzerland, 15 <strong>Rheumatology</strong> Research<br />

Center, Shariati Hospital, Tehran, Islamic Republic <strong>of</strong> Iran,<br />

16<br />

Rhumatology, Childrens Hospital, University <strong>of</strong> Tuebingen,<br />

Tübingen, Germany.<br />

2010 Program Book 229


ACR/ARHP Poster Session B<br />

1306. Plasma Fibrinogen Is More Specific Than Either ESR or CRP<br />

for Confirmation <strong>of</strong> Response to Treatment in Patients with<br />

Active Polymyalgia Rheumatica. Eoghan M. McCarthy 2 , Paul A.<br />

MacMullan 4 , Shibeb Al-Mudhaffer 4 , Anne Madigan 4 , Suzanne<br />

Donnelly 4 , Conor J. McCarthy 3 , Eamonn S. Molloy 5 and Geraldine<br />

M. McCarthy 1 , 1 Mater Misericordiae Univ. Hosp, Dublin,<br />

Ireland, 2 Mater Misericordiae University Hospital, Dublin,<br />

Ireland, 3 Mater Misericordiae University Hospital, Dublin,<br />

Ireland, 4 Mater Misericordiae University Hospital, 5 St Vincent’s<br />

University Hospital, Dublin, Ireland.<br />

1307. Prevalence <strong>of</strong> Behçet’s Disease in Southern Sweden. Aladdin<br />

Mohammad 1 , Thomas Mandl 3 , Gunnar K. Sturfelt 2 and Mårten<br />

Segelmark 2 , 1 Helsingborg Hospital, Helsingborg, Sweden, 2 Skåne<br />

University Hospital, Lund, Lund, Sweden, 3 Skåne University<br />

Hospital, Malmö, Malmö, Sweden.<br />

1308. Safe, Rapid-Onset, and Sustained Biological Activity <strong>of</strong> IL-1β<br />

Regulating Antibody XOMA 052 in Resistant Uveitis <strong>of</strong> Behçet’s<br />

Disease: Results <strong>of</strong> a Pilot Trial. Ahmet Gül 2 , Bahar Artim-<br />

Esen 2 , Alan M. Solinger 4 , Linda Giustino 4 , Charles Dinarello 3 and<br />

Ilknur M. Tugal-Tutkun 1 , 1 Istanbul, Turkey, 2 Istanbul University,<br />

Istanbul, Turkey, 3 University <strong>of</strong> Colorado, Aurora, CO, 4 XOMA<br />

(US) LLC, Berkeley, CA.<br />

1309. Serum Hepcidin Is Elevated in Patients with Giant Cell Arteritis<br />

and Is Inversely Associated with Serum Iron Levels. Curry L.<br />

Koening 2 , Jose Hernandez-Rodriguez 1 , Marc Corbera-Bellalta 1 ,<br />

Maria C. Cid 1 , Bradley Katz 3 and Ivana De Domenico 3 , 1 University<br />

<strong>of</strong> Barcelona, 2 University <strong>of</strong> Utah, Salt Lake City, UT, 3 University<br />

<strong>of</strong> Utah.<br />

1310. Severe and Opportunistic Infections during Giant Cell Arteritis<br />

Course: A Case-Control Study. Javier Narvaez 3 , Laura López<br />

Vives 1 , Paula Estrada 2 , Nuria del Castillo 4 , Montserrat Robustillo 4<br />

and Joan Miquel Nolla 4 , 1 Daprtment <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />

Universitario de Bellvitge, Barcelona, Spain, 2 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Barcelona, Spain, 3 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Hospital Universitario de Bellvitge, Barcelona,<br />

Spain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario<br />

de Bellvitge, Barcelona, Spain, Spain, 5 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Hospital Universitario de Bellvitge, Barcelona,<br />

Spain.<br />

1311. Significance <strong>of</strong> “Healed Arteritis” (HA) on Temporal Artery<br />

Biopsy. Rahul Sehgal, Elise Belilos, Matthew Geller, Lorna<br />

Ogden, Steven E. Carsons and George K. Turi, Winthrop<br />

University Hospital, Mineola, NY.<br />

1312. Some Manifestations Disappear Earlier Than Others in<br />

Behcet’s Syndrome (BS). Sevgi F. Sacli 2 , Emire Seyahi 4 , Yilmaz<br />

Ozyazgan 3 , Cem Mat 1 and Hasan Yazici 4 , 1 Cerrahpasa Medical<br />

Faculty, Dermatology Department, Turkey, 2 Cerrahpasa Medical<br />

Faculty, Internal Medicine Department, Turkey, 3 Cerrahpasa<br />

Medical Faculty, Ophthalmology Department, Turkey,<br />

4<br />

Cerrahpasa Medical Faculty, <strong>Rheumatology</strong> Department,<br />

Turkey.<br />

1313. Takayasu’s Arteritis Is Associated with HLA-B*52, but Not with<br />

B*51, in Turkey. Turkish Takayasu Study Group, Turkey.<br />

1314. Treatment with Angiotensin Converting Enzyme Inhibitors<br />

(ACEI) or Angiotensin II Receptor Antagonists (ARA) Is<br />

Associated with Higher Frequency <strong>of</strong> Ischemic Complications<br />

but Better Response to Therapy in Patients with Giant-Cell<br />

Arteritis (GCA). Marco A. Alba 3 , Ana Garcia-Martinez 1 , Georgina<br />

Espigol-Frigole 3 , Itziar Tavera 2 , Montserrat Butjosa 3 , Sergio<br />

Prieto-Gonzalez 5 , Jose Hernandez-Rodriguez 4 and Maria C. Cid 2 ,<br />

1<br />

Emergency Department, Hospital Clinic, Barcelona, Spain,<br />

2<br />

Systemic Autoimmune Diseases, Hospital Clinic, Barcelona,<br />

Spain, 3 Systemic Autoimmune Diseases. Hospital Clinic,<br />

Barcelona, Spain, 4 Systemic Autoimmune Diseases. Hospital<br />

Clininc, Barcelona, Spain, 5 Systemic Autoimmune Diseases.<br />

Hospital Clinic, Barcelona, Spain.<br />

1315. Use <strong>of</strong> Peri-Operative Glucocorticoids and Post-Operative<br />

Complications in Patients with Takayasu’s Arteritis Undergoing<br />

Vascular Surgical Procedures. Bijal A. Jayakar 1 , Gary S. H<strong>of</strong>fman 3<br />

and Carol A. Langford 2 , 1 Cleveland Clinic, Cleveland, OH,<br />

2<br />

Cleveland Clinic Foundation, Cleveland, OH, 3 Cleveland Clinic<br />

Foundation, Pepper Pike, OH.<br />

ARHP Poster Session B: Osteoporosis<br />

1316. Application <strong>of</strong> the Generalizability Theory for Determining<br />

Inter-Rater and Inter-Trial Reliability <strong>of</strong> Spine Curvature<br />

Measures in Postmenopausal Women with Osteoporosis <strong>of</strong> the<br />

Spine Using the Flexicurve Ruler and the Digital Inclinometer.<br />

Norma J. MacIntyre 1 , Lisa Bennett 2 , Alison Bonnyman 2 and Paul<br />

W. Stratford 2 , 1 McMaster University, Hamilton, ON, Canada,<br />

2<br />

McMaster University.<br />

1317. Baseline Serum Interleukin-6 (IL-6), Tumor Necrosis Factor-α<br />

(TNF-α) and C-Reactive Protein (CRP) Do Not Predict<br />

Subsequent Hip Bone Loss in Men or Women: The Framingham<br />

Osteoporosis Study. Robert R. McLean 3 , Xiaochun Zhang 4 , Joao<br />

D. T. Fontes 2 , James B. Meigs 7 , L. Adrienne Cupples 1 , Douglas<br />

P. Kiel 5 and Marian T. Hannan 6 , 1 Boston University School <strong>of</strong><br />

Public Health, 2 Framingham Heart Study and Boston University,<br />

3<br />

Hebrew Senior Life, Boston, MA, 4 Hebrew SeniorLife, 5 Hebrew<br />

SeniorLife and Harvard Medical School, 6 Hebrew SL & Harvard<br />

Med Sch, Boston, MA, 7 Massachusetts General Hospital.<br />

1318. Development <strong>of</strong> a Motivational Interviewing Protocol for<br />

Clinical Application in Osteoporosis. Maura D. Iversen 3 , Laura<br />

Rekedal 1 and Daniel Hal Solomon 2 , 1 Boston, MA, 2 Brigham<br />

and Womens Hospital, Boston, MA, 3 Northeastern University,<br />

Boston, MA.<br />

1319. Type <strong>of</strong> Activity Pacing Instruction Affects Physical Activity<br />

Variability in Adults with Symptomatic Knee or Hip<br />

Osteoarthritis. Susan L. Murphy 2 , Dylan M. Smith 1 and Angela<br />

K. Lyden, 1 StonyBrook University, 2 University <strong>of</strong> Michigan, Ann<br />

Arbor, MI.<br />

ARHP Poster Session B: Behavioral Science<br />

1320. A Prospective, Longitudinal Cohort Study Evaluating<br />

Psychosocial Risk and Protective Factors for Post Lyme Disease<br />

Syndrome. Afton L. Hassett 6 , Terry Shlimbaum 2 , Diane C.<br />

Radvanski 4 , David J. Herman 1 , Ronald Nahass 1 , Steven Buyske 3<br />

and Leonard H. Sigal 5 , 1 ID CARE, 2 Phillips-Barber Family Health<br />

Center, 3 Rutgers University, 4 UMDNJ-Robert Wood Johnson<br />

Medical School, Union City, NJ, 5 UMDNJ-Robert Wood Johnson<br />

Medical School, 6 University <strong>of</strong> Michigan Medical School, Ann<br />

Arbor, MI.<br />

230<br />

2010 Program Book


ACR/ARHP Poster Session B<br />

1321. Changing Shoes: Metaphorical Descriptions <strong>of</strong> Rheumatoid<br />

Arthritis and Identity. Catherine L. Backman 1 , Anne Townsend 2<br />

and Linda C. Li 1 , 1 University <strong>of</strong> British Columbia, Vancouver, BC,<br />

Canada, 2 W. Maurice Young Centre for Applied Ethics, University<br />

<strong>of</strong> British Columbia.<br />

1322. Emotional Response to Serial Doppler Echocardiography<br />

Examinations as a Screening Method To Detect Developing<br />

Congenital Heart Block in SSA/Ro Positive Pregnancy. Joanna<br />

Tingström 2 , Mia Barimani 1 , Sven-Erik Sonesson 1 , Marie Wahren-<br />

Herlenius 2 and Elisabet M. B. Welin Henriksson 3 , 1 Karolinska<br />

Institutet, Stockholm, Sweden, 2 Karolinska Institutet CMM,<br />

Stockholm, Sweden, 3 Karolinska Institutet Rheum, Stockholm,<br />

Sweden.<br />

1323. Psychological Factors but Not Clinical Markers <strong>of</strong> Disease<br />

Activity Predict Adherence among Rheumatoid Arthritis<br />

(RA) Patients Receiving DMARDs and Adalimumab (ADA):<br />

Results from the British Society for <strong>Rheumatology</strong> Biologics<br />

Register (BSRBR). C. Morgan 1 , J. McBeth 2 , L. Cordingley 2 , K. D.<br />

Watson 2 , BSRBR Control Centre Consortium, K. L. Hyrich 2 , D. P.<br />

M. Symmons 2 , I. N. Bruce 2 and on Behalf <strong>of</strong> the BSR Biologics<br />

Register, 1 The University <strong>of</strong> Manchester, Manchester, United<br />

Kingdom, 2 The University <strong>of</strong> Manchester.<br />

1324. Spousal Social Support and Well-Being among Persons with<br />

Rheumatoid Arthritis: Is Support in the Eye <strong>of</strong> the Beholder?<br />

Allen J. Lehman 1 , Anita DeLongis 3 , Daniel D. Pratt 3 , John B.<br />

Collins 3 and John M. Esdaile 2 , 1 Arthritis Research Centre <strong>of</strong><br />

Canada; Simon Fraser University, Vancouver, BC, Canada,<br />

2<br />

Arthritis Research Centre <strong>of</strong> Canada; University <strong>of</strong> British<br />

Columbia, Vancouver, BC, Canada, 3 University <strong>of</strong> British<br />

Columbia, Canada.<br />

1325. Sustained Reduction in Fatigue Impact in Rheumatoid<br />

Arthritis: RCT <strong>of</strong> Cognitive Behavioural Therapy. Sarah E.<br />

Hewlett 5 , Nicholas Ambler 2 , Bev Knops 2 , Alena Cliss 1 , Celia<br />

Almeida 6 , Denise Pope 3 , Alison Hammond 4 , Annette Swinkels 6 ,<br />

Karen Kitchen 3 and Jon Pollock 6 , 1 Frenchay Hospital, Bristol UK,<br />

2<br />

Frenchay Hospital, Bristol, UK, 3 University Hospitals Bristol, UK,<br />

4<br />

University <strong>of</strong> Salford, Matlock Derbyshire, United Kingdom,<br />

5<br />

University <strong>of</strong> the West <strong>of</strong> England, Bristol, United Kingdom,<br />

6<br />

University <strong>of</strong> the West <strong>of</strong> England, Bristol UK.<br />

1326. The Effect <strong>of</strong> Social Support from Physicians and Partners<br />

on the Health-Related Quality <strong>of</strong> Life <strong>of</strong> Vasculitis Patients<br />

in Relapse and Remission. Delesha M. Carpenter 2 , Jessica<br />

A. Kadis 2 , Robert F. DeVellis 2 , Susan L. Hogan 3 and Joanne M.<br />

Jordan 1 , 1 Chapel Hill, NC, 2 UNC, Chapel Hill, NC, 3 UNC.<br />

ARHP Poster Session B: Foot<br />

1327. Foot Pain in Relation to the Foot Biomechanical Measures <strong>of</strong><br />

Plantar Peak Pressures and Pressure Time Intergral. Virginia<br />

A. Casey 3 , Andrew M. Galica 3 , Alyssa B. Dufour 1 , Robert R.<br />

McLean 1 and Marian T. Hannan 2 , 1 Hebrew Senior Life, Boston,<br />

MA, 2 Hebrew SL & Harvard Med Sch, Boston, MA, 3 IFAR Hebrew<br />

SeniorLife, Boston, MA.<br />

1328. Hallux Valgus and Foot Bimechanics: Relation between<br />

Structure and Function. Andrew M. Galica 5 , Alyssa B. Dufour 1 ,<br />

Marian T. Hannan 2 , Virginia A. Casey 5 , Jocelyn C. Frey 4 , Mark W.<br />

Lenh<strong>of</strong>f 4 and Howard J. Hillstrom 3 , 1 Hebrew Senior Life, Boston,<br />

MA, 2 Hebrew SL & Harvard Med Sch, Boston, MA, 3 Hospital<br />

Special Surgery, New York, NY, 4 Hospital Special Surgery, New<br />

York, NY, 5 Institute for Aging Research.<br />

1329. Hallux Valgus and Pes Cavus Are Highly Heritable in Older Men<br />

and Women: The Framingham Foot Study. Marian T. Hannan 4 ,<br />

Yi-Hsiang Hsu 3 , L. Adrienne Cupples 2 and Joanne M. Jordan 1 ,<br />

1<br />

Chapel Hill, NC, 2 BUSPH, Boston, MA, 3 Hebrew SeniorLife, HSPH<br />

and Harvard Medical School, Boston, MA, 4 Hebrew SL & Harvard<br />

Med Sch, Boston, MA.<br />

1330. Racial Differences in Foot Disorders: The Johnston County<br />

Osteoarthritis Project. Yvonne M. Golightly 2 , Marian T. Hannan 1 ,<br />

Alyssa B. Dufour 1 and Joanne M. Jordan 2 , 1 Institute for Aging<br />

Research, Hebrew Senior Life, 2 University <strong>of</strong> North Carolina at<br />

Chapel Hill.<br />

1331. Risk Factors for Hallux Valgus (HV) in a Population-Based Study<br />

<strong>of</strong> Older Adults: The Framingham Foot Study. Alyssa B. Dufour 4 ,<br />

Virginia A. Casey 5 , Andrew M. Galica 5 , David R. Gagnon 1 ,<br />

Howard J. Hillstrom 3 and Marian T. Hannan 2 , 1 Boston University<br />

School <strong>of</strong> Public Health, Boston, MA, 2 Hebrew SL & Harvard<br />

Med Sch, Boston, MA, 3 Hospital Special Surgery, New York,<br />

NY, 4 Institute for Aging Research, Hebrew SeniorLife & Boston<br />

University School <strong>of</strong> Public Health, Boston, MA, 5 Institute for<br />

Aging Research, Hebrew SeniorLife, Boston, MA.<br />

ARHP Poster Session B: Patient Education/Support<br />

1332. A Model <strong>of</strong> Quality Patient-Health Care Provider<br />

Communication. Elizabeth Salt 1 and Graham Rowles 2 ,<br />

1<br />

University <strong>of</strong> Kentucky, Lexington, KY, 2 University <strong>of</strong> Kentucky.<br />

1333. Comparison <strong>of</strong> Physician- and Nurse Prescriber-Led Dose<br />

Adjustment <strong>of</strong> DMARD Therapy in RA. Grainne Murphy, Mary<br />

Daly, John Ryan, Fergus Shanahan, Sinead Harney and Molloy<br />

Michael, Cork University Hospital.<br />

1334. Developing an Interactive Health Communication Application<br />

within <strong>Rheumatology</strong>: What Do Patients Want? Rosalie van der<br />

Vaart 2 , Constance H. C. Drossaert 2 , Erik Taal 1 and Mart A. F. J.<br />

van de Laar 2 , 1 Arthritis Centre Twente, Institute for Behavioural<br />

Research, University <strong>of</strong> Twente & Medisch Spectrum Twente,<br />

Enschede, The Netherlands, 2 Arthritis Centre Twente, Institute<br />

for Behavioural Research, University <strong>of</strong> Twente & Medisch<br />

Spectrum Twente.<br />

1335. Does an RA Peer Support Program Impact Disease Outcomes?<br />

Melanie Zibit 3 , Jing Cui 4 , Christine K. Iannaccone 2 , Nancy A.<br />

Shadick 1 , Michael E. Weinblatt 1 , Meghan Courtney 3 , Margo<br />

Hanlan 3 , Husen Tsao 3 and Anne Fossel 3 , 1 Brigham & Womens<br />

Hospital, Boston, MA, 2 Brigham and Woemens Hospital, Boston,<br />

MA, 3 Brigham and Women’s Hospital, Boston, MA, 4 Brigham and<br />

Womens Hospital, Boston, MA.<br />

1336. Educational Needs Assessment among Patients with<br />

Rheumatic Diseases in Kenya. Ines Colmegna 1 , Susan J.<br />

Bartlett 1 , Sharon Kodhek 2 , Omondi G. Oyoo 3 and International<br />

League <strong>of</strong> Associations for <strong>Rheumatology</strong> East Africa Initiative,<br />

1<br />

McGill University, Montreal, QC, Canada, 2 Nairobi SLE Support<br />

Group, Nairobi, Kenya, 3 University <strong>of</strong> Nairobi, Nairobi, Kenya.<br />

1337. Phone Administration Compared to Self-Administration on<br />

Paper <strong>of</strong> the Main Instruments Used To Evaluate Ankylosing<br />

Spondylitis Patients. Rafael Ariza-Ariza, Blanca Hernández-<br />

Cruz, Victoria Navarro-Compán and Federico Navarro-Sarabia,<br />

Hospital Virgen Macarena, Sevilla, Spain.<br />

2010 Program Book 231


ACR/ARHP Poster Session B<br />

1338. <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals’ Care: Current and Future<br />

Tasks and Education. Emalie J. Hurkmans 3 , Rinie Geenen 1 , John<br />

Verhoef 4 and Thea P. M. Vliet Vlieland 2 , 1 Clinical and Health<br />

Psychology, Utrecht University & University Medical Center,<br />

Utrecht, The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and<br />

Orthopaedics, Leiden University Medical Center, Leiden, The<br />

Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University<br />

Medical Center, Leiden, The Netherlands, 4 Faculty <strong>of</strong> Health,<br />

University <strong>of</strong> Applied Sciences, Leiden, The Netherlands.<br />

ARHP Poster Session B: Pediatrics<br />

1339. Accuracy <strong>of</strong> the Early Detection <strong>of</strong> Juvenile Idiopathic Arthritis<br />

Questionnaire – A Multicenter Study. Claudio A. Len 7 , Luciana<br />

T. P. Paulo 7 , Maria Teresa R. A. Terreri 7 , Silvana B. Sacchetti 3 ,<br />

Virginia P. L. Ferriani 5 , Clovis A. A. Silva 4 , Cássia M. P. Barbosa 1 ,<br />

Simone Lotufo 2 and Roberto Marini 6 , 1 Hospital Darcy Vargas, São<br />

Paulo, Brazil, 2 Hospital Menino Jesus, São Paulo, Brazil, 3 Santa<br />

Casa de São Paulo, São Paulo, Brazil, 4 Universidade de São<br />

Paulo, São Paulo, Brazil, 5 Universidade de São Paulo, Ribeirão<br />

Preto, São Paulo, Brazil, 6 Universidade Estadual de Campinas,<br />

São Paulo, Brazil, 7 Universidade Federal de São Paulo, São Paulo,<br />

Brazil.<br />

1340. Engaging Youth in a Web Based Transition Intervention:<br />

Usability and Feasibility <strong>of</strong> Rheumtogrow.org. Peter Scal, Ann<br />

Garwick and Keith Horvath, University <strong>of</strong> Minnesota.<br />

1341. FEAR (False ELISA Associated Rheumatic) Syndrome in<br />

Children. Donald P. Goldsmith 1 , Carolann Martucci 3 and Svetlana<br />

Lvovich 2 , 1 St Christopher Hosp Children/Drexel University<br />

<strong>College</strong> <strong>of</strong> Medicine, Philadelphia, PA, 2 St Christopher’s Hosp<br />

Children/Drexel University <strong>College</strong> <strong>of</strong> Medicine, Philadelphia,<br />

PA, 3 St Christopher’S Hospital for Children, Philadelphia, PA.<br />

1342. Physiotherapy Management <strong>of</strong> Children with Hypermobility:<br />

A Review <strong>of</strong> an Out-Patient Self Management Exercise<br />

Programme. Susan M. Maillard 1 , David Adkins 2 , Elaine Haggart 2<br />

and Swati Bhagat 2 , 1 Great Ormond Street Hospital, London,<br />

Maidenhead, United Kingdom, 2 Great Ormond Street Hospital,<br />

London, London, United Kingdom.<br />

1343. Stress in Adolescents with Idiopathic Musculoskeletal Pain.<br />

Juliana Molina 2 , Flavia H. Santos 1 , Maria Sylvia Vitalle 2 , Maria<br />

Odete E. Hilário 2 , Maria Teresa R. A. Terreri 2 , Simone G. L. Silva 2<br />

and Claudio A. Len 2 , 1 Universidade Estadual de São Paulo, Assis,<br />

São Paulo, Brazil, 2 Universidade Federal de São Paulo, São Paulo,<br />

Brazil.<br />

1344. To Explore the Use <strong>of</strong> the PedsQL Subjective Questionnaire<br />

To Assess Levels <strong>of</strong> Fatigue in Children with Juvenile<br />

Dermatomyositis. Susan M. Maillard 1 , Amy Todd 2 , Kiran<br />

Nistala 3 , Clarissa Pilkington 2 and Abdul Hassan 2 , 1 Great Ormond<br />

Street Hospital, London, Maidenhead, United Kingdom, 2 Great<br />

Ormond Street Hospital, London, 3 Institute <strong>of</strong> Child Health,<br />

London.<br />

1345. Utilizing Social Media To Reach Young Arthritis Patients.<br />

Jane S. Brandenstein 1 , Emily Cope 3 , Allison J. Kerr 2 , Ashley M.<br />

Boynes 2 , Carol D. Popp 2 and Lori Knapp 2 , 1 Freedom, PA, 2 W Pa<br />

Arthritis Foundation, Pittsburgh, PA, 3 WPa Arthritis Foundation,<br />

Pittsburgh, PA.<br />

232<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

Halls B1 & B2<br />

WEDNESDAY, NOVEMBER 10, 2010<br />

Biology and Pathology <strong>of</strong> Bone and Joint: Osteoarthritis-Cartilage<br />

Degradation and Skeletal Turnover<br />

1466. A Novel Serum Biomarker <strong>of</strong> Cartilage Destruction, Measured<br />

in OA and RA Patients, Is Significantly Associated with<br />

Kellgren-Lawrence Score. Anne C. Bay-Jensen 1 , Erik B. Dam 3 ,<br />

Inger Byrjalsen 2 , Tanja Schubert 4 , Phillip Vergnaud 4 , Per Qvist 1<br />

and Morten A. Karsdal 1 , 1 Cartilage Biology and Biomarkers,<br />

Denmark, 2 CCBR-Synarc, Denmark, 3 Nordic Bioscience Imaging,<br />

Denmark, 4 Synarc-Lyon, France.<br />

1467. A Small Molecule c-Fos/AP-1 Inhibitor T-5224 Inhibits<br />

Osteoclastogenesis and Bone Resorption. Hidetoshi Murao 3 ,<br />

Yukihiko Aikawa 4 , Akira Hashiramoto 1 , Tetsuya Yamamoto 4 ,<br />

Hisaaki Chaki 4 , Hirokazu Narita 4 , Shuichi Hirono 2 and Shunichi<br />

Shiozawa 1 , 1 Department <strong>of</strong> Biophysics, Kobe University <strong>of</strong><br />

Graduate School <strong>of</strong> Health Sciences/The Center for Rheumatic<br />

Diseases, Kobe University Hospital, Kobe, Japan, 2 Department<br />

<strong>of</strong> Pharmaceutical Sciences, School <strong>of</strong> Pharmacy, Kitasato<br />

University, Tokyo, Japan, 3 Research Laboratories, Toyama<br />

Chemical Co., Ltd, Toyama, Japan, 4 Research Laboratories,<br />

Toyama Chemical Co., Ltd, Toyama, Japan.<br />

1468. Activation <strong>of</strong> Wnt and Bone Morphogenetic Protein Signalling<br />

Pathways in the Articular Cartilage in Frzb-/- Mice. Liesbet<br />

Lodewyckx 1 , Jeroen Eyckmans 3 , Frank P. Luyten 2 and Rik Lories 1 ,<br />

1<br />

KU Leuven, Leuven, Belgium, 2 KU Leuven, Leuven, Belgium, 3 KU<br />

Leuven.<br />

1469. Adenosine A1 Receptors Regulates RANKL-Induced Osteoclast<br />

Formation Via Regulation <strong>of</strong> c-fos and NFATc1 Expression.<br />

Wenjie He 2 , Tuere Wilder 2 and Bruce N. Cronstein 1 , 1 New York<br />

Univ Med Ctr, New York, NY, 2 NYU School <strong>of</strong> Medicine.<br />

1470. Adenosine A2A Receptor Agonists: Can They Prevent/<br />

Treat Joint Prosthesis Loosening? Aranzazu Mediero 1 , Sally<br />

R. Frenkel 2 , Tuere Wilder 1 , Igor Immerman 3 , Scott Hadley 3 ,<br />

R. Damani Howell 3 , Maya Hawly 4 , Elie Sellam 4 and Bruce N.<br />

Cronstein 5 , 1 Department <strong>of</strong> Medicine, NYU Langone Medical<br />

Center, New York, NY, 2 Department <strong>of</strong> Orthopaedic Surgery,<br />

NYU Hospital for Joint Diseases, New York, NY, 3 Department <strong>of</strong><br />

Orthopaedic Surgery, NYU Hospital for Joint Diseases, 4 Institut<br />

Supérieur des BioSciences de Paris, France, 5 New York Univ Med<br />

Ctr, New York, NY.<br />

1471. Adenosine A2A Receptor Ligation Inhibits Osteoclast<br />

Formation. Aranzazu Mediero 1 , Firas M. Kara 1 , Maya Hawly 2 ,<br />

Elie Sellam 2 and Bruce N. Cronstein 3 , 1 Department <strong>of</strong> Medicine,<br />

NYU School <strong>of</strong> Medicine, New York, NY, 2 Institut Supérieur des<br />

Biosciences de Paris, Creteil, Ile de France, France, 3 New York<br />

Univ Med Ctr, New York, NY.<br />

1472. Alarmins S100A8 and S100A9 Skew Human Chondrocytes<br />

towards a Cartilage Breakdown Phenotype. Rik F. P.<br />

Schelbergen 4 , Peter L. van Lent 5 , Arjen B. Blom 5 , Annet Sloetjes 5 ,<br />

Thomas Vogl 2 , Johannes Roth 1 and Wim B. Van Den Berg 3 ,<br />

1<br />

Children’s Hospital Eastern Ontario, Ottawa, ON, Canada,<br />

2<br />

Institute <strong>of</strong> Immunology, Muenster, 3 Radboud Univ Nijmegen<br />

Med Cntr, Nijmegen, The Netherlands, 4 Radboud University<br />

Nijmegen Medical Centre, Nijmegen, The Netherlands,<br />

5<br />

Radboud University Nijmegen Medical Centre.<br />

1473. Analysis <strong>of</strong> Secretome from Mesenchymal Stem Cells from<br />

Human Umbilical Cord Strome during the Chondrogenesis.<br />

María C. Arufe 1 , Alexandre De la Fuente 2 , Jesús Mateos 4 ,<br />

Patricia Fernández-Puente 4 , Esther Rendal 4 , Silvia Díaz 2 ,<br />

Isaac Fuentes 2 , Francisco J. De Toro 2 and Francisco J. Blanco 3 ,<br />

1<br />

INIBIC-Universidad de A Coruna, A Coruna, Osteoarticular<br />

and Aging Research Laboratory, Proteomics Unit-Associated<br />

Node to ProteoRed-Biomedical Research Center (INIBIC),<br />

Hospital Universitario A Coruna, La Coruna, Coruña, Spain,<br />

2<br />

INIBIC-Universidad de A Coruna, A Coruna, Spain, 3 INIBIC-<br />

Universidad de A Coruna, A Coruna, Spain. Osteoarticular and<br />

Aging Research Laboratory, Proteomics Unit-Associated Node<br />

to ProteoRed-Biomedical Research Center (INIBIC). Hospital<br />

Universitario A Coruna, La Coruna, Spain, 4 Osteoarticular and<br />

Aging Research Laboratory, Proteomics Unit-Associated Node<br />

to ProteoRed-Biomedical Research Center (INIBIC), Hospital<br />

Universitario A Coruña. La Coruña, Spain.<br />

1474. Biochemical Markers <strong>of</strong> Bone Balance (CTX-I/Osteocalcin)<br />

Improve with Tocilizumab Treatment in a Population <strong>of</strong> RA<br />

Patients with an Inadequate Response to Anti-TNF Therapy.<br />

Morten Karsdal 2 , Thasia G. Woodworth 3 , Andy Kenwright 4 ,<br />

Inger Byrjalsesn 1 , Adam Platt 4 and Georg Schett 5 , 1 CCBR Synarc,<br />

Ballerup, Denmark, 2 Nordic Bioscience, Herlev, Herlev, Denmark,<br />

3<br />

Roche Products Ltd., Welwyn, Welwyn Garden City, United<br />

Kingdom, 4 Roche, Welwyn, United Kingdom, 5 University <strong>of</strong><br />

Erlangen-Nuremberg, Erlangen, Germany.<br />

1475. Chondrogenic Differentiation <strong>of</strong> Bone Marrow Mesenchymal<br />

Stem Cells Grown on Type I Collagen and Heparan Sulfate<br />

Scaffolds. Silvia Díaz-Prado 4 , Emma Muiños 3 , C. G. Trejo-<br />

Iriarte 1 , D. Lozano 2 , N. García-Honduvilla 1 , Isaac Fuentes 3 ,<br />

Francisco J. De Toro 3 , P. Esbrit 2 , Julia Buján 1 and Francisco J.<br />

Blanco 3 , 1 Department <strong>of</strong> Medical Specialties. University <strong>of</strong><br />

Alcalá de Henares, Madrid, Spain, 2 Laboratory <strong>of</strong> Bone and<br />

Mineral Metabolism. Fundación Jiménez Díaz (Capio Group).<br />

Madrid, Spain, 3 Osteoarticular and Aging Res. Lab. CIBER-BBN,<br />

<strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp, Univ. A Coruña, A<br />

Coruña, SPAIN, 4 Osteoarticular and Aging Res. Lab. CIBER-BBN.<br />

<strong>Rheumatology</strong> Div. INIBIC-Complejo Hosp. Univ. A Coruña,<br />

Coruña, Spain.<br />

1476. CXCR1/2 Signalling Is Required but Is Not Sufficient To<br />

Maintain the Phenotypic Stability <strong>of</strong> Human Articular<br />

Chondrocytes. Joanna C. Sherwood 1 , Pramod Achan 2 , Giovanna<br />

Nalesso 2 , Costantino Pitzalis 2 and Francesco Dell’Accio 2 , 1 Barts<br />

and The London School <strong>of</strong> Medicine and Dentistry, Queen Mary<br />

University <strong>of</strong> London, London, United Kingdom, 2 Barts and<br />

The London School <strong>of</strong> Medicine and Dentistry, Queen Mary<br />

University <strong>of</strong> London.<br />

1477. Effects <strong>of</strong> NSAIDs and the Cyclooxygenase-Inhibiting Nitric<br />

Oxide Donator (CINOD) NCX 429 on Human Chondrocytes and<br />

Cartilage from OA Patients. Manlio Bolla 1 , Serena Viappiani 2 ,<br />

Mandar Dave 4 , Jyoti Patel 4 , Steven B. Abramson 3 and Mukundan<br />

Attur 3 , 1 NicOx Research, Sophia Antipolis, France, 2 NicOx<br />

Research, 3 NYU Hospital for Joint Diseases, New York, NY, 4 NYU<br />

Hospital for Joint Diseases.<br />

1478. Endogeneous TIMP3 Induce Death Receptor Ligand-<br />

Independent Apoptosis in Mesenchymal Cells. Christina<br />

Wunrau 2 , Doreen Wendholt 3 , Noreen Pundt 3 , Thomas Pap 1 and<br />

Berno Dankbar 3 , 1 IEMM, University Hospital Muenster, Münster,<br />

Germany, 2 Institute <strong>of</strong> Experimental Musculoskeletal Medicine-<br />

IEMM, University Hospital Muenster, Münster, Germany,<br />

3<br />

Institute <strong>of</strong> Experimental Musculoskeletal Medicine-IEMM,<br />

University Hospital Muenster, Muenster, Germany.<br />

2010 Program Book 233


ACR/ARHP Poster Session C<br />

1479. Endogenous Joint Repair after Damage in the Red-Spotted<br />

Newt. Matthias Geyer 1 , Thilo Borchardt 2 , Carina Schreiyaeck 1 ,<br />

Ulf Müller-Ladner 1 and Robert Dinser 1 , 1 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Justus Liebig University Giessen, Kerckh<strong>of</strong>f-<br />

Klinik, Bad Nauheim, 2 Max Planck Institute for Heart and Lung<br />

Research, Bad Nauheim.<br />

1480. Experimental Osteoarthritis in Rats Is Attenuated by Treatment<br />

with a Selective Inhibitor <strong>of</strong> Sphingosine Kinase 2. Leo R.<br />

Fitzpatrick 3 , Cecelia Green 1 , Lynn W. Maines 1 and Charles<br />

D. Smith 2 , 1 Apogee Biotechnology Corporation, 2 Apogee<br />

Biotechnology Corporation and Medical University <strong>of</strong> South<br />

Carolina, 3 Penn State <strong>College</strong> <strong>of</strong> Medicine, Hummelstown, PA.<br />

1481. Expression <strong>of</strong> MMP-13 and ADAMTS-5 Is Mediated Via Nuclear<br />

Orphan Receptor NR4A3 Signalling in Human Chondrocytes.<br />

Martin H. Stradner 2 , Hannes Angerer 3 , Daniela Krusch 1 ,<br />

Florentine C. Fürst 3 , Marie-Luise Kremser 3 , Daniela Setznagl 3 and<br />

Winfried B. Graninger 3 , 1 Karl-Franzens University Graz, 2 Medical<br />

University Graz, Graz, Austria, 3 Medical University Graz.<br />

1482. Histamine Contributes to Inflammatory Joint Disease by<br />

Regulating the Expression <strong>of</strong> RANKL and OPG through<br />

Altered NR4A Activity in Human Chondrocyte Cells. Viviana<br />

Marzaioli 2 , Jason P. McMorrow 2 , Alice McEvoy 1 and Evelyn P.<br />

Murphy 2 , 1 Dublin Institute <strong>of</strong> Technology, Kevin Street, Dublin,<br />

Ireland, 2 UCD Veterinary Sciences Centre and Conway Insitute<br />

for Biomolecular and Biomedical Research, Human Amniotic<br />

Membrane as Scaffold for Human Articular Cartilage Repair.<br />

Emma Muiños-López 4 , Silvia M. Díaz-Prado 3 , Tamara Hermida-<br />

Gómez 2 , Esther Rendal-Vázquez 1 , Isaac Fuentes-Boquete 3 ,<br />

María C. Arufe-Gonda 3 , Francisco J. De Toro 3 and Francisco J.<br />

Blanco 2 , 1 Cryobiology Unit. Complejo Hosp. Univ. A Coruña, A<br />

Coruña, Spain, 2 Osteoarticular and Aging Res. Lab. CIBER-BBN,<br />

<strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp, Univ. A Coruña, A<br />

Coruña, SPAIN, 3 Osteoarticular and Aging Res. Lab. CIBER-BBN,<br />

<strong>Rheumatology</strong> Div. INIBIC-Complejo Hosp, Univ. A Coruña, A<br />

Coruña, SPAIN. INIBIC-University <strong>of</strong> A Coruña, A Coruña, SPAIN,<br />

4<br />

Osteoarticular and Aging Res. Lab. CIBER-BBN. <strong>Rheumatology</strong><br />

Div. INIBIC-Complejo Hosp. Univ. A Coruña, Coruña, Spain.<br />

1484. Increased Expression <strong>of</strong> Arthritic Marker Genes in the Cartilage<br />

<strong>of</strong> SirT1 Null Mice. Odile H. Gabay 2 , Eun Jin Lee 2 , Richard<br />

Booth 2 , Viktoria Gagarina 2 , Mona Dvir-Ginzberg 1 and David J.<br />

Hall 2 , 1 Hebrew University, Jerusalem, Israel, 2 NIH, Bethesda, MD.<br />

1485. Increasing Osteoclastic Bone Loss Inspite <strong>of</strong> Fewer Osteoclast<br />

Precursors during Chronic Autoimmune SKG-Arthrtitis<br />

Evaluated by 3D Stereological Estimators. Kresten K. Keller 3 ,<br />

Kristian Stengaard-Pedersen 2 , Frederik Dagnæs-Hansen 5 , Jens<br />

R. Nyengaard 6 , Shimon Sakaguchi 1 and Ellen-Margrethe Hauge 4 ,<br />

1<br />

Department <strong>of</strong> Experimental Pathology, Institute for Frontier<br />

Medical Science, Kyoto University, 2 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Aarhus University Hospital, Aarhus, Denmark, 3 Dept. <strong>of</strong><br />

<strong>Rheumatology</strong>, Aarhus University Hospital, Århus, Denmark,<br />

4<br />

Dept. <strong>of</strong> <strong>Rheumatology</strong>, Aarhus University Hospital, Denmark,<br />

5<br />

Institut <strong>of</strong> Medical Microbiology and Immunology, Aarhus<br />

University, Denmark, 6 Stereology and Electron Microscopy<br />

Research Laboratory, Aarhus University, Denmark.<br />

1486. Influence <strong>of</strong> NPP1 on Osteoarthritis (OA)-Associated Cartilage<br />

Calcification. Jessica Bertrand 3 , Martin Fürst 5 , Wolfgang Rüther 1 ,<br />

Frank Rutsch 2 , Yvonne Nitschke 2 and Thomas Pap 4 , 1 Centre for<br />

Orthopaedics and Trauma Surgery, 2 Department <strong>of</strong> Pedriatrics,<br />

3<br />

Insitute for Experimental Musculoskeletal Medicine, Münster,<br />

Germany, 4 Insitute for Experimental Musculoskeletal Medicine,<br />

5<br />

MedBaltic.<br />

1487. Inhibitory кBα Is a Direct Bone Morphogenetic Protein Target<br />

Gene and an Essential Mediator <strong>of</strong> Anti-Catabolic Effects <strong>of</strong><br />

BMPs. Olexandr Korchynskyi 3 , Paul-Peter Tak 3 , Alisa E. Koch 2 ,<br />

Peter ten Dijke 1 and Dhavalkumar D. Patel 4 , 1 Department<br />

<strong>of</strong> Molecular Cell Biology, Leiden University Medical Cente,<br />

Leiden, The Netherlands, 2 Department <strong>of</strong> Veteran’s Affairs<br />

and the University <strong>of</strong> Michigan, Ann Arbor, MI, 3 Division <strong>of</strong><br />

Clinical Immunology & <strong>Rheumatology</strong>, Academic Medical<br />

Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

4<br />

Thurston Arthritis Research Center, University <strong>of</strong> North Carolina<br />

at Chapel Hill, Chapel Hill, NC.<br />

1488. Interleukin-10 Regulates Bone Metabolism by Suppressing<br />

Osteoclastogenesis In Vivo. Seungwoo Han 4 , Younkwan<br />

Jung 3 , Eunsoo Kim 2 and Gunwoo Kim 1 , 1 CIHR Group in Skeletal<br />

Development and Remodeling, Department <strong>of</strong> Physiology and<br />

Pharmacology, University <strong>of</strong> Western Ontario, London, ON,<br />

Canada, 2 Dongsan Medical Center, Keimyung University, Daegu,<br />

Korea, Republic <strong>of</strong>, 3 Laboratory for Arthritis and Bone Biology,<br />

Fatima Research Institute, Korea, Republic <strong>of</strong>, 4 Laboratory<br />

for Arthritis and Bone Biology, Fatima Research Institute,<br />

Department <strong>of</strong> Internal Medicine, Daegu Fatima Hospital,<br />

Daegu, Korea, Republic <strong>of</strong>.<br />

1489. Interleukin-1-Induced Cyclooxygenase-2 and Inducible Nitric<br />

Oxide Synthase Expression in Human OA Chondrocytes Is<br />

Associated with Histone H3K4 Methylation. Fatima Ezzahra<br />

El-Mansouri 3 , Nadir Chabane 3 , Nadia Zayed 3 , Johanne Martel-<br />

Pelletier 2 , Jean-Pierre Pelletier 1 and Hassan Fahmi 3 , 1 CHUM<br />

- Notre-Dame Hospital, Montreal, QC, Canada, 2 CR-CHUM,<br />

Notre-Dame Hospital, Montreal, QC, Canada, 3 Osteoarthritis<br />

Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />

(CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada.<br />

1490. miR-7 and miR-130b Are Differentially Regulated during<br />

Mesenchymal Stem Cell Commitment. Glyn Palmer 4 , Laura S.<br />

Danielson 2 , Mukundan Attur 3 , Steven B. Abramson 1 and Eva<br />

Hernando 2 , 1 Hospital for Joint Dis/NYU, New York, NY, 2 NYU-<br />

Department <strong>of</strong> Pathology, 3 NYU-Hospital for Joint Diseases,<br />

4<br />

NYU-Hospital for Joint Diseases, New York, NY.<br />

1491. MMP-3 and DKK-1 Levels in Juvenile Idiopathic Arthritis.<br />

Matthew L. Stoll 2 , Michelle L. Christadoss 2 , Marilynn G. Punaro 2<br />

and Nancy J. Olsen 1 , 1 Penn State Hershey Medical Center,<br />

Hershey, PA, 2 UT Southwestern Med Ctr, Dallas, TX.<br />

1492. Modeling Osteoclast Precursor Master Fusogens and<br />

Mononuclear OCP Donors with Raw Cell Line Clones. Yawen<br />

Ju, Masahiko Takahata, K<strong>of</strong>i Mensah, Grace Chiu, Christopher<br />

T. Ritchlin, Lianping Xing and Edward M. Schwarz, University <strong>of</strong><br />

Rochester.<br />

1493. Multi-Targeted Kinase Inhibitor PKC412 Diminishes<br />

Osteoclastogenesis and Counteracts Osteoclast Mediated<br />

Bone Resorption In Vitro. Despoina Sykoutri 1 , Silvia Hayer 3 ,<br />

Josef S. Smolen 4 and Kurt Redlich 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Internal Medicine III, Medical University <strong>of</strong><br />

Vienna, Vienna, Austria, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />

<strong>of</strong> Internal Medicine III, Medical University <strong>of</strong> Vienna, Vienna,<br />

Austria, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine III, Medical University <strong>of</strong> Vienna, 4 Krankenhaus Lainz,<br />

Vienna, Austria.<br />

1494. Potential Role <strong>of</strong> the LKB1-AMPK and CaMKKb-AMPK<br />

Pathways in Controlling the Progression <strong>of</strong> OA. Robert<br />

Terkeltaub 3 , Bing Yang 4 , Martin K. Lotz 1 and Ru L. Bryan 2 ,<br />

1<br />

Scripps Rsch Inst, La Jolla, CA, 2 UCSD/VAMC, San Diego, CA, 3 VA<br />

Medical Ctr, San Diego, CA, 4 VA Medical Ctr.<br />

234<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1495. S100A8 Enhances Osteoclastic Bone Resorption in<br />

Experimental Antigen-Induced Arthritis. Lilyanne C. Grevers 3 ,<br />

Teun J. de Vries 1 , Vincent Everts 1 , Annet W. Sloetjes 3 , Thomas<br />

Vogl 2 , Johannes Roth 2 , Wim B. van den Berg 3 and Peter L. van<br />

Lent 3 , 1 Department <strong>of</strong> Oral Cell Biology, ACTA, UVA and VU<br />

University Amsterdam, Amsterdam, The Netherlands, 2 Institute<br />

<strong>of</strong> Experimental Dermatology, University <strong>of</strong> Münster, Muenster,<br />

Germany, 3 Radboud University Nijmegen, Medical Centre,<br />

Nijmegen, The Netherlands.<br />

1496. Serum Biomarkers Predict Progressive Structural Damage in<br />

the BeSt Study. Yijing Shen 1 , Linda Dirven 4 , Guy Cavet 1 , Michael<br />

Centola 5 , B. A. C. Dijkmans 2 , Lyndal K. Hesterberg 1 , Thomas<br />

Huizinga 4 , Willem F. Lems 6 and Cornelia F. Allaart 3 , 1 Crescendo<br />

Bioscience, Inc., 2 JBI, Amsterdam, The Netherlands, 3 Leiden Univ<br />

Med Ctr, Leiden, The Netherlands, 4 Leiden University Medical<br />

Center, 5 Oklahoma Med Research Foundation, Oklahoma City,<br />

OK, 6 VU University Medical Center.<br />

1497. Strontium Ranelate Inhibits Key Factors Affecting Bone<br />

Remodelling in Human Osteoarthritic Subchondral Bone<br />

Osteoblasts. Johanne Martel-Pelletier 2 , Steeve Kwan Tat 3 ,<br />

Anne-Christine Goulet 3 , Judith Caron 1 , Daniel Lajeunesse 4 and<br />

Jean-Pierre Pelletier 4 , 1 ArthroLab Inc., Montreal, 2 CR-CHUM,<br />

Notre-Dame Hospital, Montreal, QC, Canada, 3 Osteoarthritis<br />

Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />

(CRCHUM), Notre-Dame Hospital, 4 University <strong>of</strong> Montreal<br />

Hospital Research Centre (CRCHUM), Notre-Dame Hospital,<br />

Montreal, QC, Canada.<br />

1498. Study <strong>of</strong> Chondrogenic Potential <strong>of</strong> Subpopulations <strong>of</strong> Cells<br />

Expressing Mesenchymal Stem Cell Markers Derived from<br />

Human Synovial Membranes. María C. Arufe 4 , Alexandre De la<br />

Fuente 3 , Silvia Diaz 2 , Isaac Fuentes 2 , Francisco J. de Toro 1 and<br />

Francisco J. Blanco 5 , 1 Dpto. Medicine, Area <strong>of</strong> Anatomy and<br />

Human Embryology, Campus Oza s/n. Fac. <strong>of</strong> Health Science,<br />

University <strong>of</strong> A Coruna, CIBER-BBN, Instituto de Salud Carlos<br />

III, Spain, 2 Osteoarticular and Aging Research Lab. Cellular<br />

Therapy Unit, INIBIC- CHUAC, A Coruña, Dpto. Medicine, Area<br />

<strong>of</strong> Anatomy and Human Embryology, Campus Oza s/n. Fac. <strong>of</strong><br />

Health Science, University <strong>of</strong> A Coruna, CIBER-BBN, Instituto<br />

de Salud C, 3 Osteoarticular and Aging Research Lab. Cellular<br />

Therapy Unit, INIBIC- CHUAC, A Coruña, Spain, CIBER-BBN,<br />

Instituto de Salud Carlos III, Spain, 4 Osteoarticular and Aging<br />

Research Lab. Cellular Therapy Unit. INIBIC- CHUAC, A Coruna,<br />

Dpto. Medicine, Area <strong>of</strong> Anatomy and Human Embryology,<br />

Campus Oza s/n. Fac. <strong>of</strong> Health Science, University <strong>of</strong> A Coruna,<br />

CIBER-BBN, Instituto de Salud Carlos , 5 Osteoarticular and Aging<br />

Research Lab. Cellular Therapy Unit., INIBIC- CHUAC, A Coruña.<br />

Cathedra BIOIBERICA <strong>of</strong> Cell Therapy University <strong>of</strong> A Coruna, A<br />

Coruña, SPAIN, CIBER-BBN, Instituto de Salud Carlos III, Spain.<br />

1499. TGF-β-Induced CD4+CD25+Foxp3+ Regulatory T Cells Suppress<br />

Bone Erosion in Collagen-Induced Arthritis through Restraining<br />

the Osteoclastogenesis. NIng Kong 3 , Ziyan Yang 2 , Julie Wang 3 ,<br />

Ryan Park 3 , Grant Dagliyan 3 , Peter S. Conti 3 , Hejian Zou 1 and<br />

Song Guo Zheng 3 , 1 Fudan University Medical School, 2 UCLA<br />

Department <strong>of</strong> Biomed, 3 USC Keck School <strong>of</strong> Medicine.<br />

1500. The Calcitonin Receptor Is Localized to Specific Phenotypes <strong>of</strong><br />

Cartilage Chondrocytes In Situ. Pingping Chen-An, Yadong Li,<br />

Bodil C. Sondergaard, Toni Silvestra-Segovia, Per Qvist, Morten<br />

A. Karsdal and Anne C. Bay-Jensen, Cartilage Biology and<br />

Biomarkers, Denmark.<br />

1501. The Enhanced Expression <strong>of</strong> Suppressor <strong>of</strong> Cytokine Signaling<br />

(SOCS)-3 in Human Pathological Chondrocytes Impairs the<br />

TLR4 and IGF-1 Signaling in These Cells. Fons A. J. van de Loo,<br />

Miranda B. Bennink, Onno J. Arntz, Henk M. van Beuningen,<br />

Peter M. van der Kraan, Sharon S. Veenbergen and Wim B. van<br />

den Berg, Department <strong>of</strong> <strong>Rheumatology</strong>, Radboud University<br />

Nijmegen Medical Centre, Nijmegen, The Netherlands.<br />

1502. The HCO3-/Cl- Anion Exchanger SLC4A2 Regulates pH and<br />

Actin Organization within Osteoclasts. Fabienne Coury 1 ,<br />

Andrew K. Stewart 3 , Sebastien Stephens 2 , Lynn Neff 2 , William<br />

C. Horne 2 , Seth L. Alper 3 , Roland Baron 2 and Antonios O.<br />

Aliprantis 1 , 1 Department <strong>of</strong> Immunology and Infectious<br />

Diseases, Harvard School <strong>of</strong> Public Health, and Department <strong>of</strong><br />

Medicine, Harvard Medical School, Boston, MA, 2 Department <strong>of</strong><br />

Oral Medicine Infection and Immunity, Harvard Dental School,<br />

3<br />

Division <strong>of</strong> Nephrology, Beth Israel Deaconess Medical Center.<br />

1503. WNT3A Signals Simultaneously through Multiple Pathways<br />

in Human Articular Chondrocytes, Resulting in Distinct<br />

Outcomes. Giovanna Nalesso 2 , Costantino Pitzalis 1 and<br />

Francesco Dell’Accio 2 , 1 William Harvey Research Institute, Barts<br />

and the London Queen Mary School <strong>of</strong> Medicine and Dentistry,<br />

Bromley Kent, United Kingdom, 2 William Harvey Research<br />

Institute, Barts and the London Queen Mary School <strong>of</strong> Medicine<br />

and Dentistry.<br />

Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />

1504. A Novel Role for Inducible Fucosyltransferase2 as a Regulator<br />

<strong>of</strong> Angiogenesis. Mohammad A. Amin 1 , Jeffrey H. Ruth 2 , Peisuen<br />

Tsou 2 , Phillip L. Campbell 2 , Hubert Marotte 2 , SolHee Lee 2 ,<br />

Sivakumar Nallasivam 2 , Steven E. Domino 2 and Alisa E. Koch 3 ,<br />

1<br />

University <strong>of</strong> Michigan, Ann Arbor, MI, 2 University <strong>of</strong> Michigan,<br />

3<br />

Unversity <strong>of</strong> Michigan, Ann Arbor, MI.<br />

1505. CD86 Is Involved in the Intercellullar Contacts between IL15<br />

Activated Natural Killer Cells and THP-1 Cells That Result in<br />

TNF Production. Amalia Lamana, Belen Diaz-Sanchez, Ana M.<br />

Ortiz, Santos Castañeda, Rosario Garcia-Vicuña and Isidoro<br />

Gonzalez-Alvaro, <strong>Rheumatology</strong> Department. HU La Princesa. IIS<br />

Princesa, Madrid, Spain.<br />

1506. Characterization <strong>of</strong> CCR7 and Its Ligands CCL19 and CCL21<br />

in Rheumatoid Arthritis. Sarah R. Pickens 5 , Michael V. Volin 1 ,<br />

Richard M. Pope 4 , Arthur M. Mandelin 2 and Shiva Shahrara 3 ,<br />

1<br />

Midwestern University, 2 Northwester University, Chicago, IL,<br />

3<br />

Northwestern Univ Feinberg, Chicago, IL, 4 Northwestern Univ<br />

Med School, Chicago, IL, 5 Northwestern University, Chicago, IL.<br />

1507. Chemerin Levels Are Increased in Rheumatoid Arthritis<br />

Patients Who Smoke, Correlate with Disease Activity, and<br />

Decrease after Adalimumab Treatment. Marieke Herenius 2 ,<br />

Cristina Lebre 3 , Ana Oliveira 3 , Carla Wijbrandts 3 , Daniëlle Gerlag 3<br />

and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />

Amsterdam, The Netherlands, 2 Division <strong>of</strong> Clinical Immunology<br />

and <strong>Rheumatology</strong>, Academic Medical Center, University <strong>of</strong><br />

Amsterdam, Amsterdam, Utrecht, The Netherlands, 3 Division<br />

<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical<br />

Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands.<br />

1508. Contribution <strong>of</strong> NR4A2 Gene Expression in Modulation<br />

<strong>of</strong> Thrombospondin-1 in Human Joint Disease. Jason P.<br />

McMorrow 3 , Ursula Fearon 3 , Douglas J. Veale 1 , Oliver M.<br />

FitzGerald 2 and Evelyn P. Murphy 3 , 1 St Vincents Univ Hospital,<br />

Dublin, Ireland, 2 University <strong>College</strong> Dublin, Ranelagh Dublin,<br />

Ireland, 3 University <strong>College</strong> Dublin, Dublin, Ireland.<br />

2010 Program Book 235


ACR/ARHP Poster Session C<br />

1509. Role <strong>of</strong> the Metalloproteinase ADAM-8 in the Regulation <strong>of</strong><br />

the Inflammatory Response. PSGL-1 Shedding by ADAM-8<br />

in Human Neutrophils. Maria Jesus Dominguez-Luis 4 , Ana<br />

Urzainqui-Mayayo 1 , Ada Maria Herrera-Garcia 4 , Ana Diaz-<br />

Martin 5 , Maria Teresa Arce-Franco 5 , Faustino Mollinedo 2 ,<br />

Francisco Sanchez-Madrid 1 and Federico Diaz-Gonzalez 3 ,<br />

1<br />

Immunology Service, Hospital de La Princesa, Madrid, Spain,<br />

2<br />

Instituto Superior del Cancer, Salamanca, Spain, 3 <strong>Rheumatology</strong><br />

Service, Hospital Universitario de Canarias, La Laguna, Tenerife,<br />

Spain, 4 <strong>Rheumatology</strong> Service, Hospital Universitario de<br />

Canarias, La Laguna, Spain, 5 <strong>Rheumatology</strong> Service, Hospital<br />

Universitario de Canarias, Spain.<br />

Cytokines, Mediators, Gene Regulation II<br />

1510. In Vitro Hypoxia-Induced Mitochondrial Genome Mutagenesis<br />

and Dysfunction. Monika Biniecka 2 , Edward Fox 1 , Chin T.<br />

Ng 2 , Wei Gao 2 , Ursula Fearon 2 , Douglas Veale 2 and Jacintha<br />

O’Sullivan 2 , 1 Department <strong>of</strong> Pathology, University <strong>of</strong><br />

Washington, Seattle, WA, 2 Translation Research Group, Dublin<br />

Academic Medical Centre, St. Vincent’s University Hospital,<br />

Dublin, Co. Dublin, Ireland.<br />

1511. Allograft Inflammatory Factor-1 Facilitates the Migration<br />

<strong>of</strong> Fibroblasts and Has a Correlation with the Pathogensis<br />

<strong>of</strong> Skin Fibrosis in a Murine Model <strong>of</strong> a Murine Model <strong>of</strong><br />

Sclerodermatous GVHD. Aihiro Yamamoto 1 , Eishi Ashihara 2 ,<br />

Yoko Nakagawa 2 , Hiroshi Obayashi 3 , Takahiro Seno 1 , Masatoshi<br />

Kadoya 1 , Masahide Hamaguchi 1 , Hidetaka Ishino 1 , Masataka<br />

Kohno 1 , Taira Maekawa 2 and Yutaka Kawahito 1 , 1 Department<br />

<strong>of</strong> Inflammation and Immunology, Graduate School <strong>of</strong> Medical<br />

Science, Kyoto Prefectural University <strong>of</strong> Medicine, 2 Department<br />

<strong>of</strong> Transfusion Medicine and Cell Therapy, Kyoto University<br />

Hospital, 3 Institute <strong>of</strong> Bio-Response Informatics.<br />

1512. Bach1 Regulates Heme Oxygenase-1 Expression <strong>of</strong> Human<br />

Monocytes in Response to LPS: Implication in Behcet’s<br />

Disease. Mitsuhiro Takeno, Takuya Miyazaki, Yohei Kirino, Sei<br />

Samukawa, Maasa Hama and Yoshiaki Ishigatsubo, Yokohama<br />

City University Graduate School <strong>of</strong> Medicine.<br />

1513. BMS-582949 Is a Dual Action p38 Kinase Inhibitor Well Suited<br />

To Avoid Resistance Mechanisms That Increase p38 Activation<br />

in Cells. Gary Schieven 1 , Rosemary Zhang 2 , Sidney Pitt 2 , Ding-<br />

Ren Shen 2 , Jian Cao 2 , John Sack 2 , Arthur Doweyko 2 and Petra<br />

Ross-MacDonald 2 , 1 Bristol-Myers Squibb, Princeton, NJ, 2 Bristol-<br />

Myers Squibb.<br />

1514. Both Insulin Receptor and Nampt Activity Are Implicated<br />

in Visfatin/Nampt Induced PGE2 Synthesis in Articular<br />

Chondrocytes. Marjolaine Gosset 4 , Francis Berenbaum 2 ,<br />

Colette Salvat 4 , Alain Sautet 1 , Martin Holzenberger 3 and Claire<br />

Jacques 4 , 1 Faculty <strong>of</strong> Medicine P&M Curie, Paris, France, 2 Faculty<br />

<strong>of</strong> Medicine P&M Curie, UR 4 Paris Universitas, Paris, France,<br />

3<br />

Inserm U 893 , Paris, France, 4 UR 4 Paris Universitas, Paris, France.<br />

1515. Comparison <strong>of</strong> IL-17F and IL-17A Effects and Signaling in<br />

Human Rheumatoid Arthritis Synoviocytes. Arnaud Hot,<br />

Saloua Zrioual, Anne Tournadre, Vanina Lenief and Pierre<br />

Miossec, Immunogenomics and Inflammation Research Unit<br />

and Department <strong>of</strong> Immunology and <strong>Rheumatology</strong>, Hospital<br />

Edouard Herriot, Lyon, France.<br />

1516. Down-Regulation <strong>of</strong> Pyrin Promotes Up-Regulation <strong>of</strong> the<br />

Anti-Apoptotic Gene, BCL2, Via the Signal Transducer, gp130,<br />

and Leads to the Activation <strong>of</strong> the PI3K/Akt Pathway. Geryl M.<br />

Wood 4 , James Balow, Jr 3 , Hong-Wei Sun 2 , Ivona Aksentijevich 3 ,<br />

Jae Jin-Chae 3 , Nitza Shoham 1 and Daniel L. Kastner 3 , 1 Allergy<br />

Immunology Laboratory, Meir Hospital, Kfar-Saba, Israel,<br />

2<br />

Biodata Mining and Discovery, Office <strong>of</strong> Science and<br />

Technology, National Institutes <strong>of</strong> Health, NIAMS, 3 Laboratory<br />

<strong>of</strong> Clinical Investigation, National Institutes <strong>of</strong> Health, NIAMS,<br />

4<br />

Laboratory <strong>of</strong> Clinical Investigation, National Institutes <strong>of</strong><br />

Health, NIAMS, Bethesda, MD.<br />

1517. Effect <strong>of</strong> the PEG Component <strong>of</strong> Certolizumab Pegol on Calcium<br />

Flux in Cellular Systems. Gianluca Fossati 2 and Andrew Nesbitt 1 ,<br />

1<br />

New Medicines, UCB, Slough, Berkshire, United Kingdom, 2 New<br />

Medicines, UCB, Slough, UK.<br />

1518. Expression <strong>of</strong> the Wnt Inhibitor sFRP-1 in Synovial Fibroblasts<br />

Is Regulated by the Histone Methyltransferase EZH2. Michelle<br />

Trenkmann 1 , Matthias Brock 3 , Renate E. Gay 2 , Christoph Kolling 5 ,<br />

Rudolf Speich 4 , Beat A. Michel 2 , Steffen Gay 2 and Lars C. Huber 3 ,<br />

1<br />

Center <strong>of</strong> Experimental <strong>Rheumatology</strong>, University Hospital<br />

Zurich/Zurich Center <strong>of</strong> Integrative Human Physiology (ZIHP),<br />

Zurich, Switzerland, 2 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>,<br />

University Hospital Zurich/Zurich Center <strong>of</strong> Integrative Human<br />

Physiology (ZIHP), Switzerland, 3 Center <strong>of</strong> Experimental<br />

<strong>Rheumatology</strong>, University Hospital Zurich/Zurich Center <strong>of</strong><br />

Integrative Human Physiology (ZIHP), Switzerland/Department<br />

<strong>of</strong> Internal Medicine, University Hospital, Zurich, Switzerland,<br />

4<br />

Department <strong>of</strong> Internal Medicine, University Hospital Zurich,<br />

Switzerland, 5 Schulthess Clinic, Zurich, Switzerland.<br />

1519. Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) Levels Are Elevated<br />

in Arthritis: Role <strong>of</strong> Flt3L in Regulating Monocyte Migratory<br />

Pattern in RA. Inês Ramos 2 , Ana Oliveira 3 , Geurt Schilders 3 ,<br />

Saïda Aarrass 3 , Cristina Lebre 3 and Paul P. Tak 1 , 1 Academic Med<br />

Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Division<br />

<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical<br />

Center/University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

3<br />

Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />

Medical Center/University <strong>of</strong> Amsterdam, Amsterdam, The<br />

Netherlands.<br />

1520. Functional Expression <strong>of</strong> CD13/Aminopeptidase N by RA<br />

Synovial Cells In Vitro and In Vivo. Rachel Morgan, Judith<br />

Endres and David A. Fox, University <strong>of</strong> Michigan.<br />

1521. Gottron’s Papules Exhibit Accumulation <strong>of</strong> CD44 Variant 7<br />

(CD44v7) and Its Binding Partner Osteopontin: A Unique<br />

Molecular Signature. Jessica Kim 1 and Victoria P. Werth 2 , 1 New<br />

York University School <strong>of</strong> Medicine, 2 University <strong>of</strong> Pennsylvania,<br />

Philadelphia, PA.<br />

1522. Identification <strong>of</strong> the NR4A Family <strong>of</strong> Orphan Nuclear Receptors<br />

as Mediators <strong>of</strong> Adenosine A2A Receptor Activation. Jason P.<br />

McMorrow 2 , Evelyn P. Murphy 2 and Bruce N. Cronstein 1 , 1 New<br />

York Univ Med Ctr, New York, NY, 2 University <strong>College</strong> Dublin,<br />

Dublin, Ireland.<br />

1523. Increased Expression <strong>of</strong> Acid Sensing Ion Channel (ASIC)<br />

Mediated by ERK/MAPK Pathway in Mouse Anti-Type II<br />

Collagen Antibody-Induced Arthritis. Juyoun Kim 2 , Keon Uk<br />

Park 2 , Jinyeong Chae 3 , Hyun-OK Kim 1 and Sang-Hyon Kim 2 ,<br />

1<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, <strong>College</strong> <strong>of</strong> Medicine and<br />

Institute <strong>of</strong> Health Science, Jinju, Korea, Republic <strong>of</strong>, 2 Keimyung<br />

University Dongsan Medical Center, Daegu, Kungsang Province,<br />

Korea, Republic <strong>of</strong>, 3 Keimyung University Dongsan Medical<br />

Center, Daegu, Kungsang, Korea, Republic <strong>of</strong>.<br />

236<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1524. Increased Levels <strong>of</strong> Soluble Programmed Death 1 (sPD-1) and<br />

Its Soluble Ligand (sPD-L1) in Early Rheumatoid Arthritis Are<br />

Associated with Disease Activity and Progression. Stinne R.<br />

Greisen 4 , Tue K. Rasmussen 5 , Kristian Stengaard-Pedersen 1 ,<br />

Merete L. Hetland 2 , Kim Hørslev-Petersen 6 , Malene Hvid 4 and<br />

Bent Deleuran 3 , 1 Arhus University Hospital, Aarhus, Denmark,<br />

2<br />

Copenhagen Univ Hosp Hvidovre, Hvidovre, Denmark, 3 Institute<br />

<strong>of</strong> Medical Microbiology and Immunology, University <strong>of</strong> Aarhus<br />

and 2 Department <strong>of</strong> <strong>Rheumatology</strong> Aarhus University Hospital,<br />

8000 Aarhus C, Denmark, 4 Institute <strong>of</strong> Medical Microbiology and<br />

Immunology, University <strong>of</strong> Aarhus, 8000 Aarhus C, Denmark,<br />

5<br />

Institute <strong>of</strong> Medical Microbiology and Immunology, University<br />

<strong>of</strong> Aarhus, 8000 Aarhus C, Denmark and Department <strong>of</strong><br />

Dermato-Venerology, Aarhus University Hospital, 8000 Aarhus<br />

C, Denmark, 6 King Christian X Hospital for Rheumatic Disease,<br />

University <strong>of</strong> Southern Denmark, Graasten, Denmark.<br />

1525. Lack <strong>of</strong> IL-17RA Signaling Prevents Autoimmune Inflammation<br />

<strong>of</strong> the Joint and Give Rise to a Th2-Like Phenotype in Collagen-<br />

Induced Arthritis. Anne-Marie Mus, Odilia Corneth, Patrick<br />

Asmawidjaja and Erik Lubberts, Erasmus MC, University Medical<br />

Center.<br />

1526. Lower Expression <strong>of</strong> Fli-1 Leads to Decreased Inflammatory<br />

Cell Infiltration in the Kidneys from NZM2410 Mice. Sarah<br />

Williams 4 , Emmanuel Reyes-Cortes 2 , Eva Karam 3 , Eiji Suzuki 3 ,<br />

Gary S. Gilkeson 1 and John Zhang 5 , 1 Med Univ <strong>of</strong> South<br />

Carolina, Charleston, SC, 2 Medical University <strong>of</strong> South Carolina,<br />

Charleston, SC, 3 Medical University <strong>of</strong> South Carolina, 4 Ralph H.<br />

Johnson VA Medical Center, Charleston, SC, 5 Ralph H. Johnson<br />

VA Medical Center and Medical University <strong>of</strong> South Carolina,<br />

Charleston, SC.<br />

1527. Mechanisms and Clinical Relevance <strong>of</strong> TRAIL-Triggered<br />

Responses in Synovial Fibroblasts <strong>of</strong> Rheumatoid Arthritis<br />

Patients. Rachel Audo 4 , Flavia Calmon Hamaty 5 , Dominique<br />

Baeten 1 , Bernard G. Combe 2 , Michael Hahne 4 and Jacques<br />

Morel 3 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />

The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong>. Teaching<br />

Hospital <strong>of</strong> Lapeyronie, Montpellier, France, 3 Department <strong>of</strong><br />

<strong>Rheumatology</strong>. Teaching Hospital <strong>of</strong> Lapeyronie, Montpellier,<br />

France, 4 IGMM, UMR5535, CNRS, Montpellier, Montpellier,<br />

France, 5 IGMM, UMR5535, CNRS, Montpellier.<br />

1528. Pro-Inflammatory Activity <strong>of</strong> SIRT1 in Monocytes. Fabienne<br />

Niederer 1 , Caroline Ospelt 1 , Fabia Brentano 1 , Beat A. Michel 2 ,<br />

Christoph Kolling 4 , Michael O. Hottiger 3 , Renate E. Gay 2 , Steffen<br />

Gay 2 and Diego Kyburz 2 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>,<br />

University Hospital Zurich and Zurich Center <strong>of</strong> Integrative<br />

Human Physiology (ZIHP), Zurich, Switzerland, 2 Center <strong>of</strong><br />

Experimental <strong>Rheumatology</strong>, University Hospital Zurich<br />

and Zurich Center <strong>of</strong> Integrative Human Physiology (ZIHP),<br />

Switzerland, 3 Institute <strong>of</strong> Veterinary Biochemistry and Molecular<br />

Biology, University Zurich, Switzerland, 4 Schulthess Clinic,<br />

Zurich, Switzerland.<br />

1529. Ras GTPase Homologues Make Redundant Contributions to RA<br />

FLS Activation and Broad Silencing <strong>of</strong> Ras Proteins Decreases<br />

Inflammation and Joint Destruction in Experimental Arthritis.<br />

Daphne de Launay 1 , Jeroen Vreijling 1 , Joana Abreu 1 , Aleksander<br />

Grabiec 1 , Marjolein van Maanen 2 , Marjolein Sanders 2 , Margriet<br />

Vervoordeldonk 2 , Henrik Oerum 3 , Kees Fluiter 1 , Paul Peter Tak 1<br />

and Kris Reedquist 1 , 1 Academic Medical Center, University <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />

Center, University <strong>of</strong> Amsterdam, The Netherlands, 3 Santaris<br />

Pharma A/S, Horsholm, Denmark.<br />

1530. Resveratrol Inhibits TNF-α-Induced MMP-9 Expression through<br />

a mTOR Independent Pathway. Xiaoxia Zhu 2 , Jianhua Qiu 1 and<br />

Hejian Zou 2 , 1 Department <strong>of</strong> Neurology, Massachusetts General<br />

Hospital, Harvard Medical School, Boston, MA, 2 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Huashan Hospital, Fudan University, Shanghai,<br />

China.<br />

1531. Role <strong>of</strong> Dipeptidyl Peptidase I (Cathepsin C) in the Maturation<br />

<strong>of</strong> IL-1β In Vivo. Hajime Kono 1 , Zubin Patel 2 , Tamiko Yanagida 1 ,<br />

Maki Takayama 1 and Kennth Rock 2 , 1 Teikyo University School <strong>of</strong><br />

Medicine, 2 University <strong>of</strong> Massachusetts Medical School.<br />

1532. The Expression <strong>of</strong> the Anti-Apoptotic Transcription Factor<br />

NFkappaB-P65 Is Markedly Diminished in Chondrocytes <strong>of</strong><br />

Murine Osteoarthritic Cartilage and in a Subset <strong>of</strong> Human<br />

Osteoarthritic Cartilage Samples. Fons A. J. van de Loo, Onno<br />

J. Arntz, Miranda B. Bennink, Esmeralda Blaney-Davidson, Peter<br />

M. van der Kraan and Wim B. van den Berg, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands.<br />

1533. TLR2 Mediates Acute Serum Amyloid A Induced Pro-<br />

Inflammatory Effects in Rheumatoid Arthritis. Mary Connolly 3 ,<br />

Ashwini Maratha 1 , Sinead Nic an Ultaigh 3 , Sinead Miggin 2 ,<br />

Ursula Fearon 3 and Douglas J. Veale 3 , 1 Institute <strong>of</strong> Immunology,<br />

National University <strong>of</strong> Ireland Maynooth, Maynooth, Ireland,<br />

2<br />

Institute <strong>of</strong> Immunology, National University <strong>of</strong> Ireland<br />

Maynooth, 3 Translational Research Group, Dublin Academic<br />

Medical Centre, St. Vincents University Hospital., Ireland.<br />

1534. TNF-a and Chemerin Cross-Talk in Rheumatoid Arthritis. M. C.<br />

Lebre 2 , M. I. Ramos 2 , C. H<strong>of</strong>stra 3 , H. van Eenennaam 3 , S. Aarrass 2<br />

and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />

Amsterdam, The Netherlands, 2 Division <strong>of</strong> Clinical Immunology&<br />

<strong>Rheumatology</strong>, Academic Medical Center/University <strong>of</strong><br />

Amsterdam, Amsterdam, The Netherlands, 3 Merck Research<br />

Laboratories, Oss, The Netherlands.<br />

1535. Toll-Like Receptor 4 Signalling Is Specifically TAK1-Independent<br />

in Synovial Fibroblasts. Fons A. J. van de Loo 1 , Ben T. van den<br />

Brand 1 , Shahla Abdollahi-Roodsaz 1 , Onno J. Arntz 1 , Michael<br />

Kracht 2 , Jeroen Geurts 1 and Wim B. van den Berg 1 , 1 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands, 2 Rudolf-Buchheim-Institute <strong>of</strong><br />

Pharmacology, University <strong>of</strong> Giessen, Hannover, Germany.<br />

1536. Tyrosine Kinase Inhibitors Reduce NMDA Receptor NR1<br />

Expression, Nuclear Translocation and Thermal Hyperalgesia/<br />

CentralSensitization in a Rat Arthritis Model. Terry A.<br />

McNearney 5 , Ying Lu 5 , Zaiming Ye 2 , Liping Zhang 3 , Giulio<br />

Taglialatela 5 , Todd Pappas 1 , Wen-Ru Zhang 5 and Karin N.<br />

Westlund 4 , 1 Asuragen, Inc, Austin, TX, 2 MD Anderson Medical<br />

Center, Houston, TX, 3 University <strong>of</strong> Kentucky, Lexington, TX,<br />

4<br />

University <strong>of</strong> Kentucky, Lexington, KY, 5 University <strong>of</strong> Texas<br />

Medical Branch, Galveston, TX.<br />

Epidemiology and Health Services Research: OP/OA<br />

1537. An Evaluation <strong>of</strong> Prescription Insurance Coverage<br />

Inconsistencies – Prior Authorization Does Not Mean Approval.<br />

Dawn C. Crate 2 and Daniel A. Albert 1 , 1 Dartmouth-Hitchcock<br />

Med Ctr, Lebanon, NH, 2 Dartmouth-Hitchcock Medical Center.<br />

2010 Program Book 237


ACR/ARHP Poster Session C<br />

1538. Arthritis Prevalence and Access to Care in Indigenous People:<br />

Results <strong>of</strong> a Population-Based Study. Allen J. Lehman 1 ,<br />

Matthew H. Liang 3 , Linda Li 2 , John M. Esdaile 2 , Catherine L.<br />

Backman 5 , Phyllis Jorgensen 4 , Kim Roberts 4 , Linda Lavender 4<br />

and Diane Lacaille 2 , 1 Arthritis Research Centre <strong>of</strong> Canada,<br />

Vancouver, BC, Canada, 2 Arthritis Research Centre <strong>of</strong> Canada;<br />

University <strong>of</strong> British Columbia, 3 Harvard, Boston, MA, 4 Kwakiutl<br />

District Council Health Centre, 5 University <strong>of</strong> British Columbia,<br />

Vancouver, BC, Canada.<br />

1539. Aspirin vs. Low Molecular Weight Heparin for Prophylaxis<br />

Against Venous Thromboembolism after Total Knee or<br />

Hip Replacement in Lower Risk Individuals: A Cost-Utility<br />

Analysis. John T. Schousboe 1 and Gregory A. Brown 2 , 1 Park<br />

Nicollet Institute, Minneapolis, St Louis Park, MN, 2 Park Nicollet<br />

Institute, Minneapolis, MN.<br />

1540. Assessment <strong>of</strong> the Incremental Cost <strong>of</strong> Osteoporosis-Related<br />

Fractures among Women in a Large U.S. Managed Care<br />

Population. Hema Viswanathan 1 , Jeffrey White 6 , Sally W. Wade 5 ,<br />

Jingbo Yu 3 , Jeffrey R. Curtis 4 , Bradley Stolshek 2 , Claire Merinar 2 ,<br />

Joel Kallich 2 , Akhila Balasubramanian 2 and John Adams 2 ,<br />

1<br />

Amgen Inc., Thousand Oaks, CA, 2 Amgen Inc., 3 HealthCore, Inc.,<br />

4<br />

University <strong>of</strong> Alabama - Brimingham, Birmingham, AL, 5 Wade<br />

Outcomes Research and Consulting, 6 WellPoint, Inc..<br />

1541. Bending the Cost Curve in Early RA: Sick Leave and Disability<br />

Pension before and after Initiation <strong>of</strong> Biologics or DMARD<br />

Combination Therapy. Martin Neovius 1 , Julia F. Simard 1 ,<br />

Johan Askling 2 and ARTIS Study Group 3 , 1 Karolinska Institute,<br />

Stockholm, Sweden, 2 Karolinska Institute, 3 Sweden.<br />

1542. Differences in Clinical and Economic Pr<strong>of</strong>iles <strong>of</strong> Rheumatoid<br />

Arthritis Patients Using Frequently Dosed Subcutaneous<br />

or Less Frequently Dosed Intravenous Biologic Therapy.<br />

Chureen T. Carter 1 , O. Tunceli 3 , Susan C. Bolge 2 , Leigh Denny 2 ,<br />

C. Fang 3 and Joseph Singer 3 , 1 Centocor Ortho Biotech Services,<br />

LLC, Horsham, PA, 2 Centocor Ortho Biotech Services, LLC,<br />

3<br />

HealthCore, Inc..<br />

1543. DXA Screening and Use <strong>of</strong> Osteoporosis Medications in Two<br />

Large Regional Healthcare Systems. Amy Warriner 5 , Ryan C.<br />

Outman 4 , Jeffrey R. Curtis 5 , Adrian Feldstein 1 , Harry Glauber 3 ,<br />

Junling Ren 2 , Douglas Roblin 2 , Ana Rosales 1 , Robert Unitan 3<br />

and Kenneth G. Saag 7 , 1 Kaiser Permanente Center for Health<br />

Research, Portland, OR, 2 Kaiser Permanente Center for Health<br />

Research, Atlanta, GA, 3 Kaiser Permanente Northwest, 4 Univ <strong>of</strong><br />

Alabama at Birmingham, Birmingham, AL, 5 Univ <strong>of</strong> Alabama at<br />

Birmingham, Birmingham.<br />

1544. Erectile Dysfunction Is Associated with Gout in the Campaign<br />

Against Cancer and Heart Disease (CLUE II). Janet W. Maynard,<br />

Mara A. McAdams, Alan N. Baer, Judith H<strong>of</strong>fman-Bolton, Allan<br />

C. Gelber and Josef Coresh, Johns Hopkins.<br />

1545. Floor and Ceiling Effects and Choice <strong>of</strong> Physical Function<br />

Instruments. Eswar Krishnan 3 , Bharathi Lingala 4 , Bonnie Bruce 1<br />

and James F. Fries 2 , 1 Stanford Dept <strong>of</strong> Medicine, Palo Alto, CA,<br />

2<br />

Stanford Univ Medical Ctr, Palo Alto, CA, 3 Stanford University,<br />

Palo Alto, CA, 4 Stanford University.<br />

1546. Fragility Fractures in Brazilian Community-Dwelling Elderly:<br />

Prevalence and Risk Factors. Jaqueline B. Lopes, Camille P.<br />

Figueiredo, Liliam Takayama, Valeria F. Caparbo and Rosa M.<br />

R. Pereira, <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />

Universidade de São Paulo.<br />

1547. Higher Serum Urate Levels Correlate with Increased<br />

Prevalence <strong>of</strong> Comorbidities in the US General Population:<br />

NHANES 1999-2008. Yanyan Zhu 1 , Bhavik Pandya 2 and Hyon<br />

Choi 1 , 1 Boston University <strong>of</strong> School <strong>of</strong> Medicine, Boston, MA,<br />

2<br />

Takeda Pharmaceuticals International, Inc, Deerfield, IL.<br />

1548. How Large Are the Productivity Losses in Contemporary<br />

Patients with RA, and How Soon in Relation to Diagnosis Do<br />

They Develop? A Six-Year Nationwide Cohort Study. Martin<br />

Neovius 1 , Julia F. Simard 1 , Johan Askling 2 and ARTIS Study<br />

Group 3 , 1 Karolinska Institute, Stockholm, Sweden, 2 Karolinska<br />

Institute, 3 Sweden.<br />

1549. Incidental Capture <strong>of</strong> Chikungunya Associated Chronic<br />

Rheumatism along with Other Rheumatic Musculoskeletal<br />

Disorders in a Rural Community in South India: A BJD India<br />

WHO COPCORD (Community Oriented Program for Control <strong>of</strong><br />

Rheumatic Diseases) Project. Ashish J. Mathew 3 , Vinay Goyal 2 ,<br />

Elizabeth George 2 , Dany Varughese 2 , Jacob Antony 2 and Arvind<br />

Chopra 1 , 1 BJD India Co-ordinator, Pune, India, 2 The Trivandrum<br />

COPCORD Study Group, 3 The Trivandrum COPCORD Study<br />

Group, Medical <strong>College</strong> Hospital and Health Action by People,<br />

Trivandrum, India.<br />

1550. Mortality Outcomes amongst Patients with Rheumatiod<br />

Arthritis with and without Joint Surgery: A Comparative Study.<br />

Courtney A. Shourt 1 , Cynthia S. Crowson 2 , Sherine E. Gabriel 3<br />

and Eric L. Matteson 4 , 1 Department <strong>of</strong> Medicine, Mayo Clinic<br />

<strong>College</strong> <strong>of</strong> Medicine, 2 Division <strong>of</strong> Biostatistics, Department <strong>of</strong><br />

Health Sciences Research, Mayo Clinic <strong>College</strong> <strong>of</strong> Medicine,<br />

3<br />

Division <strong>of</strong> Epidemiology, Department <strong>of</strong> Health Science<br />

Research, and Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic <strong>College</strong><br />

<strong>of</strong> Medicine, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic <strong>College</strong> <strong>of</strong><br />

Medicine.<br />

1551. Oral Tobacco Use Is Significantly Associated with Rheumatic<br />

Musculoskeletal (RMSK) Pain: Result <strong>of</strong> a WHO ILAR COPCORD<br />

(Community Oriented Program for Control <strong>of</strong> Rheumatic<br />

Diseases) Rural Population Study in India. Arvind Chopra 1 ,<br />

Sarika Chaturvedi 4 , Manjit Saluja 2 , Vaijayanti Lagoo Joshi 2 and<br />

Sanjiv Sarmukadam 3 , 1 Center for Rheumatic Diseases, Pune,<br />

India, 2 Center for Rheumatic Diseases, 3 Center for Rheumatic<br />

Diseses, 4 FRCH, Pune, India.<br />

1552. Osteoporosis Medication Adherence and Fracture Risk among<br />

Women in a Large U.S. Health Plan. Hema Viswanathan 1 , Sally<br />

W. Wade 5 , Jeffrey R. Curtis 4 , Jingbo Yu 3 , Jeffrey White 6 , Bradley<br />

Stolshek 2 , Claire Merinar 2 , Akhila Balasubramanian 2 , Joel Kallich 2<br />

and John Adams 2 , 1 Amgen Inc., Thousand Oaks, CA, 2 Amgen Inc.,<br />

3<br />

HealthCore, Inc., 4 University <strong>of</strong> Alabama at Birmingham, 5 Wade<br />

Outcomes Research and Consulting, 6 WellPoint, Inc..<br />

1553. Patient Age, Ethnicity and Wait Times Determine the<br />

Likelihood <strong>of</strong> Non-Attendance at a First Specialist<br />

<strong>Rheumatology</strong> Assessment. Valerie Milne 2 , Robin Kearns 1 and<br />

Andrew A. Harrison 2 , 1 University <strong>of</strong> Auckland, New Zealand,<br />

New Zealand, 2 University <strong>of</strong> Otago, Wellington, New Zealand,<br />

New Zealand.<br />

1554. Predictors <strong>of</strong> Vitamin D Deficiency among Veterans. Joshua<br />

Baker 3 , Alexis Ogdie 3 , Li yun Zhang 2 , Jan Dinella 4 , H. Ralph<br />

Schumacher 5 and Sally W. Pullman-Mooar 1 , 1 Philadelphia, PA,<br />

2<br />

Second Hospital <strong>of</strong> Shanxi Medical University, China, 3 University<br />

<strong>of</strong> Pennsylvania, Philadelphia, PA, 4 University <strong>of</strong> Pennsylvania,<br />

5<br />

VA Medical Center - 151K, Philadelphia, PA.<br />

238<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1555. Projecting the Effects <strong>of</strong> a 5-Point Reduction in Body Mass<br />

Index on Knee or Hip Osteoarthritis and Health-Related Quality<br />

<strong>of</strong> Life in a Closed Population to 2031: A Microsimulation<br />

Study. Eric C. Sayre 1 , Jacek A. Kopec 4 , Behnam Sharif 4 , William<br />

M. Flanagan 3 , Philippe Fines 3 , Mushfiqur Rahman 5 , Michal<br />

Abrahamowicz 2 , David Buckeridge 2 , Sam Harper 2 , John Lynch 7 ,<br />

Douglas Manuel 6 , Jillian Oderkirk 3 and Michael Wolfson 6 ,<br />

1<br />

Arthritis Research Centre <strong>of</strong> Canada, Vancouver, BC, Canada,<br />

2<br />

McGill University, Canada, 3 Statistics Canada, Canada,<br />

4<br />

University <strong>of</strong> British Columbia, Canada, 5 University <strong>of</strong> British<br />

Columbia, Canada 6 University <strong>of</strong> Ottawa, Canada, 7 University <strong>of</strong><br />

South Australia, Canada.<br />

1556. Racial Differences in Gout Risk and Uric Acid Levels in Both<br />

Men and Women in the Atherosclerosis Risk in Communities<br />

(ARIC) Study. Janet W. Maynard, Mara A. McAdams, Alan N.<br />

Baer, Allan C. Gelber and Josef Coresh, Johns Hopkins.<br />

1557. Racial/Ethnic and Sex Differences in Somatosensory<br />

Abnormalities in Subjects with or at High Risk <strong>of</strong> Knee<br />

Osteoarthritis: Preliminary Analysis <strong>of</strong> the Multicenter<br />

Osteoarthritis (MOST) Study. Jasvinder Singh 2 , Niu Jingbo 5 ,<br />

Laura Freylaw 9 , Joachim Scholz 6 , Lars Arendt-Nielsen 1 , Cora E.<br />

Lewis 8 , Clifford Woolf 6 , Larry Bradley 8 , David T. Felson 4 , Michael<br />

C. Nevitt 7 , Irina Tolstykh 7 and Tuhina Neogi 3 , 1 Aalborg University,<br />

Aalborg, Denmark, 2 Birmingham VA Medical Center and<br />

University <strong>of</strong> Alabama, Birmingham, Minneapolis, MN, 3 Boston<br />

Univ Schl <strong>of</strong> Med, Boston, MA, 4 Boston University School <strong>of</strong><br />

Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />

6<br />

Childrens Hospital and Harvard School <strong>of</strong> Medicine, 7 UCSF, San<br />

Francisco, CA, 8 University <strong>of</strong> Alabama, Birmingham, 9 University<br />

<strong>of</strong> Iowa.<br />

1558. Relationship between Physical Activity and Health-Related<br />

Utility in Knee Osteoarthritis Patients. Larry Manheim 2 ,<br />

Jing Song 2 , Rowland W. Chang 1 and Dorothy D. Dunlop 3 ,<br />

1<br />

Northwestern Univ, Chicago, IL, 2 Northwestern University,<br />

3<br />

Northwestern University Medical School, Chicago, IL.<br />

1559. Reporting <strong>of</strong> the Recruitment Process in Randomized Clinical<br />

Trials <strong>of</strong> Biological Agents for the Treatment <strong>of</strong> Rheumatoid<br />

Arthritis. Ismail Simsek and Yusuf Yazici, NYU Hospital for Joint<br />

Diseases.<br />

1560. Rheumatologists Practise Evidence Based Medicine, an<br />

Observational Study. Stephen Hall 1 , Adam Moreton 4 , Kathryn<br />

A. Gibson 2 , Barry A. Kane 2 , Vivek Thakkar 2 , J. Hanrahan 1 ,<br />

Evange Romas 1 , Timothy Godfrey 1 , Marie Feletar 1 , Alexander<br />

Stockman 1 , Jennifer Harmer 1 , Rani Axtens 1 , Peter Ryan 1 , Andrew<br />

Gibson 1 , Christopher Mack 1 , Robert J. Moots 3 and Geraldine<br />

Hassett 2 , 1 Department <strong>of</strong> Medicine, Cabrini Health, Melbourne,<br />

Australia, 2 <strong>Rheumatology</strong> Department, Liverpool Hospital,<br />

Sydney Australia, 3 School <strong>of</strong> Clinical Sciences, University<br />

<strong>of</strong> Liverpool, Liverpool United Kingdom, Liverpool, United<br />

Kingdom, 4 School <strong>of</strong> Clinical Sciences, University <strong>of</strong> Liverpool,<br />

Liverpool United Kingdom.<br />

1561. Screening and Treatment <strong>of</strong> Glucocorticoid Induced<br />

Osteoporosis in a Large U.S. National Pharmacy Database.<br />

Ryan C. Outman 2 , Nathan J. Markward 1 , Mona Khalid 1 , Ronald<br />

E. Aubert 1 , Jeffrey R. Curtis 2 , Robert S. Epstein 1 , Felix W. Frueh 1 ,<br />

Eric J. Stanek 1 , Amy Steinkellner 1 , Amy H. Warriner 2 and Kenneth<br />

G. Saag 2 , 1 Medco Health Solutions, Inc., 2 Univ <strong>of</strong> Alabama at<br />

Birmingham, Birmingham, AL.<br />

1562. Self-Management Strategies in Overweight/Obese Canadians<br />

with Arthritis. Sasha R. Bernatsky 1 , Corneliu Rusu 2 , Siobahn<br />

O’Donnell 2 , Gillian A. Hawker 5 , Crystal Mackay 4 , Louise McRae 2 ,<br />

Mayilee Canizar 4 and Elizabeth M. Badley 3 , 1 McGill UHC/RVH,<br />

Montreal, QC, Canada, 2 PHAC, 3 University <strong>of</strong> Toronto, Toronto,<br />

ON, Canada, 4 University <strong>of</strong> Toronto, 5 Women’s <strong>College</strong> Hospital,<br />

Toronto, ON, Canada.<br />

1563. State-Specific ICF Disability Pr<strong>of</strong>iles among US Adults with<br />

Arthritis. Jennifer M. Hootman 3 , Kristina A. Theis 1 , Julie Bolen 2<br />

and Charles G. Helmick 1 , 1 CDC, Atlanta, GA, 2 CDC, 3 Centers for<br />

Disease Control, Kennesaw, GA.<br />

1564. Statistical Methods Analyzing Count Data with Excessive<br />

Zeros in Arthritis Research. Bin Zhang 3 , Jingbo Niu 5 , Yanyan<br />

Zhu 6 , Tuhina Neogi 2 , Ling Xu 1 , David T. Felson 7 , Michael P.<br />

LaValley 8 and Yuqing Zhang 4 , 1 Beijing, China, 2 Boston Univ Schl<br />

<strong>of</strong> Med, Boston, MA, 3 Boston Univ Schl <strong>of</strong> Medicine, Boston,<br />

MA, 4 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 5 Boston<br />

University, Boston, MA, 6 Boston University, 7 Boston University<br />

School <strong>of</strong> Medicine, Boston, MA, 8 BU School <strong>of</strong> Public Health,<br />

Boston, MA.<br />

1565. The Association <strong>of</strong> Race with Gout: A Broadly Representative<br />

Inpatient Survey. Allan C. Gelber 1 , Janet W. Maynard 2 and<br />

Carlton Haywood, Jr 2 , 1 Baltimore, MD, 2 Johns Hopkins<br />

University, Baltimore, MD.<br />

1566. The Clinical and Economic Burden <strong>of</strong> Corticosteroid Adverse<br />

Events (AEs): A Systematic Literature Review. Evelyn F. Sarnes 2<br />

and Maria E. Watson 1 , 1 GlaxoSmithKline, Research Triangle Park,<br />

NC, 2 Xcenda, Palm Harbor, FL.<br />

1567. The Cost-Effectiveness <strong>of</strong> Corticosteroid Injection <strong>of</strong> the Carpal<br />

Tunnel. Suzanne L. DeLea 1 , Janet L. Poole 1 , Natalia Chavez-<br />

Chiang 2 , Wilmer L. Sibbitt 3 and Arthur D. Bankhurst 4 , 1 University<br />

<strong>of</strong> New Mexico, Albuquerque, NM, 2 University <strong>of</strong> New Mexico,<br />

3<br />

University <strong>of</strong> New Mexico HSC, Albuquerque, NM, 4 University<br />

<strong>of</strong> NM Med Ctr, Albuquerque, NM.<br />

1568. The Prevalence and Characteristics <strong>of</strong> Fluorosis Causing<br />

Skeletal Deformities in Rural Tanzania. Helen G. Jarvis 2 , Peta<br />

S. Heslop 2 , John Kissima 1 and Richard Walker 3 , 1 Hai District<br />

Hospital, Kilimanjaro Region, Tanzania, East Africa, 2 Newcastle<br />

upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United<br />

Kingdom, 3 Northumbria Healthcare NHS Foundation Trust, Tyne<br />

& Wear, United Kingdom.<br />

1569. Thiazide and Loop Diuretics Are Associated with Incident<br />

Gout in the Atherosclerosis Risk in Communities (ARIC) Study.<br />

Mara A. McAdams 4 , Janet W. Maynard 2 , Allan C. Gelber 1 , Alan<br />

N. Baer 3 and Josef Coresh 4 , 1 Baltimore, MD, 2 Johns Hopkins<br />

Univ, Baltimore, MD, 3 Johns Hopkins University, Baltimore, MD,<br />

4<br />

Johns Hopkins, Bloomberg School <strong>of</strong> Public Health.<br />

1570. Trends in Orthopedic Surgery Utilization among Patients<br />

with Rheumatoid Arthritis: A Focus on Surgery Type and<br />

Gender. Courtney A. Shourt 1 , Cynthia S. Crowson 2 , Sherine<br />

E. Gabriel 3 and Eric L. Matteson 4 , 1 Department <strong>of</strong> Medicine,<br />

Mayo Clinic <strong>College</strong> <strong>of</strong> Medicine, 2 Division <strong>of</strong> Biostatistics,<br />

Department <strong>of</strong> Health Science Research, Mayo Clinic <strong>College</strong><br />

<strong>of</strong> Medicine, 3 Division <strong>of</strong> Epidemiology, Department <strong>of</strong> Health<br />

Science Research, and Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic<br />

<strong>College</strong> <strong>of</strong> Medicine, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, and Division <strong>of</strong><br />

Epidemiology, Mayo Clinic <strong>College</strong> <strong>of</strong> Medicine.<br />

2010 Program Book 239


ACR/ARHP Poster Session C<br />

240<br />

1571. Understanding Billing Data: A Survey <strong>of</strong> Billing Process<br />

and Codes Used by Family Physicians for Rheumatological<br />

Conditions. Diane Lacaille, Jack Chang and Pamela Rogers,<br />

Arthritis Research Centre <strong>of</strong> Canada, Vancouver, BC, Canada.<br />

1572. Urate-Lowering Therapy in Chronic Gout Results in Clinically<br />

Important Improvements in Health-Related Quality <strong>of</strong> Life—<br />

SF-36 Is Responsive to Change in Chronic Gout. Puja Khanna 2 ,<br />

Fernando Perez-Ruiz 1 , Paul Maranian 2 and Dinesh Khanna 2 ,<br />

1<br />

Hospital de Cruces, 2 UCLA.<br />

1573. Validation <strong>of</strong> Diagnostic Codes for Subtrochanteric, Diaphyseal,<br />

and Typical Hip Fractures Using Administrative Claims Data.<br />

Pongthorn Narongroeknawin, Nivedita M. Patkar, Bita Shakoory,<br />

Archana Jain, Jeffrey R. Curtis, Elizabeth Delzell, Philip H. Lander,<br />

Robert Lopez-Ben, Michael J. Pitt, Monika M. Safford, David A.<br />

Volgas and Kenneth G. Saag, Univ <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL.<br />

1574. Vitamin C Supplementation and Serum Uric Acid: A Meta-<br />

Analysis <strong>of</strong> Randomized Controlled Trials. Stephen P. Juraschek,<br />

Edgar R. Miller and Allan C. Gelber, Johns Hopkins Medical<br />

Institutions, Baltimore, MD.<br />

1575. What Kinds <strong>of</strong> Advice Do Health Food Store Employees and<br />

Pharmacists Provide to Consumers with Acute Low Back Pain?<br />

Jaya K. Rao 2 , Dio Kavalieratos 1 , Mary Roth 1 , Morris Weinberger 1<br />

and Timothy Carey 1 , 1 Chapel Hill, NC, 2 UNC Eshelman School <strong>of</strong><br />

Pharmacy, Chapel Hill, NC.<br />

1576. Who Falls? A Decade <strong>of</strong> Experience at a Musculoskeletal<br />

Specialty Hospital. Lisa A. Mandl 1 , Michael Parks 2 , Patricia<br />

Quinlan 2 , Tina Bailey 2 , Jacklyn Katz 2 and Steven Magid 2 ,<br />

1<br />

Hospital for Special Surgery, New York, NY, 2 Hospital for Special<br />

Surgery.<br />

Genetics, Genomics and Proteomics: Rheumatoid Arthritis and<br />

SLE<br />

1577. BLK Confers a Risk for Renal Involvement in Japanese Patients<br />

with Systemic Lupus Erythematosus. Kenichi Shimane 2 , Yuta<br />

Kochi 5 , Ryo Yamada 5 , Yukinori Okada 1 , Akari Suzuki 5 , Keiko<br />

Myouzen 5 , Tetsuya Horita 3 , Tomonori Ishii 7 , Michito Hirakata 4 ,<br />

Hir<strong>of</strong>umi Amano 6 , Michiaki Kubo 1 , Yusuke Nakamura 1 , Naoyuki<br />

Kamatani 1 and Kazuhiko Yamamoto 8 , 1 CGM, RIKEN, Yokohama,<br />

Japan, 2 Department <strong>of</strong> Allergy and <strong>Rheumatology</strong>, Graduate<br />

School <strong>of</strong> Medicine, the University <strong>of</strong> Tokyo, Tokyo, Japan,<br />

3<br />

Hokkaido University Graduate School <strong>of</strong> Medicine, Sapporo,<br />

Japan, 4 Keio University School <strong>of</strong> Medicine, Tokyo, Japan,<br />

5<br />

Laboratory for Autoimmune Diseases, Center for Genomic<br />

Medicine, Institute <strong>of</strong> Physical Chemical Research (CGM, RIKEN),<br />

Tokyo, Japan, 6 School <strong>of</strong> Medicine, Juntendo University, Tokyo,<br />

Japan, 7 Tohoku University Graduate School <strong>of</strong> Medicine, Sendai,<br />

Japan, 8 Univ Tokyo Gr Schl <strong>of</strong> Med, Tokyo, Japan.<br />

1578. A Comprehensive Replication Study and Functional Analysis<br />

<strong>of</strong> SLE Associated Variants in BLK, ATG5, PXK and SCUBE1.<br />

Angelica M. Delgado-Vega 6 , Sergey Kozyrev 6 , Johan Frostegård 4 ,<br />

Lennart Truedsson 5 , Bernardo A. Pons-Estel 8 , Sandra D’Alfonso 11 ,<br />

Torsten Witte 1 , Bernard Lauwerys 9 , Emoke Endreffy 12 , László<br />

Kovács 12 , Carlos Vasconcelos 2 , Berta Martins da Silva 10 , Javier<br />

Martin 3 and Marta E. Alarcón-Riquelme 7 , 1 Hannover Medical<br />

School, Germany, 2 Hosp Santo Antonio and ICBAS, Porto,<br />

Portugal, 3 Inst d Biomedicina y Parasitología López-Neyra,<br />

Granada, Spain, 4 Karolinska University Hosp at Huddinge,<br />

Stockholm, Sweden, 5 Lund U, Sweden, 6 Rudbeck Laboratory,<br />

Uppsala U, Sweden, 7 Rudbeck Laboratory, Uppsala U, Sweden.<br />

OMRF, OK. Andalucian Center f Genomics and Oncological<br />

Research Pfizer-University <strong>of</strong> Granada-Junta de Andalucia,<br />

Spain, 8 Sanatorio Parque, Rosario, Argentina, 9 U Catholique d<br />

Louvain, Bruxells, Belgium, 10 U do Porto, Porto, Portugal, 11 U<br />

Eastern Piedmont, Novara, Italy, 12 U <strong>of</strong> Szeged, Hungary.<br />

2010 Program Book<br />

1579. A High-Density Genome-Wide Association Study by the<br />

Sjögren’s Genetics Network (SGENE) Identifies Both Novel<br />

Susceptibility Loci for Primary Sjögren’s Syndrome and<br />

Overlapping Effects with Other Autoimmune Disorders.<br />

Christopher J. Lessard 3 , Indra Adrianto 1 , Kenneth Kaufman 1 ,<br />

Roland Jonsson 14 , Gabor Illei 10 , Maureen Rischmueller 12 , Gunnel<br />

Nordmark 16 , Xavier Mariette 13 , Corrine Miceli-Richard 13 , Marie<br />

Wahren-Herlenius 9 , Torsten Witte 6 , Michael Brennan 4 , Roald<br />

Omdal 14 , Fai Ng 11 , Nelson Rhodus 15 , Barbara Segal 7 , R. Hal<br />

Sc<strong>of</strong>ield 2 , Ben Rybicki for ACCESS 8 , Courtney G. Montgomery 1 ,<br />

Juan-Manuel Anaya 5 , John B. Harley 17 and Kathy L. Moser 2 ,<br />

1<br />

Arthritis and Immunology Research Program, Oklahoma<br />

Medical Research Foundation, 2 Arthritis and Immunology<br />

Research Program, Oklahoma Medical Research Foundation<br />

and Department <strong>of</strong> Pathology, University <strong>of</strong> Oklahoma Health<br />

Sciences Center, 3 Arthritis and Immunology Research Program,<br />

Oklahoma Medical Research Foundation and Department <strong>of</strong><br />

Pathology, University <strong>of</strong> Oklahoma Health Sciences Center,<br />

Oklahoma City, OK, 4 Carolinas Medical Center, 5 Center for<br />

Autoimmune Diseases Research (CREA), Universidad del<br />

Rosario, Bogota, Columbia, 6 Hannover Medical School,<br />

Germany, 7 Hennepin County Medical Center, Minneapolis,<br />

8<br />

Henry Ford Health System, 9 Karolinska Institute, Sweden,<br />

10<br />

National Institute <strong>of</strong> Dental and Crani<strong>of</strong>acial Research, NIH,<br />

11<br />

Newcastle University, England, 12 The Queen Elizabeth Hospital<br />

and Health Service, Australia, 13 Universite Paris-Sud, 14 University<br />

<strong>of</strong> Bergen, Norway, 15 University <strong>of</strong> Minnesota, 16 Uppsala<br />

University Hospital, Sweden, 17 US Department <strong>of</strong> Veterans<br />

Affairs Medical Center, Department <strong>of</strong> Medicine, University <strong>of</strong><br />

Oklahoma Health Sciences Center, and Cincinnati Children’s<br />

Hospital Medical Center.<br />

1580. An Immune Signature Based on Ex Vivo Responsiveness <strong>of</strong><br />

Peripheral Blood Cells Is Associated with Radiographic Joint<br />

Damage in Rheumatoid Arthritis. John M. Davis III, Keith L.<br />

Knutson, Michael A. Strausbauch, Cynthia S. Crowson, Terry M.<br />

Therneau, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic,<br />

Rochester, MN.<br />

1581. An Immune Signature Based on the Ex Vivo Responsiveness<br />

<strong>of</strong> Peripheral Blood Cells for Monitoring Disease Activity<br />

in Rheumatoid Arthritis. John M. Davis III, Keith L. Knutson,<br />

Michael A. Strausbauch, Cynthia S. Crowson, Terry M. Therneau,<br />

Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester,<br />

MN.<br />

1582. Analysis <strong>of</strong> the Association <strong>of</strong> CDA (Cytidin Deaminase)<br />

(K27Q), TNF-α (-308G>A) and PTPN22 R620W Genetic<br />

Polymorphisms with Auto-Antibody Seropositive RA and the<br />

Response to B Cell Depletion. Barbara Tolusso 3 , Fabio Di Pietro 7 ,<br />

Francesca Bobbio Pallavicini 4 , Viviana Ravagnani 1 , Maurizio<br />

Benucci 5 , Edoardo Podesta’ 2 , Fabiola Atzeni 6 , Valerio Napolioni 7 ,<br />

F. Carpi 7 , Giusy Peluso 3 , Francesca Faustini 3 , Elisa Gremese 3 ,<br />

G. Biasi 1 , Mariangela Manfredi 5 , Pier Carlo Sarzi Puttini 6 ,<br />

Bruno Lagana’ 2 , Carlomaurizio Montecucco 4 and Gianfranco<br />

Ferraccioli 3 , 1 Department <strong>of</strong> Clinical and Experimental Medicine,<br />

Section <strong>of</strong> <strong>Rheumatology</strong> & Internal Medicine, University <strong>of</strong><br />

Verona, Verona, Italy, 2 Division <strong>of</strong> Clinical Immunology and<br />

<strong>Rheumatology</strong>, S. Andrea University Hospital, “Sapienza”<br />

University <strong>of</strong> Rome, II School <strong>of</strong> Medicine, Rome, Italy, 3 Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Catholic University <strong>of</strong> the Sacred Heart,<br />

Rome, Italy, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Pavia,<br />

IRCCS S. Matteo Foundation, Pavia, Italy, 5 <strong>Rheumatology</strong> Unit,<br />

Department <strong>of</strong> Internal Medicine, Ospedale di S. Giovanni di<br />

Dio, Florence, Italy, 6 <strong>Rheumatology</strong> Unit, University Hospital L.<br />

Sacco, Milan, Italy, 7 School <strong>of</strong> Biosciences and Biotechnology,<br />

University <strong>of</strong> Camerino, Camerino (MC), Italy.


ACR/ARHP Poster Session C<br />

1583. Association <strong>of</strong> PPP2CA Polymorphisms with SLE Susceptibility<br />

in Multiple Ethnic Groups. Wenfeng Tan 15 , Jian Zhao 15 , Yun<br />

Deng 15 , Kenneth M. Kaufman 2 , Jennifer A. Kelly 1 , Sang-Cheol<br />

Bae 5 , Deh-Ming Chang 9 , Yeong Wook Song 13 , Chack-Yung<br />

Yu 14 , Robert P. Kimberly 11 , Marta E. Alarcón-Riquelme 12 ,<br />

John B. Harley 4 , Chaim O. Jacob 17 , Timothy J. Vyse 6 , Timothy<br />

B. Niewold 16 , Patrick M. Gaffney 10 , Kathy L. Moser 10 , Judith<br />

A. James 10 , Gary S. Gilkeson 7 , Diane L. Kamen 8 , Jennifer M.<br />

Grossman 15 , Bevra H. Hahn 15 , George C. Tsokos 3 and Betty P.<br />

Tsao 15 , 1 Arthritis and Immunology Program, Oklahoma Medical<br />

Research Foundation, 2 Arthritis and Immunology Program,<br />

Oklahoma Medical Research Foundation and US Department <strong>of</strong><br />

Veterans Affairs Medical Center, 3 Beth Israel Deaconess Medical<br />

Center, Harvard Medical School, 4 Cincinnati Children’s Hospital<br />

Medical Center and US Department <strong>of</strong> Veterans Affairs Medical<br />

Center, 5 Hanyang University, Korean, 6 Imperial <strong>College</strong> London,<br />

Hammersmith Hospital, London, UK, 7 Medical University <strong>of</strong><br />

South Carolina, 8 Medical University <strong>of</strong> South Carolina,, 9 National<br />

Defense Medical Center, Taipei, Taiwan, 10 Oklahoma Medical<br />

Research Foundation, 11 On Behalf <strong>of</strong> PROFILE Investigators,<br />

University <strong>of</strong> Alabama, 12 On Behalf <strong>of</strong> the BIOLUPUS and GENLES<br />

Networks, Uppsala University, Sweden, Center for Genomics<br />

and Oncological Research, Granada, Spain, Oklahoma Medical<br />

Research Foundation, 13 Seoul National University, Seoul, Korea,<br />

14<br />

The Ohio State University, 15 University <strong>of</strong> California, Los<br />

Angeles, CA, 16 University <strong>of</strong> Chicago, 17 University <strong>of</strong> Southern<br />

California.<br />

1584. Association <strong>of</strong> Variants in the TLR7-TLR8 Region with Systemic<br />

Lupus Erythematosus in Non-Asian Populations. Yun Deng 8 ,<br />

Jian Zhao 8 , Wenfeng Tan 8 , Kenneth M. Kaufman 2 , Elizabeth E.<br />

Brown 7 , Jeffrey C. Edberg 7 , Diane L. Kamen 6 , Gary S. Gilkeson 10 ,<br />

Chaim O. Jacob 10 , Robert H. Sc<strong>of</strong>ield 2 , Robert P. Kimberly on<br />

behalf <strong>of</strong> PROFILE Investigators 7 , Carl D. Langefeld 12 , Jennifer A.<br />

Kelly 1 , Marta E. Alarcón-Riquelme on Behalf <strong>of</strong> the BIOLUPUS<br />

and GENLES Networks 3 , John B. Harley 4 , Timothy J. Vyse 5 , Barry<br />

I. Freedman 11 , Patrick M. Gaffney 2 , Kathy L. Moser 2 , Judith<br />

A. James 2 , Timothy B. Niewold 9 , Jennifer M. Grossman 8 , Rita<br />

M. Cantor 8 , Bevra H. Hahn 8 and Betty P. Tsao 8 , 1 Arthritis and<br />

Immunology Program, Oklahoma Medical Research Foundation,<br />

Oklahoma City, OK, 2 Arthritis and Immunology Program,<br />

Oklahoma Medical Research Foundation, Oklahoma City, OK;<br />

University <strong>of</strong> Oklahoma Health Sciences Center, Oklahoma<br />

City, OK; US Department <strong>of</strong> Veterans Affairs Medical Center,<br />

Oklahoma City, OK, 3 Center for Genomics and Oncological<br />

Research, Granada, Spain, 4 Cincinnati Children’s Hospital<br />

Medical Center and US Department <strong>of</strong> Veterans Affairs Medical<br />

Center, Cincinnati, OH, 5 Imperial <strong>College</strong> London, Hammersmith<br />

Hospital, London, United Kingdom, 6 Medical University <strong>of</strong> South<br />

Carolina, Charleston, SC, 7 University <strong>of</strong> Alabama, Birmingham,<br />

AL, 8 University <strong>of</strong> California, Los Angeles, CA, 9 University <strong>of</strong><br />

Chicago, Chicago, IL, 10 University <strong>of</strong> Southern California, Los<br />

Angeles, CA, 11 Wake Forest University Baptist Medical Center,<br />

NC, 12 Wake Forest University Health Sciences, NC.<br />

1585. Association <strong>of</strong> Variants in the TNFAIP3 Region with Systemic<br />

Lupus Erythematosus in a Multi-Ethnic Study. Indra Adrianto 5 ,<br />

Christopher J. Lessard 8 , Kenneth M. Kaufman 9 , Juan-Manuel<br />

Anaya 12 , Marta E. Alarcón-Riquelme on Behalf <strong>of</strong> the BIOLUPUS<br />

and GENLES Networks 6 , Sang-Cheol Bae 1 , Elizabeth E. Brown<br />

for PROFILE 13 , Barry I. Freedman 18 , Gary S. Gilkeson 4 , Chaim<br />

O. Jacob 16 , Judith A. James 8 , Robert P. Kimberly 13 , Javier<br />

Martin 3 , Joan T. Merrill 8 , Timothy B. Niewold 15 , So-Yeon Park 1 ,<br />

Bernardo A. Pons-Estel 10 , Betty P. Tsao 14 , Timothy J. Vyse 2 , Carl<br />

D. Langefeld 19 , Mary B. Humphrey 11 , John B. Harley 17 , Kathy L.<br />

Moser 8 , Courtney G. Montgomery 7 and Patrick M. Gaffney 7 ,<br />

1<br />

Hanyang University, Seoul, Republic <strong>of</strong> Korea, 2 Imperial <strong>College</strong><br />

London, 3 Instituto de Parasitologia y Biomedicina López-<br />

Neyra, CSIC, Granada, Spain, 4 Medical University <strong>of</strong> South<br />

Carolina, 5 Oklahoma Medical Research Foundation, Oklahoma<br />

City, OK, 6 Oklahoma Medical Research Foundation; Center<br />

<strong>of</strong> Genomics and Oncological Research (GENyO), Granada,<br />

Spain, 7 Oklahoma Medical Research Foundation; Co-Senior<br />

Authors, 8 Oklahoma Medical Research Foundation; The<br />

University <strong>of</strong> Oklahoma Health Sciences Center, 9 Oklahoma<br />

Medical Research Foundation; The University <strong>of</strong> Oklahoma<br />

Health Sciences Center; Oklahoma City VA Medical Center,<br />

10<br />

Sanatorio Parque, Rosario, Argentina, 11 The University <strong>of</strong><br />

Oklahoma Health Sciences Center, 12 Universidad del Rosario,<br />

Colombia, 13 University <strong>of</strong> Alabama at Birmingham, 14 University<br />

<strong>of</strong> California, Los Angeles, 15 University <strong>of</strong> Chicago, 16 University <strong>of</strong><br />

Southern California Keck School <strong>of</strong> Medicine, 17 US Department<br />

<strong>of</strong> Veterans Affairs Medical Center; Cincinnati Children’s Hospital<br />

Medical Center, 18 Wake Forest University Baptist Medical Center,<br />

19<br />

Wake Forest University Health Sciences.<br />

1586. Association <strong>of</strong> Variants in the NF-kB Regulatory Pathway Loci<br />

with Systemic Lupus Erythematosus in Multiple Populations.<br />

Graham Wiley 6 , Indra Adrianto 8 , Jennifer A. Kelly 5 , Kenneth M.<br />

Kaufman 11 , Juan-Manuel Anaya 13 , Marta E. Alarcón-Riquelme<br />

on Behalf <strong>of</strong> the BIOLUPUS and GENLES Networks 7 , Sang-Cheol<br />

Bae 1 , So-Young Bang 1 , Elizabeth E. Brown for PROFILE 14 , Barry<br />

I. Freedman 19 , Gary S. Gilkeson 4 , Chaim O. Jacob 17 , Judith A.<br />

James 10 , Robert P. Kimberly 14 , Javier Martin 3 , Joan T. Merrill 10 ,<br />

Timothy B. Niewold 16 , Bernardo A. Pons-Estel 12 , Betty P. Tsao 15 ,<br />

Timothy J. Vyse 2 , Carl D. Langefeld 20 , John B. Harley 18 , Kathy L.<br />

Moser 10 , Courtney G. Montgomery 9 and Patrick M. Gaffney 9 ,<br />

1<br />

Hanyang University, Seoul, Republic <strong>of</strong> Korea, 2 Imperial <strong>College</strong><br />

London, 3 Instituto de Parasitologia y Biomedicina López-Neyra,<br />

CSIC, Granada, Spain, 4 Medical University <strong>of</strong> South Carolina,<br />

5<br />

Oklahoma Medical Research Foundation, 6 Oklahoma Medical<br />

Research Foundation, Oklahoma City, OK, 7 Oklahoma Medical<br />

Research Foundation; Center <strong>of</strong> Genomics and Oncological<br />

Research (GENyO), Granada, Spain, 8 Oklahoma Medical<br />

Research Foundation; Co-First Authors, 9 Oklahoma Medical<br />

Research Foundation; Co-Senior Authors, 10 Oklahoma Medical<br />

Research Foundation; The University <strong>of</strong> Oklahoma Health<br />

Sciences Center, 11 Oklahoma Medical Research Foundation;<br />

The University <strong>of</strong> Oklahoma Health Sciences Center; Oklahoma<br />

City VA Medical Center, 12 Sanatorio Parque, Rosario, Argentina,<br />

13<br />

Universidad del Rosario, Colombia, 14 University <strong>of</strong> Alabama at<br />

Birmingham, 15 University <strong>of</strong> California, Los Angeles, 16 University<br />

<strong>of</strong> Chicago, 17 University <strong>of</strong> Southern California Keck School <strong>of</strong><br />

Medicine, 18 US Department <strong>of</strong> Veterans Affairs Medical Center;<br />

Cincinnati Children’s Hospital Medical Center, 19 Wake Forest<br />

University Baptist Medical Center, 20 Wake Forest University<br />

Health Sciences.<br />

1587. Association Study <strong>of</strong> the ILAK1 Gene with Susceptibility to<br />

Systemic Lupus Erythematosus and Systemic Sclerosis. Yuko<br />

Ota 3 , Yasushi Kawaguchi 1 , Manabu Kawamoto 2 , Kae Takagi 2 ,<br />

Akiko Tochimoto 2 , Yasuhiro Katsumata 2 , Takahisa Gono 2 ,<br />

Sayumi Baba 2 , Yuko Okamoto 2 and Hisashi Yamanaka 4 , 1 Tokyo<br />

Women’s Medical Univ, Tokyo, Japan, 2 Tokyo Women’s Medical<br />

Univ, 3 Tokyo Women’s Medical University, Tokyo, Japan, 4 Tokyo<br />

Womens Med Univ, Shinjuku-ku, Tokyo, Japan.<br />

1588. Combining Genetic and Environmental Risk Factors To Model<br />

RA Susceptibility. Lori B. Chibnik 3 , Bo Ding 7 , Brendan T. Keenan 4 ,<br />

Katherine P. Liao 2 , Karen H. Costenbader 1 , Lars Klareskog 6 , Lars<br />

Alfredsson 7 and Elizabeth W. Karlson 5 , 1 Brigham & Women,<br />

Boston, MA, 2 Brigham & Women’s Hosp, Boston, MA, 3 Brigham<br />

and Women’s Hospital, Boston, MA, 4 Brigham and Women’s<br />

Hospital, 5 Brigham and Womens Hosp, Boston, MA, 6 Karolinska<br />

University Hospital, Stockholm, Sweden, 7 Karolinska University<br />

Hospital.<br />

2010 Program Book 241


ACR/ARHP Poster Session C<br />

1589. Contribution <strong>of</strong> VpreB1 Gene Copy Number Variation to the<br />

Risk <strong>of</strong> Rheumatoid Arthritis. Seung-Cheol Shim 2 , Mi-Kyoung<br />

Lim 2 , Dong-Hyuk Sheen 2 and Yeun-Jun Chung 1 , 1 Catholic<br />

University, Seoul, Korea, Republic <strong>of</strong>, 2 Eulji University, Daejeon,<br />

Korea, Republic <strong>of</strong>.<br />

1590. Early Disease Onset Is Predicted by a Higher Genetic Risk<br />

for Lupus and Is Associated with a More Severe Phenotype<br />

in Lupus Patients. Ryan Webb 3 , Jennifer A. Kelly 3 , Emily C.<br />

Somers 7 , Travis Hughes 3 , Kenneth M. Kaufman 4 , Elena Sanchez 3 ,<br />

Swapan K. Nath 3 , Gail Bruner 3 , Marta E. Alarcon-Riquelme 5 ,<br />

Gary S. Gilkeson 2 , Diane L. Kamen 2 , Bruce C. Richardson 6 ,<br />

John B. Harley 1 and Amr H. Sawalha 8 , 1 Cincinnati Children’s<br />

Hospital Medical Center, VAMC, Oklahoma City, OK, 2 Med<br />

Univ <strong>of</strong> South Carolina, Charleston, SC, 3 Oklahoma Medical<br />

Research Foundation, 4 Oklahoma Medical Research Foundation,<br />

University <strong>of</strong> Oklahoma, US Department <strong>of</strong> Veterans Affairs<br />

Medical Center, 5 Oklahoma Medical Research Foundation,<br />

Uppsala University, Uppsala, Sweden, 6 University <strong>of</strong> Michigan,<br />

Ann Arbor, MI, 7 University <strong>of</strong> Michigan, 8 University <strong>of</strong> Oklahoma,<br />

US Department <strong>of</strong> Veterans Affairs Medical Center, Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK.<br />

1591. Ethnic Specific Genetic Associations within the FCRL Gene<br />

Cluster in SLE. Nickolas M. Pajewski 15 , Carl D. Langefeld 23 ,<br />

Kenneth M. Kaufman 11 , Adrienne Williams 23 , Mary Comeau 23 ,<br />

Graciela S. Alarcon 2 , Michelle A. Petri 1 , Rosalind Ramsey-<br />

Goldman 7 , John D. Reveille 18 , Luis M. Vila 17 , Marta E. Alarcon-<br />

Riquelme on Behalf <strong>of</strong> the BIOLUPUS and GENLES Networks 10 ,<br />

Juan-Manuel Anaya 19 , Sang-Cheol Bae 3 , Susan A. Boackle 21 ,<br />

Lindsey A. Criswell 14 , Barry I. Freedman 23 , Patrick M. Gaffney 9 ,<br />

Gary S. Gilkeson 5 , Peter K. Gregersen 6 , John B. Harley 16 , Chaim<br />

O. Jacob 22 , Judith A. James 9 , Joan T. Merrill 9 , Kathy L. Moser 9 ,<br />

Timothy B. Niewold 20 , Robert Hal Sc<strong>of</strong>ield 8 , Anne M. Stevens 12 ,<br />

Betty P. Tsao 13 , Timothy J. Vyse 4 , Elizabeth E. Brown 15 , Robert P.<br />

Kimberly 15 and Jeffrey C. Edberg 15 , 1 Timonium, MD, 2 Oakland,<br />

CA, 3 Hanyang Univ Medical Center, Seoul, Korea, Republic<br />

<strong>of</strong>, 4 Imperial <strong>College</strong> London, 5 Med Univ <strong>of</strong> South Carolina,<br />

Charleston, SC, 6 N Shore Univ Hosp Rsch Ctr, Manhasset, NY,<br />

7<br />

Northwestern University, Chicago, IL, 8 Oklahoma Med Res<br />

Foundation, Oklahoma City, OK, 9 Oklahoma Med Research<br />

Foundation, Oklahoma City, OK, 10 Oklahoma Medical Research<br />

Foundation, Uppsala, Sweden, 11 Oklahoma Medical Research<br />

Foundation; The University <strong>of</strong> Oklahoma Health Sciences<br />

Center; Oklahoma City VA Medical Center, 12 Pediatrics, U.<br />

<strong>of</strong> Washington, Seattle, WA, 13 UCLA School <strong>of</strong> Medicine,<br />

Los Angeles, CA, 14 UCSF-Box 0500, San Francisco, CA, 15 Univ<br />

Alabama Birmingham, 16 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma<br />

City, OK, 17 Univ <strong>of</strong> PuertoRico Schl <strong>of</strong> Med, San Juan, PR, 18 Univ<br />

Texas Health Sci Ctr, Houston, TX, 19 Universidad del Rosario,<br />

Colombia, 20 University <strong>of</strong> Chicago, Chicago, IL, 21 University <strong>of</strong><br />

Colorado-Denver SOM, Aurora, CO, 22 USC School <strong>of</strong> Medicine,<br />

Los Angeles, CA, 23 Wake Forest University Health Sciences.<br />

1592. European Genetic Ancestry Protects Against the Development<br />

<strong>of</strong> Renal Disease in Systemic Lupus Erythematosus. Ilana B.<br />

Richman 7 , Kimberly E. Taylor 7 , Sharon A. Chung 6 , Laura Trupin 7 ,<br />

Michelle A. Petri 4 , Edward H. Yelin 6 , Robert R. Graham 3 , Annette<br />

T. Lee 1 , Timothy W. Behrens 2 , Peter K. Gregersen 5 , Michael<br />

F. Seldin 9 and Lindsey A. Criswell 8 , 1 Feinstein Insititute Med<br />

Rsch, Manhasset, NY, 2 Genentech Inc, South San Francisco,<br />

CA, 3 Immunology Biomarkers Group, Genentech, South San<br />

Francisco, 4 Johns Hopkins University School <strong>of</strong> Medicine,<br />

Timonium, MD, 5 N Shore Univ Hosp Rsch Ctr, Manhasset, NY,<br />

6<br />

Rosalind Russell Medical Research Center for Arthritis, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> California, San Francisco, San<br />

Francisco, CA, 7 Rosalind Russell Medical Research Center for<br />

Arthritis, Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> California, San<br />

Francisco, 8 UCSF-Box 0500, San Francisco, CA, 9 University <strong>of</strong><br />

California, Davis.<br />

1593. Fine Mapping and Expression Studies Point to KIF5A as the<br />

Gene Responsible for Association <strong>of</strong> the 12q13 Locus with<br />

Rheumatoid Arthritis. Annie McClure, Steve Eyre, Wendy<br />

Thomson, Jane Worthington and Anne Barton, The University <strong>of</strong><br />

Manchester, Manchester, United Kingdom.<br />

1594. Fine Mapping and Trans-Ethnicity Genotyping in IL2/IL21<br />

Establish the Genetic Association between IL21 and Systemic<br />

Lupus Erythematosus. Travis Hughes 7 , Xana Kim 7 , Jennifer<br />

A. Kelley 7 , Kenneth M. Kaufman 9 , Carl D. Langefeld 17 , Julie<br />

Ziegler 17 , Robert P. Kimberly 10 , Jeffrey C. Edberg 15 , Rosalind<br />

Ramsey-Goldman 5 , Michelle A. Petri 1 , John D. Reveille 14 , Javier<br />

Martin 3 , Elizabeth E. Brown 11 , Luis M. Vila 13 , Judith A. James 6 ,<br />

Gary S. Gilkeson 4 , Kathy L. Moser 6 , Patrick M. Gaffney 6 , Joan T.<br />

Merrill 6 , Timothy J. Vyse 2 , Marta E. Alarcon-Riquelme 8 , Swapan<br />

K. Nath 7 , John B. Harley 12 and Amr H. Sawalha 16 , 1 Timonium,<br />

MD, 2 Imperial <strong>College</strong>, <strong>Rheumatology</strong> Section, Hammersmith<br />

Hospital, 3 Instituto de Parasitología y Biomedicina López-<br />

Neyra, Consejo Superior de Investigaciones Científicas,<br />

4<br />

Med Univ <strong>of</strong> South Carolina, Charleston, SC, 5 Northwestern<br />

University, Chicago, IL, 6 Oklahoma Med Research Foundation,<br />

Oklahoma City, OK, 7 OMRF, 8 OMRF, Center for Genomics and<br />

Oncological Research Pfizer, University <strong>of</strong> Granada, Junta de<br />

Andalucia, Uppsala, Sweden, 9 OMRF, OUHSC, VAMC, 10 Univ<br />

Alabama at Birmingham, Birmingham, AL, 11 Univ Alabama at<br />

Birmingham, 12 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma City, OK, 13 Univ<br />

<strong>of</strong> PuertoRico Schl <strong>of</strong> Med, San Juan, PR, 14 Univ Texas Health<br />

Sci Ctr, Houston, TX, 15 University <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL, 16 University <strong>of</strong> Oklahoma Health Sciences<br />

Center, OMRF, VAMC, Oklahoma City, OK, 17 Wake Forest<br />

University Health Sciences.<br />

1595. Fine Mapping <strong>of</strong> NMNAT2 for Association with SLE<br />

Susceptibility: A Multiethnic Case-Control Study. Jian Zhao 13 ,<br />

Carl D. Langefeld 16 , Kenneth M. Kaufman 2 , Jennifer A. Kelly 1 ,<br />

Patrick M. Gaffney 1 , Kathy L. Moser 1 , Marta E. Alarcón-Riquelme<br />

on Behalf <strong>of</strong> the BIOLUPUS and GENLES Networks 3 , Timothy J.<br />

Vyse 5 , Chaim O. Jacob 14 , Robert P. Kimberly 15 , Jeffrey C. Edberg 15 ,<br />

Elizabeth E. Brown on Behalf <strong>of</strong> PROFILE investigators 11 ,<br />

Lindsey A. Criswell 7 , John B. Harley 4 , Deh-Ming Chang 6 , Yeong<br />

Wook Song 9 , Chack-Yung Yu 10 , Bernardo Pons-Estel 8 , Jennifer<br />

M. Grossman 12 , Rita M. Cantor 12 , Bevra H. Hahn 12 and Betty<br />

P. Tsao 12 , 1 Arthritis and Immunology Program, Oklahoma<br />

Medical Research Foundation, Oklahoma City, OK, 2 Arthritis<br />

and Immunology Program, Oklahoma Medical Research<br />

Foundation, Oklahoma City, OK; US Department <strong>of</strong> Veterans<br />

Affairs Medical Center, Oklahoma City, OK, 3 Center for Genomics<br />

and Oncological Research, Granada, Spain, 4 Cincinnati Children’s<br />

Hospital Medical Center and US Department <strong>of</strong> Veterans Affairs<br />

Medical Center, Cincinnati, OH, 5 Imperial <strong>College</strong> London,<br />

Hammersmith Hospital, London, United Kingdom, 6 National<br />

Defense Medical Center, Taipei, Taiwan, 7 Rosalind Russell<br />

Medical Research Center for Arthritis, University <strong>of</strong> California,<br />

San Francisco, CA, 8 Sanatorio Parque, Rosario, Argentina, 9 Seoul<br />

National University, Seoul, Korea, 10 The Ohio State University,<br />

Columbus, OH, 11 University <strong>of</strong> Alabama, Birmingham, AL,<br />

12<br />

University <strong>of</strong> California, 13 University <strong>of</strong> California, Los Angeles,<br />

CA, 14 University <strong>of</strong> Southern California, Los Angeles, CA, 15 US<br />

Department <strong>of</strong> Veterans Affairs Medical Center, Oklahoma City,<br />

OK, 16 Wake Forest University Health Sciences, NC.<br />

242<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1596. Gene-Interactions Influence Methotrexate Efficacy in<br />

Rheumatoid Arthritis: Analysis <strong>of</strong> 62 SNPs Panel in a<br />

Monocentric Cohort <strong>of</strong> Rheumatoid Arthritis Affected Patients.<br />

Thomas Barnetche 1 , Caroline Rooryck-Thambo 4 , Christophe<br />

Hubert 3 , Christophe Richez 2 , Benoit Arveiler 4 and Thierry<br />

Schaeverbeke 2 , 1 Bordeaux University Hospital, <strong>Rheumatology</strong><br />

Department, Bordeaux, France, 2 Bordeaux University Hospital,<br />

<strong>Rheumatology</strong> Department, 3 Genomics-Transcriptomics Facility,<br />

Bordeaux, 4 Human Genetics Laboratory EA4137, University<br />

Victor Segalen Bordeaux 2 .<br />

1597. Genome-Wide Association Study for Rheumatoid Arthritis in<br />

the Korean Population Points to Population-Specific Candidate<br />

Loci as Well as Overlap with European Susceptibility Loci.<br />

Jan Freudenberg 2 , Hye-Soon Lee 4 , H. D. Shin 7 , B. D. Han 5 , Y. M.<br />

Kang 6 , S. C. Shim 1 , Y. K. Sung 4 , CB Choi 4 , Annette Lee 3 , Peter K.<br />

Gregersen 2 and S. C. Bae 4 , 1 Eulji University Hospital, 2 Feinstein<br />

Institute for Medical Research, Manhasset, NY, 3 Feinstein<br />

Institute for Medical Research, 4 Hanyang University Hospital<br />

for Rheumatic Diseases, 5 Korea National Institute <strong>of</strong> Health,<br />

6<br />

Kyungpook National University School <strong>of</strong> Medicine, 7 Sogang<br />

University.<br />

1598. Genome-Wide Copy-Number-Variation Study in Chinese Han<br />

Population Identifies Deletion <strong>of</strong> LCE3C_LCE3B as Susceptibility<br />

Factor for Rheumatoid Arthritis. Xiaolan Lu 2 , Jianping Guo 3 ,<br />

Ru Li 3 , Xia Liu 3 , Zuowei Wu 4 , Jinxia Shi 3 , Xinyu Wu 3 , Yingni<br />

Li 3 , Yi Zhao 3 , Chun Li 3 , Sisi Pan 3 , Lei Zhu 3 , Jing He 3 , Xu Liu 3 ,<br />

Wenjun Chen 1 , Baoli Zhu 4 and Zhanguo Li 3 , 1 Beijing Institute<br />

<strong>of</strong> Genomics, Chinese Academy <strong>of</strong> Sciences, 2 Department <strong>of</strong><br />

<strong>Rheumatology</strong> and Immunology, People’s Hospital Peking<br />

University, Beijing, China, 3 Department <strong>of</strong> <strong>Rheumatology</strong> and<br />

Immunology, People’s Hospital Peking University, 4 Institute <strong>of</strong><br />

Microbiology, Chinese Academy <strong>of</strong> Sciences.<br />

1599. Genome-Wide Pathway Analysis Identifies Oxidative Stress<br />

Related Gene MSRA as Rheumatoid Arthritis Susceptibility<br />

Locus. Jose Ezequiel Martin 5 , Behrooz Z. Alizadeh 10 , Miguel<br />

A. Gonzalez-Gay 4 , Alejandro Balsa 2 , Dora Pascual-Salcedo 2 ,<br />

Benjamín Fernández-Gutiérrez 1 , Enrique Raya 3 , Lude Franke 9 ,<br />

Ruben Van’t Slot 11 , Marieke J. H. Coenen 7 , Piet van Riel 8 , T. R.<br />

D. J. Radstake 8 , B. P. C. Koeleman 11 and Javier Martin 6 , 1 Hospital<br />

Clinico San Carlos, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Spain, 2 Hospital<br />

La Paz, Madrid, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Spain, 3 Hospital<br />

Universitario Clinico San Cecilio, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Spain,<br />

4<br />

Hospital Xeral-Calde, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Lugo, Spain,<br />

Spain, 5 Instituto de Parasitologia y Biomedicina Lopez-Neyra,<br />

CSIC, Armilla, Granada, Spain, 6 Instituto de Parasitologia y<br />

Biomedicina Lopez-Neyra, CSIC, Spain, 7 Radboud University<br />

Nijmegen Medical Center, Department <strong>of</strong> Human Genetics,<br />

The Netherlands, 8 Radboud University Nijmegen Medical<br />

Center, Department <strong>of</strong> <strong>Rheumatology</strong>, The Netherlands,<br />

9<br />

University Medical Center Groningen, Dept. Human Genetic,<br />

The Netherlands, 10 University Medical Centre Groningen, Dept.<br />

<strong>of</strong> Epidemiology, 11 University Medical Centre Utrecht, Dept.<br />

Medical Genetics, The Netherlands.<br />

1600. Identification <strong>of</strong> Genetic Markers <strong>of</strong> Rheumatoid Arthritis<br />

Severity by Genome-Wide Association Studies. Sebastien<br />

Viatte 1 , Darren Plant 2 , John Bowes 2 , Deborah Symmons 2 ,<br />

Jane Worthington 2 and Anne Barton 1 , 1 Arthritis Research UK<br />

Epidemiology Unit, The University <strong>of</strong> Manchester, Manchester,<br />

United Kingdom, 2 Arthritis Research UK Epidemiology Unit, The<br />

University <strong>of</strong> Manchester.<br />

1601. Identification <strong>of</strong> KIAA Proteins in Immune Complex Proteome<br />

from Juvenile Idiopathic Arthritis and Systemic Lupus<br />

Erythematosus. Anil Chauhan 2 , Brooke Gilliam 2 , Catherine P.<br />

Riley 1 , Jiri Adamec 1 and Terry L. Moore 3 , 1 Purdue University,<br />

2<br />

Saint Louis University, 3 St Louis University, St Louis, MO.<br />

1602. Major Histocompatibility Complex Associations with<br />

Thrombosis and Antiphospholipid Antibody Production<br />

in Systemic Lupus Erythematosus. Rachel Kaiser 4 , Sharon<br />

A. Chung 4 , Kimberly E. Taylor 5 , Suzanne L. May 2 , Patricia P.<br />

Ramsay 2 , Hong L. Quach 2 , Diana L. Quach 2 , Julie A. Lane 1 , Janelle<br />

A. Noble 1 , Michael F. Seldin 3 , Lisa Barcellos 2 and Lindsey A.<br />

Criswell 6 , 1 Children’s Hospital Oakland Research Institute, 2 UC<br />

Berkeley, 3 UC Davis, 4 UCSF, San Francisco, CA, 5 UCSF, 6 UCSF-Box<br />

0500, San Francisco, CA.<br />

1603. MMEL1 and CDK6 Are Associated with ACPA Positive and RF<br />

Positive Rheumatoid Arthritis. Marthe Thoresen Mæhlen 1 ,<br />

Tore K. Kvien 3 , Till Uhlig 2 and Benedicte A. Lie 4 , 11 .Dept.<br />

<strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital, 2 . Institute <strong>of</strong><br />

Immunology, Oslo University Hospital, Oslo, Oslo, Norway,<br />

2<br />

Dept. <strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo,<br />

Norway, 3 Diakonhjemmet Hospital, Oslo, Norway, 4 Institute <strong>of</strong><br />

Immunology, Oslo University Hospital, Oslo, Norway.<br />

1604. Multiple Expanded B-Cell Clones Are Already Present in Early<br />

Rheumatoid Arthritis: Results <strong>of</strong> a Comparison between<br />

Early and Longstanding Disease Using High Throughput<br />

Sequencing Technology. Marieke E. Doorenspleet 2 , Stefano<br />

Alivernini 2 , Marjolein J. de Hair 2 , Paul L. Klarenbeek 2 , Marieke<br />

M. Herenius 2 , Marleen G. van de Sande 2 , Barbera D. van<br />

Schaik 1 , Rebecca E. Esveldt 2 , Antoine H. van Kampen 1 , Danielle<br />

M. Gerlag 2 , Frank Baas 3 , Paul P. Tak 2 and Niek de Vries 2 , 1 Dept.<br />

<strong>of</strong> Clinical Epidemiology, Biostatistics and Bioinformatics<br />

Academic Medical Center-University <strong>of</strong> Amsterdam, 2 Div.<br />

Clinical Immunology and <strong>Rheumatology</strong> Academic Medical<br />

Center-University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

3<br />

Laboratory for Genome Analysis Academic Medical Center-<br />

University <strong>of</strong> Amsterdam.<br />

1605. New HLA-DRB1 Classifications in Association with Rheumatoid<br />

Arthritis for Global Application: Beyond the Conventional<br />

Shared Epitope Hypothesis. So-Young Bang 1 , Hye-Soon Lee 1 , Ji-<br />

Seon Lee 1 , Eun-Mi Kim 1 , Kyung Wha Lee 2 and Sang-Cheol Bae 1 ,<br />

1<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University Hospital<br />

for Rheumatic Disease, Korea, Republic <strong>of</strong>, 2 Hallym Institute for<br />

Genome Application, Hallym University Sacred Heart Hospital,<br />

Korea, Republic <strong>of</strong>.<br />

1606. Pre Analytical Effects <strong>of</strong> Serum Collection and Handling<br />

in Quantitative Immunoassays for Rheumatoid Arthritis.<br />

Ferhan Qureshi 3 , William Manning 3 , Scott Eastman 3 , Wayne<br />

Hu 3 , Michael Centola 6 , Mary Turner 7 , Craig W. Carson 5 , Ana A.<br />

Kumar 4 , Linda A. Zacharias 2 , Claire Alexander 3 , Doug Haney 3 ,<br />

Guy Cavet 3 and Lyndal K. Hesterberg 1 , 1 Crescendo Bioscience,<br />

Inc., South San Francisco, CA, 2 Crescendo Bioscience, Inc.,<br />

Edmond, OK, 3 Crescendo Bioscience, Inc., 4 OK Arthritis Center,<br />

Edmond, OK, 5 Oklahoma Arthritis Ctr, Edmond, OK, 6 Oklahoma<br />

Med Research Foundation, Oklahoma City, OK, 7 Oklahoma<br />

Medical Research Foundation.<br />

1607. Serum TNFα and IL-6 Concentrations in Systemic Lupus<br />

Erythematosus, Rheumatoid Arthritis and Controls Are<br />

Associated with Polymorphisms in PTPN2, IRF5, INFG, and<br />

NOD2. Joseph F. Solus 3 , Young Hee Rho 3 , Annette M. Oeser 4 ,<br />

Cecilia P. Chung 2 , Chun Li 3 , Jeffrey R. Smith 3 and C. Michael<br />

Stein 1 , 1 Vanderbilt University Medical Center, Nashville,<br />

TN, 2 Vanderbilt University Medical Center, Baltimore, MD,<br />

3<br />

Vanderbilt University Medical Center, 4 VUMC 23rd Ave South<br />

Pierce, Nashville, TN.<br />

2010 Program Book 243


ACR/ARHP Poster Session C<br />

244<br />

1608. SLE-Associated Genetic Variants Influence Gene Expression<br />

in Patients. Hatice Bilgic 4 , Thearith Koeuth 5 , Joseph C. Wilson 5 ,<br />

Ward Ortmann 1 , Michelle Petri 2 , Peter Gregersen 3 , Timothy<br />

Behrens 1 and Emily C. Baechler 5 , 1 Genentech, Inc., 2 Johns<br />

Hopkins School <strong>of</strong> Medicine, 3 The Feinstein Institute for<br />

Medical Research, 4 University <strong>of</strong> Minnesota, MN, 5 University <strong>of</strong><br />

Minnesota.<br />

1609. Stratification <strong>of</strong> Rheumatoid Arthritis Patients into Disease<br />

Subtypes with Clinical Implications. Glynn Dennis, Cecile<br />

Holweg, Jason Hackney, Houston Glibert, Wei Yu Lin, Lauri Diehl,<br />

Judith Endres, David Fox, Mike Townsend and Flavius Martin,<br />

Genentech.<br />

1610. The Associations between RA Genetic Risk Alleles and<br />

Seropositive but Non-Erosive Rheumatoid Arthritis. Katherine<br />

P. Liao, Jing Cui, Michael E. Weinblatt, Christine Iannaccone,<br />

Nancy Shadick, Robert M. Plenge, Daniel H. Solomon and<br />

Elizabeth W. Karlson, Brigham and Women’s Hospital, Boston,<br />

MA.<br />

1611. TNIP2 Is Associated with Joint Destruction in Patients with<br />

Rheumatoid Arthritis. Taku Suzuki 2 , Katsunori Ikari 2 , Koichiro<br />

Yano 2 , Yoshiaki Toyama 1 , Atsuo Taniguchi 2 , Hisashi Yamanaka 2<br />

and Shigeki Momohara 2 , 1 Department <strong>of</strong> Orthopaedic Surgery,<br />

Keio University, 2 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Woman’s<br />

Medical University, Japan.<br />

1612. Trait-Stratified Genome-Wide Association Study Identifies<br />

Novel and Diverse Genetic Associations with Serologic and<br />

Cytokine Phenotypes in Systemic Lupus Erythematosus.<br />

Silvia N. Kariuki 4 , Beverly S. Franek 4 , Akaash A. Kumar 4 ,<br />

Jasmine Arrington 4 , Racheal A. Mikolaitis 2 , Tammy O. Utset 4 ,<br />

Meenakshi Jolly 2 , Mary K. Crow 1 , Andrew D. Skol 3 and Timothy<br />

B. Niewold 4 , 1 Hospital for Special Surgery, Mary Kirkland Center<br />

for Lupus Research, New York, NY, 2 Rush University, Section<br />

<strong>of</strong> <strong>Rheumatology</strong>, Chicago, IL, 3 University <strong>of</strong> Chicago Pritzker<br />

School <strong>of</strong> Medicine, Section <strong>of</strong> Genetic Medicine, Chicago, IL,<br />

4<br />

University <strong>of</strong> Chicago Pritzker School <strong>of</strong> Medicine, Section<br />

<strong>of</strong> <strong>Rheumatology</strong> and Gwen Knapp Center for Lupus and<br />

Immunology Research, Chicago, IL.<br />

Imaging <strong>of</strong> Rheumatic Disease II: Ultrasound, PET, Capillary<br />

Microscopy and Molecular Imaging<br />

1613. 18FPEG-Folate: A New Potential Macrophage PET Tracer for<br />

Imaging <strong>of</strong> Arthritis. Conny J. van der Laken 3 , Inge de Greeuw 2 ,<br />

Yoony Y. J. Gent 4 , Karin Weijers 4 , Alexandre E. Voskuyl 4 , Gerrit<br />

Jansen 4 , Ben A. C. Dijkmans 4 , Adriaan A. Lammertsma 2 , Phil<br />

S. Low 1 , Sumith Kularatne 1 , Albert D. Windhorst 2 and Carla F.<br />

M. Molth<strong>of</strong>f 2 , 1 Dept. <strong>of</strong> Chemistry, Purdue University, 2 Dept.<br />

<strong>of</strong> Nuclear Medicine & PET Research, VU Medical Center,<br />

Amsterdam, 3 Dept. <strong>of</strong> <strong>Rheumatology</strong>, VU Medical Center,<br />

Amsterdam, The Netherlands, 4 Dept. <strong>of</strong> <strong>Rheumatology</strong>, VU<br />

Medical Center.<br />

1614. Asymptomatic Hyperuricemia: Ultrasonographic Findings.<br />

Carla Solano 3 , Pedro José Rodríguez-Henríquez 4 , Fritz H<strong>of</strong>mann 4 ,<br />

Araceli Bernal 4 , Norma Marín-Arriaga 4 , Alberto Gabriel<br />

López-Reyes 4 , Luis Guirado 1 , Angelica Vargas-Guerrero 1 , Luis<br />

Amezcua-Guerra 1 , Marwin Gutierréz 5 , Cristina Hernández-Díaz 4 ,<br />

Manuel Martínez-Lavín 1 and Carlos Pineda 2 , 1 Instituto Nacional<br />

de Cardiología, Mexico, 2 Instituto Nacional de Rehab, Mexico<br />

City, Mexico, 3 Instituto Nacional de Rehabilitación, El Salvador,<br />

4<br />

Instituto Nacional de Rehabilitación, Mexico, 5 Universitá<br />

Politecnicá delle Marche Ospedale “A Murri”, Italy.<br />

2010 Program Book<br />

1615. Capillary Microscopy – A Cross-Sectional Study in the<br />

Population. Oliver Sander 1 , Moritz Schroeder 3 , Benedikt<br />

Ostendorf 1 , Jutta Richter 1 , Matthias Reppel 3 , Hasan Acar 2 ,<br />

Martina Blumenroth 4 and Matthias K. Schneider 1 , 1 Dept.<br />

<strong>Rheumatology</strong>, Heinrich-Heine University, Duesseldorf,<br />

Germany, 2 Dept. <strong>Rheumatology</strong>, Heinrich-Heine University,<br />

3<br />

Heinrich-Heine University Duesseldorf, 4 Rheumazentrum Rhein-<br />

Ruhr.<br />

1616. Concordance between Ultrasound Readers Determining<br />

Presence <strong>of</strong> Monosodium Urate Crystal Deposition in Knee<br />

and Toe Joints. Rennie N. G. Howard 2 , Michael H. Pillinger 2 ,<br />

Soterios Gyftopoulos 2 , Ralf G. Thiele 4 , Christopher Swearingen 3<br />

and Jonathan Samuels 1 , 1 New York University Hospital for<br />

Joint Disease, New York, NY, 2 NYU Langone Medical Center,<br />

NYU Hospital for Joint Diseases, New York, NY, 3 University <strong>of</strong><br />

Arkansas for Medical Sciences, Little Rock, AR, 4 University <strong>of</strong><br />

Rochester, Rochester, NY.<br />

1617. Demonstrating Musculoskeletal Ultrasound Competency in a<br />

Valid and Reliable Way. Eugene Y. Kissin 4 , Jingbo Niu 5 , Ralf G.<br />

Thiele 11 , Midori Jane Nishio 1 , Jay B. Higgs 13 , Janak R. Goyal 10 ,<br />

Daniel G. Malone 12 , David A. Bong 2 , Amy M. Evangelisto 3 ,<br />

Wolfgang A. Schmidt 7 , Peter Balint 8 , Carlos Pineda 6 and Gurjit<br />

S. Kaeley 9 , 1 Lafayette, CA, 2 Bruce, WI, 3 Arthritis Rheumatic &<br />

Back Disease Association, Philadelphia, PA, 4 Boston University,<br />

Boston, MA, 5 Boston University, Boston, MA, 6 Institutu<br />

Nacional de Rehab, Mexico City, Mexico, 7 Medical Center for<br />

<strong>Rheumatology</strong> Berlin-Buch, Berlin, Germany, 8 National Institute<br />

<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />

9<br />

University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine, Ponte Vedra Beach,<br />

FL, 10 University <strong>of</strong> Medicine and Dentistry <strong>of</strong> New Jersey, Robert<br />

Wood Johnson Medical School, Perth Amboy, NJ, 11 University <strong>of</strong><br />

Rochester, Rochester, NY, 12 University <strong>of</strong> Wisconsin, Madison,<br />

WI, 13 Wilford Hall Medical Center/Brooke Army Medical Center,<br />

San Antonio, TX.<br />

1618. Effect <strong>of</strong> Musculoskeletal Ultrasound (MSKUS) Examination on<br />

Therapeutic Decision Making in Inflammatory Arthritis. Arnold<br />

Ceponis 2 , John J. Cush 1 and Arthur Kavanaugh 3 , 1 Baylor Research<br />

Institute, Dallas, TX, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Allergy and<br />

Immunology, University <strong>of</strong> California San Diego, San Diego, CA,<br />

3<br />

University <strong>of</strong> California-San Diego, La Jolla, CA.<br />

1619. Enthesopathy Detected by 18-Fluorodeoxyglucose Positron<br />

Emission Tomography in Patients with Polymyalgia<br />

Rheumatica. Hiroyuki Yamashita 2 , Kazuo Kubota 1 , Yuko<br />

Takahashi 3 , Hiroshi Kaneko 3 and Akio Mimori 3 , 1 Department<br />

<strong>of</strong> Radiology, National Center for Global Health and Medicine,<br />

2<br />

Division <strong>of</strong> Rheumatic Diseases, National Center for Global<br />

Health and Medicine, Shinjuku-ku, Tokyo-to, Japan, 3 Division<br />

<strong>of</strong> Rheumatic Diseases, National Center for Global Health and<br />

Medicine.<br />

1620. Erosive Osteoarthritis Is Not Associated with Invading<br />

Synovial Tissue: An Ultrasound Study. Ralf G. Thiele 1 , Laura<br />

A. Paxton 3 , Bethany A. Marston 2 , Darren Tabechian 4 and<br />

Allen P. Anandarajah 1 , 1 University <strong>of</strong> Rochester, Rochester, NY,<br />

2<br />

University <strong>of</strong> Rochester, Rochester, NY, 3 University <strong>of</strong> Rochester,<br />

North Chili, NY, 4 University <strong>of</strong> Rochester School <strong>of</strong> Medicine,<br />

Rochester, NY.<br />

1621. Evaluation <strong>of</strong> the 7-Joint Ultrasound Score (US7) by Detailed<br />

Joint Region-Analysis <strong>of</strong> an Arthritis Patient Cohort over One<br />

Year. Sarah Ohrndorf 3 , Beatrice Halbauer 3 , Lydia Naumann 3 ,<br />

Ekkehart Dietz 2 , Gerd R. Burmester 1 and Marina Backhaus 4 ,<br />

1<br />

Charite - University Medicine, Berlin, Germany, 2 Department<br />

<strong>of</strong> Medical Statistics Charité, Berlin, Germany, 3 Department <strong>of</strong><br />

<strong>Rheumatology</strong> and Clinical Immunology, University Hospital<br />

Charité, Berlin, Germany, 4 University Medicine Berlin: Campus<br />

Charité Mitte, Berlin, Germany.


ACR/ARHP Poster Session C<br />

1622. Fluorescence Imaging <strong>of</strong> Articular Proteinase Activities and<br />

Osteoblast Activity Showed Treatment Response to Anti-<br />

Interleukin-1 Antibodies in a Mouse Model <strong>of</strong> Collagen-<br />

Induced Arthritis. Fons A. J. van de Loo, Eline Vermeij, Onno J.<br />

Arntz, Marije Koenders and Wim B. van den Berg, Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />

Nijmegen, The Netherlands.<br />

1623. High Reliability <strong>of</strong> Nailfold Videocapillaroscopy – An Outcome<br />

Measure for Systemic Sclerosis-Related Microvsacular<br />

Disease? Herman H<strong>of</strong>stee 4 , Erik Serné 4 , Chris Roberts 2 , Roger<br />

Hesselstrand 1 , Agneta Scheja 1 , Tonia Moore 3 , Marie Wildt 1 ,<br />

Joanne Manning 2 , Anton Vonk Noordegraaf 4 , Alexandre Voskuyl 4<br />

and Ariane Herrick 2 , 1 Lund University, Sweden, 2 The University<br />

<strong>of</strong> Manchester, United Kingdom, 3 The University <strong>of</strong> Manchester,<br />

United Kingdom 4 VU University Medical Center, Amsterdam,<br />

The Netherlands.<br />

1624. Hypodermal Compressibility as a Diagnostic Test for<br />

Eosinophilic Fasciitis. Eugene Y. Kissin 1 , Michael R. York 2 and<br />

Robert W. Simms 3 , 1 Boston University, Boston, MA, 2 Boston<br />

University Medical Ctr, Boston, MA, 3 Boston University School <strong>of</strong><br />

Medicine, Boston, MA.<br />

1625. Novel PET/MR Fusion Imaging and Quantification <strong>of</strong> Knee<br />

Synovitis in Rheumatoid Arthritis. John T. Ryan 4 , C. T. Ng 1 ,<br />

Aisling Kennedy 2 , Robert G. Gibney 1 , Oliver Fitzgerald 1 , Patrick C.<br />

Brennan 5 , Eric Heffernan 1 , Jonathan McNulty 3 , Louise Rainford 3 ,<br />

Ursula Fearon 1 and Douglas Veale 1 , 1 Dublin Academic Medical<br />

Centre, Dublin, Ireland, 2 Dublin Academic Medical Centre,<br />

3<br />

University <strong>College</strong> Dublin, 4 University <strong>of</strong> Sydney, Lidcombe,<br />

NSW, Australia, 5 University <strong>of</strong> Sydney.<br />

1626. Outcomes and Cost-Effectiveness <strong>of</strong> Carpal Tunnel Injections<br />

Using Sonographic Needle Guidance. Natalia R. Chavez-Chiang 2 ,<br />

Suzanne Delea 1 , Wilmer L. Sibbitt 3 , Arthur D. Bankhurst 4 and<br />

Hillary Norton 2 , 1 University <strong>of</strong> New Mexico, Albuquerque, NM,<br />

2<br />

University <strong>of</strong> New Mexico, 3 University <strong>of</strong> New Mexico HSC,<br />

Albuquerque, NM, 4 University <strong>of</strong> NM Med Ctr, Albuquerque,<br />

NM.<br />

1627. WITHDRAWN<br />

1628. Potential Use <strong>of</strong> Matrix Metalloproteinase-13 Fluorogenic<br />

Probe for Imaging Osteoarthritis Development In Vivo. Sung<br />

Jae Choi 2 , Young Ho Lee 2 , Jong Dae Ji 2 and Gwan Gyu Song 1 ,<br />

1<br />

Korea Univ <strong>College</strong> <strong>of</strong> Med, Seoul, Korea, Republic <strong>of</strong>, 2 Korea<br />

Univ <strong>College</strong> <strong>of</strong> Medicine, Korea, Republic <strong>of</strong>.<br />

1629. Psychometric Properties <strong>of</strong> Synovitis Assessed in Rheumatoid<br />

Arthritis: Improved Intraobserver Reliability <strong>of</strong> Ultrasound vs.<br />

Clinical Evaluation in an Ancillary Study <strong>of</strong> the “Etanercept<br />

Versus DMARDs” Randomized, Prospective, Multicentre Study.<br />

Peter Mandl 5 , Peter V. Balint 5 , Yves Brault 4 , Marina Backhaus 9 ,<br />

Maria Antonietta D’Agostino 7 , Walter Grassi 1 , Desiree M. Van<br />

Der Heijde 3 , Eugenio De Miguel 8 , Richard J. Wakefield 6 , Isabelle<br />

Logeart 4 and Maxime Dougados 2 , 1 Clinica Reumatologica,<br />

Università Politecnica delle Marche, Jesi, Ancona, Italy,<br />

2<br />

Hospital Cochin, Paris, France, 3 Leiden University Medical<br />

Center, Meerssen, The Netherlands, 4 Pfizer, La Défense, Paris,<br />

France, 5 <strong>Rheumatology</strong> Department III, National Institute <strong>of</strong><br />

<strong>Rheumatology</strong> and Physiotherapy, Budapest, Pest, Hungary,<br />

6<br />

<strong>Rheumatology</strong> Department, University <strong>of</strong> Leeds, Chapel<br />

Allerton Hospital, Leeds, United Kingdom, 7 <strong>Rheumatology</strong><br />

Department, Versailles-Saint Quentin en Yvelines University;<br />

APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France,<br />

8<br />

<strong>Rheumatology</strong> Unit, La Paz University Hospital, Madrid, Spain,<br />

Spain, 9 University Medicine Berlin: Campus Charité Mitte,<br />

Berlin, Germany.<br />

1630. Sensitivity and Specificity <strong>of</strong> the Physical Examination<br />

Compared to Ultrasound in Identifying Knee and Ankle<br />

Arthritis in JIA. Ginger L. Janow 3 , Vikash Panghaal 2 , Terry L.<br />

Levin 2 and Norman T. Ilowite 1 , 1 Children’s Hospital Montefiore,<br />

Bronx, NY, 2 Department <strong>of</strong> Radiology, Montefiore Medical<br />

Center, 3 Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Children’s Hospital<br />

Montefiore, New York, NY.<br />

1631. The Comparison <strong>of</strong> Ultrasound & Physical Findings (CUSP)<br />

Remission Study – Ultrasound Remission Is Attained in Only<br />

20% <strong>of</strong> Patients on Anti-TNF Therapy. Joanne M. Kitchen 1 ,<br />

Bernadette M. Lynch 3 , Oliver M. FitzGerald 2 , Douglas J. Veale 3<br />

and David Kane 1 , 1 Adelaide and Meath Hospital, Dublin,<br />

Ireland, 2 St Vincents Univ Hospital, Ranelagh Dublin, Ireland, 3 St<br />

Vincents Univ Hospital, Dublin, Ireland.<br />

1632. The Power Doppler Ultrasonography Score from 24<br />

Synovial Sites or 6 Simplified Synovial Sites, Including the<br />

Metacarpophalangeal (MCP) Joints, Reflects Well the Clinical<br />

Disease Activity and Serum Biomarkers in Patients with<br />

Rheumatoid Arthritis. Atsushi Kawakami 1 , Shin-ya Kawashiri 1 ,<br />

Naoki Iwamoto 1 , Mami Tamai 1 , Hideki Nakamura 1 , Junko Kita 1 ,<br />

Akitomo Okada 1 , Tomohiro Koga 1 , Satoshi Yamasaki 1 , Tomoki<br />

Origuchi 1 and Katsumi Eguchi 2 , 1 Nagasaki University, Nagasaki,<br />

Japan, 2 Sasebo City General Hospital, Sasebo, Nagasaki, Japan.<br />

1633. The Role <strong>of</strong> Ultrasound in B Mode and Power Doppler<br />

Sonography in the Diagnosis <strong>of</strong> Enthesitis in Children.<br />

Dana Toib 1 , Anthony R. French 1 , Nirvikar Dahiya 2 , William<br />

D. Middleton 2 , Richard Brasington 1 and Andrew J. White 1 ,<br />

1<br />

Washington Univ Schl <strong>of</strong> Med, St Louis, MO, 2 Washington Univ<br />

Schl <strong>of</strong> Med.<br />

1634. Ultrasound Bone Erosions – Their Morphological Basis<br />

Obtained by High-Resolution Micro-Computed Tomography<br />

Imaging. Stephanie Finzel 2 , Sarah Ohrndorf 1 , Matthias<br />

Englbrecht 2 , Christian M. Stach 2 , Janin Messerschmidt 1 , Georg<br />

Schett 3 and Marina Backhaus 4 , 1 Charite University Hospital,<br />

Berlin, Germany, 2 Department <strong>of</strong> Internal Medicine 3 , University<br />

<strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany, 3 Friedrich<br />

Alexander Univ, Erlangen, Germany, 4 University Medicine Berlin:<br />

Campus Charité Mitte, Berlin, Germany.<br />

1635. Ultrasound Lung Comets. Validity, Reproducibility and<br />

Feasibility <strong>of</strong> a Simplified Assessment <strong>of</strong> Pulmonary Interstitial<br />

Fibrosis in Connective Tissue Disorders. Marwin Gutierrez 1 ,<br />

Fausto Salaffi 1 , Marina Carotti 3 , Marika Tardella 1 , Chiara<br />

Bertolazzi 1 , Elisabetta Bichisecchi 3 , Mara Giorgi 3 , Alarico Ariani 1 ,<br />

Carlos Pineda 2 , Emilio Filippucci 1 and Walter Grassi 1 , 1 Clinica<br />

Reumatologica, Università Politecnica delle Marche, Jesi,<br />

Ancona, Italy, 2 Instituto Nacional de Rehabilitacion, Mexico<br />

City, Mexico, 3 S.O.D Radiologia Clinica, Dipartimento di Scienze<br />

Radiologiche, Ospedale Riuniti, Ancona.<br />

1636. Use <strong>of</strong> Musculoskeletal Ultrasound in Diagnosis <strong>of</strong> Early<br />

Inflammatory Arthritis: Are Limited Joint Surveys Adequate?<br />

Paramvir Sidhu, Jeffrey Lisse, Rafael Grau, Eric P. Gall and Mihra<br />

Taljanovic, University <strong>of</strong> Arizona, Tucson, AZ.<br />

1637. Utility <strong>of</strong> Ultrasound in the Diagnostic Assessment <strong>of</strong><br />

Shoulder Pain in Polymyalgia Rheumatica: Results from an<br />

International, Prospective, Multi-Center Longitudinal Study.<br />

ACR–EULAR Study Group for Development <strong>of</strong> Classification<br />

Criteria for PMR. Wolfgang A. Schmidt 17 , Marco A. Cimmino 9 ,<br />

Peter Mandl 18 , Peter V. Balint 1 , Annamaria Iagnocco 22 , Richard J.<br />

Wakefield 20 , Michael Schirmer 4 , Carlo Salvarani 10 , Artur Bachta 16 ,<br />

Maria C. Cid 15 , Christina Duftner 8 , Christian Dejaco 12 , Georgina<br />

Espígol-Frigolé 2 , Pierluigi Macchioni 10 , Zsuzsa Schmidt 18 ,<br />

Novák P. Kaposi 19 , Gyula Poór 18 , Elizabeth Nordborg 23 , Haner<br />

2010 Program Book 245


ACR/ARHP Poster Session C<br />

Direskeneli 11 , Sibel Z. Aydin 11 , Colin Pease 20 , Khalid Ahmed 13 ,<br />

Mehrdad Mazlumzadeh 7 , Andy Abril 5 , Neil Gonter 21 , Hilal<br />

Maradit-Kremers 3 , Cynthia S. Crowson 3 , Bhaskar Dasgupta 14<br />

and Eric L. Matteson 6 , 13 rd <strong>Rheumatology</strong> Department, National<br />

Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest,<br />

2<br />

Center for Diagnosis Imaging, Hospital Clínic, Montserrat<br />

del Amo, Barcelona, Spain, 3 Department <strong>of</strong> Health Sciences<br />

Research, Mayo Clinic, Rochester, MN, 4 Department <strong>of</strong> Internal<br />

Medicine I, Medical University Innsbruck, Innsbruck, Austria,<br />

5<br />

Department <strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Mayo Clinic, Jacksonville, FL, 6 Department <strong>of</strong> Internal Medicine,<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN,<br />

7<br />

Department <strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Mayo Clinic, Scottsdale, AZ, 8 Department <strong>of</strong> Internal Medicine,<br />

General Hospital <strong>of</strong> the Elisabethinen, Klagenfurt, Austria,<br />

9<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Genova,<br />

Genova, Italy, 10 Department <strong>of</strong> <strong>Rheumatology</strong>, Arcispedale<br />

S. Maria Nuova, Reggio Emilia, Italy, 11 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />

Turkey, 12 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />

Graz, Graz, Austria, 13 Department <strong>of</strong> <strong>Rheumatology</strong>, Princess<br />

Alexandra Hospital, Harlow, United Kingdom, 14 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Southend University Hospital, Essex,<br />

United Kingdom, 15 Department <strong>of</strong> Systemic Autoimmune<br />

Hospital Clinic Provincial, Barcelona, Spain, 16 Deptartment<br />

<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />

Warszawa, Poland, 17 Immanuel Krankenhaus Berlin: Medical<br />

Center for <strong>Rheumatology</strong> Berlin-Buch Berlin, Berlin, Germany,<br />

18<br />

National Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy,<br />

Budapest, Hungary, 19 Radiology Department, National Institute<br />

<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />

20<br />

<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />

Leeds, Leeds, UK, 21 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />

Teaneck, NJ, 22 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />

Department, Sapienza Università di Roma, Policlinico Umberto<br />

I, Rome, Italy, 23 Sahlgren University Hospital, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Göteborg, Sweden.<br />

Infection-Related Rheumatic Disease<br />

1638. A Comparison <strong>of</strong> the Presentation, Synovial Fluid Analysis, and<br />

Treatment Course in Children and Adults with Lyme Arthritis.<br />

Brian E. Daikh 4 , Fred Emerson 3 , F. Lee Lucas 2 , Robert Smith 1 and<br />

Carol McCarthy 1 , 1 Maine Medical Center, 2 Maine Medical Center<br />

Research Institute, 3 Maine Medical Partners, 4 <strong>Rheumatology</strong><br />

Associates PC, Portland, ME.<br />

1639. Autoantibodies to a Novel Cytoplasmic Rod/Ring Structure<br />

Target CTP/GTP Synthetic Pathway in HCV Infection after<br />

Interferon/Ribavirin Therapy. Wendy C. Carcamo 2 , Angela<br />

Ceribelli 3 , Jason Y. F Chan 3 , Westley H. Reeves 2 , Giovanni Covini,<br />

Carlos A. Von Muhlen 1 , Liu Chen 3 , Minoru Satoh 2 and Edward<br />

K. .L Chan 2 , 1 Metanalysis, Porto Alegre, Brazil, 2 University <strong>of</strong><br />

Florida, Gainesville, FL, 3 University <strong>of</strong> Florida.<br />

1640. Chloroquine (CQN) Is Not Superior to Meloxicam (MCAM) in<br />

the Treatment <strong>of</strong> Early Persistent ‘Musculoskeletal Pain and<br />

Polyarthralgias’ (MSK-P) Following Chikungunya (CHIKV): A<br />

Non Commercial Investigator Initiated Community Based<br />

Controlled Drug Study. Arvind Chopra 2 , Manjit Saluja 3 and<br />

Anuradha Venugopalan 1 , 1 Center for Rheuamatic Diseases,<br />

2<br />

Center for Rheumatic Diseases, Pune, India, 3 Center for<br />

Rheumatic Diseases.<br />

1641. Clinical Features <strong>of</strong> Acute Human Parvovirus B19 in Adults:<br />

What We Could Learn from It? Hideto Oshikawa 1 , Makiko<br />

Yamamoto 2 , Akira Jibatake 2 , Kiyoharu Muranaka 2 , Kazuki<br />

Yoshida 2 , Masako Utsunomiya 2 , Tatsuo Kobayashi 2 , Mitsumasa<br />

Kishimoto 3 and Kazuo Matsui 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Kameda Medical Center, Kamogawa City, Chiba, Japan,<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Kameda Medical Center, 3 St<br />

Luke’s International Hospital, Japan.<br />

1642. Cytokines in Chikungunya (CHIKV): Storm in a Teacup or Winds<br />

before the Storm. Arvind Chopra 2 and Anuradha Venugopalan 1 ,<br />

1<br />

Center for Rheumatic Disease, Pune, India, 2 Center for<br />

Rheumatic Diseases, Pune, India.<br />

1643. Geographic Distribution <strong>of</strong> Endemic Fungal Infections among<br />

Older <strong>American</strong>s. John W. Baddley 3 , Kevin L. Winthrop 1 ,<br />

Nivedita M. Patkar 3 , Elizabeth Delzell 4 , Fenglong Xie 4 ,<br />

Lang Chen 4 and Jeffrey R. Curtis 2 , 1 Oregon Health Sciences<br />

University, 2 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />

AL, 3 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />

4<br />

University <strong>of</strong> Alabama at Birmingham, Birmingham, AL.<br />

1644. Identification <strong>of</strong> Borrelia Burgdorferi in Brazil: The Etiologic<br />

Agent <strong>of</strong> Brazilian Lyme Disease-Like Syndrome (Baggio-<br />

Yoshinari Syndrome). Elenice Mantovani, Roberta G.<br />

Marangoni, Giancarla Gauditano, Virgínia L. N. Bonoldi and<br />

Natalino H. Yoshinari, <strong>Rheumatology</strong> Division, Faculdade de<br />

Medicina da Universidade de São Paulo.<br />

1645. Prevalence, Impact and Risk Factors for Musculoskeletal Pain<br />

among HIV Infected Adults: An Epidemiologic Study. Karen<br />

Walker-Bone 1 , Edwina Lawson 2 , Duncan Churchill 2 , Yvonne<br />

Gilleece 2 , Martin Fisher 2 and Caroline Sabin 3 , 1 Brighton &Sussex<br />

Medical School, Brighton, United Kingdom, 2 Brighton &Sussex<br />

University Hospitals NHS Trust, 3 University <strong>College</strong>, London.<br />

1646. Surrogate Markers <strong>of</strong> B-Cell Non-Hodgkin Lymphoma in<br />

Patients with Hepatitis C Virus-Related Cryoglobulinemia<br />

Vasculitis. Guillaume Geri 2 , Benjamin Terrier 2 , Oren Semoun 1 ,<br />

David Saadoun 2 , Damien Sène 2 , Hélène Merle-Beral 2 , Frédéric<br />

Charlotte 2 , Lucile Musset 2 , Mathieu Resche-Rigon 1 and Patrice<br />

Cacoub 2 , 1 INSERM URMS 717, Paris 7 , Paris, France, 2 Pitié-<br />

Salpetrière Hospital, Paris, France.<br />

1647. The Diagnosis <strong>of</strong> Reactive Arthritis in the Real World and<br />

Factors That Might Contribute to Its Under/Misdiagnosis.<br />

Jenny Lin 2 , Anjali G. Shetty 2 and John D. Carter 1 , 1 Univ <strong>of</strong> South<br />

Florida, Tampa, FL, 2 University <strong>of</strong> South Florida.<br />

1648. The Infectious Risk <strong>of</strong> the Lower Respiratory Tract Is Increased<br />

in Patients with Rheumatic Diseases Treated by Biologic<br />

DMARDs, in Particular in Case <strong>of</strong> Pre-Existing Colonisation.<br />

Guillaume Geri, Sabrina Dadoun, Simon Paternotte, Maxime<br />

Dougados and Laure Gossec, Cochin Hospital, Paris, France.<br />

1649. Usefulness <strong>of</strong> Procalcitonin Measurement in Differentiating<br />

between Activity <strong>of</strong> Systemic Autoimmune Disease and<br />

Bacterial Infection. Olga Sleglova 3 , Helena Dejmkova 4 , Jana<br />

Uhrova 2 and Jaromir Belacek 1 , 1 Department <strong>of</strong> Biostatistics, 1 .<br />

Medical Faculty, Charles University, Prague, Czech Republic,<br />

2<br />

Institute <strong>of</strong> Clinical Biochemistry, Prague, Czech Republic, Czech<br />

Republic, 3 Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic,<br />

4<br />

Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic.<br />

246<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

Miscellaneous Rheumatic and Inflammatory Diseases II<br />

1650. Adalimumab Therapy in 18 Patients with Severe Hidradenitis<br />

Suppurativa. Orlando Pompei Fernández 5 , Ricardo Blanco<br />

Alonso 5 , Ignacio Villa 4 , Marcos Gonzalez López 2 , Hector<br />

Fernández LLaca 1 , M. Del Carmen González-Vela 3 , Mario Agudo<br />

Bilbao 6 , Cristina Martinez Dubois 6 , Victor M. Martinez-Taboada 7 ,<br />

M. Enriqueta Peiro Callizo 5 , Jose Luis Peña Salgredo 5 , Alfonso<br />

Fernando Corrales Martinez 5 and Miguel Angel Gonzalez-Gay<br />

Mantecon 5 , 1 Department <strong>of</strong> Dermatology, Hospital Universitario<br />

Marqués de Valdecilla, Santander, Cantabria, 2 Department<br />

<strong>of</strong> Inmunology, Hospital de Liencres, Santander, Cantabria,<br />

3<br />

Department <strong>of</strong> Pathology, Hospital Universitario Marqués de<br />

Valdecilla, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Sierrallana,<br />

5<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario Marqués<br />

de Valdecilla, Santander, Cantabria, Spain, 6 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Hospital Universitario Marqués de Valdecilla,<br />

Santander, Cantabria, 7 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />

Universitario Marqués de Valdecilla, Santander, Spain.<br />

1651. Association <strong>of</strong> Langerhans Cell Histiocytosis with Erdheim-<br />

Chester Disease: How Close Monocyte/Macrophage and<br />

Dendritic Cell Lineages Are? Baptiste Hervier, Frrederic<br />

Charlotte, Olivier Hermine, Antoine Neel, Nicole Brousse,<br />

Aude Rigolet, Christian De gennes, Eric Hachulla, Xavier Girerd,<br />

Antoine Dupuy, Zahir Amoura and Julien Haroche, CHU Pitié<br />

Salpetrière, APHP, Paris, France, French Reference Center for<br />

Lupus.<br />

1652. Blinded Multi-Rater Evaluation <strong>of</strong> Diagnosis and Candidate<br />

Classification Criteria for Polymyalgia Rheumatica (PMR).<br />

ACR – EULAR Study Group for Development <strong>of</strong> Classification<br />

Criteria for PMR. Eric L. Matteson 5 , Marco A. Cimmino 7 , Hilal<br />

Maradit-Kremers 1 , Carlo Salvarani 8 , Michael Schirmer 3 , Wolfgang<br />

A. Schmidt 13 , Maria C. Cid 12 , Christian Dejaco 10 , Pierre Duhaut 20 ,<br />

Zsuzsa Schmidt 14 , Annamaria Iagnocco 18 , Artur Bachta 2 , Carlotta<br />

Nannini 19 , Fabrizio Cantini 19 , Victor Martínez-Taboada 21 ,<br />

Haner Direskeneli 9 , Sibel Z. Aydin 9 , Raashid Luqmani 15 , Colin<br />

Pease 16 , Mehrdad Mazlumzadeh 6 , Kenneth Calamia 4 , Clement<br />

J. Michet 5 , Andy Abril 4 , Neil Gonter 17 , Cynthia S. Crowson 1 ,<br />

Rickey Carter 1 and Bhaskar Dasgupta 11 , 1 Department <strong>of</strong> Health<br />

Sciences Research, Mayo Clinic, Rochester, MN, 2 Department<br />

<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />

Warszawa, Poland, 3 Department <strong>of</strong> Internal Medicine I, Medical<br />

University Innsbruck, Innsbruck, Austria, 4 Department <strong>of</strong><br />

Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />

Jacksonville, FL, 5 Department <strong>of</strong> Internal Medicine, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN, 6 Department<br />

<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />

Scottsdale, AZ, 7 Department <strong>of</strong> Internal Medicine, University<br />

<strong>of</strong> Genova, Genova, Italy, 8 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Arcispedale S. Maria Nuova, Reggio Emilia, Italy, 9 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />

Turkey, 10 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />

Graz, Graz, Austria, 11 Department <strong>of</strong> <strong>Rheumatology</strong>, Southend<br />

University Hospital, Essex, United Kingdom, 12 Department <strong>of</strong><br />

Systemic Autoimmune Hospital Clinic Provincial, Barcelona,<br />

Spain, 13 Immanuel Krankenhaus Berlin: Medical Center for<br />

<strong>Rheumatology</strong> Berlin-Buch Berlin, Berlin, Germany, 14 National<br />

Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest,<br />

Hungary, 15 Nuffield Department <strong>of</strong> Orthopaedics, <strong>Rheumatology</strong><br />

and Musculoskeletal Sciences, Oxford University, Oxford, UK,<br />

16<br />

<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />

Leeds, Leeds, UK, 17 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />

Teaneck, NJ, 18 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />

Department, Sapienza Università di Roma, Policlinico Umberto<br />

I, Rome, Italy, 19 <strong>Rheumatology</strong> Unit, Ospedale Misericordia<br />

e Dolce, Prato, Italy, 20 Service de Medecine Interne, Amiens,<br />

France, 21 Servicio de Reumatología, Hospital Universitario<br />

Marques de Valdecilla, Facultad de Medicina, Universidad de<br />

Cantabria, Santander, Spain.<br />

1653. Bone Events in Type 1 Gaucher Disease before and during<br />

Treatment. Jerome Stirnemann 2 , Djazia Heraoui 1 , Corine<br />

Vincent 3 , Olivier Fain 2 , Bruno Fantin 1 , France Mentre 3 and Nadia<br />

Belmatoug 1 , 1 APHP - Referral Center <strong>of</strong> Lysosomal Diseases<br />

(RCLD), Clichy, France, 2 APHP - Referral Center <strong>of</strong> Lysosomal<br />

Diseases (RCLD), Bondy, France, 3 INSERM, Paris, France.<br />

1654. Development <strong>of</strong> Classification Criteria for Polymyalgia<br />

Rheumatica (PMR): Results from an International, Prospective,<br />

Multi-Center Longitudinal Study ACR – EULAR Study Group<br />

for Development <strong>of</strong> Classification Criteria for PMR. Bhaskar<br />

Dasgupta 16 , Marco A. Cimmino 10 , Hilal Maradit-Kremers 3 ,<br />

Wolfgang A. Schmidt 19 , Michael Schirmer 5 , Carlo Salvarani 5 ,<br />

Peter Mandl 20 , Artur Bachta 4 , Maria Cid 17 , Haner Direskeneli 13 ,<br />

Pierluigi Macchioni 11 , Peter V. Balint 1 , Christina Duftner 9 ,<br />

Christian Dejaco 14 , Hanna Slott Jensen 18 , Zsuza Schmidt 20 , Gyula<br />

Poór 20 , Annamaria Iagnocco 24 , Victor Martínez-Taboada 28 ,<br />

Elizabeth Nordborg 26 , Carlotta Nannini 25 , Pierre Duhaut 27 , Nicolò<br />

Pipitone 11 , Georgina Espígol-Frigolé 2 , Sibel Z. Aydin 13 , Khalid<br />

Ahmed 15 , Raashid Luqmani 21 , Brian Hazelman 12 , Colin Pease 22 ,<br />

Richard J. Wakefield 22 , Neil Gonter 23 , Ralph Marcus 23 , Clement<br />

J. Michet 7 , Mehrdad Mazlumzadeh 8 , Andy Abril 6 , Cynthia S.<br />

Crowson 3 and Eric L. Matteson 7 , 13 rd <strong>Rheumatology</strong> Department,<br />

National Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy,<br />

Budapest, 2 Center for Diagnosis Imaging, Hospital Clínic,<br />

Montserrat del Amo, Barcelona, Spain, 3 Department <strong>of</strong> Health<br />

Sciences Research, Mayo Clinic, Rochester, MN, 4 Department<br />

<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />

Warszawa, Poland, 5 Department <strong>of</strong> Internal Medicine I, Medical<br />

University Innsbruck, Innsbruck, Austria, 6 Department <strong>of</strong><br />

Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />

Jacksonville, FL, 7 Department <strong>of</strong> Internal Medicine, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN, 8 Department<br />

<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />

Scottsdale, AZ, 9 Department <strong>of</strong> Internal Medicine, General<br />

Hospital <strong>of</strong> the Elisabethinen, Klagenfurt, Austria, 10 Department<br />

<strong>of</strong> Internal Medicine, University <strong>of</strong> Genova, Genova, Italy,<br />

11<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Arcispedale S. Maria<br />

Nuova, Reggio Emilia, Italy, 12 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Cambridge University, Cambridge, UK, 13 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />

Turkey, 14 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />

Graz, Graz, Austria, 15 Department <strong>of</strong> <strong>Rheumatology</strong>, Princess<br />

Alexandra Hospital, Harlow, United Kingdom, 16 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Southend University Hospital, Essex, United<br />

Kingdom, 17 Department <strong>of</strong> Systemic Autoimmune Hospital<br />

Clinic Provincial, Barcelona, Spain, 18 Gent<strong>of</strong>te Hospital,<br />

<strong>Rheumatology</strong> Division, Hellerup, Denmark, 19 Immanuel<br />

Krankenhaus Berlin: Medical Center for <strong>Rheumatology</strong><br />

Berlin-Buch Berlin, Berlin, Germany, 20 National Institute<br />

<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />

21<br />

Nuffield Department <strong>of</strong> Orthopaedics, <strong>Rheumatology</strong> and<br />

Musculoskeletal Sciences, Oxford University, Oxford, UK,<br />

22<br />

<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />

Leeds, Leeds, UK, 23 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />

Teaneck, NJ, 24 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />

Department, Sapienza Università di Roma, Policlinico Umberto<br />

I, Rome, Italy, 25 <strong>Rheumatology</strong> Unit, Ospedale Misericordia e<br />

Dolce, Prato, Italy, 26 Sahlgren University Hospital, Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Göteborg, Sweden, 27 Service de Medecine<br />

Interne, Amiens, France, 28 Servicio de Reumatología, Hospital<br />

Universitario Marques de Valdecilla, Facultad de Medicina,<br />

Universidad de Cantabria, Santander, Spain.<br />

2010 Program Book 247


ACR/ARHP Poster Session C<br />

248<br />

1655. Different Diagnostic Criteria in the Diagnosis <strong>of</strong> Polymyalgia<br />

Rheumatica. Samy Zakout and John R. Kirwan, University <strong>of</strong><br />

Bristol, Bristol, United Kingdom.<br />

1656. Diseases Associated with Positive NOD2/CARD15 Gene<br />

Mutations: Blau’s Syndrome Versus an Intermediate Subset<br />

<strong>of</strong> Blau’s Syndrome and Crohn’s Disease. Qingping Yao 4 , Lan<br />

Zhou 3 , Philip Cusumano 2 and Le-Chu Su 1 , 1 The Department<br />

<strong>of</strong> Gastroenterology, Cleveland Clinic, Cleveland, OH, 2 The<br />

Department <strong>of</strong> Internal Medicine, Cleveland Clinic, Cleveland,<br />

OH, 3 The Department <strong>of</strong> Neurology, Cleveland Clinic, Cleveland,<br />

OH, 4 The Department <strong>of</strong> Rheumatic and Immunologic Diseases,<br />

Cleveland Clinic, Cleveland, OH.<br />

1657. Efficacy and Safety <strong>of</strong> Thalidomide on Mucocutaneous<br />

Symptoms: A Systematic Review and Meta-Analysis. Juan A.<br />

Martinez Lopez 3 , Estibaliz Loza 3 , Jesús Maese 3 , Maria Rosario<br />

Rodriguez Moreno 2 , Maria Piedad Rosario Lozano 3 and Loreto<br />

Carmona 1 , 1 Fundación Española Reumatol, Madrid, Spain,<br />

2<br />

Hospital Virgen de las Nieves, Granada, Spain, 3 Sociedad<br />

Española de Reumatología, Madrid, Spain.<br />

1658. Efficacy <strong>of</strong> High Doses <strong>of</strong> Interferon-a-2a (IFNa) in Erdheim-<br />

Chester Disease. Baptiste Hervier, Laurent Arnaud, Bertrand<br />

Wechsler, Zahir Amoura and Julien Haroche, CHU Pitié-<br />

Salpétrière, APHP, Paris France, French Reference Center for<br />

Lupus &Autoimmune Diseases.<br />

1659. Endothelial Anti-Inflammatory Effect <strong>of</strong> alpha2 Adrenergic<br />

Agonists. Ada Herrera 2 , M. Jesús Domínguez 2 , M. Teresa Arce 2 ,<br />

A. Diaz 2 , Manuel Feria 1 and Federico Diaz 2 , 1 Medical School,<br />

Spain, 2 <strong>Rheumatology</strong> Service, Hospital Universitario de<br />

Canarias, Spain.<br />

1660. Erdheim-Chester Disease: Prospective Follow-Up <strong>of</strong> a Single-<br />

Center Cohort <strong>of</strong> 48 Patients Reveals Improved Survival in<br />

Patients Treated with Interferon-alpha. Laurent Arnaud,<br />

Julien Haroche, Baptiste Hervier, Bertrand Wechsler, Nathalie<br />

Costedoat-Chalumeau, Patrice Cacoub, David Saadoun and Zahir<br />

Amoura, Department <strong>of</strong> Internal Medicine, Groupe Hospitalier<br />

Pitié-Salpêtriere, UPMC Univ Paris 6 , AP-HP, 47-83 bd de<br />

l’Hôpital, Paris, France.<br />

1661. Expression <strong>of</strong> Type 1 Interferon Related Proteins and<br />

Plasmacytoid Dendritic Cells in the Lesional Skin <strong>of</strong> Morphea<br />

Patients. Mehran Ghoreishi 1 , Cristián Vera Kellet 2 and Jan Peter<br />

Dutz 1 , 1 Department <strong>of</strong> Dermatology and Skin Science, University<br />

<strong>of</strong> British Columbia, Vancouver, BC, Canada, 2 Department <strong>of</strong><br />

Dermatology, Pontificia Universidad Católica de Chile, Santiago,<br />

Vancouver, BC, Canada.<br />

1662. Idiopathic Retroperitoneal Fibrosis: Clinical Findings in 185<br />

Patients. Tanaz A. Kermani 1 , Cynthia S. Crowson 2 and Harvinder<br />

S. Luthra 1 , 1 Mayo Clinic, Rochester, MN, 2 Mayo Clinic.<br />

1663. IL-1 Blockade for Schnitzler’s Syndrome. Rona M. Smith 1 , Helen<br />

J. Lachmann 2 and David R. W. Jayne 1 , 1 Addenbrooke’s Hospital,<br />

Cambridge, United Kingdom, 2 UK National Amyloidosis Centre,<br />

London.<br />

1664. IL-18 Binding Protein (IL-18BP) Dramatically Improves Liver<br />

Histological Lesions in an Animal Model <strong>of</strong> Macrophage<br />

Activation Syndrome (MAS). Laura Chiossone 3 , Sandra<br />

Audonnet 3 , Karin Mazodier 2 , Marc Dalod 3 , Catherine Farnarier 1 ,<br />

Daniela Novick 5 , Charles A. Dinarello 4 , Eric Vivier 3 and Gilles<br />

Kaplanski 2 , 1 Assiatnce Publique-Hôpitaux de Marseille,<br />

Marseille, France, 2 Assistance Publique-Hôpitaux de Marseille,<br />

Marseille, France, 3 CIML, Marseille, France, 4 University <strong>of</strong><br />

Colorado Health Science, Denver, CO, 5 Weizmann Institute <strong>of</strong><br />

Science, Rehovot, Israel.<br />

2010 Program Book<br />

1665. Is Pamidronate Useful as Very Effective Therapeutic<br />

Intervention in Midtarsal Arthropathy? Mani Nallasivan 2 and<br />

Tim Tait 1 , 1 Diana Princess <strong>of</strong> Wales Hospital Grimsby, Grimsby,<br />

Lincolnshire, United Kingdom, 2 Diana Princess <strong>of</strong> Wales Hospital,<br />

Grimsby, Northern Lincolnshire and Goole Hospital NHS Trust,<br />

Hull, Yorkshire, United Kingdom.<br />

1666. Nonalcoholic Steatohepatitis as a Complication <strong>of</strong> Collagen<br />

Disease. Kae Takagi, Yasushi Kawaguchi, Yuko Ota, Akiko<br />

Tochimoto, Chikako Fukazawa, Takahisa Gono, Yasuhiro<br />

Katsumata, Masako Hara and Hisashi Yamanaka, Tokyo Women’s<br />

Medical University, Tokyo, Japan.<br />

1667. Prevalence <strong>of</strong> Atherosclerotic Risk Factors and the Metabolic<br />

Syndrome in Patients with Chronic Inflammatory Arthritis. Chi<br />

Chiu Mok 2 , Tin Choi Ko 1 , Ling Yin Ho 2 , Ka Lung Yu 2 , Pak To Chan 2<br />

and Chi Hung To 2 , 1 Chinese University Hong Kong, 2 Tuen Mun<br />

Hospital.<br />

1668. Renal Dysfunction Is Associated with Increased Mortality in<br />

Adults with Macrophage Activation Syndrome. Bita Shakoory 3 ,<br />

W. Winn Chatham 3 , Graciela S. Alarcon 1 and Randy Q. Cron 2 ,<br />

1<br />

Oakland, CA, 2 Children’s Hospital <strong>of</strong> Alabama, Birmingham, AL,<br />

3<br />

Univ <strong>of</strong> Alabama-Birmingham, Birmingham, AL.<br />

1669. Retrospective Analysis <strong>of</strong> Relapsing Polychondritis in the US<br />

Department <strong>of</strong> Defense Population. Stephanie D. Mathew,<br />

Daniel F. Battafarano and Michael J. Morris, San Antonio Military<br />

Medical Consortium, Fort Sam Houston, TX.<br />

1670. Retrospective Case Series <strong>of</strong> Single Center Experience <strong>of</strong><br />

Methotrexate and Mycophenolate M<strong>of</strong>etil Monotherapy<br />

for Patients with Non Infectious Posterior, Intermediate and<br />

Panuveitis. Mariam Khan 1 , Careen Lowder 1 and Rula Hajj-Ali 2 ,<br />

1<br />

Cleveland Clinic Foundation, Cleveland, OH, 2 Clevelnad Clinic,<br />

Cleveland, OH.<br />

1671. Rituximab Therapy Is an Effective Approach in Treatment <strong>of</strong><br />

IgG4-Related Systemic Disease. Arezou Khosroshahi 3 , Donald B.<br />

Bloch 2 , Vikram Deshpande 4 and John H. Stone 1 , 1 Massachusetts<br />

General Hospital, Sudbury, MA, 2 Massachusetts General<br />

Hospital, Newton, MA, 3 Massachusetts General Hospital,<br />

Boston, MA, 4 Massachusetts General Hospital.<br />

Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Pediatric<br />

Rheumatic Diseases II<br />

1672. Anti-CADM-140/MDA5 Antibody Predicts Complication<br />

<strong>of</strong> Interstitial Lung Disease in Japanese Cases <strong>of</strong> Juvenile<br />

Dermatomyositis. Ichiro Kobayashi 1 , Yuka Okura 1 , Yasuhiro<br />

Yamazaki 1 , Shunichiro Takezaki 1 , Masafumi Yamada 1 , Masataka<br />

Kuwana 2 and Tadashi Ariga 1 , 1 Department <strong>of</strong> Pediatrics,<br />

Hokkaido University Graduate School <strong>of</strong> Medicine, Sapporo,<br />

Japan, 2 Keio University School <strong>of</strong> Med, Tokyo, Japan.<br />

1673. Characterization at Diagnosis <strong>of</strong> Children with Microscopic<br />

Polyangiitis (MPA) Defined Uniquely among Patients with<br />

ANCA-Associated Vasculitis (AAV) in a Registry for Children<br />

with Vasculitis (ARChiVe). David A. Cabral 2 , America G.<br />

Uribe 2 , Leslie S. Abramson 37 , Matthew D. Adams 5 , Susanne<br />

M. Benseler 31 , Sarah S. C. Campillo 20 , Peter Chira 30 , B. Anne<br />

Eberhard 28 , Kaleo C. Ede 24 , Aimee O. Hersh 33 , Gloria C. Higgins 21 ,<br />

Adam Huber 15 , Lisa F. Imundo 10 , Rita S. Jerath 11 , Susan Kim 8 ,<br />

Daniel J. Kingsbury 17 , Marisa S. Klein-Gitelman 12 , Suzanne C. Li 16 ,<br />

Daniel J. Lovell 9 , Thomas G. Mason 19 , Deborah K. McCurdy 18 ,<br />

Renee F. Modica 34 , Lakshmi N. Moorthy 27 , Eyal Muscal 1 ,<br />

Kabita Nanda 25 , Lorien A. Nassi 32 , Kathleen M. O’Neil 22 , Egla<br />

C. Rabinovich 14 , Andreas O. Reiff 7 , Margalit E. Rosenkranz 6 ,<br />

Kenneth N. Schikler 35 , Anne M. Stevens 23 , Mary B. Toth 4 , Linda<br />

Wagner-Weiner 13 , Dawn M. Wahezi 3 , Andrew J. White 29 , Amy


ACR/ARHP Poster Session C<br />

L. Woodward 26 , Andrew S. Zeft 36 and ARChiVe Investigators<br />

<strong>of</strong> CARRA, 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 BC<br />

Children’s Hospital, Vancouver, BC, Canada, 3 Children’s Hospital<br />

at Montefiore, Bronx, NY, 4 Children’s Hospital Med Ctr, Akron,<br />

OH, 5 Children’s Hospital <strong>of</strong> Michigan, Huntington Woods, MI,<br />

6<br />

Children’s Hospital <strong>of</strong> Pittsburgh, Pittsburgh, PA, 7 Childrens<br />

Hosp LA MS 60 , Los Angeles, CA, 8 Childrens Hospital Boston,<br />

Boston, MA, 9 Childrens Hospital Medical Center, Cincinnati,<br />

OH, 10 Childrens Hospital <strong>of</strong> NY, New York, NY, 11 Childrens Med<br />

Ctr Med Schl GA, Augusta, GA, 12 Childrens Mem Hosp/NW<br />

Univ, Chicago, IL, 13 Corner Children’s Hospital, Chicago, IL,<br />

14<br />

Duke University Medical Center, Durham, NC, 15 IWK Health<br />

Centre, Halifax, NS, Canada, 16 Joseph M Sanzari Children’s<br />

Hospital, Short Hills, NJ, 17 Legacy Emanuel Children’s Hosp,<br />

Portland, OR, 18 Mattel Children’s UCLA, Los Angeles, CA,<br />

19<br />

Mayo Clinic Rochester, Rochester, MN, 20 Montreal Children’s<br />

Hospital, Montreal, QC, Canada, 21 Nationwide Childrens Hosp,<br />

Columbus, OH, 22 OU Health Science Center, Oklahoma City, OK,<br />

23<br />

Pediatrics, U. <strong>of</strong> Washington, Seattle, WA, 24 Phoenix Children’s<br />

Hospital, Phoenix, AZ, 25 Rainbow Babies and Children’s<br />

Hospital, Beachwood, OH, 26 Riley Children’s Hospital, Nashville,<br />

TN, 27 Robert Wood Johnson Medical School, Metuchen,<br />

NJ, 28 Schneider Children’s Hospital, New Hyde Park, NY, 29 St<br />

Louis Childrens Hosp, St Louis, MO, 30 Stanford Univ Schl <strong>of</strong><br />

Med, Stanford, CA, 31 The Hospital for Sick Children, Toronto,<br />

ON, Canada, 32 TX Scottish Rite Hosp, Dallas, TX, 33 UCSF, San<br />

Francisco, CA, 34 University <strong>of</strong> Florida, Orlando, FL, 35 University <strong>of</strong><br />

Louisville SOM, Louisville, KY, 36 University <strong>of</strong> Utah, Salt Lake City,<br />

UT, 37 University <strong>of</strong> Vermont, Morrisville, VT.<br />

1674. Clinical and Serological Factors Associated with Lupus Serositis<br />

in Children: Results from the 1000 Canadian Faces Multiethnic<br />

Cohort. America G. Uribe 1 , Jaime Guzman 1 , Ross E. Petty 3 , Lori<br />

B. Tucker 2 , Laura Musyj 1 , Earl D. Silverman 4 , Gaelle Chedeville 7 ,<br />

Adam Huber 5 , Suzanne E. Ramsey 6 and Christine A. Peschken 8 ,<br />

1<br />

BC Children’s Hospital, 2 BC Childrens Hospital, Vancouver, BC,<br />

Canada, 3 BCs Childrens Hosptial, Vancouver, BC, Canada, 4 Hosp<br />

for Sick Children, Toronto, ON, Canada, 5 IWK Health Centre,<br />

Halifax, NS, Canada, 6 IWK Health Ctr, Halifax, NS, Canada,<br />

7<br />

Montreal Children’s Hospital, 8 Univ <strong>of</strong> Manitoba, Winnipeg,<br />

MB, Canada.<br />

1675. Cogan Syndrome: A Rare but Severe Vasculitis in Pediatric<br />

Age. Ilaria Pagnini 3 , Maria Elisabetta Zannin 4 , Marianna Sari 2 ,<br />

Gabriele Simonini 1 , Rolando Cimaz 6 and Francesco Zulian 5 ,<br />

1<br />

Anna Meyer Children’s Hospital, Florence, Italy, 2 Department<br />

<strong>of</strong> Medical and Surgical Specialties, Section <strong>of</strong> Otolaryngology,<br />

University <strong>of</strong> Padua, Italy, 3 Department <strong>of</strong> Pediatrics, University<br />

<strong>of</strong> Florence, Italy, 4 Department <strong>of</strong> Pediatrics, University <strong>of</strong><br />

Padua, Italy, 5 Universita Di Padova, Padova, Italy, 6 University <strong>of</strong><br />

Firenze, Firenze, Italy.<br />

1676. Decreased Vitamin D Levels in Children and Adolescents<br />

with Systemic Lupus Erythematosus. Octavio Augusto Bedin<br />

Peracchi 1 , Regina Viviane Munekata 2 , Maria Teresa Ramos<br />

Ascensão Terreri 2 , Roseli Oselka Sacardo Sarni 2 , Marise Lazaretti 2<br />

and Maria Odete Esteves Hilario 2 , 1 Universidade Federal de São<br />

Paulo, São Paulo, Brazil, 2 Universidade Federal de São Paulo,<br />

Brazil.<br />

1677. Does Atorvastatin Reduce Progression <strong>of</strong> Carotid Intimal<br />

Medial Thickening (CIMT) in Childhood SLE? Results from the<br />

Atherosclerosis Prevention in Pediatric Lupus (APPLE) Trial: A<br />

Multicenter, Randomized, Double-Blind Placebo-Controlled<br />

Study. Laura E. Schanberg 3 , Christy I. Sandborg 4 , Huiman X.<br />

Barnhart 3 , Stacy P. Ardoin 2 , Eric Yow 3 , Gregory W. Evans 5 , Kelly<br />

L. Mieszkalski 3 , Normal T. Ilowite 2 , Anne Eberhard 2 , Lisa F.<br />

Imundo 1 , Yukiko Kimura 2 , Emily Von Scheven 2 , Earl Silverman 2 ,<br />

Suzanne L. Bowyer 2 , Lynn Punaro 2 , Nora G. Singer 2 , David D.<br />

Sherry 2 , Deborah McCurdy 2 , Marisa Klein-Gittelman 2 , Carol<br />

A. Wallace 2 , Richard Silver 2 , Linda Wagner-Weiner 2 , Gloria C.<br />

Higgins 2 , Hermine I. Brunner 2 , Lawrence Jung 2 , Jennifer B. Soep 2 ,<br />

Ann Reed 2 , Charles Tegler 6 and APPLE Investigators 2 , 1 Childhood<br />

Arthitis and <strong>Rheumatology</strong> Research Alliance, New York, NY,<br />

2<br />

Childhood Arthritis and <strong>Rheumatology</strong> Research Alliance,<br />

CARRA, 3 Duke Univ Medical Center, Durham, NC, 4 Stanford<br />

Medical Center, Stanford, CA, 5 Wake Forest Univ, 6 Wake Forest<br />

University.<br />

1678. Environmental Factors Preceding Illness Onset Differ<br />

in Phenotypes <strong>of</strong> the Juvenile Idiopathic Inflammatory<br />

Myopathies. Lisa G. Rider 11 , Lan Wu 12 , Gulnara Mamyrova 4 ,<br />

David D. Sherry 13 , Maria D. Perez 9 , Carol A. Wallace 14 , Lisa F.<br />

Imundo 6 , Catherine A. Bingham 3 , Lawrence S. Zemel 1 , Carol B.<br />

Lindsley 8 , Rafael F. Rivas-Chacon 7 , Patience H. White 11 , Robert<br />

Rennebohm 12 , Michael Henrickson 10 , Ira N. Targ<strong>of</strong>f 5 , Frederick<br />

W. Miller 2 and Childhood Myositis Heterogeneity Study<br />

Group 12 , 1 Connecticut Childrens Med Ctr, Hartford, CT, 2 National<br />

Institute <strong>of</strong> Environmental Health Sciences, NIH, Kennsington,<br />

MD, 3 NIEHS, NIH, Zionsville, PA, 4 NIEHS, NIH, Washington, DC,<br />

5<br />

NIEHS, NIH, Oklahoma City, OK, 6 NIEHS, NIH, New York, NY,<br />

7<br />

NIEHS, NIH, Miami, FL, 8 NIEHS, NIH, Kansas City, KS, 9 NIEHS,<br />

NIH, Houston, TX, 10 NIEHS, NIH, Cincinnati, OH, 11 NIEHS, NIH,<br />

Bethesda, MD, 12 NIEHS, NIH, 13 The Children’s Hospital <strong>of</strong><br />

Philadelphia, Philadelphia, PA, 14 University <strong>of</strong> Washington and<br />

Seattle Childerns’s Hospital, Seattle, WA.<br />

1679. High Prevalence <strong>of</strong> Inflammatory Myositis in Patients with<br />

Pediatric Systemic Lupus Erythematosus in a Southeastern<br />

US State. Jessica L. Record 3 , Timothy Beukelman 2 and Randy<br />

Q. Cron 1 , 1 Children’s Hospital <strong>of</strong> Alabama, Birmingham,<br />

AL, 2 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />

3<br />

University <strong>of</strong> Alabama-Birmingham, Birmingham, AL.<br />

1680. Infliximab for the Treatment <strong>of</strong> Intravenous Immunoglobulin<br />

Resistant Kawasaki Disease in Chinese Children. F. Q. Wu 1 ,<br />

X. M. Hu 2 , Y. L. Zhang 2 and L. P. Yang 2 , 1 Capital Institute <strong>of</strong><br />

Pediatrics, Beijing, China, 2 Capital Institute <strong>of</strong> Pediatrics.<br />

1681. Juvenile Fibromyalgia: Responsiveness <strong>of</strong> Tools, Greatest Areas<br />

<strong>of</strong> Impairment, and Impact <strong>of</strong> an Aerobic Exercise Program.<br />

Nadia J. C. Luca 2 , Brian M. Feldman 3 , Larisa Tshantshapanyan 4 ,<br />

Lusine Abrahamyan 4 , Samantha Stephens 4 , Nicolette Bradley 4 ,<br />

Jane Schneiderman 4 , Virginia Wright 1 and Shirley M. L. Tse 3 ,<br />

1<br />

Bloorview Kids Rehab, Bloorview Research Institute, 2 Hospital<br />

for Sick Children, Toronto, ON, Canada, 3 The Hospital for Sick<br />

Children, Toronto, ON, Canada, 4 The Hospital for Sick Children.<br />

1682. Juvenile Localized Scleroderma <strong>of</strong> the Face: A Neuro-<br />

Cutaneous Disease? Francesco Zulian 2 , Mattia Parolin 3 , Fabio<br />

Vittadello 3 , Milena Calderone 3 , Giorgia Martini 3 and Susanne<br />

Ullman 1 , 1 Bispebjerg Hospital, Copenhagen, Denmark,<br />

2<br />

University <strong>of</strong> Padua, Padova, Italy, 3 University <strong>of</strong> Padua.<br />

1683. Localized Scleroderma Therapy: When Would Be a Good Time<br />

To Stop? Thaschawee Arkachaisri 1 and Kathryn S. Torok 2 , 1 KK<br />

Women’s and Children’s Hosp, Singapore, Singapore, 2 Univ <strong>of</strong><br />

Pittsburgh Med Ctr, Pittsburgh, PA.<br />

1684. Longitudinal Study on Growth Failure and Height Deflection<br />

in Juvenile Systemic Lupus Erythematosus (JSLE): The Result<br />

<strong>of</strong> a Prospective Multicentre PRINTO Study. Marite Rygg 3 ,<br />

Angela Pistorio 3 , Angelo Ravelli 3 , Mohamad Maghnie 3 , Natascia<br />

Di Iorgi 3 , Erkan Demirkaya 3 , Srdjan Pasic 3 , Huri Ozdogan 3 ,<br />

Brigitte Bader-Meunier 3 , Carlos Henrique M. Da Silva 3 , Liora<br />

Harel 3 , Maria Rosa Roldan Molina 3 , Helena Canhao 3 , Johannes<br />

Roth 3 , Carine Wouters 3 , Judith Barash 3 , Rym Hajri Ben Ammar 3 ,<br />

Christina Dracou 3 , Sylvie Gandon-Laloum 3 , Alberto Martini 2 and<br />

Nicolino Ruperto 1 , 1 IRCCS G. Gaslini/Università degli Studi di<br />

Genova, Genova, Italy, 2 IRCCS G. Gaslini/Università degli Studi di<br />

Genova, 3 PRINTO.<br />

2010 Program Book 249


ACR/ARHP Poster Session C<br />

250<br />

1685. Long-Term Follow Up <strong>of</strong> Hyper IgD Syndrome: A National<br />

Multicentre Study. Silvia Federici 8 , Alberto Tommasini 6 ,<br />

Antonella Meini 7 , Giuseppina Calcagno 5 , Francesco Zulian 2 ,<br />

Rita Consolini 3 , Martina Finetti 8 , Luciana Breda 1 , Roberta<br />

Caorsi 8 , Romina Gallizzi 5 , Maria Alessio 4 , Alberto Martini 8 and<br />

Marco Gattorno 8 , 1 Clinica Pediatrica, Divisione Reumatologia<br />

Pediatrica, Ospedale Policlinico di Chieti, 2 Dipartimento A.I.<br />

di Pediatria, Università di Padova, 3 Dipartimento di Medicina<br />

della Procreazione e dell’Eta’ Evolutiva, Università di Pisa,<br />

Italy, 4 Dipartimento di Pediatria, Università Federico II, Napoli,<br />

Italy, 5 Dipartimento di Scienze Pediatriche, AOU “G. Martino”,<br />

Messina, 6 IRCCS Burlo Gar<strong>of</strong>olo, Trieste, 7 Unità di Immunologia e<br />

Reumatologia Pediatrica, Spedali Civili, Brescia, 8 UO Pediatria II<br />

Istituto G. Gaslini, Genova, Italy.<br />

1686. Measuring Changes in Calcifications in Juvenile<br />

Dermatomyositis (JDM) Using Single Slice Computerized<br />

Tomography (CT). Maria F. Ibarra 5 , Cynthia Rigsby 3 , Gabrielle<br />

Morgan 2 , Deli Wang 1 and Lauren M. Pachman 4 , 1 Children’s<br />

Memorial Research Center’s Biostatistics Core, Chicago, IL,<br />

2<br />

Clinical Immunology, Children’s Memorial Research Center<br />

(CMRC), Chicago, IL, 3 Division <strong>of</strong> Radiology, Children’s Memorial<br />

Hospital (CMH), Feinberg School <strong>of</strong> Medicine, Northwestern<br />

University, Chicago, IL, 4 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, Children’s Memorial Research Center (CMRC),<br />

Feinberg School <strong>of</strong> Medicine, Northwestern University, Chicago,<br />

IL, 5 Division <strong>of</strong> <strong>Rheumatology</strong>, Children’s Memorial Hospital<br />

(CMH), Feinberg School <strong>of</strong> Medicine, Northwestern University,<br />

Chicago, IL.<br />

1687. Odontostomatologic Involvement in Juvenile Localized<br />

Scleroderma <strong>of</strong> the Face. Sabina Trainito 5 , Troels Herlin 4 ,<br />

Thomas Klit Pedersen 3 , Giorgia Martini, Chiara Scibetta 2 ,<br />

Giuseppe Fioretti, Vittorio Favero, Stefano Puggina 6 , Lorenzo<br />

Favero and Francesco Zulian 1 , 1 Padova, Italy, 2 Department<br />

<strong>of</strong> Dentistry, Gnatology Unit, University <strong>of</strong> Padova, Italy,<br />

3<br />

Department <strong>of</strong> Orthodontics and Radiology, University <strong>of</strong><br />

Aarhus, Denmark, 4 Department <strong>of</strong> Pediatrics, <strong>Rheumatology</strong><br />

Unit, University <strong>of</strong> Aarhus, Denmark, 5 Department <strong>of</strong> Pediatrics,<br />

<strong>Rheumatology</strong> Unit, University <strong>of</strong> Padova, Padova, Italy,<br />

6<br />

Radiology Institute, University <strong>of</strong> Padova, Italy.<br />

1688. Preliminary Criteria for Global Disease Flares in Juvenile<br />

Systemic Lupus Erythematosus (jSLE). Rina Mina 8 , Michael<br />

Beresford 12 , B. Anne Eberhard 13 , Edward H. Giannini 3 , Deborah<br />

M. Levy 15 , Clarissa Pilkington 10 , Marilynn G. Punaro 14 , Angelo<br />

Ravelli 11 , Andreas O. Reiff 2 , Claudia Saad-Magalhaes 16 , Laura E.<br />

Schanberg 9 , Lori B. Tucker 1 , Marisa S. Klein-Gitelman 4 , Shannen<br />

L. Nelson 6 , Jamie Eaton 5 , Jun Ying 17 and Hermine I. Brunner 7 ,<br />

1<br />

BC Childrens Hospital, Vancouver, BC, Canada, 2 Childrens Hosp<br />

LA MS 60 , Los Angeles, CA, 3 Childrens Hosp Med Ctr, Cincinnati,<br />

OH, 4 Childrens Mem Hosp/NW Univ, Chicago, IL, 5 Cincinnati<br />

Children’s Hospital, 6 Cincinnati Children’s Hospital, Cincinnati,<br />

OH, 7 Cincinnati Children’s Hospital Medical Ctr, Cincinnati,<br />

OH, 8 Cincinnati Children’s Med Ctr, Cincinnati, OH, 9 Duke Univ<br />

Medical Center, Durham, NC, 10 Great Ormond Street and<br />

University <strong>College</strong> London Hospitals, 11 IRCCS G Gaslini, 12 Royal<br />

Liverpool Children’s Hospital, 13 Schneider Children’s Hospital,<br />

New Hyde Park, NY, 14 Texas Scottish Rite Hospital for Children,<br />

Dallas, TX, 15 The Hospital for Sick Children, Toronto, ON, Canada,<br />

16<br />

UNESP, 17 University <strong>of</strong> Cincinnati.<br />

2010 Program Book<br />

1689. Preliminary Findings <strong>of</strong> Functional Magnetic Resonance<br />

Imaging (fMRI) Assessments <strong>of</strong> Specific Cognitive Domains<br />

in Childhood-Onset Systemic Lupus Erythematosus (cSLE)<br />

Patients and Best-Friend Controls. Blair Dina 3 , Aimee Baker 4 ,<br />

Anna Carmela Sagcal-Gironella 4 , Marisa Klein-Gitelman 3 , Frank<br />

Zelko 5 , Dean Beebe 1 , Darren Gitelman 6 , Mark DiFrancesco 2 and<br />

Hermine Brunner 4 , 1 CCHMC Division <strong>of</strong> Behavioral Medicine and<br />

Child Psychology, 2 CCHMC Neuroimaging Research Consortium,<br />

3<br />

Children’s Memorial Hospital (CMH) Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

4<br />

Cincinnati Children’s Hospital Medical Center (CCHMC), Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, 5 CMH Division <strong>of</strong> Child and Adolescent<br />

Psychiatry, 6 Northwestern University, Feinberg School <strong>of</strong><br />

Medicine.<br />

1690. Pre-Pubertal Onset Systemic Lupus Erythematosus in Girls:<br />

Clinical and Serologic Manifestations Differ from Post-Pubertal<br />

Onset SLE. Kathleen M. O’Neil 4 , Lauren M. Kickingbird 7 , Andrew<br />

S. Zeft 8 , Hermine Brunner 2 , Marilynn G. Punaro 5 , Barry L.<br />

Myones 1 , Suzanne C. Li 3 and Tracey Wright 6 , 1 Baylor <strong>College</strong><br />

<strong>of</strong> Medicine, Houston, TX, 2 Cincinnati Child Hosp Med Ctr,<br />

Cincinnati, OH, 3 Hackensack University Medical Center, Short<br />

Hills, NJ, 4 OU Health Science Center, Oklahoma City, OK, 5 Texas<br />

Scottish Rite Hospital, Dallas, TX, 6 Univ <strong>of</strong> TX Southwestern,<br />

Dallas, TX, 7 University <strong>of</strong> Oklahoma Health Sciences Center,<br />

Oklahoma City, OK, 8 University <strong>of</strong> Utah, Salt Lake City, UT.<br />

1691. Relative Performance <strong>of</strong> Two Validated Classification Systems<br />

for Wegener’s Granulomatosis among Patients with ANCA-<br />

Associated Vasculitis (AAV) in a Registry for Children with<br />

Vasculitis: e-entry (ARChiVe). America G. Uribe 3 , David A.<br />

Cabral 3 , Kimberly Morishita 2 , Leslie S. Abramson 38 , Matthew<br />

D. Adams 6 , Kevin W. Baszis 30 , Susanne M. Benseler 32 , Sarah<br />

S. C. Campillo 22 , Peter Chira 31 , B. Anne Eberhard 29 , Kaleo C.<br />

Ede 26 , Aimee O. Hersh 34 , Gloria C. Higgins 23 , Lisa F. Imundo 10 ,<br />

Rita S. Jerath 12 , Susan Kim 8 , Daniel J. Kingsbury 18 , Marisa S.<br />

Klein-Gitelman 13 , Suzanne C. Li 17 , Daniel J. Lovell 9 , Thomas G.<br />

Mason 20 , Deborah K. McCurdy 19 , Renee F. Modica 35 , Lakshmi N.<br />

Moorthy 28 , Eyal Muscal 1 , Lorien A. Nassi 33 , Kathleen M. O’Neil 24 ,<br />

Egla C. Rabinovich 15 , Suzanne E. Ramsey 16 , Andreas O. Reiff 7 ,<br />

Margalit E. Rosenkranz 11 , Kenneth N. Schikler 36 , Nora G. Singer 21 ,<br />

Anne M. Stevens 25 , Mary B. Toth 5 , Linda Wagner-Weiner 14 , Dawn<br />

M. Wahezi 4 , Amy L. Woodward 27 , Andrew S. Zeft 37 and ARChiVe<br />

Investigators <strong>of</strong> CARRA, 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston,<br />

TX, 2 BC Children’s Hospital, 3 BC Children’s Hospital, Vancouver,<br />

BC, Canada, 4 Children’s Hospital at Montefiore, Bronx, NY,<br />

5<br />

Children’s Hospital Med Ctr, Akron, OH, 6 Children’s Hospital<br />

<strong>of</strong> Michigan, Huntington Woods, MI, 7 Childrens Hosp LA MS 60 ,<br />

Los Angeles, CA, 8 Childrens Hospital Boston, Boston, MA,<br />

9<br />

Childrens Hospital Medical Center, Cincinnati, OH, 10 Childrens<br />

Hospital <strong>of</strong> NY, New York, NY, 11 Childrens Hospital <strong>of</strong> Pittsburgh,<br />

Pittsburgh, PA, 12 Childrens Med Ctr Med Schl GA, Augusta, GA,<br />

13<br />

Childrens Mem Hosp/NW Univ, Chicago, IL, 14 Corner Children’s<br />

Hospital, Chicago, IL, 15 Duke University Medical Center, Durham,<br />

NC, 16 IWK Health Ctr, Halifax, NS, Canada, 17 Joseph M Sanzari<br />

Children’s Hospital, Short Hills, NJ, 18 Legacy Emanuel Children’s<br />

Hosp, Portland, OR, 19 Mattel Children’s UCLA, Los Angeles, CA,<br />

20<br />

Mayo Clinic Rochester, Rochester, MN, 21 MetroHealth Medical<br />

Center, Cleveland, OH, 22 Montreal Children’s Hospital, Montreal,<br />

QC, Canada, 23 Nationwide Childrens Hosp, Columbus, OH, 24 OU<br />

Health Science Center, Oklahoma City, OK, 25 Pediatrics, U. <strong>of</strong><br />

Washington, Seattle, WA, 26 Phoenix Children’s Hospital, Phoenix,<br />

AZ, 27 Riley Children’s Hospital, Nashville, TN, 28 Robert Wood<br />

Johnson Medical School, Metuchen, NJ, 29 Schneider Children’s<br />

Hospital, New Hyde Park, NY, 30 St. Louis Children’s Hospital,<br />

St Louis, MO, 31 Stanford Univ Schl <strong>of</strong> Med, Stanford, CA, 32 The<br />

Hospital for Sick Children, Toronto, ON, Canada, 33 TX Scottish<br />

Rite Hosp, Dallas, TX, 34 UCSF, San Francisco, CA, 35 University <strong>of</strong><br />

Florida, Orlando, FL, 36 University <strong>of</strong> Louisville SOM, Louisville, KY,<br />

37<br />

University <strong>of</strong> Utah, Salt Lake City, UT, 38 University <strong>of</strong> Vermont,<br />

Morrisville, VT.


ACR/ARHP Poster Session C<br />

1692. Resistance to Annexin A5 Anticoagulant Activity in<br />

Children with Rheumatic Disease Correlates with Persistent<br />

Antiphospholipid Antibodies and Thrombosis. Dawn M.<br />

Wahezi 4 , Jacob H. Rand 2 , Swapnil Rajpathak 3 and Norman<br />

T. Ilowite 1 , 1 Children’s Hospital Montefiore, Bronx, NY,<br />

2<br />

Department <strong>of</strong> Pathology, Hematology Laboratories,<br />

Montefiore Medical Center, Bronx, NY, 3 Departments <strong>of</strong><br />

Medicine, Epidemiology and Population Health, Albert Einstein<br />

<strong>College</strong> <strong>of</strong> Medicine, 4 Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>,<br />

Children’s Hospital at Montefiore, Bronx, NY.<br />

1693. Safety and Efficiency <strong>of</strong> Rituximab in Juvenile<br />

Dermatomyositis: A Series <strong>of</strong> Eight Cases from the French AIR<br />

Registry. Brigitte Bader-Meunier 3 , Helene Decaluwe 5 , Pierre<br />

Quartier 3 , Albert Faye 4 , Vincent Guigonis 1 , Anne Pagnier 2 ,<br />

Christine Barnerias 3 , Jacques E. Gottenberg 6 and Christine<br />

Bodemer 3 , 1 Dupuytren Hospital, 2 Grenoble Hospital, 3 Necker<br />

Hospital, 4 Robert Debre Hospital, 5 Sainte Justine Hospital,<br />

6<br />

Strasbourg Hospitals, Strasbourg, France.<br />

1694. Safety and Immunogenicity <strong>of</strong> Influenza Vaccine (FluVac) in<br />

Patients with Juvenile Systemic Lupus Erythematosus (JSLE).<br />

Luciana M. de Carvalho 2 , Rodrigo V. D. Silvestre 1 , Wyller A.<br />

Mello 1 and Virginia P. L. Ferriani 2 , 1 Evandro Chagas Institute<br />

(WHO National Influenza Center), Ananindeua, Brazil, 2 School<br />

<strong>of</strong> Medicine <strong>of</strong> Ribeirão Preto, University <strong>of</strong> São Paulo, Ribeirão<br />

Preto, Brazil.<br />

1695. Serum Tumor Necrosis Factor alfa (TNFα) Is Associated with<br />

Disease Activity in Juvenil Systemic Lupus Erythematosus<br />

(jSLE). Mariana Postal, Karina Pereira, Karina Peliçari, Barbara<br />

Longhi, Roberto Marini, Lilian T. L. Costallat and Simone<br />

Appenzeller, State University <strong>of</strong> Campinas.<br />

1696. Study <strong>of</strong> the Growth and Body Mass Index (BMI) <strong>of</strong> 86<br />

Children with Familial Mediterranean Fever (FMF): Results <strong>of</strong><br />

the French Referral Centre for Auto-Inflammatory Diseases<br />

(CeReMAI). Aurelie Klein 1 , Alexia Letierce 1 , Anuela Kondi 1 ,<br />

Veronique Hentgen 2 , Isabelle Kone-Paut 1 and Severine<br />

Guillaume-Czitrom 1 , 1 Bicetre University Hospital, Le Kremlin<br />

Bicetre, France, 2 Versailles Hospital, Versailles, France.<br />

1697. The Disease Presentation and Outcome in Juvenile Behcet’s<br />

Syndrome. Emire Seyahi 3 , Huri Ozdogan 3 , Yilmaz Ozyazgan 2 ,<br />

Serdal Ugurlu 3 , Yesim Ozguler 1 , Gulen Hatemi 3 , Hasan Yazici 3<br />

and Sebahattin Yurdakul 3 , 1 Cerrahpasa Medical Faculty,<br />

Internal Medicine Department, 2 Cerrahpasa Medical Faculty,<br />

Ophtalmology Department, 3 Cerrahpasa Medical Faculty,<br />

<strong>Rheumatology</strong> Department.<br />

1698. The Role <strong>of</strong> Montelukast in the Management <strong>of</strong><br />

Hyperimmunoglobulinemia D with Periodic Fever Syndrome<br />

(HIDS). Donald P. Goldsmith 2 , Karyl S. Barron 1 , Anne Jones 1 ,<br />

Dawn Chapelle 1 , Beverly Barham 1 , Robert Lembo 1 , Eric Hanson 1 ,<br />

Amanda Ombrello 1 , Deborah Stone 1 and Daniel L. Kastner 3 ,<br />

1<br />

National Institutes <strong>of</strong> Health, Bethesda, MD, 2 National<br />

Institutes <strong>of</strong> Health, Drexel University <strong>College</strong> <strong>of</strong> Medicine,<br />

Philadelphia, PA, 3 NIAMS, NIH, Bethesda, MD.<br />

1699. The Use <strong>of</strong> Lenalidomide for Cutaneous Manifestations <strong>of</strong> SLE.<br />

Eveline Wu, Laura E. Schanberg, Heather VanMater and Egla C.<br />

Rabinovich, Duke University Medical Center, Durham, NC.<br />

1700. Therapeutic Approaches for the Treatment <strong>of</strong> Active Juvenile<br />

Dermatomyositis: An International Multicenter Study. Rachana<br />

Hasija 3 , Angela Pistorio 3 , Angelo Ravelli 3 , Erkan Demirkaya 3 , Raju<br />

Khubchandani 3 , Dinara Guseinova 3 , Clara Malattia 3 , Carmen<br />

De Cunto 3 , Tomas Brent Graham 3 , Kathleen Haines 3 , Christian<br />

Huemer 3 , Yukiko Kimura 3 , Harald Mangge 3 , Silvana Martino 3 ,<br />

Carlo Minetti 3 , Ellen Berit Nordal 3 , Pierre Philippet 3 , Manuel<br />

Salgado 3 , Alberto Martini 2 and Nicolino Ruperto 1 , 1 IRCCS G.<br />

Gaslini/Università degli Studi di Genova, Genova, Italy, 2 IRCCS G.<br />

Gaslini/Università degli Studi di Genova, 3 PRINTO.<br />

1701. Towards Defining Clinical Remission in Juvenile Systemic Lupus<br />

Erythematosus (jSLE). Rina Mina 5 , Laura E. Schanberg 6 , B. Anne<br />

Eberhard 14 , Marisa S. Klein-Gitelman 3 , Gloria C. Higgins 12 , Karen<br />

Onel 17 , Nora G. Singer 11 , Kathleen M. O’Neil 13 , Lori B. Tucker 1 ,<br />

Lisa F. Imundo 2 , Emily Von Scheven 16 , Shannen L. Nelson 4 , Frank<br />

Dressler 10 , Ruben Cuttica 7 , Claudia Saad Magalhães 15 , Angelo<br />

Ravelli 9 , Alberto Martini 8 and Hermine I. Brunner 5 , 1 BC Childrens<br />

Hospital, Vancouver, BC, Canada, 2 Childrens Hospital <strong>of</strong> NY, New<br />

York, NY, 3 Childrens Mem Hosp/NW Univ, Chicago, IL, 4 Cincinnati<br />

Children’s Hospital, Cincinnati, OH, 5 Cincinnati Children’s Med<br />

Ctr, Cincinnati, OH, 6 Duke Univ Medical Center, Durham, NC,<br />

7<br />

Hospital General de Ninos Pedro de Elizalde, Buenos Aires,<br />

Argentina, 8 IRCCS G Gaslini, Genova, Italy, 9 IRCCS G Gaslini,<br />

10<br />

Medizinische Hochschule, Hannover, Germany, 11 MetroHealth<br />

Medical Center, Cleveland, OH, 12 Nationwide Childrens Hosp,<br />

Columbus, OH, 13 OU Health Science Center, Oklahoma City, OK,<br />

14<br />

Schneider Children’s Hospital, New Hyde Park, NY, 15 UNESP,<br />

16<br />

Univ <strong>of</strong> Calif San Francisco, San Francisco, CA, 17 Univ <strong>of</strong><br />

Chicago, Chicago, IL.<br />

1702. Towards the Development <strong>of</strong> Standardized Treatment<br />

Protocols for Proliferative Nephritis in Juvenile Systemic Lupus<br />

Erythematosus (jSLE). Rina Mina 6 , Hermine Brunner 5 , B. Anne<br />

Eberhard 12 , Marilynn G. Punaro 14 , Stacy P. Ardoin 10 , Marisa S.<br />

Klein-Gitelman 4 , Joyce J. Hsu 13 , Lakshmi N. Moorthy 11 , Linda<br />

Wagner-Weiner 8 , Eyal Muscal 1 , Suhas M. Radhakrishna 2 , Jenny<br />

Palter 9 , Laura Schanberg 7 , Carol A. Wallace 16 , Norman T. Ilowite 3 ,<br />

Emily Von Scheven 15 and for the CARRA Lupus Disease-Specific<br />

Group, 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 Children’s<br />

Hospital Los Angeles, Los Angeles, CA, 3 Children’s Hospital<br />

Montefiore, Bronx, NY, 4 Childrens Mem Hosp/NW Univ, Chicago,<br />

IL, 5 Cincinnati Child Hosp Med Ctr, Cincinnati, OH, 6 Cincinnati<br />

Children’s Med Ctr, Cincinnati, OH, 7 Duke Medical Center,<br />

Durham, NC, 8 La Rabida Children’s Hospital, Chicago, IL, 9 Lupus<br />

Foundation, 10 Ohio State University, Columbus, OH, 11 Robert<br />

W Johnson University, Metuchen, NJ, 12 Schneider Children’s<br />

Hospital, New Hyde Park, NY, 13 Stanford University, Stanford,<br />

CA, 14 Texas Scottish Rite Hospital for Children, Dallas, TX,<br />

15<br />

Univ <strong>of</strong> Calif San Francisco, San Francisco, CA, 16 University <strong>of</strong><br />

Washington and Seattle Childerns’s Hospital, Seattle, WA.<br />

1703. Trends in Incidence and Drug Therapy <strong>of</strong> Complex Regional<br />

Pain Syndrome in Children’s Hospitals across the U.S. Cara<br />

M. H<strong>of</strong>fart 1 , Pamela F. Weiss 2 , Andrew J. Klink 2 , D. D. Sherry 2<br />

and Chris Feudtner 2 , 1 The Children’s Hospital <strong>of</strong> Philadelphia,<br />

Philadelphia, PA, 2 The Children’s Hospital <strong>of</strong> Philadelphia.<br />

1704. Update on the Juvenile Systemic Sclerosis Inception Cohort.<br />

Ivan Foeldvari 2 , Angela Wierk 1 , Claudie Len 8 , Maria Martha<br />

Katsicas 4 , Avcin Tadey 6 , Till Kallinich 7 , Isabelll Kone-Paut 9 , Kirsten<br />

Minden 7 , Luc Mouthon 10 , Juergen Brunner 5 and Yuoef Uziel 3 ,<br />

1<br />

Hamburger Zentrum Für Kinder- und Jugenrheumatologie,<br />

Hamburg, Germany, 2 Hamburger Zentrum Fuer Kinder- und<br />

Jugendrheumatologie, Hamburg, Germany, 3 Universitiy<br />

Childrens Hospital, Israel, 4 Universitiy Childrens Hosptial, Brazil,<br />

5<br />

Universitiy Childrens Hosptial, Austria, 6 University Childrens<br />

Hospital, Slovenia, 7 University Childrens Hospital, Germany,<br />

8<br />

University Childrens Hospital, Brazil, 9 University Childrens<br />

Hosptial, France, 10 University Hospital, France.<br />

1705. Validation <strong>of</strong> Birmingham Vasculitis Activity Score in Childhood<br />

Vasculitis. Erkan Demirkaya 1 , Seza Ozen 3 , Angela Pistorio 3 ,<br />

Angelo Ravelli 3 , Rachana Hasija 3 , Raju Khubchandani 3 , Salvatore<br />

Scarpato 3 , Michel Fischbach 3 , Nicolae Iagaru 3 , Srdjan Pasic 3 , Esra<br />

Baskin 3 , Frank Dressler 3 , Marion A. J. van Rossum 3 , Julia García-<br />

Consuegra 3 , Maria Teresa Apaz 3 , Maka Ioseliani 3 , Henryka<br />

Mazur-Zielinska 3 , Alberto Martini 2 , Roberta Galasso 3 , Nicolino<br />

Ruperto 2 and Pavla Dolezalova 3 , 1 IRCCS G. Gaslini, Genova, Italy,<br />

2<br />

IRCCS G. Gaslini/Università degli Studi di Genova, 3 PRINTO.<br />

2010 Program Book 251


ACR/ARHP Poster Session C<br />

1706. Validation <strong>of</strong> the Newly Developed Pediatric Criteria for<br />

the Diagnosis <strong>of</strong> Familiar Mediterranean Fever in a Large<br />

Pediatric Cohort <strong>of</strong> Western European Children with Periodic<br />

Fever. Silvia Federici 7 , Giuseppina Calcagno 5 , Martina Finetti 7 ,<br />

Antonella Meini 6 , Agata Vitale 5 , Marco Cattalini 6 , Roberta<br />

Caorsi 7 , Francesco Zulian 1 , Alberto Tommasini 3 , Maurizia Baldi 2 ,<br />

Joost Frenkel 8 , Isabella Ceccherini 4 , Alberto Martini 7 and Marco<br />

Gattorno 7 , 1 Dipartimento A.I. di Pediatria, University <strong>of</strong> Padua,<br />

2<br />

Dipartmento di Genetica Umana, Ospedale Galliera, Genoa,<br />

3<br />

IRCCS Burlo Gar<strong>of</strong>olo, Trieste, 4 Lab Genetica Molecolare Istituto<br />

G. Gaslini, Genoa, Italy, 5 Sezione di Reumatologia Pediatrica,<br />

Dipartimento di Scienze Pediatriche, AOU “G. Martino”,<br />

Messina, 6 Unità di Immunologia e Reumatologia Pediatrica,<br />

Spedali Civili, Brescia, 7 UO Pediatria II Istituto G. Gaslini, Genoa,<br />

Italy, 8 Wilhelmina Children’s Hospital, Utrecht, The Netherlands.<br />

Rheumatoid Arthritis - Animal Models: Pathogenesis, Novel<br />

Targets and Technology<br />

1707. (22-52)adrenomedullin Shifts Cytokine Balance from Th1 to<br />

Th2, Reduces IL-17A Expressions and Modulates Treg Cells in<br />

Collagen-Induced Arthritis. Marie-Dominique Ah Kioon 5 , Carine<br />

Asensio 5 , Korng Ea 5 , Sandrine Rullé 1 , Géraldine Falgarone 1 ,<br />

Corinne Collet 4 , Jean-Marie Launay 3 and Frederic P. Liote 2 ,<br />

1<br />

EA 4222, Paris 13 University, Bobigny, France, Metropolitan,<br />

2<br />

Hopital Lariboisiere, Paris, France, 3 Paris 5 University, Paris,<br />

France, Metropolitan, 4 Paris 5 University, Bobigny, France,<br />

Metropolitan, 5 UMR-S606 Inserm, Paris Diderot University,<br />

Paris, France, Metropolitan.<br />

1708. A New Humanized Mouse Model for Experimental Erosive<br />

Arthritis: A Possible Role <strong>of</strong> Epstein-Barr Virus (EBV) for<br />

Experimental Erosive Arthritis That Resembles Rheumatoid<br />

Arthritis (RA). Yoshikazu Kuwana 5 , Masami Takei 5 , Misako<br />

Yajima 3 , Hirotake Inomata 6 , Masaaki Shiozaki 7 , Natsumi Ikumi 7 ,<br />

Takamasa Nozaki 7 , Hidetaka Shiraiwa 7 , Noboru Kitamura 7 ,<br />

Shigemasa Sawada 7 , Hiroyuki Masuda 7 , Naoki Yamamoto 3 ,<br />

Norio Shimizu 4 , Mamoru Ito 1 , Ken-ichi Imadome 2 and Shigeyoshi<br />

Fujiwara 2 , 1 Central Institute for Experimental Animals, Kawasaki,<br />

Japan, 2 Department <strong>of</strong> Infectious Diseases, National Research<br />

Institute for Child Health and Development, Tokyo, Japan,<br />

3<br />

Department <strong>of</strong> Microbiology, Yong Loo Lin School <strong>of</strong> Medicine,<br />

National University <strong>of</strong> Singapore, Singapore, 4 Department<br />

<strong>of</strong> Virology, Division <strong>of</strong> Medical Science, Medical Research<br />

Institute, Tokyo Medical and Dental University, Tokyo, Japan,<br />

5<br />

Division <strong>of</strong> Hematology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Medicine, Nihon University School <strong>of</strong> Medicine, Itabashi Tokyo,<br />

Japan, 6 Division <strong>of</strong> Hematology and <strong>Rheumatology</strong>, Department<br />

<strong>of</strong> Medicine, Nihon University School <strong>of</strong> Medicine, Itabashi<br />

Tokyo, Japan, 7 Division <strong>of</strong> Hematology and <strong>Rheumatology</strong>,<br />

Department <strong>of</strong> Medicine, Nihon University School <strong>of</strong> Medicine,<br />

Tokyo, Japan.<br />

1709. ASC Plays a Role in the Priming Phase <strong>of</strong> the Immune Response<br />

to Type II Collagen in Collagen-Induced Arthritis. Hideshi<br />

Yamazaki 1 , Michiko Takeoka 1 , Masato Kitazawa 1 , Takashi Ehara 2 ,<br />

Naoki Itano 1 , Hiroyuki Kato 2 and Shun’ichiro Taniguchi 1 , 1 Shinshu<br />

University Graduate School <strong>of</strong> Medicine, Matsumoto, Japan,<br />

2<br />

Shinshu University School <strong>of</strong> Medicine, Matsumoto, Japan.<br />

1710. Asymmetric Arthritic Flare in the Knees <strong>of</strong> TNF-Tg Mice<br />

Is Mediated by Expansion <strong>of</strong> CD23+/CD21hi B Cells and<br />

Ipsilateral Collapse <strong>of</strong> Lymph Nodes in Series. Jie Li, Igor Kuzin,<br />

Christopher Ritchlin, Ignacio Sanz, Andrea Bottaro, Lianping Xing<br />

and Edward Schwarz, University <strong>of</strong> Rochester.<br />

1711. CD44 Involvement in Arthritis: The Role <strong>of</strong> cd44-Splice<br />

Variants in Development <strong>of</strong> Collagen-Induced Arthritis in<br />

Mice. Celia Menckeberg 3 , Marjolein van Maanen 4 , Ronald<br />

van der Neut 2 , Steven T. Pals 2 , Margriet Vervoordeldonk 3<br />

and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />

Amsterdam, The Netherlands, 2 Department <strong>of</strong> Pathology,<br />

Amsterdam, The Netherlands, 3 Division <strong>of</strong> Clinical Immunology<br />

and <strong>Rheumatology</strong>, Amsterdam, The Netherlands, 4 Division <strong>of</strong><br />

Clinical Immunoly, Amsterdam, The Netherlands.<br />

1712. Counter-Regulatory Role <strong>of</strong> Interferon Regulatory Factor 7<br />

in Serum Transfer K/BxN Inflammatory Arthritis. Susan E.<br />

Sweeney 1 and Trevor B. Kimbler 2 , 1 University <strong>of</strong> California San<br />

Diego, La Jolla, CA, 2 University <strong>of</strong> California San Diego.<br />

1713. Dectin-1 and NOD2 Mediate Zymosan-Induced Arthritis in<br />

Mice. Holly L. Rosenzweig 1 , Jenna S. Clowers 4 , Gabriel Nunez 3 ,<br />

James T. Rosenbaum 2 and Michael P. Davey 5 , 1 Oregon Health &<br />

Science University/VA Medical Ctr, Portland, OR, 2 Oregon Health<br />

Science Univ, Portland, OR, 3 University <strong>of</strong> Michigan Medical<br />

School, Ann Arbor, MI, 4 VA Medical Ctr, 5 VA Medical Ctr/Oregon<br />

Health &Science University, Portland, OR.<br />

1714. Dendritic Cell-Based Immunotherapy Combined with Low-<br />

Dose Methothrexate Is Effective in the Treatment <strong>of</strong> Advanced<br />

Collagen-Induced Arthritis in Mice. Mi-Sun Kang 4 , Jung-Wook<br />

Lee 4 , Hyun-Soo Lee 4 , Chan-Bum Choi 1 , Hye-Soon Lee 3 , Sang-<br />

Cheol Bae 2 and Yong-Soo Bae 5 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Hanyang University Hospital for Rheumatic Diseases, Seoul,<br />

Republic <strong>of</strong> Korea, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang<br />

University Hospital for Rheumatic Diseases, Seoul, Korea,<br />

Republic <strong>of</strong>, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University<br />

Hospital for Rheumatic Diseases, 4 Research Institute for DC<br />

Immunotherapy, CreaGene Inc., 5 Research Institute for DC<br />

Immunotherapy, CreaGene Inc., Department <strong>of</strong> Biological<br />

Science, Sungkyunkwan University.<br />

1715. Histone Deacetylase Inhibitor (HDAi) Ameliorates Chronic<br />

Arthritis in SKG Mice by Altering Conventional Dendritic Cells<br />

(cDCs) Phenotype into Tolerogenic DCs. Kenta Misaki 2 , Akio<br />

Morinobu 2 , Jun Saegusa 2 , Yoshiaki Miyamoto 2 , Shinpei Kasagi 2<br />

and Shunichi Kumagai 1 , 1 Clinical Immunology and Pathology,<br />

Kobe University, Kobe, Japan, 2 Clinical Immunology and<br />

Pathology, Kobe University, Japan.<br />

1716. IDO Expressed CD11c+CD11b+ Dendritic Cells Enhance the<br />

Differentiation <strong>of</strong> Ag Inducible CD4+CD25+ Regulatory T Cells<br />

in Induction <strong>of</strong> Oral Tolerance under the Inflammatory State.<br />

Min Jung Park 2 , Yong-Geun Jung 2 , Su-Jin Moon 2 , Ji-Min Kim 2 ,<br />

Seung-Ki Kwok 2 , Ji-Hyeon Ju 2 , Kyung-Su Park 2 , Hyun Sil Park 2 ,<br />

Mi-La Cho 2 , Sung-Hwan Park 2 and Ho-Youn Kim 1 , 1 Kang Nam St<br />

Marys Hospital, Seoul, Korea, Republic <strong>of</strong>, 2 Kang Nam St Marys<br />

Hospital.<br />

1717. Immunisation with Citrullinated Human and Porphyromonas<br />

Gingivalis Enolase Induces Rapid Onset Arthritis in HLA DR4<br />

Transgenic Mice. Andrew J. Kinloch 2 , William Brintnell 5 , David<br />

Yue 5 , Lillian Barra 5 , Natalia Wegner 1 , Karin Lundberg 1 , David A.<br />

Bell 3 , Ewa Cairns 4 and Patrick J. Venables 1 , 1 Imperial <strong>College</strong><br />

London, 2 Imperial <strong>College</strong> London, London, United Kingdom,<br />

3<br />

SJHC, London, ON, Canada, 4 Univ Western Ontario, London,<br />

ON, Canada, 5 University <strong>of</strong> Western Ontario.<br />

1718. JNK1 Deficiency Limits Macrophage Mediated Antigen Induced<br />

Arthritis. Monica Guma 1 , Gary S. Firestein 2 , Michael Karin and<br />

Mary Corr 2 , 1 UCSD, 2 UCSD School <strong>of</strong> Medicine, La Jolla, CA.<br />

252<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1719. Loss <strong>of</strong> Integrin alpha2beta1 Suppresses Joint Inflammation<br />

and Cartilage Destruction in Mouse Models <strong>of</strong> Rheumatoid<br />

Arthritis. Marvin A. Peters 4 , Doreen Wendholt 6 , Simon<br />

Strietholt 6 , Svetlana Frank 6 , Adelheid Korb 5 , Leo A. B. Joosten 2 ,<br />

Wim B. Van Den Berg 8 , George Kollias 7 , Elena Neumann 3 , Beate<br />

Eckes 1 , Ulf Muller-Ladner 9 and Thomas Pap 10 , 1 Department <strong>of</strong><br />

Dermatology, University <strong>of</strong> Cologne, 2 Department <strong>of</strong> General<br />

Internal Medicine, Radboud University Nijmegen Medical<br />

Centre, 3 Department <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>,<br />

Justus-Liebig-University Giessen, Kerckh<strong>of</strong>f Clinic, Bad Nauheim,<br />

Germany, 4 Department <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>,<br />

Justus-Liebig-University Giessen, Kerckh<strong>of</strong>f Clinic; Institute<br />

<strong>of</strong> Experimental Musculoskeletal Medicine, University <strong>of</strong><br />

Muenster, Bad Nauheim, Germany, 5 Department <strong>of</strong> Internal<br />

Medicine D, University <strong>of</strong> Muenster, 6 Institute <strong>of</strong> Experimental<br />

Musculoskeletal Medicine, University <strong>of</strong> Muenster, Muenster,<br />

Germany, 7 Institute <strong>of</strong> Immunology, Biomedical Sciences<br />

Research Center, 8 Radboud Univ Nijmegen Med Cntr, Nijmegen,<br />

The Netherlands, 9 Univ.Giessen/Kerckh<strong>of</strong>f-Clinic, Bad Nauheim,<br />

Germany, 10 University Hospital Münster, Münster, Germany.<br />

1720. Lung Inflammation and Pulmonary Function Alterations in<br />

Collagen-Induced Arthritis and in the Absence <strong>of</strong> Interferongamma<br />

Signaling. Evelien Schurgers 1 , Freya Mertens 2 , Jeroen<br />

Vanoirbeek 3 , Tania Mitera 2 , Stéphanie Put 2 , Benoit Nemery 3 and<br />

Patrick Matthys 2 , 1 Laboratory <strong>of</strong> Immunobiology, Rega Institute,<br />

Katholieke Universiteit Leuven, Leuven, Belgium, 2 Laboratory <strong>of</strong><br />

Immunobiology, Rega Institute, Katholieke Universiteit Leuven,<br />

Leuven, Belgium, 3 Research Unit <strong>of</strong> Lung Toxicology (Laboratory<br />

<strong>of</strong> Pneumology), Katholieke Universiteit Leuven, Leuven,<br />

Belgium.<br />

1721. Macrophage Migration Inhibitory Factor Plays an Important<br />

Role in Inflammatory Arthritis. Mohammad A. Amin 2 , Jeffrey<br />

H. Ruth 2 , Bradley J. Rabquer 2 , Phillip L. Campbell 2 , Solhee Lee 2 ,<br />

John R. David 1 and Alisa E. Koch 3 , 1 Harvard School <strong>of</strong> Public<br />

Health, 2 University <strong>of</strong> Michigan, 3 VA Medical Service and<br />

University <strong>of</strong> Michigan Medical School, Ann Arbor, MI.<br />

1722. Matrix Components Influence the Aggressive Behavior <strong>of</strong><br />

Rheumatoid Arthritis Synovial Fibroblasts. Stephanie Lefevre 2 ,<br />

Birgit Zimmermann 3 , Matthias Geyer 3 , Angela Lehr 5 , Henning<br />

Stürz 4 , Jürgen Steinmeyer 1 , Stefan Rehart 5 , Ulf Müller-Ladner 3<br />

and Elena Neumann 3 , 1 Dept Experimental Orthopedics,<br />

Justus-Liebig-University Giessen, 2 Dept Internal Medicine and<br />

<strong>Rheumatology</strong>, Justus-Liebig University Giessen, Bad Nauheim,<br />

Germany, 3 Dept Internal Medicine and <strong>Rheumatology</strong>, Justus-<br />

Liebig University Giessen, 4 Dept Orthopedics and Orthopedic<br />

Surgery, Justus-Liebig-University Giessen, 5 Dept Orthopedics<br />

and Trauma Surgery, Markus-Hospital, Frankfurt.<br />

1723. Monocytes Are Required for Progression but Not for Initiation<br />

<strong>of</strong> Arthritis in Mouse Model <strong>of</strong> Autoantibody-Mediated<br />

Arthritis. Alexander Misharin 1 , Evan Weber 1 and Harris R.<br />

Perlman 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Northwestern University,<br />

Chicago, IL, 2 Northwestern University, Chicago, IL.<br />

1724. Overexpression <strong>of</strong> RORγt Attenuated Collagen Induced<br />

Arthritis (CIA). Zhaojin Yao 2 , Yuya Kondo 2 , Masahiro Tahara 2 ,<br />

Satoru Takahashi 1 , Isao Matsumoto 2 and Takayuki Sumida 3 ,<br />

1<br />

Department <strong>of</strong> Anatomy and Embryology, Biomolecular, and<br />

Integrated Medical Sciences, Graduate School <strong>of</strong> Comprehensive<br />

Human Sciences, University <strong>of</strong> Tsukuba, 2 Division <strong>of</strong> Clinical<br />

Immunology, Major <strong>of</strong> Advanced Biochemical Applications,<br />

Graduate School <strong>of</strong> Comprehensive Human Science, University<br />

<strong>of</strong> Tsukuba, Ibaraki, Japan, 3 Univ <strong>of</strong> Tsukuba/Inst Clin Med,<br />

Tsukuba City, Japan.<br />

1725. Paradoxical Decrease in Collagen Induced Arthritis Severity in<br />

Gadd45β Deficient Mice. Yubin Luo 2 , David L. Boyle 1 and Gary S.<br />

Firestein 1 , 1 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 2 UCSD School<br />

<strong>of</strong> Medicine.<br />

1726. Protection from Collagen-Induced Arthritis in a CX3CR1-<br />

Deficient Mouse Strain. Grainne Murphy 1 , Arun Kumar 2 , Fergus<br />

Shanahan 1 , Sinead Harney 1 , Michael Molloy 1 and Noel Caplice 2 ,<br />

1<br />

Cork University Hospital, Cork, Ireland, 2 University <strong>College</strong> Cork,<br />

Cork, Ireland.<br />

1727. Role <strong>of</strong> the Central Nervous System (CNS) in Peripheral<br />

Inflammation: Sympathetic Innervation <strong>of</strong> the Spleen<br />

Regulates Inflammatory Arthritis. David L. Boyle 1 , Meghan<br />

Edgar 2 , Linda Sorkin 2 and Gary S. Firestein 1 , 1 UCSD School <strong>of</strong><br />

Medicine, La Jolla, CA, 2 UCSD School <strong>of</strong> Medicine.<br />

1728. SapC-DOPS Agents in Imaging Arthritis. Sherry Thornton 1 ,<br />

Malinda Pinkerton 2 , Monica DeLay 2 , Tristan Bourdeau 2 , Rachel<br />

Mason 2 , Zhengtao Chu 2 , Matthew Flick 2 and Xiaoyang Qi 1 ,<br />

1<br />

Cincinnati Children’s Research Foundation, Cincinnati, OH,<br />

2<br />

Cincinnati Children’s Research Foundation.<br />

1729. Systemic, Lentiviral Gene Delivery <strong>of</strong> the Stress Protein<br />

BiP (Binding Immunoglobulin Protein) Improves Clinical,<br />

Histological and Immunological Parameters <strong>of</strong> Collagen-<br />

Induced Arthritis Via Suppression <strong>of</strong> IL-17. Adrian M. Shields 2 ,<br />

Paul H. Wooley 3 , Rana Alyahya 2 , Gabriel S. Panayi 1 , Stephen J.<br />

Thompson 2 and Valerie M. Corrigall 2 , 1 King’s <strong>College</strong> London,<br />

London, United Kingdom, 2 King’s <strong>College</strong> London, 3 Via Christi<br />

Reg Medical Ctr, Wichita, KS.<br />

1730. Targets <strong>of</strong> Innate and Adaptive Immunity in a Humanized<br />

Arthritis Model: Research Value <strong>of</strong> the RA Synovium SCID<br />

Mouse Model. Marije I. Koenders 3 , Shahla Abdollahi-Roodsaz 4 ,<br />

Renoud J. Marijnissen 4 , Franco E. Di Padova 2 , John Dulos 1 ,<br />

Annemieke M. H. Boots 1 and Wim B. van den Berg 4 , 1 MSD,<br />

Oss, The Netherlands, 2 Novartis Pharma AG, Switzerland,<br />

3<br />

Radboud University Nijmegen Medical Centre, Nijmegen, The<br />

Netherlands, 4 Radboud University Nijmegen Medical Centre,<br />

The Netherlands.<br />

1731. The Role for TIM-2 in Collagen-Induced Arthritis. Toshio<br />

Kawamoto 2 , Hisaya Akiba 1 , Yoshiyuki Abe 2 , Shinji Morimoto 2 ,<br />

Ken Yamaji 2 , Naoto Tamura 2 and Yoshinari Takasaki 2 ,<br />

1<br />

Department <strong>of</strong> Immunology, Juntendo University School <strong>of</strong><br />

Medicine, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Juntendo University<br />

School <strong>of</strong> Medicine.<br />

1732. The TNF-Ligand APRIL Can Control CIA by Regulating Antibody-<br />

Production and Stimulating Anti-Inflammatory IL-10 Producing<br />

B Cells. Leticia Fernandez 5 , Cecilia Rocha 5 , Carla Carvalho-Pinto 6 ,<br />

Jan Paul Medema 2 , Bernard G. Combe 3 , Dominique Baeten 1 ,<br />

Jacques Morel 4 and Michael Hahne 5 , 1 Academic Med Ctr/<br />

Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Academic<br />

Medical Center, University <strong>of</strong> Amsterdam, 3 Hopital Lapeyronie,<br />

Montpellier, France, 4 Hopital Lapeyronie, 5 Institut de Génétique<br />

Moléculaire de Montpellier, 6 Universidade Federal Fluminense/<br />

UFF, Niteroi.<br />

1733. Towards Personalized Arthritis Gene Therapy: Screening <strong>of</strong><br />

Computationally-Designed Promoters in an In Vivo Mouse<br />

Model and in Human Synovial Fibroblasts. Fons A. J. van de<br />

Loo, Eline Vermeij, Onno J. Arntz, Miranda B. Bennink, Jeroen<br />

Geurts and Wim B. van den Berg, Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Radboud University Nijmegen Medial Centre, Nijmegen, The<br />

Netherlands.<br />

2010 Program Book 253


ACR/ARHP Poster Session C<br />

Rheumatoid Arthritis - Clinical Aspects: Classification, Biomarkers,<br />

Predictors <strong>of</strong> Response, Disease Activity, Severity III<br />

1734. A Longitudinal Trivariate Model <strong>of</strong> Disease Activity Score,<br />

Physical Function and Radiographic Damage: Results from<br />

SONORA Study. Maggie Chen 1 , Xiuying Li 1 , Pooneh Akhavan 2<br />

and Claire Bombardier 3 , 1 University Health Network, 2 University<br />

<strong>of</strong> Toronto, University Health Network, 3 University <strong>of</strong> Toronto,<br />

University Health Network, Mount Sinai Hospital, Toronto, ON,<br />

Canada.<br />

1735. A Randomized Controlled Trial <strong>of</strong> Rheumatologist Education<br />

Impacting on Systematic Measurements and Treatment<br />

Decisions in Rheumatoid Arthritis (RA): Results <strong>of</strong> the Metrix<br />

Study. Janet E. Pope 3 , J. Carter Thorne 2 , Alfred A. Cividino 1<br />

and Kurt Lucas, 1 McMaster University, Hamilton, ON, Canada,<br />

2<br />

Southlake Regional Health Care, Newmarket, ON, Canada, 3 St<br />

Joseph Health Care London, London, ON, Canada.<br />

1736. A Simple Fatigue Severity Scale Predicts Poor Health<br />

Outcomes, Frailty and Death in the Long-Term Follow-Up <strong>of</strong><br />

Patients with Rheumatoid Arthritis. Gisela Westh<strong>of</strong>f and Angela<br />

Zink, German Rheumatism Research Centre Berlin, Berlin,<br />

Germany.<br />

1737. Age, Sex, RF Antibodies, Baseline HAQ and DAS28 Score – But<br />

Not the Type <strong>of</strong> Initial Treatment – Are Predictive <strong>of</strong> Clinical<br />

Remission at 1 Year in Early Inflammatory Arthritis. Bindee<br />

Kuriya 9 , Boulos Haraoui 4 , Gilles Boire 2 , Carol A. Hitchon 7 , Janet<br />

E. Pope 6 , J. Carter Thorne 5 , Diane S. Ferland 3 , Ed C. Keystone 8<br />

and Vivian P. Bykerk 1 , 1 Brigham and Women’s Hospital, Toronto,<br />

ON, Canada, 2 CHUS - Sherbrooke University, Sherbrooke, QC,<br />

Canada, 3 Hospital Maisonneuve Rosemount, LaSalle, QC,<br />

Canada, 4 Institut de Rhumatologie, Montreal, QC, Canada,<br />

5<br />

Southlake Regional Health Care, Newmarket, ON, Canada, 6 St<br />

Joseph Health Care London, London, ON, Canada, 7 University<br />

<strong>of</strong> Manitoba, Winnipeg, MB, Canada, 8 University <strong>of</strong> Toronto,<br />

Toronto, ON, Canada, 9 University <strong>of</strong> Toronto, Brookline, MA.<br />

1738. Algorithm Using Genome-Wide SNP Analysis for Prediction<br />

<strong>of</strong> Progression <strong>of</strong> Joint Destruction in RA Patients from<br />

Multiple Medical Cohorts. Tsukasa Matsubara 4 , Satoru Koyano 7 ,<br />

Yoshitada Sakai 1 , Keiko Funahashi 7 , Takafumi Hagiwara 5 , Takako<br />

Miura 4 , Kosuke Okuda 4 , Akira Sagawa 8 , Takeo Sakurai 2 , Hiroaki<br />

Matsuno 6 , Tomomaro Izumihara 3 and Eisuke Shono 9 , 1 Himeji<br />

Dokkyo University, Himeji, Japan, 2 Inoue Hospital, Takasaki,<br />

Japan, 3 Izumihara Rheumatic and Medical Clinic, Kagoshima,<br />

Japan, 4 Matsubara Mayflower Hospital, Kato, Japan, 5 Matsubara<br />

Mayflower Hospital, Kato, Japan, 6 Matsuno Clinic for Rheumatic<br />

Diseases, Toyama, Japan, 7 Research Institute <strong>of</strong> Joint Diseases,<br />

Kobe, Japan, 8 Sagawa Akira <strong>Rheumatology</strong> Clinic, Sapporo,<br />

Japan, 9 Shono <strong>Rheumatology</strong> Clinic, Fukuoka, Japan.<br />

1739. An Algorithm Using Genome-Wide SNP Analysis for Prediction<br />

<strong>of</strong> Interstitial Pneumonia in RA Patients. Takeshi Nakamura 3 ,<br />

Satoru Koyano 5 , Keiko Funahashi 5 , Takafumi Hagiwara 3 , Takako<br />

Miura 3 , Kosuke Okuda 3 , Akira Sagawa 6 , Takeo Sakurai 1 , Hiroaki<br />

Matsuno 4 , Tomomaro Izumihara 2 , Eisuke Shono 7 and Tsukasa<br />

Matsubara 3 , 1 Inoue Hospital, Takasaki, Japan, 2 Izumihara<br />

Rheumatic and Medical Clinic, Kagoshima, Japan, 3 Matsubara<br />

Mayflower Hospital, Kato, Japan, 4 Matsuno Clinic for Rheumatic<br />

Diseases, Toyama, Japan, 5 Research Institute <strong>of</strong> Joint Diseases,<br />

Kobe, Japan, 6 Sagawa Akira <strong>Rheumatology</strong> Clinic, Sapporo,<br />

Japan, 7 Shono <strong>Rheumatology</strong> Clinic, Fukuoka, Japan.<br />

1740. Anti-Citrullinated Protein Antibodies Are Detected in a<br />

Significant Proportion <strong>of</strong> Patients with Anti-CCP-Negative,<br />

Early RA: Implications for Improved RA Diagnosis and Guided<br />

Therapy. Reuven Bromberg 3 , Jeremy Sokolove 2 , Piyanka<br />

Chandra 3 , Aarat Patel 8 , Stacy C<strong>of</strong>ield 7 , Theresa McVie 5 , S. Louis<br />

Bridges 4 , Larry W. Moreland 6 and William Robinson 1 , 1 Stanford<br />

Univ School <strong>of</strong> Med, Stanford, CA, 2 Stanford University,<br />

Mountain View, CA, 3 Stanford University, 4 Univ <strong>of</strong> Alabama-<br />

Birmingham, Birmingham, AL, 5 Univ <strong>of</strong> Alabama-Birmingham,<br />

6<br />

Univ <strong>of</strong> Pittsburgh Med Ctr, Pittsburgh, PA, 7 University <strong>of</strong><br />

Alabama-Birmingham, 8 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

1741. Anti-Cyclic Citrullinated Peptide Antibodies: Beyond<br />

Rheumatoid Arthritis. Dolors Grados, Melania Martinez-<br />

Morillo, Susana Holgado, Sonia Mínguez, Anna Moltó, Beatriz<br />

Tejera, Lourdes Mateo, Xavier Tena, Anna Marín, Iñaki Salvador,<br />

Eva Martínez-Caceres, Estíbaliz Ruiz and Alejandro Olivé,<br />

Hospital Universitari Germans Trias i Pujol.<br />

1742. Assessment <strong>of</strong> Nontraditional Prognostic Markers in Patients<br />

with Rheumatoid Arthritis. Bozena Targonska-Stepniak and<br />

Maria Majdan, Department <strong>of</strong> <strong>Rheumatology</strong> and Connective<br />

Tissue Diseases, Medical University <strong>of</strong> Lublin, Lublin, Poland.<br />

1743. Baseline ADAMTS5 Expression Could Sort the Prediction<br />

<strong>of</strong> Response to Infliximab or Adalimumab in Patients with<br />

Rheumatoid Arthritis. Kensei Tsuzaka 1 , Yuka Itami 2 , Naoshi<br />

Shinozaki 2 and Tetsuo Morishita 2 , 1 Tokyo Dental <strong>College</strong><br />

Ichikawa General Hospital, Ichikawa, Chiba, Japan, 2 Tokyo Dental<br />

<strong>College</strong> Ichikawa General Hospital, Ichikawa, Chiba, JAPAN.<br />

1744. Classification <strong>of</strong> Rheumatoid Arthritis – Comparison <strong>of</strong> the<br />

1987 ACR and 2010 ACR/EULAR Criteria. M. P. M. van der<br />

Linden, R. Knevel, T. W. J. Huizinga and A. H. M. van der Helmvan<br />

Mil, Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University<br />

Medical Center, Leiden, The Netherlands.<br />

1745. Clinical Utility and Validity <strong>of</strong> Self Assessed Joint Involvement<br />

in Rheumatoid Arthritis (RA) Patients with Low Active Disease.<br />

Helga Radner 4 , Tanja Alexandra Stamm 3 , Johannes Grisar 2 , Josef<br />

S. Smolen 1 and Daniel Aletaha 3 , 1 Krankenhaus Lainz, Vienna,<br />

Austria, 2 Medical Universitiy Vienna, 3 Medical University <strong>of</strong><br />

Vienna, Vienna, Austria, 4 Medical Universty Vienna, Vienna,<br />

Austria.<br />

1746. Comparing the Validity <strong>of</strong> the EuroQol-5D, Short Form-6D and<br />

the Well-Being Preference-Based Scores Using the Mean Short<br />

Form-36 Health Dimension Scores in Patients with Rheumatoid<br />

Arthritis and in Healthy Controls. Fausto Salaffi 1 , Marina<br />

Carotti 2 , Stefania Gasparini 1 , Alessandro Ciapetti 1 and Walter<br />

Grassi 1 , 1 Department <strong>of</strong> Molecular Pathology and Innovative<br />

Therapies, Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Ancona<br />

(Politecnica delle Marche), Italy, 2 Department <strong>of</strong> Radiology,<br />

University <strong>of</strong> Ancona (Politecnica delle Marche), Italy.<br />

1747. Computer Assisted Patient Reported (PR) Versus Physician<br />

Generated (PG) Joint Count (JC) and DAS28 Scores for<br />

Rheumatoid Arthritis (RA) Patients. Norman B. Gaylis 2 , Jeffrey<br />

Scott 3 , Sue North 3 , Marty True 3 , Guss Savl<strong>of</strong>f 1 and Barry V.<br />

Fortner 3 , 1 Arthritis &Rheumatic Disease Specialties, 2 Arthritis &<br />

Rheumatic Disease Specialties, Aventura, FL, 3 P4 Healthcare.<br />

1748. Concurrent Depressive or Anxiety Disorders Significantly<br />

Worsen the Health-Related Quality <strong>of</strong> Life <strong>of</strong> Patients with<br />

Rheumatoid Arthritis. Eugenia Y. C. Lok 1 , Chi Chiu Mok 2 , Fuk Chi<br />

Cheung 1 and Chi Wai Cheng 1 , 1 Castle Peak Hospital, 2 Tuen Mun<br />

Hospital.<br />

254<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1749. Construct Validity and Reliability <strong>of</strong> the Quick Disability <strong>of</strong><br />

the Arm, Shoulder and Hand Questionnaire in Rheumatoid<br />

Arthritis Based on IORRA Cohort Study. Asami Tokita 1 , Takuji<br />

Iwamoto 2 , Ryo Hiroshima 2 , Yu Sakuma 2 , Koichiro Yano 2 ,<br />

Kosei Kawakami 2 , Katsunori Ikari 2 , Atsuo Taniguchi 2 , Hisashi<br />

Yamanaka 2 and Shigeki Momohara 2 , 1 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />

Tokyo Women’s Medical University, Kawada-cho, Shinjukuku,<br />

Tokyo, Japan, 2 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s<br />

Medical University, Japan.<br />

1750. Contribution <strong>of</strong> the Rheumatoid Arthritis Impact <strong>of</strong> Disease<br />

(RAID) on Disease Activity in Rheumatoid Arthritis (RA). Till<br />

Uhlig 1 , Turid Heiberg 3 , Cathrine Austad 2 and Tore K. Kvien 1 ,<br />

1<br />

Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet<br />

Hospital, Oslo, Norway, 3 Oslo University Hospital, Oslo, Norway.<br />

1751. CXCL2 as a Potential Biomarker <strong>of</strong> Disease Activity in<br />

Rheumatoid Arthritis. Kichul Shin 2 , Ji Ah Park 3 , Jun Wan<br />

Kim 3 , Hong Hee Kim 1 , Eun Bong Lee 3 and Yeong Wook Song 3 ,<br />

1<br />

Department <strong>of</strong> Cell and Developmental Biology, BK 21 and DRI,<br />

Seoul National University School <strong>of</strong> Dentistry, Seoul, Korea,<br />

2<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />

Seoul National University Hospital, Seoul, Korea, Republic <strong>of</strong>,<br />

3<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />

Seoul National University Hospital, Seoul, Korea.<br />

1752. Development by the STPR Group <strong>of</strong> the Flare Instument, a<br />

New Tool To Identify Flare in Rheumatoid Arthritis (RA) in<br />

Clinical Practice. Jean-Marie Berthelot 4 , Michel De Bandt 2 ,<br />

Jacques Morel 1 , Arnaud Constantin 3 , Philippe Gaudin 3 , Xavier Le<br />

Loët 3 , Jean-Francis Maillefert 3 , Olivier Meyer, Thao Pham, Alain<br />

Saraux, Elisabeth Solau-Gervais, Daniel Wendling, Elisabeth<br />

Spitz, Bruno Fautrel and Francis Guillemin, 1 Montpellier, France,<br />

2<br />

Aulnay Sous Bois, France, 3 France, 4 <strong>Rheumatology</strong> Unit CHU<br />

Nantes, Nantes, France.<br />

1753. Development <strong>of</strong> a Multi-Biomarker Test for Rheumatoid<br />

Arthritis (RA) Disease Activity (Vectra DA). Marije F. Bakker 8 ,<br />

Yijing Shen 3 , Johannes W. J. Bijlsma 7 , Johannes W. G. Jacobs 8 ,<br />

Floris P. J. G. Lafeber 8 , Guy Cavet 3 , Michael Centola 4 , Doug<br />

Haney 3 , Lyndal K. Hesterberg 3 , David Chern<strong>of</strong>f 3 , John Carulli 1 ,<br />

Nancy A. Shadick 2 , Michael E. Weinblatt 2 , Max I. Hamburger 6 ,<br />

Roy M. Fleischmann 5 , Jeffrey R. Curtis 9 and Ed C. Keystone 10 ,<br />

1<br />

Biogen Idec, 2 Brigham & Womens Hospital, Boston, MA,<br />

3<br />

Crescendo Bioscience, Inc., 4 Oklahoma Med Research<br />

Foundation, Oklahoma City, OK, 5 <strong>Rheumatology</strong> Associates,<br />

Dallas, TX, 6 <strong>Rheumatology</strong> Associates <strong>of</strong> LI, Dix Hills, NY,<br />

7<br />

University Medical Ctr Utrecht, Utrecht, The Netherlands,<br />

8<br />

University Medical Ctr Utrecht, 9 University <strong>of</strong> Alabama -<br />

Brimingham, Birmingham, AL, 10 University <strong>of</strong> Toronto, Toronto,<br />

ON, Canada.<br />

1754. Evaluation <strong>of</strong> Patients with Rheumatoid Arthritis in Clinical<br />

Remission with 12 Joints Ultrasonography. Preliminary Results.<br />

José M. Senabre 1 , José C. Rosas 2 , Carlos Santos-Ramírez 2 ,<br />

Gregorio Santos-Soler 2 , Xavier Barber 3 , Nuria Llahí 2 , Catalina<br />

Cano 2 and Rosa Riestra 2 , 1 Hospital Marina Baixa, Villajoyosa,<br />

Alicante, Spain, 2 Hospital Marina Baixa, 3 University Miguel<br />

Hernández.<br />

1755. Feasibility <strong>of</strong> Online Registration <strong>of</strong> Physical Functioning by<br />

RA Patients in the Out Patient Clinic. Rosanne Koevoets 3 , N. A.<br />

de Glas 3 , I. Speyer 1 , A. A. Schouffour 3 , T. W. J. Huizinga 3 , Thea<br />

P. M. Vliet Vlieland 2 and Cornelia F. Allaart 2 , 1 Bronovo Hospital,<br />

The Hague, 2 Leiden University Medical Centre, Leiden, The<br />

Netherlands, 3 Leiden University Medical Centre, Leiden, The<br />

Netherlands.<br />

1756. Identification <strong>of</strong> a Novel Marker <strong>of</strong> Radiological Damage in RA.<br />

A. Kleszcz, M. Teare, D. Moore, J. Worthington, A. Barton and G.<br />

Wilson, The University <strong>of</strong> Sheffield.<br />

1757. Improvement <strong>of</strong> Serological Rheumatoid Arthritis Diagnostics<br />

by Autoantibody Pr<strong>of</strong>iling. Karsten Conrad 2 , Dirk Roggenbuck 1<br />

and Kirsten Lüthke 3 , 1 Generic Assays GmbH, Dahlewitz,<br />

Germany, Germany, 2 Institute <strong>of</strong> Immunology, Medical<br />

Faculty <strong>of</strong> the Technical University <strong>of</strong> Dresden, Germany,<br />

3<br />

Rheumatological Practice, Dresden, Germany, Germany.<br />

1758. In Patients with Rheumatoid Arthritis Who Are in a Low<br />

Disease Activity State or Remission, Does Lack <strong>of</strong> Fatigue<br />

Relate to Better Function and Damage Scores. George A.<br />

Wells 2 , Tracy Li 1 and Maarten Boers 3 , 1 Bristol-Myers Squibb,<br />

Princeton, NJ, 2 Univ <strong>of</strong> Ottawa Faculty <strong>of</strong> Med, Ottawa, ON,<br />

Canada, 3 VU University Medical Center, Amsterdam, The<br />

Netherlands.<br />

1759. Is Exclusion <strong>of</strong> Joints <strong>of</strong> the Feet in a Disease Activity Index<br />

like DAS28 a Clinical Problem When Assessing the Individual<br />

RA Patient? M. F. Bakker 2 , J. W. G. Jacobs 2 , P. M. J. Welsing 1 , F.<br />

P. J. G. Lafeber 2 and J. W. J. Bijlsma 2 , 1 <strong>Rheumatology</strong> & Clinical<br />

Immunology, Julius Center for Health Sciences and Primary<br />

Care, University Medical Center Utrecht, The Netherlands,<br />

2<br />

<strong>Rheumatology</strong> & Clinical Immunology, University Medical<br />

Center Utrecht, The Netherlands.<br />

1760. Level <strong>of</strong> Agreement <strong>of</strong> 1987 ACR and 2010 ACR/EULAR<br />

Classification Criteria: An Analysis Based on the ESPOIR Cohort<br />

Data. Bruno Fautrel 3 , Nathalie Rincheval 4 , Bernard G. Combe 1 ,<br />

Maxime Dougados 2 and ESPOIR Scientific Committee, 1 Hopital<br />

Lapeyronie, Montpellier, France, 2 Hospital Cochin, Paris, France,<br />

3<br />

Pitie Salpetriere Hospital, Paris, France, 4 UIRC Montpellier.<br />

1761. Levels <strong>of</strong> Soluble CD163 Is Associated with Disease Activity<br />

and Radiographic Progression in Early Rheumatoid Arthritis.<br />

Stinne R. Greisen 6 , Malene Hvid 4 , Kristian Stengaard-Pedersen 1 ,<br />

Merete L. Hetland 2 , Kim Hørslev-Petersen 7 , Holger J. Møller 3 and<br />

Bent Deleuran 5 , 1 Arhus University Hospital, Aarhus, Denmark,<br />

2<br />

Copenhagen Univ Hosp Hvidovre, Hvidovre, Denmark,<br />

3<br />

Department <strong>of</strong> Clinical Biochemistry, Aarhus University<br />

Hospital, Denmark, 4 Institute <strong>of</strong> Medical Microbiology and<br />

Immunology, University <strong>of</strong> Aarhus and Department <strong>of</strong> Dermatovenerology<br />

Aarhus University Hospital, Denmark,, 5 Institute <strong>of</strong><br />

Medical Microbiology and Immunology, University <strong>of</strong> Aarhus,<br />

and Aarhus University Hospital, Denmark, 6 Institute <strong>of</strong> Medical<br />

Microbiology and Immunology, University <strong>of</strong> Aarhus, Denmark,<br />

7<br />

King Christian X Hospital for Rheumatic Disease, University <strong>of</strong><br />

Southern Denmark.<br />

1762. Liver Injury in Patients with Rheumatic Diseases and<br />

Inflammatory Syndrom: A Case-Control Prospective Analysis<br />

Using Biomarkers (FibroTest, ActiTest and SteatoTest). Cécile<br />

Gaujoux-Viala 2 , Mathilde Benhamou 2 , Mona Munteanu 1 ,<br />

Yen Ngo 1 , Djamila Messous 1 , Françoise Imbert-Bismut 1 , Vlad<br />

Ratziu 1 , Pierre Bourgeois 2 , Thierry Poynard 1 , Bruno Fautrel 2 and<br />

SAFE-T DILI- GHPS Study Group, 1 Paris 6 – Pierre et Marie Curie<br />

University; Hepatology, Pitié-Salpêtrière Hospital, Paris, France,<br />

2<br />

Paris 6 – Pierre et Marie Curie University; <strong>Rheumatology</strong>, Pitié-<br />

Salpêtrière Hospital, Paris, France.<br />

1763. New 2010 ACR-EULAR Rheumatoid Arthritis Classification<br />

Criteria Are Highly Sensitive in Patients with Early Rheumatoid<br />

Arthritis. Sarang Chitale 2 , Nicola J. Goodson 2 , David W.<br />

Sharpley 2 , Robert N. Thompson 1 , Robert J. Moots 2 and Cristina<br />

Estrach 2 , 1 Academic <strong>Rheumatology</strong> Department, University<br />

Hospital Aintree, Liverpool, Merseyside, United Kingdom,<br />

2<br />

Academic <strong>Rheumatology</strong> Department, University <strong>of</strong> Liverpool,<br />

Liverpool, Merseyside, United Kingdom.<br />

2010 Program Book 255


ACR/ARHP Poster Session C<br />

256<br />

1764. Novel Multiplex Technology for Diagnostic Characterization <strong>of</strong><br />

Rheumatoid Arthritis. Piyanka E. Chandra 4 , Jeremy Sokolove 3 ,<br />

Berthold G. Hipp 1 , Heike Eberl 1 , Ursula Klause 1 and William<br />

Robinson 2 , 1 Roche Diagnostics, 2 Stanford Univ School <strong>of</strong> Med,<br />

Stanford, CA, 3 Stanford University, Mountain View, CA, 4 Stanford<br />

University.<br />

1765. Patient Questionnaire Scores for Physical Function and Pain<br />

Are More Likely Than Erythrocyte Sedimentation Rate (ESR) To<br />

Document a Quantitative Abnormality in New Patients with<br />

Rheumatoid Arthritis (RA). Theodore Pincus 1 and Christopher<br />

J. Swearingen 2 , 1 New York University Hospital for Joint Disease,<br />

Hastings-on-Hudson, NY, 2 University <strong>of</strong> Arkansas for Medical<br />

Sciences, Little Rock, AR.<br />

1766. Preliminary Rheumatoid Arthritis (RA) Flare Assessment for<br />

Randomized Clinical Trials (RCTs): An Outcome Measures in<br />

<strong>Rheumatology</strong> (OMERACT) Data-Driven, Patient-Centered,<br />

and Consensus-Based Initiative. Clifton O. Bingham 3 , Ernest<br />

Choy 4 , Rieke Alten 6 , Maarten Boers 11 , Peter Brooks 9 , Vivian<br />

Bykerk 1 , Robin Christensen 5 , Dan Furst 8 , Sarah Hewlett 10 , Amye<br />

Leong 2 , James May, Christ<strong>of</strong> Pohl 6 , Tessa Sanderson 10 , Vibeke<br />

Strand 7 and Thasia Woodworth, 1 Brigham and Women’s,<br />

2<br />

Healthy Motivation, 3 Johns Hopkins University, Baltimore, MD,<br />

4<br />

King’s <strong>College</strong>, 5 Parker Institute: Musculoskeletal Statistics Unit<br />

Copenhagen University Hospital, 6 Schlosspark Klinik University<br />

Charite, 7 Stanford University, 8 UCLA, 9 University <strong>of</strong> Queensland,<br />

10<br />

University <strong>of</strong> the West <strong>of</strong> England, 11 Vu University Medical<br />

Center.<br />

1767. Preliminary Validation for the Short Version <strong>of</strong> the Valued<br />

Life Activities Questionnaire (S-VLA). Afton L. Hassett 5 , Diane<br />

C. Radvanski 3 , Anagha Nadkarni 1 , Steven Buyske 2 , Sam A.<br />

Schiff 3 , Moti L. Tiku 3 and Patricia P. Katz 4 , 1 Bristol-Myers Squibb<br />

Co, Princeton, NJ, 2 Rutgers University, New Brunswick, NJ,<br />

3<br />

UMDNJ-Robert Wood Johnson Medical School, New Brunswick,<br />

NJ, 4 University <strong>of</strong> California, San Francisco, CA, 5 University <strong>of</strong><br />

Michigan Medical School, Ann Arbor, MI.<br />

1768. Presence and Predictors <strong>of</strong> Poor Functional Outcomes in<br />

US Hispanics with Rheumatoid Arthritis (RA). George A.<br />

Karpouzas 4 , Soha Dolatabadi 1 , Rosalinda C. Moran 3 , Perry<br />

Nicassio 5 and Michael H. Weisman 2 , 1 Cedars Sinai, Los Angeles,<br />

CA, 2 Cedars-Sinai Medical Center, Los Angeles, CA, 3 Harbor<br />

UCLA, Carson, CA, 4 Harbor-UCLA, Long Beach, CA, 5 UCLA.<br />

1769. Progression Patterns <strong>of</strong> Radiographic Damage: Results from<br />

SONORA Study. Maggie Chen 1 , Xiuying Li 1 , Pooneh Akhavan 2<br />

and Claire Bombardier 3 , 1 University Health Network, 2 University<br />

<strong>of</strong> Toronto, University Health Network, 3 University <strong>of</strong> Toronto,<br />

University Health Network, Mount Sinai Hospital, Toronto, ON,<br />

Canada.<br />

1770. Quantification <strong>of</strong> Periarticular Osteopenia in Rheumatoid<br />

Arthritis. Inhye E. Ahn 3 , Ji Hyeon Ju 1 , Kwi Young Kang 2 ,<br />

Seung-Ki Kwok 1 , Kyung-su Park 1 , Sung-Hwan Park 1 and Ho-<br />

Youn Kim 1 , 1 Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Catholic University <strong>of</strong> Korea, Seoul, Korea,<br />

Republic <strong>of</strong>, 2 Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Chungbuk University, Cheongju, Korea, Republic<br />

<strong>of</strong>, 3 Department <strong>of</strong> Internal Medicine, The Methodist Hospital,<br />

Houston, TX.<br />

1771. Radiological Progression in Very Early Rheumatoid Arthritis,<br />

Results <strong>of</strong> the DREAM Remission Induction Cohort. Marloes<br />

Vermeer 3 , Ina H. Kuper 3 , Monique Hoekstra 1 , Hein J. Bernelot<br />

Moens 4 , Piet L. C. M. van Riel 2 and Mart A. F. J. van de Laar 3 ,<br />

1<br />

Isala Klinieken, Zwolle, The Netherlands, 2 Radboud University<br />

Nijmegen Medical Centre, Nijmegen, The Netherlands,<br />

3<br />

University <strong>of</strong> Twente and Medisch Spectrum Twente, Enschede,<br />

The Netherlands, 4 Ziekenhuisgroep Twente, Almelo/Hengelo,<br />

The Netherlands.<br />

2010 Program Book<br />

1772. Retinal Vascular Caliber Is Altered in Patients with Rheumatoid<br />

Arthritis: A Biomarker <strong>of</strong> Disease Activity and Cardiovascular<br />

Risk? Sharon Van Doornum 3 , Gemma Strickland 2 , Ryo Kawasaki 3 ,<br />

Jing Xie 3 , Lauren Hodgson 3 , Ian Wicks 1 and Tien Wong 3 , 1 Royal<br />

Melbourne Hospital, Melbourne, Australia, 2 Royal Melbourne<br />

Hospital, 3 University <strong>of</strong> Melbourne.<br />

1773. Serum Undercarboxylated Osteocalcin Levels in Patients with<br />

Rheumatoid Arthritis. Kuninobu Wakabayashi, Kumiko Otsuka,<br />

Michihito Sato, Ryo Takahashi, Tsuyoshi Odai, Takeo Isozaki,<br />

Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine, Showa University<br />

School <strong>of</strong> Medicine, Tokyo, Japan.<br />

1774. The 2010 ACR/EULAR Criteria for Rheumatoid Arthritis<br />

Perform Well in Prediction <strong>of</strong> Clinical RA Diagnosis at 6 Months<br />

in Very Early Arthritis Patients: Longitudinal Data from the<br />

NOR-VEAC Cohort. Maria D. Mjaavatten 3 , Desiree M. Van Der<br />

Heijde 8 , Till Uhlig 5 , Anne J. Haugen 1 , Halvor Nygaard 6 , Olav<br />

Bjørneboe 9 , Nils G. Arvidson 7 , Hans C. Gulseth 2 and Tore K.<br />

Kvien 4 , 1 Østfold Hospital, Moss, Norway, 2 Betanien Hospital,<br />

Skien, Norway, 3 Diakonhjemmet Hospital, Oslo, Norway,<br />

4<br />

Diakonhjemmet Hospital, Oslo, Norway, 5 Diakonhjemmet<br />

Hospital, Oslo, Norway, 6 Hospital for Rheumatic Diseases,<br />

Lillehammer, Norway, 7 Innlandet Hospital, Kongsvinger, Norway,<br />

8<br />

Leiden University Medical Center, Meerssen, The Netherlands,<br />

9<br />

Martina Hansen’s Hospital, Sandvika, Norway.<br />

1775. The ACR/EULAR 2010 Criteria as Well as Other Predictive<br />

Algorithms for Rheumatoid Arthritis Show Good Diagnostic<br />

Performance. Celina Alves 2 , Jolanda Luime 1 , Jendé van Zeben 4 ,<br />

Margriet Huisman 4 , Angelique Weel 3 , Pieternella Barendregt 3<br />

and Johanna Hazes 1 , 1 Erasmus MC, 2 Erasmus MC, Rotterdam,<br />

The Netherlands, 3 Maasstad Ziekenhuis, 4 Sint Franciscus<br />

Gasthuis.<br />

1776. The Diagnostic Performance <strong>of</strong> the ACR/EULAR 2010 Criteria<br />

If One <strong>of</strong> Its Parameters Is Not Available. Results from the<br />

Rotterdam Early Arthritis CoHort (REACH). Celina Alves 2 ,<br />

Jolanda Luime 1 , Jendé van Zeben 4 , Margriet Huisman 4 ,<br />

Angelique Weel 3 , Pieternella Barendregt 3 and Johanna Hazes 1 ,<br />

1<br />

Erasmus MC, 2 Erasmus MC, Rotterdam, The Netherlands,<br />

3<br />

Maasstad Ziekenhuis, 4 Sint Franciscus Gasthuis.<br />

1777. The Performance <strong>of</strong> the Hospital Anxiety and Depression<br />

Scale for Screening <strong>of</strong> Depressive and Anxiety Disorders in<br />

Patients with Rheumatoid Arthritis (RA). Eugenia Y. C. Lok 1 , Chi<br />

Chiu Mok 2 , Fuk Chi Cheung 1 and Chi Wai Cheng 1 , 1 Castle Peak<br />

Hospital, 2 Tuen Mun Hospital.<br />

1778. The Role <strong>of</strong> Objective Measures vs. Patient Reported<br />

Outcomes (PROs) as a Reflection <strong>of</strong> Flares in Patients with<br />

RA: Results from the Brigham RA Sequential Study (BRASS).<br />

Vivian Bykerk 1 , Daniel Hal Solomon 5 , Clifton O. Bingham 6 ,<br />

Michelle Frits 3 , Christine Iannaccone 4 , Michael E. Weinblatt 5 and<br />

Nancy A. Shadick 5 , 1 Brigham &Women’s Hospital, Boston, MA,<br />

2<br />

Brigham and Women’s Hospital, Jamaica Plain, MA, 3 Brigham<br />

and Women’s Hospital, Boston, MA, 4 Brigham and Women’s<br />

Hospital, MA, 5 Brigham and Womens Hospital, Boston, MA,<br />

6<br />

Johns Hopkins University, Baltimore, MD.<br />

1779. Total MRI Inflammatory Score Correlates with Disease Activity<br />

Measures after Aggressive Treatment <strong>of</strong> Rheumatoid Arthritis.<br />

Veena K. Ranganath 3 , David A. Elash<strong>of</strong>f 4 , Paul Maranian 4 , Kambiz<br />

Motamedi 4 , Espen Haavardsholm 2 , Fiona M. McQueen 5 , Theresa<br />

McVie 7 , Stacey S. C<strong>of</strong>ield 7 , Larry W. Moreland 6 , Weiling Chen 4<br />

and Harold E. Paulus 1 , 1 Encino, CA, 2 Diakonhjemmet Hospital,<br />

3<br />

UCLA, Los Angeles, CA, 4 UCLA, 5 Univ <strong>of</strong> Auckland Sch <strong>of</strong> Med,<br />

Auckland, New Zealand, 6 Univ <strong>of</strong> Pittsburgh Med Ctr, Pittsburgh,<br />

PA, 7 University <strong>of</strong> Birmingham.


ACR/ARHP Poster Session C<br />

1780. Towards a Data-Driven Evaluation <strong>of</strong> the 2010 ACR/EULAR<br />

Criteria for Rheumatoid Arthritis: Is It Sensible To Look at<br />

Levels <strong>of</strong> Rheumatoid Factor? M. P. M. van der Linden 4 , M.<br />

R. Batstra 1 , L. E. Bakker-Jonges 1 , J. Detert 2 , H. Bastian 2 , H. U.<br />

Scherer 2 , G. R. Burmester 2 , M. D. Mjaavatten 3 , T. K. Kvien 3 , R. E.<br />

M. Toes 4 , T. W. J. Huizinga 4 and A. H. M. van der Helm-van Mil 4 ,<br />

1<br />

Department <strong>of</strong> Medical Laboratories, Reinier de Graaf Group,<br />

Delft, The Netherlands, on Behalf <strong>of</strong> SKML-HIM (WGHAS),<br />

2<br />

Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />

University Medicine Berlin, Berlin, Germany, 3 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway,<br />

4<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University Medical<br />

Center, Leiden, The Netherlands.<br />

1781. Ultrasound Evaluation Reveals the Reason for High Interrater<br />

Variability in Joints <strong>of</strong> the 66/68 Joint Count. Matthias<br />

Nikolaus Witt 2 , Monika Ronneberger 1 , Amelie Schnez 3 , Ruediger<br />

Laubender 4 , Matthias Engelbrecht 1 , Arthur Kavanaugh 6 , Hendrik<br />

Schulze-Koops 5 and Mathias Grunke 3 , 1 Department <strong>of</strong> Internal<br />

Medicine 3 , University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />

Germany, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Ludwig-Maximilians-<br />

University, Munich, Germany, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

Ludwig-Maximilians-University, Munich, Germany, 4 Institute <strong>of</strong><br />

Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-<br />

Maximilians-University, Munich, Germany, 5 Ludwig-Maximilians-<br />

University, Munich, Germany, 6 University <strong>of</strong> California-San<br />

Diego, La Jolla, CA.<br />

1782. Validation <strong>of</strong> a Multi-Biomarker Test for Rheumatoid Arthritis<br />

(RA) Disease Activity (Vectra DA) in a Multi-Cohort Study.<br />

Jeffrey R. Curtis 9 , Doug Haney 3 , Annette H. M. van der Helm 5 ,<br />

Yijing Shen 3 , Rachel Knevel 5 , Guy Cavet 3 , Linda Dirven 5 ,<br />

Cornelia F. Allaart 4 , Thomas W. J. Huizinga 5 , Michael Centola 6 ,<br />

Lyndal K. Hesterberg 3 , David Chern<strong>of</strong>f 3 , John Carulli 1 , Nancy<br />

A. Shadick 2 , Michael E. Weinblatt 2 , Max I. Hamburger 8 , Roy<br />

M. Fleischmann 7 and Ed C. Keystone 10 , 1 Biogen Idec, 2 Brigham<br />

&Womens Hospital, Boston, MA, 3 Crescendo Bioscience, Inc.,<br />

4<br />

Leiden Univ Med Ctr, Leiden, The Netherlands, 5 Leiden Univ<br />

Med Ctr, 6 Oklahoma Med Research Foundation, Oklahoma<br />

City, OK, 7 <strong>Rheumatology</strong> Associates, Dallas, TX, 8 <strong>Rheumatology</strong><br />

Associates <strong>of</strong> LI, Dix Hills, NY, 9 University <strong>of</strong> Alabama -<br />

Brimingham, Birmingham, AL, 10 University <strong>of</strong> Toronto, Toronto,<br />

ON, Canada.<br />

1783. Validation <strong>of</strong> New Classification Criteria for Rheumatoid<br />

Arthritis in Japanese Population. Hisanori Shimizu 1 , Hiromichi<br />

Tamaki 3 , Eishi Uechi 3 , Mitsumasa Kishimoto 2 , Ken-ichi<br />

Yamaguchi 3 and Masato Okada 1 , 1 St. Luke’s International<br />

Hospital, Tokyo, Japan, 2 St. Luke’s International Hospital, Chuoku,<br />

Tokyo, Japan, 3 St. Luke’s International Hospital.<br />

1784. Validity <strong>of</strong> Clinical Associations <strong>of</strong> Biomarkers in Translational<br />

Research Studies: The Case <strong>of</strong> Systemic Autoimmune Diseases.<br />

Maria Tektonidou 2 and Michael Ward 1 , 1 National Institute <strong>of</strong><br />

Arthritis and Musculoskeletal and Skin Diseases, 2 National<br />

University <strong>of</strong> Athens.<br />

1785. Validity <strong>of</strong> the Revised ACR/EULAR Classification Criteria for<br />

Rheumatoid Arthritis: Predicting Persistent Arthritis and Joint<br />

Erosions after 2 Years in Patients with Early Undifferentiated<br />

Arthritis. Jaap Fransen 3 , Mieke Hazes 2 and Henk Visser 1 , 1 Alysis<br />

Hospital, Arnhem, The Netherlands, 2 Erasmus Medical Centre,<br />

Rotterdam, The Netherlands, 3 Radboud University Nijmegen<br />

Medical Centre, Nijmegen, The Netherlands.<br />

1786. Vitamin D Levels Do Not Correlate with Disease Activity,<br />

Erosions, or Inflammatory Markers in Patients with Active<br />

Rheumatoid Arthritis. Joshua Baker 2 , Daniel G. Baker 1 , Gary<br />

Toedter, Justine Shults and Mary B. Leonard, 1 Centocor Inc,<br />

Malvern, PA, 2 University <strong>of</strong> Pennsylvania, Philadelphia, PA.<br />

1787. Work Disability in Early Rheumatoid Arthritis: Prognostic<br />

Factors after Two Years <strong>of</strong> Follow-Up. Fausto Salaffi 1 ,<br />

Gianfranco Ferraccioli 3 , Marina Carotti 2 , Alessandro Ciapetti 1 ,<br />

Stefania Gasparini 1 and Walter Grassi 1 , 1 Department <strong>of</strong><br />

Molecular Pathology and Innovative Therapies, Division<br />

<strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Ancona (Politecnica delle<br />

Marche), Italy, 2 Department <strong>of</strong> Radiology, University <strong>of</strong> Ancona<br />

(Politecnica delle Marche), Italy, 3 School <strong>of</strong> Medicine, Catholic<br />

University <strong>of</strong> the Sacred Heart, Rome, Italy.<br />

Rheumatoid Arthritis Treatment - Small Molecules, Biologics and<br />

Gene Therapy: Biologic DMARDs III<br />

1788. A Study To Evaluate the Effectiveness and Safety <strong>of</strong> the<br />

Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab (TCZ) after<br />

4 and 24 Weeks in Patients with Active Rheumatoid Arthritis<br />

(RA) – Final Effectiveness Results <strong>of</strong> the TAMARA Study. Eugen<br />

Feist 1 , Andrea Rubbert-Roth 2 , Jürgen Braun 6 , Jörg Kaufmann 4 ,<br />

Herbert L. Kellner 7 , Reiner Kurthen 3 , Jürgen Wollenhaupt 5 and<br />

Gerd R. Burmester 1 , 1 Campus Charité Mitte, Med. Klinik Abt.<br />

Rheumatologie u. Klin. Immunologie, Berlin, Germany, 2 Klinik I<br />

für Innere Medizin, Uniklinik Cologne, Cologne, Germany, 3 Praxis<br />

für Innere Medizin und Rheumatologie, Aachen, Germany,<br />

4<br />

Praxis für Innere Medizin und Rheumatologie, Ludwigsfelde,<br />

Germany, 5 Rheumatologikum Hamburg, Schön-Klinik Hamburg-<br />

Eilbeck, Hamburg, Germany, 6 Rheumazentrum Ruhrgebiet, St.<br />

Josefs-Krankenhaus, Herne, Germany, 7 Schwerpunktpraxis fuer<br />

Rheumatologie und Gastroenterologie, Munich, Germany.<br />

1789. Age at Onset and Comorbidities Correlate with the Health<br />

Assessment Questionnaire and Clinical Disease Activity Index<br />

(CDAI) Responses to Etanercept in Rheumatoid Arthritis<br />

Patients. Man R. Shim 6 , Harold E. Paulus 1 , Sandeep Chaudhari 3 ,<br />

JingYaun Feng 2 , David A. Elash<strong>of</strong>f 4 and Veena K. Ranganath 5 ,<br />

1<br />

Encino, CA, 2 Amgen, 3 Kforce Clinical Research/Amgen, 4 UCLA,<br />

5<br />

UCLA School <strong>of</strong> Med Rehab 32-59, Los Angeles, CA, 6 UCLA/ VA<br />

Greater Los Angeles Healthcare System, Los Angeles, CA.<br />

1790. Assessment <strong>of</strong> Real Life Efficacy <strong>of</strong> Rituximab in Rheumatoid<br />

Arthritis: Predicting Factors <strong>of</strong> the Therapeutic Maintenance<br />

and Demonstration <strong>of</strong> a Corticosteroid Sparing Effect in<br />

the AutoImmunity and Rituximab Registry. Jacques-Eric<br />

Gottenberg 10 , Philippe Ravaud 4 , Thomas Bardin 6 , Patrice<br />

Cacoub 5 , Alain Cantagrel 11 , Bernard Combe 8 , Maxime<br />

Dougados 2 , René-Marc Flipo 7 , Bertrand Godeau 3 , Loic Guillevin 2 ,<br />

Eric Hachulla 7 , Xavier Le Loët 9 , Thierry Schaeverbeke 1 , Jean<br />

Sibilia 10 , Gabriel Baron 4 and Xavier Mariette, 1 Bordeaux<br />

Hospital, 2 Cochin Hospital, 3 Henri Mondor Hospital, 4 Hotel Dieu<br />

Hospital, 5 La Pitié Hospital, 6 Lariboisière Hospital, 7 Lille Hospital,<br />

8<br />

Montpellier Hospital, 9 Rouen Hospital, 10 Strasbourg Hospital,<br />

11<br />

Toulouse Hospital.<br />

1791. Clinical and Functional Improvements in Early RA Following<br />

Treatment with Adalimumab Plus Methotrexate Compared<br />

with Methotrexate Monotherapy: 26-Week Results <strong>of</strong> the<br />

OPTIMA Trial. Arthur Kavanaugh 5 , Roy Fleischmann 6 , Paul<br />

Emery 3 , Benoit Guérette 1 , Laura Redden 2 , Kaushik Patra 2 and<br />

Josef S. Smolen 4 , 1 Abbott Laboratories, Rungis, France, 2 Abbott<br />

Laboratories, Abbott Park, IL, 3 Leeds Teaching Hospital, Leeds,<br />

United Kingdom, 4 Medical University <strong>of</strong> Vienna and Hietzing<br />

Hospital, Vienna, Austria, 5 University <strong>of</strong> California San Diego,<br />

La Jolla, CA, 6 University <strong>of</strong> Texas Southwestern Medical Center,<br />

Dallas, TX.<br />

2010 Program Book 257


ACR/ARHP Poster Session C<br />

258<br />

1792. Clinical Response during Sequential Anti-Tumor Necrosis<br />

Factor Therapy in US Veterans Enrolled in the Veterans<br />

Affairs Rheumatoid Arthritis (VARA) Registry. Grant W.<br />

Cannon 4 , Brian C. Sauer 5 , Candace L. Hayden 5 , Liron Caplan 2 ,<br />

Gail S. Kerr 7 , J. Steuart Richards 8 , Dannette S. Johnson 3 , Ted R.<br />

Mikuls 6 and Andreas M. Reimold 1 , 1 Dallas VA and University<br />

<strong>of</strong> Texas Southwestern, Dallas, TX, 2 Denver VA and University<br />

<strong>of</strong> Colorado, Aurora, CO, 3 Jackson VA and University <strong>of</strong><br />

Mississippi, Jackson, MS, 4 Salt Lake City VA and University <strong>of</strong><br />

Utah, Salt Lake City, UT, 5 Salt Lake City VA and University <strong>of</strong><br />

Utah, 6 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE, 7 Washington VA<br />

and Georgetown and Howard Universities, Washington, DC,<br />

8<br />

Washington VA and Georgetown University, Washington, DC.<br />

1793. Clinical, Structural and Functional Remission in the Treatment<br />

<strong>of</strong> Rheumatoid Arthritis with Tocilizumab in Daily Clinical<br />

Practice – REACTION-2 Study. Tsutomu Takeuchi 2 , Yoshiya<br />

Tanaka 5 , Kouichi Amano 1 , Eri Sato 4 , Masao Nawata 6 , Hayato<br />

Nagasawa 1 , Daisuke Hoshi 4 , Masayoshi Saito 6 , Syunsuke<br />

Fukuyo 6 , Kentarou Hanami 6 , Hideto Kameda 3 , Takahiko<br />

Kurasawa 1 and Hisashi Yamanaka 4 , 1 Division <strong>of</strong> <strong>Rheumatology</strong><br />

and Clinical Immunology, Department <strong>of</strong> Internal Medicine,<br />

Saitama Medical Center, Saitama Medical University, Saitama,<br />

Japan, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, School <strong>of</strong> Medicine, Keio<br />

University, Tokyo, Japan, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, School<br />

<strong>of</strong> Medicine, Keio University, Tokyo, Japan, 4 Institute <strong>of</strong><br />

<strong>Rheumatology</strong>, Tokyo Women’s Medical University, Tokyo,<br />

Japan, 5 The First Department <strong>of</strong> Internal Medicine, School <strong>of</strong><br />

Medicine, University <strong>of</strong> Occupational &Environmental Health,<br />

Kitakyusyu, Japan, 6 The First Department <strong>of</strong> Internal Medicine,<br />

School <strong>of</strong> Medicine, University <strong>of</strong> Occupational &Environmental<br />

Health, Kitakyushu, Japan.<br />

1794. Comparable Persistency and Effectiveness <strong>of</strong> Abatacept<br />

Versus Anti-TNF Agents in the Treatment <strong>of</strong> Biologic-Naïve<br />

Rheumatoid Arthritis Patients Using the CORRONA Registry.<br />

Leslie Harrold 3 , George Reed 3 , Lisa C. Rosenblatt 1 , Monica<br />

Mody 1 , Diane Moniz Reed 1 and Jeffrey Greenberg 2 , 1 Bristol-<br />

Myers Squibb, Princeton, NJ, 2 NYU Hospital <strong>of</strong> Joint Diseases,<br />

New York, NY, 3 University <strong>of</strong> Massachusetts Medical School,<br />

Worcester, MA.<br />

1795. Comparative Effectiveness <strong>of</strong> Biological Treatment Options<br />

Following Tumor Necrosis Factor α Inhibitor Failure in<br />

Rheumatoid Arthritis: Systematic Review and Indirect Pairwise<br />

Meta-Analysis. Monika Schoels 1 , John B. Wong 2 , Daniel Aletaha 3<br />

and Josef S. Smolen 4 , 1 2nd Department <strong>of</strong> Internal Medicine,<br />

Hietzing Hospital, Vienna, Austria; Div. <strong>of</strong> Clinical Decision<br />

Making, Informatics and Telemedicine, Tufts University School<br />

<strong>of</strong> Medicine, Boston, MA, 2 Div. <strong>of</strong> Clinical Decision Making,<br />

Informatics and Telemedicine, Tufts University School <strong>of</strong><br />

Medicine, Boston, MA, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />

<strong>of</strong> Medicine 3 , Medical University <strong>of</strong> Vienna, Austria, 4 Division <strong>of</strong><br />

<strong>Rheumatology</strong>, Department <strong>of</strong> Medicine 3 , Medical University <strong>of</strong><br />

Vienna, Austria; 2nd Department <strong>of</strong> Internal Medicine, Hietzing<br />

Hospital, Vienna, Austria.<br />

1796. Comparative Effectiveness <strong>of</strong> Rituximab in Combination with<br />

Either Methotrexate or Leflunomide in the Treatment <strong>of</strong><br />

Rheumatoid Arthritis. Javier Narvaez 4 , César Díaz Torné 2 , José<br />

Miguel Ruiz 3 , Maria Victoria Hernández 1 , Vicens Torrente 2 and<br />

Sergio Ros 3 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Clinic,<br />

Barcelona, Spain, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />

de la Santa Creu i Sant Pau, Barcelona, Spain, 3 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Hospital de Viladecans, Barcelona, Spain,<br />

4<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario de<br />

Bellvitge, Barcelona, Spain.<br />

2010 Program Book<br />

1797. Comparison <strong>of</strong> Tocilizumab and Infliximab Treatment for RA<br />

for a Duration <strong>of</strong> 12 Weeks, Based on MMP-3: Preliminary<br />

Report. Isamu Yokoe 1 , Hitomi Kobayashi 2 , Hiroshi Sato 2 and<br />

Shinya Nishio 2 , 1 Itabashi Chuo Medical Center, Tokyo, Japan,<br />

2<br />

Itabashi Chuo Medical Center.<br />

1798. CTLA-4-Ig Fusion Protein (Abatacept) Modulate Inflammatory<br />

Activity <strong>of</strong> Cultured Synovial Macrophages from Rheumatoid<br />

Arthritis Patients. Maurizio E. Cutolo 6 , Stefano Soldano 3 ,<br />

Paola Montagna 3 , Alberto Sulli 3 , Bruno Seriolo 3 , Barbara<br />

Villaggio 4 , Pier Franco Triolo 5 , Paolo Clerico 5 , Lamberto Felli 1 ,<br />

Luigi Molfetta 2 and Renata Brizzolara 3 , 1 Academic Orthopedic<br />

Department, University <strong>of</strong> Genova, Italy, 2 Orthopedic Unit, San<br />

Martino Hospital, Genova, Italy, 3 Research Laboratories and<br />

Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine, University <strong>of</strong> Genova, Italy, 4 Research Laboratory <strong>of</strong><br />

Nephrology, Department <strong>of</strong> Internal Medicine - University <strong>of</strong><br />

Genova, Italy, 5 Rheumatoid Arthritis Unit – Orthopedic Surgery<br />

Department. CTO Hospital, Turin, Italy, 6 University <strong>of</strong> Genova,<br />

Genova, Italy.<br />

1799. Dosing <strong>of</strong> Anti-Tumor Necrosis Factor Biologics (Anti-TNFs)<br />

for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) in<br />

Clinical Practice in the United States. J. Timothy Harrington 5 ,<br />

Dimitrios A. Pappas 2 , Susan Messing 4 , Xin Tu 4 , Rui Chen 4 ,<br />

Kimberly Kaukeinen 4 , Timothy Pietras 4 , Jeffrey D. Greenberg 1<br />

and Joel M. Kremer 3 , 1 Millburn, NJ, 2 Johns Hopkins University,<br />

Baltimore, MD, 3 The Center for <strong>Rheumatology</strong>, Albany,<br />

NY, 4 University <strong>of</strong> Rochester Medical Center, 5 University <strong>of</strong><br />

Wisconsin, Madison, WI.<br />

1800. Drug Free REmission after Cessation <strong>of</strong> Tocilizumab (Actemra)<br />

Monotherapy (DREAM Study). Norihiro Nishimoto, Wakayama<br />

Medical University, Ibaraki-City, Japan.<br />

1801. Effect <strong>of</strong> Rituximab Treatment on Il-15 and T Cell<br />

Subpopulations in Rheumatoid Arthritis Patients. Cesar Diaz-<br />

Torne 1 , Maria A. Ortiz 1 , Carme Geli 1 , Josep M. Llobet 1 , Elisabeth<br />

Cantó 1 , Elena Perez 1 , Hector Corominas 2 , Candido Juarez 1 , Cesar<br />

R. Diaz-Lopez 1 and Silvia Vidal 1 , 1 Hospital de la Santa Creu i Sant<br />

Pau, 2 Hospital Moises Broggi.<br />

1802. Effectiveness <strong>of</strong> Different DMARD Co-Therapies in Rituximab-<br />

Treated Rheumatoid Arthritis (RA) Patients – Results <strong>of</strong> a<br />

One-Year Follow Up Study from the CERRERA Collaboration.<br />

Cem Gabay 12 , Katerina Chatzidionysou 11 , Elisabeth Lie 5 , Galina<br />

Lukina 9 , Merete L. Hetland 2 , Ulrik Tarp 3 , Piet L. Van Riel 14 ,<br />

Dan Nordström 6 , Juan J. Gomez-Reino 7 , Karel Pavelka 1 , Matija<br />

Tomsic 13 , Evgeny L. Nasonov 8 , Tore K. Kvien 4 and Ronald<br />

Van Vollenhoven 10 , 1 Charles Univ, Prague, Czech Republic,<br />

2<br />

Copenhagen Univ Hosp Hvidovre, Hvidovre, Denmark,<br />

3<br />

Copenhagen Univ Hosp Hvidovre, 4 Diakonhjemmet Hospital,<br />

Oslo, Norway, 5 Diakonhjemmet Hospital, Oslo, Norway, 6 Helsinki<br />

Univ Hosp, Helsinki, Finland, 7 Hospital Clinico Universitario,<br />

Santiago, Spain, 8 Institue <strong>of</strong> <strong>Rheumatology</strong>, Moscow,<br />

Russian Federation, 9 Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow,<br />

Russia, 10 Karolinska University Hospital, Stockholm, Sweden,<br />

11<br />

Karolinska, Stockholm, Sweden, Sweden, 12 Univ Hosp <strong>of</strong><br />

Geneva, Geneva, Switzerland, 13 Univ Medical Center, Ljubljana,<br />

Ljubljana, Slovenia, 14 University Hosp Nijmegen, Nijmegen, The<br />

Netherlands.<br />

1803. Effects <strong>of</strong> Anti-TNF Agents on the Lung Function <strong>of</strong> Patients<br />

with Rheumatoid Arthritis: A Prospective Study. Meryem Can 1 ,<br />

Sait Karakurt 3 , Atilla Bulur 1 , Pamir Atagündüz 1 , Sule Yavuz 2 ,<br />

Haner Direskeneli 2 and Nevsun Inanç 2 , 1 Marmara University<br />

Medical School, Division <strong>of</strong> <strong>Rheumatology</strong>, Istanbul, Turkey,<br />

2<br />

Marmara University Medical School, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />

3<br />

Marmara University Medical SchoolDepartment <strong>of</strong> Pulmonary<br />

and Critical Care, Istanbul, Turkey.


ACR/ARHP Poster Session C<br />

1804. Effects <strong>of</strong> Subcutaneous and Intravenous Golimumab on<br />

Markers <strong>of</strong> Inflammation in Patients with Rheumatoid<br />

Arthritis. Mittie K. Doyle 4 , Mahboob U. Rahman 4 , Bart<br />

Frederick 2 , Charles A. Birbara 6 , Dick de Vries 1 , Gary Toedter 3 ,<br />

Xiaoying Wu 3 , Dion Chen 2 , Mark Westerman 5 and Daniel E.<br />

Furst 7 , 1 Centocor B.V., Leiden, The Netherlands, 2 Centocor<br />

Research and Development, Inc., Malvern, PA, 3 Centocor<br />

Research and Development, Inc., 4 Centocor Research and<br />

Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />

Malvern, PA, 5 Intrinsic Life Sciences, 6 Univ. <strong>of</strong> Massachusetts City<br />

Campus, Worcester, MA, 7 University <strong>of</strong> California Los Angeles<br />

Medical School, Los Angeles, CA.<br />

1805. Efficacy and Safety <strong>of</strong> Certolizumab Pegol in a Clinically<br />

Representative Population <strong>of</strong> Patients (Pts) with Active<br />

Rheumatoid Arthritis (RA): Results <strong>of</strong> the REALISTIC Phase<br />

IIIb Randomized Controlled Study. Michael Weinblatt 2 , Roy<br />

Fleischmann 8 , Paul Emery 3 , Niti Goel 11 , Clifton O. Bingham 5 ,<br />

Janet Pope 9 , Elena Massarotti 1 , Ronald van Vollenhoven 6 ,<br />

Thomas W. J. Huizinga 7 , Benjamin Duncan 10 and Maxime<br />

Dougados 4 , 1 Brigham and Women’s Hospital, Boston, MA,<br />

2<br />

Brigham and Women’s Hospital, 3 Chapel Allerton Hospital,<br />

Leeds, United Kingdom, 4 Hospital Cochin, Paris, France, 5 Johns<br />

Hopkins University, Baltimore, MD, 6 Karolinska Institute,<br />

Stockholm, Sweden, 7 Leiden University Medical Centre, Leiden,<br />

The Netherlands, 8 MCRC, University <strong>of</strong> Texas, Dallas, TX, 9 St.<br />

Joseph’s Health Care, University <strong>of</strong> Western Ontario, London,<br />

ON, Canada, 10 UCB, Raleigh, NC, 11 UCB, Smyrna, GA.<br />

1806. Efficacy and Safety <strong>of</strong> Certolizumab Pegol Plus Methotrexate<br />

in Patients with Rheumatoid Arthritis (RA): 3-Year Data<br />

from the RAPID 2 Study. Josef S. Smolen 4 , Ronald F. van<br />

Vollenhoven 1 , Arthur Kavanaugh 8 , Niti Goel 7 , Andreas<br />

Fichtner 6 , Vibeke Strand 3 , Jiri Vencovsky 5 and Desiree van der<br />

Heijde 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, Karolinska Institute,<br />

Stockholm, Sweden, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden<br />

University Medical Center, Leiden University Medical Center,<br />

Leiden, Meerssen, The Netherlands, 3 Division <strong>of</strong> Immunology<br />

and <strong>Rheumatology</strong>, Stanford University School <strong>of</strong> Medicine,<br />

Palo Alto, CA, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Medical University<br />

<strong>of</strong> Vienna and Hietzing Hospital, Vienna, Austria, 5 Institute<br />

<strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 6 UCB, Monheim,<br />

Germany, 7 UCB, Smyma, GA, 8 University <strong>of</strong> California-San Diego,<br />

La Jolla, CA.<br />

1807. Efficacy and Safety <strong>of</strong> Rituximab Treatment in Clinical<br />

Practice: Data from the CERERRA Collaboration. Katerina<br />

Chatzidionysiou 10 , Elisabeth Lie 5 , Galina Lukina 8 , Merete L.<br />

Hetland 3 , Ulrik Tarp 2 , Cem Gabay 12 , Piet L. Van Riel 14 , Dan C.<br />

Nordström 11 , Juan J. Gomez-Reino 6 , Karel Pavelka 1 , Matija<br />

Tomsic 13 , Evgeny L. Nasonov 7 , Tore K. Kvien 4 and Ronald Van<br />

Vollenhoven 9 , 1 Charles Univ, Prague, 2 DANBIO, Univ Hosp,<br />

Copenhagen, Denmark, 3 DANBIO, Univ Hosp, Copenhagen,<br />

Denmark, 4 Diakonhjemmet Hospital, Oslo, Norway,<br />

5<br />

Diakonhjemmet Hospital, Oslo, Norway, 6 Hospital Clinico<br />

Universitario, Santiago, Spain, 7 Institue <strong>of</strong> <strong>Rheumatology</strong>,<br />

Moscow, Russian Federation, 8 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />

Moscow, 9 Karolinska University Hospital, Stockholm, Sweden,<br />

10<br />

Karolinska University Hospital, Stockholm, 11 ROB-FIN Univ<br />

Hosp, Helsinki, 12 Univ Hosp <strong>of</strong> Geneva, Geneva, Switzerland,<br />

13<br />

Univ Med Center, Ljubljana, 14 University Hosp Nijmegen,<br />

Nijmegen, The Netherlands.<br />

1808. Efficacy and Safety <strong>of</strong> Tocilizumab in Patients with Moderate<br />

to Severe Active RA and a Previous Inadequate Response<br />

to DMARDs: The ROSE Study. Yusuf Yazici 3 , Jeffrey R. Curtis 6 ,<br />

Akgun Ince 4 , Herbert Baraf 5 , Raymond L. Malamet 1 , Carol Y.<br />

Chung 2 and Arthur Kavanaugh 7 , 1 Genentech, a Member <strong>of</strong><br />

the Roche Group, South San Francisco, South San Francisco,<br />

CA, 2 Genentech, a Member <strong>of</strong> the Roche Group, South San<br />

Francisco, CA, 3 NYU Hospital for Joint Diseases, New York,<br />

NY, 4 St. Louis University School <strong>of</strong> Medicine, St. Louis, MO,<br />

5<br />

The Center for <strong>Rheumatology</strong> and Bone Research, Wheaton,<br />

Wheaton, MD, 6 University <strong>of</strong> Alabama at Birmingham,<br />

Birmingham, AL, 7 University <strong>of</strong> California at San Diego, La Jolla,<br />

CA.<br />

1809. Efficacy <strong>of</strong> Abatacept and Tocilizumab in Rheumatoid<br />

Arthritis Patients Treated in Clinical Practice. Results from<br />

the Nationwide Danish DANBIO Registry. Henrik C. Leffers 4 ,<br />

Mikkel Ostergaard 4 , Bente Glintborg 7 , Niels Steen Krogh 10 , Heidi<br />

Foged 6 , Ulrik Tarp 1 , Tove Lorenzen 9 , Annette Hansen 3 , Michael<br />

S. Hansen 2 , Martin S. Jacobsen 8 and Merete L. Hetland 5 , 1 Aarhus<br />

University Hospital, Denmark, 2 Copenhagen University Hospital<br />

Gent<strong>of</strong>te, Denmark, 3 DANBIO Registry, and Copenhagen<br />

University Hospital Gent<strong>of</strong>te, Denmark, 4 DANBIO Registry,<br />

and Copenhagen University Hospital, Hvidovre and Glostrup,<br />

Hvidovre, Denmark, 5 DANBIO Registry, and Copenhagen<br />

University Hospital, Hvidovre and Glostrup, Denmark,<br />

6<br />

Frederiksberg Hospital, Denmark, 7 Holbæk Hospital, Denmark,<br />

8<br />

Randers Hospital, Denmark, 9 Vejle Hospital, Denmark, 10 Zitelab<br />

Aps, Denmark.<br />

1810. Efficacy <strong>of</strong> Rituximab on Pulmonary Rheumatoid Nodules:<br />

Data <strong>of</strong> 10 Patients from the French AIR/PR Registry. Baptiste<br />

Glace 7 , Jacques E. Gottenberg 13 , Xavier Mariette 1 , Antoine<br />

Roche 5 , Jean-Marie Berthelot 11 , Maxime Dougados 3 , Eric<br />

Toussirot 6 , Thao Pham 9 , Yannick Allanore 2 , Damien Loeuille 10 ,<br />

Liana E. Euller-Ziegler 4 , Thierry Lequerré 12 and Martin Soubrier 8 ,<br />

1<br />

Bicetre Hospital/Paris Univ, Le Kremlin Bicetre, France,<br />

2<br />

Hopitaux de Paris Cochin, Paris, France, 3 Hospital Cochin,<br />

Paris, France, 4 L’Archet Hospital (University), Nice, France,<br />

5<br />

Radiology Department, CHU Clermont-Ferrand, 6 <strong>Rheumatology</strong><br />

Department, CHU Besançon, 7 <strong>Rheumatology</strong> Department,<br />

CHU Clermont-Ferrand, 8 <strong>Rheumatology</strong> Department, CHU<br />

Clermont-Ferrand, 9 <strong>Rheumatology</strong> Department, CHU Marseille,<br />

10<br />

<strong>Rheumatology</strong> Department, CHU Nancy, 11 <strong>Rheumatology</strong><br />

Department, CHU Nantes, 12 <strong>Rheumatology</strong> Department, CHU<br />

Rouen, 13 Strasbourg Hospitals, Strasbourg, France.<br />

1811. Etanar® Therapy in Real-Life Patients with Rheumatoid<br />

Arthritis. Federico Rondon 11 , Alain Bautista 4 , Juan Carlos<br />

Salazar 1 , Nohemí Casas 9 , Pedro Santos 9 , Francisco Vargas 6 , Javier<br />

Márquez 2 , Fredy Pumarejo 8 , Fernando Fernández 3 , Andrés<br />

Fernández 5 , Rossana Mejía 1 , Oscar Ruiz 1 , Alberto Torrenegra 3 ,<br />

Jose Bernardo Martínez 7 and Rubén Darío Mantilla 10 , 1 CIREI,<br />

Bogota, 2 Hospital Pablo Tobon Uribe, Medellin, 3 <strong>Rheumatology</strong>,<br />

Barranquilla, 4 <strong>Rheumatology</strong>, Cucuta, 5 <strong>Rheumatology</strong>,<br />

Ibague, 6 <strong>Rheumatology</strong>, Medellin, 7 <strong>Rheumatology</strong>, Monteria,<br />

8<br />

<strong>Rheumatology</strong>, Valledupar, 9 Riesgo de Fractura-CAYRE IPS,<br />

Bogota, 10 Riesgo de Fractura-CAYRE IPS, Bogota, Colombia,<br />

11<br />

Universidad Nacional, Bogota.<br />

2010 Program Book 259


ACR/ARHP Poster Session C<br />

1812. Etanercept (ETN) Plus Methotrexate (MTX) Combination<br />

Therapy Resulted in a Better Radiographic Outcome Than<br />

ETN Monotherapy Even in Patients with Active Rheumatoid<br />

Arthritis Despite MTX Treatment: 104-Week Results from<br />

the JESMR Study. Hideto Kameda 2 , Katsuaki Kanbe 7 , Eri Sato 7 ,<br />

Yukitaka Ueki 5 , Kazuyoshi Saitoh 8 , Shouhei Nagaoka 9 , Toshihiko<br />

Hidaka 10 , Tatsuya Atsumi 1 , Michishi Tsukano 4 , Tsuyoshi Kasama 6 ,<br />

Shunichi Shiozawa 3 , Yoshiya Tanaka 8 , Hisashi Yamanaka 7 and<br />

Tsutomu Takeuchi 2 , 1 Hokkaido University Graduate School<br />

<strong>of</strong> Medicine, 2 Keio University, 3 Kobe University Hospital,<br />

4<br />

Kumamoto Orthopaedic Hospital, 5 Sasebo Chuo Hospital,<br />

6<br />

Showa University School <strong>of</strong> Medicine, 7 Tokyo Women’s Medical<br />

University Medical Center, 8 University <strong>of</strong> Occupational and<br />

Environmental Health, 9 Yokohama Minami Kyosai Hospital,<br />

10<br />

Zenjinkai Shimin-No-Mori-Hospital.<br />

1813. Etanercept Normalizes Systemic Bone Metabolism in<br />

Rheumatoid Arthritis Patients. Won Park 2 , Mie Jin Lim 1 , Seong<br />

Ryul Kwon 1 , Ji Yeol Yoon 1 , Chang Gi Moon 1 and Go Eun Ju 1 , 1 Inha<br />

University Hospital, Incheon, Republic <strong>of</strong> Korea, 2 Inha University<br />

Hospital, Choong-Gu Incheon, Korea, Republic <strong>of</strong>.<br />

1814. Golimumab, a Human Anti-TNFα Monoclonal Antibody<br />

Administered Subcutaneously Every Four Weeks as<br />

Monotherapy in Patients with Active Rheumatoid Arthritis<br />

Despite DMARD Therapy: 24-Week Results <strong>of</strong> Clinical and<br />

Radiographic Assessments. Tsutomu Takeuchi 5 , Masayoshi<br />

Harigai 8 , Yoshiya Tanaka 10 , Hisashi Yamanaka 9 , Naoki Ishiguro 7 ,<br />

Kazuhiko Yamamoto 11 , Takuya Oba 4 , Mahboob U. Rahman 1 ,<br />

Toru Yoshinari 6 , Nobuyuki Miyasaka 2 and Takao Koike 3 ,<br />

1<br />

Centocor Research and Development, Inc., Malvern, PA,<br />

2<br />

Graduate School <strong>of</strong> Medical and Dental Sciences, Tokyo, Japan,<br />

3<br />

Hokkaido University Graduate School <strong>of</strong> Medicine, 4 Janssen<br />

Pharmaceutical K.K., 5 Keio University, Toyko, Japan, 6 Mitsubishi<br />

Tanabe Pharma Corporation, 7 Nagoya University, 8 Tokyo Medical<br />

and Dental University, Tokyo, Japan, 9 Tokyo Womens Med Univ,<br />

Shinjuku-ku, Tokyo, Japan, 10 University <strong>of</strong> Occupational and<br />

Environmental Health, Kitakyushu, Japan, 11 University <strong>of</strong> Tokyo<br />

Graduate School <strong>of</strong> Medicine, Tokyo, Japan.<br />

1815. Golimumab, a Human Anti-TNFα Monoclonal Antibody<br />

Administered Subcutaneously Every Four Weeks in Patients<br />

with Active Rheumatoid Arthritis Despite Methotrexate<br />

Therapy: 24-Week Results <strong>of</strong> Clinical and Radiographic<br />

Assessments. Yoshiya Tanaka 10 , Masayoshi Harigai 8 ,<br />

Tsutomu Takeuchi 4 , Hisashi Yamanaka 9 , Naoki Ishiguro 6 ,<br />

Kazuhiko Yamamoto 7 , Takuya Oba 3 , Mahboob U. Rahman 1 ,<br />

Toru Yoshinari 5 , Nobuyuki Miyasaka 8 and Takao Koike 2 ,<br />

1<br />

Centocor Research and Development, Inc., Malvern, PA,<br />

2<br />

Hokkaido University Graduate School <strong>of</strong> Medicine, 3 Janssen<br />

Pharmaceutical K.K., 4 Keio University, Toyko, Japan, 5 Mitsubishi<br />

Tanabe Pharma Corporation, 6 Nagoya University, 7 The University<br />

<strong>of</strong> Tokyo, 8 Tokyo Medical and Dental University, Tokyo, Japan,<br />

9<br />

Tokyo Womens Medical University, Shinjuku-ku, Tokyo,<br />

Japan, 10 University <strong>of</strong> Occupational and Environmental Health,<br />

Kitakyushu, Japan.<br />

1816. Impact <strong>of</strong> Abatacept on Circulating Dendritic Cells and<br />

Regulatory T Cells in Rheumatoid Arthritis Patients with<br />

Inadequate Response or Intolerance to TNF-alpha Blockers.<br />

Emilie Shipley 1 , Christophe Richez 1 , Thomas Barnetche 2 , Cécile<br />

Contin-Bordes 2 , Patrick Blanco 2 and Thierry Schaeverbeke 1 ,<br />

1<br />

Hôpital Pellegrin, Bordeaux, France, Metropolitan, 2 Hôpital<br />

Pellegrin, France, Metropolitan.<br />

1817. Impact <strong>of</strong> Abatacept on Synovitis and Structural Damage in<br />

Methotrexate (MTX)-Inadequate Responders with Active<br />

Rheumatoid Arthritis (RA): A Randomized, Controlled<br />

Magnetic Resonance Imaging (MRI) Exploratory Study. Philip<br />

G. Conaghan 9 , Patrick Durez 8 , Rieke Alten 6 , Gerd Burmester 4 ,<br />

Paul P. Tak 1 , Lars Klareskog 5 , Corine Gaillez 2 , Manuela Le Bars 2 ,<br />

Xianhuang Zhou 3 and Charles Peterfy 7 , 1 Academic Medical<br />

Center/University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

2<br />

Bristol-Myers Squibb, Rueil-Malmaison, France, 3 Bristol-Myers<br />

Squibb, Princeton, NJ, 4 Charité-Universitatsmedizin, Berlin,<br />

Germany, 5 Karolinska University Hospital, Stockholm, Sweden,<br />

6<br />

Schlosspark-Klinik, University Medicine Berlin, Germany,<br />

7<br />

Spire Science LCC, San Francisco, CA, 8 Université Catholique de<br />

Louvain, Brussels, Belgium, 9 University <strong>of</strong> Leeds, Leeds, UK.<br />

1818. Key Pharmacological Parameters Support Monthly Dosing<br />

for Golimumab. Mahboob U. Rahman 2 , Ann Cai 1 , Eilyn Lacy 1 ,<br />

Jonathan Kay 4 , Ed C. Keystone 5 , Eric L. Matteson 3 , Chuanpu<br />

Hu 1 , Honghui Zhou 1 and Dave Shealy 1 , 1 Centocor Research and<br />

Development, Inc., 2 Centocor Research and Development,<br />

Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Malvern, PA,<br />

3<br />

Mayo Clinic, Rochester, MN, 4 UMass Memorial Medical Center,<br />

Worcester, MA, 5 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

1819. LITHE: Tocilizumab (TCZ) Inhibits Radiographic Progression<br />

and Improves Physical Function in Rheumatoid Arthritis (RA)<br />

Patients (pts) at 3 Years with Maintenance <strong>of</strong> Clinical Efficacy<br />

over Time. Joel M. Kremer 1 , Daniel E. Furst 6 , Ruben Burgos-<br />

Vargas 3 , Jean Dudler 2 , Christopher M. Mela 5 , Emma Vernon 5<br />

and Roy M. Fleischmann 4 , 1 Albany Medical <strong>College</strong>, Albany,<br />

NY, 2 Hôpital Orthopédique, Epalinges, Switzerland, 3 Hospital<br />

General de México and Universidad Nacional Autónoma de<br />

México, Mexico City, México, Mexico, 4 Metroplex Clinical<br />

Research Center, Dallas, TX, 5 Roche, Welwyn, United Kingdom,<br />

6<br />

UCLA Medical Center, Los Angeles, CA.<br />

1820. Long-Term Efficacy <strong>of</strong> Tocilizumab (TCZ) in Patients (Pts) with<br />

Rheumatoid Arthritis (RA) Treated up to 3.7 Years. Majed<br />

Khraishi 3 , Rieke Alten 8 , Juan J. Gomez-Reino 2 , Warren Rizzo 1 ,<br />

Joy Schechtman 6 , Andre Kahan 4 , Emma Vernon 5 , Monet Taylor 5<br />

and Josef Smolen 7 , 1 Advanced Arthritis Care, Scottsdale, AZ,<br />

2<br />

Hospital Clínico U. de Santiago, Santiago, Spain, 3 Memorial<br />

University <strong>of</strong> Newfoundland, St. John’s, NL, Canada, 4 Paris<br />

Descartes University, Paris, France, 5 Roche, Welwyn, UK,<br />

6<br />

SunValley Arthritis Center, Peoria, AZ, 7 University Clinic for<br />

Internal Medicine, Vienna, Austria, 8 University <strong>of</strong> Berlin, Berlin,<br />

Germany.<br />

1821. Mechanism <strong>of</strong> Inhibition <strong>of</strong> Joint Destruction by Rituximab<br />

in Rheumatoid Arthritis. Maria J. H. Boumans 2 , Rogier<br />

M. Thurlings 3 , Koen Vos 4 , Danielle M. Gerlag 3 and Paul P.<br />

Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />

The Netherlands, 2 Academic Medical Center/University <strong>of</strong><br />

Amsterdam, Amsterdam, Noord-Holland, The Netherlands,<br />

3<br />

Academic Medical Center/University <strong>of</strong> Amsterdam, 4 Academic<br />

Medical Center/University <strong>of</strong> Amsterdam/Jan van Breemen<br />

Institute.<br />

1822. Monocyte Migration to the Synovium in Rheumatoid Arthritis<br />

Patients Treated with Adalimumab. Marieke Herenius 3 , Rogier<br />

Thurlings 4 , Carla Wijbrandts 4 , Roel<strong>of</strong> Bennink 5 , Serge Dohmen 6 ,<br />

Carlijn Voermans 6 , Diana Wouters 2 , Elena Izmailova 7 , Daniëlle<br />

Gerlag 4 , Berthe van Eck-Smit 5 and Paul P. Tak 1 , 1 Academic<br />

Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

2<br />

Department <strong>of</strong> Immunopathology, Sanquin Research,<br />

Amsterdam, Noord Holland, The Netherlands, Division <strong>of</strong> Clinical<br />

260<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

Immunology and <strong>Rheumatology</strong>, Academic Medical Center<br />

/ University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

4<br />

Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />

Medical Center, University <strong>of</strong> Amsterdam, Amsterdam, The<br />

Netherlands, 5 Division <strong>of</strong> Nuclear Medicine, Academic Medical<br />

Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />

6<br />

Landsteiner Laboratory, Department <strong>of</strong> Experimental<br />

Immunohematology, Sanquin Research, Amsterdam, The<br />

Netherlands, 7 Millennium Pharmaceuticals, Inc, Department <strong>of</strong><br />

Research and Development, Cambridge, MA.<br />

1823. Multiple Regression Analysis on the Clinical Parameters<br />

Associating with Clinical, Structural and Functional Remission<br />

at 52 Weeks in RA Patients Treated with Anti-IL-6 Receptor<br />

Antibody, Tocilizumab – REACTION-2 Study. Tsutomu Takeuchi 2 ,<br />

Yoshiya Tanaka 5 , Kouichi Amano 1 , Eri Sato 4 , Masao Nawata 5 ,<br />

Hayato Nagasawa 1 , Daisuke Hoshi 4 , Kazuyoshi Saito 5 , Syunsuke<br />

Fukuyo 5 , Kentarou Hanami 5 , Takahiko Kurasawa 1 , Hideto<br />

Kameda 3 and Hisashi Yamanaka 4 , 1 Division <strong>of</strong> <strong>Rheumatology</strong> and<br />

Clinical Immunology, Department <strong>of</strong> Internal Medicine, Saitama<br />

Medical Center, Saitama Medical University, Saitama, Japan,<br />

2<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, School <strong>of</strong> Medicine, Keio University,<br />

Tokyo, Japan, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, School <strong>of</strong> Medicine,<br />

Keio University, Tokyo, Japan, 4 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />

Tokyo Women’s Medical University, Tokyo, Japan, 5 The<br />

First Department <strong>of</strong> Internal Medicine, School <strong>of</strong> Medicine,<br />

University <strong>of</strong> Occupational &Environmental Health, Kitakyushu,<br />

Japan.<br />

1824. Outcome <strong>of</strong> Interstitial Lung Disease (ILD) after Administration<br />

<strong>of</strong> Biologics in Patients with Pre-Existing ILD in RA. Shinji<br />

Motojima 1 , Tamao Nakashita 1 , Akira Inoue 1 , Kei-ichi Inoue 1<br />

and Natsuki Fujio 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Allergy,<br />

Kameda Medical Center, Kamogawa, Chiba, Japan, 2 Department<br />

<strong>of</strong> <strong>Rheumatology</strong> and Allergy, Kameda Medical Center, Japan.<br />

1825. Patients Not Responding to Etanercept Obtain Lower Trough<br />

Etanercept Concentrations Compared to Responding Patients.<br />

Anna Jamnitski 1 , Michael T. Nurmohamed 1 , Margreet M. Hart 2 ,<br />

Ben A. Dijkmans 3 , Lucien Aarden 2 and Gerrit Jan Wolbink 1 , 1 Jan<br />

van Breemen Institute, 2 Sanquin Research, 3 VU Medical Center.<br />

1826. Prevalence and Persistence <strong>of</strong> Low Infliximab Serum Trough<br />

Levels in RA Patients with Low Disease Activity in Daily Clinical<br />

Practice. Aatke van der Maas 3 , Alfons A. Den Broeder 4 , Gert-Jan<br />

Wolbink 1 , Frank H. J. van den Hoogen 4 , Piet L. C. M. van Riel 5<br />

and Bart J. F. van den Bemt 2 , 1 Department <strong>of</strong> Immunopathology,<br />

Sanquin Research, Amsterdam, The Netherlands, 2 Department<br />

<strong>of</strong> Pharmacy, St. Maartenskliniek, Nijmegen, The Netherlands,<br />

3<br />

Department <strong>of</strong> <strong>Rheumatology</strong>, St. Maartenskliniek, Nijmegen,<br />

The Netherlands, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, St.<br />

Maartenskliniek, Nijmegen, The Netherlands, 5 Department <strong>of</strong><br />

<strong>Rheumatology</strong>, St. Radboud UMCN, Nijmegen, The Netherlands.<br />

1827. Regulatory T Cells from Patients with Rheumatoid Arthritis<br />

Are Not Affected by Adalimumab and Etanercept. Thierry<br />

Lequerré 3 , Céline Blache 2 , Stéphanie Beuteux 2 , Arnaud<br />

Roucheux 1 , Ingrid Dedreux 1 , Serge Jacquot 1 , Xavier Le<br />

Loët 4 , Olivier Boyer 1 and Olivier Vittecoq 4 , 1 Department <strong>of</strong><br />

Immunology, Inserm905, Rouen University Hospital, University<br />

<strong>of</strong> Rouen, 2 Inserm905, University <strong>of</strong> Rouen, 3 <strong>Rheumatology</strong><br />

Department, Inserm905, Rouen University Hospital, University<br />

<strong>of</strong> Rouen, Rouen, France, 4 <strong>Rheumatology</strong> Department,<br />

Inserm905, Rouen University Hospital, University <strong>of</strong> Rouen.<br />

1828. Relationship between Rituximab Serum Levels and Progression<br />

<strong>of</strong> Structural Damage in Rheumatoid Arthritis Patients. Maria<br />

J. H. Boumans 2 , Y. K. O. Teng 6 , Rogier M. Thurlings 3 , Koen Vos 4 ,<br />

Steven O. Stapel 7 , Gertjan Wolbink 5 , Janneke Tekstra 8 and Paul<br />

P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />

The Netherlands, 2 Academic Medical Center/University <strong>of</strong><br />

Amsterdam, Amsterdam, Noord-Holland, The Netherlands,<br />

3<br />

Academic Medical Center/University <strong>of</strong> Amsterdam, 4 Academic<br />

Medical Center/University <strong>of</strong> Amsterdam/Jan van Breemen<br />

Institute, 5 Jan van Breemen Institute, Sanquin Research,<br />

Amsterdam, 6 Leiden University Medical Center, 7 Sanquin<br />

Research, Amsterdam, 8 University Medical Centre, Utrecht.<br />

1829. Response, Remission, and Flare during Early Treatment<br />

<strong>of</strong> Rheumatoid Arthritis with Infliximab. Ronald F. Van<br />

Vollenhoven 2 , Dimitrios Boumpas 10 , Rene Westhovens 9 ,<br />

Marek Brzosko 7 , Karin E. Svensson 8 , Olav Bjorneboe 3 , Cees<br />

Meeuwisse 5 , Shankar Srinivasan 4 , Nathan Vastesaeger 6 and<br />

Philippe Gaudin 1 , 1 CHU Hôpital Sud, Echirolles Cedex, France,<br />

2<br />

Karolinska University Hospital, Stockholm, Sweden, 3 Martina<br />

Hansens Hospital, Gjettum, Norway, 4 Merck and Company, Inc,<br />

Kenilworth, NJ, 5 MSD, Oss, The Netherlands, 6 MSD, Brussels,<br />

Belgium, 7 Pomeranian Medical University, Szczecin, Poland,<br />

8<br />

Skövde Hospital, Skövde, Sweden, 9 University Hosp KU Leuven,<br />

Leuven, Belgium, 10 University Hospital <strong>of</strong> Heraklion, Heraklion<br />

Crete, Greece.<br />

1830. Rituximab (RTX) Is More Effective in Active Sero-Positive RA<br />

Than Sero-Negative RA. Abdul Khan 3 , Taher Mahmud 4 , Tony<br />

Hammond 1 , Mike Batley 2 and Alison Leak 5 , 1 Maidstone General<br />

Hospital Hermitage Lane Maidstone Kent, Maidstone, Kent,<br />

United Kingdom, 2 Maidstone General Hospital Maidstone Kent,<br />

Maidstone, Kent, United Kingdom, 3 Maidstone General Hospital,<br />

Maidstone, Kent, Maidstone, Kent, United Kingdom, 4 Pembury<br />

Hospital, Pembury, Kent, United Kingdom, 5 Queen Elizabeth<br />

Queen Mother Hospital, Margate, Kent, United Kingdom.<br />

1831. Safety and Efficacy <strong>of</strong> IL-1 Trap in Resistant Adult Onset Still’s<br />

Disease: 24 Month Follow-Up <strong>of</strong> Open Label Treatment and<br />

Biomarkers <strong>of</strong> Response. Cailin Henderson, Mildred Wilson,<br />

Tuyet-Hang Pham, Gregory Dolan, Adriana Gobbo, Christopher<br />

Snyder, Elizabeth Joyal and Raphaela Goldbach-Mansky, NIAMS<br />

/ NIH.<br />

1832. Safety, Efficacy, and Sustained Improvements in Household<br />

Productivity and Daily Activities with Certolizumab Pegol (CZP)<br />

Monotherapy over 2 Years in Patients with Active Rheumatoid<br />

Arthritis (RA). Roy M. Fleischmann 4 , Ernest Choy 3 , Ronald van<br />

Vollenhoven 2 , Niti Goel 6 , Oana Purcaru 5 , Kristel Luijtens 5 and<br />

Vibeke Strand 1 , 1 Division <strong>of</strong> Immunology and <strong>Rheumatology</strong>,<br />

Stanford University School <strong>of</strong> Medicine, Palo Alto, CA,<br />

2<br />

Karolinska Institute, Stockholm, Sweden, 3 Kings <strong>College</strong><br />

Hospital, London, United Kingdom, 4 MCRC, University <strong>of</strong> Texas,<br />

Dallas, TX, 5 UCB, Brussels, Belgium, 6 UCB, Smyrna, GA.<br />

1833. Statins Inhibit the Anti-Rheumatic Effects <strong>of</strong> Rituximab in<br />

Rheumatoid Arthritis – Results from the Dutch Rheumatoid<br />

Arthritis Monitoring (DREAM) Registry. Elke Arts 4 , Tim L.<br />

Jansen 2 , Alfons Den Broeder 6 , Harald E. Vonkeman 3 , Ellen<br />

Dutmer 1 , Mart A. F. J. Van de Laar 3 , Piet L. C. M. Van Riel 5 and<br />

Jaap Fransen 5 , 1 Gelderse Vallei Hospital Ede, 2 Medical Centre<br />

Leeuwarden, 3 Medisch Spectrum Twente &University <strong>of</strong> Twente,<br />

4<br />

Radboud University Nijmegen Medical Centre, Nijmegen, The<br />

Netherlands, 5 Radboud University Nijmegen Medical Centre,<br />

6<br />

Sint Maartenskliniek.<br />

2010 Program Book 261


ACR/ARHP Poster Session C<br />

262<br />

1834. Subcutaneous (SC) Abatacept Is Well-Tolerated, Demonstrates<br />

Clinical Efficacy and Is Associated with Low Immunogenicity<br />

Following Withdrawal and Re-Introduction: Phase III<br />

Evaluation in Rheumatoid Arthritis (RA) Patients Responding<br />

to Abatacept. Jeffrey L. Kaine 6 , Ge<strong>of</strong>frey S. Gladstein 5 , Ingrid<br />

Strusberg 4 , Manuel Robles 2 , Ramesh Pappu 1 , Ingrid Delaet 1 ,<br />

Miranda Pans 1 and Charles L. Ludivico 3 , 1 Bristol-Myers Squibb<br />

Co, Princeton, NJ, 2 Centro Médico Toluca, Metepec, Mexico,<br />

3<br />

East Penn <strong>Rheumatology</strong> Associates, East Stroudsburg,<br />

Philadelphia, PA, 4 Instituto Reumatológico, Strusberg, Cordoba,<br />

Argentina, 5 New England Research Associates, Trumbull, CT,<br />

6<br />

Sarasota Arthritis Center, Sarasota, FL.<br />

1835. Subcutaneous Golimumab Sustains Effects <strong>of</strong> Intravenous<br />

Golimumab in Patients with Active Rheumatoid Arthritis:<br />

Results <strong>of</strong> the GO-LIVE Long Term Extension. Joel M. Kremer 4 ,<br />

Peter Taylor 3 , Alan Mendelsohn 2 , Daniel G. Baker 1 , Lilianne<br />

Kim 2 and Christopher T. Ritchlin 5 , 1 Centocor Research and<br />

Development, Inc., Malvern, PA, 2 Centocor Research and<br />

Development, Inc., 3 Imperial <strong>College</strong> <strong>of</strong> London, 4 The Center<br />

for <strong>Rheumatology</strong>, Albany, NY, 5 University <strong>of</strong> Rochester Medical<br />

Center, Rochester, NY.<br />

1836. Sustained and Clinically Meaningful Improvements in Both<br />

Day- and Night-Time Aspects <strong>of</strong> HRQoL Are Observed with<br />

Abatacept Treatment in Patients with Rheumatoid Arthritis<br />

(RA) and Previous Inadequate Response to MTX: 5-Year Data<br />

from the AIM Trial. Joel Kremer 2 , Anthony S. Russell 3 , Rene<br />

Westhovens 5 , Julie Teng 1 , Lisa Rosenblatt 1 and Paul Emery 4 ,<br />

1<br />

Bristol-Myers Squibb, Princeton, NJ, 2 Center for <strong>Rheumatology</strong>,<br />

Albany Medical <strong>College</strong>, Albany, NY, 3 University <strong>of</strong> Alberta<br />

Hospital, Edmonton, AB, Canada, 4 University <strong>of</strong> Leeds, Leeds,<br />

United Kingdom, 5 UZ Gasthuisberg, Leuven, Belgium.<br />

1837. Sustained and Clinically Meaningful Improvements in Physical<br />

Function and Fatigue and Reductions in Activity Limitation<br />

Are Observed in MTX-Naïve Patients with Early Rheumatoid<br />

Arthritis (RA) Treated with Abatacept over 2 Years <strong>of</strong> the<br />

AGREE Trial. Rene Westhovens 5 , Jurgen Wollenhaupt 4 , Boulos<br />

Haraoui 2 , Jean-Claude Becker 1 , Allison Covucci 1 , Lisa Rosenblatt 1<br />

and Joan Bathon 3 , 1 Bristol-Myers Squibb, NJ, 2 Institut de<br />

Rumatologie de Montreal, Montreal, QC, Canada, 3 John Hopkins<br />

University School <strong>of</strong> Medicine, Baltimore, MD, 4 Klinikum Eilbek,<br />

Hamburg, Germany, 5 UZ Gasthuisburg, Leuven, Belgium.<br />

1838. TNF-alpha Antagonist Therapy Leads to an Expansion <strong>of</strong> IL-17<br />

Expressing CD4+ T Cells Both In Vitro and In Vivo. Hayley<br />

G. Evans 2 , Nicola J. Gullick 3 , Bruce W. Kirkham 1 and Leonie<br />

S. Taams 3 , 1 Guy’s &St Thomas’ NHS Foundation Trust, 2 Kings<br />

<strong>College</strong> London, London, United Kingdom, 3 Kings <strong>College</strong><br />

London.<br />

1839. Tocilizumab Monotherapy Improves Arterial Stiffness<br />

Compared with Other Biologics Monotherapy in Rheumatoid<br />

Arthritis. Kensuke Kume 1 , Kanzo Amano 1 , Susumu Yamada 1 and<br />

Hiroyuki Ohta 2 , 1 Hiroshima Clinic, Hiroshima, Japan, 2 IGL School,<br />

Hiroshima, Japan.<br />

1840. Tocilizumab Treatment in Patients with Rheumatoid Arthritis<br />

and an Inadequate Response to DMARDs and/or TNF<br />

Inhibitors: ACT-SURE Preliminary Results. Vivian P. Bykerk 7 ,<br />

Jose Álvaro-Gracia 3 , Jose Andres Roman Ivorra 4 , Michael T.<br />

Nurmohamed 6 , Karel Pavelka 5 , Corrado Bernasconi 8 , Andrea<br />

Stancati 8 , Jean Sibilia 2 and Andrew Östör and the ACT-SURE<br />

Study Group 1 , 1 Addenbrookes Hospital, Cambridge, United<br />

Kingdom, 2 Hautepierre Service de Rhumatologie, Strasbourg,<br />

France, 3 Hospital Universitario de La Princesa, IIS Princesa,<br />

Madrid, Spain, 4 Hospital Universitario Dr. Peset, Valencia, Spain,<br />

5<br />

Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 6 Jan van<br />

Breemen Institute, Amsterdam, The Netherlands, 7 Mount Sinai<br />

Hospital, Toronto, ON, Canada, 8 Roche, Basel, Switzerland.<br />

2010 Program Book<br />

1841. Treatment with TNF-Inhibitors Reduces Radiographic Joint<br />

Destruction in Rheumatoid Arthritis Patients Treated in Clinical<br />

Practice. Lykke M. Ørnbjerg 1 , Mikkel Østergaard 1 , Pernille<br />

Bøyesen 12 , Anja Thormann 1 , Ulrik Tarp 6 , Wolfgang Böhme 13 ,<br />

Ditte Dencker 13 , Hanne Lindegaard 15 , Uta Poulsen 14 , Anette<br />

Hansen 2 , Vibeke Ringsdal 5 , Anette Schlemmer 5 , Niels Graudal 10 ,<br />

Anne R. Andersen 16 , Jakob Espesen 4 , Gina Kollerup 7 , Torben G.<br />

Christensen 11 , Randi Pelck 3 , Bente Glintborg 3 , Ole R. Madsen 2 ,<br />

Dorte V. Jensen 8 , Ole Majgaard 9 and Merete L. Hetland 1 ,<br />

1<br />

DANBIO Registry and Depts. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen<br />

University Hospitals at Hvidovre and Glostrup, Denmark,<br />

2<br />

Dept. <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, Gent<strong>of</strong>te<br />

University Hospital, Denmark, 3 Dept. <strong>of</strong> Internal Medicine,<br />

Copenhagen University Hospital at Holbæk, Denmark, 4 Dept.<br />

<strong>of</strong> Internal Medicine, Hospital Lillebaelt at Vejle, Denmark,<br />

5<br />

Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital at ålborg,<br />

Denmark, 6 Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital,<br />

Denmark, 7 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />

Hospital at Frederiksberg, Denmark, 8 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Copenhagen University Hospital at Hørsholm, Denmark, 9 Dept.<br />

<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at Næstved,<br />

Denmark, 10 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />

Hospital at Rigshospitalet, Denmark, 11 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Copenhagen University Hospital at Slagelse, Denmark, 12 Dept. <strong>of</strong><br />

<strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway, 13 Dept.<br />

<strong>of</strong> <strong>Rheumatology</strong>, Hospital <strong>of</strong> South West Jutland at Esbjerg,<br />

Denmark, 14 Dept. <strong>of</strong> <strong>Rheumatology</strong>, King Christian Xth Hospital,<br />

Gråsten, Denmark, 15 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Odense University<br />

Hospital, Denmark, 16 Depts. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen<br />

University Hospitals at Hvidovre and Glostrup, Denmark.<br />

Systemic Lupus Erythematosus - Clinical Aspects and Treatment-<br />

Epidemiology and Health Services III<br />

1842. Accumulation <strong>of</strong> Traditional Risk Factors for Coronary Heart<br />

Disease in Patients with Systemic Lupus Erythematosus. Rosa<br />

W. Telles 2 , Cristina C. D. Lanna 2 , Fabricia F. Simil 1 , Luana G.<br />

Machado 1 , Fabiana L. Sousa 1 , Luciana A. Rodrigues 2 and Antonio<br />

L. Ribeiro 3 , 1 Hospital das Clinicas, 2 School <strong>of</strong> Medicine, 3 School<br />

<strong>of</strong> Medicine-Universidade Federal de Minas Gerias-Brazil.<br />

1843. Analysis <strong>of</strong> the Level <strong>of</strong> Agreement between Different<br />

Measures <strong>of</strong> Disease Flare in an Exploratory Study <strong>of</strong><br />

Abatacept in Systemic Lupus Erythematosus (SLE). Caroline<br />

Gordon 3 , Jean-Claude Becker 1 , Sheila Kelly 1 , Yun Peng 2 ,<br />

Michael Kinaszczuk 1 and Joan T. Merrill 4 , 1 Bristol-Myers Squibb,<br />

Princeton, NJ, 2 Bristol-Myers Squibb, Pennington, NJ, 3 University<br />

<strong>of</strong> Birmingham, Birmingham, United Kingdom, 4 University <strong>of</strong><br />

Oklahoma, Oklahoma City, OK.<br />

1844. Anti-NR2A Antibody as a Predictor for Neuropsychiatric<br />

Systemic Lupus Erythematosus. Masanori Hanaoka 3 ,<br />

Takahisa Gono 3 , Yasushi Kawaguchi 1 , Hirotaka Kaneko 2 , Katsuji<br />

Nishimura 2 , Yasuhiro Katsumata 2 , Yuko Okamoto 2 , Sayumi<br />

Baba 2 , Sayuri Kataoka 2 and Hisashi Yamanaka 4 , 1 Tokyo Women’s<br />

Medical Univ, Tokyo, Japan, 2 Tokyo Women’s Medical Univ,<br />

3<br />

Tokyo Women’s Medical University, 4 Tokyo Womens Med Univ,<br />

Shinjuku-ku, Tokyo, Japan.<br />

1845. Assessing the ANA Test as a Screening Tool: Utility or Futility?<br />

Aryeh M. Abeles and Micha Abeles, University <strong>of</strong> Connecticut<br />

Health Center.<br />

1846. Atherosclerosis in SLE: A Cross Sectional Study <strong>of</strong> 223 Patients<br />

with 223 Individually Matched Population Controls. Johanna<br />

T. Gustafsson 2 , Kerstin Urstad Jensen 1 , Marie Herlitz-Lindberg 1 ,<br />

Sonia Möller 4 , Susanne Petterson 3 , Iva Gunnarsson 2 and<br />

Elisabet Svenungsson 2 , 1 Department <strong>of</strong> Clinical Physiology,<br />

Södersjukhuset, Karolinska Institute, Stockholm, Sweden,


ACR/ARHP Poster Session C<br />

2<br />

Department <strong>of</strong> Medicine Solna, Karolinska Institute.<br />

<strong>Rheumatology</strong> Unit, Karolinska University Hospital, Stockholm,<br />

Sweden, 3 Department <strong>of</strong> Neurobiology, Care Sciences and<br />

Society (NVS), Division <strong>of</strong> Nursing, Karolinska Institutet,<br />

<strong>Rheumatology</strong> Unit, Karolinska University Hospital, Stockholm,<br />

Sweden, 4 <strong>Rheumatology</strong> Unit, Karolinska University Hospital,<br />

Stockholm, Sweden.<br />

1847. Autoantibodies Predate the Onset <strong>of</strong> Systemic Lupus<br />

Erythematosus. Solbritt Rantapää-Dahlqvist 2 , Catharina<br />

Eriksson 1 , Heidi Kokkonen 1 , Martin Johansson 1 , Göran Hallmans 1<br />

and Göran Wadell 1 , 1 Umeå, Sweden, 2 <strong>Rheumatology</strong>, Umeå,<br />

Sweden.<br />

1848. Belimumab, a BLyS-Specific Inhibitor, Improved Fatigue and<br />

SF-36 Physical and Mental Component Summary Scores in<br />

Patients with SLE: BLISS-76 and -52 Studies. V. Strand 8 , R.<br />

A. Levy 3 , R. Cervera 2 , M. A. Petri 6 , H. Rudge 1 , L. Pineda 5 , W.<br />

Freimuth 5 , Z. J. Zhong 4 , A. E. Clarke 7 and for the BLISS- 76 and<br />

- 52 Study Group, 1 GlaxoSmithKline, Uxbridge, Uxbridge, UK,<br />

2<br />

Hospital Clinic, Barcelona, Spain, 3 Hospital Universitário Pedro<br />

Ernesto, Rio de Janeiro, Brazil, 4 Human Genome Sciences,<br />

Inc, Rockville, MD, 5 Human Genome Sciences, Inc, Rockville,<br />

Rockville, MD, 6 Johns Hopkins University School <strong>of</strong> Medicine,<br />

Timonium, MD, 7 McGill University Health Centre, Montreal, QC,<br />

Canada, 8 Stanford University, Palo Alto, Portola Valley, CA.<br />

1849. Causes and Predictors <strong>of</strong> Death in 181 Brazilian Patients with<br />

Systemic Lupus. Rosa W. Telles 2 , Cristina C. D. Lanna 2 , Rodrigo<br />

C. P. Reis 4 , Fabiana L. Sousa 1 , Luciana A. Rodrigues 2 and Antonio<br />

L. Ribeiro 3 , 1 Hospital das Clinicas, 2 School <strong>of</strong> Medicine, 3 School<br />

<strong>of</strong> Medicine-Universidade Federal de Minas Gerais-Brazil,<br />

4<br />

Statistics Department.<br />

1850. Cigarette Smoking and Cutaneous Damage in Patients with<br />

Systemic Lupus Erythematosus. Josiane Bourré-Tessier 5 ,<br />

Christine A. Peschken 13 , Lawrence Joseph 5 , Patrick Belisle 5 ,<br />

Ann E. Clarke 7 , Sasha R. Bernatsky 3 , Marie Hudson 6 , Carol A.<br />

Hitchon 14 , Shikha Mittoo 13 , Janet E. Pope 8 , Paul R. Fortin 11 , C.<br />

Douglas Smith 10 , Hector Arbillaga 2 , Dafna D. Gladman 12 , Murray<br />

B. Urowitz 9 , Michel Zummer 1 , CANIOS 1000 Canadian Faces <strong>of</strong><br />

Lupus Investigators 15 and Christian A. Pineau 4 , 1 Ch Maisonneuve-<br />

Rosemont, Montreal, QC, Canada, 2 Chinook Regional Hospital,<br />

3<br />

McGill UHC/RVH, Montreal, QC, Canada, 4 McGill Univ Health<br />

Center, Montreal, QC, Canada, 5 McGill University, 6 McGill<br />

University and Jewish General Hospital, 7 Montreal General<br />

Hospital, Montreal, QC, Canada, 8 St Joseph Health Care London,<br />

London, ON, Canada, 9 The Toronto Western Hospital, Toronto,<br />

ON, Canada, 10 TOH Riverside Campus, Ottawa, ON, Canada,<br />

11<br />

Toronto Western Hospital, Toronto, ON, Canada, 12 Toronto<br />

Western Hospital, Toronto, ON, Canada, 13 Univ <strong>of</strong> Manitoba,<br />

Winnipeg, MB, Canada, 14 University <strong>of</strong> Manitoba, Winnipeg,<br />

MB, Canada, 15 Various Sites.<br />

1851. Clinical and Serologic Characteristics <strong>of</strong> Filipino Multiplex<br />

Systemic Lupus Erythematosus (SLE). Helmar F. Soldevilla and<br />

Sandra V. Navarra, University <strong>of</strong> Santo Tomas, Philippines.<br />

1852. CNS Lupus: The Prevalence and Antibodies Depend on the<br />

Definition. Results from the 1000 Faces <strong>of</strong> Lupus Cohort. Alan<br />

Borowoy 3 , Christine A. Peschken 2 and Janet E. Pope 1 , 1 St Joseph<br />

Health Care London, London, ON, Canada, 2 Univ <strong>of</strong> Manitoba,<br />

Winnipeg, MB, Canada, 3 University <strong>of</strong> Western Ontario, London,<br />

ON, Canada.<br />

1853. Cognitive Disfunction in Young Patients within the Early-<br />

Years If the Disease. An Inception-Cohort Study. Ali Duarte-<br />

Garcia 2 , Sandra Juárez-Arellano, Juanita Romero-Diaz, Hilda<br />

Fragoso-Loyo and Jorge Sánchez-Guerrero 1 , 1 Insituto Nacional<br />

de Ciencias Medicas y Nutricion Salvador Zubiran, México,<br />

2<br />

Instituto Nacional de Nutricion Salvador Zubiran.<br />

1854. Cognitive Dysfunction in Patients with SLE: A Prospective<br />

Study. Andres Piatti 2 , Tara Adhikari 2 and Michael Luggen 1 ,<br />

1<br />

University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH,<br />

2<br />

University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine.<br />

1855. Cognitive Dysfunction in Systemic Lupus Erythematosus:<br />

Development <strong>of</strong> a Screening Tool. Tara Adhikari 2 , Andres<br />

Piatti 2 and Michael Luggen 1 , 1 University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong><br />

Medicine, Cincinnati, OH, 2 University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong><br />

Medicine.<br />

1856. Determinants <strong>of</strong> Treatment Adherence in Patients with<br />

Systemic Lupus Erythematosus (SLE). Shazia A. Beg 1 , S<strong>of</strong>ia<br />

de Achaval 2 , Michael A. Kallen 2 , Vanessa L. Cox 2 , Marsha N.<br />

Richardson 2 , John D. Reveille 3 and Maria E. Suarez-Almazor 4 ,<br />

1<br />

Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 The University <strong>of</strong><br />

Texas M. D. Anderson Cancer Center, Houston, TX, 3 Univ Texas<br />

Health Sci Ctr, Houston, TX, 4 University <strong>of</strong> Texas, MD Anderson<br />

Cancer Center, Houston, TX.<br />

1857. Discordance between Self-Report and Physician-<br />

Assessed Disease Activity in Patients with Systemic Lupus<br />

Erythematosus (SLE): Implications for Clinical Trial Design and<br />

Clinical Care. Anca D. Askanase 3 , Isabel Castrejón 4 , Jill P. Buyon 5 ,<br />

Yusuf Yazici 1 and Theodore Pincus 2 , 1 Hospital for Joint Diseases,<br />

Hastings on Hudson, NY, 2 New York University Hospital for<br />

Joint Disease, Hastings-on-Hudson, NY, 3 NYU Hospital for Joint<br />

Diseases, New York, NY, 4 NYU Hospital for Joint Diseases, 5 NYU<br />

School <strong>of</strong> Medicine, New York, NY.<br />

1858. Ethnicity Affects the Frequency <strong>of</strong> CNS Manifestations <strong>of</strong> SLE.<br />

Maryna Shayuk 2 , Hong Fang 2 and Michelle A. Petri 1 , 1 Timonium,<br />

MD, 2 Johns Hopkins University.<br />

1859. Five Year Follow-Up Study <strong>of</strong> Bone Mineral Density in Patients<br />

with Systemic Lupus Erythematosus: The Influence <strong>of</strong><br />

Corticosteroid Treatment. Anna M. Schilder, Jonathan Jacobs,<br />

Lindy-Anne Korswagen, Ben A. C. Dijkmans, Willem F. Lems,<br />

Alexandre E. Voskuyl and Irene E. M. Bultink, VU University<br />

Medical Center, Amsterdam, The Netherlands.<br />

1860. High Prevalence <strong>of</strong> Fetal Loss and Pregnancy Complications<br />

in African-<strong>American</strong> Lupus Patients: A Retrospective Case-<br />

Control Study. Kirk C. Eddleman 2 and Vikas Majithia 1 , 1 University<br />

<strong>of</strong> Mississippi Medical Center, Jackson, MS, 2 University <strong>of</strong><br />

Mississippi Medical Center.<br />

1861. Hyperuricemia Is a Predictor <strong>of</strong> Subclinical CVD in SLE Patients<br />

but Not Controls. Joseph L. Enama 2 , Robert Gilkeson 1 and<br />

Lisabeth Scalzi 2 , 1 Case Western Reserve University, 2 Penn State<br />

Univ Hershey, Hershey, PA.<br />

1862. Identifying Modifiable Risk Factors for Depression in Systemic<br />

Lupus Erythematosus. David Karol 2 , Lisa G. Criscione-Schreiber 2<br />

and Megan E. B. Clowse 1 , 1 Duke Univ Med, Durham, NC, 2 Duke<br />

University, Durham, NC.<br />

1863. In Systemic Lupus Erythematosus (SLE) Patients, Patient<br />

Reported Outcomes and Physician Assessment <strong>of</strong> Disease<br />

Activity Are Poorly Correlated: Implications for Outcome<br />

Measures in SLE. Magaly Villafradez Diaz 1 , Ashwini Shadakshari,<br />

Andy McCracken, Christopher Swearingen, Daniel Ricciardi and<br />

Yusuf Yazici 2 , 1 Long Island <strong>College</strong> Hospital, 2 NYU Hospital for<br />

Joint Diseases.<br />

1864. Incidence and Predictors <strong>of</strong> Hospitalization in Systemic Lupus<br />

Erythematosus (SLE): Results from a Large Contemporary<br />

Multi-Ethnic Cohort. June Lee 3 , Janet E. Pope 1 , Christine A.<br />

Peschken 2 and The 1000 Faces <strong>of</strong> Lupus, 1 St Joseph Health Care<br />

London, London, ON, Canada, 2 Univ <strong>of</strong> Manitoba, Winnipeg,<br />

MB, Canada, 3 University <strong>of</strong> Western Ontario, London, ON,<br />

Canada.<br />

2010 Program Book 263


ACR/ARHP Poster Session C<br />

1865. Measuring Therapeutic Adherence in Systemic Lupus<br />

Erythematosus (SLE) Using the Medication Event Monitoring<br />

System (MEMS®). Maria F. Marengo, Christian A. Waimann,<br />

S<strong>of</strong>ia de Achaval, Vanessa L. Cox, Araceli Garcia Gonzalez,<br />

Marsha N. Richardson and Maria E. Suarez-Almazor, The<br />

University <strong>of</strong> Texas M. D. Anderson Cancer Center, Houston, TX.<br />

1866. Mycophenolate M<strong>of</strong>etil (MMF): Physician Prescribing<br />

Practices. Seema Malani 1 and Ellen M. Ginzler 2 , 1 SUNY<br />

Downstate Medical Center, Brooklyn, NY, 2 SUNY-Downstate<br />

Medical Center, Brooklyn, NY.<br />

1867. Novel Cardiovascular Risk Prediction Models in Patients with<br />

Systemic Lupus Erythematosus. Vivian K. Kawai 2 , Annette<br />

M. Oeser 4 , Joseph Solus 3 , Young H. Rho 3 , Paolo Raggi 1 , Aihua<br />

Bian 3 , Tebeb Gebretsadik 3 , Ayumi Shintani 3 and C. Michael<br />

Stein 2 , 1 Emory University, 2 Vanderbilt University, Nashville, TN,<br />

3<br />

Vanderbilt University, 4 VUMC 23 rd Ave South Pierce, Nashville,<br />

TN.<br />

1868. Optimal Frequency <strong>of</strong> Visits for SLE Patients To Capture Disease<br />

Activity over Time. Dominique Ibañez 3 , Dafna D. Gladman 2 and<br />

Murray B. Urowitz 1 , 1 The Toronto Western Hospital, Toronto,<br />

ON, Canada, 2 Toronto Western Hospital, Toronto, ON, Canada,<br />

3<br />

University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital,<br />

Toronto, ON, Canada.<br />

1869. Optimal Frequency <strong>of</strong> Visits To Capture Disease Activity over<br />

Time in SLE Patients with Varying Levels <strong>of</strong> Disease Activity.<br />

Dominique Ibanez 2 , Murray B. Urowitz 3 and Dafna D. Gladman 1 ,<br />

1<br />

Toronto Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, 3 University <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />

Canada.<br />

1870. Performance <strong>of</strong> Anti-Nucleosome, Anti-C1q and Anti-dsDNA<br />

Antibodies for the Diagnosis <strong>of</strong> Concurrent Disease Activity <strong>of</strong><br />

Systemic Lupus Erythematosus. Chi Chiu Mok, Ling Yin Ho, Hoi<br />

Wah Leung and Lap Gate Wong, Tuen Mun Hospital.<br />

1871. Predictive Value <strong>of</strong> High Levels <strong>of</strong> Antinuclear Antibodies in<br />

People without Other Feature <strong>of</strong> Autoinmunity. A Prospective<br />

Study. Ignacio Villa-Blanco 4 , Marcos Lopez-Hoyos 1 , Ana Ruibal 2<br />

and Jaime Calvo-Alen 3 , 1 Hospital “Marques de Valdecilla”,<br />

2<br />

Hospital “Txagorritxu”, 3 Hospital Sierrallana, Torrelavega, Spain,<br />

4<br />

Hospital Sierrallana, Spain.<br />

1872. Preliminary Comparison <strong>of</strong> Health-Related Quality <strong>of</strong> Life<br />

in Children with Lupus across Different Continents. Lakshmi<br />

Nandini Moorthy 14 , Claudia Saad-Magalhães 1 , Juliana Oliveira<br />

Sato 1 , Claudio A. Len 10 , Maria O. Hilário 10 , Flavio Sztajnbok 9 ,<br />

Rozana Gasparello de Almeida 9 , Feng Qi Wu 2 , Xiaolan L. Huang 2 ,<br />

Fernanda Falcini 13 , Donato Rigante 11 , Rolando Cimaz 12 , Jordi<br />

Antón Lopez 8 , Consuelo Modesto 7 , Rubén J. Cuttica 5 , Lisette W.<br />

A. van Suijlekom-Smit 3 , Marieke H. Otten 3 , Maria J. Baratelli 14 ,<br />

Margaret G. E. Peterson 6 , Afton L. Hassett 15 and Thomas J. A.<br />

Lehman 4 , 1 Botucatu Medical School - São Paulo State University,<br />

Brazil, 2 Capital Institute <strong>of</strong> Pediatrics, China, 3 Erasmus MC,<br />

Sophia Childrens Hospital, The Netherlands, 4 Hosp for Special<br />

Surgery, New York, NY, 5 Hospital de Pediatría Pedro de Elizalde,<br />

Argentina, 6 Hospital for Special Surgery, 7 Hospital Infantil<br />

Valle de Hebron, Spain, 8 Hospital Sant Joan de Déu, Spain,<br />

9<br />

Universidade do Estado do Rio de Janeiro, Brazil, 10 Universidade<br />

Federal de São Paulo, Brazil, 11 Università Cattolica Sacro Cuore,<br />

Italy, 12 University <strong>of</strong> Firenze, Firenze, Italy, 13 University <strong>of</strong><br />

Florence, Florence, Italy, 14 University <strong>of</strong> Medicine and Dentistry<br />

<strong>of</strong> NJ - Robert Wood Johnson Medical School, New Brunswick,<br />

NJ, 15 University <strong>of</strong> Michigan Medical School, Ann Arbor, MI.<br />

1873. Prevalence and Risk Factors <strong>of</strong> Glucocorticoid-Induced<br />

Diabetes Mellitus in Patients with Systemic Lupus<br />

Erythematosus. You Jung Ha 1 , Kwang-Hoon Lee 2 , Se-jin Jung 1 ,<br />

Yoon Kang 1 , Min-Chan Park 3 , Sang-Won Lee 1 , Soo Kon Lee 1 and<br />

Yong-Beom Park 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />

Korea, Republic <strong>of</strong>, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />

Korea, Republic <strong>of</strong>, 3 Gangnam Severance Hospital, Seoul, Korea,<br />

Republic <strong>of</strong>.<br />

1874. Prolonged Serologically Active Clinically Quiescent (SACQ)<br />

Systemic Lupus Erythematosus (SLE): Novel Predictors <strong>of</strong><br />

Flare? Amanda Steiman 1 , Murray B. Urowitz 2 , Joan E. Wither 4 ,<br />

Dominique Ibañez 1 , Timothy Li 3 and Dafna D. Gladman 1 ,<br />

1<br />

Toronto Western Hospital, Toronto, ON, Canada, 2 Toronto<br />

Western Hospital, Toronto, ON, Canada, 3 Toronto Western<br />

Hospital, 4 University Health Network, Toronto, ON, Canada.<br />

1875. Racial Disparities in Treatment Preferences among Lupus<br />

Patients. Ernest R. Vina, Christopher M. Masi, Stephanie L.<br />

Green and Tammy O. Utset, University <strong>of</strong> Chicago Medical<br />

Center, Chicago, IL.<br />

1876. Risk Factors Associated with the Presence <strong>of</strong> Pneumonia in<br />

Patients with Lupus Erythematosus (SLE): A Nested Case-<br />

Control Study. Iñigo Rúa-Figueroa 1 , Francisco J. Nóvoa 2 , Celia<br />

Erausquin 2 , Miguel Garcia-Bello 2 , Felipe Rodríguez de Castro 2 ,<br />

Juan C. Quevedo 2 , Isabel García-Laorden 2 , Carlos Rodriguez-<br />

Gallego 2 , Felix Francisco 2 and Carlos Rodriguez-Lozano 2 ,<br />

1<br />

Hospital Dr Negrin, Las Palmas GC, Spain, 2 Hospital Dr Negrin.<br />

1877. SLE and Atherosclerotic Risk Factors by Ethnicity and<br />

Geographic Distribution at Inception in a International Cohort<br />

<strong>of</strong> SLE. Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique<br />

Ibanez 32 , Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E. Clarke 15 ,<br />

Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 , John G.<br />

Hanly 19 , David A. Isenberg 24 , Anisur Rahman 25 , Paul R. Fortin 33 ,<br />

Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 , Graciela S.<br />

Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar K. Sturfelt 27 ,<br />

Ola Nived 27 , Kristjan Steinsson 12 , Munther A. Khamashta 21 ,<br />

Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi 34 ,<br />

Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 , Cynthia B.<br />

Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 ,<br />

Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 ,<br />

Diane L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 30 , 1 West<br />

Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta,<br />

GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital,<br />

East Kilbride, United Kingdom, 6 Hanyang University Medical<br />

Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial,<br />

8<br />

Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto<br />

Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantansspital<br />

Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University<br />

Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal<br />

Infirmary, Manchester, United Kingdom, 14 Medical University<br />

<strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />

Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn<br />

Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />

18<br />

Oklahoma Medical Research Foundation, Oklahoma City, OK,<br />

19<br />

Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />

20<br />

SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />

Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />

Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />

24<br />

UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong><br />

Medicine, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 University<br />

Hospital Lund, Lund, Sweden, 28 University <strong>of</strong> Alabama, Oakland,<br />

264<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

CA, 29 University <strong>of</strong> Birmingham, Birmingham, United Kingdom,<br />

30<br />

University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 31 University<br />

<strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 32 University <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, 33 University <strong>of</strong><br />

Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />

Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA.<br />

1878. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-<br />

2K) Responder Index (SRI)-50: A Valid Index for Measuring<br />

Improvement in Disease Activity. Zahi Touma 2 , Dafna D.<br />

Gladman 1 , Dominique Ibañez 2 and Murray B. Urowitz 2 , 1 Toronto<br />

Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto<br />

Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada.<br />

1879. The Relative Importance <strong>of</strong> Current Versus Past Use <strong>of</strong><br />

Medication in Excess Rates <strong>of</strong> Adverse Cardiovascular Events<br />

among Patients with SLE. Michelle A. Petri 1 and Laurence<br />

S. Magder 2 , 1 Timonium, MD, 2 Department <strong>of</strong> Epidemiology<br />

and Preventive Medicine, University <strong>of</strong> Maryland School <strong>of</strong><br />

Medicine, Baltimore, MD.<br />

1880. Validation <strong>of</strong> CLASI Scale with Lupus Disease Activity, Damage,<br />

Body Image and Quality <strong>of</strong> Life. Meenakshi Jolly 1 , Rachel A.<br />

Mikolaitis 3 , Thomas F. Cash 2 and Joel A. Block 2 , 1 Rush University<br />

Medical Center, Chicago, IL, 2 Rush University Medical Center,<br />

Chicago, IL, 3 Rush University Medical Center.<br />

1881. Validity <strong>of</strong> the ACR Criteria and SLICC Proposed Criteria for the<br />

Diagnosis and Classification <strong>of</strong> Systemic Lupus Erythematosus.<br />

Felipe Rodriguez-García 2 , Karina Santana- de Anda 2 , Ali Duarte-<br />

García 1 , Virginia Pascual-Ramos 2 , Gabriela Hernández-Medina 2 ,<br />

Tatiana Rodríguez-Reyna 2 and Jorge Sanchez-Guerrero 3 ,<br />

1<br />

Instituto Nacional ce Ciencias Medicas y Nutricion Salvador<br />

Zubiran, 2 Instituto Nacional de Ciencias Medicas y Nutricion<br />

Salvador Zubiran, 3 Instituto Nacional de Ciencias Medicas y<br />

Nutricion Salvador Zubiran, Mexico.<br />

1882. Work Disability, Lost Productivity and Associated Risk Factors<br />

in Patients Diagnosed with Systemic Lupus Erythematosus<br />

(SLE). Tammy O. Utset 5 , Barbara M. Segal 6 , Laura Trupin 4 , Sarika<br />

Ogale 1 , Ellen Herberich 2 and Kenneth C. Kalunian 3 , 1 Genentech,<br />

2<br />

Harris Interactive, 3 UCSD School <strong>of</strong> Medicine, La Jolla, CA,<br />

4<br />

University <strong>of</strong> California, San Francisco, 5 University <strong>of</strong> Chicago,<br />

Chicago, IL, 6 University <strong>of</strong> Minnesota, Minneapolis, MN.<br />

Sjögren’s Syndrome<br />

1883. Activation <strong>of</strong> Innate Immunity and Sjögren’s Syndrome<br />

Development. Seshagiri Rao Nandula 1 , Yogesh M. Scindia 2 ,<br />

Harini Bagavant 1 and Umesh S. Deshmukh 2 , 1 University <strong>of</strong><br />

Virginia, Charlottesville, VA, 2 University <strong>of</strong> Virginia.<br />

1884. Anticentromere Antibodies (ACA)-Positive Systemic Sclerosis<br />

(SSc) Patients with Sjögren’s Syndrome: A Distintict Subset at<br />

High Risk <strong>of</strong> Lymphoma. Chiara Baldini, Sara Grossi, Alessandra<br />

Della Rossa, Nicoletta Luciano, Marica Doveri, Antonio<br />

Gaetano Tavoni and Stefano Bombardieri, <strong>Rheumatology</strong> Unit,<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Pisa, Italy.<br />

1885. Association between Lymphotoxin Alpha Genetic Variants<br />

and Primary Sjögren’s Syndrome in Scandinavian Samples.<br />

Anne Isine Bolstad 1 , Stephanie Le Hellard 2 , Gudlaug Thora<br />

Kristjansdottir 4 , Gunnel Nordmark 4 , Lilian Vasaitis 8 , Marika<br />

Kvarnström 6 , Christopher Sjöwall 13 , Svein Joar Auglænd<br />

Johnsen 9 , Per Eriksson 12 , Roald Omdal 10 , Johan G. Brun 5 , Marie<br />

Wahren-Helenius 6 , Elke Theander 7 , Ann-Christine Syvänen 3 ,<br />

Lars Rönnblom 4 and Roland Jonsson 11 , 1 Department <strong>of</strong><br />

Clinical Dentistry-Periodontics, University <strong>of</strong> Bergen, Bergen,<br />

Norway, 2 Department <strong>of</strong> Clinical Medicine, University <strong>of</strong><br />

Bergen, Center <strong>of</strong> Medical Genetics and Molecular Medicine,<br />

Haukeland University Hospital, Bergen, Norway, 3 Department<br />

<strong>of</strong> Medical Sciences, Molecular Medicine, Uppsala University,<br />

Uppsala, Sweden, 4 Department <strong>of</strong> Medical Sciences, Section<br />

<strong>of</strong> <strong>Rheumatology</strong>, Uppsala University, Uppsala, Sweden,<br />

5<br />

Department <strong>of</strong> Medicine, Section <strong>of</strong> <strong>Rheumatology</strong>, University<br />

<strong>of</strong> Bergen, Bergen, Norway, 6 Karolinska Institutet, Stockholm,<br />

Sweden, 7 Malmö University Hospital, Malmö, Sweden, 8 Section<br />

<strong>of</strong> <strong>Rheumatology</strong>, Uppsala University, Uppsala, Sweden,<br />

9<br />

Stavanger University Hospital, Stavanger, Norway, 10 Stavanger<br />

University Hospital, Stavanger, Norway 11 The Gade Institute,<br />

University <strong>of</strong> Bergen, Bergen, Norway, 12 University Hospital<br />

Linköping, Sweden, Linköping, Sweden, 13 University Hospital,<br />

Linköping, Linköping, Sweden.<br />

1886. B-Cell Pr<strong>of</strong>iling Using Multi-Color Flow Cytometry as Biomarker<br />

<strong>of</strong> Disease Progression in Primary Sjogren’s Syndrome<br />

(pSS). Mustimbo Roberts 2 , Craig Maguire 3 , Alex Rosenberg 3 ,<br />

Andreea Coca 2 , Jennifer H. Anolik 1 and Iñaki Sanz 2 , 1 University<br />

<strong>of</strong> Rochester, Rochester, NY, 2 University <strong>of</strong> Rochester Medical<br />

Center, Rochester, NY, 3 University <strong>of</strong> Rochester Medical Center.<br />

1887. Best Scintigraphic Measures <strong>of</strong> Parotid Gland Dysfunction in<br />

Sjogren’s Syndrome. Anthony Keyes 4 , Julius Birnbaum 2 , John<br />

Petronis 1 and Alan N. Baer 3 , 1 Johns Holins University School <strong>of</strong><br />

Medicine, 2 Johns Hopkins University, Baltimore, MD, 3 Johns<br />

Hopkins University, Baltimore, MD, 4 Johns Hopkins University<br />

School <strong>of</strong> Medicine.<br />

1888. Clinical and Immunological Pr<strong>of</strong>ile <strong>of</strong> Patients with Primary<br />

Sjogren Syndrome Who Developed B-Cell Lymphoma. Analysis<br />

<strong>of</strong> 1010 Spanish Patients (The GEMESS Cohort). Manuel<br />

Ramos-Casals 3 , Roser Solans 11 , Jose Rosas 6 , Maria Teresa<br />

Camps 2 , Antonio Gil 9 , Javier Del-Pino 10 , Carmen Hidalgo 12 ,<br />

Jaime Calvo 4 , Maria Luisa Mico 8 , Roberto Perez-Alvarez 7 , Rafael<br />

Belenguer 1 and Lucio Pallares 5 , 1 Hospital 9 d’Octubre, València,<br />

Spain, 2 Hospital Carlos Haya, Malaga, Spain, 3 Hospital Clinic,<br />

Barcelona, Spain, 4 Hospital de Sierrallana, Torrelavega, Spain,<br />

5<br />

Hospital de Son Dureta, Palma de Mallorca, Spain, 6 Hospital<br />

de Vilajoyosa, Alicante, Spain, 7 Hospital do Meixoeiro, Vigo,<br />

Spain, 8 Hospital La Fe, Valencia, Spain, 9 Hospital La Paz, Madrid,<br />

Spain, 10 Hospital Universitario de Salamanca, Salamanca, Spain,<br />

11<br />

Hospital Vall d’Hebron, Barcelona, Spain, 12 Hospital Virgen de<br />

las Nieves, Granada, Spain.<br />

1889. Clonal Analysis <strong>of</strong> Ig-Expressing Cells in Salivary Glands<br />

<strong>of</strong> Primary Sjögren’s Syndrome Patients after Anti-CD20<br />

Treatment. Nishath Hamza 3 , Hendrika Bootsma 4 , Rodney<br />

P. E. Pollard 2 , Jiska M. Meijer 2 , Fred K. L. Spijkervet 2 , Arjan<br />

Vissink 2 , Hans G. M. Burgerh<strong>of</strong> 5 , Frans G. M. Kroese 1 , Cees G.<br />

M. Kallenberg 4 and Nicolaas A. Bos 1 , 1 Dept. <strong>of</strong> Cell Biology,<br />

Immunology Section, University Medical Center Groningen,<br />

University <strong>of</strong> Groningen, Groningen, The Netherlands,<br />

2<br />

Dept. <strong>of</strong> Oral and Maxill<strong>of</strong>acial Surgery, University Medical<br />

Center Groningen, University <strong>of</strong> Groningen, Groningen, The<br />

Netherlands, 3 Dept. <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology<br />

& Dept. <strong>of</strong> Cell Biology, Immunology Section, University<br />

Medical Center Groningen, University <strong>of</strong> Groningen, Groningen,<br />

The Netherlands, 4 Dept. <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, University Medical Center Groningen, University<br />

<strong>of</strong> Groningen, Groningen, The Netherlands, 5 University Medical<br />

Center Groningen, University <strong>of</strong> Groningen, Groningen, The<br />

Netherlands.<br />

2010 Program Book 265


ACR/ARHP Poster Session C<br />

1890. Correlation <strong>of</strong> Serum BAFF and Markers <strong>of</strong> B-Cell Activation<br />

with Systemic Involvement Assessed by the EULAR Sjögren’s<br />

Syndrome Disease Activity Index: Results from the ASSESS<br />

Prospective Cohort. Jacques-Eric Gottenberg 16 , Raphaele<br />

Seror 2 , Joelle Benessiano 3 , Karine Inamo 2 , Philippe Dieude 3 ,<br />

Jean-Jacques Dubost 5 , Anne-Laure Fauchais 11 , Eric Hachulla 10 ,<br />

Claire Larroche 1 , Veronique Le Guern 6 , Jacques Morel 12 , Aleth<br />

Perdriger 14 , Xavier Puéchal 9 , Stéphanie Rist 13 , Alain Saraux 4 ,<br />

Damien Sene 7 , Jean Sibilia 16 , Olivier Vittecoq 15 , Charles<br />

Zarnitsky 8 , Philippe Ravaud 3 and Xavier Mariette 2 , 1 Avicenne<br />

Hospital, 2 Bicetre Hospital, 3 Bichat Hospital, 4 Brest Hospital,<br />

5<br />

Clermont-Ferrand Hospital, 6 Cochin Hospital, 7 La Pitié Hospital,<br />

8<br />

Le Havre Hospital, 9 Le Mans Hospital, 10 Lille Hospital, 11 Limoges<br />

Hospital, 12 Montpellier Hospital, 13 Orleans Hospital, 14 Rennes<br />

Hospital, 15 Rouen Hospital, 16 Strasbourg Hospital.<br />

1891. Detection <strong>of</strong> HTLV-1 p19 Protein in Labial Salivary Glands<br />

from Patients with Sjögren’s Syndrome: A Distinct Clinical<br />

Subgroup? Sung-Ji Lee 1 , Seong-Rye Seo 1 , Tae-Jong Kim 1 , Yong-<br />

Wook Park 1 and Shin-Seok Lee 2 , 1 Chonnam National University<br />

Medical School, 2 Chonnam Natl Univ Med School, Gwangju,<br />

Korea, Republic <strong>of</strong>.<br />

1892. Effect <strong>of</strong> Rituximab Treatment on BAFF Levels in Patients with<br />

Primary Sjögren’s Syndrome: A Placebo-Controlled Clinical<br />

Trial. Rodney Pollard 2 , Wayel Abdulahad 2 , Jiska Meijer 2 , Frans<br />

Kroese 2 , Fred Spijkervet 2 , Cees Kallenberg 1 , Arjan Vissink 2 and<br />

Hendrika Bootsma 2 , 1 Univer Med Center Groningen, Groningen,<br />

The Netherlands, 2 Univer Med Center Groningen.<br />

1893. Efficacy <strong>of</strong> Rituximab in Primary Sjogren’s Syndrome with<br />

Peripheral Nervous System Involvement: Results from the<br />

French AIR Registry. Arsene Mekinian 6 , Eric Hachulla 9 , Claire<br />

Larroche 2 , Jean Leone 11 , Bruno Gomberg 7 , Mohamed Hamidou 8 ,<br />

Alain G. Cantagrel 5 , Christian Marcelli 4 , Stephanie Rist 10 , Maxime<br />

A. Breban 1 , Olivier Fain 6 , Jacques E. Gottenberg 12 and Xavier<br />

Mariette 3 , 1 Courbevoie, France, 2 Avicenne Hospital, 3 Bicetre<br />

Hospital/Paris Univ, Le Kremlin Bicetre, France, 4 Caen Hospital,<br />

5<br />

Hopital Purpan, Toulouse, France, 6 Jean Verdier Hospital, 7 La<br />

Rochelle Hospital, 8 Nantes Hospital, 9 National Scleroderma<br />

Centre, Lille Cedex, France, 10 Orleans Hospital, 11 Reims Hospital,<br />

12<br />

Strasbourg Hospitals, Strasbourg, France.<br />

1894. Efficacy <strong>of</strong> Rituximab in Primary Sjogren’s Syndrome with<br />

Central Nervous System Involvement: Results from the<br />

French AIR Registry. Arsene Mekinian 4 , Claire Larroche 1 , Eric<br />

Hachulla 7 , Bruno Gomberg 6 , Claire Blanchard-Delaunay 8 , Alain<br />

G. Cantagrel 3 , Olivier Fain 5 , Jean Sibilia 9 , Jacques E. Gottenberg 10<br />

and Xavier Mariette 2 , 1 Avicenne Hospital, 2 Bicetre Hospital/Paris<br />

Univ, Le Kremlin Bicetre, France, 3 Hopital Purpan, Toulouse,<br />

France, 4 Jean Verdier Hospital, 5 Jean Verdier Hospital, 6 La<br />

Rochelle Hospital, 7 National Scleroderma Centre, Lille Cedex,<br />

France, 8 Niort Hospital, 9 Strasbourg Hospital, 10 Strasbourg<br />

Hospitals, Strasbourg, France.<br />

1895. Epitope Mapping <strong>of</strong> the Autoantigen Aquaporin-4 Reveals<br />

Linear Epitopes Located in the Intracellular Region <strong>of</strong> the<br />

Molecule. Eleni I. Kabylafka 1 , John G. Routsias 1 , Haralampos<br />

Alexopoulos 1 and Athanasios G. Tzioufas 2 , 1 Department <strong>of</strong><br />

Pathophysiology, Medical School <strong>of</strong> Athens, Athens, Greece,<br />

2<br />

Medical School-Univ <strong>of</strong> Athens, Athens, Greece.<br />

1896. EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI):<br />

Development <strong>of</strong> a Consensus Patient Index for Primary<br />

Sjögren’s Syndrome. Raphaèle Seror 5 , Philippe Ravaud 13 , Xavier<br />

Mariette 4 , Hendrika Bootsma 18 , Elke Theander 9 , Arne Hansen 3 ,<br />

Manel Ramos-Casals 1 , Thomas Dörner 3 , Stefano Bombardieri 20 ,<br />

Eric Hachulla 11 , Johan G. Brun 17 , Aike A. Kruize 19 , Sonja<br />

Praprotnik 14 , Matija Tomsic 14 , Jacques E. Gottenberg 12 , Valerie<br />

Devauchelle 6 , Salvatore Devita 16 , Cristina Vollenweider 8 , Thomas<br />

Mandl 9 , Athanasios G. Tzioufas 10 , Steven E. Carsons 22 , Alain<br />

Saraux 7 , Nurhan Sutcliffe 2 , Claudio Vitali 21 , Simon J. Bowman 15<br />

and The EULAR Sjögren’s Task Force, 1 ”Josep Font”, Hospital<br />

Barcelona, 2 Barts &The Royal London Hospital, 3 Berlin Charité,<br />

University Hospital, 4 Bicetre Hospital/Paris Univ, Le Kremlin<br />

Bicetre, France, 5 Bicetre Hospital/Paris Univ, Le Kremlin Bicetre,<br />

France, 6 CHU de la Cavale Blanche, 7 CHU de la Cavale Blanche,<br />

Brest Cedex, France, 8 German Hospital, Buenos-Aires, 9 Malmö<br />

University Hospital, 10 Medical School-Univ <strong>of</strong> Athens, Athens,<br />

Greece, 11 National Scleroderma Centre, Lille Cedex, France,<br />

12<br />

Strasbourg Hospitals, Strasbourg, France, 13 Université Paris<br />

Descartes, 14 University Clinical Centre <strong>of</strong> Ljubljana, 15 University<br />

Hospital Birmingham NHS Foundation, 16 University Hospital <strong>of</strong><br />

Udine, 17 University Hospital, Bergen, 18 University Medical Center<br />

Groningen, 19 University Medical Center Utrecht, 20 University <strong>of</strong><br />

Pisa, 21 Villamarina Hospital, 22 Winthrop Univ Hospital, Mineola,<br />

NY.<br />

1897. Evolution <strong>of</strong> Autoimmune Minor Salivary Gland (MSG) Lesions<br />

in Sjögren’s Syndrome (SS). Efstathia K. Kapsogeorgou 3 ,<br />

Maria I. Christodoulou 4 , Demosthenes B. Panagiotakos 2 ,<br />

Spyros Paikos 1 and Haralampos M. Moutsopoulos 4 , 1 Dental<br />

Department, “Laikon” General Hospital <strong>of</strong> Athens, Athens,<br />

Greece, 2 Dietetics and Nutrition Dept, Harokopio University <strong>of</strong><br />

Athens, 3 Pathophysiology Dept, School <strong>of</strong> Medicine, National<br />

University <strong>of</strong> Athens, Athens, Attica, Greece, 4 Pathophysiology<br />

Dept, School <strong>of</strong> Medicine, National University <strong>of</strong> Athens, Athens,<br />

Greece.<br />

1898. Extra-Glandular Manifestations <strong>of</strong> Primary Sjögren’s<br />

Syndrome in the SICCA International Sjögren’s Syndrome<br />

Registry. Arundathi S. Malladi 12 , Kenneth E. Sack 8 , Stephen<br />

Shiboski 10 , Caroline Shiboski 10 , Alan N. Baer 2 , Pekka Helin 7 , Bruce<br />

Kirkham 4 , Hisanori Umehara 3 , Frederick B. Vivino 6 , Cristina<br />

F. Vollenweider 1 , Yan Zhao 5 , John Greenspan 10 , Troy Daniels 9<br />

and Lindsey A. Criswell 11 , 1 German Hospital, Buenos Aires,<br />

Argentina, 2 Johns Hopkins University, Baltimore, MD, 3 Kanazawa<br />

Medical University, Ishikawa, Japan, 4 King’s <strong>College</strong> London, UK,<br />

5<br />

Peking Union Medical <strong>College</strong> Hospital, Beijing, China, 6 Penn<br />

Presbyt Med Ctr, Philadelphia, PA, 7 Rigshospitalet, Copenhagen,<br />

Denmark, 8 UCSF, Tiburon, CA, 9 UCSF, San Francisco, CA, 10 UCSF,<br />

11<br />

UCSF-Box 0500, San Francisco, CA, 12 University <strong>of</strong> California at<br />

San Francisco (UCSF), San Francisco, CA.<br />

1899. Germinal Center (GC) Formation in Salivary Gland Biopsies at<br />

Diagnosis <strong>of</strong> Primary Sjögren’s Syndrome (pSS) Is a New and<br />

Strong Predictor <strong>of</strong> Non-Hodgkin’s Lymphoma (NHL) during<br />

Follow-Up. Elke Theander 4 , Lilian Vasaitis 3 , Eva Baecklund 5 ,<br />

Gunnel Nordmark 5 , Gunnar Warfvinge 4 , Rolf Liedholm 4 , Karl<br />

Brokstad 1 , Roland Jonsson 1 and Malin V. Jonsson 2 , 1 University <strong>of</strong><br />

Bergen, Bergen, Norway, 2 University <strong>of</strong> Bergen, Bergen, Norway,<br />

3<br />

University <strong>of</strong> Lund, Uppsala, Sweden, 4 University <strong>of</strong> Lund,<br />

Malmö, Sweden, 5 University <strong>of</strong> Uppsala, Uppsala, Sweden.<br />

266<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1900. IL-7 Receptor Effector T Cells Are Increased in the Inflamed<br />

Salivary Glands <strong>of</strong> pSS Patients and Correlate with<br />

Inflammatory Markers. A. Bikker, A. A. Kruize, M. J. G. Wenting,<br />

J. W. J. Bijlsma, F. P. J. G. Lafeber and J. A. G. van Roon,<br />

<strong>Rheumatology</strong> &Clinical Immunology, University Medical Center<br />

Utrecht, The Netherlands.<br />

1901. Immunization with Ro60 Peptide Leads to Sjögren’s Like<br />

Syndrome in Mice with Appropriate Genetic Background.<br />

Biji T. Kurien 1 , Sima Asfa 3 , Anil D’souza 3 , Yaser Dorri 3 , Skyler P.<br />

Dillon 3 , Sherry Hubbel 3 , Ali W. Khalili 2 , Olga Yelios<strong>of</strong>, Yun Jong<br />

Lee, Shannon Maier 3 and R. Hal Sc<strong>of</strong>ield 3 , 1 Oklahoma Medical<br />

Research Foundation, 2 University <strong>of</strong> Oklahoma, 3 University <strong>of</strong><br />

Oklahoma Health Sciences Center.<br />

1902. Impaired Gastric Emptying in Primary Sjögren’s Syndrome.<br />

Oskar Hammar, Bodil Ohlsson, Per Wollmer and Thomas Mandl,<br />

Skåne University Hospital Malmö, Malmö, Sweden.<br />

1903. Increased Numbers <strong>of</strong> IL-7Rα-CD25+FoxP3+ T Cells in pSS<br />

Patients Do Not Prevent Th1 and Th17 Induction by IL-7. A.<br />

Bikker, F. M. Moret, A. A. Kruize, J. W. J. Bijlsma, F. P. J. G. Lafeber<br />

and J. A. G. van Roon, <strong>Rheumatology</strong> & Clinical Immunology,<br />

University Medical Center Utrecht, The Netherlands.<br />

1904. Interferon Type I Signature in Monocytes in Primary Sjögren’s<br />

Syndrome. Zana Brkic 1 , Cornelia G. van Helden-Meeuwsen 1 ,<br />

Joop van der Merwe 1 , Hemmo A. Drexhage 1 and Marjan A.<br />

Versnel 2 , 1 Dept Immunology, Rotterdam, The Netherlands, 2 Dept<br />

Immunology, Erasmus MC, Rotterdam, The Netherlands.<br />

1905. Is Retreatment with Rituximab in Patients with Primary<br />

Sjögren’s Syndrome Safe and Effective? Petra M. Meiners,<br />

Arjan Vissink, Jiska M. Meijer, Fred K. .L Spijkervet, Cees G. M.<br />

Kallenberg and Hendrika Bootsma, University Medical Center<br />

Groningen, Groningen, The Netherlands.<br />

1906. Molecular and Cellular Evolution <strong>of</strong> Functional Tertiary<br />

Lymphoid Structures in Salivary Glands <strong>of</strong> NOD Mice. Elisa<br />

Astorri 3 , Michele Bombardieri 3 , Elisa Corsiero 3 , Francesca<br />

Barone 1 , Gordon Proctor 2 and Costantino Pitzalis 3 , 1 Birmingham<br />

University, Birmingham, United Kingdom, 2 King’s <strong>College</strong>,<br />

London, London, United Kingdom, 3 Queen Mary University<br />

London, London, United Kingdom.<br />

1907. New Classification Criteria for Childhood Sjögren’s Syndrome.<br />

Naoto Yokogawa 8 , Scott M. Lieberman 1 , Sharon M. Bout-<br />

Tabaku 3 , Faizan Alawi 7 , Juan P. Palazzo 6 , Martha Guttenberg 2 ,<br />

David D. Sherry 5 and Frederick B. Vivino 4 , 1 Children’s Hosp <strong>of</strong><br />

Philadelphia, Philadelphia, PA, 2 Children’s Hosp <strong>of</strong> Philadelphia,<br />

3<br />

Nationwide Children’s Hospital, Columbus, OH, 4 Penn<br />

Presbyt Med Ctr, Philadelphia, PA, 5 The Children’s Hospital <strong>of</strong><br />

Philadelphia, Philadelphia, PA, 6 Thomas Jefferson Univ., 7 Univ. <strong>of</strong><br />

Pennsylvania, 8 Univ. <strong>of</strong> Pennsylvania / Tokyo Metropolitan Tama<br />

Medical Center.<br />

1908. New Insights in Sjögren Syndrome Associated Peripheral<br />

Neuropathies: The Small Fibre Neuropathy and Its Clinical,<br />

Immunological and Neurophysiological Features from a<br />

Moncentre Cohort <strong>of</strong> 24 Patients. Damien Sène 2 , Jean-Pascal<br />

Lefaucheur 1 , Julien Haroche 2 , David Saadoun 2 , Baptiste Hervier 2 ,<br />

Jean-Charles Piette 2 , Zahir Amoura 2 and Patrice Cacoub 2 , 1 Henri-<br />

Mondor Hospital, 2 Pitié-Salpêtrière Hospital.<br />

1909. Novel Lupus Susceptible Gene Polymorphisms in Patients with<br />

Sjögren’s Syndrome in Japanese Population. Tetsuya Horita 1 ,<br />

Hisako Nakagawa 1 , Takashi Kurita 1 , Toshio Odani 1 , Yuichiro<br />

Fujieda 1 , Kotaro Otomo 2 , Masaru Kato 1 , Shinsuke Yasuda 1 ,<br />

Tatsuya Atsumi 1 and Takao Koike 1 , 1 Medicine II, Hokkaido<br />

University, Sapporo, Hokkaido, Japan, 2 Medicine II, Hokkaido<br />

University.<br />

1910. Patients’ Complaints Depend on Systemic Status in Patient<br />

with Primary Sjögren ‘s Syndrome: Concordant Results from<br />

2 Independant Cohorts. Raphaèle Seror 3 , Philippe Ravaud 23 ,<br />

Simon J. Bowman 24 , Hendrika Boostma 25 , Manel Ramos-Casals 17 ,<br />

Elke Theander 18 , Thomas Doerner 1 , Eric Hachulla 20 , Jacques E.<br />

Gottenberg 22 , Athanasios G. Tzioufas 19 , Alain Saraux 7 , Veronique<br />

Le Guern 16 , Stephanie Rist 10 , Claire Larroche 14 , Anne Laure<br />

Fauchais 8 , Aleth Pedriger 12 , Jacques Morel 9 , Jean Sibilia 21 ,<br />

Jean-Jacques Dubost 6 , Olivier Vittecoq 13 , Philippe Dieudé 15 ,<br />

Xavier Puechal 5 , Damien Sene 11 , Charles Zarnitsky 4 , Claudio<br />

Vitali 26 and Xavier Mariette 2 , 1 Berlin Charite University Hospital,<br />

2<br />

Bicetre Hospital/Paris Univ, Le Kremlin Bicetre, France, 3 Bicetre<br />

Hospital/Paris Univ, Le Kremlin Bicetre, France, 4 CH du Havre,<br />

5<br />

CH du Mans, 6 CHU Clermont-Ferrand, 7 CHU de la Cavale<br />

Blanche, Brest Cedex, France, 8 CHU Limoges, 9 CHU Montpellier,<br />

10<br />

CHU Orléans, 11 CHU Pitié Salpetriere, 12 CHU Rennes, 13 CHU<br />

Rouen, 14 Hopital Avicenne, 15 Hopital Bichat, 16 Hopital Cochin,<br />

17<br />

Josep Font Hospital, Barcelona, 18 Malmö University Hospital,<br />

19<br />

Medical School-Univ <strong>of</strong> Athens, Athens, Greece, 20 National<br />

Scleroderma Centre, Lille Cedex, France, 21 Strasbourg Hospitals,<br />

22<br />

Strasbourg Hospitals, Strasbourg, France, 23 Universite<br />

Paris-Rene Descartes, 24 University Hospital Birmingham NHS<br />

Foundation Trust, 25 University Medical Center Groningen,<br />

26<br />

Villamarina Hospital Pimobino.<br />

1911. Primary Sjögren’s Syndrome-Associated Non Ataxic<br />

Sensory Neuropathies and Sensorimotor Neuropathies Are<br />

Characterized by Distinctive Immunological Pr<strong>of</strong>iles. Damien<br />

Sène 2 , Moez Jallouli 2 , Jean-Pascal Lefaucheur 1 , David Saadoun 2 ,<br />

Thierry Maisonobe 2 , Julien Haroche 2 , Marie-Claude Diemert 2 ,<br />

Lucile Musset 2 , Jean-Charles Piette 2 , Zahir Amoura 2 and Patrice<br />

Cacoub 2 , 1 Henri-Mondor Hospital, 2 Pitie-Salpetriére Hospital.<br />

1912. Prognosis <strong>of</strong> Non-Hodgkin Lymphomas in Primary Sjogren’s<br />

Syndrome. Michael Voulgarelis, Panayiotis D. Ziakas, Aristea<br />

Papageorgiou, Athanasios G. Tzioufas and Haralampos M.<br />

Moutsopoulos, Dept <strong>of</strong> Pathophysiology, Medical School,<br />

University <strong>of</strong> Athens, Greece.<br />

1913. Risk <strong>of</strong> Non-Hodgkin’s Lymphoma in Primary Sjögren’s<br />

Syndrome. Svein J A. Johnsen 3 , Johan G. Brun 1 , Tom B.<br />

Johannesen 2 , Lasse Gøransson 3 , Karstein Haldorsen 1 , Roland<br />

Jonsson 4 and Roald Omdal 3 , 1 Haukeland University Hospital,<br />

2<br />

Norwegian Cancer Registry, 3 Stavanger University Hospital,<br />

4<br />

University <strong>of</strong> Bergen.<br />

1914. The FMS-Like Tyrosine Kinase3-Ligand (FL) Is a Marker for<br />

Lymphoma in Primary Sjögren’s Syndrome (SS). Jacques-Olivier<br />

Pers 1 , Gabriel J. Tobon 1 , Jacques E. Gottenberg 7 , Raphaèle<br />

Seror 4 , Valérie Devauchelle 2 , Jacques Morel 5 , Stéphanie Rist 6 ,<br />

Alain Saraux 3 and Pierre Youinou 1 , 1 Brest University, Brest,<br />

France, 2 Brest University, 3 CHU de la Cavale Blanche, Brest<br />

Cedex, France, 4 Le Kremlin Bicetre Hospital, 5 Montpellier<br />

University, 6 Orleans Hospital, 7 Strasbourg Hospitals, Strasbourg,<br />

France.<br />

1915. The Role <strong>of</strong> Immunostaining Against the Panaxonal Protein<br />

PGP 9.5 in the Evaluation <strong>of</strong> Sjogren’s Sensory Neuropathies,<br />

and the Increased Frequency <strong>of</strong> Male Sex and Seronegativity<br />

to Anti-La/SS-B Autoantibody with Peripheral Neuropathies.<br />

Julius Birnbaum, Alan N. Baer and Michael Polydefkis, Johns<br />

Hopkins University, Baltimore, MD.<br />

1916. The Temporal Appearance <strong>of</strong> Symptoms and Signs in Primary<br />

Sjögren’s Syndrome. Chiara Baldini, Nicoletta Luciano, Pasquale<br />

Pepe, Rosaria Talarico, Sara Grossi, Antonio Gaetano Tavoni<br />

and Stefano Bombardieri, <strong>Rheumatology</strong> Unit, Department <strong>of</strong><br />

Internal Medicine, University <strong>of</strong> Pisa, Italy.<br />

2010 Program Book 267


ACR/ARHP Poster Session C<br />

1917. Vaccination <strong>of</strong> Patients with Primary Sjogren’s Syndrome<br />

Induces IL-7 and Skewed B Cell Maturation with Increased<br />

Levels <strong>of</strong> Plasmablasts Resulting in Higher Titers <strong>of</strong> Vaccine-<br />

Specific IgG Antibodies. Susanna R. Brauner 2 , Marika<br />

Kvarnstrom 2 , Sabrina Goergen 2 , Karl A. Brokstad 3 , Christina<br />

Trollmo 2 , Lars Klareskog 1 , Roland Jonsson 3 , Vivianne Malmstrom 2<br />

and Marie Wahren-Herlenius 2 , 1 Karolinska University Hospital,<br />

Stockholm, Sweden, 2 Reumatology Unit, Karolinska Institutet,<br />

Stockholm, Sweden, 3 University <strong>of</strong> Bergen, Bergen, Norway.<br />

1918. Validation <strong>of</strong> microRNAs as Biomarkers <strong>of</strong> Salivary Gland<br />

Inflammation in Sjögren’s Syndrome. Seyed M. Emamian 1 , Ilias<br />

Alevizos 1 and Gabor G. Illei 2 , 1 NIDCR, 2 NIDCR, NIH #10 1N114,<br />

Bethesda, MD.<br />

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects<br />

and Treatment II<br />

1919. Abatacept (ABA) in the Treatment <strong>of</strong> Psoriatic Arthritis (PsA):<br />

12-Month Results <strong>of</strong> a Phase II Study. Philip J. Mease 8 , Mark C.<br />

Genovese 9 , Ge<strong>of</strong>frey S. Gladstein 3 , Alan J. Kivitz 2 , Christopher<br />

T. Ritchlin 11 , Paul P. Tak 1 , Jurgen Wollenhaupt 7 , Jean-Claude P.<br />

Becker 4 , Sheila M. Kelly 6 , Yun Peng 5 and Dafna D. Gladman 10 ,<br />

1<br />

Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The<br />

Netherlands, 2 Altoona Arthritis & Osteo Ctr, Duncansville, PA,<br />

3<br />

Arthritis Int Med Assoc LLC, Trumbull, CT, 4 Bristol-Myers Squibb,<br />

Princeton, NJ, 5 Bristol-Myers Squibb, Pennington, NJ, 6 Bristol-<br />

Myers Squibb, Doylestown, PA, 7 Schoen Klinik, Hamburg,<br />

Germany, 8 Seattle <strong>Rheumatology</strong> Associate, Seattle, WA,<br />

9<br />

Stanford University, Sunnyvale, CA, 10 Toronto Western Hospital,<br />

Toronto, ON, Canada, 11 University <strong>of</strong> Rochester Medical Center,<br />

Rochester, NY.<br />

1920. Agreement between Total Joint Count and DAS 28 Joint Count<br />

in Psoriatic Arthritis. Jose Luis Fernandez-Sueiro 1 , Eugenia<br />

Gonzalez Diaz de Rabago 1 , J. Pinto-Tasende 1 , Sonia Pertega-<br />

Diaz 1 , J. C. Fernandez-Lopez 1 , N. Oreiro-Villar 1 , F. Galdo 1 and<br />

Francisco J. Blanco 2 , 1 Complejo Hospitalario Universitario La<br />

Coruña, La Coruña, Spain, 2 Complejo Hospitalario Universitario<br />

La Coruña, A Coruna, Spain.<br />

1921. An Initial Diagnosis <strong>of</strong> Lumbar Disc Herniation Is Associated<br />

with a Late Refferral to the Rheumatologist and a Delay in<br />

the Diagnosis <strong>of</strong> Ankylosing Spondylitis. Servet Akar 1 , Vedat<br />

Gerdan 1 , Dilek Solmaz 1 , Mehmet Sayarlioglu 4 , Mehmet Akif<br />

Ozturk 2 , Ahmet Mesut Onat 3 , Bünyamin Kisacik 3 , Mehmet<br />

Emin Tezcan 2 , Merih Birlik 1 , Fatos Onen 1 and Nurullah Akkoc 1 ,<br />

1<br />

<strong>Rheumatology</strong>, Dokuz Eylul Univerisity Faculty <strong>of</strong> Medicine,<br />

Izmir, Turkey, 2 <strong>Rheumatology</strong>, Gazi University, Ankara, Turkey,<br />

3<br />

<strong>Rheumatology</strong>, Gaziantep University Faculty <strong>of</strong> Medcine,<br />

Gaziantep, Turkey, 4 <strong>Rheumatology</strong>, KahramanMaras Sutcu Imam<br />

University Faculty <strong>of</strong> Medicine, KahramanMaras, Turkey.<br />

1922. Ankylosing Spondylitis Disease Activity Score (ASDAS):<br />

Defining Cut-Off Values for Disease Activity States and<br />

Improvement Scores. Pedro Machado 1 , Robert Landewe 7 ,<br />

Elisabeth Lie 3 , Tore K. Kvien 2 , Juergen Braun 6 , Daniel G. Baker 5<br />

and Desiree M. Van Der Heijde 4 , 1 Coimbra University Hospital,<br />

Coimbra, Portugal; Leiden University Medical Center, Leiden,<br />

The Netherlands, 2 Diakonhjemmet Hospital, Oslo, Oslo, Norway,<br />

3<br />

Diakonhjemmet Hospital, Oslo, Norway, 4 Leiden University<br />

Medical Center, Meerssen, The Netherlands, 5 Research and<br />

Development, Centocor Inc, Malvern, PA, 6 Rheumazentrum<br />

Ruhrgebiet, Herne, Germany, 7 Univ Hosp Maastricht,<br />

Maastricht, The Netherlands.<br />

1923. Ankylosing Spondylitis Patient Organisations – Are There<br />

Benefits <strong>of</strong> Membership? In-Ho Song 1 , Cornelia Brenneis 1 ,<br />

Ludwig Hammel 2 , Ernst Feldtkeller 2 , Joachim Listing 3 , Joachim<br />

Sieper 1 and Martin Rudwaleit 1 , 1 Charite Campus Benjamin-<br />

Franklin, Medical Clinic I, <strong>Rheumatology</strong>, Berlin, Germany,<br />

2<br />

German Ankylosing Spondylitis Society (DVMB), Schweinfurt,<br />

Germany, 3 German Rheumatism Research Center, Berlin,<br />

Germany.<br />

1924. Anterior Chest Wall Pain in Spondyloarthritis Is a Frequent<br />

Manifestation, Appearing Early in the Disease Course, Which<br />

May Respond to NSAIDs. Muriel Elhai 1 , Simon Paternotte 1 ,<br />

Fanny Roure 1 , Eugénie Koumakis 1 , Judith Payet 1 , Vincent Burki 1 ,<br />

Isabelle Fabreguet 1 , Magali Meyer 1 , Maxime Dougados 2 and<br />

Laure Gossec 1 , 1 Cochin Hospital and Paris Descartes University,<br />

Paris, France, 2 Hospital Cochin, Paris, France.<br />

1925. Assessment <strong>of</strong> Efficacy and Safety <strong>of</strong> Pamidronate in<br />

Undifferentiated Spondyloarthropathy (uSpA): A Placebo<br />

Control Trial in a Tertiary Level Centre. Rathindra N. Sarkar 1 ,<br />

Sibaji Phaujdar 2 , Sattik Siddhanta 2 , Siwalik Banerjee 2 , Dibeyendu<br />

De 2 , Kuntal Bhattacharyya 2 and H. K. Pal 2 , 1 Calcutta Medical<br />

<strong>College</strong>, Kolkata, West Bengal, India, 2 Calcutta Medical <strong>College</strong>,<br />

Kolkata.<br />

1926. Can Clinical Phenotype Identify Early Psoriatic Arthritis in an<br />

Early Arthritis Cohort? Laura C. Coates 3 , Philip G. Conaghan 3 ,<br />

Paul Emery 3 , Michael J. Green 4 , Gamal Ibrahim 1 , Helen MakIver 1<br />

and Philip S. Helliwell 2 , 1 Bradford Hospitals NHS Trust, UK,<br />

Bradford, United Kingdom, 2 LIMM, Section <strong>of</strong> Musculoskeletal<br />

Disease, University <strong>of</strong> Leeds, Leeds, UK, 3 LIMM, Section <strong>of</strong><br />

Musculoskeletal Disease, University <strong>of</strong> Leeds, UK, 4 York Hospital<br />

NHS Trust, York, UK.<br />

1927. Clinical Improvement with Etanercept Versus Sulfasalazine<br />

Treatment in Patients with Ankylosing Spondylitis:<br />

Comparative Performance <strong>of</strong> Various Efficacy Measurements<br />

(ASCEND). Desiree M. Van Der Heijde 2 , Juergen Braun 7 , Maxime<br />

Dougados 1 , Annette Szumski 4 , Ronald Pedersen 6 , Bonnie<br />

Vlahos 3 , Bruce Freundlich 4 and Andrew S. Koenig 5 , 1 Hospital<br />

Cochin, Paris, France, 2 Leiden University Medical Center,<br />

Meerssen, The Netherlands, 3 Pfizer, Inc., Pottstown, PA, 4 Pfizer,<br />

Inc., <strong>College</strong>ville, PA, 5 Pfizer, Inc., Blue Bell, PA, 6 Prizer, Inc.,<br />

<strong>College</strong>ville, PA, 7 Rheumazentrum Ruhrgebiet, Herne, Germany.<br />

1928. Comparison <strong>of</strong> Comorbid Disease Burden in Psoriasis and<br />

Psoriatic Arthritis (PsA). Janice Husted 1 , Arane Thavaneswaran 4 ,<br />

Vinod Chandran 4 , Lihi Eder 4 , Sutha Shanmugarajah 4 , Cheryl<br />

F. Rosen 2 and Dafna D. Gladman 3 , 1 Department <strong>of</strong> Health<br />

Studies & Gerentology, University <strong>of</strong> Waterloo, 2 Division <strong>of</strong><br />

Dermatology, Toronto Western Hospital, 3 Toronto Western<br />

Hospital, Toronto, ON, Canada, 4 University <strong>of</strong> Toronto Psoriatic<br />

Arthritis Clinic.<br />

1929. Continued Efficacy <strong>of</strong> Infliximab in the Treatment <strong>of</strong> HLA<br />

B27 Positive Very Early Ankylosing Spondylitis Following Its<br />

Discontinuation; Clinical and Imaging Results <strong>of</strong> the 40 Week<br />

Follow-Up Study <strong>of</strong> a Three Month, Randomised, Placebo-<br />

Controlled Trial. Nick Barkham 3 , Helen Keen 4 , Laura Coates 4 ,<br />

Phil O’connor 2 , Elizabeth Hensor 4 , Dennis McGonagle 4 , Helena<br />

Marzo-Ortega 4 and Paul Emery 1 , 1 Chapel Allerton Hospital,<br />

Leeds, United Kingdom, 2 Leeda University, 3 Leeds University,<br />

Leeds, Yorkshire, United Kingdom, 4 Leeds University.<br />

268<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1930. Correlation <strong>of</strong> Disease Activity, but Not Radiographic<br />

Progression, with Functional Outcomes in Adalimumab-<br />

Treated Patients with Active Psoriatic Arthritis. Arthur<br />

Kavanaugh 4 , Philip Mease 3 , Michele Olds 2 and Frederic Lavie 1 ,<br />

1<br />

Abbott Laboratories, Rungis, France, 2 Abbott Laboratories,<br />

Abbott Park, IL, 3 Swedish Medical Center and University <strong>of</strong><br />

Washington, Seattle, WA, 4 University <strong>of</strong> California San Diego, La<br />

Jolla, CA.<br />

1931. CT Scan Facilitates the Diagnosis <strong>of</strong> Sacroiliitis in Patients with<br />

Suspected Spondyloarthritis, and without Proven Sacroiliitis<br />

on Pelvic X-Ray – Results <strong>of</strong> the ECHOSPA Cohort. Valérie<br />

Devauchelle-Pensec 1 , Maria-Antonietta d’Agostino 8 , Julien<br />

Marion 1 , Sandrine Jousse-Joulin 2 , Marie Lapierre 1 , Daniele<br />

Colin 1 , Isabelle Chary-Valkenaere 6 , Christian Marcelli 3 , Damien<br />

Loeuille 7 , Philippe Aegerter 8 , Sandrine Guis 5 , Philippe Gaudin 4 ,<br />

Maxime Bréban 8 and Alain Saraux 1 , 1 CHU Brest, 2 CHU Brest,<br />

3<br />

CHU Caen, France, 4 CHU Grenoble, 5 CHU Marseille, France,<br />

6<br />

CHU Nancy, 7 CHU Nancy, 8 Hopital Ambroise Paré, France.<br />

1932. Dactylitis in Psoriatic Arthritis (PsA): Prevalence and<br />

Response to Therapy in the Biologic Era. Olga Ziouzina 2 , Arane<br />

Thavaneswaran 2 , Vinod Chandran 2 and Dafna D. Gladman 1 ,<br />

1<br />

Toronto Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong><br />

Toronto Psoriatic Arthritis Clinic.<br />

1933. Decreased Recurrence Rate <strong>of</strong> Anterior Uveitis in Ankylosing<br />

Spondylitis Treated with Adalimumab – An Interim Analysis.<br />

Irene E. van der Horst-Bruinsma 2 , J. Christiaan van Denderen 1 ,<br />

Ingrid Visman, Maria S. A. Suttorp-Schulten, Ben A. C.<br />

Dijkmans and Michael T. Nurmohamed, 1 Amsterdam, NH, The<br />

Netherlands, 2 VU University Medical Centre, Amsterdam, NH,<br />

The Netherlands.<br />

1934. Direct Imaging Evidence That Adalimumab Induces Resolution<br />

<strong>of</strong> Inflammatory Lesions in AS Patients at Sites <strong>of</strong> Complete<br />

Spinal Ankylosis. Walter P. Maksymowych, Nathalie Morency<br />

and Robert G. W. Lambert, University <strong>of</strong> Alberta, Edmonton, AB,<br />

Canada.<br />

1935. Disconnect between Radiographic Progression and Clinical<br />

Outcomes in Psoriatic Arthritis Patients Treated with<br />

Adalimumab. Philip Mease 3 , Christopher Ritchlin 4 , Michele<br />

Olds 2 and Frederic Lavie 1 , 1 Abbott Laboratories, Rungis, France,<br />

2<br />

Abbott Laboratories, Abbott Park, IL, 3 Swedish Medical Center<br />

and University <strong>of</strong> Washington, Seattle, WA, 4 University <strong>of</strong><br />

Rochester School <strong>of</strong> Medicine and Dentistry, Rochester, NY.<br />

1936. Environmental Risk Factors for Psoriatic Arthritis among<br />

Patients with Psoriasis – A Case-Control Study. Lihi Eder 3 ,<br />

Tamryn Loo 3 , Vinod Chandran 3 , Gideon Kalman-Lamb 3 , Sutha<br />

Shanmugarajah 3 , Richard Cook 1 and Dafna D. Gladman 2 ,<br />

1<br />

Department <strong>of</strong> Statistics and Actuarial Science, University <strong>of</strong><br />

Waterloo, Waterloo, ON, Canada, 2 Toronto Western Hospital,<br />

Toronto, ON, Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis<br />

Clinic, Toronto Western Hospital, Toronto, ON, Canada.<br />

1937. Estimate <strong>of</strong> the Prevalence <strong>of</strong> Psoriatic Arthritis and<br />

Improvement with Etanercept Treatment in Moderate-to-<br />

Severe Plaque Psoriasis: PASE Results from the PRISTINE<br />

Trial. M. Elaine Husni 2 , Abrar A. Qureshi 1 , Deborah Robertson 4 ,<br />

Ronald Pedersen 4 , Bruce Freundlich 4 and Charles T. Molta 3 ,<br />

1<br />

Brigham and Women’s Hospital, Boston, MA, 2 Cleveland Clinic<br />

Foundation, Cleveland, OH, 3 Pfizer, Inc., Paoli, PA, 4 Pfizer, Inc.,<br />

<strong>College</strong>ville, PA.<br />

1938. Evaluation <strong>of</strong> the New Akylosing Spondylitis Disease Activity<br />

Score (ASDAS) To Assess Disease Activity in Patient with<br />

Active Non-Radiographic Axial Spondyloarthritis Treated<br />

with Adalimumab and Retreated after Interruption <strong>of</strong><br />

Therapy and Flare. Hildrun Haibel 3 , Frank Heldmann 2 , Joachim<br />

Listing 4 , Hartmut Kupper 1 , Jürgen Braun 2 and Joachim Sieper 3 ,<br />

1<br />

Abbott GmbH & Co. KG, Ludwigshafen, Germany, 2 Centre <strong>of</strong><br />

<strong>Rheumatology</strong> Ruhrgebiet, Herne, Germany, 3 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Charité CBF, Berlin, Germany, 4 German<br />

Rheumatism Research Centre, Berlin, Germany.<br />

1939. High Prevalence <strong>of</strong> Psoriatic Arthritis in a Psoriasis Patients<br />

Cohort. Majed M. Khraishi 2 , Trevor Newhook 1 , Ian Landells 3 ,<br />

Jonathan Mong 3 and Kassem Aboushehde, 1 Nexus Clinical<br />

Research, St. Johns, NL, Canada, 2 Nexus Clinical Research, St<br />

Johns, NL, Canada, 3 Nexus Clinical Research.<br />

1940. Improved Health-Related Quality <strong>of</strong> Life (HRQOL) with<br />

Apremilast (APR) Treatment in Psoriatic Arthritis (PsA):<br />

Results from a Phase 2 Randomized Controlled Study. Vibeke<br />

Strand 3 , Adele Vessey 1 , Angela Hu 2 and Victor S. Sloan 2 , 1 Celgene<br />

Corporation, Richlandtown, PA, 2 Celgene Corporation, Basking<br />

Ridge, NJ, 3 Stanford University, Portola Valley, CA.<br />

1941. Incidence <strong>of</strong> Tuberculosis in Korean Patients with Ankylosing<br />

Spondylitis Treated with Tumor Necrosis Factor Blockers. Eun-<br />

Mi Kim 2 , Chan-Bum Choi 2 , Yoon-Kyoung Sung 2 , Wan-Sik Uhm 2 ,<br />

Jae-Bum Jun 2 , Tae-Hwan Kim 2 , Sang-Cheol Bae 1 and Dae-Hyun<br />

Yoo 1 , 1 Hanyang University Hospital for Rheumatic Diseases,<br />

Seoul, Korea, Republic <strong>of</strong>, 2 Hanyang University Hospital for<br />

Rheumatic Diseases.<br />

1942. Long-Term Drug Survival <strong>of</strong> Anti-TNF Therapy in Ankylosing<br />

Spondylitis. Qiang Li 1 , Michelle Y. Seah 2 , John A. Burgess 3 ,<br />

Shyamali Dharmage 3 , Belinda J. Martin 1 , Russell Buchanan 1<br />

and Lionel Schachna 1 , 1 Austin Health, Melbourne, Australia,<br />

2<br />

Austin Health, Melbourne, Australia, 3 University <strong>of</strong> Melbourne,<br />

Melbourne, Australia.<br />

1943. Long-Term Radiographic Outcome in Psoriatic Arthritis Patients<br />

Treated with Golimumab: 104 Week Results from the GO-<br />

REVEAL Study. Arthur Kavanaugh 7 , Desiree M. Van Der Heijde 4 ,<br />

Dafna D. Gladman 6 , Philip J. Mease 5 , Iain B. McInnes 8 , Gerald<br />

G. Krueger 9 , Weichun Xu 3 , Neil Goldstein 2 and Anna Beutler 1 ,<br />

1<br />

Centocor Research and Development, Inc, <strong>College</strong>ville, PA,<br />

2<br />

Centocor Research and Development, Inc, 3 Centocor Research<br />

and Development, Inc., 4 Leiden University Medical Center,<br />

Meerssen, The Netherlands, 5 Seattle <strong>Rheumatology</strong> Associate,<br />

Seattle, WA, 6 Toronto Western Hospital, Toronto, ON, Canada,<br />

7<br />

University <strong>of</strong> California-San Diego, La Jolla, CA, 8 University <strong>of</strong><br />

Glasgow, Glasgow, United Kingdom, 9 University <strong>of</strong> Utah Health<br />

Sciences Center.<br />

1944. Low Doses <strong>of</strong> Etanercept Can Be Effective in Ankylosing<br />

Spondylitis Patients Who Achieve Remission <strong>of</strong> the Disease.<br />

Victoria Navarro Compán, Rafael Ariza Ariza, Carmen Vargas<br />

Lebrón, Blanca Hernández Cruz, Virginia Moreira Navarrete<br />

and Federico Navarro Sarabia, Hospital Universitario Virgen<br />

Macarena.<br />

1945. Methotrexate Does Not Influence Infliximab Pharmacokinetics<br />

and Concentration-Effect Relationship in Ankylosing<br />

Spondylitis. Emilie Ducourau 2 , David Ternant 2 , Francine<br />

Lauféron 2 , Denis Mulleman 2 , Daniel Wendling 1 , Gilles Paintaud 2<br />

and Philippe Goupille 2 , 1 Universite de Franche-Comte,<br />

Besançon, France, 2 Universite François Rabelais de Tours, Tours,<br />

France.<br />

2010 Program Book 269


ACR/ARHP Poster Session C<br />

1946. Nonsteroidal Anti-Inflammatory (NSAIDs) Drug-Sparing Effect<br />

and Sustained Clinical Improvement <strong>of</strong> Etanercept in Advanced<br />

Ankylosing Spondylitis. Results <strong>of</strong> an Open Label Extension<br />

Following a Randomized Double Blind Placebo-Controlled<br />

Study (SPINE). Maxime Dougados 2 , Jürgen Braun 5 , Sandor<br />

Szanto 6 , Bernard Combe 1 , Pal Geher 4 , Veronique Leblanc 3 and<br />

Isabelle Logeart 3 , 1 Lapeyronie Hospital, Montpellier, France,<br />

2<br />

Paris-Descartes Univ, Cochin Hospital, Paris, France, 3 Pfizer<br />

France, Paris La Défense, France, 4 Polyclinic <strong>of</strong> the Hospitaller<br />

Brothers <strong>of</strong> St. John <strong>of</strong> God, Budapest, Hungary, 5 Ruhrgebiet<br />

Univ, Herne, Germany, 6 Univ <strong>of</strong> Debrecen, Debrecen, Hungary.<br />

1947. Periarticular Bone Changes in Psoriatic and Rheumatoid<br />

Arthritis Patients Following Anti-TNF-alpha Therapy. Agnes<br />

Szentpetery 2 , Phil Gallagher 2 , Susan Van der Kamp 2 , Malachi<br />

J. McKenna 1 , Douglas J. Veale 2 and Oliver FitzGerald 2 , 1 St.<br />

Vincent’s University Hospital, Department <strong>of</strong> Endocrinology,<br />

Dublin, Ireland, 2 St. Vincent’s University Hospital, Department <strong>of</strong><br />

<strong>Rheumatology</strong>, Dublin, Ireland.<br />

1948. Prediction <strong>of</strong> Early Response to Anti-TNF Therapy and<br />

Disease Activity State Using the Ankylosing Spondylitis<br />

Disease Activity Score (ASDAS). Nathan Vastesaeger 5 , Yanxin<br />

Wang 6 , Robert D. Inman 9 , Atul A. Deodhar 7 , Benjamin L. Hsu 1 ,<br />

Mahboob U. Rahman 2 , B. A. C. Dijkmans 11 , Juergen Braun 8 ,<br />

Piet P. Geusens 10 , Joachim Sieper 3 and Desiree M. Van Der<br />

Heijde 4 , 1 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />

Pennsylvania School <strong>of</strong> Medicine, Wynnewood, PA, 2 Centocor<br />

Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania School<br />

<strong>of</strong> Medicine, Malvern, PA, 3 Charite Campus Benjamin Frankl,<br />

Berlin, Germany, 4 Leiden University Medical Center, Meerssen,<br />

The Netherlands, 5 Merck and Co., Inc., Whitehouse Station,<br />

NJ, 6 Merck and Co., Inc., 7 Oregon Health Sciences University,<br />

Portland, OR, 8 Rheumazentrum Ruhrgebiet, Herne, Germany,<br />

9<br />

Toronto Western Hospital, Toronto, ON, Canada, 10 University<br />

Hasselt, Genk, Belgium, 11 VU Medical Centre, Amsterdam, The<br />

Netherlands.<br />

1949. Predictors <strong>of</strong> Radiographic Progression in Adalimumab-Treated<br />

Patients with Ankylosing Spondylitis. Walter Maksymowych 5 ,<br />

Desiree van der Heijde 3 , Robert Landewe 4 , Aileen Pangan 2 ,<br />

Steve Brown 2 and Frederic Lavie 1 , 1 Abbott Laboratories, Rungis,<br />

France, 2 Abbott Laboratories, Abbott Park, IL, 3 Leiden University<br />

Medical Center, Leiden, The Netherlands, 4 Maastricht University<br />

Medical Center, Maastricht, The Netherlands, 5 University <strong>of</strong><br />

Alberta, Alberta, BC, Canada.<br />

1950. Prevalence <strong>of</strong> Psoriatic Arthritis in Thai Psoriasis at<br />

Ramathibodi Hospital. Bodin Butthum 4 , Suphaneewan<br />

Jaovisidha 1 , Pintip Ngamjanyaporn 3 , Surachai Nithiketkul 2 and<br />

Suchela Janwityanujit 2 , 1 Department <strong>of</strong> Radiology Faculty <strong>of</strong><br />

Medicine, Ramathibodi Hospital, Mahidol University, 2 Division<br />

<strong>of</strong> Allergy Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />

Medicine Faculty <strong>of</strong> Medicine, Ramathibodi Hospital, Mahidol<br />

University, Bangkok, Thailand, 3 Division <strong>of</strong> Allergy Immunology<br />

and <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine Faculty <strong>of</strong><br />

Medicine, Ramathibodi Hospital, Mahidol University, 4 Naresuan<br />

University, Department <strong>of</strong> Medicine, Phitsanulok, Thailand.<br />

1951. Psoriatic Arthritis and Onycholysis – Results from a Study <strong>of</strong><br />

1116 Patients with Psoriasis, and Follow-Up <strong>of</strong> Those with<br />

Psoriatic Arthritis over 1-6 Years. Thorvardur J. Love 2 , Johann<br />

E. Gudjonsson 4 , Helgi Valdimarsson 1 and Bjorn Gudbjornsson 3 ,<br />

1<br />

Landspitali University Hospital, 2 Landspitali University Hospital,<br />

Boston, MA, 3 Landspitali University Hospital, Center for<br />

<strong>Rheumatology</strong> Research, 4 University <strong>of</strong> Michigan, Department<br />

<strong>of</strong> Dermatology.<br />

1952. Psoriatic Arthritis: Oligoarticular or Polyarticular Presentation?<br />

Carlotta Nannini 1 , Laura Niccoli 2 , Emanuele Cassarà 2 , Olga<br />

Kaloudi 2 and Fabrizio Cantini 2 , 1 <strong>Rheumatology</strong> Unit, Hospital <strong>of</strong><br />

Prato, Prato, Italy, 2 <strong>Rheumatology</strong> Unit, Hospital <strong>of</strong> Prato, Italy.<br />

1953. Radiographic Progression Is Associated with Resolution <strong>of</strong><br />

Systemic Inflammation in Patients with Axial Spondyloarthritis<br />

Treated with TNFα Inhibitors. Susanne Juhl Pedersen 8 , Inge<br />

Juul Sørensen 13 , Kay-Geert Hermann 4 , Patrick Garnero 17 ,<br />

Julia S. Johansen 1 , Ole Rintek Madsen 9 , Annette Hansen 15 ,<br />

Michael Sejer Hansen 10 , Gorm Thamsborg 9 , Lis Smedegaard<br />

Andersen 18 , Ole Majgaard 14 , Anne Gitte L<strong>of</strong>t 16 , Jon Erlendsson 11 ,<br />

Karsten Asmussen 7 , Anne Grethe Jurik 3 , Jakob Møller 5 , Maria<br />

Hasselquist 5 , Dorrit Mikkelsen 2 , Thomas Skjødt 6 and Mikkel<br />

Østergaard 12 , 1 Dep. <strong>of</strong> Internal Medicine, Herlev Hospital,<br />

Copenhagen, Denmark, 2 Dep. <strong>of</strong> Radiology, Aabenraa Hospital,<br />

Aabenraa, Denmark, 3 Dep. <strong>of</strong> Radiology, Aarhus University<br />

Hospitals, Aarhus, Denmark, 4 Dep. <strong>of</strong> Radiology, Charité<br />

University Hospital, Berlin, Germany, 5 Dep. <strong>of</strong> Radiology, Herlev<br />

University Hospital, Copenhagen, Denmark, 6 Dep. <strong>of</strong> Radiology,<br />

Vejle Hospital, Vejle, Denmark, 7 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Bispebjerg Hospital, Copenhagen, Denmark, 8 Dep. <strong>of</strong><br />

<strong>Rheumatology</strong>, Gent<strong>of</strong>te and Herlev Hospitals, Copenhagen,<br />

Denmark, 9 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Gent<strong>of</strong>te Hospital,<br />

Copenhagen, Denmark, 10 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Herlev<br />

Hospital, Copenhagen, Denmark, 11 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Horsens Hospital, Denmark, 12 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre<br />

and Glostrup Hospitals, Copenhagen, Denmark, 13 Dep. <strong>of</strong><br />

<strong>Rheumatology</strong>, Hvidovre and Glostrup Hospitals and DANBIO,<br />

Copenhagen, Denmark, 14 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre<br />

Hospital, Copenhagen, Denmark, 15 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Rigshospitalet, Copenhagen, Denmark, 16 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />

Vejle Hospital, Denmark, 17 INSERM Unit 664, Lyon, and Cisbio<br />

Bioassays Bagnols/Cèze, France, 18 Rheumatism Hospital,<br />

University <strong>of</strong> Southern Denmark, Graasten, Denmark.<br />

1954. Reliability <strong>of</strong> Radiographic Scoring Methods in Axial Psoriatic<br />

Arthritis. Vinod Chandran 3 , Bradley Biagioni 3 , Richard Cook 1 ,<br />

Lihi Eder 3 , Anupam Wakhlu 3 , Michael Li 3 , Hua Shen 1 and Dafna<br />

D. Gladman 2 , 1 Department <strong>of</strong> Statistics and Actuarial Science,<br />

University <strong>of</strong> Waterloo, 2 Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />

Western Hospital.<br />

1955. Rituximab in Psoriatic Arthritis Provides Modest Clinical<br />

Improvement and Reduces Expression <strong>of</strong> Inflammatory<br />

Biomarkers in Skin Lesions. Philip Mease 2 , Arthur Kavanaugh 3 ,<br />

Mark Genovese 1 , Chris Ritchlin 4 , Sanna Rosengren 3 , Alex<br />

Quistberg 5 and David Boyle 3 , 1 Stanford Univ, 2 Swedish Medical<br />

Ctr, Univ. <strong>of</strong> Washington, 3 U <strong>of</strong> Calif San Diego, 4 Univ. <strong>of</strong><br />

Rochester, 5 Univ. <strong>of</strong> Washington.<br />

1956. Smoking Is Negatively Associated with Development <strong>of</strong><br />

Psoriatic Arthritis among Psoriasis Patients. Lihi Eder 3 , Sutha<br />

Shanmugarajah 3 , Arane Thavaneswaran 3 , Vinod Chandran 3 ,<br />

Richard Cook 1 and Dafna D. Gladman 2 , 1 Department <strong>of</strong><br />

Biostatistics and Actuarial Science, University <strong>of</strong> Waterloo,<br />

Waterloo, ON, Canada, 2 Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />

Western Hospital, Toronto, ON, Canada.<br />

1957. The Dimorphic Vertebral Corner Inflammatory Lesion (CIL):<br />

A Magnetic Resonance Imaging Biomarker Associated with<br />

New Bone Formation in Patients with Ankylosing Spondylitis.<br />

Walter P. Maksymowych, Nathalie Morency and Robert G. W.<br />

Lambert, University <strong>of</strong> Alberta, Edmonton, AB, Canada.<br />

270<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1958. The Impact <strong>of</strong> Anti-TNF Therapy on Erosive Structural Changes<br />

in the Spine <strong>of</strong> Patients with Ankylosing Spondylitis. Xen<strong>of</strong>on<br />

Baraliakos 4 , Joachim Listing 2 , Martin Rudwaleit, Joachim<br />

Sieper 1 and Juergen Braun 3 , 1 Charite Campus Benjamin<br />

Frankl, Berlin, Germany, 2 German Rheumatism Research<br />

Center, 3 Rheumazentrum Ruhrgebiet, Herne, Germany,<br />

4<br />

Rheumazentrum Ruhrgebiet Herne.<br />

1959. TNF Blocking Agents Promote Resolution <strong>of</strong> Vertebral Erosions<br />

in Patients with Spondyloarthritis. Walter P. Maksymowych 2 ,<br />

Praveena Chiowchanwisawakit 1 and Robert Lambert 2 , 1 Mahidol<br />

University, Bangkok, Thailand, 2 University <strong>of</strong> Alberta, Edmonton,<br />

AB, Canada.<br />

1960. TNF Switching in PsA Patients. Eliza F. Chakravarty 1 , George<br />

Reed 5 , Dennis Decktor 3 , Susan Bolge 3 , Rebecca Bolce 3 , Michael<br />

Ingham 3 , Raphael J. DeHoratius 2 , Ying Shan 5 and Mark C.<br />

Genovese 4 , 1 Mountain View, CA, 2 Centocor Ortho-Biotech,<br />

Horsham, PA, 3 Centocor Ortho-Biotech, 4 Stanford University,<br />

Sunnyvale, CA, 5 University <strong>of</strong> Massachusetts Medical School.<br />

1961. Treatment <strong>of</strong> Active Ankylosing Spondylitis with Abatacept –<br />

An Open Label 24-Week Study. In-Ho Song 2 , Frank Heldmann 1 ,<br />

Martin Rudwaleit 3 , Hildrun Haibel 2 , Anja Weiss 4 , Jurgen<br />

Braun 1 and Joachim Sieper 2 , 1 Centre <strong>of</strong> <strong>Rheumatology</strong>, Herne,<br />

Germany, 2 Charite Campus Benjamin-Franklin, Medical Clinic<br />

I, <strong>Rheumatology</strong>, Berlin, Germany, 3 Charite Campus Benjamin-<br />

Franklin, Medical Clinic I, <strong>Rheumatology</strong>, Berlin, Germany,<br />

4<br />

German Rheumatism Research Center, Berlin, Germany.<br />

1962. Ultrasound (US) and X Rays (XR) Entheseal, Synovial and<br />

Sacroiliac Abnormalities in Early Psoriatic Arthritis (ePsA).<br />

Francesca Bandinelli 5 , Diletta Bonciani 3 , Francesca Prignano 3 ,<br />

Leonardo Giovannini 6 , Giuliana Salvadorini 6 , Ledio Collaku 1 ,<br />

Antonio Candelieri 4 , Francesca Bartoli 6 , Torello Lotti 2 and<br />

Marco Matucci Cerinic 6 , 1 Department <strong>of</strong> Internal Medicine <strong>of</strong><br />

University <strong>of</strong> Tirana, Faculty <strong>of</strong> Medicine, Albania, 2 Dermatology<br />

Unit, University <strong>of</strong> Florence, Italy, 3 Dermatology Unit, University<br />

<strong>of</strong> Florence, Italy, 4 Laboratory <strong>of</strong> Decision Engineering for<br />

Health Care Delivery, Department <strong>of</strong> Electronics, Informatics<br />

and Systems, University <strong>of</strong> Cosenza Italy, 5 <strong>Rheumatology</strong><br />

Division, University <strong>of</strong> Florence, Department <strong>of</strong> Biomedicine,<br />

Florence, Italy, 6 <strong>Rheumatology</strong> Division, University <strong>of</strong> Florence,<br />

Department <strong>of</strong> Biomedicine, Florence, Italy.<br />

1963. Validation <strong>of</strong> the ASAS Definition <strong>of</strong> a Positive MRI in a Cohort<br />

<strong>of</strong> Patients with Early SpA Followed for Eight Years. Helena<br />

Marzo-Ortega 2 , Alexander N. Bennett 2 , Dennis McGonagle 2 , Paul<br />

Emery 2 and Walter P. Maksymowych 1 , 1 University <strong>of</strong> Alberta,<br />

2<br />

University <strong>of</strong> Leeds, United Kingdom.<br />

1964. Which Clinical Variables Predict Radiographic Progression<br />

in Spondyloarthritis? An Analysis <strong>of</strong> the Spondyloarthritis<br />

Research Consortium <strong>of</strong> Canada (SPARCC) Cohort. Walter P.<br />

Maksymowych 4 , Nigil Haroon 6 , Nathalie Morency 5 , Richard<br />

Cook 7 , Hua Shen 7 , Proton Rahman 1 , Dafna D. Gladman 2 and<br />

Robert D. Inman 3 , 1 Memorial University Newfoundland, St.<br />

Johns, NL, Canada, 2 Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 Toronto Western Hospital, Toronto, ON, Canada,<br />

4<br />

University <strong>of</strong> Alberta, Edmonton, AB, Canada, 5 University <strong>of</strong><br />

Alberta, Edmonton, Canada, 6 University <strong>of</strong> Toronto, Toronto,<br />

Canada, 7 University <strong>of</strong> Waterloo.<br />

Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology,<br />

and Animal Models<br />

1965. Ankylosing Spondylitis Macrophages Produce Greater IL-23 in<br />

Response to Lipopolysaccharide without Significant Unfolded<br />

Protein Response Induction. Ling Zeng, Mary Lindstrom and<br />

Judith Smith, University <strong>of</strong> Wisconsin.<br />

1966. Association between Killer-Cell Immunoglobulin-Like Receptor<br />

(KIR) Gene Polymorphisms and Psoriatic Arthritis (PsA). Vinod<br />

Chandran 2 , Fawnda Pellett 2 , Renise Ayearst 2 , Remy Pollock 2 and<br />

Dafna D. Gladman 1 , 1 Toronto Western Hospital, Toronto, ON,<br />

Canada, 2 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />

Western Hospital.<br />

1967. Decreased TH17 Cells in the Peripheral Blood <strong>of</strong> Patients with<br />

Early Spondyloarthritis (ESpA). María Belén Bautista-Caro 2 ,<br />

Irene Arroyo-Villa 2 , Concepcion Castillo-Gallego 2 , Eugenio de<br />

Miguel-Mendieta 2 , Emilio Martín-Mola 2 and María Eugenia<br />

Miranda-Carus 1 , 1 Hospital La Paz, Madrid, Spain, 2 Hospital La<br />

Paz.<br />

1968. Distinctive Patterns <strong>of</strong> Gene Expression Post-Infliximab<br />

Therapy in Psoriasis, Rheumatoid and Psoriatic Arthritis.<br />

Christopher T. Ritchlin 3 , Yahui Grace Chiu 2 , Alexander<br />

Rosenberg 2 , Darren Tabechian 2 , Sharon Moorehead 2 , Rick<br />

Barrett 2 , Hangtao Fan 1 , Fred Baribaud 1 , H. Liu 1 , Nancy<br />

Peffer 1 , David Shealy 1 and Edward S. Schwarz 2 , 1 Centocor<br />

R&D, 2 University <strong>of</strong> Rochester Medical Center, 3 University <strong>of</strong><br />

Rochester Medical Center, Rochester, NY.<br />

1969. Endoplasmic Reticulum Aminopeptidase (ERAP) Deficiency<br />

Alters IL-17 Production and Host Response Following Yersinia<br />

Gastrointestinal Infection in B27-Transgenic Mice. Robert D.<br />

Inman 1 and Fei Zhu 2 , 1 Toronto Western Hospital, Toronto, ON,<br />

Canada, 2 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />

1970. Evaluation <strong>of</strong> T Helper 17 Axis in Ankylosing Spondylitis. Ali<br />

Taylan, Ismail Sari, Didem Kozaci, Arif Yuksel, Safak Bilge, Yasar<br />

Yildiz, Gulten Sop, ISIL Coker, Necati Gunay and Nurullah AKKOC,<br />

Izmir Tepecik Training and Research Hospital, Department <strong>of</strong><br />

Internal Medicine, Izmir, Turkey.<br />

1971. Functional Significance <strong>of</strong> mTor in FLS Proliferation and Its Role<br />

in the Pathogenesis <strong>of</strong> Psoriatic Arthritis. Siba P. Raychaudhuri 2 ,<br />

Ankit Saxena 1 and Smriti K. Raychaudhuri 3 , 1 UC Davis, 2 UC Davis/<br />

VAMC Sacramento, Davis, CA, 3 UC Davis/VAMC Sacramento.<br />

1972. Genetic Studies <strong>of</strong> Ankylosing Spondylitis in Korean Confirm<br />

Associations with ERAP1 and 2p15 Reported in Caucasian<br />

Cases. So-Young Bang 5 , Tae-Hwan Kim 5 , Bitnara Lee 5 , Eunji<br />

Kwon 5 , Sang Hyun Choi 6 , Ki Soo Lee 1 , Seung Cheol Shim 2 , Angela<br />

Pope 8 , Proton Rahman 3 , John D. Reveille 7 and Robert D. Inman 4 ,<br />

1<br />

Cornell University, Republic <strong>of</strong> Korea, 2 Eulji University, Republic<br />

<strong>of</strong> Korea, 3 FRCPC, Memorial University <strong>of</strong> Newfoundland,<br />

4<br />

FRCPC, Toronto Western Hospital, University <strong>of</strong> Toronto,<br />

5<br />

Hanyang University Hospital for Rheumatic Diseases, Republic<br />

<strong>of</strong> Korea, 6 Korean Minjok Leadership Academy, Republic <strong>of</strong><br />

Korea, 7 <strong>Rheumatology</strong> and Clinical Immunogenetics, University<br />

<strong>of</strong> Texas Health Science Center at Houston, 8 Senior Scientist,<br />

Newfound Genomics.<br />

1973. HD6: A Novel Antibody That Recognises Cell Surface HLA-B27<br />

Homodimers. Kirsty McHugh 3 , Sravan K. Payeli 1 , Simon<br />

Kollnberger 2 , Markus Thiel 1 , Jacqueline Shaw 2 , Sascha Kleber 1 ,<br />

Andreas Wadle 1 , Christoph Renner 1 and Paul Bowness 2 ,<br />

1<br />

Department <strong>of</strong> Oncology, University <strong>of</strong> Zurich, 2 MRC Human<br />

Immunology Unit, Weatherall Institute <strong>of</strong> Molecular Medicine,<br />

Oxford, 3 MRC Human Immunology Unit, Weatherall Institute <strong>of</strong><br />

Molecular Medicine, Oxford, Oxfordshire, United Kingdom.<br />

2010 Program Book 271


ACR/ARHP Poster Session C<br />

1974. HLA- B*27 and Cw*06 Are Risk Alleles for Psoriatic Arthritis<br />

among Psoriasis Patients. Lihi Eder 2 , Fawnda Pellett 2 , Vinod<br />

Chandran 2 , Sutha Shanmugarajah 2 and Dafna D. Gladman 1 ,<br />

1<br />

Toronto Western Hospital, Toronto, ON, Canada, 2 Toronto<br />

Western Hospital, Centre for Prognosis Studies in the Rheumatic<br />

Diseases, Toronto, ON, Canada.<br />

1975. HLA-Bw4 Alleles and HLA-C Alleles That Have High Cell-Surface<br />

Expression Are Associated with Susceptibility to Psoriatic<br />

Arthritis (PsA). Vinod Chandran 3 , Fawnda Pellett 2 , Renise<br />

Ayearst 2 , Remy Pollock 3 and Dafna D. Gladman 1 , 1 Toronto<br />

Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto<br />

Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, ON,<br />

Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />

Western Hospital.<br />

1976. IL-17 Receptor and Its Functional Significance in Psoriatic<br />

Arthritis. Siba P. Raychaudhuri 2 , Ankit Saxena 1 and Smriti K.<br />

Raychaudhuri 1 , 1 UC Davis, 2 UC Davis/VAMC Sacramento, Davis,<br />

CA.<br />

1977. Increase <strong>of</strong> CD5+ ‘Innate’ B Lymphocytes with Regulatory<br />

Capacities in Spondyloarthritis. Tineke Cantaert, Gabriela<br />

FrancoSalinas, Jacky Paramarta, Yvonne Tiersma, Christine<br />

Teitsma, Paul P. Tak and Dominique Baeten, Academic Medical<br />

Center/University <strong>of</strong> Amsterdam.<br />

1978. Increased Expression <strong>of</strong> Carbonic Anhydrase I in the Synovium<br />

<strong>of</strong> Patients with Ankylosing Spondylitis. Xiaotian Chang 2 , Yan<br />

Zhao, Xinfeng Yan and Yunzhong Zhang 1 , 1 China, 2 Shandong<br />

Acedemy <strong>of</strong> Medicinal Sciences, China.<br />

1979. MICA*016 Allele Differentiates Skin and Joint Manifestations<br />

<strong>of</strong> Psoriatic Disease. Vinod Chandran 3 , Remy Pollock 3 , Jessica<br />

Barrett 1 , Lihi Eder 3 , Fawnda Pellett 3 , Christopher Yao 3 , Marsel<br />

Lino 3 , Sutha Shanmugarajah 3 , Vernon Farewell 1 and Dafna D.<br />

Gladman 2 , 1 MRC Biostatistics Unit, University <strong>of</strong> Cambridge<br />

Institute <strong>of</strong> Public Health, Cambridge, UK, 2 Toronto Western<br />

Hospital, Toronto, ON, Canada, 3 University <strong>of</strong> Toronto Psoriatic<br />

Arthritis Clinic, Toronto Western Hospital.<br />

1980. Peripheral Joint Ankylosis in the Spontaneous Model <strong>of</strong><br />

Arthritis in DBA/1 Mice Is Associated with a Locus on<br />

Chromosome 3 That Contains the BMP Receptor Type 1b. Rik<br />

Lories 2 , Inge Derese 3 , Shea Carter 3 , Kirsten Braem 3 , Ana Valdes 1<br />

and Frank P. Luyten 2 , 1 King’s <strong>College</strong>, 2 KU Leuven, Leuven,<br />

Belgium, 3 KU Leuven.<br />

1981. Phenotypic, Functional and Transcriptomic Analysis <strong>of</strong><br />

Monocyte-Derived Dendritic Cells from SpA Patients Revealed<br />

Their Hypo-Stimulatory Capacity and Specific Molecular<br />

Response to LPS Compared to Healthy Controls. Maxime<br />

Breban 1 , Nelly Bonilla 2 , Badredine Mohand Oumoussa 2 , Alice<br />

Talpin 2 , Henri-Jean Garchon 2 and Gilles Chiocchia 2 , 1 AP-HP,<br />

2<br />

Inserm.<br />

1982. Plasma Cytokine Pr<strong>of</strong>les in Ankylosing Spondylitis. Brock E.<br />

Harper 4 , Michael H. Weisman 1 , Pravitt Gourh 5 , Shervin Assassi 4 ,<br />

Laura A. Diekman 4 , Michael M. Ward 2 , John D. Reveille 3 and<br />

Sandeep K. Agarwal 4 , 1 Cedars-Sinai Medical Center, Los Angeles,<br />

CA, 2 NIH, NIAMS, IRP, Bethesda, MD, 3 Univ Texas Health Sci Ctr,<br />

Houston, TX, 4 Univ. <strong>of</strong> Texas Health Science Center Houston,<br />

Houston, TX, 5 Univ. <strong>of</strong> Texas Health Science Center Houston.<br />

1983. Stromal Cell Derived Mediators <strong>of</strong> Bone Remodeling<br />

in Psoriatic Arthritis: Implications for Disordered<br />

Osteoclastogenesis and Bone Erosion. Nicola Dalbeth 1 , Bregina<br />

Pool, Timothy Smith, Karon Callon, Maria Lobo, William J. Taylor,<br />

Peter B. Jones, Jillian Cornish and Fiona M. McQueen 2 , 1 Univ<br />

Auckland, Auckland, New Zealand, 2 Univ <strong>of</strong> Auckland Sch <strong>of</strong><br />

Med, Auckland, New Zealand.<br />

1984. The Association <strong>of</strong> IL-13 Polymorphism with Psoriatic Arthritis<br />

among Psoriasis Patients. Lihi Eder 2 , Vinod Chandran 2 , Fawnda<br />

Pellett 2 , Remy Pollock 2 , Sutha Shanmugarajah 2 and Dafna D.<br />

Gladman 1 , 1 Toronto Western Hospital, Toronto, ON, Canada,<br />

2<br />

Toronto Western Hospital, Centre for Prognosis Studies in the<br />

Rheumatic Diseases, Toronto, ON, Canada.<br />

1985. The Relationship <strong>of</strong> Biomarkers and Radiographic Progression<br />

in Patients with Ankylosing Spondylitis. X. Baraliakos 5 , R.<br />

Landewe 4 , D. Van Der Heijde 3 , J. Listing 2 , D. Baker 1 , H. Benjamin 1<br />

and J. Braun 6 , 1 Centocor Inc, R&D, 2 German Rheumatism<br />

Research Center, 3 LeidenUniversity Medical Center, Meerssen,<br />

The Netherlands, 4 Maastricht University Medical Center,<br />

Maastricht, The Netherlands, 5 Rheumazentrum Ruhrgebiet<br />

Herne, 6 Rheumazentrum Ruhrgebiet, Herne, Herne, Germany.<br />

1986. Whole Blood Transcriptional Pr<strong>of</strong>iling in Ankylosing Spondylitis<br />

Identifies Novel Putative Candidate Genes for Both the<br />

Inflammatory and Tissue-Destructive Aspects <strong>of</strong> the Disease.<br />

Fernando Manuel Pimentel-Santos 2 , Dario Ligeiro 3 , Mafalda<br />

Matos 10 , Ana F. Mourão 2 , José Costa 4 , Helena Santos 9 , Elsa<br />

Sousa 1 , Anabela Barcelos 7 , Fátima Godinho 6 , João E. Fonseca 1 ,<br />

Henrique Gueds-Pinto 8 , Jaime C. Branco 2 , Matthew A. Brown 5<br />

and Gethin Thomas 5 , 1 (IMM), Faculdade de Medicina da<br />

Universidade de Lisboa, Lisboa, Portugal, 2 CEDOC, Faculdade<br />

de Ciências Médicas da Universidade Nova de Lisboa, Lisboa,<br />

Portugal, 3 Centro de Histocompatibilidade do Sul, Lisboa,<br />

Portugal, 4 Centro Hospitalar do Alto Minho (CHAM), Hospital<br />

de Ponte de Lima, Ponte de Lima, 5 Diamantina Institute<br />

for Cancer, Immunology and Metabolic Medicine, Princess<br />

Alexandra Hospital, University <strong>of</strong> Queensland, Brisbane,<br />

Australia, 6 Hospital Garcia de Orta, Almada, Portugal, 7 Hospital<br />

Infante D. Pedro, Aveiro, Portugal, 8 Instituto de Biotecnologia<br />

e Bioengenharia, Centro de Genética e Biotecnologia, da<br />

Universidade de Trás-os-Montes e Alto Douro (IBB / CGB –<br />

UTAD), Vila Real, Portugal, 9 Instituto Português de Reumatologia<br />

(IPR), Lisboa, Portugal, 10 UTAD, Universidade de Tás-os-Montes e<br />

Alto Douro, Vila Real, Portugal.<br />

Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis<br />

and Genetics II<br />

1987. Association <strong>of</strong> the Functional CD226 307Ser Variant with<br />

Systemic Sclerosis (SSc): Evidence for the Contribution <strong>of</strong><br />

Co-Stimulation Pathways in the SSc Pathogenesis. Philippe<br />

Dieudé 10 , Mickaël Guedj 6 , Marie-Elise Truchetet 4 , Gabriela<br />

Riemekasten 3 , Marco Matucci-Cerinic 2 , Inga Melchers 1 , Eric<br />

Hachulla 8 , Paolo Airo 7 , Carlo Chizzolini 5 , Catherine Boileau 11 ,<br />

Yannick Allanore 9 and and the GENESYS Consortium, 1 Clinical<br />

Research Unit for <strong>Rheumatology</strong>, University Medical Center,<br />

Freiburg, Germany, 2 Department <strong>of</strong> Biomedicine, Section <strong>of</strong><br />

<strong>Rheumatology</strong>, Florence, Italy, 3 Department <strong>of</strong> <strong>Rheumatology</strong><br />

and Clinical Immunology, Charité University Hospital, Berlin,<br />

Germany, 4 Immunology and Allergy, Geneva University Hospital<br />

and School <strong>of</strong> Medicine, Geneva, Switzerland, 5 Immunology<br />

and Allergy, Geneva University Hospital and School <strong>of</strong> Medicine,<br />

Geneva, Switzerland, 6 Laboratoire Statistique et Génome, UMR<br />

CNRS-8071 / INRA-1152 / Université d’Evry Val d’Essonne,<br />

France, 7 <strong>Rheumatology</strong> and Clinical Immunology, Spedali<br />

Civili, Brescia, Italy, 8 Université Lille II, Médecine Interne, Lille,<br />

France, 9 Université Paris Descartes, Service de Rhumatologie<br />

A, Hôpital Cochin, Paris, France, 10 Université Paris Diderot,<br />

Service de Rhumatologie, Hôpital Bichat Claude Bernard, APHP,<br />

Paris, France, 11 Université Versailles Saint Quentin Yvelines,<br />

Laboratoire de Biochimie Hormonale et Génétique, Hôpital<br />

Ambroise Paré, AP-HP, Boulogne, France.<br />

272<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

1988. Characterization <strong>of</strong> Single Histone Deacetylase Is<strong>of</strong>orms<br />

in Endothelial Cells Derived from Progenitors in Systemic<br />

Sclerosis. Hossein Hemmatazad 1 , Britta Maurer 1 , Beat A.<br />

Michel 1 , Renate E. Gay 1 , Gay Steffen 1 , Jèrome Avouac 2 , Oliver<br />

Distler 1 , Yannick Allanore 2 and Astrid Jüngel 1 , 1 Center <strong>of</strong><br />

Experimental <strong>Rheumatology</strong>, University Hospital and Zurich<br />

Center <strong>of</strong> Integrative Human Physiology (ZIHP), Zurich,<br />

Switzerland, 2 Department <strong>of</strong> <strong>Rheumatology</strong> A, Cochin Hospital,<br />

Universitè Paris Descartes, INSERM U781, Paris, France.<br />

1989. Circulating T Cell Polarization Is Associated with Respiratory<br />

Decline in Scleroderma Patients with Active Interstitial Lung<br />

Disease. Francesco Boin 1 , Fredrick Wigley 2 , Robert Wise 2 and<br />

Antony Rosen 2 , 1 Johns Hopkins University, Baltimore, MD,<br />

2<br />

Johns Hopkins University.<br />

1990. Does Treatment with Imatinib Modify Gene Expression in the<br />

Skin and Peripheral Blood Mononuclear Cells <strong>of</strong> Patient with<br />

Systemic Sclerosis? Jessica K. Gordon 1 , Robert Spiera 2 , Jamie<br />

N. Mersten 1 , Horatio F. Wildman 4 , Ziad Taimeh 3 , Neil Hackett 4 ,<br />

Sasa Vukelic 3 , Kyriakos A. Kirou 1 and Mary K. Crow 1 , 1 Hospital for<br />

Special Surgery, New York, NY, 2 Hospital for Special Surgery, New<br />

York, NY, 3 Hospital for Special Surgery, 4 Weill-Cornell Medical<br />

<strong>College</strong>.<br />

1991. Enhanced Expression <strong>of</strong> Ephrins and Thrombospondins in<br />

the Dermis <strong>of</strong> Patients with Early Diffuse Systemic Sclerosis:<br />

Potential Contribution to Perturbed Angiogenesis and Fibrosis.<br />

Jerome Avouac 6 , Maud Clemessy 2 , Jorg H. W. Distler 8 , Jean<br />

Marie Gasc 2 , Barbara Ruiz 1 , Marie Cecile Vacher-Lavenu 3 ,<br />

Julien Wipff 6 , Andre Kahan 4 , Catherine Boileau 7 , Pierre Corvol 2<br />

and Yannick Allanore 5 , 1 INSERM U781, Necker Hospital, Paris,<br />

France, 2 INSERM U833 and Collège de France, Paris, France,<br />

3<br />

Paris Descartes University, Pathophysiology Department,<br />

Cochin Hospital, Paris, France, 4 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP,<br />

Paris, France, 5 Paris Descartes University, <strong>Rheumatology</strong> A<br />

Department, Cochin Hospital, APHP, Paris and INSERM U781,<br />

Necker Hospital, Paris, France, 6 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP, Paris<br />

and INSERM U781, Necker Hospital, Paris, France, 7 U.V.S.Q<br />

University, Biochemistry, Hormonology and Molecular Genetics<br />

Department, Ambroise Paré Hospital, AP-HP, Boulogne, France,<br />

8<br />

University <strong>of</strong> Erlangen, Erlangen, Germany.<br />

1992. Enhanced IL-17A and IL-22 Production by Peripheral Blood<br />

Mononuclear Cells Distinguish Systemic Sclerosis from Healthy<br />

Individuals. Nicolò C. Brembilla 1 , Marie-Elise Truchetet 2 ,<br />

Elisa Montanari 1 , Yannick Allanore 3 and Carlo Chizzolini 1 ,<br />

1<br />

Immunology & Allergy, Geneva University Hospital, Geneva,<br />

Switzerland, 2 Immunology Allergy, Geneva University Hospital,<br />

Geneva, Switzerland, 3 <strong>Rheumatology</strong>, Cochin Hospital, Paris,<br />

Paris, France.<br />

1993. Gd Compounds Signaling through Toll-Like Receptors 4<br />

and 7 in Normal Human Macrophages: Establishment <strong>of</strong><br />

a Proinflammatory Phenotype and Implications for the<br />

Pathogenesis <strong>of</strong> Nephrogenic Systemic Fibrosis. Peter J.<br />

Wermuth 1 and Sergio A. Jimenez 2 , 1 Jefferson Institute <strong>of</strong><br />

Molecular Medicine and Division <strong>of</strong> Connective Tissue Diseases,<br />

Thomas Jefferson University, Philadelphia, PA, 2 Thomas<br />

Jefferson Univ, Philadelphia, PA.<br />

1994. Genome-Wide Association Study in Systemic Sclerosis. Yannick<br />

Allanore 5 , Mohammad Saad 2 , Philippe Dieudé 4 , Catherine<br />

Boileau 1 , Maria Martinez 3 and GENESYS Consortium, 1 Biochimie<br />

A. Paré Hospital, Université VSQ, Boulogne, France, 2 INSERM<br />

U563 Université Paul Sabatier, Toulouse, France, 3 NSERM U563<br />

Université Paul Sabatier, Toulouse, France, 4 Rhumatologie,<br />

Inserm u699, Bichat, Paris Diderot Universite, France,<br />

5<br />

Université Paris Descarte, Rhumatologie A, INSERM U781,<br />

Paris, Paris, France.<br />

1995. High Resolution Magnetic Resonance Imaging for the<br />

Assessment <strong>of</strong> Dermal Fibrosis in a Pre-Clinical Model <strong>of</strong><br />

Scleroderma. Helen Jones 1 , Emma Derrett-Smith 1 , Chris P.<br />

Denton 1 , David Abraham 1 , George Bou-Gharios 2 and Po-Wah<br />

So 3 , 1 Centre for <strong>Rheumatology</strong>, UCL Medical School, 2 Kennedy<br />

Institute <strong>of</strong> <strong>Rheumatology</strong>, Imperial <strong>College</strong> London, 3 Pre-clinical<br />

Imaging Unit, Institute <strong>of</strong> Psychiatry, King’s <strong>College</strong> London.<br />

1996. IL-6 Overexpression in Early dcSSc Associates with Poor Clinical<br />

Outcome and May Drive Fibrotic Response. Korsa Khan 1 ,<br />

Shiwen Xu 1 , Christopher P. Denton 2 and Voon Ong 1 , 1 Center for<br />

<strong>Rheumatology</strong> and Connective Tissue Diseases, UCL Medical<br />

School, Royal Free Hospital, London, United Kingdom, 2 Royal<br />

Free Hospital, London, United Kingdom.<br />

1997. Imatinib Mesylate and Rottlerin Abrogate Transforming<br />

Growth Factor-β Induction <strong>of</strong> Endothelial-to-Mesenchymal<br />

Transition in Primary Lung Endothelial Cells. Zhaodong Li and<br />

Sergio A. Jimenez, Jefferson Institute <strong>of</strong> Molecular Medicine,<br />

Thomas Jefferson Univ, Philadelphia, PA.<br />

1998. In Systemic Sclerosis, Cooperation between B-Cells and Skin<br />

Fibroblasts Promotes Fibrogenic Cytokines and Collagen<br />

Production. Antoine Francois 3 , Dominique Wachsmann 3 , Jean<br />

Sibilia 1 and Jacques E. Gottenberg 2 , 1 Strasbourg Hospitals,<br />

Illkirch Graffenstaden, France, 2 Strasbourg Hospitals, Strasbourg,<br />

France, 3 Universite de Strasbourg, Illkirch Graffenstaden, France.<br />

1999. Inhibition <strong>of</strong> Glycogen Synthase Kinase (GSK)-3β<br />

Downregulates Collagen I Gene Expression in Normal and<br />

Scleroderma Fibroblasts and Abrogates the Pr<strong>of</strong>ibrotic Effects<br />

<strong>of</strong> Transforming Growth Factor β (TGF-β). Jolanta Fertala and<br />

Sergio A. Jimenez, Jefferson Institute <strong>of</strong> Molecular Medicine,<br />

Thomas Jefferson University, Philadelphia, PA.<br />

2000. Insights into the Pathogenesis <strong>of</strong> Systemic Sclerosis<br />

Vasculopathy Based on Gene Expression Pr<strong>of</strong>ile <strong>of</strong> Endothelial<br />

Cells Issued from Progenitors. Jerome Avouac 5 , Nicolas<br />

Cagnard 1 , Jorg H. W. Distler 6 , Yoland Schoindre 2 , Barbara Ruiz 2 ,<br />

Catherine Boileau 2 , Gilles Chiocchia 3 and Yannick Allanore 4 ,<br />

1<br />

INSERM U567, Cochin Hospital, APHP, Paris, France, 2 INSERM<br />

U781, Necker Hospital, Paris, France, 3 NSERM U567, Cochin<br />

Hospital, APHP, Paris, France, 4 Paris Descartes University,<br />

<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP, Paris and<br />

INSERM U781, Necker Hospital, Paris, France, 5 Paris Descartes<br />

University, <strong>Rheumatology</strong> ADdepartment, Cochin Hospital,<br />

APHP, Paris and INSERM U781, Necker Hospital, 6 University <strong>of</strong><br />

Erlangen, Erlangen, Germany.<br />

2001. PDGF Receptor as Therapeutic and Diagnostic Target in<br />

Systemic Sclerosis. Gianluca Moroncini 4 , Antonella Grieco 5 ,<br />

Chiara Paolini 5 , Giulia Nacci 3 , Massimiliano Cuccioloni 2 , Matteo<br />

Mozzicafreddo 2 , Cecilia Tonnini 5 , Katarzyna Pozniak 5 , Silvia<br />

Svegliati 5 , Mauro Angeletti 2 , Enrico Avvedimento 1 , Ada Funaro 3<br />

and Armando Gabrielli 5 , 1 Dipartimento di Biologia e Patologia<br />

Molecolare e Cellulare, Università Federico II, Napoli, Italy,<br />

2<br />

Dipartimento di Biologia Molecolare, Cellulare e Animale,<br />

Università di Camerino, Italy, 3 Dipartimento di Genetica, Biologia<br />

e Biochimica, Università di Torino, Italy, 4 Dipartimento di Scienze<br />

Mediche e Chirurgiche, Clinica Medica, Università Politecnica<br />

delle Marche, Ancona, Italy, 5 Dipartimento di Scienze Mediche e<br />

Chirurgiche, Clinica Medica, Università Politecnica delle Marche,<br />

Ancona, Italy.<br />

2002. Proteomic Analysis <strong>of</strong> Systemic Sclerosis Serum Identifies the<br />

Toll-Like Receptor Agonists S100A8/A9 as a Novel Possible<br />

Pathogenic Marker. Lenny van Bon 3 , Arnoud Lo<strong>of</strong> 3 , Helmut<br />

Wittkowski 1 , Waander van Heerde 3 , Madelon Vonk 3 , Johannes<br />

Roth 1 , Wim B. Van Den Berg 2 , Peter van Lent 3 and Timothy<br />

Radstake 3 , 1 Interdisciplinary Centre for Clinical Research<br />

University <strong>of</strong> Muenster, 2 Radboud Univ Nijmegen Med Cntr,<br />

Nijmegen, The Netherlands, 3 Radboud University Medical<br />

Centre Nijmegen, The Netherlands.<br />

2010 Program Book 273


ACR/ARHP Poster Session C<br />

274<br />

2003. Role <strong>of</strong> Agonistic Autoantibodies Directed to the Angiotensin<br />

II Type 1 and the Endothelin-1 Type A Receptors in Systemic<br />

Sclerosis. Angela Kill 2 , Jeannine Günther 2 , Mike Oliver Becker 1 ,<br />

Gerd-Rüdiger Burmester 1 and Gabriela Riemekasten 1 , 1 Charité<br />

Berlin, Berlin, Germany, 2 Charité/DRFZ, Berlin, Germany.<br />

2004. Skewed X-Chromosomal Inactivation Impacts T Regulatory Cell<br />

Function in Systemic Sclerosis. Jasper Broen 4 , Ingrid Wolvers-<br />

Tettero 2 , Lenny Geurts-van Bon 4 , Madelon Vonk 4 , Marieke<br />

Coenen 3 , Robert A. Lafyatis 1 , Timothy Radstake 4 and Anton<br />

Langerak 2 , 1 Boston University School <strong>of</strong> Medicine, Arlington,<br />

MA, 2 Department <strong>of</strong> Immunology, Erasmus MC, University<br />

Medical Center, Rotterdam, The Netherlands, 3 Radboud<br />

University Medical Center, Dept. <strong>of</strong> Human Genetics, Nijmegen,<br />

Netherlands, 4 Radboud University Medical Center, Dept. <strong>of</strong><br />

<strong>Rheumatology</strong>, Nijmegen, Netherlands.<br />

2005. Structural and Vasomotor Dysfunction in the Thoracic and<br />

Pulmonary Vessels <strong>of</strong> the Tight-Skin 1 (Tsk-1/+) Mouse: Role <strong>of</strong><br />

Endogenous Nitric Oxide. Audrey Dooley 1 , Emma C. Derrett-<br />

Smith 1 , Xu Shiwen 1 , Nelson N. Orie 2 , Korsa Khan 1 , Christopher<br />

P. Denton 4 , Lucie Clapp 2 , Richard Bruckdorfer 3 and David<br />

Abraham 5 , 1 Center for <strong>Rheumatology</strong> and Connective Tissue<br />

Diseases, UCL Medical School, London, United Kingdom, 2 Centre<br />

for Pharmacology, UCL Medical School, Rayne Institute, London,<br />

United Kingdom, 3 Institute <strong>of</strong> Structural and Molecular Biology,<br />

UCL Medical School, London, United Kingdom, 4 Royal Free<br />

Hospital, London, United Kingdom, 5 University <strong>College</strong> London,<br />

London, United Kingdom.<br />

2006. Th1 and Th17 Cytokine Signatures in Early Pediatric Localized<br />

Scleroderma. Kathryn S. Torok 3 , Thaschawee Arkachaisri 1 ,<br />

Thomas A. Medsger 2 and Carol A. Feghali-Bostwick 4 , 1 KK<br />

Women’s and Children’s Hosp, Singapore, Singapore, 2 Univ<br />

<strong>of</strong> Pittsburgh, Pittsburgh, PA, 3 Univ <strong>of</strong> Pittsburgh Med Ctr,<br />

Pittsburgh, PA, 4 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

2007. The Effect <strong>of</strong> Oxidative Stress on Protein Tyrosine Phosphatase<br />

1B in Scleroderma Fibroblasts. Pei-Suen Tsou 5 , Nadin N. Talia 6 ,<br />

Sonsoles Piera 2 , Sergio A. Jimenez 1 , James R. Seibold 3 , Kristine<br />

Phillips 4 and Alisa E. Koch 7 , 1 Thomas Jefferson Univ, Philadelphia,<br />

PA, 2 Thomas Jefferson University, Philadelphia, PA, 3 University<br />

<strong>of</strong> Connecticut Health Center, Farmington, CT, 4 University <strong>of</strong><br />

Michigan, Ann Arbor, MI, 5 University <strong>of</strong> Michigan Medical<br />

School, Ann Arbor, MI, 6 University <strong>of</strong> Michigan Medical School,<br />

7<br />

Unversity <strong>of</strong> Michigan, Ann Arbor, MI.<br />

2008. The Wnt Signalling Inhibitor Gene, WIF1, Expression Is<br />

Downregulated in Fibroblasts Derived from Systemic Sclerosis<br />

Patients by a Persistent Oxidative Stress. Silvia Svegliati 2 ,<br />

Giusi Marrone 3 , Antonella Grieco 2 , Tatiana Spadoni 2 , Lucia<br />

De Gennaro 2 , Gianluca Moroncini 2 , Enrico Avvedimento 1 and<br />

Armando Gabrielli 2 , 1 Dipartimento di Biologia e Patologia<br />

Cellulare e Molecolare, Università Federico II, Napoli, Italy,<br />

2<br />

Dipartimento di Scienze Mediche e Chirurgiche, Università<br />

Politecnica delle Marche, Ancona, Italy, 3 Oncogenomic Center,<br />

NOGEC, CEINGE, Italy.<br />

Vasculitis II<br />

2009. Alveolar Hemorrhage (AH) in ANCA-Associated Vasculitis:<br />

Characteristics and Prognostic Factors in 65 Patients. Alex<br />

M. Kostianovsky 2 , Thomas Hauser 2 , Christian Pagnoux 2 , Pascal<br />

Cohen 2 , Eric Daugas 3 , Luc Mouthon 2 , Jean-Francois Cordier 4<br />

and Loic P. Guillevin 1 , 1 Hopital Cochin-Paris Univ, Paris, France,<br />

2<br />

Internal Medicine, Hopital Cochin, APHP, Universite Paris<br />

Descartes, Paris, France, 3 Nephrology, Assistance Publique de<br />

Paris, Paris, France, 4 Pulmonology, Hopsice Civils de Lyon, Lyon,<br />

France.<br />

2010 Program Book<br />

2010. Baseline Characteristics <strong>of</strong> Patients with Non-Infectious<br />

Mixed Cryoglobulinemia Vasculitis: Results from the French<br />

Nationwide CryoVas Survey. Benjamin Terrier 8 , Isabelle<br />

Marie 9 , Adeline Lacraz 2 , David Launay 5 , Emmanuelle Plaisier 11 ,<br />

Jean-Emmanuel Kahn 10 , Luc de Saint-Martin 3 , Fabrice Bonnet 2 ,<br />

Guillaume Le Guenno 4 , Elisabeth Diot 12 , Patricia Rullier 6 ,<br />

Raphaële Seror 1 , Estabaliz Lazaro 2 , Olivier Hermine 7 , Jean-<br />

Marc Léger 8 , Patricia Senet 11 , Xavier Mariette 1 and Patrice<br />

Cacoub 8 , 1 Bicêtre, 2 Bordeaux, 3 Brest, 4 Clermont-Ferrand, 5 Lille,<br />

6<br />

Montpellier, 7 Necker, 8 Pitié-Salpéterière, 9 Rouen, 10 Suresnes,<br />

11<br />

Tenon, 12 Tours.<br />

2011. Baseline Characteristics <strong>of</strong> Patients with Type I Monoclonal<br />

Cryoglobulinemia Vasculitis: Results from the French<br />

Nationwide CryoVas Survey. Benjamin Terrier 8 , Isabelle Marie 9 ,<br />

Jean-Emmanuel Kahn 10 , Guillaume Le Guenno 4 , Alexandre<br />

Karras 5 , Adeline Lacraz 2 , Olivier Hermine 7 , Luc de Saint-Martin 3 ,<br />

Elisabeth Diot 12 , Philippe Modiano 6 , Véronique Leblond 8 ,<br />

Patricia Senet 11 , Jean-Marc Léger 8 , Emmanuelle Plaisier 11 ,<br />

Xavier Mariette 1 , David Saadoun 8 and Patrice Cacoub 8 , 1 Bicêtre,<br />

2<br />

Bordeaux, 3 Brest, 4 Clermont-Ferrand, 5 HEGP, 6 Lille, 7 Necker,<br />

8<br />

Pitié-Salpéterière, 9 Rouen, 10 Suresnes, 11 Tenon, 12 Tours.<br />

2012. Circulating Markers <strong>of</strong> Vascular Injury in ANCA-Associated<br />

Vasculitis. Paul A. Monach 1 , Ronald D. Snyder, Ulrich Specks,<br />

John H. Stone 8 , David Cuthbertson, Linna Ding, Fernando C.<br />

Fervenza, Barri J. Fessler 10 , Gary S. H<strong>of</strong>fman 4 , David Ikle, Cees<br />

G. M. Kallenberg 11 , Carol A. Langford 3 , Mark Mueller, Philip<br />

Seo 7 , E. William St Clair 5 , Robert Spiera 6 , Nadia Tchao, Steven<br />

R. Ytterberg 9 and Peter A. Merkel 2 , 1 Boston University, Boston,<br />

MA, 2 Boston University School <strong>of</strong> Medicine, West Newton,<br />

MA, 3 Cleveland Clinic Foundation, Cleveland, OH, 4 Cleveland<br />

Clinic Foundation, Pepper Pike, OH, 5 Duke University Medical<br />

Center, Durham, NC, 6 Hospital for Special Surgery, New York,<br />

NY, 7 Johns Hopkins Bayview Medical Center, Baltimore, MD,<br />

8<br />

Massachusetts General Hospital, Sudbury, MA, 9 Mayo Clinic,<br />

Rochester, MN, 10 UAB <strong>Rheumatology</strong>, Birmingham, AL, 11 Univer<br />

Med Center Groningen, Groningen, The Netherlands.<br />

2013. Clinical and Autoimmune Manifestations <strong>of</strong> Levamisole-<br />

Adulterated Cocaine Abuse. Korey R. Ullrich 3 , Sterling G. West 4 ,<br />

Whitney High 5 , Robert J. Koval 3 , Erin Koval 5 , Srinivas Bapoje 2<br />

and Joel M. Hirsh 1 , 1 Denver Health Hospital Authority, Louisville,<br />

CO, 2 Denver Health Hospital Authority, 3 University <strong>of</strong> Colorado-<br />

Denver Medical School, Denver, CO, 4 University <strong>of</strong> Colorado-<br />

Denver Medical School, Aurora, CO, 5 University <strong>of</strong> Colorado-<br />

Denver Medical School.<br />

2014. Cluster Analysis and Clinical Phenotypes <strong>of</strong> ANCA-Associated<br />

Vasculitis. Alfred Mahr 3 , Sandrine Katsahian 1 , Loïc Guillevin 4 ,<br />

E. Christiaan Hagen 5 , Peter Höglund 2 , Peter A. Merkel 9 ,<br />

Christian Pagnoux 4 , Niels Rasmussen 8 , Kerstin Westman 6 and<br />

David Jayne 7 , 1 Clinical Epidemiology and Biostatistics, Hospital<br />

Saint-Louis, Paris, France, 2 Clinical Pharmacology, Department<br />

<strong>of</strong> Laboratory Medicine, Lund University, Lund, Sweden,<br />

3<br />

Internal Medicine, Hospital Cochin, Paris, Paris, France,<br />

4<br />

Internal Medicine, Hospital Cochin, Paris, France, 5 Internal<br />

Medicine, Meander Medical Center, Amersfoort, Netherlands,<br />

6<br />

Nephrology and Transplantation, Skane University Hospital<br />

Malmö, Lund University, Sweden, 7 Nephrology, Addenbrooke’s<br />

Hospital, Cambridge, United Kingdom, 8 Otolaryngology,<br />

Rigshospitalet, Copenhagen, Denmark, 9 <strong>Rheumatology</strong> and<br />

Clinical Epidemiology Unit, Boston University School <strong>of</strong><br />

Medicine, Boston, MA.


ACR/ARHP Poster Session C<br />

2015. CpG Stimulation <strong>of</strong> Neutrophils; a Possible Role for Bacterial<br />

DNA in Neutrophil-Mediated Pathogenesis <strong>of</strong> ANCA-<br />

Associated Vasculitis? Henko Tadema 2 , Cees G. M. Kallenberg 2 ,<br />

Sandra E. Thamerl 2 , Nikola Lepse 2 , Coen A. Stegeman 1 and<br />

Peter Heeringa 3 , 1 University Medical Center Groningen, Dept<br />

<strong>of</strong> Nephrology, Groningen, The Netherlands, 2 University<br />

Medical Center Groningen, Dept <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, Groningen, The Netherlands, 3 University Medical<br />

Center Groningen, Dept Pathology and Medical Biology,<br />

Groningen, The Netherlands.<br />

2016. CXCL16 Antagonist Ameliorates the Progression <strong>of</strong> Vasculitis<br />

in McH5/lpr Mice. Hitoshi Hasegawa 1 , Jin Lei 2 , Takuya<br />

Matsumoto 2 , Masaki Yasukawa 2 , Tatsuhiko Miyazaki 2 and<br />

Masato Nose 2 , 1 Ehime University Graduate School <strong>of</strong> Medicine,<br />

Toon, Ehime, Japan, 2 Ehime University Graduate School <strong>of</strong><br />

Medicine.<br />

2017. Describing the Performance <strong>of</strong> the Birmingham Vasculitis<br />

Activity Score (BVAS) at Diagnosis for Children with ANCA-<br />

Associated Vasculitis (AAV) in A Registry for Children with<br />

Vasculitis (ARChiVe). Kimberly A. Morishita 2 , America Uribe 2 ,<br />

Jaime Guzman 2 , Leslie S. Abramson 37 , Matthew D. Adams 8 ,<br />

Susanne M. Benseler 31 , Elizabeth B. Brooks 4 , Sarah S. C.<br />

Campillo 22 , Peter Chira 30 , B. Anne Eberhard 28 , Kaleo C. Ede 26 ,<br />

Aimee O. Hersh 33 , Gloria C. Higgins 23 , Adam Huber 18 , Lisa F.<br />

Imundo 13 , Rita S. Jerath 14 , Susan Kim 11 , Daniel J. Kingsbury 19 ,<br />

Marisa S. Klein-Gitelman 15 , Suzanne C. Li 7 , Daniel J. Lovell 12 ,<br />

Thomas G. Mason 21 , Deborah K. McCurdy 20 , Renee F. Modica 34 ,<br />

Lakshmi N. Moorthy 27 , Eyal Muscal 1 , Lorien A. Nassi 32 , Kathleen<br />

M. O’Neil 24 , Egla C. Rabinovich 17 , Andreas O. Reiff 10 , Margalit E.<br />

Rosenkranz 9 , Kenneth N. Schikler 35 , Anne M. Stevens 25 , Mary<br />

B. Toth 6 , Linda Wagner-Weiner 16 , Dawn M. Wahezi 5 , Andrew<br />

J. White 29 , Amy L. Woodward 38 , Andrew S. Zeft 36 , David A.<br />

Cabral 3 and ARChiVe Investigators <strong>of</strong> CARRA, 1 Baylor <strong>College</strong> <strong>of</strong><br />

Medicine, Houston, TX, 2 BC Children’s Hospital, 3 BC Children’s<br />

Hospital, Vancouver, BC, Canada, 4 Case Western, Beachwood,<br />

OH, 5 Children’s Hospital at Montefiore, Bronx, NY, 6 Children’s<br />

Hospital Med Ctr, Akron, OH, 7 Children’s Hospital <strong>of</strong> Boston,<br />

Short Hills, NJ, 8 Children’s Hospital <strong>of</strong> Michigan, Huntington<br />

Woods, MI, 9 Children’s Hospital <strong>of</strong> Pittsburg, Pittsburgh,<br />

PA, 10 Childrens Hosp LA MS60, Los Angeles, CA, 11 Childrens<br />

Hospital Boston, Boston, MA, 12 Childrens Hospital Medical<br />

Center, Cincinnati, OH, 13 Childrens Hospital <strong>of</strong> NY, New York,<br />

NY, 14 Childrens Med Ctr Med Schl GA, Augusta, GA, 15 Childrens<br />

Mem Hosp/NW Univ, Chicago, IL, 16 Corner Children’s Hospital,<br />

Chicago, IL, 17 Duke University Medical Center, Durham, NC,<br />

18<br />

IWK Health Centre, Halifax, NS, Canada, 19 Legacy Emanuel<br />

Children’s Hosp, Portland, OR, 20 Mattel Children’s UCLA, Los<br />

Angeles, CA, 21 Mayo Clinic Rochester, Rochester, MN, 22 Montreal<br />

Children’s Hospital, Montreal, QC, Canada, 23 Nationwide<br />

Childrens Hosp, Columbus, OH, 24 OU Health Science Center,<br />

Oklahoma City, OK, 25 Pediatrics, U. <strong>of</strong> Washington, Seattle,<br />

WA, 26 Phoenix Children’s Hospital, Phoenix, AZ, 27 Robert Wood<br />

Johnson Medical School, Metuchen, NJ, 28 Schneider Children’s<br />

Hospital, New Hyde Park, NY, 29 St Louis Childrens Hosp, St<br />

Louis, MO, 30 Stanford Univ Schl <strong>of</strong> Med, Stanford, CA, 31 The<br />

Hospital for Sick Children, Toronto, ON, Canada, 32 TX Scottish<br />

Rite Hosp, Dallas, TX, 33 UCSF, San Francisco, CA, 34 University <strong>of</strong><br />

Florida, Orlando, FL, 35 University <strong>of</strong> Louisville SOM, Louisville, KY,<br />

36<br />

University <strong>of</strong> Utah, Salt Lake City, UT, 37 University <strong>of</strong> Vermont,<br />

Morrisville, VT, 38 Vanderbilt Univ. School <strong>of</strong> Medicine, Nashville,<br />

TN.<br />

2018. Differences between PR3 and MPO-ANCA Associated Vasculitis<br />

– Population Based Study from Southern Sweden. Aladdin<br />

Mohammad 1 and Mårten Segelmark 2 , 1 Helsingborg Hospital,<br />

Helsingborg, Sweden, 2 Skåne University Hospital.<br />

2019. Early Predictors <strong>of</strong> Neurological Long-Term Deficits in Children<br />

with Primary CNS Vasculitis. Gordon S. Soon, Ivanna Yau,<br />

Gabrielle Deveber, Derek Armstrong, Pascal Tyrrell, Jeffrey<br />

Templeton, Suzanne Laughlin and Susanne M. Benseler, The<br />

Hospital for Sick Children.<br />

2020. Effects <strong>of</strong> Imatinib Mesylate on Pulmonary Vascular<br />

Remodeling <strong>of</strong> Allergic Vasculitis in Murine Mode. Nobuhito<br />

Sasaki 2 , Kohei Yamauchi 2 and Takashi Sawai 1 , 1 Department<br />

<strong>of</strong> Pathology, Iwate Medical University School <strong>of</strong> Medicine,<br />

Morioka, Iwate, Japan, 2 Division <strong>of</strong> Pulmonary Medicine, Allergy<br />

and <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, Iwate<br />

Medical University School <strong>of</strong> Medicine, Morioka, Iwate, Japan.<br />

2021. Endothelial Lineage Impairment and Increased PR3 Expression<br />

on Peripheral Cells <strong>of</strong> Endothelial Phenotype in Wegener´s<br />

Granulomatosis. Susann Patschan, Daniel Patschan, Elvira<br />

Henze, Johannes Wessels, Sabine Blaschke and Gerhard<br />

Anton Müller, Department <strong>of</strong> Nephrology and <strong>Rheumatology</strong>,<br />

University Hospital Göttingen.<br />

2022. Epidemiology <strong>of</strong> Lupus Nephritis (LN) and ANCA Associated<br />

Nephritis (AAN) – Comparison Study from a Defined<br />

Population. Aladdin Mohammad 1 , Christina Ståhl-Hallengren 3 ,<br />

Ola Nived 3 , Gunnar K. Sturfelt 3 , Anders Bengtsson 3 and Mårten<br />

Segelmark 2 , 1 Helsingborg Hospital, Helsingborg, Sweden, 2 Skåne<br />

University Hospital, Lund, Sweden, 3 Skåne University Hospital,<br />

Lund, Lund, Sweden.<br />

2023. Expression <strong>of</strong> Toll-Like Receptors 2, 4 and 9 by Peripheral Blood<br />

Leukocytes in Patients with ANCA-Associated Vasculitis. Henko<br />

Tadema 3 , Wayel H. Abdulahad 3 , Coen A. Stegeman 1 , Cees G.<br />

M. Kallenberg 3 and Peter Heeringa 2 , 1 University Medical Center<br />

Groningen, Dept <strong>of</strong> Nephrology, Groningen, The Netherlands,<br />

2<br />

University Medical Center Groningen, Dept <strong>of</strong> Pathology and<br />

Medical Biology, Groningen, The Netherlands, 3 University<br />

Medical Center Groningen, Dept <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />

Immunology, Groningen, The Netherlands.<br />

2024. Hepatitis C Virus-Associated Polyarteritis Nodosa. David<br />

Saadoun, Benjamin Terrier, Damien Sene, Thierry Maisonobe,<br />

Lucile Musset, Zahir Amoura, Mathieu Resche Rigon and Patrice<br />

Cacoub, Pitie Salpetriere Hospital.<br />

2025. IL-25: A Cytokine Linking Eosinophils and Adaptative Immunity<br />

in Churg-Strauss Syndrome. Benjamin Terrier 1 , Ivan Bieche 2 ,<br />

Thierry Maisonobe 1 , Ingrid Laurendeau 2 , Michele Rosenzwajg 1 ,<br />

Marie-Claude Diemert 1 , Lucile Musset 1 , Michel Vidaud 2 , Damien<br />

Sène 1 , Nathalie Costedoat-Chalumeau 1 , Du Le Thi Huong 1 ,<br />

Zahir Amoura 1 , David Klatzmann 1 , Patrice Cacoub 1 and David<br />

Saadoun 1 , 1 Pitié-Salpétrière, 2 UMR745 INSERM.<br />

2026. Incidence and Predictors <strong>of</strong> Urotoxic Adverse Events in<br />

Cyclophosphamide-Treated Patients with Systemic Necrotizing<br />

Vasculitides. Guillaume Le Guenno 3 , Alfred Mahr 2 , Christian<br />

Pagnoux 3 , Robin Dhote 1 and Loïc Guillevin 3 , 1 Internal Medicine,<br />

Hospital Avicenne, Bobigny, France, 2 Internal Medicine, Hospital<br />

Cochin, Paris, France, 3 Internal Medicine, Hospital Cochin, Paris,<br />

France.<br />

2010 Program Book 275


ACR/ARHP Poster Session C<br />

2027. Inflammatory Aortitis: Diagnostic Performance <strong>of</strong> Aorta Wall<br />

Thickness CT-scan Measuring. Maia Forgues 8 , Jacques Giron 12 ,<br />

Anne Hitzel 11 , Anne Julian 11 , Pierre Payoux 11 , Daniel Adoue 10 ,<br />

Frédéric Degraeve 2 , Serge Madaule 1 , Laurent Prudhomme 3 ,<br />

Yann Leveneur 4 , Francis Gaches 6 , Xavier Delbrel 5 , Leonardo<br />

Astudillo 9 , Bruno Marchou 7 , Philippe Arlet 10 and Laurent Sailler 8 ,<br />

1<br />

CHG, Albi, France, 2 CHG, Auch, France, 3 CHG, Castres, France,<br />

4<br />

CHG, Lannemezan, France, 5 CHG, Pau, France, 6 Hôpital J<br />

Ducuing, Toulouse, France, 7 Hôpital Purpan, Infectious Diseases<br />

Department, Université de Toulouse, 8 Hôpital Purpan, Internal<br />

Medicine Department, Université de Toulouse, Toulouse,<br />

France, 9 Hôpital Purpan, Internal Medicine Department,<br />

Université de Toulouse, Toulouse, 10 Hôpital Purpan, Internal<br />

Medicine Department, Université de Toulouse, 11 Hôpital Purpan,<br />

Nuclear Medicine Department, Université de Toulouse, 12 Hôpital<br />

Purpan, Radiology Department, Université de Toulouse.<br />

2028. Interleukin-32 and Its Autoantibody Are Elevated in Patients<br />

with Wegener’s Granulomatosis and Correlated with<br />

Treatment Response. Suyoung Bae 3 , Yong-Gil Kim 2 , Siyoung<br />

Lee 4 , MinWook So 2 , Chang-Keun Lee 2 , Bin Yoo 1 , Yong-Beom<br />

Park 5 and Soohyun Kim 3 , 1 ASAN Medical Ctr, Seoul, Korea,<br />

Republic <strong>of</strong>, 2 ASAN Medical Ctr, 3 Konkuk University, Seoul, Korea,<br />

Republic <strong>of</strong>, 4 Konkuk University, 5 Yonsei University.<br />

2029. Investigation <strong>of</strong> the Effect <strong>of</strong> Histone Deacetylase 2 Function<br />

on Wegener’s Granulomatosis. Dai Takagi 1 , Yuji Nakamaru 2 ,<br />

Shigeru Akazawa 2 and Satoshi Fukuda 2 , 1 Department <strong>of</strong><br />

Otolaryngology and Head &Neck Surgery Hokkaido University<br />

Graduate School <strong>of</strong> Medicine, Sapporo, Hokkaido, Japan,<br />

2<br />

Department <strong>of</strong> Otolaryngology and Head &Neck Surgery<br />

Hokkaido University Graduate School <strong>of</strong> Medicine.<br />

2030. Low 25-OH Vitamin D Serum Levels Correlate with Extra-<br />

Hepatic Manifestations in Chronic Hepatitis C Virus Infection.<br />

Benjamin Terrier 2 , Jean-Claude Souberbielle 1 , David Saadoun 3 ,<br />

Guillaume Geri 3 , Yoland Schoindre 3 , Damien Sène 3 , Lucile<br />

Musset 3 and Patrice Cacoub 4 , 1 Necker, 2 Pitié-Salpéterière, Paris,<br />

France, 3 Pitié-Salpéterière, 4 Pitié-Salpétrière.<br />

2031. Patulous Eustachian Tube: A Novel Form <strong>of</strong> Damage in<br />

Wegener’s Granulomatosis. Philip Seo 1 and Howard W. Francis 2 ,<br />

1<br />

Johns Hopkins Bayview Medical Center, Baltimore, MD, 2 Johns<br />

Hopkins University.<br />

2032. Phase 1 Clinical Safety, Pharmacokinetic and<br />

Pharmacodynamic Evaluation <strong>of</strong> the Novel C5aR Antagonist<br />

CCX168, a Potential Therapeutic for ANCA-Vasculitis. Daniel<br />

J. Dairaghi, Juan C. Jaen, Kara Deshayes, Daniel A. Johnson,<br />

Manmohan R. Leleti, Shichang Miao, Jay P. Powers, Lisa C. Seitz,<br />

Yu Wang, Thomas J. Schall and Pirow J. Bekker, ChemoCentryx.<br />

2033. Predictors <strong>of</strong> Outcome in Juvenile Polyarteritis Nodosa: A<br />

Multicenter Study. Fernanda Falcini 1 , Francesco La Torre 7 ,<br />

Giorgia Martini 7 , Fabio Vittadello 7 , Antonella Boncompagni 10 ,<br />

Fabrizia Corona 6 , Maria Alessio 3 , Elisabetta Cortis 2 , Silvia<br />

Magni-Manzoni 8 , Giuseppina Calcagno 5 , Luciana Breda 4 , Matilde<br />

Beltramelli 6 , Manuela Pardeo 9 , Serena Capannini 1 , Marco<br />

Matucci Cerinic 1 and Francesco Zulian 7 , 1 Dpt <strong>of</strong> BioMedicine,<br />

Division <strong>of</strong> <strong>Rheumatology</strong>, Transition Unit, University <strong>of</strong><br />

Florence, 2 Dpt <strong>of</strong> Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Ospedale<br />

Pediatrico, 3 Dpt <strong>of</strong> Pediatrics, <strong>Rheumatology</strong> Unit, Ospedale<br />

Federico II, 4 Dpt <strong>of</strong> Pediatrics, University <strong>of</strong> Chieti, Chieti, 5 Dpt <strong>of</strong><br />

Pediatrics, University <strong>of</strong> Messina, 6 Dpt <strong>of</strong> Pediatrics, University<br />

<strong>of</strong> Milan, 7 Dpt <strong>of</strong> Pediatrics, University <strong>of</strong> Padua, 8 San Matteo<br />

Hospital, Pavia, 9 Scientific Institute Bambino Gesu, Rome,<br />

10<br />

Scientific Institute G. Gaslini, Genoa.<br />

2034. Pregnancies in Systemic Necrotizing Vasculitides: Report on<br />

12 Women and Their 20 Pregnancies. Christian Pagnoux 3 ,<br />

Véronique Le Guern, François G<strong>of</strong>finet 1 , Elisabeth Diot, Nicolas<br />

Limal, Emmanuelle Pannier, Ursula Warzocha, Vassilis Tsatsaris,<br />

Robin Dhote, Alexandre Karras, Pascal Cohen, Richard Damade,<br />

Luc Mouthon and Loic P. Guillevin 2 , 1 Gynecology and Obstetrics,<br />

2<br />

Hopital Cochin-Paris Univ, Paris, France, 3 Hopital Cochin-Paris<br />

Universite Descartes, APHP, Paris, France.<br />

2035. Pregnancy Related Morbidity and Mortality in Patients with<br />

Systemic Vasculitis – A Single Centre Controlled Study. Shirish<br />

R. Sangle 1 , Periklis Vounotrypidis 2 , Ahlem Chaib 2 , Veronica<br />

Salas-Manzanedo 2 , Annette I. Briley 1 , Simon Angel 1 , Andrew<br />

Shennan 1 , Munther A. Khamashta 1 and David P. D’Cruz 1 , 1 St<br />

Thomas’ Hospital, London, United Kingdom, 2 St Thomas’<br />

Hospital.<br />

2036. Preliminary Classification Criteria for the Cryoglobulinemic<br />

Syndrome. Salvatore De Vita 18 , Franca Soldano 3 , Miriam Isola 3 ,<br />

Giuseppe Monti 12 , Armando Gabrielli 14 , Athanasios Tzioufas 7 ,<br />

Clodoveo Ferri 20 , Gianfranco Ferraccioli 19 , Luca Quartuccio 17 ,<br />

Laura Corazza 17 , Ginevra De Marchi 17 , Manuel Ramos-Casals 16 ,<br />

Michael Voulgarelis 5 , Marco Lenzi 4 , Francesco Saccardo 12 ,<br />

Paolo Fraticelli 14 , Maria Teresa Mascia 20 , Domenico Sansonno 23 ,<br />

Patrice Cacoub 2 , Matja Tomsic 8 , Antonio Tavoni 21 , Maurizio<br />

Pietrogrande 11 , Anna Linda Zignego 1 , Salvatore Scarpato 22 ,<br />

Cesare Mazzaro 6 , Paolo Pioltelli 13 , Serge Steinfeld 9 , Peter<br />

Lamprecht 10 , Stefano Bombardieri 21 and Massimo Galli 15 , 1 Center<br />

for Systemic Manifestations <strong>of</strong> Hepatitis Viruses (MaSVE),<br />

Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Florence,<br />

Florence, Italy, 2 Centre de Références Maladies Auto-Immunes,<br />

Service de Médecine Interne II, Hôpital Pitié-Salpêtrière, Paris,<br />

France, 3 Chair <strong>of</strong> Statistics, University <strong>of</strong> Udine, 4 Department<br />

<strong>of</strong> Clinical Medicine, University <strong>of</strong> Bologna, S. Orsola-Malpighi<br />

Hospital, Bologna, Italy, 5 Department <strong>of</strong> Hematology, Medical<br />

School, University <strong>of</strong> Athens, Greece, 6 Department <strong>of</strong> Internal<br />

Medicine, Pordenone General Hospital, Pordenone, Italy,<br />

7<br />

Department <strong>of</strong> Pathophysiology, Medical School <strong>of</strong> Athens,<br />

Athens, Greece, 8 Department <strong>of</strong> <strong>Rheumatology</strong>, University<br />

Medical Centre, Ljubljana, Slovenia, 9 Erasme University<br />

Hospital, Department <strong>of</strong> <strong>Rheumatology</strong>, Brussels, Belgium,<br />

10<br />

Institute <strong>of</strong> Immunology, University <strong>of</strong> Kiel, Kiel, Germany,<br />

11<br />

Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy,<br />

12<br />

Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera<br />

di Busto Arsizio, Saronno, VA, Italy, 13 Internal Medicine,<br />

Donizetti Hospital, Monza, Italy, 14 Internal Medicine, Università<br />

Politecnica delle Marche, Ancona, Italy, 15 Istituto di Malattie<br />

Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco,<br />

Milan, Italy, 16 Laboratorio de Enfermedades Autoinmunes Josep<br />

Font, IDIBAPS, Hospital Clínic, Barcelona, Spain, 17 <strong>Rheumatology</strong><br />

Clinic, AOU SMM, University <strong>of</strong> Udine, 18 <strong>Rheumatology</strong> Clinic,<br />

AOU SMM, University <strong>of</strong> Udine, Udine, Italy, 19 <strong>Rheumatology</strong><br />

Division, Catholic University <strong>of</strong> the Sacred Heart, School <strong>of</strong><br />

Medicine, Rome, Italy, 20 <strong>Rheumatology</strong> Unit, Department <strong>of</strong><br />

Internal Medicine, University <strong>of</strong> Modena, Italy, 21 <strong>Rheumatology</strong><br />

Unit, Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Pisa,<br />

Pisa, Italy, 22 <strong>Rheumatology</strong> Unit, M. Scarlato Hospital, Scafati,<br />

Salerno, Italy, 23 Section <strong>of</strong> Internal Medicine and Clinical<br />

Oncology, Department <strong>of</strong> Biomedical Sciences and Human<br />

Oncology, University <strong>of</strong> Bari, Medical School, Bari, Italy.<br />

2037. Primary Central Nervous System Vasculitis Presenting with<br />

Intracranial Hemorrhage. Carlo Salvarani 1 , Robert D. Brown,<br />

Jr 3 , Kenneth T. Calamia 2 , Teresa J. H. Christianson 3 , John Huston<br />

III 3 , James F. Meschia 2 , Caterina Giannini 3 and Gene G. Hunder 3 ,<br />

1<br />

Hospital <strong>of</strong> Reggio Emilia, Italy, 2 Mayo Clinic, Jacksonville, FL,<br />

3<br />

Mayo Clinic, Rochester, MN.<br />

276<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

2038. Primary Central Nervous System Vasculitis: Analysis <strong>of</strong> 131<br />

Patients. Carlo Salvarani 1 , Robert D. Brown, Jr 3 , Kenneth T.<br />

Calamia 2 , Teresa J. H. Christianson 3 , John Huston III 3 , James F.<br />

Meschia 2 , Caterina Giannini 3 and Gene G. Hunder 3 , 1 Hospital <strong>of</strong><br />

Reggio Emilia, Reggio Emilia, Italy, 2 Mayo Clinic, Jacksonville, FL,<br />

3<br />

Mayo Clinic, Rochester, MN.<br />

2039. Prognostic Factors in Hepatitis C Virus Patients with Systemic<br />

Vasculitis. Benjamin Terrier 1 , Oren Semoun 2 , David Saadoun 1 ,<br />

Damien Sène 1 , Matthieu Resche-Rigon 2 and Patrice Cacoub 1 ,<br />

1<br />

Pitié-Salpéterière, 2 Saint-Louis.<br />

2040. Risk Factors for Aortitis among Patients with Pathological<br />

Examination after Resection <strong>of</strong> the Thoracic Aorta in Denmark<br />

1997-2009: A 12-Year Nationwide Population-Based Cross-<br />

Sectional Study. Jean Schmidt 1 , Kaare Sunesen 2 , Jette Kornum 2 ,<br />

Pierre Duhaut 1 and Reimar Thomsen 2 , 1 Amiens University<br />

Hospital and RECIF, Amiens, France, 2 Department <strong>of</strong> Clinical<br />

Epidemiology, Aarhus University Hospital, Aalborg, Denmark.<br />

2041. Rituximab Maintenance Therapy for Relapsed Wegener’s<br />

Granulomatosis and Microscopic Polyangiitis. Claire Roubaud-<br />

Baudron 3 , Christian Pagnoux 3 , Julien Le Guen 3 , Mathilde de<br />

Menthon 3 , Sandra Camps 1 , Jessie Aouizerate 3 , Véronique Le<br />

Guern 3 , Pascal Cohen 3 , Luc Mouthon 3 and Loic P. Guillevin 2 ,<br />

1<br />

Department <strong>of</strong> Pharmacy, Hopital COchin, APHP, Universite<br />

Paris Descartes, 2 Hopital Cochin-Paris Univ, Paris, France,<br />

3<br />

Internal Medicine, Hopital Cochin, APHP, Universite Paris<br />

Descartes, France.<br />

2042. Safety and Efficacy <strong>of</strong> Rituximab in Non-Viral Cryoglobulinemia<br />

Vasculitis: Prospective Data from the French AIR Registry.<br />

Benjamin Terrier 15 , David Launay 6 , Gilles Kaplanski 10 ,<br />

Arnaud Hot 9 , Claire Larroche 1 , Pascal Cathebras 12 , Bernard<br />

Combe 11 , Jean-Pierre Jaureguiberry 14 , Olivier Meyer 3 , Thierry<br />

Schaeverbeke 8 , Alexandre Somogyi 5 , Leila Tricot 13 , Thierry<br />

Zenone 4 , Philippe Ravaud 3 , Jacques-Eric Gottenberg 7 , Xavier<br />

Mariette 2 and Patrice Cacoub 15 , 1 Avicenne, 2 Bicêtre, 3 Bichat, 4 CH<br />

Valence, 5 CHI Saint-Germain, 6 CHRU Lille, 7 CHRU Strasbourg,<br />

8<br />

CHU Bordeaux, 9 CHU LYon, 10 CHU Marseille, 11 CHU Montpellier,<br />

12<br />

CHU St Etienne, 13 CMC Foch, 14 HIA Toulon, 15 Pitié-Salpétrière.<br />

2043. Seasonal- (SFV) and H1N1-Flu Virus (HFV) Vaccination for<br />

Patients with Autoimmune Diseases (AID): The Prospective<br />

MAIVAX Trial on 174 Patients. Alex Kostianovsky 2 , Michele<br />

Goulet 2 , Jean Francois Alves 2 , Veronique Le Guern 2 , Christian<br />

Pagnoux 2 , Pascal Cohen 2 , Alice Berezne 2 , Anne Krivine 2 , Luc<br />

Mouthon 2 , Odile Launay 2 and Loic P. Guillevin 1 , 1 Hopital Cochin-<br />

Paris Univ, Paris, France, 2 Internal Medicine, Hopital Cochin,<br />

APHP, Universite Paris Descartes, Paris, France.<br />

2044. Small-Vessel Vasculitis Surrounding an Uninflamed Temporal<br />

Artery: A Population-Based Italian Study. Giovanna Restuccia,<br />

Luigi Boiardi, Alberto Cavazza, Luca Magnani, Maria Grazia<br />

Catanoso, Gianluigi Bajocchi, Fulvia Rossi, Pierluigi Macchioni,<br />

Ilaria Chiarolanza, Andrea Caruso, Nicolò Pipitone and Carlo<br />

Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy.<br />

2045. |Systemic Necrotizing Vasculitides in the Elderly: Baseline Data<br />

on the 101 Patients >65 Years Old Enrolled in the CORTAGE<br />

Multicenter Trial. Christian Pagnoux 8 , Florence Rollot 9 , Thomas<br />

Quemeneur 7 , Jacques Ninet 4 , Elisabeth Diot 3 , Xavier Kyndt 7 ,<br />

Benoît de Wazières 12 , Jean-Luc Reny 2 , Xavier J. Puechal 1 ,<br />

Pierre-Yves Leberruyer 13 , Olivier Lidove 11 , Pascal Godmer 10 ,<br />

Aimé Albath-Sadiki 14 , Severine Poignant 14 , Pascal Cohen 8 , Luc<br />

Mouthon 8 , Loic P. Guillevin 6 and The FVSG 5 , 1 Centre Hospitalier<br />

Du Mans, Le Mans, France, 2 CH Béziers - Narbonne, 3 CHRU<br />

TOurs, Medecine Interne, 4 CHU de Lyon - Hôpitale Edouard<br />

Herriot, Médecine Interne-Pathologie Vasculaire, 5 France,<br />

6<br />

Hopital Cochin-Paris Univ, Paris, France, 7 Internal Medicine,<br />

CH Valenciennes, 8 Internal Medicine, Hopital Cochin, APHP,<br />

Universite Paris Descartes, 9 Internal Medicine, Hopital Cochin,<br />

APHP, Universite Paris Descartes, 10 Medecine Interne, Centre<br />

Hospitalier Bretagne-Atlantique, BP 70555 56017 VANNES,<br />

11<br />

Medecine Interne, CHU Bichat, Paris Diderot, 12 Medecine<br />

Interne, CHU de Nimes, 13 Service de Medecine Interne. CHU<br />

Robert Debré. Avenue du Général Koenig. 51092 REIMS, 14 URC<br />

Cochin Tarnier, Paris Descartes.<br />

2046. Systemic Vasculitis in Patients with Hepatitis C Virus Infection<br />

with and without Detectable Mixed Cryoglobulinemia:<br />

Towards a Unique Entity. Benjamin Terrier 1 , Damien Sène 1 ,<br />

Agnès Dechartres 2 , David Saadoun 1 , Lucile Musset 1 , Matthieu<br />

Resche-Rigon 2 , Thierry Maisonobe 1 and Patrice Cacoub 1 , 1 Pitié-<br />

Salpéterière, 2 Saint-Louis.<br />

2047. The Correlation between Circulating Microparticles and<br />

Platelet Aggregation and Disease Activity in Wegener<br />

Granulomatosis. Rula Hajj-Ali 3 , Roy Silverstein 1 , Gary H<strong>of</strong>fman 1 ,<br />

Li Zhang 1 , Peter Imrey 1 and Carol A. Langford 2 , 1 Cleveland Clinic,<br />

2<br />

Cleveland Clinic Foundation, Cleveland, OH, 3 Clevelnad Clinic,<br />

Cleveland, OH.<br />

2048. The Human C5a Receptor (hC5aR) Antagonist CCX168<br />

Effectively Ameliorates a Model <strong>of</strong> ANCA Glomerulonephritis<br />

(GN) in hC5aR Knock-in Mice. Hong Xiao 2 , J. C. Jennette 3 , D.<br />

J. Dairaghi 1 , L. Ertl 1 , T. Baumgart 1 , S. Miao 1 , J. P. Powers 1 , L. C.<br />

Seitz 1 , Y. Wang 1 , P. Hu 3 , R. J. Falk 3 , T. J. Schall 1 and J. C. Jaen 1 ,<br />

1<br />

ChemoCentryx, 2 University <strong>of</strong> North Carolina, Chapel Hill, NC,<br />

3<br />

University <strong>of</strong> North Carolina.<br />

2049. The Relationship between Disease Status in Wegener’s<br />

Granulomatosis with the Development <strong>of</strong> Subclinical<br />

Atherosclerosis. Rula Hajj-Ali 5 , Roy Silverstein 2 , Douglas Joseph 1 ,<br />

Peter Imrey 2 , Gary S. H<strong>of</strong>fman 4 , Li Zhang 2 and Carol A. Langford 3 ,<br />

1<br />

Cleevland Clinic, 2 Cleveland Clinic, 3 Cleveland Clinic Foundation,<br />

Cleveland, OH, 4 Cleveland Clinic Foundation, Pepper Pike, OH,<br />

5<br />

Clevelnad Clinic, Cleveland, OH.<br />

Epidemiology and Health Services Research<br />

2089. Increased Fracture Rates among Female Osteoporosis<br />

Patients Taking Oral Bisphosphonates and Proton Pump<br />

Inhibitors Concurrently. Neetu Agashivala 1 and Wing Chan 2 ,<br />

1<br />

Novartis Pharmaceuctical Corp, East Hanover, NJ, 2 Novartis<br />

Pharmaceuctical Corp<br />

ARHP Poster Session C: Physical Exercise<br />

2050. ‘Specialized Generalists’: How Do Rehabilitation Therapists<br />

Practice in Rural Areas? Robin K. Roots, Linda C. Li, Lesley<br />

Bainbridge and Helen Brown, University <strong>of</strong> British Columbia,<br />

Vancouver, BC, Canada.<br />

2051. An Update <strong>of</strong> the Dutch Physical Therapy Guideline on<br />

Hip and Knee Osteoarthritis (HKOA). Wilfred F. H. Peter 5 ,<br />

Mariette J. Jansen 1 , Emalie J. Hurkmans 6 , Hans Bloo 12 , Leatitia<br />

M. M. C. J. Dekker-Bakker 11 , Roelien G. Dilling 10 , Wim K. H. A.<br />

Hilberdink 10 , Clarinda Kersten-Smit 3 , Mariette de Rooij 8 , Cindy<br />

Veenh<strong>of</strong> 9 , Eric M. Vermeulen 2 , Ineke de Vos 7 , Jan W. Schoones 13<br />

and Thea P. M. Vliet Vlieland 4 , 1 Centre for Evidence Based<br />

Physiotherapy (CEBP), University <strong>of</strong> Maastricht, Maastricht,<br />

The Netherlands, 2 Department <strong>of</strong> Physical Therapy, LUMC,<br />

Leiden, The Netherlands, 3 Department <strong>of</strong> Physical Therapy, St.<br />

Maartenskliniek, Nijmegen, The Netherlands, 4 Department<br />

<strong>of</strong> <strong>Rheumatology</strong>, Leiden University Medical Center (LUMC),<br />

2010 Program Book 277


ACR/ARHP Poster Session C<br />

Leiden, The Netherlands, Dept <strong>of</strong> Orthopaedics, Leiden,<br />

University Medical Center, 5 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />

Leiden University Medical Center (LUMC); Jan van Breemen<br />

Instituut, Centre for <strong>Rheumatology</strong> and Rehabilitation,<br />

Amsterdam, Leiden, The Netherlands, 6 Dept <strong>of</strong> <strong>Rheumatology</strong>,<br />

Leiden, University Medical Center, 7 Exercise Therapy Private<br />

Practice, Leiden, The Netherlands, 8 Jan van Breemen Instituut,<br />

Centre for <strong>Rheumatology</strong> and Rehabilitation, Amsterdam,<br />

The Netherlands, 9 Netherlands Institute for Health Services<br />

Research, Utrecht, The Netherlands, 10 Paramedical Center<br />

for <strong>Rheumatology</strong> and Rehabilitation, Groningen, The<br />

Netherlands, 11 Physical Therapy Private Practice, Amstelveen,<br />

The Netherlands, 12 Veenendaal en Roessingh Research<br />

&Development, Enschede, The Netherlands, 13 Walaeus Library,<br />

Leiden University Medical Center, Leiden, The Netherlands.<br />

2052. Clinical Measures Associated with Self-Reported Knee<br />

Instability in Knee Osteoarthritis (KOA). G. Kelley Fitzgerald,<br />

Sara R. Piva and Stephen R. Wisniewski, University <strong>of</strong> Pittsburgh.<br />

2053. Describing the Pattern <strong>of</strong> Outpatient Physical Therapy<br />

Utilization Following Total Knee Replacement (TKR). Carol<br />

A. Oatis 1 , Jessica M. DiRusso 1 , Mindy J. Hoover 1 , Katherine K.<br />

Johnston 1 , Monika Kasinova 1 and Patricia D. Franklin 2 , 1 Arcadia<br />

University, Glenside, PA, 2 Univ <strong>of</strong> MA Med Schl, Worcester, MA.<br />

2054. Describing the Pattern <strong>of</strong> Physical Therapy Intervention<br />

Following Total Knee Replacement (TKR). Jessica M. DiRusso 1 ,<br />

Mindy J. Hoover 1 , Katherine K. Johnston 1 , Monika Kasinova 1 ,<br />

Patricia D. Franklin 2 and Carol A. Oatis 1 , 1 Arcadia University,<br />

Glenside, PA, 2 Univ <strong>of</strong> MA Med Schl, Worcester, MA.<br />

2055. Factors Associated with the Use <strong>of</strong> Physical Therapy by People<br />

with Hip and Knee Osteoarthritis. Renata T. B. Jorge 1 , Eric C.<br />

Sayre 4 , Jacek Kopec 2 , Jolanda Cibere 2 , John M. Esdaile 2 , Sherry<br />

Bar 3 and Linda C. Li 2 , 1 Arthritis Research Centre <strong>of</strong> Canada,<br />

Vancouver, BC, Canada, 2 Arthritis Research Centre <strong>of</strong> Canada,<br />

3<br />

BC Ministry <strong>of</strong> Health Services, 4 University <strong>of</strong> British Columbia.<br />

2056. Impaired Knee Frontal Plane Neuro-Muscular Stabilization<br />

in Persons with Knee Osteoarthritis (KOA): A Biomechanical<br />

Study. Alison H. Chang 1 , Song Joo Lee 1 , Yupeng Ren 4 , Heng Zhao 3<br />

and Li-Qun Zhang 2 , 1 Northwestern University, 2 Northwestern<br />

University; Rehabilitation Institute <strong>of</strong> Chicago, 3 Rehabilitation<br />

Institute <strong>of</strong> Chicago, 4 Rehabilitation Institute <strong>of</strong> Chiicago.<br />

2057. Physical Activity Level and Poor Disability Pr<strong>of</strong>ile: A<br />

Population-Based Study <strong>of</strong> US Adults with Arthritis. Jennifer M.<br />

Hootman 2 and David Brown 1 , 1 CDC, 2 Centers for Disease Control,<br />

Kennesaw, GA.<br />

2058. The Association <strong>of</strong> Arm and Back Pain with Incidence <strong>of</strong> Slow<br />

Walking in Persons with Knee Osteoarthritis: The MOST Study.<br />

Daniel White 1 , Yuqing Zhang 2 , Jingbo Niu 2 , Michael Nevitt 3 , C.<br />

Elizabeth Lewis 4 , James Torner 5 and Tuhina Neogi 2 , 1 Boston<br />

University, Boston, MA, 2 Boston University, 3 University California<br />

San Francisco, 4 University <strong>of</strong> Alabama, 5 University <strong>of</strong> Iowa.<br />

2059. The Effect <strong>of</strong> an Exercise Program in Gait Asymmetry in<br />

Patients after Total Knee Arthroplasty. Francisco J. Maia Neto 3 ,<br />

Gustavo J. M. Almeida 2 , G. Kelley Fitzgerald 1 and Sara R. Piva 3 ,<br />

1<br />

Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh,<br />

3<br />

University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

2060. The Effectiveness <strong>of</strong> Thoracic Spine Manipulation on Pain<br />

and Disability in Patients with Neck Pain: A Pilot Randomized<br />

Clinical Trial. Samannaaz Shamsuddin Khoja, Daniel Daliman<br />

and Piva Regina Sara, University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />

2061. Validity <strong>of</strong> Portable Devices To Assess Physical Activity in<br />

Patients with Total Knee Arthroplasty. Gustavo J. M. Almeida 1 ,<br />

Kelly S. Brower 2 , Derya Celik 2 , Hua-Chen Chang 2 and Sara R.<br />

Piva 1 , 1 University <strong>of</strong> Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong><br />

Pittsburgh.<br />

ARHP Poster Session C: Research Methods<br />

2062. A Meta-Analytic Assessment <strong>of</strong> the Effects <strong>of</strong> Stanford’s Small<br />

Group English Version <strong>of</strong> the Arthritis Self Management<br />

Program. Teresa J. Brady 1 , Benita J. O’Colmain 3 , Brandy S.<br />

Mobley 4 , Michael C. Greenberg 4 and Louise Murphy 2 , 1 Center<br />

for Disease Control, Atlanta, GA, 2 Centers for Disease Control<br />

and Prevention, 3 ICF Macro, Calverton, MD, 4 ICF Macro.<br />

2063. Development <strong>of</strong> the UK-Evaluation <strong>of</strong> Daily Activity<br />

Questionnaire (UK-EDAQ): Phase 2. Alison Hammond 3 , Rachel<br />

E. Gill 3 , Sarah Tyson 3 , Ulla Nordenskiold 1 and Alan Tennant 2 ,<br />

1<br />

Sahlgrenska Academy, Goteborg, Sweden, 2 University <strong>of</strong> Leeds,<br />

Leeds, Yorkshire, United Kingdom, 3 University <strong>of</strong> Salford, Salford,<br />

Greater Manchester, United Kingdom.<br />

2064. Factors Associated with Attrition in a Longitudinal Rheumatoid<br />

Arthritis (RA) Registry. Christine K. Iannaccone 2 , Anne Fossel 2 ,<br />

Hsun Tsao 2 , Jing Cui 2 , Michael E. Weinblatt 1 and Nancy A.<br />

Shadick 1 , 1 Brigham & Womens Hospital, Boston, MA, 2 Brigham<br />

and Women’s Hospital, Boston, MA.<br />

2065. Measuring Fatigue in Patients with Inflammatory Arthritis<br />

in Clinical Practice: Single Dimension and Multidimensional<br />

Scale Comparison. Patricia Minnock 1 , Barry Bresnihan 2 , McKee<br />

Gabrielle 3 , Oliver FitzGerald 2 and Douglas Veale 2 , 1 <strong>Rheumatology</strong><br />

Rehabilitation, Our Lady’s Hospice and Care Services, Dublin,<br />

Ireland, 2 St Vincent’s University Hospital, Dublin, Ireland, 3 Trinity<br />

<strong>College</strong> Dublin, Dublin, Ireland.<br />

2066. One Monthly Patient Reported Disability, Disease Activity<br />

and Fatigue Shows More Fluctuation Then Expected Based on<br />

the 3-Monthly Clinical Evaluation by DAS-28. Margot Walter,<br />

Siti Haslinda Binti Mohd Din, Mieke Hazes and Jolanda Luime,<br />

ErasmusMC.<br />

2067. Secular Trend <strong>of</strong> Adhesive Capsulitis over 13 Years: A United<br />

Kingdom General Population Cohort. Daniel K. White 1 , Hyon<br />

K. Choi 4 , Christine Peloquin 3 , Yanyan Zhu 2 and Yuqing Zhang 2 ,<br />

1<br />

Boston Univ School <strong>of</strong> Med, Boston, MA, 2 Boston Univ School<br />

<strong>of</strong> Medicine, Boston, MA, 3 Boston Univ School <strong>of</strong> Medicine,<br />

4<br />

Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />

2068. The <strong>American</strong> Myositis Activities Pr<strong>of</strong>ile – A Valid Disease-<br />

Specific Activity/Participation Measure. Helene Alexanderson 1 ,<br />

Ann M. Reed 2 and Steven R. Ytterberg 2 , 1 Department <strong>of</strong><br />

Medicine, Karolinska Institutet, Department <strong>of</strong> Physical Therapy,<br />

Karolinska University Hospital, Solna, Stockholm, Sweden,<br />

2<br />

<strong>Rheumatology</strong> Division, Mayo Clinic, Rochester, MN.<br />

ARHP Poster Session C: Quality <strong>of</strong> Life<br />

2069. Arthritis Hurts… Your Resume: State-Specific Arthritis-<br />

Attributable Work Limitation and Employment among<br />

Working-Age (18-64) Adults. Kristina Theis 3 , Jennifer M.<br />

Hootman 2 and Charles G. Helmick 1 , 1 CDC, Atlanta, GA, 2 Centers<br />

for Disease Control, Kennesaw, GA, 3 Centers for Disease Control<br />

and Prevention.<br />

278<br />

2010 Program Book


ACR/ARHP Poster Session C<br />

2070. Assessement <strong>of</strong> Physical and Mental Health Related Quality<br />

<strong>of</strong> Life, Disease Activity and Damage, Mental Health Status,<br />

and Cognitive Impairment in Chilean Women with Systemic<br />

Lupus Erythematosus. Carla Henríquez 1 , Patricia Flores 2 , Babul<br />

Marcela 3 , Jorge Calderón 3 and Loreto Massardo 3 , 1 Pontificia<br />

Universidad Católica de Chile, Santiago, Chile, 2 Pontificia<br />

Universidad Católica de Chile, Santiago, 3 Pontificia Universidad<br />

Católica de Chile.<br />

2071. Change in Physical Activity on Sleep Quality in Persons with<br />

Arthritis. Jennifer Lias 2 , Leigh F. Callahan 1 and Jack H. Shreffler 2 ,<br />

1<br />

Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 2 University <strong>of</strong> North<br />

Carolina, Chapel Hill.<br />

2072. Depression Rates Reported by Scleroderma (SSc) Patients<br />

Using Online Subject Recruitment and Questionnaire<br />

Completion. Feasibility <strong>of</strong> Data Collection Method and<br />

Comparison <strong>of</strong> Reported Depression Rates. Evelyn Rajan 1 ,<br />

Meagan Cr<strong>of</strong>oot 3 , Jibran Fateh 3 and Ann J. Impens 2 , 1 Briarcliff<br />

High School, 2 University <strong>of</strong> Michigan, Ann Arbor, MI, 3 University<br />

<strong>of</strong> Michigan.<br />

2073. Effects <strong>of</strong> Tadalafil on Sexual Activity and Quality <strong>of</strong> Sexual<br />

Functioning in Female Scleroderma (SSc) Patients. Ann J.<br />

Impens 2 , Elena Schiopu 2 , Kristine Phillips 2 and James R. Seibold 1 ,<br />

1<br />

University <strong>of</strong> Connecticut Health Center, Farmington, CT,<br />

2<br />

University <strong>of</strong> Michigan, Ann Arbor, MI.<br />

2079. What Do We Really Know about Arthritis Impact on<br />

Employment from Prospective Studies? A Systematic Review<br />

<strong>of</strong> the Literature. Kristina A. Theis, Ross Wilkie, Lucy Busija,<br />

Gerald Elsworth and Richard Osborne, Deakin University.<br />

2074. Fibromyalgia Patients Often Visit Many Physicians before<br />

Receiving a Diagnosis. Robert S. Katz 2 , Jessica L. Polyak 1 and<br />

Lauren Kwan, 1 <strong>Rheumatology</strong> Associates, 2 Rush University<br />

Medical Center, Chicago, IL.<br />

2075. Impact <strong>of</strong> Fibromyalgia (FMS) on Work. Robert S. Katz 3 , Sharon<br />

M. Ferbert 1 , Susan Shott 4 and Katrin F. Katz 2 , 1 Advocates for<br />

Funding Fibromyalgia Treatment, Education and Research<br />

(AFFTER), Libertyville, IL, 2 <strong>Rheumatology</strong> Associates, 3 Rush<br />

University Medical Center, Chicago, IL, 4 Rush University Medical<br />

Center.<br />

2076. Improvement <strong>of</strong> Hand Function in African <strong>American</strong>s with<br />

Scleroderma: Use <strong>of</strong> a Hand Continuous Passive Motion. Paula<br />

Fenter 2 , Samina Hayat 1 and Carla Saulsbury 1 , 1 Shreveport, LA,<br />

2<br />

Louisiana State University Health Sciences Center, Shreveport,<br />

Shreveport, LA.<br />

2077. The Mary Kirkland Center for Lupus Care (MKCLC): A Multi-<br />

Disciplinary Specialized Disease Center. Pretima Persad 2 ,<br />

Suzy Kim 2 , Monica Richey 3 , Jane E. Salmon 1 , Doruk Erkan 2 and<br />

Kyriakos A. Kirou 2 , 1 Hospital for Special Surgery, New York, NY,<br />

2<br />

Hospital for Special Surgery, New York, NY, 3 Hospital for Special<br />

Surgery.<br />

2078. TNF Blockage in Spondyloarthritis: Induction <strong>of</strong> Alveolar<br />

Bone Growth in Teeth with Periodontal Disease? Gisele<br />

Maria Campos Fabri 1 , Cynthia Savioli 2 , Carla G. S. Saad 5 ,<br />

Ana Luisa Garcia Calich 5 , Julio Cesar Bertacilli Moraes 5 , Ana<br />

Cristina Medeiros Ribeiro 5 , Jozélio Freire Carvalho 5 , Percival<br />

Sampaio-Barros 5 , Clovis Almeida Silva 4 , Rosa Maria Pereira 5 ,<br />

José Tadeu Tesseroli Siqueira 3 and Eloísa Bonfá 5 , 1 Dentistry and<br />

<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />

Universidade de São Paulo, São Paulo, Brazil, 2 Dentistry and<br />

<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina<br />

da Universidade de São Paulo, 3 Dentistry Division, Faculdade<br />

de Medicina da Universidade de São Paulo, 4 Paediatric<br />

<strong>Rheumatology</strong> Unit, <strong>Rheumatology</strong> Division (CEDMAC),<br />

Faculdade de Medicina da Universidade de São Paulo,<br />

5<br />

<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />

Universidade de São Paulo.<br />

2010 Program Book 279


REF Industry Roundtable-supported Symposia<br />

MONDAY, NOVEMBER 8, 2010<br />

The events listed below are non-CME Programs wholly sponsored and<br />

supported by the commercial entities listed. By holding the Programs,<br />

the commercial entities have represented that the Programs have been<br />

developed and will be implemented in accordance with the requirements<br />

<strong>of</strong> the FDA and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />

with Healthcare Pr<strong>of</strong>essionals. The commercial entities are to observe all<br />

guidelines established by federal and state regulatory agencies regarding<br />

non-CME educational or promotional presentations throughout the<br />

duration <strong>of</strong> the Program. The content and views expressed during the<br />

Program are those <strong>of</strong> the commercial entities and presenters. The ACR by<br />

making this venue available does not guarantee, warrant or endorse the<br />

content <strong>of</strong> the Program nor the products discussed and reviewed during<br />

the Program.<br />

6:30 – 9:30 pm Non-CME Accredited Symposium<br />

Omni at CNN Center, International Ballroom<br />

Challenging Case Studies for Rheumatologists: An Industry-Sponsored<br />

Program<br />

Developed and <strong>of</strong>fered by Amgen, Inc. and Pfizer Inc<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Assess patients for appropriate management <strong>of</strong> rheumatoid arthritis<br />

and psoriatic arthritis based on evidence from clinical studies<br />

• Individualize therapeutic strategies by developing a long-term<br />

treatment plan that takes complex issues such as disease history,<br />

longevity, and progression into account<br />

• Monitor both the potential benefits and adverse effects <strong>of</strong> treatment<br />

6:30 – 7:00 pm<br />

Welcome, Dinner and Introductions<br />

Setting Expectations for FDA-regulated Symposia<br />

Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />

Albany, NY<br />

Andrew Koenig, DO; Pfizer Medical Senior Director, Inflammation Disease<br />

Area Specialty Business Unit; <strong>College</strong>ville, PA<br />

7:00 – 7:10 pm<br />

Collective Clinical Experience <strong>of</strong> ENBREL<br />

Andrew Koenig, DO; Pfizer Medical Senior Director, Inflammation Disease<br />

Area Specialty Business Unit; <strong>College</strong>ville, PA<br />

Efficacy and safety overview<br />

ENBREL indications and ISI<br />

7:10 – 7:20 pm<br />

Case Study Overview<br />

Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />

Albany, NY<br />

7:20 – 7:45 pm<br />

Case Study #1<br />

Led by Panel Member<br />

7:45 – 8:10 pm<br />

Case Study #2<br />

Led by Panel Member<br />

8:10 – 8:35 pm<br />

Case Study #3<br />

Led by Panel Member<br />

8:35 – 8:55 pm<br />

Case Study #4 – if time allows<br />

Led by Panel Member<br />

8:55 – 9:00 pm<br />

Summary and Closing Remarks<br />

Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />

Albany, NY<br />

9:00 – 9:30 pm<br />

Dessert and Cocktail Reception<br />

Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />

Albany, NY<br />

Panel Members<br />

Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>,<br />

Albany, NY<br />

Philip Mease, MD; Seattle <strong>Rheumatology</strong> Associates; Seattle, WA<br />

Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />

Roy M. Fleischmann, MD; University <strong>of</strong> Texas Southwestern Medical Center<br />

at Dallas; Dallas, TX<br />

John R. P. Tesser, MD; Arizona <strong>Rheumatology</strong> Center, Arizona Arthritis &<br />

<strong>Rheumatology</strong> Associates, P.C.; Scottsdale, AZ<br />

6:30 – 9:30 pm Non-CME Accredited Symposium<br />

Omni at CNN Center, Grand Ballroom<br />

ACTEMRA – Navigating Treatment Decisions in RA<br />

Developed and <strong>of</strong>fered by Genentech, A Member <strong>of</strong> the Roche Group<br />

Third-party organization: Health Interactions<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Review the 10 treat-to-target recommendations and the evidence<br />

supporting them from the international task force<br />

• Present the benefits <strong>of</strong> applying treatment goals in clinical practice<br />

• Discuss data that demonstrates how ACTEMRA supports the concept<br />

<strong>of</strong> treating to a target in RA<br />

6:30 – 7:00 pm<br />

Registration and Dinner<br />

7:00 – 7:10 pm<br />

Introduction: Setting the Course to Better Disease Control<br />

Josef Smolen, MD; Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />

Medicine III, Medical University <strong>of</strong> Vienna; Austria<br />

7:10 – 7:30 pm<br />

International Task Force Recommendations<br />

Allan Gib<strong>of</strong>sky, MD, JD; Weill Medical <strong>College</strong>, Cornell University, Hospital<br />

for Special Surgery; New York, NY<br />

7:30 – 7:55 pm<br />

Mapping Out Treatment Goals in Clinical Practice<br />

Maxime Dougados, MD; Hôpital Cochin, Assistance Publique Hôpitaux de<br />

Paris, and René Descartes University; Paris, France<br />

7:55 – 8:35 pm<br />

Making Treatment Decisions Using ACTEMRA<br />

Jonathan Kay, MD; University <strong>of</strong> Massachusetts Medical School; Worcester,<br />

MA<br />

8:35 – 8:50 pm<br />

Panel Discussion<br />

8:50 – 9:00 pm<br />

Summary and Adjournment<br />

280<br />

2010 Program Book


REF Industry Roundtable-supported Symposia<br />

6:30 – 9:30 pm Non-CME Accredited Symposium<br />

Atlanta Marriott Marquis, Marquis Ballroom<br />

Bridging the Gap in Rheumatoid Arthritis: Challenges <strong>of</strong> RA Patient<br />

Management<br />

Developed and <strong>of</strong>fered by Centocor Ortho Biotech Inc.<br />

6:30 – 6:50 pm<br />

Registration and Seating<br />

6:50 – 7:00 pm<br />

Welcome and Introductions<br />

7:00 – 7:20 pm<br />

Current Topics in RA Patient Management<br />

Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />

Anthony Turkiewicz, MD; <strong>Rheumatology</strong> Associates PC; Birmingham, AL<br />

Arthur Kavanaugh, MD; The University <strong>of</strong> California at San Diego; San Diego,<br />

CA<br />

7:20 – 7:40 pm<br />

Case 1: Considerations for a MTX-Experienced, Biologic-Naïve Patient<br />

Arthur Kavanaugh, MD; The University <strong>of</strong> California at San Diego; San Diego,<br />

CA<br />

7:40 – 7:50 pm<br />

Panel Discussion<br />

All Faculty<br />

7:50 – 8:10 pm<br />

Case 2: Considerations for a Biologic-Experienced Patient<br />

Anthony Turkiewicz, MD; <strong>Rheumatology</strong> Associates PC; Birmingham, AL<br />

8:10 – 8:20 pm<br />

Panel Discussion<br />

All Faculty<br />

8:20 – 8:50 pm<br />

Clinical Review <strong>of</strong> an Anti-TNF Therapy<br />

Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />

8:50 – 9:00 pm<br />

Panel Discussion and Concluding Remarks<br />

All Faculty<br />

6:30 – 9:30 pm Non-CME Accredited Symposium<br />

Atlanta Marriott Marquis, Imperial Ballroom<br />

Applying Strategies to Predict and Measure Patient Outcomes for<br />

Rheumatoid Arthritis<br />

Developed and <strong>of</strong>fered by UCB, Inc.<br />

Third-party organization: ETHOS Health Communications<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Demonstrate how early relief <strong>of</strong> signs and symptoms when treating<br />

patients with moderately to severely active rheumatoid arthritis (RA)<br />

leads to better long-term outcomes for patients<br />

• Review the utilization <strong>of</strong> tools in measuring treatment success and the<br />

applicability <strong>of</strong> these tools to clinical practice<br />

• Discuss the role <strong>of</strong> patient-reported outcomes (PROs) in measuring<br />

treatment success and applicability to daily practice<br />

6:30 – 7:00 pm<br />

Registration and Dinner<br />

7:00 – 7:05 pm<br />

Welcome and Introductions<br />

Edward Keystone, MD, FRCPC; University <strong>of</strong> Toronto; Toronto, Ontario,<br />

Canada<br />

7:05 – 7:25 pm<br />

The Importance <strong>of</strong> a Fast Response in a Chronic Disease<br />

Edward Keystone, MD, FRCPC; University <strong>of</strong> Toronto; Toronto, Ontario,<br />

Canada<br />

7:25 – 7:45 pm<br />

Measuring Success <strong>of</strong> Treatment in Daily Practice: A Clinical Point <strong>of</strong> View<br />

Alvin Wells, MD, PhD; Rosalind Franklin University <strong>of</strong> Medicine and Science;<br />

North Chicago, IL<br />

7:45 – 8:05 pm<br />

Measuring Success <strong>of</strong> Treatment Through Patient-Reported Outcomes<br />

(PROs)<br />

Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />

8:05 – 8:25 pm<br />

Shaping Future Treatment Paradigms: Algorithms, Biomarkers, and<br />

Innovation in Equal Measure?<br />

Iain McInnes, FRCP, PhD, FRSE; University <strong>of</strong> Glasgow; Glasgow, Scotland<br />

8:25 – 8:55 pm<br />

Question-and-Answer Session/Panel Discussion<br />

Faculty Panel<br />

8:55 – 9:00 pm<br />

Conclusion<br />

Edward Keystone, MD, FRCPC; University <strong>of</strong> Toronto; Toronto, Ontario,<br />

Canada<br />

WEDNESDAY, NOVEMBER 10<br />

6:30 – 9:30 pm CME-Accredited Symposium<br />

For CME-accredited symposia, the sponsoring organization is responsible for<br />

panning and providing CME credit.<br />

Omni at CNN Center, International Ballroom<br />

Assessment and Treatment <strong>of</strong> Chronic Pain in the Rheumatic Diseases<br />

Jointly sponsored by the Postgraduate Institute for Medicine and ACCELMED<br />

Supported by an educational grant from Lilly USA, LLC<br />

Physician (ACCME) Accreditation Statement<br />

This activity has been planned and implemented in accordance with the<br />

Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />

Medical Education (ACCME) through the joint sponsorship <strong>of</strong> Postgraduate<br />

Institute for Medicine (PIM) and ACCELMED. PIM is accredited by the<br />

ACCME to provide continuing medical education for physicians.<br />

Credit Designation Statement<br />

Postgraduate Institute for Medicine designates this educational activity for<br />

a maximum <strong>of</strong> 2.0 AMA PRA Category 1 Credit(s). Physicians should only<br />

claim credit commensurate with the extent <strong>of</strong> their participation in the<br />

activity.<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Develop a plan for patient evaluation that includes assessment for<br />

chronic pain in any patient with a rheumatic disease<br />

• Identify the underlying mechanisms involved in symptom expression<br />

in chronic pain<br />

• Summarize up-to-date clinical trial data on pharmacological and<br />

nonpharmacological treatments for chronic pain associated with<br />

rheumatic diseases<br />

2010 Program Book 281


REF Industry Roundtable-supported Symposia<br />

6:30 – 7:00 pm<br />

Registration and Dinner<br />

7:00 – 7:05 pm<br />

Welcome and Overview<br />

Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />

7:05 – 7:25 pm<br />

Overview <strong>of</strong> Chronic Pain Associated with Rheumatic Diseases<br />

Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />

7:25 – 7:55 pm<br />

The Pathophysiology <strong>of</strong> Chronic Pain<br />

Daniel J. Clauw, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />

7:55 – 8:25 pm<br />

The Pharmacological and Nonpharmacological Management <strong>of</strong> Chronic<br />

Pain in Rheumatic Diseases<br />

Mary-Ann Fitzcharles, MB, ChB, MRCP (UK) FRCP(C);The Pain Centre, McGill<br />

University Health Centre; Montreal, Quebec, Canada<br />

8:25 – 8:35 pm<br />

Applying the Evidence: A Case-based Discussion<br />

Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />

8:35 – 9:00 pm<br />

Question and Answer Session<br />

6:30 – 9:30 pm CME-Accredited Symposium<br />

For CME-accredited symposia, the sponsoring organization is responsible for<br />

panning and providing CME credit.<br />

Atlanta Marriott Marquis, Marquis Ballroom<br />

Advances in the Treatment <strong>of</strong> Systemic Lupus Erythematosus Learning<br />

Continuum<br />

Sponsored by Cleveland Clinic<br />

Supported by an educational grant from Human Genome Sciences, Inc.<br />

Physician (ACCME) Accreditation Statement<br />

This activity has been planned and implemented in accordance with the<br />

Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />

Medical Education (ACCME) through the sponsorship <strong>of</strong> the Cleveland<br />

Clinic. The Cleveland Clinic Foundation Center for Continuing Education<br />

is accredited by the ACCME to provide continuing medical education for<br />

physicians.<br />

Credit Designation Statement<br />

The Cleveland Clinic Foundation Center for Continuing Education designates<br />

this educational activity for a maximum <strong>of</strong> 2.0 AMA PRA Category 1<br />

Credit(s). Physicians should only claim credit commensurate with the<br />

extent <strong>of</strong> their participation in the activity.<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Review the efficacy and safety data <strong>of</strong> current treatments for systemic<br />

lupus erythematosus<br />

• List the biologic evidence base for B-cell depletion and discuss its<br />

potential application to systemic lupus erythematosus therapy<br />

• Discuss the biologic and clinical trial data for BAFF and describe their<br />

implications for clinical practice<br />

6:30 – 7:30 pm<br />

Registration and Dinner<br />

7:30 – 7:40 pm<br />

Introduction – Lupus: a Historical Perceptual<br />

Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />

7:40 – 8:00 pm<br />

The Historical Problems <strong>of</strong> SLE Study Design<br />

Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />

8:00 – 8:20 pm<br />

The Current Status <strong>of</strong> the Treatment <strong>of</strong> Lupus Nephritis<br />

David Jayne, MD; Addenbrooke’s Hospital; Cambridge, England<br />

8:20 – 8:40 pm<br />

B-Cell Targeting in SLE: Is B-Cell Depletion or Modulation Effective?<br />

Marc Levesque, MD, PhD; University <strong>of</strong> Pittsburgh Medical Center;<br />

Pittsburgh PA<br />

8:40 – 9:00 pm<br />

B-Cell Activating Factor (BAFF) in SLE: Biologic and Clinical Data<br />

W. Winn Chatham, MD; University <strong>of</strong> Alabama at Birmingham School <strong>of</strong><br />

Medicine; Birmingham, AL<br />

9:00 – 9:30 pm<br />

Panel Discussion and Questions<br />

wednesday, NOVEMBER 10, 2010<br />

The event listed below is a non-CME Program wholly sponsored and<br />

supported by Amgen. By holding the Program, Amgen has represented that<br />

the Program has been developed and will be implemented in accordance<br />

with the requirements <strong>of</strong> the FDA and applicable standards <strong>of</strong> the PhRMA<br />

Code on Interactions with Healthcare Pr<strong>of</strong>essionals. Amgen is to observe all<br />

guidelines established by federal and state regulatory agencies regarding<br />

non-CME educational or promotional presentations throughout the duration<br />

<strong>of</strong> the Program. The content and views expressed during the Program are<br />

those <strong>of</strong> Amgen and presenters. The ACR by making this venue available<br />

does not guarantee, warrant or endorse the content <strong>of</strong> the Program nor the<br />

products discussed and reviewed during the Program.<br />

6:30 – 9:30 pm Non-CME Accredited Symposium<br />

Omni at CNN Center, Grand Ballroom<br />

Prolia (denosumab): A New Approach in the Treatment <strong>of</strong> Postmenopausal<br />

Osteoporosis in Women at High Risk for Fracture<br />

Developed and <strong>of</strong>fered by Amgen<br />

6:30 – 7:15 pm<br />

Registration and Dinner<br />

7:15 – 7:35 pm<br />

The Prolia (denosumab) Innovation<br />

Nelson B. Watts, MD; University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine;<br />

Cincinnati, OH<br />

7:35 – 8:15 pm<br />

Introducing Prolia (denosumab)<br />

Speaker to be announced<br />

8:15 – 9:00 pm<br />

Question and Answer<br />

282<br />

2010 Program Book


REF Industry Roundtable-supported Symposia<br />

thursday, NOVEMBER 11, 2010<br />

1:00 – 4:00 pm CME-Accredited Symposium<br />

For CME-accredited symposia, the sponsoring organization is responsible for<br />

panning and providing CME credit.<br />

Omni at CNN Center, International Ballroom (Sections E-F)<br />

<strong>Rheumatology</strong>—The Art <strong>of</strong> the Science: Informed Decisions, Improved<br />

Outcomes<br />

Jointly sponsored by the University <strong>of</strong> Cincinnati and NACCME<br />

Supported by an educational grant from Genentech, Inc. and Biogen Idec<br />

Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc., Abbott<br />

Laboratories, and UCB, Inc.<br />

Physician (ACCME) Accreditation Statement<br />

The University <strong>of</strong> Cincinnati is accredited by the Accreditation Council for<br />

Continuing Medical Education to provide continuing medical education for<br />

physicians.<br />

Credit Designation Statement<br />

The University <strong>of</strong> Cincinnati designates this educational activity for a<br />

maximum <strong>of</strong> 2.5 AMA PRA Category 1 Credit(s). Physicians should only<br />

claim credit commensurate with the extent <strong>of</strong> their participation in the<br />

activity.<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Explain how clinical measurement tools have been used to achieve<br />

tight RA control and summarize how these tools can be used in clinical<br />

practice to optimize patient care<br />

• Describe advances in imaging techniques for the diagnosis <strong>of</strong> RA and<br />

evaluation <strong>of</strong> RA disease progression<br />

• Outline genetic associations, laboratory markers, and clinical<br />

manifestations which should be considered when initiating early,<br />

aggressive therapy<br />

• Evaluate the current ACR/EULAR diagnostic and treatment criteria and<br />

their impact on the management <strong>of</strong> RA patients<br />

• Interpret new safety and efficacy data, including those presented<br />

at ACR/ARHP, on combination therapy, triple DMARD therapy, and<br />

biologic switching<br />

• Apply clinical trial and comprehensive registry data and available<br />

guidelines regarding current and emerging pharmacologic agents into<br />

clinical practice to achieve low disease activity or remission in patients<br />

with RA<br />

• Employ best practices for treating RA in patients with comorbid<br />

conditions<br />

• Describe new treatment targets and novel approaches for RA patients<br />

who have failed on conventional therapies, including mechanisms <strong>of</strong><br />

action and safety considerations<br />

• Compare and contrast diagnostic practices and treatment approaches<br />

for patients with SpA versus RA<br />

1:00 – 1:30 pm<br />

Registration and Lunch<br />

1:30 – 1:45 pm<br />

Welcome & Introductions<br />

Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />

1:45 – 2:45 pm<br />

RA Therapy in 2010: What are Today’s Best Practices?<br />

Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />

2:45 – 3:45 pm<br />

Managing Inflammatory Arthritis Beyond 2010: A Look Into the Future<br />

Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />

3:45 – 4:00 pm<br />

Question & Answer Session<br />

Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />

Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />

1:00 – 4:00 pm<br />

For CME-accredited symposia, the sponsoring organization is responsible for<br />

panning and providing CME credit.<br />

Omni at CNN Center, International Ballroom (Sections A-B-C-D)<br />

Structure Modification in Osteoarthritis<br />

Jointly sponsored by Medical Education Resources and Consensus Medical<br />

Communications<br />

Supported by an educational grant from Bioiberica<br />

Physician (ACCME) Accreditation Statement<br />

This activity has been planned and implemented in accordance with the<br />

Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />

Medical Education (ACCME) through the joint sponsorship <strong>of</strong> Medical<br />

Education Resources and Consensus Medical Communications. Medical<br />

Education Resources is accredited by the ACCME to provide continuing<br />

medical education for physicians.<br />

Credit Designation Statement<br />

Medical Education Resources designates this educational activity for a<br />

maximum <strong>of</strong> 1.5 AMA PRA Category 1 Credit(s). Physicians should only<br />

claim credit commensurate with the extent <strong>of</strong> their participation in the<br />

educational activity.<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Discuss the pathologic effects <strong>of</strong> OA in the synovium, cartilage and<br />

bone<br />

• Assess the structural progression in OA utilizing advanced imaging<br />

techniques<br />

• Describe the pharmacologic actions and disease modifying role <strong>of</strong><br />

chondroitin sulfate in the synovium, cartilage and bone<br />

• Describe clinical outcomes <strong>of</strong> disease modification therapy in the<br />

treatment <strong>of</strong> OA<br />

1:00 – 1:30 pm<br />

Registration and Lunch<br />

1:30 – 1:35 pm<br />

Welcome and Introduction<br />

Marc Hochberg MD, MPH; University <strong>of</strong> Maryland School <strong>of</strong> Medicine;<br />

Baltimore, MD<br />

1:35 – 1:50 pm<br />

Current Concepts: The Pathophysiology <strong>of</strong> Osteoarthritis<br />

Johanna Martel Pelletier, PhD; University <strong>of</strong> Montreal; Montreal, Quebec,<br />

Canada<br />

1:50 – 2:05 pm<br />

Assessment <strong>of</strong> Structural Progression in Osteoarthritis<br />

Philip G. Conaghan MBBS, PhD, FRACP, FRCP; Chapel Allerton Hospital;<br />

Leeds, England, UK<br />

2:05 – 2:20 pm<br />

Effects <strong>of</strong> Chondroitin Sulfate on Nuclear Factor - ĸB in OA<br />

Patrick du Souich MD, PhD; University <strong>of</strong> Montreal; Montreal, Quebec,<br />

Canada<br />

2:20 – 2:35 pm<br />

Evidence that Chondroitin Sulfate has Structure Modifying Properties in<br />

OA<br />

Jean-Pierre Pelletier MD; University <strong>of</strong> Montreal; Montreal, Quebec, Canada<br />

2:35 – 2:50 pm<br />

Current Approaches to the Management <strong>of</strong> Osteoarthritis: The Role <strong>of</strong><br />

Chondroitin Sulfate<br />

Marc Hochberg MD, MPH; University <strong>of</strong> Maryland School <strong>of</strong> Medicine;<br />

Baltimore, MD<br />

2:50 – 3:00 pm<br />

Question and Answer<br />

All Faculty<br />

2010 Program Book 283


INDUSTRY-SUPPORTED POST-CONFERENCE SYMPOSIA<br />

1:00 – 4:00 pm CME-Accredited Symposium<br />

For CME-accredited symposia, the sponsoring organization is responsible for<br />

panning and providing CME credit.<br />

Omni at CNN Center, Grand Ballroom (Section E)<br />

Pulmonary Arterial Hypertension (PAH) in Connective Tissue Diseases<br />

(CTDs): Current Concepts and Cutting-Edge Constructs in Detection,<br />

Prognosis, and Clinical Management<br />

Jointly sponsored by Medical Education Resources and Cornerstone Medical<br />

Communications<br />

Supported by an educational grant from Actelion Pharmaceuticals US, Inc.<br />

Physician (ACCME) Accreditation Statement<br />

This activity has been planned and implemented in accordance with the<br />

Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />

Medical Education (ACCME) through the joint sponsorship <strong>of</strong> Medical<br />

Education Resources (MER) and Cornerstone Medical Communications.<br />

MER is accredited by the ACCME to provide continuing medical education<br />

for physicians.<br />

Credit Designation Statement<br />

Medical Education Resources designates this educational activity for a<br />

maximum <strong>of</strong> 2.0 AMA PRA Category 1 Credit(s). Physicians should only<br />

claim credit commensurate with the extent <strong>of</strong> their participation in the<br />

activity.<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Describe new insights from pulmonary hypertension registries and<br />

their prognostic implications for patients with CTDs<br />

• Identify effective screening programs to detect pulmonary<br />

complications and devise specific strategies to afford earlier<br />

identification <strong>of</strong> PAH in patients with CTDs such as scleroderma<br />

• Delineate key components <strong>of</strong> the diagnostic algorithm for PAH,<br />

evaluate current treatment guidelines and new clinical trial results,<br />

and determine how these are best applied in patients with CTDs<br />

• Assess the value <strong>of</strong> measuring patient-reported outcomes as a clinical<br />

tool for optimizing care in patients with CTDs<br />

1:00 – 1:30 pm<br />

Registration and Lunch<br />

1:30 – 1:35 pm<br />

Welcome and Introduction<br />

Richard M. Silver, MD; Medical University <strong>of</strong> South Carolina; Charleston, SC<br />

1:35 – 1:55 pm<br />

Prognosis <strong>of</strong> PAH in CTD Across the Spectrum: New Insights From the<br />

REVEAL Registry<br />

Lorinda Chung, MD, MS; Stanford University School <strong>of</strong> Medicine; Stanford,<br />

CA<br />

1:55 – 2:15 pm<br />

Screening Programs and Earlier Identification <strong>of</strong> PAH in the Scleroderma<br />

Setting<br />

Eric Hachulla, MD, PhD; Université de Lille 2; Lille, France<br />

2:15 – 2:35 pm<br />

Optimal Treatment and Achieving Goals <strong>of</strong> PAH Management in Patients<br />

with CTDs<br />

Vallerie V. McLaughlin, MD, FACC, FAHA; University <strong>of</strong> Michigan Medical<br />

School; Ann Arbor, MI<br />

2:35 – 2:55 pm<br />

Patient-Reported Outcomes in Clinical Practice: Tools for Optimizing Care<br />

in the Setting <strong>of</strong> CTDs<br />

Dinesh Khanna, MD; David Geffen School <strong>of</strong> Medicine at UCLA; Los Angeles,<br />

CA<br />

2:55 – 3:25 pm<br />

Clinical Pearls from Case-based Discussion<br />

Richard M. Silver, MD; Medical University <strong>of</strong> South Carolina; Charleston, SC<br />

3:25 – 3:30 pm<br />

Concluding Remarks<br />

Vallerie V. McLaughlin, MD, FACC, FAHA; University <strong>of</strong> Michigan Medical<br />

School; Ann Arbor, MI<br />

1:00 – 4:00 pm CME-Accredited Symposium<br />

For CME-accredited symposia, the sponsoring organization is responsible for<br />

panning and providing CME credit.<br />

Embassy Suites Hotel Atlanta at Centennial Olympic Park, Legacy<br />

Ballroom<br />

Understanding Osteoarthritis Today: Risk Factors, Management, and Novel<br />

Interventions<br />

Sponsored by Cleveland Clinic<br />

Supported by an educational grant from Covidien-Mallinckrodt, Inc.<br />

Physician (ACCME) Accreditation Statement<br />

This activity has been planned and implemented in accordance with the<br />

Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />

Medical Education (ACCME) through the sponsorship <strong>of</strong> the Cleveland<br />

Clinic. The Cleveland Clinic Foundation Center for Continuing Education<br />

is accredited by the ACCME to provide continuing medical education for<br />

physicians.<br />

Credit Designation Statement<br />

The Cleveland Clinic Foundation Center for Continuing Education designates<br />

this educational activity for a maximum <strong>of</strong> 2.0 AMA PRA Category 1<br />

Credit(s). Physicians should only claim credit commensurate with the<br />

extent <strong>of</strong> their participation in the activity.<br />

LEARNING OBJECTIVES:<br />

Upon completion <strong>of</strong> this session, participants should be able to:<br />

• Identify epidemiologic changes in osteoarthritis and discuss their<br />

impact on clinical practice<br />

• Assess efficacy and safety data from clinical trials <strong>of</strong> DMOADs and<br />

gauge their potential impact on clinical practice<br />

• Discuss new and emerging pain modulators as they apply to<br />

management <strong>of</strong> patients with osteoarthritis<br />

• Discuss the evidence indicating that osteoarthritis may be a<br />

potentially modifiable disease<br />

1:00 – 2:00 pm<br />

Registration and Lunch<br />

2:00 – 2:10 pm<br />

Introduction<br />

M. Elaine Husni, MD, MPH; Cleveland Clinic; Cleveland, OH<br />

2:10 – 2:30 pm<br />

Changing Epidemiology <strong>of</strong> Osteoarthritis and Identifying Risk Factors for<br />

Osteoarthritis<br />

Roland W. Moskowitz, MD; University Hospitals Case Medical Center;<br />

Cleveland, OH<br />

2:30 – 2:50 pm<br />

Therapeutic Potential <strong>of</strong> Disease-Modifying Osteoarthritis Drugs<br />

(DMOADs) Measuring Osteoarthritis Treatment Effects<br />

Clifton O. Bingham III, MD; Johns Hopkins University; Baltimore, MD<br />

2:50 – 3:05 pm<br />

Panel Discussion and Questions<br />

All Faculty<br />

284<br />

2010 Program Book


INDUSTRY-SUPPORTED POST-CONFERENCE SYMPOSIA<br />

3:05 – 3:25 pm<br />

Osteoarthritis: Unstoppable Disease vs. Potentially Modifiable<br />

Steven Abramson, MD; NYU School <strong>of</strong> Medicine; New York, NY<br />

3:25 – 3:45 pm<br />

Development <strong>of</strong> Novel Treatment Paradigm: Pain Modulators<br />

Thomas J. Schnitzer, MD, PhD;<br />

Northwestern University Feinberg School <strong>of</strong> Medicine; Chicago, IL<br />

3:45 – 4:00 pm<br />

Panel Discussion and Questions<br />

All Faculty<br />

thursday, NOVEMBER 11, 2010<br />

The event listed below is a non-CME Program wholly sponsored and<br />

supported by Pfizer Inc. By holding the Program, Pfizer Inc has represented<br />

that the Program has been developed and will be implemented in<br />

accordance with the requirements <strong>of</strong> the FDA and applicable standards <strong>of</strong><br />

the PhRMA Code on Interactions with Healthcare Pr<strong>of</strong>essionals. Pfizer Inc is<br />

to observe all guidelines established by federal and state regulatory agencies<br />

regarding non-CME educational or promotional presentations throughout<br />

the duration <strong>of</strong> the Program. The content and views expressed during the<br />

Program are those <strong>of</strong> Pfizer Inc and presenters. The ACR by making this<br />

venue available does not guarantee, warrant or endorse the content <strong>of</strong> the<br />

Program nor the products discussed and reviewed during the Program.<br />

1:00 – 4:00 pm Non-CME Accredited Symposium<br />

Omni at CNN Center, Grand Ballroom (Section A-B-C)<br />

The JAK Pathway in RA: Turning our Understanding ‘Outside In’<br />

Developed and <strong>of</strong>fered by Pfizer Inc<br />

LEARNING OBJECTIVES:<br />

To provide an overview <strong>of</strong> the mechanism <strong>of</strong> signaling by multiple cytokines<br />

through intracellular pathways, such as JAK, and the importance in the<br />

pathogenesis <strong>of</strong> RA.<br />

1:00 – 1:30 pm<br />

Registration and Lunch<br />

1:30 – 1:40 pm<br />

Welcome and Introductions<br />

1:40 – 2:00 pm<br />

How do Cytokines Talk to Cells?<br />

John J. O’Shea, MD; National Institute <strong>of</strong> Arthritis and Musculoskeletal and<br />

Skin Diseases; Bethesda, MD<br />

2:00 – 2:20 pm<br />

New Insights into the Role <strong>of</strong> the JAK Pathway in RA<br />

Peter C. Taylor MA, PhD, FRCP; Kennedy Institute <strong>of</strong> <strong>Rheumatology</strong> Division;<br />

Imperial <strong>College</strong>, London<br />

2:20 – 2:40 pm<br />

Question and Answer<br />

2:40 – 2:50 pm<br />

Concluding Remarks<br />

2:50 – 3:00 pm<br />

Adjourn<br />

2010 Program Book 285


ACR ref<br />

Industry<br />

Roundtable<br />

The Industry Roundtable brings together<br />

the ACR Research and Education Foundation<br />

and pharmaceutical industry leaders in<br />

a collaboration to provide training, research<br />

and educational opportunities in rheumatology<br />

while serving as a forum for dialogue<br />

between industry and the REF. Through<br />

Industry Roundtable support, the REF<br />

continues to increase funding for<br />

research and training.<br />

The REF would like to thank these<br />

organizations for their multi-year<br />

commitment to the REF and its programs.<br />

Together, the REF and the Industry<br />

Roundtable are investing in the<br />

future <strong>of</strong> rheumatology.


2010 ACR/ARHP Annual Meeting Leadership<br />

ACR and ARHP Officers<br />

Stanley B. Cohen, MD, ACR President<br />

David Borenstein, MD, ACR President-Elect<br />

James R. O’Dell, MD, ACR Secretary<br />

Audrey Uknis, MD, ACR Treasurer<br />

E. William St.Clair, MD, REF President<br />

David I. Daikh, MD, REF Vice President<br />

Linda S. Ehrlich-Jones, PhD, RN, ARHP President<br />

Nadine T. James, MSN, PhD, PT, ARHP<br />

President-Elect<br />

Susan E. Klepper, PhD, ARHP Secretary-Treasurer<br />

2010 ACR Annual Meeting Planning<br />

Subcommittee<br />

Joel A. Block, MD, Chair<br />

Steven R. Goldring, MD, Basic Science Sub-Chair<br />

Susan Manzi, MD, Clinical Sub-Chair<br />

Robert W. Simms, MD, Meet the Pr<strong>of</strong>essor/<br />

Workshop/Study Group Sub-Chair<br />

Carol A. Langford, MD, Clinical Chair, Abstract<br />

Selection<br />

Alisa E. Koch, MD, Basic Science Chair, Abstract<br />

Selection<br />

Abby Abelson, MD, Committee <strong>of</strong> <strong>Rheumatology</strong><br />

Training & Workforce Representative<br />

Jennifer H. Anolik, MD, PhD<br />

Joan Bathon, MD, A&R Representative<br />

Robert H. Carter, MD<br />

Mary E. Cronin, MD<br />

Barbara A. Eberhard, MBBS, MSc<br />

Keith B. Elkon, MD<br />

Polly J. Ferguson, MD, Committee on Research<br />

Representative<br />

James G. Freeman, MD<br />

Richard Furie, MD, Committee on Education,<br />

Chair<br />

Gregory Gardner, MD<br />

Alexei A. Grom, MD<br />

Bruce I. H<strong>of</strong>fman, MD<br />

Raymond S. Hong, MD<br />

Nancy Y. Liu, MD<br />

Richard F. Loeser, Jr., MD<br />

Richard J. Looney, MD<br />

Augustine M. Manadan, MD<br />

Brian F. Mandell, MD, PhD<br />

Kevin McKown, MD<br />

Zsuzsanna McMahan, MD, Fellows<br />

Representative<br />

Chester V. Oddis, MD<br />

Thomas Olenginski, MD<br />

Kathleen M. O’Neil, MD<br />

Janet L. Poole, PhD, OTR, ARHP Representative<br />

Christopher Ritchlin, MD, MPH, Pr<strong>of</strong>essional<br />

Meetings Committee, Chair<br />

Carlos D. Rose, MD<br />

Eric M. Ruderman, MD<br />

F. Jorge Sanchez-Guerrero, MD, MS<br />

Nan Shen, MD<br />

Robert Spiera, MD<br />

Paul P. Tak, MD, PhD<br />

John R.P. Tesser, MD<br />

Alexandra Villa-Forte, MD, MPH<br />

Raymond L. Yung, MD, Committee on Education,<br />

Program Sub-chair<br />

2010 Abstract Oversight Committee<br />

Robert Fuhlbrigge, MD, PhD<br />

Edward Yelin, PhD<br />

David Pisetsky, MD, PhD<br />

2010 ACR Abstract Selection Committee<br />

Alisa E. Koch, MD, Basic Science, Co-Chair<br />

Carol A. Langford, MD, MS, Clinical, Co-Chair<br />

1. Cytokines, Mediators, and Gene<br />

Regulation<br />

Alison Finnegan, PhD, Co-chair<br />

Iain B. McInnes, MD, Co-chair<br />

Michael Centola, PhD<br />

Lionel B. Ivashkiv, MD<br />

Erik Lubberts, PhD<br />

Pierre Miossec, MD, PhD<br />

2. Cell-cell Adhesion, Cell Trafficking and<br />

Angiogenesis<br />

Bruce N. Cronstein, MD, Co-chair<br />

Zoltan Szekanecz, MD, PhD, Co-chair<br />

Richard J. Bucala, MD, PhD<br />

Dorian O. Haskard, MD, PhD<br />

Katalin Mikecz, MD, PhD<br />

Douglas J. Veale, MD<br />

3. Innate Immunity and Rheumatic<br />

Disease<br />

Joseph M. Ahearn, MD, Chair<br />

John P. Atkinson, MD<br />

Susan A. Boackle, MD<br />

Robert M. Clancy, PhD<br />

Terry W. Du Clos, MD, PhD<br />

Tibor T. Glant, MD, PhD<br />

4. B-cell Biology and Targets in Autoimmune<br />

Disease<br />

Chaim Putterman, MD, Co-chair<br />

Yehuda Shoenfeld, MD, Co-chair<br />

Jennifer H. Anolik, MD, PhD<br />

Andrea Doria, MD<br />

William Stohl, MD, PhD<br />

Pierluigi Meroni, MD<br />

5. T-cell Biology and Targets in Autoimmune<br />

Disease<br />

C. Garrison Fathman, MD, Co-chair<br />

David A. Fox, MD, Co-chair<br />

Jorg J. Goronzy, MD, PhD<br />

Sujata Sarkar, MD<br />

Paul J. Utz, MD<br />

Cornelia M. Weyand, MD, PhD<br />

6. Biology and Pathology <strong>of</strong> Bone and<br />

Joint<br />

Tariq M. Haqqi, PhD, MPH, Co-chair<br />

Mary B. Goldring, PhD, Co-chair<br />

Hiroski Asahara, PhD<br />

Johanne Martel-Pelletier, PhD<br />

Georg Schett, MD<br />

Veena Taneja, PhD<br />

7. Osteoarthritis - Clinical Aspects<br />

Joanne M. Jordan, MD, MPH, Co-chair<br />

Timothy E. McAlindon MD, MPH, Co-chair<br />

Gillian A. Hawker, MD<br />

Amanda E. Nelson, MD, MSc<br />

Tuhina Neogi, MD, PhD<br />

Anita E. Wluka, PhD, MBBS<br />

8. Osteoporosis and Metabolic Bone Disease:<br />

Clinical Aspects and Pathogenesis<br />

Piet P. Geusens, MD, PhD, Co-chair<br />

Nancy E. Lane, MD, Co-chair<br />

Lenore Buckley, MD, MPH<br />

Ellen M. Gravallese, MD<br />

Mary Beth Humphrey, MD, PhD<br />

Anthony D. Woolf, MBBS<br />

9. Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />

Daniel J. Clauw, MD, Co-chair<br />

Don L. Goldenberg, MD, Co-chair<br />

Dennis C. Ang, MD<br />

Mary Ann Fitzcharles, MD<br />

Afton L. Hassett, PsyD<br />

Alan Rubinow, MD<br />

10. Orthopedics, Low Back Pain, and<br />

Rehabilitation<br />

Beth L. Jonas, MD, Co-chair<br />

Jeffery N. Katz, MD, Co-chair<br />

Aileen M. Davis, PhD<br />

Elaine Husni, MD, MPH<br />

Kenneth S. O’Rourke, MD<br />

Alfredo C. Rivadeneira, MD<br />

11. Pediatric <strong>Rheumatology</strong> - Clinical and<br />

Therapeutic Aspects<br />

Norman T. Ilowite, MD, Co-chair<br />

Daniel J. Lovell, MD, MPH, Co-chair<br />

Elga C. Rabinovich, MD, MPH, Co-chair<br />

Carol A. Wallace, MD, Co-chair<br />

Hermine Brunner, MD, MSC<br />

Edward Fels, MD<br />

Beth Gottlieb, MD, MS<br />

Thomas B. Graham, MD, MS<br />

Rayfel Schneider, MBBCH<br />

2010 Program Book 287


2010 ACR/ARHP Annual Meeting Leadership<br />

288<br />

Michael Shishov, MD, MPH<br />

Pamela O. Weiss, MD<br />

Lawrence S. Zemel, MD<br />

12. Pediatric <strong>Rheumatology</strong> - Pathogenesis and<br />

Genetics<br />

Barbara S. Adams, MD, Co-chair<br />

Nora G. Singer, MD, Co-chair<br />

Melissa E. Elder, MD, PhD<br />

Raphaela Goldbach-Mansky, MD<br />

Sampath Prahalad, MD, MSc<br />

James W. Verbsky, MD, PhD<br />

13. Infection-related Rheumatic Disease<br />

John S.H. Gaston, MD, Co-chair<br />

Dimitrios Vassilopoulos, MD, Co-chair<br />

John D. Carter, MD<br />

Cem Gabay, MD<br />

Stanley J. Naides, MD<br />

Daniel H. Solomon, MD, MPH<br />

14. Metabolic and Crystal Arthropathies<br />

Hyon K. Choi, MD, PhD, Co-chair<br />

John S. Sundy, MD, PhD, Co-chair<br />

Nicola Dalbeth, MD, MB, ChB<br />

Robert T. Keenan, MD, MPH<br />

Frederic P. Liote, MD, PhD<br />

George Nuki, MB<br />

15. Muscle Biology, Myositis and Myopathies<br />

Ingrid E. Lundberg, MD, PhD, Co-chair<br />

Frederick W. Miller, MD, PhD, Co-chair<br />

Lisa Christopher-Stine, MD<br />

Robert G. Cooper, MD<br />

Ann M. Reed, MD<br />

Lisa G. Rider, MD<br />

16. Imaging <strong>of</strong> Rheumatic Diseases<br />

Wolfgang A. Schmidt, MD, Co-chair<br />

Carl S. Winalski, MD, Co-chair<br />

John Carrino, MD<br />

Jon A. Jacobson, MD<br />

Mikkel Ostergaard, MD, PhD, DMSc<br />

Eugene Y. Kissin, MD<br />

17. RA: Clinical Aspects<br />

Jon T. Giles, MD, Co-chair<br />

Jonathan Kay, MD, Co-chair<br />

Eric L. Matteson, MD, Co-chair<br />

Deborah P. Symmons, MD, Co-chair<br />

Neal S. Birnbaum, MD<br />

Ernest Choy, MD<br />

Paul F. Dellaripa, MD<br />

Inmaculada del Rincon, MD, MS<br />

Darcy S. Majka, MD<br />

Joseph A. Markenson, MD<br />

Michael A. Stein, MD<br />

Piet L. van Riel, MD, PhD<br />

2010 Program Book<br />

18. RA Treatment - Small Molecules, Biologics<br />

and Gene Therapy<br />

Daniel E. Furst, MD, Co-chair<br />

Richard W. Martin, MD, MA, Co-chair<br />

Eric M. Ruderman, MD, Co-chair<br />

Josef S. Smolen, MD, Co-chair<br />

Marin Aringer, MD<br />

Maya H. Buch,PhD, MBChB<br />

Aaron T. Eggebeen, MD<br />

Jeffrey D. Greenberg, MD, MPH<br />

Andrew J. Head, MD<br />

Jerry A. Molitor, MD, PhD<br />

Harold E. Paulus, MD<br />

Alvin F. Wells, MD, PhD<br />

19. RA - Human Etiology and Pathogenesis<br />

Leslie J. Cr<strong>of</strong>ford, MD, Co-chair<br />

Paul-Peter Tak, MD, PhD, Co-chair<br />

Andrew P. Cope, MD<br />

Gary Firestein, MD, PhD<br />

Ulf Müller-Ladner, MD<br />

William Robinson, MD, PhD<br />

20. RA - Animal Models<br />

Linda K. Myers, MD, Co-chair<br />

Wim B. Vandenberg, PhD, Co-chair<br />

David S. Bradley, PhD<br />

Ernest Brahn, MD<br />

Kurt Redlich, MD<br />

Paul H. Wooley, PhD<br />

21. Systemic Sclerosis, Fibrosing Syndromes,<br />

and Raynaud’s - Clinical Aspects and<br />

Therapeutics<br />

Murray Baron, MD, Co-chair<br />

Maureen D. Mayes, MD, MPH, Co-chair<br />

Lorinda Chung, MD, MS<br />

Eric Hachulla, MD, PhD<br />

Laura K. Hummers, MD<br />

Sindhu Johnson, MD<br />

22. Systemic Sclerosis, Fibrosing Syndromes<br />

and Raynaud’s – Pathogenesis, Animal<br />

Models and Genetics<br />

Marco Matucci-Cerinic, MD, PhD, Co-chair<br />

Maria Trojanowska, PhD, Co-chair<br />

David S. Abraham, PhD, BSc<br />

Jorg H.W. Distler, MD<br />

Carol A. Feghali-Bostwick, PhD<br />

John Varga, MD<br />

23. Sjögren’s Syndrome<br />

Gabor G. Illei, MD, Co-chair<br />

Athanasios G. Tzioufas, MD, Co-chair<br />

Alan N. Baer, MD<br />

Stefano Bombardieri, MD<br />

Jacques-Eric Gottenberg, MD<br />

Cees G.M. Kallenberg, MD<br />

E. William St.Clair, MD<br />

24. Antiphospholipid Syndrome<br />

Doruk Erkan, MD, Co-chair<br />

Barry L. Myones, MD, Co-chair<br />

Pojen P. Chen, PhD<br />

Roger A. Levy, MD, PhD<br />

Joyce Rauch, PhD<br />

Robert A.S. Roubey, MD<br />

25. SLE - Clinical Aspects and Treatment<br />

Eliza F. Chakravarty, MD, Co-chair<br />

Elena M. Massarotti, MD, Co-chair<br />

Michelle Petri, MD, MPH, Co-chair<br />

Rosalind Ramsey-Goldman, MD, Co-chair<br />

Graciela S. Alarcon, MD, MPH<br />

Jennifer M. Grossman, MD<br />

Kenneth C. Kalunian, MD<br />

Amy H. Kao, MD, MPH<br />

S. Sam Lim, MD, MPH<br />

Kathleen Macsimowics-McKinnon, DO<br />

Peter H. Schur, MD<br />

Daniel J. Wallace, MD<br />

26. SLE - Human Etiology and Pathogenesis<br />

Mary K. Crow, MD, Co-chair<br />

George C. Tsokos, MD, Co-chair<br />

Anne Davidson, MB, BS<br />

Gary S. Gilkeson, MD<br />

Antonio La Cava, MD, PhD<br />

Andras Perl, MD, PhD<br />

27. SLE - Animal Models<br />

Philip L. Cohen, MD, Co-chair<br />

Jane E. Salmon, MD, Co-chair<br />

Marina J. Kaplan, MD<br />

Dwight H. Kono, MD<br />

Westley H. Reeves, MD<br />

Joan E. Wither, MD, PhD<br />

28. Spondylarthropathies and Psoriatic<br />

Arthritis: Clinical Aspects and<br />

Treatment<br />

Juergen Braun, MD, Co-chair<br />

Christopher T. Ritchlin, MD, Co-chair<br />

Desiree M. van der Heijde, MD, PhD,<br />

Co-chair<br />

Michael H. Weisman, MD, Co-chair<br />

Dominique Baeten, MD, PhD<br />

Daniel O. Clegg, MD<br />

Maxime Dougados, MD<br />

Luis R. Espinoza, MD<br />

Lianne S. Gensler, MD<br />

Robert D. Inman, MD<br />

Robert Landewe, MD<br />

Sergio Schwartzman, MD


2010 ACR/ARHP Annual Meeting Leadership<br />

29. Spondylarthropathies and Psoriatic<br />

Arthritis - Pathogenesis, Etiology<br />

Robert H. Sc<strong>of</strong>ield, MD, Co-chair<br />

Joel D. Taurog, MD, Co-chair<br />

Maxime A. Breban, MD, PhD<br />

Robert A. Colbert, MD, PhD<br />

Walter P. Maksymowych, MD<br />

Joachim Sieper, MD<br />

30. Vasculitis<br />

Simon Carette, MD, Co-chair<br />

Paul A. Monach, MD, PhD, Co-chair<br />

Loic P. Guillevin, MD<br />

Curry L. Koening, MD, MS<br />

Robert Spiera, MD<br />

Richard Watts, MD<br />

31. Epidemiology and Health Services<br />

Research<br />

Karen H. Costenbader, MD, MPH, Co-chair<br />

Allan C. Gelber, MD, Co-chair<br />

Liana Fraenkel, MD, MPH, Co-chair<br />

Lisa A. Mandl, MD, MPH, Co-chair<br />

Jolanda Cibere, MD, PhD<br />

Jeffery R. Curtis, MD, MPH<br />

John D. Fitzgerald, MD, PhD<br />

Elena Losina, PhD<br />

Kaleb D. Michaud, PhD<br />

Ted R. Mikuls, MD<br />

Shikha Mittoo, MD<br />

Lisa G. Suter, MD<br />

32. Quality Measures and Innovations<br />

in Practice Management and Care<br />

Delivery<br />

J. Timothy Harrington, MD, Co-chair<br />

Eric D. Newman, MD, Co-chair<br />

Gerson C. Bernhard, MD<br />

Matthew P. Bunyard, MD<br />

Theodore R. Fields, MD<br />

Steven S. Overman, MD, MPH<br />

33. Genetics, Genomics and Proteomics<br />

John B. Harley, MD, PhD, Co-chair<br />

John D. Reveille, MD, Co-chair<br />

David N. Glass, MD<br />

Robert M. Plenge, MD, PhD<br />

Betty P. Tsao, PhD<br />

34. Education<br />

Maria-Louise Barilla-LaBarca, MD, Co-chair<br />

Audrey B. Uknis, MD, Co-chair<br />

Abby G. Abelson, MD<br />

Seth Berney, MD<br />

Robert A. Kalish, MD<br />

Celso Velazquez, MD<br />

35. Miscellaneous Rheumatic and<br />

Inflammatory Diseases<br />

Kristine M. Lohr, MD, MS, Co-chair<br />

W. Winn Chatham, MD, Co-chair<br />

Keivan Dehghanpisheh, MD, PhD<br />

Richard M. Keating, MD<br />

Erika H. Noss, MD<br />

Kenneth J. Warrington, MD<br />

Basic Research Conference Abstract Reviewers<br />

Robert A. Colbert, MD, PhD<br />

Polly J. Ferguson, MD<br />

Lionel B. Ivashkiv, MD<br />

Ann Marshak-Rothstein, MD<br />

E. William St.Clair, MD<br />

Clinical Research Conference Abstract Reviewers<br />

Robert A. Colbert, MD, PhD<br />

Elizabeth W. Karlson, MD<br />

Kenneth G. Saag, MD, MSc<br />

ARHP Officers<br />

Linda S. Ehrlich-Jones, PhD, RN, ARHP President<br />

Nadine T. James, MSN, PhD, PT, ARHP President-<br />

Elect<br />

Susan E. Klepper, PhD, ARHP Secretary-Treasurer<br />

AHRP Annual Meeting Program Committee<br />

Janet L. Poole, PhD, OTR, Chair<br />

Kori A. Dewing, MSN, ARNP, Chair-elect<br />

Atul A. Deodhar, MD, MRCP<br />

Donna K. Everix, MPA, BS, PT<br />

Nadine M. Fisher, EdD<br />

Bernadette McNally, MS, PA-C<br />

Susan M. Oliver, MSc<br />

Elizabeth G. Salt, PhD, ARNP<br />

Emily C. Somers, PhD, ScM<br />

Benjamin J. Smith, PA-C, Chair, ARHP Committee<br />

on Education<br />

Sandra J. Watcher, BSN<br />

Mary Wright, BS, OT<br />

2010 ARHP ABSTRACT REVIEW PANELS<br />

Clinical Practice/Patient Care<br />

Debra Bancr<strong>of</strong>t-Rizzo, MSN, RNP-C<br />

Patricia Cornell, BSc<br />

James A. Jenkins, PhD<br />

Kim D. Jones, RNC, PhD<br />

Doreen M. Stiskal, PT, PhD<br />

Donna K. Everix, MPA, BS, PT<br />

Education/Community<br />

Gail C. Davis, RN, EdD<br />

Laura D. Bilek, PhD, PT<br />

Atul Deodhar, MD<br />

Linda S. Ehrlich-Jones, PhD, RN<br />

Geri B. Neuberger, RN, EdD<br />

Sandra J. Watcher, RN, BSN<br />

Epidemiology<br />

Alyssa B. Dufour, MA<br />

Charles G. Helmick, MD<br />

Howard J. Hillstrom, MD<br />

Helen B. Hubert, MPH, PhD<br />

Robert R. McLean, DSc, MPH<br />

Emily C. Somers, PhD, ScM<br />

Health Services Research<br />

Mary E. Christenson, PT, PhD<br />

Lisa M. Kastanek, RN, CCRC<br />

Linda C. Li, BSc (PT) MSc PhD<br />

Elizabeth A. Schlenk, PhD, RN<br />

Benjamin J. Smith, PA-C<br />

Kori A. Dewing, MN, ARNP<br />

Pediatrics<br />

Kelly K. Anthony, PhD<br />

Christine W. Kennedy, MSN, RN, CPNP<br />

Karen L. Kerr, MSN, NP, CPNP, APRN-BC<br />

Norma L. Liburd, RNC, MN<br />

Jamie E. Neal, CPNP<br />

Bernadette McNally, PA<br />

Psychology/Social Sciences<br />

Carol M. Greco, PhD<br />

Afton L. Hassett, PsyD<br />

Vanessa L. Malcarne, PhD<br />

Perry Nicassio, PhD<br />

Karen L. Smarr, PhD<br />

Janet L. Poole, PhD, OTR<br />

Rehabilitation Sciences<br />

Jill R. Blitz, PT<br />

Jane S. Brandenstein, BS, PT<br />

Talitha Cox, MA, OTR/L<br />

Lori Cyr, BSc, OT<br />

Mary Wright, BSc, OT<br />

Nadine M. Fisher, EdD<br />

Research Methodology<br />

Nancy A. Baker, ScD OTR/L<br />

Marian T. Hannan, DSc, MPH<br />

Nadine T. James, RN, MSN, PhD<br />

Norma J. Macintyre, PT, PhD<br />

Yuqing Zhang, DSc<br />

Elizabeth Salt, PhD, ARNP<br />

Special Interest<br />

Kori A. Dewing, MN, ARNP<br />

Nadine M. Fisher, EdD<br />

Bernadette McNally, PA<br />

Sandra J. Watcher, RN, BSN<br />

Mary Wright, BSc, OT<br />

Janet L .Poole, PhD, OTR<br />

2010 Program Book 289


FLOOR PLANS<br />

290<br />

2010 Program Book


FLOOR PLANS<br />

2010 Program Book 291


EXHIBIT HALL<br />

NEED A PLACE TO RELAX OR MEET WITH COLLEAGUES?<br />

YOU ASKED FOR MORE OPPORTUNITIES TO RELAX AND NETWORK<br />

AND WE’VE DELIVERED!<br />

Exhibit Hall and Replay Café Hours<br />

Monday, November 8<br />

9:00 am – 5:00 pm<br />

Tuesday, November 9<br />

9:00 am – 7:00 pm<br />

Wednesday, November 10<br />

9:00 am –2:00 pm<br />

Innovation Theater Schedule<br />

Monday, November 8<br />

10:00 - 10:45 am<br />

12:15 - 1:00 pm<br />

2:00 - 2:45 pm<br />

Tuesday, November 9<br />

10:00 - 10:45 am<br />

12:15 - 1:00 pm<br />

2:00 - 2:45 pm<br />

Refreshments<br />

Monday, November 8<br />

Complimentary C<strong>of</strong>fee and Light Refreshments<br />

9:00 - 10:00 am<br />

Afternoon Snack Break<br />

2:00 - 3:00 pm<br />

Tuesday, November 9<br />

Complimentary C<strong>of</strong>fee and Light Refreshments<br />

9:00 - 10:00 am<br />

Afternoon Snack Break<br />

2:00 - 3:00 pm<br />

Wine and Cheese Reception<br />

5:15 - 6:45 pm<br />

Wednesday, November 10<br />

Complimentary C<strong>of</strong>fee and Light Refreshments<br />

9:00 - 10:00 am<br />

Wednesday, November 10<br />

10:00 - 10:45 am<br />

12:15 - 1:00 pm<br />

Innovation Theater (booth # 555)<br />

The Innovation Theater is an intimate environment for you to relax<br />

and enjoy time with your peers while gaining insight into the latest<br />

developments in the field <strong>of</strong> rheumatology. Participating exhibitors will<br />

provide 45-minute presentations to showcase their noteworthy products<br />

and/or services. There is no need to register; however, seating is limited<br />

and available on a first-come, first-served basis.<br />

Schedule<br />

Monday, November 8<br />

10:00 – 10:45 am (light refreshments provided by the ACR)<br />

A Treatment Option for the Management <strong>of</strong> Fibromyalgia<br />

Presented by Forest Pharmaceuticals<br />

12:15 – 1:00 pm (boxed lunch provided by the ACR)<br />

Choices and Challenges in Managing Psoriatic Arthritis<br />

Presented by Centocor Ortho Biotech Inc.<br />

2:00 – 2:45 pm (light refreshments provided by the ACR)<br />

New Way RA – Empowering Your Patients to Live Well with RA<br />

Presented by Centocor Ortho Biotech Inc.<br />

Tuesday, November 9<br />

10:00 – 10:45 am (light refreshments provided by the ACR)<br />

Bridging the Gap: A Peer-led Discussion on Effective Physician/Patient<br />

Dialogue<br />

Presented by Genentech and Biogen Idec<br />

12:15 – 1:00 pm (boxed lunch provided by the ACR)<br />

Pathophysiology <strong>of</strong> Pain: Mechanisms and Manifestations<br />

Presented by Lilly USA, LLC<br />

2:00 – 2:45 pm (light refreshments provided by the ACR)<br />

Clinical Perils in <strong>Rheumatology</strong>: Uncovering Pulmonary Arterial<br />

Hypertension in Your High-Risk Patient Populations—The Importance<br />

<strong>of</strong> Aggressive Screening and Early Diagnosis<br />

Presented by Actelion Pharmaceuticals US, Inc.<br />

Wednesday, November 10<br />

10:00 – 10:45 am (light refreshments provided by the ACR)<br />

An Alternative for Patients with Signs and Symptoms <strong>of</strong> Osteoarthritis<br />

<strong>of</strong> the Knee(s)<br />

Presented by Covidien<br />

12:15 – 1:00 pm (boxed lunch provided by the ACR)<br />

New Insights into the Role <strong>of</strong> the JAK Pathways in RA<br />

Presented by Pfizer Inc<br />

CME is not <strong>of</strong>fered for sessions in the Innovation Theater.<br />

292<br />

2010 Program Book


VISIT THE EXHIBIT HALL<br />

New and innovative changes will welcome every<br />

attendee as they enter the Exhibit Hall this year.<br />

Whether you are looking to learn about the<br />

latest scientific developments, catch a replay<br />

<strong>of</strong> a session you missed, take a shot at winning<br />

the grand prize with the Exhibit Hall Passport,<br />

or find a place to relax and catch up with<br />

colleagues – visiting the Exhibit Hall is a must for<br />

your annual meeting check list.<br />

EXHIBIT HALL HOURS<br />

Monday, November 8:<br />

9:00 am – 5:00 pm<br />

Tuesday, November 9:<br />

9:00 am – 7:00 pm<br />

Wednesday, November 10:<br />

9:00 am – 2:00 pm<br />

Wine and Cheese Reception – NEW!<br />

Don’t miss your chance to network with<br />

colleagues and exhibitors during the Wine and<br />

Cheese Reception – to be held in the Exhibit<br />

Hall prior to the Study Groups on Tuesday,<br />

November 9th from 5:15 to 6:45 p.m.<br />

Exhibit Hall Passport – NEW!<br />

With your registration materials, you will find<br />

the Exhibit Hall Passport. Visit participating<br />

exhibitors to collect a stamp as you learn<br />

about new and noteworthy <strong>of</strong>ferings for<br />

rheumatologists and health pr<strong>of</strong>essionals. The<br />

first 1,000 attendees to drop <strong>of</strong>f their completed<br />

Passport at the ACR Concierge Center will<br />

receive an ACR giveaway and one lucky winner<br />

will be selected to win a Kindle DX Wireless<br />

Reading Device.<br />

EXHIBITORS<br />

Abbott<br />

Pharmaceuticals<br />

Booth # 1121<br />

www.abbott.com<br />

ACP/Annals <strong>of</strong> Internal Medicine<br />

Nonpr<strong>of</strong>it Organization; Publisher<br />

Booth # 713<br />

www.acponline.org<br />

ACR Concierge Center<br />

Drop <strong>of</strong>f your Exhibit Hall Passport here!<br />

Booth # 1311<br />

www.rheumatology.org/education<br />

ACR Replay Café<br />

Catch replays <strong>of</strong> sessions you missed!<br />

Booth # 123<br />

www.rheumatology.org/education<br />

Actelion Pharmaceuticals<br />

Pharmaceuticals<br />

Booth # 1924, 2025<br />

www.actelion.com<br />

<strong>American</strong> Podiatric Medical Association<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 601<br />

www.apma.org<br />

<strong>American</strong> Regent, Inc.<br />

Pharmaceuticals<br />

Booth # 1901<br />

www.americanregent.com<br />

Amgen, Inc.<br />

Biotech<br />

Booth # 1240<br />

www.amgen.com<br />

Amgen, Inc. and Pfizer Inc<br />

Pharmaceuticals<br />

Booth # 1429<br />

www.amgen.com<br />

www.pfizer.com<br />

Arthritis Foundation<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 700<br />

www.arthritis.org<br />

Aspirus Clinics<br />

Recruitment<br />

Booth # 823<br />

www.aspirus.org<br />

Autoimmune Diseases Association<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 623<br />

www.aarda.org<br />

Auxilium Pharmaceuticals<br />

Pharmaceuticals<br />

Booth # 2001<br />

www.auxilium.com<br />

Besse Medical<br />

Pharmaceuticals<br />

Booth # 1048<br />

www.besse.com<br />

Binding Site, The<br />

Diagnostic Equipment/Products<br />

Booth # 1334<br />

www.thebindingsite.com<br />

BioMed Central<br />

Publisher<br />

Booth # 727<br />

www.biomedcentral.com<br />

Bozeman Deaconess Hospital<br />

Recruitment<br />

Booth # 729<br />

www.bozemandeaconess.org<br />

EXHIBITORS<br />

Bristol-Myers Squibb<br />

Pharmaceuticals<br />

Booth # 1159<br />

www.bms.com<br />

British Society for <strong>Rheumatology</strong><br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 706<br />

www.rheumatology.org.uk<br />

Cellestis Inc.<br />

Diagnostic Equipment/Products<br />

Booth # 1206<br />

www.cellestis.com<br />

Centocor Ortho Biotech Inc.<br />

Pharmaceuticals<br />

Booth # 1108<br />

www.centocor.com<br />

Chugai Pharmaceutical Co., LTD.<br />

Pharmaceuticals<br />

Booth # 958<br />

www.chugai-pharm.co.jp/english<br />

Cleveland Clinic<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 714<br />

www.clevelandclinic.org<br />

Clinical and Experimental <strong>Rheumatology</strong><br />

Publisher<br />

Booth # 825<br />

www.clinexprheumatol.org<br />

Clinical Immunology Society<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 709<br />

www.clinimmsoc.org<br />

CORRONA, Inc.<br />

Data Registry<br />

Booth # 1736<br />

www.corrona.org<br />

Covidien - Mallinckrodt<br />

Pharmaceuticals<br />

Booth # 1841<br />

www.mallinckrodt.com<br />

Crescendo Bioscience, Inc.<br />

Diagnostic Equipment/Products<br />

Booth # 1951<br />

www.crescendobio.com<br />

CuraScript SD<br />

Pharmacy Services<br />

Booth # 1741<br />

www.curascriptonline.com<br />

CVS Caremark/CarePLUS<br />

Pharmacy Services<br />

Booth # 1633<br />

www.caremark.com<br />

2010 Program Book 293


EXHIBITORS<br />

294<br />

Cypress Bioscience Inc.<br />

Personalized Medicine Services<br />

Booth # 1645<br />

www.cypressbio.com<br />

Daiichi Sankyo<br />

Pharmaceuticals<br />

Booth # 928<br />

www.dsi.com<br />

DePuy Mitek<br />

Surgical Instruments/Supplies<br />

Booth # 1152<br />

www.depuymitek.com<br />

Dermpath Diagnostics<br />

Laboratory Services<br />

Booth # 938<br />

www.dermpathdiagnositics.com<br />

Diagnostic Instruments, Inc.<br />

Diagnostic Equipment/Products<br />

Booth # 920<br />

www.msultrasound.net<br />

DJO<br />

Medical Device<br />

Booth # 1046<br />

www.djoglobal.com<br />

EMD Serono<br />

Pharmaceuticals<br />

Booth # 2155<br />

www.emdserono.com<br />

Esaote Biosound<br />

Diagnostic Equipment/Products<br />

Booth # 1140<br />

www.biosound.com<br />

European League Against Rheumatism<br />

(EULAR)<br />

Booth # 818<br />

Nonpr<strong>of</strong>it Organization<br />

www.eular.org<br />

Euro-Diagnostica Inc<br />

Diagnostic and Laboratory Equipment/<br />

Products<br />

Booth # 2002<br />

www.eurodiagnostica.us.com<br />

Euroimmun US<br />

Biotech; Diagnostic Equipment/Products<br />

Booth # 737<br />

www.euroimmunus.com<br />

Exhibitchek<br />

Market Research<br />

Booth # 1044<br />

2010 Program Book<br />

Fallene LTD<br />

Sunblock/Skincare<br />

Booth # 2135<br />

www.totalblock.com<br />

Ferring Pharmaceuticals Inc.<br />

Pharmaceuticals<br />

Booth # 2000<br />

www.euflexxa.com<br />

Forest Pharmaceuticals, Inc.<br />

Pharmaceuticals<br />

Booth # 1701<br />

www.forestpharm.com<br />

Gebauer Company<br />

Pharmaceuticals/Topical Anesthetics<br />

Booth # 731<br />

www.gebauer.com<br />

GE Healthcare<br />

Diagnostic Equipment/Products<br />

Booth # 753<br />

www.geultrasound.com<br />

Genentech (includes Roche, Roche<br />

Diagnostics and Biogen Idec)<br />

Biotech<br />

Booth # 1609<br />

www.gene.com<br />

Genentech<br />

Biotech<br />

Suite D<br />

www.gene.com<br />

Genentech and Biogen Idec<br />

Biotech<br />

Booth # 2109<br />

www.gene.com<br />

Genzyme<br />

Biotech<br />

Booth # 1501<br />

www.genzyme.com<br />

Gilead Sciences, Inc.<br />

Biotech<br />

Booth # 1001<br />

www.gilead.com<br />

Gout & Uric Acid Education Society (GUAES)<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 715<br />

www.gouteducation.org<br />

Hattiesburg Clinic<br />

Recruitment<br />

Booth # 1053<br />

www.hattiesburgclinic.com<br />

Health Media Network<br />

Digital Media<br />

Booth # 839<br />

www.hmnads.com<br />

Hisamitsu Pharmaceutical<br />

Pharmaceuticals<br />

Booth # 2124<br />

www.salonpas.us<br />

Hologic<br />

Diagnostic Equipment/Products<br />

Booth # 722<br />

www.hologic.com<br />

Horizon Pharma, Inc.<br />

Pharmaceuticals<br />

Booth # 900<br />

www.horizon-pharma.com<br />

Hospital for Special Surgery<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 836<br />

www.hss.edu<br />

HRA Research<br />

Market Research<br />

Booth # 1635<br />

www.hraresearch.com<br />

Human Genome Sciences, Inc.<br />

Biotech<br />

Booth # 1749<br />

www.hgsi.com<br />

Innovation Theater<br />

Attend 45-minute exhibitor presentations<br />

Booth # 555<br />

www.rheumatology.org/education<br />

Inova Diagnostics, Inc.<br />

Biotech; Diagnostic Equipment/Products<br />

Booth # 2023<br />

www.inovadx.com<br />

International League <strong>of</strong> Associations for<br />

<strong>Rheumatology</strong> (ILAR)<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 1105<br />

www.ilar.org<br />

JAMA & Archives Journals<br />

Publisher<br />

Booth # 603<br />

pubs.ama-assn.org<br />

Johns Hopkins Arthritis Center<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 1035<br />

www.hopkins-arthritis.org<br />

Journal <strong>of</strong> Musculoskeletal Medicine, The<br />

Publisher<br />

Booth # 940<br />

www.musculoskeletalnetwork.com<br />

Journal <strong>of</strong> <strong>Rheumatology</strong>, The<br />

Publisher<br />

Booth # 808<br />

www.jrheum.org


EXHIBITORS<br />

La Lettre Du Rhumatologue - Edimark Santé<br />

Publisher<br />

Booth # 923<br />

www.edimark.fr<br />

LabCorp<br />

Laboratory Testing Services<br />

Booth # 1237<br />

www.labcorp.com<br />

Laclede Inc.<br />

Therapeutic/Patient Aid Products<br />

Booth # 2043<br />

www.laclede.com<br />

Lexicon Pharmaceuticals<br />

Pharmaceuticals<br />

www.lexpharma.com<br />

Lilly USA, LLC.<br />

Pharmaceuticals<br />

Booth # 1409, 1419<br />

www.lilly.com<br />

Lippincott, Williams and Wilkins<br />

Publisher<br />

Booth # 1637<br />

www.kluwer.com<br />

www.lww.com<br />

Lupus Clinical Trials Consortium, Inc<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 619<br />

www.dxlupus.org<br />

Lupus Initiative, The<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 1842<br />

www.thelupusinitiative.org<br />

McKesson Specialty Care Solutions<br />

Distributor<br />

Booth # 849<br />

www.mckesson.com<br />

MediUSA<br />

Therapeutic/Patient Aid Products<br />

Booth # 1840<br />

www.mediusa.com<br />

Merck<br />

Pharmaceuticals<br />

Booth # 1631, Suite E<br />

www.merck.com<br />

Merit Foundation<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 617<br />

www.meteorfoundation.com<br />

Metro Medical Supply<br />

Pharmacy Services/Supplies<br />

Booth # 2122<br />

www.metromedical.com<br />

Metroplex Clinical Research Center<br />

Phase I - IV Clinical Research Site<br />

Booth # 1235<br />

www.mcrcdallas.com<br />

Millipore<br />

Biotech, Laboratory Equipment/Products<br />

Booth # 1102<br />

www.millipore.com<br />

Myositis Association, The<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 816<br />

www.myositis.org<br />

National Data Bank for Rheumatic Diseases<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 717<br />

www.arthritis-research.org<br />

National Fibromyalgia Association<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 627<br />

www.fmaware.org<br />

National Fibromyalgia Partnership, Inc.<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 607<br />

www.nfpartnership.org<br />

National Institute <strong>of</strong> Arthritis and<br />

Musculoskeletal and Skin Diseases<br />

Government<br />

Booth # 716<br />

www.niams.nih.gov<br />

New Balance Athletic Shoe, Inc.<br />

Footwear<br />

Booth # 826<br />

www.newbalance.com<br />

NIH Patient-Reported Outcomes<br />

Measurement System (PROMIS)<br />

Non-Pr<strong>of</strong>it Organization/Governmental<br />

Agency<br />

Booth # 625<br />

www.nihpromis.org<br />

Novartis Pharmaceuticals Corporation<br />

Pharmaceuticals<br />

Booth # 1135, 1725<br />

www.novartis.com<br />

Nutramax Laboratories, Inc.<br />

Nutritional Products<br />

Booth # 1934<br />

www.nutramaxlabs.com<br />

NYU Hospital for Joint Diseases<br />

Academic Center<br />

Booth # 710<br />

www.hed.nyu.edu<br />

Oklahoma Medical Research Foundation<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 611<br />

www.lupus.omrf.org<br />

Optasia Medical, Inc.<br />

Diagnostic Equipment/Products<br />

Booth # 735<br />

www.optasiamedical.com<br />

Organization <strong>of</strong> Teratology Information<br />

Specialists<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 810<br />

www.otispregnancy.org<br />

Ossur Americas<br />

Braces/Supports<br />

Booth # 1336<br />

www.ossur.com<br />

Oxford Immunotec Inc<br />

Diagnostic Products<br />

Booth # 2041<br />

www.oxfordimmunotec.com<br />

Oxford University Press<br />

Publisher<br />

Booth # 922<br />

www.oxfordjournals.org<br />

Pacific Biomarkers, Inc.<br />

Contract Research<br />

Booth # 2148<br />

www.pacbio.com<br />

Pan <strong>American</strong> League <strong>of</strong> Associations for<br />

<strong>Rheumatology</strong> (PANLAR)<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 605<br />

www.panlar.org<br />

PAREXEL International<br />

Contract Research<br />

Booth # 802<br />

www.parexel.com<br />

PBL InterferonSource<br />

Contract Research<br />

Booth # 1903<br />

www.interferonsource.com<br />

Pediatric <strong>Rheumatology</strong> Journal<br />

Publisher<br />

Booth # 1052<br />

www.ped-rheum.com<br />

Perceptive Informatics<br />

Technology/Clinical Trials Solutions<br />

Booth # 821<br />

www.perceptive.com<br />

Pfizer Inc<br />

Pharmaceuticals<br />

Booth # 1250, 1445, 1651<br />

www.pfizer.com<br />

2010 Program Book 295


EXHIBITORS<br />

Phreesia<br />

Office S<strong>of</strong>tware/Equipment<br />

Booth # 1730<br />

www.phreesia.com<br />

Pikeville Medical Center<br />

Recruitment<br />

Booth # 955<br />

www.pikevillehospital.org<br />

Quidel Corporation<br />

Diagnostic Equipment/Products<br />

Booth # 1702<br />

www.quidel.com<br />

REF Philanthropy Showcase<br />

Attend REF Birthday Cake Celebration<br />

(Monday; 2:45 – 3:30 PM)<br />

Booth # 1331<br />

www.rheumatology.org/ref<br />

ReSearch Pharmaceutical Services<br />

Contract Research<br />

Booth # 2126<br />

www.rpsweb.com<br />

R. J. Fasenmyer Center for Clinical<br />

Immunology<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 712<br />

www.clevelandclinic.org/FasenmyerCenter<br />

RDL Reference Laboratory<br />

Diagnostic Testing<br />

Booth # 1625<br />

www.rdlinc.com<br />

Regeneron Pharmaceuticals, Inc.<br />

Pharmaceuticals<br />

Booth # 941<br />

www.regeneron.com<br />

<strong>Rheumatology</strong> News<br />

Publisher<br />

Booth # 1100<br />

www.rheumatologynews.com<br />

<strong>Rheumatology</strong> Nurses Society<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 613<br />

www.rns-network.org<br />

<strong>Rheumatology</strong> Practice News<br />

Publisher<br />

Booth # 2115<br />

www.rheumatologypracticenews.com<br />

Rheuminations, Inc.<br />

Nonopr<strong>of</strong>it Organization<br />

Booth # 832<br />

www.dxlupus.org<br />

Rottapharm Ltd<br />

Pharmaceuticals<br />

Booth # 1134<br />

www.rotta.com<br />

San<strong>of</strong>i-Aventis<br />

Pharmaceuticals<br />

Booth # 1101<br />

www.san<strong>of</strong>i-aventis.us<br />

Saunders/Mosby-Elsevier<br />

Publisher<br />

Booth # 1601<br />

www.elsevierhealth.com<br />

Savient Pharmaceuticals<br />

Biotech/Pharmaceuticals<br />

Booth # 531, Suite C<br />

www.savientpharma.com<br />

Scandinavian Journal <strong>of</strong> <strong>Rheumatology</strong><br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 711<br />

www.scandjrheumatol.dk<br />

Scleroderma Foundation<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 719<br />

www.scleroderma.org<br />

Siemens Medical Solutions USA Inc.<br />

Diagnostic Equipment/Products<br />

Booth # 924<br />

www.usa.siemens.com/healthcare<br />

Silver Ring Splint Company<br />

Ring Splints<br />

Booth # 1734<br />

www.sliverringsplint.com<br />

Sjögren’s Syndrome Foundation<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 718<br />

www.sjogrens.org<br />

Smith & Nephew<br />

Pharmaceuticals/Medical Device<br />

Booth # 1735<br />

www.smithnephew.com<br />

SonoSite<br />

Diagnostic Equipment/Products<br />

Booth # 2047<br />

www.sonosite.com<br />

Spondylitis Association <strong>of</strong> America<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 812<br />

www.spondylitis.org<br />

Springer<br />

Publisher<br />

Booth # 1055<br />

www.springer.com<br />

Surgin<br />

Surgical Instruments/Supplies<br />

Booth # 2113<br />

www.dualinjector.com<br />

Takeda Pharmaceuticals<br />

Pharmaceuticals<br />

Booth # 541<br />

www.tpna.com<br />

Terason<br />

Diagnostic Equipment/Products<br />

Booth # 1202<br />

www.terason.com<br />

TheraTest Laboratories, Inc.<br />

Diagnostic Equipment/Products<br />

Booth # 1835<br />

www.theratest.com<br />

Touch <strong>of</strong> Life Technologies<br />

Virtual Reality<br />

Booth # 1054<br />

www.toltech.net<br />

U.S. Food and Drug Administration<br />

Government Agency<br />

Booth # 615<br />

www.fda.gov<br />

UCB, Inc.<br />

Biotech<br />

Booth # 910<br />

www.ucb.com<br />

UpToDate<br />

Office S<strong>of</strong>tware/Equipment<br />

Booth # 1732<br />

www.uptodate.com<br />

URL Pharma<br />

Pharmaceuticals<br />

Booth # 1945<br />

www.urlpharma.com<br />

Vasculitis Foundation<br />

Nonpr<strong>of</strong>it Organization<br />

Booth # 814<br />

www.vasculitisfoundation.org<br />

Virtual Scopics<br />

Contract Research/Imaging Core Lab<br />

Booth # 1051<br />

www.virtualscopics.com<br />

VQ OrthoCare<br />

Therapeutic/Patient Aid Products<br />

Booth # 2123<br />

www.vqorthocare.com<br />

Wiley Blackwell<br />

Publisher<br />

Booth # 1700<br />

www.wiley.com<br />

296<br />

2010 Program Book


ACKNOWLEDGEMENTS<br />

The ACR, the ARHP and the REF wish to thank the following organizations<br />

for providing support for the 2010 ACR/ARHP Annual Scientific Meeting.<br />

Their support has been used to help <strong>of</strong>fset the cost <strong>of</strong> the meeting for<br />

attendees.<br />

Amgen, Inc. and Pfizer Inc<br />

Scientific Program Book<br />

Session Tracker<br />

Bristol-Myers Squibb Company<br />

Exhibit Hall Hanging Aisle Signs<br />

Centocor Ortho Biotech Inc.<br />

Convention Internet Center<br />

Exhibit Hall Internet Centers<br />

Genentech, A Member <strong>of</strong> the Roche Group<br />

Online Itinerary Builder with Abstracts and Scientific Syllabi<br />

Clinical Scenario Challenge<br />

Exhibit Hall Replay Café<br />

Exhibit Hall Recharge Kiosks<br />

2010 Program Book 297


ACKNOWLEDGEMENTS<br />

298<br />

In addition to the support provided for the 2010 ACR/ARHP Annual<br />

Scientific Meeting, the ACR, the ARHP and the REF wish to thank the<br />

following organizations for providing support for activities and programs<br />

held throughout the year.<br />

Abbott<br />

Industry Roundtable Member<br />

Fellows Education Fund<br />

<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />

<strong>Rheumatology</strong> Training Directors’ Conference<br />

State-<strong>of</strong>-the-Art Clinical Symposium<br />

Musculoskeletal Ultrasound Course for Rheumatologists<br />

Advanced Practice Skills Training Course<br />

CARE 2010<br />

ACR REF/Abbott Medical and Graduate Student Achievement Award<br />

ACR REF/Abbott Medical and Pediatric Resident Research Award<br />

ACR REF/Abbott Health Pr<strong>of</strong>essional Graduate Student Research<br />

Preceptorship<br />

ACR REF/Abbott Medical Student Clinical Preceptorship<br />

ACR REF/Abbott Medical Student Research Preceptorship<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Actelion Pharmaceuticals US, Inc.<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Amgen, Inc.<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

ACR REF <strong>Rheumatology</strong> Scientist Development Award<br />

ACR REF/Amgen Pediatric <strong>Rheumatology</strong> Visiting Pr<strong>of</strong>essorship Program<br />

ACR REF/Amgen Pediatric <strong>Rheumatology</strong> Research Award<br />

Amgen, Inc. and Pfizer Inc<br />

Fellows Education Fund<br />

ACR REF Amgen/Pfizer <strong>Rheumatology</strong> Fellowship Training Award<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

ARHP Morning Networking Forum<br />

Bioiberica<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Bristol-Myers Squibb Company<br />

Fellows Education Fund<br />

Winter <strong>Rheumatology</strong> Symposium<br />

<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />

<strong>Rheumatology</strong> Training Directors’ Conference<br />

State-<strong>of</strong>-the-Art Clinical Symposium<br />

Musculoskeletal Ultrasound Course for Rheumatologists<br />

Advanced Practice Skills Training Course<br />

CARE 2010<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Centocor Ortho Biotech Inc.<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

Annual Scientific Meeting Fellows-In-Training Travel Scholarship<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Covidien-Mallinckrodt, Inc.<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Eli Lilly and Company<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

Annual Scientific Meeting Fellows-In-Training Travel Scholarship<br />

State-<strong>of</strong>-the-Art Clinical Symposium<br />

2010 Program Book<br />

Genentech, A Member <strong>of</strong> the Roche Group<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

Fellows Education Fund<br />

2010 ACR/ARHP Membership Directory<br />

2010 Annual Scientific Meeting Registration Brochure<br />

Winter <strong>Rheumatology</strong> Symposium<br />

<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />

<strong>Rheumatology</strong> Training Directors’ Conference<br />

State-<strong>of</strong>-the-Art Clinical Symposium<br />

Musculoskeletal Ultrasound Course for Rheumatologists<br />

Advanced Practice Skills Training Course<br />

CARE 2010<br />

ACR REF <strong>Rheumatology</strong> Scientist Development Award<br />

ARHP Networking at Noon<br />

Genentech, A Member <strong>of</strong> the Roche Group and Biogen Idec Inc.<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Human Genome Sciences, Inc.<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

Pfizer Inc<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

UCB, Inc.<br />

Industry Roundtable Member<br />

Annual Scientific Meeting Industry Roundtable Symposium<br />

Annual Scientific Meeting Industry-Supported Post-Conference<br />

Symposium<br />

Annual Scientific Meeting Fellows-in-Training Travel Scholarship<br />

<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />

<strong>Rheumatology</strong> Training Directors’ Conference<br />

State-<strong>of</strong>-the-Art Clinical Symposium<br />

Musculoskeletal Ultrasound Course for Rheumatologists<br />

Advanced Practice Skills Training Course<br />

CARE 2010<br />

It is with gratitude that the ACR Research and Education<br />

Foundation acknowledges those who have demonstrated<br />

exemplary support <strong>of</strong> the Within Our Reach: Finding a<br />

Cure for Rheumatoid Arthritis campaign.<br />

Pinnacle ($5 million +)<br />

Principal ($2.5 million +)<br />

Genentech<br />

Partner Donor ($1 million +)<br />

Arthritis Foundation<br />

Scott Schweighauser and Liz Ellrodt


ACR/ARHP/REF STAFF LISTING<br />

Administration<br />

Executive Vice President<br />

Mark Andrejeski<br />

Director, Administration & Governance<br />

Julie Anderson<br />

Executive Assistant<br />

Naama Davidai<br />

Operations & Finance<br />

Vice President, Operations & Finance<br />

Colleen Merkel<br />

Controller<br />

Susan Parrish<br />

Director, Human Resources<br />

Deborah Higginbotham<br />

Treasury Accountant<br />

Erin Conner<br />

Accounting Manager, A/R<br />

Chasity Steverson<br />

Accounting Coordinator, A/P<br />

Tawanda Hawk<br />

Accounting Assistant, A/R<br />

Donna Hunt<br />

Receptionist<br />

Tammy Davis<br />

Technology & Information Systems<br />

Vice President, Technology & Information<br />

Systems<br />

Steve Blevins<br />

Web Programmer<br />

Janet Chisholm<br />

Systems & Database Administrator<br />

Norman Kwong<br />

Network Administrator<br />

Mike Crozier<br />

Information Systems Specialist<br />

Mickey Nguyen<br />

Education<br />

Vice President, Education<br />

Donna Hoyne<br />

Senior Director, Annual Scientific Meeting<br />

Nicole Cranston<br />

Senior Director, Meetings & Conferences<br />

Ron Olejko<br />

Director, Continuing Medical Education<br />

Valerie Okrend<br />

Specialist, Educational Products &<br />

Communications<br />

Kimberly Haughton<br />

Meeting Planner<br />

Lucy Beckett<br />

Specialist, Pr<strong>of</strong>essional Meetings & Meeting<br />

Planner<br />

Susan Brewster<br />

Specialist, Annual Scientific Meeting<br />

Karol Gaddis-Flowers<br />

Specialist, Abstracts & Annual Meeting<br />

TBD<br />

Specialist, Pr<strong>of</strong>essional Development<br />

Katie Duggan<br />

Administrative Support<br />

TBD<br />

Corporate Relations<br />

Director, Corporate Relations<br />

Amy Beith Miller<br />

Director, Expositions<br />

Stacey Chandler<br />

Coordinator, Expositions & Corporate Relations<br />

TBD<br />

Socioeconomic Affairs<br />

Vice President, Socioeconomic Affairs<br />

Tiffany Schmidt, JD, MBA<br />

Director, Government Affairs<br />

Aiken Hackett<br />

Director, Practice Management<br />

Antanya Chung<br />

Senior Specialist, Government Affairs<br />

Katie Jones<br />

Reimbursement Specialist<br />

Melesia Tillman<br />

Specialist, Practice Management<br />

Laura Snapp<br />

Administrative Assistant<br />

Sarah Zirkle<br />

Communications, Marketing<br />

& Membership<br />

Senior Director, Communications Marketing<br />

& Membership<br />

Tammy Tilley<br />

Director, Membership<br />

Helen Anne Richards<br />

Director, Public Relations<br />

Erin Latimer<br />

Director, Communication & Marketing<br />

Michelle Hatch<br />

Senior Specialist, Communication & Marketing<br />

Alexa Newlin<br />

Senior Specialist, Public Relations<br />

Suzanne Forte<br />

Webmaster<br />

LaDonna Johnson-Shabazz<br />

Senior Graphic Designer<br />

Todd Machen<br />

Membership Services Coordinator<br />

Janell Martin<br />

Registry, Quality & Healthcare<br />

Informatics<br />

Vice President, Registry, Quality & Healthcare<br />

Informatics<br />

Kristen McNiff<br />

Senior Specialist, Registry, Quality & Healthcare<br />

Informatics<br />

Itara Barnes<br />

Senior Director, Quality<br />

Amy Miller<br />

Director, Guidelines<br />

TBD<br />

Specialist, Quality<br />

Regina Parker<br />

Research and Training<br />

Senior Director, Research & Training<br />

Mary Wheatley<br />

Director, Research & Training<br />

LaTanya Batts<br />

Administrative Assistant, Research and Training<br />

Devane Casteel<br />

ARHP<br />

Executive Director<br />

David Haag<br />

Managing Editor, AC&R<br />

Nancy Parker<br />

Senior Specialist, Educational Programs<br />

Joan “Happy” Tyree<br />

Program Services Specialist<br />

Ramona Hilliard<br />

Manuscript Editor, AC&R<br />

TBD<br />

Manuscript Editor, AC&R<br />

Rachel Whittaker<br />

Manuscript Editor, AC&R<br />

Maggie Perry<br />

Administrative Assistant<br />

Sharon Ross<br />

REF<br />

Executive Director<br />

Steve Echard<br />

Senior Director, Development<br />

Paula Reed<br />

Director, Development<br />

Samantha Rasnake<br />

Senior Specialist, Annual Giving<br />

Melissa Francisco<br />

Senior Specialist, Awards & Grants<br />

Damian Smalls<br />

Coordinator, Development<br />

Lauren Landreth<br />

Coordinator, Awards and Grants<br />

Amy Fore<br />

Arthritis & Rheumatism Journal<br />

Managing Editor<br />

Jane Diamond<br />

Assistant Managing Editor<br />

Patricia Reichert<br />

2010 Program Book 299


ACR/ARHP/REF STAFF LISTING<br />

Senior Manuscript Editor<br />

Lesley Allen<br />

Manuscript Editor<br />

Michael Weinberg<br />

Manuscript Editor<br />

Pat Mabley<br />

Manuscript Editor<br />

Emily Wehby<br />

Manuscript Editor<br />

Kathryn Jonell<br />

Editorial Coordinator<br />

Lee Sanford<br />

Lupus Grant<br />

Director, EDLET/HP Lupus Initiative<br />

Lisa Amaker<br />

Consortium Liaison, EDLET/HP Lupus Initiative<br />

Sheryl McCalla<br />

Administrative Assistant, EDLET/HP Lupus Initiative<br />

Cirena Rolling<br />

300<br />

2010 Program Book


A<br />

Ahmed, Rafi, PhD<br />

T cell Memory . . . . . . . . . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

Allison, Jeroan, MD, MS<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Ambati, Jayakrishna, MD<br />

Molecular Mechanisms <strong>of</strong> Ocular<br />

Inflammation . . . . . . . . . . . . . . . . .121<br />

Disclosure: Allergan, 5<br />

Anderson, Lee A, BSN<br />

Nursing . . . . . . . . . . . . . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

Andrejeski, Mark<br />

ILAR Global Health Project . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Andriacchi, Thomas, PhD<br />

Walk this Way: Biomechanics and<br />

Osteoarthritis . . . . . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Anolik, Jennifer H, MD, PhD<br />

Session V: Role <strong>of</strong> B cells in Autoimmunity:<br />

Lessons from Clinical Trials . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

The Revolution <strong>of</strong> Epigenetics in<br />

Autoimmunity . . . . . . . . . . . . . . . . . 47<br />

Disclosure: Nothing to Disclose<br />

Toll-like Receptors Activation <strong>of</strong> B cells in<br />

Autoimmune Disease . . . . . . . . . . . . . 28<br />

Disclosure: Nothing to Disclose<br />

Backman, Catherine L, PhD, OT(C)<br />

Evidence-based Non-pharmacological Treatment<br />

for Hip, Knee, and Hand Osteoarthritis: The New<br />

ACR Guidelines . . . . . . . . . . . . . . . . 34<br />

Disclosure: Nothing to Disclose<br />

Work Assessments: A ‘How-To’ That Could Save<br />

Your Patient’s Life/Job. . . . . . . . . . . . .131<br />

Disclosure: Nothing to Disclose<br />

Baer, Alan N, MD<br />

Year in Review . . . . . . . . . . . . . . . . . 27<br />

Disclosure: Nothing to Disclose<br />

Baker, Nancy A, ScD OTR/L<br />

Adaptations and Solutions to Help People with<br />

Scleroderma Continue to Work . . . . . . .102<br />

Disclosure: Nothing to Disclose<br />

How to Understand and Apply the Results <strong>of</strong> a<br />

Journal Article: What You Really Need to Know<br />

About Statistics . . . . . . . . . . . . . . . .134<br />

Disclosure: Nothing to Disclose<br />

Understanding Functional Activity in<br />

Rheumatoid Arthritis: What We Know and<br />

What We Don’t Know . . . . . . . . . . . . . 86<br />

Disclosure: Nothing to Disclose<br />

Work Assessments: A ‘How-To’ That Could Save<br />

Your Patient’s Life/Job. . . . . . . . . . . . .131<br />

Disclosure: Nothing to Disclose<br />

Ballestar, Esteban, PhD<br />

The Revolution <strong>of</strong> Epigenetics in<br />

Autoimmunity . . . . . . . . . . . . . . . . . 47<br />

Disclosure: Nothing to Disclose<br />

Bancr<strong>of</strong>t Rizzo, Debra, MSN, FNP-C<br />

Money Talks: How to Incentivize Staff . . . . 46<br />

Disclosure: Nothing to Disclose<br />

Bergman, Martin J, MD<br />

Rheumatoid Arthritis: Outcome Measures in<br />

Clinical Practice . . . . . . . . . . . . . . . . 52<br />

Disclosure:, 5; Abbott, 2, 5, 8; BMS, 2; Takeda,<br />

8; UCB, 8<br />

Berney, Seth M, MD<br />

Career Opportunities in <strong>Rheumatology</strong>: Making<br />

a Choice . . . . . . . . . . . . . . . . . . . .113<br />

Disclosure: Nothing to Disclose<br />

Contract Negotiations for Physicians . . . . 65<br />

Disclosure: Nothing to Disclose<br />

Beukelman, Timothy, MD, MSCE<br />

2010 ACR Recommendations for the Treatment<br />

<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />

Disclosure: Nothing to Disclose<br />

Bilek, Laura D, PhD, PT<br />

Evidence-based Practice: Creating and Using<br />

<strong>Rheumatology</strong> Critically Appraised Topics<br />

(RheumCATS) . . . . . . . . . . . . . . . . .102<br />

Disclosure: Nothing to Disclose<br />

Ready, Aim, Get Funded! . . . . . . . . . . 131<br />

Disclosure: Nothing to Disclose<br />

Bingham, Clifton O, MD<br />

Immunizations and Rheumatic Diseases - An<br />

Update . . . . . . . . . . . . . . . . . . . . 37<br />

Disclosure: Abbott, 9; ACR-REF, 2; BMS, 2;<br />

Genentech, 2, 5; Roche, 2, 5; UCB, 5;<br />

UpToDate, 7<br />

ACR REF Within Our Reach: Finding a Cure for<br />

Rheumatoid Arthritis . . . . . . . . . . . . . 45<br />

Disclosure: Abbott, 9; ACR-REF, 2; BMS, 2;<br />

Genentech, 2, 5; Roche, 2, 5; UCB, 5;<br />

UpToDate, 7<br />

Bisoendial, Radjesh, MD, PhD<br />

A Critical Role for Lipid Metabolism in the<br />

Interplay between Atherosclerosis and<br />

Autoimmune Disorders . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

INVITED SPEAKER /MODERATOR INDEX<br />

Arnett, Frank C, MD<br />

REF Paul Klemperer, MD, Memorial Lectureship:<br />

Systemic Sclerosis: Genetic? Autoimmune? One<br />

Disease? . . . . . . . . . . . . . . . . . . . . 98<br />

Disclosure: Nothing to Disclose<br />

Baraf, Herbert, MD<br />

The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />

Disclosure: Nothing to Disclose<br />

Contract Negotiations for Physicians . . . . 65<br />

Disclosure: Nothing to Disclose<br />

Atkinson, John P, MD<br />

Year in Review . . . . . . . . . . . . . . . . . 27<br />

Disclosure: Compliment, INC, ; Genentech, Inc, 5;<br />

Idera Pharmaceuticals, 5; Kereos, INC, 5; Taligen<br />

Therapeutics (SAB), 1; Tanox INC, 5<br />

Atkinson, Karen, MD<br />

Clinicopathologic Conference . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Austin, Janet S, PhD<br />

Living with Osteoporosis . . . . . . . . . . . 61<br />

Disclosure: Nothing to Disclose<br />

B<br />

Backhaus, Marina, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound . . . . . . . . .110<br />

Disclosure: Abbott, 2<br />

Barham, Beverly K, RN, MSN, CCRC<br />

The Multidisciplinary Approach to Hereditary<br />

Periodic Fever Syndromes . . . . . . . . . . 58<br />

Disclosure: Nothing to Disclose<br />

What’s New and Noteworthy in 2010: A<br />

Review <strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />

Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

Bartholomew, John R, MD<br />

Heparin and Antiphospholipid Syndromeinduced<br />

Thrombocytopenia . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

Bateman, Helen E, MD<br />

Teaching and Assessing Arthrocentesis . . 112<br />

Disclosure: Nothing to Disclose<br />

Joint Simulator. . . . . . . . . . . . . . . 67, 97<br />

Disclosure: Nothing to Disclose<br />

Becker, Mara L, MD<br />

Using Pharmacogenomics to Improve Therapy<br />

for Pediatric Patients . . . . . . . . . . . . . 96<br />

Disclosure: Nothing to Disclose<br />

Belza, Basia, PhD, RN<br />

Building Effective Teams: Recommended<br />

Leadership Strategies . . . . . . . . . . . . 100<br />

Disclosure: Nothing to Disclose<br />

Blevins, Stephen, MBA<br />

Creating Presentations Using PowerPoint:<br />

Advanced . . . . . . . . . . . . . . . . . . . 61<br />

Disclosure: Nothing to Disclose<br />

Creating Presentations Using PowerPoint:<br />

Basic . . . . . . . . . . . . . . . . . . . . . . 29<br />

Disclosure: Nothing to Disclose<br />

Block, Joel A, MD<br />

Year in Review . . . . . . . . . . . . . . . . . 27<br />

Disclosure: KAI Inc./NIH, 9; Merck-Serono, 5;<br />

NiCOx, 5; OA and Cartilage, 9;Pleiad, 5<br />

ACR Plenary Session II: Discovery 2010 . . . 63<br />

Disclosure: KAI / NIH, 9; Merck-Serono, 5; NiCOx,<br />

5; OA and Cartilage, 9; Pleiad, 5<br />

Bode, Christina, PhD<br />

Successful Coping with Rheumatic Disease . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .135<br />

Disclosure: Nothing to Disclose<br />

Boden, Scott D, MD<br />

REF Marshall J. Schiff, MD, Memorial<br />

Lectureship: Everything a Rheumatologist<br />

Should Know About Spine Surgery but Was<br />

Afraid to Ask . . . . . . . . . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book 301


INVITED SPEAKER /MODERATOR INDEX<br />

302<br />

Boehncke, Wolf-Henning, MD<br />

Psoriatic Disease: Clinical Spectrum and<br />

Comprehensive Treatment Strategies . . . . 69<br />

Disclosure: Abbott, Biogen Idec, Essex, Janssen<br />

Cilag, Wyeth, 8; Abbott, Biogen Idec, Essex,<br />

Wyeth, 2<br />

Boers, Maarten, MD, PhD, MSc<br />

Remission in Rheumatoid Arthritis. . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Bong, David A, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Bongartz, Tim, MD<br />

Perioperative Management <strong>of</strong> Selected<br />

Problems in Patients with Rheumatic<br />

Disease . . . . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Nothing to Disclose<br />

Borenstein, David G, MD<br />

Pain: Evaluation and Treatment <strong>of</strong> Back<br />

Pain . . . . . . . . . . . . . . . . . . . . . . .130<br />

Disclosure: Nothing to Disclose<br />

ACR Leadership Town Hall Meeting . . . . .106<br />

Disclosure: Nothing to Disclose<br />

Boulware, Dennis W, MD<br />

ACR REF Memorial Lectureship: <strong>Rheumatology</strong><br />

Education 2010 . . . . . . . . . . . . . . . . 37<br />

Disclosure: Nothing to Disclose<br />

Boyle, Dennis J, MD<br />

Pain: Difficult Patient Interactions . . . . . . 29<br />

Disclosure: Nothing to Disclose<br />

Brady, Teresa J, PhD<br />

Physical Activity: The Arthritis Pain Reliever –<br />

The Revised Centers for Disease Control and<br />

Prevention Health Communications<br />

Campaign . . . . . . . . . . . . . . . . . . . 35<br />

Disclosure: Nothing to Disclose<br />

Top 10 in ‘10: Top 10 Public Health Advances<br />

in the First 10 Years <strong>of</strong> the Centers for Disease<br />

Control and Prevention Arthritis Program. .147<br />

Disclosure: Nothing to Disclose<br />

Branch, Jr, William T, MD<br />

ACR REF Clinician Scholar Educator Lecture. 53<br />

Disclosure: Nothing to Disclose<br />

Braun, Juergen, MD<br />

Spondyloarthropathy: An Update . . . . . . 83<br />

Disclosure: Abbott, 2, 5; Centocor, 2; MSD, 5;<br />

Pfizer, 5; San<strong>of</strong>i, 2<br />

Brescia, AnneMarie C, MD<br />

Pediatrics: Juvenile Idiopathic Arthritis for Adult<br />

Rheumatologists. . . . . . . . . . . . . . . . 36<br />

Disclosure: Nothing to Disclose<br />

Bruce, Susan P, PharmD<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Nothing to Disclose<br />

Bryant, Gloryanne, BS, RHIA, RHIT, CCS<br />

ICD -10 Preparation - Developing a Blueprint for<br />

Implementation . . . . . . . . . . . . . . . 133<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book<br />

Bunyard, Matthew P, MD<br />

CORC Forum: Health Care Reform – Where Are<br />

We Heading?. . . . . . . . . . . . . . . . . .101<br />

Disclosure: Nothing to Disclose<br />

Burke, Allen, MD<br />

Histopathology <strong>of</strong> Vasculitis . . . . . . . . .113<br />

Disclosure: Nothing to Disclose<br />

Burr, David B, PhD<br />

Bisphosphonates: Mechanism <strong>of</strong> Action and<br />

Optimizing Clinical Use . . . . . . . . . . . 135<br />

Disclosure: Amgen, 5; CRC Press, 7; Eli Lilly and<br />

Co., 2; Eli Lilly and Co., 5; Eli Lilly and Col, 5;<br />

Procter and Gamble, 5; Springer, 7; The Alliance<br />

for Better Bone Health, 2<br />

Byers, Peter H, MD<br />

Hypermobility . . . . . . . . . . . . . . . . 108<br />

Disclosure: Nothing to Disclose<br />

Genetic Disorders <strong>of</strong> Connective Tissue and<br />

Joint Hypermobility . . . . . . . . . . . . . . 37<br />

Disclosure: Nothing to Disclose<br />

C<br />

Calabrese, Leonard H, DO<br />

Rheumatic Disease Update: Viral Arthritis . 61<br />

Disclosure: Nothing to Disclose<br />

Callahan, Leigh F, PhD<br />

ARHP General Session II: ARHP Distinguished<br />

Lecturer . . . . . . . . . . . . . . . . . . . . 62<br />

Disclosure: Nothing to Disclose<br />

Cancro, Michael P, PhD<br />

Session IV: Emerging Concepts in B cell Directed<br />

Therapies. . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Human Genome Sciences, 2<br />

Caricchio, Roberto, MD<br />

Autophagy and Immune Function . . . . . . 59<br />

Disclosure: Nothing to Disclose<br />

Carkin, Julie L, MD<br />

CC - Osteoporosis Treatment Update . . . . 54<br />

Disclosure: Eli Lilly, 8; Novartis, 8; Warner-<br />

Chilcott, 8<br />

Carlone, Joyce P, MN, RN, FNP-BC<br />

When Pieces Don’t Fit . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

ARHP Networking for Georgia Health<br />

Pr<strong>of</strong>essionals and Physicians . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

Carsons, Steven E, MD<br />

Rheumatic Disease Update: Sjögren’s<br />

Syndrome . . . . . . . . . . . . . . . . . . . 58<br />

Disclosure: Nothing to Disclose<br />

Carter, Robert H, MD<br />

News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities. . . . . . . . . . 56<br />

Disclosure: Nothing to Disclose<br />

Caspi, Rachel, PhD<br />

Molecular Mechanisms <strong>of</strong> Ocular<br />

Inflammation . . . . . . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

Chen, Lan X, MD, PhD<br />

Crystalline Arthropathy . . . . . . . . . . . 108<br />

Disclosure: Nothing to Disclose<br />

Synovial Fluid Analysis and Crystal<br />

Identification. . . . . . . . . . . . . . 30, 68, 76<br />

Disclosure: Nothing to Disclose<br />

Chen, Qian, PhD<br />

Molecular Mechanisms <strong>of</strong> Inflammatory<br />

Signaling in Cartilage Destruction . . . . . . 27<br />

Disclosure: Nothing to Disclose<br />

Choi, Hyon K, MD, DrPH<br />

Crystal: Management <strong>of</strong> Gout . . . . . . . . 51<br />

Disclosure: Savient, 5; Takeda, 2, 5<br />

Christenson, Mary E, PT, PhD<br />

Evidence-based Practice: Creating and Using<br />

<strong>Rheumatology</strong> Critically Appraised Topics. .102<br />

Disclosure: Nothing to Disclose<br />

Patient Participation in Research. . . . . . .119<br />

Disclosure: Nothing to Disclose<br />

Physical Activity and Osteoarthritis: Learning<br />

with the Community . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Christopher-Stine, Lisa, MD<br />

Inflammatory Myopathy Update. . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

Chrousos, George P, MD<br />

2010 Hench Lecture: Glucocorticoids-<br />

Physiologic Regulation, Mechanisms <strong>of</strong> Action<br />

and Optimizing Therapeutic Applications . . 37<br />

Disclosure: Nothing to Disclose<br />

Chung, Antanya<br />

Certified <strong>Rheumatology</strong> Coder Course . . . 20<br />

Disclosure: Nothing to Disclose<br />

Certified <strong>Rheumatology</strong> Coder Examination<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 26<br />

Disclosure: Nothing to Disclose<br />

Clark, Marcus R, MD<br />

B cell Effectors and Regulators . . . . . . . 113<br />

Disclosure: Nothing to Disclose<br />

Clauw, Daniel J, MD<br />

Musculoskeletal Pain and Cognitive Issues<br />

Related to Returning Military Personnel . . 75<br />

Disclosure: Nothing to Disclose<br />

Clayburne, Gilda M, MLT<br />

Synovial Fluid Analysis and Crystal<br />

Identification. . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

Clements, Philip J, MD, MPH<br />

Systemic Sclerosis: How to Perform Skin<br />

Scores . . . . . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

Clowse, Megan E B, MD, MPH<br />

Pregnancy in Rheumatic Diseases . . . . . . 96<br />

Disclosure: Nothing to Disclose<br />

Colbert, Robert A, MD, PhD<br />

Pediatric Spondylarthropathies: From Genetics<br />

to the Clinic . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Epigenetics 101 . . . . . . . . . . . . . . . . 98<br />

Disclosure: Nothing to Disclose<br />

Colglazier, Christopher L, MD<br />

ICD -10 Preparation - Developing a Blueprint for<br />

Implementation . . . . . . . . . . . . . . . 133<br />

Disclosure: Forest Pharmaceuticals, 5<br />

Conaghan, Philip G, MD, PhD<br />

MRI . . . . . . . . . . . . . . . . . . . . . . . 91<br />

Disclosure: Nothing to Disclose<br />

Peripheral Magnetic Resonance Imaging in<br />

<strong>Rheumatology</strong> Practice . . . . . . . . . . . . 33<br />

Disclosure: Nothing to Disclose


Cooper, Max D, MD<br />

Introduction . . . . . . . . . . . . . . . . . . 20<br />

Disclosure: Nothing to Disclose<br />

Cope, James, MD<br />

Recovery Audit Contractor vs. Comprehensive<br />

Error Rate Testing Audits – Do You Know the<br />

Difference?. . . . . . . . . . . . . . . . . . . 66<br />

Disclosure: Nothing to Disclose<br />

Craig-Muller, Jurgen, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists -Day Two . . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Crawford, Donah Z, BS, MA<br />

Clinical Trial Essentials: Budgets, Contracts and<br />

Regulations . . . . . . . . . . . . . . . . . . 58<br />

Disclosure:, 2; Centocor, 2; Eli Lilly, Co., 2;<br />

Genentech, 2; Lexicon, 2; Regeneron, 2; Roche,<br />

2; UCB, 2<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Nothing to Disclose<br />

ARHP Research Coordinators Networking. . 35<br />

Disclosure: Nothing to Disclose<br />

Cronin, Mary E, MD<br />

Review Course . . . . . . . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Osteoarthritis - What is New in Old Joints .122<br />

Disclosure: Nothing to Disclose<br />

Adult Inflammatory Myopathy . . . . . . 35, 96<br />

Disclosure: Nothing to Disclose<br />

Crowther, Mark A, MD, MSc<br />

Perioperative Management <strong>of</strong> Selected<br />

Problems in Patients with Rheumatic<br />

Disease . . . . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Artisan, 5; Leo Laboratories, 2;<br />

Pfizer, 2; Pfizer, 5<br />

Curtis, Jeffrey R, MD, MPH<br />

Session II: Applications to Musculoskeletal<br />

Medicine . . . . . . . . . . . . . . . . . . . . 19<br />

Disclosure: Amgen, 2; Centocor, 2, 5; CORRONA,<br />

2, 5; Roche, 2, 5, 8; UCB, 5<br />

Cush, John J, MD<br />

<strong>Rheumatology</strong> Roundup: Highlights from the<br />

2010 Annual Scientific Meeting . . . . . . .133<br />

Disclosure: Allos, 5; BMS, 5; Celgene, 2, 5;<br />

Centocor, 2; CORRONA, 2, 5;Genentech, 2, 5;<br />

Human Genome Sciences, 5; Nicox, 5; Pfizer, 2;<br />

Roche, 2, 5; UCB, 2, 5<br />

Rheumatoid Arthritis: Difficult Cases . . . . 83<br />

Disclosure: Allos, 5; BMS, 5; Celgene, 2, 5;<br />

Centocor, 2; CORRONA, 2, 5; Genentech, 2, 5;<br />

Human Genome Sciences, 5; Nicox, 5; Pfizer, 2;<br />

Roche, 2, 5; UCB, 2, 5<br />

D<br />

Daikh, David I, MD, PhD<br />

ACR Leadership Town Hall Meeting . . . . .106<br />

Disclosure: Nothing to Disclose<br />

ACR REF Memorial Lectureship: <strong>Rheumatology</strong><br />

Education 2010 . . . . . . . . . . . . . . . . 37<br />

Disclosure: Nothing to Disclose<br />

Davidson, Anne, MB, BS<br />

Mouse to House: Lessons Learned About Lupus<br />

Therapeutics . . . . . . . . . . . . . . . . . . 39<br />

Disclosure: Biogen IDEC, 5; EMD-Serono, 5<br />

Davis, John M, MD<br />

Rheumatoid Arthritis Treatment 2010:<br />

Traditional DMARDs, Biologic DMARDs and<br />

Newer Treatment Strategies . . . . . . . . 114<br />

Disclosure: UCB Pharma, 2<br />

De Benedetti, Fabrizio, MD, PhD<br />

New Development in Systemic Juvenile<br />

Idiopathic Arthritis - From Bench to Effective<br />

Interventions . . . . . . . . . . . . . . . . .122<br />

Disclosure: BMS, 5; F H<strong>of</strong>fman La Roche, 2, 5<br />

Deal, Chad L, MD<br />

Controversies in Osteoporosis and Low Bone<br />

Mass: Who Do We Treat, For How Long, and at<br />

What Risks? . . . . . . . . . . . . . . . . . .103<br />

Disclosure: Amgen, 5, 8; Genentech, 8; Lilly, 5, 8;<br />

Novartis, 2, 8<br />

Osteoporosis: Focus on Dual Energy X-ray<br />

Absorptiometry Interpretation. . . . . . . .120<br />

Disclosure: Amgen, 5, 8; Genentech, 8; Lilly, 5, 8;<br />

Novartis, 2, 8<br />

DeLeo, Joyce A, PhD<br />

Pain, the Brain, and the Immune System: Links<br />

to Understanding Pain Management . . . .134<br />

Disclosure: Nothing to Disclose<br />

Dellaripa, Paul F, MD<br />

Pulmonary Manifestations <strong>of</strong> Rheumatic<br />

Disease . . . . . . . . . . . . . . . . . . . 65, 96<br />

Disclosure: genentech, 2<br />

Interstitial Lung Diseases in the Rheumatic<br />

Diseases . . . . . . . . . . . . . . . . . . . .109<br />

Disclosure: genentech, 2<br />

DeMarco, Paul J, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Sonosite, 5<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Sonosite, 5<br />

Denay, Jane M, BSN, MSN, CFNP<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 75<br />

Nothing to Disclose<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Nothing to Disclose<br />

Dennis, Gregory J, MD<br />

Contract Negotiations for Physicians . . . . 65<br />

Disclosure: Human Genome Sciences (HGSI), 3<br />

Denton, Christopher P, MD, PhD<br />

Scleroderma: Systemic Sclerosis . . . . . 57, 97<br />

Disclosure: Actelion Pharmaceuticals, 2;<br />

Actelion Pharmaceuticals, Pfizer, 5; Actelion<br />

Pharmaceuticals, Pfizer, GSK, 9<br />

Deodhar, Atul A, MD, MRCP<br />

CAM is a SCAM! Complementary and<br />

Alternative “Medicince” Has No Place in<br />

<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />

Disclosure: Nothing to Disclose<br />

Iatrogenic Misadventures: Complex Cases . 85<br />

Disclosure: Nothing to Disclose<br />

Reactive Arthritis: An Update . . . . . . . . 57<br />

Disclosure: Nothing to Disclose<br />

Joint Injection Techniques . . . . . . . 29, 113<br />

Disclosure: Nothing to Disclose<br />

Deretic, Vojo, PhD<br />

Autophagy and Immune Function . . . . . . 59<br />

Disclosure: Nothing to Disclose<br />

Dewing, Kori A, MN, ARNP<br />

Osteoporosis Treatment Update . . . . . . . 54<br />

Disclosure: Nothing to Disclose<br />

Pain Management in the Age <strong>of</strong> Abuse and<br />

Litigation . . . . . . . . . . . . . . . . . . . 100<br />

Disclosure: Nothing to Disclose<br />

Diamond, Betty, MD<br />

Session V: Role <strong>of</strong> B cells in Autoimmunity:<br />

Lessons from Clinical Trials . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Dixit, Rajiv K, MD<br />

Rheumatic Disease Update: Osteoarthritis <strong>of</strong><br />

the Spine . . . . . . . . . . . . . . . . . . . .103<br />

Disclosure: Nothing to Disclose<br />

Dodge, Carole V, OT CHT<br />

Practice Potpourri . . . . . . . . . . . . . . . 86<br />

Disclosure: Nothing to Disclose<br />

Dore, Robin K, MD<br />

The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />

Workforce: Gender Issues in the Workplace . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 94<br />

Disclosure: Nothing to Disclose<br />

Dufour, Alyssa B, MA<br />

You’ve Got the Power: How to Use and Teach<br />

Statistical Power for Studies and Grants. . . 47<br />

Disclosure: Nothing to Disclose<br />

Dunlop, Dorothy D, PhD<br />

Basic Statistical Concepts for the Medical<br />

Researcher . . . . . . . . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

E<br />

Edwards, Jonathan C.W, MD<br />

Session V: Role <strong>of</strong> B cells in Autoimmunity:<br />

Lessons from Clinical Trials . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Edwards, N Lawrence, MD<br />

Crystallizing Your Assessment and Treatment <strong>of</strong><br />

Difficult to Treat Gout . . . . . . . . . . . . .114<br />

Disclosure: Savient Pharmaceuticals, 5<br />

Takeda Pharmaceuticals North America, 5<br />

Crystalline Arthropathy . . . . . . . . . . . 108<br />

Disclosure: Savient Pharmaceuticals, 5<br />

Takeda Pharmaceuticals North America, 5<br />

Ehrenstein, Michael, PhD<br />

T cell Memory . . . . . . . . . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

Ehrlich-Jones, Linda S, PhD, RN<br />

An Infectious Etiology <strong>of</strong> Rheumatoid<br />

Arthritis . . . . . . . . . . . . . . . . . . . . 26<br />

Disclosure: Abbott, 1<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Abbott1<br />

ARHP Networking Forum . . . . . . . . . . . 30<br />

Disclosure: Abbott, 1<br />

El Baalbaki, Ghassan, PhD<br />

Measure by Measure: Assessing Psychological<br />

Health and Well-Being in Scleroderma . . .135<br />

Disclosure: Nothing to Disclose<br />

El-Gabalawy, Hani S, MD<br />

The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />

Towards Prevention <strong>of</strong> Disease? . . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book 303<br />

INVITED SPEAKER /MODERATOR INDEX


INVITED SPEAKER /MODERATOR INDEX<br />

304<br />

Elkon, Keith B, MD<br />

Cell Death: Receptors, Sensors and<br />

Inflammatory Pathways. . . . . . . . . . . .114<br />

Disclosure: Nothing to Disclose<br />

Autophagy and Immune Function . . . . . . 59<br />

Disclosure: Nothing to Disclose<br />

T cell Memory . . . . . . . . . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

Embi, Peter J, MD, MS<br />

Designing a Web Site for Your Practice . . . 33<br />

Disclosure: Nothing to Disclose<br />

Emery, Helen M, MD<br />

Rheumatic Disease Update: Juvenile Idiopathic<br />

Arthritis . . . . . . . . . . . . . . . . . . . .100<br />

Disclosure: Nothing to Disclose<br />

Rehabilitative <strong>Rheumatology</strong>. . . . . . . . .111<br />

Disclosure: Nothing to Disclose<br />

Empson, Stacey, JD, MHA<br />

Transforming Rheumatologic Care with the<br />

Electronic Health Record . . . . . . . . . . . 30<br />

Disclosure: ACR, 6; IBM, 1<br />

Erickson, Mary W, OTR, MAOL<br />

Musculoskeletal Pain and Cognitive Issues<br />

Related to Returning Military Personnel . . 75<br />

Disclosure: Nothing to Disclose<br />

Erkan, Doruk, MD<br />

Antiphospholipid Syndrome . . . . . . 51, 105<br />

Disclosure: BMS, 2; Genentech, 2; Lupus Clinical<br />

Trials Consortium, 2<br />

Espinoza, Luis R, MD<br />

When Pieces Don’t Fit . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

ILAR Global Health Project . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Evangelisto, Amy M, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Abbott, 5, 8<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Abbott, 5, 8<br />

F<br />

Feinstein, David E, DO<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Felson, David T, MD, MPH<br />

Remission in Rheumatoid Arthritis. . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Ferguson, Karen M, MS<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Genentech, 8; McKesson, 9<br />

Ferguson, Polly J, MD<br />

Pediatrics: Periodic Fevers in Children. . . . 65<br />

Disclosure: Nothing to Disclose<br />

Kawasaki Disease in the 21st Century - Genes,<br />

Pathogenesis, and Biologics . . . . . . . . . 90<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book<br />

Fett, Nicole, MD<br />

Cutaneous Vasculitis . . . . . . . . . . . . . 36<br />

Disclosure: Nothing to Disclose<br />

Dermatological Manifestations <strong>of</strong> Rheumatic<br />

Diseases . . . . . . . . . . . . . . . . . 29, 129<br />

Disclosure: Nothing to Disclose<br />

Skin Diseases. . . . . . . . . . . . . . . . . . 93<br />

Disclosure: Nothing to Disclose<br />

Filipovich, Lisa, MD<br />

Autologous Stem Cell Transplantation in<br />

Pediatric <strong>Rheumatology</strong>: Indications and<br />

Associated Morbidity . . . . . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

Filippucci, Emilio, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Firestein, Gary S, MD<br />

Kinases as Therapeutic Targets. . . . . . . . 59<br />

Disclosure: Ambit, 5; Intellikine, 2; Merck, 5;<br />

Rigel, 5; Takeda Pharmaceuticals, 5<br />

Fisher, Nadine M, EdD<br />

Physical Activity and Osteoarthritis: Learning<br />

with the Community . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Fisseha, Senait, MD, JD<br />

Reproductive and Sexual Health Issues for<br />

Women with Rheumatic Disease. . . . . . . 54<br />

Disclosure: Nothing to Disclose<br />

Fitzgerald, G. Kelley, PhD, PT<br />

Evidence-based Non-pharmacological Treatment<br />

for Hip, Knee, and Hand Osteoarthritis: The New<br />

ACR Guidelines . . . . . . . . . . . . . . . . 34<br />

Disclosure: Nothing to Disclose<br />

Putting ACR Osteoarthritis Guidelines into<br />

Practice: Clinical Applications for the Hip and<br />

Knee . . . . . . . . . . . . . . . . . . . . . .142<br />

Disclosure: Nothing to Disclose<br />

Flood, Joseph, MD<br />

Career Opportunities in <strong>Rheumatology</strong>: Making<br />

a Choice . . . . . . . . . . . . . . . . . . . .113<br />

Disclosure: Nothing to Disclose<br />

Fox, David A, MD<br />

ILAR Global Health Project . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Franchin, Giovanni, MD, PhD<br />

The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />

Workforce: Gender Issues in the Workplace 94<br />

Disclosure: Nothing to Disclose<br />

Freedman, John, MD, MBA<br />

CORC Forum: Health Care Reform – Where Are<br />

We Heading?. . . . . . . . . . . . . . . . . .101<br />

Disclosure: Nothing to Disclose<br />

Furie, Richard A, MD<br />

Mouse to House: Lessons Learned About Lupus<br />

Therapeutics . . . . . . . . . . . . . . . . . . 39<br />

Disclosure: Nothing to Disclose<br />

Thieves’ Market: Show Me Your Best Cases. 69<br />

Disclosure: Nothing to Disclose<br />

ACR Plenary Session II: Discovery 2010 . . . 63<br />

Disclosure: Nothing to Disclose<br />

Excel Spreadsheets: Basic Concepts to Elevate<br />

Your Skills Beyond Those <strong>of</strong> Your Children . 57<br />

Disclosure: Nothing to Disclose<br />

Furst, Daniel E, MD<br />

The Great Debate: Is it Time to Use Biologics as<br />

First-line Therapy in Rheumatoid Arthritis?<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 39<br />

Disclosure: Abbott, Actelion, Amgen, BMS,<br />

Biogenidec, Centocor, Genentech, Gilead, GSK,<br />

Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />

5; Abbott, Actelion, Amgen, BMS, Genentech,<br />

Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />

Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />

RC - Rheumatoid Arthritis: From Bench to<br />

Bedside in 40 Minutes . . . . . . . . . . . . 24<br />

Disclosure: Abbott, Actelion, Amgen, BMS,<br />

Biogenidec, Centocor, Genentech, Gilead, GSK,<br />

Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />

5; Abbott, Actelion, Amgen, BMS, Genentech,<br />

Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />

Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />

Systemic Sclerosis: How to Perform Skin<br />

Scores . . . . . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Abbott, Actelion, Amgen, BMS,<br />

Biogenidec, Centocor, Genentech, Gilead, GSK,<br />

Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />

5; Abbott, Actelion, Amgen, BMS, Genentech,<br />

Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />

Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />

Plenary III . . . . . . . . . . . . . . . . . . .104<br />

Disclosure: Abbott, Actelion, Amgen, BMS,<br />

Biogenidec, Centocor, Genentech, Gilead, GSK,<br />

Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />

5; Abbott, Actelion, Amgen, BMS, Genentech,<br />

Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />

Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />

G<br />

Gale, Judith R, MPH, DPT, PT<br />

Living with Osteoporosis . . . . . . . . . . . 61<br />

Disclosure: Nothing to Disclose<br />

Gall, Victoria, PT, MEd<br />

ARHP Networking at Noon . . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

Total Shoulder Arthroplasty and Reverse Total<br />

Shoulder Arthroplasty: Surgery<br />

and Rehabilitation. . . . . . . . . . . . . . .147<br />

Disclosure: Nothing to Disclose<br />

Gardner, Gregory C, MD<br />

Review Course . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Diabetes 2010: More than Autoimmunity and<br />

Adipocytes . . . . . . . . . . . . . . . . . . . 94<br />

Disclosure: Nothing to Disclose<br />

Teaching and Assessing Arthrocentesis . . 112<br />

Disclosure: Nothing to Disclose<br />

Joint Injections (Knee and Ankle Prosthetics)<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

Joint Injections (Shoulder and Wrist<br />

Prosthetics) . . . . . . . . . . . . . . . . . . 58<br />

Disclosure: Nothing to Disclose<br />

Garnoc, Josephine C, BSN<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Centocor, 8; Genentech, 8; UCB, 8<br />

Gay, Steffen, MD<br />

The Revolution <strong>of</strong> Epigenetics in<br />

Autoimmunity . . . . . . . . . . . . . . . . . 47<br />

Disclosure: Nothing to Disclose


Gerlag, Danielle Marie, MD, PhD<br />

The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />

Towards Prevention <strong>of</strong> Disease? . . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

Gib<strong>of</strong>sky, Allan, MD, JD<br />

Pain Management in the Age <strong>of</strong> Abuse and<br />

Litigation . . . . . . . . . . . . . . . . . . . 100<br />

Disclosure: Abbott, 8; Amgen, 8; BMS, 8; J&J, 1;<br />

Nicox, 5; Pfizer, 1, 8; UCB, 8; United States Food<br />

and Drug Administration, 5<br />

Gibson, Kyle, MS, PhD<br />

Putting ACR Osteoarthritis Guidelines into<br />

Practice: Clinical Applications for the Hip<br />

and Knee . . . . . . . . . . . . . . . . . . . .142<br />

Disclosure: Nothing to Disclose<br />

Giles, Jon T, MD<br />

Neuro Endocrine Immunology . . . . . . . . 91<br />

Disclosure: Nothing to Disclose<br />

Ginzler, Ellen M, MD, MPH<br />

Systemic Lupus Erythematosus: Novel<br />

Treatments. . . . . . . . . . . . . . . . . . .106<br />

Disclosure: Nothing to Disclose<br />

Gitomer, Richard S, MD, MBA<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Gladman, Dafna D, MD<br />

Psoriatic Disease: Clinical Spectrum and<br />

Comprehensive Treatment Strategies . . . . 69<br />

Disclosure: Abbott, Amgen, Wyeth, BMS, 5<br />

Psoriatic Arthritis . . . . . . . . . . . . . . .130<br />

Disclosure: Abbott, Amgen, Wyeth, BMS, 5;<br />

Abbott, Pfizer, Amgen, Wyeth, 2<br />

Glennie, Martin J, PhD<br />

Session IV: Emerging Concepts in B cell Directed<br />

Therapies. . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Goldberg, Lynne J, MD<br />

Dermatopathology <strong>of</strong> Rheumatic Diseases . 57<br />

Disclosure: Nothing to Disclose<br />

Goldring, Mary B, PhD<br />

Molecular Mechanisms <strong>of</strong> Inflammatory<br />

Signaling in Cartilage Destruction . . . . . . 27<br />

Disclosure: Nothing to Disclose<br />

Goldring, Steven R, MD<br />

Bisphosphonates: Mechanism <strong>of</strong> Action and<br />

Optimizing Clinical Use . . . . . . . . . . . 135<br />

Disclosure: Nothing to Disclose<br />

2010 Hench Lecture: Glucocorticoids-<br />

Physiologic Regulation, Mechanisms <strong>of</strong> Action<br />

and Optimizing Therapeutic Applications . . 37<br />

Disclosure: Nothing to Disclose<br />

Gottenberg, Jacques-Eric MD, PhD<br />

Sjögren’s Syndrome . . . . . . . . . . . . . . 92<br />

Gourley, Mark F, MD<br />

Myopathy: Issues in Diagnosis and<br />

Treatment . . . . . . . . . . . . . . . . . . .105<br />

Disclosure: Nothing to Disclose<br />

Goyal, Janak R, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasonography: Basic . . 29<br />

Disclosure: Nothing to Disclose<br />

Grahame, Rodney, MD<br />

Hypermobility . . . . . . . . . . . . . . . . 108<br />

Disclosure: Nothing to Disclose<br />

Joint Hypermobility Syndrome . . . . . . . . 90<br />

Disclosure: Nothing to Disclose<br />

Genetic Disorders <strong>of</strong> Connective Tissue<br />

and Joint Hypermobility . . . . . . . . . . . 37<br />

Disclosure: Nothing to Disclose<br />

Green, Carmen R, MD<br />

Disparities and Pain: Examining Research,<br />

Practice and Policy . . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Grom, Alexei A, MD<br />

Autologous Stem Cell Transplantation in<br />

Pediatric <strong>Rheumatology</strong>: Indications and<br />

Associated Morbidity . . . . . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

New Development in Systemic Juvenile<br />

Idiopathic Arthritis - From Bench to Effective<br />

Interventions . . . . . . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

Gultekin, Sakir Humayun, MD<br />

Muscle Involvement in Rheumatic Diseases . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .101<br />

Disclosure: Nothing to Disclose<br />

Gunawardena, Harsha, MD<br />

Inflammatory Myopathy Update. . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

H<br />

Haberman, Ann M, PhD<br />

Session II: B cell Activation and Trafficking . 22<br />

Disclosure: Nothing to Disclose<br />

Hahn, Bevra H, MD<br />

Mouse to House: Lessons Learned About Lupus<br />

Therapeutics . . . . . . . . . . . . . . . . . . 39<br />

Disclosure: Alderbio Pharm, 5; Aspreva, 2;<br />

Bristol Myers Squibbs, 9<br />

Hajj-Ali, Rula, MD<br />

Central Nervous System Vasculitis . . . . . . 28<br />

Disclosure: Nothing to Disclose<br />

Hamilton, John A, PhD, DSc<br />

Macrophage Differentiation . . . . . . . . . 55<br />

Disclosure: CSL Ltd, 5; Morphosys AG, 2, 5, 7;<br />

NovoNordisk, 5<br />

Hanly, John G, MD<br />

The Brain and Systemic Lupus Erythematosus:<br />

2010 Update . . . . . . . . . . . . . . . . . . 66<br />

Disclosure: Genentech USA, 5; GSK Canada, 5;<br />

Roche Canada, 2, 5<br />

Hannan, Marian T, DSc, MPH<br />

A Foot Orthotic Is Not Just a Foot Orthotic . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .131<br />

Disclosure: Nothing to Disclose<br />

Building Effective Teams: Recommended<br />

Leadership Strategies . . . . . . . . . . . . 100<br />

Disclosure: Nothing to Disclose<br />

You’ve Got the Power: How to Use and Teach<br />

Statistical Power for Studies and Grants. . . 47<br />

Disclosure: Nothing to Disclose<br />

Hansen, Karen E, MD<br />

Vitamin D and Bone Health. . . . . . . . . . 36<br />

Disclosure: NIH, 2<br />

Hardy, Richard R, PhD<br />

Session I: B cell Development . . . . . . . . 20<br />

Disclosure: Nothing to Disclose<br />

Harrington, J. Timothy, MD<br />

Session II: Applications to Musculoskeletal<br />

Medicine . . . . . . . . . . . . . . . . . . . . 19<br />

Disclosure: CORRONA, 5; Murray Electronics, 4;<br />

Wyeth, 8<br />

Haskard, Dorian O, DM<br />

Behçet’s Disease. . . . . . . . . . . . . . . . 88<br />

Disclosure: Nothing to Disclose<br />

Hazes, Johanna, MD, PhD<br />

Rheumatoid Arthritis: Early Rheumatoid<br />

Arthritis . . . . . . . . . . . . . . . . . . . . 36<br />

Disclosure: BMS, 8; Roche, 2; Wyeth, 2<br />

Helmick, Charles G, MD<br />

Top 10 in ‘10: Top 10 Public Health Advances<br />

in the First 10 Years <strong>of</strong> the Centers for Disease<br />

Control and Prevention Arthritis Program. .147<br />

Disclosure: Nothing to Disclose<br />

Higgs, Jay B, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Hirsch, Irl B, MD<br />

Diabetes 2010: More than Autoimmunity and<br />

Adipocytes . . . . . . . . . . . . . . . . . . . 94<br />

Disclosure: Abbott Diabetes Care, 5; Bayer, 5;<br />

Johnson & Johnson, 5; Novo Nordisk, 2; Roche, 5<br />

Ho, Nancy A, MHA<br />

Money Talks: How to Incentivize Staff . . . . 46<br />

Disclosure: Nothing to Disclose<br />

Hochberg, Marc C, MD, MPH<br />

Evidence-based Non-pharmacological Treatment<br />

for Hip, Knee, and Hand Osteoarthritis: The New<br />

ACR Guidelines . . . . . . . . . . . . . . . . 34<br />

Disclosure:, 8; Astra-Zeneca Pharmaceutical<br />

CO, 8; Bayer HealthCare LLC, 8; Bioberica SA, 8;<br />

CombinatoRx, 8; Covidien, 8; Eli Lilly Co., 8; Endo<br />

Pharmaceuticals, 8; GlaxoSmithKline, 8; Merck<br />

& Co., Inc., 8; Merck Serono International SA, 8;<br />

NicOX SA, 8; Novartis Pharma AG, 8; Pfizer Inc.,<br />

8; Pozen, Inc., 8; San<strong>of</strong>i Aventis SA, 8; Smith &<br />

Nephew, 8; Stryker Biotech, 8<br />

Osteoarthritis - What is New in Old Joints .122<br />

Disclosure:, 8; Astra-Zeneca Pharmaceutical<br />

CO, 8; Bayer HealthCare LLC, 8; Bioberica SA, 8;<br />

CombinatoRx, 8; Covidien, 8; Eli Lilly Co., 8; Endo<br />

Pharmaceuticals, 8; GlaxoSmithKline, 8; Merck<br />

& Co., Inc., 8; Merck Serono International SA, 8;<br />

NicOX SA, 8; Novartis Pharma AG, 8; Pfizer Inc.,<br />

8; Pozen, Inc., 8; San<strong>of</strong>i Aventis SA, 8; Smith &<br />

Nephew, 8; Stryker Biotech, 8<br />

H<strong>of</strong>fman, Bruce I, MD<br />

Crystallizing Your Assessment and Treatment <strong>of</strong><br />

Difficult to Treat Gout . . . . . . . . . . . . .114<br />

Disclosure: Nothing to Disclose<br />

H<strong>of</strong>fman, Gary S, MD<br />

Giant Cell Arteritis - Diagnosis and Therapy. 69<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book 305<br />

INVITED SPEAKER /MODERATOR INDEX


INVITED SPEAKER /MODERATOR INDEX<br />

306<br />

Holers, V. Michael, MD<br />

The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

Hong, Raymond, MD, MBA<br />

CORC Forum: Health Care Reform – Where Are<br />

We Heading?. . . . . . . . . . . . . . . . . .101<br />

Disclosure: Novartis, 8<br />

ICD -10 Preparation - Developing a Blueprint for<br />

Implementation . . . . . . . . . . . . . . . 133<br />

Disclosure: Novartis, 8<br />

Hootman, Jennifer M, PhD<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Nothing to Disclose<br />

Evidence-based Practice: Creating and Using<br />

<strong>Rheumatology</strong> Critically Appraised Topics. .102<br />

Disclosure: Nothing to Disclose<br />

Ready, Aim, Get Funded! . . . . . . . . . . 131<br />

Disclosure: Nothing to Disclose<br />

Houssiau, Frederic A, MD, PhD<br />

Systemic Lupus Erythematosus: Lupus<br />

Nephritis . . . . . . . . . . . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Huber, Adam, MD<br />

Pediatrics: Dermatomyositis . . . . . . . . . 57<br />

Disclosure: Abbott, 9<br />

Huizinga, Thomas W. J, MD<br />

The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

Hunder, Gene G, MD<br />

Temporal Arteritis . . . . . . . . . . . . . . . 97<br />

Disclosure: Nothing to Disclose<br />

Ilowite, Norman T, MD<br />

2010 ACR Recommendations for the Treatment<br />

<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />

Disclosure: Regeneron, 2<br />

New Development in Systemic Juvenile<br />

Idiopathic Arthritis - From Bench to Effective<br />

Interventions . . . . . . . . . . . . . . . . .121<br />

Disclosure: Regeneron, 2<br />

Inman, Christi J, MD<br />

Transforming Rheumatologic Care with the<br />

Electronic Health Record . . . . . . . . . . . 30<br />

Disclosure: Nothing to Disclose<br />

Ishimori, Mariko L, MD<br />

Osteoarthritis - What is New in Old Joints .122<br />

Disclosure: Nothing to Disclose<br />

Ivashkiv, Lionel B, MD<br />

Stem Cell Reprogramming: Molecular<br />

Mechanisms and Clinical Applications and<br />

Implications . . . . . . . . . . . . . . . . . .102<br />

Disclosure: Nothing to Disclose<br />

Iversen, Maura D, PT, DPT, SD, MPH<br />

Building Effective Teams: Recommended<br />

Leadership Strategies . . . . . . . . . . . . 100<br />

Disclosure: Nothing to Disclose<br />

Daltroy Memorial Lecture: Adherence to<br />

Medical Regimens for Rheumatic Diseases<br />

and the Importance <strong>of</strong> Patient-Clinician<br />

Communication . . . . . . . . . . . . . . . . 61<br />

Disclosure: Nothing to Disclose<br />

Physical Activity and Osteoarthritis: Learning<br />

with the Community . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book<br />

I<br />

James, Nadine T, RN, MSN, PhD<br />

Patient Participation in Research. . . . . . .119<br />

Disclosure: Nothing to Disclose<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Nothing to Disclose<br />

Janisse, Dennis J, C Ped<br />

A Foot Orthotic Is Not Just a Foot Orthotic . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .131<br />

Disclosure: Nothing to Disclose<br />

Jarvis, James N, MD<br />

Career Opportunities in <strong>Rheumatology</strong>: Making<br />

a Choice . . . . . . . . . . . . . . . . . . . .112<br />

Disclosure: Nothing to Disclose<br />

Jayne, David, MD<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />

Microscopic Polyangiitis: Understanding and<br />

Applying the Data from Recent Clinical Trials<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />

Disclosure: H<strong>of</strong>fmann La Roche, 5; Human<br />

Genome Science, 5<br />

Jennings, Michael J, RT, CBDT<br />

Building Effective Teams: Recommended<br />

Leadership Strategies . . . . . . . . . . . . 100<br />

Disclosure: Nothing to Disclose<br />

Jones, Dina L., PhD, PT<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Nothing to Disclose<br />

Jones, Karla B, MS, RN, CPNP<br />

Teaching Our Pediatric Patients: Making the<br />

Complex Simple . . . . . . . . . . . . . . . 142<br />

Disclosure: Nothing to Disclose<br />

Jorgensen, Christian, MD, PhD<br />

Therapeutic Use <strong>of</strong> Mesenchymal Stem Cells in<br />

Rheumatologic Diseases . . . . . . . . . . .133<br />

Disclosure: Nothing to Disclose<br />

Joseph, Amy M, MD<br />

Hepatitis C for the Rheumatologist . . . . . 24<br />

Disclosure: Nothing to Disclose<br />

J<br />

K<br />

Kaeley, Gurjit S, MBBS<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . 17, 18<br />

Disclosure: Sonosite, Biosound Esaote, 2<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Sonosite, Biosound Esaote, 2<br />

Musculoskeletal Ultrasound . . . . . .109, 110<br />

Disclosure: Sonosite, Biosound Esaote, 2<br />

Musculoskeletal Ultrasonography: Basic . . 29<br />

Disclosure: Sonosite, Biosound Esaote, 2<br />

Kalish, Robert A, MD<br />

ACR/ABIM Maintenance <strong>of</strong> Certification<br />

Learning Session – 2010 Update . . . . . . . 21<br />

Disclosure: Nothing to Disclose<br />

<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Lower<br />

Extremity and Lumbosacral Spine: Anatomical<br />

Correlates . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Nothing to Disclose<br />

<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Upper<br />

Extremity and Cervical Spine: Anatomical<br />

Correlates . . . . . . . . . . . . . . . . . . . 97<br />

Disclosure: Nothing to Disclose<br />

Kaplan, Mariana J, MD<br />

ACR/EULAR Academic Exchange Program. . 86<br />

Disclosure: Nothing to Disclose<br />

News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities. . . . . . . . . . 56<br />

Disclosure: Nothing to Disclose<br />

Karp, David R, MD<br />

ACR REF Within Our Reach: Finding a Cure<br />

for Rheumatoid Arthritis . . . . . . . . . . . 45<br />

Disclosure: Nothing to Disclose<br />

Kashikar-Zuck, Susmita, PhD<br />

Juvenile Fibromyalgia . . . . . . . . . . . . . 53<br />

Disclosure: National Institutes <strong>of</strong> Health, 2<br />

Kastanek, Lisa M, RN, CCRC<br />

Clinical Trial Essentials: Budgets, Contracts<br />

and Regulations . . . . . . . . . . . . . . . . 58<br />

Disclosure: BMS,UCB,Roche, 8<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Disclosure: BMS,UCB,Roche, 8<br />

ARHP Research Coordinators Networking. . 35<br />

Disclosure: BMS,UCB,Roche, 8<br />

Katz, Patricia P, PhD<br />

Understanding Functional Activity in<br />

Rheumatoid Arthritis: What We Know and What<br />

We Don’t Know . . . . . . . . . . . . . . . . 86<br />

Disclosure: Nothing to Disclose<br />

Kavanaugh, Arthur, MD<br />

Immunizations and Rheumatic Diseases - An<br />

Update . . . . . . . . . . . . . . . . . . . . . 37<br />

Disclosure: Nothing to Disclose<br />

Psoriatic Disease: Clinical Spectrum and<br />

Comprehensive Treatment Strategies . . . . 69<br />

Disclosure: abbott, 2; amgen, 2; bms, 2;<br />

Centocor, 2; roche, 2; ucb, 2<br />

<strong>Rheumatology</strong> Roundup: Highlights from the<br />

2010 Annual Scientific Meeting . . . . . . .133<br />

Disclosure: Nothing to Disclose<br />

Kazi, Salahuddin, MD<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 26<br />

Disclosure: Centocor, 8; Genentech, 8<br />

Session II: Applications to Musculoskeletal<br />

Medicine . . . . . . . . . . . . . . . . . . . . 19<br />

Disclosure: Centocor, 8; Genentech, 8<br />

Transforming Rheumatologic Care with the<br />

Electronic Health Record . . . . . . . . . . . 30<br />

Disclosure: Centocor, 8; Genentech, 8<br />

Electronic Health Record . . . . . . . . . . 101<br />

Disclosure: Centocor, 8; Genentech, 8<br />

Kerr, Karen L, MSN, NP, CPNP, PNP<br />

Rheumatic Disease Update: Juvenile Idiopathic<br />

Arthritis . . . . . . . . . . . . . . . . . . . .100<br />

Disclosure: Nothing to Disclose<br />

ARHP Networking at Noon . . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

Keysor, Julie J, PhD, PT<br />

Work Assessments: A ‘How-To’ That Could Save<br />

Your Patient’s Life/Job. . . . . . . . . . . . .131<br />

Disclosure: Nothing to Disclose<br />

Keystone, Edward C, MD<br />

Rheumatoid Arthritis: Challenging<br />

Cases . . . . . . . . . . . . . . . . . . . 29, 106<br />

Disclosure: Abbott, 9; Abbott Laboratores, 5;<br />

Amgen, 9; Amgen Inc., 5; Astrazeneca Inc., 5;<br />

Bristol-Myers Squibb, 5, 9; Centocor Inc., 5; F.<br />

H<strong>of</strong>fman La Roche, 5, 9; Merck, 5; Pfizer, 5, 8;<br />

Schering Plough, 5, 9; UCB Pharmaceuticals, 5;<br />

Wyeth Pharmaceuticals, 5


Physical Examination Skills for Improved<br />

Detection <strong>of</strong> Synovitis and Cervical<br />

Thoracolumbar Disorders. . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

Khanna, Dinesh, MD, MSc<br />

Pulmonary Hypertension in the Rheumatic<br />

Diseases . . . . . . . . . . . . . . . . . . . . 29<br />

Disclosure: Actelion, 2; Actelion, 5; Fibrogen, 5;<br />

Gilead, 2, 5; MediQuest, 5; United Therapeutics, 5<br />

Systemic Sclerosis: How to Perform Skin<br />

Scores . . . . . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Actelion, 2; Actelion, 5; Fibrogen, 5;<br />

Gilead, 2, 5; MediQuest, 5; United Therapeutics, 5<br />

Kiefe, Catarina, MD, PhD<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Kimpton, Kimberly F, PT<br />

Rheumatic Disease Update: Osteoarthritis <strong>of</strong> the<br />

Spine . . . . . . . . . . . . . . . . . . . . . 103<br />

Disclosure: Nothing to Disclose<br />

Kimura, Yukiko, MD<br />

ACR REF Clinician Scholar Educator Lecture. 53<br />

Disclosure: Nothing to Disclose<br />

Kincade, Paul W, PhD<br />

Session I: B cell Development . . . . . . . . 20<br />

Disclosure: Nothing to Disclose<br />

King, Charles M, MD<br />

Transforming Rheumatologic Care with the<br />

Electronic Health Record . . . . . . . . . . . 30<br />

Disclosure: Nothing to Disclose<br />

Kissin, Eugene Y, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Amgen, 5; GE, 2; SonoSite, 9; UCB, 5<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . 22, 23<br />

Disclosure: Amgen, 5; GE, 2; SonoSite, 9; UCB, 5<br />

Musculoskeletal Ultrasound . . . . . . . . . 47<br />

Disclosure: Amgen, 5; GE, 2; SonoSite, 9; UCB, 5;<br />

Amgen, 5; GE, 2; SonoSite, 9; UCB, 5<br />

Klareskog, Lars, MD, PhD<br />

The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />

Towards Prevention <strong>of</strong> Disease? . . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

Klepper, Susan E, PhD, PT<br />

What’s New and Noteworthy in 2010: A<br />

Review <strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />

Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

Koch, Alisa E, MD<br />

The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />

Disclosure: Bristol-Myers Squibb, 2; CME Peer<br />

Review, LLC, 5; Cypress Bioscience, 5; Fund for<br />

Autoimmune Research, 6; Gerson Lehrman<br />

Group <strong>of</strong> Healthcare and Biomedical Advisors,<br />

5; Guidepoint Global, 5; HealthCare Venture,<br />

LLC, 5; NiCox SA, 5; Pharmacia and Upjohn<br />

Company, 2; Roche Pharmaceuticals, 2; Takeda<br />

Pharmaceuticals North America, Inc, 2; UCB<br />

Pharmaceuticals, 6<br />

ACR Plenary Session III: Discovery 2010 . . .104<br />

Disclosure: Bristol-Myers Squibb, 2; CME Peer<br />

Review, LLC, 5; Cypress Bioscience, 5; Fund for<br />

Autoimmune Research, 6; Gerson Lehrman<br />

Group <strong>of</strong> Healthcare and Biomedical Advisors, 5;<br />

Guidepoint Global, 5; HealthCare Ventures, LLC,<br />

5; NiCox SA, 5; Pharmacia and Upjohn, 2; Roche<br />

Pharmaceuticals, 2; Takeda Pharmaceuticals, 2;<br />

UCB Pharmaceuticals, 6<br />

Kolasinski, Sharon L, MD<br />

ACR REF Clinician Scholar Educator Lecture. 53<br />

Disclosure: Nothing to Disclose<br />

Kortan, Joyce M, RN<br />

Practice Potpourri . . . . . . . . . . . . . . . 86<br />

Disclosure: Amgen, 8; Bristol Meyers Squibb,<br />

8; Centocor, 8; Genetech/Roche, 8; Novartis, 9;<br />

PRIME, 9; RNS, 9; The Institute <strong>of</strong> Continuing<br />

Health Education, 9; UCB, 8; Wyeth, 8<br />

Kremer, Joel M, MD<br />

Methotrexate 2010 . . . . . . . . . . . . . . 56<br />

Disclosure: Nothing to Disclose<br />

Krohn, Kelly D, MD<br />

Knee Braces and Foot Orthosis for Knee<br />

Osteoarthritis . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

Kyburz, Diego, MD<br />

Toll-like Receptors and Inflammation: Towards<br />

Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Nothing to Disclose<br />

L<br />

Lafyatis, Robert A, MD<br />

Immunopathogenesis <strong>of</strong> Systemic<br />

Sclerosis . . . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Actelion, 2; Celgene, 2; Medimmune,<br />

2; Novartis, 2<br />

Scleroderma-Biomarkers . . . . . . . . . . 111<br />

Disclosure: Actelion, 2; Celgene, 2; Medimmune,<br />

2; Novartis, 2<br />

Lahita, Robert G, MD, PhD<br />

Systemic Lupus Erythematosus: Novel<br />

Treatments. . . . . . . . . . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Lakhanpal, Sharad, MB, MD<br />

Legislative Update from Capitol Hill . . . . . 52<br />

Disclosure: Nothing to Disclose<br />

Langford, Carol A, MD, MHS<br />

ACR/ABIM Maintenance <strong>of</strong> Certification<br />

Learning Session -2010 Update . . . . . . . 21<br />

Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />

Microscopic Polyangiitis: Understanding and<br />

Applying the Data from Recent Clinical Trials . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />

Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />

ACR Plenary Session III: Discovery 2010 . . .104<br />

Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />

Takayasu’s Arteritis . . . . . . . . . . . . . .112<br />

Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />

Lapteva, Larissa Y, MD, MHS<br />

Update on Safety Issues in the Treatment <strong>of</strong><br />

Rheumatic Diseases – From the Food and Drug<br />

Administration and Beyond . . . . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

Law, Karen L, MD<br />

Clinicopathologic Conference . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Lawry, George V, MD<br />

Evidence-based Snacks for Rheumatologists 25<br />

Disclosure: McGraw Hill, 7<br />

Musculoskeletal Exam Skills I: General<br />

Musculoskeletal Examination Skills<br />

for Educators. . . . . . . . . . . . . . . . . . 67<br />

Disclosure: McGraw Hill, 7<br />

Musculoskeletal Exam Skills II: Regional<br />

Examinations <strong>of</strong> the Shoulder and Low Back .<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 97<br />

Disclosure: McGraw Hill, 7<br />

Musculoskeletal Exam Skills III: Regional<br />

Examinations <strong>of</strong> the Knee. . . . . . . . . . .102<br />

Disclosure: McGraw Hill, 7<br />

Learch, Thomas J, MD<br />

Pediatric Spondylarthropathies: From Genetics<br />

to the Clinic . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Lee, David M, MD, PhD<br />

Basic Immunology for Clinical<br />

Rheumatologists. . . . . . . . . . . . . 64, 105<br />

Disclosure: Johnson & Johnson, 5; Novartis, 1;<br />

Synovex, 1, 5, 7; UCB Pharma, 5<br />

Lemke, Greg E, PhD<br />

Cell Death: Receptors, Sensors and<br />

Inflammatory Pathways. . . . . . . . . . . .114<br />

Disclosure: Xetrios Therapeutics, 4<br />

Levine, Stuart M, MD<br />

Vasculitis: An Update . . . . . . . . . . . . 130<br />

Disclosure: Nothing to Disclose<br />

Li, Linda C, BSc (PT) MSc PhD<br />

ARHP Occupational and Physical Therapy<br />

Networking . . . . . . . . . . . . . . . . . .105<br />

Disclosure: Nothing to Disclose<br />

Liebling, Michael R, MD<br />

When Pieces Don’t Fit . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

Liew, Foo Y, BSc, PhD, DSc<br />

Immunopathogenesis <strong>of</strong> Systemic Sclerosis. . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Lightfoot, Robert W, MD<br />

Labs and Treatment Options: What Do They<br />

Mean and How Do You Use? . . . . . . . . 131<br />

Disclosure: Nothing to Disclose<br />

Lim, S Sam, MD, MPH<br />

Clinicopathologic Conference . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Limanni, Alex, MD<br />

Insurance Roundtable Discussion . . . . . . 94<br />

Disclosure: Nothing to Disclose<br />

Liu, Nancy Y, MD<br />

Update on Multiple Sclerosis. . . . . . . . . 59<br />

Disclosure: Nothing to Disclose<br />

Loeser, Richard F, MD<br />

Molecular Mechanisms <strong>of</strong> Inflammatory<br />

Signaling in Cartilage Destruction . . . . . . 27<br />

Disclosure: Nothing to Disclose<br />

Osteoarthritis: Update 2010 . . . . . . . . . 57<br />

Disclosure: Omeros, 2<br />

Walk this Way: Biomechanics and<br />

Osteoarthritis . . . . . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Looney, Richard J, MD<br />

Epigenetics 101 . . . . . . . . . . . . . . . . 98<br />

Disclosure: Nothing to Disclose<br />

Innate Immunity and Inflammation . . . . . 30<br />

Disclosure: Nothing to Disclose<br />

Macrophage Differentiation . . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Therapeutic Use <strong>of</strong> Mesenchymal Stem Cells in<br />

Rheumatologic Diseases . . . . . . . . . . .133<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book 307<br />

INVITED SPEAKER /MODERATOR INDEX


INVITED SPEAKER /MODERATOR INDEX<br />

308<br />

Louie, Grant H, MD, MHS<br />

Finding and Using Secondary Data Resources<br />

for Research: Beyond the National Health and<br />

Nutrition Examination Survey and the Usual<br />

Suspects . . . . . . . . . . . . . . . . . . . 103<br />

Disclosure: Nothing to Disclose<br />

Lovell, Daniel J, MD, MPH<br />

2010 ACR Recommendations for the Treatment<br />

<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />

Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />

& Rheumatism & Arthritis and Rheumatism, 9;<br />

Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />

Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />

Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />

Wyeth Pharm., 9; Xoma, Inc., 5<br />

Update on Safety Issues in the Treatment <strong>of</strong><br />

Rheumatic Diseases – From the Food and Drug<br />

Administration and Beyond . . . . . . . . . 77<br />

Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />

& Rheumatism & Arthritis and Rheumatism, 9;<br />

Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />

Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />

Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />

Wyeth Pharm., 9; Xoma, Inc., 5<br />

Lundberg, Ingrid E, MD, PhD<br />

Inflammatory Myopathy Update. . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

M<br />

MacDonald, Patricia A, BSN, NP<br />

Adaptations and Solutions to Help People with<br />

Scleroderma Continue to Work . . . . . . .102<br />

Disclosure: Nothing to Disclose<br />

MacLean, Catherine H, MD, PhD<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: WellPoint, 3<br />

Maksymowych, Walter P, MD<br />

Ankylosing Spondylitis: Disease Modification. .<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 28<br />

Disclosure: Abbott, 2, 5; Merck, 2, 5; Pfizer, 2, 5<br />

Mandelin, Arthur M, MD, PhD<br />

Adult Musculoskeletal Upper/Lower<br />

Examinations . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Abbott, 8; UCB, 8<br />

Mandell, Brian F, MD, PhD<br />

Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />

Disclosure: merck, 9; takeda, 5; url, 5<br />

Perioperative Management <strong>of</strong> Selected<br />

Problems in Patients with Rheumatic Disease<br />

. . . . . . . . . . . . . . . . . . . . . . . . .122<br />

Disclosure: merck, 9; takeda, 5; url, 5<br />

Synovial Fluid Analysis and Crystal<br />

Identification. . . . . . . . . . . . . . 30, 68, 76<br />

Disclosure: merck, 9; takeda, 5; url, 5<br />

Mandl, Thomas, MD, PhD<br />

Sjögren’s Syndrome . . . . . . . . . . . . . . 92<br />

Marcus, Donald M, MD<br />

CAM is a SCAM! Complementary and<br />

Alternative “Medicince” Has No Place in<br />

<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />

Disclosure: Nothing to Disclose<br />

Marder, Wendy, MD<br />

Reproductive and Sexual Health Issues for<br />

Women with Rheumatic Disease. . . . . . . 54<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book<br />

Maricic, Michael J, MD<br />

Osteoporosis: Novel Treatments . . . . . . . 36<br />

Disclosure: Lilly, Novartis, Amgen, Roche,<br />

Genetech, Proctor and Gamble, 8<br />

<strong>Rheumatology</strong> Practice 101: Starting Out in<br />

Practice for The Graduating Fellow . . . . .130<br />

Disclosure: Lilly, Novartis, Amgen, Roche,<br />

Genetech, Proctor and Gamble, 8<br />

The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />

Disclosure: Lilly, Novartis, Amgen, Roche,<br />

Genetech, Proctor and Gamble, 8<br />

REF Oscar S. Gluck, MD, Memorial Lectureship<br />

- Osteoimmunology: Crosstalk Between the<br />

Immune and Bone Systems: Biologic and Clinical<br />

Implications . . . . . . . . . . . . . . . . . . 28<br />

Disclosure: Lilly, Novartis, Amgen, Roche,<br />

Genetech, Proctor and Gamble, 8<br />

Marshak-Rothstein, Ann, PhD<br />

The Immunology <strong>of</strong> B Cells: From Antibodies to<br />

Immunoregulation . . . . . . . . . . . . . . 20<br />

Disclosure: Idera Pharmaceuticals, 5<br />

Session III: Factors Promoting B Cell<br />

Autoreactivity and Protective Immunity. . . 23<br />

Disclosure: Idera Pharmceuticals, 5<br />

Toll-like Receptors Activation <strong>of</strong> B cells in<br />

Autoimmune Disease . . . . . . . . . . . . . 28<br />

Disclosure: Idera Pharmceuticals, 5<br />

Toll-Like Receptor Signaling in B Cells and<br />

Atoimmune Disease. . . . . . . . . . . . . . 23<br />

Disclosure: Idera Pharmceuticals, 5<br />

Martinez-Lavin, Manuel, MD<br />

Fibromyalgia . . . . . . . . . . . . . . . . . . 57<br />

Disclosure: Nothing to Disclose<br />

Massarotti, Elena M, MD<br />

Systemic Lupus Erythematosus: Difficult to Treat<br />

Systemic Lupus Erythematosus . . . . . . . 97<br />

Disclosure: Cypress Bioscience, 9; EMD Serono,<br />

9; Human Genome Sciences, 5; NIH Ace Grant--<br />

Subcontract, 9; Up to Date, 9<br />

Matteson, Eric L, MD<br />

Infections in Patients on Tumor Necrosis Factor<br />

Therapy . . . . . . . . . . . . . . . . . 56, 130<br />

Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />

centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />

2; human genome sciences, 2; mayo<br />

foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB, 2<br />

Interstitial Lung Diseases in the Rheumatic<br />

Diseases . . . . . . . . . . . . . . . . . . . .109<br />

Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />

centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />

2; human genome sciences, 2; mayo<br />

foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB, 2<br />

Polymyalgia Rheumatica . . . . . . . . . . . 91<br />

Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />

centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />

2; human genome sciences, 2; mayo<br />

foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB,<br />

2; Mauri, Claudia, PhD<br />

B cell Effectors and Regulators . . . . . . . 113<br />

Disclosure: Nothing to Disclose<br />

Mayes, Maureen D, MD, MPH<br />

Systemic Sclerosis: How to Perform Skin<br />

Scores . . . . . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

McCarthy, Geraldine M, MD<br />

Crystal: Pseudogout . . . . . . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

McInnes, Iain B, PhD<br />

Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />

Disclosure: BMS, 2, 5; Pfizer, 2; Roche, 2;<br />

Schering Plough, 2, 8<br />

McLean, Robert R, DSc, MPH<br />

Finding and Using Secondary Data Resources<br />

for Research: Beyond the National Health and<br />

Nutrition Examination Survey and the Usual<br />

Suspects . . . . . . . . . . . . . . . . . . . 103<br />

Disclosure: Nothing to Disclose<br />

How to Understand and Apply the Results <strong>of</strong> a<br />

Journal Article: What You Really Need to Know<br />

About Statistics . . . . . . . . . . . . . . . .134<br />

Disclosure: Nothing to Disclose<br />

You’ve Got the Power: How to Use and Teach<br />

Statistical Power for Studies and Grants. . . 47<br />

Disclosure: Nothing to Disclose<br />

McLellan, Alastair R, MD<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

McMahan, Zsuzsanna H, MD<br />

Immunizations and Rheumatic Diseases - An<br />

Update . . . . . . . . . . . . . . . . . . . . . 37<br />

Disclosure: Nothing to Disclose<br />

Thieves’ Market: Show Me Your Best<br />

Cases . . . . . . . . . . . . . . . . . . . . . . 69<br />

Disclosure: Nothing to Disclose<br />

McNally, Bernadette, MS, PAC<br />

The Multidisciplinary Approach to Hereditary<br />

Periodic Fever Syndromes . . . . . . . . . . 58<br />

Disclosure: Nothing to Disclose<br />

Using Pharmacogenomics to Improve Therapy<br />

for Pediatric Patients . . . . . . . . . . . . . 96<br />

Disclosure: Nothing to Disclose<br />

Mease, Philip J, MD<br />

Psoriatic Disease: Clinical Spectrum and<br />

Comprehensive Treatment Strategies . . . . 69<br />

Disclosure: Abbott, Amgen, BiogenIDEC, BMS,<br />

Centocor, Genentech, Roche, Wyeth and Pfizer,<br />

2; Abbott, Amgen, BiogenIDEC, BMS, Centocor,<br />

Genentech, Roche, Wyeth, Pfizer, UCB, 5<br />

Disclosure: Abbott, Amgen, BiogenIDEC, BMS,<br />

Centocor, Genentech, Roche, Wyeth, Pfizer,<br />

UCB, 8<br />

Meffre, Eric, PhD<br />

Session IV: B Cell Regulation and B Cell<br />

Regulators . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

B cell Effectors and Regulators . . . . . . . 113<br />

Disclosure: Nothing to Disclose<br />

Melton, Alton, MD<br />

Immunodeficiency Syndromes . . . . . . . . 52<br />

Disclosure: Nothing to Disclose<br />

Merkel, Peter A, MD, MPH<br />

Vasculitis: Update . . . . . . . . . . . . . 65, 97<br />

Disclosure: Biovitrum, 5; Bristol Myers Squibb,<br />

2; Celgene, 2; EMD Serono, 5; Genentech, 2;<br />

Genzyme, 5; Nordic Group, 5; Novartis, 5; Smith<br />

Kline Beecham, 5<br />

Takayasu’s Arteritis . . . . . . . . . . . . . .112<br />

Disclosure: Biovitrum, 5; Bristol Myers Squibb,<br />

2; Celgene, 2; EMD Serono, 5; Genentech, 2;<br />

Genzyme, 5; Nordic Group, 5; Novartis, 5; Smith<br />

Kline Beecham, 5


Meroni, Pierluigi, MD<br />

Autoantibodies in Diagnosis and Follow Up <strong>of</strong><br />

Rheumatic Diseases . . . . . . . . . . . . . . 87<br />

Disclosure: Nothing to Disclose<br />

Mevorach, Dror, MD<br />

Cell Death: Receptors, Sensors and<br />

Inflammatory Pathways. . . . . . . . . . . .114<br />

Disclosure: Enlivex, 1, 3<br />

Milette, Katherine, BSc<br />

Measure by Measure: Assessing Psychological<br />

Health and Well-Being in Scleroderma . . .135<br />

Disclosure: Nothing to Disclose<br />

Miller, Donald R, PharmD<br />

Putting ACR Osteoarthritis Guidelines into<br />

Practice: Clinical Applications for the Hip and<br />

Knee . . . . . . . . . . . . . . . . . . . . . .142<br />

Disclosure: Nothing to Disclose<br />

Miller, Frederick W, MD, PhD<br />

Myositis 2010: A to Z . . . . . . . . . . . . . 98<br />

Disclosure: Nothing to Disclose<br />

Myositis . . . . . . . . . . . . . . . . . . . .110<br />

Disclosure: Nothing to Disclose<br />

Moanna, Abeer, MD<br />

Clinicopathologic Conference . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Moen, Laura K, PhD<br />

News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities. . . . . . . . . . 56<br />

Disclosure: Nothing to Disclose<br />

Monrad, Seetha U, MD<br />

Labs and Treatment Options: What Do They<br />

Mean and How Do You Use? . . . . . . . . 131<br />

Disclosure: Nothing to Disclose<br />

Moreland, Larry W, MD<br />

Rheumatoid Arthritis: Biological Agents. . . 96<br />

Disclosure: Nothing to Disclose<br />

Morgan, Matthew W, MD<br />

Transforming Rheumatologic Care with the<br />

Electronic Health Record . . . . . . . . . . . 30<br />

Disclosure: Courtyard Group, 3, 4<br />

Morgan DeWitt, Esi M, MD, MSCE<br />

Session II: Applications to Musculoskeletal<br />

Medicine . . . . . . . . . . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Morrison, William, MD<br />

Musculoskeletal Imaging . . . . . . . . . . 113<br />

Disclosure: Apriomed, inc, 5; Oni, Inc(GE), 9<br />

Muller-Ladner, Ulf, MD<br />

Neuro Endocrine Immunology . . . . . . . . 91<br />

Disclosure: German Research Foundation (DFG), 2<br />

From Fat to Joints - The Vicious Side <strong>of</strong><br />

Adipokines . . . . . . . . . . . . . . . . . . . 98<br />

Disclosure: German Research Foundation (DFG), 2<br />

Murphy, Susan L, ScD, OTR<br />

Ready, Aim, Get Funded! . . . . . . . . . . 131<br />

Disclosure: Nothing to Disclose<br />

Murray, David M, PhD<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Myers, Jennifer S, MD<br />

Diagnostic Errors in <strong>Rheumatology</strong>: Why They<br />

Happen and How We Can Avoid Them . . . 67<br />

Disclosure: Nothing to Disclose<br />

N<br />

Naredo, Esperanza, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 18<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Newman, Eric D, MD<br />

Session II: Applications to Musculoskeletal<br />

Medicine . . . . . . . . . . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Newman, Stanton P, PhD<br />

Successful Coping with Rheumatic Disease . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .135<br />

Disclosure: Nothing to Disclose<br />

Nigrovic, Peter A, MD<br />

Pediatric <strong>Rheumatology</strong> for Adult<br />

Rheumatologists. . . . . . . . . . . . . . . . 57<br />

Disclosure: Nothing to Disclose<br />

Nishio, Midori Jane, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Abbott, 8<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Abbott, 8<br />

Nola, Kamala M, PharmD, MS<br />

From Managed Care to Medicare:<br />

Understanding Reimbursement . . . . . . . 75<br />

Disclosure: Nothing to Disclose<br />

Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54<br />

Disclosure: Nothing to Disclose<br />

O<br />

Oatis, Carol A, PT, PhD<br />

Evidence-based Non-pharmacological Treatment<br />

for Hip, Knee, and Hand Osteoarthritis: The New<br />

ACR Guidelines . . . . . . . . . . . . . . . . 34<br />

Disclosure: Nothing to Disclose<br />

Putting ACR Osteoarthritis Guidelines into<br />

Practice: Clinical Applications for the Hip and<br />

Knee . . . . . . . . . . . . . . . . . . . . . .142<br />

Disclosure: Nothing to Disclose<br />

Oddis, Chester V, MD<br />

Inflammatory Myopathy Update. . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

Myositis 2010: A to Z . . . . . . . . . . . . . 98<br />

Disclosure: Nothing to Disclose<br />

O’Dell, James R, MD<br />

ACR Leadership Town Hall Meeting . . . . .106<br />

Disclosure: Nothing to Disclose<br />

Oeser, Annette M, BS<br />

Web-based Support <strong>of</strong> Clinical Practice and<br />

Teaching: Twittering, Blogging, and Doing the<br />

Wiki. . . . . . . . . . . . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

You’ve Got the Power: How to Use and Teach<br />

Statistical Power for Studies and Grants. . . 47<br />

Disclosure: Nothing to Disclose<br />

Olech, Ewa, MD<br />

Peripheral Magnetic Resonance Imaging in<br />

Clinical <strong>Rheumatology</strong> . . . . . . . . . . . . 38<br />

Disclosure: Biogen Idec, 2; Bio-rad, 2<br />

Olech, Ewa, MD<br />

Peripheral Magnetic Resonance Imaging in<br />

Clinical <strong>Rheumatology</strong> . . . . . . . . . . . . 62<br />

Disclosure: Centocor, 2; Crescendo, 2;<br />

Genentech, 2, 5, 8; Pfizer, 5; Roche, 2; UCB, 2, 8;<br />

Vertex, 2<br />

Olenginski, Thomas P, MD<br />

Osteoporosis: Applying FRAX Methodology. 64<br />

Disclosure: Eli Lilly, Inc2, 5; Pfizer, Forest, Abbott,<br />

Novartis, Amgen,Sanogi-Aventis, Procter and<br />

Gamble, Genentech, 8; Roche, Genentech, 2<br />

Oliver, Susan M, RN, MSc<br />

Reproductive and Sexual Health Issues for<br />

Women with Rheumatic Disease. . . . . . . 54<br />

Disclosure: Nothing to Disclose<br />

O’Neil, Kathleen M, MD<br />

Juvenile Dermatomyositis in 2010 - From Bench<br />

to Bedside . . . . . . . . . . . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

New Insights into Primary Central Nervous<br />

System Vasculitis in Children<br />

. . . . . . . . . . . . . . . . . . . . . . . . .133<br />

Disclosure: Nothing to Disclose<br />

O’Neill, Luke A, PhD<br />

Cell Death: Receptors, Sensors and<br />

Inflammatory Pathways. . . . . . . . . . . .114<br />

Disclosure: Nothing to Disclose<br />

Toll-like Receptors and Inflammation: Towards<br />

Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Nothing to Disclose<br />

Opava, Christina H, PhD<br />

Patient Participation in Research. . . . . . .119<br />

Disclosure: Nothing to Disclose<br />

Patient Perspective on Outcomes: Patients as<br />

Partners in the Research Process . . . . . .111<br />

Disclosure: Nothing to Disclose<br />

What’s New and Noteworthy in 2010: A<br />

Review <strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />

Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

O’Rourke, Kenneth S, MD<br />

Teaching and Assessing Arthrocentesis . . 112<br />

Disclosure: Nothing to Disclose<br />

Joint Injection Techniques . . . . . . . . . .113<br />

Disclosure: Nothing to Disclose<br />

O’Shea, John J, MD<br />

Kinases as Therapeutic Targets. . . . . . . . 59<br />

Disclosure: Pfizer, 9<br />

Østergaard, Mikkel, MD, PhD, DMSc<br />

MRI . . . . . . . . . . . . . . . . . . . . . . . 91<br />

Disclosure: Nothing to Disclose<br />

Peripheral Magnetic Resonance Imaging in<br />

<strong>Rheumatology</strong> Practice . . . . . . . . . . . . 33<br />

Disclosure: Nothing to Disclose<br />

Overman, Steven S, MD, MPH<br />

CAM is a SCAM! Complementary and<br />

Alternative “Medicince” Has No Place in<br />

<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />

Disclosure: Nothing to Disclose<br />

Oyoo, Omondi G, MD, MMed<br />

ILAR Global Health Project . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book 309<br />

INVITED SPEAKER /MODERATOR INDEX


INVITED SPEAKER /MODERATOR INDEX<br />

P<br />

Paget, Stephen A, MD<br />

Giant Cell Arteritis - Diagnosis<br />

and Therapy . . . . . . . . . . . . . . . . . . 69<br />

Disclosure: Nothing to Disclose<br />

REF Marshall J. Schiff, MD, Memorial<br />

Lectureship: Everything a Rheumatologist<br />

Should Know About Spine Surgery but Was<br />

Afraid to Ask . . . . . . . . . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Paiva, Eduardo S, MD<br />

When Pieces Don’t Fit . . . . . . . . . . . .120<br />

Disclosure: Apsen Brazil, 5; Eli Lilly Brazil, 8;<br />

Pfizer Brazil, 8<br />

Passo, Murray H, MD<br />

Pediatrics: Difficult to Treat Juvenile Idiopathic<br />

Arthritis . . . . . . . . . . . . . . . . . . . . 29<br />

Disclosure: Pfizer, 2, 5<br />

Pennington, Scott D, MD<br />

Total Shoulder Arthroplasty and Reverse Total<br />

Shoulder Arthroplasty: Surgery<br />

and Rehabilitation. . . . . . . . . . . . . . .147<br />

Disclosure: Nothing to Disclose<br />

Perez-Masuelli, Carmen, MD<br />

The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />

Disclosure: Nothing to Disclose<br />

Perlman, Harris R, PhD<br />

Innate Immunity and Inflammation . . . . . 30<br />

Disclosure: Nothing to Disclose<br />

Phillips, Kristine, MD, PhD<br />

Disparities and Pain: Examining Research,<br />

Practice and Policy . . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Interstitial Lung Diseases in the Rheumatic<br />

Diseases . . . . . . . . . . . . . . . . . . . .109<br />

Disclosure: Nothing to Disclose<br />

Pierangeli, Silvia S, PhD<br />

Antiphospholipid Syndrome . . . . . . . . . 87<br />

Disclosure: Nothing to Disclose<br />

Pillai, Shiv, MD, PhD<br />

Session I: B cell Development . . . . . . . . 20<br />

Disclosure: Nothing to Disclose<br />

Pincus, Theodore, MD<br />

WK - Patient Questionnaires to Monitor Status<br />

and Document Improvement in Standard Care:<br />

Practical Considerations . . . . . . . . . . .102<br />

Disclosure: Nothing to Disclose<br />

Clinical Research Methodology . . . . . . .107<br />

Disclosure: Nothing to Disclose<br />

Pisetsky, David S, MD, PhD<br />

From Fat to Joints - The Vicious Side <strong>of</strong><br />

Adipokines . . . . . . . . . . . . . . . . . . . 98<br />

Disclosure: Nothing to Disclose<br />

Plaas, Anna H, PhD<br />

Molecular Mechanisms <strong>of</strong> Inflammatory<br />

Signaling in Cartilage Destruction . . . . . . 27<br />

Disclosure: Pfizer, 2; Smith Nephew, 2<br />

Osteoarthritis . . . . . . . . . . . . . . . . .110<br />

Disclosure: Pfizer Inc, 2; Smith Nephew, 2<br />

Plass, Nicole D, BSN, MPA<br />

The Multidisciplinary Approach to Hereditary<br />

Periodic Fever Syndromes . . . . . . . . . . 58<br />

Disclosure: Nothing to Disclose<br />

Pollock, P. Scott MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: TBA<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: TBA<br />

Poole, Janet L, PhD, OTR<br />

Adaptations and Solutions to Help People with<br />

Scleroderma Continue to Work . . . . . . .102<br />

Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

Research Education Foundation, 2<br />

Measure by Measure: Assessing Psychological<br />

Health and Well-Being in Scleroderma . . .135<br />

Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

Research Education Foundation, 2<br />

Practice Potpourri . . . . . . . . . . . . . . . 86<br />

Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

Research Education Foundation, 2<br />

ARHP General Session I - Keynote<br />

Address. . . . . . . . . . . . . . . . . . . . . 32<br />

Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

Research Education Foundation, 2<br />

ARHP General Session II: ARHP Distinguished<br />

Lecturer . . . . . . . . . . . . . . . . . . . . 62<br />

Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

Research Education Foundation, 2<br />

Moderators Orientation . . . . . . . . . . . 27<br />

Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />

Research Education Foundation, 2<br />

Pope, Janet E, MD, MPH<br />

Raynaud’s and Digital Ischemia . . . . 65, 105<br />

Disclosure: Actelion, 2, 5; Mediquest, 5; Pfizer,<br />

5; UT, 2<br />

Pope, Richard M, MD<br />

Toll-like Receptors and Inflammation: Towards<br />

Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Nothing to Disclose<br />

Porter, Duncan, MD<br />

Rheumatoid Arthritis Treatment 2010:<br />

Traditional DMARDs, Biologic DMARDs and<br />

Newer Treatment Strategies . . . . . . . . 114<br />

Disclosure: Abbott, 5, 8; Pfizer, 2; Roche, 2, 5;<br />

Schering Plough, 5, 8; UCB, 5; Wyeth, 2<br />

Pruijn, Ger, PhD<br />

The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

R<br />

Radbruch, Andreas H, PhD<br />

Session II: B cell Activation and<br />

Trafficking . . . . . . . . . . . . . . . . . . . 20<br />

Disclosure: Nothing to Disclose<br />

Radstake, Timothy RDJ, MD, PhD<br />

Toll-like Receptors and Inflammation: Towards<br />

Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Nothing to Disclose<br />

Scleroderma-Biomarkers . . . . . . . . . . 111<br />

Disclosure: Nothing to Disclose<br />

Randall, Troy, PhD<br />

Session III: B cells in the Immune Response. 23<br />

Disclosure: Vaccinex, 2<br />

Rap<strong>of</strong>f, Michael A, PhD<br />

Daltroy Memorial Lecture: Adherence to<br />

Medical Regimens for Rheumatic Diseases<br />

and the Importance <strong>of</strong> Patient-Clinician<br />

Communication . . . . . . . . . . . . . . . . 61<br />

Disclosure: Nothing to Disclose<br />

ARHP Networking at Noon . . . . . . . . . . 63<br />

Disclosure: Nothing to Disclose<br />

Rawlings, David J, MD<br />

Session II: B cell Activation and Trafficking . 20<br />

Disclosure: Nothing to Disclose<br />

Ray, Laura E, MA, MLS<br />

Web-based Support <strong>of</strong> Clinical Practice and<br />

Teaching: Twittering, Blogging, and Doing the<br />

Wiki. . . . . . . . . . . . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

ARHP Networking at Noon . . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

Raza, Karim, BA, PhD<br />

The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />

Towards Prevention <strong>of</strong> Disease? . . . . . . . 76<br />

Disclosure: Cellzome, 2; UCB, 2, 5; Wyeth, 2<br />

Reed, Ann M, MD<br />

Juvenile Dermatomyositis in 2010 - From Bench<br />

to Bedside . . . . . . . . . . . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

Reiff, Andreas O, MD<br />

Inflammatory Eye Disease . . . . . . . . . . 35<br />

Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 26<br />

Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8<br />

Richardson, Bruce C, MD, PhD<br />

The Revolution <strong>of</strong> Epigenetics in<br />

Autoimmunity . . . . . . . . . . . . . . . . . 47<br />

Disclosure: Nothing to Disclose<br />

Rider, Lisa G, MD<br />

Practice Potpourri . . . . . . . . . . . . . . . 86<br />

Disclosure: Nothing to Disclose<br />

Myositis . . . . . . . . . . . . . . . . . . . .110<br />

Disclosure: Nothing to Disclose<br />

Ridley, David J, MD<br />

The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />

Disclosure: BMS, 2; Celgene, 2; Centacor, 2;<br />

Genentech, 2; UCB, 2<br />

Rigby, William F. C, MD<br />

ACR REF Within Our Reach: Finding a Cure for<br />

Rheumatoid Arthritis . . . . . . . . . . . . . 45<br />

Disclosure: Nothing to Disclose<br />

Riskind, Peter, MD, PhD<br />

Update on Multiple Sclerosis. . . . . . . . . 59<br />

Disclosure: Biogen idec, 5; Teva, 5, 9<br />

Rock, Kenneth L, MD<br />

Cell Death: Receptors, Sensors and<br />

Inflammatory Pathways. . . . . . . . . . . .114<br />

Disclosure: San<strong>of</strong>i-Aventis, 2<br />

Roediger, Joan M, JD, LLM<br />

Contract Negotiations for Physicians . . . . 65<br />

Disclosure: Nothing to Disclose<br />

310<br />

2010 Program Book


Rogers, Joan C, PhD, OTR/ L<br />

Understanding Functional Activity in<br />

Rheumatoid Arthritis: What We Know and What<br />

We Don’t Know . . . . . . . . . . . . . . . . 86<br />

Disclosure: Nothing to Disclose<br />

Rose, Carlos D, MD<br />

Pediatric Spondylarthropathies: From Genetics<br />

to the Clinic . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Nothing to Disclose<br />

ILAR Global Health Project . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Rosenbaum, James T, MD<br />

Molecular Mechanisms <strong>of</strong> Ocular<br />

Inflammation . . . . . . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

Rosenzweig, Holly L, PhD<br />

Molecular Mechanisms <strong>of</strong> Ocular<br />

Inflammation . . . . . . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

Roth, Johannes, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 18<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . 22Disclosure:<br />

Nothing to Disclose<br />

Imaging. . . . . . . . . . . . . . . . . . . . .108<br />

Disclosure: Nothing to Disclose<br />

Roth-Wojcicki, Elizabeth L, RN MS CPNP<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Nothing to Disclose<br />

Roubey, Robert A. S, MD<br />

Antiphospholipid Syndrome . . . . . . . . . 56<br />

Disclosure: Quest Diagnostics, 5<br />

Ruderman, Eric M, MD<br />

The Great Debate: Is it Time to Use Biologics as<br />

First-line Therapy in Rheumatoid Arthritis? . 39<br />

Disclosure: Nothing to Disclose<br />

Update on Safety Issues in the Treatment <strong>of</strong><br />

Rheumatic Diseases – From the Food and Drug<br />

Administration and Beyond . . . . . . . . . 77<br />

Disclosure: Nothing to Disclose<br />

Methotrexate 2010 . . . . . . . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Ruffing, Victoria L, RN<br />

Patient Education on the Run . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Rye, Kerry-Anne, PhD<br />

A Critical Role for Lipid Metabolism in the<br />

Interplay between Atherosclerosis and<br />

Autoimmune Disorders . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

S<br />

Saag, Kenneth G, MD, MSc<br />

Welcome and Introductions . . . . . . . . . 19<br />

Disclosure: Amgen, 5, 8; AstraZenica, 5; Eli Lilly,<br />

5; Genentech, 5; GlaxoSmithKline, 5; Merck,<br />

5; NicOx, 5; Nitec, 5; Novartis, 5, 8; Pfizer, 5;<br />

Proctor & Gamble, 5; Takeda, 5; UCB, 5<br />

Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />

Disclosure: Amgen, 5, 8; AstraZenica, 5; Eli Lilly,<br />

5; Genentech, 5; GlaxoSmithKline, 5; Merck, 5;<br />

NicOx, 5; Nitec, 5; Novartis, 5, 8; Pfizer, 5<br />

Proctor & Gamble, 5; Takeda, 5; UCB, 5<br />

Salmon, Jane E, MD<br />

Antiphospholipid Syndrome . . . . . . . . . 87<br />

Disclosure: Nothing to Disclose<br />

Salt, Elizabeth G, PhD, ARNP<br />

Juvenile Fibromyalgia . . . . . . . . . . . . . 53<br />

Disclosure: Nothing to Disclose<br />

Samuels, Jonathan, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 18<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Sanchez-Guerrero, F. Jorge, MD<br />

The Brain and Systemic Lupus Erythematosus:<br />

2010 Update (Clinical Review) . . . . . . . . 66<br />

Disclosure: Nothing to Disclose<br />

Systemic Lupus Erythematosus: Central Nervous<br />

System . . . . . . . . . . . . . . . . . . 52, 106<br />

Disclosure: Nothing to Disclose<br />

Sandborg, Christy I, MD<br />

The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />

Workforce: Gender Issues in the Workplace<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 94<br />

Disclosure: Nothing to Disclose<br />

Sanz, Inaki, MD<br />

Session III: B cells in the Immune<br />

Response. . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Biogen, 2; GSK, 2, 5<br />

Scalapino, Kenneth J, MD<br />

Iatrogenic Misadventures: Complex Cases . 85<br />

Disclosure: Nothing to Disclose<br />

Scanzello, Carla R, MD, PhD<br />

Osteoarthritis . . . . . . . . . . . . . . . . .110<br />

Disclosure: Amgen, 9<br />

Schlenk, Elizabeth A, PhD, RN<br />

What’s New and Noteworthy in 2010: A Review<br />

<strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />

Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />

Disclosure: Nothing to Disclose<br />

ARHP Networking at Noon . . . . . . . . . . 64<br />

Disclosure: Nothing to Disclose<br />

Schlesinger, Naomi, MD<br />

Crystallizing Your Assessment and Treatment <strong>of</strong><br />

Difficult to Treat Gout . . . . . . . . . . . . .114<br />

Disclosure: Novartis, 2, 5;Takeda, 8; URL<br />

Pharma, 9<br />

Schmidt, Wolfgang A, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists-Day One . . . . . . . . . . 18<br />

Disclosure: Abbott, 2; Abbott, 8; Actelion, 2,<br />

8; Berlin Chemie, 8; BMS, 2, 8; Chugai, 2, 8;<br />

Esaote, 2, 8; Essex, 2, 8; GE, 2; Lilly, 2; Medac,<br />

2, 8; Merck, 8; MSD, 2, 8; Novartis, 2, 8; Pfizer,<br />

2, 8; Roche, 2, 8; Schering - Plough, 2, 8; UCB, 2;<br />

Wyeth, 2, 8<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Abbott, 2, 8; Actelion, 2, 8; Berlin<br />

Chemie, 8; BMS, 2, 8; Chugai, 2, 8; Esaote, 2, 8;<br />

Essex, 2, 8; GE, 2; Lilly, 2; Medac, 2, 8; Merck, 8;<br />

MSD, 2, 8; Novartis, 2, 8; Pfizer, 2, 8; Roche, 2, 8;<br />

Schering - Plough, 2, 8; UCB, 2; Wyeth, 2, 8<br />

Schneider, Rayfel, MBBCh<br />

Still’s Disease, Febrile Illnesses . . . . . . . . 83<br />

Disclosure: H<strong>of</strong>fman-La Roche, 5<br />

Schnitzer, Thomas J, MD, PhD<br />

Osteoarthritis - What is New in Old Joints .122<br />

Disclosure: AstraZeneca, 9; Eli Lilly & Co., 5;<br />

Logical Therapeutics, 5; NicOx, 1, 5; Nordic<br />

Bioscience, 2; Pfizer, 2<br />

Seo, Philip, MD<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />

Microscopic Polyangiitis: Understanding and<br />

Applying the Data from Recent Clinical Trials . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />

Disclosure: Nothing to Disclose<br />

Serre, Guy B, MD, PhD<br />

The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />

Disclosure: bioMérieux (FRANCE), 7<br />

Shadick, Nancy A, MD, MPH<br />

Rheumatoid Arthritis: Difficult Cases . . . .130<br />

Disclosure: AMGEN, 2; Biogen Idec, 2; Crescendo<br />

Biosciences, 2<br />

Rheumatoid Arthritis: Difficult Rheumatoid<br />

Arthritis . . . . . . . . . . . . . . . . . . . . 29<br />

Disclosure: AMGEN, 2; Biogen Idec, 2; Crescendo<br />

Biosciences, 2<br />

Shakoor, Najia, MD<br />

Osteoarthritis - What is New in Old Joints .122<br />

Disclosure: Nothing to Disclose<br />

Shen, Nan, MD<br />

B cell Effectors and Regulators . . . . . . . 113<br />

Disclosure: Nothing to Disclose<br />

Tolerogenic Dendritic Cells: Regulators <strong>of</strong><br />

Immune Reactivity and Therapeutic Agents in<br />

Autoimmune Disease . . . . . . . . . . . . 101<br />

Disclosure: Nothing to Disclose<br />

Sherry, David D, MD<br />

Career Opportunities in <strong>Rheumatology</strong>: Making<br />

a Choice . . . . . . . . . . . . . . . . . . . .112<br />

Disclosure: Nothing to Disclose<br />

Shulman, Neil, MD<br />

ARHP General Session I - Keynote Address . 32<br />

Disclosure: Nothing to Disclose<br />

Silver, Richard M, MD<br />

Systemic Sclerosis: New Therapeutic<br />

Approaches . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Boehringer Ingelheim, 2<br />

Silverman, Gregg J, MD<br />

Session V: Emerging Concepts in B cell Directed<br />

Therapies. . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Neostasis, 5<br />

ACR REF Within Our Reach: Finding a Cure for<br />

Rheumatoid Arthritis . . . . . . . . . . . . . 45<br />

Disclosure: Neostasis, 5<br />

Silverman, Stuart L, MD<br />

Controversies in Osteoporosis and Low Bone<br />

Mass: Who Do We Treat, For How Long, and at<br />

What Risks? . . . . . . . . . . . . . . . . . .103<br />

Disclosure: Nothing to Disclose<br />

Osteoporosis: Interpreting Dual Energy X-ray<br />

Absorptiometry and Clinical Risk Factors: The<br />

New Fracture Risk Assessment Algorithm. . . .<br />

. . . . . . . . . . . . . . . . . . . . . . . 33, 62<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book 311<br />

INVITED SPEAKER /MODERATOR INDEX


INVITED SPEAKER /MODERATOR INDEX<br />

312<br />

Silvers, J. B, PhD<br />

CORC Forum: Health Care Reform – Where Are<br />

We Heading?. . . . . . . . . . . . . . . . . .101<br />

Disclosure: Nothing to Disclose<br />

Simkin, Peter A, MD<br />

Crystal: Management <strong>of</strong> Gout . . . . . . . . 56<br />

Disclosure: Nothing to Disclose<br />

Simms, Robert W, MD<br />

Systemic Sclerosis: New Therapeutic<br />

Approaches . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Nothing to Disclose<br />

Slusher, Barbara A, PA-C, MSW<br />

Networking at Noon . . . . . . . . . . . . . 64<br />

From Managed Care to Medicare:<br />

Understanding Reimbursement . . . . . . . 75<br />

Disclosure: Nothing to Disclose<br />

Smith, Benjamin J, PA-C<br />

Rheumatic Disease Update: Sjögren’s<br />

Syndrome . . . . . . . . . . . . . . . . . . . 58<br />

Disclosure: Amgen, 5; NicOx, 5; Pfizer, 5<br />

ARHP Networking Forum . . . . . . . . . . . 30<br />

Disclosure: Amgen, 5; NicOx, 5; Pfizer, 5<br />

Smolen, Josef S, MD<br />

Remission in Rheumatoid Arthritis. . . . . .135<br />

Disclosure: Abbott, Astra-Zeneca, BMS,<br />

Centocor, Novo, Roche, San<strong>of</strong>i-Aventis, Schering-<br />

Plough, UCB, Wyeth, 5; Abbott, BMS, Centocor,<br />

Roche, Schering-Plough, UCB, Wyeth, 9; Abbott,<br />

BMS, Roche, Schering-Plough, UCB, Wyeth, 2<br />

Rheumatoid Arthritis Treatment 2010:<br />

Traditional DMARDs, Biologic DMARDs and<br />

Newer Treatment Strategies . . . . . . . . 114<br />

Disclosure: Abbott, Astra-Zeneca, BMS,<br />

Centocor, Novo, Roche, San<strong>of</strong>i-Aventis, Schering-<br />

Plough, UCB, Wyeth, 5; Abbott, BMS, Centocor,<br />

Roche, Schering-Plough, UCB, Wyeth, 9; Abbott,<br />

BMS, Roche, Schering-Plough, UCB, Wyeth, 2<br />

Solomon, Daniel H, MD, MPH<br />

Session II: Applications to Musculoskeletal<br />

Medicine . . . . . . . . . . . . . . . . . . . . 19<br />

Disclosure: abbott, amgen, 2<br />

Rheumatoid Arthritis: Safety <strong>of</strong> Novel<br />

Therapies. . . . . . . . . . . . . . . . . . . . 65<br />

Disclosure: abbott, amgen, 2<br />

Somers, Emily C, PhD, ScM<br />

Top 10 in ‘10: Top 10 Public Health Advances<br />

in the First 10 Years <strong>of</strong> the Centers for Disease<br />

Control and Prevention Arthritis Program. .147<br />

Disclosure: Nothing to Disclose<br />

Specks, Ulrich, MD<br />

Clinicopathologic Conference . . . . . . . . 55<br />

Disclosure: Nothing to Disclose<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />

Microscopic Polyangiitis: Understanding and<br />

Applying the Data from Recent Clinical Trials . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />

Disclosure: Nothing to Disclose<br />

Spiera, Robert, MD<br />

Giant Cell Arteritis - Diagnosis and Therapy. 69<br />

Disclosure: Nothing to Disclose<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />

Microscopic Polyangiitis: Understanding and<br />

Applying the Data from Recent Clinical Trials<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book<br />

Srivastava, Sunil Kumar, MD<br />

Inflammatory Eye Disease/Uveitis . . . . . . 83<br />

Disclosure: Bausch and Lomb, 5<br />

St.Clair, E William, MD<br />

Session VI: Role <strong>of</strong> B cells in Autoimmunity:<br />

Lessons from Clinical Trials . . . . . . . . . . 23<br />

Disclosure: Genentech, 2<br />

ACR Leadership Town Hall Meeting . . . . .106<br />

Disclosure: Genentech, 2<br />

REF Edmond L. Dubois, MD, Memorial<br />

Lectureship . . . . . . . . . . . . . . . . . . 53<br />

Disclosure: Genentech, 2<br />

REF Paul Klemperer, MD, Memorial Lectureship:<br />

Systemic Sclerosis: Genetic? Autoimmune? One<br />

Disease? . . . . . . . . . . . . . . . . . . . . 98<br />

Disclosure: Genentech, 2<br />

Starz, Terence W, MD<br />

Understanding Functional Activity in<br />

Rheumatoid Arthritis: What We Know and What<br />

We Don’t Know . . . . . . . . . . . . . . . . 86<br />

Disclosure: Pfizer, 5<br />

Steen, Virginia D, MD<br />

Mixed Connective Tissue Disease is Not Really<br />

that Mixed . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Sterrett, Ashley G, MD<br />

Teaching and Assessing Arthrocentesis . . 112<br />

Disclosure: Nothing to Disclose<br />

Joint Simulator. . . . . . . . . . . . . . . 67, 97<br />

Disclosure: Nothing to Disclose<br />

Stevens, Anne M, MD, PhD<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Nothing to Disclose<br />

Kawasaki Disease in the 21st Century - Genes,<br />

Pathogenesis, and Biologics . . . . . . . . . 90<br />

Disclosure: Nothing to Disclose<br />

Stone, John H, MD, MPH<br />

Session VI: Role <strong>of</strong> B cells in Autoimmunity:<br />

Lessons from Clinical Trials . . . . . . . . . . 23<br />

Disclosure: Nothing to Disclose<br />

Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />

Disclosure: Nothing to Disclose<br />

Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />

Microscopic Polyangiitis: Understanding and<br />

Applying the Data from Recent Clinical Trials<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />

Disclosure: Nothing to Disclose<br />

Suarez-Almazor, Maria E, MD, PhD<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Sukumaran, Sukesh, MBBS, MD<br />

Inflammatory Eye Disease . . . . . . . . . . 35<br />

Disclosure: Nothing to Disclose<br />

Sulich, Andrew J, MD<br />

Hand X-ray Review and Interpretation. . . . 58<br />

Disclosure: Nothing to Disclose<br />

Symmons, Deborah P, MD<br />

Economic Evaluations . . . . . . . . . . . . . 88<br />

Disclosure: Nothing to Disclose<br />

Szekanecz, Zoltan, MD, PhD, DSC<br />

A Critical Role for Lipid Metabolism in the<br />

Interplay between Atherosclerosis and<br />

Autoimmune Disorders . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

Szer, Ilona S, MD<br />

Pediatric Systemic Lupus . . . . . . . . . . . 52<br />

Disclosure: Nothing to Disclose<br />

T<br />

Tabechian, Darren, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 18<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Tak, Paul P, MD, PhD<br />

The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />

Towards Prevention <strong>of</strong> Disease? . . . . . . . 76<br />

Disclosure: Roche/Genentech, 2, 5<br />

Toll-like Receptors and Inflammation: Towards<br />

Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: NovImmune, 5<br />

Takayanagi, Hiroshi, MD, PhD<br />

REF Oscar S. Gluck, MD, Memorial Lectureship<br />

- Osteoimmunology: Crosstalk Between the<br />

Immune and Bone Systems: Biologic and Clinical<br />

Implications . . . . . . . . . . . . . . . . . . 28<br />

Disclosure: Nothing to Disclose<br />

Tall, Alan, MD<br />

A Critical Role for Lipid Metabolism in the<br />

Interplay between Atherosclerosis and<br />

Autoimmune Disorders . . . . . . . . . . . 121<br />

Disclosure: BI, 5; Merck, 5; Novartis, 5; Pfizer, 5;<br />

Roache, 5<br />

Talley, Anne Camille, MBA<br />

The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />

Workforce: Gender Issues in the Workplace<br />

. . . . . . . . . . . . . . . . . . . . . . . . . 94<br />

Disclosure: Merck Telerx Division, 3; Schering<br />

Plough, 5; Various Investments in Stock & bond<br />

funds, 1<br />

Talmadge, W. Tracy, PhD<br />

Reproductive and Sexual Health Issues for<br />

Women with Rheumatic Disease. . . . . . . 54<br />

Disclosure: Nothing to Disclose<br />

Tan, Filemon K, MD, PhD<br />

Immunopathogenesis <strong>of</strong> Systemic Sclerosis. . .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Taylor, Mihaela, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 18<br />

Disclosure: Nothing to Disclose<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Nothing to Disclose<br />

Tedder, Thomas, PhD<br />

Mouse to House: Lessons Learned About Lupus<br />

Therapeutics . . . . . . . . . . . . . . . . . . 39<br />

Disclosure: Angelica Therapeutics, Inc., 1, 5<br />

MedImmune, Inc., 5<br />

Session IV: B Cell Regulation and B Cell<br />

Regulators . . . . . . . . . . . . . . . . . . . 23<br />

Disclosure: Angelica Therapeutics, Inc., 1<br />

MedImmune, Inc., 5


Terkeltaub, Robert, MD<br />

Crystallizing Your Assessment and Treatment <strong>of</strong><br />

Difficult to Treat Gout . . . . . . . . . . . . .114<br />

Disclosure: Amgen Veterinary, 5; Anadys, 5;<br />

ARDEA, 5; BioCryst, 5; Celgene, 5; Metabolex,<br />

5; NIH, 2; Novartis, 5; Nuon, 5; Pfizer, 5;<br />

Prescription Solutions, 5; Regeneron, 5; Takeda,<br />

9; UCB, 5; URL, 5; VA, 2<br />

Tesser, John RP, MD<br />

Controversies in Osteoporosis and Low Bone<br />

Mass: Who Do We Treat, For How Long, and at<br />

What Risks? . . . . . . . . . . . . . . . . . .103<br />

Disclosure: Nothing to Disclose<br />

Scleroderma: The Promise <strong>of</strong> Anti-fibrotic<br />

Therapies - A Translational Approach . . . . 67<br />

Disclosure: Nothing to Disclose<br />

Theis, Kristina A, MPH<br />

Work Assessments: A ‘How-To’ That Could Save<br />

Your Patient’s Life/Job. . . . . . . . . . . . .131<br />

Disclosure: Nothing to Disclose<br />

Thiele, Ralf G, MD<br />

Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day One. . . . . . . . . . 17<br />

Disclosure: Abbott, 8; Amgen, 5; GE Healthcare,<br />

9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5<br />

MSUS - Musculoskeletal Ultrasound Course for<br />

Rheumatologists - Day Two. . . . . . . . . . 22<br />

Disclosure: Abbott, 8; Amgen, 5; GE Healthcare,<br />

9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5<br />

Psoriatic Arthritis and Periarticular Imaging:<br />

Focus on Enthesitis, Dactylitis, and Nail<br />

Disease . . . . . . . . . . . . . . . . . . . . . 92<br />

Disclosure: Abbott, 8; Amgen, 5; GE Healthcare,<br />

9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5<br />

Thombs, Brett D, BA, MA, PhD<br />

Measure by Measure: Assessing Psychological<br />

Health and Well-Being in Scleroderma . . .135<br />

Disclosure: Nothing to Disclose<br />

Thomson, Angus W, PhD<br />

Tolerogenic Dendritic Cells: Regulators <strong>of</strong><br />

Immune Reactivity and Therapeutic Agents in<br />

Autoimmune Disease . . . . . . . . . . . . 101<br />

Disclosure: Nothing to Disclose<br />

Tietge, Uwe J. F, MD<br />

A Critical Role for Lipid Metabolism in the<br />

Interplay between Atherosclerosis and<br />

Autoimmune Disorders . . . . . . . . . . . .121<br />

Disclosure: Nothing to Disclose<br />

Tillman, Melesia<br />

Certified <strong>Rheumatology</strong> Coder Course . . . 20<br />

Disclosure: Nothing to Disclose<br />

Ting, Tracy V, MD<br />

Juvenile Fibromyalgia . . . . . . . . . . . . . 53<br />

Disclosure: Nothing to Disclose<br />

Torgerson, Troy R, MD, PhD<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Nothing to Disclose<br />

Trizuto, Jennifer L, MPT<br />

Total Shoulder Arthroplasty and Reverse<br />

Total Shoulder Arthroplasty: Surgery and<br />

Rehabilitation . . . . . . . . . . . . . . . . .147<br />

Disclosure: Nothing to Disclose<br />

Troum, Orrin M, MD<br />

Peripheral Magnetic Resonance Imaging in<br />

Clinical <strong>Rheumatology</strong> . . . . . . . . . . 38, 62<br />

Disclosure: International Society <strong>of</strong> Extremity<br />

MRI in <strong>Rheumatology</strong>, 6; Intersocietal<br />

Commission for the Accrediation <strong>of</strong> MRI<br />

Laboratories, 6<br />

Troxell, Megan, MD<br />

Renal Histopathology in Systemic Lupus<br />

Erythematosus and Vasculitis . . . . . . 33, 47<br />

Disclosure: Nothing to Disclose<br />

Tse, Shirley, MD<br />

Pediatric Spondylarthropathies: From Genetics<br />

to the Clinic . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Abbott, 5; Merck/Schering Plough,<br />

5; Wyeth, 5<br />

Pediatrics: Spondyloarthritis in Children . . 96<br />

Disclosure: Abbott, 5; Merck/Schering Plough,<br />

5; Wyeth, 5<br />

Tuan, Rocky S., PhD<br />

Stem Cell Reprogramming: Molecular<br />

Mechanisms and Clinical Applications and<br />

Implications . . . . . . . . . . . . . . . . . .102<br />

Disclosure: Nothing to Disclose<br />

Tyndall, Alan G, MD<br />

Systemic Sclerosis: New Therapeutic<br />

Approaches . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Nothing to Disclose<br />

Scleroderma Mimics . . . . . . . . . . . . . 65<br />

Disclosure: Nothing to Disclose<br />

U<br />

Uknis, Audrey B, MD<br />

ACR Leadership Town Hall Meeting . . . . .106<br />

Disclosure: Nothing to Disclose<br />

V<br />

Valeriano-Marcet, Joanne, MD<br />

Rheumatic Manifestations <strong>of</strong> Neoplastic<br />

Diseases . . . . . . . . . . . . . . . . . . . . 24<br />

Disclosure: Nothing to Disclose<br />

Teaching and Assessing Arthrocentesis . . 112<br />

Disclosure: Nothing to Disclose<br />

Joint Simulator. . . . . . . . . . . . . . . 67, 97<br />

Disclosure: Nothing to Disclose<br />

van de Laar, Mart A, MD<br />

Successful Coping with Rheumatic Disease 135<br />

Disclosure: Nothing to Disclose<br />

Economic Evaluations . . . . . . . . . . . . . 88<br />

Disclosure: Nothing to Disclose<br />

Van den Bosch, Filip E, MD, PhD<br />

Bowel Associated Rheumatologic Diseases . 24<br />

Disclosure: Nothing to Disclose<br />

Van Der Heijde, Desiree M, MD, PhD<br />

Ankylosing Spondylitis: 2010 Update . 36, 105<br />

Disclosure: abbott, 5; amgen, 5; bristol meyers<br />

squibb, 5; centocor, 5; chugai, 5; msd, 5;<br />

novartis, 5; pfizer, 5; roche, 5; ucb, 5<br />

Van Lent, Peter, MD<br />

Molecular Mechanisms <strong>of</strong> Inflammatory<br />

Signaling in Cartilage Destruction . . . . . . 27<br />

Disclosure: Nothing to Disclose<br />

Varga, John, MD<br />

Scleroderma: The Promise <strong>of</strong> Anti-fibrotic<br />

Therapies - A Translational Approach . . . . 67<br />

Disclosure: BMS, 2; novartis, 2<br />

Villa-Forte, Alexandra, MD, MPH<br />

Heparin and Antiphospholipid Syndromeinduced<br />

Thrombocytopenia . . . . . . . . . 31<br />

Disclosure: Nothing to Disclose<br />

Vasculitis Mimics . . . . . . . . . . . . . . . 57<br />

Disclosure: Nothing to Disclose<br />

Villasenor Ovies, Pablo, MD<br />

<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Lower<br />

Extremity and Lumbosacral Spine: Anatomical<br />

Correlates . . . . . . . . . . . . . . . . . . . 38<br />

Disclosure: Nothing to Disclose<br />

<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Upper<br />

Extremity and Cervical Spine: Anatomical<br />

Correlates . . . . . . . . . . . . . . . . . . . 97<br />

Disclosure: Nothing to Disclose<br />

Vivino, Frederick B, MD<br />

Controversies in Sjogren’s Syndrome . . 28, 83<br />

Disclosure: Nothing to Disclose<br />

Vogler, Larry B, MD<br />

Pediatric Spondylarthropathies: From Genetics<br />

to the Clinic . . . . . . . . . . . . . . . . . .136<br />

Disclosure: Nothing to Disclose<br />

Von Feldt, Joan Marie, MD, MS Ed<br />

Diagnostic Errors in <strong>Rheumatology</strong>: Why They<br />

Happen and How We Can Avoid Them . . . 67<br />

Disclosure: Nothing to Disclose<br />

W<br />

Wallace, Carol A, MD<br />

Remission in Rheumatoid Arthritis. . . . . .137<br />

Disclosure: Nothing to Disclose<br />

Ward, Michael M, MD<br />

Finding and Using Secondary Data Resources<br />

for Research: Beyond the National Health and<br />

Nutrition Examination Survey and the Usual<br />

Suspects . . . . . . . . . . . . . . . . . . . 103<br />

Disclosure: Nothing to Disclose<br />

Ware, John, PhD<br />

Session I: The Essentials . . . . . . . . . . . 19<br />

Disclosure: Nothing to Disclose<br />

Wasko, Mary Chester<br />

ACR/ABIM Maintenance <strong>of</strong> Certification<br />

Learning Session -2010 Update . . . . . . . 21<br />

Disclosure: Nothing to Disclose<br />

Watcher, Sandra J, BSN<br />

Inflammatory Eye Disease . . . . . . . . . . 35<br />

Disclosure: Nothing to Disclose<br />

Teaching Our Pediatric Patients: Making the<br />

Complex Simple . . . . . . . . . . . . . . . 142<br />

Disclosure: Nothing to Disclose<br />

Integrating Immunology and Biologics into<br />

Clinical Practice . . . . . . . . . . . . . . . . 25<br />

Disclosure: Nothing to Disclose<br />

INVITED SPEAKER /MODERATOR INDEX<br />

2010 Program Book 313


INVITED SPEAKER /MODERATOR INDEX<br />

Watts, Nelson B, MD<br />

Controversies in Osteoporosis and Low Bone<br />

Mass: Who Do We Treat, For How Long, and at<br />

What Risks? . . . . . . . . . . . . . . . . . .103<br />

Disclosure: Amgen, 2, 5, 9; Baxter Healthcare,<br />

5; Eli-Lilly, 2; InteKrin, 5; Johnson & Johnson, 5;<br />

MannKind, 5; MedPace, 5; Merck, 2; Novartis,<br />

9; NPS, 2, 5; Pfizer, 5; Proctor & Gamble, 5, 9;<br />

san<strong>of</strong>i-aventis, 5, 9; Takeda Pharmaceuticals, 5;<br />

Warner Chilcott, 5, 9<br />

Weaver, Cynthia A, MD<br />

Recovery Audit Contractor vs. Comprehensive<br />

Error Rate Testing Audits – Do You Know the<br />

Difference?. . . . . . . . . . . . . . . . . . . 66<br />

Disclosure: Nothing to Disclose<br />

Wedderburn, Lucy R, MD, PhD<br />

Autologous Stem Cell Transplantation in<br />

Pediatric <strong>Rheumatology</strong>: Indications and<br />

Associated Morbidity . . . . . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

Weinblatt, Michael E, MD<br />

Methotrexate 2010 . . . . . . . . . . . . . . 55<br />

Disclosure: cypress, 5<br />

Weisman, Michael H, MD<br />

Year in Review . . . . . . . . . . . . . . . . . 27<br />

Disclosure: Nothing to Disclose<br />

Epidemiology <strong>of</strong> Axial Spondyloarthritis. . . 88<br />

Disclosure: Nothing to Disclose<br />

Weissmann, Gerald, MD<br />

An Infectious Etiology <strong>of</strong> Rheumatoid<br />

Arthritis . . . . . . . . . . . . . . . . . . . . 26<br />

Disclosure: Nothing to Disclose<br />

Weitz, Howard H, MD<br />

Perioperative Management <strong>of</strong> Selected<br />

Problems in Patients with Rheumatic Disease .<br />

. . . . . . . . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Nothing to Disclose<br />

Wener, Mark H, MD<br />

Labs and Treatment Options: What Do They<br />

Mean and How Do You Use? . . . . . . . . 131<br />

Disclosure: BioRad Laboratories, 9<br />

RC - <strong>Rheumatology</strong> Laboratory Testing: How it is<br />

Done and Why We Need to Know . . . . . . 24<br />

Disclosure: BioRad Laboratories, 9<br />

Wiener, Aimee, ARNP C, MSN<br />

Hand X-ray Review and Interpretation. . . . 58<br />

Disclosure: Nothing to Disclose<br />

Wigley, Fredrick M, MD<br />

Systemic Sclerosis: New Therapeutic<br />

Approaches . . . . . . . . . . . . . . . . . .122<br />

Disclosure: Actelion Pharmaceutical, 9;<br />

Bristol Myers-Squibb, 5; Novartis, 5; United<br />

Therapeutics, 9<br />

Williams, David A, PhD<br />

Disparities and Pain: Examining Research,<br />

Practice and Policy . . . . . . . . . . . . . . 95<br />

Disclosure: Nothing to Disclose<br />

Williams, John, PhD<br />

News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities. . . . . . . . . . 56<br />

Disclosure: Nothing to Disclose<br />

Winthrop, Kevin L, MD, MPH<br />

Iatrogenic Misadventures: Complex<br />

Cases . . . . . . . . . . . . . . . . . . . . . . 85<br />

Disclosure: Genentech, 5; Oxford Immunotech,<br />

2; Wyeth, 5<br />

Practice Potpourri . . . . . . . . . . . . . . . 86<br />

Disclosure: Genentech, 5; Oxford Immunotech,<br />

2; Wyeth, 5<br />

Wolpaw, Terry M, MD, MHPE<br />

ACR REF Clinician Scholar Educator<br />

Lecture . . . . . . . . . . . . . . . . . . . . . 53<br />

Disclosure: Nothing to Disclose<br />

Clinical Teaching Strategies in the Outpatient<br />

Clinic Setting . . . . . . . . . . . . . . . . . . 66<br />

Disclosure: Nothing to Disclose<br />

Wright, Mary, BS, OT<br />

Musculoskeletal Pain and Cognitive Issues<br />

Related to Returning Military Personnel . . 75<br />

Disclosure: Nothing to Disclose<br />

Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54<br />

Disclosure: Nothing to Disclose<br />

Wulffraat, Nico M, MD<br />

Autologous Stem Cell Transplantation in<br />

Pediatric <strong>Rheumatology</strong>: Indications and<br />

Associated Morbidity . . . . . . . . . . . . . 68<br />

Disclosure: Nothing to Disclose<br />

X<br />

Ximenes, Antonio C, PhD<br />

ILAR Global Health Project . . . . . . . . . . 84<br />

Disclosure: Nothing to Disclose<br />

Y<br />

Yazici, Hasan, MD<br />

Behcet’s Disease. . . . . . . . . . . . . . . . 28<br />

Disclosure: Nothing to Disclose<br />

ACR/EULAR Academic Exchange<br />

Program . . . . . . . . . . . . . . . . . . . . 86<br />

Disclosure: Nothing to Disclose<br />

Clinical Research Methodology . . . . . . .108<br />

Disclosure: Nothing to Disclose<br />

Yazici, Yusuf, MD<br />

Clinical Research Methodology . . . . . . .107<br />

Disclosure: BMS, Celgene, Centocor, Genentech,<br />

Roche, UCB, 5; BMS, Genentech, 8; Centocor, 2<br />

York, Michael R, MD<br />

Scleroderma: Systemic Sclerosis . . . . . . 106<br />

Disclosure: Nothing to Disclose<br />

Yung, Raymond L, MD<br />

Geriatric <strong>Rheumatology</strong> . . . . . . . . . . . 89<br />

Disclosure: Nothing to Disclose<br />

News from the National Institutes <strong>of</strong> Health:<br />

Updates and Opportunities . . . . . . . . . 56<br />

Disclosure: National Institute <strong>of</strong> Health, 2<br />

Z<br />

Zibit, Melanie, MEd, MBA<br />

Web-based Support <strong>of</strong> Clinical Practice and<br />

Teaching: Twittering, Blogging, and Doing the<br />

Wiki. . . . . . . . . . . . . . . . . . . . . . .120<br />

Disclosure: Nothing to Disclose<br />

314<br />

2010 Program Book


A<br />

Aarden, L 1825<br />

Aarrass, S 1519, 1534<br />

Abaci, N 2217<br />

Abad, MA 516<br />

Abbott, C 1141<br />

Abdollahi-Roodsaz, S 713, 1535,<br />

1730, 2230<br />

Abdou, NI 462<br />

Abdul Nasser, O 816<br />

Abdulahad, D 1195<br />

Abdulahad, W 1892, 2023<br />

Abe, Y 1731<br />

Abeles, AM 1845<br />

Abeles, M 1845<br />

Abellar, R 2231<br />

Abignano, G 572, 671, 673<br />

Ablin, JN 812<br />

Aboushehde, K 1939<br />

Abraham, D 674, 613, 1995, 2005<br />

Abrahamowicz, M 72, 1036, 1056,<br />

1555<br />

Abrahamyan, L 1681<br />

Abram, F 196, 938<br />

Abramson, LS 234, 1673, 1691,<br />

2017<br />

Abramson, SB 137, 707, 708,<br />

1390, 1477, 1490<br />

Abreu, J 1529<br />

Abril, A 777, 1637, 1652, 1654<br />

Abud-Mendoza, C 416, 1146,<br />

1166, 1407<br />

Abufayyah, M 2152<br />

Acar, H 1615<br />

Acasuso, M 835<br />

Accogli, A 265<br />

Achan, P 1476<br />

Achenbach, S 705, 959<br />

Ackermann, F 2239<br />

ACR/EULAR Commission To<br />

Redefine Remission in Rheumatoid<br />

Arthritis 2108<br />

ACT-SURE Study Group 1840<br />

Adachi, JD 969<br />

Adam, P 2282<br />

Adamec, J 1601<br />

Adams, J 1540, 1552<br />

Adams, MD 1673, 1691, 2017<br />

Adebajo, AO 2082<br />

Adhikari, T 1854, 1855<br />

Adkins, D 1342<br />

Adlerberth, I 1248<br />

Adoue, D 2027<br />

Adrianto, I 1579, 1585, 1586,<br />

2144, 2147<br />

Aegerter, P 1931<br />

Affandi, A 1210<br />

Afklint, E 394<br />

Afridi, KS 2112<br />

Afsarmanesh, N 998<br />

Agarwal, S 602, 603, 612, 824,<br />

1210, 1218, 1982, 2214<br />

Agarwal, V 2086<br />

Agashivala, N 2089<br />

Ager, J 468<br />

Aggarwal, R 563, 913, 925, 929,<br />

930, 1147, 1175, 1193<br />

Aghdassi, E 1156, 1165, 1178,<br />

2120<br />

Agrawal, H 853, 859<br />

Agrawal, N 2205<br />

Agrawal, S 856, 862<br />

Agudo Bilbao, M 1650<br />

Agüero-Balbin, J 1296<br />

Aguilar -Valenzuela, R 1360<br />

Aguilar-Salinas, C 459<br />

Aguilar-Valenzuela, R 12, 1361<br />

Aguilar-Valenzuela, RA 2253<br />

Aguirre, D 953<br />

Aguirre, MA 1357<br />

Ah Kioon, M-D 1707<br />

Ahearn, JM 620, 1399, 2106<br />

Ahern, MJ 177<br />

Ahl, J 105, 113<br />

Åhlin, E 695, 1015<br />

Ahluwalia, J 4<br />

Ahmad, Y 769, 795, 1177<br />

Ahmadi, N 1046, 1443, 2164,<br />

2165, 2166<br />

Ahmed, I 704, 910<br />

Ahmed, K 777, 1637, 1654<br />

Ahn, CW 1226<br />

Ahn, IE 842, 1770<br />

Ahn, JK 366, 372, 1297<br />

Aigner, S 1125<br />

Aikawa, N 224, 539, 1437<br />

Aikawa, Y 280, 1467<br />

Air, G 9, 24, 466<br />

Airo, P 824, 829, 1987, 2214, 2226<br />

Ajani, A 1052<br />

Ajeganova, S 88<br />

Ajmone Marsan, N 582<br />

Akar, S 544, 666, 1282, 1283,<br />

1921<br />

Akazawa, S 2029<br />

Akhavan, P 306, 336, 343, 1734,<br />

1769<br />

Akhlaghi, M 1289<br />

Akhmetshina, A 607, 611, 614,<br />

615, 616, 672<br />

Akhtar, N 632, 633<br />

Akhter, E 14, 487, 733, 2121<br />

Akiba, H 1731<br />

Akikusa, J 226, 248<br />

Akin, C 307<br />

Akiyama, C 434<br />

Akkineni, R 992<br />

Akkoc, N 544, 666, 1282, 1283,<br />

1921<br />

Akkoc, N 1970<br />

Akkoc, Y 544<br />

Aksentijevich, I 914, 1516, 2105<br />

Aksu, K 822<br />

Al Ghanim, N 1152<br />

Al Mayouf, S 1305<br />

Al Saleh, G 1413<br />

Al Sarraf, N 816<br />

Aláez, C 106<br />

Alaka, K 175<br />

Alarcón, G 445, 448, 476, 731,<br />

1591, 1668, 1877, 2104, 2240,<br />

2243<br />

Alarcon, RT 356<br />

Alarcón-Riquelme, ME 500, 1583,<br />

1578, 1584, 1585, 1586, 1590,<br />

1591, 1594, 1595, 2145, 2147,<br />

2148, 2274<br />

Alatorre, CI 52<br />

Alaupovic, P 1030<br />

Alavi, A 1105<br />

Alawi, F 1907<br />

Alba, MA 1314<br />

Albath-Sadiki, A 2045<br />

Albert, DA 992, 1537<br />

Alberton, V 1173<br />

Albert-Sabonnadiere, C 976<br />

Albertsson, K 1392, 1393<br />

Albesa, R 2250, 2251, 2252<br />

Albom, MS 2233<br />

Aldag, JC 49, 83<br />

Al-Dhanhani, A 2120<br />

Alegre, C 814<br />

Alele, JD 960<br />

Alessandri, E 578, 1236<br />

Alessio, M 1439, 1685, 2033<br />

Aletaha, D 73, 79, 296, 1013,<br />

1745, 1795, 2256, 2258<br />

Alevizos, I 1918, 2179<br />

Alexander, C 1606<br />

Alexander, K 464, 698<br />

Alexanderson, H 2068<br />

Alexopoulos, H 1895<br />

Alfredsson, L 64, 645, 832, 1057,<br />

1588, 2118, 2259<br />

Ali, S 807<br />

Aliabadi, P 198, 872<br />

Alias, A 44<br />

Aliprantis, AO 675, 1502<br />

Alivernini, S 1069, 1239, 1604<br />

Alizadeh, BZ 1599, 2214<br />

All CATCH Investigators 306<br />

Allaart, CF 295, 328, 334, 663,<br />

1396, 1496, 1755, 1782<br />

Allaire, SH 1349, 2143<br />

Allam, Y 976<br />

Allanore, Y 576, 580, 607, 616,<br />

728, 729, 1810, 1991, 1994, 1987,<br />

1988, 1992, 2000, 2226<br />

Allen, D 1176<br />

Allen, R 226, 248<br />

Allgood, S 1192<br />

Allievi, A 1173<br />

Allison, J 1005<br />

Allison, SJ 912<br />

Alloza, I 896<br />

Alm, GV 503<br />

Almagor, O 2100<br />

Almeida, C 1325<br />

Almeida, GJM 2059, 2061<br />

Almeida, JS 1403<br />

Almodovar, R 986<br />

Al-Mudhaffer, S 1306<br />

Alonso-Ruiz, A 873<br />

Alper, SL 1502<br />

Alsalawy, A 798<br />

Alsaleh, G 858<br />

Alten, R 392, 770, 987, 1123,<br />

1766, 1817, 1820, 2173<br />

Alth<strong>of</strong>f, C 669, 2271<br />

Altman, RD 187, 907<br />

Altpeter, M 691, 2141<br />

Alvarez, AA 1014<br />

Alvarez-Carbonell, D 2231<br />

Alvarez-Horine, S 97, 815<br />

Alvarez-Leon, E 96<br />

Alvarez-Rodriguez, L 1296<br />

Álvaro-Gracia, J 1840<br />

Alves, C 1775, 1776<br />

Alves, JF 2043<br />

Alyahya, R 1729<br />

Amalini, C 717<br />

Amano, H 1577<br />

Amano, K 1793, 1823, 1839<br />

Amarilyo, G 998<br />

Ambarus, CA 2272<br />

Ambler, N 1325<br />

Amdur, RL 970<br />

Amendola, A 176<br />

Amengual, O 5, 10, 2254<br />

Amezcua-Guerra, L 1614<br />

Amin, MA 1417, 1504, 1721<br />

Amin, S 15, 959<br />

Amir, S 697<br />

Amjadi, S 1058<br />

Amos, C 2214, 2217<br />

Amoura, Z 478, 915, 917, 1287,<br />

1651, 1658, 1660, 1908, 1911,<br />

2024, 2025, 2239<br />

Ampel, NM 415<br />

Anandarajah, A 849, 1051, 1369,<br />

1620<br />

Anania, C 1194<br />

Ananyeva, LP 580<br />

2010 Program Book 315<br />

abstract author Index


aBSTRACT author Index<br />

316<br />

Anatoly, L 598<br />

Anaya, J-M 1048, 1579, 1585,<br />

1586, 1591, 2147<br />

Ancuta, I 405<br />

Anders, H-J 441<br />

Andersen, AR 1444, 1841<br />

Andersen, LS 134, 1953<br />

Anderson, C 1201<br />

Anderson, DD 176<br />

Anderson, J 9, 331, 562, 1197<br />

Anderson, M 225<br />

Andersson, K 1248<br />

Andersson, M 1181<br />

Andersson, S 293<br />

Andrade, D 427, 1183, 1199<br />

Andrade, F 487, 2167, 1074<br />

Andrade, LEC 356, 504, 579, 498<br />

Andrade, PC 887<br />

Andrés, R 1137<br />

Andres Cerezo, L 638<br />

Ang, D 93, 797<br />

Angel, S 2035<br />

Angeles, TS 2233<br />

Angeles-Han, S 255, 256, 1405<br />

Angeletti, M 2001<br />

Angelini, F 540<br />

Angerer, H 1481<br />

Anisfeld, A 120, 125<br />

Annunziato, F 246<br />

Anolik, J 436, 733, 849, 1085,<br />

1886<br />

Anouk, M 1238<br />

Anthony, KK 1406, 2248<br />

Antivalle, M 784<br />

Antohe, J 345, 1442<br />

Antolini, CR 25<br />

Anton, A 450<br />

Anton, J 1305<br />

Antón Lopez, J 1872<br />

Antonini, G 2160<br />

Antony, J 1549<br />

Antovic, A 7<br />

Aoki, S 433<br />

Aouizerate, J 2041<br />

Aoyagi, K 1371<br />

Apaz, MT 1705<br />

Apkarian, AV 2097<br />

Appel, GB 1453, 2085<br />

Appenzeller, S 1170, 1695<br />

APPLE Investigators 1677<br />

APS Clinical Research Task Force 6<br />

Arad, U 697<br />

Arai, S 472<br />

Aranda, R 390, 416, 2168, 2173<br />

Aranow, C 445, 448, 476, 1146,<br />

1877, 2243, 2240<br />

Aranzamendi-Zaldunbide, M 1296<br />

2010 Program Book<br />

Arbillaga, H 1850<br />

Arbogast, P 54<br />

Arce, MT 1659<br />

Arce-Franco, MT 389, 1509<br />

Archambault, T 820<br />

ARChiVe Investigators <strong>of</strong> CARRA<br />

1673, 1691, 2017<br />

Ardanaz, N 1137<br />

Arden, NK 823, 841<br />

Ardoin, SP 1008, 1400, 1677,<br />

1702<br />

Arefiev, K 1213<br />

Arend, WP 2227<br />

Arendt-Nielsen, L 1385, 1557,<br />

2098<br />

Arfi, S 571<br />

Arguedas, O 210<br />

Ariani, A 1635<br />

Arias-Flores, R 1150<br />

Ariga, T 1672<br />

Arima, K 1371<br />

Aringer, M 1111<br />

Ariza Ariza, R 1944,1337<br />

Arjmand, P 267<br />

Arkachaisri, T 1683, 2006<br />

Arlet, P 917, 2027<br />

Armbrust, W 219<br />

Armstrong, C 989, 2112<br />

Armstrong, D 2019, 2107<br />

Armstrong, NE 655<br />

Armstrong, RC 269<br />

Arnaud, L 1287, 1658, 1660<br />

Arnett, F 603, 612, 725, 824, 829,<br />

1211, 1216, 1218, 1227, 2214<br />

Arnold, L 94, 105, 113, 805<br />

Arntz, OJ 713, 1501, 1532, 1535,<br />

1622, 1733<br />

Arrington, J 496, 1612<br />

Arroyo-Villa, I 1967<br />

Arthur, JM 1403<br />

Artim-Esen, B 1308<br />

ARTIS Study Group 1541, 1548<br />

Arts, E 1833<br />

Arufe, MC 1473, 1498<br />

Arufe-Gonda, MC 1483<br />

Arulmani, U 145, 1423, 2087<br />

Arundine, M 74<br />

Arveiler, B 1596<br />

Arvidson, NG 1774<br />

Asako, K 1285<br />

Asanuma, Y 1017<br />

Ascherman, D 913, 925, 929, 930,<br />

935<br />

Asensio, C 1707<br />

Asfa, S 1901<br />

Ashihara, E 1511<br />

Ashouri, J 1157<br />

Ashrafzadeh, A 2169<br />

Askanase, AD 990, 1190, 1857<br />

Askin, F 677, 681<br />

Askling, J 1015, 1054, 1057, 1541,<br />

1548, 2259<br />

Aslanidis, S 11<br />

Aslanov, R 554<br />

Asli, B 2239<br />

Asmawidjaja, P 38, 287, 715,<br />

1259, 1274, 1525<br />

Asmussen, K 134, 1953<br />

Assaad-Khalil, S 1305<br />

Assassi, S 522, 562, 612, 725, 824,<br />

1211, 1216, 1218, 1219, 1227,<br />

1982, 2185, 2214<br />

Astorri, E 1906<br />

Astudillo, L 2027<br />

Atagündüz, P 1133, 1803<br />

Atallah, M 491<br />

Atayde, SA 887<br />

Atkins, CJ 1060<br />

Atkinson, E 959<br />

Atkinson, JP 846, 1262<br />

Ator, MA 2233<br />

Atsumi, T 5, 10, 621, 1812, 1909,<br />

2254<br />

Atteno, M 532<br />

Attinger, CE 1045<br />

Attur, M 137, 707, 708, 1390,<br />

1477, 1490<br />

Atumi, T 2<br />

Atzeni, F 532, 784, 1098, 1582<br />

Au, KM 594<br />

Aubert, RE 1561<br />

Audo, R 1527<br />

Audonnet, S 1664<br />

Audrey, P 2267<br />

Augustovski, F 324<br />

Aukrust, P 479<br />

Aumaître, O 2239<br />

Austad, C 1750<br />

Austin, H 493, 1161<br />

Australo-Anglo-<strong>American</strong><br />

Spondyloarthritis Consortium<br />

1355<br />

Authier, F-J 576<br />

Autran, B 478<br />

Avalos, IB 2123<br />

Avigan, M 75<br />

Avila, M 552<br />

Avila-Armengol, HE 457<br />

Avina-Zubieta, A 1036<br />

Avitable, M 1431<br />

Avouac, J 599, 607, 614, 616, 728,<br />

1988, 1991, 2000<br />

Avshovich, N 550<br />

Avvedimento, E 2001, 2008<br />

Axelsson, T 832<br />

Axford, JS 1105<br />

Axtens, R 1560<br />

Ayanian, J 60<br />

Aydin, S 524, 553, 777, 1291,<br />

1398, 1637, 1652, 1654<br />

Ayearst, R 1966, 1975<br />

Ayers, DC 2136<br />

Ayoub, W 977<br />

Ayub, S 473<br />

Aziz, FA 58<br />

Azzari, C 261<br />

Azzini, C 1162<br />

B<br />

Baas, F 1069, 1604<br />

Baba, S 447, 746, 916, 923, 1184,<br />

1587, 1844<br />

Bacani, AK 53, 78<br />

Bachta, A 777, 1637, 1652, 1654<br />

Backhaus, M 1621, 1629, 1634<br />

Backlin, C 1015<br />

Backman, CL 1321, 1538, 2282<br />

Baddley, J 304, 404, 721, 722,<br />

1643, 2103<br />

Bade, MJ 171<br />

Bader-Meunier, B 1684, 1693<br />

Badesch, D 1223<br />

Badley, EM 1562, 2208<br />

Bae, E-K 372<br />

Bae, S 387, 445, 448, 476, 1092,<br />

1583, 1585, 1586, 1591, 1597,<br />

1605, 1714, 1877, 1941, 2028,<br />

2147, 2240, 2274<br />

Bae, Y-S 1714<br />

Baechler, EC 15, 934, 1608, 2149<br />

Baecklund, E 1015, 1899<br />

Baek, S 276, 277, 1209<br />

Baer, AN 1364, 1544, 1556, 1569,<br />

1887, 1898, 1915<br />

Baerwald, C 936, 1025<br />

Baeten, D 629, 753, 1449, 1527,<br />

1732, 1977, 2272<br />

Bagaglia, P 1109<br />

Bagavant, H 1883<br />

Bagnasco, SM 440<br />

Bagnoud, N 2151<br />

Bailey, T 1576<br />

Bain, G 606<br />

Bainbridge, L 2050<br />

Bair, MJ 175<br />

Bajocchi, G 1290, 1302, 2044<br />

Bak, L 133<br />

Baker, A 1689<br />

Baker, D 1786, 1835, 1922, 1985<br />

Baker, J 456, 1554, 1786<br />

Baker, K 951<br />

Baker, NA 2142, 2143<br />

Baker-LePain, J 624<br />

Bakewell, C 931<br />

Bakke, A 758


Bakker, AAB 1095<br />

Barendregt, B 753<br />

2167, 2260<br />

Bello, KJ 1163, 1180<br />

Bakker, MF 380, 388, 1753, 1759<br />

Barendregt, P 1775, 1776<br />

Batley, M 1830<br />

Bellomo, G 2160<br />

Bakker-Jonges, LE 1780<br />

Barham, B 1698, 2105<br />

Batstra, MR 1780<br />

Belloni-Fortina, A 1439<br />

Balandraud, N 2269<br />

Balanescu, A 848<br />

Balasubramanian, A 1540, 1552<br />

Balbir, A 1238<br />

Balbir-Gurman, A 378, 550<br />

Baldi, M 1706<br />

Baldini, C 811, 839, 1884, 1916<br />

Balfour, A 2087<br />

Baliga, R 674<br />

Baliki, MN 2097<br />

Balint, P 777, 1617, 1629, 1637,<br />

1654<br />

Balitsky, AK 13<br />

Ballal, M 989<br />

Ballantine, L 1422<br />

Balow, J 1161<br />

Balow, Jr, J 1516<br />

Balsa, A 349, 1078, 1599<br />

Balsa, D 1137<br />

Baltzis, D 1021<br />

Bambara, LM 297<br />

Band, P 947<br />

Band, PA 2225<br />

Banda, NK 2227<br />

Bandinelli, F 558, 1962<br />

Bandoli, G 2210<br />

Bandy, R 93, 797<br />

Banerjee, S 1925<br />

Bang, D 2217<br />

Bang, S-Y 1092, 1586, 1605, 1972<br />

Bangert, C 920<br />

Bankhurst, AD 947, 1055, 1567,<br />

1626, 2225<br />

Banks, SE 211<br />

Bao, G 790<br />

Baribaud, F 1968<br />

Barimani, M 1322<br />

Barker, C 967<br />

Barkham, N 1929<br />

Barkhuizen, A 1395<br />

Barnabe, CCM 119, 309, 775, 785<br />

Barnado, A 475<br />

Barnerias, C 1693<br />

Barnes, I 993<br />

Barnes, MG 653<br />

Barnetche, T 393, 408, 1596, 1816<br />

Barnhart, HX 1677<br />

Baron, G 376, 400, 1790<br />

Baron, JA 2137<br />

Baron, M 577, 1202, 1203, 1221,<br />

1225, 1346, 1347, 1348, 2196,<br />

2247<br />

Baron, R 1502<br />

Barone, F 1906<br />

Barr, SG 119, 330<br />

Barra, G 246<br />

Barra, L 1071, 1717<br />

Barrat, F 2231<br />

Barrett, A 967<br />

Barrett, J 1979<br />

Barrett, R 521, 1968<br />

Barron, KS 1698, 2105<br />

Bartel, P 493<br />

Bartelds, GM 1445<br />

Bartels, CM 1000<br />

Bartels, LW 121<br />

Bartlett, SJ 310, 1336<br />

Bartley, EJ 101<br />

Bartok, B 362<br />

Bartoli, F 593, 1962<br />

Battafarano, DF 1044, 1049, 1669,<br />

2163<br />

Battellino, M 784<br />

Batthish, M 225<br />

Batticciotto, A 784<br />

Battle, T 44<br />

Bauer, JW 2149<br />

Baum, P 1025<br />

Baumgart, T 2048<br />

Baumgartner, SW 1103<br />

Bautista, A 1811<br />

Bautista, W 517, 552<br />

Bautista-Caro, MB 1967<br />

Bax, JJ 582<br />

Bay-Jensen, AC 1466, 1500<br />

Bazin, D 875<br />

Bazzichi, L 811, 839<br />

Beard, S 1382<br />

Beasley, M 646, 649<br />

Beatriz-Christmann, R 1210<br />

Beaulieu, A 938, 1441<br />

Beauvais, C 63<br />

Bebak, M 243<br />

Becciolini, A 547<br />

Bechtel, A 594<br />

Becker, C 1125<br />

Becker, J-C 1837, 1843, 1919<br />

Becker, M 158, 165, 253, 254,<br />

2003, 2219<br />

Becvar, R 614<br />

Beebe, D 1689<br />

Beeton, C 1128<br />

Beg, SA 1856<br />

Behin, A 915<br />

Behrens, EM 233, 1354, 2219<br />

Belmatoug, N 1653<br />

Belmont, HM 996<br />

Belomestnov, P 1121<br />

Belostocki, K 1072<br />

Belouski, S 1141<br />

Belter, M 12<br />

Beltramelli, M 2033<br />

Ben Ammar, RH 1684<br />

Ben M’Barek, R 2269<br />

Bena, JF 574<br />

Benamour, S 1305<br />

Ben-Ari, R 46, 1432<br />

Benavente, Y 1280<br />

Bencardino, J 137, 707, 708<br />

Bender, S 41<br />

Benedict, A 2266<br />

Benegas, M 50<br />

Benessiano, J 1890<br />

Bengtsson, A 2022<br />

Bengtsson, C 645, 2118<br />

Benhamou, M 1762<br />

Benito-Garcia, E 89<br />

Benito-Miguel, M 349<br />

Benjamin, H 1985<br />

Bennell, K 192<br />

Bennett, A 524, 553, 1963<br />

Bennett, L 1316<br />

Bennett, M 268, 2106<br />

Bennett, RM 97, 647, 806, 814<br />

Bennin, DA 1421<br />

Bennink, MB 713, 1501, 1532,<br />

1733<br />

Bennink, R 1822<br />

Benseler, S 894, 899, 900, 1408,<br />

1673, 1691, 2017, 2019, 2107<br />

abstract author Index<br />

Bapoje, S 2013<br />

Baptista, F 626<br />

Bar, S 2055<br />

Baraf, H 157, 166, 1808<br />

Baraliakos, X 526, 668, 1958,<br />

1985, 2270<br />

Barash, J 1684<br />

Baratelli, MJ 1872<br />

Baratham, A 943<br />

Barbarroja, N 1357<br />

Barbasso Helmers, S 924<br />

Barbe, MF 2244<br />

Barber, X 1754<br />

Barberà, JA 1070<br />

Barbosa, CMP 1339<br />

Barcellos, L 502, 1602<br />

Barcelos, A 1986<br />

Barclay, M 417<br />

Bardin, T 400, 1790<br />

Barton, A 264, 266, 833, 1075,<br />

1394, 1593, 1600, 1756, 2215<br />

Barton, JL 1024<br />

Bartos, A 1185, 1196, 2275<br />

Bartrolí, J 1137<br />

Baser, O 307<br />

Bashir, MM 1198<br />

Basic, J 217<br />

Baskin, E 1705<br />

Bass, DL 757, 764<br />

Bassel, M 1346<br />

Basta, MC 1173<br />

Bastacky, S 1399<br />

Bastian, H 1780<br />

Baszis, KW 216, 1691<br />

Batal, I 1399<br />

Bateman, H 44<br />

Bathon, J 385, 386, 949, 1018,<br />

1022, 1030, 1065, 1074, 1148,<br />

1368, 1441, 1837, 2096, 2162,<br />

Behrens, F 599<br />

Behrens, T 473, 502, 1592, 1608,<br />

2149<br />

Behring, K 1059<br />

Bekker, PJ 1100, 2032<br />

Bel, M 792<br />

Belacek, J 1649<br />

Belenguer, R 1888<br />

Belilos, E 1072, 1311<br />

Belisle, P 1142, 1850<br />

Belitskaya-Lévy, I 137<br />

Bell, C 1000<br />

Bell, DA 1071, 1717<br />

Bell, K 2255<br />

Bell, MJ 778, 794<br />

Bellan, M 962, 2160<br />

Bellando-Randone, S 593<br />

Belli, B 269<br />

Bello, AE 945, 946<br />

Benson, B 814, 815<br />

Bentley, MJ 1010<br />

Benucci, M 1098, 1582<br />

Benveniste, O 915<br />

Beratarrechea, A 324<br />

Berclaz, P-Y 2172<br />

Berenbaum, F 37, 781, 1514<br />

Beresford, M 1688<br />

Beretta, L 824, 829, 1235, 2214<br />

Bérezné, A 576, 1204, 1217, 2043<br />

Berg, IJ 534<br />

Berger, FH 1069<br />

Berger, M 151<br />

Berger, T 2186<br />

Bergersen, TK 1220<br />

Berggren, O 503<br />

Berghea, F 848<br />

Berglin, E 2115<br />

Bergman, MJ 331, 644, 985, 2109<br />

2010 Program Book 317


aBSTRACT author Index<br />

318<br />

Bergman, S 2209<br />

Berman, A 50<br />

Berman, H 50<br />

Berman, J 43<br />

Bernal, A 1614<br />

Bernardi, L 290<br />

Bernasconi, C 1840<br />

Bernatsky, S 57, 214, 313, 341,<br />

342, 445, 448, 454, 476, 731, 1142,<br />

1562, 1850, 1877, 2240, 2243<br />

Bernelot Moens, HJ 314, 662,<br />

1771<br />

Bernstein, CN 1068, 1094<br />

Berry, JL 1200<br />

Berry, L 1245<br />

Berry, P 173, 1383<br />

Bershadsky, B 191<br />

Bertamino, M 207<br />

Berthelot, J-M 29, 701, 1752,<br />

1810, 2261, 2269<br />

Berthier, C 2276, 2278<br />

Bertin, P 987<br />

Bertin-Maghit, S 1116<br />

Bertoia, M 71<br />

Bertola, DR 260<br />

Bertolazzi, C 547, 1635<br />

Bertolino, AP 560, 566<br />

Bertolo, MB 356<br />

Bertrand, J 1130, 1486<br />

Bessette, L 785, 938<br />

Bessis, D 2238<br />

Bessis, N 2236<br />

Bethunaickan, R 2188, 2276<br />

Beukelman, T 213, 239, 404, 721,<br />

722, 1679, 2084, 2103<br />

Beuteux, S 1827<br />

Beutler, A 890, 908, 1943, 2264<br />

Beyer, C 607, 614, 616, 672<br />

Bhagat, L 856<br />

Bhagat, S 395, 1342<br />

Bhagwat, S 269<br />

Bhakuni, DS 2086<br />

Bhalla, V 2153<br />

Bharadwaj, R 66<br />

Bhatt, S 470<br />

Bhattacharya, I 1154<br />

Bhattacharyya, K 1925<br />

Bhavsar, R 650<br />

Bhole, V 523, 720<br />

Biagioni, B 1954<br />

Bian, A 1023, 1034, 1867<br />

Bianchi, L 261<br />

Bianconi, S 914<br />

Biasi, D 547, 671<br />

Biasi, G 1098, 1582<br />

Bichisecchi, E 1635<br />

Bieche, I 2025<br />

Biedermann, S 1121<br />

2010 Program Book<br />

Bierma-Zeinstra, SMA 124, 184<br />

Biesenbach, P 469<br />

Bigatti, S 93, 797<br />

Bijl, M 1195, 1210, 1455<br />

Bijlsma, JWJ 124, 184, 278, 333,<br />

380, 942, 952, 973, 1753, 1759,<br />

1900, 1903<br />

Bijsterbosch, J 179<br />

Bikker, A 1900, 1903<br />

Bilge, S 1970<br />

Bilgic, H 15, 934, 1608<br />

Bili, A 345, 1442<br />

Binder, W 14, 2250, 2251, 2252<br />

Bingham, C 41, 211, 391, 948,<br />

1074, 1678, 1766, 1778, 1805,<br />

2167, 2169<br />

Bingham III, CO 45<br />

Biniecka, M 360, 1510<br />

Binstadt, B 1256<br />

Binti Mohd Din, SH 2066<br />

BIOLUPUS Network 2147<br />

BIOLUPUS and GENLES Networks<br />

1584, 1585, 1586, 1591, 1595<br />

Birbara, CA 1804<br />

Bird, P 118, 141, 319, 1369<br />

Birkett, R 854<br />

Birlik, M 544, 666, 1282, 1283,<br />

1921<br />

Birmingham, DJ 1400<br />

Birmingham, JD 209<br />

Birnbaum, H 763<br />

Birnbaum, J 1887, 1915<br />

Bisch<strong>of</strong>f, S 770<br />

Bisoendial, R 629<br />

Bitman, B 398, 1117<br />

Bitner, C 1382<br />

Biton, J 2236<br />

Bittner, S 1255<br />

Bjersing, JL 103<br />

Björnådal, L 1224<br />

Bjorneboe, O 1774, 1829<br />

Blache, C 1827<br />

Blachere, N 863<br />

Blackburn, MR 602, 612<br />

Blagojevic, J 593<br />

Blake, C 2135<br />

Blanchard-Delaunay, C 1894<br />

Blanco, F 538, 541, 835, 840,<br />

1078, 1473, 1475, 1483, 1498,<br />

1920<br />

Blanco, I 939, 2095<br />

Blanco, P 1816<br />

Blanco, R 1296, 1301, 2262<br />

Blanco Alonso, R 1650<br />

Blaney-Davidson, E 1532<br />

Blaschke, S 138, 2021<br />

Blauvelt, A 758<br />

BLISS-52 and -76 Study Groups<br />

451, 452, 1146, 1456, 1848<br />

BLISS-52 and -76, and LBSL02/99<br />

Study Groups 1172<br />

BLISS-76 Study Group 457, 1454<br />

Bloch, C 915<br />

Bloch, DB 1671<br />

Block, JA 200, 765, 1147, 1175,<br />

1880, 2099<br />

Blom, A 845, 1472<br />

Bloo, H 2051<br />

Blum, S 99, 800<br />

Blumenroth, M 1615, 2081<br />

Blumenthal, DR 161, 1431<br />

Blumenthal, R 2162, 2260<br />

Blüml, S 1351<br />

Boackle, SA 730, 1591<br />

Boateng, BA 46, 1429, 1432<br />

Bobak, N 1255<br />

Bobbio Pallavicini, F 1098, 1582<br />

Bodaghi, B 1249<br />

Bodemer, C 1693<br />

Bodnár, N 519<br />

Bodukam, V 1205<br />

Boelle, P-Y 533<br />

Boers, M 392, 723, 1758, 1766,<br />

2108<br />

Bogatkevich, G 604<br />

Bohl-Bühler, M 2271<br />

Böhme, W 1444, 1841<br />

Bohnsack, JF 245, 250, 255, 256,<br />

654<br />

Boiardi, L 1290, 1302, 2044<br />

Boilard, E 363<br />

Boileau, C 1987, 1991, 1994,<br />

2000, 2226<br />

Boin, F 596, 1201, 1989, 2192<br />

Boire, G 300, 306, 343, 659, 978,<br />

1737<br />

Boissier, M-C 997, 2236<br />

Bojinca, V 848<br />

Bokarewa, M 103, 293<br />

Bokhari, A 1051<br />

Bolce, R 420, 1960, 2270<br />

Bolen, J 689, 1563, 2080<br />

Bolge, S 51, 1542, 1960<br />

Bolla, M 1477<br />

Bollag, G 273<br />

Bolosiu, H 405<br />

Bolstad, AI 1885<br />

Bolster, M 561, 591<br />

Bolton H<strong>of</strong>fman, JA 1364<br />

Bomalaski, JS 144<br />

Bombardier, C 57, 336, 341, 1734,<br />

1769, 313<br />

Bombardieri, M 1389, 1906<br />

Bombardieri, S 558, 811, 839,<br />

1011, 1884, 1896, 1916, 2036,<br />

2201<br />

Bonciani, D 1962<br />

Boncompagni, A 2033<br />

Bone, HG 2157<br />

Bonelli, M 1351<br />

Bonetti, LA 1072<br />

Bonewald, L 965<br />

Bonfa, E 284, 481, 513, 539, 626,<br />

1384, 1437, 2078, 2204<br />

Bong, DA 1617, 2223<br />

Bonilla, N 1981<br />

Bonner, A 396, 1202, 1203, 1221<br />

Bonner, M 622<br />

Bonnet, F 2010<br />

Bonnyman, A 1316<br />

Bonoldi, VLN 1644<br />

Bonome-González, V 835<br />

Boom, HD 663<br />

Boomershine, CS 115, 802, 813<br />

Boon, L 38<br />

Boonen, A 65, 557, 760, 1369<br />

Boonen, S 971<br />

Boostma, H 1910<br />

Booth, R 1484<br />

Booth, SL 872<br />

Booth-LaForce, C 1106<br />

Boots, AMH 275, 1730<br />

Bootsma, H 1889, 1892, 1896,<br />

1905<br />

Borba, EF 481, 626<br />

Borchardt, T 1479<br />

Borg, AA 172<br />

Borghi, MO 1356<br />

Borghini, S 657<br />

Bork, DJ 574<br />

Borowoy, A 1852<br />

Borriello, F 246<br />

Bortoluzzi, A 1162<br />

Borzutzky, A 229, 241<br />

Bos, NA 1889<br />

Bose, N 574<br />

Bosello, SL 355, 1239<br />

Botello-Corzo, D 1048<br />

Botsios, C 290<br />

Bottaro, A 712, 1710<br />

Botto, M 430<br />

Boucher, R 75<br />

Boudreau, R 193<br />

Bou-Gharios, G 1995<br />

Boulman, N 550, 909<br />

Bouma, S 1026<br />

Boumans, M 333, 1095, 1821,<br />

1828, 2170<br />

Boumier, P 2221<br />

Boumpas, D 496, 1829, 2265<br />

Bourdeau, T 1728<br />

Bourgeois, P 141, 787, 917, 1762,<br />

2221<br />

Bourne, T 751, 752, 1243, 1245<br />

Bourré-Tessier, J 1142, 1850


Boutin-Le Thi Huong, D 478<br />

Bout-Tabaku, SM 1907<br />

Bowes, J 833, 1600, 2215<br />

Bowes, MA 118<br />

Bowman, SJ 1896, 1910<br />

Bowness, P 1973<br />

Bowyer, SL 1677<br />

Box, JH 416, 2173<br />

Boychev, G 1419<br />

Boyd, SK 119<br />

Boyer, O 915, 1827<br />

Bøyesen, P 132, 141, 142, 1369,<br />

1444, 1841<br />

Boyle, D 34, 271, 362, 635, 639,<br />

855, 1240, 1725, 1727, 1955<br />

Boyle, JJ 2200<br />

Boynes, AM 1345<br />

Braakman-Jansen, LMA 2207,<br />

2281<br />

Bracci-Laudiero, L 18<br />

Bradley, J 1129, 2171<br />

Bradley, L 1557, 2098<br />

Bradley, N 1681<br />

Brady, A 2135<br />

Brady, TJ 689, 1465, 2062, 2080<br />

Braem, K 1980<br />

Brahn, E 285, 289<br />

Branch, VK 1188<br />

Branco, JC 1986<br />

Brand, C 1052<br />

Brand, D 1266<br />

Brandenstein, JS 1345<br />

Brandi, ML 222, 1155, 2157, 2202<br />

Brandorff, J 2119<br />

Brandt, KD 948<br />

Brasington, R 216, 1077, 1633<br />

Bratt, J 1393, 1392<br />

Brault, M 687, 2138<br />

Brault, Y 1629<br />

Braun, J 526, 665, 668, 895, 1425,<br />

1788, 1922, 1927, 1938, 1946,<br />

1948, 1958, 1961, 1985, 2270<br />

Brauner, M 997<br />

Brauner, SR 1917<br />

Breban, M 527, 533, 551, 701,<br />

1087, 1893, 1931, 1981<br />

Breda, L 261, 1685, 2033<br />

Breedveld, F 403, 1013<br />

Bremander, ABI 761, 2209<br />

Brembilla, NC 1992<br />

Bremme, K 7<br />

Brennan, M 1579, 2117<br />

Brennan, PC 1625<br />

Brennan, S 183<br />

Brenneis, C 1923<br />

Brenner, MB 602, 603, 1388<br />

Brentano, F 1389, 1528<br />

Bresci, C 1436<br />

Bresnihan, B 1032, 1105, 2065<br />

Bretz, W 1390<br />

Breuer, S 406<br />

Breuil, V 976<br />

Breunig, M 1026<br />

Briassouli, P 489<br />

Bridges, SL 299, 1077, 1368, 1386,<br />

1740<br />

Briesacher, B 322, 791<br />

Brigham, D 269<br />

Brihaye, B 2239<br />

Briley, AI 2035<br />

Brinker, A 75<br />

Brintnell, W 1717<br />

Brion, R 29<br />

Briot, K 548<br />

British Society for <strong>Rheumatology</strong><br />

Biologics Register 374, 421<br />

Britsemmer, K 85, 723, 1033<br />

Brizi, MG 837<br />

Brizzolara, R 1798<br />

Brkic, Z 1904<br />

Brock, M 35, 1518<br />

Brockbank, J 40<br />

Brocq, O 69<br />

Broder, AR 1179<br />

Broen, J 824, 829, 1210, 2004,<br />

2214<br />

Broere, F 278<br />

Broggini, V 1356<br />

Brokstad, K 1899, 1917<br />

Bromberg, MH 1406, 2248<br />

Bromberg, R 1740, 2116<br />

Brook, RD 1041<br />

Brookhart, MA 60, 2104<br />

Brooks, EB 2017<br />

Brooks, P 1766<br />

Brouard, S 753<br />

Broussard, C 575, 834<br />

Brousse, N 1651<br />

Brouwer, C 829<br />

Brouwer, E 2170<br />

Brower, KS 2061<br />

Brown, A 141<br />

Brown, D 751, 752, 2057, 2102<br />

Brown, EE 1584, 1585, 1586,<br />

1591, 1594, 1595, 2147, 2274<br />

Brown, GA 1539<br />

Brown, H 2050<br />

Brown, J 1012, 2157, 2161<br />

Brown, KK 1212<br />

Brown, M 250, 255, 256, 1355,<br />

1446, 1986, 2184<br />

Brown, R 441<br />

Brown, S 518, 559, 1949<br />

Brown, TD 176<br />

Brown, Jr, RD 2037, 2038<br />

Brox, JI 170<br />

Bruce, B 1545<br />

Bruce, H 2125<br />

Bruce, I 445, 448, 476, 766, 769,<br />

795, 833, 1067, 1177, 1200, 1323,<br />

1394, 1877, 2240, 2243<br />

Bruckdorfer, R 2005<br />

Brumwell, AN 609<br />

Brun, J 891, 1885, 1896, 1913<br />

Brunck, M 1116<br />

Bruner, G 1164, 1590<br />

Brunetta, P 1455<br />

Brunette, A 1<br />

Brunner, H 218, 268, 1012, 1434,<br />

1677, 1688, 1689, 1690, 1701,<br />

1702, 2106<br />

Brunner, J 1704<br />

Bruno, F 902<br />

Brus, HLM 662<br />

Bruyere, O 979<br />

Bryan, RL 1494<br />

Brzosko, M 1829<br />

Bshouty, Z 1176<br />

BSR Biologics Register 1323<br />

BSRBR Control Centre Consortium<br />

374, 421, 1323<br />

Bucci-Rechtweg, C 2156<br />

Buchanan, R 1942<br />

Buchbinder, R 204, 1001, 1009<br />

Buckeridge, D 1555<br />

Buckner, J 77, 658, 1094<br />

Bud<strong>of</strong>f, M 1046, 1443, 2164,<br />

2165, 2166<br />

Buehring, B 191<br />

Bueno, C 224<br />

Bugaralli, A 284<br />

Bugatti, S 623, 1397<br />

Buggy, JJ 286<br />

Buhr, K 1000<br />

Buhrmann, C 106<br />

Buischi, Y 1390<br />

Buitinga, L 2207, 2281<br />

Buján, J 1475<br />

Bukulmez, H 259<br />

Bulinckx, LM 2279<br />

Bultink, IEM 1859<br />

Bulur, A 1133, 1803<br />

Bunn, C 1207<br />

Bunn, D 766, 779, 796, 1067,<br />

1110<br />

Buoncompagni, A 265<br />

Burbine, SA 2090, 2092<br />

Burgerh<strong>of</strong>, HGM 1889<br />

Burgess, JA 1942<br />

Burghardt, AJ 136<br />

Bürgis, S 2237<br />

Burgos Vargas, R 151, 1407, 1819<br />

Burke, J 764<br />

Burke, L 403<br />

Burkhardt, H 2234<br />

Burki, V 529, 1924<br />

Burkly, L 1243, 1244, 1245<br />

Burlingame, R 735<br />

Burmester, G 630, 782, 911, 1013,<br />

1295, 1418, 1621, 1780, 1788,<br />

1817, 2003, 2271<br />

Burnham, JM 206<br />

Burns, A 1207<br />

Burns, JM 2277<br />

Burns, LC 523, 720<br />

Burns, MB 1012<br />

Burr, DB 716<br />

Burton, B 273<br />

Busch, R 331, 843<br />

Buschmann, J 668<br />

Bush, H 994<br />

Busija, L 204, 2079, 2139<br />

Buskila, D 812<br />

Buss, B 2181<br />

Busso, N 2151<br />

Bussone, G 575<br />

Butherus, K 2203<br />

Butjosa, M 1294, 1314<br />

Butter, C 1059<br />

Buttgereit, F 392, 630, 1123, 1418<br />

Butthum, B 1950<br />

Buyon, J 489, 495, 637, 656, 732,<br />

990, 1190, 1438, 1857, 2231<br />

Buyske, S 625, 1320, 1767<br />

Bykerk, V 300, 306, 308, 343, 396,<br />

659, 785, 794, 978, 1737, 1766,<br />

1778, 1840<br />

Byrjalsen, I 1466, 1474<br />

Byron, J 584<br />

Cabane, J 576<br />

Caban-Martinez, AJ 786<br />

Cabral, DA 1673, 1691, 2017<br />

Cachafeiro-Vilar, A 874<br />

Cacoub, P 400, 906, 1249, 1287,<br />

1646, 1660, 1790, 1908, 1911,<br />

2010, 2011, 2024, 2025, 2030,<br />

2036, 2039, 2042, 2046, 2131<br />

Caeiro, F 50<br />

Cagnard, N 2000<br />

Cagnoli, PC 1158<br />

Cahue, S 186, 189<br />

Cai, A 1818<br />

Cai, C 431<br />

Cai, Y 274, 1107<br />

Cairns, E 1071, 1717<br />

Cakar, E 114<br />

Cakir, V 1282, 1283<br />

Calabozo, M 873<br />

Calabrese, LH 700<br />

Calamia, K 1652, 2037, 2038<br />

C<br />

2010 Program Book 319<br />

abstract author Index


Calamia, V 840<br />

Cantó, E 1801<br />

Carter, R 1652<br />

Ceponis, A 1618<br />

Calaza, M 1076, 1078<br />

Cantor, RM 1584, 1595<br />

Carter, S 1980<br />

Ceribelli, A 501, 735, 1639<br />

aBSTRACT author Index<br />

Calcagno, G 1155, 1685, 1706,<br />

2033, 2202<br />

Calderón, J 2070<br />

Calderone, M 1682<br />

Calich, AL 481, 2078, 2204<br />

Caliz, R 1078<br />

Callahan, LF 690, 691, 1077, 1460,<br />

1461, 1462, 1463, 2071, 2140,<br />

2141<br />

Callen, J 920<br />

Callon, K 881, 1983<br />

Calmon Hamaty, F 1527<br />

Calvo, E 552<br />

Calvo, I 1434<br />

Calvo, J 1888<br />

Calvo-Alen, J 1296, 1871<br />

Camacho, EM 779<br />

Camargo, LM 628<br />

Camargo, TM 1458<br />

Cambi, A 844<br />

Cambon-Thomsen, A 2218<br />

Cambridge, G 739, 743<br />

Caminade, A-M 281<br />

Camoin, L 834<br />

Campana, C 540<br />

Campanini, M 2201<br />

Campbell, PL 1504, 1721<br />

Campbell, RT 692<br />

Campillo, S 1408, 1673, 1691,<br />

2017<br />

Campo, E 1280<br />

Campos, LM 224, 1437<br />

Camps, MT 824, 1888<br />

Camps, S 2041<br />

Can, G 544, 666, 1282, 1283<br />

Can, M 1133, 1208, 1803<br />

Canadian Scleroderma Research<br />

Group (CSRG) 1225, 1347, 1348,<br />

2247<br />

Candelieri, A 558, 1962<br />

Canestri, S 355, 744<br />

Cañete, J 20, 538, 543, 1070,<br />

1078, 1449<br />

Canhao, H 1684<br />

CANIOS 1000 Canadian Faces <strong>of</strong><br />

Lupus Investigators 1850<br />

Canizar, M 1562<br />

Cann, J 2191<br />

Canning, C 339, 1066<br />

Cannon, GW 304, 397, 970, 1099,<br />

1792<br />

Cano, C 1754<br />

Cantaert, T 753, 1449, 1977<br />

Cantagrel, A 281, 400, 1088, 1790,<br />

1893, 1894, 2218<br />

Cantarini, L 837<br />

Cantini, F 528, 1652, 1952<br />

Cantrell, RA 52<br />

Canzoni, M 547<br />

Cao, J 1513<br />

Cao, Q 438, 2191<br />

Caorsi, R 657, 1685, 1706<br />

Capacci, A 1239<br />

Capannini, S 222, 1155, 2033,<br />

2202<br />

Caparbo, VF 1546<br />

Capellino, S 1089<br />

Capelozzi, VL 605, 887<br />

Capini, C 1116<br />

Caplan, L 62, 397, 970, 1099,<br />

1395, 1792<br />

Caplice, N 22, 1726<br />

Capone, M 246<br />

Caporali, R 623, 1397<br />

Caputo, R 240, 1436<br />

Caramaschi, P 580<br />

Caramez, B 369<br />

Carassiti, D 430<br />

Carbonell, J 975<br />

Carcamo, WC 1639<br />

Carcelain, G 376<br />

Cardiel-Rios, M 1013<br />

Cardoso-Oliveira, J 356<br />

Carette, S 2198<br />

Carey, JJ 817, 818, 989, 2111,<br />

2112<br />

Carey, T 1575<br />

Caricchio, R 422, 439<br />

Carlos, F 767<br />

Carmona, L 516, 986, 1657<br />

Carneiro-Sampaio, M 260<br />

Caroli, F 657<br />

Caron, J 1497<br />

Carotti, M 1635, 1746, 1787<br />

Carpenter, DM 1326<br />

Carpenter, EL 708<br />

Carpi, F 1582<br />

Carpintero, M 852<br />

Carr, J 203, 1168<br />

CARRA Lupus Disease-Specific<br />

Group 1702<br />

Carrat, F 2131<br />

Carreira, P 824, 1171, 2214<br />

Carrera-Marin, AL 1361<br />

Carreño, L 1276<br />

Carson, CW 1606<br />

Carsons, SE 1072, 1311, 1896<br />

Carta, S 657<br />

Carter, C 51, 76, 1542<br />

Carter, E 869<br />

Carter, JD 44, 696, 1647<br />

Carter, MJ 168<br />

Cartin-Ceba, R 680<br />

Cartwright, R 895, 1425, 1435<br />

Carty, A 545, 556<br />

Carulli, J 1753, 1782<br />

Caruso, A 1302, 2044<br />

Carvalho, J 513, 539, 2078, 2204<br />

Carvalho, MS 927<br />

Carvalho-Pinto, C 1732<br />

Carvello, F 18<br />

Casali, M 1290<br />

Casalla, L 50<br />

Casanova, A 598, 1004<br />

Casas, N 1811<br />

Casciola-Rosen, L 487<br />

Casey, VA 1327, 1328, 1331<br />

Cash, TF 1880<br />

Caspi, D 697, 1159<br />

Cassarà, E 528, 1952<br />

Cassidy, C 1234<br />

Cassidy, EA 913, 925, 929, 930<br />

Castañeda, S 1229, 1301, 1505<br />

Castelar-Pinheiro, G 2262<br />

Castelino, FV 606<br />

Castell, E 210<br />

Castellvi, I 824<br />

Castillo-Gallego, C 1967<br />

Castrejón, I 990, 1857<br />

Castro, C 914<br />

Catalán Pellet, A 50<br />

Catanoso, MG 2044<br />

Catanozi, S 887<br />

Catapano, F 678<br />

CATCH Investigators 300, 343, 659<br />

CATCH Scientific Advisory<br />

Committee 396<br />

Cathebras, P 2042<br />

Catrina, AI 394<br />

Cattalini, M 1436, 1706<br />

Cattogio, L 50<br />

Cauli, A 532<br />

Cavalcanti, F 1137<br />

Cavalli, L 222<br />

Cavazza, A 2044<br />

Cavet, G 1030, 1496, 1606, 1753,<br />

1782<br />

Ceccato, F 50<br />

Ceccherini, I 657, 1706<br />

Cecilia, G 902<br />

Cefle, A 822<br />

Celik, D 2061<br />

Celis, R 20<br />

Cellucci, T 2107<br />

Cemerski, S 1350<br />

Centola, M 1030, 1496, 1606,<br />

1753, 1782<br />

Cervera, R 451, 452, 1172, 1398,<br />

1848<br />

Cha, H-S 366, 372, 1297<br />

Cha, S 2174<br />

Chabane, N 1489<br />

Chae, J 1523<br />

Chafey, P 834<br />

Chai, A 403<br />

Chaib, A 2035<br />

Chaiban, R 215<br />

Chaisson, C 1362, 1366<br />

Chaisson, RE 908<br />

Chaki, H 280, 1467<br />

Chakravarty, EF 325, 401, 991,<br />

1043, 1960<br />

Chakravarty, K 664<br />

Chalès, G 2261<br />

Chambers, C 325, 1043, 2210<br />

Chami, H 976<br />

Chams-Davatchi, C 1289<br />

Chan, E 501, 600, 735, 1639<br />

Chan, J 735, 1639<br />

Chan, PT 467, 773, 1667<br />

Chan, W 1060, 2089<br />

Chandra, P 1083, 1740, 1764,<br />

2116<br />

Chandran, V 521, 530, 536, 783,<br />

1928, 1932, 1936, 1954, 1956,<br />

1966, 1974, 1975, 1979, 1984,<br />

2273<br />

Chang, AH 189, 202, 2056<br />

Chang, BY 286<br />

Chang, D 58, 1583, 1595<br />

Chang, H 573, 1003, 2061<br />

Chang, J 692, 1571<br />

Chang, N-H 424, 425<br />

Chang, RW 1558, 2096<br />

Chang, S-K 1388<br />

Chang, X 1978<br />

Chang, Y 71<br />

Chapelle, D 260, 1698<br />

Chapman, HA 609<br />

Chapman, P 417<br />

Chapurlat, R 964, 969, 2157<br />

Charis, P 621<br />

Charles, J 1218<br />

Charles-Schoeman, C 299, 471,<br />

933, 1058<br />

Charlotte, F 1646, 1651<br />

Charlton-Menys, V 1067<br />

Charnock, B 690, 2141<br />

Charrier, C 29<br />

Charuel, J-L 915<br />

Chary-Valckenaere, I 551, 768<br />

Chary-Valkenaere, I 1931<br />

Chatelus, E 1237<br />

320<br />

2010 Program Book


Chatham, WW 457, 1146, 1454,<br />

1457, 1668<br />

Chatterjee, S 564, 574, 592<br />

Chaturvedi, S 1551<br />

Chatzidionysiou, K 55, 410, 418,<br />

1807<br />

Chatzidionysou, K 1802<br />

Chaudhari, S 1789<br />

Chaudhary, P 562<br />

Chaudhry, A 678<br />

Chauhan, A 263, 846, 1262, 1601<br />

Chaussade, S 580<br />

Chaves, I 89<br />

Chavez, M 608<br />

Chavez, R 248<br />

Chavez Chiang, N 1055<br />

Chavez-Chiang, N 947, 1567,<br />

1626, 2225<br />

Checa, AE 885<br />

CHECK Group 184<br />

Chédeville, G 236, 1674<br />

Chefo, S 165<br />

Chemel, M 29<br />

Chen, C 1362, 1366<br />

Chen, D 1080, 1127, 1804<br />

Chen, G 1270<br />

Chen, H 570<br />

Chen, J 129, 2088<br />

Chen, K 1151<br />

Chen, L 299, 304, 404, 721, 722,<br />

1077, 1117, 1639, 1643, 2084,<br />

2103<br />

Chen, M 336, 1186, 1734, 1769<br />

Chen, N 65, 557, 644, 760<br />

Chen, PP 8<br />

Chen, Q 432<br />

Chen, R 52, 1799<br />

Chen, W 286, 805, 1598, 1779,<br />

2241<br />

Chen, X 562<br />

Chen, Y 242, 243, 247, 251, 258,<br />

655, 944<br />

Chen-An, P 1500<br />

Cheng, CW 1748, 1777<br />

Cheng, Q 492, 1414<br />

Cheol-Bae, S 2243<br />

Cherascu, BN 970<br />

Chern<strong>of</strong>f, D 1753, 1782<br />

Chetcuti Zammit, S 172<br />

Cheung, AM 1156<br />

Cheung, FC 1748, 1777<br />

Cheung, Y 429, 2190<br />

Chevrant-Breton, J 2238<br />

Chevreul, K 781<br />

Chhana, A 881<br />

Chiarelli, P 888<br />

Chiari, A 2132<br />

Chiarolanza, I 1302, 2044<br />

Chiba, A 896, 2232<br />

Chibnik, LB 1082, 1588<br />

Chiesa, S 657<br />

Chifflot, H 1237<br />

Chighizola, C 590<br />

Childhood Myositis Heterogeneity<br />

Study Group 1678<br />

Chines, A 979<br />

Chiocchia, G 1087, 1413, 1981,<br />

2000<br />

Chiodo, L 468<br />

Chiorini, JA 1413, 2178<br />

Chiossone, L 1664<br />

Chiowchanwisawakit, P 667, 1959<br />

Chipping, J 796<br />

Chira, P 1008, 1409, 1673, 1691,<br />

2017<br />

Chitale, S 661, 1763<br />

Chiu, B 696<br />

Chiu, G 849, 1492<br />

Chiu, S 1233<br />

Chiu, YG 521, 1968<br />

Chizzolini, C 1987, 1992<br />

Chmiel, JS 186, 189, 2100<br />

Cho, M 163, 276, 353, 370, 1716<br />

Cho, S-H 602<br />

Cho, Y 505, 2217<br />

Chobaz, V 2151<br />

Choe, J-Y 323, 903<br />

Chohan, S 158, 165<br />

Choi, C 1597, 1714, 1941<br />

Choi, H 72, 523, 720, 879, 1036,<br />

1056, 1363, 1366, 1547, 2067,<br />

2152, 2154, 2155, 2199, 2212,<br />

2213<br />

Choi, IA 387<br />

Choi, J 1246, 2158<br />

Choi, K 1389<br />

Choi, L 75<br />

Choi, S 92, 285, 289, 359, 1209,<br />

1628, 1972<br />

Choi, T-Y 1046, 1443, 2164, 2165,<br />

2166<br />

Chong, K 1131<br />

Chopra, A 66, 1549, 1551, 1640,<br />

1642<br />

Choquette, D 74, 196<br />

Chou, RC 640, 1427<br />

Chow, YW 1278<br />

Choy, E 819, 1766, 1832<br />

Christadoss, ML 1491<br />

Christensen, R 1766<br />

Christensen, TG 1444, 1841<br />

Christiane, AE 1026<br />

Christianson, TJH 2037, 2038<br />

Christodoulou, MI 1897<br />

Christophe, R 2267<br />

Christopher-Stine, L 919<br />

Chu, AD 428<br />

Chu, B-C 338<br />

Chu, ME 58<br />

Chu, SY 1350<br />

Chu, Z 1728<br />

Chu Miow Lin, D 143, 988<br />

Chubinskaya, S 1147<br />

Chun, J 606<br />

Chun, W 885<br />

Chung, C 120, 1034, 1607, 1808,<br />

2123, 2260<br />

Chung, JB 1141<br />

Chung, L 561, 570, 573, 586,<br />

1157, 1213, 1223, 1378<br />

Chung, S 27, 500, 502, 1592,<br />

1602, 2145<br />

Chung, W 257<br />

Chung, Y-J 1589<br />

Church, L 1263<br />

Churchill, D 1645<br />

Ciapetti, A 1746, 1787<br />

Cibere, J 2055<br />

Ciciriello, S 1001, 1009<br />

Cicuttini, F 173, 183, 192, 1383<br />

Cid, M 777, 1276, 1280, 1292,<br />

1294, 1309, 1314, 1637, 1652,<br />

1654<br />

Cifaldi, M 65, 91, 307, 327, 382,<br />

535, 557, 644, 760, 763, 771, 788,<br />

2266<br />

Cifuentes, RA 1048<br />

Cigler, T 898<br />

Cimaz, R 246, 1675, 1872, 240,<br />

1305, 1436<br />

Cimbora, D 493<br />

Cimmino, MA 777, 1637, 1652,<br />

1654<br />

Cinzia, DL 240<br />

Ciregia, F 811<br />

Cistrone, C 1085<br />

Citera, G 324, 50<br />

Ciullini Mannurita, S 261<br />

Cividino, AA 57, 313, 341, 1735<br />

Clair, B 1185, 1196<br />

Clancy, MM 198<br />

Clancy, R 443, 489, 495, 637, 656,<br />

1190, 2231<br />

Clapp, L 2005<br />

Clark, E 747<br />

Clark, P 767<br />

Clark, TB 1382<br />

Clarke, A 214, 445, 448, 454, 476,<br />

731, 1142, 1146, 1170, 1848, 1850,<br />

1877, 2240, 2243<br />

Clarke, J 920<br />

Clary, G 834<br />

Clauw, DJ 100, 650<br />

Clavert, V 1237<br />

Clegg, DO 948<br />

Clemens, P 935<br />

Clements, P 598, 729, 1228, 1232,<br />

2194, 2195, 1205<br />

Clements-Baker, MI 126<br />

Clemessy, M 1991<br />

Clerico, P 1798<br />

Cleveland, C 446<br />

Clifford, B 245, 256<br />

Cliss, A 1325<br />

Close, D 1455, 2085<br />

Clower, J 152, 1713<br />

Clowse, ME 325, 461, 1043, 1154,<br />

1192, 1862<br />

Club Rhumatismes et Inflammation<br />

(CRI) 904<br />

Cluzel, P 1287<br />

Co, S 2152<br />

Coates, L 514, 1926, 1929, 2182,<br />

2183<br />

Coca, A 1886<br />

Cocuzza, M 513<br />

Codding, CE 1441<br />

Codreanu, C 405, 1013<br />

Coenen, M 824, 829, 1599, 2004,<br />

2214<br />

C<strong>of</strong>ield, S 299, 1740<br />

C<strong>of</strong>ield, SS 1368, 1779<br />

Coghlan, G 590<br />

Coghlan, JG 727<br />

Cohen, H 812<br />

Cohen, MJ 187<br />

Cohen, P 2009, 2034, 2041, 2043,<br />

2045<br />

Cohen, RB 390<br />

Cohen, SB 403, 1154<br />

Cohen Tervaert, JW 676<br />

Coker, I 1970<br />

Colaci, M 581, 1627<br />

Colato, C 671<br />

Colbert, CJ 186, 189, 202<br />

Colbert, RA 1376<br />

Colin, D 1931<br />

Colin, E 38, 1274<br />

Collaku, L 1962<br />

Collantes, E 525, 986, 2268<br />

Collantes-Estevez, E 1357<br />

Collée, G 1396<br />

Collet, C 1707<br />

Collier, DS 25<br />

Collins, C 1062, 1210<br />

Collins, ES 1105<br />

Collins, JB 1324<br />

Colmegna, I 351, 1336<br />

Colombo, PC 1183<br />

Coman, I 1185<br />

Combe, B 301, 376, 400, 1790,<br />

1946, 2042<br />

Combe, BG 303, 383, 408, 1527,<br />

1732, 1760<br />

2010 Program Book 321<br />

abstract author Index


aBSTRACT author Index<br />

322<br />

Combesure, C 792<br />

Comeau, M 1591<br />

Comeau, ME 500, 2145<br />

Compaoré, C 2269<br />

Conaghan, PG 118, 120, 140, 141,<br />

143, 181, 199, 1097, 1114, 1369,<br />

1817, 1926, 2182, 2183, 2264<br />

Condon, KW 716<br />

Conforti, ML 593<br />

Conigliaro, J 994<br />

Conn, DL 1077<br />

Conneely, K 255<br />

Connell, CA 1129, 2171<br />

Connelly, M 1406, 2248<br />

Connolly, AJ 2117<br />

Connolly, K 920<br />

Connolly, M 871, 1391, 1533<br />

Connop, B 285<br />

Connors, G 1022<br />

Conrad, K 1757<br />

Consolaro, A 208, 232<br />

Consolini, R 1685<br />

Consortium, E 2276<br />

Constantin, A 1752<br />

Constantin, AL 2218<br />

Conti, PS 1499<br />

Contin-Bordes, C 1816<br />

Contreras-Yáñez, I 337<br />

Cook, R 530, 556, 783, 1936,<br />

1954, 1956, 1964<br />

Cook, RJ 512, 545<br />

Cook, TH 430<br />

Cooke, D 2100<br />

Cooney, L 1271<br />

Cooper, C 841<br />

Cooper, S 451, 1172, 1454, 1456<br />

Cooper, T 780<br />

Cooray, D 699<br />

Cope, AP 412<br />

Cope, E 1345<br />

Corazza, L 2036<br />

Corbera-Bellalta, M 1292, 1294,<br />

1309<br />

Cordel, N 2238<br />

Cordier, J-F 2009<br />

Cordingley, L 1323<br />

Coresh, J 1364, 1544, 1556, 1569<br />

Coriat, R 580<br />

Cormier, G 2269<br />

Cornec, D 2261<br />

Cornelissen, F 287, 1259<br />

Corneth, O 287, 715, 1525<br />

Cornish, J 881, 1983<br />

Corominas, H 1801<br />

Corona, F 2033<br />

Corr, M 271, 624, 1718<br />

Corrales Martinez, AF 1650<br />

2010 Program Book<br />

Correa, MJU 579<br />

Corrigall, VM 1729<br />

Corscadden, D 1090, 1254<br />

Corsiero, E 1906<br />

Cortez, V 1060<br />

Cortis, E 209, 2033<br />

Cortot, CF 235<br />

Corvol, P 1991<br />

Cosan, F 1281, 2217<br />

Cosentino, M 1089<br />

Cosmi, L 246<br />

Cosnes, A 2238<br />

Costa, J 1986<br />

Costa Antunes, M 566<br />

Costallat, LTL 1695<br />

Costantino, F 768<br />

Coste, J 2094<br />

Coste, P 948<br />

Costedoat-Chalumeau, N 478,<br />

732, 1249, 1287, 1660, 2025, 2238,<br />

2239<br />

Costello, S 995<br />

Costenbader, K 41, 64, 325, 762,<br />

1043, 1082, 1588, 2104<br />

Cosyns, J-P 1398<br />

Cot<strong>of</strong>ana, S 182, 1380<br />

Cottrell, JED 2279<br />

Cottrell, TR 596<br />

Cotty, P 130<br />

Couchot, M 130<br />

Couderc, M 917<br />

Coughlan, RJ 989, 2111, 2112<br />

Countryman, P 125<br />

Courtney, M 1335<br />

Coury, F 1502<br />

Covarrubias, JA 2173<br />

Covini, G 1639<br />

Covucci, A 1120, 1837<br />

Cox, AJ 226<br />

Cox, E 1404<br />

Cox, SM 2282<br />

Cox, VL 87, 1047, 1428, 1856,<br />

1865<br />

Coyle, A 741<br />

Cozic, C 29<br />

Craft, JE 1246<br />

Crane, MM 58<br />

Crate, DC 1537<br />

Crema, MD 193<br />

Creswell, L 536<br />

CRI 701, 902<br />

Crighton, KA 70<br />

Criscione-Schreiber, LG 1862<br />

Crisostomo, M 2251, 2252<br />

Crispino, JD 854<br />

Criswell, LA 446, 500, 502, 789,<br />

1591, 1592, 1595, 1602, 1898,<br />

2113, 2145, 2147, 2148<br />

Crittenden, D 148, 883<br />

Croca, SC 465, 1140, 1144<br />

Cr<strong>of</strong>ford, LJ 726, 864, 994<br />

Cr<strong>of</strong>oot, M 2072<br />

Cron, RQ 208, 209, 213, 1668,<br />

1679<br />

Cronin, M 493<br />

Cronstein, BN 148, 600, 827, 956,<br />

1469, 1470, 1471, 1522<br />

Crook, K 751, 752<br />

Crooks, E 1158<br />

Crow, MK 167, 508, 1181, 1183,<br />

1199, 1612, 1990, 2193<br />

Crowe, S 9, 24, 466<br />

Crowson, CS 15, 53, 67, 78, 316,<br />

705, 777, 1304, 1379, 1550, 1570,<br />

1580, 1581, 1637, 1652, 1654,<br />

1662, 2216<br />

Croxford, R 2208<br />

Cruz-Cruz, P 1150<br />

Cruz-Martínez, J 2268<br />

Cryer, B 937, 953<br />

Csernok, E 679<br />

CSRG 1202, 1221<br />

Csuka, ME 726<br />

Cuadrado, MJ 1357<br />

Cuccioloni, M 2001<br />

Cuda, CM 853, 859, 861<br />

Cuevas-Orta, E 1166<br />

Cui, J 308, 1050, 1335, 1610, 2064<br />

Cummings, SR 982, 2157<br />

Cunningham, F 1395<br />

Cuomo, G 572<br />

Cupples, LA 1317, 1329<br />

Curran, ML 47<br />

Curtis, C 153<br />

Curtis, JR 54, 68, 86, 239, 299,<br />

304, 379, 404, 721, 722, 1005,<br />

1006, 1010, 1031, 1099, 1117,<br />

1368, 1540, 1543, 1552, 1561,<br />

1573, 1643, 1753, 1782, 1808,<br />

2084, 2103<br />

Cusack, T 2135<br />

Cush, JJ 890, 908, 1618<br />

Cusumano, P 1656<br />

Cuthbert, R 1090, 1126, 1254<br />

Cuthbertson, D 2012, 2198<br />

Cutolo, M 578, 1236, 1798<br />

Cutrone, M 1439<br />

Cuttica, R 1434, 1701, 1872<br />

Cuyun Carter, G 52<br />

Czeloth, N 1125<br />

Czerwinski, E 2157<br />

D<br />

Da Costa, D 2120<br />

Da Silva, CHM 1684<br />

Da Valle, Y 839<br />

Dabbagh, K 288<br />

Dabbous, O 878<br />

DaCosta, D 1156<br />

Dadoun, S 781, 1648<br />

Dadu, E 694<br />

Daelken, B 1125<br />

Dagfinrud, H 534<br />

Dagliyan, G 1499<br />

Dagnæs-Hansen, F 1485<br />

D’Agostino, MA 527, 533, 551,<br />

1629, 1931<br />

Daher, J 200<br />

Dahiya, N 1633<br />

Dai, H 254<br />

Dai, L 367<br />

Dai, W 965<br />

Dai, X 274, 1107<br />

Daien, CI 393<br />

Daikh, BE 1638<br />

Dairaghi, DJ 1100, 2032, 2048<br />

Daizadeh, NS 2157<br />

Dalbeth, N 146, 881, 1983, 1372<br />

Dale, N 769, 795<br />

D’Alfonso, S 1578<br />

Daliman, D 2060<br />

Dalod, M 1664<br />

D’Aloisio, AA 61<br />

Dalpoto, J 288<br />

DalPra, F 50<br />

Dalprà, S 207<br />

Daly, M 1333<br />

Dam, EB 1466<br />

Damade, R 2034<br />

D’Ambrosio, L 99<br />

Damjanov, N 217<br />

Dancea, S 345, 1442<br />

Dang, JT 2185<br />

D’Angelo, S 532<br />

Daniel, G 81<br />

Daniels, T 1898<br />

Danielson, LS 1490<br />

Danila, MI 1077<br />

Dankaerts, W 520<br />

Dankbar, B 1478<br />

Dan<strong>of</strong>f, S 919, 1022<br />

D’Antona, G 744<br />

Dao, A 269<br />

Darce Bello, M 1305<br />

Darnell, R 863<br />

Das, L 268<br />

Das, R 841<br />

Dasari, S 2110<br />

d’Ascanio, A 839<br />

Dasgupta, A 642<br />

Dasgupta, B 777, 1637, 1652,<br />

1654<br />

Dasilva, V 976<br />

Dass, S 1126


Daudon, M 875<br />

Daugas, E 2009<br />

Davatchi, F 1289<br />

Dave, M 1477<br />

Davelaar, N 1259<br />

Davey, MP 1447, 1713<br />

Davì, S 208<br />

David, JR 1721<br />

David, S 2125<br />

Davidson, A 1410, 2188, 2276<br />

Davies, R 374, 509<br />

Davies-Tuck, M 173<br />

Davignon, J-L 281<br />

Davis, AM 682<br />

Davis, C 203<br />

Davis, J 1122<br />

Davis, KW 245<br />

Davis, LA 397<br />

Davis, M 147, 350, 920<br />

Davis, WE 1007<br />

Davis III, JM 67, 1580, 1581, 2216<br />

Dawood, M 449, 1185<br />

Dawson-Hughes, B 706<br />

Dayer, J-M 1088<br />

Dayoub, E 763<br />

D’Cruz, D 444, 463, 1456, 2035<br />

De, D 1925<br />

D’Elia, G 222<br />

de Achaval, S 87, 1047, 1428,<br />

1856, 1865<br />

de Almeida, BP 513<br />

De Angelis, R 547, 1627<br />

de Baere, E 2214<br />

De Bandt, M 701, 917, 1752<br />

de Benedetti, F 18, 1434<br />

de Boer, IG 2284<br />

de Boer, KVC 1396<br />

de Boer, M 1095<br />

de Boer, TN 942<br />

de Carvalho, LM 1694<br />

De Carvalho, M 768<br />

De Cunto, C 1700<br />

De Domenico, I 1309<br />

De Gennaro, L 2008<br />

De gennes, C 1651<br />

de Glas, NA 1755<br />

de Graaf, J 1210<br />

de Greeuw, I 1613<br />

de Groot, P 1360<br />

de Hair, MJ 1069, 1604<br />

de Jager, W 719<br />

de Jong, HWAM 121<br />

de Jong, PHP 317<br />

De Keyser, F 340, 824<br />

de Keyser, F 2214<br />

de Koning, M 1091<br />

De la Fuente, A 1473, 1498<br />

de la Serna, AR 1078<br />

De la Torre, I 739, 743<br />

de Langhe, E 610<br />

de Larranaga, G 3<br />

de Launay, D 32, 1529<br />

De Libero, C 1436<br />

de Longueville, M 995<br />

de Man, YA 1073<br />

De Marchi, G 2036, 2201<br />

De Marco, G 532<br />

de Martino, M 261<br />

de Menthon, M 2041<br />

De Meulemeester, M 145, 1423,<br />

2087<br />

de Miguel, E 986, 1629<br />

de Miguel-Mendieta, E 1967<br />

De Palma, R 246<br />

De Pasquale, L 18<br />

de Rijke, YB 1073<br />

De Riva, A 843<br />

de Rooij, M 2051<br />

De Rosa, M 781<br />

De Rycke, L 753, 2272<br />

de Sa Pinto, AL 1384<br />

de Saint-Martin, L 2010, 2011<br />

de Sanjose, S 1280<br />

De Santis, M 1239<br />

de Steenwinkel, FDO 1073<br />

De Toro, FJ 1473, 1475, 1483,<br />

1498<br />

De Vera, M 72, 720, 1056<br />

de Vernejoul, M-C 964<br />

De Vita, S 2036, 2201<br />

De Vito, A 1162<br />

de Vlam, K 520<br />

De Vooght, V 610<br />

de Vos, I 2051<br />

de Vries, D 1804<br />

de Vries, N 1069, 1604<br />

de Vries, RRP 2114<br />

de Vries, TJ 1495<br />

De Waal Malefijt, M 641<br />

de Waard-van der Spek, FB 219<br />

de Wazières, B 2045<br />

de Wit, M 1013<br />

Deane, K 71, 77, 658, 1083, 1094,<br />

2116, 2119<br />

Deberg, M 835<br />

Decaluwe, H 1693<br />

Dechant, C 2130<br />

Dechartres, A 2046<br />

DeCherrie, L 2110<br />

Decktor, D 420, 1960<br />

Dedeke, AB 9, 24, 780<br />

Dedreux, I 1827<br />

Deering, DE 647<br />

Deery, MJ 843<br />

Dees, C 607, 611, 614, 616, 672<br />

Degli Esposti, M 1446<br />

Degraeve, F 2027<br />

Dehlendorf, A 263<br />

Dehlin, M 103, 293<br />

Dehlinger, V 571<br />

Dehoratius, R 420<br />

DeHoratius, RJ 1960<br />

Dejaco, C 777, 1637, 1652, 1654,<br />

2222<br />

Dejmkova, H 1649<br />

Dekker, J 184<br />

Dekker-Bakker, LMMCJ 2051<br />

del Castillo, N 1310<br />

Del Galdo, F 671, 673<br />

del Junco, DJ 725<br />

Del Medico, P 1627<br />

Del Pino, J 975<br />

Del Rincon, I 1035, 1044, 1049,<br />

2163<br />

deLaat, B 2250<br />

Delaet, I 390, 416, 1834, 2173<br />

Delano, M 742<br />

Delany, K 750<br />

Delauter, SK 1382<br />

Delavallée, L 2236<br />

DeLay, M 1728<br />

Delbrel, X 2027<br />

Delea, S 947, 1055, 1567, 1626,<br />

2225<br />

Deleon, F 978<br />

Deleuran, B 1524, 1761<br />

Delgado, A 2145<br />

Delgado, R 804<br />

Delgado-Frias, E 389<br />

Delgado-Vega, AM 1578<br />

Deligny, C 571<br />

Della Rossa, A 1884<br />

Dellacasagrande, J 16<br />

Dell’Accio, F 1476, 1503<br />

Dellaripa, PF 1212<br />

Delle Sedie, A 558<br />

Delles, C 1441<br />

Delmas, PD 964<br />

DeLongis, A 1027, 1324<br />

Del-Pino, J 1888<br />

DelVentura, JL 101<br />

Delzell, E 54, 304, 404, 721, 722,<br />

1573, 1643, 2084, 2103<br />

DeMaria, DM 1045<br />

DeMartino, JA 288, 1270<br />

Demirkaya, E 1684, 1700, 1705<br />

Demoruelle, K 1094<br />

Dempsey, A 192<br />

Dempsey-Robertson, M 223<br />

Dempster, DW 2161<br />

Den Adel, M 2170<br />

Den Broeder, A 641, 1826, 1833<br />

Den Heijer, M 1210<br />

den Uyl, D 961<br />

Denaro, V 222, 1155<br />

Dencker, D 1444, 1841<br />

Deng, W 274<br />

Deng, Y 1583, 1584<br />

Dennis, G 757, 764, 1609<br />

Denny, L 1542<br />

Dent, R 2161<br />

Denton, C 560, 566, 590, 599,<br />

613, 674, 727, 829, 1207, 1212,<br />

1995, 1996, 2005<br />

Deodhar, AA 758, 1948<br />

Depresseux, G 1398<br />

Derancourt, C 571<br />

Derber, L 77, 658, 1083, 1094,<br />

2116<br />

Derby, CA 939, 2095<br />

Derese, I 1980<br />

Derfler, K 469<br />

Derk, CT 580<br />

Derksen, R 6<br />

Dernis, E 904<br />

DeRoo, LA 61<br />

Derrett-Smith, E 674, 1207, 1995,<br />

2005<br />

Dervieux, T 827<br />

Desai, P 692<br />

Deshayes, K 2032<br />

Deshmukh, US 1883<br />

Deshpande, P 2127<br />

Deshpande, V 1671<br />

Desjarlais, JR 1350<br />

Desvignes-Engelbert, A 551<br />

Detert, J 782, 1780<br />

Detilleux, J 979<br />

Devarajan, P 268, 2106<br />

Devauchelle, V 1896, 1914<br />

Devauchelle-Pensec, V 1931, 2261<br />

Deveber, G 2019<br />

DeVellis, RF 181, 1326<br />

Develly, PC 1458<br />

Devignes, J 1<br />

Devilliers, H 478<br />

Devita, S 1896<br />

Devogelaer, J-P 2156<br />

Dhanyamraju, PK 694<br />

Dhar, JP 468<br />

Dharmage, S 1942<br />

Dhawale, R 185<br />

Dhote, R 2026, 2034<br />

Di Duca, M 657<br />

Di Iorgi, N 1684<br />

Di Padova, FE 1730<br />

Di Pietro, F 1582<br />

Diamantopoulos, A 972<br />

2010 Program Book 323<br />

abstract author Index


aBSTRACT author Index<br />

Diamond, B 426, 1191, 2083<br />

Dias, VC 398<br />

Diaz, A 1659<br />

Diaz, F 1659<br />

Diaz, MV 1863<br />

Díaz, S 1473, 1498<br />

Díaz López, C 1118<br />

Díaz Torné, C 1118, 1796, 1801<br />

Diaz-Gallo, L 824, 2214<br />

Diaz-Gonzalez, F 389, 1509<br />

Diaz-Lopez, CR 1801<br />

Diaz-Martin, A 1509<br />

Díaz-Prado, S 1475, 1483<br />

Diaz-Sanchez, B 1505<br />

Dib, H 575, 834<br />

DiBonaventura, M 51, 327, 382<br />

DiCarlo, E 167, 1080<br />

DiCarlo, J 125<br />

Dieguez-Gonzalez, R 1076<br />

Diehl, A 1154<br />

Diehl, L 1609<br />

Diekman, LA 522, 1982<br />

Diel, R 782<br />

Diemert, M-C 1911, 2025<br />

Dietz, E 1621<br />

Dieude, P 1087, 1890, 1910, 1987,<br />

1994, 2226<br />

DiFrancesco, M 1689<br />

Dijkmans, BA 90, 295, 328, 332,<br />

334, 643, 663, 1084, 1613, 1859,<br />

1933, 1091, 1445, 1496, 1825,<br />

1948<br />

Dilling, RG 2051<br />

Dillon, SP 1901<br />

Dimic, A 1096, 2168<br />

Dina, B 1689<br />

Dinarello, C 371, 1308, 1664<br />

Dincer, U 114<br />

Dinella, J 1554<br />

Dinesh, RK 1257<br />

Ding, B 832, 1588, 2161<br />

Ding, L 2012<br />

Ding, Y 1250<br />

Dinser, R 1479<br />

Dintinger, H 768<br />

Diot, E 2010, 2011, 2034, 2045<br />

DiPlacido, L 1246<br />

Direskeneli, H 777, 822, 1133,<br />

1291, 1303, 1637, 1652, 1654,<br />

1803, 2200<br />

Direz, G 130, 904<br />

DiRusso, JM 2053, 2054<br />

Dirven, L 328, 334, 1496, 1782<br />

Distler, J 560, 566, 607, 611, 614,<br />

615, 616, 672, 1991, 2000<br />

Distler, O 560, 566, 599, 607, 611,<br />

616, 1212, 614, 672, 1988<br />

Disu, T 1358<br />

Ditto, MC 784<br />

Dixon, J 173, 1383<br />

Dixon, W 342, 421<br />

Dlott, J 12<br />

Do, HT 174, 898<br />

Doan, E 12, 2253<br />

Dobrzanski, P 2233<br />

Dockhorn, R 1111<br />

Dodd, A 250<br />

Doerner, T 1910<br />

Dogan, S 1283<br />

Doherty, EH 2275<br />

Doherty, M 841<br />

Doherty, S 841<br />

Dohmen, S 1822<br />

Dolan, G 1831<br />

Dolatabadi, S 1768, 305<br />

Dolezalova, P 1705<br />

Dolhain, RJEM 1073<br />

Dolman, KM 219<br />

Dolphi, F 953<br />

Domínguez, MJ 1659<br />

Dominguez, N 2274<br />

Dominguez, PR 501<br />

Dominguez-Luis, MJ 1509<br />

Domino, SE 1504<br />

Domsic, RT 569, 586, 1231<br />

Donadio, E 839<br />

Dong, Q 1107<br />

Dong, W 698<br />

Donn, RP 445<br />

Donnell-Fink, L 2092<br />

Donnelly, S 1306<br />

Dooley, A 674, 2005<br />

Dooley, M 445, 448, 451, 476,<br />

731, 1453, 1877, 2085, 2240, 2243<br />

Doorenspleet, ME 1069, 1604<br />

Dorais, M 196, 938<br />

Doria, A 1402, 1456<br />

Döring, G 1123<br />

Dörner, T 414, 745, 1411, 1896<br />

Dorri, Y 1901<br />

Dorris, M 1448<br />

Dorsey, B 2233<br />

dos Santos, MM 1458<br />

Dotzlaw, H 886<br />

Douce, T 493<br />

Dougados, M 69, 82, 321, 400,<br />

414, 529, 542, 548, 917, 948, 1013,<br />

1104, 1629, 1648, 1760, 1790,<br />

1805, 1810, 1924, 1927, 1946<br />

Douglas, KB 730<br />

Douma, S 11<br />

Doumas, M 11<br />

Doveri, M 1884<br />

Doweyko, A 1513<br />

Doyle, A 1372<br />

Doyle, MK 326, 890, 908, 1804<br />

Drachman, JG 1273<br />

Dracou, C 1684<br />

Draeger, H 562, 725, 1211, 1218,<br />

1227<br />

Dragone, L 748, 2128<br />

Drapé, J-L 728<br />

Drappa, J 1455<br />

Dreher, D 182<br />

Drenkard, CM 790<br />

Drenth, J 1210<br />

Dressler, F 1701, 1705<br />

Drews-Botsch, C 1405<br />

Drexhage, HA 1904<br />

Dreyfus, P 1413<br />

Driban, J 122, 706, 709<br />

Driscoll, PC 1358, 1359<br />

Drosos, AA 1215<br />

Drossaert, CHC 1334<br />

Drouot, L 915<br />

Drummond, W 150<br />

D’souza, A 1901<br />

D’Souza, C 1163<br />

du Bois, RM 2119<br />

Du Clos, T 850<br />

Duan, R 2184<br />

Duarte-García, A 1853, 1881<br />

Dübel, S 2234<br />

Dubner, SE 206<br />

Dubois, A 2269<br />

Dubost, J-J 375, 701, 1890, 1910<br />

Dubourg, O 922<br />

Dubreuil, M 2199<br />

Duch, D 41<br />

Ducourau, E 988, 1945<br />

Duda, G 630, 1418<br />

Dudler, J 1819<br />

Duer-Jensen, A 133, 1370<br />

Duff, GW 831, 838<br />

Duffy, C 214, 1408<br />

Dufour, AB 1327, 1328, 1330,<br />

1331<br />

Duftner, C 777, 1637, 1654, 2222<br />

Dugan, B 2233<br />

Duhaut, P 777, 1652, 1654, 2040,<br />

2238<br />

Dulos, J 1730<br />

Dummer, W 383, 414, 2169<br />

Dumont-Fischer, D 997<br />

Duncan, B 1805, 2246<br />

Dunlop, DD 186, 189, 202, 1558,<br />

2096<br />

Dunne, A 1426<br />

Dunussi-Joannopoulos, K 1154<br />

Duny, Y 393<br />

Dupont, F 221<br />

Dupuy, A 1651<br />

Duquesne, A 905<br />

Duquesroix, B 936, 953<br />

Durand, E 533<br />

Durand-Zaleski, I 781<br />

Durez, P 123, 340, 1013, 1817,<br />

2173, 2263<br />

Durham, K 823<br />

Durmus, O 114<br />

Durnez, A 311<br />

Duryee, MJ 2235<br />

Dutmer, E 1833<br />

Dutz, JP 523, 1661<br />

Dvir-Ginzberg, M 1484<br />

Dweik, R 564<br />

Dyer, AR 1168<br />

Dzeing-Ella, A 576<br />

Ea, H-K 413, 875, 888, 2151<br />

Ea, K 1707<br />

Eastman, S 1606<br />

Eaton, C 71, 2096<br />

Eaton, J 1688, 2106<br />

Ebeling, PR 982<br />

Eberhard, A 1677<br />

Eberhard, BA 1673, 1688, 1691,<br />

1701, 1702, 2017<br />

Eberl, H 1764<br />

Eberle, E 515<br />

Eckes, B 1719<br />

Eckstein, F 182, 1380<br />

Edberg, JC 828, 868, 1584, 1591,<br />

1594, 1595, 2147<br />

Eddleman, KC 1860<br />

Ede, KC 1673, 1691, 2017<br />

Edelmann, E 138<br />

Edelstein, D 178<br />

Eder, L 455, 521, 530, 783, 1928,<br />

1936, 1954, 1956, 1974, 1979,<br />

1984<br />

Edgar, M 635, 639, 1727<br />

Edgerton, CC 346<br />

Edison, JD 1083, 2116<br />

Edlin, H 1067<br />

Edmundowicz, D 1168<br />

Edogawa, S 298<br />

Edwards, JCW 739, 743<br />

Edwards, KA 115<br />

Edwards, RR 949<br />

Eftekhari, A 2152<br />

Egbuna, OI 982<br />

Egerer, K 911<br />

Eggebeen, AT 209<br />

Eguchi, K 364, 1371, 1632<br />

Ehara, T 1709<br />

Ehman, RL 129<br />

Ehrenstein, MR 738, 740<br />

E<br />

324<br />

2010 Program Book


Ehst, B 758<br />

Eicher, JL 688<br />

Eisen, S 62, 1395<br />

Ejbjerg, B 133, 141, 1370<br />

Ekholm, L 926<br />

Eksioglu-Demiralp, E 2200<br />

Ekström Smedby, K 1015<br />

El Baalbaki, G 2247<br />

Elash<strong>of</strong>f, DA 1779, 1789<br />

Elash<strong>of</strong>f, M 326<br />

El-Gabalawy, HS 1068, 1094, 1176<br />

Elhai, M 529, 1924<br />

Elias, M 550<br />

Eliasson, H 832<br />

Eljaafari, A 1247<br />

El-Kadi, HS 420<br />

Elkayam, JG 682<br />

Elkayam, O 697, 1238<br />

Elkins, J 176<br />

Elkon, KB 494, 499<br />

Eller, M 801<br />

Ellis, J 248, 2219<br />

Ellis, L 1424<br />

Ellis, R 463<br />

El-Mansouri, FE 1489<br />

Eloranta, M-L 503<br />

Elshafie, A 695<br />

El-Shanti, H 260<br />

Elston, E 912<br />

Elsworth, G 2079, 2139<br />

Emamian, SM 1918<br />

Emerling, D 164<br />

Emerson, F 1638<br />

Emery, H 1433<br />

Emery, P 118, 141, 321, 326, 391,<br />

403, 414, 524, 553, 671, 673, 1013,<br />

1063, 1090, 1097, 1101, 1114,<br />

1126, 1127, 1136, 1254, 1791,<br />

1805, 1836, 1926, 1929, 1963,<br />

2182, 2183, 2264<br />

Emilie, D 376<br />

Emir, B 94, 813<br />

Emkey, GR 25<br />

Emu, B 1122<br />

Enama, JL 1861<br />

Endo, H 619<br />

Endreffy, E 1578<br />

Endres, J 1271, 1520, 1609<br />

Engelbrecht, M 1781<br />

Engelke, K 128<br />

Engel-Nitz, N 757, 764<br />

Englbrecht, M 128, 1027, 1634<br />

Engling, A 1125<br />

Englund, M 131, 182, 761, 963,<br />

2209<br />

Eng-Wong, J 912<br />

Enjuanes, A 1280<br />

Ennis, H 1234<br />

Ens, A 238<br />

Epifania, B 615<br />

Epstein, RS 1561<br />

Equinda, M 1390<br />

Erausquin, C 1876<br />

Ergen, A 822<br />

Ergonul, O 1133<br />

Ergun, T 1303<br />

Erik, PJ 15<br />

Eriksson, C 1847<br />

Eriksson, P 1885<br />

Erkan, D 2077, 6<br />

Erlandsson, M 103, 293<br />

Erlendsson, J 134, 1953<br />

Ernestam, S 1392, 1393<br />

Ernet, C 128<br />

Ershova, O 1125<br />

Ertl, G 1026<br />

Ertl, J 327, 382<br />

Ertl, L 2048<br />

Ervin, JE 710<br />

Esbrit, P 1475<br />

Escalante, A 1044, 1049, 2163,<br />

1035<br />

Esdaile, J 1036, 1152, 1324, 1538,<br />

2055<br />

Eshed, I 1369<br />

Espesen, J 1444, 1841<br />

Espígol-Frigolé, G 777, 1276,<br />

1292, 1314, 1637, 1654<br />

Espinosa, G 824<br />

ESPOIR Scientific Committee 1760<br />

Esposito, D 1358<br />

Essenmacher, L 468<br />

Esserman, D 19<br />

Estrach, C 661, 1763<br />

Estrada, P 1016, 1277, 1299, 1310<br />

Estrada Y Martin, R 1218, 1227<br />

Esveldt, RE 1069, 1604<br />

Etchepare, F 2221<br />

Ethirajulu, K 717<br />

Etrolpolski, M 950<br />

EULAR Sjögren’s Task Force 1896<br />

Euller Ziegler, L 917, 976, 1810,<br />

2094<br />

Evangelisto, AM 1617<br />

Evans, GW 1677<br />

Evans, HG 1263, 1838<br />

Evans, RR 152, 153<br />

Everts, V 1495<br />

Eveslage, M 1111, 1112<br />

Eweis, I 798<br />

Eyckmans, J 1468<br />

Eymard, B 915, 922<br />

Eyre, S 264, 266, 1075, 1394,<br />

1593<br />

Ezeonyeji, AN 1153<br />

F<br />

Fabian, G 1273<br />

Fabreguet, I 529, 1924<br />

Fabri, GMC 2078, 2204<br />

Fabricio-Silva, GM 356<br />

Faezi, T 1289<br />

Fahmi, H 1489<br />

Fahrleitner-Pammer, A 967<br />

Fain, O 701, 917, 1653, 1893,<br />

1894, 2239<br />

Fak, J 863<br />

Fakharzadeh, S 920<br />

Falcini, F 222, 261, 1155, 1439,<br />

1872, 2033, 2202<br />

Falgarone, G 997, 1707<br />

Falissard, B 82<br />

Falk, RJ 2048<br />

Fall, N 244, 653<br />

Falzer, P 2249<br />

Fan, H 326, 442, 1127, 1968<br />

Fang, C 1542<br />

Fang, H 474, 1163, 1180, 1858<br />

Fang, L 1107<br />

Fang, MA 169<br />

Fang, Y 1167<br />

Fantin, B 1653<br />

Faraone, S 449<br />

Fardellone, P 69, 787, 971, 2094<br />

Farewell, V 536, 1979, 2242, 2243<br />

Faria, AGA 498<br />

Farina, G 675<br />

Faris, P 775<br />

Farmer, MV 648<br />

Farmer, P 391, 401<br />

Farnarier, C 1664<br />

Farragher, TM 779<br />

Farris, AD 1267<br />

Fassold, A 361<br />

Fateh, J 2072<br />

Fathi, M 924<br />

Fauchais, A 1890, 1910<br />

Faure, G 768<br />

Faustini, F 744, 1239, 1582<br />

Fautrel, B 141, 301, 781, 787,<br />

984, 1104, 1752, 1760, 1762, 2094,<br />

2221<br />

Favarato, MHS 531<br />

Favero, L 1687<br />

Favero, V 1687<br />

Faye, A 1305, 1693<br />

Fazio, S 1034<br />

Fazzini, B 1173<br />

Fearon, U 16, 360, 871, 1391,<br />

1508, 1510, 1533, 1625<br />

Federici, C 834<br />

Federici, S 265, 1685, 1706<br />

Fedorora, T 282<br />

Feghali-Bostwick, CA 670, 2006<br />

Fehm, T 1145<br />

Fehringer, EV 168<br />

Feist, E 56, 911, 1788<br />

Feld, J 550<br />

Feldman, BM 225, 1408, 1681<br />

Feldstein, A 1543<br />

Feldtkeller, E 1923<br />

Feletar, M 1560<br />

Felli, L 1798<br />

Felsher, DW 434<br />

Felson, D 131, 197, 198, 201, 205,<br />

683, 685, 686, 723, 836, 872, 951,<br />

1373, 1385, 1464, 1557, 1564,<br />

2098, 2100, 2108, 2133<br />

Feng, J 1789<br />

Feng, R 920<br />

Feng, X 918, 1143, 1182<br />

Fenter, P 2076<br />

Ferbas, J 1141<br />

Ferbert, SM 2075<br />

Feria, M 1659<br />

Ferland, D 300, 306, 343, 659,<br />

978, 1737<br />

Fernandes, A 228, 356, 754, 2132<br />

Fernandes, BLF 1458<br />

Fernández, A 1811<br />

Fernandez, DR 437, 1185, 2275<br />

Fernández, F 1811<br />

Fernandez, I 608, 852<br />

Fernandez, L 1732<br />

Fernández, P 600<br />

Fernández LLaca, H 1650<br />

Fernández-Carballido, C 986<br />

Fernández-Gutiérrez, B 1078,<br />

1301, 1599<br />

Fernández-López, C 835<br />

Fernández-Lopez, JC 541, 1920<br />

Fernandez-Luna, JL 1296<br />

Fernández-Moreno, M 835<br />

Fernandez-Nebro, A 824<br />

Fernández-Puente, P 840, 1473<br />

Fernandez-Sueiro, JL 538, 541,<br />

1920<br />

Ferraccioli, G 297, 355, 414, 744,<br />

1098, 1239, 1582, 1627, 1787,<br />

2036<br />

Ferrant, J 1243, 1244, 1245<br />

Ferraz-Amaro, I 389<br />

Ferrazzi, V 904<br />

Ferreira, A 1423, 1425<br />

Ferreira, T 936<br />

Ferreiro, A 1078<br />

Ferri, C 297, 581, 1627, 2036,<br />

2201<br />

Ferriani, VPL 1339, 1694<br />

Ferrone, C 578<br />

Fertala, J 1999<br />

Fert-Bober, J 2167<br />

2010 Program Book 325<br />

abstract author Index


aBSTRACT author Index<br />

326<br />

Fertig, N 563, 913, 925, 929, 930<br />

Ferucci, ED 892<br />

Fervenza, FC 680, 2012<br />

Fessler, B 445, 448, 476, 1877,<br />

2012, 2240, 2243<br />

Fester, A 740<br />

Fett, N 920<br />

Feuchtenberger, M 782, 1026,<br />

1255, 1411<br />

Feudtner, C 233, 1703<br />

Fichtner, A 1806<br />

Fidelus-Gort, R 2172<br />

Field, J 783<br />

Fields, K 1405<br />

Figueiredo, CP 1546<br />

Fike, F 509<br />

Filer, A 1263<br />

Filipovich, AH 653<br />

Filippini, D 2201<br />

Filippucci, E 547, 1635<br />

Filkova, M 638<br />

Filocamo, G 207, 232<br />

Filopoulos, M 1284, 1298, 1303<br />

Finckh, A 2257, 940<br />

Fines, P 1555<br />

Finetti, M 1685, 1706<br />

Finkel, TH 233, 2219<br />

Finzel, S 128, 1634<br />

Fiocco, M 2284<br />

Fiorentino, D 573, 1213, 1378<br />

Fioretti, G 1687<br />

Fiori, G 593<br />

Fiorino, T 144<br />

Firestein, GS 271, 362, 635, 639,<br />

855, 1240, 1718, 1725, 1727<br />

Firneno, C 156<br />

Fischbach, M 1219, 1226, 1407,<br />

1705<br />

Fischer, A 591, 2119<br />

Fischer, S 1420<br />

Fisheleva, E 383, 414<br />

Fisher, M 25, 966, 1645<br />

Fisk, JD 2242<br />

Fiskesund, R 88<br />

Fitzcharles, M 100, 107<br />

Fitzgerald, GK 2059, 2052<br />

FitzGerald, J 8, 471, 933, 1058,<br />

2241<br />

FitzGerald, O 514, 555, 833, 1032,<br />

1105, 1508, 1625, 1631, 1947,<br />

2065, 2135<br />

Fitz-Gibbon, PD 316<br />

Fitzhugh, DJ 19<br />

Fitzpatrick, LR 1480<br />

Fitz-Patrick, D 150<br />

Flahault, A 533<br />

Flaherty, K 402, 1212<br />

Flahive, J 969<br />

2010 Program Book<br />

Flanagan, C 785<br />

Flanagan, WM 1555<br />

Flatø, B 2219<br />

Fleckner, J 508<br />

Fleischmann, R 321, 385, 391,<br />

420, 1114, 1127, 1136, 1154, 1753,<br />

1782, 1791, 1805, 1819, 1832,<br />

2262, 2264<br />

Fleming, R 953<br />

Fleming, S 1063<br />

Fleury, TW 1403<br />

Flick, M 1728<br />

Flipo, R-M 376, 400, 787, 904,<br />

1790<br />

Flom, PL 161<br />

Flores, P 2070<br />

Flores, R 144, 2172<br />

Florica, B 1165<br />

Flory, P 976<br />

Fluiter, K 1529<br />

Flynn, DL 289<br />

Flynn, E 264, 266<br />

Foeldvari, I 220, 227, 230, 599,<br />

1435, 1704<br />

Foged, H 1809<br />

Fogg, LF 2099<br />

Foltz, V 141, 1369, 2221<br />

Fong, AM 19<br />

Fongen, C 534<br />

Fonollosa, V 824<br />

Fonseca, C 829<br />

Fonseca, JE 1986, 1013<br />

Fontaine, K 310, 1065<br />

Fontalba, A 1296<br />

Fontes, JDT 1317<br />

Forastiero, R 3, 2251, 2252<br />

Forgues, M 2027<br />

Formisano, D 1290<br />

Førre, O 2219<br />

Forslind, K 1392, 1393<br />

Fort, JG 937<br />

Fortin, É 236<br />

Fortin, P 13, 445, 448, 476, 731,<br />

1156, 1165, 1178, 1850, 1877,<br />

2120, 2240, 2243<br />

Fortner, BV 1747<br />

Fossati, G 1517<br />

Fossati-Jimack, LM 430<br />

Fossel, A 1335, 2064<br />

Foucher, KC 2099<br />

Foulkes, R 752<br />

Fournié, J-J 281<br />

Fox, D 1271, 1520, 1609<br />

Fox, E 360, 1510<br />

Fox-Talbot, K 1074<br />

Fraenkel, L 59, 1459, 2249<br />

Fragoso, J-M 96<br />

Fragoso-Loyo, H 1853<br />

Frakes, E 175<br />

Frallonardo, P 540<br />

Frampton, C 417<br />

Francès, C 2238, 2239<br />

Franceschelli, F 1155, 2202<br />

Francesco, LT 1155<br />

Francesco, M 286<br />

Francis, B 1124<br />

Francis, HW 2031<br />

Francis, L 449, 1185, 1196<br />

Francis, S 1147<br />

Francisco, F 1876<br />

Franco Salinas, G 753<br />

Francois, A 1413, 1998<br />

Francois, F 883<br />

Franco-Maside, A 389<br />

FrancoSalinas, G 1977<br />

Franek, BS 495, 496, 1164, 1612<br />

Franek, E 982<br />

Frank, MB 243, 247, 251, 258, 655<br />

Frank, S 368, 1719<br />

Franke, L 1599<br />

Franklin, J 963<br />

Franklin, PD 2053, 2054, 2136<br />

Franks, L 1406, 2248<br />

Fransen, J 641, 1785, 1833, 2196<br />

Frantz, RP 595<br />

Fraser, AD 2224<br />

Fraser, L 463<br />

Fraser, O 1105<br />

Fraticelli, P 2036<br />

Frayssinet, H 936<br />

Frech, T 561, 1228<br />

Frederick, B 1804<br />

Frederick, M 244<br />

Frederiksen, KS 508<br />

Fredman, L 683<br />

Freebody, J 922<br />

Freedman, B 1028, 1584, 1585,<br />

1586, 1591, 2147<br />

Freeston, J 118, 141, 1369<br />

Freimuth, W 452, 457, 1146,<br />

1172, 1454, 1456, 1457, 1848<br />

French, AR 216, 1633<br />

French, MR 682<br />

Frenkel, J 905, 1706<br />

Frenkel, SR 1470<br />

Fresko, I 1279<br />

Freudenberg, J 1597<br />

Freundlich, B 1927, 1937, 669,<br />

2271<br />

Frey, B 2150<br />

Frey, JC 1328<br />

Frey, S 857<br />

Frey Law, L 205<br />

Freylaw, L 1557<br />

Frey-Law, L 1385, 2098<br />

Fridén, C 2245<br />

Friedman, A 1374<br />

Friedman, D 732<br />

Fries, J 642, 877, 1545, 2153<br />

Frits, M 308, 1050, 1778<br />

Fritz, C 526<br />

Fritzler, MJ 1216, 1227<br />

Froger, P 984<br />

Frosali, F 246<br />

Frostegård, J 88, 1194, 1578<br />

Frueh, FW 1561<br />

Fu, B 421<br />

Fuentes, I 1473, 1475, 1498<br />

Fuentes-Boquete, I 1483<br />

Fuhlbrigge, R 860<br />

Fujieda, M 652<br />

Fujieda, Y 2, 5, 10, 1909, 2254<br />

Fujii, H 1079<br />

Fujii, K 1086<br />

Fujii, T 1377<br />

Fujimoto, M 724, 1230<br />

Fujio, N 1824<br />

Fujita, T 2227<br />

Fujita, Y 1264<br />

Fujiwara, S 1708<br />

Fukazawa, C 1666<br />

Fukuda, S 2029<br />

Fukuda, T 472<br />

Fukuyo, S 1793, 1823<br />

Fuller, P 954, 955<br />

Fuller, R 1384, 2134<br />

Fulton, S 407<br />

Funahashi, K 1138, 1738, 1739<br />

Funaki, S 893<br />

Funaro, A 2001<br />

Funck-Brentano, T 2221<br />

Funovits, J 723, 2108<br />

Furet, O 1014<br />

Furie, RA 452, 1172, 1454, 1455,<br />

1456, 1457<br />

Fürnrohr, BG 607, 614<br />

Furst, D 147, 155, 347, 378, 391,<br />

561, 583, 594, 599, 726, 729, 1004,<br />

1010, 1106, 1205, 1213, 1228,<br />

1232, 1365, 1766, 1804, 1819,<br />

2194, 2195<br />

Fürst, FC 1481<br />

Fürst, M 1486<br />

Furukawa, S 10<br />

Furuya, K 921<br />

Furuya, T 968<br />

Fusetti, C 623<br />

Fusfeld, L 754<br />

FVSG 2045<br />

G<br />

Gabay, C 792, 940, 1802, 1807,<br />

2257


Gabay, OH 1484<br />

Gaber, T 630, 1418<br />

Gabriel, SE 53, 67, 78, 1550, 1570,<br />

1580, 1581, 2216<br />

Gabriele, A 125<br />

Gabrielle, M 2065<br />

Gabrielli, A 2001, 2008, 2036,<br />

2201<br />

Gaches, F 2027<br />

Gaddy, JR 780<br />

Gadina, M 260, 2217<br />

Gadler, F 832<br />

Gaedigk, R 253, 254<br />

Gaffney, PM 500, 502, 1583,<br />

1584, 1585, 1586, 1591, 1594,<br />

1595, 2144, 2145, 2146, 2147,<br />

2148, 2274<br />

Gaffo, AL 1367<br />

Gagarina, V 1484<br />

Gagnon, DR 1331<br />

Gaillez, C 1817<br />

Gal, N 1197<br />

Galanopoulou, V 1021<br />

Galant, C 2263<br />

Galasso, R 210, 1705<br />

Galdo, F 1920<br />

Galeazzi, M 615, 837<br />

Galica, AM 1327, 1328, 1331<br />

Galicier, L 2239<br />

Galindo, M 482, 1171<br />

Gall, EP 415, 1014, 1636<br />

Galla, L 259<br />

Gallacher, A 451, 452, 1172<br />

Gallagher, KT 998<br />

Gallagher, P 1947<br />

Gallagher, S 741<br />

Gallant, C 2145<br />

Gallant, MA 716<br />

Galli, M 2036, 2201<br />

Gallizzi, R 1685<br />

Gallo, A 2179<br />

Galloway, J 374, 421<br />

Gambineri, E 261<br />

Gamsa, A 107<br />

Gandjbakhch, F 141, 1369, 2221<br />

Gandon-Laloum, S 1684<br />

Ganser, G 220<br />

Gao, F 507<br />

Gao, I 138<br />

Gao, L 1119<br />

Gao, W 1510<br />

Garber, E 1244, 1245<br />

Garbutt, J 216<br />

Garchon, H-J 1981<br />

Garchow, B 422<br />

Garcia, BA 2191<br />

Garcia, L 1413<br />

Garcia, R 449, 1185, 1196<br />

Garcia de la Peña, P 824<br />

García de Vicuña, R 1276<br />

Garcia de Yebenes, MJ 975<br />

Garcia Gonzalez, A 1047, 1865<br />

Garcia Gonzalez, E 615<br />

García Llorente, JF 986<br />

García Salinas, R 50<br />

García-Arias, MJ 1229<br />

Garcia-Bello, M 1876<br />

Garcia-Carmona, Y 349<br />

García-Consuegra, J 1705<br />

García-Hernandez, FJ 824<br />

García-Honduvilla, N 1475<br />

García-Laorden, I 1876<br />

Garcia-Martinez, A 1292, 1314<br />

Garcia-Meijide, JA 1119<br />

Garcia-Vicuña, R 1229, 1505<br />

García-Yébenes, MJ 986<br />

Gardner, G 163, 1433<br />

Garen, T 1275<br />

Garg, R 339<br />

Garlantezec, R 315<br />

Garman, L 734<br />

Garneau, K 42<br />

Garnero, P 134, 1953<br />

Garrido, J 975<br />

Garris, CP 757, 764<br />

Garwick, A 1340<br />

Garza Elizondo, MA 416<br />

Garza-Garcia, A 1358, 1359<br />

Gasc, JM 1991<br />

Gascon, D 792, 940<br />

Gasparello de Almeida, R 1872<br />

Gasparini, S 1746, 1787<br />

Gaston, J.S.Hill 1424<br />

Gathany, T 1136<br />

Gatti, RA 509<br />

Gattorno, M 265, 657, 895, 905,<br />

1305, 1425, 1435, 1685, 1706<br />

Gaudin, P 63, 1752, 1829, 1931<br />

Gauditano, G 1644<br />

Gaujoux, T 413<br />

Gaujoux-Viala, C 413, 787, 984,<br />

1762<br />

Gauna, AE 2174<br />

Gautam, S 640<br />

Gauthier, C 1007<br />

Gay, RE 21, 35, 357, 679, 1093,<br />

1518, 1528, 1988<br />

Gay, S 21, 35, 357, 638, 679, 1093,<br />

1389, 1518, 1528<br />

Gaylis, NB 125, 1747<br />

Gaynor, P 105, 113<br />

Gea-Banacloche, J 1161<br />

Gebay, C 55<br />

Geborek, P 1037, 1381, 1392,<br />

1393, 1440<br />

Gebretsadik, T 1023, 1034, 1867<br />

Geenen, R 1338<br />

Geha, PY 2097<br />

Gehad, A 860<br />

Geher, P 1946<br />

Gehlbach, S 969<br />

Gelber, AC 45, 589, 919, 1364,<br />

1544, 1556, 1565, 1569, 1574,<br />

2162, 2260<br />

Gelfand, EW 2128<br />

Geli, C 1801<br />

Geller, M 1311<br />

Gellert, P 247<br />

Gelperin, K 75<br />

Genant, HK 1369<br />

Gendreau, J 805<br />

Gendreau, JF 302<br />

Gendreau, RM 98, 648, 805, 806<br />

Generini, S 558<br />

GENESYS Consortium 1987, 1994,<br />

2226<br />

Genovese, M 326, 385, 403, 411,<br />

414, 945, 946, 1097, 1103, 1114,<br />

1119, 1136, 1919, 1955, 1960,<br />

2169, 2173<br />

Gent, YYJ 1613<br />

Georg, S 1027<br />

George, E 1549<br />

George, M 919<br />

Georgescu, L 405<br />

Gerber, DA 161<br />

Gerdan, V 544, 1282, 1921<br />

Gergely, Jr, P 560, 566<br />

Geri, G 1249, 1646, 1648, 2030<br />

Gerlag, D 32, 719, 1069, 1095,<br />

1507, 1604, 1821, 1822, 2170<br />

Gerli, R 297<br />

Gerloni, V 261, 1407<br />

Gerlovin, H 2091, 2092<br />

Germanò, G 1290, 1302<br />

Gertner, E 910<br />

Gessner, A 2237<br />

Geurts, J 1535, 1733<br />

Geurts-van Bon, L 829, 2004<br />

Geusens, PP 1948<br />

Geyer, M 1479, 1722<br />

Ghali, WA 309<br />

Ghanem, A 1152<br />

Ghazan-Shahi, S 109<br />

Ghidey Alemayehu, W 2114<br />

Ghinoi, A 1302<br />

Ghiran, IC 2277<br />

Ghirmire, S 640<br />

Ghoreishi, M 1661<br />

Ghosh, A 2086<br />

Ghosh, P 163, 2086<br />

Giacomelli, C 811, 839<br />

Giacomelli, R 297<br />

Giacovelli, G 948<br />

Giampietro, C 413<br />

Giani, T 240<br />

Giannakopoulos, B 621<br />

Giannini, C 2037, 2038<br />

Giannini, EH 1407, 1688<br />

Gibney, RG 1625<br />

Gib<strong>of</strong>sky, A 1013<br />

Gibson, A 868, 1560<br />

Gibson, KA 1560<br />

Gibson, KL 252<br />

Gibson, N 198<br />

Gieger, C 711<br />

Gierut, AK 861<br />

Gigante, M 1239<br />

Gil, A 1888<br />

Gil, KM 1406, 2248<br />

Gilbert, D 915<br />

Gilbert, JL 75<br />

Gilbert, L 694<br />

Gilchrist, N 971<br />

Giles, I 1358, 1359, 2255<br />

Giles, J 1018, 1022, 1030, 1065,<br />

1074, 1441, 2162, 2167, 2260<br />

Gilkeson, GS 435, 437, 475, 510,<br />

960, 1526, 1583, 1584, 1585, 1586,<br />

1590, 1591, 1594, 2274<br />

Gilkeson, R 470, 1861<br />

Gill, M 2119<br />

Gill, N 1408<br />

Gill, RE 2063<br />

Gill, TM 1459<br />

Gilleece, Y 966, 1645<br />

Gillespie, E 473<br />

Gillespie, J 671, 673<br />

Gilliam, B 263, 1601<br />

Gilliland, WR 1083, 2116<br />

Gillis, JZ 789, 2113<br />

Gillis, R 1382<br />

Gillott, T 974<br />

Gindea, S 2186, 2187<br />

Gingrich, D 2233<br />

Ginzler, E 445, 448, 451, 476, 731,<br />

1453, 1456, 1457, 1866, 1877,<br />

2085, 2240<br />

Giorgi, M 1635<br />

Giovannini, L 1962<br />

Girerd, X 1651<br />

Giron, J 2027<br />

Girschick, H 227<br />

Gitelman, D 1689<br />

Giuggioli, D 581<br />

Giusti, L 811, 839<br />

Giustino, L 1308<br />

Gkazinou, C 646, 649<br />

Glace, B 1810<br />

Gladman, D 13, 445, 448, 450,<br />

452, 455, 476, 521, 523, 530, 536,<br />

545, 731, 772, 783, 1165, 1451,<br />

2010 Program Book 327<br />

abstract author Index


aBSTRACT author Index<br />

1456, 1850, 1868, 1869, 1874,<br />

1877, 1878, 1919, 1928, 1932,<br />

1936, 1943, 1954, 1956, 1964,<br />

1966, 1974, 1975, 1979, 1984,<br />

2240, 2243, 2273<br />

Gladstein, GS 1834, 1919<br />

Gladys Mulle, J 250<br />

Glant, T 1447, 2184<br />

Glass, DN 255, 654<br />

Glauber, H 1543<br />

Gleason, RM 807<br />

Glenmark, B 2245<br />

Glibert, H 1609<br />

Glikmann-Johnston, I 1159<br />

Glimcher, L 675<br />

Glintborg, B 1444, 1809, 1841<br />

Glocke, S 1059<br />

Glogowska, MJ 2227<br />

Gobbo, A 1831<br />

Gobbo, M 986<br />

Gobezie, R 363, 2229<br />

Godeau, B 400, 1790<br />

Godfrey, T 1560<br />

Godinho, F 1986<br />

Godmer, P 2045<br />

Goeb, V 571<br />

Goebel, K 1255<br />

Goehner, K 1011<br />

Goehring, Jr, EL 698<br />

Goekoop-Ruyterman, Y 295<br />

Goel, N 1805, 1806, 1832<br />

Goemaere, S 982<br />

Goergen, S 1917<br />

G<strong>of</strong>finet, F 2034<br />

Goh, KC 717<br />

Goktay, Y 1282, 1283<br />

Golbin, J 680<br />

Goldbach-Mansky, R 260, 905,<br />

1831<br />

Goldberg, D 850<br />

Goldberg, G 757<br />

Goldberg, J 1000<br />

Goldblum, R 160<br />

Goldenberg, D 100, 483, 1183<br />

Goldenstein-Schainberg, C 224,<br />

531, 1407<br />

Golding, A 487<br />

Goldman, CT 821<br />

Goldman, JA 420<br />

Goldmuntz, E 726<br />

Goldring, SR 167, 1080<br />

Goldsmith, DP 1341, 1698, 2105<br />

Goldstein, BL 1082<br />

Goldstein, N 1943<br />

Golightly, YM 1330<br />

Golovaty, I 2090, 2091<br />

Gómara, MJ 1070<br />

Gomberg, B 1893, 1894<br />

Gomberg-Maitland, M 569<br />

Gomez, J 87, 2241<br />

Gómez, L 1137<br />

Gómez Puerta, JA 1070<br />

Gomez Vaquero, C 1277, 1299<br />

Gómez-Gracia, I 824<br />

Gomez-Reino, J 55, 1076, 1078,<br />

1802, 1807, 1820, 2170<br />

Gómez-Reino, J-J 409<br />

Gómez-Vaquero, C 1016, 1301<br />

Gomnberg-Maitland, M 586<br />

Gonçalves, C 513, 531, 539<br />

Gono, T 447, 746, 897, 916, 923,<br />

1184, 1587, 1666, 1844<br />

Gonter, N 777, 1637, 1652, 1654<br />

González, EB 2253<br />

González-Escribano, MF 2214<br />

González-Gay, MA 824, 2214<br />

González-Vela, MDC 1650<br />

Gonzales, B 2083<br />

Gonzales-Crespo, MR 407<br />

Gonzalez, A 1076, 1078<br />

Gonzalez, E 562, 725, 1211, 1218,<br />

1219<br />

Gonzalez, JM 324<br />

Gonzalez Diaz de Rabago, E 1920<br />

Gonzalez López, M 1650<br />

Gonzalez Martin, JJ 804<br />

Gonzalez Rivera, TC 2276<br />

Gonzalez-Alvarez, I 1078<br />

Gonzalez-Alvaro, I 1505<br />

Gonzalez-Gay, M 159, 829, 882,<br />

1301, 1599, 1650<br />

Gonzalez-Rivera, T 1158<br />

Gonzalo, E 482<br />

Good, J 213<br />

Goodall, JC 1424<br />

Gooden, A 40<br />

Goodson, NJ 661, 1763<br />

Gopinath, J 1106<br />

Goran, A 382<br />

Gøransson, L 1913<br />

Gordon, C 445, 448, 453, 476,<br />

1452, 1843, 1877, 2240, 2243<br />

Gordon, JK 569, 586, 1990, 2193<br />

Gordon, TP 656<br />

Goreshi, R 920<br />

Gorla, R 297<br />

Gorlova, O 562, 2214<br />

Gorn, AH 471<br />

Gorodkin, R 1200<br />

Goronzy, JJ 351, 1079, 2127<br />

Gorski, K 1141<br />

Gorter, KJ 184<br />

Gorter, SL 219<br />

Goss, TF 754<br />

Gossec, L 63, 143, 529, 542, 1027,<br />

1104, 1648, 1924<br />

Gosset, M 37, 1514<br />

Gottenberg, JE 400, 858, 917,<br />

1088, 1237, 1413, 1693, 1790,<br />

1810, 1890, 1893, 1894, 1896,<br />

1910, 1914, 1998, 2042<br />

Gottwald, M 1059<br />

Gould, EM 944<br />

Gould, KA 423<br />

Gould, N 12<br />

Goulet, A-C 1497<br />

Goulet, M 2043<br />

Goulielmos, G 496<br />

Goupille, P 130, 376, 384, 988,<br />

1945, 2221<br />

Gourh, P 824, 829, 1982, 2214<br />

Gourley, I 1154<br />

Gourley, M 914<br />

Gove, J 892<br />

Govoni, M 1162<br />

Goyal, JR 1617<br />

Goyal, V 1549<br />

Goycochea-Robles, MV 1056<br />

Grabiec, A 1529<br />

Gracie, JA 1422<br />

Grader-Beck, T 440<br />

Grados, D 1741<br />

Graf, J 135<br />

Graf, JD 1024<br />

Graham, D 75<br />

Graham, RR 500, 1592<br />

Graham, TB 218, 1700<br />

Grahn, A 392, 945, 946, 1123<br />

Gramlich, K 894, 899, 900<br />

Gran, JT 1220, 1275<br />

Granados, J 874<br />

Grandpeix, C 2239<br />

Graninger, WB 1013, 1481, 2222<br />

Grassi, W 297, 547, 1629, 1635,<br />

1746, 1787<br />

Gratacos, J 1276<br />

Grattagliano, V 1627<br />

Gratton, SB 135<br />

Grau, A 491<br />

Grau, R 415, 1014, 1636<br />

Graudal, N 1444, 1841<br />

Grauer, A 971, 2157, 2161<br />

Gravallese, EM 716<br />

Gray, JD 1242<br />

Gray-McGuire, C 2144<br />

Grayson, P 198, 720, 2155, 2198<br />

Grecco, M 498, 504<br />

Green, C 1141, 1480<br />

Green, MJ 1926, 2182, 2183<br />

Green, N 736<br />

Green, S 193, 1164, 1875<br />

Greenberg, J 52, 148, 347, 379,<br />

515, 707, 1003, 1010, 1794, 1799<br />

Greenberg, MC 2062<br />

Greenblatt, M 675<br />

Greenlee, R 1000<br />

Greenspan, J 1898<br />

Greenwald, MW 2172<br />

Greenwell, CA 462<br />

Gregersen, P 77, 658, 825, 1094,<br />

1386, 1591, 1592, 1597, 1608,<br />

2083, 2149, 2217, 2214<br />

Gregoire, L 468<br />

Gregory, J 583<br />

Greidinger, EL 608, 852<br />

Greis, K 268<br />

Greisen, SR 1524, 1761<br />

Gremese, E 355, 744, 1098, 1582<br />

Gress, R 1161<br />

Greve, JMD 2134<br />

Grevers, LC 1495<br />

Grieco, A 2001, 2008<br />

Griffin, C 1063<br />

Griffin, K 1405<br />

Griffin, MR 54<br />

Griffin, TA 1012<br />

Griffith, SG 160<br />

Griffiths, CEM 833<br />

Griffiths, H 319<br />

Grigorian, M 614<br />

Grijalva, C 54, 404, 722, 2103<br />

Grillet, BAM 1396<br />

Grillo, I 71<br />

Grisar, J 1745<br />

Grisot, C 976<br />

Groenendael, JHLM 1396<br />

Grogan, J 1122<br />

Grogan, S 634<br />

Groh, BP 211<br />

Grom, AA 244, 653<br />

Gronwall, C 2121<br />

Groot Kormelink, T 333<br />

Gross, BH 585<br />

Gross, D 693<br />

Gross, KD 201<br />

Gross, WL 679, 2203<br />

Grossi, C 1356<br />

Grossi, S 1884, 1916<br />

Grossman, J 8, 471, 497, 1189,<br />

1583, 1584, 1595, 2241<br />

Grotle, M 170<br />

Grouard-Vogel, G 2236<br />

Grøvle, L 170<br />

Gruen, SD 2246<br />

Grundmeier, R 233<br />

Grunert, VP 381<br />

Grunke, M 1781, 2130<br />

Gu, W 274<br />

Gu, X 935, 2250<br />

Guadagnoli, M 2178<br />

Gualano, B 1384<br />

328<br />

2010 Program Book


Guan, M 965<br />

Guañabens, N 975<br />

Gudbjornsson, B 1951<br />

Gudbrandsson, B 1275<br />

Gudjonsson, JE 1951<br />

Guedj, M 1987, 2226<br />

Gueds-Pinto, H 1986<br />

Guerette, B 1101, 1102, 1113,<br />

1791<br />

Guérini, H 728<br />

Guermazi, A 131, 193, 197, 198,<br />

202, 1373, 2100<br />

Guerne, P-A 792<br />

Guerry, M-J 678<br />

Guggenbuhl, P 888<br />

Guiducci, S 593<br />

Guigonis, V 1693<br />

Guillard, G 118<br />

Guillaume, S 904<br />

Guillaume-Czitrom, S 1696<br />

Guillemin, F 781, 787, 1752, 2094<br />

Guillevin, L 400, 575, 576, 1204,<br />

1217, 1790, 2009, 2014, 20262034,<br />

2041, 2043, 2045<br />

Guillimen, F 794<br />

Guillot, X 997<br />

Guimarães, AS 228<br />

Guimarães, LS 1458<br />

Guinta, DR 97<br />

Guirado, L 1614<br />

Guis, S 1931<br />

Guissa, VR 224<br />

Gujrathi, S 390, 416<br />

Gul, A 1281, 2217, 1308<br />

Gulcu, A 1282, 1283<br />

Gülfe, A 1381<br />

Gulko, PS 1128, 1387<br />

Gullick, NJ 1263, 1838<br />

Gulseth, HC 1774<br />

Guma, M 1718<br />

Gunawardhana, L 149<br />

Gunay, N 1970<br />

Gunduz, O 544<br />

Gunnarsson, I 1846<br />

Gunraj, N 57, 313, 341<br />

Günther, J 2003<br />

Guo, J 1598<br />

Guo, S 2187<br />

Gurevitz, I 812<br />

Gurwitz, JH 322, 791<br />

Guseinova, D 208, 1700<br />

Gust, C 68, 86<br />

Gustafson, NP 2142<br />

Gustafsson, JT 1846<br />

Gustafsson, T 1194<br />

Gutala, RV 1218<br />

Guthridge, JM 24, 2274<br />

Gutierrez, M 547, 1635, 1614<br />

Gutierrez-Roelens, I 2263<br />

Gutierrez-Urena, SR 157<br />

Guttenberg, M 1907<br />

Guzman, J 1674, 2017<br />

Gúzman, R 451, 1172, 1455<br />

Gyftopoulos, S 1616<br />

Gyger, G 1225<br />

H<br />

Ha, YJ 1061, 1873<br />

Haas, CS 1417<br />

Haas, JP 654<br />

Haavardsholm, E 132, 141, 142,<br />

1369, 1779<br />

Habets, G 273<br />

Hachulla, E 580, 917, 1893, 1894,<br />

1896, 1910, 2226, 400, 576, 895,<br />

1217, 1425, 1435, 1651, 1790,<br />

1890, 1987<br />

Hack, CE 636<br />

Hackett, N 1990<br />

Hackney, BS 690<br />

Hackney, J 1609<br />

Hadd, M 269<br />

Haddix, E 1012<br />

Hadjinicolaou, A 395<br />

Hadley, S 1470<br />

Hafström, I 88<br />

Hagberg, N 503<br />

Hagen, EC 2014<br />

Haggart, E 1342<br />

Hagino, N 703<br />

Hagiwara, T 1138, 1738, 1739<br />

Haglund, E 761<br />

Hahn, BH 8, 431, 471, 497, 594,<br />

1189, 1257, 1583, 1584, 1595,<br />

2241<br />

Hahne, M 1418, 1527, 1732<br />

Haibel, H 665, 669, 1938, 1961,<br />

2271<br />

Haines, GK 853, 859<br />

Haines, K 1700<br />

Haines III, GK 1417<br />

Hajj-Ali, R 1670, 2047, 2049<br />

Hajji, O 816<br />

Hajsadeghi, F 1046, 1443, 2164,<br />

2165, 2166<br />

Hakim, F 1161<br />

Hakonarson, H 2217, 2219<br />

Halbauer, B 1621<br />

Haldorsen, K 1913<br />

Hall, DJ 1484<br />

Hall, S 1560<br />

Halladay, W 801<br />

Haller, C 2157<br />

Halliday, W 2107<br />

Hallinen, TA 759<br />

Hallmans, G 1847, 2115<br />

Halushka, MK 1074, 2167<br />

Hama, M 139, 1512, 2217<br />

Hamada, M 298<br />

Hamaguchi, M 1511<br />

Hamann, D 1091<br />

Hamburger, MI 1753, 1782<br />

Hamburger, S 146<br />

Hameed, S 1151<br />

Hamidou, M 1893<br />

Hamilton, J 1121<br />

Hammaker, D 635, 855<br />

Hammann, J 43<br />

Hammar, O 1902<br />

Hammel, L 1923<br />

Hammond, A 1325, 2063<br />

Hammond, T 1830<br />

Hammonds, CL 802<br />

Hamsten, A 832<br />

Hamuryudan, V 1013, 1288<br />

Hamza, N 1889<br />

Han, BD 1597<br />

Han, C 1136<br />

Han, H 2180<br />

Han, KH 295<br />

Han, L 1459<br />

Han, S 1488<br />

Hanami, K 1793, 1823<br />

Hanaoka, M 897, 916, 923, 1844<br />

Hanczko, R 1185, 1196<br />

Handler, C 727<br />

Haney, D 1606, 1753, 1782<br />

Hanlan, M 1335<br />

Hanly, J 445, 448, 454, 476, 731,<br />

1877, 2240, 2242, 2243<br />

Hanna, F 192<br />

Hannaford, P 646<br />

Hannan, MT 684, 1317, 1327,<br />

1328, 1329, 1330, 1331<br />

Hannon, MJ 185, 193<br />

Hannouche, D 875<br />

Hanrahan, J 1560<br />

Hans, G 163<br />

Hansen, A 134, 1444, 1809, 1841,<br />

1896, 1953<br />

Hansen, C 920<br />

Hansen, MS 133, 134, 1809, 1953<br />

Hanslik, T 533<br />

Hansmann, S 894, 899, 900<br />

Hanson, E 1698<br />

Hanumanthaiah, M 522<br />

Haqqi, TM 632, 633<br />

Haque, S 769, 795, 1177, 1200<br />

Haque, UJ 310<br />

Hara, M 746, 1184, 447, 1666<br />

Hara, R 237<br />

Hara, T 237<br />

Hara, Y 2228<br />

Harada, ND 169<br />

Haraoui, B 123, 196, 300, 306,<br />

343, 344, 659, 978, 987, 1013,<br />

1101, 1102, 1737, 1837, 2169<br />

Harari, O 1243, 1245<br />

Hardi, L 994<br />

Harding, S 1202, 1203<br />

Hardwick, D 1161<br />

Hardy, J 2251, 2252<br />

Hareendran, A 99<br />

Harel, L 1684<br />

Hargrove, JB 647<br />

Harigai, M 399, 1814, 1815<br />

Harigane, K 335<br />

Hariri, A 878<br />

Harley, JB 500, 502, 1164, 1197,<br />

1579, 1583, 1584, 1585, 1586,<br />

1590, 1591, 1594, 1595, 2144,<br />

2145, 2146, 2147, 2148, 2274<br />

Harmer, J 1560<br />

Harney, S 1333, 1726<br />

Haro, I 1070<br />

Haroche, J 478, 1287, 1651, 1658,<br />

1660, 1908, 1911<br />

Haroon, N 545, 549, 556, 1450,<br />

1964<br />

Harper, BE 1982<br />

Harper, S 1555<br />

Harrell, MI 1251<br />

Harrington, JT 1003, 1010, 1799<br />

Harrington, L 1094<br />

Harrington, TM 977<br />

Harris, HW 799, 820<br />

Harrison, AA 776, 1553<br />

Harrison, M 779<br />

Harrison, MJ 769, 795, 1405<br />

Harrold, L 156, 162, 322, 791,<br />

1003, 1010, 1794<br />

Hart, D 711, 823, 841, 1068, 1094<br />

Hart, JE 64<br />

Hart, MM 1825<br />

Hart, S 717<br />

Hartgring, SAY 278<br />

Harty, L 360<br />

Harvey, BP 1269<br />

Harvey, P 2120<br />

Harvey, WF 195, 2101<br />

Hasegawa, H 1265, 2016<br />

Hasegawa, M 724, 1230<br />

Hashimoto, T 983<br />

Hashiramoto, A 280, 348, 434,<br />

511, 893, 983, 1467<br />

Hasija, R 1700, 1705<br />

Haskard, D 430, 2200<br />

Hasni, SA 1161<br />

Hassan, A 1344<br />

Hassan, W 40<br />

Hassan El Safi, S 695<br />

2010 Program Book 329<br />

abstract author Index


aBSTRACT author Index<br />

330<br />

Hasselquist, M 134, 1953<br />

Hassett, A 110, 112, 625, 651,<br />

1320, 1767, 1872<br />

Hassett, G 1560<br />

Hassoun, PM 1223<br />

Hatemi, G 1279, 1288, 1697<br />

Hauge, E-M 1485<br />

Haugeberg, G 972<br />

Haugen, AJ 170, 1774<br />

Haugen, IK 142, 182<br />

Hauser, T 676, 2009<br />

Häuser, W 100, 110, 111, 112<br />

Haverhals, L 397, 1395<br />

Hawker, GA 682, 1562, 2208<br />

Hawkins, PN 895, 1425, 1435<br />

Hawly, M 1470, 1471<br />

Hayashi, D 131<br />

Hayat, S 2076<br />

Hayden, CL 970, 1099, 1792<br />

Hayder, M 281<br />

Hayem, G 2269<br />

Hayer, S 272, 1493<br />

Hayes, J 931<br />

Hayes, KW 186, 189, 202<br />

Hayes, OA 788<br />

Haynes, K 2084<br />

Hays, R 155, 1205, 1228, 1365<br />

Haythornthwaite, JA 1348<br />

Haythornwaite, JA 949<br />

Haywood, Jr, C 1565<br />

Hazelman, B 777, 1654<br />

Hazes, J 38, 317, 1073, 1775, 1776<br />

Hazes, M 1274, 1785, 2066<br />

Hazlett, J 33<br />

He, J 1107, 1598<br />

He, W 274, 1469<br />

Hebert, LA 1400<br />

Hebert, P 1400<br />

Heeringa, P 2015, 2023<br />

Heffernan, E 1625<br />

Heiberg, T 1750<br />

Heimbürger, M 1194<br />

Hein, MS 1376<br />

Heinberg, L 1348<br />

Heiney, C 169<br />

Heinhuis, B 371<br />

Heldmann, F 1938, 1961, 2270<br />

Helin, P 1898<br />

Hellard, SL 1885<br />

Helliwell, P 514, 1926, 2082,<br />

2182, 2183<br />

Hellmich, B 2203<br />

Helmick, CG 687, 1563, 2069,<br />

2138<br />

Hemmatazad, H 1988<br />

Hench, RP 1041<br />

Henderson, C 1831<br />

2010 Program Book<br />

Hendiani, A 725<br />

Hendler, T 1159<br />

Hendrickson, P 242, 826, 928<br />

Hendriks, R 715<br />

Henes, JC 1145<br />

Henes, M 1145<br />

Henrickson, M 1678<br />

Henríquez, C 2070<br />

Henrotin, Y 835<br />

Henry, M 183<br />

Henshaw, K 1090, 1254<br />

Hensor, E 1929<br />

Hentgen, V 905, 1696<br />

Henze, E 2021<br />

Heraoui, D 1653<br />

Herberich, E 1882<br />

Herbst, R 741<br />

Herenius, M 719, 1507, 1604,<br />

1822<br />

Herlin, T 1687<br />

Herlitz, L 2186<br />

Herlitz-Lindberg, M 1846<br />

Herman, DJ 1320<br />

Hermann, K-G 134, 669, 1369,<br />

1953, 2271<br />

Hermes, H 673<br />

Hermida-Gómez, T 1483<br />

Hermine, O 1651, 2010, 2011<br />

Hernández, MV 1070, 1118, 1796<br />

Hernández-Cruz, B 1337, 1944<br />

Hernández-Díaz, C 1614<br />

Hernandez-Diaz, S 81<br />

Hernández-Hernández, V 389<br />

Hernández-Medina, G 1881<br />

Hernandez-Molina, G 874<br />

Hernández-Núñez, E 1166<br />

Hernandez-Rodriguez, J 1280,<br />

1292, 1294, 1309, 1314<br />

Hernando, E 1490<br />

Herrera, A 1659<br />

Herrera-Garcia, AM 1509<br />

Herrero-Beaumont, G 804, 1078<br />

Herrero-Beites, AM 159, 873, 882<br />

Herrick, A 588, 824, 829, 1234,<br />

1623, 2214<br />

Herrinton, LJ 404<br />

Herrmann, AM 1255<br />

Herrmann, M 490, 2150<br />

Herrmann, S 2237<br />

Hersh, AO 484, 1673, 1691, 2017<br />

Herson, S 915, 922<br />

Hervier, B 478, 1651, 1658, 1660,<br />

1908<br />

Herzer, P 1112<br />

Heslop, PS 1568<br />

Hesselstrand, R 824, 829, 1210,<br />

1623, 2214<br />

Hessian, P 33, 1252<br />

Hesterberg, LK 1496, 1606, 1753,<br />

1782<br />

Hetherington, R 1408<br />

Hetland, ML 55, 133, 381, 1370,<br />

1444, 1524, 1761, 1802, 1807,<br />

1809, 1841<br />

Hewagama, A 1253<br />

Hewitt, S 1156<br />

Hewlett, S 1325, 1766<br />

Heymann, D 29<br />

Heymann, M-F 29<br />

Heywood, W 2255<br />

Hickey, MJ 492<br />

Hidaka, T 1812<br />

Hidalgo, C 1888<br />

Hider, S 1394<br />

Hiemann, R 911<br />

Hiepe, F 1146, 1295, 1414<br />

Hietpas, J 2100<br />

Higgins, GC 209, 1673, 1677,<br />

1691, 1701, 2017<br />

Higgs, JB 1617<br />

High, W 2013<br />

Highton, J 1252, 33<br />

Hilário, MO 1343, 1676, 1872, 228<br />

Hilberdink, WKHA 2051<br />

Hilda, D 824<br />

Hill, C 177, 584<br />

Hill, HR 245<br />

Hill, N 1004<br />

Hilliquin, P 69<br />

Hillmann, A 2237<br />

Hillstrom, HJ 1328, 1331<br />

Hilton, W 1094<br />

Hilton-Jones, D 922<br />

Himes, M 688<br />

Hinchcliff, M 591, 729, 2214<br />

Hines, AE 1395<br />

Hines, T 487<br />

Hinks, A 264, 266, 654, 1075<br />

Hinze, CH 218<br />

Hipp, BG 1764<br />

Hirai, K 921<br />

Hirakata, M 1577<br />

Hiraki, LT 762, 2104<br />

Hirata, Y 298<br />

Hirko, K 199<br />

Hirohata, S 291, 568, 1285, 1293<br />

Hiromura, K 358<br />

Hirono, S 280, 1467<br />

Hiroshima, R 1749<br />

Hirsh, JM 2013<br />

Hirth, P 273<br />

Hitchon, C 300, 306, 343, 659,<br />

978, 1176, 1737, 1850<br />

Hitzel, A 2027<br />

Hmamouchi, I 301<br />

Ho, B 1100<br />

Ho, LY 458, 467, 773, 1206, 1667,<br />

1870, 2159<br />

Ho, P 833, 1200<br />

Hoang, S 2261<br />

Hobbs, A 674<br />

Hochberg, E 1015<br />

Hochberg, F 1015<br />

Hochberg, MC 186, 390, 937, 972,<br />

2096<br />

Hochman, J 306, 343<br />

Hodge, L 1430<br />

Hodgson, L 1772<br />

Hoehle, M 127<br />

Hoekstra, M 314, 662, 1771<br />

Hoeltzel, MF 234, 253, 254<br />

Hoeper, MM 599<br />

Hoes, JN 973<br />

H<strong>of</strong>bauer, A 437, 622<br />

H<strong>of</strong>er, M 1305<br />

H<strong>of</strong>fart, CM 1703<br />

H<strong>of</strong>fman, G 1315, 2012, 2047,<br />

2049, 2198<br />

H<strong>of</strong>fman, H 905<br />

H<strong>of</strong>fman, I 340<br />

H<strong>of</strong>fman, S 622<br />

H<strong>of</strong>fman-Bolton, J 1544<br />

H<strong>of</strong>fmann-Vold, A-M 1220, 2214<br />

H<strong>of</strong>kens, W 283<br />

H<strong>of</strong>mann, F 1614<br />

H<strong>of</strong>stee, H 1623<br />

H<strong>of</strong>stra, C 1534<br />

H<strong>of</strong>tman, ADC 262<br />

Hogan, SL 1326<br />

Hoganson, DD 129, 316<br />

Hoglund, LT 2244<br />

Höglund, P 2014<br />

Hogrefe, J 50<br />

Hoi, A 492<br />

Hojjati, M 473<br />

Hokken, ACS 1073<br />

Holcomb, R 493<br />

Holers, M 71<br />

Holers, V 77, 658, 1083, 1094,<br />

2116, 2227, 2229<br />

Holgado, S 1741<br />

Holladay, MW 269<br />

Holliday, KL 836<br />

Hollister, AS 150<br />

Holl-Ulrich, K 679<br />

Holman, AJ 102, 815<br />

Holman, ER 582<br />

Holmqvist, M 64, 1057, 2259<br />

Holmström, M 7<br />

Holt, RW 203<br />

Holtkamp, G 2170<br />

Holweg, C 1609<br />

Holzenberger, M 1514


Homme, CL 730<br />

Honda, E 434<br />

Hong, JY 115, 802<br />

Hong, S 209, 803, 1038<br />

Hong, Y 369, 2158<br />

Hooker, RS 1395<br />

Hootman, JM 687, 691, 1563,<br />

2057, 2069, 2096, 2138<br />

Hoover, MJ 2053, 2054<br />

Hoover, SE 415<br />

Hopia, L 1181<br />

Hopman, W 109<br />

Hoppenreijs, EPAH 219<br />

Hori, Y 10<br />

Horita, T 2, 5, 10, 1577, 1909,<br />

2254<br />

Horiuchi, T 511<br />

Horn, A 607, 611, 614, 616, 672<br />

Horn, E 569<br />

Horne, WC 1502<br />

Horneff, G 220, 227, 230<br />

Horner, BJ 702<br />

Hornum, L 847<br />

Horowitz, ZD 146, 166<br />

Horrigan, FT 1128<br />

Hørslev-Petersen, K 133, 141,<br />

1370, 1524, 1761, 2280<br />

Horton, HM 1350<br />

Horvath, K 1340<br />

Horwitz, DA 442, 1242, 1268<br />

Hoshi, D 1793, 1823<br />

Hoshi, K 568<br />

Hoskin, TL 104, 108<br />

Hosoi, T 968<br />

Hosono, Y 1377<br />

Hossler, J 733, 1085<br />

Hot, A 354, 917, 1515, 2042<br />

Hotaling, J 931<br />

Hottiger, MO 1528<br />

Hou, A 384<br />

Hou, Y 1143<br />

Houard, X 37<br />

Houbiers, J 2170<br />

Houenou, LO 691<br />

Hough, D 451, 452, 457, 1146,<br />

1454, 1456<br />

Houssiau, F 453, 1398, 2214, 2263<br />

Houvenagel, E 2269<br />

Howard, BV 1062<br />

Howard, G 299, 1368<br />

Howard, RNG 1390, 1616<br />

Howard, T 654<br />

Howell, RD 1470<br />

Hoyer, BF 1295, 1414<br />

Hoyer, J 895, 1425, 1435<br />

Hsia, EC 326, 385, 386, 890, 908,<br />

1097, 1114, 1127, 1136, 2264<br />

Hsu, BL 890, 908, 1948<br />

Hsu, H-C 1135, 1250, 1260, 1412,<br />

2189<br />

Hsu, JJ 1702<br />

Hsu, P-Y 288<br />

Hsu, Y 1245, 1329<br />

Hu, A 1940<br />

Hu, C 1818<br />

Hu, P 2048<br />

Hu, W 1606<br />

Hu, X 1128, 1680<br />

Hua, X 1194<br />

Huang, D 1178<br />

Huang, J 1182<br />

Huang, MM 286<br />

Huang, Q 854, 1353<br />

Huang, W 1410, 2188<br />

Huang, XL 1872<br />

Huang, Y 733<br />

Huang, Z 854<br />

Hubbel, S 1901<br />

Huber, A 238, 1673, 1674, 2017,<br />

1408<br />

Huber, G 692<br />

Huber, LC 35, 1518<br />

Hubert, C 1596<br />

Hubert, H 642<br />

Huck, M 931<br />

Hudson, AP 696<br />

Hudson, M 577, 1225, 1346,<br />

1347, 1348, 1850, 2247<br />

Hueber, W 1083<br />

Huemer, C 1700<br />

Hughes, G 747<br />

Hughes, LB 1077<br />

Hughes, SL 692<br />

Hughes, T 822, 1590, 1594<br />

Hughes-Austin, J 77, 658, 1094<br />

Huijbens, R 844<br />

Huisman, AM 942<br />

Huisman, M 1775, 1776<br />

Huizing, M 914<br />

Huizinga, T 179, 334, 582, 660,<br />

1015, 1396, 1496, 1782, 1805,<br />

2114, 295, 328, 663, 1744, 1755,<br />

1780<br />

Hulejova, H 638, 926<br />

Hulot, J-S 2239<br />

Hulsmans, HMJ 328<br />

Humbert, M 599<br />

Humbría, A 1229<br />

Hummers, LK 569, 587, 589, 1201,<br />

1222, 2192<br />

Humphrey, MB 1585<br />

Hunder, GG 1304, 2037, 2038<br />

Hung, EW 726<br />

Hunt, B 154<br />

Hunt, KJ 960<br />

Hunter, CD 2235<br />

Hunter, DJ 140, 199, 203, 1362,<br />

1366, 2091, 2092<br />

Hunter, J 1422<br />

Hunzelmann, N 824, 829, 2214<br />

Hurkmans, EJ 1338, 2051, 2283<br />

Hurlburt, KJ 892<br />

Husa, M 634<br />

Husain, M 468<br />

Huscher, D 599, 770, 1212<br />

Husni, ME 191, 1937<br />

Hussain, H 885<br />

Husted, J 1928<br />

Huston III, J 2037, 2038<br />

Hutcheson, JG 1186<br />

Hutchinson, A 1405<br />

Huttenlocher, A 1421<br />

Hutto, D 1243<br />

Huynh, T 1142<br />

Hvid, M 1524, 1761<br />

Hwang, C 937<br />

Hwang, I 1386<br />

Hwang, J 366, 372, 1297<br />

Hwang, L-J 565<br />

Hyde, C 1116<br />

Hyrich, K 374, 421, 1323<br />

I<br />

Iagaru, N 1705<br />

Iagnocco, A 777, 1637, 1652, 1654<br />

Iannaccone, CK 308, 1050, 1335,<br />

1610, 1778, 2064<br />

Ibanez, D 445, 448, 450, 455, 476,<br />

772, 1868, 1869, 1874, 1877, 1878,<br />

2240<br />

Ibarra, MF 1686<br />

Ibrahim, F 664, 819<br />

Ibrahim, G 1926, 2182, 2183<br />

Ibrahim, P 273<br />

Ichida, H 897, 923<br />

Ichikawa, T 436<br />

Ideguchi, H 139, 480<br />

Ieko, M 10<br />

Iglesias-Gamarra, A 1048<br />

Iguchi, M 298<br />

Ihata, A 139<br />

Ihlebaek, C 170<br />

Iikuni, N 497<br />

Iizuka, M 2176<br />

Ikari, K 1611, 1749<br />

Ikeuchi, H 358<br />

Ikle, D 2012<br />

Ikumi, N 1708<br />

Illei, GG 1161, 1579, 1918, 2178,<br />

2179<br />

Ilowite, NT 209, 1630, 1677, 1692,<br />

1702<br />

Imadojemu, S 456<br />

Imadome, K-i 1708<br />

Imagawa, T 237<br />

Imai, M 1115<br />

Imbert-Bismut, F 1762<br />

Imboden, J 135, 136, 1024<br />

Immerman, I 1470<br />

Impens, A 402, 567, 570, 585,<br />

1205, 2072, 2073<br />

Imperio, C 784<br />

Imrey, P 2047, 2049<br />

Imundo, LF 234, 257, 1673, 1677,<br />

1678, 1691, 1701, 2017<br />

Imura, Y 1377<br />

Inamo, K 1890<br />

Inanç, N 1133, 1208, 1303, 1803<br />

Ince, A 1808<br />

Infante, O 808<br />

Ingham, M 51, 76, 1960<br />

Inman, RD 512, 545, 549, 556,<br />

696, 1450, 1451, 1948, 1964, 1969,<br />

1972<br />

Inoko, H 2217<br />

Inokuma, S 399, 703<br />

Inomata, H 1708<br />

Inoue, A 292, 352, 1824<br />

Inoue, E 968, 1053<br />

Inoue, H 433<br />

Inoue, K-i 1824<br />

Intema, F 176, 1380<br />

International League <strong>of</strong><br />

Associations for <strong>Rheumatology</strong><br />

East Africa Initiative 1336<br />

Ioan-Facsinay, A 179<br />

Ioannidis, G 969<br />

Ioannou, Y 621, 1358, 1359<br />

Ionescu, R 405, 848<br />

Ionnadis, G 126<br />

Ioseliani, M 1705<br />

Iotti, A 1173<br />

Irazola, V 324<br />

Isaacs, C 912<br />

Isaacs, J 2170<br />

Isenberg, D 445, 448, 454, 465,<br />

476, 738, 740, 1140, 1144, 1153,<br />

1187, 1358, 1359, 1453, 1877,<br />

2085, 2240, 2243, 2255<br />

Ishigaki, K 932<br />

Ishigatsubo, Y 139, 480, 1081,<br />

1293, 1300, 1512, 2217<br />

Ishiguro, N 399, 1814, 1815<br />

Ishii, K 335<br />

Ishii, T 1577<br />

Ishikura, A 2170<br />

Ishimori, ML 187, 1197<br />

Ishino, H 1511<br />

Islam, SS 2086<br />

Isola, M 2036, 2201<br />

Isozaki, T 26, 1773<br />

Israelsson, L 2118<br />

Italiaander, A 2214<br />

2010 Program Book 331<br />

abstract author Index


aBSTRACT author Index<br />

Itami, Y 1743<br />

Itano, N 1709<br />

Ito, H 365<br />

Ito, K 399<br />

Ito, M 1708<br />

Ito, S 2228<br />

Iudici, M 572<br />

Ivana, H 479<br />

Iversen, M 42, 1318<br />

Ivorra, JAR 1840<br />

Iwahashi, M 1138<br />

Iwakura, Y 1427<br />

Iwamoto, N 1371, 1632<br />

Iwamoto, T 1749<br />

Izac, B 1087<br />

Izmailova, E 1822<br />

Izmirly, PM 732, 990, 1190, 1390,<br />

1438<br />

Izumihara, T 1138, 1738, 1739<br />

Izzedine, H 906<br />

J<br />

Jackson, R 154, 165, 1062, 2096<br />

Jacob, CO 500, 1583, 1584, 1585,<br />

1586, 1591, 1595, 2145, 2147,<br />

2148, 2187<br />

Jacob, N 2187<br />

Jacobs, DR 1367<br />

Jacobs, J 380, 388, 973, 1753,<br />

1759, 1859<br />

Jacobs, P 330<br />

Jacobsen, MS 1809<br />

Jacobsen, S 454, 731<br />

Jacobson, EW 1095<br />

Jacobsson, L 774, 1020, 1054,<br />

1057, 2259<br />

Jacques, C 1514<br />

Jacques, S 1413<br />

Jacquot, S 1827<br />

Jaen, JC 1100, 2032, 2048<br />

Jain, A 1573<br />

Jain, M 637<br />

Jain, R 2110<br />

Jais, J-P 1087<br />

Jakicic, JM 193<br />

Jakob, F 967<br />

Jakobsson, K 774<br />

Jakstadt, M 630, 1418<br />

Jallal, B 741<br />

Jallouli, M 1911, 2239<br />

Jamal, SA 982<br />

James, J 9, 24, 417, 466, 734, 780,<br />

892, 1164, 1197, 1583, 1584, 1585,<br />

1586, 1591, 1594, 2147, 2274<br />

James, S 2259<br />

Jamin, C 737<br />

Jamnitski, A 1825<br />

Jan, L 1261<br />

Jan, S 42<br />

Janer, G 1137<br />

Jani, J 460<br />

Janko, C 490, 2150<br />

Jannaut-Pena, MJ 1013<br />

Janow, GL 209, 1630<br />

Jansen, G 1613<br />

Jansen, MJ 2051<br />

Jansen, TL 1833<br />

Janssen, EM 209<br />

Janwityanujit, S 1950<br />

Jaovisidha, S 1950<br />

Jara, LJ 1150<br />

Jares, P 1280<br />

Jarjour, WN 1374<br />

Järvenpää, S 80<br />

Jarvis, HG 1568<br />

Jarvis, JN 243, 247, 251, 258, 655<br />

Jaskowski, TD 245<br />

Jasson, M 1121<br />

Jatwani, S 2253<br />

Jaureguiberry, J-P 2042<br />

Javier, R-M 2269<br />

Jayakar, BA 1315<br />

Jayaraj, D 1263<br />

Jayaraman, R 717<br />

Jayne, D 676, 678, 1278, 1453,<br />

1455, 1663, 2014, 2085<br />

Jean Baptiste, G 571<br />

Jejurkar, P 286<br />

Jelinek, J 869<br />

Jenks, SA 486, 749<br />

Jennette, JC 2048<br />

Jennings, W 152<br />

Jensen, B 43<br />

Jensen, DV 1444, 1841<br />

Jensen-Urstad, K 1224<br />

Jeon, C-H 366, 1297<br />

Jeong, Y-G 370, 756<br />

Jeong, Y-J 1209<br />

Jepson, B 40<br />

Jerath, RS 1673, 1691, 2017<br />

Jesus, AA 224, 260<br />

Jewett, LR 1347, 1348<br />

Jhingran, P 757, 764<br />

Ji, J 92, 359, 1107, 1628<br />

Jia, J 965<br />

Jiang, H-R 28<br />

Jiang, K 243, 247, 251, 258, 655<br />

Jiang, L 1107<br />

Jiang, Y 255<br />

Jibatake, A 1641<br />

Jimah, J 1185, 1196<br />

Jimenez, R 1146<br />

Jimenez, SA 673, 1993, 1997,<br />

1999, 2007<br />

Jin, H 276, 277, 618<br />

Jin, S 288<br />

Jin-Chae, J 1516<br />

Jingbo, N 1557<br />

Joel, G 1197<br />

Joetham, A 2128<br />

Jog, NR 439<br />

Jogestrand, T 1194<br />

Joh, K 921<br />

Johannesen, TB 1913<br />

Johansen, JS 133, 134, 381, 1953<br />

Johansson, M 1847<br />

John, A 68, 86, 1031<br />

Johnsen, SJA 1885, 1913<br />

Johnsen, V 972<br />

Johnson, CR 1055<br />

Johnson, D 397, 970, 1031, 1040,<br />

1099, 1100, 1792, 2032, 2210<br />

Johnson, SR 2196<br />

Johnsrud, I 972<br />

Johnsrud, K 1275<br />

Johnston, KK 2053, 2054<br />

Johnston, S 338<br />

Jolly, M 496, 765, 1147, 1164,<br />

1175, 1612, 1880<br />

Jonas, A 2125<br />

Jonas, BL 1077<br />

Jonas, M 2279<br />

Jones, A 1698, 2105, 2132<br />

Jones, DL 688<br />

Jones, EA 646<br />

Jones, G 173, 649, 1383<br />

Jones, H 1995<br />

Jones, JK 698<br />

Jones, K 209, 1128<br />

Jones, P 1372, 1983<br />

Jones, RB 676, 678<br />

Jönsson, G 1037, 1440<br />

Jonsson, MV 1899<br />

Jonsson, R 1579, 1885, 1899,<br />

1917, 1913<br />

Jonuleit, H 1125<br />

Jonzon, A 832<br />

Joosten, LAB 275, 371, 1719<br />

Jordan, JM 181, 831, 838, 1326,<br />

1329, 1330, 1463, 2140<br />

Jorge, R 2055, 2132<br />

Jorgensen, P 1538<br />

Josef, S 1351<br />

Joseph, D 2049<br />

Joseph, L 1142, 1850<br />

Jouen, F 915<br />

Joung, C-I 803<br />

Jousse, S 2221<br />

Jousse-Joulin, S 1931, 2261<br />

Jovanovic, V 753<br />

Joyal, E 1831<br />

Ju, GE 1813<br />

Ju, J 353, 370, 756, 842, 1716,<br />

1770<br />

Ju, Y 1492<br />

Juanola, X 525, 2268<br />

Juarez, C 1801<br />

Juárez-Arellano, S 1853<br />

Judet, O 551<br />

Julian, A 2027<br />

Julian, L 627, 789, 1024, 2113<br />

Jun, J-B 359, 1941<br />

June, R 470<br />

Juneja, M 58<br />

Jung, J 733<br />

Jung, L 1677<br />

Jung, S 1061, 1873<br />

Jung, Y 353, 1488, 1716<br />

Jüngel, A 21, 679, 1988<br />

Junker, P 1370<br />

Juraschek, SP 1574<br />

Jurik, AG 134, 1953<br />

Jury, EC 1187<br />

Ka, K 2246<br />

Kabylafka, EI 1895<br />

Kadi, A 1087<br />

Kadis, JA 1326<br />

Kadoya, M 1511<br />

Kaeley, GS 1617<br />

Kaffenberger, B 1374<br />

Kahaleh, B 1214, 1352<br />

Kahaly, OR 1214, 1352<br />

Kahan, A 580, 728, 1820, 1991<br />

Kahn, J-E 701, 2010, 2011<br />

Kahn, V 571<br />

Kaine, JL 120, 1834<br />

Kaiser, L 792<br />

Kaiser, MJ 340<br />

Kaiser, R 1602<br />

Kaklamanis, P 2217<br />

Kalden, J 1013<br />

Kaleth, A 93, 797<br />

Källberg, H 64, 645<br />

Kallen, MA 87, 178, 1428, 1856<br />

Kallenberg, C 1195, 1210, 1889,<br />

1892, 1905, 2012, 2015, 2023<br />

Kallich, J 1540, 1552<br />

Kallinich, T 1704<br />

Kalman-Lamb, G 1936<br />

Kaloudi, O 528, 1952<br />

Kalsi, HS 738<br />

Kalstad, S 377<br />

Kalunian, K 445, 448, 453, 476,<br />

1452, 1877, 1882, 2240, 2243<br />

Kam, YNW 1389<br />

Kamatani, N 1577<br />

Kamath, T 338<br />

K<br />

332<br />

2010 Program Book


Kambayashi, T 1354<br />

Kamdar, AA 1160<br />

Kameda, H 1793, 1812, 1823<br />

Kamel, MM 798<br />

Kamen, D 448, 475, 476, 510,<br />

960, 1583, 1584, 1590, 1877, 2125,<br />

2240, 2243<br />

Kamp, S 138, 1186<br />

Kampagianni, O 2126, 2277<br />

Kanbe, K 1812<br />

Kanda, V 167<br />

Kandimalla, ER 856, 862<br />

Kane, BA 1560<br />

Kane, D 1631<br />

Kane, MA 640<br />

Kaneko, H 1042, 1619, 1844<br />

Kaneko, K 619<br />

Kang, EH 935<br />

Kang, KY 1770<br />

Kang, M-S 1714<br />

Kang, X 1464<br />

Kang, Y 1061, 1597, 1873<br />

Kantner, C 441<br />

Kanz, L 1145<br />

Kao, AH 620, 1399<br />

Kapetanovic, M 645, 1037, 1440<br />

Kaplan, MJ 1041, 1158, 2278<br />

Kaplan, S 627, 2083<br />

Kaplanski, G 1664, 2042<br />

Kapoor, A 2086<br />

Kaposi, NP 1637<br />

Kapsogeorgou, EK 1897<br />

Kara, FM 1471<br />

Karakurt, S 1803<br />

Karam, E 1526<br />

Karasawa, R 631, 652<br />

Karin, M 1718<br />

Kariuki, SN 495, 496, 1612<br />

Karjalainen, A 891<br />

Karlson, EW 64, 762, 793, 1082,<br />

1588, 1610<br />

Karol, D 1862<br />

Karouzakis, E 21, 357<br />

Karp, DR 1188<br />

Karpouzas, GA 305, 699, 1046,<br />

1443, 1768, 2164, 2165, 2166<br />

Karras, A 2011, 2034<br />

Karras, D 967<br />

Karsdal, M 1466, 1474, 1500<br />

Kasagi, S 1715<br />

Kasama, T 26, 1773, 1812<br />

Käsermann, F 494<br />

Kasinova, M 2053, 2054<br />

Kasitanon, N 1011<br />

Kaslow, RA 828<br />

Kasper, G 630, 1418<br />

Kastner, D 914, 1281, 1516, 1698,<br />

2105, 2217<br />

Kataoka, S 897, 916, 923, 1844<br />

Katayama, K 1138<br />

Kates, J 597<br />

Kato, H 1271, 1709<br />

Kato, M 2, 5, 10, 1909, 2254<br />

Katsahian, S 2014<br />

Katsicas, MM 212, 1704<br />

Katsounaros, M 1021<br />

Katsumata, Y 447, 746, 897, 916,<br />

923, 935, 1184, 1587, 1666, 1844<br />

Katsumoto, TR 609<br />

Kattah, NH 428<br />

Katz, B 1309<br />

Katz, J 31, 60, 140, 167, 1576,<br />

2090, 2091, 2092, 2137<br />

Katz, KF 2075<br />

Katz, P 625, 627, 789, 1767, 2113<br />

Katz, RS 98, 100, 110, 112, 117,<br />

2074, 2075<br />

Kaufman, I 1238<br />

Kaufman, K 500, 1579, 1583,<br />

1584, 1585, 1586, 1590, 1591,<br />

1594, 1595, 2144, 2145, 2146,<br />

2147, 2148, 2274<br />

Kaufmann, C 377<br />

Kaufmann, J 56, 1788<br />

Kaukeinen, K 52, 1799<br />

Kaul, MS 461<br />

Kaul, S 1119<br />

Kauppi, MJ 759<br />

Kausor, T 40<br />

Kautiainen, H 80, 312, 891<br />

Kavalieratos, D 1575<br />

Kavanaugh, A 1102, 1117, 1618,<br />

1781, 1791, 1806, 1808, 1930,<br />

1943, 1955<br />

Kawabata, D 1377<br />

Kawaguchi, H 1464<br />

Kawaguchi, Y 447, 746, 916, 923,<br />

1184, 1587, 1844, 897, 1666<br />

Kawahito, Y 1511<br />

Kawai, H 298<br />

Kawai, S 619<br />

Kawai, V 54, 1023, 1867, 2123<br />

Kawakami, A 364, 1371, 1632<br />

Kawakami, K 1749<br />

Kawamoto, M 746, 897, 1184,<br />

1587<br />

Kawamoto, T 1731<br />

Kawasaki, R 1772<br />

Kawasaki, Y 983<br />

Kawashiri, S-y 364, 1371, 1632<br />

Kay, J 1015, 1818<br />

Kayakabe, K 358<br />

Kaymakcalan, Z 1269<br />

Kayser, C 579<br />

Kazantseva, M 1252<br />

Kazi, S 993<br />

Keane, MB 817, 818<br />

Kearns, R 776, 1553<br />

Keating, RM 77, 658, 1094<br />

Keddache, M 654<br />

Kee, S-J 505<br />

Keeley, P 646<br />

Keen, H 1929<br />

Keenan, BT 1588<br />

Keenan, RT 148, 883<br />

Keir, G 727<br />

Keiserman, MW 2173<br />

Keitzer, R 1295<br />

Kekow, J 406<br />

Keller, A 170<br />

Keller, KK 1485<br />

Kellet, CV 523<br />

Kelley, JA 1594<br />

Kelley, L 453, 1452<br />

Kellner, HL 420, 1788<br />

Kelly, J 500, 502, 1164, 1583,<br />

1584, 1586, 1590, 1595, 2144,<br />

2145, 2146, 2147, 2148, 2274<br />

Kelly, S 390, 1843, 1919, 2170<br />

Kelman, A 401<br />

Kennedy, A 1625<br />

Kennedy, CW 255, 256<br />

Kennedy, M 268<br />

Kenny, D 1109<br />

Kenwright, A 1434, 1474<br />

Keogh, B 16<br />

Keogh, KA 680<br />

Kerekes, G 519<br />

Keren, R 233<br />

Kermani, TA 705, 1304, 1662<br />

Kern, MH 2083<br />

Kerr, AJ 1345<br />

Kerr, GS 397, 546, 970, 1099, 1792<br />

Kerr, LD 2110<br />

Kerstens, PJSM 334, 295, 328, 663<br />

Kersten-Smit, C 2051<br />

Kesel, N 679<br />

Keser, G 822<br />

Kessel, A 909<br />

Kettle, T 870<br />

Keyes, A 1887<br />

Keyes-Elstein, L 726<br />

Keysor, JJ 683, 686, 2143<br />

Keysser, G 138<br />

Keystone, EC 300, 306, 321, 343,<br />

391, 403, 416, 659, 978, 987, 995,<br />

1097, 1101, 1102, 1113, 1114,<br />

1120, 1136, 1737, 1753, 1782,<br />

1818<br />

Kezic, JM 1447<br />

Kezouh, A 342<br />

Khademi, M 1181<br />

Khalatbari, S 1041<br />

Khalid, M 1561<br />

Khalidi, N 126, 2198<br />

Khalili, AW 1901<br />

Khalili, H 825<br />

Khalilova, I 870<br />

Khamashta, M 445, 448, 476, 732,<br />

1357, 1877, 2035, 2240, 2243<br />

Khan, A 1830<br />

Khan, F 259<br />

Khan, K 1996, 2005<br />

Khan, M 780, 1670, 2224<br />

Khan, N 390<br />

Khan, U 12<br />

Khanna, D 147, 155, 347, 561,<br />

570, 583, 594, 729, 1106, 1205,<br />

1212, 1213, 1228, 1232, 1365,<br />

1572, 2194, 2195, 2196<br />

Khanna, P 155, 1365, 1572<br />

Khimdas, S 1202, 1203<br />

KHOALA Group 2094<br />

Khodair, A 816<br />

Khoja, SS 2060<br />

Khong, PL 1233<br />

Khosla, S 959<br />

Khosroshahi, A 25, 1671<br />

Khraishi, M 554, 1820, 1939<br />

Khubchandani, R 1700, 1705<br />

Kiani, A 268, 479, 485, 1148, 2122<br />

Kickingbird, LM 1690<br />

Kickler, TS 460<br />

Kiel, DP 684, 1317<br />

Kielhorn, A 56<br />

Kiener, H 829, 2214<br />

Kievit, W 59, 641, 2207<br />

Kikly, K 287<br />

Kikuchi, H 1285, 1293<br />

Kikuchi, M 237<br />

Kil, L 715<br />

Kilgallen, B 453, 1452<br />

Kilgore, ML 1005<br />

Kill, A 2003<br />

Kim, AH 1415<br />

Kim, C 387<br />

Kim, E 1092, 1488, 1605, 1941<br />

Kim, G 276, 277, 1209, 1488<br />

Kim, H 353, 370, 461, 756, 803,<br />

1464, 1523, 1716, 1751, 1770,<br />

2084<br />

Kim, I 1464<br />

Kim, J 276, 277,353, 370, 387,<br />

756, 1521, 1523, 1716, 1751<br />

Kim, KK 609<br />

Kim, L 1835<br />

Kim, M 732, 1199<br />

Kim, ND 25, 1427<br />

Kim, PW 260<br />

Kim, S 31, 276, 277, 323, 387,<br />

497, 803, 903, 1066, 1209, 1246,<br />

1523, 1673, 1691, 2017, 2077,<br />

2028, 2155<br />

Kim, T 27, 116, 359, 505, 1891,<br />

2010 Program Book 333<br />

abstract author Index


aBSTRACT author Index<br />

334<br />

1941, 1972<br />

Kim, X 1594<br />

Kim, Y 288, 876, 2028<br />

Kimberly, RP 500, 868, 1583,<br />

1584, 1585, 1586, 1591, 1594,<br />

1595, 2145, 2147, 2148<br />

Kimbler, TB 1712<br />

Kimel, M 91<br />

Kimura, Y 70, 1677, 1700<br />

Kimura-Hayama, E 459<br />

Kinaszczuk, M 1843<br />

Kinds, MB 121, 124, 952<br />

King, A 216<br />

King, C 606<br />

King, S 860<br />

King-Davis, S 152, 153<br />

Kingetsu, I 921<br />

Kingsbury, DJ 1673, 1691, 2017<br />

Kingsley, GH 664<br />

Kinjo, M 958<br />

Kinloch, AJ 1717<br />

Kiralp, MZ 114<br />

Kirbach, C 2251<br />

Kirbach, SE 788<br />

Kirchner, HL 345, 1442<br />

Kiriakidou, M 422<br />

Kirino, Y 1281, 1512, 2217<br />

Kirkham, B 385, 386, 1263, 1838,<br />

1898<br />

Kirou, KA 508, 1199, 1990, 2077,<br />

2193<br />

Kirschning, C 857<br />

Kirson, N 763<br />

Kirstin, H 61<br />

Kirwan, JR 392, 1655<br />

Kisacik, B 1921<br />

Kishimoto, M 1641, 1783<br />

Kiss, L 1399<br />

Kissima, J 1568<br />

Kissin, EY 1617, 1624<br />

Kita, J 1371, 1632<br />

Kitakawa, H 10<br />

Kitamura, N 1708<br />

Kitas, GD 664<br />

Kitazawa, M 1709<br />

Kitchen, JM 1631<br />

Kitchen, K 1325<br />

Kitchin, E 1006<br />

Kitt, MM 160<br />

Kivitz, A 944<br />

Kivitz, AJ 144, 710, 945, 946, 1919<br />

Kivovich, V 694<br />

Klaasen, R 719<br />

Klaman, LD 285<br />

Klarenbeek, NB 328, 334, 663<br />

Klarenbeek, PL 1069, 1604<br />

Klareskog, L 64, 645, 832, 1015,<br />

1097, 1588, 1817, 1917, 2118,<br />

2010 Program Book<br />

2214<br />

Klassen, LW 2235<br />

Klatt, S 361<br />

Klatzman, D 1249<br />

Klatzmann, D 2025, 2131<br />

Klause, U 381, 1764<br />

Kleber, S 1973<br />

Klein, A 220, 1696<br />

Klein, J 1457<br />

Klein, R 894<br />

Klein, W 780<br />

Kleinert, S 745, 782, 1026, 1255,<br />

1411<br />

Klein-Gitelman, M 1673, 1688,<br />

1689, 1691, 1701, 1702, 2017<br />

Klein-Gittelman, M 1677<br />

Klersy, C 2220<br />

Kleszcz, A 1756<br />

Klink, AJ 233, 1703<br />

Kloiber, S 2193<br />

Kloppenburg, M 179<br />

Klosowska, K 17, 39, 1131<br />

Klüter, A 886<br />

Knapp, L 1345<br />

Knauer, C 1123<br />

Kneitz, C 782<br />

Knevel, R 1744, 1782<br />

Knight, A 891<br />

Knight, E 515<br />

Knight, JB 1463<br />

Knops, B 1325<br />

Knowlton, N 655, 1030<br />

Knutson, KL 1580, 1581, 2216<br />

Ko, TC 1667<br />

Koarada, S 433<br />

Kobayashi, H 139, 1797<br />

Kobayashi, I 1672<br />

Kobayashi, K 139<br />

Kobayashi, S 1377<br />

Kobayashi, T 1641<br />

Kobelt, G 761<br />

Kobialko, M 406<br />

Kobie, J 849, 1085<br />

Koçak, M 1208<br />

Koch, AE 282, 1417, 1419, 1487,<br />

1504, 1721, 2007<br />

Koch, H 1125<br />

Kochi, Y 1577<br />

Kockum, I 832<br />

Kodhek, S 1336<br />

Koehoorn, M 2093<br />

Koeleman, BPC 1599, 2214<br />

Koenders, MI 275, 371, 1351,<br />

1622, 1730, 2230<br />

Koenig, AS 1103, 1927<br />

Koenig, MF 440<br />

Koening, CL 1309<br />

Koerbl, B 138<br />

Koetter, I 899, 900, 1145<br />

Koeuth, T 934, 1608, 2149<br />

Koevoets, R 295, 1755<br />

Koga, T 364, 1371, 1632<br />

Koh, E-M 366, 372, 1297<br />

Kohno, M 1511<br />

Kohsaka, H 1375<br />

Köhler, D 679<br />

Koike, T 2, 5, 10, 399, 621, 981,<br />

1814, 1815, 1909, 2254<br />

Koitschev, A 899, 900<br />

Koitschev, C 899, 900<br />

Kojima, F 864<br />

Kokkonen, H 1847, 2115<br />

Kolar, P 630, 1418<br />

Kolfenbach, JR 77, 658, 702, 1094<br />

Kollerup, G 1444, 1841<br />

Kollias, G 368, 1719, 2237<br />

Kolling, C 21, 357, 1093, 1518,<br />

1528<br />

Kollnberger, S 1973<br />

Kolta, S 548<br />

Komai, K 511, 893<br />

Komura, K 617<br />

Konatalapalli, RM 869<br />

Kondi, A 261, 1696<br />

Kondo, S 433<br />

Kondo, Y 1724<br />

Kondos, G 1168<br />

Kondragunta, V 831, 838<br />

Kone-Paut, I 895, 905, 1305,<br />

1425, 1435, 1696, 1704<br />

Kong, N 1266, 1499<br />

Kono, H 1285, 1531<br />

Koo, G 427, 866, 1199<br />

Koopman-Keemink, Y 219<br />

Kopec, J 72, 1056, 1555, 2055,<br />

2093<br />

Kopecky, EA 944<br />

Korb, A 1719, 2237<br />

Korchynskyi, O 1487<br />

Korendowych, E 833<br />

Koretzky, GA 1354<br />

Kornman, K 707, 831, 838<br />

Kornum, J 2040<br />

Korpela, M 80<br />

Korswagen, L-A 1859<br />

Kosek, E 2245<br />

Koshy, S 1128<br />

Koss, MN 2187<br />

Kostianovsky, A 2009, 2043<br />

Kosugi, Y 893<br />

Kotowicz, M 183<br />

Kotsakis, S 2175<br />

Koumakis, E 529, 1924<br />

Kovács, L 1578<br />

Koval, E 2013<br />

Koval, RJ 2013<br />

Kowal-Bielecka, O 599, 1212<br />

Kowalczyk, A 664<br />

Kowatari, K 329<br />

Koyama, Y 1086<br />

Koyano, S 1138, 1738, 1739<br />

Kozaci, D 1282, 1970<br />

Kozyrev, S 1578<br />

Kracht, M 1535<br />

Kraemer, KL 1039<br />

Kramer, HR 1018, 1065<br />

Krammer, G 1435, 2087<br />

Krasnokutsky, S 137, 707, 708<br />

Krasnow, R 877<br />

Krasowska, D 580<br />

Kraus, V 180, 181, 707<br />

Krause, A 2271<br />

Krause, ML 2216<br />

Krausz, S 1095<br />

Krege, JH 957<br />

Kreiger, PA 1354<br />

Kremer, J 1836<br />

Kremer, JM 347, 378, 379, 416,<br />

515, 1003, 1799, 1819, 1835, 2169,<br />

2262<br />

Kremser, M-L 1481<br />

Kretzler, M 2276, 2278<br />

Kreuter, A 2214<br />

Krieckaert, CL 1445<br />

Krieg, M-A 2157<br />

Krintel, SB 381<br />

Krishna Kumar, PR 1106<br />

Krishnamurthy, A 161<br />

Krishnan, E 154, 877, 878, 1378,<br />

1545, 2153<br />

Krishnan, G 574<br />

Kristjansdottir, GT 1885<br />

Krivine, A 478, 2043<br />

Kroese, F 1889, 1892<br />

Krogh, NS 1809<br />

Krohn, KD 980<br />

Krueger, GG 1943<br />

Krueger, K 782<br />

Kruize, AA 1896, 1900, 1903<br />

Krummel-Lorenz, B 1112<br />

Krusch, D 1481<br />

Krystufkova, O 926<br />

Kuan, W-P 1028<br />

Kubo, M 1577<br />

Kubota, K 1619<br />

Kubota, T 2228<br />

Kuemmerle-Deschner, J 894, 895,<br />

899, 900, 905, 1425, 1435<br />

Kuhr, K 294<br />

Kularatne, S 1613<br />

Kulkarni, OP 441


Kuller, LH 71<br />

Kumabe, M 1164<br />

Kumagai, S 1715<br />

Kumar, A 1606, 1612, 1726<br />

Kumar, D 190, 194<br />

Kumar, N 1064<br />

Kumar, S 2086, 2169<br />

Kume, K 1839<br />

Kümmerle-Deschner, J 1305<br />

Kumora, K 601<br />

Kuo, D 135<br />

Kuper, IH 314, 662, 1771<br />

Kupper, H 123, 1101, 1108, 1938<br />

Kurasawa, K 472<br />

Kurasawa, T 1793, 1823<br />

Kurhanewicz, C 136<br />

Kurien, BT 1901<br />

Kurita, T 1909<br />

Kuriya, B 81, 1737<br />

Kuroiwa, T 358<br />

Kurosaka, D 921<br />

Kurosaka, M 983<br />

Kurowska-Stolarska, M 28, 1422<br />

Kurrasch, RH 58<br />

Kurt, R 1351<br />

Kurthen, R 1788<br />

Kusunoki, N 619<br />

Kusunoki, Y 619<br />

Kuwana, M 916, 1293, 1672<br />

Kuwana, Y 1708<br />

Kuzin, I 712, 1710<br />

Kvarnstrom, M 1885, 1917<br />

Kvien, T 55, 132, 141, 142, 182,<br />

377, 534, 1013, 1027, 1603, 1750,<br />

1774, 1802, 1807, 1922, 1780<br />

Kwak, H-B 2158<br />

Kwan, L 2074<br />

Kwan Tat, S 1497<br />

Kwekkeboom, J 179<br />

Kwoh, CK 185, 193, 2096<br />

Kwok, RCL 773<br />

Kwok, S-K 353, 370, 756, 1716,<br />

1770<br />

Kwon, E 1972<br />

Kwon, H-H 323<br />

Kwon, SR 1813<br />

Kwon, Y-J 27<br />

Kwong, T 820<br />

Kyburz, D 829, 1389, 1528<br />

Kyndt, X 2045<br />

Kyogoku, M 291<br />

Kyriakidis, NC 2175<br />

Kyttaris, VC 2126, 2277<br />

La Cava, A 431, 497<br />

La Torre, F 1439, 2033, 2202<br />

L<br />

Labrecque, J 214, 731<br />

Lacaille, D 72, 523, 535, 771,<br />

1036, 1056, 1152, 1538, 1571<br />

Lachmann, H 895, 905, 1425,<br />

1663<br />

Lacraz, A 2010, 2011<br />

Lacy, E 1818<br />

Lacy, JP 2235<br />

Lafeber, FPJG 121, 124, 176, 278,<br />

333, 380, 636, 942, 952, 1380,<br />

1753, 1759, 1900, 1903<br />

Laforet, P 922<br />

Lafyatis, R 560, 566, 675, 1210,<br />

2004<br />

Lagana’, B 1098, 1582<br />

Lagoo Joshi, V 1551<br />

Lagunas, T 229<br />

Lai, C 94, 814, 819<br />

Lai, Z 1185, 1196<br />

Lainez, B 1246<br />

Laishram, GD 2086<br />

Lajeunesse, D 1497<br />

Lakos, G 2251, 2252<br />

Lales, G 221<br />

Laliberte, K 597<br />

Lalwani, N 282<br />

Lam, J 1465<br />

Lam, KSL 1233<br />

Lamana, A 1505<br />

Lambert, C 888<br />

Lambert, R 134, 551, 667, 1934,<br />

1957, 1959<br />

Lambert, S 1405<br />

Lambrianides, A 2255<br />

Lammertsma, AA 1613<br />

Lamprecht, P 2036<br />

Lan, C 1268<br />

Lan, Y 1427<br />

Lanas, A 953, 1031<br />

Lanasa, M 1192<br />

Lancaster, W 468<br />

Lancha Junior, AH 1384<br />

Lancrenon, S 888<br />

Landells, I 1939<br />

Lander, PH 1573<br />

Landewe, R 303, 1113, 1922,<br />

1949, 1985<br />

Landolt-Marticorena, C 13, 2190<br />

Landon, GC 178<br />

Lane, JA 502, 1602<br />

Lane, NE 182, 624, 957, 965, 2212<br />

Lang, BA 238<br />

Langan, MA 989, 2112<br />

Langdahl, B 967<br />

Lange, B 950<br />

Lange, R 950, 1059<br />

Langefeld, C 500, 654, 1584,<br />

1585, 1586, 1591, 1594, 1595,<br />

2145, 2148, 2274<br />

Langer, A 1004<br />

Langerak, A 2004<br />

Langford, CA 1315, 2012, 2047,<br />

2049, 2198<br />

Langleben, D 565<br />

Langman, C 1168<br />

Lanna, CCD 1169, 1842, 1849<br />

Lanni, S 2220<br />

Lanot, S 2269<br />

Lanz, S 888<br />

Lanzarotti, A 948<br />

Lapadula, G 297<br />

Lapierre, M 1931<br />

Laragione, T 1128, 1387<br />

Laria, A 744<br />

Larida, B 2252<br />

Larimi, R 1289<br />

Laroche, M 964<br />

Larroche, C 917, 1890, 1893,<br />

1894, 1910, 2042<br />

Larsson, A 103<br />

Lasigliè, D 265, 657<br />

Lasky, A 253, 254<br />

Lasky, RE 1218, 1227<br />

Lassere, M 141, 1369<br />

Laster, AJ 383<br />

Latchman, DS 1358, 1359, 2255<br />

Lateef, A 460, 1149<br />

Latek, R 1119<br />

Lateur, L 311<br />

Latinis, K 457<br />

Lattanzi, B 210, 232<br />

Lau, CS 1139, 1233, 2156<br />

Lau, H 621<br />

Laubender, R 1781<br />

Lauber, K 490<br />

Laudes, M 294<br />

Laudien, M 679<br />

Lauféron, F 1945<br />

Laughlin, S 2019, 2107<br />

Launay, D 2010, 2042<br />

Launay, J-M 1707<br />

Launay, O 533, 2043<br />

Laurendeau, I 2025<br />

Lauri, J 172<br />

Laurindo, I 356, 1013<br />

Laurino, S 678<br />

Lauwerys, B 1578<br />

Lauwerys, BR 2263<br />

LaValley, M 706, 872, 1564, 2143,<br />

2155<br />

Lavender, L 1538<br />

Laveskog, A 1181<br />

Lavie, F 518, 559, 1930, 1935,<br />

1949<br />

Law, C-L 1273<br />

Lawrence, C 1267<br />

Lawrenz, B 1145<br />

Lawson, E 1645<br />

Laxer, RM 225<br />

Lazaretti, M 1676<br />

Lazarevic, D 217<br />

Lazaro, D 161, 970, 1431<br />

Lazaro, E 2010<br />

Lazarus, MN 738, 740<br />

LBSL02/99 Study Group 1457<br />

Le, E 589, 2192<br />

Le, TT 602<br />

Le Bars, M 1817<br />

Le Blay, P 408<br />

Le Boutin, D 1249<br />

Le Gall, M 834<br />

Le G<strong>of</strong>f, B 29, 30<br />

Le Guen, J 2041<br />

Le Guenno, G 2010, 2011, 2026<br />

Le Guern, V 1398, 1890, 1910,<br />

2034, 2041, 2043, 2239<br />

Le Henaff, C 2261<br />

Le Loët, X 301, 400, 1087, 1752,<br />

1790, 1827<br />

Le Pottier, L 2177<br />

Le Thi Huong, D 2025, 2239<br />

Le Thi Huong-Boutin, D 1287<br />

Leak, A 1830<br />

Leandro, MJ 739, 743<br />

Leask, A 613<br />

Leaverton, PE 823<br />

Leberruyer, P-Y 2045<br />

Leblanc, V 1946<br />

Leblond, V 2011<br />

Lebre, C 1507, 1519<br />

Lebre, MC 1534<br />

Lechat, P 2239<br />

Lechtzin, N 1022<br />

LeClercq, S 785<br />

Lecompte, T 1<br />

Lederman, S 799, 820<br />

Lee, AT 825, 992, 1386, 1592,<br />

1597, 2214<br />

Lee, B 359, 1972<br />

Lee, C 876, 2028, 2158, 2172<br />

Lee, D 167, 363, 2229<br />

Lee, E 274, 387, 1484, 1751<br />

Lee, H-J 323, 903<br />

Lee, H-S 803, 1092, 1597, 1605,<br />

1714<br />

Lee, J 75, 276, 366, 372, 1122,<br />

1156, 1297, 1864<br />

Lee, JLF 214, 731<br />

Lee, JM 817, 818<br />

Lee, JS 1092, 1441, 1605<br />

Lee, JH 803, 1209<br />

Lee, J-W 277, 1209, 1714<br />

Lee, JY 122, 706<br />

Lee, K 148, 883, 1028, 1092,<br />

2010 Program Book 335<br />

abstract author Index


aBSTRACT author Index<br />

336<br />

1605, 1972<br />

Lee, K-H 1061, 1873<br />

Lee, L 920<br />

Lee, MB 828<br />

Lee, MS 2158<br />

Lee, S 876, 1504, 1721, 2028<br />

Lee, S-H 1038<br />

Lee, SJ 116, 505, 1891, 2056<br />

Lee, SK 27, 1061, 1873<br />

Lee, S-S 116, 505, 803, 1891<br />

Lee, SW 1061, 1873<br />

Lee, VW 1028<br />

Lee, Y 92, 95, 174, 359, 366, 372,<br />

387, 933, 949, 1050, 1058, 1297,<br />

1628, 1901<br />

Lee, Y-A 803, 1038<br />

Leeder, JS 253, 254<br />

Lefaucheur, J-P 1908, 1911<br />

Lefevre, S 1420, 1722<br />

Leffers, HC 1809<br />

Leffler, MG 206<br />

Legault, C 203<br />

Léger, J-M 2010, 2011<br />

Leggerton, CW 2173<br />

Lehane, P 391<br />

Lehman, AJ 1324, 1538<br />

Lehman, TJA 1872<br />

Lehmann, A 148, 883<br />

Lehmann, B 911<br />

Lehr, A 1420, 1722<br />

Lei, J 1265, 2016<br />

Leipe, J 2130<br />

Leirisalo-Repo, M 420<br />

Leite, I 922<br />

Leitman, S 1161<br />

Leleti, MR 2032<br />

Leman, M 376<br />

Lembo, R 1698<br />

Lemeiter, D 2236<br />

Lemoine, S 737<br />

Lems, W 967<br />

Lems, WF 332, 961, 1033, 1084,<br />

1496, 1859<br />

Len, CA 1339, 1343, 1704, 1872<br />

Lencina, V 324<br />

Lenhart, P 1405<br />

Lenh<strong>of</strong>f, MW 1328<br />

Lenief, V 354, 1515<br />

Lent, PV 2151<br />

Lenzi, M 2036, 2201<br />

Leo, J 1210<br />

Leon, G 2173<br />

Leonard, G 1170<br />

Leonard, MB 206, 1786<br />

Leoncini, G 1155, 2202<br />

Leone, J 1893<br />

Leong, A 1766<br />

2010 Program Book<br />

Lepore, L 1435, 1436<br />

Lepse, N 2015<br />

Lequen, L 701<br />

Lequerré, T 1087, 1810, 1827<br />

Lerma, C 808<br />

Leroux, G 2239<br />

Lertnawapan, R 1023<br />

Lertratanakul, A 620, 1168, 1399<br />

Leslie, K 895, 1425, 1435<br />

Lessard, CJ 1579, 1585, 2147<br />

Lessov-Schlaggar, CN 877<br />

Letierce, A 1305, 1696<br />

Leung, HW 1870<br />

Leung, L 1386<br />

Leung, YT 422<br />

Leutenegger, E 984<br />

Levartovsky, D 697<br />

Leveille, SG 684<br />

Levels, HHM 332<br />

Leveneur, Y 2027<br />

Levin, J 780<br />

Levin, R 31<br />

Levin, TL 1630<br />

Levine, AB 898<br />

Levine, BE 2186<br />

Levine, SM 677, 681<br />

Levy, AR 535, 771<br />

Levy, DM 234, 1688<br />

Levy, R 6, 451, 452, 1172, 1848,<br />

2172<br />

Levy-Neto, M 927<br />

Lew, BR 271<br />

Lewis, C 131, 201, 205, 683, 686,<br />

693, 872, 951, 1367, 1557, 2058,<br />

2100, 2133<br />

Lewis, EE 1158<br />

Lewis, JD 2084<br />

Lewis, MJ 430<br />

Ley, R 40<br />

Leyva, AL 1219<br />

Li, C 151, 747, 1598, 1607, 2205<br />

Li, EK 451, 1028<br />

Li, G 2127<br />

Li, H 1260, 2189<br />

Li, J 712, 1107, 1135, 1260, 1412,<br />

1710, 2189<br />

Li, L 1321, 1538, 2050, 2055, 2282<br />

Li, M 1028, 1954<br />

Li, Q 1188, 1942<br />

Li, R 1182, 1598<br />

Li, SC 1673, 1690, 1691, 2017<br />

Li, T 625, 1028, 1758, 1874<br />

Li, W 2136<br />

Li, X 135, 136, 336, 868, 1734,<br />

1769<br />

Li, Y 501, 735, 742, 1500, 1598<br />

Li, Z 1134, 1598, 1997<br />

Lian, JB 716<br />

Liang, J 918, 1143, 2172<br />

Liang, KP 774<br />

Liang, KV 1399<br />

Liang, MH 1538<br />

Liao, C 288<br />

Liao, KP 1588, 1610<br />

Lias, J 2071<br />

Libanati, C 2157<br />

Lidove, O 2045<br />

Lidtke, RH 2099<br />

Lie, BA 1603, 2214, 2219<br />

Lie, E 55, 377, 1802, 1807, 1922<br />

Lieberman, SM 1907<br />

Liebhaber, A 1112<br />

Liedholm, R 1899<br />

Liew, FY 28, 1422<br />

Ligeiro, D 1986<br />

Lii, H 1167<br />

Lillegraven, S 132, 142, 1369<br />

Lim, A 597<br />

Lim, B 248<br />

Lim, C 1187<br />

Lim, MJ 1813<br />

Lim, M-K 488, 830, 1589<br />

Lim, S 226, 448, 476, 790, 1431,<br />

1877, 2240, 2243<br />

Lima, FR 626, 1384<br />

Limal, N 2034, 2239<br />

Limburg, P 1195<br />

Lin, CP 2144<br />

Lin, H-Y 2087<br />

Lin, J 1464, 1647<br />

Lin, P 273<br />

Lin, WY 1609<br />

Lin, Y 564, 1167<br />

Lindegaard, H 133, 1444, 1841<br />

Lindsley, CB 1678<br />

Lindsley, HB 943<br />

Lindstrom, M 1965<br />

Lindstrom, TM 2229<br />

Linehan, T 2242<br />

Lingala, B 642, 1378, 1545, 2153<br />

Linge, CP 1387<br />

Link, R 406<br />

Link, TM 135, 136<br />

Linnik, MD 321<br />

Linn-Rasker, SP 380<br />

Lino, M 1979<br />

Linos, E 1378<br />

Linton, MF 1034<br />

Lioté, F 376, 413, 875, 888, 1707,<br />

2151, 2239<br />

Liotta, F 246<br />

Lips, P 971<br />

Lipsker, D 2238<br />

Lipsky, P 1161<br />

Lipton, RB 939, 2095<br />

Lisk, L 1453, 2085<br />

Lisse, J 415, 1014, 1636<br />

Listing, J 526, 668, 669, 1111,<br />

1112, 1923, 1938, 1958, 1985,<br />

2270, 2271<br />

Litinsky, I 1159, 1238<br />

Little, MA 1207<br />

Littlefield, M 1072<br />

Littlejohn, G 320<br />

Littman, DR 1390<br />

Liu, G 269<br />

Liu, H 385, 600, 1968<br />

Liu, J 81, 339, 1066<br />

Liu, L 404<br />

Liu, P 19<br />

Liu, X 423, 565, 1598<br />

Liu, Y 1134<br />

Liu, Z 442, 2129, 2188<br />

Liu-Bryan, R 634<br />

Livingston, S 892<br />

Li-Yu, J 151<br />

Ljung, L 891, 1054<br />

Ljunggren, O 967, 982<br />

Llahí, N 1754<br />

Llanos, C 732<br />

Llobet, JM 1801<br />

Lloyd, D 192<br />

Lloyd, R 1372<br />

Lo, C 1014<br />

Lo, E 577, 1225<br />

Lo, GH 122, 188, 195, 706, 709,<br />

2101<br />

Lo Monaco, A 1627<br />

Lo Nigro, A 540<br />

Lober, J 2247<br />

Lobo, M 1372, 1983<br />

Locher, J 1005<br />

Lockard, MA 2244<br />

Lockshin, MD 6, 1151<br />

Lococo, B 1173<br />

Lodde, BM 1095<br />

Lodewyckx, L 1468<br />

Loeser, RF 203<br />

Loeuille, D 551, 768, 1810, 1931<br />

L<strong>of</strong>t, AG 134, 1953<br />

Logeart, I 69, 1629, 1946<br />

Loh, C 424, 425<br />

Loh, YK 717<br />

Lohanatha, F 630, 1418<br />

Lok, EYC 1748, 1777<br />

Lombardi, Jr, I 2132<br />

Londoño, J 517, 552<br />

Long, SG 391<br />

Longhi, B 1695<br />

Longy-Boursier, M 701<br />

Loo, T 1936<br />

Lo<strong>of</strong>, A 2002


Looney, C 941<br />

Looney, MR 609<br />

Looney, RJ 849<br />

Lopes, JB 1546<br />

López Vives, L 1016, 1277, 1299,<br />

1310<br />

Lopez-Ben, R 1573<br />

Lopez-Benitez, JM 231, 1404<br />

López-Bote, JP 1229<br />

Lopez-Fernandez, J 389<br />

Lopez-Hoyos, M 1296, 1871<br />

Lopez-Lazaro, L 1273<br />

Lopez-Longo, FJ 1078, 1276<br />

López-Mejías, R 538<br />

Lopez-Olivo, MA 178, 407, 755,<br />

941<br />

Lopez-Pedrera, C 1357<br />

López-Reyes, AG 1614<br />

Loppin, E 315<br />

Lord, G 617<br />

Lorenz, H-M 138<br />

Lorenzen, T 1809<br />

Lorenzin, M 540<br />

Lorenzini, S 615<br />

Lories, R 610, 1468, 1980, 2263<br />

Lorrain, D 606<br />

Lorusso, M 1436<br />

Losina, E 140, 143, 199, 2090,<br />

2091, 2092, 2137<br />

Lotti, T 1962<br />

Lotufo, S 1339<br />

Lotz, M 369, 634, 1494<br />

Lough, KM 730<br />

Louie, GH 786<br />

Louie, J 347, 699<br />

Louie, M 565<br />

Lourenco, EV 431, 497<br />

Loury, DJ 286<br />

Love, TJ 793, 1951<br />

Lovell, DJ 1407, 1434, 1673, 1691,<br />

2017<br />

Lovell, K 646<br />

Low, PS 1613<br />

Lowder, C 1670<br />

Loza, E 482, 516, 975, 1657<br />

Lozano, D 1475<br />

Lozano, E 1292, 1294<br />

Lozano, F 538<br />

Lu, B 949, 1050, 2104<br />

Lu, C 1107<br />

Lu, G 621<br />

Lu, J 386<br />

Lu, LD 2233<br />

Lu, Q 507<br />

Lu, R 2274<br />

Lu, X 1598<br />

Lu, Y 1536<br />

Lubbeke-Wolff, A 2257<br />

Lubberts, E 38, 287, 715, 1259,<br />

1274, 1525<br />

Lubrano, E 532<br />

Luca, D 1122<br />

Luca, NJC 1681<br />

Lucacchini, A 811, 839<br />

Lucas, FL 1638<br />

Lucas, K 1735<br />

Lucas, M 288, 563, 929, 930<br />

Lucherini, OM 837<br />

Luchi, ME 2172<br />

Luciano, N 1884, 1916<br />

Lucier, S 781<br />

Ludivico, CL 1834<br />

Ludwicka-Bradley, A 604<br />

Luedtke, C 104, 108<br />

Luetkecosmann, S 1418<br />

Lufkin, J 1095<br />

Luggen, M 416, 1854, 1855<br />

Lui, NL 512, 545, 556<br />

Luijtens, K 1832<br />

Luime, J 317, 1775, 1776, 2066,<br />

2180<br />

Luini, A 1089<br />

Lukas, C 301, 303, 1088, 1104,<br />

2218, 2221<br />

Luker, K 624<br />

Lukert, BP 943<br />

Lukina, G 55, 1802, 1807<br />

Lumezanu, E 869<br />

Lund Hetland, M 141<br />

Lundberg, IE 924, 926, 2245<br />

Lundberg, K 1717, 2118<br />

Lundell, A-C 1248<br />

Lundsgaard, D 508<br />

Luning-Prak, E 439<br />

Lunt, M 374, 421, 445, 766, 779,<br />

796, 1067, 1110<br />

Luo, A 390, 416<br />

Luo, Y 1725<br />

Luong, F 809<br />

Luqmani, R 676, 777, 1652, 1654<br />

Luster, A 25, 606, 1427<br />

Lustig, S 1041<br />

Lüthke, K 1757<br />

Luthra, HS 705, 1662<br />

Luukkainen, R 891<br />

Luyten, FP 610, 1468, 1980<br />

Luzina, IG 432<br />

Lvovich, S 1341<br />

Lyden, AK 1319<br />

Lydon, EJ 996<br />

Lyman, S 2193<br />

Lynch, BM 1631<br />

Lynch, J 202, 624, 1555, 2100<br />

Lyons, A 817, 818<br />

M<br />

Ma, KM 1206, 2159<br />

Ma, MHY 412<br />

Ma, X 1182<br />

MacAllister, R 674<br />

Macarios, D 971<br />

Macchioni, P 777, 1302, 1637,<br />

1654, 2044<br />

MacDonald, D 554<br />

MacDonald, PA 154, 165<br />

Macdougald, O 601<br />

Macey, K 391<br />

Macfarlane, GJ 646, 649<br />

Machado, LG 1842<br />

Machado, P 1922<br />

Machicao, V 726<br />

Machida, T 435<br />

Machin, S 6<br />

Machnik, A 2234<br />

MacIntyre, NJ 1316<br />

Maciuca, R 1455<br />

Mack, C 1560<br />

Mack, M 1127<br />

Mackay, C 1562<br />

Mackey, RH 71<br />

Mackiewicz, K 999<br />

MacMullan, PA 1109, 1306<br />

Macrae, J 1431<br />

Macwana, S 2274<br />

Madaule, S 2027<br />

Madden, J 791<br />

Maddison, P 445, 448, 476, 664,<br />

1877, 2240<br />

Mader, R 550<br />

Madhok, R 2214<br />

Madigan, A 1109, 1306<br />

Madrakian, H 533<br />

Madrid, A 801<br />

Madsen, OR 134, 1444, 1841,<br />

1953<br />

Mæhlen, MT 1603<br />

Maekawa, T 1511<br />

Maese, J 1657<br />

Maeshima, A 358<br />

Maezawa, R 472<br />

Magalhães, CS 1407<br />

Magaña-Aquino, M 1166<br />

Magder, L 460, 474, 479, 485,<br />

1148, 1149, 1163, 1180, 1879,<br />

2122, 2124<br />

Maggi, D 510<br />

Maggi, E 246<br />

Maggi, L 246<br />

Maghnie, M 1684<br />

Magid, S 1576<br />

Magnani, A 210<br />

Magnani, L 1290, 1302, 2044<br />

Magni-Manzoni, S 207, 210, 2033,<br />

2220<br />

Magro, C 2193<br />

Maguire, C 1886<br />

Mahadevan, U 718<br />

Mahapatra, A 1106<br />

Mahmood, F 567, 585<br />

Mahmud, T 1830<br />

Mahr, A 533, 2014, 2026<br />

Maia Neto, FJ 2059<br />

Maier, S 1901<br />

Maillard, SM 1342, 1344<br />

Maillefert, J-F 140, 143, 1752<br />

Maines, LW 1480<br />

Maisonobe, T 1911, 2024, 2025,<br />

2046<br />

Majdan, M 1742<br />

Majgaard, O 134, 1444, 1841,<br />

1953<br />

Majhi, B 2086<br />

Majithia, V 1401, 1860<br />

Major, G 584<br />

Majoral, J-P 281<br />

Majumdar, S 136<br />

Mak, KF 1233<br />

Mak, TW 2186<br />

Makinson, G 2205<br />

MakIver, H 1926, 2182, 2183<br />

Makris, UE 1459<br />

Maksymowych, W 330, 535, 549,<br />

551, 557, 667, 760, 771, 1451,<br />

1934, 1949, 1957, 1959, 1963,<br />

1964<br />

Malamet, RL 1808<br />

Malani, S 1866<br />

Malattia, C 1434, 1700<br />

Malbos, S 548<br />

Malchau, H 2137<br />

Maldonado Cocco, J 50<br />

Malfait, A-M 823, 841<br />

Malik, R 966<br />

Malik, TH 430<br />

Malladi, AS 1898<br />

Malmstrom, V 1125, 1917, 2118<br />

Malone, DG 1617<br />

Maloney-Saxon, GL 999<br />

Malouf, J 975<br />

Malvar Perrin, A 1173<br />

Malysheva, O 1025<br />

Mammou, S 988<br />

Mamyrova, G 1678<br />

Man, Z 2157<br />

Manal, K 190<br />

Manara, M 532<br />

Manda, G 848<br />

Mandal, A 164<br />

Mandel, DR 166<br />

Mandelboim, M 697, 1238<br />

2010 Program Book 337<br />

abstract author Index


aBSTRACT author Index<br />

338<br />

Mandelin, AM 270, 714, 1506<br />

Mandl, LA 174, 898, 1080, 1576<br />

Mandl, P 777, 1629, 1637, 1654<br />

Mandl, T 1307, 1896, 1902<br />

Manfredi, A 581, 1627<br />

Manfredi, M 1098, 1582<br />

Mangge, H 1700<br />

Manheim, L 1558<br />

Mani, C 286<br />

Manjarraz-Orduno, N 825<br />

Mann, A 1395<br />

Mann, H 926<br />

Mannalithara, A 2206<br />

Mannerkorpi, K 103<br />

Manning, CA 716<br />

Manning, J 588, 1623<br />

Manning, W 1606<br />

Mannion, M 209<br />

Manno, RL 587, 589, 948<br />

Manohar, PR 1106<br />

Manson, JE 1062<br />

Manson, S 58<br />

Mansoori, L 1395<br />

Mansour, S 1221<br />

Mantilla, RD 1048, 1811<br />

Mantovani, E 1644<br />

Manuel, D 1555<br />

Manzi, S 448, 476, 620, 731, 754,<br />

1399, 1877, 2240, 445, 452, 457,<br />

1456, 2243<br />

Manzo, A 623<br />

Mao, J 216<br />

Maradit-Kremers, H 777, 1637,<br />

1652, 1654<br />

Marangoni, RG 605, 1644<br />

Maranhão, R 284<br />

Maranian, P 147, 155, 583, 729,<br />

1205, 1213, 1228, 1232, 1365,<br />

1572, 1779, 2195<br />

Maratha, A 1533<br />

Marceau, G 375<br />

Marcela, B 2070<br />

Marcelli, C 1893, 1931<br />

Marchesin, V 1100<br />

Marchesoni, A 297, 532<br />

Marchou, B 2027<br />

Marcos, J 50<br />

Marcus, R 777, 1654<br />

Marcuz, J 225<br />

Marder, W 1158, 1041<br />

Marenco, JL 1078<br />

Marengo, MF 941, 1047, 1865<br />

Margaretten, ME 1024<br />

Marguerite, G 922<br />

Marí-Alfonso, B 1301<br />

Marie, I 915, 2010, 2011<br />

Marie, SKN 927<br />

Mariette, X 548, 917, 1810, 1893,<br />

2010 Program Book<br />

1894, 1896, 1910, 376, 400, 1088,<br />

1413, 1579, 1790, 1890, 2010,<br />

2011, 2042<br />

Marijnissen, ACA 121, 124, 952,<br />

1380<br />

Marijnissen, RJ 275, 1730<br />

Marín, A 1741<br />

Marin, E 486, 733<br />

Marin, F 967<br />

Marin, MJ 1296<br />

Marín-Arriaga, N 1614<br />

Marini, R 1339, 1695<br />

Marino, F 1089<br />

Marion, J 1931<br />

Marion, M 654<br />

Marion, T 1410<br />

Mariz, HA 579<br />

Markello, T 914<br />

Märker-Hermann, E 665<br />

Markovitz, D 550<br />

Markward, NJ 1561<br />

Marotte, H 282, 1504<br />

Marques, R 89<br />

Márquez, J 1811<br />

Marrone, G 2008<br />

Marshak-Rothstein, A 736<br />

Marshall, D 1244<br />

Marshall, NJ 1064<br />

Marshall, T 796, 1067<br />

Marston, BA 1620<br />

Martel-Pelletier, J 196, 938, 1489,<br />

1497<br />

Martin, A 2261, 2269<br />

Martin, B 309, 1942<br />

Martin, C 250, 383<br />

Martin, F 1609<br />

Martin, J 824, 829, 1301, 1578,<br />

1585, 1586, 1594, 1599, 2147,<br />

2214<br />

Martin, JE 1599, 2214<br />

Martin, KR 690, 691, 1460, 1461,<br />

1462, 2140, 2141<br />

Martin, L 119, 330<br />

Martin, P 264, 266, 1394<br />

Martin, R 2119<br />

Martin, SA 94<br />

Martin, TM 1447<br />

Martin, TJ 30<br />

Martineau, G 82<br />

Martinez, A 96, 808<br />

Martínez, JB 1811<br />

Martinez, L 608, 852<br />

Martinez, M 1994<br />

Martinez, R 1256<br />

Martinez Avila, E 435<br />

Martinez Dubois, C 1650<br />

Martinez Lopez, JA 516, 1657<br />

Martínez-Caceres, E 1741<br />

Martinez-Lavin, M 96, 808, 1614<br />

Martinez-Lopez, JA 407<br />

Martínez-Martínez, MU 1166<br />

Martinez-Morillo, M 1741<br />

Martínez-Taboada, V 777, 1276,<br />

1296, 1650, 1652, 1654<br />

Martinez-Vidal, MP 482<br />

Martini, A 207, 208, 210, 232,<br />

265, 657, 905, 1407, 1434, 1684,<br />

1685, 1700, 1701, 1705, 1706<br />

Martini, G 1439, 1682, 1687, 2033<br />

Martin-Mola, E 414, 349, 1967<br />

Martino, S 1439, 1700<br />

Martins da Silva, B 1578<br />

Martinuzzo, M 3<br />

Martucci, C 1341<br />

Maruyama, J 703, 932<br />

Mary, F-TK 2167<br />

Mary, T 598<br />

Marzaioli, V 1482<br />

Marzan, K 241<br />

Marzan, KAB 2102<br />

Marzo-Ortega, H 524, 553, 1929,<br />

1963<br />

Mascaró, C 1137<br />

Mascia, MT 2036, 2201<br />

Masciocchi, M 580<br />

Mashida, A 511, 893<br />

Masi, AT 49, 83<br />

Masi, CM 1875<br />

Masi, L 222, 1155, 2202<br />

Masih, S 169<br />

Masolini, P 2201<br />

Mason, JL 2233<br />

Mason, R 1728<br />

Mason, TG 1673, 1691, 2017<br />

Massardo, L 2070<br />

Massarotti, E 1805<br />

Massarotti, EM 339<br />

Mastbergen, SC 176, 942, 1380<br />

Masteller, E 288<br />

Masuda, H 1708<br />

Masuda, I 897, 916, 923<br />

Mat, C 1288, 1312<br />

Mata, C 1296<br />

Mateo, I 1171<br />

Mateo, L 1741<br />

Mateos, J 840, 1473<br />

Mathew, AJ 1549<br />

Mathew, SD 1669<br />

Mathian, A 478, 2187<br />

Mathieu, A 728<br />

Mathieu, S 375, 542<br />

Mathsson, L 1020<br />

Matnani, RG 864<br />

Matos, M 1986<br />

Matos Costa, J 1011<br />

Matsubara, T 1138, 1738, 1739<br />

Matsui, K 1641<br />

Matsui, T 568<br />

Matsumoto, I 292, 352, 1724,<br />

2176<br />

Matsumoto, T 1265, 2016<br />

Matsuno, H 1138, 1738, 1739<br />

Matsuo, K 365<br />

Matsuo, N 2176<br />

Matteson, EL 53, 67, 78, 129, 316,<br />

326, 385, 403, 774, 777, 890, 908,<br />

1212, 1550, 1570, 1580, 1581,<br />

1637, 1652, 1654, 1818, 2216<br />

Matthys, P 1720<br />

Mattias, K 2251, 2252<br />

Mattinzoli, D 2278<br />

Mattocks, K 2249<br />

Mattson, MP 672<br />

Matucci Cerinic, M 222, 558, 560,<br />

565, 566, 580, 583, 593, 599, 1155,<br />

1987, 1962, 2033, 2196, 2202,<br />

2226<br />

Matzelle, MM 716<br />

Matzkies, F 537<br />

Matzko, CK 999<br />

Maurer, B 1988<br />

Mavers, M 861<br />

Mavragani, CP 1181<br />

Maxwell, JL 1385<br />

May, J 1766<br />

May, SL 502, 1602<br />

May Chee, M 2214<br />

Mayes, M 562, 591, 603, 612,<br />

725, 726, 824, 829, 1211, 1216,<br />

1218, 1219, 1226, 1227, 1205,<br />

2214<br />

Maynard, JW 1364, 1544, 1556,<br />

1565, 1569<br />

Mayr, G 1351<br />

Mazieres, B 917, 2094<br />

Mazlumzadeh, M 777, 1637,<br />

1652, 1654<br />

Mazodier, K 1664<br />

Mazor, KM 156<br />

Mazur-Zielinska, H 1705<br />

Mazzaro, C 2036, 2201<br />

Mazzuca, S 93, 1627<br />

Mazzuca, SA 797, 948<br />

McAdams, E 195, 2101<br />

McAdams, MA 1364, 1544, 1556,<br />

1569<br />

McAlear, C 2198<br />

McAlindon, T 95, 122, 188, 195,<br />

706, 709, 2101<br />

McBeth, J 646, 836, 1323<br />

McBurney, CA 620<br />

McCahan, J 736<br />

McCann, B 950<br />

McCarthy, C 1306, 1638<br />

McCarthy, EM 1306


McCarthy, GM 1109, 1306, 1426<br />

McCausland, J 2112<br />

McCloskey, J 912<br />

McClung, MR 982<br />

McClure, A 1593<br />

McCollum, L 84<br />

McCormack, W 16<br />

McCormick, J 871, 1391<br />

McCracken, A 1863<br />

McCraken, A 1284<br />

McCroskery, P 398<br />

McCune, J 457, 1457<br />

McCune, WJ 1158<br />

McCurdy, D 262, 509, 998, 1673,<br />

1677, 1691, 2017<br />

McDaniel, G 180<br />

McDonald, JR 62, 1395<br />

McDonald, S 843<br />

McDonnell, E 637<br />

McEarchern, JA 1273<br />

McEvoy, A 1482<br />

McGann, M 1106<br />

McGinnis, MW 19<br />

McGonagle, D 524, 553, 1929,<br />

1963<br />

McGoon, M 595, 1223<br />

McGovern, D 537<br />

McGrath, P 1408<br />

McGregor, NM 30<br />

McGuirk, P 16<br />

McHale, T 1399<br />

McHugh, K 1973<br />

McHugh, N 664, 833<br />

McInnes, IB 28, 1389, 1422, 1441,<br />

1943<br />

McKay, J 457, 1457<br />

McKee, G 1032<br />

McKeever, E 2172<br />

McKenna, MJ 1947<br />

McKenna, S 221<br />

McKeon, B 167<br />

McKeown, E 978<br />

McLaughlin, V 598, 1004<br />

McLean, RR 1317, 1327<br />

McMahon, BJ 892<br />

McMahon, M 471, 594, 1058,<br />

1189, 2241<br />

McMorrow, JP 1482, 1508, 1522<br />

McMurray, RW 1040<br />

McNallan, KT 15, 934, 1379<br />

McNally, B 245<br />

McNamara, S 989, 2111<br />

McNamee, P 646<br />

McNearney, T 562, 1211, 1218,<br />

1219, 1226, 1227, 1536<br />

McNeill, L 1424<br />

McNiff, K 993<br />

McNulty, J 1625<br />

McQueen, FM 141, 881, 1369,<br />

1372, 1779, 1983<br />

McRae, L 1562<br />

McSweeney, P 726<br />

McVie, T 299, 1740, 1779<br />

Mease, P 94, 99, 100, 113, 1096,<br />

1919, 1930, 1935, 1943, 1955,<br />

2168, 2169<br />

Medeiros, A 539<br />

Medema, JP 1732, 2178<br />

Mediero, A 1470, 1471<br />

Medina, G 1150<br />

Medina, J 1276<br />

Medinger, C 940<br />

Medsger, T 1231<br />

Medsger, TA 563, 2006<br />

Meehan, S 1190<br />

Meek, IL 1019<br />

Meesters, JJL 2284<br />

Meeuwisse, C 1829, 2265<br />

Meguro, A 2217<br />

Mehta, DP 392<br />

Mehta, M 2193<br />

Mei, Y 618<br />

Meier, S 792<br />

Meigs, JB 1317<br />

Meijer, J 1889, 1892, 1905<br />

Meiners, PM 1905<br />

Meini, A 1685, 1706<br />

Mejía, R 1811<br />

Mekinian, A 1893, 1894<br />

Mela, C 1819, 2262<br />

Melander, O 774<br />

Melchers, I 1987, 2226<br />

Melchiorre, D 532<br />

Melendez, AJ 28<br />

Melichian, DS 601<br />

Meliconi, R 1290<br />

Mellins, ED 255<br />

Mellis, SJ 710, 1121<br />

Mello, SBV 284<br />

Mello, WA 1694<br />

Mellstrom, D 2157<br />

Melo-Gomes (Andre Dos Santos),<br />

JA 1407<br />

Melson, PG 218<br />

Melton, LJ 959<br />

Menashe, L 199<br />

Menckeberg, C 1711<br />

Mendelsohn, A 1835<br />

Mendelson, CF 1349<br />

Mendelson, E 697, 1238<br />

Meng Choong, L 463<br />

Mensah, K 1492<br />

Mentre, F 1653<br />

Menz, H 173<br />

Mera, A 1076<br />

Mercer, L 421<br />

Mercieca, C 172<br />

Meriem, R 902<br />

Merikapudi, G 279<br />

Merinar, C 1540, 1552<br />

Merkel, PA 1291, 2012, 2014,<br />

2198<br />

Merle-Beral, H 1646<br />

Merli, P 2220<br />

Merlos, M 1137<br />

Meroni, P 590, 1356<br />

Merrill, J 445, 448, 452, 476,<br />

1186, 1190, 1454, 1456, 1457,<br />

1585, 1586, 1591, 1594, 1843,<br />

1877, 2147, 2240, 2241, 2243<br />

Merriman, T 33<br />

Mersten, J 1990, 2193<br />

Mertens, F 1720<br />

Meschia, JF 2037, 2038<br />

Messerschmidt, J 1634<br />

Messier, SP 203<br />

Messing, S 52, 515, 1799<br />

Messous, D 1762<br />

Mestre-Stanislas, C 1204<br />

Metcalf, B 192<br />

Meuth, SG 1255<br />

Mevorach, D 491<br />

Meyer, A 475, 510<br />

Meyer, C 2149<br />

Meyer, M 529, 1924<br />

Meyer, O 1752, 2042, 2269<br />

Miao, S 1100, 2032, 2048<br />

Miceli, C 1087<br />

Miceli-Richard, C 548, 1579<br />

Michael, JG 1403<br />

Michael, M 1333<br />

Michael, S 777<br />

Michaud, K 89, 325<br />

Michaud, KD 168, 318, 331, 346,<br />

651, 1043, 1132<br />

Michel, BA 21, 35, 357, 1518,<br />

1528, 1988<br />

Michelutti, A 355<br />

Michet, CJ 129, 777, 1652, 1654<br />

Mico, ML 1888<br />

Middleton, WD 1633<br />

Midtvet, O 1220<br />

Mielke, F 782<br />

Mielke, L 1426<br />

Miescher, S 494<br />

Mieszkalski, KL 1677<br />

Miettunen, PM 209<br />

Miggin, S 1533<br />

Migliaresi, S 2201<br />

Migone, TS 457, 1146<br />

Miguel, L 1187<br />

Mikami, M 280<br />

Mikkelsen, D 134, 1953<br />

Mikkelsen, K 377<br />

Miklossy, G 1185, 1196<br />

Mikolaitis, R 496, 765, 1147,<br />

1164, 1175, 1612, 1880, 2099<br />

Mikuls, TR 77, 168, 304, 318, 397,<br />

658, 970, 1094, 1099, 1367, 1395,<br />

1792, 2235<br />

Miles, J 1358<br />

Miller, C 1382<br />

Miller, DP 1223<br />

Miller, E 122, 188, 483, 1574<br />

Miller, FW 1678<br />

Miller, K 992<br />

Miller, LC 231<br />

Miller, ML 221<br />

Miller, P 980, 982<br />

Mills, KHG 1426<br />

Mills, P 192<br />

Milne, G 2123<br />

Milne, V 776, 1553<br />

Mimori, A 1042, 1619<br />

Mimori, T 932, 1377<br />

Mimura, T 1017<br />

Mina, R 218, 1688, 1701, 1702,<br />

2106<br />

Mina-Osario, P 1191<br />

Minden, K 227, 1704<br />

Minetti, C 1700<br />

Mínguez, S 1741<br />

Miniati, I 593<br />

Minihan, C 817, 818<br />

Minnock, P 1032, 2065<br />

Miossec, P 354, 1247, 1515<br />

Miossi, R 626<br />

Miranda-Carus, ME 349, 1967<br />

Miranda-Filloy, JA 1301<br />

Mirjafari, H 1067<br />

Misaki, K 1715<br />

Misharin, A 859, 861, 1723<br />

Mishra, N 438, 750, 2191<br />

Mishra, P 75<br />

Misra, D 720, 872<br />

Mitchel, E 54<br />

Mitchell, GH 463<br />

Mitera, T 1720<br />

Mithal, A 2206<br />

Mitomi, H 365<br />

Mitsuda, T 237<br />

Mitsugi, N 335<br />

Mitterwald-Modra, M 926<br />

Mittoo, S 1176, 1850<br />

Miura, T 1138, 1738, 1739<br />

Miwa, Y 1773<br />

Miyagi, M 363<br />

Miyake, K 1184<br />

Miyake, S 896, 2232<br />

Miyaki, S 369<br />

2010 Program Book 339<br />

abstract author Index


aBSTRACT author Index<br />

340<br />

Miyamae, T 237<br />

Miyamoto, Y 1715<br />

Miyara, M 478<br />

Miyasaka, N 1375, 1814, 1815<br />

Miyazaki, T 1512, 2016<br />

Miyazaki, Y 867, 1272, 2232<br />

Miyoshi, H 298<br />

Mizuhara, M 348<br />

Mizuki, N 2217<br />

Mizuno, M 896<br />

Mjaavatten, MD 1774, 1780<br />

Mjriafari, H 766<br />

Mo, Y-q 367<br />

Mobley, BS 2062<br />

Mochida, Y 335<br />

Modena, MG 581<br />

Modesti, M 1416<br />

Modesti, V 540<br />

Modesto, C 1872<br />

Modiano, P 2011<br />

Modica, RF 1673, 1691, 2017<br />

Mody, M 1407, 1794<br />

Mogavero, G 728<br />

Mogi, S 1115<br />

Mogil, JS 823<br />

Mohammad, A 817, 818, 1307,<br />

2018, 2022, 2112<br />

Mohan, N 185<br />

Mohand Oumoussa, B 1981<br />

Mohler III, ER 456<br />

Mohs, R 113<br />

Mohyde, M 99<br />

Moisini, I 1410<br />

Moisio, K 189, 202<br />

Moizant, F 753<br />

Mok, CC 458, 467, 477, 773, 1206,<br />

1667, 1748, 1777, 1870, 2159<br />

Mok, MY 1139, 1233<br />

Mold, C 850<br />

Moldawer, L 742<br />

Mold<strong>of</strong>sky, H 820<br />

Molfetta, L 1798<br />

Molina, J 1343<br />

Molina, MRR 1684<br />

Moll, C 538<br />

Mollahasanoglu, A 1208<br />

Moller Dohn, U 141<br />

Møller, HJ 1761<br />

Möller, I 2223<br />

Møller, J 133, 134, 1953<br />

Möller, S 1846<br />

Møller Døhn, U 1369, 1370<br />

Mollinedo, F 1509<br />

Molloy, ES 700, 1306<br />

Molloy, M 22, 1726<br />

Molta, CT 514, 1937<br />

Molth<strong>of</strong>f, CFM 1613<br />

2010 Program Book<br />

Moltó, A 1741<br />

Momohara, S 968, 1053, 1611,<br />

1749<br />

Monach, PA 2012, 2198<br />

Monclus, L 409<br />

Mong, J 1939<br />

Mongey, AB 2135<br />

Moniz Reed, D 1120, 1794<br />

Monshie-Vahabzadeh, H 546<br />

Montagna, P 1798<br />

Montagne, J 440<br />

Montanari, E 1992<br />

Montanelli, G 1235<br />

Montecucco, C 623, 766, 1013,<br />

1098, 1397, 1582, 2220<br />

Monteiro, CMC 628<br />

Montepane, M 532<br />

Montes, A 1076<br />

Montgomery, CG 1579, 1585,<br />

1586, 2147<br />

Monti, G 2036, 2201<br />

Montiel-Cervantes, LA 1150<br />

Montilla, C 538<br />

Monu, J 1051<br />

Moon, CG 1813<br />

Moon, H 876<br />

Moon, S-J 353, 756, 1716<br />

Moore, A 817, 818<br />

Moore, AB 898<br />

Moore, D 1756<br />

Moore, J 456<br />

Moore, N 286<br />

Moore, TL 263, 588, 846, 1262,<br />

1601, 1623<br />

Moorehead, S 521, 1968<br />

Moorthy, LN 1673, 1691, 1702,<br />

1872, 2017<br />

Moosavi, S 384<br />

Moosig, F 2203<br />

Moots, RJ 661, 1560, 1763<br />

Morado, IC 1301<br />

Moraes, J 224, 539, 2078, 2204<br />

Morales, A 975<br />

Moran, R 305<br />

Moran, RC 699, 1768<br />

Morand, EF 492<br />

Morassi, F 355<br />

Moreira, ES 498<br />

Moreira Navarrete, V 1944<br />

Morel, J 393, 1527, 1732, 1752,<br />

1890, 1910, 1914, 2218<br />

Morel, LM 426<br />

Morel, N 478<br />

Moreland, LW 71, 299, 390, 1062,<br />

1077, 1368, 1740, 1779<br />

Morell-Dubois, S 1204, 1217<br />

Morency, N 1451, 1934, 1957,<br />

1964<br />

Moreno-Valdés, R 1166<br />

Moret, FM 636, 1903<br />

Moreton, A 1560<br />

Morgan, AW 833<br />

Morgan, C 1323<br />

Morgan, G 242, 826, 1686<br />

Morgan, MD 676<br />

Morgan, R 1520<br />

Morgan, SL 1006<br />

Morgan DeWitt, EM 1012<br />

Mori, M 237<br />

Morimoto, S 1731<br />

Morin, F 938<br />

Morin, K 2251, 2252<br />

Morin, M-P 236<br />

Morinobu, A 1715<br />

Morishita, K 1691, 2017<br />

Morishita, T 1743<br />

Mork, C 1220<br />

Moroncini, G 2001, 2008<br />

Morris, C 850<br />

Morris, E 1251<br />

Morris, J 734<br />

Morris, MF 599<br />

Morris, MJ 1669<br />

Morris, SJ 345, 1442<br />

Morrison, S 1156, 2120<br />

Morrissey, S 2224<br />

Morva, A 737<br />

Morvan, J 2094, 2261<br />

Mosca, M 1011<br />

Moscatelli, S 1627<br />

Moseley, A 421<br />

Moser, DW 1012<br />

Moser, KL 500, 502, 1579, 1583,<br />

1584, 1585, 1586, 1591, 1594,<br />

1595, 2144, 2145, 2147, 2148,<br />

2274<br />

Mostoufi-Moab, S 206<br />

Mota, F 780<br />

Motamedi, K 1779<br />

Motojima, S 1824<br />

Möttönen, T 80<br />

Mount, DB 164<br />

Mountz, JD 1135, 1250, 1260,<br />

1412, 2189<br />

Moura, R 739, 743<br />

Mourão, AF 1986<br />

Mouterde, G 408<br />

Mouthon, L 575, 576, 580, 834,<br />

1204, 1217, 1704, 2009, 2034,<br />

2041, 2043, 2045<br />

Moutsopoulos, HM 621, 1897,<br />

1912<br />

Moyen, M 1176<br />

Moyer, AR 24<br />

Mozaffarian, N 1101, 1102<br />

Mozzicafreddo, M 2001<br />

Mrozek, N 375<br />

Mu, R 1134<br />

Mueller, DL 1256<br />

Mueller, M 2012<br />

Muhammad, K 745, 1411<br />

Muiños, E 1475<br />

Muiños-López, E 1483<br />

Mukherjee, D 2086<br />

Mukherjee, R 1096<br />

Mulero, J 525, 986, 2268<br />

Mulherin, DM 664<br />

Mullan, RM 871<br />

Mullazehi, M 2115<br />

Mulleman, D 130, 988, 1945<br />

Müller, GA 2021<br />

Muller-Esterl, W 2275<br />

Müller-Ladner, U 138, 406, 1420,<br />

1479, 1719, 1722<br />

Mumcu, G 1303<br />

Mumtaz, A 514<br />

Mumtaz, IM 1295, 1414<br />

Munekata, RV 1676<br />

Munger, K 762<br />

Muñiz, JR 389<br />

Munoz, L 490<br />

Munoz, S 1046, 1173, 1443, 2164,<br />

2165, 2166<br />

Muñoz Gomariz, E 525<br />

Muñoz-Fernández, S 986<br />

Munro, J 226, 248, 2219<br />

Munteanu, M 1762<br />

Murakami, A 1377<br />

Murali, M 1015<br />

Muranaka, K 1641<br />

Murao, H 280, 1467<br />

Muraro, P 1161<br />

Muratore, V 2220<br />

Murphey, M 869<br />

Murphy, E 989, 1482, 1508, 1522<br />

Murphy, G 22, 1333, 1726<br />

Murphy, L 689, 2062, 2080<br />

Murphy, SL 1319<br />

Murphy, V 145, 1423<br />

Murray, AK 588<br />

Murray, E 401<br />

Murthy, VL 2253<br />

Mus, A-M 38, 287, 715, 1259,<br />

1274, 1525<br />

Muscal, E 1673, 1691, 1702, 2017<br />

MUSICIAN Study Team 646<br />

Musset, L 906, 915, 1249, 1646,<br />

1911, 2024, 2025, 2030, 2046,<br />

2131, 2239<br />

Musyj, L 1674<br />

Muthuppalaniappan, M 279<br />

Mutti, A 784<br />

Myles, JD 1041<br />

Myones, BL 1160, 1690


Myouzen, K 1577<br />

Mysiw, WJ 2096<br />

Mysler, EF 1455, 2087, 2173<br />

N<br />

Na, K-S 359<br />

Nabatian, AS 1198<br />

Naccache, J-M 997<br />

Nacci, F 593<br />

Nacci, G 2001<br />

Nadig, A 822<br />

Nadji, A 1289<br />

Nadkarni, A 1767<br />

Nadler, D 1121<br />

Nagafuchi, H 1293<br />

Nagai, T 568<br />

Nagaoka, S 480, 1812<br />

Nagasawa, H 1793, 1823<br />

Nagasawa, K 433<br />

Nagpal, S 647<br />

Nah, S-S 803<br />

Nahar, E 1152<br />

Nahas, SA 509<br />

Nahass, R 1320<br />

Nahema, I 2267<br />

Naides, SJ 694<br />

Naik, H 149<br />

Naim, AB 51<br />

Nair, A 167<br />

Nair, DK 1211, 1219, 1227<br />

Nair, V 2276<br />

Naismith, D 1060<br />

Nakagawa, H 2, 1909<br />

Nakagawa, Y 2, 1511<br />

Nakajima, A 1053<br />

Nakamaru, Y 2029<br />

Nakamura, H 364, 981, 1371,<br />

1632<br />

Nakamura, T 1739<br />

Nakamura, Y 329, 1577, 2176<br />

Nakandakare, ER 887<br />

Nakase, T 298<br />

Nakashima, H 1115<br />

Nakashima, R 932, 1377<br />

Nakashita, T 1824<br />

Nalesso, G 1476, 1503<br />

Nallasivam, S 1504<br />

Nallasivan, M 974, 1665<br />

Nam, J 1090, 1254<br />

Nanda, K 1673<br />

Nandiwada, S 1256<br />

Nandula, SR 1883<br />

Nannini, C 528, 777, 1652, 1654,<br />

1952<br />

Naot, D 881<br />

Napalkov, P 698<br />

Napolioni, V 1582<br />

Narayanan, SA 1014<br />

Naredo, E 2223<br />

Nariai, A 237<br />

Narita, H 280, 1467<br />

Narongroeknawin, P 1573<br />

Narula, SK 288<br />

Narvaez, J 1016, 1078, 1118,<br />

1276, 1277, 1299, 1301, 1310,<br />

1796<br />

Naseem, S 4<br />

Nash, P 584, 599, 2173<br />

Nash, R 726<br />

Nasonov, E 55, 1802, 1807, 2087,<br />

2173<br />

Nassi, LA 1673, 1691, 2017<br />

Nataf, H 82<br />

Nath, SK 1590, 1594, 2274<br />

Natour, J 2132<br />

Natvig, B 170<br />

Naumann, L 1621<br />

Navarra, S 451, 452, 1172, 1197,<br />

1456, 1851<br />

Navarro, F 1078<br />

Navarro, TP 1169<br />

Navarro Compán, V 1944<br />

Navarro Sarabia, F 1944<br />

Navarro-Compán, V 1337<br />

Navarro-Millan, I 1117<br />

Navarro-Sarabia, F 1337<br />

Navarta, DA 324<br />

Naviglio, S 1436<br />

Navis, D 302<br />

Navratil, JS 620<br />

Nawata, M 1793, 1823<br />

Nayak, S 168<br />

Naylor, D 441<br />

Neagoe, IV 848<br />

Nearney, T 824<br />

Neeck, G 886<br />

Neel, A 1651<br />

Neff, L 1502<br />

Negrei, C 848<br />

Neidhart, M 21, 357, 679<br />

Nelissen, RLH 2265<br />

Nelson, AE 181<br />

Nelson, DR 52<br />

Nelson, JL 1060<br />

Nelson, RK 423<br />

Nelson, SL 268, 1688, 1701<br />

Nelson, V 2250, 2251, 2252<br />

Nemery, B 1720<br />

Neogi, T 205, 693, 836, 872, 951,<br />

1362, 1366, 1385, 1557, 1564,<br />

2058, 2098, 2133<br />

Neovius, M 1541, 1548<br />

Nepomuceno, R 269<br />

Neregård, P 394<br />

Nesbitt, A 1517<br />

Nespi, M 273<br />

Netea, MG 371<br />

Neumann, E 1420, 1719, 1722<br />

Neven, B 905<br />

Neves Junior, MT 1384<br />

Neville, C 1156<br />

Nevitt, M 131, 182, 201, 202, 205,<br />

624, 693, 872, 951, 971, 1464,<br />

1557, 2058, 2096, 2098, 2100,<br />

2133<br />

Newhook, T 1939<br />

Newkirk, M 1068<br />

Newman, ED 999<br />

Newton, R 2172<br />

Ng, B 87<br />

Ng, CT 360, 871, 1105, 1510, 1625<br />

Ng, F 1579<br />

Ng, WL 477<br />

Ngamjanyaporn, P 1950<br />

Ngian, G-S 584<br />

Ngo, Y 1762<br />

Nguyen, BY 725<br />

Nguyen, C 875, 1204, 1217, 2151<br />

Nguyen, D 2210<br />

Nguyen, H 2205, 2251, 2252<br />

Nguyen, JX 609<br />

Nguyen, U-SDT 684, 685<br />

Nguyen, V 432<br />

Nguyen-Khoa, B-A 698<br />

Nic An Ultaigh, S 16, 1533<br />

Nicassio, P 1211, 1768<br />

Niccoli, L 528, 1952<br />

Nicholson, G 183<br />

Nickerson-Nutter, C 275<br />

Nicklas, B 203<br />

Nicolaou, S 2152<br />

Nicolini, A 1302<br />

Nicolls, MR 1223<br />

NicUltaigh, S 1391<br />

Niederer, F 1528<br />

Niedermeier, M 2237<br />

Niederreiter, B 272, 1351<br />

Nielen, MMJ 1029, 2211<br />

Nielsen, S 1305<br />

Niemann, G 1125<br />

Nietert, PJ 604<br />

Niewerth, M 227<br />

Niewold, TB 262, 495, 496, 1147,<br />

1164, 1583, 1584, 1585, 1586,<br />

1591, 1612, 2147, 2274<br />

Nigon, D 2218<br />

Nigrovic, P 209, 363<br />

Nihei, K 10<br />

Nihtyanova, S 566, 1207<br />

Nikolov, NP 1161<br />

Nimmerjahn, F 2234<br />

Ninaber, MK 582<br />

Ninet, J 2045, 2239<br />

Nishimoto, N 1800<br />

Nishimura, K 1844<br />

Nishio, MJ 1617<br />

Nishio, S 1797<br />

Nistala, K 1344<br />

Nithiketkul, S 1950<br />

Nitichaikulvatana, P 162<br />

Nititham, J 502<br />

Nitobe, T 329<br />

Nitschke, Y 1486<br />

Niu, H 426<br />

Niu, J 131, 197, 198, 201, 205,<br />

685, 693, 1373, 1385, 1564, 1617,<br />

2058, 2098, 2133, 2143<br />

Nived, O 445, 448, 476, 731,<br />

1877, 2022, 2240, 2243<br />

Noamani, B 2190<br />

Noble, JA 502, 1602<br />

Nochlin, J 188<br />

Noda, K 921<br />

Nojima, T 1377<br />

Nojima, Y 358<br />

Nolla, JM 1016, 1118, 1277, 1299,<br />

1310<br />

Nomoto, S 365<br />

Noordenbos, T 1449<br />

Noort, A-R 1416<br />

Nordal, EB 1700<br />

Nordborg, E 777, 1637, 1654<br />

Nordenskiold, U 2063<br />

Nordin, A 1224<br />

Nordmark, B 645<br />

Nordmark, G 1579, 1885, 1899<br />

Nordström, D 55, 891, 1802, 1807<br />

Norman, G 2250, 2251, 2252<br />

Norman, J 613<br />

Norris, J 77, 658, 1083, 1094,<br />

2116<br />

North, S 1747<br />

Norton, H 947, 1055, 1626, 2225<br />

Nose, M 511, 2016<br />

Noss, EH 1388<br />

Novick, D 1664<br />

Nóvoa, FJ 1876<br />

Novotny, PJ 595<br />

Nowatzky, J 1298<br />

Nowling, TK 1251<br />

Nozaki, T 1708<br />

Nti, AA 2137<br />

Nuite, M 195, 706, 2101<br />

Nukumizu, LA 513<br />

Numéric, P 571<br />

Nunez, G 1713<br />

Nunn, PA 1270<br />

Nur, MAM 695<br />

Nurmohamed, MT 90, 332, 643,<br />

961, 1029, 1033, 1084, 1445, 1825,<br />

1840, 1933, 2211<br />

2010 Program Book 341<br />

abstract author Index


aBSTRACT author Index<br />

342<br />

Nuzzo, A 581<br />

Nyengaard, JR 1485<br />

Nygaard, H 1774<br />

Nys, M 1407<br />

Nytrova, P 1174<br />

Nzeusseu Toukap, A 2263<br />

O<br />

Oates, J 437, 622, 1403, 2123,<br />

2125<br />

Oatis, CA 684, 2053, 2054, 2136<br />

Oba, T 1814, 1815<br />

Obayashi, H 1511<br />

O’Brien, A 989, 2112<br />

O’Brien, W 148, 883<br />

O’Colmain, BJ 2062<br />

O’Connor, CR 885<br />

O’Connor, P 1929<br />

Odai, T 1773<br />

Odani, T 2, 1909<br />

Odden, AJ 402<br />

Oddis, CV 913, 925, 929, 930,<br />

1212, 1379<br />

Odeh, M 550<br />

O’Dell, JR 77, 299, 658, 1094,<br />

1368, 2235<br />

Oderkirk, J 1555<br />

Odom, J 1161<br />

O’Donnell, CI 1083<br />

O’Donnell, JL 417<br />

O’Donnell, S 1562<br />

Oelke, KR 383<br />

Oen, KG 214<br />

Oerum, H 1529<br />

Oeser, A 1023, 1034, 1607, 1867,<br />

2123<br />

Oess, S 2275<br />

Offutt, C 1122<br />

Ogale, S 68, 338, 1882<br />

Ogden, L 1311<br />

Ogdie, A 1554<br />

O’Grady, M 817, 818<br />

Oh, C 707, 708<br />

Oh, J 366, 372, 876, 1297, 2158<br />

Oh, TH 104, 108<br />

Oh, U 1161<br />

Ohinmaa, A 330<br />

Ohlsson, B 1902<br />

Ohmura, K 1377<br />

Ohno, S 139, 480, 1081, 2217<br />

Ohrndorf, S 1621, 1634<br />

Ohta, A 433<br />

Ohta, H 1839<br />

Ohta, K 652<br />

Ohta, S 1115<br />

Ohtsuka, K 26<br />

Oishi, H 351<br />

2010 Program Book<br />

Okada, A 364, 1371, 1632<br />

Okada, J 568<br />

Okada, M 1783<br />

Okada, Y 1577<br />

Okamoto, Y 447, 746, 897, 916,<br />

923, 1184, 1587, 1844<br />

Okano, T 981<br />

Okawa, J 920<br />

Okiyama, N 1375<br />

Oku, K 10, 2254<br />

Okuda, K 1138, 1738, 1739<br />

Okura, Y 1672<br />

Olds, M 1930, 1935<br />

O’Leary, D 1148, 2163<br />

Olech, E 101, 120, 125, 414<br />

Olenginski, TP 999<br />

Olferiev, M 508, 1183<br />

Olivé, A 1741<br />

Oliveira, A 1507, 1519<br />

Oliveira, SK 210<br />

Oliveira Sato, J 1872<br />

Olivier, B 922<br />

Olivieri, I 532<br />

Olsen, NJ 1188, 1491<br />

Olson, AK 828<br />

Olsson, L 825<br />

Olsson, T 832<br />

Ombrello, A 1698, 2105<br />

Ombrello, MJ 1281, 2217<br />

Omdal, R 1579, 1885, 1913<br />

O’Meara, M 1095<br />

Ometto, F 290<br />

Onat, AM 1921<br />

Onat, D 1183<br />

One Thousand Faces <strong>of</strong> Lupus<br />

1864<br />

O’Neil, KM 1673, 1690, 1691,<br />

1701, 2017<br />

O’Neill, L 16, 2111<br />

Onel, K 464, 1701<br />

Onen, F 544, 666, 1282, 1283,<br />

1921<br />

Ong, V 590, 1996<br />

Ono, Y 1285<br />

Oomae, T 298<br />

Oortwijn, A 2270<br />

Opava, CH 2245<br />

Oph<strong>of</strong>f, RA 2214<br />

Opitz, CF 599<br />

Oppermann, BP 977<br />

Optimising Patient Outcomes in<br />

Australian RheumatoLogy [OPAL]<br />

Consortium 319<br />

Orange, D 863<br />

Oranje, AP 219<br />

Orcel, P 413<br />

Oreiro, N 835<br />

Oreiro-Villar, N 541, 1920<br />

Oribe, M 1138<br />

Orie, NN 2005<br />

Origuchi, T 1371, 1632<br />

Orlov-Morozov, A 1125<br />

Ormseth, MJ 1034<br />

Ørnbjerg, LM 1444, 1841<br />

Oro, S 2238<br />

Orozco, G 1075<br />

Orozco, J 1407<br />

Ortego-Centeno, N 824, 829,<br />

1301, 2214<br />

Ortel, T 6<br />

Ortiz, AM 516, 1505<br />

Ortiz, MA 1801<br />

Ortmann, W 1608<br />

Orzechowski, NM 595<br />

Osban, J 247, 655<br />

Osborne, R 204, 1001, 1009,<br />

2079, 2139<br />

Osgood, KG 1395<br />

O’Shea, FD 512<br />

Oshikawa, H 1641<br />

Osman, M 816<br />

Ospelt, C 21, 1093, 1528<br />

Ossanna, MJ 175<br />

Östberg, T 832<br />

Østergaard, M 132, 133, 134, 141,<br />

1097, 1114, 1369, 1370, 1444,<br />

1809, 1841, 1953, 2264<br />

Ostendorf, B 138, 1615<br />

Osterroth, F 1125<br />

Osting, V 44<br />

Ostor, A 395, 1840<br />

Ostrov, BE 1002<br />

O’Sullivan, B 1116<br />

O’Sullivan, J 360, 1510<br />

Ota, T 1086<br />

Ota, Y 447, 746, 897, 916, 923,<br />

1184, 1587, 1666<br />

Otomo, K 2, 5, 10, 1909, 2254<br />

Otsuka, K 1773<br />

Otsuki, S 369<br />

Otten, MH 219, 1872<br />

Ottery, F 157, 166<br />

Ou, J-N 506<br />

Oudiz, R 598<br />

Ouellet-Hellstrom, R 54<br />

Outman, RC 1005, 1006, 1543,<br />

1561<br />

Ouyang, W 715<br />

Owada, T 472<br />

Owen, S-A 1394<br />

Owen, T 436<br />

Owens, EK 17<br />

Oyoo, OG 1336<br />

Ozaki, S 365<br />

Ozdemir, B 114<br />

Ozdemir, FT 2200<br />

Ozdogan, H 1279, 1684, 1697<br />

Ozen, S 905, 1305, 1705<br />

Ozguler, Y 1697<br />

Ozturk, MA 1921<br />

Ozyazgan, Y 1288, 1312, 1697<br />

P<br />

Pablos, JL 20, 482, 1078<br />

Paccou, J 904<br />

Pachman, LM 242, 826, 928, 1686<br />

Packham, J 264, 266, 664, 833<br />

Padovan, M 1162<br />

Padykov, L 2214<br />

Padyukov, L 832, 2118<br />

Paessler, M 1354<br />

Page, GG 949<br />

Paget, SA 43<br />

Pagnier, A 1693<br />

Pagnini, I 240, 1675<br />

Pagnoux, C 2009, 2014, 2026,<br />

2034, 2041, 2043, 2045<br />

Paikos, S 1897<br />

Paintaud, G 988, 1945<br />

Paira, S 50<br />

Pajewski, NM 1591<br />

Pajot, C 1305<br />

Pak, CH 178<br />

Pal, HK 1925<br />

Palacios, S 971<br />

Palanichamy, A 1085<br />

Palau, J 2223<br />

Palazzo, JP 1907<br />

Palframan, R 1245<br />

Pallares, L 1888<br />

Palm, O 1275<br />

Palmer, E 486, 733<br />

Palmer, G 1490<br />

Palmer, RH 98, 806<br />

Palmisani, E 207<br />

Pals, ST 1711<br />

Palter, J 1702<br />

Palumbo, K 607, 611, 614, 615,<br />

616, 672<br />

Pamer, E 1390<br />

Pan, S 1242, 1598<br />

Pan, W-H 2088<br />

Pan, Z-j 1267<br />

Panagiotakos, DB 1897<br />

Panayi, GS 1729<br />

Pandya, B 878, 879, 1363, 1547,<br />

2154<br />

Panepento, B 521, 849<br />

Pangan, A 518, 559, 1949<br />

Panghaal, V 1630<br />

Panicker, S 1270<br />

Pannier, E 2034<br />

Panopalis, P 107, 789, 2113


Pans, M 1834<br />

Parra, ER 605, 887<br />

Peda, MA 901<br />

Perry, M 562, 725<br />

Paolini, C 2001<br />

Parsa, MF 998<br />

Pedersen, R 514, 1927, 1937<br />

Pers, J-O 737, 1914, 2177<br />

Pap, T 368, 1130, 1478, 1486,<br />

1719, 2237<br />

Papadopoulos, N 1021<br />

Papageorgiou, A 1912<br />

Papagoras, C 1215<br />

Papalardo, E 1361, 2251, 2252,<br />

2253<br />

Papapoulos, S 2157<br />

Papo, T 2239<br />

Pappa, C 1395<br />

Pappas, DA 45, 1022, 1799<br />

Pappas, J 150<br />

Pappas, T 1536<br />

Pappu, R 390, 1834, 2173<br />

Paradisi, M 1439<br />

Paragh, G 519<br />

Paramarta, J 1977, 2272<br />

Parambil, J 564, 592<br />

Paran, D 697, 1159, 1238<br />

Pardeo, M 209, 2033<br />

Pardo, P 144, 1154<br />

Parimi, N 624<br />

Parish, M 1094<br />

Park, E-J 366, 372, 1297<br />

Park, GS 1103, 1117<br />

Park, HS 1716<br />

Park, JK 677, 681, 919, 2167<br />

Park, JL 255<br />

Park, JA 1751<br />

Park, JS 842<br />

Park, K 2225<br />

Park, KS 353, 370, 756, 1716,<br />

1770<br />

Park, KU 1523<br />

Park, M-C 27, 1061, 1873, 387<br />

Park, MJ 1716<br />

Park, M-K 353<br />

Park, R 1499<br />

Park, S 84, 276<br />

Park, S-H 277, 323, 353, 370, 756,<br />

903, 1209, 1716, 1770<br />

Park, S-Y 1585<br />

Park, W 1813<br />

Park, Y 276<br />

Park, Y-B 27, 387, 1061, 1873,<br />

2028<br />

Park, Y-E 277, 1209<br />

Park, Y-W 116, 505, 1891<br />

Parker, B 1177<br />

Parker, J 1207<br />

Parks, C 61, 1062<br />

Parks, EL 2097<br />

Parks, M 1576<br />

Parmar, K 42<br />

Parmar, R 1090, 1126, 1254<br />

Parolin, M 1682<br />

Parsons, L 1223<br />

Parvu, M 405, 848<br />

Paschides, CA 1215<br />

Pasco, J 183<br />

Pascoli, L 240<br />

Pascual-Ramos, V 337, 1881<br />

Pascual-Salcedo, D 1599<br />

Pasic, S 1684, 1705<br />

Pasoto, SG 481<br />

Passarelli, M 887<br />

Pasternak, R 1119<br />

Pastrak, A 285<br />

Patel, A 1740<br />

Patel, DD 19, 1487<br />

Patel, DR 1253<br />

Patel, J 1477<br />

Patel, N 895, 1425<br />

Patel, RK 1430<br />

Patel, S 126<br />

Patel, V 288, 1270<br />

Patel, Z 1531<br />

Paternotte, S 63, 529, 948, 1648,<br />

1924<br />

Paterson, JM 57, 313, 341<br />

Patil, S 456<br />

Patkar, NM 304, 404, 722, 1573,<br />

1643, 2103<br />

Patra, K 123, 1101, 1102, 1108,<br />

1113, 1791<br />

Patrizi, A 1439<br />

Patschan, D 2021<br />

Patschan, S 2021<br />

Patternotte, S 1104<br />

Patterson, N 153<br />

Pau, E 424, 425, 429<br />

Paul, B 620, 1399<br />

Pauley, KM 2174<br />

Paulo, LTP 1339<br />

Paulus, H 155, 299, 583, 1058,<br />

1365, 1368, 1779, 1789<br />

Pauly, T 368<br />

Pavelka, K 55, 638, 971, 1802,<br />

1807, 1840<br />

Pavenstädt, H 2237<br />

Pavletic, S 1161<br />

Pavy, S 548<br />

Pawar, R 2186<br />

Paxton, LA 1620<br />

Payeli, SK 1973<br />

Payet, J 529, 1924<br />

Payne, AJ 1030<br />

Payoux, P 2027<br />

Paz, E 1407<br />

Pearce, W 1168<br />

Pease, C 777, 1637, 1652, 1654<br />

Pecchi, E 37<br />

Pedersen, SJ 134, 1953<br />

Pedersen, TK 1687<br />

Pedriger, A 1910<br />

Pedro, S 89<br />

Peeters, AJ 1396<br />

Peeva, V 13, 1156, 2120<br />

Peffer, N 1968<br />

Peh, CA 676<br />

Peikert, T 680<br />

Peinado, V 1070<br />

Peiro, M 1296<br />

Peiro Callizo, ME 1650<br />

Pelajo, CF 231<br />

Pelck, R 1444, 1841<br />

Peliçari, K 1695<br />

Pelletier, J-P 196, 938, 1489, 1497<br />

Pellett, F 530, 1966, 1974, 1975,<br />

1979, 1984<br />

Peloquin, C 2067, 2212, 2213<br />

Peluso, G 355, 744, 1098, 1582<br />

Pemberton, P 1067<br />

Peña Salgredo, JL 1650<br />

Peña-Arrébola, A 2268<br />

Penadés, IC 1407<br />

Penco, F 265<br />

Pendl, J 218, 268, 2106<br />

Peng, SL 901<br />

Peng, Y 1843, 1919<br />

Penney, CJ 330<br />

Pennington, LF 748<br />

Penya, J 1137<br />

Pepe, P 811, 1916<br />

Peracchi, OAB 1676<br />

Perard, L 2239<br />

Perdriger, A 63, 701, 1890<br />

Pereira, K 356, 498, 504, 1695<br />

Pereira, RM 1384, 1437, 1546,<br />

2078, 2134<br />

Pereira Da Silva, JA 1013<br />

Perell-Gerson, KL 169<br />

Perez, E 1801<br />

Perez, MD 1678<br />

Perez-Alvarez, R 1888<br />

Perez-Pampin, E 1076, 1078<br />

Perez-Ruiz, F 159, 873, 151, 882,<br />

1572<br />

Perez-Sanchez, C 1357<br />

Pericleous, C 1358, 1359<br />

Perilongo, G 1439<br />

Perino, G 427<br />

Perl, A 437, 449, 1185, 1196, 2275<br />

Perlman, H 853, 854, 859, 861,<br />

1723<br />

Perrella, O 2201<br />

Perrot, S 97<br />

Persad, P 2077<br />

Persselin, J 155, 1365<br />

Pértega, S 835<br />

Pertega-Diaz, S 541, 1920<br />

Peschken, C 448, 476, 731, 1176,<br />

1674, 1850, 1852, 1864, 1877,<br />

2240, 2243<br />

Petchprapa, C 708<br />

Peter, WFH 2051<br />

Peterfy, C 120, 123, 125, 1369,<br />

1817<br />

Peters, C 1243, 1245<br />

Peters, MA 368, 1719<br />

Peters, MJL 90, 643, 1029, 2211<br />

Peterson, D 156, 322, 791<br />

Peterson, EJ 934<br />

Peterson, LK 748, 2128<br />

Peterson, MGE 1872<br />

Petersson, I 761, 963, 1392, 1393,<br />

2209<br />

Petri, M 14, 268, 445, 448, 452,<br />

453, 454, 460, 473, 474, 476, 479,<br />

485, 487, 731, 733, 765, 1148,<br />

1149, 1163, 1180, 1403, 1452,<br />

1454, 1456, 1457, 1591, 1592,<br />

1594, 1608, 1848, 1858, 1877,<br />

1879, 2121, 2122, 2124, 2149,<br />

2162, 2240, 2243, 2260<br />

Petrich, J 574<br />

Petronis, J 1887<br />

Petterson, S 1846<br />

Pettersson, E 1381<br />

Pettersson, T 891<br />

Pettijohn, K 509<br />

Pettinger, M 1062<br />

Pettit, A 2184<br />

Petty, RE 1674<br />

Pezic, A 248<br />

Pfaefflin, A 770<br />

Pfeffer, S 858<br />

Pham, T 260, 1752, 1810, 1831,<br />

2269<br />

PHAROS Investigators 561, 569,<br />

570, 586, 591, 729<br />

Phaujdar, S 1925<br />

Phelps, D 1395<br />

Philippe, L 858<br />

Philippet, P 1700<br />

Phillips, CR 62<br />

Phillips, K 402, 567, 585, 1212,<br />

1222, 2007, 2073<br />

Phillips, PE 1185, 1196<br />

Piatti, A 1854, 1855<br />

Pickard, L 969<br />

Pickens, SR 23, 270, 714, 1506<br />

Piera, S 2007<br />

Pierangeli, S 3, 6, 12, 1360, 1361,<br />

2250, 2251, 2252, 2253, 2255<br />

2010 Program Book 343<br />

abstract author Index


aBSTRACT author Index<br />

344<br />

Pierre, B 902<br />

Pietras, T 1799<br />

Pietrogrande, M 2036, 2201<br />

Piette, J-C 478, 1908, 1911, 2239<br />

Pike, B 1170<br />

Pike, MC 453<br />

Pikhlak, A 145, 1423<br />

Pilkington, C 1344, 1688<br />

Pillet, P 905<br />

Pillinger, MH 43, 148, 883, 1390,<br />

1616<br />

Pimentel-Santos, FM 1986<br />

Pincus, T 84, 312, 985, 990, 995,<br />

1765, 1857, 2109<br />

Pineau, C 454, 1142, 1850, 2120<br />

Pineda, C 1614, 1617, 1635<br />

Pineda, L 451, 452, 1146, 1172,<br />

1457, 1848<br />

Pinheiro, GRC 356<br />

Pinheiro, MM 628<br />

Pinkerton, M 1728<br />

Pinner, E 2246<br />

Pinney, AJ 282<br />

Pinto, ALS 626<br />

Pinto, JA 541<br />

Pinto-Tasende, J 1920<br />

Pioltelli, P 2036, 2201<br />

Pipitone, N 777, 1290, 1302,<br />

1654, 2044<br />

Piram, M 905<br />

Pirisi, M 962, 2160<br />

Pirruccio, P 1173<br />

Pisetsky, DS 1192<br />

Piskin, O 1283<br />

Pisoni, C 732<br />

Pistorio, A 208, 210, 232, 1684,<br />

1700, 1705<br />

Pitashny, M 2186<br />

Pitt, MJ 1573<br />

Pitt, S 1513<br />

Pittrow, D 599, 1212<br />

Pitzalis, C 623, 1389, 1476, 1503,<br />

1906<br />

Piva, SR 2052, 2059, 2061<br />

Pizzorni, C 578, 1236<br />

Plaisier, E 2010, 2011<br />

Planas-Rigol, E 1292, 1294<br />

Planck, SR 1447<br />

Plant, D 1600, 2215<br />

Plass, N 260<br />

Platt, A 1474<br />

Platt, PN 1064<br />

Plenge, RM 1610<br />

Plontke, S 899, 900<br />

Plotnik, J 892<br />

PLUS Study 2239<br />

Poddubnyy, D 665, 2181<br />

Pødenphant, J 1370<br />

2010 Program Book<br />

Podesta’, E 1098, 1582<br />

Pogosian, S 1035, 1049<br />

Pohjolainen, T 80<br />

Pohl, C 1766<br />

Poignant, S 2045<br />

Poiraudeau, S 1204<br />

Pokelsek, A 259<br />

Pokrzywinski, R 99<br />

Polak, AA 942<br />

Polak, J 2162<br />

Polanska, M 638<br />

Pollak-Dorocic, I 2118<br />

Pollard, R 1889, 1892<br />

Pollock, J 1325<br />

Pollock, R 1966, 1975, 1979, 1984<br />

Pollono, EN 407<br />

Polo Cueto, J 407<br />

Polyak, JL 2074<br />

Polydefkis, M 1915<br />

Polzer, K 629<br />

Pompei, O 1296<br />

Pompei Fernández, O 1650<br />

Ponchel, F 1090, 1126, 1254<br />

Ponder, L 256, 1405<br />

Pong, E 1350<br />

Pons-Estel, B 1578, 1585, 1586,<br />

1595, 2147, 2148<br />

Ponsonby, A-L 248<br />

Pool, B 881, 1983<br />

Poole, JL 1349, 1567<br />

Poór, G 777, 1013, 1637, 1654<br />

Pope, A 1972<br />

Pope, D 1325<br />

Pope, J 57, 300, 306, 306, 313,<br />

341, 343, 344, 396, 419, 659, 978,<br />

1156, 1202, 1203, 1221, 1735,<br />

1737, 1805, 1850, 1852, 1864,<br />

2120, 2196<br />

Pope, RM 23, 854, 1353, 1506<br />

Popp, CD 1345<br />

Porawska, W 2173<br />

Porras, M 517, 552, 1137<br />

Portman, M 828<br />

Porto, LCM 356<br />

Posfay-Barbe, K 792<br />

Possemato, N 558<br />

Post, W 1148, 2162, 2260<br />

Postal, M 1695<br />

Posthumus, MD 662<br />

Pott, H-G 138<br />

Pouchot, J 905, 2094<br />

Poulsen, U 1444, 1841<br />

Poupot, M 281<br />

Poupot, R 281<br />

Powchik, P 710<br />

Powell, B 273<br />

Powell, S 218<br />

Powers, JP 1100, 2032, 2048<br />

Poynard, T 1762<br />

Pozniak, K 2001<br />

Prado, DML 626<br />

Prahalad, S 245, 250, 255, 256,<br />

654, 1405<br />

Prakken, B 719<br />

Praprotnik, S 1896<br />

Pratt, DD 1324<br />

Precioso, AR 224, 481, 1437<br />

Precopio, M 862<br />

Predeteanu, D 848<br />

Preiss, R 895, 900, 1425, 1435<br />

Preissner, KT 1420<br />

Preoteasa, V 848<br />

Prescott, GJ 646<br />

Prescott, KH 880<br />

Presson, A 262<br />

Prestat-Tilly, M 1<br />

Prevosto, C 843<br />

Priam, S 37<br />

Price, DD 809, 821<br />

Price, LL 706, 709<br />

Prieto-González, S 1294, 1314<br />

Prignano, F 1962<br />

Primdahl, J 2280<br />

Prince, FHM 219, 308<br />

Princic, N 338<br />

Privitera, R 355<br />

Proctor, G 1906<br />

PROFILE 1585, 1586, 2147, 2274<br />

PROFILE Investigators 1584, 1595<br />

Proietto, J 173, 1383<br />

Pros, A 824<br />

Proudman, S 584<br />

Provan, SA 534<br />

Proven, A 891<br />

Provenzano, G 532<br />

Prozonic, J 250, 255, 256<br />

Prudhomme, L 2027<br />

Pryschep, S 351<br />

Psenak, O 1011<br />

Puchner, A 1351<br />

Puéchal, X 701, 1890, 1910, 2045<br />

Puggina, S 1687<br />

Pullman-Mooar, SW 1554<br />

Pulsatelli, L 1290<br />

Pumarejo, F 1811<br />

Punaro, L 1677<br />

Punaro, M 223, 255, 654, 1491,<br />

1688, 1690, 1702, 2219<br />

Pundt, N 1478<br />

Punzi, L 290, 297, 540, 547<br />

Puolakka, K 80, 759<br />

Purcaru, O 1832<br />

Purser, J 181<br />

Purvey, S 474<br />

Pushparaj, PN 28<br />

Put, S 1720<br />

Putova, I 1174<br />

Putterman, C 939, 1179, 2095,<br />

2186, 2187<br />

Pyrpasopoulou, A 11<br />

Q<br />

Qi, JC 621<br />

Qi, K 390<br />

Qi, M 621<br />

Qi, X 1728<br />

Qing, W 1107<br />

Qing, X 427<br />

Qiu, J 1530<br />

Qiu, Y 274<br />

Quach, C 236<br />

Quach, DL 502, 1602<br />

Quach, HL 502, 1602<br />

Quach, L 684<br />

Quaglierini, F 1011<br />

Quan, H 775<br />

Quan, J 1188<br />

Quartier, P 895, 1407, 1425, 1435,<br />

1693<br />

Quartuccio, L 2036, 2201<br />

Quataert, S 849<br />

Quattrocchi, E 58<br />

Qubti, MA 45, 919<br />

Quemeneur, T 2045<br />

Queralt, C 1280<br />

Querci, V 246<br />

Quevedo, A 1173<br />

Quevedo, JC 389, 1876<br />

Quinet, RJ 1007<br />

Quinlan, P 1576<br />

Quinzanos, I 1395<br />

Quirbach, C 2252<br />

Quismorio, FP 46, 1429, 1432<br />

Quistberg, A 1955<br />

Qureshi, AA 1937<br />

Qureshi, F 1606<br />

Qvist, P 1466, 1500<br />

R<br />

Rabe, H 1248<br />

Rabinovich, EC 209, 234, 252,<br />

1673, 1691, 1699, 2017<br />

Rabquer, BJ 282, 1419, 1721<br />

Rachabattula, S 1429<br />

Rachel, D 444<br />

Rachlis, A 225<br />

Racine, A 566<br />

Racovan, M 1062<br />

Radbruch, A 1295, 1414<br />

Raddatz, DA 515<br />

Radhakrishna, SM 1702, 2102<br />

Radin, AR 1121


Radka, S 1174<br />

Radner, H 296, 1745<br />

Radominski, S 2157<br />

Radstake, T 824, 829, 844, 1599,<br />

1210, 2002, 2004, 2214<br />

Radvanski, DC 625, 1320, 1767<br />

Raffeiner, B 290, 547<br />

Ragavan, S 1125<br />

Ragavendra, N 594<br />

Raggi, P 1023, 1034, 1867<br />

Raghu, G 931<br />

Ragi-Eis, S 971<br />

Rahimi, H 865<br />

Rahman, A 445, 448, 476, 621,<br />

1358, 1359, 1877, 2082, 2240,<br />

2243, 2255<br />

Rahman, M 326, 385, 386, 890,<br />

908, 1036, 1097, 1114, 1127, 1136,<br />

1555, 1804, 1814, 1815, 1818,<br />

1948, 2264, 2265<br />

Rahman, P 549, 1451, 1964, 1972<br />

Rai, E 2146<br />

Rainford, L 1625<br />

Rajan, E 2072<br />

Rajappa, SM 1286<br />

Rajpathak, S 1692<br />

Rajzbaum, G 967<br />

Ramirez, AA 1160<br />

Ramirez, C 1049<br />

Ramírez, J 20, 538, 543, 1070<br />

Ramming, A 1241, 1261<br />

Ramnoruth, S 1116<br />

Ramonda, R 540<br />

Ramos, E 1435<br />

Ramos, I 449, 1196, 1519<br />

Ramos, M 233, 445, 448, 476,<br />

1534, 1877, 2240<br />

Ramos, PS 500, 654, 2145, 2148<br />

Ramos-Casals, M 1888, 1896,<br />

1910, 2036, 2243<br />

Rampersad, R 19<br />

Ramsay, PP 502, 1602<br />

Ramsey, SE 238, 1674, 1691<br />

Ramsey-Goldman, R 214, 448,<br />

476, 731, 960, 1591, 1594, 1877,<br />

2240, 445, 859, 1168, 2243<br />

Rand, J 1692, 2250<br />

Ranganath, V 347, 933, 1058,<br />

1779, 1789<br />

Ranganathan, P 62, 1395<br />

Rannou, F 1204<br />

Ranque, B 576<br />

Rantalaiho, V 80, 891<br />

Rantapää-Dahlqvist, S 1054, 1847,<br />

2115<br />

Rao, JK 1575<br />

Rao, KCS 363<br />

Rao, P 1158<br />

Rao, S 535, 557, 660, 760, 763,<br />

771, 1354<br />

Raschi, E 1356<br />

Rasheed, Z 632, 633<br />

Rasmussen, A 2148<br />

Rasmussen, N 2014<br />

Rasmussen, TK 1524<br />

Rasouliyan, L 347<br />

Rastaldi, M-P 2278<br />

Rat, A-C 768, 787, 2094<br />

Raterman, HG 332, 961, 1029,<br />

1084<br />

Rath, T 294<br />

Ratziu, V 1762<br />

Ratzlaff, CR 2093<br />

Rau, L 1382<br />

Rauh, M 490<br />

Ravagnani, V 547, 1098, 1582<br />

Ravaud, P 303, 376, 400, 1790,<br />

1890, 1896, 1910, 2042<br />

Raveendran, KG 1106<br />

Ravelingien, I 1398<br />

Ravelli, A 207, 208, 210, 232, 261,<br />

1684, 1688, 1700, 1701, 1705,<br />

2220<br />

Ravenell, RL 2125<br />

Ravera, F 578, 1236<br />

Rawat, A 4<br />

Rawat, G 931<br />

Rawstron, AC 1126<br />

Raya, E 1599<br />

Raychaudhuri, SK 1971, 1976<br />

Raychaudhuri, SP 1971, 1976<br />

Raymond, R 1119<br />

Raynauld, J-P 196, 938<br />

Reaume, M 225<br />

Rebello, R 126<br />

Record, JL 1679<br />

Redden, L 1791<br />

Reddy, SM 1390<br />

Reddy, ST 933, 1058<br />

Redecha, P 427, 1199<br />

Redegeld, FA 333<br />

Redlich, K 1493, 272<br />

Redondo, N 482<br />

Reed, A 15, 255, 934, 1376, 1379,<br />

1677, 2068<br />

Reed, G 52, 379, 515, 1003, 1010,<br />

1794, 1960<br />

Reed, JH 656<br />

Reed, MR 263<br />

Reedquist, K 32, 1095, 1529<br />

Reeves, WH 501, 735, 742, 1639<br />

Reeves-Robb, R 1405<br />

Regatte, R 137<br />

Reginster, J 979, 2156, 2157<br />

Regnault, V 1<br />

Rego-Pérez, I 835<br />

Rehart, S 1722<br />

Rehman, A 44<br />

Rehrig, C 157, 166<br />

Reich, N 672<br />

Reichelt, D 138<br />

Reichmann, WM 140, 143, 199,<br />

2090, 2091, 2092<br />

Reid, A 2135<br />

Reid, DM 2156<br />

Reid, G 2152<br />

Reiff, A 241<br />

Reiff, AO 1673, 1688, 1691, 2017,<br />

2102<br />

Reilly, CM 435, 2191<br />

Reilly, M 16<br />

Reimold, A 397, 546, 880, 970,<br />

1099, 1792<br />

Reindl, C 2130<br />

Reis, RCP 1169, 1849<br />

Reis Neto, ET 628<br />

Reisman, D 194<br />

Reiss, AB 1072<br />

Reiss, W 403<br />

Rekedal, L 1318<br />

Remmers, E 914, 1281, 2217<br />

Ren, H 710<br />

Ren, J 1543<br />

Ren, P 1107<br />

Ren, Y 2056<br />

Rendal, E 1473<br />

Rendal-Vázquez, E 1483<br />

Rengel, Y 21<br />

Rennebohm, R 1678<br />

Renner, C 1973<br />

Renner, J 180, 181, 831, 838,<br />

1463, 2140<br />

Reny, J-L 2045<br />

Reppel, M 1615<br />

Resch, H 2157<br />

Resche-Rigon, M 1646, 2024,<br />

2039, 2046<br />

Respicio, G 446<br />

Restrepo, JF 1044, 1035<br />

Restuccia, G 1302, 2044<br />

Retamozo, S 50<br />

Reuschel, E 2219<br />

Reveille, J 87, 522, 725, 824,<br />

1210, 1211, 1216, 1219, 1226,<br />

1227, 1591, 1594, 1856, 1982,<br />

2185, 1972<br />

Revicki, D 91, 971<br />

Revu, S 394<br />

Reychan, I 550<br />

Reyes-Cortes, E 1526<br />

Reynard, M 321<br />

Reynolds, JA 1200<br />

Reynolds, K 1002<br />

Reynolds, MA 1074<br />

Rezaei, H 1392, 1393<br />

Rhiannon, JJ 163<br />

Rho, YH 1023, 1034, 1607, 1867<br />

Rhodus, N 1579<br />

Rhudy, JL 101<br />

Riato, L 1627<br />

Ribeiro, AL 1169, 1842, 1849<br />

Ribeiro, ACM 1437, 2078, 2204<br />

Ricciardi, D 1863<br />

Riccieri, V 580, 1627<br />

Richard, C 598<br />

Richard, D 145, 1423, 2087<br />

Richards, B 493<br />

Richards, HL 1234<br />

Richards, JS 397, 546, 970, 1099,<br />

1792<br />

Richardson, BC 1253, 1590<br />

Richardson, MN 87, 1047, 1428,<br />

1856, 1865<br />

Riche, D 1401<br />

Richey, M 2077<br />

Richez, C 1596, 1816<br />

Richman, IB 1592<br />

Richmond, JC 167<br />

Richter, J 1615<br />

Rider, LG 1678<br />

Rider, V 462<br />

Ridjab, D 1059<br />

Riedel, AA 757<br />

Rieder, SW 419<br />

Riemekasten, G 824, 829, 1987,<br />

2003, 2214, 2226<br />

Riente, L 558<br />

Riese, R 1129, 2171<br />

Riestra, R 1754<br />

Riet, A 29<br />

Rifkin, D 489<br />

Rigante, D 1872<br />

Rigby, W 378, 383, 414<br />

Righter, G 629<br />

Rigolet, A 1651<br />

Rigsby, C 1686<br />

Riley, CP 1601<br />

Rillo, O 50<br />

Rimar, D 550, 909<br />

Rincheval, N 1760<br />

Ringsdal, V 1444, 1841<br />

Rios, R 824<br />

Ripert, M 69<br />

Ripley, M 195, 2101<br />

Rischmueller, M 1579<br />

Rist, S 1890, 1893, 1910, 1914<br />

Ristori, J-M 375, 904<br />

Ritchlin, C 521, 712, 849, 1051,<br />

1492, 1710, 1835, 1919, 1935,<br />

1955, 1968<br />

Ritterhouse, LL 24<br />

Rittner, L 1170<br />

Rival, C 1448<br />

Rivas-Chacon, RF 1678<br />

2010 Program Book 345<br />

abstract author Index


aBSTRACT author Index<br />

Rizo-Rodríguez, JC 1166<br />

Rizvi, TJ 87<br />

Rizzo, W 378, 1820<br />

Roberts, C 1623<br />

Roberts, K 1538<br />

Roberts, M 1886<br />

Roberts, V 24, 780<br />

Robertson, D 1937<br />

Robinson, AB 252<br />

Robinson, B 71<br />

Robinson, DB 1068, 1094, 1176<br />

Robinson, E 1372<br />

Robinson, KC 178<br />

Robinson, M 809, 821, 1243, 1245<br />

Robinson, S 2082<br />

Robinson, W 77, 573, 1083, 1386,<br />

1740, 1764, 2116, 2117, 2229<br />

Robles, M 1834<br />

Roblin, D 1543<br />

Robustillo, M 1016, 1310<br />

Roccatello, D 2201<br />

Rocha, B 840<br />

Rocha, C 1732<br />

Roche, A 1810<br />

Rock, K 1531<br />

Roddy, J 584<br />

Rødevand, E 377<br />

Rodgers, J 2172<br />

Rodrigues, A 89<br />

Rodrigues, LA 1169, 1842, 1849<br />

Rodrigues, PT 2134<br />

Rodrigues, T 1140<br />

Rodriguez, E 44, 1171<br />

Rodriguez, M 975<br />

Rodríguez, R 543<br />

Rodríguez de Castro, F 1876<br />

Rodriguez de la Serna, A 1118<br />

Rodriguez Moreno, MR 1657<br />

Rodriguez-Ariza, A 1357<br />

Rodriguez-Gallego, C 1876<br />

Rodriguez-García, F 1881<br />

Rodríguez-Henríquez, PJ 1614<br />

Rodríguez-Lozano, C 1876, 2268<br />

Rodriguez-Moreno, J 1016<br />

Rodríguez-Reyna, T 1881<br />

Rodríguez-Rodríguez, L 1301<br />

Roehrs, T 294<br />

Roemer, F 131, 193, 197, 202,<br />

1373, 2100<br />

Roescher, N 1413, 2178<br />

Roger, VL 67<br />

Rogers, JC 2142<br />

Rogers, P 1571<br />

Roggenbuck, D 911, 1757<br />

Rohde, G 972<br />

Rojas-Villarraga, A 1048<br />

Rojkovich, B 1122, 2170<br />

Roll, P 745, 1411<br />

Rollins, K 597, 1201, 1222<br />

Rollot, F 2045<br />

Romagnani, S 246<br />

Román, J 1137<br />

Roman, M 483<br />

Roman Ivorra, JA 2157<br />

Romas, E 30, 1560<br />

Romay Penabad, Z 1360, 1361<br />

Römer, U 392<br />

Romero, A-B 409<br />

Romero-Diaz, J 445, 459, 1853<br />

Romero-Sánchez, C 552<br />

Romero-Sánchez, GT 1150<br />

Romick-Rosendale, L 268<br />

Rommel, C 362<br />

Ronacher, L 271<br />

Ronday, HK 295, 1396<br />

Rondon, F 1811<br />

Ronis, T 1008<br />

Rönnblom, L 503, 1885<br />

Ronneberger, M 1781<br />

Rönnelid, J 695, 1015, 1020, 2115<br />

Rooryck-Thambo, C 1596<br />

Roots, RK 2050<br />

Ros, S 1118, 1796<br />

Rosales, A 1543<br />

Rosario, MP 516<br />

Rosario Lozano, MP 1657<br />

Rosas, J 1754, 1888<br />

Roschel, H 1384<br />

Rose, CD 654<br />

Rose, G 752<br />

Rose, M 920<br />

Roselló, R 1276<br />

Roseman, C 1037, 1440<br />

Rosen, A 440, 487, 677, 681,<br />

1989, 2167<br />

Rosen, C 783, 1928<br />

Rosenbaum, JT 1447, 1713<br />

Rosenberg, A 214, 733, 849, 1886,<br />

1968<br />

Rosenblatt, L 1407, 1794, 1836,<br />

1837<br />

Rosenblum, GC 1072<br />

Rosengren, S 34, 1240, 1955<br />

Rosenkranz, ME 1673, 1691, 2017<br />

Rosenstein, ED 70<br />

Rosenthal, PB 1390<br />

Rosenzwajg, M 1249, 2025, 2131<br />

Rosenzweig, HL 1447, 1713<br />

Roske, A-E 56<br />

Rosner, I 550, 909<br />

Ross, JM 48<br />

Rossi, F 2044<br />

Rossi, R 581<br />

Rossi, S 2220<br />

Ross-MacDonald, P 1513<br />

Roth, J 845, 1472, 1495, 1684,<br />

2002<br />

Roth, M 1575<br />

Roth, SH 954, 955<br />

Rothfuss, M 381<br />

Rothlein, L 19<br />

Rotter, JI 187<br />

Rotunno, L 532<br />

Rouanet, S 82, 964<br />

Roubaud-Baudron, C 2041<br />

Roubey, RAS 6<br />

Roubinis, N 599<br />

Roucheux, A 1827<br />

Roure, F 529, 1924<br />

Routhu, KV 279<br />

Routsias, JG 1895, 2175<br />

Roux, C 548, 976, 2094, 2156<br />

Roux-Lombard, P 1088<br />

Rovati, LC 948<br />

Rovensky, J 2087<br />

Rovin, BH 1400<br />

Rowe, DS 396<br />

Rowles, G 1332<br />

Roy, A 1119<br />

Roy, S 65, 91, 307, 327, 382, 644,<br />

1113, 2266<br />

Rozelle, AL 2229<br />

Rozenbaum, M 550, 909<br />

Rozenberg, F 478<br />

Rua-Figueroa, I 1276, 1876<br />

Rubartelli, A 657<br />

Rubbert-Roth, A 294, 378, 384,<br />

411, 1788<br />

Rubenfire, M 567<br />

Rubin, BR 1430<br />

Rubin, L 598, 599<br />

Rubinstein, F 324<br />

Rubio-Perez, N 1407<br />

Rudd, MK 250<br />

Rudge, H 1848<br />

Rudin, A 1248<br />

Rudnev, A 1125<br />

Rudolph, KS 190, 194<br />

Rudwaleit, M 665, 669, 1923,<br />

1958, 1961, 2181, 2271<br />

Rueda, B 824, 829, 2214<br />

Ruff, V 980<br />

Ruggeri, BA 2233<br />

Ruhí, R 106<br />

Ruibal, A 1871<br />

Ruiz, B 1991, 2000<br />

Ruiz, E 1741<br />

Ruiz, JM 1118, 1796<br />

Ruiz, N 808<br />

Ruiz, O 1811<br />

Ruiz, P 435, 573<br />

Ruiz, T 1296<br />

Ruiz-Esquide, V 1070<br />

Ruiz-Irastorza, G 448, 476, 1877,<br />

2240, 2243<br />

Ruiz-Limon, P 1357<br />

Ruiz-Romero, C 840<br />

Rull-Gabayet, M 337, 874<br />

Rullé, S 1707<br />

Rullier, P 2010<br />

Rullo, OJ 262, 998<br />

Ruperto, N 207, 210, 232, 1407,<br />

1434, 1684, 1700, 1705<br />

Ruprecht, J 221<br />

Rus, H 432<br />

Rus, V 432<br />

Rushing, E 914<br />

Russell, AS 100, 330, 416, 1836<br />

Russell, IJ 97, 100, 814<br />

Russell, LP 2145<br />

Russo, RAG 212<br />

Rusu, C 1562<br />

Rüter, C 1130<br />

Ruth, JH 1417, 1419, 1504, 1721<br />

Ruth, NM 510<br />

Rüther, W 1486<br />

Rutsch, F 1486<br />

Ruutu, M 1446<br />

Ruyssen-Witrand, A 2218<br />

Ryan, J 22, 1333, 1625<br />

Ryan, M 654<br />

Ryan, P 1560<br />

Rybak, L 137, 707, 708<br />

Rybicki for ACCESS, B 1579<br />

Rygg, M 1684<br />

Ryu, HH 387<br />

Ryu, J 399<br />

Ryu, M 441<br />

S<br />

Saad, CG 481, 513, 531, 1437,<br />

2078, 2204<br />

Saad, M 1994<br />

Saad-Magalhães, C 1688, 1701,<br />

1872<br />

Saadoun, D 906, 1249, 1646,<br />

1660, 1908, 1911, 2011, 2024,<br />

2025, 2030, 2039, 2046, 2131<br />

Saag, K 152, 304, 392, 404, 721,<br />

722, 969, 1005, 1006, 1123, 1367,<br />

1543, 1561, 1573, 2084, 2103,<br />

2156<br />

Saavedra Salinas, MA 1150<br />

Saber, T 16, 1391<br />

Sabin, C 1645<br />

Saccardo, F 2036<br />

Sacchetti, SB 1339<br />

Sacco, S 2201<br />

Sack, J 1513<br />

346<br />

2010 Program Book


Sack, KE 1898<br />

Sacli, SF 1312<br />

Saddic, N 2197<br />

Sadeghi Abdollahi, B 1289<br />

Sadik, C 1427<br />

Saech, J 294<br />

Saeed, A 2224<br />

Saegusa, J 1715<br />

Safa-Leathers, S 2169<br />

SAFE-T DILI- GHPS Study Group<br />

1762<br />

Safford, M 299, 304, 1573<br />

Sagawa, A 1138, 1738, 1739<br />

Sagcal-Gironella, AC 1012, 1689<br />

Saggar, R 561, 561, 729, 729, 907,<br />

907, 1232, 1232<br />

Sague, S 326<br />

Saha, C 93, 797<br />

Sahai, M 1044, 1049, 2163<br />

Sahakian, L 471, 594, 1189, 2241<br />

Sahhar, J 584<br />

Sai, Y 1107<br />

Saidenberg-Kermanac’h, N 997<br />

Said-Nahal, R 527, 533<br />

Saiki, O 373<br />

Sailler, L 2027, 2239<br />

Sainaghi, PP 962, 2160<br />

Saito, K 1823<br />

Saito, M 1793<br />

Saito, O 513<br />

Saito, T 335<br />

Saitoh, K 1812<br />

Sakaguchi, S 1485, 2128<br />

Sakai, Y 983, 1738<br />

Sakellariou, G 1397<br />

Saketkoo, LA 1212<br />

Sakuma, Y 1749<br />

Sakurai, N 358<br />

Sakurai, T 1138, 1738, 1739<br />

Salaffi, F 547, 1635, 1746, 1787<br />

Salah, S 833<br />

Salas, J 1137<br />

Salas-Manzanedo, V 2035<br />

Salazar, JC 1811<br />

Saldaña-Barnad, M 1166<br />

Salgado, E 1171<br />

Salgado, M 1700<br />

Sallstig, P 145, 1423, 2087<br />

Sallum, AM 224, 927<br />

Salmon, D 376<br />

Salmon, JE 427, 483, 866, 1183,<br />

1199, 1441, 2077<br />

Salomonsson, S 832<br />

Salt, E 1332<br />

Saltzman, CL 176<br />

Saluja, M 1551, 1640<br />

Salvador, I 1741<br />

Salvadorini, G 558, 1962<br />

Salvarani, C 532, 777, 1290, 1302,<br />

1637, 1652, 1654, 2037, 2038,<br />

2044<br />

Salvat, C 1514<br />

Salvo, D 1290<br />

Samarawickrama, A 966<br />

Sambrook, PN 2156<br />

Sampaio-Barros, P 531, 525, 2078<br />

Sampalis, J 344<br />

Samuels, J 137, 707, 708, 1390,<br />

1616<br />

Samukawa, S 1512<br />

San Martin, J 2161<br />

Sanchez, E 444, 1590<br />

Sánchez, J 1171<br />

Sanchez, RJ 2246<br />

Sanchez-Guerrero, FJ 448, 476,<br />

1877, 2240<br />

Sanchez-Guerrero, J 445, 459,<br />

1456, 1853, 1881, 2243<br />

Sanchez-Madrid, F 1509<br />

Sanchez-Rodriguez, E 2148<br />

Sandborg, CI 1677<br />

Sander, O 1615<br />

Sanders, M 1529<br />

Sanderson, T 1766<br />

Sandler, DP 61<br />

Sanford, T 733<br />

Sangle, S 463<br />

Sangle, SR 444, 2035<br />

Sanmartí, R 20, 409, 538, 1070,<br />

1118<br />

Sansonno, D 2036<br />

Santana- de Anda, K 1881<br />

Santaniello, A 1235<br />

Santarlasci, V 246<br />

Santegoets, KCM 844<br />

Santer, DM 494, 499<br />

Santiago, B 482<br />

Santos, AM 552<br />

Santos, FH 1343<br />

Santos, H 1986<br />

Santos, P 552, 1811<br />

Santos, VC 498, 504<br />

Santos Moreno, PI 1013<br />

Santos-Ramírez, C 1754<br />

Santos-Soler, G 1754<br />

Sanz, I 486, 733, 749, 849, 712,<br />

1085, 1710, 1886<br />

Sapienza, MT 1384<br />

Sara, PR 2060<br />

Sarah, R 620<br />

Saraux, A 781, 888, 1896, 1910,<br />

1914, 1088, 1752, 1890, 1931,<br />

2094, 2221, 2261<br />

Sardy, M 441<br />

Sargent, J 675<br />

Sari, I 1970<br />

Sari, M 1675<br />

Sarin, R 1106<br />

Sarkar, RN 1925<br />

Sarmukadam, S 1551<br />

Sarnes, EF 1566<br />

Sarni, R 1676<br />

Sarsour, K 52<br />

Sartorius, J 345, 1442<br />

Saruhan-Direskeneli, G 822, 2200<br />

Sarzi Puttini, P 297, 532, 784, 815,<br />

1098, 1582<br />

Sasaki, N 2020<br />

Sato, E 628, 1793, 1812, 1823<br />

Sato, H 1797<br />

Sato, M 26, 1773<br />

Sato, S 681, 1230<br />

Satoh, M 501, 735, 1639<br />

Satoh, T 916<br />

Sattar, A 620<br />

Sattar, N 483, 1441<br />

Satumtira, N 1448<br />

Sauer, BC 1099, 1792<br />

Saulsbury, C 2076<br />

Sautet, A 1514<br />

Savage, CO 676<br />

Savioli, C 2078, 2204<br />

Savl<strong>of</strong>f, G 1747<br />

Sawada, S 1708<br />

Sawada, T 1293<br />

Sawai, T 2020<br />

Sawalha, AH 822, 1590, 1594<br />

Saxena, A 1438, 1971, 1976<br />

Saxne, T 1037, 1440<br />

Sayarlioglu, M 1921<br />

Sayles, HR 318<br />

Sayre, EC 1555, 2055<br />

Scaini, P 2201<br />

Scal, P 1340<br />

Scali, JJ 411<br />

Scalzi, L 470, 1861<br />

Scalzi, LV 1002<br />

Scanzello, CR 167<br />

Scarf, J 794<br />

Scarf, JP 778<br />

Scarpa, R 532<br />

Scarpato, S 1705, 2036, 2201<br />

Scarry, M 817, 818<br />

Schachna, L 1942<br />

Schaeverbeke, T 917, 400, 701,<br />

1596, 1790, 1816, 2042<br />

Schall, TJ 1100, 2032, 2048<br />

Schanberg, L 1406, 1677, 1688,<br />

1699, 1701, 1702, 2248<br />

Scharnert, J 1130<br />

Schechtman, J 1820<br />

Scheers-Masters, J 1431<br />

Scheinberg, M 1146, 1407<br />

Scheja, A 1623<br />

Schelbergen, R 845, 1472<br />

Schellevis, FG 1029, 2211<br />

Scher, JU 1390<br />

Scherer, A 138, 2257<br />

Scherer, HU 1780<br />

Schett, G 128, 490, 560, 566, 607,<br />

611, 614, 616, 629, 639, 672, 857,<br />

1474, 1634, 2150, 2234<br />

Schiappapietra, B 207<br />

Schieir, O 1346<br />

Schieven, G 1119, 1513<br />

Schiff, MH 945, 946<br />

Schiff, SA 625, 1767<br />

Schikler, KN 1673, 1691, 2017<br />

Schilder, AM 1859<br />

Schilders, G 1519<br />

Schilling, S 800<br />

Schillinger, D 1024<br />

Schimmel, E 1284<br />

Schiopu, E 402, 561, 567, 585,<br />

1222, 2073<br />

Schiotis, R 525, 986<br />

Schirmer, M 1637, 1652, 1654,<br />

2222<br />

Schleh, A 12<br />

Schlemmer, A 1444, 1841<br />

Schlesinger, N 145, 889, 1423,<br />

2087<br />

Schluger, N 908<br />

Schmajuk, G 484, 789, 991, 2113<br />

Schmaldienst, S 469<br />

Schmid, CH 95<br />

Schmidt, A 1130<br />

Schmidt, H 56<br />

Schmidt, J 2040<br />

Schmidt, WA 777, 1617, 1637,<br />

1652, 1654<br />

Schmidt, Z 777, 1637, 1652, 1654<br />

Schmidt-Wilcke, T 102, 650<br />

Schneck, L 148, 883<br />

Schneeweiss, S 31, 60, 339, 1066<br />

Schneider, DJ 602, 612<br />

Schneider, E 709<br />

Schneider, M 111, 138, 770, 1615,<br />

2081<br />

Schneider, R 1434<br />

Schneider, U 1295<br />

Schneiderman, J 1681<br />

Schnez, A 1781<br />

Schnitzer, T 936, 2097<br />

Schoels, M 1795<br />

Schoindre, Y 2000, 2030<br />

Scholte-Voshaar, M 1027<br />

Scholz, J 1385, 1557, 2098<br />

Schoones, JW 2051, 2283<br />

Schorn, C 490, 2150<br />

Schorscher-Petcu, A 823<br />

2010 Program Book 347<br />

abstract author Index


aBSTRACT author Index<br />

348<br />

Schoster, B 691, 1460, 1461,<br />

1462, 1463, 2140<br />

Schouffoer, AA 328, 582, 1396<br />

Schouffour, AA 1755<br />

Schousboe, JT 1539<br />

Schreiber, B 590, 727<br />

Schreiner, P 1148<br />

Schreiyaeck, C 1479<br />

Schrieber, L 584<br />

Schroeder, AE 749<br />

Schroeder, M 1615<br />

Schubert, T 1466<br />

Schuerwegh, AJ 582, 2214<br />

Schulman, KL 1031<br />

Schultz, D 468<br />

Schultz, O 294<br />

Schulz, M 886<br />

Schulze-Koops, H 1261, 1781,<br />

2130, 406, 1108, 1241<br />

Schumacher, HR 152, 153, 1554,<br />

151<br />

Schumacher, U 679<br />

Schumann, M 745<br />

Schurgers, E 1720<br />

Schwab, P 970<br />

Schwarting, A 1454<br />

Schwartz, A 468<br />

Schwartz, T 181, 691<br />

Schwarz, E 712, 1492, 1710, 1968<br />

Schwarz, H 2257<br />

Scibetta, C 1687<br />

Scindia, YM 1883<br />

Scinocca, M 1071<br />

Scirè, CA 1397, 2220, 766<br />

Sc<strong>of</strong>ield, RH 1193, 1579, 1584,<br />

1901, 2147, 1591<br />

Scolnik, M 324<br />

Scorza, R 824, 829, 1235, 2214<br />

Scott, D 412, 664, 1110<br />

Scott, J 1747<br />

Seager, N 493<br />

Seah, MY 1942<br />

Seavey, MM 2233<br />

Sebastiani, M 1627<br />

Sebba, A 411, 980<br />

Sedlis, S 148<br />

See, K 957<br />

Segal, B 569, 586, 1579, 1882<br />

Segal, N 131, 2100<br />

Segarra, M 1292, 1294<br />

Segelmark, M 676, 1307, 2018,<br />

2022<br />

Sehgal, A 2206<br />

Sehgal, R 1311<br />

Sehnert, B 2234<br />

Seiberling, M 1273<br />

Seibold, J 561, 565, 583, 585, 599,<br />

729, 1004, 1212, 1222, 2007, 2073,<br />

2010 Program Book<br />

1205<br />

Seibold, T 1411<br />

Seiders, J 606<br />

Seipelt, E 227<br />

Seitz, LC 1100, 2032, 2048<br />

Sekine, H 435<br />

Seldin, MF 502, 1592, 1602<br />

Sellam, E 1470, 1471<br />

Sellam, J 548<br />

Selvi, E 615<br />

Semanik, P 2096<br />

Semb, AG 534<br />

Semerano, L 997, 2236<br />

Semoun, O 1646, 2039<br />

Sen, R 487<br />

Senabre, JM 1754<br />

Sène, D 1646, 1890, 1908, 1910,<br />

1911, 2024, 2025, 2030, 2039,<br />

2046<br />

Senecal, J-L 731<br />

Senet, P 2010, 2011<br />

Senior, J 75<br />

Seno, T 1511<br />

Senolt, L 614, 638<br />

Sensky, T 987<br />

Seo, G-S 1051<br />

Seo, P 2012, 2031, 2198<br />

Seo, S-R 116, 505, 1891<br />

Sequeira, W 1147, 1175<br />

Serafini, T 164<br />

Serdik<strong>of</strong>f, C 2233<br />

Seres, I 519<br />

Seriolo, B 578, 1236, 1798<br />

Serné, E 1623<br />

Sernissi, F 811, 839<br />

Seror, R 1217, 1890, 1896, 1910,<br />

1914, 2010<br />

Seshan, S 1151<br />

Sesseng, S 132, 142<br />

Seto, M 1377<br />

Setoguchi, K 932<br />

Setoguchi, S 958<br />

Seton, M 25<br />

Setti, E 269<br />

Setznagl, D 1481<br />

Seung, E 1427<br />

Seyahi, E 1288, 1312, 1697<br />

Seyfert, C 368<br />

Seymour, AB 823<br />

Seymour, K 99<br />

Seymour, RB 692<br />

Sfriso, P 290<br />

Sgarlat, CM 1404<br />

Shadakshari, A 1863<br />

Shadick, N 308, 1050, 1335, 1610,<br />

1753, 1778, 1782, 2064<br />

Shafait, I 40<br />

Shah, AA 569, 1201, 1222, 2192<br />

Shaham, B 2102<br />

Shahane, A 592<br />

Shahdad, S 1455<br />

Shahouri, SH 331<br />

Shahram, F 1289, 1305<br />

Shahrara, S 23, 270, 714, 1506<br />

Shainberg, M 1405<br />

Shakib, S 1124<br />

Shakibaei, M 106<br />

Shakoor, N 205, 2099<br />

Shakoory, B 1573, 1668<br />

Shalamberidze, L 1096, 2168<br />

Shan, Y 379, 1010, 1960<br />

Shanafelt, TD 595<br />

Shanahan, EM 177<br />

Shanahan, F 22, 1333, 1726<br />

Shanahan, KR 177<br />

Shang, Q 1028<br />

Shanmugam, VK 912, 1045, 2197<br />

Shanmugarajah, S 521, 530, 545,<br />

1928, 1936, 1956, 1974, 1979,<br />

1984<br />

Shao, L 1079<br />

Shapira-Lichter, I 1159<br />

Shapiro, DJ 484<br />

Sharif, B 1555<br />

Sharif, R 522, 1211, 1216, 1218,<br />

1219, 1227<br />

Sharma, A 2086<br />

Sharma, L 131, 186, 189, 202,<br />

2096, 2100<br />

Sharma, R 1374<br />

Sharpe, A 456<br />

Sharpe, O 2117<br />

Sharpe, T 213<br />

Sharpley, DW 661, 1763<br />

Shaver, TS 331<br />

Shaw, AS 1415<br />

Shaw, J 1973<br />

Shaw, LA 748, 2128<br />

Shaw, ML 1154<br />

Shaw, S 752, 1244<br />

Shaw, T 403<br />

Shaw, TM 125<br />

Shaw, Y 755<br />

Shaykevich, T 60, 2104<br />

Shayuk, M 1858<br />

Shealy, D 1818, 1968<br />

Sheen, D-H 488, 830, 1589<br />

Sheikh, S 2107<br />

Shelef, MA 1421<br />

Shelmerdine, J 769, 795, 1177<br />

Shen, D-R 1513<br />

Shen, H 512, 530, 545, 556, 783,<br />

1954, 1964<br />

Shen, N 2274<br />

Shen, W 274<br />

Shen, Y 1496, 1753, 1782<br />

Shendre, A 828<br />

Shennan, A 2035<br />

Shepard, S 2172<br />

Sherman, JW 945, 946<br />

Sherry, DD 47, 233, 1677, 1678,<br />

1703, 1907<br />

Sherwood, JC 1476<br />

Shetty, AG 1647<br />

Shevkoplyas, SS 2277<br />

Shi, B 1353<br />

Shi, H 948<br />

Shi, J 1598<br />

Shibata, TN 365<br />

Shiboski, C 1898<br />

Shiboski, S 1898<br />

Shields, AM 1729<br />

Shiels, P 2214<br />

Shikany, J 1062<br />

Shilagard, T 1360<br />

Shim, MR 1789<br />

Shim, S 488, 830, 1589, 1597,<br />

1972<br />

Shima, Y 2228<br />

Shimada, Y 1017<br />

Shimane, K 1577<br />

Shimizu, H 1783<br />

Shimizu, N 1708<br />

Shin, H 1597, 2142<br />

Shin, K 387, 1751<br />

Shinjo, SK 927<br />

Shinozaki, N 1743<br />

Shintani, A 1023, 1034, 1867<br />

Shiow-Ling, C 1270<br />

Shiozaki, M 1708<br />

Shiozawa, K 511, 893<br />

Shiozawa, S 280, 348, 434, 511,<br />

616, 851, 867, 893, 983, 1258,<br />

1264, 1272, 1467, 1812<br />

Shipley, E 1816<br />

Shir, Y 107<br />

Shiraiwa, H 1708<br />

Shivers, D 2219<br />

Shiwen, X 613, 2005<br />

Shiyanov, P 268<br />

Shlimbaum, T 1320<br />

Shmerling, RH 684<br />

Shock, A 751, 752, 1243, 1244,<br />

1245<br />

Shoelson, AJ 2099<br />

Shoham, N 1516<br />

Shojania, K 2152<br />

Sholter, D 330<br />

Shono, E 1115, 1138, 1738, 1739<br />

Shoor, S 573<br />

Shott, S 2075<br />

Shourt, CA 1550, 1570<br />

Shreffler, JH 690, 691, 1460, 1462,


1463, 2071, 2140, 2141<br />

Singh, K 2127<br />

Snyder, RD 2012<br />

Sostek, M 937, 2206<br />

Shrestha, S 242, 826, 828, 928<br />

Singh, MK 2195<br />

So, A 145, 1423, 2087, 2151<br />

Sotnikova, T 1125<br />

Shulman, AI 209<br />

Singh, RP 497, 1257<br />

So, M 876, 2028<br />

Soto, R 1270<br />

Shults, J 206, 1786<br />

Singh, S 4<br />

So, P-W 1995<br />

Sotocinal, SG 823<br />

Shums, Z 14, 2250, 2251, 2252<br />

Singh, UN 2086<br />

Soares, MG 356<br />

Souberbielle, J-C 2030<br />

Sibbitt, WL 947, 1055, 1567, 1626,<br />

2225<br />

Sibilia, J 303, 400, 701, 858, 917,<br />

1104, 1237, 1413, 1790, 1840,<br />

1890, 1894, 1910, 1998, 2218<br />

Sibonga, J 959<br />

Siddhanta, S 1925<br />

Sidhu, P 1636<br />

Siegrist, C-A 792<br />

Sieper, J 518, 526, 559, 665, 669,<br />

1923, 1938, 1948, 1958, 1961,<br />

2181, 2270, 2271<br />

Siero, W 248<br />

Siff, SJ 178<br />

Sigal, LH 1320<br />

Sijtsma, F 1367<br />

Sikora, KA 653<br />

Silingardi, M 1302<br />

Silva, AE 628<br />

Silva, C 224, 260, 513, 539, 927,<br />

1339, 1407, 1437, 2078, 2204<br />

Silva, I 539<br />

Silva, NP 356, 498, 504, 628<br />

Silva, SGL 1343<br />

Silver, R 604, 622, 1004, 1677<br />

Silverman, E 1674, 1677<br />

Silverman, GJ 2121<br />

Silverman, SL 815, 969, 971, 980<br />

Silverstein, R 2047, 2049<br />

Silvestra-Segovia, T 1500<br />

Silvestre, RVD 1694<br />

Simard, JF 454, 1054, 1541, 1548<br />

Simecka, J 1430<br />

Simeon, C 824, 829, 2214<br />

Simil, FF 1842<br />

Siminovitch, K 2217<br />

Simkin, PA 163<br />

Simms, RW 1624<br />

Simon, A 905<br />

Simon, J 971, 2173<br />

Simonini, G 1675, 240, 246, 1436<br />

Simons, DG 647<br />

Simpfendorfer, KR 825<br />

Sims, J 260<br />

Sims, NA 30<br />

Simsek, I 1559<br />

Sinead, H 22<br />

Singer, J 1542<br />

Singer, NG 1677, 1691, 1701<br />

Singer, O 898<br />

Singh, G 2205, 2206<br />

Singh, J 304, 951, 1385, 1395,<br />

1557<br />

Singh, Y 2082<br />

Sipe, JD 49<br />

Siqueira, JTT 2078, 2204<br />

Siris, E 971<br />

Siu, G 1141<br />

Sjöwall, C 1885<br />

Skaggs, B 471, 1189, 2241<br />

Skapenko, A 1108, 1241, 1261,<br />

2130<br />

Skific, D 710, 1121<br />

Skjødt, T 134, 1953<br />

Skljarevski, V 175<br />

Skoie, IM 972<br />

Skol, AD 1612<br />

Slade, K 1354<br />

Slagboom, PE 179<br />

Slatkowsky-Christensen, B 142<br />

Slawsky, KA 754<br />

Slegen 2274<br />

SLEGEN International Consortium<br />

500, 2145, 2148<br />

Sleglova, O 1649<br />

SLICC Group 454<br />

Sloan, JA 595<br />

Sloan, VS 70, 1940<br />

Sloane, R 180<br />

Slobodin, G 550, 909<br />

Sloetjes, A 845, 1472, 1495<br />

Slot, O 884<br />

Slott Jensen, H 777, 1654<br />

Sluka, KA 1226<br />

Smail, A 2239<br />

Smeets, RL 275<br />

Smith, CD 1480, 1850<br />

Smith, CJ 318<br />

Smith, DM 1319<br />

Smith, EA 1077<br />

Smith, J 895, 1096, 1124, 1425,<br />

1607, 1965, 2168<br />

Smith, KA 734<br />

Smith, M 177, 949<br />

Smith, R 678, 1278, 1638, 1663<br />

Smith, S 647, 1119<br />

Smith, T 1983<br />

Smith, V 2214<br />

Smith, Z 1438<br />

Smolen, J 73, 79, 272, 296, 469,<br />

723, 1013, 1119, 1493, 1745, 1791,<br />

1795, 1806, 1820, 2108, 2256,<br />

2258, 2265<br />

Smolik, I 1068, 1094<br />

Snowhite, I 750<br />

Snyder, C 1831<br />

Sobel, ES 501, 735, 742<br />

Socci, N 1390<br />

Soejima, M 935<br />

Soep, JB 1677<br />

Sohn, J 359<br />

Soini, EJO 759<br />

Sokka, T 84, 312, 985, 1027<br />

Sokol, RJ 468<br />

Sokolove, J 1083, 1740, 1764,<br />

2116, 2117<br />

Solano, C 63, 1614<br />

Solans, R 1888<br />

Solari, N 207<br />

Solau-Gervais, E 315, 1752<br />

Soldano, F 2036<br />

Soldano, S 1798<br />

Soldevilla, HF 1851<br />

Solinger, AM 1308<br />

Solmaz, D 544, 666, 1283, 1921<br />

Solomon, DH 31, 42, 54, 60, 81,<br />

308, 339, 793, 958, 991, 1050,<br />

1066, 1318, 1610, 1778, 2091,<br />

2092, 2104<br />

Solomon, G 1390<br />

Solomon, JJ 2119<br />

Solomons, N 1453, 2085<br />

Soltész, P 519<br />

Solus, J 1023, 1034, 1607, 1867<br />

Somers, EC 1158, 1590<br />

Somogyi, A 2042<br />

Son, KM 1038<br />

Son, MBF 209<br />

Sondergaard, BC 1500<br />

Sonesson, S-E 832, 1322<br />

Song, GG 92, 359, 1628<br />

Song, I-H 669, 1923, 1961, 2271<br />

Song, J 186, 189, 202, 1386, 1558,<br />

2096, 2244<br />

Song, R 1038<br />

Song, YW 387, 1583, 1595, 1751<br />

Sonnaville, PBJ 1396<br />

Sonnylal, S 613<br />

Soon, GS 2019<br />

Sop, G 1970<br />

Soranzo, N 711<br />

Sordet, C 63, 1237<br />

Sorell, L 852<br />

Sørensen, IJ 134, 1953<br />

Sorge, RE 823<br />

Sorgi, ML 547<br />

Soriano, E 50, 324<br />

Soriano, T 2110<br />

Sorkin, L 1727<br />

Soubrier, M 375, 542, 917, 1104,<br />

1810<br />

Soulillou, J-P 753<br />

Soumerai, SB 791<br />

Sousa, E 1986<br />

Sousa, FL 1169, 1842, 1849<br />

Soutou, B 2238<br />

Souza, AJ 1169<br />

Souza, LO 1458<br />

Souza, M 2132<br />

Souza, S 228<br />

Sowden, E 40<br />

Soybilgic, A 464<br />

Soysal, O 666<br />

Spada, C 931<br />

Spadaro, A 532<br />

Spadoni, T 2008<br />

Spaeth, M 97<br />

Sparks, S 1192<br />

Specks, U 680, 2012<br />

Spector, TD 711, 841<br />

Speich, R 35, 1518<br />

Spencer, J 463<br />

Spera, A 805<br />

Spevak, W 273<br />

Speyer, I 1396, 1755<br />

Spiegel, L 225, 1408<br />

Spiera, R 1990, 2012, 2193<br />

Spijkervet, F 1892<br />

Spijkervet, FKL 1889, 1905<br />

Spiller, I 2181<br />

Spindler, AJ 1455<br />

Spitz, E 1752<br />

Sportes, C 1161<br />

Squier, W 922<br />

Sredni, S 242, 928<br />

Sridharan, ST 1154<br />

Srinivasan, S 1829<br />

Srivastava, S 1405<br />

St Clair, EW 461, 1368, 2265,<br />

2012, 2265<br />

Staccini, P 976<br />

Stach, C 128, 1634<br />

Stagi, S 222<br />

Stahl, GL 2227<br />

Ståhl-Hallengren, C 2022<br />

Stamm, TA 1745<br />

Stamp, LK 33, 146, 417, 870, 1252<br />

Stancati, A 1840<br />

Stanczyk, J 1093<br />

Stanek, EJ 1561<br />

Stanislawska-Biernat, E 1013<br />

2010 Program Book 349<br />

abstract author Index


aBSTRACT author Index<br />

350<br />

Stankovic-stojanovic, K 905<br />

Stankus, A 800<br />

Stapel, SO 1828<br />

Stappers, MHT 275<br />

Stark, A 468<br />

Starz, TW 2246<br />

Staud, R 809, 821<br />

Steck, R 1446<br />

Steele, R 577<br />

Steen, V 561, 569, 570, 586, 591,<br />

729, 1004, 1231, 2197<br />

Steere, AC 25<br />

Steffen, G 1988<br />

Stegeman, CA 2015, 2023<br />

Stehle, T 1419<br />

Stehman-Breen, C 982<br />

Steiman, A 1874<br />

Stein, CM 1023, 1034, 54, 1607,<br />

1867, 2123<br />

Steinberg, E 241<br />

Steinberg, G 82<br />

Steinfeld, S 2036<br />

Steinkellner, A 1561<br />

Steinmeyer, J 1420, 1722<br />

Steinsson, K 445, 448, 476, 1877,<br />

2240, 2243<br />

Stengaard-Pedersen, K 1370,<br />

1485, 1524, 1761<br />

Stephens, S 1502, 1681<br />

Sterling, KL 52<br />

Stern, S 241<br />

Sterrett, AG 44<br />

Steup, A 950<br />

Steven, KA 621<br />

Stevens, A 506, 1591, 1673, 1691,<br />

2017, 2119<br />

Stevens, S 225<br />

Stevens, W 584<br />

Stevens-Lapsley, JE 171<br />

Stewart, AK 1502<br />

Stewart, S 780<br />

Stinson, J 1408<br />

Stirnemann, J 1653, 2239<br />

Stobaugh, J 253<br />

Stockman, A 1560<br />

Stoenoiu, M 1398<br />

Stoerk, S 1026<br />

Stohl, W 2129, 2187, 457, 1146,<br />

1454, 1457<br />

Stojanov, S 905<br />

Stolarski, BE 1422<br />

Stolk, J 582<br />

Stoll, M 223, 1491<br />

Stoll, T 445, 448, 476, 1877, 2240,<br />

445<br />

Stolshek, B 1540, 1552<br />

Stoltz, RR 160<br />

Stone, D 260, 1698<br />

2010 Program Book<br />

Stone, JH 25, 1671, 2012<br />

Storan, ER 817, 818<br />

Storm, G 283<br />

Stormont, R 780<br />

Stradner, MH 1481<br />

Strand, V 65, 1063, 1096, 1125,<br />

1212, 1452, 1806, 1832, 1940,<br />

1766, 1848, 2168<br />

Strangfeld, A 1111, 1112<br />

Strassburger, K 138<br />

Stratford, PW 1316<br />

Stratton, R 613<br />

Straub, RH 361, 1089<br />

Strausbauch, MA 1580, 1581,<br />

2216<br />

Strauss, B 173, 1383<br />

Street, S 1116<br />

Stricker, K 1423<br />

Strickland, G 1772<br />

Strietholt, S 368, 1719<br />

Stringer, E 238<br />

Strippoli, R 18<br />

Strle, K 25<br />

Strömbeck, B 761<br />

Struessel, T 171<br />

Strusberg, I 1834<br />

Strutton, G 1116, 1446<br />

Stryker, S 398<br />

Studenic, P 79<br />

Stummvoll, GH 469<br />

Stump, KL 2233<br />

Sturfelt, G 445, 448, 476, 731,<br />

1020, 1307, 1877, 2022, 2240,<br />

2243<br />

Sturgess, A 584, 621<br />

Stürz, H 1420, 1722<br />

Su, G 2156<br />

Su, J 13, 1165, 1178, 1194, 2120<br />

Su, L 350, 1245, 1656, 2242, 2243<br />

Su, W 274, 1107<br />

Suarez, B 538<br />

Suarez-Almazor, ME 87, 178, 407,<br />

755, 941, 1047, 1428, 1856, 1865<br />

Subbaiah, RS 363<br />

Suda, A 480<br />

Sudman, M 654<br />

Suematsu, R 433<br />

Suffert, G 858<br />

Sufka, PH 1395<br />

Sugihara, T 1375<br />

Sugiura, T 923<br />

Suhre, K 711<br />

Suissa, S 342<br />

Sulli, A 578, 1236, 1798<br />

Sullivan, BA 1141<br />

Sullivan, C 555<br />

Sullivan, K 726, 865, 2194<br />

Sullivan, T 856<br />

Sumegi, J 653<br />

Sumida, T 292, 352, 1724, 2176<br />

Summers, K 1071<br />

Sumner, DR 200<br />

Sun, C 2274<br />

Sun, H 999, 1516, 2217<br />

Sun, L 918, 1128, 1143, 1182<br />

Sun, M 1448<br />

Sun, Y 306, 343<br />

Sun, Z 1158<br />

Sundararajan, V 1052<br />

Sundel, RP 215, 229, 235<br />

Sundy, JS 157, 160<br />

Sunesen, K 2040<br />

Sung, Y 1157, 1597, 1941<br />

Sunkureddi, PR 302<br />

Supronik, J 392<br />

Suri, D 4<br />

Susic, G 217<br />

Susini, M 528<br />

Sutcliffe, N 1896<br />

Suter, LG 2090, 2092<br />

Sutton, D 1244<br />

Sutton-Tyrrell, K 1168<br />

Suttorp-Schulten, MSA 1933<br />

Suzaki, M 1115<br />

Suzuki, A 1577<br />

Suzuki, E 435, 1526<br />

Suzuki, M 268<br />

Suzuki, T 1611<br />

Svegliati, S 2001, 2008<br />

Svenson, J 1251<br />

Svensson, KE 1829<br />

Svensson, O 937<br />

Svenungsson, E 7, 1181, 1224,<br />

1846<br />

Sverdrup, B 645<br />

Swaim, BH 167<br />

Swallow, E 763<br />

Swan, GE 877<br />

Swan, JT 1401<br />

Swaney, J 606<br />

Swanik, CB 194<br />

Swanink, R 416<br />

Swart, JF 219<br />

Swearingen, C 985, 1284, 1298,<br />

1616, 1765, 1863<br />

Swedish Congenital Heart Block<br />

Study Group 832<br />

Sweeney, SE 1712<br />

Sweetser, M 391, 403<br />

SWEFOT Study Group 1393<br />

Sweiss, N 591<br />

Swetz, KM 595<br />

Swift, L 1034<br />

Swigris, JJ 2119<br />

Swinkels, A 1325<br />

Swinnen, T 520<br />

Swistowski, DR 2197<br />

Sykoutri, D 1493<br />

Sylvestre, M-P 1036<br />

Symmons, D 374, 421, 646, 766,<br />

779, 796, 1067, 1110, 1323, 1600<br />

Syvänen, A-C 1885<br />

Szabo, SM 535, 771<br />

Szanto, S 519, 1946<br />

Szechinski, J 392, 1123<br />

Szekanecz, Z 519<br />

Szentpetery, A 1947<br />

Szklo, M 1148, 2162, 2260<br />

Szmyrka-Kaczmarek, M 1011<br />

Sznajd, J 1011<br />

Szombati, I 392<br />

Sztajnbok, F 1407, 1872<br />

Szücs, G 519<br />

Szumski, A 1927<br />

Szymanski, G 375<br />

Szymkowski, DE 1350<br />

T<br />

Taal, E 1334, 2207, 2281<br />

Taams, LS 1263, 1838<br />

Tabechian, D 849, 1620, 1968<br />

Tabrizi, EN 994<br />

Tada, M 981<br />

Tada, Y 433<br />

Taddio, A 1436<br />

Tadema, H 2015, 2023<br />

Tadey, A 1704<br />

Tadina, C 428<br />

Tadoori, R 148, 883<br />

Tager, AM 606<br />

Taglialatela, G 1536<br />

Tahara, M 1724<br />

Taillefer, SS 1346<br />

Taimeh, Z 1990<br />

Tait, T 1665<br />

Tajana Messi, E 948<br />

Tajima, R 896, 2232<br />

Tak, P 21, 32, 271, 333, 414, 629,<br />

719, 753, 1069, 1095, 1353, 1413,<br />

1416, 1449, 1487, 1507, 1519,<br />

1529, 1534, 1604, 1711, 1817,<br />

1821, 1822, 1828, 1919, 1977,<br />

2169, 2170, 2178, 2272<br />

Takagi, D 2029<br />

Takagi, K 447, 746, 916, 923,<br />

1184, 1587, 1666<br />

Takagishi, TK 704<br />

Takahashi, E 921<br />

Takahashi, K 2227<br />

Takahashi, M 36, 2227<br />

Takahashi, R 26, 1773<br />

Takahashi, S 1724<br />

Takahashi, Y 1042, 1619


Takahata, M 1492<br />

Takasaki, Y 1731<br />

Takase, K 139, 1081<br />

Takayama, L 1546<br />

Takayama, M 1285, 1531<br />

Takehara, K 724, 1230<br />

Takei, M 1708<br />

Takei, S 399<br />

Takeno, M 139, 480, 1081, 1293,<br />

1300, 1512, 2217<br />

Takeoka, M 1709<br />

Takeuchi, T 399, 1013, 1814,<br />

1815, 1793, 1812, 1823<br />

Takezaki, S 1672<br />

Taki, N 335<br />

Takimoto, M 851<br />

Takizawa, Y 932<br />

Talaei, N 2190<br />

Talarico, R 839, 1916<br />

Talia, NN 2007<br />

Taljanovic, M 1636<br />

Talpin, A 1981<br />

Talwalkar, JA 129<br />

Tam, A 613<br />

Tam, L-S 1028<br />

Tamai, M 1371, 1632<br />

Tamaki, H 1783<br />

Tamby, MC 575, 834<br />

Tamura, N 1731<br />

Tan, FK 603, 612, 824, 2214<br />

Tan, M 1004<br />

Tan, Q 1068<br />

Tan, W 1583, 1584<br />

Tan, YC 717<br />

Tanaka, C 983<br />

Tanaka, D 329<br />

Tanaka, E 1053<br />

Tanaka, J 568<br />

Tanaka, S 568<br />

Tanaka, Y 399, 292, 352, 352, 511,<br />

1793, 1812, 1814, 1815, 1823,<br />

2169<br />

Tanaka-Watanabe, Y 292<br />

Tanamas, S 173<br />

Tanangunan, R 1197<br />

Tandon, M 2179<br />

Tang, JX 856<br />

Tang, M 1122<br />

Tang, P 1107<br />

Tani, C 1011<br />

Taniguchi, A 968, 1053, 1611,<br />

1749<br />

Taniguchi, N 369<br />

Taniguchi, S 1709<br />

Tardella, M 1635<br />

Tarelli, E 1105<br />

Targan, S 537<br />

Targ<strong>of</strong>f, IN 1678<br />

Targonska-Stepniak, B 1742<br />

Taroumian, S 415<br />

Tarp, U 55, 1444, 1802, 1807,<br />

1809, 1841<br />

Tarrant, TK 19<br />

Tartelin, M-L 1247<br />

Tarumi, E 1115<br />

Tas, SW 1416<br />

Tascilar, K 1288<br />

Tashkin, DP 2194<br />

Tassi, S 657<br />

Tassinari, A 188, 709<br />

Taurog, JD 1448, 2185<br />

Tavares, R 778, 794<br />

Tavarez, ER 284<br />

Tavera, I 1292, 1314<br />

Tavoni, A 1884, 1916, 2036, 2201<br />

Tayar, JH 407<br />

Taylan, A 1970<br />

Taylor, F 1243, 1245<br />

Taylor, H 664<br />

Taylor, K 446, 502, 980, 1592,<br />

1602<br />

Taylor, M 1058, 1820<br />

Taylor, P 978, 1835<br />

Taylor, W 146, 1372, 1983<br />

Tchao, N 2012<br />

Teal, SA 565, 599<br />

Team, E 2282<br />

TEAR Trial Investigators 1368<br />

Teare, M 1756<br />

Tebo, AE 245<br />

Tegler, C 1677<br />

Tegzova, D 457, 1174, 1454<br />

Teh, L-S 40, 769, 795, 1200<br />

Tehrani, R 704<br />

Teitsma, C 1449, 1977<br />

Tejera, B 1741<br />

Tekarico, T 1185<br />

Tekin, L 114<br />

Tekstra, J 333, 1828<br />

Tektonidou, M 786, 1398, 1784<br />

Telarico, T 437, 1196, 2275<br />

Telles, RW 1169, 1842, 1849<br />

Templeton, J 2019<br />

ten Cate, R 219<br />

ten Dijke, P 1487<br />

ten Kate, R 261<br />

Tena, X 1741<br />

Teng, J 1836, 2173<br />

Teng, YKO 1828<br />

Tennant, A 2063<br />

Teodoro, WR 605, 887<br />

Terao, K 1115<br />

Terauchi, K 139<br />

Terkeltaub, R 147, 152, 153, 634,<br />

1494<br />

Ternant, D 988, 1945<br />

Terreri, M 228, 1339, 1343, 1676<br />

Terrier, B 906, 1249, 1646, 2010,<br />

2011, 2024, 2025, 2030, 2039,<br />

2042, 2046<br />

Terry, EL 101<br />

Teruel, M 2214<br />

Tesar, V 676<br />

Tesolin, P 324<br />

Tezcan, ME 1921<br />

Thacker, SG 2278<br />

Thakkar, V 1560<br />

Thamerl, SE 2015<br />

Thamsborg, G 134, 1953<br />

Thavaneswaran, A 1928, 1932,<br />

1956, 2273<br />

Theander, E 1885, 1896, 1899,<br />

1910<br />

Theate, I 2263<br />

Theis, KA 687, 689, 1563, 2069,<br />

2079, 2080, 2138, 2139<br />

Theriault, C 2243<br />

Therneau, TM 67, 1580, 1581,<br />

2216<br />

Theulin, A 858<br />

Thiel, M 1973<br />

Thiele, GM 2235<br />

Thiele, K 770<br />

Thiele, RG 849, 889, 1051, 1616,<br />

1617, 1620<br />

Thiemann, P 286<br />

Thienel, U 1119<br />

Thierry, S 2267<br />

Thierry-Palmer, M 252<br />

Thomas, B 253, 254, 2267<br />

Thomas, G 1446, 1986, 2184<br />

Thomas, J 1141<br />

Thomas, M 1146, 1172<br />

Thomas, O 74<br />

Thomas, R 1116, 1446<br />

Thomas, S 1256<br />

Thomas, T 176, 964<br />

Thombs, BD 1346, 1347, 1348,<br />

2247<br />

Thome, N 230<br />

Thompson, AE 419<br />

Thompson, C 91<br />

Thompson, JM 108<br />

Thompson, K 2243<br />

Thompson, L 9, 24, 466, 734<br />

Thompson, RN 661, 1763<br />

Thompson, S 243, 255, 654, 1729<br />

Thomsen, R 2040<br />

Thomson, W 264, 266, 654, 836,<br />

1075, 1394, 1593<br />

Thoors, U 2245<br />

Thorel, J-B 2261<br />

Thormann, A 1444, 1841<br />

Thorne, C 300<br />

Thorne, JC 57, 306, 313, 341, 343,<br />

344, 396, 659, 978, 1735, 1737<br />

Thornton, S 244, 1728<br />

Thorp, LE 200<br />

Thuemmler, K 1261<br />

Thurlings, R 333, 1821, 1822,<br />

1828<br />

Tian, W 618<br />

Tieng, AT 2186<br />

Tiersma, Y 1977<br />

Tiku, ML 1767<br />

Tily, H 1185, 1196<br />

Timenetsky, M 224, 481, 1437<br />

Tinazzi, I 671<br />

Tindall, EA 993<br />

Ting, MHX 445<br />

Tingström, J 1322<br />

Tiseo, P 710<br />

To, CH 467, 1206, 1667, 2159<br />

Tobon, GJ 1914, 2177<br />

Tochimoto, A 923, 1587, 1666<br />

Todd, A 1344<br />

Todesco, S 290<br />

Todoerti, M 1397<br />

Toedter, G 1786, 1804<br />

Toes, R 1015, 2114, 1780<br />

Toib, D 216, 1633<br />

Tokita, A 1749<br />

Tola, MR 1162<br />

Toledano, D 1287<br />

Tolstykh, I 683, 686, 872, 951,<br />

1385, 1557, 2098<br />

Tolusso, B 355, 744, 1098, 1239,<br />

1582<br />

Tom, BDM 664<br />

Tomasson, G 2198<br />

Tomcik, M 607, 611, 614, 616, 672<br />

Tomi, C 896<br />

Tomita, T 291, 298<br />

Tomlinson, B 1028<br />

Tommasini, A 1685, 1706<br />

Tomsic, M 55, 1802, 1807, 1896,<br />

2036<br />

Ton, E 380<br />

Tonev, D 286<br />

Tonks, L 1251<br />

Tonner, C 789, 2113<br />

Tonnini, C 2001<br />

Tony, H 383, 745, 782, 1026,<br />

1255, 1411<br />

Topolewski, K 635, 855<br />

Torbeyns, A 390<br />

Tornehave, D 847<br />

Torner, J 201, 693, 683, 686, 872,<br />

951, 2058, 2100, 2133<br />

Tornero, J 975<br />

Torok, KS 1683, 2006<br />

Torralba, KMD 46, 1429, 1432<br />

2010 Program Book 351<br />

abstract author Index


aBSTRACT author Index<br />

Torrenegra, A 1811<br />

Torrent, A 106<br />

Torrente, V 1118, 1796<br />

Torres, A 874<br />

Torrijos, A 975<br />

Tortorella, M 823<br />

Toska, K 1220<br />

Tosteson, A 992<br />

Toth, M 259, 1673, 1691, 2017<br />

Touboul, P-J 386<br />

Touby, E 909<br />

Touchais, S 29<br />

Touma, Z 772, 783, 1878<br />

Tourkina, E 622<br />

Tourkodimitris, S 800<br />

Tournadre, A 917, 1515<br />

Toussirot, E 701, 1810, 2269<br />

Towheed, TE 109<br />

Townsend, A 1321, 2282<br />

Townsend, M 1609<br />

Toyama, Y 1611<br />

Tracy, R 1148, 2260<br />

Traggiai, E 265<br />

Trainito, S 1687<br />

Tran, A 1446<br />

Tran, CL 1418<br />

Tran, T-A 1249, 1305<br />

Trapiella, L 824<br />

Travers, H 383, 414, 2169<br />

Treat to Target Taskforce 1013<br />

Trejo-Iriarte, CG 1475<br />

Trenkmann, M 35, 1518<br />

Trevisani, VFM 1458<br />

Triadafilopoulos, G 2205, 2206<br />

Triantafyllou, A 11<br />

Tricot, L 2042<br />

Triolo, G 297, 1627<br />

Triolo, PF 1798<br />

Trivedi, A 991<br />

Trollmo, C 1125, 1917<br />

Tron, F 915<br />

Trotta, F 297, 1162<br />

Troum, OM 120<br />

Trouw, LA 2114<br />

Truchetet, M 571, 1987, 1992<br />

Trudes, G 1437<br />

True, M 1747<br />

Truedsson, L 1037, 1440, 1578<br />

Trugman, JM 648<br />

Trunick, CM 574<br />

Trupin, L 627, 789, 991, 1024,<br />

1592, 1882, 2113<br />

Tsai, M 149<br />

Tsang, K 675<br />

Tsao, BP 262, 500, 730, 1182,<br />

1583, 1584, 1585, 1586, 1591,<br />

1595, 2145, 2147, 2148, 2274<br />

Tsao, H 42, 1335, 2064<br />

Tsatsaris, V 2034<br />

Tschopp, J 1426<br />

Tse, SM 225, 1408, 1681<br />

Tseng, C-E 990<br />

Tseng, C-h 729<br />

Tseung, L 1028<br />

Tshantshapanyan, L 1681<br />

Tsiaousis, G 1021<br />

Tsifetaki, N 1215<br />

Tso, A 1233<br />

Tsokos, GC 1583, 2126, 2277<br />

Tsoras, M 654<br />

Tsou, P 282, 1504, 2007<br />

Tsuboi, H 2176<br />

Tsuchida, T 1138<br />

Tsui, FW 549, 1450<br />

Tsuji, S 298<br />

Tsuji, WH 125<br />

Tsukano, M 1812<br />

Tsumiyama, K 851, 867, 1258,<br />

1264, 1272<br />

Tsumoto, C 298<br />

Tsuru, T 1115, 1138<br />

Tsuruno, K 1086<br />

Tsuzaka, K 1743<br />

Tu, X 52, 1799<br />

Tubach, F 376<br />

Tucker, L 1408, 1674, 1688, 1701<br />

Tugal-Tuktun, I 1305, 1308<br />

Tugwell, P 794<br />

Tumyan, A 880<br />

Tunca, M 666<br />

Tunceli, O 1542<br />

Tuncer, N 1208<br />

Tung, KSK 1448<br />

Turesson, C 774, 1020<br />

Turi, GK 1311<br />

Turk, DC 2246<br />

Turkiewicz, A 761<br />

Turkish Takayasu Study Group<br />

1291, 1313<br />

Turnbull, EM 214, 731<br />

Turner, M 1606<br />

Turner-Stokes, T 740<br />

Turrin, CO 281<br />

Twardowsky, AO 539<br />

Twilt, M 219<br />

Tymms, K 320, 584<br />

Tyndall, A 2196<br />

Tyrrell, P 2019, 2107<br />

Tyson, S 2063<br />

Tzioufas, A 1895, 1896, 1910,<br />

1912, 2036, 2175<br />

U<br />

Ubeda, C 1390<br />

Uchimura, T 237<br />

Uda, H 373<br />

Uechi, E 1783<br />

Ueda, A 139<br />

Ueda, Y 1042<br />

Ueki, Y 1812<br />

Ueland, T 479<br />

Uesato, R 329<br />

Uetani, M 1371<br />

Ugurlu, S 1288, 1697<br />

Uherek, C 1125<br />

Uhlig, T 377, 1603, 1750, 1774<br />

Uhm, W-S 1941<br />

Uhrova, J 1649<br />

Ukichi, T 921<br />

Ulgiati, D 730<br />

Ullman, S 1682<br />

Ullrich, KR 2013<br />

Ullrich, S 679<br />

Umeda, N 292, 352<br />

Umehara, H 1898<br />

Umoh, E 167<br />

Umscheid, T 1420<br />

Unitan, R 1543<br />

Upchurch, K 162<br />

Urata, Y 329<br />

Urban, A 220<br />

Urbonaviciute, V 857<br />

Uribe, A 1673, 1674, 1691, 2017<br />

Urowitz, MB 13, 445, 448, 450,<br />

455, 476, 731, 772, 1165, 1850,<br />

1868, 1869, 1874, 1877, 1878,<br />

2240, 2243<br />

Urquhart, D 1383<br />

Urstad Jensen, K 1846<br />

Ursum, J 85<br />

Urzainqui-Mayayo, A 1509<br />

Usnayo, MJG 356<br />

Ustianowski, A 421<br />

Usui, T 1377<br />

Utset, TO 457, 464, 496, 1164,<br />

1612, 1875, 1882<br />

Utsunomiya, M 1641<br />

Utz, PJ 428<br />

Uziel, Y 1704<br />

V<br />

Vacher-Lavenu, MC 1991<br />

Vaddi, K 2172<br />

Vahadat, S 546<br />

Vahldiek, J 2181<br />

Vail, A 588<br />

Vakil, E 1159<br />

Vakkalanka, S 279<br />

Valdes, A 823, 841, 1980<br />

Valdimarsson, H 1951<br />

Valduga, CJ 284<br />

Valente, RM 2173<br />

Valentini, G 572, 1627<br />

Valeriano-Marcet, J 44<br />

Valerio, CJ 727<br />

Valle, RR 517<br />

Vallejo, M 96<br />

Valle-Oñate, R 552<br />

Vallongo, C 1439<br />

Valor, L 739<br />

Valrie, CR 1406<br />

van Baarsen, LGM 271<br />

van Beuningen, HM 1501<br />

van Bon, L 844, 1210, 2002<br />

van Booma-Frankfort, C 380<br />

van de Laar, MAFJ 314, 662, 1019,<br />

1334, 1771, 1833, 2207, 2281<br />

van de Loo, FAJ 713, 1501, 1532,<br />

1535, 1622, 1733, 2230<br />

van de Sande, G 32<br />

van de Sande, M 32, 1069, 1449,<br />

1604<br />

van de Stadt, LA 1091<br />

van de Stadt, RJ 1091<br />

van den Bemt, BJF 1826<br />

van den Berg, W 275, 283, 371,<br />

713, 844, 845, 1210, 1472, 1495,<br />

1501, 1532, 1535, 1622, 1719,<br />

1730, 1733, 2002, 2230<br />

van den Brand, BT 713, 1535<br />

van den Broek, M 328, 334, 663<br />

van den Ende, CHM 2283<br />

Van den Eynde, B 2263<br />

van den Hoogen, F 1826, 2196<br />

van den Oever, IAM 643<br />

van Denderen, JC 1933<br />

van der Burg, M 753<br />

van der Giesen, FJ 2283<br />

Van der Goes, MC 973<br />

Van der Heijde, DM 142, 295, 303,<br />

518, 559, 1013, 1077, 1113, 1114,<br />

1368, 1629, 1774, 1806, 1922,<br />

1927, 1943, 1948, 1949, 1985,<br />

2270<br />

van der Helm, AHM 1782<br />

van der Helm-van Mil, AHM 660,<br />

1744, 1780<br />

van der Horst-Bruinsma, IE 1933<br />

Van der Kamp, S 1947<br />

van der Kraan, PM 1501, 1532<br />

van der Laken, CJ 1613<br />

van der Linden, MPM 1744, 1780<br />

van der Lubbe, PAHM 334<br />

van der Maas, A 1826<br />

van der Merwe, J 1904<br />

van der Neut, R 1711<br />

van der PouwKraan, TCTM 1084<br />

van der Vaart, R 1334<br />

van der Westhuizen, N 1060<br />

van der Woude, D 2114<br />

van der Wurff-Jacobs, KMG 278,<br />

352<br />

2010 Program Book


636<br />

van Dongen, CJJ 90<br />

Van Doornum, S 584, 1052, 1772<br />

van Duijnhoven, W 2265<br />

van Eck-Smit, B 1822<br />

van Eenennaam, H 1534<br />

van Eyk, J 2167<br />

van Haandel, L 253<br />

van Hamburg, JP 38, 1259, 1274<br />

van Heerde, W 1210, 2002<br />

van Helden-Meeuwsen, CG 1904<br />

van Hoeven, L 2180<br />

van Hulst, L 59<br />

van Kampen, AH 1069, 1604<br />

van Krugten, MV 334<br />

van Kuijk, AWR 1095<br />

van Laar, J 2214<br />

van Leeuwen, H 38, 1274<br />

van Lent, P 283, 845, 2002<br />

van Lent, PL 1472, 1495<br />

van Maanen, M 1529, 1711<br />

van Paassen, P 676<br />

van Riel, P 55, 59, 314, 371, 641,<br />

662, 844, 1210, 1599, 1771, 1802,<br />

1807, 1826, 1833, 2207, 2214<br />

van Roermund, PM 1380<br />

van Roon, JAG 278, 333, 636, 973,<br />

1900, 1903<br />

van Rossum, MAJ 209, 219, 1705<br />

van Ryn, J 604<br />

van Schaardenburg, D 85, 723,<br />

1033, 1091<br />

van Schaik, BD 1069, 1604<br />

van Schouwenburg, P 1445<br />

van Sijl, AM 90, 643, 2211<br />

van Suijlekom-Smit, LWA 219,<br />

1872<br />

van Tuyl, LHD 723, 961, 2108<br />

van Vollenhoven, R 55, 65, 378,<br />

391, 410, 411, 418, 445, 451, 452,<br />

454, 1172, 1392, 1393, 1454, 1802,<br />

1805, 1806, 1807, 1829, 1832,<br />

2243, 2265<br />

van Zeben, J 1775, 1776<br />

van Zoest, KPM 1416<br />

Van’t Slot, R 1599, 2214<br />

Vanags, D 441<br />

Vandam, W 2251, 2252<br />

Vandenbroeck, K 896<br />

Vander Cruyssen, B 340<br />

Vanderschueren, G 311<br />

VanMater, H 1699<br />

Vanness, DJ 2266<br />

Vanoirbeek, J 1720<br />

Vanthuyne, M 824<br />

Varache, S 2261<br />

Varanasi, KVS 279<br />

Varga, J 560, 566, 601, 617, 2214<br />

Vargas, A 96, 808<br />

Vargas, F 1811<br />

Vargas, G 1360<br />

Vargas Lebrón, C 1944<br />

Vargas-Alarcon, G 96<br />

Vargas-Guerrero, A 1614<br />

Vargas-Worackova, F 459<br />

Varisco, V 532<br />

Varley, C 758<br />

Varnier, GC 210, 232<br />

Varughese, D 1549<br />

Vasaitis, L 1885, 1899<br />

Vasconcelos, C 1398, 1578<br />

Vasconcelos, J 89<br />

Vasconcelos, MM 1458<br />

Vastesaeger, N 1829, 1948, 2265<br />

Vasudevan, A 445, 1080, 2243<br />

Vaughn, FL 823<br />

Vaz, B 415<br />

Vazquez-Mellado, J 157, 525<br />

Vazquez-Rodriguez, TR 1301<br />

Veale, D 16, 360, 871, 1032, 1105,<br />

1391, 1508, 1510, 1533, 1625,<br />

1631, 1947, 2065, 2145<br />

Veenbergen, SS 1501<br />

Veenh<strong>of</strong>, C 2051<br />

Veeraraghavan, S 279<br />

Vega, R 758<br />

Vega-Ostertag, M 3<br />

Vela-Ojeda, J 1150<br />

Velasco, F 1357<br />

Velasco, J 1446<br />

Velosa, APP 605, 887<br />

Venables, PJ 1717<br />

Vencovsky, J 926, 1174, 638, 1806<br />

Venkatraman, MM 1106<br />

Venugopalan, A 66, 1640, 1642<br />

Vera Kellet, C 1661<br />

Vera-Lastra, O 1150<br />

Verghese, J 2095<br />

Vergnaud, P 1466<br />

Verheij, RA 1029, 2211<br />

Verhoef, J 1338<br />

Vermeer, M 314, 662, 1771<br />

Vermeij, E 1622, 1733<br />

Vermeulen, EM 2051<br />

Vernon, E 378, 411, 1819, 1820,<br />

2262<br />

Verrouil, E 2094<br />

Versari, A 1290<br />

Verschueren, P 311, 2170<br />

Versnel, MA 1904<br />

Verstappen, SM 766, 779, 796,<br />

1067, 1110<br />

Vervoordeldonk, M 1353, 1529,<br />

1711<br />

Verweij, CL 1084<br />

Vessey, A 1940<br />

Vestweber, D 2234<br />

Vettori, S 572<br />

Viale, A 1390<br />

Viana, V 481, 1437<br />

Viappiani, S 1477<br />

Viatte, S 1600, 2215<br />

Vibert, J-F 533<br />

Vicente, EF 1229<br />

Victor, T 598<br />

Vidal, S 1801<br />

Vidaud, M 2025<br />

Vieira, VM 64<br />

Vielleux, M 1170<br />

Viergever, MA 121, 124, 952<br />

Vignoli, M 261<br />

Vignon, EP 952<br />

Vigus, A 245<br />

Vihervaara, V 759<br />

Vijayvergiya, R 2086<br />

Vijenthira, A 1408<br />

Vikerfors, A 7<br />

Vila, LM 1591, 1594<br />

Villa, I 1296, 1650<br />

Villa-Blanco, I 1871<br />

Villaggio, B 1798<br />

Villalba, JM 1357<br />

Villeneuve, E 1090, 1254<br />

Vina, ER 1875<br />

Vincent, A 101, 104, 108<br />

Vincent, C 1653<br />

Vincent, G 118<br />

Vincken, KL 121<br />

Vinterberg, H 133<br />

Virayavanich, W 135<br />

Virta, L 80<br />

Visconti, C 2220<br />

Visconti, RP 622<br />

Visman, I 90, 643, 1933<br />

Visser, H 1785, 2207<br />

Visser, K 1396<br />

Vissink, A 1889, 1892, 1905<br />

Vista, EG 9, 466, 1197<br />

Visvanathan, S 1127<br />

Viswanadha, S 279<br />

Viswanathan, H 971, 1540, 1552<br />

Vital, EJ 118<br />

Vital, EM 1126<br />

Vitale, A 1706<br />

Vitali, C 1896, 1910<br />

Vitalle, MS 1343<br />

Vitolo, B 623<br />

Vittadello, F 1439, 1682, 2033<br />

Vittecoq, O 1087, 1827, 1890,<br />

1910<br />

Vivier, E 1664<br />

Vivino, FB 1898, 1907<br />

Vlachoyiannopoulos, P 621<br />

Vlad, SC 2213<br />

Vlaeyen, J 520<br />

Vlahos, B 1927<br />

Vlamakis, VE 1246<br />

Vliet Vlieland, TPM 582, 1338,<br />

1755, 2051, 2283, 2284<br />

Voermans, C 1822<br />

Vogel-Claussen, J 2122<br />

Vogl, T 845, 1472, 1495<br />

Vogler, LB 255, 256, 790<br />

Voitzsch, A 1025<br />

Vojinovic, J 217<br />

Volgas, DA 1573<br />

Volin, MV 17, 23, 270, 714, 1506<br />

Voll, R 857, 2234<br />

Vollenhoven, RV 448, 476, 891,<br />

1877, 2240<br />

Vollenweider, C 1896, 1898<br />

Voloshyna, I 1072<br />

von der Recke, A 668<br />

Von Feldt, JM 456<br />

von Hinueber, U 770<br />

Von Muhlen, CA 383, 1639<br />

Von Scheven, E 1701, 1702, 1677<br />

Vonk, M 824, 829, 1210, 2002,<br />

2004, 2214<br />

Vonk Noordegraaf, A 1623<br />

Vonkeman, HE 1019, 1833<br />

Vos, K 333, 1821, 1828<br />

Voskuyl, A 332, 643, 1084, 1613,<br />

1623, 1859, 2214<br />

Vosslamber, S 1084<br />

Vosters, JL 1413, 2178<br />

Voulgarelis, M 1912, 2036<br />

Vounotrypidis, P 2035<br />

Vreijling, J 1529<br />

Vreugdenhil, SA 380<br />

Vugler, A 1244<br />

Vukatana, G 1627<br />

Vukelic, M 427, 866<br />

Vukelic, S 1990<br />

Vyse, TJ 500, 1583, 1584, 1585,<br />

1586, 1591, 1594, 1595, 2145,<br />

2147, 2148<br />

W<br />

Wachsmann, D 858, 1998<br />

Wactawski-Wende, J 1062<br />

Wada, T 568<br />

Wade, M 1201<br />

Wade, SW 1540, 1552<br />

Wadell, G 1847, 2115<br />

Wadle, A 1973<br />

Wagegg, M 630<br />

Wages, J 1030<br />

Wagman, RB 2161<br />

Wagner, B 950<br />

Wagner, C 1127<br />

Wagner, L 2280<br />

2010 Program Book 353<br />

abstract author Index


aBSTRACT author Index<br />

354<br />

Wagner, M 654<br />

Wagner-Weiner, L 464, 1673,<br />

1691, 1702, 2017, 1677<br />

Wahezi, DM 1673, 1691, 1692,<br />

2017<br />

Wahl, D 1<br />

Wahren-Herlenius, M 832, 1322,<br />

1579, 1885, 1917<br />

Waimann, C 50, 941, 1047, 1865<br />

Wainmann, C 324<br />

Waite, P 213<br />

Waiter, GD 649<br />

Wakabayashi, K 26, 1773<br />

Wakefield, I 1243, 1245<br />

Wakefield, RJ 777, 1629, 1637,<br />

1654<br />

Wakeland, EK 2146<br />

Wakhlu, A 1954<br />

Wakitani, S 981<br />

Waldman, T 763<br />

Walitt, B 71, 110, 112, 117, 651,<br />

1062<br />

Walker, D 1064, 1186, 2082<br />

Walker, R 1568<br />

Walker, S 597, 1201, 1222<br />

Walker-Bone, K 966, 1645<br />

Wallace, CA 243, 255, 1677, 1678,<br />

1702<br />

Wallace, D 234, 445, 448, 451,<br />

453, 454, 457, 471, 476, 1172,<br />

1452, 1454, 1457, 1877, 2240,<br />

2243<br />

Wallace, E 694<br />

Wallin, H 1392, 1393<br />

Wallston, KA 115, 802<br />

Wallwiener, D 1145<br />

Walsh, D 676<br />

Walsh, J 546, 967<br />

Walsh, M 676<br />

Walsh, NC 30, 716<br />

Walter, M 2066<br />

Walther, M 138<br />

Wan, X 980<br />

Wandinger, K-P 1174<br />

Wang, A 971<br />

Wang, BC 1117<br />

Wang, C 95<br />

Wang, D 423, 918, 1143, 1182,<br />

1686<br />

Wang, F 94, 105, 113<br />

Wang, H 618<br />

Wang, J 1119, 152, 153, 420, 442,<br />

509, 1107, 1266, 1268, 1499, 2129,<br />

2189<br />

Wang, J-CE 849<br />

Wang, K 836, 1464, 2217<br />

Wang, L 274, 694<br />

Wang, M 826<br />

Wang, Q 473, 2229<br />

2010 Program Book<br />

Wang, S 331, 1134<br />

Wang, T 907, 1386<br />

Wang, W 436<br />

Wang, X 1068, 1107, 1119<br />

Wang, Y 97, 98, 183, 192, 648,<br />

741, 806, 813, 814, 815, 1100,<br />

1214, 1352, 1383, 1948, 2032,<br />

2048<br />

Ward, M 522, 642, 786, 1039,<br />

1784, 1982, 2185<br />

Ward, RJ 122<br />

Ware, M 107<br />

Warfvinge, G 1899<br />

Warner, M 957<br />

Warren, RB 833<br />

Warren, ST 250<br />

Warriner, A 1006, 1543, 1561<br />

Warrington, KJ 774, 1304, 2198<br />

Wartenberg-Demand, A 1125<br />

Warzocha, U 2034<br />

Wasko, MC 385, 345, 386, 642,<br />

1039, 1442<br />

Wason, S 147<br />

Watanabe, N 1375<br />

Watanabe, R 139, 1300<br />

Watanabe, T 139<br />

Watier, H 988<br />

Watkins, M 2251, 2252<br />

Watson, K 421<br />

Watson, KD 374, 1323<br />

Watson, ME 1566<br />

Watt, S 565<br />

Wattiaux, M-J 2269<br />

Webb, C 2274<br />

Webb, R 1590<br />

Weber, DA 306, 343<br />

Weber, E 853, 859, 861, 1723<br />

Wechsler, B 478, 1249, 1658,<br />

1660<br />

Weckerle, CE 1164<br />

Weel, A 317, 1775, 1776, 2180<br />

Wegner, N 1717<br />

Wei, C 733, 1085<br />

Wei, J 601, 617<br />

Wei, N 1382<br />

Wei, X-n 367<br />

Weide, T 2237<br />

Weidensaul, DN 331<br />

Weijers, K 1613<br />

Weinberger, M 1575<br />

Weinblatt, M 41, 308, 390, 945,<br />

946, 1050, 1102, 1119, 1335, 1610,<br />

1753, 1778, 1782, 1805, 2064<br />

Weingarten, TN 108<br />

Weinstein, A 869, 1457, 2090<br />

Weinstein, J 742<br />

Weinstein, SP 152, 153<br />

Weisbarth-Riedel, E 1435<br />

Weisman, M 77, 187, 305, 471,<br />

522, 537, 658, 1094, 1197, 1768,<br />

1982, 2185<br />

Weiss, A 609, 665, 1961<br />

Weiss, H 2222<br />

Weiss, JE 234<br />

Weiss, P 233, 1703<br />

Weissmann, G 1390<br />

Weitz, M 980<br />

Welin Henriksson, EMB 1322<br />

Wellborne, F 1146<br />

Wellcome Trust Case-Control<br />

Consortium 2 1355<br />

Wells, A 727, 1120, 1212<br />

Wells, GA 723, 794, 1758, 2108<br />

Welsh, P 483<br />

Welsing, PMJ 124, 380, 388, 952,<br />

1759<br />

Wendholt, D 1478, 1719<br />

Wendling, D 2269, 904, 1752,<br />

1945<br />

Wenink, M 844, 1210<br />

Wenting, MJG 1900<br />

Wermuth, PJ 1993<br />

Wernitzsch, H 886<br />

Werth, V 920, 1198, 1213, 1521<br />

Werther, W 1031<br />

Wesseling, J 184<br />

Wessels, J 2021, 2234<br />

West, B 273<br />

West, SG 702, 2013<br />

Westedt, ML 663<br />

Westerman, M 1804<br />

Westh<strong>of</strong>f, G 1736<br />

Westhovens, R 311, 340, 390,<br />

520, 1120, 1829, 1836, 1837, 2170,<br />

2214<br />

Westlund, KN 1536<br />

Westman, K 676, 2014<br />

Westphal, L 44<br />

Westra, J 1195<br />

Wettstein, D 493<br />

Weyand, CM 351, 1079, 2127<br />

Weyer, M-G 911<br />

Whalen, E 813<br />

Whang, M-H 2158<br />

Wheeler, M 841<br />

Wheless, L 475<br />

Whipple, MO 104<br />

White, AJ 216, 1633, 1673, 2017<br />

White, D 683, 693, 2058, 2067,<br />

2133<br />

White, J 1540, 1552<br />

White, ME 1408<br />

White, P 689, 1008, 1678, 2080<br />

Whitfield, M 573, 675<br />

Whitlow, HJ 694<br />

Whitney-Mahoney, K 225<br />

Wichuk, S 1451<br />

Wicks, I 584, 1001, 1009, 1052,<br />

1772<br />

Widdifield, J 57, 313, 341<br />

Widmer, A 895, 1425, 1435<br />

Wiedeman, A 494, 506<br />

Wiegant, K 1380<br />

Wieman, M 944<br />

Wiendl, H 1255<br />

Wiener, HW 828<br />

Wierenga, W 269<br />

Wierk, A 1704<br />

Wigler, I 697<br />

Wigley, FM 560, 566, 587, 589,<br />

596, 1201, 1222, 1348, 1989, 2192<br />

Wijbrandts, C 32, 1507, 1822<br />

Wilder, T 1469, 1470<br />

Wildi, LM 938<br />

Wildman, H 1990, 2193<br />

Wildt, M 1623<br />

Wiley, G 1586, 2144, 2146<br />

Wilkie, R 2079, 2139<br />

Willemze, A 2114<br />

Williams, A 500, 827, 1591, 2145,<br />

2148<br />

Williams, DA 94, 650, 800<br />

Williams, M 1122<br />

Williams, S 321, 1526<br />

Williams, WV 2172<br />

Willis, CR 278<br />

Wilson, D 931<br />

Wilson, E 1071<br />

Wilson, G 1756<br />

Wilson, IB 1404<br />

Wilson, J 934, 1608, 2149<br />

Wilson, M 914, 1831<br />

Wilson, N 620, 1399, 2106<br />

Wilson, P 734, 1067<br />

Wimmer, M 200, 2099<br />

Windhorst, AD 1613<br />

Winfield, JB 100, 814<br />

Wing, H 627<br />

Winiarska, M 994<br />

Winkelmayer, W 2104<br />

Winthrop, K 404, 721, 722, 758,<br />

1643, 2103<br />

Wipff, J 580, 1991, 2226<br />

Wipfler-Freissmuth, E 2222<br />

Wise, B 1385, 2212<br />

Wise, C 255, 654, 2219<br />

Wise, R 596, 1201, 1989<br />

Wise, SC 289<br />

Wisniewski, SR 2052<br />

Wither, JE 424, 425, 429, 1874,<br />

2190<br />

Witko-Sarsat, V 834<br />

Witt, MN 1781<br />

Witte, S 392, 1123


Witte, T 824, 1578, 1579, 2214<br />

Wittkowski, H 2002<br />

Wluka, A 173, 183, 1383<br />

Woby, S 646<br />

W<strong>of</strong>sy, D 1453, 2085<br />

Wohlreich, M 105, 113<br />

Wolbink, G 1091, 1445, 1825,<br />

1826, 1828<br />

Wold, AE 1248<br />

Wolf, D 718<br />

Wolfe, F 89, 100, 110, 111, 112,<br />

117, 331, 346, 651, 810, 1132<br />

Wolff, C 1089<br />

Wolff, R 397, 1099<br />

Wolfson, M 1555<br />

Wollenhaupt, J 1788, 1837, 1919<br />

Wollman, J 697<br />

Wollmer, P 1902<br />

Wolvers-Tettero, I 2004<br />

Wong, A 249, 747<br />

Wong, B 225, 273, 288<br />

Wong, JB 1795<br />

Wong, LG 1870<br />

Wong, M 428, 497<br />

Wong, T 1772<br />

Wong, WS 1233<br />

Woo, J 1060<br />

Woo, JMP 262, 998<br />

Woo, J-H 359<br />

Woo, P 1434<br />

Wood, GM 1516<br />

Wood, J 717<br />

Wood, LS 823<br />

Wood, PB 102<br />

Wood, S 1129, 2171<br />

Wood, T 573<br />

Woods, JM 17, 39, 1131<br />

Woodward, AL 1673, 1691, 2017<br />

Woodward, JG 864<br />

Woodworth, T 1474, 1766<br />

Wooley, PH 1729<br />

Woolf, C 1385, 1557, 2098<br />

Wootton, J 234<br />

Worthington, J 264, 266, 824,<br />

829, 833, 1075, 1593, 1600, 1756,<br />

2214, 2215<br />

Wouters, C 1434, 1684<br />

Wouters, D 1822<br />

Wright, EA 2091, 2137<br />

Wright, J 2137<br />

Wright, N 1062<br />

Wright, S 1434<br />

Wright, T 560, 566, 1080, 1690<br />

Wright, V 1681<br />

Wrigley, T 192<br />

Wu, E 1699<br />

Wu, FQ 1680, 1872<br />

Wu, HJ 1139<br />

Wu, J 149<br />

Wu, L 1678<br />

Wu, M 8, 602, 603, 612<br />

Wu, P 1168<br />

Wu, Q 1135, 1260, 1412, 2189<br />

Wu, R 710, 1121<br />

Wu, W 1441<br />

Wu, X 507, 831, 838, 1598, 1804<br />

Wu, Z 1598<br />

Wulffraat, NM 219<br />

Wunrau, C 1478<br />

Wuttge, D 1210<br />

Wysocka, M 1198<br />

Xavier, R 1434<br />

Xian, H 1395<br />

Xiang, S 944<br />

Xiao, H 2048<br />

Xie, F 239, 404, 721, 722, 1643,<br />

2084, 2103<br />

Xie, H 826<br />

Xie, J 1772<br />

Xie, L 86, 426<br />

Xie, S 1412<br />

Xing, L 712, 1492, 1710<br />

Xu, D 28<br />

Xu, L 1464, 1564<br />

Xu, M 564, 592<br />

Xu, S 443, 1114, 1190, 1996<br />

Xu, W 386, 1097, 1114, 1943,<br />

2264<br />

Xu, Y 742<br />

Xue, W 1107<br />

X<br />

Yadav, B 1446<br />

Yadav, MK 2086<br />

Yagüe, J 1280<br />

Yajima, M 1708<br />

Yajima, N 1773<br />

Yamada, A 921<br />

Yamada, H 365<br />

Yamada, M 1672<br />

Yamada, R 1577<br />

Yamada, S 1839<br />

Yamada, T 1053<br />

Yamaguchi, K-i 1783<br />

Yamaguchi, Y 670<br />

Yamaji, K 1731<br />

Yamamoto, A 1511<br />

Yamamoto, K 1577, 1814, 292,<br />

352, 1815<br />

Yamamoto, M 280, 1641<br />

Yamamoto, N 1708<br />

Yamamoto, T 619, 1467<br />

Y<br />

Yamamura, T 896, 2232<br />

Yamanaka, H 399, 447, 746, 897,<br />

916, 923, 968, 1053, 1184, 1587,<br />

1611, 1666, 1749, 1793, 1812,<br />

1814, 1815, 1823, 1844<br />

Yamasaki, S 364, 1371, 1632<br />

Yamashita, H 1042, 1619<br />

Yamauchi, K 2020<br />

Yamazaki, H 1709<br />

Yamazaki, Y 1672<br />

Yan, C 330<br />

Yan, J 1107<br />

Yan, K 438, 2191<br />

Yan, X 1978<br />

Yanagida, T 1531<br />

Yanagimachi, M 921<br />

Yanes, J 415<br />

Yang, B 260, 634, 1494, 2217<br />

Yang, H 634, 1038<br />

Yang, L 742, 1680<br />

Yang, P 1135, 1260, 1412, 2189<br />

Yang, S 299, 304, 1117<br />

Yang, X 274, 1107<br />

Yang, Y-C 971, 982<br />

Yang, Z 1499<br />

Yano, K 1611, 1749<br />

Yao, C 1979<br />

Yao, Q 1656<br />

Yao, W 965<br />

Yao, Z 1724<br />

Yarboro, C 1161<br />

Yarlagadda, S 1253<br />

Yasuda, S 2, 5, 10, 1909, 2254<br />

Yasukawa, M 1265, 2016<br />

Yau, I 2019<br />

Yavuz, S 1133, 1208, 1803<br />

Yazbek, M 356<br />

Yazdany, J 627, 789, 991, 2113<br />

Yazdanyar, A 1039<br />

Yazici, A 822<br />

Yazici, H 84, 1288, 1312, 1697<br />

Yazici, Y 985, 990, 1298, 1857,<br />

1284, 1303, 1390, 1559, 1808,<br />

1863<br />

Ye, Z 1536<br />

Yeleswaram, S 2172<br />

Yelin, EH 60, 484, 627, 789, 991,<br />

1024, 1592, 2090, 2091, 2113<br />

Yelios<strong>of</strong>, O 1901<br />

Yentes, JM 169<br />

Yeo, E 13<br />

Yeremenko, N 629, 1449<br />

Yet Lin, L 444<br />

Yeung, RSM 249, 267<br />

Yew, M 2122<br />

Yildirim, S 1279<br />

Yildirim-Toruner, C 1191<br />

Yildiz, Y 1970<br />

Yilmaz, H 1282<br />

Yilmaz, N 1208<br />

Yilmaz, V 822, 2200<br />

Yim, CW 477<br />

Yin, F 1107<br />

Yin, H 507<br />

Yin, J 1119<br />

Yin, M 129<br />

Ying, J 1099, 1688<br />

Ying, KY 477<br />

Yip, G 1028<br />

Yip, PSF 773<br />

Yiu, KH 582<br />

Yokoe, I 1797<br />

Yokogawa, N 1907<br />

Yokota, S 237<br />

Yoo, B 387, 876, 2028<br />

Yoo, D-H 359, 1941<br />

Yoo, WH 387, 1209<br />

Yood, RA 156, 157, 166<br />

Yoon, JY 1813<br />

York, M 1210, 1624<br />

Yoshida, K 348, 511, 921, 1258,<br />

1641<br />

Yoshida, Y 1042<br />

Yoshikawa, H 291, 298<br />

Yoshimi, R 139<br />

Yoshimura, N 1464<br />

Yoshinari, NH 605, 887, 1644<br />

Yoshinari, T 1814, 1815<br />

You, X 827<br />

Youinou, P 737, 1914, 2177, 2261<br />

Young, JS 70<br />

Young, NA 1374<br />

Youssef, P 584<br />

Yow, E 1677<br />

Ytterberg, SR 15, 680, 934, 1304,<br />

2012, 2068, 2198<br />

Yu, C-M 1028<br />

Yu, C-Y 1400, 1583, 1595<br />

Yu, D 621, 862<br />

Yu, J 1107, 1540, 1552<br />

Yu, KL 467, 1667, 2159<br />

Yu, M 2127<br />

Yu, X 1266<br />

Yu, Y 1107<br />

Yuan, F 423<br />

Yücel, AE 145, 1423<br />

Yudoh, K 631, 652<br />

Yue, D 1717<br />

Yukawa, N 1377<br />

Yuksel, A 1970<br />

Yuksel, F 544, 666, 1283<br />

Yurdakul, S 1279, 1288, 1697<br />

Yusuf, E 179<br />

Yusuf, I 741<br />

2010 Program Book 355<br />

abstract author Index


aBSTRACT author Index<br />

356<br />

Zablocki, R 94, 302, 660<br />

Zacharias, LA 1606<br />

Zack, DJ 398<br />

Zaenker, M 1059<br />

Zahr, N 2238<br />

Zaiss, MM 639<br />

Zakout, S 1655<br />

Zamani, O 1172, 1454<br />

Zamanian, R 1157, 1223<br />

Zamboulis, C 11<br />

Zampogna, G 578, 1236<br />

Zanchetta, JR 2161<br />

Zanetakis, EI 420<br />

Zang, Y 608, 852<br />

Zannin, ME 1675<br />

Zanotti, B 17<br />

Zarnitsky, C 1890, 1910<br />

Zarro, VJ 885<br />

Zavada, J 1174<br />

Zavadil, J 2231<br />

Zayed, N 1489<br />

Zeboulon-Ktorza, N 527, 533<br />

Zeft, AS 209, 245, 250, 255, 256,<br />

1673, 1690, 1691, 2017<br />

Zeidel, ML 2277<br />

Zeidler, H 665<br />

Zelko, F 1689<br />

Zemel, BS 206<br />

Zemel, LS 234, 1434, 1678<br />

Zeng, L 1965<br />

Zenone, T 2042<br />

Zeringue, AL 62, 1395<br />

Zerr, P 607, 611, 614, 616, 672<br />

Zetterberg, H 103<br />

Zhai, G 711<br />

Zhang, B 367, 683, 685, 686, 723,<br />

1564, 2108<br />

Zhang, C 273<br />

Zhang, H 918, 1143, 2219<br />

Zhang, J 273, 621, 622, 1251,<br />

1526<br />

Zhang, L 456, 1536, 1554, 2047,<br />

2049, 2056<br />

Zhang, M 417, 1141<br />

Zhang, N 1256<br />

Zhang, P 1100<br />

Zhang, Q 507<br />

Zhang, R 688, 1513<br />

Zhang, S 175<br />

Zhang, W 199, 1536<br />

Zhang, X 1317, 1368<br />

Zhang, Y 197, 201, 684, 685,<br />

1362, 1366, 1564, 1680, 2067,<br />

2098, 2212, 2213, 1373, 1464,<br />

1978, 2058, 2199<br />

Zhang, Z 144, 618, 2126<br />

Zhao, H 274, 1107, 2056<br />

Z<br />

2010 Program Book<br />

Zhao, J 1583, 1584, 1595<br />

Zhao, M 507<br />

Zhao, SZ 398<br />

Zhao, Y 618, 1598, 1898, 1978<br />

Zheng, D-h 367<br />

Zheng, SG 442, 1266, 1268, 1499,<br />

2129<br />

Zhong, ZJ 451, 452, 457, 1172,<br />

1454, 1456, 1457, 1848<br />

Zhou, H 1818<br />

Zhou, L 1656<br />

Zhou, X 442, 1268, 1817, 2129<br />

Zhou, Y 274<br />

Zhou, Z 274<br />

Zhu, B 1598<br />

Zhu, F 1969<br />

Zhu, JW 609<br />

Zhu, J-F 493<br />

Zhu, L 367, 1598<br />

Zhu, X 1530<br />

Zhu, Y 720, 879, 1363, 1547,<br />

1564, 2067, 2154, 2199<br />

Zhu, Z 289<br />

Ziakas, PD 1912<br />

Zibit, M 1335<br />

Zidovetzki, R 500<br />

Ziegler, G 976<br />

Ziegler, J 1594<br />

Ziglar, L 956<br />

Zignego, AL 2036, 2201<br />

Zilberstein, M 378, 411<br />

Zimmermann, B 1420, 1722<br />

Zink, A 227,770, 1111, 1112, 1736<br />

Zinkernagel, M 1446<br />

Ziouzina, O 1932<br />

Zisman, D 550, 783, 1238<br />

Zlateva, G 813<br />

Zochling, J 584<br />

Zoma, A 445, 448, 476, 1877,<br />

2240<br />

Zou, H 442, 1266, 1499, 1530<br />

Zou, Q 1167<br />

Zou, Y-r 426<br />

Zrioual, S 354, 1515<br />

Zuily, S 1<br />

Zulian, F 1675, 1682, 1687, 1435,<br />

1439, 1685, 1706, 2033<br />

Zummer, M 1850<br />

Zuniga, R 1035<br />

Zuniga-Montes, LR 1044<br />

Zurakowski, D 229<br />

Zwerina, J 629, 672, 2234<br />

Zwerner, J 1213<br />

Zwillich, SH 1129, 2171<br />

Zwir, L 228


A<br />

α-galactosylceramide 505<br />

A2A knock out mice 1471<br />

abatacept 240, 375, 390, 400, 416, 1120, 1247,<br />

1407, 1505, 1758, 1794, 1798, 1809, 1816,<br />

1817, 1834, 1836, 1837, 1843, 1919, 1961, 2173<br />

absenteeism 1882<br />

academic detailing 984<br />

accelerometer 1319, 2096<br />

access to care 776, 789, 986, 1007, 1538, 1553,<br />

2077, 2113, 2282<br />

accuracy 947<br />

ACE-inhibitors 958<br />

acid-sensing ion channel 1523<br />

ACPA 2118<br />

acquired resistance to activated protein C 1<br />

ACR 1805, 1806, 1832, 1881<br />

ACR 1987 criteria 1770<br />

acro-osteolysis 728<br />

actin cytoskeleton 1502<br />

active diffuse cutaneous disease 2192<br />

active immunotherapy 2236<br />

active vitamin D 973<br />

activities <strong>of</strong> daily living (ADL) 172, 2063, 2068<br />

activity difficulties 2248<br />

activity monitor 93, 2061<br />

activity score 212, 225, 232, 295, 308, 317,<br />

343, 508, 524, 525, 638, 905, 1040, 1632, 1752,<br />

1758, 1792, 2017, 2124<br />

acupuncture 941<br />

acute coronary syndrome 1054<br />

acute-phase reactants 35, 1663<br />

acute-phase serum amyloid A (A-SAA) 49<br />

acylated ghrelin 1282<br />

adalimumab 123, 127, 216, 518, 559, 719,<br />

1101, 1102, 1105, 1108, 1113, 1436, 1445,<br />

1631, 1743, 1791, 1822, 1930, 1933, 1934,<br />

1935, 1938, 1949, 1960<br />

adaptive immunity 747<br />

adenosine 1522<br />

adenosine A1 receptor 1469<br />

adenosine receptors 956, 1469, 1470, 1471<br />

ADHD 449<br />

adherence 970, 1047, 1335, 1552, 1865<br />

adhesion molecules 492, 602, 860, 1261, 1391,<br />

1419, 1509<br />

adhesive capsulitis 2067<br />

adinopectin 1282<br />

adipocytes 630<br />

adipocytokines 37, 179, 471, 719, 1666<br />

adiposity 523<br />

administrative claims data 764, 1573<br />

administrative databases 1099, 1571<br />

adolescence 762<br />

adolescent patients 1008, 1340, 1409, 1437<br />

adolescents 1677<br />

adult-onset Still’s disease 26, 703, 891, 902,<br />

903<br />

adverse event reporting system 700<br />

adverse events 40, 75, 159, 161, 177, 373, 386,<br />

472, 792, 1123, 1273, 1277, 1566, 2026, 2205,<br />

2206, 2210<br />

advocacy 2110<br />

aerobic 1681<br />

African-<strong>American</strong>s 475, 510, 1077, 1216, 1875,<br />

2076, 2090, 2185<br />

Afro-Caribbean 571<br />

age 587<br />

age <strong>of</strong> onset 255<br />

aging 634, 1789<br />

AICAR TF 827<br />

AID 1389<br />

algometry 2245<br />

all-cause mortality 148<br />

allelic frequency <strong>of</strong> M694V 666<br />

allograft inflammatory factor 1511<br />

allopurinol 154, 160, 161, 992, 2088<br />

allopurinol hypersensitivity syndrome 158<br />

alpha2 1719<br />

alpha-adrenergic receptor 799<br />

alveolar hemorrhage 2009<br />

alveolitis 1212<br />

Alzheimer’s dementia 640<br />

ambrisentan 574<br />

ambulatory medical clinic 48<br />

aminopeptidase 1450<br />

aminopeptidase N 1520<br />

anakinra 163, 209, 260, 894, 900, 902, 1663<br />

analgesics 821<br />

ANAM 1855<br />

ANCA 680, 1207, 2009, 2013, 2014, 2015,<br />

2017, 2018, 2022, 2023, 2029, 2031, 2032, 2048<br />

ancestry 1164<br />

anemia 1309<br />

anergy 1256<br />

anergy mouse models 425<br />

angiogenesis 291, 358, 671, 714, 1081, 1314,<br />

1391, 1418, 1419, 1504, 1506, 1508, 1533,<br />

1991, 2278<br />

angiogenic factors 23<br />

angiopoietin 358<br />

angiopoietin-like 4 244<br />

angiotensin 1314, 2003<br />

angiotensin converting enzyme inhibitor 2125<br />

animal models 283, 285, 289, 422, 424, 425,<br />

426, 427, 431, 603, 604, 605, 607, 608, 612,<br />

614, 616, 674, 830, 866, 935, 1360, 1374, 1375,<br />

1386, 1447, 1448, 1470, 1484, 1664, 1708,<br />

1711, 1713, 1717, 1721, 1726, 1730, 1883,<br />

1901, 2005, 2048, 2151, 2184, 2189, 2190,<br />

2230, 2235, 2276<br />

ankle 180<br />

ankle support 2134<br />

ankle-brachial index 470, 1049<br />

ankylosing spondylitis (AS) 512, 513, 518, 519,<br />

522, 526, 534, 535, 537, 539, 542, 545, 546,<br />

548, 550, 551, 553, 555, 556, 558, 559, 665,<br />

667, 668, 669, 756, 761, 771, 785, 963, 1078,<br />

1279, 1337, 1355, 1450, 1451, 1921, 1922,<br />

1923, 1927, 1929, 1933, 1934, 1938, 1941,<br />

1942, 1944, 1945, 1946, 1948, 1949, 1954,<br />

1957, 1958, 1959, 1961, 1963, 1964, 1965,<br />

1970, 1972, 1973, 1978, 1980, 1982, 1986,<br />

2078, 2181, 2184, 2185, 2209, 2268, 2270, 2271<br />

annexins 1692, 2250<br />

antagonist 856<br />

anterior uveitis 528<br />

anti C1q antibodies 444<br />

anti IL 5 antibody 2203<br />

anti TNF 997<br />

anti U3-RNP 1216<br />

anti-aminoacyl-tRNA synthetase antibody 1377<br />

anti-b2glycoprotein I antibodies 2250, 2251<br />

anti-b2GP1 IgA antibodies 2165<br />

antibiotics 696, 2212<br />

antibodies 381, 543, 563, 591, 621, 658, 747,<br />

780, 864, 901, 913, 915, 988, 1174, 1191, 1194,<br />

1273, 1322, 1341, 1852, 2118, 2165<br />

antibody-secreting cell 436<br />

anticardiolipin 3, 7, 11, 12, 14, 427, 1357, 1360,<br />

1410, 2250, 2251<br />

anticardiolipin antibodies 4<br />

anti-CCP antibodies 71, 660, 735, 1015, 1021,<br />

1060, 1071, 1092, 1094, 1118, 1717, 1763,<br />

1830, 2114, 2115, 2119<br />

anti-CD20 436<br />

anti-CD20 antibody 1833<br />

anti-CD22 453, 751, 752, 1452<br />

anti-centromere antibodies (ACA) 824, 1224,<br />

1884, 2214<br />

anti-citrullinated protein/peptide antibodies<br />

(ACPA) 661, 663, 1061, 1071, 1076, 1078, 1091,<br />

1116, 1390, 1598, 1603, 1740, 1741, 1757,<br />

1764, 2116, 2117, 2215<br />

anticoagulation 1160<br />

anti-collagen antibodies 2227<br />

anti-CXCL1 270<br />

anti-CXCL5 270<br />

anti-cytokine vaccination 2236<br />

anti-cytoplasmic antibody 913<br />

anti-DNA antibody 694<br />

anti-domain I antibodies 1359<br />

anti-dsDNA 442, 462, 508, 892, 1186, 1410,<br />

1414, 1847, 1870, 2186<br />

anti-dsDNA antibody 1195<br />

anti-endothelial cell antibodies 652<br />

anti-fibrillarin antibody 1216<br />

antigen cross-presentation 851, 1272<br />

antigen induced arthritis model 1718<br />

2010 Program Book 357<br />

abstract KEYWORD INDEX


abstract KEYWORD INDEX<br />

358<br />

antigen-presenting cells 851, 867<br />

anti-HMGB1 abtibodies 1195<br />

antihypertensives 958<br />

anti-IL-1 therapy 1375<br />

anti-Jo-1 926<br />

anti-lymphocyte antibodies 749<br />

antimalarial drugs 459, 1879<br />

antimalarials 445<br />

anti-MCV 660<br />

anti-MDA5 antibody 1672<br />

anti-melanoma differentiation–associated gene<br />

5 antibody 916<br />

anti-mullerian hormone 1145<br />

anti-mutated citrullinated vimentin 1741<br />

anti-N-methyl-D-aspartate receptor antibody<br />

1844<br />

anti-NMO IgG 1174<br />

antinuclear antibodies (ANA) 210, 911, 913,<br />

1188, 1341, 1845, 1871, 2197<br />

antioxidants 1510<br />

anti-phosphatidylserine/prothrombin 14<br />

antiphospholipid antibodies 1360, 1361<br />

antiphospholipid syndrome 1, 2, 3, 4, 5, 6, 7, 8,<br />

9, 10, 11, 13, 14, 621, 1160, 1356, 1357, 1358,<br />

1359, 1360, 1692, 2251, 2253, 2254<br />

antiprothombin antibodies 12<br />

anti-prothrombin/phosphatidylserine antibodies<br />

12<br />

anti-Ro antibodies 489<br />

anti-Ro/SSA antibodies 1142<br />

anti-SRP 915<br />

antisynthetase syndrom 917<br />

antithrombin 8<br />

anti-TNF 849, 1804<br />

anti-TNF therapy 56, 76, 90, 139, 239, 290,<br />

291, 297, 305, 309, 329, 330, 338, 344, 371,<br />

374, 376, 377, 385, 386, 387, 393, 402, 405,<br />

408, 409, 415, 420, 421, 516, 538, 539, 548,<br />

640, 698, 699, 718, 753, 756, 758, 767, 768,<br />

782, 904, 908, 1032, 1054, 1059, 1097, 1099,<br />

1104, 1105, 1114, 1127, 1136, 1375, 1381,<br />

1391, 1445, 1517, 1541, 1542, 1631, 1792,<br />

1794, 1811, 1812, 1813, 1814, 1815, 1818,<br />

1825, 1827, 1835, 1838, 1929, 1941, 1943,<br />

1948, 1960, 1970, 2078, 2084, 2103, 2135,<br />

2204, 2207, 2236, 2264, 2269, 2271, 2272<br />

anti-topoisomeras I antibodies 2214<br />

anti-U1RNP autoantibodies 893<br />

anti-viral prophylaxis 387<br />

aortitis 2040<br />

AP-1 616<br />

AP-1 inhibitor 280, 1467<br />

apheresis 469<br />

apoER2 1360<br />

apoptosis 106, 249, 368, 372, 439, 486, 489,<br />

490, 491, 498, 694, 736, 853, 859, 965, 1079,<br />

1135, 1195, 1214, 1260, 1478, 1516, 2121, 2174<br />

2010 Program Book<br />

apoptotic bodies 694<br />

appointment attendance 776, 1553<br />

appointment reminders 1007<br />

APRIL 1732<br />

aquaporin 1895<br />

arbovirus 1640, 1642<br />

aromatase inhibitor 898, 912<br />

arterial stiffness 375, 1839<br />

arteriosclerosis 448, 461, 1148, 1839, 1877,<br />

2120, 2121, 2122, 2165, 2166<br />

arteriovenous anastomoses 1220<br />

arthralgia 898<br />

arthralgia syndrome 912<br />

arthritis 691, 786, 1447<br />

arthritis self management program 2062<br />

arthritis symptoms 688<br />

arthrocentesis 1431<br />

arthropathy 886<br />

arthroplasty 168, 178, 1080, 1385, 2059, 2061,<br />

2137<br />

arthroscopy 885, 1095<br />

ASAS 552<br />

ASAS criteria 544<br />

ASC 2151<br />

ASDAS 1927, 1938<br />

aspirin 2123<br />

assessment 7, 94, 402, 813, 905, 1291, 1344,<br />

1431, 1623, 1747, 1754, 1840, 1857, 2031,<br />

2063, 2109, 2110<br />

assistive devices 169<br />

association 833<br />

association studies 1578<br />

association study 824, 1974<br />

asymptomatic 1614<br />

atherosclerosis 430, 438, 448, 455, 471, 519,<br />

531, 594, 637, 719, 865, 1017, 1023, 1028,<br />

1058, 1072, 1189, 1194, 1224, 1378, 1667,<br />

1677, 1846, 1877, 2049, 2117, 2124, 2125,<br />

2162, 2241, 2259, 2260<br />

attrition 2064<br />

atypical fracture 1573<br />

audiogram 899, 900<br />

augmentation index 534, 1028<br />

autoantibodies 24, 28, 77, 428, 433, 439, 486,<br />

487, 499, 510, 575, 652, 656, 702, 715, 734,<br />

742, 743, 748, 749, 753, 857, 892, 894, 925,<br />

929, 934, 988, 1068, 1091, 1146, 1164, 1188,<br />

1226, 1231, 1250, 1258, 1264, 1272, 1448,<br />

1639, 1672, 1732, 1757, 1780, 1847, 1870,<br />

1871, 1885, 1901, 2001, 2003, 2008, 2189,<br />

2231, 2243<br />

autoantibody phenotype 1678<br />

autoantibody-inducing CD4 T cells 1258<br />

autoantibody-inducing CD4+ T cell 867<br />

autoantigens 350, 439, 487, 734, 1374, 2175,<br />

2176<br />

autoimmune arthritis 2130<br />

autoimmune diseases 264, 287, 439, 500, 700,<br />

715, 737, 758, 780, 792, 843, 895, 920, 927,<br />

962, 1002, 1048, 1107, 1161, 1188, 1225, 1229,<br />

1244, 1249, 1250, 1258, 1264, 1265, 1266,<br />

1350, 1435, 1499, 1525, 1649, 1883, 1885,<br />

1889, 1898, 1900, 1901, 2043, 2128, 2129,<br />

2160, 2176, 2177, 2217, 2234<br />

autoimmune hepatitis 892<br />

autoimmune infiltrates 1897<br />

autoimmune pancreatitis 1671<br />

autoimmune thyroid disease 1038<br />

autoinflammatory 2105<br />

autoinflammatory disease 260, 657, 1656,<br />

1706<br />

autoinflammatory syndromes 1685<br />

automated 118<br />

automatic neuropyschologic assessment metrics<br />

1854<br />

autonomic disorders 626, 809, 1025, 1902<br />

autonomic nervous system 808<br />

autophagy 965<br />

Avise PG 302<br />

axial spondyloarthritis 544, 666<br />

ayurveda 1106<br />

azathioprine 1398, 1401, 1453, 2085<br />

B<br />

B CD20 lymphocytes 1810<br />

B cell activation markers 1911<br />

B cell depleting 1802<br />

B cell depleting therapy 741<br />

B cell depletion 436<br />

B cell modulation 751<br />

B cell monoclonal proliferation markers 1911<br />

B cell tolerance 425<br />

B cells 15, 286, 333, 349, 355, 367, 424, 425,<br />

608, 623, 712, 715, 730, 733, 734, 736, 737,<br />

738, 739, 740, 741, 743, 744, 745, 746, 748,<br />

749, 750, 751, 752, 753, 825, 1085, 1088, 1126,<br />

1141, 1146, 1154, 1192, 1295, 1350, 1389,<br />

1410, 1411, 1412, 1413, 1415, 1589, 1710,<br />

1731, 1790, 1801, 1886, 1889, 1890, 1892,<br />

1906, 1917, 1977, 2178, 2187, 2189, 2274<br />

B7RP-1 1141<br />

back pain 172, 175, 869, 971, 1383, 1458,<br />

1459, 1575, 2180<br />

bacterial infections 2015<br />

BAFF 15, 24, 741, 926, 1126, 1379, 1389, 1413,<br />

1890, 1892, 1998, 2129, 2177, 2187<br />

Barrett’s esophagus 580<br />

BASDAI 212, 534<br />

BASDI 1925<br />

BAX gene expression 1214<br />

B-cell 1833, 1998<br />

Bcl-2 family 859<br />

BCX4208 150<br />

Behçet’s disease 822, 839, 1249, 1281, 1285,<br />

1289, 1293, 1297, 1305, 1308, 1307, 2200, 2217


Behcet’s syndrome 1284, 1288, 1298, 1303,<br />

1312, 1697<br />

belimumab 451, 452, 457, 1146, 1172, 1454,<br />

1456, 1457, 1848<br />

benzbromarone 2088<br />

beta2-glycoprotein I 656<br />

beta2-glycoprotein I receptors 1356<br />

bias 1132<br />

BILAG 453, 1452, 1456<br />

Bim 859<br />

bioactivity 282<br />

biologic agents 758<br />

biologic response modifiers 74, 76, 237, 300,<br />

322, 326, 385, 386, 407, 415, 419, 420, 454,<br />

514, 720, 890, 908, 1012, 1097, 1114, 1127,<br />

1136, 1542, 1648, 1714, 1795, 1799, 1804,<br />

1814, 1818, 1835, 1927, 1937, 1943, 1982,<br />

2264, 2267<br />

biologicals 891<br />

biologics 68, 88, 981, 1041, 1110, 1824, 1932<br />

biologics registries 1111, 1112<br />

bioluminescence 1622<br />

biomarkers 25, 49, 103, 134, 217, 245, 268,<br />

363, 443, 506, 541, 588, 590, 711, 724, 725,<br />

733, 808, 811, 835, 845, 861, 924, 927, 951,<br />

979, 1098, 1146, 1147, 1175, 1190, 1218, 1230,<br />

1379, 1399, 1403, 1451, 1466, 1491, 1496,<br />

1601, 1606, 1608, 1740, 1751, 1753, 1764,<br />

1782, 1784, 1804, 1886, 1890, 1899, 1904,<br />

1908, 1911, 1918, 1953, 1968, 1985, 2012,<br />

2047, 2049, 2106, 2116, 2149, 2161, 2265<br />

biomechanical testing 169, 1327, 1328, 2056,<br />

2099, 2101, 2134<br />

biomechanics 195<br />

BiP 1376, 1729<br />

Birmingham vasculitis activity score (BVAS)<br />

2035<br />

birth cohort 2067<br />

bisphosphonates 31, 970, 981, 994, 1005,<br />

1372, 1543, 1561, 1665, 2089, 2213<br />

bladder cancer 2026<br />

blastomycosis 1643<br />

Blau syndrome 1656, 1713<br />

bleomycin 622<br />

blood brain barrier 1191<br />

BLyS 451, 452, 457, 1172, 1186, 1454, 1456,<br />

1457, 1848<br />

body composition 1018, 1065<br />

body image dissatisfaction 1234<br />

body mass 95, 173, 183, 222, 231, 515, 774,<br />

1018, 1065, 1696<br />

body mass index 523<br />

bone density 121, 176, 188, 195, 206, 222, 798,<br />

958, 959, 960, 974, 979, 982, 1156, 1206, 1317,<br />

1546, 1859<br />

bone disease 241, 624, 1485, 1499, 1978, 1983<br />

bone edema 1371<br />

bone erosion 716, 881, 1499, 1610<br />

bone geometry 960<br />

bone marrow 137, 183, 630, 713, 1085, 2158<br />

bone marrow edema 135, 1963<br />

bone marrow lesion 122, 131, 709<br />

bone marrow macrophages 2158<br />

bone metabolism 548, 957, 965, 973, 981,<br />

1467, 1813, 2078, 2161<br />

bone mineral density 994, 2157<br />

bone morphogenetic proteins 610, 1468, 1487,<br />

1980<br />

bone resorption 1978<br />

bone turnover 134, 1953<br />

bone turnover markers 943, 2157<br />

bony enlargements 185<br />

botulinum toxin 114<br />

brain activity 2097<br />

brain magnetic resonance imaging 1162<br />

breast cancer 912<br />

bronchiectasis 1648<br />

Btk 286<br />

burden 204<br />

BXD2 1412<br />

C reactive protein 326, 491, 1000, 1077, 1804<br />

C1q 1184<br />

C4 498<br />

C5a receptor antagonist 2032<br />

C5aR 847<br />

C6-deficient mice 1361<br />

CACP 261<br />

cadherin 602<br />

cadherin-11 603, 1388<br />

caffeine 1362<br />

calcification 1978<br />

calcineurin 2126<br />

calcinosis 728, 1486, 1686<br />

calcitonin 1500<br />

calcium regulation 2179<br />

calibrators 2251<br />

calprotectin 537<br />

CAM provider 1575<br />

camk2 1503<br />

camptodactyly arthropathy coxa vara<br />

pericarditis 261<br />

canakinumab 894, 900<br />

cancer 468<br />

cancer treatments 977<br />

candidate gene 92, 1592<br />

cannabinoid 615, 841<br />

capillaroscopy 11, 1236, 1615<br />

capillary microscopy 1615<br />

CAPS 2228<br />

C<br />

carboxypeptidase B 1386<br />

cardiovascular disease 67, 86, 90, 148, 309,<br />

385, 389, 456, 461, 470, 479, 483, 485, 519,<br />

531, 534, 554, 581, 582, 590, 628, 643, 771,<br />

784, 793, 832, 870, 961, 1016, 1019, 1021,<br />

1026, 1029, 1030, 1034, 1039, 1041, 1049,<br />

1052, 1054, 1064, 1067, 1109, 1142, 1148,<br />

1168, 1169, 1177, 1200, 1286, 1627, 1742,<br />

1772, 1846, 1861, 1879, 2088, 2120, 2122,<br />

2163, 2167, 2209, 2211, 2259<br />

cardiovascular markers 375<br />

cardiovascular risk 871, 1016, 1026<br />

cardiovascular risk factors 542, 584<br />

carotid plaque area 455<br />

carotid ultrasound 2163<br />

carpal tunnel 1567<br />

carpal tunnel syndrome 1626<br />

CARRA 1677<br />

cartilage 122, 183, 192, 193, 215, 840, 875,<br />

885, 1369, 1380, 1466, 1468, 1475, 1476, 1480,<br />

1483, 1485, 1494, 1503, 1669, 1722, 2151<br />

cartilage damage 1373, 2256<br />

cartilage erosion 1388<br />

cartilage loss 706<br />

cartilage turnover 134, 1953<br />

cartilage volume 938<br />

case ascertainment 2093<br />

case control study 2213<br />

case-control 64<br />

catabolism 1494<br />

catenin 1503<br />

caveolin-1 622<br />

CAVI 1839<br />

CCL4 503<br />

CCP 2118<br />

CCR7 1506<br />

CD T cells 1242, 1248, 1253, 1268<br />

CD138 1186<br />

CD154 1243, 1244, 1245<br />

CD226 1987<br />

CD28 1505<br />

CD3 830<br />

CD3+ CD4- CD8- double negative T cell 434<br />

CD36 2254<br />

CD40L 267, 1243, 1244, 1245<br />

CD70 1273<br />

CD80 1505<br />

CD86 1505<br />

CDAI 73<br />

celecoxib 151, 937<br />

cell biology 634, 848, 860, 863, 1262, 1500,<br />

1971, 1976<br />

cell death 490, 1262<br />

cell fusion 842<br />

cell proliferation 505, 1262<br />

abstract KEYWORD INDEX<br />

2010 Program Book 359


abstract KEYWORD INDEX<br />

cell signaling 749, 1419<br />

cell traffiking 23, 714<br />

central nervous system involvement 103, 1162,<br />

1191, 1682, 1727, 1853, 1858, 2037, 2038, 2107<br />

central sensitization 1385, 2098<br />

cerebral angiography 2037<br />

cerebrospinal fluid 1293<br />

cerebrovascular disease 53, 78, 620, 1036,<br />

1057<br />

certolizumab pegol 718, 1517, 1805, 1806,<br />

1832<br />

cervical cancer 468<br />

cervical dysplasia 468<br />

cervical spine 102<br />

cFMS inhibitor 289<br />

c-fos 1469<br />

change over time 772<br />

channelopathy 96<br />

chaperonin 10 441<br />

CHB 489<br />

cheiroarthropathy 1624<br />

chemerin 1534<br />

chemokines 17, 19, 22, 25, 26, 39, 167, 270,<br />

501, 671, 675, 742, 1083, 1100, 1131, 1210,<br />

1230, 1240, 1403, 1417, 1427, 1476, 1507,<br />

1520, 1534, 1726, 1751, 1906, 1992, 2016, 2253<br />

chemotaxis 17, 39, 1419<br />

chest scan 997<br />

chikungunya 1640, 1642<br />

chikungunya arthritis 1549<br />

chikungunya rheumatism 1642<br />

child 245<br />

childhood 2107<br />

childhood chronic uveitis 240, 1436<br />

childhood Sjögren’s syndrome 1907<br />

children 1677, 1696, 2019<br />

Chinese 1680<br />

cholecalciferol 962<br />

cholesterol 332, 534, 594, 933, 1058, 1072<br />

cholinergic agonists 866<br />

chondrocalcinosis 872, 873, 885<br />

chondrocytes 37, 632, 633, 634, 1472, 1473,<br />

1477, 1481, 1482, 1483, 1484, 1489, 1490,<br />

1494, 1500, 1501, 1503, 1514, 1532, 2227<br />

chondroitin 940<br />

chondroitin sulfate 938<br />

chondrolysis 215<br />

chronic conditions 2208<br />

chronic fatigue syndrome 804<br />

chronic lymphocytic leukemia 2177<br />

chronic non-bacterial osteomyelitis 241<br />

chronic therapy 946<br />

chronic widespread pain 646, 649<br />

chronotherapy 392, 1123<br />

Churg-Strauss syndrome 2020, 2025, 2034,<br />

2043, 2203<br />

CIA 276, 830, 1499<br />

CIA model 286<br />

cigarette smoking 83<br />

CINOD 1477<br />

circulating endothelial cells 1283<br />

circulating endothelial progenitor cells 1283<br />

cis-associations 1608<br />

citrullination 1074, 1421<br />

citrulline 1074, 2167, 2235<br />

CLASI 1880<br />

classification criteria 85, 208, 210, 226, 552,<br />

659, 777, 838, 1151, 1225, 1637, 1652, 1654,<br />

1673, 1744, 1760, 1763, 1774, 1780, 1783,<br />

1881, 1907, 1926, 2014, 2036, 2182, 2183, 2196<br />

clinical disease activity index (CDA)I 317<br />

clinical manifestations 517<br />

clinical outcomes 1396<br />

clinical pharmacology 254<br />

clinical practice 331<br />

clinical practice guidelines 70, 211, 1011, 1560,<br />

1759<br />

clinical practice guidelines implementation 984<br />

clinical registry 993<br />

clinical remission 216, 290<br />

clinical remission criteria 308<br />

clinical research 6<br />

clinical trials 6, 94, 125, 150, 153, 154, 157,<br />

196, 220, 234, 328, 334, 414, 453, 518, 533,<br />

559, 560, 566, 663, 669, 676, 706, 710, 797,<br />

801, 814, 815, 891, 945, 946, 953, 1108, 1115,<br />

1119, 1121, 1122, 1132, 1154, 1161, 1273,<br />

1368, 1452, 1455, 1458, 1629, 1640, 1766,<br />

1781, 1805, 1806, 1811, 1832, 1875, 1930,<br />

1935, 1949, 1961, 2032, 2169<br />

clonal 1256<br />

clonal expansions 1069, 1604<br />

coagulation disorder 8, 1160<br />

cobra 311<br />

cocaine 2013<br />

coccidioidomycosis 1643<br />

coccidiomycosis 415<br />

co-expression 847<br />

cognition 98<br />

cognitive adaptibility 802<br />

cognitive behavior therapy 646, 802. 1325<br />

cognitive dysfunction 113, 1208, 1343, 1853,<br />

1854, 1855, 2070, 2242<br />

cohort 517, 527, 1853<br />

cohort study 701, 1036, 1329, 1331<br />

colchicine 147, 148, 1288, 2087<br />

collagen 106, 279, 606, 613, 1475, 1711, 1998,<br />

1999<br />

collagen antibody induced arthritis 2227<br />

collagen-induced arthritis (CIA) 277, 285, 288,<br />

289, 635, 714, 1523, 1622, 1707, 1732<br />

combination therapies 319, 937, 962, 1396<br />

communication 1332, 1575<br />

community intervention 2141<br />

community programs 689, 2062, 2110<br />

community-based cohort 1544<br />

comorbidity 58, 147, 170, 184, 879, 882, 1016,<br />

1022, 1235, 1789, 1928, 1951, 2209<br />

comparative analysis 566<br />

comparative effectiveness 1702, 1795<br />

complement 263, 430, 491, 1146, 1180, 1399,<br />

2032, 2048, 2277<br />

complement activation 1160<br />

complement C6 1361<br />

complement pathways 2227<br />

complement receptor 2 730<br />

complement split products 866<br />

complement system 498<br />

complex regional pain syndrome 1703<br />

compliance 74<br />

complications 415, 1381<br />

complimentary and alternative therapy 95,<br />

1575<br />

computed tomography (CT) 128, 136, 176, 585,<br />

869, 1046, 1443, 1486, 1810, 2027, 2164, 2166<br />

computer assisted assessment 1747<br />

computerized skin score 1439<br />

computerized tomography 1686<br />

conceptual model 204<br />

confirmatory factor analysis 2247<br />

congenital heart block 656, 732, 832, 1322,<br />

1438, 2231<br />

connective tissue diseases 618, 704, 1026,<br />

1212, 1223, 1635, 2005, 2040<br />

consensus 1701<br />

consensus formation 1702<br />

consensus methodology 1688<br />

consumer health information 2284<br />

continuum <strong>of</strong> care 2282<br />

COPCORD 66, 1551<br />

coping skills 1027, 1211<br />

copy number variant 250<br />

copy number variation 1589, 2217<br />

core competencies 1429<br />

coronary artery calcification 459<br />

coronary artery disease 456, 584, 1046, 1053,<br />

1209, 1233, 1443, 1627, 1842, 2164<br />

correlation 915<br />

cortical 647<br />

corticosteroids 54, 213, 451, 480, 678, 922,<br />

943, 1235, 1276, 1277, 1292, 1311, 1453, 1561,<br />

1566, 1567, 1626, 1649, 1859, 1879, 2037,<br />

2045, 2225<br />

cost 51, 238<br />

cost development 770<br />

cost <strong>of</strong> fracture 1540<br />

costimulation 2189<br />

360<br />

2010 Program Book


cost-utility 759, 1539<br />

couples 1324<br />

COX inhibitors 298, 942<br />

CPDAI 514<br />

CPM 2076<br />

CRAC channel 279<br />

C-reactive protein (CRP) 86, 312, 490, 850, 919,<br />

1304<br />

creatine 1384<br />

creatine kinase 915<br />

critical care 2102<br />

Crohn’s disease 1279, 1656<br />

cross cultural validation 1872<br />

CRP 148, 2258<br />

cry<strong>of</strong>ibrinogenemia 906<br />

cryoglobulinemia 1646, 2010, 2011, 2024,<br />

2030, 2036, 2039, 2042, 2046, 2201<br />

crystal-induced arthritis 144, 146, 153, 166,<br />

873, 875, 1531, 2151<br />

CSF1R Fms 273<br />

CTGF 613<br />

c-type natriuretic peptide 259<br />

curriculum 1430<br />

cutaneous lupus 2238<br />

cutaneous lupus erythematosus 1198, 1699,<br />

1880<br />

cutaneous manifestations 1213, 1521, 1850,<br />

1880<br />

cutaneous vasculitis 444<br />

cut-<strong>of</strong>f point 525<br />

CXCL12 21<br />

CXCL13 323, 1250<br />

CXCL16 1417<br />

CXCL2 1751<br />

CXCR4 354, 622<br />

CXCR5 1250<br />

CXCR6 1417<br />

cyclic citrullinated peptide 245<br />

cyclobenzaprine 820<br />

cyclooxygenase 633, 936, 1489<br />

cyclophosphamide 1401, 2026<br />

cyclosporine 874<br />

cystatin C 1023<br />

cytokine 2233<br />

cytokine receptor signaling 1525<br />

cytokines 16, 20, 25, 33, 36, 38, 77, 103, 259,<br />

272, 275, 285, 287, 292, 366, 431, 497, 505,<br />

619, 632, 635, 636, 638, 696, 715, 741, 856,<br />

862, 871, 896, 1071, 1073, 1083, 1089, 1095,<br />

1122, 1133, 1259, 1280, 1308, 1317, 1351,<br />

1354, 1403, 1424, 1515, 1525, 1526, 1533,<br />

1580, 1581, 1594, 1642, 1709, 1725, 1730,<br />

1732, 1798, 1803, 1831, 1914, 1965, 1967,<br />

1976, 1982, 1992, 1993, 2006, 2025, 2115,<br />

2176, 2216, 2253<br />

cytotoxic T lymphocyte 867, 1272<br />

D<br />

dabigatran 604<br />

dactylitis 1932<br />

daily living 1217<br />

damage 262, 2031, 2070<br />

DAM-HAQ 2256<br />

DAMPs 845<br />

DAPSA 514<br />

Darly arthritis 1067<br />

DAS 1734<br />

DAS score 1631<br />

DAS28 73, 662, 1806<br />

DAS28CRP 1782<br />

DC-STAMP 521, 1492<br />

death 72, 1166, 1378, 2157<br />

death receptor 3 348<br />

decision analysis 59, 759<br />

dectin-1 1713<br />

Delphi 2196, 2279<br />

Delphi survey 1701<br />

delta-BAFF 1413<br />

demyelinating events 57<br />

dendrimers 281<br />

dendritic cells 293, 636, 637, 847, 849, 851,<br />

852, 862, 863, 1116, 1139, 1150, 1252, 1424,<br />

1661, 1714, 1715, 1716, 1816, 1981, 2217<br />

denosumab 2157, 2161<br />

depo provera(medroxyprogesterone acetate)<br />

974<br />

depression 1024, 1862, 1882<br />

dermatomyositis 916, 920, 921, 923, 934,<br />

1198, 1376, 1378, 1521, 1686, 1693<br />

DEXA 974<br />

diabetes 339, 888, 1039, 1442, 1873<br />

diagnosis 50, 133, 532, 547, 550, 555, 558, 621,<br />

768, 880, 899, 1090, 1186, 1254, 1289, 1339,<br />

1359, 1571, 1637, 1644, 1647, 1656, 1740,<br />

1757, 1760, 1783, 1855, 1881, 1915, 1918,<br />

1926, 1931, 1950, 2180, 2181, 2183, 2246, 2261<br />

diagnostic codes 1571<br />

diagnostic criteria 100, 110, 111, 112, 572, 575,<br />

658, 780, 911, 1305, 1655, 1706, 1775, 1776,<br />

1785, 2027, 2093, 2261<br />

diagnostic delay 558, 1921<br />

diameter <strong>of</strong> pulmonary artery 585<br />

diastolic dysfunction 1059<br />

dicl<strong>of</strong>enac 954, 955<br />

diet 888<br />

differentiation 630, 1271, 1490<br />

diffuse idiopathic skeletal hyperostosis (DISH)<br />

668<br />

digital 121<br />

digital analysis 124<br />

digital ulcera 1220<br />

digital x-ray radiogrammetry (DXR) 1770<br />

dipyridamole 2126<br />

DIRA 260<br />

direct costs 754<br />

disability 173, 186, 189, 683, 686, 687, 766,<br />

922, 975, 1044, 1217, 1321, 1349, 1383, 1563,<br />

1750, 1768, 2057, 2060, 2069, 2138, 2139,<br />

2143, 2256<br />

discriminative capacity 1927<br />

discriminatory capacity 1629<br />

disease activity 372, 459, 1200, 1255, 1291,<br />

1581, 1606, 1750, 1753, 1782, 1868, 1869,<br />

1878, 1922, 2047, 2049, 2070, 2107, 2149, 2272<br />

disease activity and therapeutic response<br />

criteria 1212<br />

disease activity index 1759<br />

disease activity measure 1147<br />

disease activity score (DAS) 295, 317, 1099,<br />

1686, 1829<br />

disease burden 1928<br />

disease modification 664<br />

disease phenotype 2272<br />

disease severity 757, 1312, 1697<br />

disease worsening 1752, 1766, 1778<br />

disease-modifying antirheumatic drugs 58, 60,<br />

74, 209, 229, 412, 417, 641, 791, 1010, 1066,<br />

2282<br />

DKK-1 548, 629, 1491<br />

DMARDs 52, 54, 68, 74, 81, 82, 303, 305, 306,<br />

324, 325, 337, 338, 415, 543, 848, 991, 1047,<br />

1110, 1255, 1640, 1796, 1805, 2204<br />

DNA 509, 631, 2146<br />

DNA methylation 21, 357<br />

DNA modification 694<br />

doctors’ preferences 68<br />

dopamine 1089<br />

Doppler 1754<br />

Doppler ultrasound 567, 1004, 1162, 1322,<br />

1632<br />

dose optimization 1829, 2265<br />

dose response relation 388<br />

dose-response 1566<br />

double strand break repair 509<br />

doxycycline 318<br />

DR5 1135<br />

drug interactions 597, 801, 1575<br />

drug levels 1825<br />

drug safety 319<br />

drug survival 1942<br />

drug toxicity 2013<br />

dry eyes and dry mouth 1901<br />

dual energy CT scan 2152<br />

dual energy x-ray absorptiometry (DEXA) 206,<br />

976, 981, 1006, 1018, 1543<br />

duloxetine 105, 175<br />

durability clinical remission 308<br />

duration <strong>of</strong> RA 83<br />

dyadic coping 1324<br />

abstract KEYWORD INDEX<br />

2010 Program Book 361


abstract KEYWORD INDEX<br />

EAE 2129<br />

early arthritis 787, 1774, 2183<br />

early arthritis clinic 661<br />

early axial spondyloarthritis 669<br />

E<br />

early diagnosis 550, 585<br />

early disease 2183<br />

early inflammatory arthritis (EIA) 659, 978,<br />

1737<br />

early inflammatory polyarthritis 796, 1110<br />

early life microbial exposure 248<br />

early osteoarthritis 184<br />

early psoriatic arthritis 1962<br />

early RA 1541, 1548<br />

early response 380<br />

early rheumatoid arthritis 300, 337, 396, 1104,<br />

1837<br />

echocardiography 1004<br />

economics 51, 55, 296, 322, 754, 755, 761,<br />

764, 767, 769, 770, 781, 791, 795, 969, 1539,<br />

1548, 2091, 2139, 2246<br />

education, medical 41, 42, 43, 44, 45, 46, 47,<br />

48, 50, 162, 984, 1429, 1431, 1432, 1433, 1617,<br />

1735<br />

education, patient 40, 42, 108, 156, 211, 996,<br />

1001, 1221, 1335, 1336, 2080, 2082, 2268,<br />

2279, 2284<br />

educational advertising 2081<br />

effectiveness 1802<br />

efficacy 163, 937, 1454, 1456, 1832, 2173<br />

effusion 1754<br />

e-health 1334<br />

elderly people 1546<br />

electronic health record 1005<br />

electronic medical record 221, 998<br />

electronic monitored system 1047, 1865<br />

electronic reports 2248<br />

electrostimulation 647<br />

ELISA 1377<br />

employment 796, 2069, 2138<br />

employment impact 2079<br />

employment status 1217<br />

en bloc biopsy 921<br />

end row capillary loops 1686<br />

end stage renal disease 2018<br />

endoplasmic reticulum 1376<br />

endoscopy 298<br />

endothelial cells 834, 1183, 1190, 1214, 1352,<br />

1356, 1416, 1418, 1419, 1420, 1504, 1988,<br />

1997, 2000, 2003, 2021<br />

endothelial dysfunction 519<br />

endothelial function 628<br />

endothelial progenitor cells 456<br />

endothelial protein C receptor 1190<br />

endothelin 1294, 2003<br />

endothelin receptor A antagonist 574<br />

endothelin receptor antagonists 1214<br />

endothelin-1 2231<br />

enkephalins 1226<br />

enolase 1717<br />

entecavir 387<br />

enteric coated mycophenolic adid (EC-MPS)<br />

1402<br />

entheses 1962<br />

enthesitis 233, 512, 1619, 1633<br />

environmental factors 61, 248, 510, 533, 686,<br />

1070, 1252, 1678, 1936, 1956, 2118<br />

enzyme-linked immunoabsorbant assays (ELISA)<br />

1844<br />

eosinophilic fasciitis 1624<br />

ephrins 1991<br />

epicardial adipose tissue 2166<br />

epidemiologic studies 645<br />

epidemiology 58, 100, 248, 535, 571, 649,<br />

963, 1307, 1327, 1329, 1331, 1366, 1544, 1913,<br />

2067, 2093, 2094<br />

epigenetics 507, 750, 858, 1253, 1352, 1422,<br />

1518, 1528, 1585, 1586, 1988, 2004, 2191<br />

epistatic interactions 1596<br />

epithelial to mesenchymal transition (EMT) 602<br />

epitope mapping 2001<br />

epratuzumab 453, 751, 752, 1452<br />

Epstein Barr virus 1082, 1708<br />

EQ-5D 2207<br />

EQ-5D/SF-6D 787<br />

eQTL 1608<br />

ERAP 1969<br />

ERAP1 1972<br />

Erdheim-Chester disease 1660<br />

erectile dysfunction 1544<br />

ergocalciferol 310<br />

ERK 32<br />

ERK/MAPK expression 1523<br />

erosion 889, 1370, 1621, 2256<br />

erosive arthritis 728<br />

erosive osteoarthritis 187, 1620<br />

erythrocyte sedimentation rate (ESR) 919, 1304<br />

ESCAPE RA 1018<br />

esomeprazole 597, 937<br />

ESRD 2022<br />

estrogen 462<br />

estrogen receptor 462<br />

etanercept 69, 216, 219, 227, 229, 230, 290,<br />

398, 514, 669, 1103, 1105, 1117, 1368, 1631,<br />

1825, 1927, 1937, 1944, 1946, 1960<br />

ethnic studies 571, 1464, 1674, 1877, 2082<br />

ethnicity 446<br />

EULAR response 1829<br />

evidence based medicine 1560<br />

exercise 93, 200, 628, 646, 688, 689, 691, 692,<br />

784, 797, 1384, 1465, 1558, 1681, 2057, 2071,<br />

2135, 2268, 2283<br />

exercise program 2059<br />

exercises 1458<br />

exome 2144<br />

experimental arthritis 278, 1532<br />

expert opinion 1291<br />

expression 1593<br />

extraarticular manifestations 528, 904, 1447,<br />

1933, 1952, 2117<br />

extracellular DNA 1420<br />

extracellular matrix 1722<br />

extracellular matrix proteins 673, 887, 1294,<br />

1421, 1719<br />

extracellular RNA 1420<br />

extractable nuclear antigen 1847<br />

extra-glandular manifestations 1898<br />

eye disease 1298<br />

F<br />

facet joint injection 172<br />

factor analysis 181<br />

falls 1576<br />

familial Mediterranean fever 666, 905, 909,<br />

1516, 1696, 1706<br />

family functioning 625<br />

family physicians 1571<br />

family studies 1068, 1145, 1193, 1851, 2083,<br />

2144<br />

famotidine 945, 946<br />

Fas 853<br />

fasciitis 921<br />

fat mass 173, 1383<br />

fat mass index 1018<br />

fatigue 97, 99, 105, 113, 627, 628, 799, 800,<br />

804, 815, 817, 819, 820, 1032, 1211, 1219,<br />

1228, 1325, 1344, 1736, 1758, 1848, 1882, 2065<br />

fatigue severity scale 1219<br />

Fc gamma receptor 504<br />

Fc receptors 504, 828, 846, 868, 1350, 2230<br />

Fc-IgG receptors CD16 and CD32 538<br />

fear 520<br />

febuxostat 149, 154, 158<br />

feet involvement 1759<br />

fellowship training 45, 47<br />

ferritin 102, 916, 923<br />

fertility 1043, 1145<br />

fetal loss 1193, 1860<br />

fever 897, 2105<br />

fewer male siblings 1193<br />

FGF23 1155, 2202<br />

fibrin network 7<br />

fibrinogen 350, 1306<br />

fibroblast 1511<br />

362<br />

2010 Program Book


fibroblast like synoviocyte 27<br />

fibroblast-epithelial cell interactions 613<br />

fibroblast-like synoviocytes 366, 1388<br />

fibroblasts 17, 21, 23, 36, 39, 244, 349, 357,<br />

364, 489, 600, 606, 611, 613, 615, 616, 629,<br />

670, 679, 1089, 1131, 1210, 1274, 1389, 1420,<br />

1506, 1518, 1529, 1722, 1733, 1991, 1999,<br />

2003, 2007, 2231<br />

fibromyalgia 92, 93, 94, 95, 96, 97, 98, 99, 100,<br />

101, 102, 103, 104, 105, 107, 108, 109, 110,<br />

111, 112, 113, 115, 116, 117, 532, 646, 647,<br />

648, 650, 651, 797, 798, 799, 800, 801, 802,<br />

803, 804, 805, 806, 807, 808, 809, 810, 811,<br />

812, 813, 814, 815, 816, 817, 818, 819, 820,<br />

821, 990, 1320, 1681, 2074, 2075, 2109, 2246<br />

fibromyalgia impact questionnaire 115<br />

fibrosing 1212<br />

fibrosis 601, 609, 614, 675, 1210, 2007, 2231<br />

fine-specificity 2114<br />

first-degree relative 77<br />

flare 452, 757, 764, 1362, 1752, 1766, 1778<br />

flare criteria 1688<br />

flip 854<br />

flow cytometry 1492, 1728<br />

Flt3-ligand 293<br />

fluoroquinolone 2212<br />

fMRI 2097<br />

FMS-like tyrosine kinase3-ligand 1914<br />

foam cell 1072<br />

focus group 2281<br />

focus score 1907<br />

follicular dendritic cells 730<br />

follow-up 1963<br />

foot 173<br />

foot disorders 1327, 1328, 1329, 1330, 1331<br />

foot pain 1327<br />

formal joint count 995<br />

Fourier-transform infrared spectroscopy 875<br />

Foxp3 909, 1257<br />

Foxp3+ Treg cells 1266, 1499<br />

fracture risk 1552<br />

fractures 31, 960, 963, 966, 968, 969, 971, 976,<br />

977, 979, 980, 982, 989, 999, 1005, 1546, 2089,<br />

2112, 2157<br />

frailty 186<br />

FRAX 968, 1156<br />

free fatty acids 1034<br />

free heavy chain 1450<br />

function 806, 814<br />

functional connectivity 650<br />

functional impairment 115<br />

functional MRI 1159<br />

functional status 186, 189, 314, 555, 1749,<br />

1755, 2069, 2076, 2095, 2138, 2142<br />

fungal infection 415<br />

future expectations 2281<br />

G<br />

gadolinium contrast agents 1993<br />

gait 200, 201, 202, 2099<br />

gait parameters 2059<br />

gait velocity 2095<br />

galectin 372<br />

gallic acid 27<br />

gastric antral vascular ectasia 726<br />

gastrointestinal complications 298, 535, 726,<br />

945, 946, 953, 1902<br />

Gaucher disease 1653<br />

GAVE 726<br />

gender 440, 1188, 1257, 1557, 2096<br />

gender differences 550<br />

gene compy number 498<br />

gene expression 1188, 1251, 1257, 1578, 1990,<br />

2149<br />

gene expression pr<strong>of</strong>iles 285<br />

gene polymorphism 356, 504<br />

gene regulation 507, 1578<br />

gene therapy 1129, 1413, 1729, 1733, 2174,<br />

2178<br />

gene-environment interactions 1588<br />

generalizability theory 1316<br />

generalized osteoarthritis 182<br />

genetic ancestry 1592<br />

genetic association 831, 838, 841, 1313, 1446,<br />

1979, 2274<br />

genetic association study 1585, 1586<br />

genetic disorders 500, 837, 877, 897, 1329,<br />

1583, 1597, 1599, 1656, 1987, 2105, 2226<br />

genetic epidemiology 828, 1984<br />

genetic factors 1076<br />

genetic markers 1600, 2215<br />

genetic susceptibility 832<br />

genetic variants 1077<br />

genetics 250, 262, 822, 1078, 1355, 1593,<br />

1594, 2146, 2148<br />

GENISOS 1211<br />

genome-wide 836<br />

genome-wide association study 1600, 2219<br />

genomics 2, 242, 243, 247, 250, 251, 254, 255,<br />

258, 264, 266, 495, 496, 498, 502, 573, 653,<br />

654, 655, 823, 825, 826, 829, 830, 842, 843,<br />

928, 1075, 1084, 1099, 1280, 1301, 1386, 1577,<br />

1578, 1579, 1587, 1589, 1590, 1591, 1596,<br />

1597, 1598, 1600, 1603, 1608, 1609, 1610,<br />

1611, 1918, 1969, 1994, 2144, 2146, 2149,<br />

2214, 2215, 2219<br />

genotype-phenotype relationships 843<br />

genotyping 1885<br />

geriatrics 154, 624, 1459, 2045<br />

germinal center 432, 1412<br />

giant cell arteritis 126, 774, 1277, 1280, 1292,<br />

1294, 1296, 1299, 1301, 1304, 1309, 1310,<br />

1311, 1314, 2198, 2199<br />

gingivalis 1717<br />

global 1151<br />

global disease flare 1688<br />

global health 1336<br />

glomerulonephritis 2048<br />

glucocorticoid induced osteoporosis (GIOP)<br />

978, 2156<br />

glucocorticoids 283, 342, 392, 423, 957, 965,<br />

966, 978, 981, 983, 994, 1036, 1123, 1179,<br />

1314, 1397, 1437, 1873, 2159, 2213<br />

GLUT9 164<br />

glutathione 1185<br />

glycosylation 494<br />

golimumab 326, 386, 890, 908, 1097, 1114,<br />

1127, 1136, 1804, 1814, 1815, 1835, 1943, 2264<br />

gout 144, 145, 146, 147, 148, 150, 151, 152,<br />

154, 155, 156, 157, 158, 159, 160, 162, 163,<br />

164, 165, 166, 869, 870, 873, 876, 877, 879,<br />

880, 881, 882, 883, 884, 888, 889, 1362, 1364,<br />

1366, 1423, 1544, 1547, 1556, 1565, 1569,<br />

1572, 1574, 1616, 2087, 2150, 2152, 2153, 2154<br />

growth 1684, 1696<br />

growth factors 259, 2202<br />

GRP78 1729<br />

guideline 2051<br />

GWAS follow-up 1599<br />

gynecologic issues 104, 468<br />

H1N1 224, 450, 1437<br />

H1N1 influenza 235<br />

H1N1 influenza A/California/7/2009 481<br />

hallux valgus 1328<br />

hand 142<br />

hand disorders 187, 708, 940, 1220, 1237,<br />

1749, 2076, 2142<br />

hand dysfunction 2076<br />

hand osteoarthritis 179, 185<br />

haplotype 707, 1280<br />

HAQ 1734<br />

HBV 329<br />

HDAC 750<br />

HDAC2 2029<br />

HDL composition 332<br />

healed arteritis 1311<br />

health assessment questionnaire 166, 314,<br />

690, 779, 1204, 1423, 1425, 1460, 1549, 1755,<br />

1765<br />

health behaviors 87, 156, 776, 1318, 1332,<br />

1428, 1553, 1562, 1576, 1856, 2096<br />

health care 1337<br />

health care disparities 790<br />

health care services 2284<br />

health care utilization 790<br />

health communications 1465<br />

health disparities 1336, 1875<br />

H<br />

abstract KEYWORD INDEX<br />

2010 Program Book 363


abstract KEYWORD INDEX<br />

health education 1006, 1318, 1336, 1337,<br />

1338, 1465, 2062, 2077, 2082, 2249<br />

health information technology 998<br />

health related quality <strong>of</strong> life 1872<br />

health services research 72<br />

health services use 2055<br />

health status 184, 1462<br />

health status outcomes 1461<br />

healthcare 969<br />

health-related quality <strong>of</strong> life (HRQoL) 1407,<br />

1837<br />

healthy controls 2245<br />

healthy volunteers 1273<br />

heart disease 459, 626, 1059<br />

heart failure 1059<br />

heart rate variability 808<br />

heath utility 1558<br />

heat-shock proteins 681, 1093, 1729<br />

heavy metal 2153<br />

helplessness 2140<br />

help-seeking 2282<br />

hematopoietic stem cells 351, 426<br />

hemochromatosis 818, 886<br />

hemophagocytic lymphohistiocytosis 653<br />

hemophagocytic syndrome 26<br />

hemorrhagic cystitis 2026<br />

hepatic disorders 1178, 1762<br />

hepatic magnetic elastography 129<br />

hepatitis 387, 892, 1639, 1646, 2030, 2039,<br />

2046<br />

hepatitis C 1646, 2024, 2131<br />

hepatotoxicity 75<br />

hepcidin 1309<br />

heritability 877<br />

heterogeneity 52<br />

HFE gene 886<br />

HIDS 1698<br />

HIF 1418<br />

high density lipoprotein 1189<br />

high mobility group box 1 1195<br />

high throughput sequencing 1604<br />

highly active anti-retroviral therapies (HAART)<br />

966<br />

high-resolution computed tomography 119<br />

hip 963, 2137<br />

hip disorders 529, 972, 2094<br />

hip fracture 972<br />

hip structure analysis 960<br />

hippocampus 1159<br />

Hispanic patients 305, 1465, 1768, 2148<br />

histochemistry 927<br />

histone 507, 750<br />

histone deacethylase inhibitor (Trishostatin A)<br />

1715<br />

histone deacetylase 1484, 2191<br />

histopathology 1151<br />

histoplasmosis 1643<br />

HLA 725<br />

HLA class II associations 66<br />

HLA-B27 552, 1448, 1969, 1973<br />

HLA-DRB1 shared epitope 2118<br />

HMGB1 1297<br />

home health 1005<br />

homebound 2110<br />

hormones 747, 1040<br />

hospitalized patients 163<br />

hr-pqct 136<br />

human 1270<br />

human anti-chimeric antibodies (HACA’s) 1826<br />

human follicular helper T cell 1246<br />

human immunodeficiency virus (HIV) 966,<br />

1645<br />

human leukocyte antigens (HLA) 66, 256, 549,<br />

645, 832, 1092, 1216, 1313, 1355, 1450, 1605,<br />

1966, 1973, 1974, 1975, 1979, 2114<br />

human papillomavirus (HPV) 464, 996<br />

humanized SLE mouse 427<br />

hyaluronate 1711<br />

hydroxychloroquine 463, 484, 732, 1860, 1865,<br />

2150, 2238, 2239, 2241, 2255<br />

hygiene hypothesis 248<br />

hyper IgD 1685<br />

hyper-IgD syndrome 2105<br />

hyperimmunoglobulinemia D with periodic<br />

fever syndrome 1698<br />

hypermobility 1342<br />

hypertension 878, 888, 1367, 1565, 1569, 2155<br />

hyperuricemia 160, 161, 874, 876, 878, 879,<br />

883, 884, 992, 1363, 1367, 1547, 1614, 1861,<br />

2088, 2154, 2155<br />

hypodermis 1624<br />

hypothalamic-pituitary-adrenal axis 649<br />

hypoxia 360, 630, 1418, 1510<br />

ibandronate 964<br />

ibupr<strong>of</strong>en 945, 946<br />

ICOS 1141<br />

idiopathic pulmonary artery hypertension 598<br />

IFNa 494<br />

IFN-gamma 428<br />

IgA antiphospholipid assays 14<br />

IgG4-related systemic disease 1671<br />

IKKβ 1107<br />

IL-1 265, 897, 1622<br />

IL-1 receptor antagobist 260<br />

IL-1 suppression 891<br />

IL-1 trap 1831<br />

I<br />

IL-1ß 2150<br />

IL-10 274, 1732<br />

IL13 833<br />

IL-13 polymorphism 1984<br />

IL-15 1801<br />

IL-17 276, 323, 365, 428, 896, 1041, 1730,<br />

1838, 1970, 1992, 2130, 2232<br />

IL-17 F 1515<br />

IL-17 induced arthritis 270<br />

IL-17 receptor 1976<br />

IL-17A 1274, 1515<br />

IL-18 903, 923, 1664<br />

IL-18 binding protein 1664<br />

IL-18BP 282<br />

IL-2 therapy 2131<br />

IL-21 432, 1088, 1594<br />

IL-22 275, 715, 1992<br />

IL-23 1260, 1970<br />

IL-23R 1078<br />

IL-27 276, 714<br />

IL-32 371<br />

IL-33 28<br />

IL-5 2203<br />

IL-6 18, 1109, 1293, 1800, 1996<br />

IL-6R 1996<br />

IL-7 receptor 1900, 1903<br />

IL-9 1241<br />

ILD 402<br />

imaging 1022<br />

imaging techniques 118, 119, 120, 136, 138,<br />

540, 650, 889, 964, 1051, 1370, 1617, 1622,<br />

1624, 1625, 1628, 1634, 1728, 1822, 1887,<br />

1931, 1983, 2097<br />

imatinib 560, 566, 573, 1189, 1990, 1997,<br />

2020, 2193<br />

imiglucerase 1653<br />

immune 1313<br />

immune complexes 263, 499, 1020, 1399, 1601<br />

immune reconstitution 1161<br />

immune response 752, 1037, 1440, 1580,<br />

1581, 2216<br />

immune response to vaccination 792<br />

immune complex 504, 866<br />

immunizations 457<br />

immunogenicity 464<br />

immunoglobulin (IG) 465, 504, 828, 1085, 1604<br />

immunoglobulin free light chains 333<br />

immunohistochemistry 482, 927<br />

immunological pr<strong>of</strong>ile 1908<br />

immunology 1430<br />

immunoregulation 442<br />

immunosuppression 1157, 2043<br />

immunosuppressive drugs 1865<br />

immunotherapy 1116, 1714<br />

364<br />

2010 Program Book


impact 1063, 1325<br />

inactive disease 2220<br />

INCB028050 2172<br />

inception cohort 2273<br />

incidence 112, 568<br />

incidence rate 972<br />

inclusion body myositis 922<br />

index 1878<br />

indigenous peoples 1538<br />

indomethacin 151<br />

indoor falls 684<br />

inducible NO synthase (iNOS) 1489<br />

inefficacy 1110<br />

infection 237, 248, 313, 316, 335, 341, 342,<br />

346, 400, 403, 414, 421, 698, 758, 782, 1381,<br />

1390, 1638, 1640, 1642, 1643, 1648, 1649,<br />

1669, 1678, 1876, 1969, 2023, 2103, 2216<br />

inflammasome 265, 2228<br />

inflammation 86, 88, 106, 134, 145, 151, 260,<br />

270, 288, 360, 369, 441, 443, 499, 536, 675,<br />

679, 714, 844, 854, 855, 864, 866, 949, 1034,<br />

1041, 1081, 1109, 1130, 1239, 1270, 1296,<br />

1309, 1422, 1424, 1426, 1470, 1506, 1509,<br />

1512, 1524, 1525, 1533, 1607, 1622, 1707,<br />

1728, 1761, 1785, 1813, 1883, 1953, 2044,<br />

2078, 2109, 2150, 2162, 2200, 2204, 2229,<br />

2231, 2233, 2260<br />

inflammatory arthritis 19, 28, 300, 629, 659,<br />

712, 716, 766, 778, 794, 890, 901, 904, 978,<br />

997, 1029, 1067, 1391, 1418, 1427, 1665, 1710,<br />

1729, 1737, 2227<br />

inflammatory back pain 544<br />

inflammatory bowel disease (IBD) 223, 537,<br />

901<br />

inflammatory diseases 2217<br />

inflammatory markers 385<br />

infliximab 216, 234, 328, 352, 381, 420, 988,<br />

1276, 1300, 1436, 1542, 1680, 1743, 1826,<br />

1829, 1945, 1960, 2265<br />

influenza 224, 237, 478, 1238<br />

influenza vaccine 1694<br />

information needs 1408<br />

information technology 221, 2111, 2284<br />

infusion therapy 1002<br />

inhibitor 1358<br />

inhibitory kappaB 1487<br />

injection 947, 1567, 1626, 2225<br />

innate immune cells 866<br />

innate immunity 845, 935, 1883, 2230<br />

innate lymphocyte 2232<br />

in-patient 1576<br />

insole 2134<br />

instrument validation 1337<br />

insulin receptor 1514<br />

insulin resistance 389<br />

insulin-like growth factor 670, 1501<br />

integrins 844, 865, 1719<br />

intensive care unit 2102<br />

inter- and intra-observer agreement 1623<br />

inter- and intra-rater variability 1623<br />

inter-disciplinary consensus 1212<br />

interferon regulatory factor 433, 1712<br />

interferon signature 1904<br />

interferon-γ assay 756<br />

interferon-gamma release assay 782<br />

interferon-regulatory factor-4 435<br />

interferons 271, 428, 433, 493, 494, 496, 501,<br />

503, 850, 868, 934, 1164, 1181, 1183, 1199,<br />

1376, 1660, 1661, 1712, 1904, 2187, 2188,<br />

2189, 2278<br />

interfreon-alpha 1181<br />

interleukin (IL) -32 277<br />

interleukin 1 1831<br />

interleukin 1 receptor antagonist 271<br />

interleukin 6 1247<br />

interleukin-1 272<br />

interleukin-1 receptor associated kinase-1 1587<br />

interleukin-13 675<br />

interleukin-17 1271<br />

interleukin-18 703<br />

interleukin-1b (IL-1)- 1489<br />

interleukin-23 1271<br />

interleukin-6 30, 272, 1096, 2168<br />

interleukin-7 278<br />

interleukins (IL) 18, 19, 29, 35, 152, 153, 260,<br />

265, 271, 276, 278, 282, 353, 358, 369, 371,<br />

373, 432, 629, 637, 657, 707, 831, 895, 903,<br />

1088, 1121, 1124, 1126, 1241, 1260, 1270,<br />

1308, 1412, 1435, 1488, 1531, 1607, 1664,<br />

1831, 1903, 1970, 2158, 2203<br />

interlleukin-2 receptor alpha (sIL-2Ra) 49<br />

intermittent and constant osteoarthritis pain<br />

(ICOAP) 682<br />

international 969, 1013<br />

internet 1340, 1362<br />

internet survey 807<br />

internet use 1409<br />

interpr<strong>of</strong>essional practice 2050<br />

inter-rater discrimination 1652<br />

interstitial keratitis 1675<br />

interstitial lung disease 592, 602, 919, 932,<br />

1035, 1044, 1086, 1377, 1672, 1803, 1824<br />

interstitial pneumonia 1042<br />

intestinal Behcet’s disease 1300<br />

intestinal involvement 1297<br />

intestinal microbiota 1390<br />

intestinal parasitosis 539<br />

intima media thickness 455<br />

intimal hyperplasia 1294<br />

intima-media thickness 1028<br />

intra articular 943, 947, 2225<br />

intracellular signalling 1357<br />

intracranial hemorrhage 2037<br />

intravenous immunoglobulin (IVIG) 494, 576<br />

invasion 1387, 1421<br />

ion channels 1270<br />

iontophoresis 218<br />

IRF-1 282<br />

IRF5 1607<br />

iridocyclitis 528<br />

IR-induced DNA damage 509<br />

ITGAM 637<br />

J<br />

JAK1/JAK2 2172<br />

janus kinase (JAK) 269, 717, 1137, 1240, 2171,<br />

2172, 2233<br />

janus kinase 2 (JAK2) inhibition 2233<br />

janus-kinase-1 2200<br />

Japanese 237, 399, 1285, 1577, 1672<br />

JNK 32<br />

job 2139<br />

job loss 80, 781, 1541, 1548, 2079<br />

joint count 166, 723, 1759<br />

joint damage 2109<br />

joint destruction 32, 73, 132, 272, 367, 536,<br />

716, 887, 1470, 1479, 1482, 1495, 1600, 1610,<br />

1738, 1747, 1785, 1812, 1821, 1828, 2256,<br />

2258, 2273<br />

joint distraction 176, 1380<br />

joint examination 1781<br />

joint procedures 1539<br />

joint space distance 136<br />

joint space narrowing 132, 707, 1369<br />

joint swelling 79, 2258<br />

junctional adhesion molecule 1419<br />

juvenile arthritis 207, 220, 224, 251, 259, 1407,<br />

2219<br />

juvenile dermatomyositis 242, 252, 928, 1344,<br />

1672, 1678, 1700<br />

juvenile fibromyalgia 807<br />

juvenile idiopathic arthritis (JIA) 206, 208, 209,<br />

210, 213, 214, 216, 217, 218, 219, 222, 224,<br />

226, 227, 228, 229, 230, 231, 232, 235, 236,<br />

237, 238, 239, 243, 244, 245, 247, 248, 250,<br />

253, 254, 255, 256, 258, 263, 264, 654, 655,<br />

1012, 1339, 1404, 1405, 1406, 1408, 1434,<br />

1491, 1601, 1630, 2084, 2103, 2219, 2220, 2248<br />

juvenile idiopathic arthritis-enthesitis (ERA)<br />

219, 233, 235, 266<br />

juvenile localized scleroderma <strong>of</strong> the face 1687<br />

juvenile myositis 1379, 1678<br />

juvenile onset patients 1697<br />

juvenile polyarteritis nodosa 2033<br />

juvenile psoriatic arthritis 219<br />

juvenile scleroderma 1439, 1682, 1687, 1704<br />

juvenile sclerosis 1704<br />

juvenile spondylarthropathy 212, 225, 266,<br />

1633<br />

abstract KEYWORD INDEX<br />

2010 Program Book 365


abstract KEYWORD INDEX<br />

K/BxN 1417<br />

K2P5.1 1255<br />

kappa score 522<br />

Karn<strong>of</strong>sky performance status 1204<br />

Kawasaki disease 249, 267, 652, 828, 1680,<br />

2202<br />

kidney disease 857<br />

kinase 273, 286, 493, 635, 1119, 1493, 1513,<br />

1516, 2234<br />

kinase inhibitor 273, 288, 1107<br />

KIR (Killer Ig like receptor) 1966<br />

knee 131, 140, 180, 191, 194, 200, 201, 682,<br />

684, 693, 708, 941, 943, 947, 963, 1382, 1385,<br />

1558, 2052, 2053, 2054, 2055, 2059, 2061,<br />

2094, 2096, 2098, 2101, 2132, 2134, 2244<br />

knee loading 2099<br />

knee osteoarthritis 186, 189, 2059, 2100<br />

knee pain 685<br />

knockout line 854<br />

knowledge 1009<br />

knowledge transfer 984<br />

L 1073<br />

La/SSB 2175<br />

labial salivary gland 1900<br />

laboratory tests 312, 378, 909, 1293, 1359,<br />

1765, 1845<br />

language 1024<br />

laser Doppler imaging 579<br />

laser Doppler perfusion imaging 574<br />

late onset rheumatoid arthritis 1061<br />

latent tuberculosis infection (LTBI) 699, 782<br />

latitudes variation 783<br />

lecithin cholesterol acyl:transferas 1058<br />

leflunomide 75, 229, 319, 1796<br />

lenalidomide 1699<br />

lentivirus 1729<br />

leukocyte homing 860<br />

levamisole 2013<br />

LFA-1 503<br />

lidocaine patch 5% 944<br />

lipase 438<br />

lipids 86, 345, 385, 393, 438, 471, 1000, 1019,<br />

1030, 1033, 1064, 1187<br />

literature search 1291<br />

liver fibrosis 129<br />

liver function 319<br />

loading 190<br />

localized scleroderma 1683, 2006<br />

long term 97<br />

K<br />

L<br />

longitudinal studies 77, 110, 380, 731, 779,<br />

1219, 1400, 1406, 1459, 1541, 1548, 1685,<br />

1854, 1951, 2064, 2079<br />

long-term outcome 380, 1683<br />

low back pain 1458<br />

low disease activity 1826<br />

low dose 1944<br />

low dose aspirin 945<br />

low dose strategy 290<br />

low-field MRI 138<br />

lumbar disc herniation 1921<br />

lung 563, 596, 604, 605, 622, 704, 724, 852,<br />

907, 924, 1022, 1086, 1176, 1212, 1635, 1739,<br />

1989, 2119, 2194<br />

lupus 2189<br />

lupus anticoagulant 4, 12<br />

lupus arthritis 446<br />

lupus gradient 510<br />

lupus nephritis 268, 423, 430, 433, 434, 435,<br />

440, 467, 469, 477, 851, 867, 1140, 1144, 1151,<br />

1173, 1251, 1398, 1399, 1402, 1403, 1414,<br />

1453, 1455, 1702, 1866, 2085, 2104, 2121,<br />

2186, 2188<br />

Lyme arthritis 1638<br />

Lyme disease 1320, 1638, 1644<br />

lymph node 1069, 1710<br />

lymphadenopathy 903<br />

lymphatic draining 1710<br />

lymphocytes 422, 463, 492, 747, 846<br />

lymphocytopenia 316<br />

lymphoid neogenesis 1906<br />

lymphoma 398, 720, 1015, 1884, 1888, 1912,<br />

1914, 1916<br />

lymphotoxin 1885<br />

lymphotoxin alpha 1122<br />

M<br />

machine learning 1403<br />

macromolecular therapy 423<br />

macrophage activation syndrome 18, 208, 653,<br />

903, 1354, 1664, 1668<br />

macrophage migration 1718<br />

macrophage migration inhibitory factor (MIF)<br />

903<br />

macrophages 23, 273, 283, 359, 844, 845, 847,<br />

853, 854, 859, 861, 1100, 1135, 1353, 1506,<br />

1522, 1613, 1718, 1723, 1761, 1798, 1965,<br />

1993, 2230, 2276<br />

magnetic resonance imaging (MRI) 122, 123,<br />

125, 126, 127, 130, 132, 133, 134, 135, 137,<br />

138, 141, 142, 182, 188, 193, 197, 228, 461,<br />

524, 540, 551, 553, 650, 667, 706, 709, 921,<br />

938, 1159, 1167, 1170, 1293, 1369, 1370, 1371,<br />

1372, 1373, 1380, 1625, 1682, 1779, 1817,<br />

1929, 1934, 1957, 1958, 1959, 1963, 2100<br />

maintenance treatment 2041<br />

MAIT cell 2232<br />

major histocompatibility complex (MHC) 502,<br />

1281, 1579, 1979, 2185<br />

malalignment 131, 2100<br />

male vs female 1158<br />

malignancy 62, 214, 398, 407, 408, 468, 580,<br />

720, 731, 883, 996, 1899, 2084<br />

mammalian target <strong>of</strong> rapamycin (mTOR) 1530<br />

managed care 757, 764<br />

management 888<br />

manzamine A 1131<br />

MAP kinases 17, 39<br />

MAPK 632<br />

MAPKK 635<br />

mass communication 2081<br />

mast cells 28, 333, 896, 1449, 1732<br />

matrix metalloproteinase (MMP) 21, 267, 366,<br />

541, 1086, 1292, 1388, 1466, 1472, 1481, 1491,<br />

1497, 1530, 1628, 1797, 1800<br />

MCTD 608, 852<br />

MDRD 147<br />

measure 1927<br />

measurement scales 2065<br />

mediation analysis 1461<br />

medical resident 46, 48, 1431, 1432<br />

medication 1001<br />

medication adherence 1404<br />

medication compliance 338, 1056<br />

medication cost 1462<br />

membrane attack complex 846, 1262<br />

memory 1159<br />

men 1546<br />

meniscal tear 202, 885<br />

meniscectomy 167, 192<br />

menopause 301, 2245<br />

mental health status 2070<br />

mepolizumab 2203<br />

mesenchymal stem cells 630, 840, 918, 1134,<br />

1143, 1182, 1247, 1382, 1475, 1490, 1498<br />

messenger RNA (mRNA) 2008, 2219, 2276<br />

meta-analysis 168, 412, 419, 720, 824, 1574,<br />

1657, 1795, 2145, 2155<br />

metabolic syndrome 445, 476, 547, 871, 888,<br />

1177, 1178, 1507, 1667<br />

metabolomics 711<br />

metacarpophalangeal joints 1634<br />

metalloproteases 1484<br />

methionine sulfoxide reductase A (MsrA) 1599<br />

methodology 952<br />

methotrexate (MTX) 40, 74, 129, 220, 230,<br />

253, 254, 284, 302, 319, 335, 377, 380, 388,<br />

394, 396, 397, 417, 664, 827, 1009, 1060, 1096,<br />

1101, 1106, 1117, 1333, 1392, 1393, 1394,<br />

1395, 1439, 1596, 1670, 1796, 1806, 1812,<br />

1815, 1836, 2171, 2267<br />

methotrexate polyglutamates (MTXPG) 302<br />

methotrexate responder 1392<br />

366<br />

2010 Program Book


methylation 826, 1253, 1489<br />

methyltransferases1 1352<br />

mevalonate kinase deficiency 905<br />

MHC class I polypeptide-related sequence A<br />

511<br />

MHC-disease associations 843<br />

MICA alleles 1979<br />

microangiopathy 578, 1236<br />

microarray 1986, 1990, 2000, 2200<br />

microchimerism 1060<br />

micro-computed tomography 1634<br />

microCT 1471<br />

microCT scan 964<br />

microgravity 959<br />

microparticles 2047<br />

microRNA 35, 359, 422, 501, 842, 858, 1253,<br />

1352, 1422, 1490, 2179<br />

microscopic polyangiitis 676, 1691, 2009, 2012,<br />

2014<br />

microsporidiosis 539<br />

microvascular dysfunction 1041<br />

midtarsal arthropathy 1665<br />

migration 17, 39, 1511, 1722<br />

migration inhibitory factor (MIF) 973, 1721<br />

milnacipran 98, 648, 805, 806<br />

Milwaukee shoulder 2151<br />

mind map 2082<br />

mind-body exercise 95<br />

minocycline 318<br />

minor salivary gland 1897<br />

miR-146a 501<br />

mir-19b 858<br />

miRNA 247, 633<br />

mitochondria 360, 437, 631, 835, 1185, 1510<br />

mitochondrial dysfunction 1510<br />

mitochondrial mutagenesis 360<br />

mitochondrial mutations 1510<br />

mixed connective tissue disease (MCTD) 568,<br />

893, 1223<br />

MLR 1270<br />

MMP 368<br />

MMP-2 1387<br />

MMP-3 1491<br />

mode <strong>of</strong> action 1517<br />

modeling 190<br />

modified stoke ankylosing spondylitis spinal<br />

score (MSASSS) 549<br />

monitoring 295, 1755<br />

monoclonal antibodies 145, 710, 895, 1096,<br />

1425, 1435, 2087, 2168, 2170<br />

monocyte chemokines 23<br />

monocytes 506, 622, 657, 740, 865, 1189,<br />

1198, 1512, 1513, 1528, 1723, 1904, 1981, 2200<br />

monosodium iodoacetate 1480<br />

monotherapy 74<br />

Monte Carlo simulation 1555<br />

montelukast 1698<br />

Montreal cognitive assessment questionnaire<br />

1855<br />

mood 805<br />

morbidity and mortality 49, 53, 71, 83, 620,<br />

642, 651, 773, 930, 1044, 1052, 1057, 1140,<br />

1179, 1438, 1550, 1668, 1777, 1849, 2088,<br />

2102, 2124, 2163, 2194, 2240<br />

morphea 1661<br />

mortality 651, 1049<br />

motivational interviewing 797<br />

mouse model 823, 1446<br />

movement 2076<br />

MRI 131, 1370<br />

mRNA metabolism 364<br />

mthotrexate polyglutamates 417<br />

mTOR 1185, 1196, 1971<br />

MTX 849<br />

Muckle-Wells syndrome 265, 657, 894, 899,<br />

900, 905, 2228<br />

multicenter cohort 1852<br />

multicenter study 1691, 1864, 2172<br />

multidimensional health assessment<br />

questionnaire (MDHAQ) 990<br />

multi-disciplinary center 2077<br />

multiple medication use 2208<br />

multiple TNFi failure 1795<br />

muscle area 1065<br />

muscle density 1065<br />

muscle strength 171, 191, 203, 627, 2056,<br />

2245, 2283<br />

musculoskeletal disorders 44, 45, 242, 687,<br />

826, 907, 915, 927, 928, 1549, 2208<br />

musculoskeletal pain 2136<br />

MVK mutations 2105<br />

mycophenolate m<strong>of</strong>etil 467, 477, 1398, 1401,<br />

1402, 1453, 1670, 1866, 2085, 2192, 2241<br />

myelitis 702<br />

myeloid dendritic cells 1198<br />

myeloperoxidase (MPO) 676, 870<br />

myocardial infarction 148, 542, 1052, 2124<br />

my<strong>of</strong>ascial pain syndrome 114<br />

myoloid homeostasis 854<br />

myositis 15, 576, 914, 915, 917, 919, 921, 922,<br />

924, 925, 926, 929, 930, 932, 933, 934, 935,<br />

1374, 1376, 1379, 1679, 2068<br />

N<br />

NAD biosynthesis pathway 1595<br />

nail changes 1951<br />

nailfold capillaroscopy 1623<br />

NALP3 2151<br />

NALP3 inflammasome 2150<br />

Nam’s score 522<br />

nampt 1514<br />

naproxen 937, 2206<br />

Native <strong>American</strong>s 780, 1538<br />

natural antibodies 88, 1194<br />

natural killer (NK) cells 277, 503, 511, 860,<br />

1354, 1505<br />

natural killer T cell 505, 1264<br />

neck pain 1458, 2060<br />

necrosis 491<br />

negative binomial distribution 1564<br />

neonatal disorders 489, 495, 656, 732, 1438<br />

neonatal lupus 732<br />

neonatal outcomes 775<br />

nephritis 159, 422, 482, 906, 1400, 1401, 1526,<br />

2022<br />

nephrogenic fibrosing dermopathy 1993<br />

nerve entrapment 2223<br />

neurocognitive dysfunction 1689<br />

neuroendocrine immune (NEI) 361, 1025,<br />

1226, 1536<br />

neuroimaging 1689<br />

neurologic involvement 1165, 1208, 1293,<br />

1893, 1894, 1902, 1908, 1911, 1915<br />

neurological outcome 2019<br />

neuromuscular control 194<br />

neuromyelitis optica 702, 1174<br />

neuropathy 205<br />

neuropeptides 1536<br />

neuropsychiatric disorders 1174, 1181, 1844,<br />

1852, 1915, 2242, 2243<br />

neuropsychiatric involvement in SLE (NPSLE)<br />

1852<br />

neuropsychiatric SLE 1689<br />

neutrophils 247, 251, 492, 681, 854, 1427,<br />

1531, 2015<br />

neutrophils and tocilizumab 294<br />

new bone formation 1978<br />

NFAT 2126<br />

NFATc1 1469<br />

NF-kappaB 1412, 1487<br />

NF-kappaB P65 1532<br />

NF-kB 632, 633<br />

NGF 37<br />

NHANES 879, 1363, 1547, 2154<br />

NHI criteria 1275<br />

nine years 1963<br />

nitric oxide 437, 618, 936, 953, 1477, 2277<br />

NLRP1 2226<br />

NLRP12 657<br />

NLRP3 2228<br />

NMDA receptor 1536<br />

NMNAT2 1595<br />

nociception 841<br />

nociceptive flexion reflex (NFR) 101<br />

NOD2 1607, 1713<br />

abstract KEYWORD INDEX<br />

2010 Program Book 367


abstract KEYWORD INDEX<br />

NOD2 gene mutation 1656<br />

nod-like receptor (NLR) 1713, 2226<br />

nominal group technique (NGT) 2196<br />

nonalcoholic fatty liver disease 1666<br />

non-attendance 1007<br />

non-cardiovascular disease 49<br />

non-Hodgkin´s lymphoma 1913<br />

non-inflammatory symptoms 990<br />

non-invasive 647<br />

nonoparticles <strong>of</strong> LDE 284<br />

nonrestful sleep 820<br />

nonsteroidal antiinflammatory drugs (NSAIDs)<br />

151, 882, 942, 945, 946, 954, 955, 1477, 2205,<br />

2206<br />

north and south 783<br />

north India 4<br />

NOS3 1352<br />

novel cardiovascular risk factors 1067<br />

novel therapeutic 2032<br />

NSAIDs 298<br />

NT-proBNP 483, 1059<br />

nuclear hormone receptor 611<br />

nuclear receptor 1387, 1481<br />

nurse perspective 2279<br />

nursing consultations 2280<br />

nutrition 1366<br />

NZB/W mice 1414<br />

obesity 95, 179, 231, 297, 515, 627, 685, 939,<br />

1330, 1331, 1364, 1562, 2257<br />

observational 405, 1036<br />

observational study 1381<br />

obstetrical outcomes 775<br />

occupational therapy 1319, 2050, 2063, 2143<br />

ocrelizumab 383, 414, 1455, 2169<br />

ocular involvement 240, 256, 512, 1405, 1670<br />

odontostomatologic involvement 1687<br />

older adults 692, 2071<br />

Olf1/EBF associated zinc finger protein 1182<br />

oncostatin M 30<br />

online resources 1345<br />

onycholysis 1951<br />

open label 97<br />

open, randomized trial 891<br />

opportunistic infections 472, 700, 1310, 1643<br />

opsonisation 490<br />

optimally effective MTX dose 388<br />

optimising health care resources 776, 1553<br />

oral 1074, 1716<br />

oral microbiota 1390<br />

organ involvement 578<br />

orthopedic 1381, 1576<br />

O<br />

orthopedic surgery 1550, 1570<br />

osteoarthritis 37, 46, 121, 122, 124, 128, 131,<br />

137, 140, 142, 143, 167, 168, 169, 171, 176,<br />

178, 179, 180, 181, 184, 185, 186, 187, 188,<br />

189, 190, 191, 193, 194, 195, 196, 197, 200,<br />

201, 202, 203, 204, 205, 624, 631, 632, 633,<br />

634, 682, 683, 684, 685, 686, 692, 693, 706,<br />

707, 708, 709, 710, 711, 823, 831, 835, 838,<br />

840, 841, 845, 875, 936, 937, 938, 939, 940,<br />

941, 942, 943, 944, 948, 949, 950, 951, 952,<br />

953, 954, 955, 963, 1319, 1373, 1380, 1382,<br />

1384, 1426, 1463, 1464, 1472, 1476, 1477,<br />

1480, 1484, 1486, 1489, 1494, 1497, 1503,<br />

1532, 1555, 1557, 1558, 1620, 1628, 2051,<br />

2052, 2055, 2056, 2058, 2091, 2092, 2093,<br />

2094, 2096, 2097, 2098, 2099, 2100, 2101,<br />

2132, 2133, 2134, 2136, 2140, 2205, 2211,<br />

2229, 2244<br />

osteoblasts 630, 716, 881, 956, 1487, 1490<br />

osteoclast differentiation and bone turnover<br />

1471<br />

osteoclast inhibition 273<br />

osteoclast-mediated bone resorption 1470<br />

osteoclastogenesis 281, 353, 365, 677, 1130,<br />

1467, 1469, 1488, 1492, 1493, 1495, 2237<br />

osteoclasts 22, 521, 639, 677, 842, 1351, 1471,<br />

1485, 1492, 1493, 1502, 2158<br />

osteocytes 965<br />

osteolysis 1080<br />

osteomalacia 2082<br />

osteonecrosis 1653, 2213<br />

osteopenia 964, 1770<br />

osteophytosis 185, 1373<br />

osteopontin 262, 612, 1521, 2170<br />

osteoporosis 31, 798, 956, 957, 958, 960, 961,<br />

966, 967, 968, 969, 970, 972, 974, 976, 977,<br />

978, 980, 982, 983, 989, 994, 999, 1005, 1006,<br />

1066, 1156, 1316, 1317, 1318, 1540, 1543,<br />

1552, 1561, 1773, 2112, 2157, 2159, 2161<br />

osteoprotegerin 479, 623, 1017, 1497<br />

outcome 1315, 1626, 1736<br />

outcome measures 79, 107, 108, 117, 142, 143,<br />

181, 217, 227, 306, 337, 567, 570, 577, 586,<br />

599, 769, 772, 777, 795, 800, 920, 1014, 1112,<br />

1157, 1213, 1284, 1303, 1316, 1369, 1463,<br />

1545, 1559, 1668, 1683, 1688, 1700, 1745,<br />

1766, 1787, 1809, 1863, 1878, 1896, 1922,<br />

2091, 2095, 2137, 2222, 2225, 2280<br />

outcome studies 651<br />

outcomes 705, 1747<br />

outdoor falls 684<br />

over dispersion 1564<br />

oxidative damage 360<br />

oxidative stress 621, 631, 1357<br />

oxoguanine 631<br />

P selectin 492<br />

p21 861<br />

P<br />

P2Y12 10<br />

p38 32, 274, 1513<br />

p38 MAPK 1119<br />

paced visual serial adding test (PVSAT) 1167<br />

Paget 975, 2237<br />

PAH 402<br />

PAH-QuERI 598<br />

pain 79, 96, 97, 151, 170, 173, 174, 184, 647,<br />

682, 785, 809, 810, 814, 819, 821, 823, 836,<br />

841, 936, 939, 949, 950, 951, 1050, 1063, 1343,<br />

1385, 1464, 1551, 1557, 1567, 1568, 1645,<br />

1665, 1703, 1778, 1862, 1882, 2058, 2097,<br />

2098, 2245, 2247, 2248, 2249<br />

pain measures 2244<br />

pamidronate 1925<br />

pandemic 478<br />

pandemic H1N1 influenza 323<br />

papillary thyroid cancer 1038<br />

paradoxical effect 904<br />

parathyroid hormone 2160<br />

parenteral 396<br />

parotid gland 1887<br />

PARP-1 440<br />

Parry-Romberg syndrome 1687<br />

parvovirus B19 694, 1641<br />

PASE questionnaire 1937<br />

patell<strong>of</strong>emoral joint 2244<br />

path analysis 819<br />

pathergy phenomenon 1289<br />

pathergy test 1289<br />

pathogen-associated molecular pattern 1446<br />

pathogenesis 1374, 1971, 1993<br />

pathology 367<br />

patient care 1335<br />

patient characteristics 68<br />

patient doctor communication 1428<br />

patient global assessment 79, 166<br />

patient global impression <strong>of</strong> change 814, 950<br />

patient organizations 1923<br />

patient outcomes 1735<br />

patient perception 998<br />

patient preferences 324<br />

patient questionnaires 63, 69, 84, 115, 178,<br />

802, 985, 990, 1007, 1027, 1303, 1750, 1755,<br />

1857, 1910, 2066, 2068<br />

patient satisfaction 177, 1002<br />

patient specific functional scale 115<br />

pattern 1769<br />

pattern recognition receptors 2230<br />

pDC 494<br />

PDGF receptor 2001<br />

PDGFR inhibitor 289<br />

pediatric 1305, 2017<br />

pediatric Behçet’s disease 1305<br />

pediatric rheumatology 4, 47, 211, 214, 221,<br />

368<br />

2010 Program Book


233, 234, 240, 243, 252, 262, 268, 790, 998,<br />

1008, 1305, 1341, 1342, 1404, 1434, 1436,<br />

1673, 1674, 1675, 1676, 1679, 1684, 1685,<br />

1686, 1687, 1688, 1689, 1691, 1692, 1693,<br />

1699, 1701, 1702, 1703, 1705, 1706, 1872,<br />

2006, 2102, 2104, 2105, 2106, 2248<br />

peer support 1335<br />

pegloticase 157<br />

pegsiticase 144<br />

peptide library 2001<br />

peptidomimetics 861<br />

peptidylarginine deiminase 1074<br />

perceived helplessness 1461<br />

perfusion 1201<br />

periarticular osteopenia 1770<br />

peridontal disease 2204<br />

periodic fever 1706<br />

periodontal 1074<br />

periodontal disease 1390, 2078<br />

periodontitis 2204<br />

perioperative risk 1039<br />

peripheral neuropathy 1165<br />

peripheral vascular disease 78, 470<br />

peroxisome proliferator-activated receptor<br />

1265<br />

PET/CT 1275<br />

PGE2 365<br />

pH 1502<br />

pharmacist 1575<br />

pharmacodynamics 801<br />

pharmacoepidemiology 72, 2213<br />

pharmacogenetics 828, 1596<br />

pharmacogenomics 254<br />

pharmacokinetic-pharmacodynamics 1945<br />

pharmacokinetics 149, 150, 417, 597, 801,<br />

1222<br />

pharmacology 253, 1818, 1945<br />

phase2a 2172<br />

phenotype 1373<br />

phophatidylserine 1728<br />

phosphatase 609, 2007<br />

phosphodiesterase inhibitors 2086<br />

phospholipid-binding proteins 10<br />

phosphorylation arrays 613<br />

phosphorylcholine 88, 1194<br />

physcial function 191<br />

physical activity 93, 692, 693, 2061<br />

physical activity guidelines 1558, 2096<br />

physical examination 84, 985<br />

physical function 104, 116, 203, 520, 688, 690,<br />

1044, 1065, 1335, 1384, 2136, 2244<br />

physical performance 180<br />

physical performance measures 2244<br />

physical therapy 115, 171, 1316, 2050, 2051,<br />

2053, 2054, 2055, 2060, 2143<br />

physician education 1735<br />

physician global assessment 79, 2109<br />

PI3K 288, 362<br />

pictorial representation 2082<br />

placebo 1892<br />

plain radiographic progression 1371<br />

plasma 1072<br />

plasma cells 742, 1186, 1414<br />

plasmablasts 1295<br />

plasmacytoid dendritic cells (pDCs) 503, 1661<br />

platelet aggregation 10<br />

platelet C4d 620<br />

platelet reactivity 1109<br />

platelet-derived growth factor and receptor<br />

2007<br />

platelets 10, 267, 363, 1109, 2047<br />

pleuritis 1176<br />

pneumo renal syndrome 2009<br />

pneumococcal polysaccharide vaccine 1037<br />

pneumococcal conjugate vaccine 1037, 1440<br />

pneumococcal polysaccharide vaccine 1440<br />

pneumonia 1876<br />

podosome 1502<br />

polyamines 357<br />

polyarteritis nodosa 2016, 2024, 2033<br />

polyarthritis 796<br />

polychondritis 1669<br />

polymerase chain reaction (PCR) 1644<br />

polymorphism 33, 92, 96, 348, 397, 488, 511,<br />

538, 824, 836, 841, 1087, 1313, 1582, 1583,<br />

1591, 1595, 1602, 1885, 1909, 1972, 1994,<br />

2148, 2218<br />

polymyalgia rheumatica 777, 1276, 1296, 1304,<br />

1306, 1311, 1619, 1637, 1652, 1654, 1655<br />

polymyositis/dermatomyositis (PM/DM) 917,<br />

918, 931, 1375, 1377<br />

polyp 883<br />

polysomnography 820<br />

pooled analysis 814, 815<br />

population studies 66, 71, 571, 831, 838, 878,<br />

1299, 1327, 1328, 1331, 1336, 1363, 1538,<br />

1547, 1551, 1555, 1563, 1568, 1615, 2040,<br />

2069, 2080, 2138, 2139, 2180<br />

population-based 2137<br />

population-based study 1556<br />

positive affect 1320<br />

positron emission tomography (PET) 1613<br />

post chikungunya rheumatism 1640<br />

post marketing surveillance 399<br />

post-transcriptional regulation 364<br />

postural assessment 1316<br />

practice guidelines 396, 699, 984, 1008, 1202,<br />

1203<br />

pre-clinical 1083, 1116<br />

pre-clinical rheumatoid arthritis 1094<br />

predating disease onset 1847<br />

prediction 111, 112, 1083<br />

prediction model 311<br />

predictive validity 2108<br />

predictors 93, 300, 536, 1737, 1778<br />

predictors <strong>of</strong> treatment response 52<br />

prednisolone, prednisone 452, 1047, 1153,<br />

1396, 1439, 1773, 1865, 2038<br />

pre-eclampsia 1149<br />

pregabalin 648<br />

pregnancy 81, 325, 384, 401, 458, 475, 545,<br />

718, 775, 779, 1043, 1073, 1149, 1150, 1192,<br />

1193, 1199, 1322, 1860, 2034, 2035, 2210<br />

pre-mRNA 348<br />

prescribing trends 68, 80, 641, 1960<br />

prevalence 58, 112, 197, 975, 976, 1363, 1373,<br />

1538, 1852, 1939, 2154, 2180<br />

prevention 152, 236, 387, 478, 784, 1062,<br />

1288, 1329, 1555, 2092<br />

prilocaine 114<br />

primary care 1029, 2180<br />

primary Sjøgren’s syndrome 1900, 1903, 1904,<br />

1913, 1917<br />

primary/secondary necrosis 490<br />

pro-angiogenic cells 456<br />

procalcitonin 1649<br />

productivity 1882<br />

progesterone 747<br />

progesterone receptors 747<br />

prognosis 1312, 1912<br />

prognostic biomarker 2121<br />

prognostic factors 189, 301, 311, 388, 460, 658,<br />

796, 931, 932, 1110, 1149, 1152, 1227, 1392,<br />

1742, 1759, 1899, 1964, 2052, 2221, 2258<br />

progression 124, 707, 1769, 2273<br />

progressive multifocal leukencephalopathy 700<br />

progressive resistance exercise 2132<br />

prolifeartion 846, 1971<br />

promoters 1733<br />

prostaglandins 864, 1201, 1222, 1514<br />

prosthetic wear particles 1470<br />

protease inhibitor 1645<br />

proteinase 3 681<br />

proteinuria 252, 469, 1415<br />

proteoglycan 1447, 1480<br />

proteomics 487, 652, 834, 839, 843, 1601,<br />

2002, 2229<br />

proton pump inhibitors 2089<br />

proximal tubule 164<br />

P-selectin glycoprotein ligand-1 1246<br />

pseudogout 885<br />

psoriasis 521, 833, 1125, 1273, 1928, 1979<br />

abstract KEYWORD INDEX<br />

2010 Program Book 369


abstract KEYWORD INDEX<br />

psoriatic arthritis 20, 128, 215, 514, 515, 521,<br />

523, 528, 530, 531, 532, 536, 538, 541, 543,<br />

546, 554, 664, 758, 761, 783, 793, 833, 849,<br />

856, 1105, 1372, 1618, 1621, 1634, 1667, 1799,<br />

1919, 1920, 1926, 1928, 1930, 1932, 1935,<br />

1936, 1937, 1939, 1940, 1943, 1950, 1951,<br />

1952, 1954, 1955, 1956, 1960, 1962, 1966,<br />

1968, 1971, 1974, 1975, 1976, 1979, 1983,<br />

1984, 2130, 2182, 2183, 2273<br />

psychological status 449, 802, 1024, 1343,<br />

1862<br />

psychosocial factors 449, 683, 1320, 1321,<br />

1324, 1347, 1348, 1428, 1645, 1748, 2064<br />

PTPN2 1607<br />

PTPN22 824, 1076<br />

public health 974<br />

public relation 2081<br />

pulmonary arterial hypertension 564, 565, 568,<br />

618, 1157, 1210, 1223<br />

pulmonary complications 83, 561, 568, 569,<br />

570, 585, 586, 587, 599, 602, 618, 619, 727,<br />

829, 916, 923, 931, 1004, 1042, 1044, 1157,<br />

1166, 1218, 1227, 1231, 1395, 1669, 1720<br />

pulmonary embolism 1285<br />

pulmonary fibrosis 604<br />

pulmonary hypertension 567, 569, 570, 585,<br />

586, 592, 595, 598, 727, 1004<br />

pulmonary interstitial fibrosis 1635<br />

pulmonary rheumatoid nodules 1810<br />

purine nucleoside phosphorylase inhibition 150<br />

purpura 2013<br />

Q<br />

qualitative 1332<br />

qualitative research 1321<br />

quality appraisal 755<br />

quality improvement 221, 993<br />

quality indicators 2113<br />

quality measurement 993<br />

quality <strong>of</strong> care 59, 70, 72, 87, 162, 484, 789,<br />

985, 986, 989, 991, 993, 995, 998, 999, 1002,<br />

1007, 1010, 1011, 1056, 1332, 1334, 1338,<br />

1428, 1571, 1735, 1856, 1923, 2112, 2113, 2279<br />

quality <strong>of</strong> life 99, 116, 146, 155, 172, 207, 296,<br />

572, 595, 625, 628, 688, 759, 769, 772, 795,<br />

817, 818, 967, 975, 1063, 1096, 1165, 1204,<br />

1325, 1326, 1337, 1340, 1346, 1347, 1423,<br />

1425, 1572, 1645, 1685, 1747, 1748, 1767,<br />

1777, 1787, 1836, 1848, 1872, 1920, 1928,<br />

2070, 2072, 2073, 2090, 2195, 2207, 2281<br />

quantiferon 997<br />

quantitative imaging marker 135<br />

questionnaires 44, 207, 225, 522, 625, 813,<br />

1001, 1009, 1013, 1339, 1348, 1405, 1563,<br />

1752, 1767, 1778, 1920, 1923, 2057, 2072,<br />

2073, 2093, 2110, 2279<br />

QuickDASH 1749<br />

quinolone 2212<br />

R<br />

RA prediction model 133<br />

rabbit 1111<br />

race/ethnicity 501, 589, 1140, 1330, 1556,<br />

1557, 1565, 1592, 1875, 2095, 2145<br />

radai 1750<br />

radial tunnel syndrome 2223<br />

radiographic joint damage 1580<br />

radiographic outcomes 1496<br />

radiographic progression 669, 1120<br />

radiography 121, 124, 139, 140, 143, 181, 182,<br />

185, 187, 303, 311, 665, 668, 728, 952, 1368,<br />

1393, 1611, 1771, 1950, 1953, 1954, 1962,<br />

1985, 2257<br />

radioisotope bone scan 1665<br />

radiological progression 290<br />

Raf kinase inhibitor protein 366<br />

RAGE 632<br />

RAID 1750<br />

RAMRIS 118, 125, 1369<br />

randomized trials 574, 646, 664, 676, 690,<br />

1102, 1113, 1129, 1319, 1325, 1368, 1545,<br />

1559, 1560, 1791, 1808, 1839, 2280<br />

RANK/RANKL pathway 30, 394, 842, 1269,<br />

1482, 1488, 1492, 1497<br />

ranking 687<br />

rapamycin 1185, 1196<br />

RAPID3 1120<br />

rare variants 2144<br />

RA-related autoimmunity 77<br />

Ras GTPase 1529<br />

rats 1480<br />

raw 246.7 1492<br />

Raynaud’s phenomenon 574, 579, 593, 608,<br />

1201, 1215, 2086<br />

reactivation 329<br />

reactive arthritis 552, 696, 761, 1647<br />

reactive oxygen species 631<br />

real life 315<br />

recombinant domain I 1358<br />

recruitment 1559, 2083<br />

recurrent idiopathic pericarditis 837<br />

red blood cells 2277<br />

regeneration 1479<br />

register study 761<br />

registry 400, 454, 569, 975, 17901792, 1802,<br />

2064<br />

regulatory cells 292, 737, 1125, 1242, 1248,<br />

1256, 1257, 1261, 1265, 1267, 1268, 1374,<br />

1827, 1903, 1977, 2236<br />

regulatory natural antibodies 2121<br />

regulatory T cell 442, 738, 909, 2128, 2131<br />

rehabilitation 1321, 1342, 1458, 2050, 2060<br />

relative risk 1036<br />

reliability 140, 1316, 1616, 1623, 1629, 1749,<br />

1954<br />

remission 73, 138, 141, 232, 251, 308, 315,<br />

317, 320, 331, 337, 343, 347, 480, 655, 662,<br />

723, 766, 1050, 1051, 1103, 1278, 1396, 1631,<br />

1701, 1737, 1754, 1758, 1793, 1800, 1823,<br />

1829, 2108<br />

renal 147, 1453<br />

renal biopsy 1399<br />

renal disease 164, 441, 443, 556, 643, 725,<br />

1173, 1190, 1195, 1399, 1415, 1592<br />

renal failure 1662<br />

renal function 161, 1023<br />

replication 329<br />

reporters 1733<br />

repulsion factors 361<br />

resistance training 1384<br />

responder definition 94<br />

response 175<br />

response criteria 1809, 1922<br />

responsiveness 140, 772, 2207<br />

resveratrol 1530<br />

retinal vascular caliber 1772<br />

retreatment 1905<br />

retroperitoneal fibrosis 705, 1662<br />

revision risk 2137<br />

rheumatic diseases 962, 1026<br />

rheumatoid arthritis (RA) 16, 17, 21, 22, 27,<br />

33, 39, 41, 42, 46, 49, 50, 52, 53, 56, 57, 58, 59,<br />

60, 61, 63, 64, 66, 67, 68, 69, 70, 72, 73, 77, 78,<br />

79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 90, 101,<br />

112, 118, 119, 125, 129, 132, 133, 135, 136,<br />

138, 139, 141, 168, 274, 279, 282, 288, 290,<br />

295, 296, 297, 300, 301, 302, 303, 306, 308,<br />

309, 310, 313, 314, 315, 316, 317, 320, 321,<br />

323, 324, 326, 329, 330, 331, 332, 333, 334,<br />

335, 336, 337, 338, 339, 340, 343, 344, 345,<br />

346, 347, 348, 350, 351, 356, 357, 362, 363,<br />

365, 368, 374, 375, 378, 383, 389, 390, 391,<br />

393, 394, 397, 398, 401, 402, 403, 406, 409,<br />

413, 414, 416, 419, 421, 523, 539, 636, 638,<br />

639, 640, 643, 645, 658, 659, 660, 661, 697,<br />

698, 717, 723, 735, 739, 743, 745, 755, 756,<br />

759, 762, 770, 775, 778, 781, 785, 787, 794,<br />

827, 847, 848, 849, 853, 856, 858, 861, 871,<br />

880, 968, 970, 981, 983, 984, 987, 991, 993,<br />

995, 1009, 1013, 1014, 1015, 1016, 1017, 1018,<br />

1019, 1020, 1021, 1022, 1023, 1024, 1025,<br />

1026, 1027, 1028, 1030, 1034, 1035, 1037,<br />

1038, 1039, 1040, 1041, 1042, 1043, 1044,<br />

1045, 1047, 1048, 1049, 1050, 1052, 1053,<br />

1056, 1057, 1058, 1060, 1062, 1063, 1064,<br />

1065, 1066, 1067, 1068, 1070, 1072, 1073,<br />

1074, 1075, 1077, 1079, 1081, 1083, 1086,<br />

1087, 1089, 1091, 1094, 1096, 1101, 1102,<br />

1103, 1104, 1106, 1109, 1110, 1113, 1117,<br />

1124, 1125, 1128, 1131, 1133, 1136, 1138,<br />

1223, 1255, 1263, 1269, 1271, 1324, 1325,<br />

1332, 1333, 1369, 1370, 1386, 1392, 1395,<br />

1411, 1421, 1432, 1442, 1443, 1496, 1504,<br />

1517, 1518, 1520, 1524, 1527, 1528, 1534,<br />

1545, 1550, 1559, 1570, 1571, 1580, 1581,<br />

1582, 1588, 1589, 1593, 1596, 1597, 1598,<br />

370<br />

2010 Program Book


1599, 1600, 1603, 1605, 1606, 1609, 1610,<br />

1611, 1618, 1621, 1629, 1632, 1634, 1636,<br />

1641, 1648, 1708, 1712, 1721, 1722, 1724,<br />

1731, 1735, 1736, 1738, 1739, 1741, 1742,<br />

1743, 1744, 1745, 1747, 1748, 1749, 1750,<br />

1751, 1752, 1753, 1754, 1757, 1758, 1759,<br />

1760, 1761, 1762, 1763, 1765, 1767, 1768,<br />

1769, 1770, 1772, 1773, 1774, 1775, 1776,<br />

1777, 1778, 1779, 1780, 1781, 1782, 1783,<br />

1784, 1785, 1786, 1787, 1788, 1789, 1790,<br />

1793, 1794, 1795, 1797, 1798, 1803, 1809,<br />

1811, 1815, 1817, 1823, 1824, 1825, 1826,<br />

1834, 1835, 2063, 2064, 2065, 2066, 2081,<br />

2108, 2114, 2115, 2118, 2119, 2127, 2135,<br />

2142, 2162, 2163, 2165, 2166, 2167, 2168,<br />

2169, 2172, 2173, 2182, 2207, 2210, 2211,<br />

2215, 2216, 2217, 2218, 2221, 2222, 2245,<br />

2256, 2257, 2258, 2259, 2260, 2261, 2267,<br />

2279, 2280, 2283, 2284<br />

rheumatoid arthritis synovial tissue 371<br />

rheumatoid arthritis, animal models 269, 270,<br />

271, 272, 276, 278, 280, 281, 284, 285, 286,<br />

289, 292, 635, 713, 714, 716, 855, 896, 1130,<br />

1137, 1256, 1266, 1351, 1417, 1420, 1495,<br />

1613, 1622, 1708, 1709, 1712, 1714, 1715,<br />

1717, 1719, 1720, 1723, 1725, 1726, 1727,<br />

1728, 1731, 1733, 2128, 2227, 2232, 2234,<br />

2236, 2237<br />

rheumatoid arthritis, disease activity<br />

measurement 1003<br />

rheumatoid arthritis, pathogenesis 25, 30, 245,<br />

250, 255, 349, 352, 354, 356, 359, 361, 364,<br />

366, 370, 371, 372, 1071, 1076, 1078, 1080,<br />

1082, 1085, 1088, 1090, 1092, 1093, 1247,<br />

1252, 1254, 1353, 1390, 1391, 1417, 1505,<br />

1506, 1786, 1801, 1968, 2116, 2130<br />

rheumatoid arthritis, synovium 23, 29, 36, 291,<br />

353, 355, 360, 364, 367, 623, 1051, 1069, 1240,<br />

1387, 1416, 1508, 1515, 1527, 1529, 1535,<br />

1604, 1822<br />

rheumatoid arthritis, treatment 51, 54, 55, 62,<br />

75, 76, 120, 123, 273, 278, 280, 281, 284, 298,<br />

311, 312, 318, 319, 322, 324, 328, 330, 339,<br />

341, 342, 344, 357, 376, 377, 380, 381, 392,<br />

396, 400, 405, 407, 408, 410, 411, 412, 417,<br />

418, 420, 641, 642, 662, 663, 744, 791, 1003,<br />

1010, 1013, 1032, 1036, 1046, 1054, 1055,<br />

1084, 1095, 1097, 1098, 1099, 1100, 1105,<br />

1108, 1111, 1112, 1114, 1115, 1116, 1118,<br />

1119, 1120, 1121, 1122, 1123, 1127, 1129,<br />

1132, 1134, 1135, 1137, 1387, 1393, 1394,<br />

1396, 1397, 1440, 1444, 1445, 1467, 1507,<br />

1542, 1715, 1718, 1730, 1766, 1771, 1791,<br />

1792, 1796, 1799, 1802, 1805, 1806, 1807,<br />

1808, 1810, 1814, 1816, 1819, 1820, 1821,<br />

1827, 1828, 1829, 1830, 1832, 1833, 1838,<br />

1840, 1841, 2164, 2170, 2171, 2204, 2233,<br />

2262, 2263, 2264, 2265, 2282<br />

rheumatoid factor (RF) 660<br />

rheumatoid factor negative 1830<br />

rheumatoid factor positive 1830<br />

rheumatoid nodule 1060<br />

rheumatoid vasculitis 1020<br />

rheumatologic practice 41, 48, 310, 995, 1003,<br />

1024, 1338, 1560, 2109<br />

rheumatology fellows 1429<br />

rheumatology practice 109<br />

rheumatology practice audit 1735<br />

ribonucleoprotein (RNP) 608, 852, 1267, 2175<br />

right heart pressures 567<br />

risedronate 2156<br />

risk 1956<br />

risk assessment 5, 521, 554, 562, 589, 793,<br />

919, 972, 997, 1026, 1039, 1048, 1053, 1082,<br />

1233, 1285, 1551, 1554, 1576, 1588, 1842,<br />

1849, 1914, 2153, 2212<br />

risk factors 774, 976, 1877, 1936, 2100<br />

Ritchie articular index 295<br />

rituximab 55, 321, 332, 333, 340, 375, 391,<br />

401, 403, 405, 406, 409, 465, 678, 680, 700,<br />

738, 739, 740, 744, 767, 917, 1084, 1098, 1118,<br />

1144, 1153, 1295, 1379, 1582, 1671, 1693,<br />

1790, 1801, 1807, 1810, 1821, 1828, 1830,<br />

1833, 1889, 1892, 1893, 1894, 1905, 1955,<br />

2041, 2042, 2201, 2263<br />

RNA- and DNA-based agonists 862<br />

RNA binding protein 487<br />

RNA polymerase III antibody 1231<br />

RNA-binding protein 934<br />

RNAi therapeutics 2174<br />

Ro/SSA 2175<br />

Ro60 1901<br />

ROC curves 1775<br />

RORgamma t 1260<br />

ROS 657<br />

rural health care 2050<br />

S<br />

S100 proteins 845, 1472<br />

S100A4 614<br />

S100A8 1495, 2002<br />

sacroiliac joints 1962<br />

sacroiliitis 527, 665, 1279<br />

safety 97, 147, 163, 177, 390, 1172, 1454,<br />

1795, 2173<br />

salivary function 2179<br />

salivary gland 1413<br />

SAPHO syndrome 2269<br />

scanning electron microscopy 875<br />

scavenger receptor 1072<br />

sciatica 170<br />

SCID mice 1266<br />

scintigraphy 1887<br />

scleritis 413<br />

scleroderma 561, 562, 563, 564, 565, 567, 569,<br />

585, 587, 589, 591, 592, 594, 595, 598, 600,<br />

601, 609, 612, 617, 622, 674, 675, 726, 727,<br />

729, 1004, 1202, 1203, 1209, 1210, 1213, 1214,<br />

1228, 1232, 1238, 1349, 1352, 1661, 1683,<br />

1987, 1990, 1992, 1996, 2001, 2006, 2007,<br />

2072, 2073, 2086, 2193, 2194, 2195, 2196,<br />

2197, 2214, 2247<br />

scn9a 96<br />

score 1621<br />

scoring methods 1954<br />

SCOT trial (Scleroderma Cyclophosphamide or<br />

Transplant) 726<br />

screening 1004, 1937, 1939<br />

screening guideline adherence 1000<br />

SDAI 73<br />

seasonal variation 783<br />

secular trend 685<br />

segmental 1151<br />

SELENA-SLEDAI 1456<br />

self-directed program 691<br />

self-efficacy 2280<br />

self-management 689, 1334, 1408, 1562, 1745,<br />

2062, 2282<br />

self-reported arthritis 1460, 1462<br />

semaphorins 361<br />

semi-structured interview 1322<br />

sensitive 118<br />

sensitivity 522<br />

sensitivity and specificity 1775<br />

septic arthritis 1638<br />

sequential therapy 1792<br />

seroconversion 699<br />

serologic tests 911, 1764<br />

serotonin receptor 799<br />

serum complement 1149<br />

serum glycosylation 1105<br />

serum trough levels 1826<br />

service delivery 776, 1553<br />

severity 707, 1087, 1600, 1876, 2218<br />

sex bias 1193<br />

sex hormones 63, 361, 1257<br />

sex-differences 684<br />

sexual dysfunction 812<br />

sexual functioning 2073<br />

SF-36 1211, 1848<br />

SF-6D 2207<br />

sham acupuncture 941<br />

shared care 2280<br />

shared decision making 1024<br />

shared epitope 255, 1035, 1071, 1076, 2114,<br />

2215<br />

Sharp score 1734<br />

Sharp/van der Heijde 1368<br />

shingles 421<br />

shoewear 1331<br />

short form McGill pain questionnaire 2247<br />

shoulder disorders 177<br />

shrinking lung syndrome 1176<br />

sicca 1886<br />

side effects 31<br />

abstract KEYWORD INDEX<br />

2010 Program Book 371


abstract KEYWORD INDEX<br />

signal transduction 18, 32, 35, 289, 351, 362,<br />

370, 609, 639, 855, 868, 1196, 1412, 1416,<br />

1471, 1478, 1501, 1514, 1529, 1535, 1718,<br />

1725, 2127, 2275<br />

simplified disease activity index (SDAI) 317<br />

single item measure 2247<br />

single nucleotide polymorphism (SNP) 730,<br />

1280, 1584, 1587, 1972<br />

siRNA 1450<br />

Sirt1 knockout mice 1484<br />

sitaxentan 565<br />

Sj 1215, 1893, 1894, 1895, 1897, 1908, 1909,<br />

1911, 1914, 2174<br />

sJIA 1434<br />

Sjogren’s syndrome 103, 495, 702, 1413, 1579,<br />

1883, 1884, 1886, 1887, 1888, 1889, 1890,<br />

1891, 1896, 1898, 1899, 1901, 1902, 1904,<br />

1905, 1908, 1910, 1911, 1912, 1914, 1916,<br />

2174, 2175, 2177, 2178<br />

skeletal fluorosis 1568<br />

SKG mice 1715<br />

skin 860<br />

skin blood flow 1220<br />

skin fibrosis 596<br />

skin ulcers 932<br />

SLE indices 990<br />

SLEDAI 462, 1437, 1878<br />

SLEDAI-2K 772<br />

sleep 815<br />

sleep disorders 786, 799, 808, 820, 1228, 1406,<br />

2071<br />

SLICC 1881<br />

SLICC/ACR Damage Index (SDI) 474<br />

small fibre neuropathy 1908<br />

small interfering RNA 2174<br />

small molecule therapy 285<br />

small molecules 1119, 2233<br />

smoking 645, 661, 765, 1092, 1252, 1956,<br />

1984, 2114<br />

smooth muscle 1490<br />

SNP 1608, 1885<br />

social media 1345, 2083<br />

social support 174, 1324, 1326, 1334, 1335,<br />

1340, 1409<br />

socioeconomic factors 61, 776, 790, 1221,<br />

1460, 1463, 1553, 2140<br />

SOCS3 1501<br />

sodium channels 96<br />

soluble binding domain I apoER2 1360<br />

somatosensory 1557<br />

sonography 889, 1626, 2225<br />

SOST 548<br />

spaceflight 959<br />

spatial variation 64<br />

specialized disease center 2077<br />

speckle tracking echocardiography 582<br />

sphingosine kinase 1480<br />

spine involvement 130, 1446<br />

splicing 348, 893<br />

spondylarthropathy 130, 134, 223, 516, 517,<br />

520, 522, 524, 525, 527, 528, 529, 533, 535,<br />

540, 546, 547, 549, 550, 551, 552, 553, 558,<br />

665, 667, 697, 761, 778, 794, 986, 1037, 1279,<br />

1337, 1355, 1432, 1440, 1446, 1447, 1448,<br />

1449, 1450, 1451, 1647, 1922, 1924, 1931,<br />

1938, 1952, 1953, 1957, 1959, 1964, 1967,<br />

1969, 1973, 1977, 1981, 1985, 2078, 2180,<br />

2181, 2184, 2269, 2271, 2272<br />

spondyloarthritis 665, 904, 1938, 2181<br />

SSA/Ro 656<br />

stable isotope labelling 843<br />

standardisation 1781<br />

standardized incidence ratio 398<br />

standardized response mean 140<br />

staphylococcus aureus 758<br />

STAT3 370<br />

static alignment 195<br />

statins 72, 1028, 1056, 1677, 1833, 2255<br />

statistical methods 577, 1564, 1585, 1586,<br />

1588, 1942, 2079<br />

stem cells 1473<br />

stereology 1485<br />

steroids 335, 445<br />

Still’s disease 653, 701, 891, 902, 1831<br />

stool studies 537<br />

stress 1025<br />

stroke 2124<br />

strontium ranelate 1497<br />

structural damage 1606<br />

structural damage progression 1496<br />

subchondral bone 192, 709, 1497<br />

subcutaneous 396, 416, 1124, 1834, 2173<br />

subendocardial variability ratio 1028<br />

subset 733<br />

sulfatase 369<br />

SUMO 368<br />

superantigens 267<br />

supplementation regimens 962<br />

suprascapular nerve block 177<br />

surgery 1315<br />

surgical site infections 335<br />

surveillance 699<br />

survey 109, 1013, 1565<br />

survey criteria 100<br />

survival 2018, 2022, 2037<br />

susceptibility 255, 521, 1975, 2148, 2215<br />

sustained remission 308, 336<br />

Swefot trial 1392<br />

swine influenza 697<br />

switch 298<br />

sympathetic nerve fibers 361<br />

symptom management 1319<br />

symptom modification 664<br />

symptoms 1346<br />

synaptotagmin VII 1374<br />

synovial cells, synovial fluid 29, 30, 244, 352,<br />

354, 355, 359, 362, 369, 858, 887, 1128, 1247,<br />

1387, 1388, 1421, 1422, 1520, 1527, 1535,<br />

1536, 1604, 1971, 1978, 2219<br />

synovial tissue 847<br />

synovitis 20, 32, 118, 167, 1449, 1620, 1621,<br />

1638, 1781, 2220<br />

synthetase syndrome 913, 930, 1377<br />

syringe 1567<br />

systematic analysis 143<br />

systematic review 92, 516, 941, 952<br />

systemic inflammation 919<br />

systemic juvenile idiopathic arthritis 209<br />

systemic lupus erythematosus (SLE) 1, 4, 9, 13,<br />

24, 252, 262, 323, 422, 424, 425, 426, 427, 428,<br />

430, 431, 432, 434, 435, 436, 437, 438, 441,<br />

442, 444, 445, 446, 447, 448, 449, 450, 451,<br />

452, 453, 454, 455, 456, 457, 458, 459, 460,<br />

461, 462, 463, 464, 465, 466, 467, 468, 470,<br />

474, 475, 476, 477, 478, 479, 480, 481, 482,<br />

483, 484, 485, 486, 487, 488, 490, 491, 492,<br />

493, 494, 495, 496, 497, 498, 499, 500, 501,<br />

502, 503, 504, 505, 506, 507, 508, 509, 510,<br />

511, 620, 625, 627, 628, 637, 656, 694, 702,<br />

730, 731, 733, 735, 738, 740, 746, 748, 749,<br />

750, 751, 752, 754, 757, 762, 764, 765, 769,<br />

772, 775, 789, 790, 795, 832, 850, 857, 859,<br />

862, 865, 990, 996, 1000, 1011, 1075, 1139,<br />

1141, 1142, 1143, 1145, 1146, 1147, 1148,<br />

1149, 1150, 1151, 1152, 1153, 1154, 1155,<br />

1156, 1157, 1158, 1159, 1160, 1162, 1163,<br />

1164, 1165, 1166, 1167, 1169, 1170, 1171,<br />

1172, 1173, 1174, 1175, 1176, 1177, 1178,<br />

1179, 1180, 1181, 1182, 1183, 1184, 1185,<br />

1186, 1187, 1191, 1192, 1193, 1194, 1195,<br />

1196, 1197, 1199, 1200, 1223, 1243, 1245,<br />

1257, 1272, 1400, 1401, 1402, 1437, 1452,<br />

1454, 1456, 1457, 1577, 1578, 1583, 1584,<br />

1585, 1586, 1587, 1590, 1591, 1592, 1594,<br />

1595, 1602, 1608, 1639, 1641, 1666, 1674,<br />

1676, 1677, 1679, 1684, 1688, 1689, 1694,<br />

1695, 1701, 1702, 1784, 1842, 1843, 1844,<br />

1845, 1846, 1847, 1848, 1849, 1850, 1851,<br />

1852, 1853, 1854, 1855, 1856, 1857, 1858,<br />

1859, 1860, 1861, 1862, 1863, 1864, 1865,<br />

1866, 1868, 1869, 1870, 1871, 1872, 1873,<br />

1874, 1875, 1876, 1877, 1878, 1878, 1880,<br />

1881, 1882, 1895, 1909, 2070, 2077, 2083,<br />

2106, 2113, 2120, 2122, 2123, 2125, 2126,<br />

2144, 2145, 2146, 2148, 2149, 2175, 2190,<br />

2191, 2239, 2240, 2242, 2243, 2274, 2275,<br />

2277, 2278<br />

systemic sclerosis 560, 566, 568, 569, 570, 571,<br />

572, 573, 574, 575, 576, 577, 578, 579, 580,<br />

581, 582, 584, 586, 588, 590, 593, 596, 597,<br />

598, 599, 603, 604, 605, 606, 607, 609, 610,<br />

611, 613, 614, 615, 616, 619, 670, 671, 673,<br />

724, 725, 726, 728, 824, 829, 1201, 1204, 1206,<br />

1207, 1208, 1211, 1215, 1216, 1217, 1218,<br />

1219, 1220, 1221, 1222, 1223, 1224, 1225,<br />

372<br />

2010 Program Book


1226, 1227, 1229, 1230, 1231, 1233, 1234,<br />

1235, 1236, 1237, 1239, 1346, 1347, 1348,<br />

1587, 1623, 1624, 1627, 1704, 1987, 1988,<br />

1989, 1990, 1991, 1994, 1997, 1998, 1999,<br />

2000, 2001, 2002, 2004, 2005, 2007, 2008,<br />

2086, 2192, 2193, 2196, 2226, 2247<br />

systems biology 733<br />

T cell anergy 1264<br />

T cell help 867<br />

T cell receptor revision 1272<br />

T cells 38, 265, 275, 287, 350, 370, 372, 432,<br />

434, 435, 437, 442, 462, 488, 497, 505, 507,<br />

636, 740, 825, 830, 846, 863, 867, 909, 935,<br />

1069, 1079, 1090, 1125, 1141, 1150, 1185,<br />

1187, 1196, 1241, 1242, 1244, 1245, 1248,<br />

1249, 1250, 1251, 1254, 1255, 1256, 1258,<br />

1259, 1260, 1261, 1262, 1263, 1264, 1265,<br />

1266, 1267, 1268, 1269, 1270, 1271, 1272,<br />

1274, 1278, 1446, 1499, 1524, 1525, 1724,<br />

1801, 1838, 1843, 1900, 1903, 1919, 1967,<br />

1989, 2004, 2126, 2127, 2128, 2129, 2130,<br />

2188, 2190, 2191, 2232, 2275<br />

T follicular helper cell 432, 1141<br />

T helper cells 1992<br />

T helper subsets 635<br />

TFH 1250<br />

T-5224 280, 1467<br />

TACI 2178<br />

tadalafil 2086<br />

tai chi 690<br />

TAK1 1535<br />

Takayasu 1275, 1279, 1286, 1287, 1290, 1291,<br />

1295, 1313, 1315, 2198<br />

Takayasu’s arteritis 1282, 1283<br />

targeted resequencing 2146<br />

TASK2 1255<br />

TCZ 1434, 1840<br />

team-based learning 46, 1432<br />

technology 1334<br />

telangiectases 1234<br />

temporal arteritis 1302, 2044<br />

temporal artery biopsy 1311<br />

temporomandibular joint 213, 218, 228<br />

tender 1434<br />

tendinopathies 106<br />

tendonitis 898<br />

tendonitis/bursitis 2212<br />

tenocytes 106<br />

teratozoospermia 513<br />

teriparatide 967, 980<br />

testicular function 513<br />

testing 1543, 1561<br />

TGF-beta 244, 442, 489<br />

Th1 and Th17 1903<br />

Th1, Th2, Th17 cells 435<br />

T<br />

Th17 265, 275, 370, 715, 1241, 1249, 1274,<br />

1838, 2130<br />

Th17 cells 1970, 2129<br />

Th9 1241<br />

thalidomide 1657<br />

theophylline 149<br />

therapeutic approaches 1700<br />

therapeutic delay 558<br />

therapeutic targets 733<br />

therapy 1683, 1831, 2048<br />

therapy monitoring 138<br />

therapy response 83<br />

thermography 1439<br />

thoracic manipulation 2060<br />

thrombin 604<br />

thrombin generation 1<br />

thrombosis 1, 2, 3, 5, 6, 8, 13, 14, 374, 460,<br />

482, 906, 1243, 1357, 1602, 2255<br />

thrombospondins 1991<br />

thymic negative selection 1260<br />

thyroid 1029, 1038<br />

thyroid nodule 1038<br />

tight control 380, 1104, 1753<br />

TIM-2 1731<br />

TIM-3 372<br />

tissue factor 2254<br />

tissue inhibitor <strong>of</strong> metalloproteinase 3 (TIMP3)<br />

1478<br />

tissue regeneration 1380<br />

tissue remodelling 629<br />

tissue targeting 852<br />

tlda 1986<br />

TLR2 858<br />

TLR-2 ligand 267<br />

TLR4 1495, 1501, 1535, 1730<br />

TLR7 1410<br />

TNF 1695<br />

TNF antagonists 216<br />

TNF genes polymorphism 217<br />

TNF inhibitor 419<br />

TNF-alpha 371<br />

TNFRSF1A gene 837<br />

tobacco 1551<br />

tobacco use 470, 562, 661, 1035, 1070, 1093,<br />

1152, 1546, 1850<br />

tocilizumab 56, 120, 237, 329, 373, 378, 384,<br />

399, 411, 701, 745, 759, 1115, 1138, 1411,<br />

1434, 1788, 1793, 1797, 1800, 1808, 1809,<br />

1819, 1820, 1823, 1839, 1840, 2262<br />

tolerance 1116, 1717<br />

tolerogenic dendritic cells 1715<br />

toll-like receptor 2 16, 857<br />

toll-like receptor 4 713<br />

toll-like receptor 7 856, 862, 1584<br />

toll-like receptor 9 856, 862<br />

toll-like receptors (TLR) 424, 1296, 1391, 1501,<br />

1883, 1993, 2023<br />

tophaceous 2152<br />

tophi 157<br />

topical 944<br />

total elbow replacement 1080<br />

total joint replacement 174, 196, 1539, 1576,<br />

2053, 2054, 2090, 2136, 2137<br />

total knee arthroplasty 171<br />

trabecular morphometry 709<br />

traditional cardiovascular risk factors 1067<br />

TRAIL 1527<br />

tranilast 160<br />

transcription factor 38, 258, 507, 616, 1251,<br />

1259, 1469, 1487, 1508, 1522, 1526, 1724,<br />

2177, 2274<br />

transcriptional targeting 1733<br />

transcriptomics 1422, 1981<br />

trans-ethnic mapping 1595<br />

transforming growth factor 600, 602, 617, 673,<br />

674, 1241, 1997<br />

transition 211, 1340<br />

transition care 1008, 1409<br />

translational research 607<br />

transmigration 1420<br />

transplantation 704, 713, 874, 907, 918, 1143,<br />

1161, 2104<br />

transracial mapping 2274<br />

transverse myelitis 1174<br />

traps 905<br />

trauma 1551<br />

treatment 117, 196, 218, 676, 705, 902, 1306,<br />

1315, 1380, 1543, 1561, 1670, 1675, 2273<br />

treatment decision 82, 1899<br />

treatment preference 1875<br />

treatment protocols 1702<br />

treatment response 453, 828, 1452<br />

treatment strategies 311<br />

Treg 370, 1196<br />

Treg activator 1125<br />

Treg cells 2129<br />

treprostinil 1201, 1222<br />

treprostinil diethanolamine 597<br />

trial 1892<br />

trimethoprim-sulphamethoxazole 472<br />

triple therapy 1368<br />

tuberculosis 376, 404, 699, 768, 782, 890, 908,<br />

997, 1012, 1310, 1941<br />

tuberculosis skin test 756, 782<br />

tumor necrosis factor (TNF) 62, 88, 241, 249,<br />

345, 356, 406, 712, 897, 1020, 1133, 1198,<br />

1442, 1444, 1487, 1530, 1532, 1534, 1607,<br />

1643, 1680, 1841, 1942, 1958<br />

tumor necrosis factor receptor associated<br />

periodic syndrome 837<br />

twin study 877<br />

abstract KEYWORD INDEX<br />

2010 Program Book 373


abstract KEYWORD INDEX<br />

type I IFN signature 1084<br />

type I interferon 1188, 1379<br />

type II collagen 1709, 2235<br />

typing 2142<br />

tyrosine kinase 293, 1536<br />

tyrosine kinase inhibitor 286<br />

tyrosine phosphorylation 609<br />

UA 1371<br />

U<br />

ulcers 593, 1045, 1217, 1222, 1239, 1278, 1657<br />

ultrasonography 889<br />

ultrasound 45, 127, 455, 889, 1038, 1055,<br />

1169, 1220, 1237, 1263, 1302, 1397, 1614,<br />

1616, 1617, 1618, 1620, 1621, 1624, 1626,<br />

1629, 1630, 1631, 1633, 1634, 1635, 1636,<br />

1754, 1962, 2220, 2221, 2222, 2223, 2225<br />

undercarboxylated osteocalcin 983, 1773<br />

undifferentiated arthritis 658, 659, 1396, 1785<br />

undifferentiated spondyloarthritis 2272<br />

unexplained symptoms 170<br />

unfolded protein response 634, 1376, 1965<br />

urantide 618<br />

URAT1 164<br />

urate lowering therapy 2088<br />

uric acid 144, 150, 154, 157, 160, 161, 164,<br />

165, 877, 884, 992, 1367, 1556, 1574, 1616,<br />

2153<br />

uricase 144<br />

US adults 687<br />

USpA 1925<br />

utility 787<br />

utilization review 60, 969, 1675, 1864<br />

uveitis 230, 234, 546, 904, 1308, 1447, 1670,<br />

1933<br />

V<br />

vaccination 849<br />

vaccines 9, 224, 235, 236, 323, 450, 457, 466,<br />

478, 481, 645, 697, 792, 1037, 1238, 1437,<br />

1440, 1694, 1917, 2043<br />

validation 625, 659, 1774<br />

validity 1749, 2061, 2068<br />

value <strong>of</strong> information 759<br />

Van der Heijde modified Sharp score 1392<br />

variant 2177<br />

varicella zoster virus 421<br />

varicocele 513<br />

varus thrust 195, 202, 2101<br />

vascular involvement 1285<br />

vascular remodelling 1314<br />

vascular stiffness 519, 1200<br />

vasculitis 126, 680, 774, 822, 1045, 1207, 1249,<br />

1275, 1280, 1284, 1285, 1286, 1287, 1290,<br />

1291, 1297, 1298, 1299, 1301, 1302, 1303,<br />

1305, 1307, 1308, 1313, 1314, 1315, 1326,<br />

1512, 1646, 1663, 1669, 1673, 1675, 1691,<br />

1695, 1705, 2009, 2010, 2011, 2012, 2013,<br />

2014, 2016, 2017, 2018, 2019, 2020, 2021,<br />

2023, 2024, 2025, 2026, 2027, 2029, 2030,<br />

2032, 2035, 2036, 2037, 2038, 2039, 2040,<br />

2041, 2042, 2043, 2044, 2045, 2046, 2048,<br />

2107, 2131, 2198, 2200, 2201, 2203<br />

VCAM-1 492<br />

VEGF 1418<br />

venous thromboembolism 53, 78, 1539<br />

vertebral fracture assessment by morphometry<br />

(VFA) 976<br />

very early presentation 661<br />

vestibuloauditory symptoms 1675<br />

veterans 1099, 1792<br />

vibratory sense 205<br />

viral conversion 510<br />

virtual teaching 44<br />

viruses 804, 1197, 1478, 1642, 1694, 1891<br />

visfatin 619, 1514<br />

visit frequency 1868, 1869<br />

visual ischemic manifestations 1301<br />

vitamin D 310, 706, 1163, 1180, 2030<br />

vitamin K 1773<br />

vitamins 252, 310, 872, 1574<br />

VLA-4 865<br />

voxel based morphometry (VBM) 1167<br />

VpreB 1589<br />

vulnerable coronary plaque 1046, 1443, 2164,<br />

2165<br />

W<br />

walking 2141<br />

walking speed 2133<br />

watchful waiting 992<br />

web-based 44<br />

Wegener’s granulomatosis 676, 677, 678, 679,<br />

681, 2009, 2012, 2014, 2018, 2021, 2022, 2026,<br />

2028, 2029, 2031, 2034, 2043, 2047, 2049<br />

widespread pain 550<br />

withholding <strong>of</strong> therapy 1381<br />

Wnt 601, 629, 1468, 1503<br />

Wnt pathway 624<br />

Wnt signaling 716<br />

WOMAC 706<br />

women 1546, 2132<br />

women’s health 165, 325, 347, 447, 974, 1063,<br />

2083, 2092<br />

work activity limitation 2141<br />

work disability 1211, 1349, 2139<br />

work limitations 2069, 2138<br />

work productivity 51, 2195<br />

working age 2069, 2138<br />

worst case 2281<br />

wound fluid analysis 1239<br />

X chromosome 2004<br />

xenotropic murine leukemia virus-related virus<br />

804<br />

x-ray findings 185<br />

X<br />

Y<br />

young arthritis patients 1345<br />

Zc3h12a 364<br />

zero-inflation 1564<br />

zoledronic acid 2156<br />

zymosan-induced arthritis 1713<br />

Z<br />

374<br />

2010 Program Book


Abelson, Abby Goulder, MD<br />

Education<br />

Disclosure:Nothing to Disclose<br />

Abraham, David, MD<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Pathogenesis, Animal Models and<br />

Genetics<br />

Disclosure:Nothing to Disclose<br />

Adams, Barbara S, MD<br />

Pediatric <strong>Rheumatology</strong> - Pathogenesis<br />

and Genetics: Biological Basis for Pediatric<br />

Rheumatic Disease<br />

Disclosure:<br />

Aringer, Martin<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Safety<br />

and Efficacy I<br />

Disclosure: Centocor, 2; Roche, 5<br />

Asahara, Hiroshi, MD, PhD<br />

Biology and Pathology <strong>of</strong> Bone and Joint:<br />

Molecular Basis <strong>of</strong> Osteoarthritis<br />

Disclosure:Nothing to Disclose<br />

Backman, Catherine L, PhD, OT(C)<br />

Keep Working with Arthritis<br />

Disclosure: Nothing to Disclose<br />

A<br />

B<br />

Baer, Alan N, MD<br />

Sjögren’s Syndrome<br />

Disclosure:Nothing to Disclose<br />

Baron, Murray<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Clinical Aspects and Therapeutics II<br />

Disclosure: Nothing to Disclose<br />

Birnbaum, Neal S, MD<br />

Rheumatoid Arthritis - Clinical Aspects:<br />

Preclinical RA and Early RA I<br />

Disclosure: AMgen/Pfizer, Amgen, Centocor,<br />

UCB, Genentech, 8<br />

Block, Joel A, MD<br />

Osteoarthritis - Clinical Aspects: Pain and<br />

Biomechanics<br />

Disclosure: KAI / NIH, 9; NiCOx, 5; OA and<br />

Cartilage, 9; Pleiad, 5<br />

Brandenstein, Jane S, MD<br />

Physical and Psychosocial Challenges in<br />

Scleroderma<br />

Braun, Juergen, MD<br />

Spondylarthropathies and Psoriatic Arthritis -<br />

Clinical Aspects and Treatment: Imaging I<br />

Breban, Maxime A<br />

Spondylarthritis and Psoriatic Arthritis:<br />

Pathogenesis, Etiology, and Animal Models<br />

Disclosure: Nothing to Disclose<br />

Brunner, Hermine, MD<br />

ACR/ARHP Combined Pediatric <strong>Rheumatology</strong>:<br />

Clinical and Therapeutic Aspects: Quality <strong>of</strong> Life<br />

in Children and Adolescents with Arthritis<br />

Buch, Maya H, MD, PhD<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Safety<br />

and Efficacy I<br />

Disclosure: Abbott, 5; Pfizer/Wyeth, 5; Roche, 5<br />

Bunyard, Matthew P, MD<br />

Quality Measures and Innovation in Practice<br />

Management and Care Delivery<br />

Disclosure: Nothing to Disclose<br />

C<br />

Carette, Simon, MD<br />

ANCA-associated Vasculitis I<br />

Disclosure:Nothing to Disclose<br />

Carlone, Joyce P, MD<br />

Rheumatoid Arthritis: From Clinic to Home<br />

Disclosure:Nothing to Disclose<br />

Chakravarty, Eliza F, MD<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment: Renal<br />

Disclosure:Nothing to Disclose<br />

Chatham, W. Wimm, MD<br />

Miscellaneous Rheumatic and Inflammatory<br />

Diseases<br />

Disclosure: Nothing to Disclose<br />

Chen, Pojen P, MD<br />

Antiphospholipid Syndrome I<br />

Disclosure:Nothing to Disclose<br />

Choy, Ernest, MD<br />

Rheumatoid Arthritis - Clinical Aspects:<br />

Radiographic and Other Outcomes in RA IV<br />

Disclosure: Abbott Immunology Laboratories,<br />

5; Astra Zeneca, 5; Chelsea Therapeutics, 2;<br />

Chugai Pharma, 5; Chugai Pharma, 8; Eli Lilly, 5;<br />

Eli Lilly, 8; GSK, 5; Jazz Pharmaceuticals, 2; Jazz<br />

Pharmaceuticals, 5; MSD, 2; Pfizer, 5; Roche, 2;<br />

Roche, 5; Roche, 8; Synovate, 5; UCB, 2l UCB, 5;<br />

UCB, 8; Wyeth, 5<br />

Cibere, Jolanda<br />

Epidemiology and Health Services Research:<br />

General Interest<br />

Disclosure: Amgen Inc, 2l Centocor Research and<br />

Development Inc, 2<br />

Clancy, Robert M, MD<br />

Innate Immunity and Rheumatic Disease<br />

Disclosure:Nothing to Disclose<br />

Clauw, Daniel J, MD<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />

Disclosure:Nothing to Disclose<br />

Clegg, Daniel O, MD<br />

Spondylarthropathies and Psoriatic Arthritis -<br />

Clinical Aspects and Treatment: Biomarkers II<br />

Disclosure:Nothing to Disclose<br />

Cohen, Philip L, MD<br />

Systemic Lupus Erythematosus - Animal Models<br />

Disclosure: Nothing to Disclose<br />

Cooper, Robert G, MD<br />

Muscle Biology, Myositis and Myopathies:<br />

Insights into the Pathogenesis and Outcomes <strong>of</strong><br />

Myositis<br />

Disclosure:Nothing to Disclose<br />

Cohen, Philip L, MD<br />

Systemic Lupus Erythematosus - Animal Models<br />

Disclosure: Nothing to Disclose<br />

Cope, Andrew P<br />

Rheumatoid Arthritis - Human Etiology and<br />

Pathogenesis: Anti-CCP in RA Etiology and<br />

Pathogenesis II<br />

Disclosure: Nothing to Disclose<br />

Cornell, Patricia J, BSc<br />

Issues in Lupus<br />

Disclosure:Nothing to Disclose<br />

Criswell, Lindsey A<br />

Genetics, Genomics and Proteomics: RA and<br />

Other Rheumatic Diseases<br />

Disclosure: Nothing to Disclose<br />

Cronstein, Bruce N<br />

Cell-Cell Adhesion, Cell Trafficking and<br />

Angiogenesis<br />

Disclosure: Can-Fite Biopharmaceuticals, 1;<br />

Endocyte, 5; King Pharmaceuticals, 7; NIH, 2;<br />

NYU SoM, 9; OSI Pharmaceuticals, 2; Regeneron,<br />

5 URL, 5<br />

Curtis, Jeffrey R, MD, MPH<br />

Epidemiology and Health Services Research:<br />

Gout<br />

Disclosure:Nothing to Disclose<br />

D<br />

DallEra, Maria<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment: New Therapies<br />

Disclosure: Nothing to Disclose<br />

De Pablo, Paola, MD<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment: SLE and Cardiovascular Disease<br />

Disclosure: Nothing to Disclose<br />

Dellaripa, Paul F, MD<br />

Rheumatoid Arthritis - Clinical Aspects: RA and<br />

Cardiovascular Disease III<br />

Disclosure:Nothing to Disclose<br />

Distler, Oliver<br />

Cytokines, Mediators, Gene Regulation I<br />

Disclosure: Actelion, Pfizer, Encysive and<br />

ERgonex, 9; Actelion, Pfizer, Encysive, FibroGen,<br />

Ergonex, NicOx, BMS, Biovitrium, 2; Biovitrium, 5<br />

Dougados, Maxime, MD<br />

Spondylarthropathies and Psoriatic Arthritis -<br />

Clinical Aspects and Treatment: Therapy III<br />

Disclosure: Abbott, 2, 5; Pfizer, 2, 5; Roche, 2, 5;<br />

San<strong>of</strong>i, 2, 5<br />

Espinoza, Luis R, MD<br />

Spondylarthropathies and Psoriatic Arthritis -<br />

Clinical Aspects and Treatment: Therapy III<br />

Disclosure:Nothing to Disclose<br />

Finnegan, Alison, PhD<br />

Cytokines, Mediators, Gene Regulation I<br />

Disclosure:Nothing to Disclose<br />

F<br />

ABSTRACT MODERATOR DISCLOSURE<br />

2010 Program Book 375


ABSTRACT MODERATOR DISCLOSURE<br />

376<br />

Firestein, Gary S, MD<br />

Rheumatoid Arthritis - Human Etiology<br />

and Pathogenesis: RA Human Etiology and<br />

Pathogenesis II<br />

Disclosure:Nothing to Disclose<br />

Fisher, Nadine M, EdD<br />

Physical Activity: Just “Move It”<br />

Disclosure:Nothing to Disclose<br />

FitzGerald, John D, MD<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Existing<br />

Biologics IV<br />

Disclosure:Nothing to Disclose<br />

Furst, Daniel E, MD<br />

Infection-Related Rheumatic Disease<br />

Disclosure:Nothing to Disclose<br />

Gabay, Cem, MD<br />

Infection-Related Rheumatic Disease<br />

Disclosure:Nothing to Disclose<br />

Goker, Berna, MD<br />

Osteoporosis and Metabolic Bone Disease:<br />

Clinical Aspects and Pathogensis<br />

Disclosure:Nothing to Disclose<br />

Goldenberg, Don L, MD<br />

Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />

Disclosure:Nothing to Disclose<br />

Goronzy, Jorg J<br />

T Cell Biology and Targets in Autoimmune<br />

Disease<br />

Disclosure: Nothing to Disclose<br />

Gravallese, Ellen M<br />

Rheumatoid Arthritis - Human Etiology<br />

and Pathogenesis: RA Human Etiology and<br />

Pathogenesis II<br />

Disclosure: Nothing to Disclose<br />

Greenberg, Jeffrey, D<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Novel<br />

Compounds III<br />

Disclosure:Nothing to Disclose<br />

Guillevin, Loic P<br />

ANCA-associated Vasculitis I<br />

Disclosure: ROCHE, 2, 9<br />

G<br />

H<br />

Hachulla, Eric<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Clinical Aspects and Therapeutics II<br />

Disclosure: ACTELION, GSK, PFIZER, LILLY, United<br />

Therapeutics, 5<br />

Haqqi, Tariq M, PhD, MPH<br />

Biology and Pathology <strong>of</strong> Bone and Joint:<br />

Molecular Basis <strong>of</strong> Osteoarthritis<br />

Disclosure:Nothing to Disclose<br />

Harley, John B, MD<br />

Genetics, Genomics and Proteomics: RA and<br />

Other Rheumatic Diseases<br />

Disclosure: Nothing to Disclose<br />

2010 Program Book<br />

Harrington, J Timothy, MD<br />

Quality Measures and Innovation in Practice<br />

Management and Care Delivery<br />

Disclosure: Murray Electronics, 1; CORRONA, 5<br />

Hawker, Gillian A, MD<br />

Osteoarthritis - Clinical Aspects: Pain and<br />

Biomechanics<br />

Disclosure:Nothing to Disclose<br />

Holoshitz, Joseph<br />

T Cell Biology and Targets in Autoimmune<br />

Disease<br />

Disclosure: Nothing to Disclose<br />

Houssiau, Frederic A, MD, PhD<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment: Renal<br />

Disclosure: Nothing to Disclose<br />

Hummers, Laura K<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Clinical Aspects and Therapeutics I<br />

Disclosure: Nothing to Disclose<br />

I<br />

Iagnocco, Annamaria, MD<br />

Imaging <strong>of</strong> Rheumatic Disease: Ultrasound<br />

Disclosure: Nothing to Disclose<br />

Ilowite, Norman T, MD<br />

Pediatric <strong>Rheumatology</strong> - Clinical and<br />

Therapeutic Aspects: Therapeutics<br />

Disclosure:Nothing to Disclose<br />

Inanc, Murat, MD<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment<br />

Disclosure: Nothing to Disclose<br />

Inman, Robert D, MD<br />

Genetics, Genomics and Proteomics: SLE<br />

Disclosure:Nothing to Disclose<br />

Jonas, Beth L<br />

Orthopedics, Low Back Pain and Rehabilitation<br />

Disclosure: Nothing to Disclose<br />

Jordan, Joanne M, MD<br />

Impact on Osteoarthritis<br />

Disclosure:Nothing to Disclose<br />

J<br />

K<br />

Kamen, Diane L<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment<br />

Disclosure: Nothing to Disclose<br />

Kaplan, Mariana J, MD<br />

Systemic Lupus Erythematosus - Human Etiology<br />

and Pathogenesis: Etiology and Pathogenesis<br />

Disclosure:Nothing to Disclose<br />

Katz, Jeffrey N, MD<br />

Orthopedics, Low Back Pain and Rehabilitation<br />

Disclosure:Nothing to Disclose<br />

Kay, Jonathan, MD<br />

Rheumatoid Arthritis - Clinical Aspects:<br />

Preclinical RA and Early RA I<br />

Disclosure: Nothing to Disclose<br />

Kerr, Karen L, MSN, NP, CPNP, PNP<br />

ACR/ARHP Combined Pediatric <strong>Rheumatology</strong> -<br />

Clinical and Therapeutic Aspects: Quality <strong>of</strong> Life<br />

in Children and Adolescents with Arthritis<br />

Disclosure: Nothing to Disclose<br />

Kimpton, Kimberly F, PT<br />

ACR/ARHP Combined Orthopedics, Low Back<br />

Pain and Rehabilitation Abstracts: Hips and<br />

Knees: Focus on Function<br />

Disclosure: Nothing to Disclose<br />

L<br />

Lafyatis, Robert A, MD<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Pathogenesis, Animal Models and<br />

Genetics<br />

Disclosure: Actelion, 2; Celgene, 2;Medimmune,<br />

2; Novartis, 2<br />

Landewe, Robert<br />

Spondylarthropathies and Psoriatic Arthritis -<br />

Clinical Aspects and Treatment - Biomarkers II<br />

Disclosure: Nothing to Disclose<br />

Lane, Nancy E, MD<br />

Osteoporosis and Metabolic Bone Disease:<br />

Clinical Aspects and Pathogensis<br />

Disclosure:Nothing to Disclose<br />

Liote, Frederic P<br />

Metabolic and Crystal Arthropathies -<br />

Pathogenesis, Prevalence, Imaging, and New<br />

Therapy<br />

Disclosure: Nothing to Disclose<br />

Lohr, Kristine M, MD<br />

Miscellaneous Rheumatic and Inflammatory<br />

Diseases<br />

Disclosure: Nothing to Disclose<br />

Losina, Elena, MD<br />

Epidemiology and Health Services Research:<br />

Osteoarthritis<br />

Disclosure:Nothing to Disclose<br />

Lovell, Daniel J, MD, MPH<br />

Pediatric <strong>Rheumatology</strong> - Clinical and<br />

Therapeutic Aspects-Outcomes<br />

Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />

& Rheumatism & Arthritis and Rheumatism, 9;<br />

Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />

Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />

Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />

Wyeth Pharm., 9; Xoma, Inc., 5<br />

Lubberts, Erik, PhD<br />

Cytokines, Mediators, Gene Regulation II<br />

Disclosure: Nothing to Disclose<br />

M<br />

Maksymowych, Walter P, MD<br />

Spondylarthritis and Psoriatic Arthritis:<br />

Pathogenesis, Etiology, and Animal Models<br />

Disclosure: Merck, 2, 5; Pfizer, 2, 5, Abbott, 2, 5<br />

Markenson, Joseph A, MD<br />

Rheumatoid Arthritis - Clinical Aspects:<br />

Outcomes Associated with Biologic Therapy for<br />

RA II<br />

Disclosure:Nothing to Disclose


Massarotti, Elena M, MD<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment: New Therapies<br />

Disclosure:Nothing to Disclose<br />

Matteson, Eric L, MD<br />

Rheumatoid Arthritis - Clinical Aspects:<br />

Outcomes Associated with Biologic Therapy for<br />

RA II<br />

Disclosure:Nothing to Disclose<br />

Mayes, Maureen D, MD<br />

Systemic Sclerosis, Fibrosing Syndromes, and<br />

Raynaud’s - Clinical Aspects and Therapeutics I<br />

Disclosure:Nothing to Disclose<br />

McAlindon, Timothy E, MD<br />

Osteoarthritis - Clinical Aspects: Genetics, Novel<br />

Approaches, and Therapy<br />

Disclosure:Nothing to Disclose<br />

McLean, Robert R, MD<br />

Impact on Osteoarthritis<br />

Disclosure:Nothing to Disclose<br />

Michaud, Kaleb D, PhD<br />

Epidemiology and Health Services Research:<br />

Rheumatoid Arthritis<br />

Disclosure: Nothing to Disclose<br />

Mikuls, Ted R, MD<br />

Epidemiology and Health Services Research:<br />

Rheumatoid Arthritis<br />

Disclosure: Nothing to Disclose<br />

Miller, Donald R, PharmD<br />

Rheumatic Medications: More or Less?<br />

Disclosure: Nothing to Disclose<br />

Miossec, Pierre, MD<br />

Rheumatoid Arthritis - Animal Models: Insight in<br />

Pathogenesis and Novel Therapeutic Targets I<br />

Disclosure:Nothing to Disclose<br />

Mittoo, Shikha, MD<br />

Epidemiology and Health Services Research:<br />

General Interest<br />

Disclosure:Nothing to Disclose<br />

Monach, Paul A, MD<br />

Vasculitis II<br />

Disclosure:Nothing to Disclose<br />

Muller-Ladner, Ulf, MD<br />

Rheumatoid Arthritis - Human Etiology and<br />

Pathogenesis: Anti-CCP in RA Etiology and<br />

Pathogenesis II<br />

Disclosure: German Research Foundation (DFG), 2<br />

Myers, Linda K, MD<br />

Rheumatoid Arthritis - Animal Models: T cell<br />

Pathogenesis an Novel Therapeutic Targets II<br />

Disclosure:Nothing to Disclose<br />

N<br />

Neogi, Tuhina, MD, PhD<br />

Osteoarthritis - Clinical Aspects: Genetics, Novel<br />

Approaches, and Therapy<br />

Disclosure: Nothing to Disclose<br />

Nuki, George, MD<br />

Metabolic and Crystal Arthropathies:<br />

Pathogenesis, Prevalence, Imaging, and New<br />

Therapy<br />

Disclosure:Nothing to Disclose<br />

Østergaard, Mikkel, MD, PhD<br />

Imaging <strong>of</strong> Rheumatic Disease: X-ray and MRI<br />

Disclosure:Nothing to Disclose<br />

O<br />

P<br />

Perl, Andras<br />

Systemic Lupus Erythematosus - Human Etiology<br />

and Pathogenesis: Etiology and Pathogenesis<br />

Disclosure: Nothing to Disclose<br />

Peschken, Christine A<br />

Systemic Lupus Erythematosus - Clinical Aspects<br />

and Treatment: SLE and Cardiovascular Disease<br />

Disclosure: Nothing to Disclose<br />

Pierangeli, Silvia S, PhD<br />

Antiphospholipid Syndrome II<br />

Disclosure: Nothing to Disclose<br />

Putterman, Chaim<br />

B-Cell Biology and Targets in Autoimmune<br />

Disease<br />

Disclosure: biogen idec, 2<br />

R<br />

Rabinovich, Egla C<br />

Pediatric <strong>Rheumatology</strong> - Clinical and<br />

Therapeutic Aspects-Therapeutics<br />

Disclosure: Abbott, 2; CARRA, 2; Pfizer, 2<br />

Ranganath, Veena K, MD<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Existing<br />

Biologics IV<br />

Disclosure: UCB, 2; H<strong>of</strong>fman and Roche; 2;<br />

Wyeth, 2<br />

Reed, Ann M, MD<br />

Muscle Biology, Myositis and Myopathies:<br />

Insights into the Pathogenesis and Outcomes <strong>of</strong><br />

Myositis<br />

Disclosure:Nothing to Disclose<br />

Roubey, Robert A S, MD<br />

Antiphospholipid Syndrome I<br />

Antiphospholipid Syndrome II<br />

Disclosure:Nothing to Disclose<br />

Ruderman, Eric M, MD<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Existing<br />

Non-Biologic DMARDs II<br />

Disclosure:Nothing to Disclose<br />

S<br />

Salmon, Jane E, MD<br />

Systemic Lupus Erythematosus - Animal Models<br />

Disclosure:Nothing to Disclose<br />

Scanzello, Carla R, MD, PhD<br />

Cytokines, Mediators, Gene Regulation II<br />

Disclosure: Amgen, 9<br />

Schlenk, Elizabeth A, PhD, RN<br />

Be Creative with Rheumatic Education: Where<br />

and How to Get It<br />

Disclosure: Nothing to Disclose<br />

Schmidt, Wolfgang A, MD<br />

Imaging <strong>of</strong> Rheumatic Disease: Ultrasound<br />

Shoenfeld, Yehuda, MD<br />

B-Cell Biology and Targets in Autoimmune<br />

Disease<br />

Singer, Nora G<br />

Pediatric <strong>Rheumatology</strong> - Pathogenesis<br />

and Genetics: Biological Basis for Pediatric<br />

Rheumatic Disease<br />

Disclosure: Nothing to Disclose<br />

Solomon, Daniel H, MD<br />

Infection-Related Rheumatic Disease<br />

Disclosure:Nothing to Disclose<br />

Strand, Vibeke, MD<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Novel<br />

Compounds III<br />

Disclosure:Nothing to Disclose<br />

Suter, Lisa G<br />

Epidemiology and Health Services Research:<br />

Gout<br />

Disclosure: Arthritis Foundation, 2; NIH, 2; Yale<br />

New Hospital Center for Outcomes Research, 5<br />

Symmons, Deborah P, MD<br />

Rheumatoid Arthritis - Clinical Aspects: RA and<br />

Cardiovascular Disease III<br />

Disclosure:Nothing to Disclose<br />

Szekanecz, Zoltan, MD<br />

Cell-Cell Adhesion, Cell Trafficking and<br />

Angiogenesis<br />

Disclosure:Nothing to Disclose<br />

Thombs, Brett D, BA, MA, PhD<br />

What a Pain Rheumatic Diseases Can Be!<br />

Disclosure: Nothing to Disclose<br />

Tsao, Betty P, PhD<br />

Genetics, Genomics and Proteomics: SLE<br />

Disclosure: Nothing to Disclose<br />

Tsokos, George C, MD<br />

Innate Immunity and Rheumatic Disease<br />

Disclosure: Nothing to Disclose<br />

Tzioufas, Athanasios G, MD<br />

Sjögren’s Syndrome<br />

Disclosure: Nothing to Disclose<br />

V<br />

Van Der Heijde, Desiree M, MD, PhD<br />

Spondylarthropathies and Psoriatic Arthritis -<br />

Clinical Aspects and Treatment - Imaging I<br />

Disclosure: abbott, 5; amgen, 5; bristol meyers<br />

squibb, 5; centocor, 5; chugai, 5; msd, 5;<br />

novartis, 5; pfizer, 5; roche, 5; ucb, 5<br />

T<br />

Van Den Berg, Wim, PhD<br />

Rheumatoid Arthritis - Animal Models: Insight in<br />

Pathogenesis and Novel Therapeutic Targets I<br />

Disclosure:Nothing to Disclose<br />

Van Riel, Piet L<br />

Rheumatoid Arthritis - Clinical Aspects:<br />

Radiographic and Other Outcomes in RA IV<br />

Disclosure: Abbott, 2; BMS, 2; MSD, 2; Pfizer, 2;<br />

Roche, 2; San<strong>of</strong>i Aventis, 2; Schering Plough, 2;<br />

2010 Program Book 377<br />

ABSTRACT MODERATOR DISCLOSURE


UCB, 2; Wyeth, 2<br />

Von Feldt, Joan Marie, MD, MS Ed<br />

Education<br />

Disclosure:Nothing to Disclose<br />

W<br />

Wallace, Carol A, MD<br />

Pediatric <strong>Rheumatology</strong> - Clinical and<br />

Therapeutic Aspects-Outcomes<br />

Disclosure:Nothing to Disclose<br />

Weissman, Barbara N, MD<br />

Imaging <strong>of</strong> Rheumatic Disease: X-ray and MRI<br />

Disclosure:Nothing to Disclose<br />

Wells, Alvin F, MD<br />

Rheumatoid Arthritis Treatment - Small<br />

Molecules, Biologics and Gene Therapy: Existing<br />

Non-Biologic DMARDs II<br />

Disclosure:Nothing to Disclose<br />

Weyand, Cornelia, MD, PhD<br />

Vasculitis II<br />

Disclosure:Nothing to Disclose<br />

Williams, David A, PhD<br />

Don’t Despair Over Health Disparities<br />

Disclosure: Nothing to Disclose<br />

Wooley, Paul H<br />

Rheumatoid Arthritis - Animal Models: T cell<br />

Pathogenesis an Novel Therapeutic Targets II<br />

Disclosure: Nothing to Disclose<br />

ABSTRACT MODERATOR DISCLOSURE<br />

378<br />

2010 Program Book


ACR Annual Meeting<br />

fellowS-in-training scholArship<br />

Through the ACR Fellows Education Fund,<br />

the ACR is able to present the ACR Annual<br />

Meeting Fellows-In-Training Scholarship.<br />

In addition to travel assistance, all fellow<br />

attendees at the annual meeting are<br />

invited to special educational sessions<br />

and networking events.<br />

Through programs like the ACR Annual<br />

Meeting Fellows-In-Training Scholarship,<br />

the ACR is committed to meeting the<br />

challenge <strong>of</strong> ensuring high-quality<br />

rheumatic care for years to come.<br />

The ACR wishes to thank the following<br />

organizations for their generous support<br />

<strong>of</strong> the 2010 Fellows Education Fund:<br />

Platinum<br />

GOLD<br />

SilVER<br />

Abbott<br />

SUPPORTER<br />

Bristol-Myers Squibb Company<br />

The ACR wishes to thank Centocor Ortho<br />

Biotech Inc., Lilly USA, LLC, and UCB, Inc.<br />

for their generous support <strong>of</strong> the 2010 ACR<br />

Fellows-In-Training Travel Scholarship.<br />

2010 Program Book 379


NOTES<br />

380<br />

2010 Program Book


NOTES<br />

2010 Program Book 381


NOTES<br />

382<br />

2010 Program Book


Enbrel ® (etanercept) Brief Summary<br />

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION<br />

WARNINGS<br />

SERIOUS INFECTIONS AND MALIGNANCIES<br />

Patients treated with Enbrel are at increased risk for developing serious<br />

infections that may lead to hospitalization or death [see Warnings and<br />

Precautions and Adverse Reactions]. Most patients who developed these<br />

infections were taking concomitant immunosuppressants such as<br />

methotrexate or corticosteroids.<br />

Enbrel should be discontinued if a patient develops a serious infection<br />

or sepsis.<br />

Reported infections include:<br />

• Active tuberculosis, including reactivation <strong>of</strong> latent tuberculosis. Patients<br />

with tuberculosis have frequently presented with disseminated or<br />

extrapulmonary disease. Patients should be tested for latent tuberculosis<br />

before Enbrel use and during therapy. Treatment for latent infection<br />

should be initiated prior to Enbrel use.<br />

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis,<br />

candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients<br />

with histoplasmosis or other invasive fungal infections may present with<br />

disseminated, rather than localized, disease. Antigen and antibody<br />

testing for histoplasmosis may be negative in some patients with active<br />

infection. Empiric anti-fungal therapy should be considered in patients at<br />

risk for invasive fungal infections who develop severe systemic illness.<br />

• Bacterial, viral, and other infections due to opportunistic pathogens.<br />

The risks and benefits <strong>of</strong> treatment with Enbrel should be carefully<br />

considered prior to initiating therapy in patients with chronic or recurrent<br />

infection.<br />

Patients should be closely monitored for the development <strong>of</strong> signs and<br />

symptoms <strong>of</strong> infection during and after treatment with Enbrel, including<br />

the possible development <strong>of</strong> tuberculosis in patients who tested negative<br />

for latent tuberculosis infection prior to initiating therapy.<br />

MALIGNANCIES<br />

Lymphoma and other malignancies, some fatal, have been reported<br />

in children and adolescent patients treated with TNF blockers,<br />

including Enbrel.<br />

INDICATIONS AND USAGE<br />

Rheumatoid Arthritis<br />

Enbrel is indicated for reducing signs and symptoms, inducing major clinical<br />

response, inhibiting the progression <strong>of</strong> structural damage, and improving<br />

physical function in patients with moderately to severely active rheumatoid<br />

arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX)<br />

or used alone.<br />

Polyarticular Juvenile Idiopathic Arthritis<br />

Enbrel is indicated for reducing signs and symptoms <strong>of</strong> moderately to severely<br />

active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2<br />

and older.<br />

Psoriatic Arthritis<br />

Enbrel is indicated for reducing signs and symptoms, inhibiting the<br />

progression <strong>of</strong> structural damage <strong>of</strong> active arthritis, and improving physical<br />

function in patients with psoriatic arthritis (PsA). Enbrel can be used in<br />

combination with methotrexate (MTX) in patients who do not respond<br />

adequately to MTX alone.<br />

Ankylosing Spondylitis<br />

Enbrel is indicated for reducing signs and symptoms in patients with active<br />

ankylosing spondylitis (AS).<br />

Plaque Psoriasis<br />

Enbrel is indicated for the treatment <strong>of</strong> adult patients (18 years or older) with<br />

chronic moderate to severe plaque psoriasis (PsO) who are candidates for<br />

systemic therapy or phototherapy.<br />

CONTRAINDICATIONS<br />

Enbrel should not be administered to patients with sepsis.<br />

WARNINGS AND PRECAUTIONS<br />

Infections<br />

Serious and sometimes fatal infections due to bacterial, mycobacterial,<br />

invasive fungal, viral, or other opportunistic pathogens have been reported in<br />

patients receiving TNF-blocking agents. Among opportunistic infections,<br />

tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis,<br />

listeriosis, and pneumocystosis were the most commonly reported. Patients<br />

have frequently presented with disseminated rather than localized disease,<br />

and are <strong>of</strong>ten taking concomitant immunosuppressants such as methotrexate<br />

or corticosteroids with Enbrel.<br />

Treatment with Enbrel should not be initiated in patients with an active<br />

infection, including clinically important localized infections. The risks and<br />

benefits <strong>of</strong> treatment should be considered prior to initiating therapy in<br />

patients: with chronic or recurrent infection; who have been exposed to<br />

tuberculosis; who have resided or traveled in areas <strong>of</strong> endemic tuberculosis or<br />

endemic mycoses, such as histoplasmosis, coccidioidomycosis, or<br />

blastomycosis; or with underlying conditions that may predispose them to<br />

infection, such as advanced or poorly controlled diabetes [see Adverse<br />

Reactions].<br />

Patients should be closely monitored for the development <strong>of</strong> signs and<br />

symptoms <strong>of</strong> infection during and after treatment with Enbrel.<br />

Enbrel should be discontinued if a patient develops a serious infection or<br />

sepsis. A patient who develops a new infection during treatment with Enbrel<br />

should be closely monitored, undergo a prompt and complete diagnostic<br />

workup appropriate for an immunocompromised patient, and appropriate<br />

antimicrobial therapy should be initiated.<br />

Tuberculosis<br />

Cases <strong>of</strong> reactivation <strong>of</strong> tuberculosis or new tuberculosis infections have been<br />

observed in patients receiving Enbrel, including patients who have previously<br />

received treatment for latent or active tuberculosis. Data from clinical trials<br />

and preclinical studies suggest that the risk <strong>of</strong> reactivation <strong>of</strong> latent<br />

tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal<br />

antibodies. Nonetheless, postmarketing cases <strong>of</strong> tuberculosis reactivation<br />

have been reported for TNF blockers, including Enbrel. Tuberculosis has<br />

developed in patients who tested negative for latent tuberculosis prior to<br />

initiation <strong>of</strong> therapy. Patients should be evaluated for tuberculosis risk factors<br />

and tested for latent infection prior to initiating Enbrel and periodically during<br />

therapy. Tests for latent tuberculosis infection may be falsely negative while<br />

on therapy with Enbrel.<br />

Treatment <strong>of</strong> latent tuberculosis infection prior to therapy with TNF-blocking<br />

agents has been shown to reduce the risk <strong>of</strong> tuberculosis reactivation during<br />

therapy. Induration <strong>of</strong> 5 mm or greater with tuberculin skin testing should be<br />

considered a positive test result when assessing if treatment for latent<br />

tuberculosis is needed prior to initiating Enbrel, even for patients previously<br />

vaccinated with Bacille Calmette-Guerin (BCG).<br />

Anti-tuberculosis therapy should also be considered prior to initiation <strong>of</strong><br />

Enbrel in patients with a past history <strong>of</strong> latent or active tuberculosis in whom<br />

an adequate course <strong>of</strong> treatment cannot be confirmed, and for patients with a<br />

negative test for latent tuberculosis but having risk factors for tuberculosis<br />

infection. Consultation with a physician with expertise in the treatment <strong>of</strong><br />

tuberculosis is recommended to aid in the decision whether initiating antituberculosis<br />

therapy is appropriate for an individual patient.<br />

Tuberculosis should be strongly considered in patients who develop a new<br />

infection during Enbrel treatment, especially in patients who have previously<br />

or recently traveled to countries with a high prevalence <strong>of</strong> tuberculosis, or who<br />

have had close contact with a person with active tuberculosis.<br />

Invasive Fungal Infections<br />

Cases <strong>of</strong> serious and sometimes fatal fungal infections, including<br />

histoplasmosis, have been reported with TNF blockers, including Enbrel. For<br />

patients who reside or travel in regions where mycoses are endemic, invasive<br />

fungal infection should be suspected if they develop a serious systemic<br />

illness. Appropriate empiric antifungal therapy should be considered while a<br />

diagnostic workup is being performed. Antigen and antibody testing for<br />

histoplasmosis may be negative in some patients with active infection. When<br />

feasible, the decision to administer empiric antifungal therapy in these<br />

patients should be made in consultation with a physician with expertise in the<br />

diagnosis and treatment <strong>of</strong> invasive fungal infections and should take into<br />

account both the risk for severe fungal infection and the risks <strong>of</strong> antifungal<br />

therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved<br />

indications representing 27,169 patient-years <strong>of</strong> exposure (17,696 patients)<br />

from the United States and Canada, no histoplasmosis infections were<br />

reported among patients treated with Enbrel.<br />

Neurologic Events<br />

Treatment with TNF-blocking agents, including Enbrel, has been associated<br />

with rare (< 0.1%) cases <strong>of</strong> new onset or exacerbation <strong>of</strong> central nervous<br />

system demyelinating disorders, some presenting with mental status changes<br />

and some associated with permanent disability. Cases <strong>of</strong> transverse myelitis,<br />

optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral<br />

demyelinating neuropathies, and new onset or exacerbation <strong>of</strong> seizure<br />

disorders have been reported in postmarketing experience with Enbrel<br />

therapy. Prescribers should exercise caution in considering the use <strong>of</strong> Enbrel<br />

in patients with preexisting or recent-onset central or peripheral nervous<br />

system demyelinating disorders [see Adverse Reactions].<br />

Malignancies<br />

Lymphomas<br />

In the controlled portions <strong>of</strong> clinical trials <strong>of</strong> TNF-blocking agents, more cases<br />

<strong>of</strong> lymphoma have been observed among patients receiving a TNF blocker<br />

compared to control patients. During the controlled portions <strong>of</strong> Enbrel trials in<br />

adult patients with RA, AS, and PsA, 2 lymphomas were observed among<br />

3306 Enbrel-treated patients versus 0 among 1521 control patients (duration<br />

<strong>of</strong> controlled treatment ranged from 3 to 36 months).<br />

Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in<br />

controlled and uncontrolled portions <strong>of</strong> clinical trials, representing<br />

approximately 12,845 patient-years <strong>of</strong> therapy, the observed rate <strong>of</strong><br />

lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than<br />

the rate <strong>of</strong> lymphoma expected in the general US population based on the<br />

Surveillance, Epidemiology, and End Results (SEER) Database. An increased<br />

rate <strong>of</strong> lymphoma up to several-fold has been reported in the RA patient<br />

population, and may be further increased in patients with more severe disease<br />

activity.<br />

Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36<br />

months, representing approximately 4278 patient-years <strong>of</strong> therapy, the observed<br />

rate <strong>of</strong> lymphoma was 0.05 cases per 100 patient-years, which is comparable<br />

to the rate in the general population. No cases were observed in Enbrel- or<br />

placebo-treated patients during the controlled portions <strong>of</strong> these trials.<br />

Leukemia<br />

Cases <strong>of</strong> acute and chronic leukemia have been reported in association with<br />

postmarketing TNF-blocker use in rheumatoid arthritis and other indications.<br />

Even in the absence <strong>of</strong> TNF-blocker therapy, patients with rheumatoid<br />

arthritis may be at higher risk (approximately 2-fold) than the general<br />

population for the development <strong>of</strong> leukemia.<br />

During the controlled portions <strong>of</strong> Enbrel trials, 2 cases <strong>of</strong> leukemia were<br />

observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated<br />

patients versus 0 among 2890 (0%) control patients (duration <strong>of</strong> controlled<br />

treatment ranged from 3 to 48 months).<br />

Among 15,401 patients treated with Enbrel in controlled and open portions <strong>of</strong><br />

clinical trials representing approximately 23,325 patient-years <strong>of</strong> therapy, the<br />

observed rate <strong>of</strong> leukemia was 0.03 cases per 100 patient-years.<br />

Other Malignancies<br />

Information is available from 10,953 adult patients with 17,123 patient-years<br />

and 696 pediatric patients with 1282 patient-years <strong>of</strong> experience across 45<br />

Enbrel clinical studies.<br />

For malignancies other than lymphoma and non-melanoma skin cancer, there<br />

was no difference in exposure-adjusted rates between the Enbrel and control<br />

arms in the controlled portions <strong>of</strong> clinical studies for all indications. Analysis<br />

<strong>of</strong> the malignancy rate in combined controlled and uncontrolled portions <strong>of</strong><br />

studies has demonstrated that types and rates are similar to what is expected<br />

in the general US population based on the SEER database and suggests no<br />

increase in rates over time. Whether treatment with Enbrel might influence the<br />

development and course <strong>of</strong> malignancies in adults is unknown.<br />

Non-melanoma skin cancer (NMSC)<br />

Non-melanoma skin cancer has been reported in patients treated with TNF<br />

antagonists including etanercept. Among 3306 adult rheumatology (RA, PsA,<br />

AS) patients treated with Enbrel in controlled clinical trials representing<br />

approximately 2669 patient-years <strong>of</strong> therapy, the observed rate <strong>of</strong> NMSC was<br />

0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among<br />

1521 control-treated patients representing 1077 patient-years. Among 1245<br />

adult psoriasis patients treated with Enbrel in controlled clinical trials,<br />

representing approximately 283 patient-years <strong>of</strong> therapy, the observed rate <strong>of</strong><br />

NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patientyears<br />

among 720 control-treated patients representing 156 patient-years.<br />

Periodic skin examinations should be considered for all patients at increased<br />

risk for NMSC.<br />

Pediatric Patients<br />

Malignancies, some fatal, have been reported among children, adolescents,<br />

and young adults who received treatment with TNF-blocking agents (initiation<br />

<strong>of</strong> therapy at ≤ 18 years <strong>of</strong> age), including Enbrel. Approximately half the cases<br />

were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The<br />

other cases represented a variety <strong>of</strong> different malignancies and included rare<br />

malignancies usually associated with immunosuppression and malignancies<br />

that are not usually observed in children and adolescents. The malignancies<br />

occurred after a median <strong>of</strong> 30 months <strong>of</strong> therapy (range 1 to 84 months). Most<br />

<strong>of</strong> the patients were receiving concomitant immunosuppressants. These<br />

cases were reported postmarketing and are derived from a variety <strong>of</strong> sources,<br />

including registries and spontaneous postmarketing reports.<br />

In clinical trials <strong>of</strong> 696 patients representing 1282 patient-years <strong>of</strong> therapy, no<br />

malignancies, including lymphoma or NMSC, have been reported.<br />

Postmarketing Use<br />

In global postmarketing adult and pediatric use, lymphoma and other<br />

malignancies have been reported.<br />

Patients With Heart Failure<br />

Two clinical trials evaluating the use <strong>of</strong> Enbrel in the treatment <strong>of</strong> heart failure<br />

were terminated early due to lack <strong>of</strong> efficacy. One <strong>of</strong> these studies suggested<br />

higher mortality in Enbrel-treated patients compared to placebo [see Adverse<br />

Reactions]. There have been postmarketing reports <strong>of</strong> worsening <strong>of</strong><br />

congestive heart failure (CHF), with and without identifiable precipitating<br />

factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports<br />

<strong>of</strong> new onset CHF, including CHF in patients without known preexisting<br />

cardiovascular disease. Some <strong>of</strong> these patients have been under 50 years <strong>of</strong><br />

age. Physicians should exercise caution when using Enbrel in patients who<br />

also have heart failure, and monitor patients carefully.<br />

Hematologic Events<br />

Rare (< 0.1%) reports <strong>of</strong> pancytopenia, including very rare (< 0.01%) reports<br />

<strong>of</strong> aplastic anemia, some with a fatal outcome, have been reported in patients<br />

treated with Enbrel. The causal relationship to Enbrel therapy remains<br />

unclear. Although no high-risk group has been identified, caution should be<br />

exercised in patients being treated with Enbrel who have a previous history <strong>of</strong><br />

significant hematologic abnormalities. All patients should be advised to seek<br />

immediate medical attention if they develop signs and symptoms suggestive<br />

<strong>of</strong> blood dyscrasias or infection (eg, persistent fever, bruising, bleeding,<br />

pallor) while on Enbrel. Discontinuation <strong>of</strong> Enbrel therapy should be<br />

considered in patients with confirmed significant hematologic abnormalities.<br />

Two percent <strong>of</strong> patients treated concurrently with Enbrel and anakinra<br />

developed neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient<br />

developed cellulitis that resolved with antibiotic therapy.<br />

Hepatitis B Virus Reactivation<br />

Use <strong>of</strong> TNF-blocking agents has been associated with reactivation <strong>of</strong> hepatitis<br />

B virus (HBV), including very rare cases (< 0.01%) with Enbrel, in patients who<br />

are chronic carriers <strong>of</strong> this virus. In some instances, HBV reactivation<br />

occurring in conjunction with TNF-blocker therapy has been fatal. The<br />

majority <strong>of</strong> these reports have occurred in patients concomitantly receiving<br />

other medications that suppress the immune system, which may also<br />

contribute to HBV reactivation. Patients at risk for HBV infection should be<br />

evaluated for prior evidence <strong>of</strong> HBV infection before initiating TNF-blocker<br />

therapy. Prescribers should exercise caution in prescribing TNF blockers for<br />

patients identified as carriers <strong>of</strong> HBV. Adequate data are not available on the<br />

safety or efficacy <strong>of</strong> treating patients who are carriers <strong>of</strong> HBV with anti viral<br />

therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation.<br />

Patients who are carriers <strong>of</strong> HBV and require treatment with Enbrel should be<br />

closely monitored for clinical and laboratory signs <strong>of</strong> active HBV infection<br />

throughout therapy and for several months following termination <strong>of</strong> therapy. In<br />

patients who develop HBV reactivation, consideration should be given to<br />

stopping Enbrel and initiating anti viral therapy with appropriate supportive<br />

treatment. The safety <strong>of</strong> resuming Enbrel therapy after HBV reactivation is<br />

controlled is not known. Therefore, prescribers should weigh the risks and<br />

benefits when considering resumption <strong>of</strong> therapy in this situation.<br />

Allergic Reactions<br />

Allergic reactions associated with administration <strong>of</strong> Enbrel during clinical<br />

trials have been reported in < 2% <strong>of</strong> patients. If an anaphylactic reaction or<br />

other serious allergic reaction occurs, administration <strong>of</strong> Enbrel should be<br />

discontinued immediately and appropriate therapy initiated.<br />

Caution: The needle cap on the prefilled syringe and on the SureClick<br />

autoinjector contains dry natural rubber (a derivative <strong>of</strong> latex) that may cause<br />

allergic reactions in individuals sensitive to latex.<br />

Immunizations<br />

Live vaccines should not be given concurrently with Enbrel. It is recommended<br />

that pediatric patients, if possible, be brought up-to-date with all<br />

immunizations in agreement with current immunization guidelines prior to<br />

initiating Enbrel therapy [see Drug Interactions].<br />

Autoimmunity<br />

Treatment with Enbrel may result in the formation <strong>of</strong> autoantibodies [see<br />

Adverse Reactions] and, rarely (< 0.1%), in the development <strong>of</strong> a lupus-like<br />

syndrome or autoimmune hepatitis [see Adverse Reactions], which may<br />

resolve following withdrawal <strong>of</strong> Enbrel. If a patient develops symptoms and<br />

findings suggestive <strong>of</strong> a lupus-like syndrome or autoimmune hepatitis<br />

following treatment with Enbrel, treatment should be discontinued and the<br />

patient should be carefully evaluated.<br />

Immunosuppression<br />

TNF mediates inflammation and modulates cellular immune responses. TNFblocking<br />

agents, including Enbrel, affect host defenses against infections. The<br />

effect <strong>of</strong> TNF inhibition on the development and course <strong>of</strong> malignancies is not<br />

fully understood. In a study <strong>of</strong> 49 patients with RA treated with Enbrel, there<br />

was no evidence <strong>of</strong> depression <strong>of</strong> delayed-type hypersensitivity, depression <strong>of</strong><br />

immunoglobulin levels, or change in enumeration <strong>of</strong> effector cell populations<br />

[see Adverse Reactions].<br />

Use in Wegener’s Granulomatosis Patients<br />

The use <strong>of</strong> Enbrel in patients with Wegener’s granulomatosis receiving<br />

immunosuppressive agents is not recommended. In a study <strong>of</strong> patients with<br />

Wegener’s granulomatosis, the addition <strong>of</strong> Enbrel to standard therapy (including<br />

cyclophosphamide) was associated with a higher incidence <strong>of</strong> non cutaneous


solid malignancies and was not associated with improved clinical outcomes<br />

when compared with standard therapy alone [see Drug Interactions].<br />

Use with Anakinra or Abatacept<br />

Use <strong>of</strong> Enbrel with anakinra or abatacept is not recommended [see<br />

Drug Interactions].<br />

Use in Patients with Moderate to Severe Alcoholic Hepatitis<br />

In a study <strong>of</strong> 48 hospitalized patients treated with Enbrel or placebo for<br />

moderate to severe alcoholic hepatitis, the mortality rate in patients treated<br />

with Enbrel was similar to patients treated with placebo at 1 month but<br />

significantly higher after 6 months. Physicians should use caution when using<br />

Enbrel in patients with moderate to severe alcoholic hepatitis.<br />

ADVERSE REACTIONS<br />

Across clinical studies and postmarketing experience, the most serious<br />

adverse reactions with Enbrel were infections, neurologic events, CHF, and<br />

hematologic events [see Warnings and Precautions]. The most common<br />

adverse reactions with Enbrel were infections and injection site reactions.<br />

Clinical Studies Experience<br />

Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic<br />

Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis<br />

The data described below reflect exposure to Enbrel in 2219 adult patients<br />

with RA followed for up to 80 months, in 182 patients with PsA for up to 24<br />

months, in 138 patients with AS for up to 6 months, and in 1204 adult patients<br />

with PsO for up to 18 months.<br />

In controlled trials, the proportion <strong>of</strong> Enbrel-treated patients who discontinued<br />

treatment due to adverse events was approximately 4% in the indications studied.<br />

Because clinical trials are conducted under widely varying conditions, adverse<br />

reactions rates observed in the clinical trials <strong>of</strong> a drug cannot be directly<br />

compared to rates in the clinical trials <strong>of</strong> another drug and may not predict the<br />

rates observed in clinical practice.<br />

Infections<br />

Infections, including viral, bacterial, and fungal infections, have been<br />

observed in adult and pediatric patients. Infections have been noted in all body<br />

systems and have been reported in patients receiving Enbrel alone or in<br />

combination with other immunosuppressive agents.<br />

In controlled portions <strong>of</strong> trials, the types and severity <strong>of</strong> infection were similar<br />

between Enbrel and the respective control group (placebo or MTX for RA and<br />

PsA patients) in RA, PsA, AS, and PsO patients. Rates <strong>of</strong> infections in RA<br />

and PsO patients are provided in Table 3 and Table 4, respectively.<br />

Infections consisted primarily <strong>of</strong> upper respiratory tract infection, sinusitis,<br />

and influenza.<br />

In controlled portions <strong>of</strong> trials in RA, PsA, AS, and PsO, the rates <strong>of</strong> serious<br />

infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/<br />

Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications,<br />

serious infections experienced by patients have included, but are not limited<br />

to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis,<br />

pyelonephritis, sepsis, abscess, and osteomyelitis. In clinical trials in PsO,<br />

serious infections experienced by patients have included, but are not limited<br />

to, pneumonia, cellulitis, gastroenteritis, abscess, and osteomyelitis. The rate<br />

<strong>of</strong> serious infections was not increased in open-label extension trials and was<br />

similar to that observed in Enbrel- and placebo-treated patients from<br />

controlled trials.<br />

In 66 global clinical trials <strong>of</strong> 17,505 patients (21,015 patient-years <strong>of</strong> therapy),<br />

tuberculosis was observed in approximately 0.02% <strong>of</strong> patients. In 17,696<br />

patients (27,169 patient-years <strong>of</strong> therapy) from 38 clinical trials and 4 cohort<br />

studies in the US and Canada, tuberculosis was observed in approximately<br />

0.006% <strong>of</strong> patients. These studies include reports <strong>of</strong> pulmonary and<br />

extrapulmonary tuberculosis [see Warnings and Precautions].<br />

Injection Site Reactions<br />

In placebo-controlled trials in rheumatologic indications, approximately 37%<br />

<strong>of</strong> patients treated with Enbrel developed injection site reactions. In controlled<br />

trials in patients with PsO, 15% <strong>of</strong> patients treated with Enbrel developed<br />

injection site reactions during the first 3 months <strong>of</strong> treatment. All injection site<br />

reactions were described as mild to moderate (erythema, itching, pain,<br />

swelling, bleeding, bruising) and generally did not necessitate drug<br />

discontinuation. Injection site reactions generally occurred in the first month<br />

and subsequently decreased in frequency. The mean duration <strong>of</strong> injection site<br />

reactions was 3 to 5 days. Seven percent <strong>of</strong> patients experienced redness at<br />

a previous injection site when subsequent injections were given.<br />

Immunogenicity<br />

Patients with RA, PsA, AS, or PsO were tested at multiple time points for<br />

antibodies to etanercept. Antibodies to the TNF receptor portion or other<br />

protein components <strong>of</strong> the Enbrel drug product were detected at least once in<br />

sera <strong>of</strong> approximately 6% <strong>of</strong> adult patients with RA, PsA, AS, or PsO. These<br />

antibodies were all non-neutralizing. Results from JIA patients were similar to<br />

those seen in adult RA patients treated with Enbrel.<br />

In PsO studies that evaluated the exposure <strong>of</strong> etanercept for up to 120 weeks,<br />

the percentage <strong>of</strong> patients testing positive at the assessed time points <strong>of</strong> 24,<br />

48, 72, and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing.<br />

The percentage <strong>of</strong> patients testing positive increased with an increase in the<br />

duration <strong>of</strong> study; however, the clinical significance <strong>of</strong> this finding is unknown.<br />

No apparent correlation <strong>of</strong> antibody development to clinical response or<br />

adverse events was observed. The immunogenicity data <strong>of</strong> Enbrel beyond 120<br />

weeks <strong>of</strong> exposure are unknown.<br />

The data reflect the percentage <strong>of</strong> patients whose test results were considered<br />

positive for antibodies to etanercept in an ELISA assay, and are highly<br />

dependent on the sensitivity and specificity <strong>of</strong> the assay. Additionally, the<br />

observed incidence <strong>of</strong> any antibody positivity in an assay is highly dependent<br />

on several factors, including assay sensitivity and specificity, assay<br />

methodology, sample handling, timing <strong>of</strong> sample collection, concomitant<br />

medications, and underlying disease. For these reasons, comparison <strong>of</strong> the<br />

incidence <strong>of</strong> antibodies to etanercept with the incidence <strong>of</strong> antibodies to other<br />

products may be misleading.<br />

Autoantibodies<br />

Patients with RA had serum samples tested for autoantibodies at multiple<br />

time points. In RA Studies I and II, the percentage <strong>of</strong> patients evaluated for<br />

antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40)<br />

was higher in patients treated with Enbrel (11%) than in placebo-treated<br />

patients (5%). The percentage <strong>of</strong> patients who developed new positive antidouble-stranded<br />

DNA antibodies was also higher by radioimmunoassay (15%<br />

<strong>of</strong> patients treated with Enbrel compared to 4% <strong>of</strong> placebo-treated patients)<br />

and by Crithidia luciliae assay (3% <strong>of</strong> patients treated with Enbrel compared to<br />

none <strong>of</strong> placebo-treated patients). The proportion <strong>of</strong> patients treated with<br />

Enbrel who developed anticardiolipin antibodies was similarly increased<br />

compared to placebo-treated patients. In RA Study III, no pattern <strong>of</strong> increased<br />

autoantibody development was seen in Enbrel patients compared to MTX<br />

patients [see Autoimmunity].<br />

Other Adverse Reactions<br />

Table 3 summarizes adverse reactions reported in adult RA patients. The<br />

types <strong>of</strong> adverse reactions seen in patients with PsA or AS were similar to the<br />

types <strong>of</strong> adverse reactions seen in patients with RA.<br />

Table 3. Percent <strong>of</strong> Adult RA Patients Experiencing Adverse<br />

Reactions in Controlled Clinical Trials<br />

Placebo Controlled a<br />

(Studies I, II, and a<br />

Phase 2 Study)<br />

Placebo<br />

(N = 152)<br />

Enbrel c<br />

(N = 349)<br />

Active Controlled b<br />

(Study III)<br />

MTX<br />

(N = 217)<br />

Enbrel c<br />

(N = 415)<br />

Reaction Percent <strong>of</strong> Patients Percent <strong>of</strong> Patients<br />

Infection d (total)<br />

Upper Respiratory<br />

Infections e<br />

Non-upper Respiratory<br />

Infections<br />

Injection Site<br />

Reactions<br />

Diarrhea<br />

Rash<br />

Pruritus<br />

Pyrexia<br />

Urticaria<br />

Hypersensitivity<br />

39<br />

30<br />

15<br />

11<br />

9<br />

2<br />

1<br />

–<br />

1<br />

–<br />

50<br />

38<br />

21<br />

37<br />

8<br />

3<br />

2<br />

3<br />

–<br />

–<br />

86<br />

70<br />

59<br />

18<br />

16<br />

19<br />

5<br />

4<br />

4<br />

1<br />

81<br />

65<br />

54<br />

43<br />

16<br />

13<br />

5<br />

2<br />

2<br />

1<br />

a<br />

Includes data from the 6-month study in which patients received<br />

concurrent MTX therapy in both arms.<br />

b<br />

Study duration <strong>of</strong> 2 years.<br />

c<br />

Any dose.<br />

d<br />

Includes bacterial, viral, and fungal infections.<br />

e<br />

Most frequent Upper Respiratory Infections were upper respiratory<br />

tract infection, sinusitis, and influenza.<br />

In placebo-controlled PsO trials, the percentages <strong>of</strong> patients reporting<br />

adverse reactions in the 50 mg twice a week dose group were similar to those<br />

observed in the 25 mg twice a week dose group or placebo group.<br />

Table 4 summarizes adverse reactions reported in adult PsO patients from<br />

Studies I and II.<br />

Table 4. Percent <strong>of</strong> Adult PsO Patients Experiencing Adverse<br />

Reactions in Placebo-Controlled Portions <strong>of</strong> Clinical Trials<br />

(Studies I & II)<br />

Reaction<br />

Infection b (total)<br />

Non-upper Respiratory<br />

Infections<br />

Upper Respiratory<br />

Infections c<br />

Injection Site<br />

Reactions<br />

Diarrhea<br />

Rash<br />

Pruritus<br />

Urticaria<br />

Hypersensitivity<br />

Pyrexia<br />

Placebo<br />

(N = 359)<br />

Enbrel a<br />

(N = 876)<br />

Percent <strong>of</strong> Patients<br />

28<br />

14<br />

17<br />

6<br />

2<br />

1<br />

2<br />

–<br />

–<br />

1<br />

27<br />

12<br />

a<br />

Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC<br />

BIW doses.<br />

b<br />

Includes bacterial, viral, and fungal infections.<br />

c<br />

Most frequent Upper Respiratory Infections were upper respiratory<br />

tract infection, nasopharyngitis, and sinusitis.<br />

Adverse Reactions in Pediatric Patients<br />

In general, the adverse reactions in pediatric patients were similar in frequency<br />

and type as those seen in adult patients [see Warnings and Precautions]. The<br />

types <strong>of</strong> infections reported in pediatric patients were generally mild and<br />

consistent with those commonly seen in the general pediatric population. Two<br />

JIA patients developed varicella infection and signs and symptoms <strong>of</strong> aseptic<br />

meningitis, which resolved without sequelae.<br />

In open-label clinical studies <strong>of</strong> children with JIA, adverse reactions reported<br />

in those ages 2 to 4 years were similar to adverse reactions reported in<br />

older children.<br />

Postmarketing Experience<br />

Adverse reactions have been reported during post approval use <strong>of</strong> Enbrel in<br />

adults and pediatric patients. Because these reactions are reported voluntarily<br />

from a population <strong>of</strong> uncertain size, it is not always possible to reliably estimate<br />

their frequency or establish a causal relationship to Enbrel exposure.<br />

Adverse reactions are listed by body system below:<br />

Blood and lymphatic pancytopenia, anemia, leukopenia, neutropenia,<br />

system disorders:<br />

thrombocytopenia, lymphadenopathy, aplastic<br />

anemia [see Warnings and Precautions]<br />

Cardiac disorders:<br />

congestive heart failure [see Warnings<br />

and Precautions]<br />

General disorders:<br />

angioedema, chest pain<br />

Hepatobiliary disorders: autoimmune hepatitis, elevated transaminases<br />

Immune disorders:<br />

macrophage activation syndrome<br />

Musculoskeletal and lupus-like syndrome<br />

connective tissue disorders:<br />

Neoplasms benign, Non-melanoma skin cancers<br />

malignant, and unspecified: [see Warnings and Precautions]<br />

Nervous system disorders: convulsions, multiple sclerosis, demyelination,<br />

optic neuritis, transverse myelitis, paresthesias<br />

[see Warnings and Precautions]<br />

Ocular disorders:<br />

uveitis<br />

Respiratory, thoracic, interstitial lung disease<br />

and mediastinal disorders:<br />

17<br />

15<br />

3<br />

1<br />

1<br />

1<br />

1<br />

–<br />

Skin and subcutaneous<br />

tissue disorders:<br />

cutaneous lupus erythematous, cutaneous<br />

vasculitis (including leukocytoclastic vasculitis),<br />

erythema multiforme, Stevens-Johnson syndrome,<br />

toxic epidermal necrolysis, subcutaneous nodule,<br />

new or worsening psoriasis (all sub-types<br />

including pustular and palmoplantar)<br />

Opportunistic infections, including atypical mycobacterial infection, herpes<br />

zoster, aspergillosis, and Pneumocystis jiroveci pneumonia, and protozoal<br />

infections have also been reported in postmarketing use.<br />

DRUG INTERACTIONS<br />

Specific drug interaction studies have not been conducted with Enbrel.<br />

Vaccines<br />

Most PsA patients receiving Enbrel were able to mount effective B-cell<br />

immune responses to pneumococcal polysaccharide vaccine, but titers in<br />

aggregate were moderately lower and fewer patients had 2-fold rises in titers<br />

compared to patients not receiving Enbrel. The clinical significance <strong>of</strong> this is<br />

unknown. Patients receiving Enbrel may receive concurrent vaccinations,<br />

except for live vaccines. No data are available on the secondary transmission<br />

<strong>of</strong> infection by live vaccines in patients receiving Enbrel.<br />

Patients with a significant exposure to varicella virus should temporarily<br />

discontinue Enbrel therapy and be considered for prophylactic treatment with<br />

varicella zoster immune globulin [see Warnings and Precautions].<br />

Immune-Modulating Biologic Products<br />

In a study in which patients with active RA were treated for up to 24 weeks<br />

with concurrent Enbrel and anakinra therapy, a 7% rate <strong>of</strong> serious infections<br />

was observed, which was higher than that observed with Enbrel alone (0%)<br />

[see Warnings and Precautions] and did not result in higher ACR response<br />

rates compared to Enbrel alone. The most common infections consisted <strong>of</strong><br />

bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with<br />

pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent<br />

<strong>of</strong> patients treated concurrently with Enbrel and anakinra developed<br />

neutropenia (ANC < 1 x 10 9 /L).<br />

In clinical studies, concurrent administration <strong>of</strong> abatacept and Enbrel resulted<br />

in increased incidences <strong>of</strong> serious adverse events, including infections, and<br />

did not demonstrate increased clinical benefit [see Warnings and Precautions].<br />

Cyclophosphamide<br />

The use <strong>of</strong> Enbrel in patients receiving concurrent cyclophosphamide therapy<br />

is not recommended [see Warnings and Precautions].<br />

Sulfasalazine<br />

Patients in a clinical study who were on established therapy with sulfasalazine,<br />

to which Enbrel was added, were noted to develop a mild decrease in mean<br />

neutrophil counts in comparison to groups treated with either Enbrel or<br />

sulfasalazine alone. The clinical significance <strong>of</strong> this observation is unknown.<br />

USE IN SPECIFIC POPULATIONS<br />

Pregnancy<br />

Pregnancy Category B. Developmental toxicity studies have been performed<br />

in rats and rabbits at doses ranging from 60- to 100-fold higher than the<br />

human dose and have revealed no evidence <strong>of</strong> harm to the fetus due to Enbrel.<br />

There are, however, no studies in pregnant women. Because animal<br />

reproduction studies are not always predictive <strong>of</strong> human response, this drug<br />

should be used during pregnancy only if clearly needed.<br />

Pregnancy Registry: To monitor outcomes <strong>of</strong> pregnant women exposed to<br />

Enbrel, a pregnancy registry has been established. Physicians are encouraged<br />

to register patients by calling 1-877-311-8972.<br />

Nursing Mothers<br />

It is not known whether Enbrel is excreted in human milk or absorbed<br />

systemically after ingestion. Because many drugs and immunoglobulins are<br />

excreted in human milk, and because <strong>of</strong> the potential for serious adverse<br />

reactions in nursing infants from Enbrel, a decision should be made whether<br />

to discontinue nursing or to discontinue the drug.<br />

Pediatric Use<br />

Enbrel is indicated for treatment <strong>of</strong> polyarticular JIA in patients ages 2 years<br />

and older [see Indications and Usage, Warnings and Precautions, Adverse<br />

Reactions].<br />

Enbrel has not been studied in children < 2 years <strong>of</strong> age with JIA. The safety<br />

and efficacy <strong>of</strong> Enbrel in pediatric patients with PsO have not been studied.<br />

Geriatric Use<br />

A total <strong>of</strong> 480 RA patients ages 65 years or older have been studied in clinical<br />

trials. In PsO randomized clinical trials, a total <strong>of</strong> 138 out <strong>of</strong> 1965 subjects<br />

treated with Enbrel or placebo were age 65 or older. No overall differences in<br />

safety or effectiveness were observed between these patients and younger<br />

patients, but the number <strong>of</strong> geriatric PsO subjects is too small to determine<br />

whether they respond differently from younger subjects. Because there is a<br />

higher incidence <strong>of</strong> infections in the elderly population in general, caution<br />

should be used in treating the elderly.<br />

Use in Diabetics<br />

There have been reports <strong>of</strong> hypoglycemia following initiation <strong>of</strong> Enbrel therapy<br />

in patients receiving medication for diabetes, necessitating a reduction in<br />

anti-diabetic medication in some <strong>of</strong> these patients.<br />

Rx Only.<br />

This brief summary is based on ENBREL prescribing information<br />

v. 40: 7/2010<br />

Manufactured by:<br />

Immunex Corporation<br />

Thousand Oaks, CA 91320-1799<br />

U.S. License Number 1132<br />

Marketed by Amgen Inc. and Pfizer Inc.<br />

© 1998 – 2010 Immunex Corporation. All rights reserved.<br />

U.S. Patent Nos. 5,395,760; 5,605,690, Re. 36,755.<br />

For more information please call 1-888-436-2735 or visit www.enbrel.com<br />

© 2010 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc.<br />

All rights reserved.


Prescription Enbrel ® (etanercept) is administered by injection.<br />

IMPORTANT SAFETY INFORMATION<br />

SERIOUS INFECTIONS<br />

Patients treated with ENBREL are at increased risk for developing<br />

serious infections that may lead to hospitalization or death. Most<br />

patients who developed these infections were taking concomitant<br />

immunosuppressants such as methotrexate or corticosteroids or were<br />

predisposed to infection because <strong>of</strong> their underlying disease. ENBREL<br />

should not be initiated in the presence <strong>of</strong> sepsis, active infections, or<br />

allergy to ENBREL or its components. ENBREL should be discontinued<br />

if a patient develops a serious infection or sepsis. Reported infections<br />

include: 1) Active tuberculosis (TB), including reactivation <strong>of</strong> latent<br />

TB. Patients with TB have frequently presented with disseminated or<br />

extrapulmonary disease. Patients should be tested for latent TB before<br />

ENBREL use and periodically during therapy. Treatment for latent<br />

infection should be initiated prior to ENBREL use, 2) Invasive fungal<br />

infections, including histoplasmosis, coccidioidomycosis, candidiasis,<br />

aspergillosis, blastomycosis, and pneumocystosis. Patients with<br />

histoplasmosis or other invasive fungal infections may present with<br />

disseminated, rather than localized, disease. Antigen and antibody<br />

testing for histoplasmosis may be negative in some patients with active<br />

infection. Empiric antifungal therapy should be considered in patients<br />

at risk for invasive fungal infections who develop severe systemic<br />

illness, and 3) Bacterial, viral, and other infections due to opportunistic<br />

pathogens, such as listeriosis.<br />

The risks and benefits <strong>of</strong> treatment with ENBREL should be carefully<br />

considered prior to initiating therapy in patients 1) with chronic or<br />

recurrent infection, 2) who have been exposed to TB, 3) who have<br />

resided or traveled in areas <strong>of</strong> endemic TB or endemic mycoses, or<br />

4) with underlying conditions that may predispose them to infections such<br />

as advanced or poorly controlled diabetes. Patients should be closely<br />

monitored for the development <strong>of</strong> signs and symptoms <strong>of</strong> infection<br />

during and after treatment with ENBREL, including the possible<br />

development <strong>of</strong> TB in patients who tested negative for latent TB prior<br />

to initiating therapy.<br />

MALIGNANCIES<br />

Lymphoma and other malignancies, some fatal, have been reported in<br />

children and adolescent patients treated with tumor necrosis factor<br />

(TNF) blockers, including ENBREL.<br />

In clinical trials <strong>of</strong> all TNF blockers, more cases <strong>of</strong> lymphoma were seen<br />

compared to control patients. The risk <strong>of</strong> lymphoma may be up to several-fold<br />

higher in RA and psoriasis patients. The role <strong>of</strong> TNF blocker therapy in the<br />

development <strong>of</strong> malignancies is unknown.<br />

Cases <strong>of</strong> acute and chronic leukemia have been reported in association<br />

with postmarketing TNF blocker use in RA and other indications. The risk <strong>of</strong><br />

leukemia may be higher in patients with RA (approximately 2-fold) than the<br />

general population.<br />

Non-melanoma skin cancer (NMSC) has been reported in patients treated<br />

with TNF blockers, including ENBREL. Periodic skin examinations should be<br />

considered for all patients at increased risk for NMSC.<br />

Pediatric Patients<br />

In patients who initiated therapy at ≤ 18 years <strong>of</strong> age, approximately half <strong>of</strong><br />

the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s<br />

lymphoma). Other cases included rare malignancies usually associated<br />

with immunosuppression and malignancies that are not usually observed<br />

in children and adolescents. Most <strong>of</strong> the patients were receiving<br />

concomitant immunosuppressants.<br />

NEUROLOGIC EVENTS<br />

Treatment with TNF-blocking agents, including ENBREL, has been associated<br />

with rare (< 0.1%) cases <strong>of</strong> new onset or exacerbation <strong>of</strong> central nervous<br />

system demyelinating disorders, some presenting with mental status<br />

changes and some associated with permanent disability, and with peripheral<br />

nervous system demyelinating disorders. Cases <strong>of</strong> transverse myelitis,<br />

optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral<br />

demyelinating neuropathies, and new onset or exacerbation <strong>of</strong> seizure<br />

disorders have been reported in postmarketing experience with ENBREL<br />

therapy. Prescribers should exercise caution in considering the use <strong>of</strong><br />

ENBREL in patients with preexisting or recent-onset central or peripheral<br />

nervous system demyelinating disorders.<br />

HEMATOLOGIC EVENTS<br />

Rare cases <strong>of</strong> pancytopenia, including aplastic anemia, some fatal, have been<br />

reported. The causal relationship to ENBREL therapy remains unclear.<br />

Exercise caution when considering ENBREL in patients who have a previous<br />

history <strong>of</strong> significant hematologic abnormalities. Advise patients to seek<br />

immediate medical attention if they develop signs or symptoms <strong>of</strong> blood<br />

dyscrasias or infection. Consider discontinuing ENBREL if significant<br />

hematologic abnormalities are confirmed.<br />

WEGENER’S GRANULOMATOSIS PATIENTS<br />

The use <strong>of</strong> ENBREL in patients with Wegener’s granulomatosis receiving<br />

immunosuppressive agents (e.g., cyclophosphamide) is not recommended.<br />

HEPATITIS B VIRUS REACTIVATION<br />

Use <strong>of</strong> TNF blockers, including ENBREL, has been associated with reactivation<br />

<strong>of</strong> hepatitis B virus (HBV) in chronic carriers <strong>of</strong> this virus. The majority <strong>of</strong><br />

these reports occurred in patients on concomitant immunosuppressive<br />

agents, which may also contribute to HBV reactivation. Exercise caution when<br />

considering ENBREL in patients identified as carriers <strong>of</strong> HBV.<br />

MODERATE TO SEVERE ALCOHOLIC HEPATITIS<br />

Based on a study <strong>of</strong> patients treated for alcoholic hepatitis, exercise caution<br />

when using ENBREL in patients with moderate to severe alcoholic hepatitis.<br />

ALLERGIC REACTIONS<br />

Allergic reactions have been reported in < 2% <strong>of</strong> patients in clinical trials<br />

<strong>of</strong> ENBREL.<br />

CONGESTIVE HEART FAILURE<br />

Cases <strong>of</strong> worsening congestive heart failure (CHF) and, rarely, new onset<br />

cases have been reported in patients taking ENBREL. Caution should be used<br />

when using ENBREL in patients with CHF. These patients should be<br />

carefully monitored.<br />

IMMUNIZATIONS<br />

Live vaccines should not be administered to patients on ENBREL. JIA patients,<br />

if possible, should be brought up to date with all immunizations prior to<br />

initiating ENBREL. In patients with exposure to varicella virus, consider<br />

temporary discontinuation <strong>of</strong> ENBREL and prophylactic treatment with<br />

Varicella Zoster Immune Globulin.<br />

AUTOIMMUNITY<br />

Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or<br />

autoimmune hepatitis may occur. These may resolve upon withdrawal <strong>of</strong><br />

ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune<br />

hepatitis develops.<br />

DRUG INTERACTIONS<br />

The use <strong>of</strong> ENBREL in patients receiving concurrent cyclophosphamide<br />

therapy is not recommended. The risk <strong>of</strong> serious infection may increase with<br />

concomitant use <strong>of</strong> abatacept therapy. Concurrent therapy with ENBREL and<br />

anakinra is not recommended. Hypoglycemia has been reported following<br />

initiation <strong>of</strong> ENBREL therapy in patients receiving medication for diabetes,<br />

necessitating a reduction in anti-diabetic medication in some <strong>of</strong><br />

these patients.<br />

ADVERSE EVENTS<br />

The most commonly reported adverse events in RA clinical trials were<br />

injection site reaction, infection, and headache. In clinical trials <strong>of</strong> all other<br />

adult indications, adverse events were similar to those reported in RA<br />

clinical trials.<br />

Please see adjacent Brief Summary <strong>of</strong> Prescribing Information.<br />

© 2010 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc. All rights reserved.<br />

MC50381-B-1 06-10 www.enbrelhcp.com<br />

EXPERIENCE STARTS HERE


Come to booth #1429<br />

Approved in RA since 1998.<br />

ENBREL is indicated for reducing signs and symptoms, inducing major clinical<br />

response, inhibiting the progression <strong>of</strong> structural damage, and improving physical<br />

function in patients with moderately to severely active rheumatoid arthritis (RA).<br />

ENBREL can be initiated in combination with methotrexate (MTX) or used alone.<br />

See Important Safety Information on the adjacent page concerning the risks <strong>of</strong><br />

serious infections, including TB and other opportunistic infections, lymphoma<br />

and other malignancies, and other serious adverse events.<br />

You are part <strong>of</strong> Generation ENBREL, a<br />

generation <strong>of</strong> rheumatologists practicing<br />

since the approval <strong>of</strong> ENBREL. Join your<br />

peers at Booth #1429 to take a journey<br />

through our years <strong>of</strong> experience. Review<br />

data in moderate to severe rheumatoid<br />

arthritis and in psoriatic arthritis.<br />

Look for the ENBREL symposium,<br />

sponsored by Amgen and Pfizer,<br />

coming up this week.<br />

GeorGia world<br />

ConGress Center<br />

november 6–11, 2010, atlanta, Ga<br />

Please see Brief Summary <strong>of</strong> Prescribing Information on the following pages.<br />

EXPERIENCE STARTS HERE

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!